Famotidine	8701013	0	O
-	-	10	O
associated	-	11	O
delirium	-	22	B
.	-	30	O

A	8701013	32	O
series	-	34	O
of	-	41	O
six	-	44	O
cases	-	48	O
.	-	53	O

Famotidine	8701013	55	O
is	-	66	O
a	-	69	O
histamine	-	71	O
H2	-	81	O
-	-	83	O
receptor	-	84	O
antagonist	-	93	O
used	-	104	O
in	-	109	O
inpatient	-	112	O
settings	-	122	O
for	-	131	O
prevention	-	135	O
of	-	146	O
stress	-	149	O
ulcers	-	156	B
and	-	163	O
is	-	167	O
showing	-	170	O
increasing	-	178	O
popularity	-	189	O
because	-	200	O
of	-	208	O
its	-	211	O
low	-	215	O
cost	-	219	O
.	-	223	O

Although	8701013	225	O
all	-	234	O
of	-	238	O
the	-	241	O
currently	-	245	O
available	-	255	O
H2	-	265	O
-	-	267	O
receptor	-	268	O
antagonists	-	277	O
have	-	289	O
shown	-	294	O
the	-	300	O
propensity	-	304	O
to	-	315	O
cause	-	318	O
delirium	-	324	B
,	-	332	O
only	-	334	O
two	-	339	O
previously	-	343	O
reported	-	354	O
cases	-	363	O
have	-	369	O
been	-	374	O
associated	-	379	O
with	-	390	O
famotidine	-	395	O
.	-	405	O

The	8701013	407	O
authors	-	411	O
report	-	419	O
on	-	426	O
six	-	429	O
cases	-	433	O
of	-	439	O
famotidine	-	442	O
-	-	452	O
associated	-	453	O
delirium	-	464	B
in	-	473	O
hospitalized	-	476	O
patients	-	489	O
who	-	498	O
cleared	-	502	O
completely	-	510	O
upon	-	521	O
removal	-	526	O
of	-	534	O
famotidine	-	537	O
.	-	547	O

The	8701013	549	O
pharmacokinetics	-	553	O
of	-	570	O
famotidine	-	573	O
are	-	584	O
reviewed	-	588	O
,	-	596	O
with	-	598	O
no	-	603	O
change	-	606	O
in	-	613	O
its	-	616	O
metabolism	-	620	O
in	-	631	O
the	-	634	O
elderly	-	638	O
population	-	646	O
seen	-	657	O
.	-	661	O

The	8701013	663	O
implications	-	667	O
of	-	680	O
using	-	683	O
famotidine	-	689	O
in	-	700	O
elderly	-	703	O
persons	-	711	O
are	-	719	O
discussed	-	723	O
.	-	732	O

Indomethacin	439781	0	O
induced	-	13	O
hypotension	-	21	B
in	-	33	O
sodium	-	36	O
and	-	43	O
volume	-	47	O
depleted	-	54	O
rats	-	63	O
.	-	67	O

After	439781	69	O
a	-	75	O
single	-	77	O
oral	-	84	O
dose	-	89	O
of	-	94	O
4	-	97	O
mg	-	99	O
/	-	101	O
kg	-	102	O
indomethacin	-	105	O
(	-	118	O
IDM	-	119	O
)	-	122	O
to	-	124	O
sodium	-	127	O
and	-	134	O
volume	-	138	O
depleted	-	145	O
rats	-	154	O
plasma	-	159	O
renin	-	166	O
activity	-	172	O
(	-	181	O
PRA	-	182	O
)	-	185	O
and	-	187	O
systolic	-	191	O
blood	-	200	O
pressure	-	206	O
fell	-	215	O
significantly	-	220	O
within	-	234	O
four	-	241	O
hours	-	246	O
.	-	251	O

In	439781	253	O
sodium	-	256	O
repleted	-	263	O
animals	-	272	O
indomethacin	-	280	O
did	-	293	O
not	-	297	O
change	-	301	O
systolic	-	308	O
blood	-	317	O
pressure	-	323	O
(	-	332	O
BP	-	333	O
)	-	335	O
although	-	337	O
plasma	-	346	O
renin	-	353	O
activity	-	359	O
was	-	368	O
decreased	-	372	O
.	-	381	O

Thus	439781	383	O
,	-	387	O
indomethacin	-	389	O
by	-	402	O
inhibition	-	405	O
of	-	416	O
prostaglandin	-	419	O
synthesis	-	433	O
may	-	443	O
diminish	-	447	O
the	-	456	O
blood	-	460	O
pressure	-	466	O
maintaining	-	475	O
effect	-	487	O
of	-	494	O
the	-	497	O
stimulated	-	501	O
renin	-	512	O
-	-	517	O
angiotensin	-	518	O
system	-	530	O
in	-	537	O
sodium	-	540	O
and	-	547	O
volume	-	551	O
depletion	-	558	O
.	-	567	O

Late	22836123	0	O
-	-	4	O
onset	-	5	O
scleroderma	-	11	B
renal	-	23	I
crisis	-	29	I
induced	-	36	O
by	-	44	O
tacrolimus	-	47	O
and	-	58	O
prednisolone	-	62	O
:	-	74	O
a	-	76	O
case	-	78	O
report	-	83	O
.	-	89	O

Scleroderma	22836123	91	B
renal	-	103	I
crisis	-	109	I
(	-	116	O
SRC	-	117	B
)	-	120	O
is	-	122	O
a	-	125	O
rare	-	127	O
complication	-	132	O
of	-	145	O
systemic	-	148	B
sclerosis	-	157	I
(	-	167	O
SSc	-	168	B
)	-	171	O
but	-	173	O
can	-	177	O
be	-	181	O
severe	-	184	O
enough	-	191	O
to	-	198	O
require	-	201	O
temporary	-	209	O
or	-	219	O
permanent	-	222	O
renal	-	232	O
replacement	-	238	O
therapy	-	250	O
.	-	257	O

Moderate	22836123	259	O
to	-	268	O
high	-	271	O
dose	-	276	O
corticosteroid	-	281	O
use	-	296	O
is	-	300	O
recognized	-	303	O
as	-	314	O
a	-	317	O
major	-	319	O
risk	-	325	O
factor	-	330	O
for	-	337	O
SRC	-	341	B
.	-	344	O

Furthermore	22836123	346	O
,	-	357	O
there	-	359	O
have	-	365	O
been	-	370	O
reports	-	375	O
of	-	383	O
thrombotic	-	386	B
microangiopathy	-	397	I
precipitated	-	413	O
by	-	426	O
cyclosporine	-	429	O
in	-	442	O
patients	-	445	O
with	-	454	O
SSc	-	459	B
.	-	462	O

In	22836123	464	O
this	-	467	O
article	-	472	O
,	-	479	O
we	-	481	O
report	-	484	O
a	-	491	O
patient	-	493	O
with	-	501	O
SRC	-	506	B
induced	-	510	O
by	-	518	O
tacrolimus	-	521	O
and	-	532	O
corticosteroids	-	536	O
.	-	551	O

The	22836123	553	O
aim	-	557	O
of	-	561	O
this	-	564	O
work	-	569	O
is	-	574	O
to	-	577	O
call	-	580	O
attention	-	585	O
to	-	595	O
the	-	598	O
risk	-	602	O
of	-	607	O
tacrolimus	-	610	O
use	-	621	O
in	-	625	O
patients	-	628	O
with	-	637	O
SSc	-	642	B
.	-	645	O

The	23433219	0	O
risk	-	4	O
and	-	9	O
associated	-	13	O
factors	-	24	O
of	-	32	O
methamphetamine	-	35	O
psychosis	-	51	B
in	-	61	O
methamphetamine	-	64	O
-	-	79	O
dependent	-	80	O
patients	-	90	O
in	-	99	O
Malaysia	-	102	O
.	-	110	O

OBJECTIVE	23433219	112	O
:	-	121	O
The	-	123	O
objective	-	127	O
of	-	137	O
this	-	140	O
study	-	145	O
was	-	151	O
to	-	155	O
determine	-	158	O
the	-	168	O
risk	-	172	O
of	-	177	O
lifetime	-	180	O
and	-	189	O
current	-	193	O
methamphetamine	-	201	O
-	-	216	O
induced	-	217	O
psychosis	-	225	B
in	-	235	O
patients	-	238	O
with	-	247	O
methamphetamine	-	252	O
dependence	-	268	O
.	-	278	O

The	23433219	280	O
association	-	284	O
between	-	296	O
psychiatric	-	304	O
co	-	316	O
-	-	318	O
morbidity	-	319	O
and	-	329	O
methamphetamine	-	333	O
-	-	348	O
induced	-	349	O
psychosis	-	357	B
was	-	367	O
also	-	371	O
studied	-	376	O
.	-	383	O

METHODS	23433219	385	O
:	-	392	O

This	23433219	394	O
was	-	399	O
a	-	403	O
cross	-	405	O
-	-	410	O
sectional	-	411	O
study	-	421	O
conducted	-	427	O
concurrently	-	437	O
at	-	450	O
a	-	453	O
teaching	-	455	O
hospital	-	464	O
and	-	473	O
a	-	477	O
drug	-	479	O
rehabilitation	-	484	O
center	-	499	O
in	-	506	O
Malaysia	-	509	O
.	-	517	O

Patients	23433219	519	O
with	-	528	O
the	-	533	O
diagnosis	-	537	O
of	-	547	O
methamphetamine	-	550	O
based	-	566	O
on	-	572	O
DSM	-	575	O
-	-	578	O
IV	-	579	O
were	-	582	O
interviewed	-	587	O
using	-	599	O
the	-	605	O
Mini	-	609	O
International	-	614	O
Neuropsychiatric	-	628	O
Interview	-	645	O
(	-	655	O
M	-	656	O
.	-	657	O
I	-	658	O
.	-	659	O
N	-	660	O
.	-	661	O
I	-	662	O
.	-	663	O
)	-	664	O
for	-	666	O
methamphetamine	-	670	O
-	-	685	O
induced	-	686	O
psychosis	-	694	B
and	-	704	O
other	-	708	O
Axis	-	714	O
I	-	719	O
psychiatric	-	721	B
disorders	-	733	I
.	-	742	O

The	23433219	744	O
information	-	748	O
on	-	760	O
sociodemographic	-	763	O
background	-	780	O
and	-	791	O
drug	-	795	O
use	-	800	O
history	-	804	O
was	-	812	O
obtained	-	816	O
from	-	825	O
interview	-	830	O
or	-	840	O
medical	-	843	O
records	-	851	O
.	-	858	O

RESULTS	23433219	860	O
:	-	867	O

Of	23433219	869	O
292	-	872	O
subjects	-	876	O
,	-	884	O
47	-	886	O
.	-	888	O
9	-	889	O
%	-	890	O
of	-	892	O
the	-	895	O
subjects	-	899	O
had	-	908	O
a	-	912	O
past	-	914	O
history	-	919	O
of	-	927	O
psychotic	-	930	B
symptoms	-	940	I
and	-	949	O
13	-	953	O
.	-	955	O
0	-	956	O
%	-	957	O
of	-	959	O
the	-	962	O
patients	-	966	O
were	-	975	O
having	-	980	O
current	-	987	O
psychotic	-	995	B
symptoms	-	1005	I
.	-	1013	O

Co	23433219	1015	O
-	-	1017	O
morbid	-	1018	O
major	-	1025	O
depressive	-	1031	B
disorder	-	1042	I

(	23433219	1051	O
OR	-	1052	O
=	-	1054	O
7	-	1055	O
.	-	1056	O
18	-	1057	O
,	-	1059	O
95	-	1061	O
CI	-	1064	O
=	-	1066	O
2	-	1067	O
.	-	1068	O
612	-	1069	O
-	-	1072	O
19	-	1073	O
.	-	1075	O
708	-	1076	O
)	-	1079	O
,	-	1080	O
bipolar	-	1082	B
disorder	-	1090	I
(	-	1099	O
OR	-	1100	O
=	-	1102	O
13	-	1103	O
.	-	1105	O
807	-	1106	O
,	-	1109	O
95	-	1111	O
CI	-	1114	O
=	-	1116	O
5	-	1117	O
.	-	1118	O
194	-	1119	O
-	-	1122	O
36	-	1123	O
.	-	1125	O
706	-	1126	O
)	-	1129	O
,	-	1130	O
antisocial	-	1132	B
personality	-	1143	I
disorder	-	1155	I
(	-	1164	O
OR	-	1165	O
=	-	1167	O
12	-	1168	O
.	-	1170	O
619	-	1171	O
,	-	1174	O
95	-	1176	O
CI	-	1179	O
=	-	1181	O
6	-	1182	O
.	-	1183	O
702	-	1184	O
-	-	1187	O
23	-	1188	O
.	-	1190	O
759	-	1191	O
)	-	1194	O
and	-	1196	O
heavy	-	1200	O
methamphetamine	-	1206	O
uses	-	1222	O
were	-	1227	O
significantly	-	1232	O
associated	-	1246	O
with	-	1257	O
lifetime	-	1262	O
methamphetamine	-	1271	O
-	-	1286	O
induced	-	1287	O
psychosis	-	1295	B
after	-	1305	O
adjusted	-	1311	O
for	-	1320	O
other	-	1324	O
factors	-	1330	O
.	-	1337	O

Major	23433219	1339	B
depressive	-	1345	I
disorder	-	1356	I
(	-	1365	O
OR	-	1366	O
=	-	1368	O
2	-	1369	O
.	-	1370	O
870	-	1371	O
,	-	1374	O
CI	-	1376	O
=	-	1378	O
1	-	1379	O
.	-	1380	O
154	-	1381	O
-	-	1384	O
7	-	1385	O
.	-	1386	O
142	-	1387	O
)	-	1390	O
and	-	1392	O
antisocial	-	1396	B
personality	-	1407	I
disorder	-	1419	I
(	-	1428	O
OR	-	1429	O
=	-	1431	O
3	-	1432	O
.	-	1433	O
299	-	1434	O
,	-	1437	O
95	-	1439	O
CI	-	1442	O
=	-	1444	O
1	-	1445	O
.	-	1446	O
375	-	1447	O
-	-	1450	O
7	-	1451	O
.	-	1452	O
914	-	1453	O
)	-	1456	O
were	-	1458	O
the	-	1463	O
only	-	1467	O
factors	-	1472	O
associated	-	1480	O
with	-	1491	O
current	-	1496	O
psychosis	-	1504	B
.	-	1513	O

CONCLUSION	23433219	1515	O
:	-	1525	O

There	23433219	1527	O
was	-	1533	O
a	-	1537	O
high	-	1539	O
risk	-	1544	O
of	-	1549	O
psychosis	-	1552	B
in	-	1562	O
patients	-	1565	O
with	-	1574	O
methamphetamine	-	1579	O
dependence	-	1595	O
.	-	1605	O

It	23433219	1607	O
was	-	1610	O
associated	-	1614	O
with	-	1625	O
co	-	1630	O
-	-	1632	O
morbid	-	1633	O
affective	-	1640	B
disorder	-	1650	I
,	-	1658	O
antisocial	-	1660	B
personality	-	1671	I
,	-	1682	O
and	-	1684	O
heavy	-	1688	O
methamphetamine	-	1694	O
use	-	1710	O
.	-	1713	O

It	23433219	1715	O
is	-	1718	O
recommended	-	1721	O
that	-	1733	O
all	-	1738	O
cases	-	1742	O
of	-	1748	O
methamphetamine	-	1751	O
dependence	-	1767	O
should	-	1778	O
be	-	1785	O
screened	-	1788	O
for	-	1797	O
psychotic	-	1801	B
symptoms	-	1811	I
.	-	1819	O

Cerebellar	23535177	0	O
sensory	-	11	O
processing	-	19	O
alterations	-	30	O
impact	-	42	O
motor	-	49	O
cortical	-	55	O
plasticity	-	64	O
in	-	75	O
Parkinson	-	78	B
's	-	87	I
disease	-	90	I
:	-	97	O
clues	-	99	O
from	-	105	O
dyskinetic	-	110	B
patients	-	121	O
.	-	129	O

The	23535177	131	O
plasticity	-	135	O
of	-	146	O
primary	-	149	O
motor	-	157	O
cortex	-	163	O
(	-	170	O
M1	-	171	O
)	-	173	O
in	-	175	O
patients	-	178	O
with	-	187	O
Parkinson	-	192	B
's	-	201	I
disease	-	204	I
(	-	212	O
PD	-	213	B
)	-	215	O
and	-	217	O
levodopa	-	221	O
-	-	229	O
induced	-	230	O
dyskinesias	-	238	B
(	-	250	O
LIDs	-	251	B
)	-	255	O
is	-	257	O
severely	-	260	O
impaired	-	269	O
.	-	277	O

We	23535177	279	O
recently	-	282	O
reported	-	291	O
in	-	300	O
young	-	303	O
healthy	-	309	O
subjects	-	317	O
that	-	326	O
inhibitory	-	331	O
cerebellar	-	342	O
stimulation	-	353	O
enhanced	-	365	O
the	-	374	O
sensorimotor	-	378	O
plasticity	-	391	O
of	-	402	O
M1	-	405	O
that	-	408	O
was	-	413	O
induced	-	417	O
by	-	425	O
paired	-	428	O
associative	-	435	O
stimulation	-	447	O
(	-	459	O
PAS	-	460	O
)	-	463	O
.	-	464	O

This	23535177	466	O
study	-	471	O
demonstrates	-	477	O
that	-	490	O
the	-	495	O
deficient	-	499	O
sensorimotor	-	509	O
M1	-	522	O
plasticity	-	525	O
in	-	536	O
16	-	539	O
patients	-	542	O
with	-	551	O
LIDs	-	556	B
could	-	561	O
be	-	567	O
reinstated	-	570	O
by	-	581	O
a	-	584	O
single	-	586	O
session	-	593	O
of	-	601	O
real	-	604	O
inhibitory	-	609	O
cerebellar	-	620	O
stimulation	-	631	O
but	-	643	O
not	-	647	O
sham	-	651	O
stimulation	-	656	O
.	-	667	O

This	23535177	669	O
was	-	674	O
evident	-	678	O
only	-	686	O
when	-	691	O
a	-	696	O
sensory	-	698	O
component	-	706	O
was	-	716	O
involved	-	720	O
in	-	729	O
the	-	732	O
induction	-	736	O
of	-	746	O
plasticity	-	749	O
,	-	759	O
indicating	-	761	O
that	-	772	O
cerebellar	-	777	O
sensory	-	788	O
processing	-	796	O
function	-	807	O
is	-	816	O
involved	-	819	O
in	-	828	O
the	-	831	O
resurgence	-	835	O
of	-	846	O
M1	-	849	O
plasticity	-	852	O
.	-	862	O

The	23535177	864	O
benefit	-	868	O
of	-	876	O
inhibitory	-	879	O
cerebellar	-	890	O
stimulation	-	901	O
on	-	913	O
LIDs	-	916	B
is	-	921	O
known	-	924	O
.	-	929	O

To	23535177	931	O
explore	-	934	O
whether	-	942	O
this	-	950	O
benefit	-	955	O
is	-	963	O
linked	-	966	O
to	-	973	O
the	-	976	O
restoration	-	980	O
of	-	992	O
sensorimotor	-	995	O
plasticity	-	1008	O
of	-	1019	O
M1	-	1022	O
,	-	1024	O
we	-	1026	O
conducted	-	1029	O
an	-	1039	O
additional	-	1042	O
study	-	1053	O
looking	-	1059	O
at	-	1067	O
changes	-	1070	O
in	-	1078	O
LIDs	-	1081	B
and	-	1086	O
PAS	-	1090	O
-	-	1093	O
induced	-	1094	O
plasticity	-	1102	O
after	-	1113	O
10	-	1119	O
sessions	-	1122	O
of	-	1131	O
either	-	1134	O
bilateral	-	1141	O
,	-	1150	O
real	-	1152	O
inhibitory	-	1157	O
cerebellar	-	1168	O
stimulation	-	1179	O
or	-	1191	O
sham	-	1194	O
stimulation	-	1199	O
.	-	1210	O

Only	23535177	1212	O
real	-	1217	O
and	-	1222	O
not	-	1226	O
sham	-	1230	O
stimulation	-	1235	O
had	-	1247	O
an	-	1251	O
antidyskinetic	-	1254	O
effect	-	1269	O
and	-	1276	O
it	-	1280	O
was	-	1283	O
paralleled	-	1287	O
by	-	1298	O
a	-	1301	O
resurgence	-	1303	O
in	-	1314	O
the	-	1317	O
sensorimotor	-	1321	O
plasticity	-	1334	O
of	-	1345	O
M1	-	1348	O
.	-	1350	O

These	23535177	1352	O
results	-	1358	O
suggest	-	1366	O
that	-	1374	O
alterations	-	1379	O
in	-	1391	O
cerebellar	-	1394	O
sensory	-	1405	O
processing	-	1413	O
function	-	1424	O
,	-	1432	O
occurring	-	1434	O
secondary	-	1444	O
to	-	1454	O
abnormal	-	1457	O
basal	-	1466	O
ganglia	-	1472	O
signals	-	1480	O
reaching	-	1488	O
it	-	1497	O
,	-	1499	O
may	-	1501	O
be	-	1505	O
an	-	1508	O
important	-	1511	O
element	-	1521	O
contributing	-	1529	O
to	-	1542	O
the	-	1545	O
maladaptive	-	1549	O
sensorimotor	-	1561	O
plasticity	-	1574	O
of	-	1585	O
M1	-	1588	O
and	-	1591	O
the	-	1595	O
emergence	-	1599	O
of	-	1609	O
abnormal	-	1612	B
involuntary	-	1621	I
movements	-	1633	I
.	-	1642	O

The	23666265	0	O
function	-	4	O
of	-	13	O
P2X3	-	16	O
receptor	-	21	O
and	-	30	O
NK1	-	34	O
receptor	-	38	O
antagonists	-	47	O
on	-	59	O
cyclophosphamide	-	62	O
-	-	78	O
induced	-	79	O
cystitis	-	87	B
in	-	96	O
rats	-	99	O
.	-	103	O

PURPOSE	23666265	105	O
:	-	112	O

The	23666265	114	O
purpose	-	118	O
of	-	126	O
the	-	129	O
study	-	133	O
is	-	139	O
to	-	142	O
explore	-	145	O
the	-	153	O
function	-	157	O
of	-	166	O
P2X3	-	169	O
and	-	174	O
NK1	-	178	O
receptors	-	182	O
antagonists	-	192	O
on	-	204	O
cyclophosphamide	-	207	O
(	-	224	O
CYP	-	225	O
)	-	228	O
-	-	229	O
induced	-	230	O
cystitis	-	238	B
in	-	247	O
rats	-	250	O
.	-	254	O

METHODS	23666265	256	O
:	-	263	O

Sixty	23666265	265	O
female	-	271	O
Sprague	-	278	O
-	-	285	O
Dawley	-	286	O
(	-	293	O
SD	-	294	O
)	-	296	O
rats	-	298	O
were	-	303	O
randomly	-	308	O
divided	-	317	O
into	-	325	O
three	-	330	O
groups	-	336	O
.	-	342	O

The	23666265	344	O
rats	-	348	O
in	-	353	O
the	-	356	O
control	-	360	O
group	-	368	O
were	-	374	O
intraperitoneally	-	379	O
(	-	397	O
i	-	398	O
.	-	399	O
p	-	400	O
.	-	401	O
)	-	402	O
injected	-	404	O
with	-	413	O
0	-	418	O
.	-	419	O
9	-	420	O
%	-	421	O
saline	-	423	O
(	-	430	O
4	-	431	O
ml	-	433	O
/	-	435	O
kg	-	436	O
)	-	438	O
;	-	439	O
the	-	441	O
rats	-	445	O
in	-	450	O
the	-	453	O
model	-	457	O
group	-	463	O
were	-	469	O
i	-	474	O
.	-	475	O
p	-	476	O
.	-	477	O

injected	23666265	479	O
with	-	488	O
CYP	-	493	O
(	-	497	O
150	-	498	O
mg	-	502	O
/	-	504	O
kg	-	505	O
)	-	507	O
;	-	508	O
and	-	510	O
the	-	514	O
rats	-	518	O
in	-	523	O
the	-	526	O
intervention	-	530	O
group	-	543	O
were	-	549	O
i	-	554	O
.	-	555	O
p	-	556	O
.	-	557	O

injected	23666265	559	O
with	-	568	O
CYP	-	573	O
with	-	577	O
subsequently	-	582	O
perfusion	-	595	O
of	-	605	O
bladder	-	608	O
with	-	616	O
P2X3	-	621	O
and	-	626	O
NK1	-	630	O
receptors	-	634	O
'	-	643	O
antagonists	-	645	O
,	-	656	O
Suramin	-	658	O
and	-	666	O
GR	-	670	O
82334	-	673	O
.	-	678	O

Spontaneous	23666265	680	O
pain	-	692	B
behaviors	-	697	O
following	-	707	O
the	-	717	O
administration	-	721	O
of	-	736	O
CYP	-	739	O
were	-	743	O
observed	-	748	O
.	-	756	O

Urodynamic	23666265	758	O
parameters	-	769	O
,	-	779	O
bladder	-	781	O
pressure	-	789	O
-	-	797	O
volume	-	798	O
curve	-	805	O
,	-	810	O
maximum	-	812	O
voiding	-	820	O
pressure	-	828	O
(	-	837	O
MVP	-	838	O
)	-	841	O
,	-	842	O
and	-	844	O
maximum	-	848	O
cystometric	-	856	O
capacity	-	868	O
(	-	877	O
MCC	-	878	O
)	-	881	O
,	-	882	O
were	-	884	O
recorded	-	889	O
.	-	897	O

Pathological	23666265	899	O
changes	-	912	O
in	-	920	O
bladder	-	923	O
tissue	-	931	O
were	-	938	O
observed	-	943	O
.	-	951	O

Immunofluorescence	23666265	953	O
was	-	972	O
used	-	976	O
to	-	981	O
detect	-	984	O
the	-	991	O
expression	-	995	O
of	-	1006	O
P2X3	-	1009	O
and	-	1014	O
NK1	-	1018	O
receptors	-	1022	O
in	-	1032	O
bladder	-	1035	O
.	-	1042	O

RESULTS	23666265	1044	O
:	-	1051	O

Cyclophosphamide	23666265	1053	O
treatment	-	1070	O
increased	-	1080	O
the	-	1090	O
spontaneous	-	1094	O
pain	-	1106	B
behaviors	-	1111	O
scores	-	1121	O
.	-	1127	O

The	23666265	1129	O
incidence	-	1133	O
of	-	1143	O
bladder	-	1146	O
instability	-	1154	O
during	-	1166	O
urine	-	1173	O
storage	-	1179	O
period	-	1187	O
of	-	1194	O
model	-	1197	O
group	-	1203	O
was	-	1209	O
significantly	-	1213	O
higher	-	1227	O
than	-	1234	O
intervention	-	1239	O
group	-	1252	O
(	-	1258	O
X	-	1259	O
(	-	1260	O
2	-	1261	O
)	-	1262	O
=	-	1264	O

7	23666265	1266	O
.	-	1267	O
619	-	1268	O
,	-	1271	O
P	-	1273	O
=	-	1275	O
0	-	1277	O
.	-	1278	O
007	-	1279	O
)	-	1282	O
and	-	1284	O
control	-	1288	O
group	-	1296	O
(	-	1302	O
X	-	1303	O
(	-	1304	O
2	-	1305	O
)	-	1306	O
=	-	1308	O

13	23666265	1310	O
.	-	1312	O
755	-	1313	O
,	-	1316	O
P	-	1318	O
=	-	1320	O
0	-	1322	O
.	-	1323	O
000	-	1324	O
)	-	1327	O
.	-	1328	O

MCC	23666265	1330	O
in	-	1334	O
the	-	1337	O
model	-	1341	O
group	-	1347	O
was	-	1353	O
lower	-	1357	O
than	-	1363	O
the	-	1368	O
control	-	1372	O
and	-	1380	O
intervention	-	1384	O
groups	-	1397	O
(	-	1404	O
P	-	1405	O
<	-	1407	O
0	-	1409	O
.	-	1410	O
01	-	1411	O
)	-	1413	O
.	-	1414	O

Histological	23666265	1416	O
changes	-	1429	O
evident	-	1437	O
in	-	1445	O
model	-	1448	O
and	-	1454	O
intervention	-	1458	O
groups	-	1471	O
rats	-	1478	O
'	-	1482	O
bladder	-	1484	O
included	-	1492	O
edema	-	1501	B
,	-	1506	O
vasodilation	-	1508	O
,	-	1520	O
and	-	1522	O
infiltration	-	1526	O
of	-	1539	O
inflammatory	-	1542	O
cells	-	1555	O
.	-	1560	O

In	23666265	1562	O
model	-	1565	O
group	-	1571	O
,	-	1576	O
the	-	1578	O
expression	-	1582	O
of	-	1593	O
P2X3	-	1596	O
receptor	-	1601	O
increased	-	1610	O
in	-	1620	O
urothelium	-	1623	O
and	-	1634	O
suburothelium	-	1638	O
,	-	1651	O
and	-	1653	O
NK1	-	1657	O
receptor	-	1661	O
increased	-	1670	O
in	-	1680	O
suburothelium	-	1683	O
,	-	1696	O
while	-	1698	O
the	-	1704	O
expression	-	1708	O
of	-	1719	O
them	-	1722	O
in	-	1727	O
intervention	-	1730	O
group	-	1743	O
was	-	1749	O
lower	-	1753	O
.	-	1758	O

CONCLUSIONS	23666265	1760	O
:	-	1771	O

In	23666265	1773	O
CYP	-	1776	O
-	-	1779	O
induced	-	1780	O
cystitis	-	1788	B
,	-	1796	O
the	-	1798	O
expression	-	1802	O
of	-	1813	O
P2X3	-	1816	O
and	-	1821	O
NK1	-	1825	O
receptors	-	1829	O
increased	-	1839	O
in	-	1849	O
urothelium	-	1852	O
and	-	1863	O
/	-	1866	O
or	-	1867	O
suburothelium	-	1870	O
.	-	1883	O

Perfusion	23666265	1885	O
of	-	1895	O
bladder	-	1898	O
with	-	1906	O
P2X3	-	1911	O
and	-	1916	O
NK1	-	1920	O
receptors	-	1924	O
antagonists	-	1934	O
ameliorated	-	1946	O
the	-	1958	O
bladder	-	1962	O
function	-	1970	O
.	-	1978	O

Acute	23846525	0	O
hepatitis	-	6	B
associated	-	16	O
with	-	27	O
clopidogrel	-	32	O
:	-	43	O
a	-	45	O
case	-	47	O
report	-	52	O
and	-	59	O
review	-	63	O
of	-	70	O
the	-	73	O
literature	-	77	O
.	-	87	O

Drug	23846525	89	O
-	-	93	O
induced	-	94	O
hepatotoxicity	-	102	B
is	-	117	O
a	-	120	O
common	-	122	O
cause	-	129	O
of	-	135	O
acute	-	138	O
hepatitis	-	144	B
,	-	153	O
and	-	155	O
the	-	159	O
recognition	-	163	O
of	-	175	O
the	-	178	O
responsible	-	182	O
drug	-	194	O
may	-	199	O
be	-	203	O
difficult	-	206	O
.	-	215	O

We	23846525	217	O
describe	-	220	O
a	-	229	O
case	-	231	O
of	-	236	O
clopidogrel	-	239	O
-	-	250	O
related	-	251	O
acute	-	259	O
hepatitis	-	265	B
.	-	274	O

The	23846525	276	O
diagnosis	-	280	O
is	-	290	O
strongly	-	293	O
suggested	-	302	O
by	-	312	O
an	-	315	O
accurate	-	318	O
medical	-	327	O
history	-	335	O
and	-	343	O
liver	-	347	O
biopsy	-	353	O
.	-	359	O

Reports	23846525	361	O
about	-	369	O
cases	-	375	O
of	-	381	O
hepatotoxicity	-	384	B
due	-	399	O
to	-	403	O
clopidogrel	-	406	O
are	-	418	O
increasing	-	422	O
in	-	433	O
the	-	436	O
last	-	440	O
few	-	445	O
years	-	449	O
,	-	454	O
after	-	456	O
the	-	462	O
increased	-	466	O
use	-	476	O
of	-	480	O
this	-	483	O
drug	-	488	O
.	-	492	O

In	23846525	494	O
conclusion	-	497	O
,	-	507	O
we	-	509	O
believe	-	512	O
that	-	520	O
physicians	-	525	O
should	-	536	O
carefully	-	543	O
consider	-	553	O
the	-	562	O
risk	-	566	O
of	-	571	O
drug	-	574	O
-	-	578	O
induced	-	579	O
hepatic	-	587	B
injury	-	595	I
when	-	602	O
clopidogrel	-	607	O
is	-	619	O
prescribed	-	622	O
.	-	632	O

Bortezomib	23864035	0	O
and	-	11	O
dexamethasone	-	15	O
as	-	29	O
salvage	-	32	O
therapy	-	40	O
in	-	48	O
patients	-	51	O
with	-	60	O
relapsed	-	65	O
/	-	73	O
refractory	-	74	O
multiple	-	85	B
myeloma	-	94	I
:	-	101	O
analysis	-	103	O
of	-	112	O
long	-	115	O
-	-	119	O
term	-	120	O
clinical	-	125	O
outcomes	-	134	O
.	-	142	O

Bortezomib	23864035	144	O
(	-	155	O
bort	-	156	O
)	-	160	O
-	-	161	O
dexamethasone	-	162	O
(	-	176	O
dex	-	177	O
)	-	180	O
is	-	182	O
an	-	185	O
effective	-	188	O
therapy	-	198	O
for	-	206	O
relapsed	-	210	O
/	-	218	O
refractory	-	219	O
(	-	230	O
R	-	231	O
/	-	232	O
R	-	233	O
)	-	234	O
multiple	-	236	B
myeloma	-	245	I
(	-	253	O
MM	-	254	B
)	-	256	O
.	-	257	O

This	23864035	259	O
retrospective	-	264	O
study	-	278	O
investigated	-	284	O
the	-	297	O
combination	-	301	O
of	-	313	O
bort	-	316	O
(	-	321	O
1	-	322	O
.	-	323	O
3	-	324	O
mg	-	326	O
/	-	328	O
m	-	329	O
(	-	330	O
2	-	331	O
)	-	332	O
on	-	334	O
days	-	337	O
1	-	342	O
,	-	343	O
4	-	345	O
,	-	346	O
8	-	348	O
,	-	349	O
and	-	351	O
11	-	355	O
every	-	358	O
3	-	364	O
weeks	-	366	O
)	-	371	O
and	-	373	O
dex	-	377	O
(	-	381	O
20	-	382	O
mg	-	385	O
on	-	388	O
the	-	391	O
day	-	395	O
of	-	399	O
and	-	402	O
the	-	406	O
day	-	410	O
after	-	414	O
bort	-	420	O
)	-	424	O
as	-	426	O
salvage	-	429	O
treatment	-	437	O
in	-	447	O
85	-	450	O
patients	-	453	O
with	-	462	O
R	-	467	O
/	-	468	O
R	-	469	O
MM	-	471	B
after	-	474	O
prior	-	480	O
autologous	-	486	O
stem	-	497	O
cell	-	502	O
transplantation	-	507	O
or	-	523	O
conventional	-	526	O
chemotherapy	-	539	O
.	-	551	O

The	23864035	553	O
median	-	557	O
number	-	564	O
of	-	571	O
prior	-	574	O
lines	-	580	O
of	-	586	O
therapy	-	589	O
was	-	597	O
2	-	601	O
.	-	602	O

Eighty	23864035	604	O
-	-	610	O
seven	-	611	O
percent	-	617	O
of	-	625	O
the	-	628	O
patients	-	632	O
had	-	641	O
received	-	645	O
immunomodulatory	-	654	O
drugs	-	671	O
included	-	677	O
in	-	686	O
some	-	689	O
line	-	694	O
of	-	699	O
therapy	-	702	O
before	-	710	O
bort	-	717	O
-	-	721	O
dex	-	722	O
.	-	725	O

The	23864035	727	O
median	-	731	O
number	-	738	O
of	-	745	O
bort	-	748	O
-	-	752	O
dex	-	753	O
cycles	-	757	O
was	-	764	O
6	-	768	O
,	-	769	O
up	-	771	O
to	-	774	O
a	-	777	O
maximum	-	779	O
of	-	787	O
12	-	790	O
cycles	-	793	O
.	-	799	O

On	23864035	801	O
an	-	804	O
intention	-	807	O
-	-	816	O
to	-	817	O
-	-	819	O
treat	-	820	O
basis	-	826	O
,	-	831	O
55	-	833	O
%	-	836	O
of	-	838	O
the	-	841	O
patients	-	845	O
achieved	-	854	O
at	-	863	O
least	-	866	O
partial	-	872	O
response	-	880	O
,	-	888	O
including	-	890	O
19	-	900	O
%	-	903	O
CR	-	905	O
and	-	908	O
35	-	912	O
%	-	915	O
achieved	-	917	O
at	-	926	O
least	-	929	O
very	-	935	O
good	-	940	O
partial	-	945	O
response	-	953	O
.	-	961	O

Median	23864035	963	O
durations	-	970	O
of	-	980	O
response	-	983	O
,	-	991	O
time	-	993	O
to	-	998	O
next	-	1001	O
therapy	-	1006	O
and	-	1014	O
treatment	-	1018	O
-	-	1027	O
free	-	1028	O
interval	-	1033	O
were	-	1042	O
8	-	1047	O
,	-	1048	O
11	-	1050	O
.	-	1052	O
2	-	1053	O
,	-	1054	O
and	-	1056	O
5	-	1060	O
.	-	1061	O
1	-	1062	O
months	-	1064	O
,	-	1070	O
respectively	-	1072	O
.	-	1084	O

The	23864035	1086	O
most	-	1090	O
relevant	-	1095	O
adverse	-	1104	O
event	-	1112	O
was	-	1118	O
peripheral	-	1122	B
neuropathy	-	1133	I
,	-	1143	O
which	-	1145	O
occurred	-	1151	O
in	-	1160	O
78	-	1163	O
%	-	1166	O
of	-	1168	O
the	-	1171	O
patients	-	1175	O
(	-	1184	O
grade	-	1185	O
II	-	1191	O
,	-	1193	O
38	-	1195	O
%	-	1198	O
;	-	1199	O
grade	-	1201	O
III	-	1207	O
,	-	1210	O
21	-	1212	O
%	-	1215	O
)	-	1216	O
and	-	1218	O
led	-	1222	O
to	-	1226	O
treatment	-	1229	O
discontinuation	-	1239	O
in	-	1255	O
6	-	1258	O
%	-	1260	O
.	-	1261	O

With	23864035	1263	O
a	-	1268	O
median	-	1270	O
follow	-	1277	O
up	-	1284	O
of	-	1287	O
22	-	1290	O
months	-	1293	O
,	-	1299	O
median	-	1301	O
time	-	1308	O
to	-	1313	O
progression	-	1316	O
,	-	1327	O
progression	-	1329	O
-	-	1340	O
free	-	1341	O
survival	-	1346	O
(	-	1355	O
PFS	-	1356	O
)	-	1359	O
and	-	1361	O
overall	-	1365	O
survival	-	1373	O
(	-	1382	O
OS	-	1383	O
)	-	1385	O
were	-	1387	O
8	-	1392	O
.	-	1393	O
9	-	1394	O
,	-	1395	O
8	-	1397	O
.	-	1398	O
7	-	1399	O
,	-	1400	O
and	-	1402	O
22	-	1406	O
months	-	1409	O
,	-	1415	O
respectively	-	1417	O
.	-	1429	O

Prolonged	23864035	1431	O
PFS	-	1441	O
and	-	1445	O
OS	-	1449	O
were	-	1452	O
observed	-	1457	O
in	-	1466	O
patients	-	1469	O
achieving	-	1478	O
CR	-	1488	O
and	-	1491	O
receiving	-	1495	O
bort	-	1505	O
-	-	1509	O
dex	-	1510	O
a	-	1514	O
single	-	1516	O
line	-	1523	O
of	-	1528	O
prior	-	1531	O
therapy	-	1537	O
.	-	1544	O

Bort	23864035	1546	O
-	-	1550	O
dex	-	1551	O
was	-	1555	O
an	-	1559	O
effective	-	1562	O
salvage	-	1572	O
treatment	-	1580	O
for	-	1590	O
MM	-	1594	B
patients	-	1597	O
,	-	1605	O
particularly	-	1607	O
for	-	1620	O
those	-	1624	O
in	-	1630	O
first	-	1633	O
relapse	-	1639	O
.	-	1646	O

Pubertal	23871786	0	O
exposure	-	9	O
to	-	18	O
Bisphenol	-	21	O
A	-	31	O
increases	-	33	O
anxiety	-	43	B
-	-	50	O
like	-	51	O
behavior	-	56	O
and	-	65	O
decreases	-	69	O
acetylcholinesterase	-	79	O
activity	-	100	O
of	-	109	O
hippocampus	-	112	O
in	-	124	O
adult	-	127	O
male	-	133	O
mice	-	138	O
.	-	142	O

The	23871786	144	O
negative	-	148	O
effects	-	157	O
of	-	165	O
Bisphenol	-	168	O
A	-	178	O
(	-	180	O
BPA	-	181	O
)	-	184	O
on	-	186	O
neurodevelopment	-	189	O
and	-	206	O
behaviors	-	210	O
have	-	220	O
been	-	225	O
well	-	230	O
established	-	235	O
.	-	246	O

Acetylcholinesterase	23871786	248	O
(	-	269	O
AChE	-	270	O
)	-	274	O
is	-	276	O
a	-	279	O
regulatory	-	281	O
enzyme	-	292	O
which	-	299	O
is	-	305	O
involved	-	308	O
in	-	317	O
anxiety	-	320	B
-	-	327	O
like	-	328	O
behavior	-	333	O
.	-	341	O

This	23871786	343	O
study	-	348	O
investigated	-	354	O
behavioral	-	367	O
phenotypes	-	378	O
and	-	389	O
AChE	-	393	O
activity	-	398	O
in	-	407	O
male	-	410	O
mice	-	415	O
following	-	420	O
BPA	-	430	O
exposure	-	434	O
during	-	443	O
puberty	-	450	O
.	-	457	O

On	23871786	459	O
postnatal	-	462	O
day	-	472	O
(	-	476	O
PND	-	477	O
)	-	480	O
35	-	482	O
,	-	484	O
male	-	486	O
mice	-	491	O
were	-	496	O
exposed	-	501	O
to	-	509	O
50	-	512	O
mg	-	514	O
BPA	-	517	O
/	-	520	O
kg	-	521	O
diet	-	524	O
per	-	529	O
day	-	533	O
for	-	537	O
a	-	541	O
period	-	543	O
of	-	550	O
35	-	553	O
days	-	556	O
.	-	560	O

On	23871786	562	O
PND71	-	565	O
,	-	570	O
a	-	572	O
behavioral	-	574	O
assay	-	585	O
was	-	591	O
performed	-	595	O
using	-	605	O
the	-	611	O
elevated	-	615	O
plus	-	624	O
maze	-	629	O
(	-	634	O
EPM	-	635	O
)	-	638	O
and	-	640	O
the	-	644	O
light	-	648	O
/	-	653	O
dark	-	654	O
test	-	659	O
.	-	663	O

In	23871786	665	O
addition	-	668	O
,	-	676	O
AChE	-	678	O
activity	-	683	O
was	-	692	O
measured	-	696	O
in	-	705	O
the	-	708	O
prefrontal	-	712	O
cortex	-	723	O
,	-	729	O
hypothalamus	-	731	O
,	-	743	O
cerebellum	-	745	O
and	-	756	O
hippocampus	-	760	O
.	-	771	O

Results	23871786	773	O
from	-	781	O
our	-	786	O
behavioral	-	790	O
phenotyping	-	801	O
indicated	-	813	O
that	-	823	O
anxiety	-	828	B
-	-	835	O
like	-	836	O
behavior	-	841	O
was	-	850	O
increased	-	854	O
in	-	864	O
mice	-	867	O
exposed	-	872	O
to	-	880	O
BPA	-	883	O
.	-	886	O

AChE	23871786	888	O
activity	-	893	O
was	-	902	O
significantly	-	906	O
decreased	-	920	O
in	-	930	O
the	-	933	O
hippocampus	-	937	O
of	-	949	O
mice	-	952	O
with	-	957	O
BPA	-	962	O
compared	-	966	O
to	-	975	O
control	-	978	O
mice	-	986	O
,	-	990	O
whereas	-	992	O
no	-	1000	O
difference	-	1003	O
was	-	1014	O
found	-	1018	O
in	-	1024	O
the	-	1027	O
prefrontal	-	1031	O
cortex	-	1042	O
,	-	1048	O
hypothalamus	-	1050	O
and	-	1063	O
cerebellum	-	1067	O
.	-	1077	O

Our	23871786	1079	O
findings	-	1083	O
showed	-	1092	O
that	-	1099	O
pubertal	-	1104	O
BPA	-	1113	O
exposure	-	1117	O
increased	-	1126	O
anxiety	-	1136	B
-	-	1143	O
like	-	1144	O
behavior	-	1149	O
,	-	1157	O
which	-	1159	O
may	-	1165	O
be	-	1169	O
associated	-	1172	O
with	-	1183	O
decreased	-	1188	O
AChE	-	1198	O
activity	-	1203	O
of	-	1212	O
the	-	1215	O
hippocampus	-	1219	O
in	-	1231	O
adult	-	1234	O
male	-	1240	O
mice	-	1245	O
.	-	1249	O

Further	23871786	1251	O
studies	-	1259	O
are	-	1267	O
necessary	-	1271	O
to	-	1281	O
investigate	-	1284	O
the	-	1296	O
cholinergic	-	1300	O
signaling	-	1312	O
of	-	1322	O
the	-	1325	O
hippocampus	-	1329	O
in	-	1341	O
PBE	-	1344	O
induced	-	1348	O
anxiety	-	1356	B
-	-	1363	O
like	-	1364	O
behaviors	-	1369	O
.	-	1378	O

Biochemical	23872883	0	O
effects	-	12	O
of	-	20	O
Solidago	-	23	O
virgaurea	-	32	O
extract	-	42	O
on	-	50	O
experimental	-	53	O
cardiotoxicity	-	66	B
.	-	80	O

Cardiovascular	23872883	82	B
diseases	-	97	I
(	-	106	O
CVDs	-	107	B
)	-	111	O
are	-	113	O
the	-	117	O
major	-	121	O
health	-	127	O
problem	-	134	O
of	-	142	O
advanced	-	145	O
as	-	154	O
well	-	157	O
as	-	162	O
developing	-	165	O
countries	-	176	O
of	-	186	O
the	-	189	O
world	-	193	O
.	-	198	O

The	23872883	200	O
aim	-	204	O
of	-	208	O
the	-	211	O
present	-	215	O
study	-	223	O
was	-	229	O
to	-	233	O
investigate	-	236	O
the	-	248	O
protective	-	252	O
effect	-	263	O
of	-	270	O
the	-	273	O
Solidago	-	277	O
virgaurea	-	286	O
extract	-	296	O
on	-	304	O
isoproterenol	-	307	O
-	-	320	O
induced	-	321	O
cardiotoxicity	-	329	B
in	-	344	O
rats	-	347	O
.	-	351	O

The	23872883	353	O
subcutaneous	-	357	O
injection	-	370	O
of	-	380	O
isoproterenol	-	383	O
(	-	397	O
30	-	398	O
mg	-	401	O
/	-	403	O
kg	-	404	O
)	-	406	O
into	-	408	O
rats	-	413	O
twice	-	418	O
at	-	424	O
an	-	427	O
interval	-	430	O
of	-	439	O
24	-	442	O
h	-	445	O
,	-	446	O
for	-	448	O
two	-	452	O
consecutive	-	456	O
days	-	468	O
,	-	472	O
led	-	474	O
to	-	478	O
a	-	481	O
significant	-	483	O
increase	-	495	O
in	-	504	O
serum	-	507	O
lactate	-	513	O
dehydrogenase	-	521	O
,	-	534	O
creatine	-	536	O
phosphokinase	-	545	O
,	-	558	O
alanine	-	560	O
transaminase	-	568	O
,	-	580	O
aspartate	-	582	O
transaminase	-	592	O
,	-	604	O
and	-	606	O
angiotensin	-	610	O
-	-	621	O
converting	-	622	O
enzyme	-	633	O
activities	-	640	O
,	-	650	O
total	-	652	O
cholesterol	-	658	O
,	-	669	O
triglycerides	-	671	O
,	-	684	O
free	-	686	O
serum	-	691	O
fatty	-	697	O
acid	-	703	O
,	-	707	O
cardiac	-	709	O
tissue	-	717	O
malondialdehyde	-	724	O
(	-	740	O
MDA	-	741	O
)	-	744	O
,	-	745	O
and	-	747	O
nitric	-	751	O
oxide	-	758	O
levels	-	764	O
and	-	771	O
a	-	775	O
significant	-	777	O
decrease	-	789	O
in	-	798	O
levels	-	801	O
of	-	808	O
glutathione	-	811	O
and	-	823	O
superoxide	-	827	O
dismutase	-	838	O
in	-	848	O
cardiac	-	851	O
tissue	-	859	O
as	-	866	O
compared	-	869	O
to	-	878	O
the	-	881	O
normal	-	885	O
control	-	892	O
group	-	900	O
(	-	906	O
P	-	907	O
<	-	909	O
0	-	911	O
.	-	912	O
05	-	913	O
)	-	915	O
.	-	916	O

Pretreatment	23872883	918	O
with	-	931	O
S	-	936	O
.	-	937	O
virgaurea	-	939	O
extract	-	949	O
for	-	957	O
5	-	961	O
weeks	-	963	O
at	-	969	O
a	-	972	O
dose	-	974	O
of	-	979	O
250	-	982	O
mg	-	986	O
/	-	988	O
kg	-	989	O
followed	-	992	O
by	-	1001	O
isoproterenol	-	1004	O
injection	-	1018	O
significantly	-	1028	O
prevented	-	1042	O
the	-	1052	O
observed	-	1056	O
alterations	-	1065	O
.	-	1076	O

Captopril	23872883	1078	O
(	-	1088	O
50	-	1089	O
mg	-	1092	O
/	-	1094	O
kg	-	1095	O
/	-	1097	O
day	-	1098	O
,	-	1101	O
given	-	1103	O
orally	-	1109	O
)	-	1115	O
,	-	1116	O
an	-	1118	O
inhibitor	-	1121	O
of	-	1131	O
angiotensin	-	1134	O
-	-	1145	O
converting	-	1146	O
enzyme	-	1157	O
used	-	1164	O
as	-	1169	O
a	-	1172	O
standard	-	1174	O
cardioprotective	-	1183	O
drug	-	1200	O
,	-	1204	O
was	-	1206	O
used	-	1210	O
as	-	1215	O
a	-	1218	O
positive	-	1220	O
control	-	1229	O
in	-	1237	O
this	-	1240	O
study	-	1245	O
.	-	1250	O

The	23872883	1252	O
data	-	1256	O
of	-	1261	O
the	-	1264	O
present	-	1268	O
study	-	1276	O
suggest	-	1282	O
that	-	1290	O
S	-	1295	O
.	-	1296	O
virgaurea	-	1298	O
extract	-	1308	O
exerts	-	1316	O
its	-	1323	O
protective	-	1327	O
effect	-	1338	O
by	-	1345	O
decreasing	-	1348	O
MDA	-	1359	O
level	-	1363	O
and	-	1369	O
increasing	-	1373	O
the	-	1384	O
antioxidant	-	1388	O
status	-	1400	O
in	-	1407	O
isoproterenol	-	1410	O
-	-	1423	O
treated	-	1424	O
rats	-	1432	O
.	-	1436	O

The	23872883	1438	O
study	-	1442	O
emphasizes	-	1448	O
the	-	1459	O
beneficial	-	1463	O
action	-	1474	O
of	-	1481	O
S	-	1484	O
.	-	1485	O
virgaurea	-	1487	O
extract	-	1497	O
as	-	1505	O
a	-	1508	O
cardioprotective	-	1510	O
agent	-	1527	O
.	-	1532	O

""""	23892921	0	O
Real	-	1	O
-	-	5	O
world	-	6	O
""""	-	11	O
data	-	13	O
on	-	18	O
the	-	21	O
efficacy	-	25	O
and	-	34	O
safety	-	38	O
of	-	45	O
lenalidomide	-	48	O
and	-	61	O
dexamethasone	-	65	O
in	-	79	O
patients	-	82	O
with	-	91	O
relapsed	-	96	O
/	-	104	O
refractory	-	105	O
multiple	-	116	B
myeloma	-	125	I
who	-	133	O
were	-	137	O
treated	-	142	O
according	-	150	O
to	-	160	O
the	-	163	O
standard	-	167	O
clinical	-	176	O
practice	-	185	O
:	-	193	O
a	-	195	O
study	-	197	O
of	-	203	O
the	-	206	O
Greek	-	210	O
Myeloma	-	216	B
Study	-	224	O
Group	-	230	O
.	-	235	O

Lenalidomide	23892921	237	O
and	-	250	O
dexamethasone	-	254	O
(	-	268	O
RD	-	269	O
)	-	271	O
is	-	273	O
a	-	276	O
standard	-	278	O
of	-	287	O
care	-	290	O
for	-	295	O
relapsed	-	299	O
/	-	307	O
refractory	-	308	O
multiple	-	319	B
myeloma	-	328	I
(	-	336	O
RRMM	-	337	B
)	-	341	O
,	-	342	O
but	-	344	O
there	-	348	O
is	-	354	O
limited	-	357	O
published	-	365	O
data	-	375	O
on	-	380	O
its	-	383	O
efficacy	-	387	O
and	-	396	O
safety	-	400	O
in	-	407	O
the	-	410	O
""""	-	414	O
real	-	415	O
world	-	420	O
""""	-	425	O
(	-	427	O
RW	-	428	O
)	-	430	O
,	-	431	O
according	-	433	O
to	-	443	O
the	-	446	O
International	-	450	O
Society	-	464	O
of	-	472	O
Pharmacoeconomics	-	475	O
and	-	493	O
Outcomes	-	497	O
Research	-	506	O
definition	-	515	O
.	-	525	O

We	23892921	527	O
studied	-	530	O
212	-	538	O
RRMM	-	542	B
patients	-	547	O
who	-	556	O
received	-	560	O
RD	-	569	O
in	-	572	O
RW	-	575	O
.	-	577	O

Objective	23892921	579	O
response	-	589	O
(	-	598	O
>	-	599	O
PR	-	600	O
(	-	603	O
partial	-	604	O
response	-	612	O
)	-	620	O
)	-	621	O
rate	-	623	O
was	-	628	O
77	-	632	O
.	-	634	O
4	-	635	O
%	-	637	O
(	-	639	O
complete	-	640	O
response	-	649	O
(	-	658	O
CR	-	659	O
)	-	661	O
,	-	662	O
20	-	664	O
.	-	666	O
2	-	667	O
%	-	669	O
)	-	670	O
.	-	671	O

Median	23892921	673	O
time	-	680	O
to	-	685	O
first	-	688	O
and	-	694	O
best	-	698	O
response	-	703	O
was	-	712	O
2	-	716	O
and	-	718	O
5	-	722	O
months	-	724	O
,	-	730	O
respectively	-	732	O
.	-	744	O

Median	23892921	746	O
time	-	753	O
to	-	758	O
CR	-	761	O
when	-	764	O
RD	-	769	O
was	-	772	O
given	-	776	O
as	-	782	O
2nd	-	785	O
or	-	789	O
>	-	792	O
2	-	793	O
(	-	794	O
nd	-	795	O
)	-	797	O
-	-	798	O
line	-	799	O
treatment	-	804	O
at	-	814	O
4	-	817	O
and	-	819	O
11	-	823	O
months	-	826	O
,	-	832	O
respectively	-	834	O
.	-	846	O

Quality	23892921	848	O
of	-	856	O
response	-	859	O
was	-	868	O
independent	-	872	O
of	-	884	O
previous	-	887	O
lines	-	896	O
of	-	902	O
therapies	-	905	O
or	-	915	O
previous	-	918	O
exposure	-	927	O
to	-	936	O
thalidomide	-	939	O
or	-	951	O
bortezomib	-	954	O
.	-	964	O

Median	23892921	966	O
duration	-	973	O
of	-	982	O
response	-	985	O
was	-	994	O
34	-	998	O
.	-	1000	O
4	-	1001	O
months	-	1003	O
,	-	1009	O
and	-	1011	O
it	-	1015	O
was	-	1018	O
higher	-	1022	O
in	-	1029	O
patients	-	1032	O
who	-	1041	O
received	-	1045	O
RD	-	1054	O
until	-	1057	O
progression	-	1063	O
(	-	1075	O
not	-	1076	O
reached	-	1080	O
versus	-	1088	O
19	-	1095	O
months	-	1098	O
,	-	1104	O
p	-	1106	O
<	-	1108	O
0	-	1110	O
.	-	1111	O
001	-	1112	O
)	-	1115	O
.	-	1116	O

Improvement	23892921	1118	O
of	-	1130	O
humoral	-	1133	O
immunity	-	1141	O
occurred	-	1150	O
in	-	1159	O
60	-	1162	O
%	-	1165	O
of	-	1167	O
responders	-	1170	O
(	-	1181	O
p	-	1182	O
<	-	1184	O
0	-	1186	O
.	-	1187	O
001	-	1188	O
)	-	1191	O
and	-	1193	O
in	-	1197	O
the	-	1200	O
majority	-	1204	O
of	-	1213	O
patients	-	1216	O
who	-	1225	O
achieved	-	1229	O
stable	-	1238	O
disease	-	1245	O
.	-	1252	O

Adverse	23892921	1254	O
events	-	1262	O
were	-	1269	O
reported	-	1274	O
in	-	1283	O
68	-	1286	O
.	-	1288	O
9	-	1289	O
%	-	1291	O
of	-	1293	O
patients	-	1296	O
(	-	1305	O
myelosuppression	-	1306	B
in	-	1323	O
49	-	1326	O
.	-	1328	O
4	-	1329	O
%	-	1331	O
)	-	1332	O
and	-	1334	O
12	-	1338	O
.	-	1340	O
7	-	1341	O
%	-	1343	O
of	-	1345	O
patients	-	1348	O
needed	-	1357	O
hospitalization	-	1364	O
.	-	1379	O

Peripheral	23892921	1381	B
neuropathy	-	1392	I
was	-	1403	O
observed	-	1407	O
only	-	1416	O
in	-	1421	O
2	-	1424	O
.	-	1425	O
5	-	1426	O
%	-	1428	O
of	-	1430	O
patients	-	1433	O
and	-	1442	O
deep	-	1446	B
vein	-	1451	I
thrombosis	-	1456	I
in	-	1467	O
5	-	1470	O
.	-	1471	O
7	-	1472	O
%	-	1474	O
.	-	1475	O

Dose	23892921	1477	O
reductions	-	1482	O
were	-	1493	O
needed	-	1498	O
in	-	1505	O
31	-	1508	O
%	-	1511	O
of	-	1513	O
patients	-	1516	O
and	-	1525	O
permanent	-	1529	O
discontinuation	-	1539	O
in	-	1555	O
38	-	1558	O
.	-	1560	O
9	-	1561	O
%	-	1563	O
.	-	1564	O

Median	23892921	1566	O
time	-	1573	O
to	-	1578	O
treatment	-	1581	O
discontinuation	-	1591	O
was	-	1607	O
16	-	1611	O
.	-	1613	O
8	-	1614	O
months	-	1616	O
.	-	1622	O

Performance	23892921	1624	O
status	-	1636	O
(	-	1643	O
PS	-	1644	O
)	-	1646	O
and	-	1648	O
initial	-	1652	O
lenalidomide	-	1660	O
dose	-	1673	O
predicted	-	1678	O
for	-	1688	O
treatment	-	1692	O
discontinuation	-	1702	O
.	-	1717	O

Extra	23892921	1719	O
-	-	1724	O
medullary	-	1725	O
relapses	-	1735	O
occurred	-	1744	O
in	-	1753	O
3	-	1756	O
.	-	1757	O
8	-	1758	O
%	-	1760	O
of	-	1762	O
patients	-	1765	O
.	-	1773	O

Our	23892921	1775	O
study	-	1779	O
confirms	-	1785	O
that	-	1794	O
RD	-	1799	O
is	-	1802	O
effective	-	1805	O
and	-	1815	O
safe	-	1819	O
in	-	1824	O
RRMM	-	1827	B
in	-	1832	O
the	-	1835	O
RW	-	1839	O
;	-	1841	O
it	-	1843	O
produces	-	1846	O
durable	-	1855	O
responses	-	1863	O
especially	-	1873	O
in	-	1884	O
patients	-	1887	O
who	-	1896	O
continue	-	1900	O
on	-	1909	O
treatment	-	1912	O
till	-	1922	O
progression	-	1927	O
and	-	1939	O
improves	-	1943	O
humoral	-	1952	O
immunity	-	1960	O
even	-	1969	O
in	-	1974	O
patients	-	1977	O
with	-	1986	O
stable	-	1991	O
disease	-	1998	O
.	-	2005	O

The	23949582	0	O
cytogenetic	-	4	O
action	-	16	O
of	-	23	O
ifosfamide	-	26	O
,	-	36	O
mesna	-	38	O
,	-	43	O
and	-	45	O
their	-	49	O
combination	-	55	O
on	-	67	O
peripheral	-	70	O
rabbit	-	81	O
lymphocytes	-	88	O
:	-	99	O
an	-	101	O
in	-	104	O
vivo	-	107	O
/	-	111	O
in	-	112	O
vitro	-	115	O
cytogenetic	-	121	O
study	-	133	O
.	-	138	O

Ifosfamide	23949582	140	O
(	-	151	O
IFO	-	152	O
)	-	155	O
is	-	157	O
an	-	160	O
alkylating	-	163	O
nitrogen	-	174	O
mustard	-	183	O
,	-	190	O
administrated	-	192	O
as	-	206	O
an	-	209	O
antineoplasmic	-	212	O
agent	-	227	O
.	-	232	O

It	23949582	234	O
is	-	237	O
characterized	-	240	O
by	-	254	O
its	-	257	O
intense	-	261	O
urotoxic	-	269	O
action	-	278	O
,	-	284	O
leading	-	286	O
to	-	294	O
hemorrhagic	-	297	B
cystitis	-	309	I
.	-	317	O

This	23949582	319	O
side	-	324	O
effect	-	329	O
of	-	336	O
IFO	-	339	O
raises	-	343	O
the	-	350	O
requirement	-	354	O
for	-	366	O
the	-	370	O
co	-	374	O
-	-	376	O
administration	-	377	O
with	-	392	O
sodium	-	397	O
2	-	404	O
-	-	405	O
sulfanylethanesulfonate	-	406	O
(	-	430	O
Mesna	-	431	O
)	-	436	O
aiming	-	438	O
to	-	445	O
avoid	-	448	O
or	-	454	O
minimize	-	457	O
this	-	466	O
effect	-	471	O
.	-	477	O

IFO	23949582	479	O
and	-	483	O
Mesna	-	487	O
were	-	493	O
administrated	-	498	O
separately	-	512	O
on	-	523	O
rabbit	-	526	O
's	-	532	O
lymphocytes	-	535	O
in	-	547	O
vivo	-	550	O
,	-	554	O
which	-	556	O
were	-	562	O
later	-	567	O
developed	-	573	O
in	-	583	O
vitro	-	586	O
.	-	591	O

Cytogenetic	23949582	593	O
markers	-	605	O
for	-	613	O
sister	-	617	O
chromatid	-	624	O
exchanges	-	634	O
(	-	644	O
SCEs	-	645	O
)	-	649	O
,	-	650	O
proliferation	-	652	O
rate	-	666	O
index	-	671	O
(	-	677	O
PRI	-	678	O
)	-	681	O
and	-	683	O
Mitotic	-	687	O
Index	-	695	O
were	-	701	O
recorded	-	706	O
.	-	714	O

Mesna	23949582	716	O
's	-	721	O
action	-	724	O
,	-	730	O
in	-	732	O
conjunction	-	735	O
with	-	747	O
IFO	-	752	O
reduces	-	756	O
the	-	764	O
frequency	-	768	O
of	-	778	O
SCEs	-	781	O
,	-	785	O
in	-	787	O
comparison	-	790	O
with	-	801	O
the	-	806	O
SCEs	-	810	O
recordings	-	815	O
obtained	-	826	O
when	-	835	O
IFO	-	840	O
is	-	844	O
administered	-	847	O
alone	-	860	O
.	-	865	O

In	23949582	867	O
addition	-	870	O
to	-	879	O
this	-	882	O
,	-	886	O
when	-	888	O
high	-	893	O
concentrations	-	898	O
of	-	913	O
Mesna	-	916	O
were	-	922	O
administered	-	927	O
alone	-	940	O
significant	-	946	O
reductions	-	958	O
of	-	969	O
the	-	972	O
PRI	-	976	O
were	-	980	O
noted	-	985	O
,	-	990	O
than	-	992	O
with	-	997	O
IFO	-	1002	O
acting	-	1006	O
at	-	1013	O
the	-	1016	O
same	-	1020	O
concentration	-	1025	O
on	-	1039	O
the	-	1042	O
lymphocytes	-	1046	O
.	-	1057	O

Mesna	23949582	1059	O
significantly	-	1065	O
reduces	-	1079	O
IFO	-	1087	O
's	-	1090	O
genotoxicity	-	1093	B
,	-	1105	O
while	-	1107	O
when	-	1113	O
administered	-	1118	O
in	-	1131	O
high	-	1134	O
concentrations	-	1139	O
it	-	1154	O
acts	-	1157	O
in	-	1162	O
an	-	1165	O
inhibitory	-	1168	O
fashion	-	1179	O
on	-	1187	O
the	-	1190	O
cytostatic	-	1194	O
action	-	1205	O
of	-	1212	O
the	-	1215	O
drug	-	1219	O
.	-	1223	O

Risk	23952588	0	O
factors	-	5	O
and	-	13	O
predictors	-	17	O
of	-	28	O
levodopa	-	31	O
-	-	39	O
induced	-	40	O
dyskinesia	-	48	B
among	-	59	O
multiethnic	-	65	O
Malaysians	-	77	O
with	-	88	O
Parkinson	-	93	B
's	-	102	I
disease	-	105	I
.	-	112	O

Chronic	23952588	114	O
pulsatile	-	122	O
levodopa	-	132	O
therapy	-	141	O
for	-	149	O
Parkinson	-	153	B
's	-	162	I
disease	-	165	I
(	-	173	O
PD	-	174	B
)	-	176	O
leads	-	178	O
to	-	184	O
the	-	187	O
development	-	191	O
of	-	203	O
motor	-	206	O
fluctuations	-	212	O
and	-	225	O
dyskinesia	-	229	B
.	-	239	O

We	23952588	241	O
studied	-	244	O
the	-	252	O
prevalence	-	256	O
and	-	267	O
predictors	-	271	O
of	-	282	O
levodopa	-	285	O
-	-	293	O
induced	-	294	O
dyskinesia	-	302	B
among	-	313	O
multiethnic	-	319	O
Malaysian	-	331	O
patients	-	341	O
with	-	350	O
PD	-	355	B
.	-	357	O

METHODS	23952588	359	O
:	-	366	O

This	23952588	368	O
is	-	373	O
a	-	376	O
cross	-	378	O
-	-	383	O
sectional	-	384	O
study	-	394	O
involving	-	400	O
95	-	410	O
patients	-	413	O
with	-	422	O
PD	-	427	B
on	-	430	O
uninterrupted	-	433	O
levodopa	-	447	O
therapy	-	456	O
for	-	464	O
at	-	468	O
least	-	471	O
6	-	477	O
months	-	479	O
.	-	485	O

The	23952588	487	O
instrument	-	491	O
used	-	502	O
was	-	507	O
the	-	511	O
UPDRS	-	515	O
questionnaires	-	521	O
.	-	535	O

The	23952588	537	O
predictors	-	541	O
of	-	552	O
dyskinesia	-	555	B
were	-	566	O
determined	-	571	O
using	-	582	O
multivariate	-	588	O
logistic	-	601	O
regression	-	610	O
analysis	-	621	O
.	-	629	O

RESULTS	23952588	631	O
:	-	638	O

The	23952588	640	O
mean	-	644	O
age	-	649	O
was	-	653	O
65	-	657	O
.	-	659	O
6	-	660	O
+	-	662	O
8	-	664	O
.	-	665	O
5	-	666	O
years	-	668	O
.	-	673	O

The	23952588	675	O
mean	-	679	O
onset	-	684	O
age	-	690	O
was	-	694	O
58	-	698	O
.	-	700	O
5	-	701	O
+	-	703	O
9	-	705	O
.	-	706	O
8	-	707	O
years	-	709	O
.	-	714	O

The	23952588	716	O
median	-	720	O
disease	-	727	O
duration	-	735	O
was	-	744	O
6	-	748	O
(	-	750	O
7	-	751	O
)	-	752	O
years	-	754	O
.	-	759	O

Dyskinesia	23952588	761	B
was	-	772	O
present	-	776	O
in	-	784	O
44	-	787	O
%	-	789	O
(	-	791	O
n	-	792	O
=	-	794	O
42	-	796	O
)	-	798	O
with	-	800	O
median	-	805	O
levodopa	-	812	O
therapy	-	821	O
of	-	829	O
3	-	832	O
years	-	834	O
.	-	839	O

There	23952588	841	O
were	-	847	O
64	-	852	O
.	-	854	O
3	-	855	O
%	-	856	O
Chinese	-	858	O
,	-	865	O
31	-	867	O
%	-	869	O
Malays	-	871	O
,	-	877	O
and	-	879	O
3	-	883	O
.	-	884	O
7	-	885	O
%	-	886	O
Indians	-	888	O
and	-	896	O
other	-	900	O
ethnic	-	906	O
groups	-	913	O
.	-	919	O

Eighty	23952588	921	O
-	-	927	O
one	-	928	O
percent	-	932	O
of	-	940	O
patients	-	943	O
with	-	952	O
dyskinesia	-	957	B
had	-	968	O
clinical	-	972	O
fluctuations	-	981	O
.	-	993	O

Patients	23952588	995	O
with	-	1004	O
dyskinesia	-	1009	B
had	-	1020	O
lower	-	1024	O
onset	-	1030	O
age	-	1036	O
(	-	1040	O
p	-	1042	O
<	-	1044	O
0	-	1046	O
.	-	1047	O
001	-	1048	O
)	-	1051	O
,	-	1052	O
longer	-	1054	O
duration	-	1061	O
of	-	1070	O
levodopa	-	1073	O
therapy	-	1082	O
(	-	1090	O
p	-	1092	O
<	-	1094	O
0	-	1096	O
.	-	1097	O
001	-	1098	O
)	-	1101	O
,	-	1102	O
longer	-	1104	O
disease	-	1111	O
duration	-	1119	O
(	-	1128	O
p	-	1130	O
<	-	1132	O
0	-	1134	O
.	-	1135	O
001	-	1136	O
)	-	1139	O
,	-	1140	O
higher	-	1142	O
total	-	1149	O
daily	-	1155	O
levodopa	-	1161	O
dose	-	1170	O
(	-	1175	O
p	-	1177	O
<	-	1179	O
0	-	1181	O
.	-	1182	O
001	-	1183	O
)	-	1186	O
,	-	1187	O
and	-	1189	O
higher	-	1193	O
total	-	1200	O
UPDRS	-	1206	O
scores	-	1212	O
(	-	1219	O
p	-	1221	O
=	-	1223	O
0	-	1225	O
.	-	1226	O
005	-	1227	O
)	-	1230	O
than	-	1232	O
patients	-	1237	O
without	-	1246	O
dyskinesia	-	1254	B
.	-	1264	O

The	23952588	1266	O
three	-	1270	O
significant	-	1276	O
predictors	-	1288	O
of	-	1299	O
dyskinesia	-	1302	B
were	-	1313	O
duration	-	1318	O
of	-	1327	O
levodopa	-	1330	O
therapy	-	1339	O
,	-	1346	O
onset	-	1348	O
age	-	1354	O
,	-	1357	O
and	-	1359	O
total	-	1363	O
daily	-	1369	O
levodopa	-	1375	O
dose	-	1384	O
.	-	1388	O

CONCLUSIONS	23952588	1390	O
:	-	1401	O

The	23952588	1403	O
prevalence	-	1407	O
of	-	1418	O
levodopa	-	1421	O
-	-	1429	O
induced	-	1430	O
dyskinesia	-	1438	B
in	-	1449	O
our	-	1452	O
patients	-	1456	O
was	-	1465	O
44	-	1469	O
%	-	1471	O
.	-	1472	O

The	23952588	1474	O
most	-	1478	O
significant	-	1483	O
predictors	-	1495	O
were	-	1506	O
duration	-	1511	O
of	-	1520	O
levodopa	-	1523	O
therapy	-	1532	O
,	-	1539	O
total	-	1541	O
daily	-	1547	O
levodopa	-	1553	O
dose	-	1562	O
,	-	1566	O
and	-	1568	O
onset	-	1572	O
age	-	1578	O
.	-	1581	O

An	24040781	0	O
unexpected	-	3	O
diagnosis	-	14	O
in	-	24	O
a	-	27	O
renal	-	29	O
-	-	34	O
transplant	-	35	O
patient	-	46	O
with	-	54	O
proteinuria	-	59	B
treated	-	71	O
with	-	79	O
everolimus	-	84	O
:	-	94	O
AL	-	96	B
amyloidosis	-	99	B
.	-	110	O

Proteinuria	24040781	112	B
is	-	124	O
an	-	127	O
expected	-	130	O
complication	-	139	O
in	-	152	O
transplant	-	155	O
patients	-	166	O
treated	-	175	O
with	-	183	O
mammalian	-	188	O
target	-	198	O
of	-	205	O
rapamycin	-	208	O
inhibitors	-	218	O
(	-	229	O
mTOR	-	230	O
-	-	234	O
i	-	235	O
)	-	236	O
.	-	237	O

However	24040781	239	O
,	-	246	O
clinical	-	248	O
suspicion	-	257	O
should	-	267	O
always	-	274	O
be	-	281	O
supported	-	284	O
by	-	294	O
histological	-	297	O
evidence	-	310	O
in	-	319	O
order	-	322	O
to	-	328	O
investigate	-	331	O
potential	-	343	O
alternate	-	353	O
diagnoses	-	363	O
such	-	373	O
as	-	378	O
acute	-	381	O
or	-	387	O
chronic	-	390	O
rejection	-	398	O
,	-	407	O
interstitial	-	409	O
fibrosis	-	422	B
and	-	431	O
tubular	-	435	O
atrophy	-	443	B
,	-	450	O
or	-	452	O
recurrent	-	455	O
or	-	465	O
de	-	468	O
novo	-	471	O
glomerulopathy	-	476	B
.	-	490	O

In	24040781	492	O
this	-	495	O
case	-	500	O
we	-	505	O
report	-	508	O
the	-	515	O
unexpected	-	519	O
diagnosis	-	530	O
of	-	540	O
amyloidosis	-	543	B
in	-	555	O
a	-	558	O
renal	-	560	O
-	-	565	O
transplant	-	566	O
patient	-	577	O
with	-	585	O
pre	-	590	O
-	-	593	O
transplant	-	594	O
monoclonal	-	605	O
gammapathy	-	616	O
of	-	627	O
undetermined	-	630	O
significance	-	643	O
who	-	656	O
developed	-	660	O
proteinuria	-	670	B
after	-	682	O
conversion	-	688	O
from	-	699	O
tacrolimus	-	704	O
to	-	715	O
everolimus	-	718	O
.	-	728	O

An	24067251	0	O
investigation	-	3	O
of	-	17	O
the	-	20	O
pattern	-	24	O
of	-	32	O
kidney	-	35	B
injury	-	42	I
in	-	49	O
HIV	-	52	O
-	-	55	O
positive	-	56	O
persons	-	65	O
exposed	-	73	O
to	-	81	O
tenofovir	-	84	O
disoproxil	-	94	O
fumarate	-	105	O
:	-	113	O
an	-	115	O
examination	-	118	O
of	-	130	O
a	-	133	O
large	-	135	O
population	-	141	O
database	-	152	O
(	-	161	O
MHRA	-	162	O
database	-	167	O
)	-	175	O
.	-	176	O

The	24067251	178	O
potential	-	182	O
for	-	192	O
tenofovir	-	196	O
to	-	206	O
cause	-	209	O
a	-	215	O
range	-	217	O
of	-	223	O
kidney	-	226	O
syndromes	-	233	O
has	-	243	O
been	-	247	O
established	-	252	O
from	-	264	O
mechanistic	-	269	O
and	-	281	O
randomised	-	285	O
clinical	-	296	O
trials	-	305	O
.	-	311	O

However	24067251	313	O
,	-	320	O
the	-	322	O
exact	-	326	O
pattern	-	332	O
of	-	340	O
kidney	-	343	O
involvement	-	350	O
is	-	362	O
still	-	365	O
uncertain	-	371	O
.	-	380	O

We	24067251	382	O
undertook	-	385	O
a	-	395	O
descriptive	-	397	O
analysis	-	409	O
of	-	418	O
Yellow	-	421	O
Card	-	428	O
records	-	433	O
of	-	441	O
407	-	444	O
HIV	-	448	O
-	-	451	O
positive	-	452	O
persons	-	461	O
taking	-	469	O
tenofovir	-	476	O
disoproxil	-	486	O
fumarate	-	497	O
(	-	506	O
TDF	-	507	O
)	-	510	O
as	-	512	O
part	-	515	O
of	-	520	O
their	-	523	O
antiretroviral	-	529	O
therapy	-	544	O
regimen	-	552	O
and	-	560	O
submitted	-	564	O
to	-	574	O
the	-	577	O
Medicines	-	581	O
and	-	591	O
Healthcare	-	595	O
Products	-	606	O
Regulatory	-	615	O
Agency	-	626	O
(	-	633	O
MHRA	-	634	O
)	-	638	O
with	-	640	O
suspected	-	645	O
kidney	-	655	O
adverse	-	662	O
effects	-	670	O
.	-	677	O

Reports	24067251	679	O
that	-	687	O
satisfy	-	692	O
defined	-	700	O
criteria	-	708	O
were	-	717	O
classified	-	722	O
as	-	733	O
acute	-	736	B
kidney	-	742	I
injury	-	749	I
,	-	755	O
kidney	-	757	B
tubular	-	764	I
dysfunction	-	772	I
and	-	784	O
Fanconi	-	788	B
syndrome	-	796	I
.	-	804	O

Of	24067251	806	O
the	-	809	O
407	-	813	O
Yellow	-	817	O
Card	-	824	O
records	-	829	O
analysed	-	837	O
,	-	845	O
106	-	847	O
satisfied	-	851	O
criteria	-	861	O
for	-	870	O
TDF	-	874	O
-	-	877	O
related	-	878	O
kidney	-	886	B
disease	-	893	I
,	-	900	O
of	-	902	O
which	-	905	O
53	-	911	O
(	-	914	O
50	-	915	O
%	-	917	O
)	-	918	O
had	-	920	O
features	-	924	O
of	-	933	O
kidney	-	936	B
tubular	-	943	I
dysfunction	-	951	I
,	-	962	O
35	-	964	O
(	-	967	O
33	-	968	O
%	-	970	O
)	-	971	O
were	-	973	O
found	-	978	O
to	-	984	O
have	-	987	O
features	-	992	O
of	-	1001	O
glomerular	-	1004	B
dysfunction	-	1015	I
and	-	1027	O
18	-	1031	O
(	-	1034	O
17	-	1035	O
%	-	1037	O
)	-	1038	O
had	-	1040	O
Fanconi	-	1044	B
syndrome	-	1052	I
.	-	1060	O

The	24067251	1062	O
median	-	1066	O
TDF	-	1073	O
exposure	-	1077	O
was	-	1086	O
316	-	1090	O
days	-	1094	O
(	-	1099	O
interquartile	-	1100	O
range	-	1114	O
120	-	1120	O
-	-	1123	O
740	-	1124	O
)	-	1127	O
.	-	1128	O

The	24067251	1130	O
incidence	-	1134	O
of	-	1144	O
hospitalisation	-	1147	O
for	-	1163	O
TDF	-	1167	O
kidney	-	1171	O
adverse	-	1178	O
effects	-	1186	O
was	-	1194	O
high	-	1198	O
,	-	1202	O
particularly	-	1204	O
amongst	-	1217	O
patients	-	1225	O
with	-	1234	O
features	-	1239	O
of	-	1248	O
Fanconi	-	1251	B
syndrome	-	1259	I
.	-	1267	O

The	24067251	1269	O
pattern	-	1273	O
of	-	1281	O
kidney	-	1284	O
syndromes	-	1291	O
in	-	1301	O
this	-	1304	O
population	-	1309	O
series	-	1320	O
mirrors	-	1327	O
that	-	1335	O
reported	-	1340	O
in	-	1349	O
randomised	-	1352	O
clinical	-	1363	O
trials	-	1372	O
.	-	1378	O

Cessation	24067251	1380	O
of	-	1390	O
TDF	-	1393	O
was	-	1397	O
associated	-	1401	O
with	-	1412	O
complete	-	1417	O
restoration	-	1426	O
of	-	1438	O
kidney	-	1441	O
function	-	1448	O
in	-	1457	O
up	-	1460	O
half	-	1463	O
of	-	1468	O
the	-	1471	O
patients	-	1475	O
in	-	1484	O
this	-	1487	O
report	-	1492	O
.	-	1498	O

Incidence	24068571	0	O
of	-	10	O
postoperative	-	13	B
delirium	-	27	I
is	-	36	O
high	-	39	O
even	-	44	O
in	-	49	O
a	-	52	O
population	-	54	O
without	-	65	O
known	-	73	O
risk	-	79	O
factors	-	84	O
.	-	91	O

PURPOSE	24068571	93	O
:	-	100	O

Postoperative	24068571	102	B
delirium	-	116	I
is	-	125	O
a	-	128	O
recognized	-	130	O
complication	-	141	O
in	-	154	O
populations	-	157	O
at	-	169	O
risk	-	172	O
.	-	176	O

The	24068571	178	O
aim	-	182	O
of	-	186	O
this	-	189	O
study	-	194	O
is	-	200	O
to	-	203	O
assess	-	206	O
the	-	213	O
prevalence	-	217	O
of	-	228	O
early	-	231	O
postoperative	-	237	B
delirium	-	251	I
in	-	260	O
a	-	263	O
population	-	265	O
without	-	276	O
known	-	284	O
risk	-	290	O
factors	-	295	O
admitted	-	303	O
to	-	312	O
the	-	315	O
ICU	-	319	O
for	-	323	O
postoperative	-	327	O
monitoring	-	341	O
after	-	352	O
elective	-	358	O
major	-	367	O
surgery	-	373	O
.	-	380	O

The	24068571	382	O
secondary	-	386	O
outcome	-	396	O
investigated	-	404	O
is	-	417	O
to	-	420	O
identify	-	423	O
eventual	-	432	O
independent	-	441	O
risk	-	453	O
factors	-	458	O
among	-	466	O
demographic	-	472	O
data	-	484	O
and	-	489	O
anesthetic	-	493	O
drugs	-	504	O
used	-	510	O
.	-	514	O

METHODS	24068571	516	O
:	-	523	O

An	24068571	525	O
observational	-	528	O
,	-	541	O
prospective	-	543	O
study	-	555	O
was	-	561	O
conducted	-	565	O
on	-	575	O
a	-	578	O
consecutive	-	580	O
cohort	-	592	O
of	-	599	O
patients	-	602	O
admitted	-	611	O
to	-	620	O
our	-	623	O
ICU	-	627	O
within	-	631	O
and	-	638	O
for	-	642	O
at	-	646	O
least	-	649	O
24	-	655	O
h	-	658	O
after	-	660	O
major	-	666	O
surgical	-	672	O
procedures	-	681	O
.	-	691	O

Exclusion	24068571	693	O
criteria	-	703	O
were	-	712	O
any	-	717	O
preexisting	-	721	O
predisposing	-	733	O
factor	-	746	O
for	-	753	O
delirium	-	757	B
or	-	766	O
other	-	769	O
potentially	-	775	O
confounding	-	787	O
neurological	-	799	B
dysfunctions	-	812	I
.	-	824	O

Patients	24068571	826	O
were	-	835	O
assessed	-	840	O
daily	-	849	O
using	-	855	O
the	-	861	O
confusion	-	865	B
assessment	-	875	O
method	-	886	O
for	-	893	O
the	-	897	O
ICU	-	901	O
scale	-	905	O
for	-	911	O
3	-	915	O
days	-	917	O
after	-	922	O
the	-	928	O
surgical	-	932	O
procedure	-	941	O
.	-	950	O

Early	24068571	952	O
postoperative	-	958	B
delirium	-	972	I
incidence	-	981	O
risk	-	991	O
factors	-	996	O
were	-	1004	O
then	-	1009	O
assessed	-	1014	O
through	-	1023	O
three	-	1031	O
different	-	1037	O
multiple	-	1047	O
regression	-	1056	O
models	-	1067	O
.	-	1073	O

RESULTS	24068571	1075	O
:	-	1082	O

According	24068571	1084	O
to	-	1094	O
the	-	1097	O
confusion	-	1101	O
assessment	-	1111	O
method	-	1122	O
for	-	1129	O
the	-	1133	O
ICU	-	1137	O
scale	-	1141	O
,	-	1146	O
28	-	1148	O
%	-	1151	O
of	-	1153	O
patients	-	1156	O
were	-	1165	O
diagnosed	-	1170	O
with	-	1180	O
early	-	1185	O
postoperative	-	1191	B
delirium	-	1205	I
.	-	1213	O

The	24068571	1215	O
use	-	1219	O
of	-	1223	O
thiopentone	-	1226	O
was	-	1238	O
significantly	-	1242	O
associated	-	1256	O
with	-	1267	O
an	-	1272	O
eight	-	1275	O
-	-	1280	O
fold	-	1281	O
-	-	1285	O
higher	-	1286	O
risk	-	1293	O
for	-	1298	O
delirium	-	1302	B
compared	-	1311	O
to	-	1320	O
propofol	-	1323	O
(	-	1332	O
57	-	1333	O
.	-	1335	O
1	-	1336	O
%	-	1337	O
vs	-	1339	O
.	-	1341	O
7	-	1343	O
.	-	1344	O
1	-	1345	O
%	-	1346	O
,	-	1347	O
RR	-	1349	O
=	-	1352	O
8	-	1354	O
.	-	1355	O
0	-	1356	O
,	-	1357	O
X2	-	1359	O
=	-	1362	O
4	-	1364	O
.	-	1365	O
256	-	1366	O
;	-	1369	O
df	-	1371	O
=	-	1374	O
1	-	1376	O
;	-	1377	O
0	-	1379	O
.	-	1380	O
05	-	1381	O
<	-	1384	O
p	-	1386	O
<	-	1388	O
0	-	1390	O
.	-	1391	O
02	-	1392	O
)	-	1394	O
.	-	1395	O

CONCLUSION	24068571	1397	O
:	-	1407	O

In	24068571	1409	O
this	-	1412	O
study	-	1417	O
early	-	1423	O
postoperative	-	1429	B
delirium	-	1443	I
was	-	1452	O
found	-	1456	O
to	-	1462	O
be	-	1465	O
a	-	1468	O
very	-	1470	O
common	-	1475	O
complication	-	1482	O
after	-	1495	O
major	-	1501	O
surgery	-	1507	O
,	-	1514	O
even	-	1516	O
in	-	1521	O
a	-	1524	O
population	-	1526	O
without	-	1537	O
known	-	1545	O
risk	-	1551	O
factors	-	1556	O
.	-	1563	O

Thiopentone	24068571	1565	O
was	-	1577	O
independently	-	1581	O
associated	-	1595	O
with	-	1606	O
an	-	1611	O
increase	-	1614	O
in	-	1623	O
its	-	1626	O
relative	-	1630	O
risk	-	1639	O
.	-	1643	O

A	24072398	0	O
single	-	2	O
neurotoxic	-	9	B
dose	-	20	O
of	-	25	O
methamphetamine	-	28	O
induces	-	44	O
a	-	52	O
long	-	54	O
-	-	58	O
lasting	-	59	O
depressive	-	67	B
-	-	77	O
like	-	78	O
behaviour	-	83	O
in	-	93	O
mice	-	96	O
.	-	100	O

Methamphetamine	24072398	102	O
(	-	118	O
METH	-	119	O
)	-	123	O
triggers	-	125	O
a	-	134	O
disruption	-	136	O
of	-	147	O
the	-	150	O
monoaminergic	-	154	O
system	-	168	O
and	-	175	O
METH	-	179	O
abuse	-	184	O
leads	-	190	O
to	-	196	O
negative	-	199	O
emotional	-	208	O
states	-	218	O
including	-	225	O
depressive	-	235	B
symptoms	-	246	I
during	-	255	O
drug	-	262	O
withdrawal	-	267	O
.	-	277	O

However	24072398	279	O
,	-	286	O
it	-	288	O
is	-	291	O
currently	-	294	O
unknown	-	304	O
if	-	312	O
the	-	315	O
acute	-	319	O
toxic	-	325	O
dosage	-	331	O
of	-	338	O
METH	-	341	O
also	-	346	O
causes	-	351	O
a	-	358	O
long	-	360	O
-	-	364	O
lasting	-	365	O
depressive	-	373	B
phenotype	-	384	O
and	-	394	O
persistent	-	398	O
monoaminergic	-	409	O
deficits	-	423	O
.	-	431	O

Thus	24072398	433	O
,	-	437	O
we	-	439	O
now	-	442	O
assessed	-	446	O
the	-	455	O
depressive	-	459	B
-	-	469	O
like	-	470	O
behaviour	-	475	O
in	-	485	O
mice	-	488	O
at	-	493	O
early	-	496	O
and	-	502	O
long	-	506	O
-	-	510	O
term	-	511	O
periods	-	516	O
following	-	524	O
a	-	534	O
single	-	536	O
high	-	543	O
METH	-	548	O
dose	-	553	O
(	-	558	O
30	-	559	O
mg	-	562	O
/	-	564	O
kg	-	565	O
,	-	567	O
i	-	569	O
.	-	570	O
p	-	571	O
.	-	572	O
)	-	573	O
.	-	574	O

METH	24072398	576	O
did	-	581	O
not	-	585	O
alter	-	589	O
the	-	595	O
motor	-	599	O
function	-	605	O
and	-	614	O
procedural	-	618	O
memory	-	629	O
of	-	636	O
mice	-	639	O
as	-	644	O
assessed	-	647	O
by	-	656	O
swimming	-	659	O
speed	-	668	O
and	-	674	O
escape	-	678	O
latency	-	685	O
to	-	693	O
find	-	696	O
the	-	701	O
platform	-	705	O
in	-	714	O
a	-	717	O
cued	-	719	O
version	-	724	O
of	-	732	O
the	-	735	O
water	-	739	O
maze	-	745	O
task	-	750	O
.	-	754	O

However	24072398	756	O
,	-	763	O
METH	-	765	O
significantly	-	770	O
increased	-	784	O
the	-	794	O
immobility	-	798	O
time	-	809	O
in	-	814	O
the	-	817	O
tail	-	821	O
suspension	-	826	O
test	-	837	O
at	-	842	O
3	-	845	O
and	-	847	O
49	-	851	O
days	-	854	O
post	-	859	O
-	-	863	O
administration	-	864	O
.	-	878	O

This	24072398	880	O
depressive	-	885	B
-	-	895	O
like	-	896	O
profile	-	901	O
induced	-	909	O
by	-	917	O
METH	-	920	O
was	-	925	O
accompanied	-	929	O
by	-	941	O
a	-	944	O
marked	-	946	O
depletion	-	953	O
of	-	963	O
frontostriatal	-	966	O
dopaminergic	-	981	O
and	-	994	O
serotonergic	-	998	O
neurotransmission	-	1011	O
,	-	1028	O
indicated	-	1030	O
by	-	1040	O
a	-	1043	O
reduction	-	1045	O
in	-	1055	O
the	-	1058	O
levels	-	1062	O
of	-	1069	O
dopamine	-	1072	O
,	-	1080	O
DOPAC	-	1082	O
and	-	1088	O
HVA	-	1092	O
,	-	1095	O
tyrosine	-	1097	O
hydroxylase	-	1106	O
and	-	1118	O
serotonin	-	1122	O
,	-	1131	O
observed	-	1133	O
at	-	1142	O
both	-	1145	O
3	-	1150	O
and	-	1152	O
49	-	1156	O
days	-	1159	O
post	-	1164	O
-	-	1168	O
administration	-	1169	O
.	-	1183	O

In	24072398	1185	O
parallel	-	1188	O
,	-	1196	O
another	-	1198	O
neurochemical	-	1206	O
feature	-	1220	O
of	-	1228	O
depression	-	1231	B
-	-	1241	O
-	-	1242	O
astroglial	-	1243	O
dysfunction	-	1254	O
-	-	1265	O
-	-	1266	O
was	-	1267	O
unaffected	-	1271	O
in	-	1282	O
the	-	1285	O
cortex	-	1289	O
and	-	1296	O
the	-	1300	O
striatal	-	1304	O
levels	-	1313	O
of	-	1320	O
the	-	1323	O
astrocytic	-	1327	O
protein	-	1338	O
marker	-	1346	O
,	-	1352	O
glial	-	1354	O
fibrillary	-	1360	O
acidic	-	1371	O
protein	-	1378	O
,	-	1385	O
were	-	1387	O
only	-	1392	O
transiently	-	1397	O
increased	-	1409	O
at	-	1419	O
3	-	1422	O
days	-	1424	O
.	-	1428	O

These	24072398	1430	O
findings	-	1436	O
demonstrate	-	1445	O
for	-	1457	O
the	-	1461	O
first	-	1465	O
time	-	1471	O
that	-	1476	O
a	-	1481	O
single	-	1483	O
high	-	1490	O
dose	-	1495	O
of	-	1500	O
METH	-	1503	O
induces	-	1508	O
long	-	1516	O
-	-	1520	O
lasting	-	1521	O
depressive	-	1529	B
-	-	1539	O
like	-	1540	O
behaviour	-	1545	O
in	-	1555	O
mice	-	1558	O
associated	-	1563	O
with	-	1574	O
a	-	1579	O
persistent	-	1581	O
disruption	-	1592	O
of	-	1603	O
frontostriatal	-	1606	O
dopaminergic	-	1621	O
and	-	1634	O
serotonergic	-	1638	O
homoeostasis	-	1651	O
.	-	1663	O

Linezolid	24088636	0	O
-	-	9	O
induced	-	10	O
optic	-	18	B
neuropathy	-	24	I
.	-	34	O

Many	24088636	36	O
systemic	-	41	O
antimicrobials	-	50	O
have	-	65	O
been	-	70	O
implicated	-	75	O
to	-	86	O
cause	-	89	O
ocular	-	95	O
adverse	-	102	O
effects	-	110	O
.	-	117	O

This	24088636	119	O
is	-	124	O
especially	-	127	O
relevant	-	138	O
in	-	147	O
multidrug	-	150	O
therapy	-	160	O
where	-	168	O
more	-	174	O
than	-	179	O
one	-	184	O
drug	-	188	O
can	-	193	O
cause	-	197	O
a	-	203	O
similar	-	205	O
ocular	-	213	O
adverse	-	220	O
effect	-	228	O
.	-	234	O

We	24088636	236	O
describe	-	239	O
a	-	248	O
case	-	250	O
of	-	255	O
progressive	-	258	O
loss	-	270	B
of	-	275	I
vision	-	278	I
associated	-	285	O
with	-	296	O
linezolid	-	301	O
therapy	-	311	O
.	-	318	O

A	24088636	320	O
45	-	322	O
-	-	324	O
year	-	325	O
-	-	329	O
old	-	330	O
male	-	334	O
patient	-	339	O
who	-	347	O
was	-	351	O
on	-	355	O
treatment	-	358	O
with	-	368	O
multiple	-	373	O
second	-	382	O
-	-	388	O
line	-	389	O
anti	-	394	O
-	-	398	O
tuberculous	-	399	O
drugs	-	411	O
including	-	417	O
linezolid	-	427	O
and	-	437	O
ethambutol	-	441	O
for	-	452	O
extensively	-	456	B
drug	-	468	I
-	-	472	I
resistant	-	473	I
tuberculosis	-	483	I
(	-	496	O
XDR	-	497	B
-	-	500	I
TB	-	501	I
)	-	503	O
presented	-	505	O
to	-	515	O
us	-	518	O
with	-	521	O
painless	-	526	O
progressive	-	535	O
loss	-	547	B
of	-	552	I
vision	-	555	I
in	-	562	O
both	-	565	O
eyes	-	570	O
.	-	574	O

Color	24088636	576	O
vision	-	582	O
was	-	589	O
defective	-	593	O
and	-	603	O
fundus	-	607	O
examination	-	614	O
revealed	-	626	O
optic	-	635	B
disc	-	641	I
edema	-	646	I
in	-	652	O
both	-	655	O
eyes	-	660	O
.	-	664	O

Ethambutol	24088636	666	O
-	-	676	O
induced	-	677	O
toxic	-	685	B
optic	-	691	I
neuropathy	-	697	I
was	-	708	O
suspected	-	712	O
and	-	722	O
tablet	-	726	O
ethambutol	-	733	O
was	-	744	O
withdrawn	-	748	O
.	-	757	O

Deterioration	24088636	759	B
of	-	773	I
vision	-	776	I
occurred	-	783	O
despite	-	792	O
withdrawal	-	800	O
of	-	811	O
ethambutol	-	814	O
.	-	824	O

Discontinuation	24088636	826	O
of	-	842	O
linezolid	-	845	O
resulted	-	855	O
in	-	864	O
marked	-	867	O
improvement	-	874	O
of	-	886	O
vision	-	889	O
.	-	895	O

Our	24088636	897	O
report	-	901	O
emphasizes	-	908	O
the	-	919	O
need	-	923	O
for	-	928	O
monitoring	-	932	O
of	-	943	O
visual	-	946	O
function	-	953	O
in	-	962	O
patients	-	965	O
on	-	974	O
long	-	977	O
-	-	981	O
term	-	982	O
linezolid	-	987	O
treatment	-	997	O
.	-	1006	O

Resuscitation	24091473	0	O
with	-	14	O
lipid	-	19	O
,	-	24	O
epinephrine	-	26	O
,	-	37	O
or	-	39	O
both	-	42	O
in	-	47	O
levobupivacaine	-	50	O
-	-	65	O
induced	-	66	O
cardiac	-	74	B
toxicity	-	82	I
in	-	91	O
newborn	-	94	O
piglets	-	102	O
.	-	109	O

BACKGROUND	24091473	111	O
:	-	121	O

The	24091473	123	O
optimal	-	127	O
dosing	-	135	O
regimens	-	142	O
of	-	151	O
lipid	-	154	O
emulsion	-	160	O
,	-	168	O
epinephrine	-	170	O
,	-	181	O
or	-	183	O
both	-	186	O
are	-	191	O
not	-	195	O
yet	-	199	O
determined	-	203	O
in	-	214	O
neonates	-	217	O
in	-	226	O
cases	-	229	O
of	-	235	O
local	-	238	O
anaesthetic	-	244	O
systemic	-	256	O
toxicity	-	265	B
(	-	274	O
LAST	-	275	O
)	-	279	O
.	-	280	O

METHODS	24091473	282	O
:	-	289	O

Newborn	24091473	291	O
piglets	-	299	O
received	-	307	O
levobupivacaine	-	316	O
until	-	332	O
cardiovascular	-	338	B
collapse	-	353	I
occurred	-	362	O
.	-	370	O

Standard	24091473	372	O
cardiopulmonary	-	381	O
resuscitation	-	397	O
was	-	411	O
started	-	415	O
and	-	423	O
electrocardiogram	-	427	O
(	-	445	O
ECG	-	446	O
)	-	449	O
was	-	451	O
monitored	-	455	O
for	-	465	O
ventricular	-	469	B
tachycardia	-	481	I
,	-	492	O
fibrillation	-	494	B
,	-	506	O
or	-	508	O
QRS	-	511	O
prolongation	-	515	O
.	-	527	O

Piglets	24091473	529	O
were	-	537	O
then	-	542	O
randomly	-	547	O
allocated	-	556	O
to	-	566	O
four	-	569	O
groups	-	574	O
:	-	580	O
control	-	582	O
(	-	590	O
saline	-	591	O
)	-	597	O
,	-	598	O
Intralipid	-	600	O
(	-	610	O
)	-	612	O
alone	-	614	O
,	-	619	O
epinephrine	-	621	O
alone	-	633	O
,	-	638	O
or	-	640	O
a	-	643	O
combination	-	645	O
of	-	657	O
Intralipd	-	660	O
plus	-	670	O
epinephrine	-	675	O
.	-	686	O

Resuscitation	24091473	688	O
continued	-	702	O
for	-	712	O
30	-	716	O
min	-	719	O
or	-	723	O
until	-	726	O
there	-	732	O
was	-	738	O
a	-	742	O
return	-	744	O
of	-	751	O
spontaneous	-	754	O
circulation	-	766	O
(	-	778	O
ROSC	-	779	O
)	-	783	O
accompanied	-	785	O
by	-	797	O
a	-	800	O
mean	-	802	O
arterial	-	807	O
pressure	-	816	O
at	-	825	O
or	-	828	O
superior	-	831	O
to	-	840	O
the	-	843	O
baseline	-	847	O
pressure	-	856	O
and	-	865	O
normal	-	869	O
sinus	-	876	O
rhythm	-	882	O
for	-	889	O
a	-	893	O
period	-	895	O
of	-	902	O
30	-	905	O
min	-	908	O
.	-	911	O

RESULTS	24091473	913	O
:	-	920	O

ROSC	24091473	922	O
was	-	927	O
achieved	-	931	O
in	-	940	O
only	-	943	O
one	-	948	O
of	-	952	O
the	-	955	O
control	-	959	O
piglets	-	967	O
compared	-	975	O
with	-	984	O
most	-	989	O
of	-	994	O
the	-	997	O
treated	-	1001	O
piglets	-	1009	O
.	-	1016	O

Mortality	24091473	1018	O
was	-	1028	O
not	-	1032	O
significantly	-	1036	O
different	-	1050	O
between	-	1060	O
the	-	1068	O
three	-	1072	O
treatment	-	1078	O
groups	-	1088	O
,	-	1094	O
but	-	1096	O
was	-	1100	O
significantly	-	1104	O
lower	-	1118	O
in	-	1124	O
all	-	1127	O
the	-	1131	O
treatment	-	1135	O
groups	-	1145	O
compared	-	1152	O
with	-	1161	O
control	-	1166	O
.	-	1173	O

The	24091473	1175	O
number	-	1179	O
of	-	1186	O
ECG	-	1189	O
abnormalities	-	1193	O
was	-	1207	O
zero	-	1211	O
in	-	1216	O
the	-	1219	O
Intralipid	-	1223	O
only	-	1234	O
group	-	1239	O
,	-	1244	O
but	-	1246	O
14	-	1250	O
and	-	1253	O
17	-	1257	O
,	-	1259	O
respectively	-	1261	O
,	-	1273	O
in	-	1275	O
the	-	1278	O
epinephrine	-	1282	O
and	-	1294	O
epinephrine	-	1298	O
plus	-	1310	O
lipid	-	1315	O
groups	-	1321	O
(	-	1328	O
P	-	1329	O
<	-	1330	O
0	-	1331	O
.	-	1332	O
05	-	1333	O
)	-	1335	O
.	-	1336	O

CONCLUSIONS	24091473	1338	O
:	-	1349	O

Lipid	24091473	1351	O
emulsion	-	1357	O
with	-	1366	O
or	-	1371	O
without	-	1374	O
epinephrine	-	1382	O
,	-	1393	O
or	-	1395	O
epinephrine	-	1398	O
alone	-	1410	O
were	-	1416	O
equally	-	1421	O
effective	-	1429	O
in	-	1439	O
achieving	-	1442	O
a	-	1452	O
return	-	1454	O
to	-	1461	O
spontaneous	-	1464	O
circulation	-	1476	O
in	-	1488	O
this	-	1491	O
model	-	1496	O
of	-	1502	O
LAST	-	1505	O
.	-	1509	O

Epinephrine	24091473	1511	O
alone	-	1523	O
or	-	1529	O
in	-	1532	O
combination	-	1535	O
with	-	1547	O
lipid	-	1552	O
was	-	1558	O
associated	-	1562	O
with	-	1573	O
an	-	1578	O
increased	-	1581	O
number	-	1591	O
of	-	1598	O
ECG	-	1601	O
abnormalities	-	1605	O
compared	-	1619	O
with	-	1628	O
lipid	-	1633	O
emulsion	-	1639	O
alone	-	1648	O
.	-	1653	O

Incidence	24100055	0	O
of	-	10	O
heparin	-	13	O
-	-	20	O
induced	-	21	O
thrombocytopenia	-	29	B
type	-	46	I
II	-	51	I
and	-	54	O
postoperative	-	58	O
recovery	-	72	O
of	-	81	O
platelet	-	84	O
count	-	93	O
in	-	99	O
liver	-	102	O
graft	-	108	O
recipients	-	114	O
:	-	124	O
a	-	126	O
retrospective	-	128	O
cohort	-	142	O
analysis	-	149	O
.	-	157	O

BACKGROUND	24100055	159	O
:	-	169	O
Thrombocytopenia	-	171	B
in	-	188	O
patients	-	191	O
with	-	200	O
end	-	205	B
-	-	208	I
stage	-	209	I
liver	-	215	I
disease	-	221	I
is	-	229	O
a	-	232	O
common	-	234	O
disorder	-	241	O
caused	-	250	O
mainly	-	257	O
by	-	264	O
portal	-	267	B
hypertension	-	274	I
,	-	286	O
low	-	288	O
levels	-	292	O
of	-	299	O
thrombopoetin	-	302	O
,	-	315	O
and	-	317	O
endotoxemia	-	321	B
.	-	332	O

The	24100055	334	O
impact	-	338	O
of	-	345	O
immune	-	348	O
-	-	354	O
mediated	-	355	O
heparin	-	364	O
-	-	371	O
induced	-	372	O
thrombocytopenia	-	380	B
type	-	397	I
II	-	402	I
(	-	405	O
HIT	-	406	B
type	-	410	I
II	-	415	I
)	-	417	O
as	-	419	O
a	-	422	O
cause	-	424	O
of	-	430	O
thrombocytopenia	-	433	B
after	-	450	O
liver	-	456	O
transplantation	-	462	O
is	-	478	O
not	-	481	O
yet	-	485	O
understood	-	489	O
,	-	499	O
with	-	501	O
few	-	506	O
literature	-	510	O
citations	-	521	O
reporting	-	531	O
contradictory	-	541	O
results	-	555	O
.	-	562	O

The	24100055	564	O
aim	-	568	O
of	-	572	O
our	-	575	O
study	-	579	O
was	-	585	O
to	-	589	O
demonstrate	-	592	O
the	-	604	O
perioperative	-	608	O
course	-	622	O
of	-	629	O
thrombocytopenia	-	632	B
after	-	649	O
liver	-	655	O
transplantation	-	661	O
and	-	677	O
determine	-	681	O
the	-	691	O
occurrence	-	695	O
of	-	706	O
clinical	-	709	O
HIT	-	718	B
type	-	722	I
II	-	727	I
.	-	729	O

METHOD	24100055	731	O
:	-	737	O

We	24100055	739	O
retrospectively	-	742	O
evaluated	-	758	O
the	-	768	O
medical	-	772	O
records	-	780	O
of	-	788	O
205	-	791	O
consecutive	-	795	O
adult	-	807	O
patients	-	813	O
who	-	822	O
underwent	-	826	O
full	-	836	O
-	-	840	O
size	-	841	O
liver	-	846	O
transplantation	-	852	O
between	-	868	O
January	-	876	O
2006	-	884	O
and	-	889	O
December	-	893	O
2010	-	902	O
due	-	907	O
to	-	911	O
end	-	914	B
-	-	917	I
stage	-	918	I
or	-	924	I
malignant	-	927	I
liver	-	937	I
disease	-	943	I
.	-	950	O

Preoperative	24100055	952	O
platelet	-	965	O
count	-	974	O
,	-	979	O
postoperative	-	981	O
course	-	995	O
of	-	1002	O
platelets	-	1005	O
,	-	1014	O
and	-	1016	O
clinical	-	1020	O
signs	-	1029	O
of	-	1035	O
HIT	-	1038	B
type	-	1042	I
II	-	1047	I
were	-	1050	O
analyzed	-	1055	O
.	-	1063	O

RESULTS	24100055	1065	O
:	-	1072	O

A	24100055	1074	O
total	-	1076	O
of	-	1082	O
155	-	1085	O
(	-	1089	O
75	-	1090	O
.	-	1092	O
6	-	1093	O
%	-	1094	O
)	-	1095	O
of	-	1097	O
205	-	1100	O
patients	-	1104	O
had	-	1113	O
thrombocytopenia	-	1117	B
before	-	1134	O
transplantation	-	1141	O
,	-	1156	O
significantly	-	1158	O
influenced	-	1172	O
by	-	1183	O
Model	-	1186	O
of	-	1192	O
End	-	1195	B
-	-	1198	I
Stage	-	1199	I
Liver	-	1205	I
Disease	-	1211	I
score	-	1219	O
and	-	1225	O
liver	-	1229	B
cirrhosis	-	1235	I
.	-	1244	O

The	24100055	1246	O
platelet	-	1250	O
count	-	1259	O
exceeded	-	1265	O
100	-	1274	O
,	-	1277	O
000	-	1278	O
/	-	1281	O
uL	-	1282	O
in	-	1285	O
most	-	1288	O
of	-	1293	O
the	-	1296	O
patients	-	1300	O
(	-	1309	O
n	-	1310	O
=	-	1312	O
193	-	1314	O
)	-	1317	O
at	-	1319	O
a	-	1322	O
medium	-	1324	O
of	-	1331	O
7	-	1334	O
d	-	1336	O
.	-	1337	O
Regarding	-	1339	O
HIT	-	1349	B
II	-	1353	I
,	-	1355	O
there	-	1357	O
were	-	1363	O
four	-	1368	O
(	-	1373	O
1	-	1374	O
.	-	1375	O
95	-	1376	O
%	-	1378	O
)	-	1379	O
patients	-	1381	O
with	-	1390	O
a	-	1395	O
background	-	1397	O
of	-	1408	O
HIT	-	1411	B
type	-	1415	I
II	-	1420	I
.	-	1422	O

CONCLUSIONS	24100055	1424	O
:	-	1435	O

The	24100055	1437	O
incidence	-	1441	O
of	-	1451	O
HIT	-	1454	B
in	-	1458	O
patients	-	1461	O
with	-	1470	O
end	-	1475	B
-	-	1478	I
stage	-	1479	I
hepatic	-	1485	I
failure	-	1493	I
is	-	1501	O
,	-	1503	O
with	-	1505	O
about	-	1510	O
1	-	1516	O
.	-	1517	O
95	-	1518	O
%	-	1520	O
,	-	1521	O
rare	-	1523	O
.	-	1527	O

For	24100055	1529	O
further	-	1533	O
reduction	-	1541	O
of	-	1551	O
HIT	-	1554	B
type	-	1558	I
II	-	1563	I
,	-	1565	O
the	-	1567	O
use	-	1571	O
of	-	1575	O
intravenous	-	1578	O
heparin	-	1590	O
should	-	1598	O
be	-	1605	O
avoided	-	1608	O
and	-	1616	O
the	-	1620	O
prophylactic	-	1624	O
anticoagulation	-	1637	O
should	-	1653	O
be	-	1660	O
performed	-	1663	O
with	-	1673	O
low	-	1678	O
-	-	1681	O
molecular	-	1682	O
-	-	1691	O
weight	-	1692	O
heparin	-	1699	O
after	-	1707	O
normalization	-	1713	O
of	-	1727	O
platelet	-	1730	O
count	-	1739	O
.	-	1744	O

Takotsubo	24100257	0	B
syndrome	-	10	I
(	-	19	O
or	-	20	O
apical	-	23	B
ballooning	-	30	I
syndrome	-	41	I
)	-	49	O
secondary	-	51	O
to	-	61	O
Zolmitriptan	-	64	O
.	-	76	O

Takotsubo	24100257	78	B
syndrome	-	88	I
(	-	97	O
TS	-	98	B
)	-	100	O
,	-	101	O
also	-	103	O
known	-	108	O
as	-	114	O
broken	-	117	B
heart	-	124	I
syndrome	-	130	I
,	-	138	O
is	-	140	O
characterized	-	143	O
by	-	157	O
left	-	160	O
ventricle	-	165	O
apical	-	175	O
ballooning	-	182	O
with	-	193	O
elevated	-	198	O
cardiac	-	207	O
biomarkers	-	215	O
and	-	226	O
electrocardiographic	-	230	O
changes	-	251	O
suggestive	-	259	O
of	-	270	O
an	-	273	O
acute	-	276	B
coronary	-	282	I
syndrome	-	291	I
(	-	300	O
ie	-	301	O
,	-	303	O
ST	-	305	O
-	-	307	O
segment	-	308	O
elevation	-	316	O
,	-	325	O
T	-	327	O
wave	-	329	O
inversions	-	334	O
,	-	344	O
and	-	346	O
pathologic	-	350	O
Q	-	361	O
waves	-	363	O
)	-	368	O
.	-	369	O

We	24100257	371	O
report	-	374	O
a	-	381	O
case	-	383	O
of	-	388	O
54	-	391	O
-	-	393	O
year	-	394	O
-	-	398	O
old	-	399	O
woman	-	403	O
with	-	409	O
medical	-	414	O
history	-	422	O
of	-	430	O
mitral	-	433	B
valve	-	440	I
prolapse	-	446	I
and	-	455	O
migraines	-	459	B
,	-	468	O
who	-	470	O
was	-	474	O
admitted	-	478	O
to	-	487	O
the	-	490	O
hospital	-	494	O
for	-	503	O
substernal	-	507	O
chest	-	518	B
pain	-	524	I
and	-	529	O
electrocardiogram	-	533	O
demonstrated	-	551	O
1	-	564	O
/	-	565	O
2	-	566	O
mm	-	568	O
ST	-	571	O
-	-	573	O
segment	-	574	O
elevation	-	582	O
in	-	592	O
leads	-	595	O
II	-	601	O
,	-	603	O
III	-	605	O
,	-	608	O
aVF	-	610	O
,	-	613	O
V5	-	615	O
,	-	617	O
and	-	619	O
V6	-	623	O
and	-	626	O
positive	-	630	O
troponin	-	639	O
I	-	648	O
.	-	649	O
Emergent	-	651	O
coronary	-	660	O
angiogram	-	669	O
revealed	-	679	O
normal	-	688	O
coronary	-	695	O
arteries	-	704	O
with	-	713	O
moderately	-	718	O
reduced	-	729	O
left	-	737	O
ventricular	-	742	O
ejection	-	754	O
fraction	-	763	O
with	-	772	O
wall	-	777	O
motion	-	782	O
abnormalities	-	789	O
consistent	-	803	O
with	-	814	O
TS	-	819	B
.	-	821	O

Detailed	24100257	823	O
history	-	832	O
obtained	-	840	O
retrospectively	-	849	O
revealed	-	865	O
that	-	874	O
the	-	879	O
patient	-	883	O
took	-	891	O
zolmitriptan	-	896	O
sparingly	-	909	O
only	-	919	O
when	-	924	O
she	-	929	O
had	-	933	O
migraines	-	937	B
.	-	946	O

But	24100257	948	O
before	-	952	O
this	-	959	O
event	-	964	O
,	-	969	O
she	-	971	O
was	-	975	O
taking	-	979	O
zolmitriptan	-	986	O
2	-	999	O
-	-	1000	O
3	-	1001	O
times	-	1003	O
daily	-	1009	O
for	-	1015	O
several	-	1019	O
days	-	1027	O
because	-	1032	O
of	-	1040	O
a	-	1043	O
persistent	-	1045	O
migraine	-	1056	B
headache	-	1065	I
.	-	1073	O

She	24100257	1075	O
otherwise	-	1079	O
reported	-	1089	O
that	-	1098	O
she	-	1103	O
is	-	1107	O
quite	-	1110	O
active	-	1116	O
,	-	1122	O
rides	-	1124	O
horses	-	1130	O
,	-	1136	O
and	-	1138	O
does	-	1142	O
show	-	1147	O
jumping	-	1152	O
without	-	1160	O
any	-	1168	O
limitations	-	1172	O
in	-	1184	O
her	-	1187	O
physical	-	1191	O
activity	-	1200	O
.	-	1208	O

There	24100257	1210	O
was	-	1216	O
no	-	1220	O
evidence	-	1223	O
of	-	1232	O
any	-	1235	O
recent	-	1239	O
stress	-	1246	O
or	-	1253	O
status	-	1256	B
migrainosus	-	1263	I
.	-	1274	O

Extensive	24100257	1276	O
literature	-	1286	O
search	-	1297	O
revealed	-	1304	O
multiple	-	1313	O
cases	-	1322	O
of	-	1328	O
coronary	-	1331	B
artery	-	1340	I
vasospasm	-	1347	I
secondary	-	1357	O
to	-	1367	O
zolmitriptan	-	1370	O
,	-	1382	O
but	-	1384	O
none	-	1388	O
of	-	1393	O
the	-	1396	O
cases	-	1400	O
were	-	1406	O
associated	-	1411	O
with	-	1422	O
TS	-	1427	B
.	-	1429	O

Depression	24114426	0	B
,	-	10	O
impulsiveness	-	12	B
,	-	25	O
sleep	-	27	O
,	-	32	O
and	-	34	O
memory	-	38	O
in	-	45	O
past	-	48	O
and	-	53	O
present	-	57	O
polydrug	-	65	O
users	-	74	O
of	-	80	O
3	-	83	O
,	-	84	O
4	-	85	O
-	-	86	O
methylenedioxymethamphetamine	-	87	O
(	-	117	O
MDMA	-	118	O
,	-	122	O
ecstasy	-	124	O
)	-	131	O
.	-	132	O

RATIONALE	24114426	134	O
:	-	143	O
Ecstasy	-	145	O
(	-	153	O
3	-	154	O
,	-	155	O
4	-	156	O
-	-	157	O
methylenedioxymethamphetamine	-	158	O

,	24114426	187	O
MDMA	-	189	O
)	-	193	O
is	-	195	O
a	-	198	O
worldwide	-	200	O
recreational	-	210	O
drug	-	223	O
of	-	228	O
abuse	-	231	O
.	-	236	O

Unfortunately	24114426	238	O
,	-	251	O
the	-	253	O
results	-	257	O
from	-	265	O
human	-	270	O
research	-	276	O
investigating	-	285	O
its	-	299	O
psychological	-	303	O
effects	-	317	O
have	-	325	O
been	-	330	O
inconsistent	-	335	O
.	-	347	O

OBJECTIVES	24114426	349	O
:	-	359	O

The	24114426	361	O
present	-	365	O
study	-	373	O
aimed	-	379	O
to	-	385	O
be	-	388	O
the	-	391	O
largest	-	395	O
to	-	403	O
date	-	406	O
in	-	411	O
sample	-	414	O
size	-	421	O
and	-	426	O
5HT	-	430	O
-	-	433	O
related	-	434	O
behaviors	-	442	O
;	-	451	O
the	-	453	O
first	-	457	O
to	-	463	O
compare	-	466	O
present	-	474	O
ecstasy	-	482	O
users	-	490	O
with	-	496	O
past	-	501	O
users	-	506	O
after	-	512	O
an	-	518	O
abstinence	-	521	O
of	-	532	O
4	-	535	O
or	-	537	O
more	-	540	O
years	-	545	O
,	-	550	O
and	-	552	O
the	-	556	O
first	-	560	O
to	-	566	O
include	-	569	O
robust	-	577	O
controls	-	584	O
for	-	593	O
other	-	597	O
recreational	-	603	O
substances	-	616	O
.	-	626	O

METHODS	24114426	628	O
:	-	635	O

A	24114426	637	O
sample	-	639	O
of	-	646	O
997	-	649	O
participants	-	653	O
(	-	666	O
52	-	667	O
%	-	670	O
male	-	672	O
)	-	676	O
was	-	678	O
recruited	-	682	O
to	-	692	O
four	-	695	O
control	-	700	O
groups	-	708	O
(	-	715	O
non	-	716	O
-	-	719	O
drug	-	720	O
(	-	725	O
ND	-	726	O
)	-	728	O
,	-	729	O
alcohol	-	731	O
/	-	738	O
nicotine	-	739	O
(	-	748	O
AN	-	749	O
)	-	751	O
,	-	752	O
cannabis	-	754	O
/	-	762	O
alcohol	-	763	O
/	-	770	O
nicotine	-	771	O
(	-	780	O
CAN	-	781	O
)	-	784	O
,	-	785	O
non	-	787	O
-	-	790	O
ecstasy	-	791	O
polydrug	-	799	O
(	-	808	O
PD	-	809	O
)	-	811	O
)	-	812	O
,	-	813	O
and	-	815	O
two	-	819	O
ecstasy	-	823	O
polydrug	-	831	O
groups	-	840	O
(	-	847	O
present	-	848	O
(	-	856	O
MDMA	-	857	O
)	-	861	O
and	-	863	O
past	-	867	O
users	-	872	O
(	-	878	O
EX	-	879	O
-	-	881	O
MDMA	-	882	O
)	-	886	O
.	-	887	O

Participants	24114426	889	O
completed	-	902	O
a	-	912	O
drug	-	914	O
history	-	919	O
questionnaire	-	927	O
,	-	940	O
Beck	-	942	O
Depression	-	947	B
Inventory	-	958	O
,	-	967	O
Barratt	-	969	O
Impulsiveness	-	977	B
Scale	-	991	O
,	-	996	O
Pittsburgh	-	998	O
Sleep	-	1009	O
Quality	-	1015	O
Index	-	1023	O
,	-	1028	O
and	-	1030	O
Wechsler	-	1034	O
Memory	-	1043	O
Scale	-	1050	O
-	-	1055	O
Revised	-	1056	O
which	-	1064	O
,	-	1069	O
in	-	1071	O
total	-	1074	O
,	-	1079	O
provided	-	1081	O
13	-	1090	O
psychometric	-	1093	O
measures	-	1106	O
.	-	1114	O

RESULTS	24114426	1116	O
:	-	1123	O

While	24114426	1125	O
the	-	1131	O
CAN	-	1135	O
and	-	1139	O
PD	-	1143	O
groups	-	1146	O
tended	-	1153	O
to	-	1160	O
record	-	1163	O
greater	-	1170	O
deficits	-	1178	O
than	-	1187	O
the	-	1192	O
non	-	1196	O
-	-	1199	O
drug	-	1200	O
controls	-	1205	O
,	-	1213	O
the	-	1215	O
MDMA	-	1219	O
and	-	1224	O
EX	-	1228	O
-	-	1230	O
MDMA	-	1231	O
groups	-	1236	O
recorded	-	1243	O
greater	-	1252	O
deficits	-	1260	O
than	-	1269	O
all	-	1274	O
the	-	1278	O
control	-	1282	O
groups	-	1290	O
on	-	1297	O
ten	-	1300	O
of	-	1304	O
the	-	1307	O
13	-	1311	O
psychometric	-	1314	O
measures	-	1327	O
.	-	1335	O

Strikingly	24114426	1337	O
,	-	1347	O
despite	-	1349	O
prolonged	-	1357	O
abstinence	-	1367	O
(	-	1378	O
mean	-	1379	O
,	-	1383	O
4	-	1385	O
.	-	1386	O
98	-	1387	O
;	-	1389	O
range	-	1391	O
,	-	1396	O
4	-	1398	O
-	-	1399	O
9	-	1400	O
years	-	1402	O
)	-	1407	O
,	-	1408	O
past	-	1410	O
ecstasy	-	1415	O
users	-	1423	O
showed	-	1429	O
few	-	1436	O
signs	-	1440	O
of	-	1446	O
recovery	-	1449	O
.	-	1457	O

Compared	24114426	1459	O
with	-	1468	O
present	-	1473	O
ecstasy	-	1481	O
users	-	1489	O
,	-	1494	O
the	-	1496	O
past	-	1500	O
users	-	1505	O
showed	-	1511	O
no	-	1518	O
change	-	1521	O
for	-	1528	O
ten	-	1532	O
measures	-	1536	O
,	-	1544	O
increased	-	1546	O
impairment	-	1556	O
for	-	1567	O
two	-	1571	O
measures	-	1575	O
,	-	1583	O
and	-	1585	O
improvement	-	1589	O
on	-	1601	O
just	-	1604	O
one	-	1609	O
measure	-	1613	O
.	-	1620	O

CONCLUSIONS	24114426	1622	O
:	-	1633	O

Given	24114426	1635	O
this	-	1641	O
record	-	1646	O
of	-	1653	O
impaired	-	1656	B
memory	-	1665	I
and	-	1672	O
clinically	-	1676	O
significant	-	1687	O
levels	-	1699	O
of	-	1706	O
depression	-	1709	B
,	-	1719	O
impulsiveness	-	1721	B
,	-	1734	O
and	-	1736	O
sleep	-	1740	B
disturbance	-	1746	I
,	-	1757	O
the	-	1759	O
prognosis	-	1763	O
for	-	1773	O
the	-	1777	O
current	-	1781	O
generation	-	1789	O
of	-	1800	O
ecstasy	-	1803	O
users	-	1811	O
is	-	1817	O
a	-	1820	O
major	-	1822	O
cause	-	1828	O
for	-	1834	O
concern	-	1838	O
.	-	1845	O

Association	24126708	0	O
of	-	12	O
common	-	15	O
genetic	-	22	O
variants	-	30	O
of	-	39	O
HOMER1	-	42	O
gene	-	49	O
with	-	54	O
levodopa	-	59	O
adverse	-	68	O
effects	-	76	O
in	-	84	O
Parkinson	-	87	B
's	-	96	I
disease	-	99	I
patients	-	107	O
.	-	115	O

Levodopa	24126708	117	O
is	-	126	O
the	-	129	O
most	-	133	O
effective	-	138	O
symptomatic	-	148	O
therapy	-	160	O
for	-	168	O
Parkinson	-	172	B
's	-	181	I
disease	-	184	I
,	-	191	O
but	-	193	O
its	-	197	O
chronic	-	201	O
use	-	209	O
could	-	213	O
lead	-	219	O
to	-	224	O
chronic	-	227	O
adverse	-	235	O
outcomes	-	243	O
,	-	251	O
such	-	253	O
as	-	258	O
motor	-	261	O
fluctuations	-	267	O
,	-	279	O
dyskinesia	-	281	B
and	-	292	O
visual	-	296	B
hallucinations	-	303	I
.	-	317	O

HOMER1	24126708	319	O
is	-	326	O
a	-	329	O
protein	-	331	O
with	-	339	O
pivotal	-	344	O
function	-	352	O
in	-	361	O
glutamate	-	364	O
transmission	-	374	O
,	-	386	O
which	-	388	O
has	-	394	O
been	-	398	O
related	-	403	O
to	-	411	O
the	-	414	O
pathogenesis	-	418	O
of	-	431	O
these	-	434	O
complications	-	440	O
.	-	453	O

This	24126708	455	O
study	-	460	O
investigates	-	466	O
whether	-	479	O
polymorphisms	-	487	O
in	-	501	O
the	-	504	O
HOMER1	-	508	O
gene	-	515	O
promoter	-	520	O
region	-	529	O
are	-	536	O
associated	-	540	O
with	-	551	O
the	-	556	O
occurrence	-	560	O
of	-	571	O
the	-	574	O
chronic	-	578	O
complications	-	586	O
of	-	600	O
levodopa	-	603	O
therapy	-	612	O
.	-	619	O

A	24126708	621	O
total	-	623	O
of	-	629	O
205	-	632	O
patients	-	636	O
with	-	645	O
idiopathic	-	650	B
Parkinson	-	661	I
's	-	670	I
disease	-	673	I
were	-	681	O
investigated	-	686	O
.	-	698	O

Patients	24126708	700	O
were	-	709	O
genotyped	-	714	O
for	-	724	O
rs4704559	-	728	O
,	-	737	O
rs10942891	-	739	O
and	-	750	O
rs4704560	-	754	O
by	-	764	O
allelic	-	767	O
discrimination	-	775	O
with	-	790	O
Taqman	-	795	O
assays	-	802	O
.	-	808	O

The	24126708	810	O
rs4704559	-	814	O
G	-	824	O
allele	-	826	O
was	-	833	O
associated	-	837	O
with	-	848	O
a	-	853	O
lower	-	855	O
prevalence	-	861	O
of	-	872	O
dyskinesia	-	875	B
(	-	886	O
prevalence	-	887	O
ratio	-	898	O
(	-	904	O
PR	-	905	O
)	-	907	O
=	-	908	O
0	-	909	O
.	-	910	O
615	-	911	O
,	-	914	O
95	-	916	O
%	-	918	O
confidence	-	920	O
interval	-	931	O
(	-	940	O
CI	-	941	O
)	-	943	O
0	-	945	O
.	-	946	O
426	-	947	O
-	-	950	O
0	-	951	O
.	-	952	O
887	-	953	O
,	-	956	O
P	-	958	O
=	-	959	O
0	-	960	O
.	-	961	O
009	-	962	O
)	-	965	O
and	-	967	O
visual	-	971	B
hallucinations	-	978	I
(	-	993	O
PR	-	994	O
=	-	996	O
0	-	997	O
.	-	998	O
515	-	999	O
,	-	1002	O
95	-	1004	O
%	-	1006	O
CI	-	1008	O
0	-	1011	O
.	-	1012	O
295	-	1013	O
-	-	1016	O
0	-	1017	O
.	-	1018	O
899	-	1019	O
,	-	1022	O
P	-	1024	O
=	-	1025	O
0	-	1026	O
.	-	1027	O
020	-	1028	O
)	-	1031	O
.	-	1032	O

Our	24126708	1034	O
data	-	1038	O
suggest	-	1043	O
that	-	1051	O
HOMER1	-	1056	O
rs4704559	-	1063	O
G	-	1073	O
allele	-	1075	O
has	-	1082	O
a	-	1086	O
protective	-	1088	O
role	-	1099	O
for	-	1104	O
the	-	1108	O
development	-	1112	O
of	-	1124	O
levodopa	-	1127	O
adverse	-	1136	O
effects	-	1144	O
.	-	1151	O

Crocin	24132704	0	O
improves	-	7	O
lipid	-	16	O
dysregulation	-	22	O
in	-	36	O
subacute	-	39	O
diazinon	-	48	O
exposure	-	57	O
through	-	66	O
ERK1	-	74	O
/	-	78	O
2	-	79	O
pathway	-	81	O
in	-	89	O
rat	-	92	O
liver	-	96	O
.	-	101	O

INTRODUCTION	24132704	103	O
:	-	115	O

Diazinon	24132704	117	O
Yis	-	126	O
one	-	130	O
of	-	134	O
the	-	137	O
most	-	141	O
broadly	-	146	O
used	-	154	O
organophosphorus	-	159	O
insecticides	-	176	O
in	-	189	O
agriculture	-	192	O
.	-	203	O

It	24132704	205	O
has	-	208	O
been	-	212	O
shown	-	217	O
that	-	223	O
exposure	-	228	O
to	-	237	O
diazinon	-	240	O
may	-	249	O
interfere	-	253	O
with	-	263	O
lipid	-	268	O
metabolism	-	274	O
.	-	284	O

Moreover	24132704	286	O
,	-	294	O
the	-	296	O
hypolipidemic	-	300	O
effect	-	314	O
of	-	321	O
crocin	-	324	O
has	-	331	O
been	-	335	O
established	-	340	O
.	-	351	O

Earlier	24132704	353	O
studies	-	361	O
revealed	-	369	O
the	-	378	O
major	-	382	O
role	-	388	O
of	-	393	O
Extracellular	-	396	O
signal	-	410	O
-	-	416	O
regulated	-	417	O
kinase	-	427	O
(	-	434	O
ERK	-	435	O
)	-	438	O
pathways	-	440	O
in	-	449	O
low	-	452	O
-	-	455	O
density	-	456	O
lipoprotein	-	464	O
receptor	-	476	O
(	-	485	O
LDLr	-	486	O
)	-	490	O
expression	-	492	O
.	-	502	O

The	24132704	504	O
aim	-	508	O
of	-	512	O
this	-	515	O
study	-	520	O
was	-	526	O
to	-	530	O
evaluate	-	533	O
changes	-	542	O
in	-	550	O
the	-	553	O
regulation	-	557	O
of	-	568	O
lipid	-	571	O
metabolism	-	577	O
,	-	587	O
ERK	-	589	O
and	-	593	O
LDLr	-	597	O
expression	-	602	O
in	-	613	O
the	-	616	O
liver	-	620	O
of	-	626	O
rats	-	629	O
exposed	-	634	O
to	-	642	O
subacute	-	645	O
diazinon	-	654	O
.	-	662	O

Furthermore	24132704	664	O
ameliorating	-	676	O
effect	-	689	O
of	-	696	O
crocin	-	699	O
on	-	706	O
diazinon	-	709	O
induced	-	718	O
disturbed	-	726	O
cholesterol	-	736	O
homeostasis	-	748	O
was	-	760	O
studied	-	764	O
.	-	771	O

METHODS	24132704	773	O
:	-	780	O

24	24132704	782	O
Rats	-	785	O
were	-	790	O
divided	-	795	O
into	-	803	O
4	-	808	O
groups	-	810	O
and	-	817	O
received	-	821	O
following	-	830	O
treatments	-	840	O
for	-	851	O
4	-	855	O
weeks	-	857	O
;	-	862	O
Corn	-	864	O
oil	-	869	O
(	-	873	O
control	-	874	O
)	-	881	O
,	-	882	O
diazinon	-	884	O
(	-	893	O
15mg	-	894	O
/	-	898	O
kg	-	899	O
per	-	902	O
day	-	906	O
,	-	909	O
orally	-	911	O
)	-	917	O
and	-	919	O
crocin	-	923	O
(	-	930	O
12	-	931	O
.	-	933	O
5	-	934	O
and	-	936	O
25mg	-	940	O
/	-	944	O
kg	-	945	O
per	-	948	O
day	-	952	O
,	-	955	O
intraperitoneally	-	957	O
)	-	974	O
in	-	976	O
combination	-	979	O
with	-	991	O
diazinon	-	996	O
(	-	1005	O
15	-	1006	O
mg	-	1009	O
/	-	1011	O
kg	-	1012	O
)	-	1014	O
.	-	1015	O

The	24132704	1017	O
levels	-	1021	O
of	-	1028	O
cholesterol	-	1031	O
,	-	1042	O
triglyceride	-	1044	O
and	-	1057	O
LDL	-	1061	O
in	-	1065	O
blood	-	1068	O
of	-	1074	O
rats	-	1077	O
were	-	1082	O
analyzed	-	1087	O
.	-	1095	O

Moreover	24132704	1097	O
mRNA	-	1106	O
levels	-	1111	O
of	-	1118	O
LDLr	-	1121	O
and	-	1126	O
ERK1	-	1130	O
/	-	1134	O
2	-	1135	O
as	-	1137	O
well	-	1140	O
as	-	1145	O
protein	-	1148	O
levels	-	1156	O
of	-	1163	O
total	-	1166	O
and	-	1172	O
activated	-	1176	O
forms	-	1186	O
of	-	1192	O
ERK1	-	1195	O
/	-	1199	O
2	-	1200	O
in	-	1202	O
rat	-	1205	O
liver	-	1209	O
were	-	1215	O
evaluated	-	1220	O
by	-	1230	O
Western	-	1233	O
blotting	-	1241	O
and	-	1250	O
quantitative	-	1254	O
real	-	1267	O
time	-	1272	O
polymerase	-	1277	O
chain	-	1288	O
reaction	-	1294	O
analysis	-	1303	O
.	-	1311	O

RESULTS	24132704	1313	O
:	-	1320	O

Our	24132704	1322	O
data	-	1326	O
showed	-	1331	O
that	-	1338	O
subacute	-	1343	O
exposure	-	1352	O
to	-	1361	O
diazinon	-	1364	O
significantly	-	1373	O
increased	-	1387	O
concentrations	-	1397	O
of	-	1412	O
cholesterol	-	1415	O
,	-	1426	O
triglyceride	-	1428	O
and	-	1441	O
LDL	-	1445	O
.	-	1448	O

Moreover	24132704	1450	O
diazinon	-	1459	O
decreased	-	1468	O
ERK1	-	1478	O
/	-	1482	O
2	-	1483	O
protein	-	1485	O
phosphorylation	-	1493	O
and	-	1509	O
LDLr	-	1513	O
transcript	-	1518	O
.	-	1528	O

Crocin	24132704	1530	O
reduced	-	1537	O
inhibition	-	1545	O
of	-	1556	O
ERK	-	1559	O
activation	-	1563	O
and	-	1574	O
diazinon	-	1578	O
-	-	1586	O
induced	-	1587	O
hyperlipemia	-	1595	B
and	-	1608	O
increased	-	1612	O
levels	-	1622	O
of	-	1629	O
LDLr	-	1632	O
transcript	-	1637	O
.	-	1647	O

CONCLUSIONS	24132704	1649	O
:	-	1660	O

Crocin	24132704	1662	O
may	-	1669	O
be	-	1673	O
considered	-	1676	O
as	-	1687	O
a	-	1690	O
novel	-	1692	O
protective	-	1698	O
agent	-	1709	O
in	-	1715	O
diazinon	-	1718	O
-	-	1726	O
induced	-	1727	O
hyperlipemia	-	1735	B
through	-	1748	O
modulating	-	1756	O
of	-	1767	O
ERK	-	1770	O
pathway	-	1774	O
and	-	1782	O
increase	-	1786	O
of	-	1795	O
LDLr	-	1798	O
expression	-	1803	O
.	-	1813	O

GEM	24158386	0	O
-	-	3	O
P	-	4	O
chemotherapy	-	6	O
is	-	19	O
active	-	22	O
in	-	29	O
the	-	32	O
treatment	-	36	O
of	-	46	O
relapsed	-	49	O
Hodgkin	-	58	B
lymphoma	-	66	I
.	-	74	O

Hodgkin	24158386	76	B
lymphoma	-	84	I
(	-	93	O
HL	-	94	B
)	-	96	O
is	-	98	O
a	-	101	O
relatively	-	103	O
chemosensitive	-	114	O
malignancy	-	129	B
.	-	139	O

However	24158386	141	O
,	-	148	O
for	-	150	O
those	-	154	O
who	-	160	O
relapse	-	164	O
,	-	171	O
high	-	173	O
-	-	177	O
dose	-	178	O
chemotherapy	-	183	O
with	-	196	O
autologous	-	201	O
stem	-	212	O
cell	-	217	O
transplant	-	222	O
is	-	233	O
the	-	236	O
treatment	-	240	O
of	-	250	O
choice	-	253	O
which	-	260	O
relies	-	266	O
on	-	273	O
adequate	-	276	O
disease	-	285	O
control	-	293	O
with	-	301	O
salvage	-	306	O
chemotherapy	-	314	O
.	-	326	O

Regimens	24158386	328	O
commonly	-	337	O
used	-	346	O
often	-	351	O
require	-	357	O
inpatient	-	365	O
administration	-	375	O
and	-	390	O
can	-	394	O
be	-	398	O
difficult	-	401	O
to	-	411	O
deliver	-	414	O
due	-	422	O
to	-	426	O
toxicity	-	429	B
.	-	437	O

Gemcitabine	24158386	439	O
and	-	451	O
cisplatin	-	455	O
have	-	465	O
activity	-	470	O
in	-	479	O
HL	-	482	B
,	-	484	O
non	-	486	O
-	-	489	O
overlapping	-	490	O
toxicity	-	502	B
with	-	511	O
first	-	516	O
-	-	521	O
line	-	522	O
chemotherapeutics	-	527	O
,	-	544	O
and	-	546	O
may	-	550	O
be	-	554	O
delivered	-	557	O
in	-	567	O
an	-	570	O
outpatient	-	573	O
setting	-	584	O
.	-	591	O

In	24158386	593	O
this	-	596	O
retrospective	-	601	O
single	-	615	O
-	-	621	O
centre	-	622	O
analysis	-	629	O
,	-	637	O
patients	-	639	O
with	-	648	O
relapsed	-	653	O
or	-	662	O
refractory	-	665	O
HL	-	676	B
treated	-	679	O
with	-	687	O
gemcitabine	-	692	O
1	-	704	O
,	-	705	O
000	-	706	O
mg	-	710	O
/	-	712	O
m	-	713	O
(	-	714	O
2	-	715	O
)	-	716	O
day	-	718	O
(	-	722	O
D	-	723	O
)	-	724	O
1	-	725	O
,	-	726	O
D8	-	728	O
and	-	731	O
D15	-	735	O
;	-	738	O
methylprednisolone	-	740	O
1	-	759	O
,	-	760	O
000	-	761	O
mg	-	765	O
D1	-	768	O
-	-	770	O
5	-	771	O
;	-	772	O
and	-	774	O
cisplatin	-	778	O
100	-	788	O
mg	-	792	O
/	-	794	O
m	-	795	O
(	-	796	O
2	-	797	O
)	-	798	O
D15	-	800	O
,	-	803	O
every	-	805	O
28	-	811	O
days	-	814	O
(	-	819	O
GEM	-	820	O
-	-	823	O
P	-	824	O
)	-	825	O
were	-	827	O
included	-	832	O
.	-	840	O

Demographic	24158386	842	O
,	-	853	O
survival	-	855	O
,	-	863	O
response	-	865	O
and	-	874	O
toxicity	-	878	B
data	-	887	O
were	-	892	O
recorded	-	897	O
.	-	905	O

Forty	24158386	907	O
-	-	912	O
one	-	913	O
eligible	-	917	O
patients	-	926	O
were	-	935	O
identified	-	940	O
:	-	950	O
median	-	952	O
age	-	959	O
27	-	963	O
.	-	965	O

One	24158386	967	O
hundred	-	971	O
and	-	979	O
twenty	-	983	O
-	-	989	O
two	-	990	O
cycles	-	994	O
of	-	1001	O
GEM	-	1004	O
-	-	1007	O
P	-	1008	O
were	-	1010	O
administered	-	1015	O
in	-	1028	O
total	-	1031	O
(	-	1037	O
median	-	1038	O
3	-	1045	O
cycles	-	1047	O
;	-	1053	O
range	-	1055	O
1	-	1061	O
-	-	1062	O
6	-	1063	O
)	-	1064	O
.	-	1065	O

Twenty	24158386	1067	O
of	-	1074	O
41	-	1077	O
(	-	1080	O
48	-	1081	O
%	-	1084	O
)	-	1085	O
patients	-	1087	O
received	-	1096	O
GEM	-	1105	O
-	-	1108	O
P	-	1109	O
as	-	1111	O
second	-	1114	O
-	-	1120	O
line	-	1121	O
treatment	-	1126	O
and	-	1136	O
11	-	1140	O
/	-	1142	O
41	-	1143	O
(	-	1146	O
27	-	1147	O
%	-	1150	O
)	-	1151	O
as	-	1153	O
third	-	1156	O
-	-	1161	O
line	-	1162	O
therapy	-	1167	O
.	-	1174	O

Overall	24158386	1176	O
response	-	1184	O
rate	-	1193	O
(	-	1198	O
ORR	-	1199	O
)	-	1202	O
to	-	1204	O
GEM	-	1207	O
-	-	1210	O
P	-	1211	O
in	-	1213	O
the	-	1216	O
entire	-	1220	O
cohort	-	1227	O
was	-	1234	O
80	-	1238	O
%	-	1241	O
(	-	1243	O
complete	-	1244	O
response	-	1253	O
(	-	1262	O
CR	-	1263	O
)	-	1265	O
37	-	1267	O
%	-	1270	O
,	-	1271	O
partial	-	1273	O
response	-	1281	O
44	-	1290	O
%	-	1293	O
)	-	1294	O
with	-	1296	O
14	-	1301	O
/	-	1303	O
15	-	1304	O
CR	-	1307	O
confirmed	-	1310	O
as	-	1320	O
a	-	1323	O
metabolic	-	1325	O
CR	-	1335	O
on	-	1338	O
PET	-	1341	O
and	-	1345	O
ORR	-	1349	O
of	-	1353	O
85	-	1356	O
%	-	1359	O
in	-	1361	O
the	-	1364	O
20	-	1368	O
second	-	1371	O
-	-	1377	O
line	-	1378	O
patients	-	1383	O
.	-	1391	O

The	24158386	1393	O
most	-	1397	O
common	-	1402	O
grade	-	1409	O
3	-	1415	O
/	-	1416	O
4	-	1417	O
toxicities	-	1419	B
were	-	1430	O
haematological	-	1435	O
:	-	1449	O
neutropenia	-	1451	B
54	-	1463	O
%	-	1466	O
and	-	1468	O
thrombocytopenia	-	1472	B
51	-	1489	O
%	-	1492	O
.	-	1493	O

Median	24158386	1495	O
follow	-	1502	O
-	-	1508	O
up	-	1509	O
from	-	1512	O
the	-	1517	O
start	-	1521	O
of	-	1527	O
GEM	-	1530	O
-	-	1533	O
P	-	1534	O
was	-	1536	O
4	-	1540	O
.	-	1541	O
5	-	1542	O
years	-	1544	O
.	-	1549	O

Following	24158386	1551	O
GEM	-	1561	O
-	-	1564	O
P	-	1565	O
,	-	1566	O
5	-	1568	O
-	-	1569	O
year	-	1570	O
progression	-	1575	O
-	-	1586	O
free	-	1587	O
survival	-	1592	O
was	-	1601	O
46	-	1605	O
%	-	1608	O
(	-	1610	O
95	-	1611	O
%	-	1614	O
confidence	-	1616	O
interval	-	1627	O
(	-	1636	O
CI	-	1637	O
)	-	1639	O
,	-	1640	O
30	-	1642	O
-	-	1644	O
62	-	1645	O
%	-	1648	O
)	-	1649	O
and	-	1651	O
5	-	1655	O
-	-	1656	O
year	-	1657	O
overall	-	1662	O
survival	-	1670	O
was	-	1679	O
59	-	1683	O
%	-	1686	O
(	-	1688	O
95	-	1689	O
%	-	1692	O
CI	-	1694	O
,	-	1696	O
43	-	1698	O
-	-	1700	O
74	-	1701	O
%	-	1704	O
)	-	1705	O
.	-	1706	O

Fourteen	24158386	1708	O
of	-	1717	O
41	-	1720	O
patients	-	1723	O
proceeded	-	1732	O
directly	-	1742	O
to	-	1751	O
autologous	-	1754	O
transplant	-	1765	O
.	-	1775	O

GEM	24158386	1777	O
-	-	1780	O
P	-	1781	O
is	-	1783	O
a	-	1786	O
salvage	-	1788	O
chemotherapy	-	1796	O
with	-	1809	O
relatively	-	1814	O
high	-	1825	O
response	-	1830	O
rates	-	1839	O
,	-	1844	O
leading	-	1846	O
to	-	1854	O
successful	-	1857	O
transplantation	-	1868	O
in	-	1884	O
appropriate	-	1887	O
patients	-	1899	O
,	-	1907	O
in	-	1909	O
the	-	1912	O
treatment	-	1916	O
of	-	1926	O
relapsed	-	1929	O
or	-	1938	O
refractory	-	1941	O
HL	-	1952	B
.	-	1954	O

Basal	24190587	0	O
functioning	-	6	O
of	-	18	O
the	-	21	O
hypothalamic	-	25	O
-	-	37	O
pituitary	-	38	O
-	-	47	O
adrenal	-	48	O
(	-	56	O
HPA	-	57	O
)	-	60	O
axis	-	62	O
and	-	67	O
psychological	-	71	O
distress	-	85	O
in	-	94	O
recreational	-	97	O
ecstasy	-	110	O
polydrug	-	118	O
users	-	127	O
.	-	132	O

RATIONALE	24190587	134	O
:	-	143	O
Ecstasy	-	145	O
(	-	153	O
MDMA	-	154	O
)	-	158	O
is	-	160	O
a	-	163	O
psychostimulant	-	165	O
drug	-	181	O
which	-	186	O
is	-	192	O
increasingly	-	195	O
associated	-	208	O
with	-	219	O
psychobiological	-	224	B
dysfunction	-	241	I
.	-	252	O

While	24190587	254	O
some	-	260	O
recent	-	265	O
studies	-	272	O
suggest	-	280	O
acute	-	288	O
changes	-	294	O
in	-	302	O
neuroendocrine	-	305	O
function	-	320	O
,	-	328	O
less	-	330	O
is	-	335	O
known	-	338	O
about	-	344	O
long	-	350	O
-	-	354	O
term	-	355	O
changes	-	360	O
in	-	368	O
HPA	-	371	O
functionality	-	375	O
in	-	389	O
recreational	-	392	O
users	-	405	O
.	-	410	O

OBJECTIVES	24190587	412	O
:	-	422	O

The	24190587	424	O
current	-	428	O
study	-	436	O
is	-	442	O
the	-	445	O
first	-	449	O
to	-	455	O
explore	-	458	O
the	-	466	O
effects	-	470	O
of	-	478	O
ecstasy	-	481	O
-	-	488	O
polydrug	-	489	O
use	-	498	O
on	-	502	O
psychological	-	505	O
distress	-	519	O
and	-	528	O
basal	-	532	O
functioning	-	538	O
of	-	550	O
the	-	553	O
HPA	-	557	O
axis	-	561	O
through	-	566	O
assessing	-	574	O
the	-	584	O
secretion	-	588	O
of	-	598	O
cortisol	-	601	O
across	-	610	O
the	-	617	O
diurnal	-	621	O
period	-	629	O
.	-	635	O

METHOD	24190587	637	O
:	-	643	O
Seventy	-	645	O
-	-	652	O
six	-	653	O
participants	-	657	O
(	-	670	O
21	-	671	O
nonusers	-	674	O
,	-	682	O
29	-	684	O
light	-	687	O
ecstasy	-	693	O
-	-	700	O
polydrug	-	701	O
users	-	710	O
,	-	715	O
26	-	717	O
heavy	-	720	O
ecstasy	-	726	O
-	-	733	O
polydrug	-	734	O
users	-	743	O
)	-	748	O
completed	-	750	O
a	-	760	O
substance	-	762	O
use	-	772	O
inventory	-	776	O
and	-	786	O
measures	-	790	O
of	-	799	O
psychological	-	802	O
distress	-	816	O
at	-	825	O
baseline	-	828	O
,	-	836	O
then	-	838	O
two	-	843	O
consecutive	-	847	O
days	-	859	O
of	-	864	O
cortisol	-	867	O
sampling	-	876	O
(	-	885	O
on	-	886	O
awakening	-	889	O
,	-	898	O
30	-	900	O
min	-	903	O
post	-	907	O
awakening	-	912	O
,	-	921	O
between	-	923	O
1400	-	931	O
and	-	936	O
1600	-	940	O
hours	-	945	O
and	-	951	O
pre	-	955	O
bedtime	-	959	O
)	-	966	O
.	-	967	O

On	24190587	969	O
day	-	972	O
2	-	976	O
,	-	977	O
participants	-	979	O
also	-	992	O
attended	-	997	O
the	-	1006	O
laboratory	-	1010	O
to	-	1021	O
complete	-	1024	O
a	-	1033	O
20	-	1035	O
-	-	1037	O
min	-	1038	O
multitasking	-	1042	O
stressor	-	1055	O
.	-	1063	O

RESULTS	24190587	1065	O
:	-	1072	O

Both	24190587	1074	O
user	-	1079	O
groups	-	1084	O
exhibited	-	1091	O
significantly	-	1101	O
greater	-	1115	O
levels	-	1123	O
of	-	1130	O
anxiety	-	1133	B
and	-	1141	O
depression	-	1145	B
than	-	1156	O
nonusers	-	1161	O
.	-	1169	O

On	24190587	1171	O
day	-	1174	O
1	-	1178	O
,	-	1179	O
all	-	1181	O
participants	-	1185	O
exhibited	-	1198	O
a	-	1208	O
typical	-	1210	O
cortisol	-	1218	O
profile	-	1227	O
,	-	1234	O
though	-	1236	O
light	-	1243	O
users	-	1249	O
had	-	1255	O
significantly	-	1259	O
elevated	-	1273	O
levels	-	1282	O
pre	-	1289	O
-	-	1292	O
bed	-	1293	O
.	-	1296	O

On	24190587	1298	O
day	-	1301	O
2	-	1305	O
,	-	1306	O
heavy	-	1308	O
users	-	1314	O
demonstrated	-	1320	O
elevated	-	1333	O
levels	-	1342	O
upon	-	1349	O
awakening	-	1354	O
and	-	1364	O
all	-	1368	O
ecstasy	-	1372	O
-	-	1379	O
polydrug	-	1380	O
users	-	1389	O
demonstrated	-	1395	O
elevated	-	1408	O
pre	-	1417	O
-	-	1420	O
bed	-	1421	O
levels	-	1425	O
compared	-	1432	O
to	-	1441	O
non	-	1444	O
-	-	1447	O
users	-	1448	O
.	-	1453	O

Significant	24190587	1455	O
between	-	1467	O
group	-	1475	O
differences	-	1481	O
were	-	1493	O
also	-	1498	O
observed	-	1503	O
in	-	1512	O
afternoon	-	1515	O
cortisol	-	1525	O
levels	-	1534	O
and	-	1541	O
in	-	1545	O
overall	-	1548	O
cortisol	-	1556	O
secretion	-	1565	O
across	-	1575	O
the	-	1582	O
day	-	1586	O
.	-	1589	O

CONCLUSIONS	24190587	1591	O
:	-	1602	O

The	24190587	1604	O
increases	-	1608	O
in	-	1618	O
anxiety	-	1621	B
and	-	1629	O
depression	-	1633	B
are	-	1644	O
in	-	1648	O
line	-	1651	O
with	-	1656	O
previous	-	1661	O
observations	-	1670	O
in	-	1683	O
recreational	-	1686	O
ecstasy	-	1699	O
-	-	1706	O
polydrug	-	1707	O
users	-	1716	O
.	-	1721	O

Dysregulated	24190587	1723	O
diurnal	-	1736	O
cortisol	-	1744	O
may	-	1753	O
be	-	1757	O
indicative	-	1760	O
of	-	1771	O
inappropriate	-	1774	O
anticipation	-	1788	O
of	-	1801	O
forthcoming	-	1804	O
demands	-	1816	O
and	-	1824	O
hypersecretion	-	1828	O
may	-	1843	O
lead	-	1847	O
to	-	1852	O
the	-	1855	O
increased	-	1859	O
psychological	-	1869	O
and	-	1883	O
physical	-	1887	O
morbidity	-	1896	O
associated	-	1906	O
with	-	1917	O
heavy	-	1922	O
recreational	-	1928	O
use	-	1941	O
of	-	1945	O
ecstasy	-	1948	O
.	-	1955	O

Ifosfamide	24209900	0	O
related	-	11	O
encephalopathy	-	19	B
:	-	33	O
the	-	35	O
need	-	39	O
for	-	44	O
a	-	48	O
timely	-	50	O
EEG	-	57	O
evaluation	-	61	O
.	-	71	O

BACKGROUND	24209900	73	O
:	-	83	O
Ifosfamide	-	85	O
is	-	96	O
an	-	99	O
alkylating	-	102	O
agent	-	113	O
useful	-	119	O
in	-	126	O
the	-	129	O
treatment	-	133	O
of	-	143	O
a	-	146	O
wide	-	148	O
range	-	153	O
of	-	159	O
cancers	-	162	B
including	-	170	O
sarcomas	-	180	B
,	-	188	O
lymphoma	-	190	B
,	-	198	O
gynecologic	-	200	B
and	-	212	I
testicular	-	216	I
cancers	-	227	I
.	-	234	O

Encephalopathy	24209900	236	B
has	-	251	O
been	-	255	O
reported	-	260	O
in	-	269	O
10	-	272	O
-	-	274	O
40	-	275	O
%	-	277	O
of	-	279	O
patients	-	282	O
receiving	-	291	O
high	-	301	O
-	-	305	O
dose	-	306	O
IV	-	311	O
ifosfamide	-	314	O
.	-	324	O

OBJECTIVE	24209900	326	O
:	-	335	O

To	24209900	337	O
highlight	-	340	O
the	-	350	O
role	-	354	O
of	-	359	O
electroencephalogram	-	362	O
(	-	383	O
EEG	-	384	O
)	-	387	O
in	-	389	O
the	-	392	O
early	-	396	O
detection	-	402	O
and	-	412	O
management	-	416	O
of	-	427	O
ifosfamide	-	430	O
related	-	441	O
encephalopathy	-	449	B
.	-	463	O

METHODS	24209900	465	O
:	-	472	O

Retrospective	24209900	474	O
chart	-	488	O
review	-	494	O
including	-	501	O
clinical	-	511	O
data	-	520	O
and	-	525	O
EEG	-	529	O
recordings	-	533	O
was	-	544	O
done	-	548	O
on	-	553	O
five	-	556	O
patients	-	561	O
,	-	569	O
admitted	-	571	O
to	-	580	O
MD	-	583	O
Anderson	-	586	O
Cancer	-	595	B
Center	-	602	O
between	-	609	O
years	-	617	O
2009	-	623	O
and	-	628	O
2012	-	632	O
,	-	636	O
who	-	638	O
developed	-	642	O
ifosfamide	-	652	O
related	-	663	O
acute	-	671	O
encephalopathy	-	677	B
.	-	691	O

RESULTS	24209900	693	O
:	-	700	O

All	24209900	702	O
five	-	706	O
patients	-	711	O
experienced	-	720	O
symptoms	-	732	O
of	-	741	O
encephalopathy	-	744	B
soon	-	759	O
after	-	764	O
(	-	770	O
within	-	771	O
12	-	778	O
h	-	781	O
-	-	782	O
2	-	783	O
days	-	785	O
)	-	789	O
receiving	-	791	O
ifosfamide	-	801	O
.	-	811	O

Two	24209900	813	O
patients	-	817	O
developed	-	826	O
generalized	-	836	O
convulsions	-	848	B
while	-	860	O
one	-	866	O
patient	-	870	O
developed	-	878	O
continuous	-	888	O
non	-	899	B
-	-	902	I
convulsive	-	903	I
status	-	914	I
epilepticus	-	921	I
(	-	933	O
NCSE	-	934	B
)	-	938	O
that	-	940	O
required	-	945	O
ICU	-	954	O
admission	-	958	O
and	-	968	O
intubation	-	972	O
.	-	982	O

Initial	24209900	984	O
EEG	-	992	O
showed	-	996	O
epileptiform	-	1003	O
discharges	-	1016	O
in	-	1027	O
three	-	1030	O
patients	-	1036	O
;	-	1044	O
run	-	1046	O
of	-	1050	O
triphasic	-	1053	O
waves	-	1063	O
in	-	1069	O
one	-	1072	O
patient	-	1076	O
and	-	1084	O
moderate	-	1088	O
degree	-	1097	O
diffuse	-	1104	O
generalized	-	1112	O
slowing	-	1124	O
.	-	1131	O

Mixed	24209900	1133	O
pattern	-	1139	O
with	-	1147	O
the	-	1152	O
presence	-	1156	O
of	-	1165	O
both	-	1168	O
sharps	-	1173	O
and	-	1180	O
triphasic	-	1184	O
waves	-	1194	O
were	-	1200	O
also	-	1205	O
noted	-	1210	O
.	-	1215	O

Repeat	24209900	1217	O
EEGs	-	1224	O
within	-	1229	O
24_h	-	1236	O
of	-	1241	O
symptom	-	1244	O
onset	-	1252	O
showed	-	1258	O
marked	-	1265	O
improvement	-	1272	O
that	-	1284	O
was	-	1289	O
correlated	-	1293	O
with	-	1304	O
clinical	-	1309	O
improvement	-	1318	O
.	-	1329	O

CONCLUSIONS	24209900	1331	O
:	-	1342	O

Severity	24209900	1344	O
of	-	1353	O
ifosfamide	-	1356	O
related	-	1367	O
encephalopathy	-	1375	B
correlates	-	1390	O
with	-	1401	O
EEG	-	1406	O
changes	-	1410	O
.	-	1417	O

We	24209900	1419	O
suggest	-	1422	O
a	-	1430	O
timely	-	1432	O
EEG	-	1439	O
evaluation	-	1443	O
for	-	1454	O
patients	-	1458	O
receiving	-	1467	O
ifosfamide	-	1477	O
who	-	1488	O
develop	-	1492	O
features	-	1500	O
of	-	1509	O
encephalopathy	-	1512	B
.	-	1526	O

Incidence	24220752	0	O
of	-	10	O
contrast	-	13	O
-	-	21	O
induced	-	22	O
nephropathy	-	30	B
in	-	42	O
hospitalised	-	45	O
patients	-	58	O
with	-	67	O
cancer	-	72	B
.	-	78	O

OBJECTIVES	24220752	80	O
:	-	90	O

To	24220752	92	O
determine	-	95	O
the	-	105	O
frequency	-	109	O
of	-	119	O
and	-	122	O
possible	-	126	O
factors	-	135	O
related	-	143	O
to	-	151	O
contrast	-	154	O
-	-	162	O
induced	-	163	O
nephropathy	-	171	B
(	-	183	O
CIN	-	184	O
)	-	187	O
in	-	189	O
hospitalised	-	192	O
patients	-	205	O
with	-	214	O
cancer	-	219	B
.	-	225	O

METHODS	24220752	227	O
:	-	234	O

Ninety	24220752	236	O
adult	-	243	O
patients	-	249	O
were	-	258	O
enrolled	-	263	O
.	-	271	O

Patients	24220752	273	O
with	-	282	O
risk	-	287	O
factors	-	292	O
for	-	300	O
acute	-	304	B
renal	-	310	I
failure	-	316	I
were	-	324	O
excluded	-	329	O
.	-	337	O

Blood	24220752	339	O
samples	-	345	O
were	-	353	O
examined	-	358	O
the	-	367	O
day	-	371	O
before	-	375	O
contrast	-	382	O
-	-	390	O
enhanced	-	391	O
computed	-	400	O
tomography	-	409	O
(	-	420	O
CT	-	421	O
)	-	423	O
and	-	425	O
serially	-	429	O
for	-	438	O
3	-	442	O
days	-	444	O
thereafter	-	449	O
.	-	459	O

CIN	24220752	461	O
was	-	465	O
defined	-	469	O
as	-	477	O
an	-	480	O
increase	-	483	O
in	-	492	O
serum	-	495	O
creatinine	-	501	O
(	-	512	O
Cr	-	513	O
)	-	515	O
of	-	517	O
0	-	520	O
.	-	521	O
5	-	522	O
mg	-	524	O
/	-	526	O
dl	-	527	O
or	-	530	O
more	-	533	O
,	-	537	O
or	-	539	O
elevation	-	542	O
of	-	552	O
Cr	-	555	O
to	-	558	O
25	-	561	O
%	-	564	O
over	-	566	O
baseline	-	571	O
.	-	579	O

Relationships	24220752	581	O
between	-	595	O
CIN	-	603	O
and	-	607	O
possible	-	611	O
risk	-	620	O
factors	-	625	O
were	-	633	O
investigated	-	638	O
.	-	650	O

RESULTS	24220752	652	O
:	-	659	O

CIN	24220752	661	O
was	-	665	O
detected	-	669	O
in	-	678	O
18	-	681	O
/	-	683	O
90	-	684	O
(	-	687	O
20	-	688	O
%	-	691	O
)	-	692	O
patients	-	694	O
.	-	702	O

CIN	24220752	704	O
developed	-	708	O
in	-	718	O
25	-	721	O
.	-	723	O
5	-	724	O
%	-	726	O
patients	-	728	O
who	-	737	O
underwent	-	741	O
chemotherapy	-	751	O
and	-	764	O
in	-	768	O
11	-	771	O
%	-	774	O
patients	-	776	O
who	-	785	O
did	-	789	O
not	-	793	O
(	-	797	O
P	-	798	O
=	-	800	O
0	-	802	O
.	-	803	O
1	-	804	O
)	-	805	O
.	-	806	O

CIN	24220752	808	O
more	-	812	O
frequently	-	817	O
developed	-	828	O
in	-	838	O
patients	-	841	O
who	-	850	O
had	-	854	O
undergone	-	858	O
CT	-	868	O
within	-	871	O
45	-	878	O
days	-	881	O
after	-	886	O
the	-	892	O
last	-	896	O
chemotherapy	-	901	O
(	-	914	O
P	-	915	O
=	-	917	O
0	-	919	O
.	-	920	O
005	-	921	O
)	-	924	O
;	-	925	O
it	-	927	O
was	-	930	O
also	-	934	O
an	-	939	O
independent	-	942	O
risk	-	954	O
factor	-	959	O
(	-	966	O
P	-	967	O
=	-	969	O
0	-	971	O
.	-	972	O
017	-	973	O
)	-	976	O
.	-	977	O

CIN	24220752	979	O
was	-	983	O
significantly	-	987	O
more	-	1001	O
after	-	1006	O
treatment	-	1012	O
with	-	1022	O
bevacizumab	-	1027	O
/	-	1038	O
irinotecan	-	1039	O
(	-	1050	O
P	-	1051	O
=	-	1053	O
0	-	1055	O
.	-	1056	O
021	-	1057	O
)	-	1060	O
and	-	1062	O
in	-	1066	O
patients	-	1069	O
with	-	1078	O
hypertension	-	1083	B
(	-	1096	O
P	-	1097	O
=	-	1099	O
0	-	1101	O
.	-	1102	O
044	-	1103	O
)	-	1106	O
.	-	1107	O

CONCLUSIONS	24220752	1109	O
:	-	1120	O

The	24220752	1122	O
incidence	-	1126	O
of	-	1136	O
CIN	-	1139	O
after	-	1143	O
CT	-	1149	O
in	-	1152	O
hospitalised	-	1155	O
oncological	-	1168	O
patients	-	1180	O
was	-	1189	O
20	-	1193	O
%	-	1196	O
.	-	1197	O

CIN	24220752	1199	O
developed	-	1203	O
4	-	1213	O
.	-	1214	O
5	-	1215	O
-	-	1216	O
times	-	1217	O
more	-	1223	O
frequently	-	1228	O
in	-	1239	O
patients	-	1242	O
with	-	1251	O
cancer	-	1256	B
who	-	1263	O
had	-	1267	O
undergone	-	1271	O
recent	-	1281	O
chemotherapy	-	1288	O
.	-	1300	O

Hypertension	24220752	1302	B
and	-	1315	O
the	-	1319	O
combination	-	1323	O
of	-	1335	O
bevacizumab	-	1338	O
/	-	1349	O
irinotecan	-	1350	O
may	-	1361	O
be	-	1365	O
additional	-	1368	O
risk	-	1379	O
factors	-	1384	O
for	-	1392	O
CIN	-	1396	O
development	-	1400	O
.	-	1411	O

KEY	24220752	1413	O
POINTS	-	1417	O
:	-	1423	O
.	-	1425	O

Contrast	24220752	1427	O
-	-	1435	O
induced	-	1436	O
nephropathy	-	1444	B
(	-	1456	O
CIN	-	1457	O
)	-	1460	O
is	-	1462	O
a	-	1465	O
concern	-	1467	O
for	-	1475	O
oncological	-	1479	O
patients	-	1491	O
undergoing	-	1500	O
CT	-	1511	O
.	-	1513	O
.	-	1515	O

CIN	24220752	1517	O
occurs	-	1521	O
more	-	1528	O
often	-	1533	O
when	-	1539	O
CT	-	1544	O
is	-	1547	O
performed	-	1550	O
<	-	1560	O
45	-	1561	O
days	-	1564	O
after	-	1569	O
chemotherapy	-	1575	O
.	-	1587	O
.	-	1589	O

Hypertension	24220752	1591	B
and	-	1604	O
treatment	-	1608	O
with	-	1618	O
bevacizumab	-	1623	O
appear	-	1635	O
to	-	1642	O
be	-	1645	O
additional	-	1648	O
risk	-	1659	O
factors	-	1664	O
.	-	1671	O

Syndrome	24234943	0	B
of	-	9	I
inappropriate	-	12	I
antidiuretic	-	26	I
hormone	-	39	I
secretion	-	47	O
associated	-	57	O
with	-	68	O
desvenlafaxine	-	73	O
.	-	87	O

OBJECTIVE	24234943	89	O
:	-	98	O

To	24234943	100	O
report	-	103	O
a	-	110	O
case	-	112	O
of	-	117	O
syndrome	-	120	B
of	-	129	I
inappropriate	-	132	I
anti	-	146	I
-	-	150	I
diuretic	-	151	I
hormone	-	160	I
(	-	168	O
SIADH	-	169	B
)	-	174	O
secretion	-	176	O
associated	-	186	O
with	-	197	O
desvenlafaxine	-	202	O
.	-	216	O

CASE	24234943	218	O
SUMMARY	-	223	O
:	-	230	O

A	24234943	232	O
57	-	234	O
-	-	236	O
year	-	237	O
old	-	242	O
female	-	246	O
with	-	253	O
hyponatraemia	-	258	B
.	-	271	O

Her	24234943	273	O
medications	-	277	O
included	-	289	O
desvenlafaxine	-	298	O
,	-	312	O
and	-	314	O
symptoms	-	318	O
included	-	327	O
nausea	-	336	B
,	-	342	O
anxiety	-	344	B
and	-	352	O
confusion	-	356	B
.	-	365	O

The	24234943	367	O
serum	-	371	O
sodium	-	377	O
at	-	384	O
this	-	387	O
time	-	392	O
was	-	397	O
120	-	401	O
mmol	-	405	O
/	-	409	O
L	-	410	O
,	-	411	O
serum	-	413	O
osmolality	-	419	O
was	-	430	O
263	-	434	O
mosmol	-	438	O
/	-	444	O
kg	-	445	O
,	-	447	O
urine	-	449	O
osmolality	-	455	O
410	-	466	O
mosmol	-	470	O
/	-	476	O
kg	-	477	O
and	-	480	O
urine	-	484	O
sodium	-	490	O
63	-	497	O
mmol	-	500	O
/	-	504	O
L	-	505	O
,	-	506	O
consistent	-	508	O
with	-	519	O
a	-	524	O
diagnosis	-	526	O
of	-	536	O
SIADH	-	539	B
.	-	544	O

Desvenlafaxine	24234943	546	O
was	-	561	O
ceased	-	565	O
and	-	572	O
fluid	-	576	O
restriction	-	582	O
implemented	-	594	O
.	-	605	O

After	24234943	607	O
4	-	613	O
days	-	615	O
the	-	620	O
sodium	-	624	O
increased	-	631	O
to	-	641	O
128	-	644	O
mmol	-	648	O
/	-	652	O
L	-	653	O
and	-	655	O
fluid	-	659	O
restriction	-	665	O
was	-	677	O
relaxed	-	681	O
.	-	688	O

During	24234943	690	O
her	-	697	O
further	-	701	O
3	-	709	O
weeks	-	711	O
inpatient	-	717	O
admission	-	727	O
the	-	737	O
serum	-	741	O
sodium	-	747	O
ranged	-	754	O
from	-	761	O
134	-	766	O
to	-	770	O
137	-	773	O
mmol	-	777	O
/	-	781	O
L	-	782	O
during	-	784	O
treatment	-	791	O
with	-	801	O
mirtazapine	-	806	O
.	-	817	O

DISCUSSION	24234943	819	O
:	-	829	O

SIADH	24234943	831	B
has	-	837	O
been	-	841	O
widely	-	846	O
reported	-	853	O
with	-	862	O
a	-	867	O
range	-	869	O
of	-	875	O
antidepressants	-	878	O
.	-	893	O

This	24234943	895	O
case	-	900	O
report	-	905	O
suggests	-	912	O
that	-	921	O
desvenlafaxine	-	926	O
might	-	941	O
cause	-	947	O
clinically	-	953	O
significant	-	964	O
hyponatremia	-	976	B
.	-	988	O

CONCLUSIONS	24234943	990	O
:	-	1001	O

Clinicians	24234943	1003	O
should	-	1014	O
be	-	1021	O
aware	-	1024	O
of	-	1030	O
the	-	1033	O
potential	-	1037	O
for	-	1047	O
antidepressants	-	1051	O
to	-	1067	O
cause	-	1070	O
hyponatremia	-	1076	B
,	-	1088	O
and	-	1089	O
take	-	1093	O
appropriate	-	1098	O
corrective	-	1110	O
action	-	1121	O
where	-	1128	O
necessary	-	1134	O
.	-	1143	O

Oxidative	24275640	0	O
stress	-	10	O
on	-	17	O
cardiotoxicity	-	20	B
after	-	35	O
treatment	-	41	O
with	-	51	O
single	-	56	O
and	-	63	O
multiple	-	67	O
doses	-	76	O
of	-	82	O
doxorubicin	-	85	O
.	-	96	O

The	24275640	98	O
mechanism	-	102	O
of	-	112	O
doxorubicin	-	115	O
(	-	127	O
DOX	-	128	O
)	-	131	O
-	-	132	O
induced	-	133	O
cardiotoxicity	-	141	B
remains	-	156	O
controversial	-	164	O
.	-	177	O

Wistar	24275640	179	O
rats	-	186	O
(	-	191	O
n	-	192	O
=	-	194	O
66	-	196	O
)	-	198	O
received	-	200	O
DOX	-	209	O
injections	-	213	O
intraperitoneally	-	224	O
and	-	242	O
were	-	246	O
randomly	-	251	O
assigned	-	260	O
to	-	269	O
2	-	272	O
experimental	-	274	O
protocols	-	287	O
:	-	296	O
(	-	298	O
1	-	299	O
)	-	300	O
rats	-	302	O
were	-	307	O
killed	-	312	O
before	-	319	O
(	-	326	O
-	-	327	O
24	-	328	O
h	-	331	O
,	-	332	O
n	-	334	O
=	-	336	O
8	-	338	O
)	-	339	O
and	-	341	O
24	-	345	O
h	-	348	O
after	-	350	O
(	-	356	O
+	-	357	O
24	-	358	O
h	-	361	O
,	-	362	O
n	-	364	O
=	-	366	O
8	-	368	O
)	-	369	O
a	-	371	O
single	-	373	O
dose	-	380	O
of	-	385	O
DOX	-	388	O
(	-	392	O
4	-	393	O
mg	-	395	O
/	-	397	O
kg	-	398	O
body	-	401	O
weight	-	406	O
)	-	412	O
to	-	414	O
determine	-	417	O
the	-	427	O
DOX	-	431	O
acute	-	435	O
effect	-	441	O
and	-	448	O
(	-	452	O
2	-	453	O
)	-	454	O
rats	-	456	O
(	-	461	O
n	-	462	O
=	-	464	O
58	-	466	O
)	-	468	O
received	-	470	O
4	-	479	O
injections	-	481	O
of	-	492	O
DOX	-	495	O
(	-	499	O
4	-	500	O
mg	-	502	O
/	-	504	O
kg	-	505	O
body	-	508	O
weight	-	513	O
/	-	519	O
week	-	520	O
)	-	524	O
and	-	526	O
were	-	530	O
killed	-	535	O
before	-	542	O
the	-	549	O
first	-	553	O
injection	-	559	O
(	-	569	O
M0	-	570	O
)	-	572	O
and	-	574	O
1	-	578	O
week	-	580	O
after	-	585	O
each	-	591	O
injection	-	596	O
(	-	606	O
M1	-	607	O
,	-	609	O
M2	-	611	O
,	-	613	O
M3	-	615	O
,	-	617	O
and	-	619	O
M4	-	623	O
)	-	625	O
to	-	627	O
determine	-	630	O
the	-	640	O
chronological	-	644	O
effects	-	658	O
.	-	665	O

Animals	24275640	667	O
used	-	675	O
at	-	680	O
M0	-	683	O
(	-	686	O
n	-	687	O
=	-	689	O
8	-	691	O
)	-	692	O
were	-	694	O
also	-	699	O
used	-	704	O
at	-	709	O
moment	-	712	O
-	-	719	O
24	-	720	O

h	24275640	723	O
of	-	725	O
acute	-	728	O
study	-	734	O
.	-	739	O

Cardiac	24275640	741	O
total	-	749	O
antioxidant	-	755	O
performance	-	767	O
(	-	779	O
TAP	-	780	O
)	-	783	O
,	-	784	O
DNA	-	786	O
damage	-	790	O
,	-	796	O
and	-	798	O
morphology	-	802	O
analyses	-	813	O
were	-	822	O
carried	-	827	O
out	-	835	O
at	-	839	O
each	-	842	O
time	-	847	O
point	-	852	O
.	-	857	O

Single	24275640	859	O
dose	-	866	O
of	-	871	O
DOX	-	874	O
was	-	878	O
associated	-	882	O
with	-	893	O
increased	-	898	O
cardiac	-	908	B
disarrangement	-	916	I
,	-	930	O
necrosis	-	932	B
,	-	940	O
and	-	942	O
DNA	-	946	O
damage	-	950	O
(	-	957	O
strand	-	958	O
breaks	-	965	O
(	-	972	O
SBs	-	973	O
)	-	976	O
and	-	978	O
oxidized	-	982	O
pyrimidines	-	991	O
)	-	1002	O
and	-	1004	O
decreased	-	1008	O
TAP	-	1018	O
.	-	1021	O

The	24275640	1023	O
chronological	-	1027	O
study	-	1041	O
showed	-	1047	O
an	-	1054	O
effect	-	1057	O
of	-	1064	O
a	-	1067	O
cumulative	-	1069	O
dose	-	1080	O
on	-	1085	O
body	-	1088	O
weight	-	1093	O
(	-	1100	O
R	-	1101	O
=	-	1103	O
-	-	1105	O
0	-	1106	O
.	-	1107	O
99	-	1108	O
,	-	1110	O
p	-	1112	O
=	-	1114	O
0	-	1116	O
.	-	1117	O
011	-	1118	O
)	-	1121	O
,	-	1122	O
necrosis	-	1124	B
(	-	1133	O
R	-	1134	O
=	-	1136	O
1	-	1138	O
.	-	1139	O
00	-	1140	O
,	-	1142	O
p	-	1144	O
=	-	1146	O
0	-	1148	O
.	-	1149	O
004	-	1150	O
)	-	1153	O
,	-	1154	O
TAP	-	1156	O
(	-	1160	O
R	-	1161	O
=	-	1163	O
0	-	1165	O
.	-	1166	O
95	-	1167	O
,	-	1169	O
p	-	1171	O
=	-	1173	O
0	-	1175	O
.	-	1176	O
049	-	1177	O
)	-	1180	O
,	-	1181	O
and	-	1183	O
DNA	-	1187	O
SBs	-	1191	O
(	-	1195	O
R	-	1196	O
=	-	1198	O
-	-	1200	O
0	-	1201	O
.	-	1202	O
95	-	1203	O
,	-	1205	O
p	-	1207	O
=	-	1209	O
0	-	1211	O
.	-	1212	O
049	-	1213	O
)	-	1216	O
.	-	1217	O

DNA	24275640	1219	O
SBs	-	1223	O
damage	-	1227	O
was	-	1234	O
negatively	-	1238	O
associated	-	1249	O
with	-	1260	O
TAP	-	1265	O
(	-	1269	O
R	-	1270	O
=	-	1272	O
-	-	1274	O
0	-	1275	O
.	-	1276	O
98	-	1277	O
,	-	1279	O
p	-	1281	O
=	-	1283	O
0	-	1285	O
.	-	1286	O
018	-	1287	O
)	-	1290	O
,	-	1291	O
and	-	1293	O
necrosis	-	1297	B
(	-	1306	O
R	-	1307	O
=	-	1309	O
-	-	1311	O
0	-	1312	O
.	-	1313	O
97	-	1314	O
,	-	1316	O
p	-	1318	O
=	-	1320	O
0	-	1322	O
.	-	1323	O
027	-	1324	O
)	-	1327	O
.	-	1328	O

Our	24275640	1330	O
results	-	1334	O
suggest	-	1342	O
that	-	1350	O
oxidative	-	1355	O
damage	-	1365	O
is	-	1372	O
associated	-	1375	O
with	-	1386	O
acute	-	1391	O
cardiotoxicity	-	1397	B
induced	-	1412	O
by	-	1420	O
a	-	1423	O
single	-	1425	O
dose	-	1432	O
of	-	1437	O
DOX	-	1440	O
only	-	1444	O
.	-	1448	O

Increased	24275640	1450	O
resistance	-	1460	O
to	-	1471	O
the	-	1474	O
oxidative	-	1478	O
stress	-	1488	O
is	-	1495	O
plausible	-	1498	O
for	-	1508	O
the	-	1512	O
multiple	-	1516	O
dose	-	1525	O
of	-	1530	O
DOX	-	1533	O
.	-	1536	O

Thus	24275640	1538	O
,	-	1542	O
different	-	1544	O
mechanisms	-	1554	O
may	-	1565	O
be	-	1569	O
involved	-	1572	O
in	-	1581	O
acute	-	1584	O
toxicity	-	1590	B
versus	-	1599	O
chronic	-	1606	O
toxicity	-	1614	B
.	-	1622	O

Tacrolimus	24283660	0	O
-	-	10	O
related	-	11	O
seizure	-	19	B
after	-	27	O
pediatric	-	33	O
liver	-	43	O
transplantation	-	49	O
-	-	64	O
-	-	65	O
a	-	66	O
single	-	68	O
-	-	74	O
center	-	75	O
experience	-	82	O
.	-	92	O

To	24283660	94	O
identify	-	97	O
the	-	106	O
risk	-	110	O
factors	-	115	O
for	-	123	O
new	-	127	O
-	-	130	O
onset	-	131	O
seizures	-	137	B
after	-	146	O
pediatric	-	152	O
LT	-	162	O
and	-	165	O
to	-	169	O
assess	-	172	O
their	-	179	O
clinical	-	185	O
implications	-	194	O
and	-	207	O
long	-	211	O
-	-	215	O
term	-	216	O
prognosis	-	221	O
.	-	230	O

The	24283660	232	O
clinical	-	236	O
and	-	245	O
laboratory	-	249	O
data	-	260	O
of	-	265	O
27	-	268	O
consecutive	-	271	O
children	-	283	O
who	-	292	O
underwent	-	296	O
LT	-	306	O
from	-	309	O
January	-	314	O
2007	-	322	O
to	-	327	O
December	-	330	O
2010	-	339	O
in	-	344	O
our	-	347	O
center	-	351	O
were	-	358	O
analyzed	-	363	O
retrospectively	-	372	O
.	-	387	O

Patients	24283660	389	O
were	-	398	O
divided	-	403	O
into	-	411	O
seizures	-	416	B
group	-	425	O
and	-	431	O
a	-	435	O
non	-	437	O
-	-	440	O
seizures	-	441	B
group	-	450	O
.	-	455	O

Pre	24283660	457	O
-	-	460	O
operative	-	461	O
,	-	470	O
intra	-	472	O
-	-	477	O
operative	-	478	O
,	-	487	O
and	-	489	O
post	-	493	O
-	-	497	O
operative	-	498	O
data	-	508	O
were	-	513	O
collected	-	518	O
.	-	527	O

Seizures	24283660	529	B
occurred	-	538	O
in	-	547	O
four	-	550	O
children	-	555	O
,	-	563	O
an	-	565	O
incidence	-	568	O
of	-	578	O
14	-	581	O
.	-	583	O
8	-	584	O
%	-	585	O
.	-	586	O

All	24283660	588	O
exhibited	-	592	O
generalized	-	602	O
tonic	-	614	B
-	-	619	I
clonic	-	620	I
seizures	-	627	I
within	-	636	O
the	-	643	O
first	-	647	O
two	-	653	O
wk	-	657	O
after	-	660	O
LT	-	666	O
.	-	668	O

Univariate	24283660	670	O
analysis	-	681	O
showed	-	690	O
that	-	697	O
the	-	702	O
risk	-	706	O
factors	-	711	O
associated	-	719	O
with	-	730	O
seizures	-	735	B
after	-	744	O
pediatric	-	750	O
LT	-	760	O
included	-	763	O
gender	-	772	O
,	-	778	O
pediatric	-	780	O
end	-	790	B
-	-	793	I
stage	-	794	I
liver	-	800	I
disease	-	806	I
score	-	814	O
before	-	820	O
surgery	-	827	O
,	-	834	O
Child	-	836	O
-	-	841	O

Pugh	24283660	842	O
score	-	847	O
before	-	853	O
surgery	-	860	O
,	-	867	O
serum	-	869	O
total	-	875	O
bilirubin	-	881	O
after	-	891	O
surgery	-	897	O
,	-	904	O
and	-	906	O
trough	-	910	O
TAC	-	917	O
level	-	921	O
.	-	926	O

Multivariate	24283660	928	O
analysis	-	941	O
showed	-	950	O
that	-	957	O
trough	-	962	O

TAC	24283660	969	O
level	-	973	O
was	-	979	O
the	-	983	O
only	-	987	O
independent	-	992	O
risk	-	1004	O
factor	-	1009	O
associated	-	1016	O
with	-	1027	O
the	-	1032	O
seizures	-	1036	B
.	-	1044	O

All	24283660	1046	O
children	-	1050	O
who	-	1059	O
experienced	-	1063	O
seizures	-	1075	B
survived	-	1084	O
with	-	1093	O
good	-	1098	O
graft	-	1103	O
function	-	1109	O
and	-	1118	O
remained	-	1122	O
seizure	-	1131	B
-	-	1138	O
free	-	1139	O
without	-	1144	O
anti	-	1152	O
-	-	1156	O
epileptic	-	1157	B
drugs	-	1167	O
over	-	1173	O
a	-	1178	O
mean	-	1180	O
follow	-	1185	O
-	-	1191	O
up	-	1192	O
period	-	1195	O
of	-	1202	O
33	-	1205	O
.	-	1207	O
7	-	1208	O
+	-	1210	O
14	-	1212	O
.	-	1214	O
6	-	1215	O
months	-	1217	O
.	-	1223	O

High	24283660	1225	O
trough	-	1230	O

TAC	24283660	1237	O
level	-	1241	O
was	-	1247	O
the	-	1251	O
predominant	-	1255	O
factor	-	1267	O
that	-	1274	O
contributed	-	1279	O
to	-	1291	O
seizures	-	1294	B
in	-	1303	O
the	-	1306	O
early	-	1310	O
post	-	1316	O
-	-	1320	O
operative	-	1321	O
period	-	1331	O
after	-	1338	O
pediatric	-	1344	O
LT	-	1354	O
.	-	1356	O

High	24283660	1358	O
PELD	-	1363	O
and	-	1368	O
Child	-	1372	O
-	-	1377	O
Pugh	-	1378	O
scores	-	1383	O
before	-	1390	O
LT	-	1397	O
and	-	1400	O
high	-	1404	O
post	-	1409	O
-	-	1413	O
operative	-	1414	O
serum	-	1424	O
Tbil	-	1430	O
may	-	1435	O
be	-	1439	O
contributory	-	1442	O
risk	-	1455	O
factors	-	1460	O
for	-	1468	O
TAC	-	1472	O
-	-	1475	O
related	-	1476	O
seizures	-	1484	B
.	-	1492	O

The	24284476	0	O
flavonoid	-	4	O
apigenin	-	14	O
delays	-	23	O
forgetting	-	30	O
of	-	41	O
passive	-	44	O
avoidance	-	52	O
conditioning	-	62	O
in	-	75	O
rats	-	78	O
.	-	82	O

The	24284476	84	O
present	-	88	O
experiments	-	96	O
were	-	108	O
performed	-	113	O
to	-	123	O
study	-	126	O
the	-	132	O
effect	-	136	O
of	-	143	O
the	-	146	O
flavonoid	-	150	O
apigenin	-	160	O
(	-	169	O
20	-	170	O
mg	-	173	O
/	-	175	O
kg	-	176	O
intraperitoneally	-	179	O
(	-	197	O
i	-	198	O
.	-	199	O
p	-	200	O
.	-	201	O
)	-	202	O
,	-	203	O

1	24284476	205	O
h	-	207	O
before	-	209	O
acquisition	-	216	O
)	-	227	O
,	-	228	O
on	-	230	O
24	-	233	O
h	-	236	O
retention	-	238	O
performance	-	248	O
and	-	260	O
forgetting	-	264	O
of	-	275	O
a	-	278	O
step	-	280	O
-	-	284	O
through	-	285	O
passive	-	293	O
avoidance	-	301	O
task	-	311	O
,	-	315	O
in	-	317	O
young	-	320	O
male	-	326	O
Wistar	-	331	O
rats	-	338	O
.	-	342	O

There	24284476	344	O
were	-	350	O
no	-	355	O
differences	-	358	O
between	-	370	O
saline	-	378	O
-	-	384	O
and	-	386	O
apigenin	-	390	O
-	-	398	O
treated	-	399	O
groups	-	407	O
in	-	414	O
the	-	417	O
24	-	421	O
h	-	424	O
retention	-	426	O
trial	-	436	O
.	-	441	O

Furthermore	24284476	443	O
,	-	454	O
apigenin	-	456	O
did	-	465	O
not	-	469	O
prevent	-	473	O
the	-	481	O
amnesia	-	485	B
induced	-	493	O
by	-	501	O
scopolamine	-	504	O
(	-	516	O
1mg	-	517	O
/	-	520	O
kg	-	521	O
,	-	523	O
i	-	525	O
.	-	526	O
p	-	527	O
.	-	528	O

,	24284476	529	O
30	-	531	O
min	-	534	O
before	-	538	O
the	-	545	O
acquisition	-	549	O
)	-	560	O
.	-	561	O

The	24284476	563	O
saline	-	567	O
-	-	573	O
and	-	575	O
apigenin	-	579	O
-	-	587	O
treated	-	588	O
rats	-	596	O
that	-	601	O
did	-	606	O
not	-	610	O
step	-	614	O
through	-	619	O
into	-	627	O
the	-	632	O
dark	-	636	O
compartment	-	641	O
during	-	653	O
the	-	660	O
cut	-	664	O
-	-	667	O
off	-	668	O
time	-	672	O
(	-	677	O
540	-	678	O
s	-	682	O
)	-	683	O
were	-	685	O
retested	-	690	O
weekly	-	699	O
for	-	706	O
up	-	710	O
to	-	713	O
eight	-	716	O
weeks	-	722	O
.	-	727	O

In	24284476	729	O
the	-	732	O
saline	-	736	O
treated	-	743	O
group	-	751	O
,	-	756	O
the	-	758	O
first	-	762	O
significant	-	768	O
decline	-	780	O
in	-	788	O
passive	-	791	O
avoidance	-	799	O
response	-	809	O
was	-	818	O
observed	-	822	O
at	-	831	O
four	-	834	O
weeks	-	839	O
,	-	844	O
and	-	846	O
complete	-	850	O
memory	-	859	B
loss	-	866	I
was	-	871	O
found	-	875	O
five	-	881	O
weeks	-	886	O
after	-	892	O
the	-	898	O
acquisition	-	902	O
of	-	914	O
the	-	917	O
passive	-	921	O
avoidance	-	929	O
task	-	939	O
.	-	943	O

At	24284476	945	O
the	-	948	O
end	-	952	O
of	-	956	O
the	-	959	O
experimental	-	963	O
period	-	976	O
,	-	982	O
60	-	984	O
%	-	986	O
of	-	988	O
the	-	991	O
animals	-	995	O
treated	-	1003	O
with	-	1011	O
apigenin	-	1016	O
still	-	1025	O
did	-	1031	O
not	-	1035	O
step	-	1039	O
through	-	1044	O
.	-	1051	O

These	24284476	1053	O
data	-	1059	O
suggest	-	1064	O
that	-	1072	O
1	-	1077	O
)	-	1078	O
apigenin	-	1080	O
delays	-	1089	O
the	-	1096	O
long	-	1100	O
-	-	1104	O
term	-	1105	O
forgetting	-	1110	O
but	-	1121	O
did	-	1125	O
not	-	1129	O
modulate	-	1133	O
the	-	1142	O
24	-	1146	O
h	-	1149	O
retention	-	1151	O
of	-	1161	O
fear	-	1164	O
memory	-	1169	O
and	-	1176	O
2	-	1180	O
)	-	1181	O
the	-	1183	O
obtained	-	1187	O
beneficial	-	1196	O
effect	-	1207	O
of	-	1214	O
apigenin	-	1217	O
on	-	1226	O
the	-	1229	O
passive	-	1233	O
avoidance	-	1241	O
conditioning	-	1251	O
is	-	1264	O
mediated	-	1267	O
by	-	1276	O
mechanisms	-	1279	O
that	-	1290	O
do	-	1295	O
not	-	1298	O
implicate	-	1302	O
its	-	1312	O
action	-	1316	O
on	-	1323	O
the	-	1326	O
muscarinic	-	1330	O
cholinergic	-	1341	O
system	-	1353	O
.	-	1359	O

Cholecystokinin	24309294	0	O
-	-	15	O
octapeptide	-	16	O
restored	-	28	O
morphine	-	37	O
-	-	45	O
induced	-	46	O
hippocampal	-	54	O
long	-	66	O
-	-	70	O
term	-	71	O
potentiation	-	76	O
impairment	-	89	O
in	-	100	O
rats	-	103	O
.	-	107	O

Cholecystokinin	24309294	109	O
-	-	124	O
octapeptide	-	125	O
(	-	137	O
CCK	-	138	O
-	-	141	O
8	-	142	O
)	-	143	O
,	-	144	O
which	-	146	O
is	-	152	O
a	-	155	O
typical	-	157	O
brain	-	165	O
-	-	170	O
gut	-	171	O
peptide	-	175	O
,	-	182	O
exerts	-	184	O
a	-	191	O
wide	-	193	O
range	-	198	O
of	-	204	O
biological	-	207	O
activities	-	218	O
on	-	229	O
the	-	232	O
central	-	236	O
nervous	-	244	O
system	-	252	O
.	-	258	O

We	24309294	260	O
have	-	263	O
previously	-	268	O
reported	-	279	O
that	-	288	O
CCK	-	293	O
-	-	296	O
8	-	297	O
significantly	-	299	O
alleviated	-	313	O
morphine	-	324	O
-	-	332	O
induced	-	333	O
amnesia	-	341	B
and	-	349	O
reversed	-	353	O
spine	-	362	O
density	-	368	O
decreases	-	376	O
in	-	386	O
the	-	389	O
CA1	-	393	O
region	-	397	O
of	-	404	O
the	-	407	O
hippocampus	-	411	O
in	-	423	O
morphine	-	426	O
-	-	434	O
treated	-	435	O
animals	-	443	O
.	-	450	O

Here	24309294	452	O
,	-	456	O
we	-	458	O
investigated	-	461	O
the	-	474	O
effects	-	478	O
of	-	486	O
CCK	-	489	O
-	-	492	O
8	-	493	O
on	-	495	O
long	-	498	O
-	-	502	O
term	-	503	O
potentiation	-	508	O
(	-	521	O
LTP	-	522	O
)	-	525	O
in	-	527	O
the	-	530	O
lateral	-	534	O
perforant	-	542	O
path	-	552	O
(	-	557	O
LPP	-	558	O
)	-	561	O
-	-	562	O
granule	-	563	O
cell	-	571	O
synapse	-	576	O
of	-	584	O
rat	-	587	O
dentate	-	591	O
gyrus	-	599	O
(	-	605	O
DG	-	606	O
)	-	608	O
in	-	610	O
acute	-	613	O
saline	-	619	O
or	-	626	O
morphine	-	629	O
-	-	637	O
treated	-	638	O
rats	-	646	O
.	-	650	O

Population	24309294	652	O
spikes	-	663	O
(	-	670	O
PS	-	671	O
)	-	673	O
,	-	674	O
which	-	676	O
were	-	682	O
evoked	-	687	O
by	-	694	O
stimulation	-	697	O
of	-	709	O
the	-	712	O
LPP	-	716	O
,	-	719	O
were	-	721	O
recorded	-	726	O
in	-	735	O
the	-	738	O
DG	-	742	O
region	-	745	O
.	-	751	O

Acute	24309294	753	O
morphine	-	759	O
(	-	768	O
30mg	-	769	O
/	-	773	O
kg	-	774	O
,	-	776	O
s	-	778	O
.	-	779	O
c	-	780	O
.	-	781	O
)	-	782	O

treatment	24309294	784	O
significantly	-	794	O
attenuated	-	808	O
hippocampal	-	819	O
LTP	-	831	O
and	-	835	O
CCK	-	839	O
-	-	842	O
8	-	843	O
(	-	845	O
1ug	-	846	O
,	-	849	O
i	-	851	O
.	-	852	O
c	-	853	O
.	-	854	O
v	-	855	O
.	-	856	O
)	-	857	O
restored	-	859	O
the	-	868	O
amplitude	-	872	O
of	-	882	O
PS	-	885	O
that	-	888	O
was	-	893	O
attenuated	-	897	O
by	-	908	O
morphine	-	911	O
injection	-	920	O
.	-	929	O

Furthermore	24309294	931	O
,	-	942	O
microinjection	-	944	O
of	-	959	O
CCK	-	962	O
-	-	965	O
8	-	966	O
(	-	968	O
0	-	969	O
.	-	970	O
1	-	971	O
and	-	973	O
1ug	-	977	O
,	-	980	O
i	-	982	O
.	-	983	O
c	-	984	O
.	-	985	O
v	-	986	O
.	-	987	O
)	-	988	O

also	24309294	990	O
significantly	-	995	O
augmented	-	1009	O
hippocampal	-	1019	O
LTP	-	1031	O
in	-	1035	O
saline	-	1038	O
-	-	1044	O
treated	-	1045	O
(	-	1053	O
1ml	-	1054	O
/	-	1057	O
kg	-	1058	O
,	-	1060	O
s	-	1062	O
.	-	1063	O
c	-	1064	O
.	-	1065	O
)	-	1066	O
rats	-	1068	O
.	-	1072	O

Pre	24309294	1074	O
-	-	1077	O

treatment	24309294	1078	O
of	-	1088	O
the	-	1091	O
CCK2	-	1095	O
receptor	-	1100	O
antagonist	-	1109	O
L	-	1120	O
-	-	1121	O
365	-	1122	O
,	-	1125	O
260	-	1126	O
(	-	1130	O
10ug	-	1131	O
,	-	1135	O
i	-	1137	O
.	-	1138	O
c	-	1139	O
.	-	1140	O
v	-	1141	O
)	-	1142	O
reversed	-	1144	O
the	-	1153	O
effects	-	1157	O
of	-	1165	O
CCK	-	1168	O
-	-	1171	O
8	-	1172	O
,	-	1173	O
but	-	1175	O
the	-	1179	O
CCK1	-	1183	O
receptor	-	1188	O
antagonist	-	1197	O
L	-	1208	O
-	-	1209	O
364	-	1210	O
,	-	1213	O
718	-	1214	O
(	-	1218	O
10ug	-	1219	O
,	-	1223	O
i	-	1225	O
.	-	1226	O
c	-	1227	O
.	-	1228	O
v	-	1229	O
)	-	1230	O
did	-	1232	O
not	-	1236	O
.	-	1239	O

The	24309294	1241	O
present	-	1245	O
results	-	1253	O
demonstrate	-	1261	O
that	-	1273	O
CCK	-	1278	O
-	-	1281	O
8	-	1282	O
attenuates	-	1284	O
the	-	1295	O
effect	-	1299	O
of	-	1306	O
morphine	-	1309	O
on	-	1318	O
hippocampal	-	1321	O
LTP	-	1333	O
through	-	1337	O
CCK2	-	1345	O
receptors	-	1350	O
and	-	1360	O
suggest	-	1364	O
an	-	1372	O
ameliorative	-	1375	O
function	-	1388	O
of	-	1397	O
CCK	-	1400	O
-	-	1403	O
8	-	1404	O
on	-	1406	O
morphine	-	1409	O
-	-	1417	O
induced	-	1418	O
memory	-	1426	B
impairment	-	1433	I
.	-	1443	O

Glial	24333387	0	O
activation	-	6	O
and	-	17	O
post	-	21	O
-	-	25	O
synaptic	-	26	O
neurotoxicity	-	35	B
:	-	48	O
the	-	50	O
key	-	54	O
events	-	58	O
in	-	65	O
Streptozotocin	-	68	O
(	-	83	O
ICV	-	84	O
)	-	87	O
induced	-	89	O
memory	-	97	B
impairment	-	104	I
in	-	115	O
rats	-	118	O
.	-	122	O

In	24333387	124	O
the	-	127	O
present	-	131	O
study	-	139	O
the	-	145	O
role	-	149	O
of	-	154	O
glial	-	157	O
activation	-	163	O
and	-	174	O
post	-	178	O
synaptic	-	183	O
toxicity	-	192	B
in	-	201	O
ICV	-	204	O
Streptozotocin	-	208	O
(	-	223	O
STZ	-	224	O
)	-	227	O
induced	-	229	O
memory	-	237	B
impaired	-	244	I
rats	-	253	O
was	-	258	O
explored	-	262	O
.	-	270	O

In	24333387	272	O
experiment	-	275	O
set	-	286	O
up	-	290	O
1	-	293	O
:	-	294	O
Memory	-	296	B
deficit	-	303	I
was	-	311	O
found	-	315	O
in	-	321	O
Morris	-	324	O
water	-	331	O
maze	-	337	O
test	-	342	O
on	-	347	O
14	-	350	O
-	-	352	O
16	-	353	O
days	-	356	O
after	-	361	O
STZ	-	367	O
(	-	371	O
ICV	-	372	O
;	-	375	O
3mg	-	377	O
/	-	380	O
Kg	-	381	O
)	-	383	O
administration	-	385	O
.	-	399	O

STZ	24333387	401	O
causes	-	405	O
increased	-	412	O
expression	-	422	O
of	-	433	O
GFAP	-	436	O
,	-	440	O
CD11b	-	442	O
and	-	448	O
TNF	-	452	O
-	-	455	O
a	-	456	O
indicating	-	458	O
glial	-	469	O
activation	-	475	O
and	-	486	O
neuroinflammation	-	490	B
.	-	507	O

STZ	24333387	509	O
also	-	513	O
significantly	-	518	O
increased	-	532	O
the	-	542	O
level	-	546	O
of	-	552	O
ROS	-	555	O
,	-	558	O
nitrite	-	560	O
,	-	567	O
Ca	-	569	O
(	-	571	O
2	-	572	O
+	-	573	O
)	-	574	O
and	-	576	O
reduced	-	580	O
the	-	588	O
mitochondrial	-	592	O
activity	-	606	O
in	-	615	O
synaptosomal	-	618	O
preparation	-	631	O
illustrating	-	643	O
free	-	656	O
radical	-	661	O
generation	-	669	O
and	-	680	O
excitotoxicity	-	684	B
.	-	698	O

Increased	24333387	700	O
expression	-	710	O
and	-	721	O
activity	-	725	O
of	-	734	O
Caspase	-	737	O
-	-	744	O
3	-	745	O
was	-	747	O
also	-	751	O
observed	-	756	O
in	-	765	O
STZ	-	768	O
treated	-	772	O
rat	-	780	O
which	-	784	O
specify	-	790	O
apoptotic	-	798	O
cell	-	808	O
death	-	813	O
in	-	819	O
hippocampus	-	822	O
and	-	834	O
cortex	-	838	O
.	-	844	O

STZ	24333387	846	O
treatment	-	850	O
showed	-	860	O
decrease	-	867	O
expression	-	876	O
of	-	887	O
post	-	890	O
synaptic	-	895	O
markers	-	904	O
CaMKIIa	-	912	O
and	-	920	O
PSD	-	924	O
-	-	927	O
95	-	928	O
,	-	930	O
while	-	932	O
,	-	937	O
expression	-	939	O
of	-	950	O
pre	-	953	O
synaptic	-	957	O
markers	-	966	O
(	-	974	O
synaptophysin	-	975	O
and	-	989	O
SNAP	-	993	O
-	-	997	O
25	-	998	O
)	-	1000	O
remains	-	1002	O
unaltered	-	1010	O
indicating	-	1020	O
selective	-	1031	O
post	-	1041	O
synaptic	-	1046	O
neurotoxicity	-	1055	B
.	-	1068	O

Oral	24333387	1070	O
treatment	-	1075	O
with	-	1085	O
Memantine	-	1090	O
(	-	1100	O
10mg	-	1101	O
/	-	1105	O
kg	-	1106	O
)	-	1108	O
and	-	1110	O
Ibuprofen	-	1114	O
(	-	1124	O
50	-	1125	O
mg	-	1128	O
/	-	1130	O
kg	-	1131	O
)	-	1133	O
daily	-	1135	O
for	-	1141	O
13	-	1145	O
days	-	1148	O
attenuated	-	1153	O
STZ	-	1164	O
induced	-	1168	O
glial	-	1176	O
activation	-	1182	O
,	-	1192	O
apoptotic	-	1194	O
cell	-	1204	O
death	-	1209	O
and	-	1215	O
post	-	1219	O
synaptic	-	1224	O
neurotoxicity	-	1233	B
in	-	1247	O
rat	-	1250	O
brain	-	1254	O
.	-	1259	O

Further	24333387	1261	O
,	-	1268	O
in	-	1270	O
experiment	-	1273	O
set	-	1284	O
up	-	1288	O
2	-	1291	O
:	-	1292	O
where	-	1294	O
memory	-	1300	O
function	-	1307	O
was	-	1316	O
not	-	1320	O
affected	-	1324	O
i	-	1333	O
.	-	1334	O
e	-	1335	O
.	-	1336	O
7	-	1338	O
-	-	1339	O
9	-	1340	O
days	-	1342	O
after	-	1347	O
STZ	-	1353	O
treatment	-	1357	O
.	-	1366	O

The	24333387	1368	O
level	-	1372	O
of	-	1378	O
GFAP	-	1381	O
,	-	1385	O
CD11b	-	1387	O
,	-	1392	O
TNF	-	1394	O
-	-	1397	O
a	-	1398	O
,	-	1399	O
ROS	-	1401	O
and	-	1405	O
nitrite	-	1409	O
levels	-	1417	O
were	-	1424	O
increased	-	1429	O
.	-	1438	O

On	24333387	1440	O
the	-	1443	O
other	-	1447	O
hand	-	1453	O
,	-	1457	O
apoptotic	-	1459	O
marker	-	1469	O
,	-	1475	O
synaptic	-	1477	O
markers	-	1486	O
,	-	1493	O
mitochondrial	-	1495	O
activity	-	1509	O
and	-	1518	O
Ca	-	1522	O
(	-	1524	O
2	-	1525	O
+	-	1526	O
)	-	1527	O
levels	-	1529	O
remained	-	1536	O
unaffected	-	1545	O
.	-	1555	O

Collective	24333387	1557	O
data	-	1568	O
indicates	-	1573	O
that	-	1583	O
neuroinflammatory	-	1588	B
process	-	1606	O
and	-	1614	O
oxidative	-	1618	O
stress	-	1628	O
occurs	-	1635	O
earlier	-	1642	O
to	-	1650	O
apoptosis	-	1653	O
and	-	1663	O
does	-	1667	O
not	-	1672	O
affect	-	1676	O
memory	-	1683	O
function	-	1690	O
.	-	1698	O

Present	24333387	1700	O
study	-	1708	O
clearly	-	1714	O
suggests	-	1722	O
that	-	1731	O
glial	-	1736	O
activation	-	1742	O
and	-	1753	O
post	-	1757	O
synaptic	-	1762	O
neurotoxicity	-	1771	B
are	-	1785	O
the	-	1789	O
key	-	1793	O
factors	-	1797	O
in	-	1805	O
STZ	-	1808	O
induced	-	1812	O
memory	-	1820	B
impairment	-	1827	I
and	-	1838	O
neuronal	-	1842	O
cell	-	1851	O
death	-	1856	O
.	-	1861	O

Comparison	24341598	0	O
of	-	11	O
effects	-	14	O
of	-	22	O
isotonic	-	25	O
sodium	-	34	O
chloride	-	41	O
with	-	50	O
diltiazem	-	55	O
in	-	65	O
prevention	-	68	O
of	-	79	O
contrast	-	82	O
-	-	90	O
induced	-	91	O
nephropathy	-	99	B
.	-	110	O

INTRODUCTION	24341598	112	O
AND	-	125	O
OBJECTIVE	-	129	O
:	-	138	O

Contrast	24341598	140	O
-	-	148	O
induced	-	149	O
nephropathy	-	157	B
(	-	169	O
CIN	-	170	O
)	-	173	O
significantly	-	175	O
increases	-	189	O
the	-	199	O
morbidity	-	203	O
and	-	213	O
mortality	-	217	O
of	-	227	O
patients	-	230	O
.	-	238	O

The	24341598	240	O
aim	-	244	O
of	-	248	O
this	-	251	O
study	-	256	O
is	-	262	O
to	-	265	O
investigate	-	268	O
and	-	280	O
compare	-	284	O
the	-	292	O
protective	-	296	O
effects	-	307	O
of	-	315	O
isotonic	-	318	O
sodium	-	327	O
chloride	-	334	O
with	-	343	O
sodium	-	348	O
bicarbonate	-	355	O
infusion	-	367	O
and	-	376	O
isotonic	-	380	O
sodium	-	389	O
chloride	-	396	O
infusion	-	405	O
with	-	414	O
diltiazem	-	419	O
,	-	428	O
a	-	430	O
calcium	-	432	O
channel	-	440	O
blocker	-	448	O
,	-	455	O
in	-	457	O
preventing	-	460	O
CIN	-	471	O
.	-	474	O

MATERIALS	24341598	476	O
AND	-	486	O
METHODS	-	490	O
:	-	497	O

Our	24341598	499	O
study	-	503	O
included	-	509	O
patients	-	518	O
who	-	527	O
were	-	531	O
administered	-	536	O
30	-	549	O
-	-	551	O
60	-	552	O
mL	-	555	O
of	-	558	O
iodinated	-	561	O
contrast	-	571	O
agent	-	580	O
for	-	586	O
percutaneous	-	590	O
coronary	-	603	O
angiography	-	612	O
(	-	624	O
PCAG	-	625	O
)	-	629	O
,	-	630	O
all	-	632	O
with	-	636	O
creatinine	-	641	O
values	-	652	O
between	-	659	O
1	-	667	O
.	-	668	O
1	-	669	O
and	-	671	O
3	-	675	O
.	-	676	O
1	-	677	O
mg	-	679	O
/	-	681	O
dL	-	682	O
.	-	684	O
Patients	-	686	O
were	-	695	O
divided	-	700	O
into	-	708	O
three	-	713	O
groups	-	719	O
and	-	726	O
each	-	730	O
group	-	735	O
had	-	741	O
20	-	745	O
patients	-	748	O
.	-	756	O

The	24341598	758	O
first	-	762	O
group	-	768	O
of	-	774	O
patients	-	777	O
was	-	786	O
administered	-	790	O
isotonic	-	803	O
sodium	-	812	O
chloride	-	819	O
;	-	827	O
the	-	829	O
second	-	833	O
group	-	840	O
was	-	846	O
administered	-	850	O
a	-	863	O
solution	-	865	O
that	-	874	O
of	-	879	O
5	-	882	O
%	-	883	O
dextrose	-	885	O
and	-	894	O
sodium	-	898	O
bicarbonate	-	905	O
,	-	916	O
while	-	918	O
the	-	924	O
third	-	928	O
group	-	934	O
was	-	940	O
administered	-	944	O
isotonic	-	957	O
sodium	-	966	O
chloride	-	973	O
before	-	982	O
and	-	989	O
after	-	993	O
the	-	999	O
contrast	-	1003	O
injection	-	1012	O
.	-	1021	O

The	24341598	1023	O
third	-	1027	O
group	-	1033	O
received	-	1039	O
an	-	1048	O
additional	-	1051	O
injection	-	1062	O
of	-	1072	O
diltiazem	-	1075	O
the	-	1085	O
day	-	1089	O
before	-	1093	O
and	-	1100	O
first	-	1104	O
2	-	1110	O
days	-	1112	O
after	-	1117	O
the	-	1123	O
contrast	-	1127	O
injection	-	1136	O
.	-	1145	O

All	24341598	1147	O
of	-	1151	O
the	-	1154	O
patients	-	1158	O
'	-	1166	O
plasma	-	1168	O
blood	-	1175	O
urea	-	1181	O
nitrogen	-	1186	O
(	-	1195	O
BUN	-	1196	O
)	-	1199	O
and	-	1201	O
creatinine	-	1205	O
levels	-	1216	O
were	-	1223	O
measured	-	1228	O
on	-	1237	O
the	-	1240	O
second	-	1244	O
and	-	1251	O
seventh	-	1255	O
day	-	1263	O
after	-	1267	O
the	-	1273	O
administration	-	1277	O
of	-	1292	O
intravenous	-	1295	O
contrast	-	1307	O
material	-	1316	O
.	-	1324	O

RESULTS	24341598	1326	O
:	-	1333	O

The	24341598	1335	O
basal	-	1339	O
creatinine	-	1345	O
levels	-	1356	O
were	-	1363	O
similar	-	1368	O
for	-	1376	O
all	-	1380	O
three	-	1384	O
groups	-	1390	O
(	-	1397	O
p	-	1398	O
>	-	1400	O
0	-	1402	O
.	-	1403	O
05	-	1404	O
)	-	1406	O
.	-	1407	O

Among	24341598	1409	O
a	-	1415	O
total	-	1417	O
of	-	1423	O
60	-	1426	O
patients	-	1429	O
included	-	1438	O
in	-	1447	O
the	-	1450	O
study	-	1454	O
,	-	1459	O
16	-	1461	O
patients	-	1464	O
developed	-	1473	O
acute	-	1483	B
renal	-	1489	I
failure	-	1495	I
(	-	1503	O
ARF	-	1504	B
)	-	1507	O
on	-	1509	O
the	-	1512	O
second	-	1516	O
day	-	1523	O
after	-	1527	O
contrast	-	1533	O
material	-	1542	O
was	-	1551	O
injected	-	1555	O
(	-	1564	O
26	-	1565	O
.	-	1567	O
6	-	1568	O
%	-	1569	O
)	-	1570	O
.	-	1571	O

The	24341598	1573	O
number	-	1577	O
of	-	1584	O
patients	-	1587	O
who	-	1596	O
developed	-	1600	O
ARF	-	1610	B
on	-	1614	O
the	-	1617	O
second	-	1621	O
day	-	1628	O
after	-	1632	O
the	-	1638	O
injection	-	1642	O
in	-	1652	O
the	-	1655	O
first	-	1659	O
group	-	1665	O
was	-	1671	O
five	-	1675	O
(	-	1680	O
25	-	1681	O
%	-	1683	O
)	-	1684	O
,	-	1685	O
in	-	1687	O
the	-	1690	O
second	-	1694	O
group	-	1701	O
was	-	1707	O
six	-	1711	O
(	-	1715	O
30	-	1716	O
%	-	1718	O
)	-	1719	O
and	-	1721	O
the	-	1725	O
third	-	1729	O
group	-	1735	O
was	-	1741	O
five	-	1745	O
(	-	1750	O
25	-	1751	O
%	-	1753	O
)	-	1754	O
(	-	1756	O
p	-	1757	O
>	-	1759	O
0	-	1761	O
.	-	1762	O
05	-	1763	O
)	-	1765	O
.	-	1766	O

CONCLUSION	24341598	1768	O
:	-	1778	O

There	24341598	1780	O
was	-	1786	O
no	-	1790	O
significant	-	1793	O
difference	-	1805	O
between	-	1816	O
isotonic	-	1824	O
sodium	-	1833	O
chloride	-	1840	O
,	-	1848	O
sodium	-	1850	O
bicarbonate	-	1857	O
and	-	1869	O
isotonic	-	1873	O
sodium	-	1882	O
chloride	-	1889	O
with	-	1898	O
diltiazem	-	1903	O
application	-	1913	O
in	-	1925	O
prevention	-	1928	O
of	-	1939	O
CIN	-	1942	O
.	-	1945	O

Neurocognitive	24345882	0	O
and	-	15	O
neuroradiologic	-	19	O
central	-	35	O
nervous	-	43	O
system	-	51	O
late	-	58	O
effects	-	63	O
in	-	71	O
children	-	74	O
treated	-	83	O
on	-	91	O
Pediatric	-	94	O
Oncology	-	104	O
Group	-	113	O
(	-	119	O
POG	-	120	O
)	-	123	O
P9605	-	125	O
(	-	131	O
standard	-	132	O
risk	-	141	O
)	-	145	O
and	-	147	O
P9201	-	151	O
(	-	157	O
lesser	-	158	O
risk	-	165	O
)	-	169	O
acute	-	171	B
lymphoblastic	-	177	I
leukemia	-	191	I
protocols	-	200	O
(	-	210	O
ACCL0131	-	211	O
)	-	219	O
:	-	220	O
a	-	222	O
methotrexate	-	224	O
consequence	-	237	O
?	-	248	O

A	24345882	250	O
report	-	252	O
from	-	259	O
the	-	264	O
Children	-	268	O
's	-	276	O
Oncology	-	279	O
Group	-	288	O
.	-	293	O

Concerns	24345882	295	O
about	-	304	O
long	-	310	O
-	-	314	O
term	-	315	O
methotrexate	-	320	O
(	-	333	O
MTX	-	334	O
)	-	337	O
neurotoxicity	-	339	B
in	-	353	O
the	-	356	O
1990s	-	360	O
led	-	366	O
to	-	370	O
modifications	-	373	O
in	-	387	O
intrathecal	-	390	O
(	-	402	O
IT	-	403	O
)	-	405	O
therapy	-	407	O
,	-	414	O
leucovorin	-	416	O
rescue	-	427	O
,	-	433	O
and	-	435	O
frequency	-	439	O
of	-	449	O
systemic	-	452	O
MTX	-	461	O
administration	-	465	O
in	-	480	O
children	-	483	O
with	-	492	O
acute	-	497	B
lymphoblastic	-	503	I
leukemia	-	517	I
.	-	525	O

In	24345882	527	O
this	-	530	O
study	-	535	O
,	-	540	O
neurocognitive	-	542	O
outcomes	-	557	O
and	-	566	O
neuroradiologic	-	570	O
evidence	-	586	O
of	-	595	O
leukoencephalopathy	-	598	B
were	-	618	O
compared	-	623	O
in	-	632	O
children	-	635	O
treated	-	644	O
with	-	652	O
intense	-	657	O
central	-	665	O
nervous	-	673	O
system	-	681	O
(	-	688	O
CNS	-	689	O
)	-	692	O
-	-	693	O
directed	-	694	O
therapy	-	703	O
(	-	711	O
P9605	-	712	O
)	-	717	O
versus	-	719	O
those	-	726	O
receiving	-	732	O
fewer	-	742	O
CNS	-	748	O
-	-	751	O
directed	-	752	O
treatment	-	761	O
days	-	771	O
during	-	776	O
intensive	-	783	O
consolidation	-	793	O
(	-	807	O
P9201	-	808	O
)	-	813	O
.	-	814	O

A	24345882	816	O
total	-	818	O
of	-	824	O
66	-	827	O
children	-	830	O
from	-	839	O
16	-	844	O
Pediatric	-	847	O
Oncology	-	857	O
Group	-	866	O
institutions	-	872	O
with	-	885	O
""""	-	890	O
standard	-	891	O
-	-	899	O
risk	-	900	O
""""	-	904	O
acute	-	906	B
lymphoblastic	-	912	I
leukemia	-	926	I
,	-	934	O
1	-	936	O
.	-	937	O
00	-	938	O
to	-	941	O
9	-	944	O
.	-	945	O
99	-	946	O
years	-	949	O
at	-	955	O
diagnosis	-	958	O
,	-	967	O
without	-	969	O
evidence	-	977	O
of	-	986	O
CNS	-	989	O
leukemia	-	993	B
at	-	1002	O
diagnosis	-	1005	O
were	-	1015	O
enrolled	-	1020	O
on	-	1029	O
ACCL0131	-	1032	O
:	-	1040	O
28	-	1042	O
from	-	1045	O
P9201	-	1050	O
and	-	1056	O
38	-	1060	O
from	-	1063	O
P9605	-	1068	O
.	-	1073	O

Magnetic	24345882	1075	O
resonance	-	1084	O
imaging	-	1094	O
scans	-	1102	O
and	-	1108	O
standard	-	1112	O
neuropsychological	-	1121	O
tests	-	1140	O
were	-	1146	O
performed	-	1151	O
>	-	1161	O
2	-	1162	O
.	-	1163	O
6	-	1164	O
years	-	1166	O
after	-	1172	O
the	-	1178	O
end	-	1182	O
of	-	1186	O
treatment	-	1189	O
.	-	1198	O

Significantly	24345882	1200	O
more	-	1214	O
P9605	-	1219	O
patients	-	1225	O
developed	-	1234	O
leukoencephalopathy	-	1244	B
compared	-	1264	O
with	-	1273	O
P9201	-	1278	O
patients	-	1284	O
(	-	1293	O
68	-	1294	O
%	-	1296	O
,	-	1297	O
95	-	1299	O
%	-	1301	O
confidence	-	1303	O
interval	-	1314	O
49	-	1323	O
%	-	1325	O
-	-	1326	O
83	-	1327	O
%	-	1329	O
vs	-	1331	O
.	-	1333	O
22	-	1335	O
%	-	1337	O
,	-	1338	O
95	-	1340	O
%	-	1342	O
confidence	-	1344	O
interval	-	1355	O
5	-	1364	O
%	-	1365	O
-	-	1366	O
44	-	1367	O
%	-	1369	O
;	-	1370	O
P	-	1372	O
=	-	1373	O
0	-	1374	O
.	-	1375	O
001	-	1376	O
)	-	1379	O
identified	-	1381	O
as	-	1392	O
late	-	1395	O
as	-	1400	O
7	-	1403	O
.	-	1404	O
7	-	1405	O
years	-	1407	O
after	-	1413	O
the	-	1419	O
end	-	1423	O
of	-	1427	O
treatment	-	1430	O
.	-	1439	O

Overall	24345882	1441	O
,	-	1448	O
40	-	1450	O
%	-	1452	O
of	-	1454	O
patients	-	1457	O
scored	-	1466	O
<	-	1473	O
85	-	1474	O
on	-	1477	O
either	-	1480	O
Verbal	-	1487	O
or	-	1494	O
Performance	-	1497	O
IQ	-	1509	O
.	-	1511	O

Children	24345882	1513	O
on	-	1522	O
both	-	1525	O
studies	-	1530	O
had	-	1538	O
significant	-	1542	O
attention	-	1554	B
problems	-	1564	I
,	-	1572	O
but	-	1574	O
P9605	-	1578	O
children	-	1584	O
scored	-	1593	O
below	-	1600	O
average	-	1606	O
on	-	1614	O
more	-	1617	O
neurocognitive	-	1622	O
measures	-	1637	O
than	-	1646	O
those	-	1651	O
treated	-	1657	O
on	-	1665	O
P9201	-	1668	O
(	-	1674	O
82	-	1675	O
%	-	1677	O
,	-	1678	O
14	-	1680	O
/	-	1682	O
17	-	1683	O
measures	-	1686	O
vs	-	1695	O
.	-	1697	O
24	-	1699	O
%	-	1701	O
,	-	1702	O
4	-	1704	O
/	-	1705	O
17	-	1706	O
measures	-	1709	O
)	-	1717	O
.	-	1718	O

This	24345882	1720	O
supports	-	1725	O
ongoing	-	1734	O
concerns	-	1742	O
about	-	1751	O
intensive	-	1757	O
MTX	-	1767	O
exposure	-	1771	O
as	-	1780	O
a	-	1783	O
major	-	1785	O
contributor	-	1791	O
to	-	1803	O
CNS	-	1806	O
late	-	1810	O
effects	-	1815	O
.	-	1822	O

Tranexamic	24434397	0	O
acid	-	11	O
overdosage	-	16	O
-	-	26	O
induced	-	27	O
generalized	-	35	O
seizure	-	47	B
in	-	55	O
renal	-	58	B
failure	-	64	I
.	-	71	O

We	24434397	73	O
report	-	76	O
a	-	83	O
45	-	85	O
-	-	87	O
year	-	88	O
-	-	92	O
old	-	93	O
lady	-	97	O
with	-	102	O
chronic	-	107	B
kidney	-	115	I
disease	-	122	I
stage	-	130	O
4	-	136	O
due	-	138	O
to	-	142	O
chronic	-	145	O
tubulointerstial	-	153	B
disease	-	170	I
.	-	177	O

She	24434397	179	O
was	-	183	O
admitted	-	187	O
to	-	196	O
our	-	199	O
center	-	203	O
for	-	210	O
severe	-	214	O
anemia	-	221	B
due	-	228	O
to	-	232	O
menorrhagia	-	235	B
and	-	247	O
deterioration	-	251	B
of	-	265	I
renal	-	268	I
function	-	274	I
.	-	282	O

She	24434397	284	O
was	-	288	O
infused	-	292	O
three	-	300	O
units	-	306	O
of	-	312	O
packed	-	315	O
cells	-	322	O
during	-	328	O
a	-	335	O
session	-	337	O
of	-	345	O
hemodialysis	-	348	O
.	-	360	O

Tranexamic	24434397	362	O
acid	-	373	O
(	-	378	O
TNA	-	379	O
)	-	382	O

1	24434397	384	O
g	-	386	O
8	-	388	O
-	-	389	O
hourly	-	390	O
was	-	397	O
administered	-	401	O
to	-	414	O
her	-	417	O
to	-	421	O
control	-	424	O
bleeding	-	432	B
per	-	441	O
vaginum	-	445	O
.	-	452	O

Two	24434397	454	O
hours	-	458	O
after	-	464	O
the	-	470	O
sixth	-	474	O
dose	-	480	O
of	-	485	O
TNA	-	488	O
,	-	491	O
she	-	493	O
had	-	497	O
an	-	501	O
episode	-	504	O
of	-	512	O
generalized	-	515	O
tonic	-	527	B
clonic	-	533	I
convulsions	-	540	I
.	-	551	O

TNA	24434397	553	O
was	-	557	O
discontinued	-	561	O
.	-	573	O

Investigations	24434397	575	O
of	-	590	O
the	-	593	O
patient	-	597	O
revealed	-	605	O
no	-	614	O
biochemical	-	617	O
or	-	629	O
structural	-	632	O
central	-	643	O
nervous	-	651	B
system	-	659	I
abnormalities	-	666	I
that	-	680	O
could	-	685	O
have	-	691	O
provoked	-	696	O
the	-	705	O
convulsions	-	709	B
.	-	720	O

She	24434397	722	O
did	-	726	O
not	-	730	O
require	-	734	O
any	-	742	O
further	-	746	O
dialytic	-	754	O
support	-	763	O
.	-	770	O

She	24434397	772	O
had	-	776	O
no	-	780	O
further	-	783	O
episodes	-	791	O
of	-	800	O
convulsion	-	803	B
till	-	814	O
dis	-	819	O
-	-	822	O
charge	-	823	O
and	-	830	O
during	-	834	O
the	-	841	O
two	-	845	O
months	-	849	O
of	-	856	O
follow	-	859	O
-	-	865	O
up	-	866	O
.	-	868	O

Thus	24434397	870	O
,	-	874	O
the	-	876	O
precipitating	-	880	O
cause	-	894	O
of	-	900	O
convulsions	-	903	B
was	-	915	O
believed	-	919	O
to	-	928	O
be	-	931	O
an	-	934	O
overdose	-	937	B
of	-	946	O
TNA	-	949	O
.	-	952	O

Pre	24438483	0	O
-	-	3	O
treatment	-	4	O
of	-	14	O
bupivacaine	-	17	O
-	-	28	O
induced	-	29	O
cardiovascular	-	37	B
depression	-	52	I
using	-	63	O
different	-	69	O
lipid	-	79	O
formulations	-	85	O
of	-	98	O
propofol	-	101	O
.	-	109	O

BACKGROUND	24438483	111	O
:	-	121	O
Pre	-	123	O
-	-	126	O
treatment	-	127	O
with	-	137	O
lipid	-	142	O
emulsions	-	148	O
has	-	158	O
been	-	162	O
shown	-	167	O
to	-	173	O
increase	-	176	O
lethal	-	185	O
doses	-	192	O
of	-	198	O
bupivacaine	-	201	O
,	-	212	O
and	-	214	O
the	-	218	O
lipid	-	222	O
content	-	228	O
of	-	236	O
propofol	-	239	O
may	-	248	O
alleviate	-	252	O
bupivacaine	-	262	O
-	-	273	O
induced	-	274	O
cardiotoxicity	-	282	B
.	-	296	O

The	24438483	298	O
aim	-	302	O
of	-	306	O
this	-	309	O
study	-	314	O
is	-	320	O
to	-	323	O
investigate	-	326	O
the	-	338	O
effects	-	342	O
of	-	350	O
propofol	-	353	O
in	-	362	O
intralipid	-	365	O
or	-	376	O
medialipid	-	379	O
emulsions	-	390	O
on	-	400	O
bupivacaine	-	403	O
-	-	414	O
induced	-	415	O
cardiotoxicity	-	423	B
.	-	437	O

METHODS	24438483	439	O
:	-	446	O

Rats	24438483	448	O
were	-	453	O
anaesthetised	-	458	O
with	-	472	O
ketamine	-	477	O
and	-	486	O
were	-	490	O
given	-	495	O
0	-	501	O
.	-	502	O
5	-	503	O
mg	-	505	O
/	-	507	O
kg	-	508	O
/	-	510	O
min	-	511	O
propofol	-	515	O
in	-	524	O
intralipid	-	527	O
(	-	538	O
Group	-	539	O
P	-	545	O
)	-	546	O
,	-	547	O
propofol	-	549	O
in	-	558	O
medialipid	-	561	O
(	-	572	O
Group	-	573	O
L	-	579	O
)	-	580	O
,	-	581	O
or	-	583	O
saline	-	586	O
(	-	593	O
Group	-	594	O
C	-	600	O
)	-	601	O
over	-	603	O
20	-	608	O
min	-	611	O
.	-	614	O

Thereafter	24438483	616	O
,	-	626	O
2	-	628	O
mg	-	630	O
/	-	632	O
kg	-	633	O
/	-	635	O
min	-	636	O
bupivacaine	-	640	O
0	-	652	O
.	-	653	O
5	-	654	O
%	-	655	O
was	-	657	O
infused	-	661	O
.	-	668	O

We	24438483	670	O
recorded	-	673	O
time	-	682	O
to	-	687	O
first	-	690	O
dysrhythmia	-	696	B
occurrence	-	708	O
,	-	718	O
respective	-	720	O
times	-	731	O
to	-	737	O
25	-	740	O
%	-	742	O
and	-	744	O
50	-	748	O
%	-	750	O
reduction	-	752	O
of	-	762	O
the	-	765	O
heart	-	769	O
rate	-	775	O
(	-	780	O
HR	-	781	O
)	-	783	O
and	-	785	O
mean	-	789	O
arterial	-	794	O
pressure	-	803	O
,	-	811	O
and	-	813	O
time	-	817	O
to	-	822	O
asystole	-	825	B
and	-	834	O
total	-	838	O
amount	-	844	O
of	-	851	O
bupivacaine	-	854	O
consumption	-	866	O
.	-	877	O

Blood	24438483	879	O
and	-	885	O
tissue	-	889	O
samples	-	896	O
were	-	904	O
collected	-	909	O
following	-	919	O
asystole	-	929	B
.	-	937	O

RESULTS	24438483	939	O
:	-	946	O

The	24438483	948	O
time	-	952	O
to	-	957	O
first	-	960	O
dysrhythmia	-	966	B
occurrence	-	978	O
,	-	988	O
time	-	990	O
to	-	995	O
25	-	998	O
%	-	1000	O
and	-	1002	O
50	-	1006	O
%	-	1008	O
reductions	-	1010	O
in	-	1021	O
HR	-	1024	O
,	-	1026	O
and	-	1028	O
time	-	1032	O
to	-	1037	O
asystole	-	1040	B
were	-	1049	O
longer	-	1054	O
in	-	1061	O
Group	-	1064	O
P	-	1070	O
than	-	1072	O
the	-	1077	O
other	-	1081	O
groups	-	1087	O
.	-	1093	O

The	24438483	1095	O
cumulative	-	1099	O
bupivacaine	-	1110	O
dose	-	1122	O
given	-	1127	O
at	-	1133	O
those	-	1136	O
time	-	1142	O
points	-	1147	O
was	-	1154	O
higher	-	1158	O
in	-	1165	O
Group	-	1168	O
P	-	1174	O
.	-	1175	O
Plasma	-	1177	O
bupivacaine	-	1184	O
levels	-	1196	O
were	-	1203	O
significantly	-	1208	O
lower	-	1222	O
in	-	1228	O
Group	-	1231	O
P	-	1237	O
than	-	1239	O
in	-	1244	O
Group	-	1247	O
C	-	1253	O
.	-	1254	O
Bupivacaine	-	1256	O
levels	-	1268	O
in	-	1275	O
the	-	1278	O
brain	-	1282	O
and	-	1288	O
heart	-	1292	O
were	-	1298	O
significantly	-	1303	O
lower	-	1317	O
in	-	1323	O
Group	-	1326	O
P	-	1332	O
and	-	1334	O
Group	-	1338	O
L	-	1344	O
than	-	1346	O
in	-	1351	O
Group	-	1354	O
C	-	1360	O
.	-	1361	O
CONCLUSION	-	1363	O
:	-	1373	O

We	24438483	1375	O
conclude	-	1378	O
that	-	1387	O
pre	-	1392	O
-	-	1395	O
treatment	-	1396	O
with	-	1406	O
propofol	-	1411	O
in	-	1420	O
intralipid	-	1423	O
,	-	1433	O
compared	-	1435	O
with	-	1444	O
propofol	-	1449	O
in	-	1458	O
medialipid	-	1461	O
or	-	1472	O
saline	-	1475	O
,	-	1481	O
delayed	-	1483	O
the	-	1491	O
onset	-	1495	O
of	-	1501	O
bupivacaine	-	1504	O
-	-	1515	O
induced	-	1516	O
cardiotoxic	-	1524	B
effects	-	1536	O
as	-	1544	O
well	-	1547	O
as	-	1552	O
reduced	-	1555	O
plasma	-	1563	O
bupivacaine	-	1570	O
levels	-	1582	O
.	-	1588	O

Further	24438483	1590	O
studies	-	1598	O
are	-	1606	O
needed	-	1610	O
to	-	1617	O
explore	-	1620	O
tissue	-	1628	O
bupivacaine	-	1635	O
levels	-	1647	O
of	-	1654	O
propofol	-	1657	O
in	-	1666	O
medialipid	-	1669	O
and	-	1680	O
adapt	-	1684	O
these	-	1690	O
results	-	1696	O
to	-	1704	O
clinical	-	1707	O
practice	-	1716	O
.	-	1724	O

Drug	24451297	0	B
-	-	4	I
Induced	-	5	I
Acute	-	13	I
Liver	-	19	I
Injury	-	25	I

Within	24451297	32	O
12	-	39	O
Hours	-	42	O

After	24451297	48	O
Fluvastatin	-	54	O
Therapy	-	66	O
.	-	73	O

Although	24451297	75	O
statins	-	84	O
are	-	92	O
generally	-	96	O
well	-	106	O
-	-	110	O
tolerated	-	111	O
drugs	-	121	O
,	-	126	O
recent	-	128	O
cases	-	135	O
of	-	141	O
drug	-	144	B
-	-	148	I
induced	-	149	I
liver	-	157	I
injury	-	163	I
associated	-	170	O
with	-	181	O
their	-	186	O
use	-	192	O
have	-	196	O
been	-	201	O
reported	-	206	O
.	-	214	O

A	24451297	216	O
52	-	218	O
-	-	220	O
year	-	221	O
-	-	225	O
old	-	226	O
Chinese	-	230	O
man	-	238	O
reported	-	242	O
with	-	251	O
liver	-	256	B
damage	-	262	I
,	-	268	O
which	-	270	O
appeared	-	276	O
12	-	285	O
hours	-	288	O
after	-	294	O
beginning	-	300	O
treatment	-	310	O
with	-	320	O
fluvastatin	-	325	O
.	-	336	O

Patient	24451297	338	O
presented	-	346	O
with	-	356	O
complaints	-	361	O
of	-	372	O
increasing	-	375	O
nausea	-	386	B
,	-	392	O
anorexia	-	394	B
,	-	402	O
and	-	404	O
upper	-	408	O
abdominal	-	414	B
pain	-	424	I
.	-	428	O

His	24451297	430	O
laboratory	-	434	O
values	-	445	O
showed	-	452	O
elevated	-	459	O
creatine	-	468	O
kinase	-	477	O
and	-	484	O
transaminases	-	488	O
.	-	501	O

Testing	24451297	503	O
for	-	511	O
autoantibodies	-	515	O
was	-	530	O
also	-	534	O
negative	-	539	O
.	-	547	O

The	24451297	549	O
liver	-	553	O
biochemistries	-	559	O
eventually	-	574	O
normalized	-	585	O
within	-	596	O
3	-	603	O
weeks	-	605	O
of	-	611	O
stopping	-	614	O
the	-	623	O
fluvastatin	-	627	O
.	-	638	O

Therefore	24451297	640	O
,	-	649	O
when	-	651	O
prescribing	-	656	O
statins	-	668	O
,	-	675	O
the	-	677	O
possibility	-	681	O
of	-	693	O
hepatic	-	696	B
damage	-	704	I
should	-	711	O
be	-	718	O
taken	-	721	O
into	-	727	O
account	-	732	O
.	-	739	O

Fluconazole	24459006	0	O
associated	-	12	O
agranulocytosis	-	23	B
and	-	39	O
thrombocytopenia	-	43	B
.	-	59	O

CASE	24459006	61	O
:	-	65	O

We	24459006	67	O
describe	-	70	O
a	-	79	O
second	-	81	O
case	-	88	O
of	-	93	O
fluconazole	-	96	O
associated	-	108	O
agranulocytosis	-	119	B
with	-	135	O
thrombocytopenia	-	140	B
and	-	157	O
recovery	-	161	O
upon	-	170	O
discontinuation	-	175	O
of	-	191	O
therapy	-	194	O
.	-	201	O

The	24459006	203	O
patient	-	207	O
began	-	215	O
to	-	221	O
have	-	224	O
changes	-	229	O
in	-	237	O
white	-	240	O
blood	-	246	O
cells	-	252	O
and	-	258	O
platelets	-	262	O
within	-	272	O
48	-	279	O
h	-	282	O
of	-	284	O
administration	-	287	O
of	-	302	O
fluconazole	-	305	O
and	-	317	O
began	-	321	O
to	-	327	O
recover	-	330	O
with	-	338	O
48	-	343	O
h	-	346	O
of	-	348	O
discontinuation	-	351	O
.	-	366	O

This	24459006	368	O
case	-	373	O
highlights	-	378	O
that	-	389	O
drug	-	394	O
-	-	398	O
induced	-	399	O
blood	-	407	B
dyscrasias	-	413	I
can	-	424	O
occur	-	428	O
unexpectedly	-	434	O
as	-	447	O
a	-	450	O
result	-	452	O
of	-	459	O
treatment	-	462	O
with	-	472	O
a	-	477	O
commonly	-	479	O
used	-	488	O
drug	-	493	O
thought	-	498	O
to	-	506	O
be	-	509	O
""""	-	512	O
safe	-	513	O
""""	-	517	O
.	-	518	O

CONCLUSION	24459006	520	O
:	-	530	O

According	24459006	532	O
to	-	542	O
Naranjo	-	545	O
's	-	552	O
algorithm	-	555	O
the	-	565	O
likelihood	-	569	O
that	-	580	O
our	-	585	O
patient	-	589	O
's	-	596	O
agranulocytosis	-	599	B
and	-	615	O
thrombocytopenia	-	619	B
occurred	-	636	O
as	-	645	O
a	-	648	O
result	-	650	O
of	-	657	O
therapy	-	660	O
with	-	668	O
fluconazole	-	673	O
is	-	685	O
probable	-	688	O
,	-	696	O
with	-	698	O
a	-	703	O
total	-	705	O
of	-	711	O
six	-	714	O
points	-	718	O
.	-	724	O

We	24459006	726	O
feel	-	729	O
that	-	734	O
the	-	739	O
weight	-	743	O
of	-	750	O
the	-	753	O
overall	-	757	O
evidence	-	765	O
of	-	774	O
this	-	777	O
evidence	-	782	O
is	-	791	O
strong	-	794	O
.	-	800	O

In	24459006	802	O
particular	-	805	O
the	-	816	O
temporal	-	820	O
relationship	-	829	O
of	-	842	O
bone	-	845	B
marrow	-	850	I
suppression	-	857	I
to	-	869	O
the	-	872	O
initiation	-	876	O
of	-	887	O
fluconazole	-	890	O
and	-	902	O
the	-	906	O
abatement	-	910	O
of	-	920	O
symptoms	-	923	O
that	-	932	O
rapidly	-	937	O
reversed	-	945	O
immediately	-	954	O
following	-	966	O
discontinuation	-	976	O
.	-	991	O

Two	24464946	0	O
-	-	3	O
dimensional	-	4	O
speckle	-	16	O
tracking	-	24	O
echocardiography	-	33	O
combined	-	50	O
with	-	59	O
high	-	64	O
-	-	68	O
sensitive	-	69	O
cardiac	-	79	O
troponin	-	87	O
T	-	96	O
in	-	98	O
early	-	101	O
detection	-	107	O
and	-	117	O
prediction	-	121	O
of	-	132	O
cardiotoxicity	-	135	B
during	-	150	O
epirubicine	-	157	O
-	-	168	O
based	-	169	O
chemotherapy	-	175	O
.	-	187	O

AIMS	24464946	189	O
:	-	193	O

To	24464946	195	O
investigate	-	198	O
whether	-	210	O
alterations	-	218	O
of	-	230	O
myocardial	-	233	B
strain	-	244	I
and	-	251	O
high	-	255	O
-	-	259	O
sensitive	-	260	O
cardiac	-	270	O
troponin	-	278	O
T	-	287	O
(	-	289	O
cTnT	-	290	O
)	-	294	O
could	-	296	O
predict	-	302	O
future	-	310	O
cardiac	-	317	B
dysfunction	-	325	I
in	-	337	O
patients	-	340	O
after	-	349	O
epirubicin	-	355	O
exposure	-	366	O
.	-	374	O

METHODS	24464946	376	O
:	-	383	O
Seventy	-	385	O
-	-	392	O
five	-	393	O
patients	-	398	O
with	-	407	O
non	-	412	B
-	-	415	I
Hodgkin	-	416	I
lymphoma	-	424	I
treated	-	433	O
with	-	441	O
epirubicin	-	446	O
were	-	457	O
studied	-	462	O
.	-	469	O

Blood	24464946	471	O
collection	-	477	O
and	-	488	O
echocardiography	-	492	O
were	-	509	O
performed	-	514	O
at	-	524	O
baseline	-	527	O
,	-	535	O
1	-	537	O
day	-	539	O
after	-	543	O
the	-	549	O
third	-	553	O
cycle	-	559	O
,	-	564	O
and	-	566	O
1	-	570	O
day	-	572	O
after	-	576	O
completion	-	582	O
of	-	593	O
chemotherapy	-	596	O
.	-	608	O

Patients	24464946	610	O
were	-	619	O
studied	-	624	O
using	-	632	O
echocardiography	-	638	O
during	-	655	O
follow	-	662	O
-	-	668	O
up	-	669	O
.	-	671	O

Global	24464946	673	O
longitudinal	-	680	O
(	-	693	O
GLS	-	694	O
)	-	697	O
,	-	698	O
circumferential	-	700	O
(	-	716	O
GCS	-	717	O
)	-	720	O
,	-	721	O
and	-	723	O
radial	-	727	O
strain	-	734	O
(	-	741	O
GRS	-	742	O
)	-	745	O
were	-	747	O
calculated	-	752	O
using	-	763	O
speckle	-	769	O
tracking	-	777	O
echocardiography	-	786	O
.	-	802	O

Left	24464946	804	O
ventricular	-	809	O
ejection	-	821	O
fraction	-	830	O
was	-	839	O
analysed	-	843	O
by	-	852	O
real	-	855	O
-	-	859	O
time	-	860	O
3D	-	865	O
echocardiography	-	868	O
.	-	884	O

Cardiotoxicity	24464946	886	B
was	-	901	O
defined	-	905	O
as	-	913	O
a	-	916	O
reduction	-	918	O
of	-	928	O
the	-	931	O
LVEF	-	935	O
of	-	940	O
>	-	943	O
5	-	944	O
%	-	945	O
to	-	947	O
<	-	950	O
55	-	951	O
%	-	953	O
with	-	955	O
symptoms	-	960	O
of	-	969	O
heart	-	972	B
failure	-	978	I
or	-	986	O
an	-	989	O
asymptomatic	-	992	O
reduction	-	1005	O
of	-	1015	O
the	-	1018	O
LVEF	-	1022	O
of	-	1027	O
>	-	1030	O
10	-	1031	O
%	-	1033	O
to	-	1035	O
<	-	1038	O
55	-	1039	O
%	-	1041	O
.	-	1042	O

RESULTS	24464946	1044	O
:	-	1051	O

Fourteen	24464946	1053	O
patients	-	1062	O
(	-	1071	O
18	-	1072	O
.	-	1074	O
67	-	1075	O
%	-	1077	O
)	-	1078	O
developed	-	1080	O
cardiotoxicity	-	1090	B
after	-	1105	O
treatment	-	1111	O
.	-	1120	O

GLS	24464946	1122	O
(	-	1126	O
-	-	1127	O
18	-	1128	O
.	-	1130	O
48	-	1131	O
+	-	1134	O
1	-	1136	O
.	-	1137	O
72	-	1138	O
%	-	1140	O
vs	-	1142	O
.	-	1144	O
-	-	1146	O
15	-	1147	O
.	-	1149	O
96	-	1150	O
+	-	1153	O
1	-	1155	O
.	-	1156	O
6	-	1157	O
%	-	1158	O
)	-	1159	O
,	-	1160	O
GCS	-	1162	O
(	-	1166	O
-	-	1167	O
20	-	1168	O
.	-	1170	O
93	-	1171	O
+	-	1174	O
2	-	1176	O
.	-	1177	O
86	-	1178	O
%	-	1180	O
vs	-	1182	O
.	-	1184	O
-	-	1186	O
19	-	1187	O
.	-	1189	O
20	-	1190	O
+	-	1193	O
3	-	1195	O
.	-	1196	O
21	-	1197	O
%	-	1199	O
)	-	1200	O
,	-	1201	O
and	-	1203	O
GRS	-	1207	O
(	-	1211	O
39	-	1212	O
.	-	1214	O
23	-	1215	O
+	-	1218	O
6	-	1220	O
.	-	1221	O
44	-	1222	O
%	-	1224	O
vs	-	1226	O
.	-	1228	O
34	-	1230	O
.	-	1232	O
98	-	1233	O
+	-	1236	O
6	-	1238	O
.	-	1239	O
2	-	1240	O
%	-	1241	O
)	-	1242	O
were	-	1244	O
markedly	-	1249	O
reduced	-	1258	O
and	-	1266	O
cTnT	-	1270	O
was	-	1275	O
elevated	-	1279	O
from	-	1288	O
0	-	1293	O
.	-	1294	O
0010	-	1295	O
+	-	1300	O
0	-	1302	O
.	-	1303	O
0020	-	1304	O
to	-	1309	O
0	-	1312	O
.	-	1313	O
0073	-	1314	O
+	-	1319	O
0	-	1321	O
.	-	1322	O
0038	-	1323	O
ng	-	1328	O
/	-	1330	O
mL	-	1331	O
(	-	1334	O
P	-	1335	O
all	-	1337	O
<	-	1341	O
0	-	1343	O
.	-	1344	O
01	-	1345	O
)	-	1347	O
at	-	1349	O
the	-	1352	O
completion	-	1356	O
of	-	1367	O
chemotherapy	-	1370	O
compared	-	1383	O
with	-	1392	O
baseline	-	1397	O
values	-	1406	O
.	-	1412	O

A	24464946	1414	O
>	-	1416	O
15	-	1417	O
.	-	1419	O
9	-	1420	O
%	-	1421	O
decrease	-	1423	O
in	-	1432	O
GLS	-	1435	O
[	-	1439	O
sensitivity	-	1440	O
,	-	1451	O
86	-	1453	O
%	-	1455	O
;	-	1456	O
specificity	-	1458	O
,	-	1469	O
75	-	1471	O
%	-	1473	O
;	-	1474	O
area	-	1476	O
under	-	1481	O
the	-	1487	O
curve	-	1491	O
(	-	1497	O
AUC	-	1498	O
)	-	1501	O
=	-	1503	O

0	24464946	1505	O
.	-	1506	O
815	-	1507	O

;	24464946	1510	O
P	-	1512	O
=	-	1514	O
0	-	1516	O
.	-	1517	O
001	-	1518	O
]	-	1521	O
and	-	1523	O
a	-	1527	O
>	-	1529	O
0	-	1530	O
.	-	1531	O
004	-	1532	O
ng	-	1536	O
/	-	1538	O
mL	-	1539	O
elevation	-	1542	O
in	-	1552	O
cTnT	-	1555	O

(	24464946	1560	O
sensitivity	-	1561	O
,	-	1572	O
79	-	1574	O
%	-	1576	O
;	-	1577	O
specificity	-	1579	O
,	-	1590	O
64	-	1592	O
%	-	1594	O
;	-	1595	O
AUC	-	1597	O
=	-	1601	O
0	-	1603	O
.	-	1604	O
757	-	1605	O
;	-	1608	O
P	-	1610	O
=	-	1612	O
0	-	1614	O
.	-	1615	O
005	-	1616	O
)	-	1619	O
from	-	1621	O
baseline	-	1626	O
to	-	1635	O
the	-	1638	O
third	-	1642	O
cycle	-	1648	O
of	-	1654	O
chemotherapy	-	1657	O
predicted	-	1670	O
later	-	1680	O
cardiotoxicity	-	1686	B
.	-	1700	O

The	24464946	1702	O
decrease	-	1706	O
in	-	1715	O
GLS	-	1718	O
remained	-	1722	O
the	-	1731	O
only	-	1735	O
independent	-	1740	O
predictor	-	1752	O
of	-	1762	O
cardiotoxicity	-	1765	B
(	-	1780	O
P	-	1781	O
=	-	1783	O
0	-	1785	O
.	-	1786	O
000	-	1787	O
)	-	1790	O
.	-	1791	O

CONCLUSIONS	24464946	1793	O
:	-	1804	O

GLS	24464946	1806	O
combined	-	1810	O
with	-	1819	O
cTnT	-	1824	O
may	-	1829	O
provide	-	1833	O
a	-	1841	O
reliable	-	1843	O
and	-	1852	O
non	-	1856	O
-	-	1859	O
invasive	-	1860	O
method	-	1869	O
to	-	1876	O
predict	-	1879	O
cardiac	-	1887	B
dysfunction	-	1895	I
in	-	1907	O
patients	-	1910	O
receiving	-	1919	O
anthracycline	-	1929	O
-	-	1942	O
based	-	1943	O
chemotherapy	-	1949	O
.	-	1961	O

Prevention	24535067	0	O
of	-	11	O
etomidate	-	14	O
-	-	23	O
induced	-	24	O
myoclonus	-	32	B
:	-	41	O
which	-	43	O
is	-	49	O
superior	-	52	O
:	-	60	O
Fentanyl	-	62	O
,	-	70	O
midazolam	-	72	O
,	-	81	O
or	-	83	O
a	-	86	O
combination	-	88	O
?	-	99	O

A	24535067	101	O
Retrospective	-	103	O
comparative	-	117	O
study	-	129	O
.	-	134	O

BACKGROUND	24535067	136	O
:	-	146	O

In	24535067	148	O
this	-	151	O
retrospective	-	156	O
comparative	-	170	O
study	-	182	O
,	-	187	O
we	-	189	O
aimed	-	192	O
to	-	198	O
compare	-	201	O
the	-	209	O
effectiveness	-	213	O
of	-	227	O
fentanyl	-	230	O
,	-	238	O
midazolam	-	240	O
,	-	249	O
and	-	251	O
a	-	255	O
combination	-	257	O
of	-	269	O
fentanyl	-	272	O
and	-	281	O
midazolam	-	285	O
to	-	295	O
prevent	-	298	O
etomidate	-	306	O
-	-	315	O
induced	-	316	O
myoclonus	-	324	B
.	-	333	O

MATERIAL	24535067	335	O
AND	-	344	O
METHODS	-	348	O
:	-	355	O

This	24535067	357	O
study	-	362	O
was	-	368	O
performed	-	372	O
based	-	382	O
on	-	388	O
anesthesia	-	391	O
records	-	402	O
.	-	409	O

Depending	24535067	411	O
on	-	421	O
the	-	424	O
drugs	-	428	O
that	-	434	O
would	-	439	O
be	-	445	O
given	-	448	O
before	-	454	O
the	-	461	O
induction	-	465	O
of	-	475	O
anesthesia	-	478	O
with	-	489	O
etomidate	-	494	O
,	-	503	O
the	-	505	O
patients	-	509	O
were	-	518	O
separated	-	523	O
into	-	533	O
4	-	538	O
groups	-	540	O
:	-	546	O
no	-	548	O
pretreatment	-	551	O
(	-	564	O
Group	-	565	O
NP	-	571	O
)	-	573	O
,	-	574	O
fentanyl	-	576	O
1	-	585	O
ug	-	587	O
.	-	589	O
kg	-	590	O
-	-	592	O
1	-	593	O
(	-	595	O
Group	-	596	O
F	-	602	O
)	-	603	O
,	-	604	O
midazolam	-	606	O
0	-	616	O
.	-	617	O
03	-	618	O
mg	-	621	O
.	-	623	O
kg	-	624	O
-	-	626	O
1	-	627	O
(	-	629	O
Group	-	630	O
M	-	636	O
)	-	637	O
,	-	638	O
and	-	640	O
midazolam	-	644	O
0	-	654	O
.	-	655	O
015	-	656	O
mg	-	660	O
.	-	662	O
kg	-	663	O
-	-	665	O
1	-	666	O
+	-	668	O
fentanyl	-	670	O
0	-	679	O
.	-	680	O
5	-	681	O
ug	-	683	O
.	-	685	O
kg	-	686	O
-	-	688	O
1	-	689	O
(	-	691	O
Group	-	692	O
FM	-	698	O
)	-	700	O
.	-	701	O

Patients	24535067	703	O
who	-	712	O
received	-	716	O
the	-	725	O
same	-	729	O
anesthetic	-	734	O
procedure	-	745	O
were	-	755	O
selected	-	760	O
:	-	768	O
2	-	770	O
minutes	-	772	O
after	-	780	O
intravenous	-	786	O
injections	-	798	O
of	-	809	O
the	-	812	O
pretreatment	-	816	O
drugs	-	829	O
,	-	834	O
anesthesia	-	836	O
is	-	847	O
induced	-	850	O
with	-	858	O
0	-	863	O
.	-	864	O
3	-	865	O
mg	-	867	O
.	-	869	O
kg	-	870	O
-	-	872	O
1	-	873	O
etomidate	-	875	O
injected	-	885	O
intravenously	-	894	O
over	-	908	O
a	-	913	O
period	-	915	O
of	-	922	O
20	-	925	O
-	-	927	O
30	-	928	O
seconds	-	931	O
.	-	938	O

Myoclonic	24535067	940	B
movements	-	950	I
are	-	960	O
evaluated	-	964	O
,	-	973	O
which	-	975	O
were	-	981	O
observed	-	986	O
and	-	995	O
graded	-	999	O
according	-	1006	O
to	-	1016	O
clinical	-	1019	O
severity	-	1028	O
during	-	1037	O
the	-	1044	O
2	-	1048	O
minutes	-	1050	O
after	-	1058	O
etomidate	-	1064	O
injection	-	1074	O
.	-	1083	O

The	24535067	1085	O
severity	-	1089	O
of	-	1098	O
pain	-	1101	B
due	-	1106	O
to	-	1110	O
etomidate	-	1113	O
injection	-	1123	O
,	-	1132	O
mean	-	1134	O
arterial	-	1139	O
pressure	-	1148	O
,	-	1156	O
heart	-	1158	O
rate	-	1164	O
,	-	1168	O
and	-	1170	O
adverse	-	1174	O
effects	-	1182	O
were	-	1190	O
also	-	1195	O
evaluated	-	1200	O
.	-	1209	O

RESULTS	24535067	1211	O
:	-	1218	O

Study	24535067	1220	O
results	-	1226	O
showed	-	1234	O
that	-	1241	O
myoclonus	-	1246	B
incidence	-	1256	O
was	-	1266	O
85	-	1270	O
%	-	1272	O
,	-	1273	O
40	-	1275	O
%	-	1277	O
,	-	1278	O
70	-	1280	O
%	-	1282	O
,	-	1283	O
and	-	1285	O
25	-	1289	O
%	-	1291	O
in	-	1293	O
Group	-	1296	O
NP	-	1302	O
,	-	1304	O
Group	-	1306	O
F	-	1312	O
,	-	1313	O
Group	-	1315	O
M	-	1321	O
,	-	1322	O
and	-	1324	O
Group	-	1328	O
FM	-	1334	O
,	-	1336	O
respectively	-	1338	O
,	-	1350	O
and	-	1352	O
were	-	1356	O
significantly	-	1361	O
lower	-	1375	O
in	-	1381	O
Group	-	1384	O
F	-	1390	O
and	-	1392	O
Group	-	1396	O
FM	-	1402	O
.	-	1404	O

CONCLUSIONS	24535067	1406	O
:	-	1417	O

We	24535067	1419	O
conclude	-	1422	O
that	-	1431	O
pretreatment	-	1436	O
with	-	1449	O
fentanyl	-	1454	O
or	-	1463	O
combination	-	1466	O
of	-	1478	O
fentanyl	-	1481	O
and	-	1490	O
midazolam	-	1494	O
was	-	1504	O
effective	-	1508	O
in	-	1518	O
preventing	-	1521	O
etomidate	-	1532	O
-	-	1541	O
induced	-	1542	O
myoclonus	-	1550	B
.	-	1559	O

Cholestatic	24554916	0	B
presentation	-	12	O
of	-	25	O
yellow	-	28	O
phosphorus	-	35	O
poisoning	-	46	B
.	-	55	O

Yellow	24554916	57	O
phosphorus	-	64	O
,	-	74	O
a	-	76	O
component	-	78	O
of	-	88	O
certain	-	91	O
pesticide	-	99	O
pastes	-	109	O
and	-	116	O
fireworks	-	120	O
,	-	129	O
is	-	131	O
well	-	134	O
known	-	139	O
to	-	145	O
cause	-	148	O
hepatotoxicity	-	154	B
.	-	168	O

Poisoning	24554916	170	B
with	-	180	O
yellow	-	185	O
phosphorus	-	192	O
classically	-	203	O
manifests	-	215	O
with	-	225	O
acute	-	230	B
hepatitis	-	236	I
leading	-	246	O
to	-	254	O
acute	-	257	B
liver	-	263	I
failure	-	269	I
which	-	277	O
may	-	283	O
need	-	287	O
liver	-	292	O
transplantation	-	298	O
.	-	313	O

We	24554916	315	O
present	-	318	O
a	-	326	O
case	-	328	O
of	-	333	O
yellow	-	336	O
phosphorus	-	343	O
poisoning	-	354	B
in	-	364	O
which	-	367	O
a	-	373	O
patient	-	375	O
presented	-	383	O
with	-	393	O
florid	-	398	O
clinical	-	405	O
features	-	414	O
of	-	423	O
cholestasis	-	426	B
highlighting	-	438	O
the	-	451	O
fact	-	455	O
that	-	460	O
cholestasis	-	465	B
can	-	477	O
rarely	-	481	O
be	-	488	O
a	-	491	O
presenting	-	493	O
feature	-	504	O
of	-	512	O
yellow	-	515	O
phosphorus	-	522	O
hepatotoxicity	-	533	B
.	-	547	O

Vasovagal	24571687	0	B
syncope	-	10	I
and	-	18	O
severe	-	22	O
bradycardia	-	29	B
following	-	41	O
intranasal	-	51	O
dexmedetomidine	-	62	O
for	-	78	O
pediatric	-	82	O
procedural	-	92	O
sedation	-	103	O
.	-	111	O

We	24571687	113	O
report	-	116	O
syncope	-	123	B
and	-	131	O
bradycardia	-	135	B
in	-	147	O
an	-	150	O
11	-	153	O
-	-	155	O
year	-	156	O
-	-	160	O
old	-	161	O
girl	-	165	O
following	-	170	O
administration	-	180	O
of	-	195	O
intranasal	-	198	O
dexmedetomidine	-	209	O
for	-	225	O
sedation	-	229	O
for	-	238	O
a	-	242	O
voiding	-	244	O
cystourethrogram	-	252	O
.	-	268	O

Following	24571687	270	O
successful	-	280	O
completion	-	291	O
of	-	302	O
VCUG	-	305	O
and	-	310	O
a	-	314	O
60	-	316	O
-	-	318	O
min	-	319	O
recovery	-	323	O
period	-	332	O
,	-	338	O
the	-	340	O
patient	-	344	O
's	-	351	O
level	-	354	O
of	-	360	O
consciousness	-	363	O
and	-	377	O
vital	-	381	O
signs	-	387	O
returned	-	393	O
to	-	402	O
presedation	-	405	O
levels	-	417	O
.	-	423	O

Upon	24571687	425	O
leaving	-	430	O
the	-	438	O
sedation	-	442	O
area	-	451	O
,	-	455	O
the	-	457	O
patient	-	461	O
collapsed	-	469	O
,	-	478	O
with	-	480	O
no	-	485	O
apparent	-	488	O
inciting	-	497	O
event	-	506	O
.	-	511	O

The	24571687	513	O
patient	-	517	O
quickly	-	525	O
regained	-	533	O
consciousness	-	542	O
and	-	556	O
no	-	560	O
injury	-	563	O
occurred	-	570	O
.	-	578	O

The	24571687	580	O
primary	-	584	O
abnormality	-	592	O
found	-	604	O
was	-	610	O
persistent	-	614	O
bradycardia	-	625	B
,	-	636	O
and	-	638	O
she	-	642	O
was	-	646	O
admitted	-	650	O
to	-	659	O
the	-	662	O
hospital	-	666	O
for	-	675	O
telemetric	-	679	O
observation	-	690	O
.	-	701	O

The	24571687	703	O
bradycardia	-	707	B
lasted	-	719	O
~	-	726	O
2	-	727	O
h	-	729	O
,	-	730	O
and	-	732	O
further	-	736	O
cardiac	-	744	O
workup	-	752	O
revealed	-	759	O
no	-	768	O
underlying	-	771	O
abnormality	-	782	O
.	-	793	O

Unanticipated	24571687	795	O
and	-	809	O
previously	-	813	O
unreported	-	824	O
outcomes	-	835	O
may	-	844	O
be	-	848	O
witnessed	-	851	O
as	-	861	O
we	-	864	O
expand	-	867	O
the	-	874	O
use	-	878	O
of	-	882	O
certain	-	885	O
sedatives	-	893	O
to	-	903	O
alternative	-	906	O
routes	-	918	O
of	-	925	O
administration	-	928	O
.	-	942	O

Paradoxical	24582773	0	O
severe	-	12	O
agitation	-	19	B
induced	-	29	O
by	-	37	O
add	-	40	O
-	-	43	O
on	-	44	O
high	-	47	O
-	-	51	O
doses	-	52	O
quetiapine	-	58	O
in	-	69	O
schizo	-	72	B
-	-	78	I
affective	-	79	I
disorder	-	89	I
.	-	97	O

We	24582773	99	O
report	-	102	O
the	-	109	O
case	-	113	O
of	-	118	O
a	-	121	O
35	-	123	O
-	-	125	O
year	-	126	O
-	-	130	O
old	-	131	O
patient	-	135	O
suffering	-	143	O
from	-	153	O
schizo	-	158	B
-	-	164	I
affective	-	165	I
disorder	-	175	I
since	-	184	O
the	-	190	O
age	-	194	O
of	-	198	O
19	-	201	O
years	-	204	O
,	-	209	O
treated	-	211	O
by	-	219	O
a	-	222	O
combination	-	224	O
of	-	236	O
first	-	239	O
-	-	244	O
generation	-	245	O
antipsychotics	-	256	O
,	-	270	O
zuclopenthixol	-	272	O
(	-	287	O
100	-	288	O
mg	-	292	O
/	-	294	O
day	-	295	O
)	-	298	O
and	-	300	O
lithium	-	304	O
(	-	312	O
1200	-	313	O
mg	-	318	O
/	-	320	O
day	-	321	O
)	-	324	O
(	-	326	O
serum	-	327	O
lithium	-	333	O
=	-	340	O
0	-	341	O
.	-	342	O
85	-	343	O
mEq	-	346	O
/	-	349	O
l	-	350	O
)	-	351	O
.	-	352	O

This	24582773	354	O
patient	-	359	O
had	-	367	O
no	-	371	O
associated	-	374	O
personality	-	385	B
disorder	-	397	I
(	-	406	O
particularly	-	407	O
no	-	420	O
antisocial	-	423	B
disorder	-	434	I
)	-	442	O
and	-	444	O
no	-	448	O
substance	-	451	B
abuse	-	461	I
disorder	-	467	I
.	-	475	O

Within	24582773	477	O
the	-	484	O
48	-	488	O
h	-	491	O
following	-	493	O
the	-	503	O
gradual	-	507	O
introduction	-	515	O
of	-	528	O
quetiapine	-	531	O
(	-	542	O
up	-	543	O
to	-	546	O
600	-	549	O
mg	-	553	O
/	-	555	O
day	-	556	O
)	-	559	O
,	-	560	O
the	-	562	O
patient	-	566	O
presented	-	574	O
severe	-	584	O
agitation	-	591	B
without	-	601	O
an	-	609	O
environmental	-	612	O
explanation	-	626	O
,	-	637	O
contrasting	-	639	O
with	-	651	O
the	-	656	O
absence	-	660	O
of	-	668	O
a	-	671	O
history	-	673	O
of	-	681	O
aggressiveness	-	684	B
or	-	699	O
personality	-	702	B
disorder	-	714	I
.	-	722	O

The	24582773	724	O
diagnoses	-	728	O
of	-	738	O
manic	-	741	B
shift	-	747	O
and	-	753	O
akathisia	-	757	B
were	-	767	O
dismissed	-	772	O
.	-	781	O

The	24582773	783	O
withdrawal	-	787	O
and	-	798	O
the	-	802	O
gradual	-	806	O
reintroduction	-	814	O
of	-	829	O
quetiapine	-	832	O
2	-	843	O
weeks	-	845	O
later	-	851	O
,	-	856	O
which	-	858	O
led	-	864	O
to	-	868	O
another	-	871	O
severe	-	879	O
agitation	-	886	B
,	-	895	O
enabled	-	897	O
us	-	905	O
to	-	908	O
attribute	-	911	O
the	-	921	O
agitation	-	925	B
specifically	-	935	O
to	-	948	O
quetiapine	-	951	O
.	-	961	O

Antioxidant	24587916	0	O
effects	-	12	O
of	-	20	O
bovine	-	23	O
lactoferrin	-	30	O
on	-	42	O
dexamethasone	-	45	O
-	-	58	O
induced	-	59	O
hypertension	-	67	B
in	-	80	O
rat	-	83	O
.	-	86	O

Dexamethasone	24587916	88	O
-	-	101	O
(	-	103	O
Dex	-	104	O
-	-	107	O
)	-	108	O
induced	-	110	O
hypertension	-	118	B
is	-	131	O
associated	-	134	O
with	-	145	O
enhanced	-	150	O
oxidative	-	159	O
stress	-	169	O
.	-	175	O

Lactoferrin	24587916	177	O
(	-	189	O
LF	-	190	O
)	-	192	O
is	-	194	O
an	-	197	O
iron	-	200	O
-	-	204	O
binding	-	205	O
glycoprotein	-	213	O
with	-	226	O
antihypertensive	-	231	O
properties	-	248	O
.	-	258	O

In	24587916	260	O
this	-	263	O
study	-	268	O
,	-	273	O
we	-	275	O
investigated	-	278	O
the	-	291	O
effect	-	295	O
of	-	302	O
chronic	-	305	O
administration	-	313	O
of	-	328	O
LF	-	331	O
on	-	334	O
oxidative	-	337	O
stress	-	347	O
and	-	354	O
hypertension	-	358	B
upon	-	371	O
Dex	-	376	O
administration	-	380	O
.	-	394	O

Male	24587916	396	O
Wistar	-	401	O
rats	-	408	O
were	-	413	O
treated	-	418	O
by	-	426	O
Dex	-	429	O
(	-	433	O
30	-	434	O
u	-	438	O
g	-	440	O
/	-	441	O
kg	-	442	O
/	-	444	O
day	-	445	O
subcutaneously	-	449	O
)	-	463	O
or	-	465	O
saline	-	468	O
for	-	475	O
14	-	479	O
days	-	482	O
.	-	486	O

Oral	24587916	488	O
bovine	-	493	O
LF	-	500	O
(	-	503	O
30	-	504	O
,	-	506	O
100	-	508	O
,	-	511	O
300	-	513	O
mg	-	517	O
/	-	519	O
kg	-	520	O
)	-	522	O
was	-	524	O
given	-	528	O
from	-	534	O
day	-	539	O
8	-	543	O
to	-	545	O
14	-	548	O
in	-	551	O
a	-	554	O
reversal	-	556	O
study	-	565	O
.	-	570	O

In	24587916	572	O
a	-	575	O
prevention	-	577	O
study	-	588	O
,	-	593	O
rats	-	595	O
received	-	600	O
4	-	609	O
days	-	611	O
of	-	616	O
LF	-	619	O
treatment	-	622	O
followed	-	632	O
by	-	641	O
Dex	-	644	O
and	-	648	O
continued	-	652	O
during	-	662	O
the	-	669	O
test	-	673	O
period	-	678	O
.	-	684	O

Systolic	24587916	686	O
blood	-	695	O
pressure	-	701	O
(	-	710	O
SBP	-	711	O
)	-	714	O
was	-	716	O
measured	-	720	O
using	-	729	O
tail	-	735	O
-	-	739	O
cuff	-	740	O
method	-	745	O
.	-	751	O

Thymus	24587916	753	O
weight	-	760	O
was	-	767	O
used	-	771	O
as	-	776	O
a	-	779	O
marker	-	781	O
of	-	788	O
glucocorticoid	-	791	O
activity	-	806	O
.	-	814	O

Plasma	24587916	816	O
hydrogen	-	823	O
peroxide	-	832	O
(	-	841	O
H2O2	-	842	O
)	-	846	O
concentration	-	848	O
and	-	862	O
ferric	-	866	O
reducing	-	873	O
antioxidant	-	882	O
power	-	894	O
(	-	900	O
FRAP	-	901	O
)	-	905	O
value	-	907	O
were	-	913	O
determined	-	918	O
.	-	928	O

Dexamethasone	24587916	930	O
significantly	-	944	O
increased	-	958	O
SBP	-	968	O
and	-	972	O
plasma	-	976	O
H2O2	-	983	O
level	-	988	O
and	-	994	O
decreased	-	998	O
thymus	-	1008	O
and	-	1015	O
body	-	1019	O
weights	-	1024	O
.	-	1031	O

LF	24587916	1033	O
lowered	-	1036	O
(	-	1044	O
P	-	1045	O
<	-	1047	O
0	-	1049	O
.	-	1050	O
01	-	1051	O
)	-	1053	O
and	-	1055	O
dose	-	1059	O
dependently	-	1064	O
prevented	-	1076	O
(	-	1086	O
P	-	1087	O
<	-	1089	O
0	-	1091	O
.	-	1092	O
001	-	1093	O
)	-	1096	O

Dex	24587916	1098	O
-	-	1101	O
induced	-	1102	O
hypertension	-	1110	B
.	-	1122	O

LF	24587916	1124	O
prevented	-	1127	O
body	-	1137	O
weight	-	1142	B
loss	-	1149	I
and	-	1154	O
significantly	-	1158	O
reduced	-	1172	O
the	-	1180	O
elevated	-	1184	O
plasma	-	1193	O
H2O2	-	1200	O
and	-	1205	O
increased	-	1209	O
FRAP	-	1219	O
values	-	1224	O
.	-	1230	O

Chronic	24587916	1232	O
administration	-	1240	O
of	-	1255	O
LF	-	1258	O
strongly	-	1261	O
reduced	-	1270	O
the	-	1278	O
blood	-	1282	O
pressure	-	1288	O
and	-	1297	O
production	-	1301	O
of	-	1312	O
ROS	-	1315	O
and	-	1319	O
improved	-	1323	O
antioxidant	-	1332	O
capacity	-	1344	O
in	-	1353	O
Dex	-	1356	O
-	-	1359	O
induced	-	1360	O
hypertension	-	1368	B
,	-	1380	O
suggesting	-	1382	O
the	-	1393	O
role	-	1397	O
of	-	1402	O
inhibition	-	1405	O
of	-	1416	O
oxidative	-	1419	O
stress	-	1429	O
as	-	1436	O
another	-	1439	O
mechanism	-	1447	O
of	-	1457	O
antihypertensive	-	1460	O
action	-	1477	O
of	-	1484	O
LF	-	1487	O
.	-	1489	O

The	24588023	0	O
association	-	4	O
between	-	16	O
tranexamic	-	24	O
acid	-	35	O
and	-	40	O
convulsive	-	44	B
seizures	-	55	B
after	-	64	O
cardiac	-	70	O
surgery	-	78	O
:	-	85	O
a	-	87	O
multivariate	-	89	O
analysis	-	102	O
in	-	111	O
11	-	114	O
529	-	117	O
patients	-	121	O
.	-	129	O

Because	24588023	131	O
of	-	139	O
a	-	142	O
lack	-	144	O
of	-	149	O
contemporary	-	152	O
data	-	165	O
regarding	-	170	O
seizures	-	180	B
after	-	189	O
cardiac	-	195	O
surgery	-	203	O
,	-	210	O
we	-	212	O
undertook	-	215	O
a	-	225	O
retrospective	-	227	O
analysis	-	241	O
of	-	250	O
prospectively	-	253	O
collected	-	267	O
data	-	277	O
from	-	282	O
11	-	287	O
529	-	290	O
patients	-	294	O
in	-	303	O
whom	-	306	O
cardiopulmonary	-	311	O
bypass	-	327	O
was	-	334	O
used	-	338	O
from	-	343	O
January	-	348	O
2004	-	356	O
to	-	361	O
December	-	364	O
2010	-	373	O
.	-	377	O

A	24588023	379	O
convulsive	-	381	B
seizure	-	392	B
was	-	400	O
defined	-	404	O
as	-	412	O
a	-	415	O
transient	-	417	O
episode	-	427	O
of	-	435	O
disturbed	-	438	O
brain	-	448	O
function	-	454	O
characterised	-	463	O
by	-	477	O
abnormal	-	480	B
involuntary	-	489	I
motor	-	501	I
movements	-	507	I
.	-	516	O

Multivariate	24588023	518	O
regression	-	531	O
analysis	-	542	O
was	-	551	O
performed	-	555	O
to	-	565	O
identify	-	568	O
independent	-	577	O
predictors	-	589	O
of	-	600	O
postoperative	-	603	O
seizures	-	617	B
.	-	625	O

A	24588023	627	O
total	-	629	O
of	-	635	O
100	-	638	O
(	-	642	O
0	-	643	O
.	-	644	O
9	-	645	O
%	-	646	O
)	-	647	O
patients	-	649	O
developed	-	658	O
postoperative	-	668	O
convulsive	-	682	B
seizures	-	693	B
.	-	701	O

Generalised	24588023	703	B
and	-	715	I
focal	-	719	I
seizures	-	725	I
were	-	734	O
identified	-	739	O
in	-	750	O
68	-	753	O
and	-	756	O
32	-	760	O
patients	-	763	O
,	-	771	O
respectively	-	773	O
.	-	785	O

The	24588023	787	O
median	-	791	O
(	-	798	O
IQR	-	799	O
[	-	803	O
range	-	804	O
]	-	809	O
)	-	810	O
time	-	812	O
after	-	817	O
surgery	-	823	O
when	-	831	O
the	-	836	O
seizure	-	840	B
occurred	-	848	O
was	-	857	O
7	-	861	O
(	-	863	O
6	-	864	O
-	-	865	O
12	-	866	O
[	-	869	O
1	-	870	O
-	-	871	O
216	-	872	O
]	-	875	O
)	-	876	O
h	-	878	O
and	-	880	O
8	-	884	O
(	-	886	O
6	-	887	O
-	-	888	O
11	-	889	O
[	-	892	O
4	-	893	O
-	-	894	O
18	-	895	O
]	-	897	O
)	-	898	O
h	-	900	O
,	-	901	O
respectively	-	903	O
.	-	915	O

Epileptiform	24588023	917	O
findings	-	930	O
on	-	939	O
electroencephalography	-	942	O
were	-	965	O
seen	-	970	O
in	-	975	O
19	-	978	O
patients	-	981	O
.	-	989	O

Independent	24588023	991	O
predictors	-	1003	O
of	-	1014	O
postoperative	-	1017	O
seizures	-	1031	B
included	-	1040	O
age	-	1049	O
,	-	1052	O
female	-	1054	O
sex	-	1061	O
,	-	1064	O
redo	-	1066	O
cardiac	-	1071	O
surgery	-	1079	O
,	-	1086	O
calcification	-	1088	O
of	-	1102	O
ascending	-	1105	O
aorta	-	1115	O
,	-	1120	O
congestive	-	1122	B
heart	-	1133	I
failure	-	1139	I
,	-	1146	O
deep	-	1148	O
hypothermic	-	1153	B
circulatory	-	1165	O
arrest	-	1177	O
,	-	1183	O
duration	-	1185	O
of	-	1194	O
aortic	-	1197	O
cross	-	1204	O
-	-	1209	O
clamp	-	1210	O
and	-	1216	O
tranexamic	-	1220	O
acid	-	1231	O
.	-	1235	O

When	24588023	1237	O
tested	-	1242	O
in	-	1249	O
a	-	1252	O
multivariate	-	1254	O
regression	-	1267	O
analysis	-	1278	O
,	-	1286	O
tranexamic	-	1288	O
acid	-	1299	O
was	-	1304	O
a	-	1308	O
strong	-	1310	O
independent	-	1317	O
predictor	-	1329	O
of	-	1339	O
seizures	-	1342	B
(	-	1351	O
OR	-	1352	O
14	-	1355	O
.	-	1357	O
3	-	1358	O
,	-	1359	O
95	-	1361	O
%	-	1363	O
CI	-	1365	O
5	-	1368	O
.	-	1369	O
5	-	1370	O
-	-	1371	O
36	-	1372	O
.	-	1374	O
7	-	1375	O
;	-	1376	O
p	-	1378	O
<	-	1380	O
0	-	1382	O
.	-	1383	O
001	-	1384	O
)	-	1387	O
.	-	1388	O

Patients	24588023	1390	O
with	-	1399	O
convulsive	-	1404	B
seizures	-	1415	B
had	-	1424	O
2	-	1428	O
.	-	1429	O
5	-	1430	O
times	-	1432	O
higher	-	1438	O
in	-	1445	O
-	-	1447	O
hospital	-	1448	O
mortality	-	1457	O
rates	-	1467	O
and	-	1473	O
twice	-	1477	O
the	-	1483	O
length	-	1487	O
of	-	1494	O
hospital	-	1497	O
stay	-	1506	O
compared	-	1511	O
with	-	1520	O
patients	-	1525	O
without	-	1534	O
convulsive	-	1542	B
seizures	-	1553	B
.	-	1561	O

Mean	24588023	1563	O
(	-	1568	O
IQR	-	1569	O
[	-	1573	O
range	-	1574	O
]	-	1579	O
)	-	1580	O

length	24588023	1582	O
of	-	1589	O
stay	-	1592	O
in	-	1597	O
the	-	1600	O
intensive	-	1604	O
care	-	1614	O
unit	-	1619	O
was	-	1624	O
115	-	1628	O
(	-	1632	O
49	-	1633	O
-	-	1635	O
228	-	1636	O
[	-	1640	O
32	-	1641	O
-	-	1643	O
481	-	1644	O
]	-	1647	O
)	-	1648	O
h	-	1650	O
in	-	1652	O
patients	-	1655	O
with	-	1664	O
convulsive	-	1669	B
seizures	-	1680	B
compared	-	1689	O
with	-	1698	O
26	-	1703	O
(	-	1706	O
22	-	1707	O
-	-	1709	O
69	-	1710	O
[	-	1713	O
14	-	1714	O
-	-	1716	O
1080	-	1717	O
]	-	1721	O
)	-	1722	O
h	-	1724	O
in	-	1726	O
patients	-	1729	O
without	-	1738	O
seizures	-	1746	B
(	-	1755	O
p	-	1756	O
<	-	1758	O
0	-	1760	O
.	-	1761	O
001	-	1762	O
)	-	1765	O
.	-	1766	O

Convulsive	24588023	1768	B
seizures	-	1779	B
are	-	1788	O
a	-	1792	O
serious	-	1794	O
postoperative	-	1802	B
complication	-	1816	I
after	-	1829	O
cardiac	-	1835	O
surgery	-	1843	O
.	-	1850	O

As	24588023	1852	O
tranexamic	-	1855	O
acid	-	1866	O
is	-	1871	O
the	-	1874	O
only	-	1878	O
modifiable	-	1883	O
factor	-	1894	O
,	-	1900	O
its	-	1902	O
administration	-	1906	O
,	-	1920	O
particularly	-	1922	O
in	-	1935	O
doses	-	1938	O
exceeding	-	1944	O
80	-	1954	O
mg	-	1957	O
.	-	1959	O
kg	-	1960	O
(	-	1962	O
-	-	1963	O
1	-	1964	O
)	-	1965	O
,	-	1966	O
should	-	1968	O
be	-	1975	O
weighed	-	1978	O
against	-	1986	O
the	-	1994	O
risk	-	1998	O
of	-	2003	O
postoperative	-	2006	O
seizures	-	2020	B
.	-	2028	O

Dysfunctional	24595967	0	B
overnight	-	14	I
memory	-	24	I
consolidation	-	31	O
in	-	45	O
ecstasy	-	48	O
users	-	56	O
.	-	61	O

Sleep	24595967	63	O
plays	-	69	O
an	-	75	O
important	-	78	O
role	-	88	O
in	-	93	O
the	-	96	O
consolidation	-	100	O
and	-	114	O
integration	-	118	O
of	-	130	O
memory	-	133	O
in	-	140	O
a	-	143	O
process	-	145	O
called	-	153	O
overnight	-	160	O
memory	-	170	O
consolidation	-	177	O
.	-	190	O

Previous	24595967	192	O
studies	-	201	O
indicate	-	209	O
that	-	218	O
ecstasy	-	223	O
users	-	231	O
have	-	237	O
marked	-	242	O
and	-	249	O
persistent	-	253	O
neurocognitive	-	264	O
and	-	279	O
sleep	-	283	B
-	-	288	I
related	-	289	I
impairments	-	297	I
.	-	308	O

We	24595967	310	O
extend	-	313	O
past	-	320	O
research	-	325	O
by	-	334	O
examining	-	337	O
overnight	-	347	O
memory	-	357	O
consolidation	-	364	O
among	-	378	O
regular	-	384	O
ecstasy	-	392	O
users	-	400	O
(	-	406	O
n	-	407	O
=	-	408	O
12	-	409	O
)	-	411	O
and	-	413	O
drug	-	417	O
naive	-	422	O
healthy	-	428	O
controls	-	436	O
(	-	445	O
n	-	446	O
=	-	447	O
26	-	448	O
)	-	450	O
.	-	451	O

Memory	24595967	453	O
recall	-	460	O
of	-	467	O
word	-	470	O
pairs	-	475	O
was	-	481	O
evaluated	-	485	O
before	-	495	O
and	-	502	O
after	-	506	O
a	-	512	O
period	-	514	O
of	-	521	O
sleep	-	524	O
,	-	529	O
with	-	531	O
and	-	536	O
without	-	540	O
interference	-	548	O
prior	-	561	O
to	-	567	O
testing	-	570	O
.	-	577	O

In	24595967	579	O
addition	-	582	O
,	-	590	O
we	-	592	O
assessed	-	595	O
neurocognitive	-	604	O
performances	-	619	O
across	-	632	O
tasks	-	639	O
of	-	645	O
learning	-	648	O
,	-	656	O
memory	-	658	O
and	-	665	O
executive	-	669	O
functioning	-	679	O
.	-	690	O

Ecstasy	24595967	692	O
users	-	700	O
demonstrated	-	706	O
impaired	-	719	B
overnight	-	728	I
memory	-	738	I
consolidation	-	745	O
,	-	758	O
a	-	760	O
finding	-	762	O
that	-	770	O
was	-	775	O
more	-	779	O
pronounced	-	784	O
following	-	795	O
associative	-	805	O
interference	-	817	O
.	-	829	O

Additionally	24595967	831	O
,	-	843	O
ecstasy	-	845	O
users	-	853	O
demonstrated	-	859	O
impairments	-	872	O
on	-	884	O
tasks	-	887	O
recruiting	-	893	O
frontostriatal	-	904	O
and	-	919	O
hippocampal	-	923	O
neural	-	935	O
circuitry	-	942	O
,	-	951	O
in	-	953	O
the	-	956	O
domains	-	960	O
of	-	968	O
proactive	-	971	O
interference	-	981	O
memory	-	994	O
,	-	1000	O
long	-	1002	O
-	-	1006	O
term	-	1007	O
memory	-	1012	O
,	-	1018	O
encoding	-	1020	O
,	-	1028	O
working	-	1030	O
memory	-	1038	O
and	-	1045	O
complex	-	1049	O
planning	-	1057	O
.	-	1065	O

We	24595967	1067	O
suggest	-	1070	O
that	-	1078	O
ecstasy	-	1083	O
-	-	1090	O
associated	-	1091	O
dysfunction	-	1102	O
in	-	1114	O
fronto	-	1117	O
-	-	1123	O
temporal	-	1124	O
circuitry	-	1133	O
may	-	1143	O
underlie	-	1147	O
overnight	-	1156	O
consolidation	-	1166	O
memory	-	1180	B
impairments	-	1187	I
in	-	1199	O
regular	-	1202	O
ecstasy	-	1210	O
users	-	1218	O
.	-	1223	O

Normoammonemic	24614773	0	O
encephalopathy	-	15	B
:	-	29	O
solely	-	31	O
valproate	-	38	O
induced	-	48	O
or	-	56	O
multiple	-	59	O
mechanisms	-	68	O
?	-	78	O

A	24614773	80	O
77	-	82	O
-	-	84	O
year	-	85	O
-	-	89	O
old	-	90	O
woman	-	94	O
presented	-	100	O
with	-	110	O
subacute	-	115	O
onset	-	124	O
progressive	-	130	O
confusion	-	142	B
,	-	151	O
aggression	-	153	B
,	-	163	O
auditory	-	165	B
hallucinations	-	174	I
and	-	189	O
delusions	-	193	B
.	-	202	O

In	24614773	204	O
the	-	207	O
preceding	-	211	O
months	-	221	O
,	-	227	O
the	-	229	O
patient	-	233	O
had	-	241	O
a	-	245	O
number	-	247	O
of	-	254	O
admissions	-	257	O
with	-	268	O
transient	-	273	O
unilateral	-	283	O
hemiparesis	-	294	B
with	-	306	O
facial	-	311	O
droop	-	318	O
,	-	323	O
and	-	325	O
had	-	329	O
been	-	333	O
started	-	338	O
on	-	346	O
valproate	-	349	O
for	-	359	O
presumed	-	363	O
hemiplegic	-	372	B
migraine	-	383	I
.	-	391	O

Valproate	24614773	393	O
was	-	403	O
withdrawn	-	407	O
soon	-	417	O
after	-	422	O
admission	-	428	O
and	-	438	O
her	-	442	O
cognitive	-	446	O
abilities	-	456	O
have	-	466	O
gradually	-	471	O
improved	-	481	O
over	-	490	O
3	-	495	O
months	-	497	O
of	-	504	O
follow	-	507	O
-	-	513	O
up	-	514	O
.	-	516	O

Valproate	24614773	518	O
levels	-	528	O
taken	-	535	O
prior	-	541	O
to	-	547	O
withdrawal	-	550	O
were	-	561	O
subtherapeutic	-	566	O
and	-	581	O
the	-	585	O
patient	-	589	O
was	-	597	O
normoammonaemic	-	601	O
.	-	616	O

EEG	24614773	618	O
undertaken	-	622	O
during	-	633	O
inpatient	-	640	O
stay	-	650	O
showed	-	655	O
changes	-	662	O
consistent	-	670	O
with	-	681	O
encephalopathy	-	686	B
,	-	700	O
and	-	702	O
low	-	706	O
titre	-	710	O
N	-	716	O
-	-	717	O
methyl	-	718	O
-	-	724	O
D	-	725	O
-	-	726	O
aspartate	-	727	O
(	-	737	O
NMDA	-	738	O
)	-	742	O
receptor	-	744	O
antibodies	-	753	O
were	-	764	O
present	-	769	O
in	-	777	O
this	-	780	O
patient	-	785	O
.	-	792	O

The	24614773	794	O
possible	-	798	O
aetiologies	-	807	O
of	-	819	O
valproate	-	822	O
-	-	831	O
induced	-	832	O
encephalopathy	-	840	B
and	-	855	O
NMDA	-	859	O
receptor	-	864	O
-	-	872	O
associated	-	873	O
encephalitis	-	884	B
present	-	897	O
a	-	905	O
diagnostic	-	907	O
dilemma	-	918	O
.	-	925	O

We	24614773	927	O
present	-	930	O
a	-	938	O
putative	-	940	O
combinatorial	-	949	O
hypothesis	-	963	O
to	-	974	O
explain	-	977	O
this	-	985	O
patient	-	990	O
's	-	997	O
symptoms	-	1000	O
.	-	1008	O

Cerebellar	24618873	0	B
and	-	11	I
oculomotor	-	15	I
dysfunction	-	26	I
induced	-	38	O
by	-	46	O
rapid	-	49	O
infusion	-	55	O
of	-	64	O
pethidine	-	67	O
.	-	76	O

Pethidine	24618873	78	O
is	-	88	O
an	-	91	O
opioid	-	94	O
that	-	101	O
gains	-	106	O
its	-	112	O
popularity	-	116	O
for	-	127	O
the	-	131	O
effective	-	135	O
pain	-	145	B
control	-	150	O
through	-	158	O
acting	-	166	O
on	-	173	O
the	-	176	O
opioid	-	180	O
-	-	186	O
receptors	-	187	O
.	-	196	O

However	24618873	198	O
,	-	205	O
rapid	-	207	O
pain	-	213	B
relief	-	218	O
sometimes	-	225	O
brings	-	235	O
about	-	242	O
unfavourable	-	248	O
side	-	261	O
effects	-	266	O
that	-	274	O
largely	-	279	O
limit	-	287	O
its	-	293	O
clinical	-	297	O
utility	-	306	O
.	-	313	O

Common	24618873	315	O
side	-	322	O
effects	-	327	O
include	-	335	O
nausea	-	343	B
,	-	349	O
vomiting	-	351	B
and	-	360	O
hypotension	-	364	B
.	-	375	O

In	24618873	377	O
patients	-	380	O
with	-	389	O
impaired	-	394	B
renal	-	403	I
and	-	409	I
liver	-	413	I
function	-	419	I
,	-	427	O
and	-	429	O
those	-	433	O
who	-	439	O
need	-	443	O
long	-	448	O
-	-	452	O
term	-	453	O
pain	-	458	B
control	-	463	O
,	-	470	O
pethidine	-	472	O
may	-	482	O
cause	-	486	O
excitatory	-	492	O
central	-	503	O
nervous	-	511	O
system	-	519	O
(	-	526	O
CNS	-	527	O
)	-	530	O
effects	-	532	O
through	-	540	O
its	-	548	O
neurotoxic	-	552	B
metabolite	-	563	O
,	-	573	O
norpethidine	-	575	O
,	-	587	O
resulting	-	589	O
in	-	599	O
irritability	-	602	B
and	-	615	O
seizure	-	619	B
attack	-	627	O
.	-	633	O

On	24618873	635	O
the	-	638	O
contrary	-	642	O
,	-	650	O
though	-	652	O
not	-	659	O
clinically	-	663	O
apparent	-	674	O
,	-	682	O
pethidine	-	684	O
potentially	-	694	O
causes	-	706	O
inhibitory	-	713	O
impacts	-	724	O
on	-	732	O
the	-	735	O
CNS	-	739	O
and	-	743	O
impairs	-	747	O
normal	-	755	O
cerebellar	-	762	O
and	-	773	O
oculomotor	-	777	O
function	-	788	O
in	-	797	O
the	-	800	O
short	-	804	O
term	-	810	O
.	-	814	O

In	24618873	816	O
this	-	819	O
case	-	824	O
report	-	829	O
,	-	835	O
we	-	837	O
highlight	-	840	O
opioid	-	850	O
's	-	856	O
inhibitory	-	859	O
side	-	870	O
effects	-	875	O
on	-	883	O
the	-	886	O
cerebellar	-	890	O
structure	-	901	O
that	-	911	O
causes	-	916	O
dysmetria	-	923	B
,	-	932	O
dysarthria	-	934	B
,	-	944	O
reduced	-	946	O
smooth	-	954	O
pursuit	-	961	O
gain	-	969	O
and	-	974	O
decreased	-	978	O
saccadic	-	988	O
velocity	-	997	O
.	-	1005	O

Baboon	24641119	0	B
syndrome	-	7	I
induced	-	16	O
by	-	24	O
ketoconazole	-	27	O
.	-	39	O

A	24641119	41	O
27	-	43	O
-	-	45	O
year	-	46	O
-	-	50	O
old	-	51	O
male	-	55	O
patient	-	60	O
presented	-	68	O
with	-	78	O
a	-	83	O
maculopapular	-	85	B
eruption	-	99	I
on	-	108	O
the	-	111	O
flexural	-	115	O
areas	-	124	O
and	-	130	O
buttocks	-	134	O
after	-	143	O
using	-	149	O
oral	-	155	O
ketoconazole	-	160	O
.	-	172	O

The	24641119	174	O
patient	-	178	O
was	-	186	O
diagnosed	-	190	O
with	-	200	O
drug	-	205	O
-	-	209	O
induced	-	210	O
baboon	-	218	B
syndrome	-	225	I
based	-	234	O
on	-	240	O
his	-	243	O
history	-	247	O
,	-	254	O
which	-	256	O
included	-	262	O
prior	-	271	O
sensitivity	-	277	O
to	-	289	O
topical	-	292	O
ketoconazole	-	300	O
,	-	312	O
a	-	314	O
physical	-	316	O
examination	-	325	O
,	-	336	O
and	-	338	O
histopathological	-	342	O
findings	-	360	O
.	-	368	O

Baboon	24641119	370	B
syndrome	-	377	I
is	-	386	O
a	-	389	O
drug	-	391	O
-	-	395	O
or	-	397	O
contact	-	400	O
allergen	-	408	O
-	-	416	O
related	-	417	O
maculopapular	-	425	B
eruption	-	439	I
that	-	448	O
typically	-	453	O
involves	-	463	O
the	-	472	O
flexural	-	476	O
and	-	485	O
gluteal	-	489	O
areas	-	497	O
.	-	502	O

To	24641119	504	O
the	-	507	O
best	-	511	O
of	-	516	O
our	-	519	O
knowledge	-	523	O
,	-	532	O
this	-	534	O
is	-	539	O
the	-	542	O
first	-	546	O
reported	-	552	O
case	-	561	O
of	-	566	O
ketoconazole	-	569	O
-	-	581	O
induced	-	582	O
baboon	-	590	B
syndrome	-	597	I
in	-	606	O
the	-	609	O
English	-	613	O
literature	-	621	O
.	-	631	O

A	24653743	0	O
Case	-	2	O
of	-	7	O
Sudden	-	10	B
Cardiac	-	17	I
Death	-	25	I
due	-	31	O
to	-	35	O
Pilsicainide	-	38	O
-	-	50	O
Induced	-	51	O
Torsades	-	59	B
de	-	68	I
Pointes	-	71	I
.	-	78	O

An	24653743	80	O
84	-	83	O
-	-	85	O
year	-	86	O
-	-	90	O
old	-	91	O
male	-	95	O
received	-	100	O
oral	-	109	O
pilsicainide	-	114	O
,	-	126	O
a	-	128	O
pure	-	130	O
sodium	-	135	O
channel	-	142	O
blocker	-	150	O
with	-	158	O
slow	-	163	O
recovery	-	168	O
kinetics	-	177	O
,	-	185	O
to	-	187	O
convert	-	190	O
his	-	198	O
paroxysmal	-	202	O
atrial	-	213	B
fibrillation	-	220	I
to	-	233	O
a	-	236	O
sinus	-	238	O
rhythm	-	244	O
;	-	250	O
the	-	252	O
patient	-	256	O
developed	-	264	O
sudden	-	274	B
cardiac	-	281	I
death	-	289	I
two	-	295	O
days	-	299	O
later	-	304	O
.	-	309	O

The	24653743	311	O
Holter	-	315	O
electrocardiogram	-	322	O
,	-	339	O
which	-	341	O
was	-	347	O
worn	-	351	O
by	-	356	O
chance	-	359	O
,	-	365	O
revealed	-	367	O
torsade	-	376	B
de	-	384	I
pointes	-	387	I
with	-	395	O
gradually	-	400	O
prolonged	-	410	O
QT	-	420	O
intervals	-	423	O
.	-	432	O

This	24653743	434	O
drug	-	439	O
is	-	444	O
rapidly	-	447	O
absorbed	-	455	O
from	-	464	O
the	-	469	O
gastrointestinal	-	473	O
tract	-	490	O
,	-	495	O
and	-	497	O
most	-	501	O
of	-	506	O
it	-	509	O
is	-	512	O
excreted	-	515	O
from	-	524	O
the	-	529	O
kidney	-	533	O
.	-	539	O

Although	24653743	541	O
the	-	550	O
patient	-	554	O
's	-	561	O
renal	-	564	O
function	-	570	O
was	-	579	O
not	-	583	O
highly	-	587	O
impaired	-	594	O
and	-	603	O
the	-	607	O
dose	-	611	O
of	-	616	O
pilsicainide	-	619	O
was	-	632	O
low	-	636	O
,	-	639	O
the	-	641	O
plasma	-	645	O
concentration	-	652	O
of	-	666	O
pilsicainide	-	669	O
may	-	682	O
have	-	686	O
been	-	691	O
high	-	696	O
,	-	700	O
which	-	702	O
can	-	708	O
produce	-	712	O
torsades	-	720	B
de	-	729	I
pointes	-	732	I
in	-	740	O
the	-	743	O
octogenarian	-	747	O
.	-	759	O

Although	24653743	761	O
the	-	770	O
oral	-	774	O
administration	-	779	O
of	-	794	O
class	-	797	O
IC	-	803	O
drugs	-	806	O
,	-	811	O
including	-	813	O
pilsicainide	-	823	O
,	-	835	O
is	-	837	O
effective	-	840	O
to	-	850	O
terminate	-	853	O
atrial	-	863	B
fibrillation	-	870	I
,	-	882	O
careful	-	884	O
consideration	-	892	O
must	-	906	O
be	-	911	O
taken	-	914	O
before	-	920	O
giving	-	927	O
these	-	934	O
drugs	-	940	O
to	-	946	O
octogenarians	-	949	O
.	-	962	O

All	24658375	0	O
-	-	3	O
trans	-	4	O
retinoic	-	10	O
acid	-	19	O
-	-	23	O
induced	-	24	O
inflammatory	-	32	O
myositis	-	45	B
in	-	54	O
a	-	57	O
patient	-	59	O
with	-	67	O
acute	-	72	B
promyelocytic	-	78	I
leukemia	-	92	I
.	-	100	O

All	24658375	102	O
-	-	105	O
trans	-	106	O
retinoic	-	112	O
acid	-	121	O
(	-	126	O
ATRA	-	127	O
)	-	131	O
,	-	132	O
a	-	134	O
component	-	136	O
of	-	146	O
standard	-	149	O
therapy	-	158	O
for	-	166	O
acute	-	170	B
promyelocytic	-	176	I
leukemia	-	190	I
(	-	199	O
APL	-	200	B
)	-	203	O
,	-	204	O
is	-	206	O
associated	-	209	O
with	-	220	O
potentially	-	225	O
serious	-	237	O
but	-	245	O
treatable	-	249	O
adverse	-	259	O
effects	-	267	O
involving	-	275	O
numerous	-	285	O
organ	-	294	O
systems	-	300	O
,	-	307	O
including	-	309	O
rare	-	319	O
skeletal	-	324	O
muscle	-	333	O
involvement	-	340	O
.	-	351	O

Only	24658375	353	O
a	-	358	O
handful	-	360	O
of	-	368	O
cases	-	371	O
of	-	377	O
ATRA	-	380	O
-	-	384	O
induced	-	385	O
myositis	-	393	B
in	-	402	O
children	-	405	O
have	-	414	O
been	-	419	O
reported	-	424	O
,	-	432	O
and	-	434	O
none	-	438	O
in	-	443	O
the	-	446	O
radiology	-	450	O
literature	-	460	O
.	-	470	O

We	24658375	472	O
present	-	475	O
such	-	483	O
a	-	488	O
case	-	490	O
in	-	495	O
a	-	498	O
15	-	500	O
-	-	502	O
year	-	503	O
-	-	507	O
old	-	508	O
boy	-	512	O
with	-	516	O
APL	-	521	B
,	-	524	O
where	-	526	O
recognition	-	532	O
of	-	544	O
imaging	-	547	O
findings	-	555	O
played	-	564	O
a	-	571	O
crucial	-	573	O
role	-	581	O
in	-	586	O
making	-	589	O
the	-	596	O
diagnosis	-	600	O
and	-	610	O
facilitated	-	614	O
prompt	-	626	O
,	-	632	O
effective	-	634	O
treatment	-	644	O
.	-	653	O

Tolerability	24659727	0	O
of	-	13	O
lomustine	-	16	O
in	-	26	O
combination	-	29	O
with	-	41	O
cyclophosphamide	-	46	O
in	-	63	O
dogs	-	66	O
with	-	71	O
lymphoma	-	76	B
.	-	84	O

This	24659727	86	O
retrospective	-	91	O
study	-	105	O
describes	-	111	O
toxicity	-	121	B
associated	-	130	O
with	-	141	O
a	-	146	O
protocol	-	148	O
of	-	157	O
lomustine	-	160	O
(	-	170	O
CCNU	-	171	O
)	-	175	O
and	-	177	O
cyclophosphamide	-	181	O
(	-	198	O
CTX	-	199	O
)	-	202	O
in	-	204	O
dogs	-	207	O
with	-	212	O
lymphoma	-	217	B
.	-	225	O

CCNU	24659727	227	O
was	-	232	O
administered	-	236	O
per	-	249	O
os	-	253	O
(	-	256	O
PO	-	257	O
)	-	259	O
at	-	261	O
a	-	264	O
targeted	-	266	O
dosage	-	275	O
of	-	282	O
60	-	285	O
mg	-	288	O
/	-	290	O
m	-	291	O
(	-	292	O
2	-	293	O
)	-	294	O
body	-	296	O
surface	-	301	O
area	-	309	O
on	-	314	O
day	-	317	O
0	-	321	O
,	-	322	O
CTX	-	324	O
was	-	328	O
administered	-	332	O
PO	-	345	O
at	-	348	O
a	-	351	O
targeted	-	353	O
dosage	-	362	O
of	-	369	O
250	-	372	O
mg	-	376	O
/	-	378	O
m	-	379	O
(	-	380	O
2	-	381	O
)	-	382	O
divided	-	384	O
over	-	392	O
days	-	397	O
0	-	402	O
through	-	404	O
4	-	412	O
,	-	413	O
and	-	415	O
all	-	419	O
dogs	-	423	O
received	-	428	O
prophylactic	-	437	O
antibiotics	-	450	O
.	-	461	O

Ninety	24659727	463	O
treatments	-	470	O
were	-	481	O
given	-	486	O
to	-	492	O
the	-	495	O
57	-	499	O
dogs	-	502	O
included	-	507	O
in	-	516	O
the	-	519	O
study	-	523	O
.	-	528	O

Neutropenia	24659727	530	B
was	-	542	O
the	-	546	O
principal	-	550	O
toxic	-	560	O
effect	-	566	O
,	-	572	O
and	-	574	O
the	-	578	O
overall	-	582	O
frequency	-	590	O
of	-	600	O
grade	-	603	O
4	-	609	O
neutropenia	-	611	B
after	-	623	O
the	-	629	O
first	-	633	O
treatment	-	639	O
of	-	649	O
CCNU	-	652	O
/	-	656	O
CTX	-	657	O
was	-	661	O
30	-	665	O
%	-	667	O
(	-	669	O
95	-	670	O
%	-	672	O
confidence	-	674	O
interval	-	685	O
,	-	693	O
19	-	695	O
-	-	697	O
43	-	698	O
%	-	700	O
)	-	701	O
.	-	702	O

The	24659727	704	O
mean	-	708	O
body	-	713	O
weight	-	718	O
of	-	725	O
dogs	-	728	O
with	-	733	O
grade	-	738	O
4	-	744	O
neutropenia	-	746	B
(	-	758	O
19	-	759	O
.	-	761	O
7	-	762	O
kg	-	764	O
+	-	767	O
13	-	769	O
.	-	771	O
4	-	772	O
kg	-	774	O
)	-	776	O
was	-	778	O
significantly	-	782	O
less	-	796	O
than	-	801	O
the	-	806	O
mean	-	810	O
body	-	815	O
weight	-	820	O
of	-	827	O
dogs	-	830	O
that	-	835	O
did	-	840	O
not	-	844	O
develop	-	848	O
grade	-	856	O
4	-	862	O
neutropenia	-	864	B
(	-	876	O
31	-	877	O
.	-	879	O
7	-	880	O
kg	-	882	O
+	-	885	O
12	-	887	O
.	-	889	O
4	-	890	O
kg	-	892	O
;	-	894	O
P	-	896	O
=	-	898	O
.	-	900	O
005	-	901	O
)	-	904	O
.	-	905	O

One	24659727	907	O
dog	-	911	O
(	-	915	O
3	-	916	O
%	-	917	O
)	-	918	O
developed	-	920	O
hematologic	-	930	O
changes	-	942	O
suggestive	-	950	O
of	-	961	O
hepatotoxicity	-	964	B
.	-	978	O

No	24659727	980	O
dogs	-	983	O
had	-	988	O
evidence	-	992	O
of	-	1001	O
either	-	1004	O
renal	-	1011	B
toxicity	-	1017	I
or	-	1026	O
hemorrhagic	-	1029	B
cystitis	-	1041	I
.	-	1049	O

Adverse	24659727	1051	O
gastrointestinal	-	1059	O
effects	-	1076	O
were	-	1084	O
uncommon	-	1089	O
.	-	1097	O

On	24659727	1099	O
the	-	1102	O
basis	-	1106	O
of	-	1112	O
the	-	1115	O
findings	-	1119	O
reported	-	1128	O
herein	-	1137	O
,	-	1143	O
a	-	1145	O
dose	-	1147	O
of	-	1152	O
60	-	1155	O
mg	-	1158	O
/	-	1160	O
m	-	1161	O
(	-	1162	O
2	-	1163	O
)	-	1164	O
of	-	1166	O
CCNU	-	1169	O
combined	-	1174	O
with	-	1183	O
250	-	1188	O
mg	-	1192	O
/	-	1194	O
m	-	1195	O
(	-	1196	O
2	-	1197	O
)	-	1198	O
of	-	1200	O
CTX	-	1203	O
(	-	1207	O
divided	-	1208	O
over	-	1216	O
5	-	1221	O
days	-	1223	O
)	-	1227	O
q	-	1229	O
4	-	1231	O
wk	-	1233	O
is	-	1236	O
tolerable	-	1239	O
in	-	1249	O
tumor	-	1252	B
-	-	1257	O
bearing	-	1258	O
dogs	-	1266	O
.	-	1270	O

Nelarabine	24664478	0	O
neurotoxicity	-	11	B
with	-	25	O
concurrent	-	30	O
intrathecal	-	41	O
chemotherapy	-	53	O
:	-	65	O

Case	24664478	67	O
report	-	72	O
and	-	79	O
review	-	83	O
of	-	90	O
literature	-	93	O
.	-	103	O

Severe	24664478	105	O
nelarabine	-	112	O
neurotoxicity	-	123	B
in	-	137	O
a	-	140	O
patient	-	142	O
who	-	150	O
received	-	154	O
concurrent	-	163	O
intrathecal	-	174	O
(	-	186	O
IT	-	187	O
)	-	189	O
chemotherapy	-	191	O
is	-	204	O
reported	-	207	O
.	-	215	O

A	24664478	217	O
37	-	219	O
-	-	221	O
year	-	222	O
-	-	226	O
old	-	227	O
Caucasian	-	231	O
woman	-	241	O
with	-	247	O
a	-	252	O
history	-	254	O
of	-	262	O
T	-	265	B
-	-	266	I
cell	-	267	I
lymphoblastic	-	272	I
lymphoma	-	286	I
was	-	295	O
admitted	-	299	O
for	-	308	O
relapsed	-	312	O
disease	-	321	O
.	-	328	O

She	24664478	330	O
was	-	334	O
originally	-	338	O
treated	-	349	O
with	-	357	O
induction	-	362	O
chemotherapy	-	372	O
followed	-	385	O
by	-	394	O
an	-	397	O
autologous	-	400	O
transplant	-	411	O
.	-	421	O

She	24664478	423	O
developed	-	427	O
relapsed	-	437	O
disease	-	446	O
10	-	454	O
months	-	457	O
later	-	464	O
with	-	470	O
leukemic	-	475	B
involvement	-	484	O
.	-	495	O

She	24664478	497	O
was	-	501	O
re	-	505	O
-	-	507	O
induced	-	508	O
with	-	516	O
nelarabine	-	521	O
1500	-	532	O

mg	24664478	537	O
/	-	539	O
m	-	540	O
(	-	541	O
2	-	542	O
)	-	543	O
on	-	545	O
days	-	548	O
1	-	553	O
,	-	554	O
3	-	556	O
,	-	557	O
and	-	559	O
5	-	563	O
with	-	565	O
1	-	570	O
dose	-	572	O
of	-	577	O
IT	-	580	O
cytarabine	-	583	O
100	-	594	O
mg	-	598	O
on	-	601	O
day	-	604	O
2	-	608	O
as	-	610	O
central	-	613	O
nervous	-	621	O
system	-	629	O
(	-	636	O
CNS	-	637	O
)	-	640	O
prophylaxis	-	642	O
.	-	653	O

At	24664478	655	O
the	-	658	O
time	-	662	O
of	-	667	O
treatment	-	670	O
,	-	679	O
she	-	681	O
was	-	685	O
on	-	689	O
continuous	-	692	O
renal	-	703	O
replacement	-	709	O
therapy	-	721	O
due	-	729	O
to	-	733	O
sequelae	-	736	O
of	-	745	O
tumor	-	748	B
lysis	-	754	I
syndrome	-	760	I
(	-	769	O
TLS	-	770	B
)	-	773	O
.	-	774	O

She	24664478	776	O
tolerated	-	780	O
therapy	-	790	O
well	-	798	O
,	-	802	O
entered	-	804	O
a	-	812	O
complete	-	814	O
remission	-	823	O
,	-	832	O
and	-	834	O
recovered	-	838	O
her	-	848	O
renal	-	852	O
function	-	858	O
.	-	866	O

She	24664478	868	O
received	-	872	O
a	-	881	O
second	-	883	O
cycle	-	890	O
of	-	896	O
nelarabine	-	899	O
without	-	910	O
additional	-	918	O
IT	-	929	O
prophylaxis	-	932	O
one	-	944	O
month	-	948	O
later	-	954	O
.	-	959	O

A	24664478	961	O
week	-	963	O
after	-	968	O
this	-	974	O
second	-	979	O
cycle	-	986	O
,	-	991	O
she	-	993	O
noted	-	997	O
numbness	-	1003	O
in	-	1012	O
her	-	1015	O
lower	-	1019	O
extremities	-	1025	O
.	-	1036	O

Predominantly	24664478	1038	O
sensory	-	1052	O
,	-	1059	O
though	-	1061	O
also	-	1068	O
motor	-	1073	O
and	-	1079	O
autonomic	-	1083	O
,	-	1092	O
peripheral	-	1094	B
neuropathy	-	1105	I
started	-	1116	O
in	-	1124	O
her	-	1127	O
feet	-	1131	O
,	-	1135	O
ascended	-	1137	O
proximally	-	1146	O
to	-	1157	O
the	-	1160	O
mid	-	1164	O
-	-	1167	O
thoracic	-	1168	O
region	-	1177	O
,	-	1183	O
and	-	1185	O
eventually	-	1189	O
included	-	1200	O
her	-	1209	O
distal	-	1213	O
upper	-	1220	O
extremities	-	1226	O
.	-	1237	O

A	24664478	1239	O
magnetic	-	1241	O
resonance	-	1250	O
imaging	-	1260	O
(	-	1268	O
MRI	-	1269	O
)	-	1272	O
of	-	1274	O
her	-	1277	O
spine	-	1281	O
demonstrated	-	1287	O
changes	-	1300	O
from	-	1308	O
C2	-	1313	O
to	-	1316	O
C6	-	1319	O
consistent	-	1322	O
with	-	1333	O
subacute	-	1338	O
combined	-	1347	O
degeneration	-	1356	O
.	-	1368	O

Nelarabine	24664478	1370	O
was	-	1381	O
felt	-	1385	O
to	-	1390	O
be	-	1393	O
the	-	1396	O
cause	-	1400	O
of	-	1406	O
her	-	1409	O
symptoms	-	1413	O
.	-	1421	O

Her	24664478	1423	O
neuropathy	-	1427	B
stabilized	-	1438	O
and	-	1449	O
showed	-	1453	O
slight	-	1460	O
improvement	-	1467	O
and	-	1479	O
ultimately	-	1483	O
received	-	1494	O
an	-	1503	O
unrelated	-	1506	O
,	-	1515	O
reduced	-	1517	O
-	-	1524	O
intensity	-	1525	O
allogeneic	-	1535	O
transplant	-	1546	O
while	-	1557	O
in	-	1563	O
complete	-	1566	O
remission	-	1575	O
,	-	1584	O
but	-	1586	O
relapsed	-	1590	O
disease	-	1599	O
10	-	1607	O
weeks	-	1610	O
later	-	1616	O
.	-	1621	O

She	24664478	1623	O
is	-	1627	O
currently	-	1630	O
being	-	1640	O
treated	-	1646	O
with	-	1654	O
best	-	1659	O
supportive	-	1664	O
care	-	1675	O
.	-	1679	O

To	24664478	1681	O
our	-	1684	O
knowledge	-	1688	O
,	-	1697	O
this	-	1699	O
is	-	1704	O
the	-	1707	O
first	-	1711	O
published	-	1717	O
case	-	1727	O
report	-	1732	O
of	-	1739	O
severe	-	1742	O
neurotoxicity	-	1749	B
caused	-	1763	O
by	-	1770	O
nelarabine	-	1773	O
in	-	1784	O
a	-	1787	O
patient	-	1789	O
who	-	1797	O
received	-	1801	O
concurrent	-	1810	O
IT	-	1821	O
chemotherapy	-	1824	O
.	-	1836	O

Valproate	24665854	0	O
-	-	9	O
induced	-	10	O
hyperammonemic	-	18	B
encephalopathy	-	33	B
in	-	48	O
a	-	51	O
renal	-	53	O
transplanted	-	59	O
patient	-	72	O
.	-	79	O

Neurological	24665854	81	B
complications	-	94	I
after	-	108	O
renal	-	114	O
transplantation	-	120	O
constitute	-	136	O
an	-	147	O
important	-	150	O
cause	-	160	O
of	-	166	O
morbidity	-	169	O
and	-	179	O
mortality	-	183	O
.	-	192	O

Their	24665854	194	O
differential	-	200	O
diagnosis	-	213	O
is	-	223	O
difficult	-	226	O
and	-	236	O
essential	-	240	O
for	-	250	O
subsequent	-	254	O
patient	-	265	O
's	-	272	O
management	-	275	O
.	-	285	O

Valproate	24665854	287	O
-	-	296	O
induced	-	297	O
hyperammonemic	-	305	B
encephalopathy	-	320	B
is	-	335	O
an	-	338	O
uncommon	-	341	O
but	-	350	O
serious	-	354	O
effect	-	362	O
of	-	369	O
valproate	-	372	O
treatment	-	382	O
.	-	391	O

Here	24665854	393	O
,	-	397	O
we	-	399	O
describe	-	402	O
the	-	411	O
case	-	415	O
of	-	420	O
a	-	423	O
15	-	425	O
-	-	427	O
year	-	428	O
-	-	432	O
old	-	433	O
girl	-	437	O
who	-	442	O
was	-	446	O
on	-	450	O
a	-	453	O
long	-	455	O
-	-	459	O
term	-	460	O
therapy	-	465	O
with	-	473	O
valproate	-	478	O
due	-	488	O
to	-	492	O
epilepsy	-	495	B
and	-	504	O
revealed	-	508	O
impaired	-	517	B
consciousness	-	526	I
with	-	540	O
hyperammonemia	-	545	B
12	-	560	O
days	-	563	O
after	-	568	O
renal	-	574	O
transplantation	-	580	O
.	-	595	O

After	24665854	597	O
withdraw	-	603	O
of	-	612	O
valproate	-	615	O
,	-	624	O
patients	-	626	O
'	-	634	O
symptoms	-	636	O
resolved	-	645	O
within	-	654	O
24	-	661	O
h	-	664	O
.	-	665	O
Clinicians	-	667	O
should	-	678	O
increase	-	685	O
their	-	694	O
awareness	-	700	O
for	-	710	O
potential	-	714	O
complication	-	724	O
of	-	737	O
valproate	-	740	O
,	-	749	O
especially	-	751	O
in	-	762	O
transplanted	-	765	O
patients	-	778	O
.	-	786	O

Necrotising	24671324	0	B
fasciitis	-	12	I
after	-	22	O
bortezomib	-	28	O
and	-	39	O
dexamethasone	-	43	O
-	-	56	O
containing	-	57	O
regimen	-	68	O
in	-	76	O
an	-	79	O
elderly	-	82	O
patient	-	90	O
of	-	98	O
Waldenstrom	-	101	B
macroglobulinaemia	-	113	I
.	-	131	O

Bortezomib	24671324	133	O
and	-	144	O
high	-	148	O
-	-	152	O
dose	-	153	O
dexamethasone	-	158	O
-	-	171	O
containing	-	172	O
regimens	-	183	O
are	-	192	O
considered	-	196	O
to	-	207	O
be	-	210	O
generally	-	213	O
tolerable	-	223	O
with	-	233	O
few	-	238	O
severe	-	242	O
bacterial	-	249	B
infections	-	259	I
in	-	270	O
patients	-	273	O
with	-	282	O
B	-	287	O
-	-	288	O
cell	-	289	O
malignancies	-	294	B
.	-	306	O

However	24671324	308	O
,	-	315	O
information	-	317	O
is	-	329	O
limited	-	332	O
concerning	-	340	O
the	-	351	O
safety	-	355	O
of	-	362	O
the	-	365	O
regimen	-	369	O
in	-	377	O
elderly	-	380	O
patients	-	388	O
.	-	396	O

We	24671324	398	O
report	-	401	O
a	-	408	O
case	-	410	O
of	-	415	O
a	-	418	O
76	-	420	O
-	-	422	O
year	-	423	O
-	-	427	O
old	-	428	O
man	-	432	O
with	-	436	O
Waldenstrom	-	441	B
macroglobulinaemia	-	453	I
who	-	472	O
suffered	-	476	O
necrotising	-	485	B
fasciitis	-	497	I
without	-	507	O
neutropenia	-	515	B
after	-	527	O
the	-	533	O
combination	-	537	O
treatment	-	549	O
with	-	559	O
bortezomib	-	564	O
,	-	574	O
high	-	576	O
-	-	580	O
dose	-	581	O
dexamethasone	-	586	O
and	-	600	O
rituximab	-	604	O
.	-	613	O

Despite	24671324	615	O
immediate	-	623	O
intravenous	-	633	O
antimicrobial	-	645	O
therapy	-	659	O
,	-	666	O
he	-	668	O
succumbed	-	671	O
23	-	681	O
h	-	684	O
after	-	686	O
the	-	692	O
onset	-	696	O
.	-	701	O

Physicians	24671324	703	O
should	-	714	O
recognise	-	721	O
the	-	731	O
possibility	-	735	O
of	-	747	O
fatal	-	750	O
bacterial	-	756	B
infections	-	766	I
related	-	777	O
to	-	785	O
bortezomib	-	788	O
plus	-	799	O
high	-	804	O
-	-	808	O
dose	-	809	O
dexamethasone	-	814	O
in	-	828	O
elderly	-	831	O
patients	-	839	O
,	-	847	O
and	-	849	O
we	-	853	O
believe	-	856	O
this	-	864	O
case	-	869	O
warrants	-	874	O
further	-	883	O
investigation	-	891	O
.	-	904	O

An	24675088	0	O
integrated	-	3	O
characterization	-	14	O
of	-	31	O
serological	-	34	O
,	-	45	O
pathological	-	47	O
,	-	59	O
and	-	61	O
functional	-	65	O
events	-	76	O
in	-	83	O
doxorubicin	-	86	O
-	-	97	O
induced	-	98	O
cardiotoxicity	-	106	B
.	-	120	O

Many	24675088	122	O
efficacious	-	127	O
cancer	-	139	B
treatments	-	146	O
cause	-	157	O
significant	-	163	O
cardiac	-	175	O
morbidity	-	183	O
,	-	192	O
yet	-	194	O
biomarkers	-	198	O
or	-	209	O
functional	-	212	O
indices	-	223	O
of	-	231	O
early	-	234	O
damage	-	240	O
,	-	246	O
which	-	248	O
would	-	254	O
allow	-	260	O
monitoring	-	266	O
and	-	277	O
intervention	-	281	O
,	-	293	O
are	-	295	O
lacking	-	299	O
.	-	306	O

In	24675088	308	O
this	-	311	O
study	-	316	O
,	-	321	O
we	-	323	O
have	-	326	O
utilized	-	331	O
a	-	340	O
rat	-	342	O
model	-	346	O
of	-	352	O
progressive	-	355	O
doxorubicin	-	367	O
(	-	379	O
DOX	-	380	O
)	-	383	O
-	-	384	O
induced	-	385	O
cardiomyopathy	-	393	B
,	-	407	O
applying	-	409	O
multiple	-	418	O
approaches	-	427	O
,	-	437	O
including	-	439	O
cardiac	-	449	O
magnetic	-	457	O
resonance	-	466	O
imaging	-	476	O
(	-	484	O
MRI	-	485	O
)	-	488	O
,	-	489	O
to	-	491	O
provide	-	494	O
the	-	502	O
most	-	506	O
comprehensive	-	511	O
characterization	-	525	O
to	-	542	O
date	-	545	O
of	-	550	O
the	-	553	O
timecourse	-	557	O
of	-	568	O
serological	-	571	O
,	-	582	O
pathological	-	584	O
,	-	596	O
and	-	598	O
functional	-	602	O
events	-	613	O
underlying	-	620	O
this	-	631	O
toxicity	-	636	B
.	-	644	O

Hannover	24675088	646	O
Wistar	-	655	O
rats	-	662	O
were	-	667	O
dosed	-	672	O
with	-	678	O
1	-	683	O
.	-	684	O
25	-	685	O
mg	-	688	O
/	-	690	O
kg	-	691	O
DOX	-	694	O
weekly	-	698	O
for	-	705	O
8	-	709	O
weeks	-	711	O
followed	-	717	O
by	-	726	O
a	-	729	O
4	-	731	O
week	-	733	O
off	-	738	O
-	-	741	O
dosing	-	742	O
""""	-	749	O
recovery	-	750	O
""""	-	758	O
period	-	760	O
.	-	766	O

Electron	24675088	768	O
microscopy	-	777	O
of	-	788	O
the	-	791	O
myocardium	-	795	O
revealed	-	806	O
subcellular	-	815	B
degeneration	-	827	I
and	-	840	O
marked	-	844	O
mitochondrial	-	851	O
changes	-	865	O
after	-	873	O
a	-	879	O
single	-	881	O
dose	-	888	O
.	-	892	O

Histopathological	24675088	894	O
analysis	-	912	O
revealed	-	921	O
progressive	-	930	O
cardiomyocyte	-	942	B
degeneration	-	956	I
,	-	968	O
hypertrophy	-	970	B
/	-	981	O
cytomegaly	-	982	O
,	-	992	O
and	-	994	O
extensive	-	998	O
vacuolation	-	1008	O
after	-	1020	O
two	-	1026	O
doses	-	1030	O
.	-	1035	O

Extensive	24675088	1037	O
replacement	-	1047	O
fibrosis	-	1059	B
(	-	1068	O
quantified	-	1069	O
by	-	1080	O
Sirius	-	1083	O
red	-	1090	O
staining	-	1094	O
)	-	1102	O
developed	-	1104	O
during	-	1114	O
the	-	1121	O
off	-	1125	O
-	-	1128	O
dosing	-	1129	O
period	-	1136	O
.	-	1142	O

Functional	24675088	1144	O
indices	-	1155	O
assessed	-	1163	O
by	-	1172	O
cardiac	-	1175	O
MRI	-	1183	O
(	-	1187	O
including	-	1188	O
left	-	1198	O
ventricular	-	1203	O
ejection	-	1215	O
fraction	-	1224	O
(	-	1233	O
LVEF	-	1234	O
)	-	1238	O
,	-	1239	O
cardiac	-	1241	O
output	-	1249	O
,	-	1255	O
and	-	1257	O
E	-	1261	O
/	-	1262	O
A	-	1263	O
ratio	-	1265	O
)	-	1270	O
declined	-	1272	O
progressively	-	1281	O
,	-	1294	O
reaching	-	1296	O
statistical	-	1305	O
significance	-	1317	O
after	-	1330	O
two	-	1336	O
doses	-	1340	O
and	-	1346	O
culminating	-	1350	O
in	-	1362	O
""""	-	1365	O
clinical	-	1366	O
""""	-	1374	O
LV	-	1376	B
dysfunction	-	1379	I
by	-	1391	O
12	-	1394	O
weeks	-	1397	O
.	-	1402	O

Significant	24675088	1404	O
increases	-	1416	O
in	-	1426	O
peak	-	1429	O
myocardial	-	1434	O
contrast	-	1445	O
enhancement	-	1454	O
and	-	1466	O
serological	-	1470	O
cardiac	-	1482	O
troponin	-	1490	O

I	24675088	1499	O
(	-	1501	O
cTnI	-	1502	O
)	-	1506	O
emerged	-	1508	O
after	-	1516	O
eight	-	1522	O
doses	-	1528	O
,	-	1533	O
importantly	-	1535	O
preceding	-	1547	O
the	-	1557	O
LVEF	-	1561	O
decline	-	1566	O
to	-	1574	O
<	-	1577	O
50	-	1578	O
%	-	1580	O
.	-	1581	O

Troponin	24675088	1583	O
I	-	1592	O
levels	-	1594	O
positively	-	1601	O
correlated	-	1612	O
with	-	1623	O
delayed	-	1628	O
and	-	1636	O
peak	-	1640	O
gadolinium	-	1645	O
contrast	-	1656	O
enhancement	-	1665	O
,	-	1676	O
histopathological	-	1678	O
grading	-	1696	O
,	-	1703	O
and	-	1705	O
diastolic	-	1709	B
dysfunction	-	1719	I
.	-	1730	O

In	24675088	1732	O
summary	-	1735	O
,	-	1742	O
subcellular	-	1744	O
cardiomyocyte	-	1756	B
degeneration	-	1770	I
was	-	1783	O
the	-	1787	O
earliest	-	1791	O
marker	-	1800	O
,	-	1806	O
followed	-	1808	O
by	-	1817	O
progressive	-	1820	O
functional	-	1832	O
decline	-	1843	O
and	-	1851	O
histopathological	-	1855	O
manifestations	-	1873	O
.	-	1887	O

Myocardial	24675088	1889	O
contrast	-	1900	O
enhancement	-	1909	O
and	-	1921	O
elevations	-	1925	O
in	-	1936	O
cTnI	-	1939	O
occurred	-	1944	O
later	-	1953	O
.	-	1958	O

However	24675088	1960	O
,	-	1967	O
all	-	1969	O
indices	-	1973	O
predated	-	1981	O
""""	-	1990	O
clinical	-	1991	O
""""	-	1999	O
LV	-	2001	B
dysfunction	-	2004	I
and	-	2016	O
thus	-	2020	O
warrant	-	2025	O
further	-	2033	O
evaluation	-	2041	O
as	-	2052	O
predictive	-	2055	O
biomarkers	-	2066	O
.	-	2076	O

Intradermal	24684312	0	O
glutamate	-	12	O
and	-	22	O
capsaicin	-	26	O
injections	-	36	O
:	-	46	O
intra	-	48	O
-	-	53	O
and	-	55	O
interindividual	-	59	O
variability	-	75	O
of	-	87	O
provoked	-	90	O
hyperalgesia	-	99	B
and	-	112	O
allodynia	-	116	B
.	-	125	O

Intradermal	24684312	127	O
injections	-	139	O
of	-	150	O
glutamate	-	153	O
and	-	163	O
capsaicin	-	167	O
are	-	177	O
attractive	-	181	O
to	-	192	O
use	-	195	O
in	-	199	O
human	-	202	O
experimental	-	208	O
pain	-	221	B
models	-	226	O
because	-	233	O
hyperalgesia	-	241	B
and	-	254	O
allodynia	-	258	B
mimic	-	268	O
isolated	-	274	O
aspects	-	283	O
of	-	291	O
clinical	-	294	O
pain	-	303	B
disorders	-	308	I
.	-	317	O

The	24684312	319	O
aim	-	323	O
of	-	327	O
the	-	330	O
present	-	334	O
study	-	342	O
was	-	348	O
to	-	352	O
investigate	-	355	O
the	-	367	O
reproducibility	-	371	O
of	-	387	O
these	-	390	O
models	-	396	O
.	-	402	O

Twenty	24684312	404	O
healthy	-	411	O
male	-	419	O
volunteers	-	424	O
(	-	435	O
mean	-	436	O
age	-	441	O
24	-	445	O
years	-	448	O
;	-	453	O
range	-	455	O
18	-	461	O
-	-	463	O
38	-	464	O
years	-	467	O
)	-	472	O
received	-	474	O
intradermal	-	483	O
injections	-	495	O
of	-	506	O
glutamate	-	509	O
and	-	519	O
capsaicin	-	523	O
in	-	533	O
the	-	536	O
volar	-	540	O
forearm	-	546	O
.	-	553	O

Magnitudes	24684312	555	O
of	-	566	O
secondary	-	569	O
pinprick	-	579	O
hyperalgesia	-	588	B
and	-	601	O
brush	-	605	O
-	-	610	O
evoked	-	611	O
allodynia	-	618	B
were	-	628	O
investigated	-	633	O
using	-	646	O
von	-	652	O
Frey	-	656	O
filaments	-	661	O
(	-	671	O
gauges	-	672	O
10	-	679	O
,	-	681	O
15	-	683	O
,	-	685	O
60	-	687	O
and	-	690	O
100	-	694	O
g	-	698	O
)	-	699	O
and	-	701	O
brush	-	705	O
strokes	-	711	O
.	-	718	O

Areas	24684312	720	O
of	-	726	O
secondary	-	729	B
hyperalgesia	-	739	I
and	-	752	O
allodynia	-	756	B
were	-	766	O
quantified	-	771	O
immediately	-	782	O
after	-	794	O
injection	-	800	O
and	-	810	O
after	-	814	O
15	-	820	O
,	-	822	O
30	-	824	O
and	-	827	O
60	-	831	O
min	-	834	O
.	-	837	O

Two	24684312	839	O
identical	-	843	O
experiments	-	853	O
separated	-	865	O
by	-	875	O
at	-	878	O
least	-	881	O
7	-	887	O
days	-	889	O
were	-	894	O
performed	-	899	O
.	-	908	O

Reproducibility	24684312	910	O
across	-	926	O
and	-	933	O
within	-	937	O
volunteers	-	944	O
(	-	955	O
inter	-	956	O
-	-	961	O
and	-	963	O
intra	-	967	O
-	-	972	O
individual	-	973	O
variation	-	984	O
,	-	993	O
respectively	-	995	O
)	-	1007	O
was	-	1009	O
assessed	-	1013	O
using	-	1022	O
intraclass	-	1028	O
correlation	-	1039	O
coefficient	-	1051	O
(	-	1063	O
ICC	-	1064	O
)	-	1067	O
and	-	1069	O
coefficient	-	1073	O
of	-	1085	O
variation	-	1088	O
(	-	1098	O
CV	-	1099	O
)	-	1101	O
.	-	1102	O

Secondary	24684312	1104	O
pinprick	-	1114	O
hyperalgesia	-	1123	B
was	-	1136	O
observed	-	1140	O
as	-	1149	O
a	-	1152	O
marked	-	1154	O
increase	-	1161	O
in	-	1170	O
the	-	1173	O
visual	-	1177	O
analogue	-	1184	O
scale	-	1193	O
(	-	1199	O
VAS	-	1200	O
)	-	1203	O
response	-	1205	O
to	-	1214	O
von	-	1217	O
Frey	-	1221	O
gauges	-	1226	O
60	-	1233	O
and	-	1236	O
100	-	1240	O
g	-	1244	O
(	-	1246	O
P	-	1247	O
<	-	1249	O
0	-	1251	O
.	-	1252	O
001	-	1253	O
)	-	1256	O
after	-	1258	O
glutamate	-	1264	O
injection	-	1274	O
.	-	1283	O

For	24684312	1285	O
capsaicin	-	1289	O
,	-	1298	O
secondary	-	1300	O
pinprick	-	1310	O
hyperalgesia	-	1319	B
was	-	1332	O
detected	-	1336	O
with	-	1345	O
all	-	1350	O
von	-	1354	O
Frey	-	1358	O
gauges	-	1363	O
(	-	1370	O
P	-	1371	O
<	-	1373	O
0	-	1375	O
.	-	1376	O
001	-	1377	O
)	-	1380	O
.	-	1381	O

Glutamate	24684312	1383	O
evoked	-	1393	O
reproducible	-	1400	O
VAS	-	1413	O
response	-	1417	O
to	-	1426	O
all	-	1429	O
von	-	1433	O
Frey	-	1437	O
gauges	-	1442	O
(	-	1449	O
ICC	-	1450	O
>	-	1454	O
0	-	1456	O
.	-	1457	O
60	-	1458	O
)	-	1460	O
and	-	1462	O
brush	-	1466	O
strokes	-	1472	O
(	-	1480	O
ICC	-	1481	O
>	-	1485	O
0	-	1487	O
.	-	1488	O
83	-	1489	O
)	-	1491	O
.	-	1492	O

Capsaicin	24684312	1494	O
injection	-	1504	O
was	-	1514	O
reproducible	-	1518	O
for	-	1531	O
secondary	-	1535	B
hyperalgesia	-	1545	I
(	-	1558	O
ICC	-	1559	O
>	-	1563	O
0	-	1565	O
.	-	1566	O
70	-	1567	O
)	-	1569	O
and	-	1571	O
allodynia	-	1575	B
(	-	1585	O
ICC	-	1586	O
>	-	1590	O
0	-	1592	O
.	-	1593	O
71	-	1594	O
)	-	1596	O
.	-	1597	O

Intra	24684312	1599	O
-	-	1604	O
individual	-	1605	O
variability	-	1616	O
was	-	1628	O
generally	-	1632	O
lower	-	1642	O
for	-	1648	O
the	-	1652	O
VAS	-	1656	O
response	-	1660	O
to	-	1669	O
von	-	1672	O
Frey	-	1676	O
and	-	1681	O
brush	-	1685	O
compared	-	1691	O
with	-	1700	O
areas	-	1705	O
of	-	1711	O
secondary	-	1714	B
hyperalgesia	-	1724	I
and	-	1737	O
allodynia	-	1741	B
.	-	1750	O

In	24684312	1752	O
conclusion	-	1755	O
,	-	1765	O
glutamate	-	1767	O
and	-	1777	O
capsaicin	-	1781	O
yield	-	1791	O
reproducible	-	1797	O
hyperalgesic	-	1810	B
and	-	1823	O
allodynic	-	1827	B
responses	-	1837	O
,	-	1846	O
and	-	1848	O
the	-	1852	O
present	-	1856	O
model	-	1864	O
is	-	1870	O
well	-	1873	O
suited	-	1878	O
for	-	1885	O
basic	-	1889	O
research	-	1895	O
,	-	1903	O
as	-	1905	O
well	-	1908	O
as	-	1913	O
for	-	1916	O
assessing	-	1920	O
the	-	1930	O
modulation	-	1934	O
of	-	1945	O
central	-	1948	O
phenomena	-	1956	O
.	-	1965	O

Ocular	24691439	0	O
-	-	6	O
specific	-	7	O
ER	-	16	O
stress	-	19	O
reduction	-	26	O
rescues	-	36	O
glaucoma	-	44	B
in	-	53	O
murine	-	56	O
glucocorticoid	-	63	O
-	-	77	O
induced	-	78	O
glaucoma	-	86	B
.	-	94	O

Administration	24691439	96	O
of	-	111	O
glucocorticoids	-	114	O
induces	-	130	O
ocular	-	138	B
hypertension	-	145	I
in	-	158	O
some	-	161	O
patients	-	166	O
.	-	174	O

If	24691439	176	O
untreated	-	179	O
,	-	188	O
these	-	190	O
patients	-	196	O
can	-	205	O
develop	-	209	O
a	-	217	O
secondary	-	219	O
glaucoma	-	229	B
that	-	238	O
resembles	-	243	O
primary	-	253	B
open	-	261	I
-	-	265	I
angle	-	266	I
glaucoma	-	272	I
(	-	281	O
POAG	-	282	B
)	-	286	O
.	-	287	O

The	24691439	289	O
underlying	-	293	O
pathology	-	304	O
of	-	314	O
glucocorticoid	-	317	O
-	-	331	O
induced	-	332	O
glaucoma	-	340	B
is	-	349	O
not	-	352	O
fully	-	356	O
understood	-	362	O
,	-	372	O
due	-	374	O
in	-	378	O
part	-	381	O
to	-	386	O
lack	-	389	O
of	-	394	O
an	-	397	O
appropriate	-	400	O
animal	-	412	O
model	-	419	O
.	-	424	O

Here	24691439	426	O
,	-	430	O
we	-	432	O
developed	-	435	O
a	-	445	O
murine	-	447	O
model	-	454	O
of	-	460	O
glucocorticoid	-	463	O
-	-	477	O
induced	-	478	O
glaucoma	-	486	B
that	-	495	O
exhibits	-	500	O
glaucoma	-	509	B
features	-	518	O
that	-	527	O
are	-	532	O
observed	-	536	O
in	-	545	O
patients	-	548	O
.	-	556	O

Treatment	24691439	558	O
of	-	568	O
WT	-	571	O
mice	-	574	O
with	-	579	O
topical	-	584	O
ocular	-	592	O
0	-	599	O
.	-	600	O
1	-	601	O
%	-	602	O
dexamethasone	-	604	O
led	-	618	O
to	-	622	O
elevation	-	625	O
of	-	635	O
intraocular	-	638	O
pressure	-	650	O
(	-	659	O
IOP	-	660	O
)	-	663	O
,	-	664	O
functional	-	666	O
and	-	677	O
structural	-	681	O
loss	-	692	O
of	-	697	O
retinal	-	700	B
ganglion	-	708	I
cells	-	717	O
,	-	722	O
and	-	724	O
axonal	-	728	B
degeneration	-	735	I
,	-	747	O
resembling	-	749	O
glucocorticoid	-	760	O
-	-	774	O
induced	-	775	O
glaucoma	-	783	B
in	-	792	O
human	-	795	O
patients	-	801	O
.	-	809	O

Furthermore	24691439	811	O
,	-	822	O
dexamethasone	-	824	O
-	-	837	O
induced	-	838	O
ocular	-	846	B
hypertension	-	853	I
was	-	866	O
associated	-	870	O
with	-	881	O
chronic	-	886	O
ER	-	894	O
stress	-	897	O
of	-	904	O
the	-	907	O
trabecular	-	911	O
meshwork	-	922	O
(	-	931	O
TM	-	932	O
)	-	934	O
.	-	935	O

Similar	24691439	937	O
to	-	945	O
patients	-	948	O
,	-	956	O
withdrawal	-	958	O
of	-	969	O
dexamethasone	-	972	O
treatment	-	986	O
reduced	-	996	O
elevated	-	1004	O
IOP	-	1013	O
and	-	1017	O
ER	-	1021	O
stress	-	1024	O
in	-	1031	O
this	-	1034	O
animal	-	1039	O
model	-	1046	O
.	-	1051	O

Dexamethasone	24691439	1053	O
induced	-	1067	O
the	-	1075	O
transcriptional	-	1079	O
factor	-	1095	O
CHOP	-	1102	O
,	-	1106	O
a	-	1108	O
marker	-	1110	O
for	-	1117	O
chronic	-	1121	O
ER	-	1129	O
stress	-	1132	O
,	-	1138	O
in	-	1140	O
the	-	1143	O
anterior	-	1147	O
segment	-	1156	O
tissues	-	1164	O
,	-	1171	O
and	-	1173	O
Chop	-	1177	O
deletion	-	1182	O
reduced	-	1191	O
ER	-	1199	O
stress	-	1202	O
in	-	1209	O
these	-	1212	O
tissues	-	1218	O
and	-	1226	O
prevented	-	1230	O
dexamethasone	-	1240	O
-	-	1253	O
induced	-	1254	O
ocular	-	1262	B
hypertension	-	1269	I
.	-	1281	O

Furthermore	24691439	1283	O
,	-	1294	O
reduction	-	1296	O
of	-	1306	O
ER	-	1309	O
stress	-	1312	O
in	-	1319	O
the	-	1322	O
TM	-	1326	O
with	-	1329	O
sodium	-	1334	O
4	-	1341	O
-	-	1342	O
phenylbutyrate	-	1343	O
prevented	-	1358	O
dexamethasone	-	1368	O
-	-	1381	O
induced	-	1382	O
ocular	-	1390	B
hypertension	-	1397	I
in	-	1410	O
WT	-	1413	O
mice	-	1416	O
.	-	1420	O

Our	24691439	1422	O
data	-	1426	O
indicate	-	1431	O
that	-	1440	O
ER	-	1445	O
stress	-	1448	O
contributes	-	1455	O
to	-	1467	O
glucocorticoid	-	1470	O
-	-	1484	O
induced	-	1485	O
ocular	-	1493	B
hypertension	-	1500	I
and	-	1513	O
suggest	-	1517	O
that	-	1525	O
reducing	-	1530	O
ER	-	1539	O
stress	-	1542	O
has	-	1549	O
potential	-	1553	O
as	-	1563	O
a	-	1566	O
therapeutic	-	1568	O
strategy	-	1580	O
for	-	1589	O
treating	-	1593	O
glucocorticoid	-	1602	O
-	-	1616	O
induced	-	1617	O
glaucoma	-	1625	B
.	-	1633	O

Effects	24709919	0	O
of	-	8	O
ginsenosides	-	11	O
on	-	24	O
opioid	-	27	O
-	-	33	O
induced	-	34	O
hyperalgesia	-	42	B
in	-	55	O
mice	-	58	O
.	-	62	O

Opioid	24709919	64	O
-	-	70	O
induced	-	71	O
hyperalgesia	-	79	B
(	-	92	O
OIH	-	93	B
)	-	96	O
is	-	98	O
characterized	-	101	O
by	-	115	O
nociceptive	-	118	O
sensitization	-	130	O
caused	-	144	O
by	-	151	O
the	-	154	O
cessation	-	158	O
of	-	168	O
chronic	-	171	O
opioid	-	179	O
use	-	186	O
.	-	189	O

OIH	24709919	191	B
can	-	195	O
limit	-	199	O
the	-	205	O
clinical	-	209	O
use	-	218	O
of	-	222	O
opioid	-	225	O
analgesics	-	232	O
and	-	243	O
complicate	-	247	O
withdrawal	-	258	O
from	-	269	O
opioid	-	274	B
addiction	-	281	I
.	-	290	O

In	24709919	292	O
this	-	295	O
study	-	300	O
,	-	305	O
we	-	307	O
investigated	-	310	O
the	-	323	O
effects	-	327	O
of	-	335	O
Re	-	338	O
,	-	340	O
Rg1	-	342	O
,	-	345	O
and	-	347	O
Rb1	-	351	O
ginsenosides	-	355	O
,	-	367	O
the	-	369	O
bioactive	-	373	O
components	-	383	O
of	-	394	O
ginseng	-	397	O
,	-	404	O
on	-	406	O
OIH	-	409	B
.	-	412	O

OIH	24709919	414	B
was	-	418	O
achieved	-	422	O
in	-	431	O
mice	-	434	O
after	-	439	O
subcutaneous	-	445	O
administration	-	458	O
of	-	473	O
morphine	-	476	O
for	-	485	O
7	-	489	O
consecutive	-	491	O
days	-	503	O
three	-	508	O
times	-	514	O
per	-	520	O
day	-	524	O
.	-	527	O

During	24709919	529	O
withdrawal	-	536	O
(	-	547	O
days	-	548	O
8	-	553	O
and	-	555	O
9	-	559	O
)	-	560	O
,	-	561	O
these	-	563	O
mice	-	569	O
were	-	574	O
administered	-	579	O
Re	-	592	O
,	-	594	O
Rg1	-	596	O
,	-	599	O
or	-	601	O
Rb1	-	604	O
intragastrically	-	608	O
two	-	625	O
times	-	629	O
per	-	635	O
day	-	639	O
.	-	642	O

On	24709919	644	O
the	-	647	O
test	-	651	O
day	-	656	O
(	-	660	O
day	-	661	O
10	-	665	O
)	-	667	O
,	-	668	O
mice	-	670	O
were	-	675	O
subjected	-	680	O
to	-	690	O
the	-	693	O
thermal	-	697	O
sensitivity	-	705	O
test	-	717	O
and	-	722	O
the	-	726	O
acetic	-	730	O
acid	-	737	O
-	-	741	O
induced	-	742	O
writhing	-	750	O
test	-	759	O
.	-	763	O

Re	24709919	765	O
(	-	768	O
300	-	769	O
mg	-	773	O
/	-	775	O
kg	-	776	O
)	-	778	O
inhibited	-	780	O
OIH	-	790	B
in	-	794	O
both	-	797	O
the	-	802	O
thermal	-	806	O
sensitivity	-	814	O
test	-	826	O
and	-	831	O
the	-	835	O
acetic	-	839	O
acid	-	846	O
-	-	850	O
induced	-	851	O
writhing	-	859	O
test	-	868	O
.	-	872	O

However	24709919	874	O
,	-	881	O
the	-	883	O
Rg1	-	887	O
and	-	891	O
Rb1	-	895	O
ginsenosides	-	899	O
failed	-	912	O
to	-	919	O
prevent	-	922	O
OIH	-	930	B
in	-	934	O
either	-	937	O
test	-	944	O
.	-	948	O

Furthermore	24709919	950	O
,	-	961	O
Rg1	-	963	O
showed	-	967	O
a	-	974	O
tendency	-	976	O
to	-	985	O
aggravate	-	988	O
OIH	-	998	B
in	-	1002	O
the	-	1005	O
acetic	-	1009	O
acid	-	1016	O
-	-	1020	O
induced	-	1021	O
writhing	-	1029	O
test	-	1038	O
.	-	1042	O

Our	24709919	1044	O
data	-	1048	O
suggested	-	1053	O
that	-	1063	O
the	-	1068	O
ginsenoside	-	1072	O
Re	-	1084	O
,	-	1086	O
but	-	1088	O
not	-	1092	O
Rg1	-	1096	O
or	-	1100	O
Rb1	-	1103	O
,	-	1106	O
may	-	1108	O
contribute	-	1112	O
toward	-	1123	O
reversal	-	1130	O
of	-	1139	O
OIH	-	1142	B
.	-	1145	O

A	24717468	0	O
comparison	-	2	O
of	-	13	O
severe	-	16	O
hemodynamic	-	23	O
disturbances	-	35	O
between	-	48	O
dexmedetomidine	-	56	O
and	-	72	O
propofol	-	76	O
for	-	85	O
sedation	-	89	O
in	-	98	O
neurocritical	-	101	O
care	-	115	O
patients	-	120	O
.	-	128	O

OBJECTIVE	24717468	130	O
:	-	139	O

Dexmedetomidine	24717468	141	O
and	-	157	O
propofol	-	161	O
are	-	170	O
commonly	-	174	O
used	-	183	O
sedatives	-	188	O
in	-	198	O
neurocritical	-	201	O
care	-	215	O
as	-	220	O
they	-	223	O
allow	-	228	O
for	-	234	O
frequent	-	238	O
neurologic	-	247	O
examinations	-	258	O
.	-	270	O

However	24717468	272	O
,	-	279	O
both	-	281	O
agents	-	286	O
are	-	293	O
associated	-	297	O
with	-	308	O
significant	-	313	O
hemodynamic	-	325	O
side	-	337	O
effects	-	342	O
.	-	349	O

The	24717468	351	O
primary	-	355	O
objective	-	363	O
of	-	373	O
this	-	376	O
study	-	381	O
is	-	387	O
to	-	390	O
compare	-	393	O
the	-	401	O
prevalence	-	405	O
of	-	416	O
severe	-	419	O
hemodynamic	-	426	O
effects	-	438	O
in	-	446	O
neurocritical	-	449	O
care	-	463	O
patients	-	468	O
receiving	-	477	O
dexmedetomidine	-	487	O
and	-	503	O
propofol	-	507	O
.	-	515	O

DESIGN	24717468	517	O
:	-	523	O

Multicenter	24717468	525	O
,	-	536	O
retrospective	-	538	O
,	-	551	O
propensity	-	553	O
-	-	563	O
matched	-	564	O
cohort	-	572	O
study	-	579	O
.	-	584	O

SETTING	24717468	586	O
:	-	593	O

Neurocritical	24717468	595	O
care	-	609	O
units	-	614	O
at	-	620	O
two	-	623	O
academic	-	627	O
medical	-	636	O
centers	-	644	O
with	-	652	O
dedicated	-	657	O
neurocritical	-	667	O
care	-	681	O
teams	-	686	O
and	-	692	O
board	-	696	O
-	-	701	O
certified	-	702	O
neurointensivists	-	712	O
.	-	729	O

PATIENTS	24717468	731	O
:	-	739	O

Neurocritical	24717468	741	O
care	-	755	O
patients	-	760	O
admitted	-	769	O
between	-	778	O
July	-	786	O
2009	-	791	O
and	-	796	O
September	-	800	O
2012	-	810	O
were	-	815	O
evaluated	-	820	O
and	-	830	O
then	-	834	O
matched	-	839	O
1	-	847	O
:	-	848	O
1	-	849	O
based	-	851	O
on	-	857	O
propensity	-	860	O
scoring	-	871	O
of	-	879	O
baseline	-	882	O
characteristics	-	891	O
.	-	906	O

INTERVENTIONS	24717468	908	O
:	-	921	O

Continuous	24717468	923	O
sedation	-	934	O
with	-	943	O
dexmedetomidine	-	948	O
or	-	964	O
propofol	-	967	O
.	-	975	O

MEASUREMENTS	24717468	977	O
AND	-	990	O
MAIN	-	994	O
RESULTS	-	999	O
:	-	1006	O

A	24717468	1008	O
total	-	1010	O
of	-	1016	O
342	-	1019	O
patients	-	1023	O
(	-	1032	O
105	-	1033	O
dexmedetomidine	-	1037	O
and	-	1053	O
237	-	1057	O
propofol	-	1061	O
)	-	1069	O
were	-	1071	O
included	-	1076	O
in	-	1085	O
the	-	1088	O
analysis	-	1092	O
,	-	1100	O
with	-	1102	O
190	-	1107	O
matched	-	1111	O
(	-	1119	O
95	-	1120	O
in	-	1123	O
each	-	1126	O
group	-	1131	O
)	-	1136	O
by	-	1138	O
propensity	-	1141	O
score	-	1152	O
.	-	1157	O

The	24717468	1159	O
primary	-	1163	O
outcome	-	1171	O
of	-	1179	O
this	-	1182	O
study	-	1187	O
was	-	1193	O
a	-	1197	O
composite	-	1199	O
of	-	1209	O
severe	-	1212	O
hypotension	-	1219	B
(	-	1231	O
mean	-	1232	O
arterial	-	1237	O
pressure	-	1246	O
<	-	1255	O
60	-	1257	O
mm	-	1260	O
Hg	-	1263	O
)	-	1265	O
and	-	1267	O
bradycardia	-	1271	B
(	-	1283	O
heart	-	1284	O
rate	-	1290	O
<	-	1295	O
50	-	1297	O
beats	-	1300	O
/	-	1305	O
min	-	1306	O
)	-	1309	O
during	-	1311	O
sedative	-	1318	O
infusion	-	1327	O
.	-	1335	O

No	24717468	1337	O
difference	-	1340	O
in	-	1351	O
the	-	1354	O
primary	-	1358	O
composite	-	1366	O
outcome	-	1376	O
in	-	1384	O
both	-	1387	O
the	-	1392	O
unmatched	-	1396	O
(	-	1406	O
30	-	1407	O
%	-	1409	O
vs	-	1411	O
30	-	1414	O
%	-	1416	O
,	-	1417	O
p	-	1419	O
=	-	1421	O
0	-	1423	O
.	-	1424	O
94	-	1425	O
)	-	1427	O
or	-	1429	O
matched	-	1432	O
cohorts	-	1440	O
(	-	1448	O
28	-	1449	O
%	-	1451	O
vs	-	1453	O
34	-	1456	O
%	-	1458	O
,	-	1459	O
p	-	1461	O
=	-	1463	O
0	-	1465	O
.	-	1466	O
35	-	1467	O
)	-	1469	O
could	-	1471	O
be	-	1477	O
found	-	1480	O
.	-	1485	O

When	24717468	1487	O
analyzed	-	1492	O
separately	-	1501	O
,	-	1511	O
no	-	1513	O
differences	-	1516	O
could	-	1528	O
be	-	1534	O
found	-	1537	O
in	-	1543	O
the	-	1546	O
prevalence	-	1550	O
of	-	1561	O
severe	-	1564	O
hypotension	-	1571	B
or	-	1583	O
bradycardia	-	1586	B
in	-	1598	O
either	-	1601	O
the	-	1608	O
unmatched	-	1612	O
or	-	1622	O
matched	-	1625	O
cohorts	-	1633	O
.	-	1640	O

CONCLUSIONS	24717468	1642	O
:	-	1653	O

Severe	24717468	1655	O
hypotension	-	1662	B
and	-	1674	O
bradycardia	-	1678	B
occur	-	1690	O
at	-	1696	O
similar	-	1699	O
prevalence	-	1707	O
in	-	1718	O
neurocritical	-	1721	O
care	-	1735	O
patients	-	1740	O
who	-	1749	O
receive	-	1753	O
dexmedetomidine	-	1761	O
or	-	1777	O
propofol	-	1780	O
.	-	1788	O

Providers	24717468	1790	O
should	-	1800	O
similarly	-	1807	O
consider	-	1817	O
the	-	1826	O
likelihood	-	1830	O
of	-	1841	O
hypotension	-	1844	B
or	-	1856	O
bradycardia	-	1859	B
before	-	1871	O
starting	-	1878	O
either	-	1887	O
sedative	-	1894	O
.	-	1902	O

Hydroxytyrosol	24727461	0	O
ameliorates	-	15	O
oxidative	-	27	O
stress	-	37	O
and	-	44	O
mitochondrial	-	48	B
dysfunction	-	62	I
in	-	74	O
doxorubicin	-	77	O
-	-	88	O
induced	-	89	O
cardiotoxicity	-	97	B
in	-	112	O
rats	-	115	O
with	-	120	O
breast	-	125	B
cancer	-	132	I
.	-	138	O

Oxidative	24727461	140	O
stress	-	150	O
is	-	157	O
involved	-	160	O
in	-	169	O
several	-	172	O
processes	-	180	O
including	-	190	O
cancer	-	200	B
,	-	206	O
aging	-	208	O
and	-	214	O
cardiovascular	-	218	B
disease	-	233	I
,	-	240	O
and	-	242	O
has	-	246	O
been	-	250	O
shown	-	255	O
to	-	261	O
potentiate	-	264	O
the	-	275	O
therapeutic	-	279	O
effect	-	291	O
of	-	298	O
drugs	-	301	O
such	-	307	O
as	-	312	O
doxorubicin	-	315	O
.	-	326	O

Doxorubicin	24727461	328	O
causes	-	340	O
significant	-	347	O
cardiotoxicity	-	359	B
characterized	-	374	O
by	-	388	O
marked	-	391	O
increases	-	398	O
in	-	408	O
oxidative	-	411	O
stress	-	421	O
and	-	428	O
mitochondrial	-	432	B
dysfunction	-	446	I
.	-	457	O

Herein	24727461	459	O
,	-	465	O
we	-	467	O
investigate	-	470	O
whether	-	482	O
doxorubicin	-	490	O
-	-	501	O
associated	-	502	O
chronic	-	513	O
cardiac	-	521	B
toxicity	-	529	I
can	-	538	O
be	-	542	O
ameliorated	-	545	O
with	-	557	O
the	-	562	O
antioxidant	-	566	O
hydroxytyrosol	-	578	O
in	-	593	O
rats	-	596	O
with	-	601	O
breast	-	606	B
cancer	-	613	I
.	-	619	O

Thirty	24727461	621	O
-	-	627	O
six	-	628	O
rats	-	632	O
bearing	-	637	O
breast	-	645	B
tumors	-	652	I
induced	-	659	O
chemically	-	667	O
were	-	678	O
divided	-	683	O
into	-	691	O
4	-	696	O
groups	-	698	O
:	-	704	O
control	-	706	O
,	-	713	O
hydroxytyrosol	-	715	O
(	-	730	O
0	-	731	O
.	-	732	O
5mg	-	733	O
/	-	736	O
kg	-	737	O
,	-	739	O
5days	-	741	O
/	-	746	O
week	-	747	O
)	-	751	O
,	-	752	O
doxorubicin	-	754	O
(	-	766	O
1mg	-	767	O
/	-	770	O
kg	-	771	O
/	-	773	O
week	-	774	O
)	-	778	O
,	-	779	O
and	-	781	O
doxorubicin	-	785	O
plus	-	797	O
hydroxytyrosol	-	802	O
.	-	816	O

Cardiac	24727461	818	B
disturbances	-	826	I
at	-	839	O
the	-	842	O
cellular	-	846	O
and	-	855	O
mitochondrial	-	859	O
level	-	873	O
,	-	878	O
mitochondrial	-	880	O
electron	-	894	O
transport	-	903	O
chain	-	913	O
complexes	-	919	O
I	-	929	O
-	-	930	O
IV	-	931	O
and	-	934	O
apoptosis	-	938	O
-	-	947	O
inducing	-	948	O
factor	-	957	O
,	-	963	O
and	-	965	O
oxidative	-	969	O
stress	-	979	O
markers	-	986	O
have	-	994	O
been	-	999	O
analyzed	-	1004	O
.	-	1012	O

Hydroxytyrosol	24727461	1014	O
improved	-	1029	O
the	-	1038	O
cardiac	-	1042	B
disturbances	-	1050	I
enhanced	-	1063	O
by	-	1072	O
doxorubicin	-	1075	O
by	-	1087	O
significantly	-	1090	O
reducing	-	1104	O
the	-	1113	O
percentage	-	1117	O
of	-	1128	O
altered	-	1131	O
mitochondria	-	1139	O
and	-	1152	O
oxidative	-	1156	O
damage	-	1166	O
.	-	1172	O

These	24727461	1174	O
results	-	1180	O
suggest	-	1188	O
that	-	1196	O
hydroxytyrosol	-	1201	O
improve	-	1216	O
the	-	1224	O
mitochondrial	-	1228	O
electron	-	1242	O
transport	-	1251	O
chain	-	1261	O
.	-	1266	O

This	24727461	1268	O
study	-	1273	O
demonstrates	-	1279	O
that	-	1292	O
hydroxytyrosol	-	1297	O
protect	-	1312	O
rat	-	1320	O
heart	-	1324	B
damage	-	1330	I
provoked	-	1337	O
by	-	1346	O
doxorubicin	-	1349	O
decreasing	-	1361	O
oxidative	-	1372	O
damage	-	1382	O
and	-	1389	O
mitochondrial	-	1393	O
alterations	-	1407	O
.	-	1418	O

Amiodarone	24729111	0	O
-	-	10	O
induced	-	11	O
myxoedema	-	19	B
coma	-	29	I
.	-	33	O

A	24729111	35	O
62	-	37	O
-	-	39	O
year	-	40	O
-	-	44	O
old	-	45	O
man	-	49	O
was	-	53	O
found	-	57	O
to	-	63	O
have	-	66	O
bradycardia	-	71	B
,	-	82	O
hypothermia	-	84	B
and	-	96	O
respiratory	-	100	B
failure	-	112	I
3	-	120	O
weeks	-	122	O
after	-	128	O
initiation	-	134	O
of	-	145	O
amiodarone	-	148	O
therapy	-	159	O
for	-	167	O
atrial	-	171	B
fibrillation	-	178	I
.	-	190	O

Thyroid	24729111	192	O
-	-	199	O
stimulating	-	200	O
hormone	-	212	O
was	-	220	O
found	-	224	O
to	-	230	O
be	-	233	O
168	-	236	O
uIU	-	240	O
/	-	243	O
mL	-	244	O
(	-	247	O
nl	-	248	O
.	-	250	O
0	-	252	O
.	-	253	O
3	-	254	O
-	-	255	O
5	-	256	O
uIU	-	258	O
/	-	261	O
mL	-	262	O
)	-	264	O
and	-	266	O
free	-	270	O
thyroxine	-	275	O
(	-	285	O
FT4	-	286	O
)	-	289	O
was	-	291	O
<	-	295	O
0	-	296	O
.	-	297	O
2	-	298	O
ng	-	300	O
/	-	302	O
dL	-	303	O
(	-	306	O
nl	-	307	O
.	-	309	O
0	-	311	O
.	-	312	O
8	-	313	O
-	-	314	O
1	-	315	O
.	-	316	O
8	-	317	O
ng	-	319	O
/	-	321	O
dL	-	322	O
)	-	324	O
.	-	325	O

He	24729111	327	O
received	-	330	O
intravenous	-	339	O
fluids	-	351	O
,	-	357	O
vasopressor	-	359	O
therapy	-	371	O
and	-	379	O
stress	-	383	O
dose	-	390	O
steroids	-	395	O
;	-	403	O
he	-	405	O
was	-	408	O
intubated	-	412	O
and	-	422	O
admitted	-	426	O
to	-	435	O
the	-	438	O
intensive	-	442	O
care	-	452	O
unit	-	457	O
.	-	461	O

He	24729111	463	O
received	-	466	O
500	-	475	O
ug	-	479	O
of	-	482	O
intravenous	-	485	O
levothyroxine	-	497	O
in	-	511	O
the	-	514	O
first	-	518	O
18	-	524	O
h	-	527	O
of	-	529	O
therapy	-	532	O
,	-	539	O
and	-	541	O
150	-	545	O
ug	-	549	O
intravenous	-	552	O
daily	-	564	O
thereafter	-	570	O
.	-	580	O

Haemodynamic	24729111	582	O
improvement	-	595	O
,	-	606	O
along	-	608	O
with	-	614	O
complete	-	619	O
recovery	-	628	O
of	-	637	O
mental	-	640	O
status	-	647	O
,	-	653	O
occurred	-	655	O
after	-	664	O
48	-	670	O
h	-	673	O
.	-	674	O

Twelve	24729111	676	O
hours	-	683	O
after	-	689	O
the	-	695	O
initiation	-	699	O
of	-	710	O
therapy	-	713	O
,	-	720	O
FT4	-	722	O
was	-	726	O
0	-	730	O
.	-	731	O
96	-	732	O
ng	-	735	O
/	-	737	O
dL	-	738	O
.	-	740	O
The	-	742	O
patient	-	746	O
was	-	754	O
maintained	-	758	O
on	-	769	O
levothyroxine	-	772	O
175	-	786	O
(	-	790	O
g	-	791	O
POorally	-	793	O
daily	-	802	O
.	-	807	O

A	24729111	809	O
thyroid	-	811	O
ultrasound	-	819	O
showed	-	830	O
diffuse	-	837	O
heterogeneity	-	845	O
.	-	858	O

The	24729111	860	O
24	-	864	O
hour	-	867	O
excretion	-	872	O
of	-	882	O
iodine	-	885	O
was	-	892	O
3657	-	896	O
(	-	901	O
mcg	-	902	O
(	-	906	O
25	-	907	O
-	-	909	O
756	-	910	O
(	-	914	O
mcg	-	916	O
)	-	919	O
.	-	920	O

The	24729111	922	O
only	-	926	O
two	-	931	O
cases	-	935	O
of	-	941	O
amiodarone	-	944	O
-	-	954	O
induced	-	955	O
myxoedema	-	963	B
coma	-	973	I
in	-	978	O
the	-	981	O
literature	-	985	O
report	-	996	O
patient	-	1003	O
death	-	1011	O
despite	-	1017	O
supportive	-	1025	O
therapy	-	1036	O
and	-	1044	O
thyroid	-	1048	O
hormone	-	1056	O
replacement	-	1064	O
.	-	1075	O

This	24729111	1077	O
case	-	1082	O
represents	-	1087	O
the	-	1098	O
most	-	1102	O
thoroughly	-	1107	O
investigated	-	1118	O
case	-	1131	O
of	-	1136	O
amiodarone	-	1139	O
-	-	1149	O
induced	-	1150	O
myxoedema	-	1158	B
coma	-	1168	I
with	-	1173	O
a	-	1178	O
history	-	1180	O
significant	-	1188	O
for	-	1200	O
subclinical	-	1204	O
thyroid	-	1216	B
disease	-	1224	I
.	-	1231	O

Use	24733133	0	O
of	-	4	O
argatroban	-	7	O
and	-	18	O
catheter	-	22	O
-	-	30	O
directed	-	31	O
thrombolysis	-	40	B
with	-	53	O
alteplase	-	58	O
in	-	68	O
an	-	71	O
oncology	-	74	O
patient	-	83	O
with	-	91	O
heparin	-	96	O
-	-	103	O
induced	-	104	O
thrombocytopenia	-	112	B
with	-	129	O
thrombosis	-	134	B
.	-	144	O

PURPOSE	24733133	146	O
:	-	153	O

The	24733133	155	O
case	-	159	O
of	-	164	O
an	-	167	O
oncology	-	170	O
patient	-	179	O
who	-	187	O
developed	-	191	O
heparin	-	201	O
-	-	208	O
induced	-	209	O
thrombocytopenia	-	217	B
with	-	234	O
thrombosis	-	239	B
(	-	250	O
HITT	-	251	B
)	-	255	O
and	-	257	O
was	-	261	O
treated	-	265	O
with	-	273	O
argatroban	-	278	O
plus	-	289	O
catheter	-	294	O
-	-	302	O
directed	-	303	O
thrombolysis	-	312	B
(	-	325	O
CDT	-	326	O
)	-	329	O
with	-	331	O
alteplase	-	336	O
is	-	346	O
presented	-	349	O
.	-	358	O

SUMMARY	24733133	360	O
:	-	367	O

A	24733133	369	O
63	-	371	O
-	-	373	O
year	-	374	O
-	-	378	O
old	-	379	O
Caucasian	-	383	O
man	-	393	O
with	-	397	O
renal	-	402	O
amyloidosis	-	408	B
undergoing	-	420	O
peripheral	-	431	O
blood	-	442	O
stem	-	448	O
cell	-	453	O
collection	-	458	O
for	-	469	O
an	-	473	O
autologous	-	476	O
stem	-	487	O
cell	-	492	O
transplant	-	497	O
developed	-	508	O
extensive	-	518	O
bilateral	-	528	O
upper	-	538	B
-	-	543	I
extremity	-	544	I
deep	-	554	I
venous	-	559	I
thrombosis	-	566	I
(	-	577	O
DVT	-	578	B
)	-	581	O
and	-	583	O
pulmonary	-	587	B
embolism	-	597	I
secondary	-	606	O
to	-	616	O
heparin	-	619	O
-	-	626	O
induced	-	627	O
thrombocytopenia	-	635	B
.	-	651	O

A	24733133	653	O
continuous	-	655	O
i	-	666	O
.	-	667	O
v	-	668	O
.	-	669	O

infusion	24733133	671	O
of	-	680	O
argatroban	-	683	O
was	-	694	O
initiated	-	698	O
,	-	707	O
and	-	709	O
the	-	713	O
patient	-	717	O
was	-	725	O
managed	-	729	O
on	-	737	O
the	-	740	O
general	-	744	O
medical	-	752	O
floor	-	760	O
.	-	765	O

After	24733133	767	O
one	-	773	O
week	-	777	O
of	-	782	O
therapy	-	785	O
,	-	792	O
he	-	794	O
was	-	797	O
transferred	-	801	O
to	-	813	O
the	-	816	O
intensive	-	820	O
care	-	830	O
unit	-	835	O
with	-	840	O
cardiopulmonary	-	845	O
compromise	-	861	O
related	-	872	O
to	-	880	O
superior	-	883	B
vena	-	892	I
cava	-	897	I
(	-	902	I
SVC	-	903	I
)	-	906	I
syndrome	-	908	I
.	-	916	O

A	24733133	918	O
percutaneous	-	920	O
mechanical	-	933	O
thrombectomy	-	944	O
and	-	957	O
CDT	-	961	O
with	-	965	O
alteplase	-	970	O
were	-	980	O
attempted	-	985	O
,	-	994	O
but	-	996	O
the	-	1000	O
procedure	-	1004	O
was	-	1014	O
aborted	-	1018	O
due	-	1026	O
to	-	1030	O
epistaxis	-	1033	B
.	-	1042	O

The	24733133	1044	O
epistaxis	-	1048	B
resolved	-	1058	O
the	-	1067	O
next	-	1071	O
day	-	1076	O
,	-	1079	O
and	-	1081	O
the	-	1085	O
patient	-	1089	O
was	-	1097	O
restarted	-	1101	O
on	-	1111	O
argatroban	-	1114	O
.	-	1124	O

A	24733133	1126	O
second	-	1128	O
percutaneous	-	1135	O
mechanical	-	1148	O
thrombectomy	-	1159	O
was	-	1172	O
performed	-	1176	O
six	-	1186	O
days	-	1190	O
later	-	1195	O
and	-	1201	O
resulted	-	1205	O
in	-	1214	O
partial	-	1217	O
revascularization	-	1225	O
of	-	1243	O
the	-	1246	O
SVC	-	1250	O
and	-	1254	O
central	-	1258	O
veins	-	1266	O
.	-	1271	O

Postthrombectomy	24733133	1273	O
continuous	-	1290	O
CDT	-	1301	O
with	-	1305	O
alteplase	-	1310	O
was	-	1320	O
commenced	-	1324	O
while	-	1334	O
argatroban	-	1340	O
was	-	1351	O
withheld	-	1355	O
,	-	1363	O
and	-	1365	O
complete	-	1369	O
patency	-	1378	O
of	-	1386	O
the	-	1389	O
SVC	-	1393	O
and	-	1397	O
central	-	1401	O
veins	-	1409	O
was	-	1415	O
achieved	-	1419	O
after	-	1428	O
three	-	1434	O
days	-	1440	O
of	-	1445	O
therapy	-	1448	O
.	-	1455	O

Alteplase	24733133	1457	O
was	-	1467	O
discontinued	-	1471	O
,	-	1483	O
and	-	1485	O
the	-	1489	O
patient	-	1493	O
was	-	1501	O
reinitiated	-	1505	O
on	-	1517	O
argatroban	-	1520	O
;	-	1530	O
ultimately	-	1532	O
,	-	1542	O
he	-	1544	O
was	-	1547	O
transitioned	-	1551	O
to	-	1564	O
warfarin	-	1567	O
for	-	1576	O
long	-	1580	O
-	-	1584	O
term	-	1585	O
anticoagulation	-	1590	O
.	-	1605	O

Although	24733133	1607	O
the	-	1616	O
patient	-	1620	O
recovered	-	1628	O
,	-	1637	O
he	-	1639	O
experienced	-	1642	O
permanent	-	1654	O
vision	-	1664	B
and	-	1671	I
hearing	-	1675	I
loss	-	1683	I
,	-	1687	O
as	-	1689	O
well	-	1692	O
as	-	1697	O
end	-	1700	B
-	-	1703	I
stage	-	1704	I
renal	-	1710	I
disease	-	1716	I
.	-	1723	O

CONCLUSION	24733133	1725	O
:	-	1735	O

A	24733133	1737	O
63	-	1739	O
-	-	1741	O
year	-	1742	O
-	-	1746	O
old	-	1747	O
man	-	1751	O
with	-	1755	O
renal	-	1760	O
amyloidosis	-	1766	B
and	-	1778	O
SVC	-	1782	B
syndrome	-	1786	I
secondary	-	1795	O
to	-	1805	O
HITT	-	1808	B
was	-	1813	O
successfully	-	1817	O
treated	-	1830	O
with	-	1838	O
argatroban	-	1843	O
and	-	1854	O
CDT	-	1858	O
with	-	1862	O
alteplase	-	1867	O
.	-	1876	O

Effects	24739405	0	O
of	-	8	O
dehydroepiandrosterone	-	11	O
in	-	34	O
amphetamine	-	37	O
-	-	48	O
induced	-	49	O
schizophrenia	-	57	B
models	-	71	O
in	-	78	O
mice	-	81	O
.	-	85	O

OBJECTIVE	24739405	87	O
:	-	96	O

To	24739405	98	O
examine	-	101	O
the	-	109	O
effects	-	113	O
of	-	121	O
dehydroepiandrosterone	-	124	O
(	-	147	O
DHEA	-	148	O
)	-	152	O
on	-	154	O
animal	-	157	O
models	-	164	O
of	-	171	O
schizophrenia	-	174	B
.	-	187	O

METHODS	24739405	189	O
:	-	196	O

Seventy	24739405	198	O
Swiss	-	206	O
albino	-	212	O
female	-	219	O
mice	-	226	O
(	-	231	O
25	-	232	O
-	-	234	O
35	-	235	O
g	-	238	O
)	-	239	O
were	-	241	O
divided	-	246	O
into	-	254	O
4	-	259	O
groups	-	261	O
:	-	267	O
amphetamine	-	269	O
-	-	280	O
free	-	281	O
(	-	286	O
control	-	287	O
)	-	294	O
,	-	295	O
amphetamine	-	297	O
,	-	308	O
50	-	310	O
,	-	312	O
and	-	314	O
100	-	318	O
mg	-	322	O
/	-	324	O
kg	-	325	O
DHEA	-	328	O
.	-	332	O

The	24739405	334	O
DHEA	-	338	O
was	-	343	O
administered	-	347	O
intraperitoneally	-	360	O
(	-	378	O
ip	-	379	O
)	-	381	O
for	-	383	O
5	-	387	O
days	-	389	O
.	-	393	O

Amphetamine	24739405	395	O
(	-	407	O
3	-	408	O
mg	-	410	O
/	-	412	O
kg	-	413	O
ip	-	416	O
)	-	418	O
induced	-	420	O
hyper	-	428	B
locomotion	-	434	O
,	-	444	O
apomorphine	-	446	O
(	-	458	O
1	-	459	O
.	-	460	O
5	-	461	O
mg	-	463	O
/	-	465	O
kg	-	466	O
subcutaneously	-	469	O
[	-	484	O
sc	-	485	O
]	-	487	O
)	-	488	O
induced	-	490	O
climbing	-	498	O
,	-	506	O
and	-	508	O
haloperidol	-	512	O
(	-	524	O
1	-	525	O
.	-	526	O
5	-	527	O
mg	-	529	O
/	-	531	O
kg	-	532	O
sc	-	535	O
)	-	537	O
induced	-	539	O
catalepsy	-	547	B
tests	-	557	O
were	-	563	O
used	-	568	O
as	-	573	O
animal	-	576	O
models	-	583	O
of	-	590	O
schizophrenia	-	593	B
.	-	606	O

The	24739405	608	O
study	-	612	O
was	-	618	O
conducted	-	622	O
at	-	632	O
the	-	635	O
Animal	-	639	O
Experiment	-	646	O
Laboratories	-	657	O
,	-	669	O
Department	-	671	O
of	-	682	O
Pharmacology	-	685	O
,	-	697	O
Medical	-	699	O
School	-	707	O
,	-	713	O
Eskisehir	-	715	O
Osmangazi	-	725	O
University	-	735	O
,	-	745	O
Eskisehir	-	747	O
,	-	756	O
Turkey	-	758	O
between	-	765	O
March	-	773	O
and	-	779	O
May	-	783	O
2012	-	787	O
.	-	791	O

Statistical	24739405	793	O
analysis	-	805	O
was	-	814	O
carried	-	818	O
out	-	826	O
using	-	830	O
Kruskal	-	836	O
-	-	843	O
Wallis	-	844	O
test	-	851	O
for	-	856	O
hyper	-	860	B
locomotion	-	866	O
,	-	876	O
and	-	878	O
one	-	882	O
-	-	885	O
way	-	886	O
ANOVA	-	890	O
for	-	896	O
climbing	-	900	O
and	-	909	O
catalepsy	-	913	B
tests	-	923	O
.	-	928	O

RESULTS	24739405	930	O
:	-	937	O

In	24739405	939	O
the	-	942	O
amphetamine	-	946	O
-	-	957	O
induced	-	958	O
locomotion	-	966	O
test	-	977	O
,	-	981	O
there	-	983	O
were	-	989	O
significant	-	994	O
increases	-	1006	O
in	-	1016	O
all	-	1019	O
movements	-	1023	O
compared	-	1033	O
with	-	1042	O
the	-	1047	O
amphetamine	-	1051	O
-	-	1062	O
free	-	1063	O
group	-	1068	O
.	-	1073	O

Both	24739405	1075	O
DHEA	-	1080	O
50	-	1085	O
mg	-	1088	O
/	-	1090	O
kg	-	1091	O
(	-	1094	O
p	-	1095	O
<	-	1096	O
0	-	1097	O
.	-	1098	O
05	-	1099	O
)	-	1101	O
,	-	1102	O
and	-	1104	O
100	-	1108	O
mg	-	1112	O
/	-	1114	O
kg	-	1115	O
(	-	1118	O
p	-	1119	O
<	-	1120	O
0	-	1121	O
.	-	1122	O
01	-	1123	O
)	-	1125	O
significantly	-	1127	O
decreased	-	1141	O
all	-	1151	O
movements	-	1155	O
compared	-	1165	O
with	-	1174	O
the	-	1179	O
amphetamine	-	1183	O
-	-	1194	O
induced	-	1195	O
locomotion	-	1203	O
group	-	1214	O
.	-	1219	O

There	24739405	1221	O
was	-	1227	O
a	-	1231	O
significant	-	1233	O
difference	-	1245	O
between	-	1256	O
groups	-	1264	O
in	-	1271	O
the	-	1274	O
haloperidol	-	1278	O
-	-	1289	O
induced	-	1290	O
catalepsy	-	1298	B
test	-	1308	O
(	-	1313	O
p	-	1314	O
<	-	1315	O
0	-	1316	O
.	-	1317	O
05	-	1318	O
)	-	1320	O
.	-	1321	O

There	24739405	1323	O
was	-	1329	O
no	-	1333	O
significant	-	1336	O
difference	-	1348	O
between	-	1359	O
groups	-	1367	O
in	-	1374	O
terms	-	1377	O
of	-	1383	O
total	-	1386	O
climbing	-	1392	O
time	-	1401	O
in	-	1406	O
the	-	1409	O
apomorphine	-	1413	O
-	-	1424	O
induced	-	1425	O
climbing	-	1433	O
test	-	1442	O
(	-	1447	O
p	-	1448	O
>	-	1449	O
0	-	1450	O
.	-	1451	O
05	-	1452	O
)	-	1454	O
.	-	1455	O

CONCLUSION	24739405	1457	O
:	-	1467	O

We	24739405	1469	O
observed	-	1472	O
that	-	1481	O
DHEA	-	1486	O
reduced	-	1491	O
locomotor	-	1499	O
activity	-	1509	O
and	-	1518	O
increased	-	1522	O
catalepsy	-	1532	B
at	-	1542	O
both	-	1545	O
doses	-	1550	O
,	-	1555	O
while	-	1557	O
it	-	1563	O
had	-	1566	O
no	-	1570	O
effect	-	1573	O
on	-	1580	O
climbing	-	1583	O
behavior	-	1592	O
.	-	1600	O

We	24739405	1602	O
suggest	-	1605	O
that	-	1613	O
DHEA	-	1618	O
displays	-	1623	O
typical	-	1632	O
neuroleptic	-	1640	O
-	-	1651	O
like	-	1652	O
effects	-	1657	O
,	-	1664	O
and	-	1666	O
may	-	1670	O
be	-	1674	O
used	-	1677	O
in	-	1682	O
the	-	1685	O
treatment	-	1689	O
of	-	1699	O
schizophrenia	-	1702	B
.	-	1715	O

Availability	24742750	0	O
of	-	13	O
human	-	16	O
induced	-	22	O
pluripotent	-	30	O
stem	-	42	O
cell	-	47	O
-	-	51	O
derived	-	52	O
cardiomyocytes	-	60	O
in	-	75	O
assessment	-	78	O
of	-	89	O
drug	-	92	O
potential	-	97	O
for	-	107	O
QT	-	111	B
prolongation	-	114	I
.	-	126	O

Field	24742750	128	O
potential	-	134	O
duration	-	144	O
(	-	153	O
FPD	-	154	O
)	-	157	O
in	-	159	O
human	-	162	O
-	-	167	O
induced	-	168	O
pluripotent	-	176	O
stem	-	188	O
cell	-	193	O
-	-	197	O
derived	-	198	O
cardiomyocytes	-	206	O
(	-	221	O
hiPS	-	222	O
-	-	226	O
CMs	-	227	O
)	-	230	O
,	-	231	O
which	-	233	O
can	-	239	O
express	-	243	O
QT	-	251	O
interval	-	254	O
in	-	263	O
an	-	266	O
electrocardiogram	-	269	O
,	-	286	O
is	-	288	O
reported	-	291	O
to	-	300	O
be	-	303	O
a	-	306	O
useful	-	308	O
tool	-	315	O
to	-	320	O
predict	-	323	O
K	-	331	O
(	-	332	O
+	-	333	O
)	-	334	O
channel	-	336	O
and	-	344	O
Ca	-	348	O
(	-	350	O
2	-	351	O
+	-	352	O
)	-	353	O
channel	-	355	O
blocker	-	363	O
effects	-	371	O
on	-	379	O
QT	-	382	O
interval	-	385	O
.	-	393	O

However	24742750	395	O
,	-	402	O
there	-	404	O
is	-	410	O
no	-	413	O
report	-	416	O
showing	-	423	O
that	-	431	O
this	-	436	O
technique	-	441	O
can	-	451	O
be	-	455	O
used	-	458	O
to	-	463	O
predict	-	466	O
multichannel	-	474	O
blocker	-	487	O
potential	-	495	O
for	-	505	O
QT	-	509	B
prolongation	-	512	I
.	-	524	O

The	24742750	526	O
aim	-	530	O
of	-	534	O
this	-	537	O
study	-	542	O
is	-	548	O
to	-	551	O
show	-	554	O
that	-	559	O
FPD	-	564	O
from	-	568	O
MEA	-	573	O
(	-	577	O
Multielectrode	-	578	O
array	-	593	O
)	-	598	O
of	-	600	O
hiPS	-	603	O
-	-	607	O
CMs	-	608	O
can	-	612	O
detect	-	616	O
QT	-	623	B
prolongation	-	626	I
induced	-	639	O
by	-	647	O
multichannel	-	650	O
blockers	-	663	O
.	-	671	O

hiPS	24742750	673	O
-	-	677	O
CMs	-	678	O
were	-	682	O
seeded	-	687	O
onto	-	694	O
MEA	-	699	O
and	-	703	O
FPD	-	707	O
was	-	711	O
measured	-	715	O
for	-	724	O
2min	-	728	O
every	-	733	O
10min	-	739	O
for	-	745	O
30min	-	749	O
after	-	755	O
drug	-	761	O
exposure	-	766	O
for	-	775	O
the	-	779	O
vehicle	-	783	O
and	-	791	O
each	-	795	O
drug	-	800	O
concentration	-	805	O
.	-	818	O

IKr	24742750	820	O
and	-	824	O
IKs	-	828	O
blockers	-	832	O
concentration	-	841	O
-	-	854	O
dependently	-	855	O
prolonged	-	867	O
corrected	-	877	O
FPD	-	887	O
(	-	891	O
FPDc	-	892	O
)	-	896	O
,	-	897	O
whereas	-	899	O
Ca	-	907	O
(	-	909	O
2	-	910	O
+	-	911	O

)	24742750	912	O
channel	-	914	O
blockers	-	922	O
concentration	-	931	O
-	-	944	O
dependently	-	945	O
shortened	-	957	O
FPDc	-	967	O
.	-	971	O

Also	24742750	973	O
,	-	977	O
the	-	979	O
multichannel	-	983	O
blockers	-	996	O
Amiodarone	-	1005	O
,	-	1015	O
Paroxetine	-	1017	O
,	-	1027	O
Terfenadine	-	1029	O
and	-	1041	O
Citalopram	-	1045	O
prolonged	-	1056	O
FPDc	-	1066	O
in	-	1071	O
a	-	1074	O
concentration	-	1076	O
dependent	-	1090	O
manner	-	1100	O
.	-	1106	O

Finally	24742750	1108	O
,	-	1115	O
the	-	1117	O
IKr	-	1121	O
blockers	-	1125	O
,	-	1133	O
Terfenadine	-	1135	O
and	-	1147	O
Citalopram	-	1151	O
,	-	1161	O
which	-	1163	O
are	-	1169	O
reported	-	1173	O
to	-	1182	O
cause	-	1185	O
Torsade	-	1191	B
de	-	1199	I
Pointes	-	1202	I
(	-	1210	O
TdP	-	1211	B
)	-	1214	O
in	-	1216	O
clinical	-	1219	O
practice	-	1228	O
,	-	1236	O
produced	-	1238	O
early	-	1247	O
afterdepolarization	-	1253	O
(	-	1273	O
EAD	-	1274	O
)	-	1277	O
.	-	1278	O

hiPS	24742750	1280	O
-	-	1284	O
CMs	-	1285	O
using	-	1289	O
MEA	-	1295	O
system	-	1299	O
and	-	1306	O
FPDc	-	1310	O
can	-	1315	O
predict	-	1319	O
the	-	1327	O
effects	-	1331	O
of	-	1339	O
drug	-	1342	O
candidates	-	1347	O
on	-	1358	O
QT	-	1361	O
interval	-	1364	O
.	-	1372	O

This	24742750	1374	O
study	-	1379	O
also	-	1385	O
shows	-	1390	O
that	-	1396	O
this	-	1401	O
assay	-	1406	O
can	-	1412	O
help	-	1416	O
detect	-	1421	O
EAD	-	1428	O
for	-	1432	O
drugs	-	1436	O
with	-	1442	O
TdP	-	1447	B
potential	-	1451	O
.	-	1460	O

Dermal	24753331	0	O
developmental	-	7	O
toxicity	-	21	B
of	-	30	O
N	-	33	O
-	-	34	O
phenylimide	-	35	O
herbicides	-	47	O
in	-	58	O
rats	-	61	O
.	-	65	O

BACKGROUND	24753331	67	O
:	-	77	O

S	24753331	79	O
-	-	80	O
53482	-	81	O
and	-	87	O
S	-	91	O
-	-	92	O
23121	-	93	O
are	-	99	O
N	-	103	O
-	-	104	O
phenylimide	-	105	O
herbicides	-	117	O
and	-	128	O
produced	-	132	O
embryolethality	-	141	B
,	-	156	O
teratogenicity	-	158	B
(	-	173	O
mainly	-	174	O
ventricular	-	181	B
septal	-	193	I
defects	-	200	I
and	-	208	O
wavy	-	212	O
ribs	-	217	O
)	-	221	O
,	-	222	O
and	-	224	O
growth	-	228	B
retardation	-	235	I
in	-	247	O
rats	-	250	O
in	-	255	O
conventional	-	258	O
oral	-	271	O
developmental	-	276	O
toxicity	-	290	B
studies	-	299	O
.	-	306	O

Our	24753331	308	O
objective	-	312	O
in	-	322	O
this	-	325	O
study	-	330	O
was	-	336	O
to	-	340	O
investigate	-	343	O
whether	-	355	O
the	-	363	O
compounds	-	367	O
induce	-	377	O
developmental	-	384	O
toxicity	-	398	B
via	-	407	O
the	-	411	O
dermal	-	415	O
route	-	422	O
,	-	427	O
which	-	429	O
is	-	435	O
more	-	438	O
relevant	-	443	O
to	-	452	O
occupational	-	455	O
exposure	-	468	O
,	-	476	O
hence	-	478	O
better	-	484	O
addressing	-	491	O
human	-	502	O
health	-	508	O
risks	-	515	O
.	-	520	O

METHODS	24753331	522	O
:	-	529	O

S	24753331	531	O
-	-	532	O
53482	-	533	O
was	-	539	O
administered	-	543	O
dermally	-	556	O
to	-	565	O
rats	-	568	O
at	-	573	O
30	-	576	O
,	-	578	O
100	-	580	O
,	-	583	O
and	-	585	O
300	-	589	O
mg	-	593	O
/	-	595	O
kg	-	596	O
during	-	599	O
organogenesis	-	606	O
,	-	619	O
and	-	621	O
S	-	625	O
-	-	626	O
23121	-	627	O
was	-	633	O
administered	-	637	O
at	-	650	O
200	-	653	O
,	-	656	O
400	-	658	O
,	-	661	O
and	-	663	O
800	-	667	O
mg	-	671	O
/	-	673	O
kg	-	674	O
(	-	677	O
the	-	678	O
maximum	-	682	O
applicable	-	690	O
dose	-	701	O
level	-	706	O
)	-	711	O
.	-	712	O

Fetuses	24753331	714	O
were	-	722	O
obtained	-	727	O
by	-	736	O
a	-	739	O
Cesarean	-	741	O
section	-	750	O
and	-	758	O
examined	-	762	O
for	-	771	O
external	-	775	O
,	-	783	O
visceral	-	785	O
,	-	793	O
and	-	795	O
skeletal	-	799	O
alterations	-	808	O
.	-	819	O

RESULTS	24753331	821	O
:	-	828	O

Dermal	24753331	830	O
exposure	-	837	O
of	-	846	O
rats	-	849	O
to	-	854	O
S	-	857	O
-	-	858	O
53482	-	859	O
at	-	865	O
300	-	868	O
mg	-	872	O
/	-	874	O
kg	-	875	O
produced	-	878	O
patterns	-	887	O
of	-	896	O
developmental	-	899	O
toxicity	-	913	B
similar	-	922	O
to	-	930	O
those	-	933	O
resulting	-	939	O
from	-	949	O
oral	-	954	O
exposure	-	959	O
.	-	967	O

Toxicity	24753331	969	B
included	-	978	O
embryolethality	-	987	B
,	-	1002	O
teratogenicity	-	1004	B
,	-	1018	O
and	-	1020	O
growth	-	1024	B
retardation	-	1031	I
.	-	1042	O

Dermal	24753331	1044	O
administration	-	1051	O
of	-	1066	O
S	-	1069	O
-	-	1070	O
23121	-	1071	O
at	-	1077	O
800	-	1080	O
mg	-	1084	O
/	-	1086	O
kg	-	1087	O
resulted	-	1090	O
in	-	1099	O
an	-	1102	O
increased	-	1105	O
incidence	-	1115	O
of	-	1125	O
embryonic	-	1128	B
death	-	1138	I
and	-	1144	O
ventricular	-	1148	B
septal	-	1160	I
defect	-	1167	I
,	-	1173	O
but	-	1175	O
retarded	-	1179	O
fetal	-	1188	O
growth	-	1194	O
was	-	1201	O
not	-	1205	O
observed	-	1209	O
as	-	1218	O
it	-	1221	O
was	-	1224	O
following	-	1228	O
oral	-	1238	O
exposure	-	1243	O
to	-	1252	O
S	-	1255	O
-	-	1256	O
23121	-	1257	O
.	-	1262	O

CONCLUSIONS	24753331	1264	O
:	-	1275	O

Based	24753331	1277	O
on	-	1283	O
the	-	1286	O
results	-	1290	O
,	-	1297	O
S	-	1299	O
-	-	1300	O
53482	-	1301	O
and	-	1307	O
S	-	1311	O
-	-	1312	O
23121	-	1313	O
were	-	1319	O
teratogenic	-	1324	B
when	-	1336	O
administered	-	1341	O
dermally	-	1354	O
to	-	1363	O
pregnant	-	1366	O
rats	-	1375	O
as	-	1380	O
were	-	1383	O
the	-	1388	O
compounds	-	1392	O
administered	-	1402	O
orally	-	1415	O
.	-	1421	O

Thus	24753331	1423	O
,	-	1427	O
investigation	-	1429	O
of	-	1443	O
the	-	1446	O
mechanism	-	1450	O
and	-	1460	O
its	-	1464	O
human	-	1468	O
relevancy	-	1474	O
become	-	1484	O
more	-	1491	O
important	-	1496	O
.	-	1505	O

Rates	24778426	0	O
of	-	6	O
Renal	-	9	B
Toxicity	-	15	I
in	-	24	O
Cancer	-	27	B
Patients	-	34	O
Receiving	-	43	O
Cisplatin	-	53	O
With	-	63	O
and	-	68	O
Without	-	72	O
Mannitol	-	80	O
.	-	88	O

BACKGROUND	24778426	90	O
:	-	100	O

Cisplatin	24778426	102	O
is	-	112	O
a	-	115	O
widely	-	117	O
used	-	124	O
antineoplastic	-	129	O
.	-	143	O

One	24778426	145	O
of	-	149	O
the	-	152	O
major	-	156	O
complications	-	162	O
of	-	176	O
cisplatin	-	179	O
use	-	189	O
is	-	193	O
dose	-	196	O
-	-	200	O
limiting	-	201	O
nephrotoxicity	-	210	B
.	-	224	O

There	24778426	226	O
are	-	232	O
many	-	236	O
strategies	-	241	O
to	-	252	O
prevent	-	255	O
this	-	263	O
toxicity	-	268	B
,	-	276	O
including	-	278	O
the	-	288	O
use	-	292	O
of	-	296	O
mannitol	-	299	O
as	-	308	O
a	-	311	O
nephroprotectant	-	313	O
in	-	330	O
combination	-	333	O
with	-	345	O
hydration	-	350	O
.	-	359	O

OBJECTIVE	24778426	361	O
:	-	370	O
We	-	372	O
aimed	-	375	O
to	-	381	O
evaluate	-	384	O
the	-	393	O
rates	-	397	O
of	-	403	O
cisplatin	-	406	O
-	-	415	O
induced	-	416	O
nephrotoxicity	-	424	B
in	-	439	O
cancer	-	442	B
patients	-	449	O
receiving	-	458	O
single	-	468	O
-	-	474	O
agent	-	475	O
cisplatin	-	481	O
with	-	491	O
and	-	496	O
without	-	500	O
mannitol	-	508	O
.	-	516	O

METHODS	24778426	518	O
:	-	525	O

This	24778426	527	O
single	-	532	O
-	-	538	O
center	-	539	O
retrospective	-	546	O
analysis	-	560	O
was	-	569	O
a	-	573	O
quasi	-	575	O
experiment	-	581	O
created	-	592	O
by	-	600	O
the	-	603	O
national	-	607	O
mannitol	-	616	O
shortage	-	625	O
.	-	633	O

Data	24778426	635	O
were	-	640	O
collected	-	645	O
on	-	655	O
adult	-	658	O
cancer	-	664	B
patients	-	671	O
receiving	-	680	O
single	-	690	O
-	-	696	O
agent	-	697	O
cisplatin	-	703	O
as	-	713	O
an	-	716	O
outpatient	-	719	O
from	-	730	O
January	-	735	O
2011	-	743	O
to	-	748	O
September	-	751	O
2012	-	761	O
.	-	765	O

The	24778426	767	O
primary	-	771	O
outcome	-	779	O
was	-	787	O
acute	-	791	B
kidney	-	797	I
injury	-	804	I
(	-	811	O
AKI	-	812	B
)	-	815	O
.	-	816	O

RESULTS	24778426	818	O
:	-	825	O

We	24778426	827	O
evaluated	-	830	O
143	-	840	O
patients	-	844	O
who	-	853	O
received	-	857	O
single	-	866	O
-	-	872	O
agent	-	873	O
cisplatin	-	879	O
;	-	888	O
97	-	890	O
.	-	892	O
2	-	893	O
%	-	894	O
of	-	896	O
patients	-	899	O
had	-	908	O
head	-	912	B
and	-	917	I
neck	-	921	I
cancer	-	926	I
as	-	933	O
their	-	936	O
primary	-	942	O
malignancy	-	950	B
.	-	960	O

Patients	24778426	962	O
who	-	971	O
did	-	975	O
not	-	979	O
receive	-	983	O
mannitol	-	991	O
were	-	1000	O
more	-	1005	O
likely	-	1010	O
to	-	1017	O
develop	-	1020	O
nephrotoxicity	-	1028	B
:	-	1042	O
odds	-	1044	O
ratio	-	1049	O
[	-	1055	O
OR	-	1056	O
]	-	1058	O

=	24778426	1060	O
2	-	1062	O
.	-	1063	O
646	-	1064	O
(	-	1068	O
95	-	1069	O
%	-	1071	O
CI	-	1073	O
=	-	1076	O
1	-	1078	O
.	-	1079	O
008	-	1080	O
,	-	1083	O
6	-	1085	O
.	-	1086	O
944	-	1087	O
;	-	1090	O
P	-	1092	O
=	-	1094	O
0	-	1096	O
.	-	1097	O
048	-	1098	O
)	-	1101	O
.	-	1102	O

Patients	24778426	1104	O
who	-	1113	O
received	-	1117	O
the	-	1126	O
100	-	1130	O
mg	-	1134	O
/	-	1136	O
m	-	1137	O
(	-	1138	O
2	-	1139	O
)	-	1140	O
dosing	-	1142	O
and	-	1149	O
patients	-	1153	O
who	-	1162	O
had	-	1166	O
a	-	1170	O
history	-	1172	O
of	-	1180	O
hypertension	-	1183	B
also	-	1196	O
had	-	1201	O
a	-	1205	O
higher	-	1207	O
likelihood	-	1214	O
of	-	1225	O
developing	-	1228	O
nephrotoxicity	-	1239	B
:	-	1253	O
OR	-	1255	O
=	-	1258	O
11	-	1260	O
.	-	1262	O
494	-	1263	O
(	-	1267	O
95	-	1268	O
%	-	1270	O
CI	-	1272	O
=	-	1275	O
4	-	1277	O
.	-	1278	O
149	-	1279	O
,	-	1282	O
32	-	1284	O
.	-	1286	O
258	-	1287	O
;	-	1290	O
P	-	1292	O
<	-	1294	O
0	-	1296	O
.	-	1297	O
0001	-	1298	O
)	-	1302	O
and	-	1304	O
OR	-	1308	O
=	-	1311	O
3	-	1313	O
.	-	1314	O
219	-	1315	O
(	-	1319	O
95	-	1320	O
%	-	1322	O
CI	-	1324	O
=	-	1327	O
1	-	1329	O
.	-	1330	O
228	-	1331	O
,	-	1334	O
8	-	1336	O
.	-	1337	O
439	-	1338	O
;	-	1341	O
P	-	1343	O
=	-	1345	O
0	-	1347	O
.	-	1348	O
017	-	1349	O
)	-	1352	O
,	-	1353	O
respectively	-	1355	O
.	-	1367	O

CONCLUSIONS	24778426	1369	O
:	-	1380	O

When	24778426	1382	O
limited	-	1387	O
quantities	-	1395	O
of	-	1406	O
mannitol	-	1409	O
are	-	1418	O
available	-	1422	O
,	-	1431	O
it	-	1433	O
should	-	1436	O
preferentially	-	1443	O
be	-	1458	O
given	-	1461	O
to	-	1467	O
patients	-	1470	O
at	-	1479	O
particularly	-	1482	O
high	-	1495	O
risk	-	1500	O
of	-	1505	O
nephrotoxicity	-	1508	B
.	-	1522	O

Our	24778426	1524	O
analysis	-	1528	O
suggests	-	1537	O
that	-	1546	O
those	-	1551	O
patients	-	1557	O
receiving	-	1566	O
the	-	1576	O
dosing	-	1580	O
schedule	-	1587	O
of	-	1596	O
100	-	1599	O
mg	-	1603	O
/	-	1605	O
m	-	1606	O
(	-	1607	O
2	-	1608	O
)	-	1609	O
cisplatin	-	1611	O
every	-	1621	O
3	-	1627	O
weeks	-	1629	O
and	-	1635	O
those	-	1639	O
with	-	1645	O
hypertension	-	1650	B
are	-	1663	O
at	-	1667	O
the	-	1670	O
greatest	-	1674	O
risk	-	1683	O
of	-	1688	O
nephrotoxicity	-	1691	B
and	-	1706	O
would	-	1710	O
benefit	-	1716	O
from	-	1724	O
the	-	1729	O
addition	-	1733	O
of	-	1742	O
mannitol	-	1745	O
.	-	1753	O

Metformin	24802403	0	O
protects	-	10	O
against	-	19	O
seizures	-	27	B
,	-	35	O
learning	-	37	B
and	-	46	I
memory	-	50	I
impairments	-	57	I
and	-	69	O
oxidative	-	73	O
damage	-	83	O
induced	-	90	O
by	-	98	O
pentylenetetrazole	-	101	O
-	-	119	O
induced	-	120	O
kindling	-	128	O
in	-	137	O
mice	-	140	O
.	-	144	O

Cognitive	24802403	146	B
impairment	-	156	I
,	-	166	O
the	-	168	O
most	-	172	O
common	-	177	O
and	-	184	O
severe	-	188	O
comorbidity	-	195	O
of	-	207	O
epilepsy	-	210	B
,	-	218	O
greatly	-	220	O
diminishes	-	228	O
the	-	239	O
quality	-	243	O
of	-	251	O
life	-	254	O
.	-	258	O

However	24802403	260	O
,	-	267	O
current	-	269	O
therapeutic	-	277	O
interventions	-	289	O
for	-	303	O
epilepsy	-	307	B
can	-	316	O
also	-	320	O
cause	-	325	O
untoward	-	331	O
cognitive	-	340	O
effects	-	350	O
.	-	357	O

Thus	24802403	359	O
,	-	363	O
there	-	365	O
is	-	371	O
an	-	374	O
urgent	-	377	O
need	-	384	O
for	-	389	O
new	-	393	O
kinds	-	397	O
of	-	403	O
agents	-	406	O
targeting	-	413	O
both	-	423	O
seizures	-	428	B
and	-	437	O
cognition	-	441	B
deficits	-	451	I
.	-	459	O

Oxidative	24802403	461	O
stress	-	471	O
is	-	478	O
considered	-	481	O
to	-	492	O
play	-	495	O
an	-	500	O
important	-	503	O
role	-	513	O
in	-	518	O
epileptogenesis	-	521	O
and	-	537	O
cognitive	-	541	B
deficits	-	551	I
,	-	559	O
and	-	561	O
antioxidants	-	565	O
have	-	578	O
a	-	583	O
putative	-	585	O
antiepileptic	-	594	O
potential	-	608	O
.	-	617	O

Metformin	24802403	619	O
,	-	628	O
the	-	630	O
most	-	634	O
commonly	-	639	O
prescribed	-	648	O
antidiabetic	-	659	O
oral	-	672	O
drug	-	677	O
,	-	681	O
has	-	683	O
antioxidant	-	687	O
properties	-	699	O
.	-	709	O

This	24802403	711	O
study	-	716	O
was	-	722	O
designed	-	726	O
to	-	735	O
evaluate	-	738	O
the	-	747	O
ameliorative	-	751	O
effects	-	764	O
of	-	772	O
metformin	-	775	O
on	-	785	O
seizures	-	788	B
,	-	796	O
cognitive	-	798	B
impairment	-	808	I
and	-	819	O
brain	-	823	O
oxidative	-	829	O
stress	-	839	O
markers	-	846	O
observed	-	854	O
in	-	863	O
pentylenetetrazole	-	866	O
-	-	884	O
induced	-	885	O
kindling	-	893	O
animals	-	902	O
.	-	909	O

Male	24802403	911	O
C57BL	-	916	O
/	-	921	O
6	-	922	O
mice	-	924	O
were	-	929	O
administered	-	934	O
with	-	947	O
subconvulsive	-	952	O
dose	-	966	O
of	-	971	O
pentylenetetrazole	-	974	O
(	-	993	O
37	-	994	O
mg	-	997	O
/	-	999	O
kg	-	1000	O
,	-	1002	O
i	-	1004	O
.	-	1005	O
p	-	1006	O
.	-	1007	O
)	-	1008	O

every	24802403	1010	O
other	-	1016	O
day	-	1022	O
for	-	1026	O
14	-	1030	O
injections	-	1033	O
.	-	1043	O

Metformin	24802403	1045	O
was	-	1055	O
injected	-	1059	O
intraperitoneally	-	1068	O
in	-	1086	O
dose	-	1089	O
of	-	1094	O
200mg	-	1097	O
/	-	1102	O
kg	-	1103	O
along	-	1106	O
with	-	1112	O
alternate	-	1117	O
-	-	1126	O
day	-	1127	O
PTZ	-	1131	O
.	-	1134	O

We	24802403	1136	O
found	-	1139	O
that	-	1145	O
metformin	-	1150	O
suppressed	-	1160	O
the	-	1171	O
progression	-	1175	O
of	-	1187	O
kindling	-	1190	O
,	-	1198	O
ameliorated	-	1200	O
the	-	1212	O
cognitive	-	1216	B
impairment	-	1226	I
and	-	1237	O
decreased	-	1241	O
brain	-	1251	O
oxidative	-	1257	O
stress	-	1267	O
.	-	1273	O

Thus	24802403	1275	O
the	-	1280	O
present	-	1284	O
study	-	1292	O
concluded	-	1298	O
that	-	1308	O
metformin	-	1313	O
may	-	1323	O
be	-	1327	O
a	-	1330	O
potential	-	1332	O
agent	-	1342	O
for	-	1348	O
the	-	1352	O
treatment	-	1356	O
of	-	1366	O
epilepsy	-	1369	B
as	-	1378	O
well	-	1381	O
as	-	1386	O
a	-	1389	O
protective	-	1391	O
medicine	-	1402	O
against	-	1411	O
cognitive	-	1419	B
impairment	-	1429	I
induced	-	1440	O
by	-	1448	O
seizures	-	1451	B
.	-	1459	O

P53	24812279	0	O
inhibition	-	4	O
exacerbates	-	15	O
late	-	27	O
-	-	31	O
stage	-	32	O
anthracycline	-	38	O
cardiotoxicity	-	52	B
.	-	66	O

AIMS	24812279	68	O
:	-	72	O

Doxorubicin	24812279	74	O
(	-	86	O
DOX	-	87	O
)	-	90	O
is	-	92	O
an	-	95	O
effective	-	98	O
anti	-	108	O
-	-	112	O
cancer	-	113	B
therapeutic	-	120	O
,	-	131	O
but	-	133	O
is	-	137	O
associated	-	140	O
with	-	151	O
both	-	156	O
acute	-	161	O
and	-	167	O
late	-	171	O
-	-	175	O
stage	-	176	O
cardiotoxicity	-	182	B
.	-	196	O

Children	24812279	198	O
are	-	207	O
particularly	-	211	O
sensitive	-	224	O
to	-	234	O
DOX	-	237	O
-	-	240	O
induced	-	241	O
heart	-	249	B
failure	-	255	I
.	-	262	O

Here	24812279	264	O
,	-	268	O
the	-	270	O
impact	-	274	O
of	-	281	O
p53	-	284	O
inhibition	-	288	O
on	-	299	O
acute	-	302	O
vs	-	308	O
.	-	310	O
late	-	312	O
-	-	316	O
stage	-	317	O
DOX	-	323	O
cardiotoxicity	-	327	B
was	-	342	O
examined	-	346	O
in	-	355	O
a	-	358	O
juvenile	-	360	O
model	-	369	O
.	-	374	O

METHODS	24812279	376	O
AND	-	384	O
RESULTS	-	388	O
:	-	395	O

Two	24812279	397	O
-	-	400	O
week	-	401	O
-	-	405	O
old	-	406	O
MHC	-	410	O
-	-	413	O
CB7	-	414	O
mice	-	418	O
(	-	423	O
which	-	424	O
express	-	430	O
dominant	-	438	O
-	-	446	O
interfering	-	447	O
p53	-	459	O
in	-	463	O
cardiomyocytes	-	466	O
)	-	480	O
and	-	482	O
their	-	486	O
non	-	492	O
-	-	495	O
transgenic	-	496	O
(	-	507	O
NON	-	508	O
-	-	511	O
TXG	-	512	O
)	-	515	O
littermates	-	517	O
received	-	529	O
weekly	-	538	O
DOX	-	545	O
injections	-	549	O
for	-	560	O
5	-	564	O
weeks	-	566	O
(	-	572	O
25	-	573	O
mg	-	576	O
/	-	578	O
kg	-	579	O
cumulative	-	582	O
dose	-	593	O
)	-	597	O
.	-	598	O

One	24812279	600	O
week	-	604	O
after	-	609	O
the	-	615	O
last	-	619	O
DOX	-	624	O
treatment	-	628	O
(	-	638	O
acute	-	639	O
stage	-	645	O
)	-	650	O
,	-	651	O
MHC	-	653	O
-	-	656	O
CB7	-	657	O
mice	-	661	O
exhibited	-	666	O
improved	-	676	O
cardiac	-	685	O
function	-	693	O
and	-	702	O
lower	-	706	O
levels	-	712	O
of	-	719	O
cardiomyocyte	-	722	O
apoptosis	-	736	O
when	-	746	O
compared	-	751	O
with	-	760	O
the	-	765	O
NON	-	769	O
-	-	772	O
TXG	-	773	O
mice	-	777	O
.	-	781	O

Surprisingly	24812279	783	O
,	-	795	O
by	-	797	O
13	-	800	O
weeks	-	803	O
following	-	809	O
the	-	819	O
last	-	823	O
DOX	-	828	O
treatment	-	832	O
(	-	842	O
late	-	843	O
stage	-	848	O
)	-	853	O
,	-	854	O
MHC	-	856	O
-	-	859	O
CB7	-	860	O
exhibited	-	864	O
a	-	874	O
progressive	-	876	O
decrease	-	888	O
in	-	897	O
cardiac	-	900	O
function	-	908	O
and	-	917	O
higher	-	921	O
rates	-	928	O
of	-	934	O
cardiomyocyte	-	937	O
apoptosis	-	951	O
when	-	961	O
compared	-	966	O
with	-	975	O
NON	-	980	O
-	-	983	O
TXG	-	984	O
mice	-	988	O
.	-	992	O

p53	24812279	994	O
inhibition	-	998	O
blocked	-	1009	O
transient	-	1017	O
DOX	-	1027	O
-	-	1030	O
induced	-	1031	O
STAT3	-	1039	O
activation	-	1045	O
in	-	1056	O
MHC	-	1059	O
-	-	1062	O
CB7	-	1063	O
mice	-	1067	O
,	-	1071	O
which	-	1073	O
was	-	1079	O
associated	-	1083	O
with	-	1094	O
enhanced	-	1099	O
induction	-	1108	O
of	-	1118	O
the	-	1121	O
DNA	-	1125	O
repair	-	1129	O
proteins	-	1136	O
Ku70	-	1145	O
and	-	1150	O
Ku80	-	1154	O
.	-	1158	O

Mice	24812279	1160	O
with	-	1165	O
cardiomyocyte	-	1170	O
-	-	1183	O
restricted	-	1184	O
deletion	-	1195	O
of	-	1204	O
STAT3	-	1207	O
exhibited	-	1213	O
worse	-	1223	O
cardiac	-	1229	O
function	-	1237	O
,	-	1245	O
higher	-	1247	O
levels	-	1254	O
of	-	1261	O
cardiomyocyte	-	1264	O
apoptosis	-	1278	O
,	-	1287	O
and	-	1289	O
a	-	1293	O
greater	-	1295	O
induction	-	1303	O
of	-	1313	O
Ku70	-	1316	O
and	-	1321	O
Ku80	-	1325	O
in	-	1330	O
response	-	1333	O
to	-	1342	O
DOX	-	1345	O
treatment	-	1349	O
during	-	1359	O
the	-	1366	O
acute	-	1370	O
stage	-	1376	O
when	-	1382	O
compared	-	1387	O
with	-	1396	O
control	-	1401	O
animals	-	1409	O
.	-	1416	O

CONCLUSION	24812279	1418	O
:	-	1428	O

These	24812279	1430	O
data	-	1436	O
support	-	1441	O
a	-	1449	O
model	-	1451	O
wherein	-	1457	O
a	-	1465	O
p53	-	1467	O
-	-	1470	O
dependent	-	1471	O
cardioprotective	-	1481	O
pathway	-	1498	O
,	-	1505	O
mediated	-	1507	O
via	-	1516	O
STAT3	-	1520	O
activation	-	1526	O
,	-	1536	O
mitigates	-	1538	O
DOX	-	1548	O
-	-	1551	O
induced	-	1552	O
myocardial	-	1560	O
stress	-	1571	O
during	-	1578	O
drug	-	1585	O
delivery	-	1590	O
.	-	1598	O

Furthermore	24812279	1600	O
,	-	1611	O
these	-	1613	O
data	-	1619	O
suggest	-	1624	O
an	-	1632	O
explanation	-	1635	O
as	-	1647	O
to	-	1650	O
how	-	1653	O
p53	-	1657	O
inhibition	-	1661	O
can	-	1672	O
result	-	1676	O
in	-	1683	O
cardioprotection	-	1686	O
during	-	1703	O
drug	-	1710	O
treatment	-	1715	O
and	-	1725	O
,	-	1728	O
paradoxically	-	1730	O
,	-	1743	O
enhanced	-	1745	O
cardiotoxicity	-	1754	B
long	-	1769	O
after	-	1774	O
the	-	1780	O
cessation	-	1784	O
of	-	1794	O
drug	-	1797	O
treatment	-	1802	O
.	-	1811	O

Metronidazole	24816962	0	O
-	-	13	O
induced	-	14	O
encephalopathy	-	22	B
:	-	36	O
an	-	38	O
uncommon	-	41	O
scenario	-	50	O
.	-	58	O

Metronidazole	24816962	60	O
can	-	74	O
produce	-	78	O
neurological	-	86	O
complications	-	99	O
although	-	113	O
it	-	122	O
is	-	125	O
not	-	128	O
a	-	132	O
common	-	134	O
scenario	-	141	O
.	-	149	O

We	24816962	151	O
present	-	154	O
a	-	162	O
case	-	164	O
where	-	169	O
a	-	175	O
patient	-	177	O
developed	-	185	O
features	-	195	O
of	-	204	O
encephalopathy	-	207	B
following	-	222	O
prolonged	-	232	O
metronidazole	-	242	O
intake	-	256	O
.	-	262	O

Magnetic	24816962	264	O
resonance	-	273	O
imaging	-	283	O
(	-	291	O
MRI	-	292	O
)	-	295	O
brain	-	297	O
showed	-	303	O
abnormal	-	310	O
signal	-	319	O
intensity	-	326	O
involving	-	336	O
both	-	346	O
dentate	-	351	O
nuclei	-	359	O
of	-	366	O
cerebellum	-	369	O
and	-	380	O
splenium	-	384	O
of	-	393	O
corpus	-	396	O
callosum	-	403	O
.	-	411	O

The	24816962	413	O
diagnosis	-	417	O
of	-	427	O
metronidazole	-	430	O
toxicity	-	444	B
was	-	453	O
made	-	457	O
by	-	462	O
the	-	465	O
MRI	-	469	O
findings	-	473	O
and	-	482	O
supported	-	486	O
clinically	-	496	O
.	-	506	O

Aconitine	24840785	0	O
-	-	9	O
induced	-	10	O
Ca2	-	18	O
+	-	21	O
overload	-	23	O
causes	-	32	O
arrhythmia	-	39	B
and	-	50	O
triggers	-	54	O
apoptosis	-	63	O
through	-	73	O
p38	-	81	O
MAPK	-	85	O
signaling	-	90	O
pathway	-	100	O
in	-	108	O
rats	-	111	O
.	-	115	O

Aconitine	24840785	117	O
is	-	127	O
a	-	130	O
major	-	132	O
bioactive	-	138	O
diterpenoid	-	148	O
alkaloid	-	160	O
with	-	169	O
high	-	174	O
content	-	179	O
derived	-	187	O
from	-	195	O
herbal	-	200	O
aconitum	-	207	O
plants	-	216	O
.	-	222	O

Emerging	24840785	224	O
evidence	-	233	O
indicates	-	242	O
that	-	252	O
voltage	-	257	O
-	-	264	O
dependent	-	265	O
Na	-	275	O
(	-	277	O
+	-	278	O
)	-	279	O
channels	-	281	O
have	-	290	O
pivotal	-	295	O
roles	-	303	O
in	-	309	O
the	-	312	O
cardiotoxicity	-	316	B
of	-	331	O
aconitine	-	334	O
.	-	343	O

However	24840785	345	O
,	-	352	O
no	-	354	O
reports	-	357	O
are	-	365	O
available	-	369	O
on	-	379	O
the	-	382	O
role	-	386	O
of	-	391	O
Ca	-	394	O
(	-	396	O
2	-	397	O
+	-	398	O
)	-	399	O
in	-	401	O
aconitine	-	404	O
poisoning	-	414	B
.	-	423	O

In	24840785	425	O
this	-	428	O
study	-	433	O
,	-	438	O
we	-	440	O
explored	-	443	O
the	-	452	O
importance	-	456	O
of	-	467	O
pathological	-	470	O
Ca	-	483	O
(	-	485	O
2	-	486	O
+	-	487	O
)	-	488	O
signaling	-	490	O
in	-	500	O
aconitine	-	503	O
poisoning	-	513	B
in	-	523	O
vitro	-	526	O
and	-	532	O
in	-	536	O
vivo	-	539	O
.	-	543	O

We	24840785	545	O
found	-	548	O
that	-	554	O
Ca	-	559	O
(	-	561	O
2	-	562	O

+	24840785	563	O
)	-	564	O
overload	-	566	O
lead	-	575	O
to	-	580	O
accelerated	-	583	O
beating	-	595	O
rhythm	-	603	O
in	-	610	O
adult	-	613	O
rat	-	619	O
ventricular	-	623	O
myocytes	-	635	O
and	-	644	O
caused	-	648	O
arrhythmia	-	655	B
in	-	666	O
conscious	-	669	O
freely	-	679	O
moving	-	686	O
rats	-	693	O
.	-	697	O

To	24840785	699	O
investigate	-	702	O
effects	-	714	O
of	-	722	O
aconitine	-	725	O
on	-	735	O
myocardial	-	738	B
injury	-	749	I
,	-	755	O
we	-	757	O
performed	-	760	O
cytotoxicity	-	770	B
assay	-	783	O
in	-	789	O
neonatal	-	792	O
rat	-	801	O
ventricular	-	805	O
myocytes	-	817	O
(	-	826	O
NRVMs	-	827	O
)	-	832	O
,	-	833	O
as	-	835	O
well	-	838	O
as	-	843	O
measured	-	846	O
lactate	-	855	O
dehydrogenase	-	863	O
level	-	877	O
in	-	883	O
the	-	886	O
culture	-	890	O
medium	-	898	O
of	-	905	O
NRVMs	-	908	O
and	-	914	O
activities	-	918	O
of	-	929	O
serum	-	932	O
cardiac	-	938	O
enzymes	-	946	O
in	-	954	O
rats	-	957	O
.	-	961	O

The	24840785	963	O
results	-	967	O
showed	-	975	O
that	-	982	O
aconitine	-	987	O
resulted	-	997	O
in	-	1006	O
myocardial	-	1009	B
injury	-	1020	I
and	-	1027	O
reduced	-	1031	O
NRVMs	-	1039	O
viability	-	1045	O
dose	-	1055	O
-	-	1059	O
dependently	-	1060	O
.	-	1071	O

To	24840785	1073	O
confirm	-	1076	O
the	-	1084	O
pro	-	1088	O
-	-	1091	O
apoptotic	-	1092	O
effects	-	1102	O
,	-	1109	O
we	-	1111	O
performed	-	1114	O
flow	-	1124	O
cytometric	-	1129	O
detection	-	1140	O
,	-	1149	O
cardiac	-	1151	O
histology	-	1159	O
,	-	1168	O
transmission	-	1170	O
electron	-	1183	O
microscopy	-	1192	O
and	-	1203	O
terminal	-	1207	O
deoxynucleotidyl	-	1216	O
transferase	-	1233	O
-	-	1244	O
mediated	-	1245	O
dUTP	-	1254	O
-	-	1258	O
biotin	-	1259	O
nick	-	1266	O
end	-	1271	O
labeling	-	1275	O
assay	-	1284	O
.	-	1289	O

The	24840785	1291	O
results	-	1295	O
showed	-	1303	O
that	-	1310	O
aconitine	-	1315	O
stimulated	-	1325	O
apoptosis	-	1336	O
time	-	1346	O
-	-	1350	O
dependently	-	1351	O
.	-	1362	O

The	24840785	1364	O
expression	-	1368	O
analysis	-	1379	O
of	-	1388	O
Ca	-	1391	O
(	-	1393	O
2	-	1394	O
+	-	1395	O
)	-	1396	O
handling	-	1398	O
proteins	-	1407	O
demonstrated	-	1416	O
that	-	1429	O
aconitine	-	1434	O
promoted	-	1444	O
Ca	-	1453	O
(	-	1455	O
2	-	1456	O
+	-	1457	O
)	-	1458	O
overload	-	1460	O
through	-	1469	O
the	-	1477	O
expression	-	1481	O
regulation	-	1492	O
of	-	1503	O
Ca	-	1506	O
(	-	1508	O
2	-	1509	O
+	-	1510	O
)	-	1511	O
handling	-	1513	O
proteins	-	1522	O
.	-	1530	O

The	24840785	1532	O
expression	-	1536	O
analysis	-	1547	O
of	-	1556	O
apoptosis	-	1559	O
-	-	1568	O
related	-	1569	O
proteins	-	1577	O
revealed	-	1586	O
that	-	1595	O
pro	-	1600	O
-	-	1603	O
apoptotic	-	1604	O
protein	-	1614	O
expression	-	1622	O
was	-	1633	O
upregulated	-	1637	O
,	-	1648	O
and	-	1650	O
anti	-	1654	O
-	-	1658	O
apoptotic	-	1659	O
protein	-	1669	O
BCL	-	1677	O
-	-	1680	O
2	-	1681	O
expression	-	1683	O
was	-	1694	O
downregulated	-	1698	O
.	-	1711	O

Furthermore	24840785	1713	O
,	-	1724	O
increased	-	1726	O
phosphorylation	-	1736	O
of	-	1752	O
MAPK	-	1755	O
family	-	1760	O
members	-	1767	O
,	-	1774	O
especially	-	1776	O
the	-	1787	O
P	-	1791	O
-	-	1792	O
P38	-	1793	O
/	-	1796	O
P38	-	1797	O
ratio	-	1801	O
was	-	1807	O
found	-	1811	O
in	-	1817	O
cardiac	-	1820	O
tissues	-	1828	O
.	-	1835	O

Hence	24840785	1837	O
,	-	1842	O
our	-	1844	O
results	-	1848	O
suggest	-	1856	O
that	-	1864	O
aconitine	-	1869	O
significantly	-	1879	O
aggravates	-	1893	O
Ca	-	1904	O
(	-	1906	O
2	-	1907	O
+	-	1908	O
)	-	1909	O
overload	-	1911	O
and	-	1920	O
causes	-	1924	O
arrhythmia	-	1931	B
and	-	1942	O
finally	-	1946	O
promotes	-	1954	O
apoptotic	-	1963	O
development	-	1973	O
via	-	1985	O
phosphorylation	-	1989	O
of	-	2005	O
P38	-	2008	O
mitogen	-	2012	O
-	-	2019	O
activated	-	2020	O
protein	-	2030	O
kinase	-	2038	O
.	-	2044	O

Chronic	24842192	0	O
treatment	-	8	O
with	-	18	O
metformin	-	23	O
suppresses	-	33	O
toll	-	44	O
-	-	48	O
like	-	49	O
receptor	-	54	O
4	-	63	O
signaling	-	65	O
and	-	75	O
attenuates	-	79	O
left	-	90	B
ventricular	-	95	I
dysfunction	-	107	I
following	-	119	O
myocardial	-	129	B
infarction	-	140	I
.	-	150	O

Acute	24842192	152	O
treatment	-	158	O
with	-	168	O
metformin	-	173	O
has	-	183	O
a	-	187	O
protective	-	189	O
effect	-	200	O
in	-	207	O
myocardial	-	210	B
infarction	-	221	I
by	-	232	O
suppression	-	235	O
of	-	247	O
inflammatory	-	250	O
responses	-	263	O
due	-	273	O
to	-	277	O
activation	-	280	O
of	-	291	O
AMP	-	294	O
-	-	297	O
activated	-	298	O
protein	-	308	O
kinase	-	316	O
(	-	323	O
AMPK	-	324	O
)	-	328	O
.	-	329	O

In	24842192	331	O
the	-	334	O
present	-	338	O
study	-	346	O
,	-	351	O
the	-	353	O
effect	-	357	O
of	-	364	O
chronic	-	367	O
pre	-	375	O
-	-	378	O
treatment	-	379	O
with	-	389	O
metformin	-	394	O
on	-	404	O
cardiac	-	407	B
dysfunction	-	415	I
and	-	427	O
toll	-	431	O
-	-	435	O
like	-	436	O
receptor	-	441	O
4	-	450	O
(	-	452	O
TLR4	-	453	O
)	-	457	O
activities	-	459	O
following	-	470	O
myocardial	-	480	B
infarction	-	491	I
and	-	502	O
their	-	506	O
relation	-	512	O
with	-	521	O
AMPK	-	526	O
were	-	531	O
assessed	-	536	O
.	-	544	O

Male	24842192	546	O
Wistar	-	551	O
rats	-	558	O
were	-	563	O
randomly	-	568	O
assigned	-	577	O
to	-	586	O
one	-	589	O
of	-	593	O
5	-	596	O
groups	-	598	O
(	-	605	O
n	-	606	O
=	-	607	O
6	-	608	O
)	-	609	O
:	-	610	O
normal	-	612	O
control	-	619	O
and	-	627	O
groups	-	631	O
were	-	638	O
injected	-	643	O
isoproterenol	-	652	O
after	-	666	O
chronic	-	672	O
pre	-	680	O
-	-	683	O
treatment	-	684	O
with	-	694	O
0	-	699	O
,	-	700	O
25	-	702	O
,	-	704	O
50	-	706	O
,	-	708	O
or	-	710	O
100mg	-	713	O
/	-	718	O
kg	-	719	O
of	-	722	O
metformin	-	725	O
twice	-	735	O
daily	-	741	O
for	-	747	O
14	-	751	O
days	-	754	O
.	-	758	O

Isoproterenol	24842192	760	O
(	-	774	O
100mg	-	775	O
/	-	780	O
kg	-	781	O
)	-	783	O
was	-	785	O
injected	-	789	O
subcutaneously	-	798	O
on	-	813	O
the	-	816	O
13th	-	820	O
and	-	825	O
14th	-	829	O
days	-	834	O
to	-	839	O
induce	-	842	O
acute	-	849	B
myocardial	-	855	I
infarction	-	866	I
.	-	876	O

Isoproterenol	24842192	878	O
alone	-	892	O
decreased	-	898	O
left	-	908	O
ventricular	-	913	O
systolic	-	925	O
pressure	-	934	O
and	-	943	O
myocardial	-	947	O
contractility	-	958	O
indexed	-	972	O
as	-	980	O
LVdp	-	983	O
/	-	987	O
dtmax	-	988	O
and	-	994	O
LVdp	-	998	O
/	-	1002	O
dtmin	-	1003	O
.	-	1008	O

The	24842192	1010	O
left	-	1014	B
ventricular	-	1019	I
dysfunction	-	1031	I
was	-	1043	O
significantly	-	1047	O
lower	-	1061	O
in	-	1067	O
the	-	1070	O
groups	-	1074	O
treated	-	1081	O
with	-	1089	O
25	-	1094	O
and	-	1097	O
50mg	-	1101	O
/	-	1105	O
kg	-	1106	O
of	-	1109	O
metformin	-	1112	O
.	-	1121	O

Metfromin	24842192	1123	O
markedly	-	1133	O
lowered	-	1142	O
isoproterenol	-	1150	O
-	-	1163	O
induced	-	1164	O
elevation	-	1172	O
in	-	1182	O
the	-	1185	O
levels	-	1189	O
of	-	1196	O
TLR4	-	1199	O
mRNA	-	1204	O
,	-	1208	O
myeloid	-	1210	O
differentiation	-	1218	O
protein	-	1234	O
88	-	1242	O
(	-	1245	O
MyD88	-	1246	O
)	-	1251	O
,	-	1252	O
tumor	-	1254	B
necrosis	-	1260	B
factor	-	1269	O
-	-	1275	O
alpha	-	1276	O
(	-	1282	O
TNF	-	1283	O
-	-	1286	O
a	-	1287	O
)	-	1288	O
,	-	1289	O
and	-	1291	O
interleukin	-	1295	O
6	-	1307	O
(	-	1309	O
IL	-	1310	O
-	-	1312	O
6	-	1313	O
)	-	1314	O
in	-	1316	O
the	-	1319	O
heart	-	1323	O
tissues	-	1329	O
.	-	1336	O

Similar	24842192	1338	O
changes	-	1346	O
were	-	1354	O
also	-	1359	O
seen	-	1364	O
in	-	1369	O
the	-	1372	O
serum	-	1376	O
levels	-	1382	O
of	-	1389	O
TNF	-	1392	O
-	-	1395	O
a	-	1396	O
and	-	1398	O
IL	-	1402	O
-	-	1404	O
6	-	1405	O
.	-	1406	O

However	24842192	1408	O
,	-	1415	O
the	-	1417	O
lower	-	1421	O
doses	-	1427	O
of	-	1433	O
25	-	1436	O
and	-	1439	O
50mg	-	1443	O
/	-	1447	O
kg	-	1448	O
were	-	1451	O
more	-	1456	O
effective	-	1461	O
than	-	1471	O
100mg	-	1476	O
/	-	1481	O
kg	-	1482	O
.	-	1484	O

Phosphorylated	24842192	1486	O
AMPKa	-	1501	O
(	-	1507	O
p	-	1508	O
-	-	1509	O
AMPK	-	1510	O
)	-	1514	O
in	-	1516	O
the	-	1519	O
myocardium	-	1523	O
was	-	1534	O
significantly	-	1538	O
elevated	-	1552	O
by	-	1561	O
25mg	-	1564	O
/	-	1568	O
kg	-	1569	O
of	-	1572	O
metformin	-	1575	O
,	-	1584	O
slightly	-	1586	O
by	-	1595	O
50mg	-	1598	O
/	-	1602	O
kg	-	1603	O
,	-	1605	O
but	-	1607	O
not	-	1611	O
by	-	1615	O
100mg	-	1618	O
/	-	1623	O
kg	-	1624	O
.	-	1626	O

Chronic	24842192	1628	O
pre	-	1636	O
-	-	1639	O
treatment	-	1640	O
with	-	1650	O
metformin	-	1655	O
reduces	-	1665	O
post	-	1673	O
-	-	1677	O
myocardial	-	1678	B
infarction	-	1689	I
cardiac	-	1700	O
dysfunction	-	1708	O
and	-	1720	O
suppresses	-	1724	O
inflammatory	-	1735	O
responses	-	1748	O
,	-	1757	O
possibly	-	1759	O
through	-	1768	O
inhibition	-	1776	O
of	-	1787	O
TLR4	-	1790	O
activities	-	1795	O
.	-	1805	O

This	24842192	1807	O
mechanism	-	1812	O
can	-	1822	O
be	-	1826	O
considered	-	1829	O
as	-	1840	O
a	-	1843	O
target	-	1845	O
to	-	1852	O
protect	-	1855	O
infarcted	-	1863	O
myocardium	-	1873	O
.	-	1883	O

Neuroleptic	24881749	0	B
malignant	-	12	I
syndrome	-	22	I
induced	-	31	O
by	-	39	O
combination	-	42	O
therapy	-	54	O
with	-	62	O
tetrabenazine	-	67	O
and	-	81	O
tiapride	-	85	O
in	-	94	O
a	-	97	O
Japanese	-	99	O
patient	-	108	O
with	-	116	O
Huntington	-	121	B
's	-	131	I
disease	-	134	I
at	-	142	O
the	-	145	O
terminal	-	149	O
stage	-	158	O
of	-	164	O
recurrent	-	167	O
breast	-	177	B
cancer	-	184	I
.	-	190	O

We	24881749	192	O
herein	-	195	O
describe	-	202	O
the	-	211	O
case	-	215	O
of	-	220	O
an	-	223	O
81	-	226	O
-	-	228	O
year	-	229	O
-	-	233	O
old	-	234	O
Japanese	-	238	O
woman	-	247	O
with	-	253	O
neuroleptic	-	258	B
malignant	-	270	I
syndrome	-	280	I
that	-	289	O
occurred	-	294	O
36	-	303	O
days	-	306	O
after	-	311	O
the	-	317	O
initiation	-	321	O
of	-	332	O
combination	-	335	O
therapy	-	347	O
with	-	355	O
tiapride	-	360	O
(	-	369	O
75	-	370	O
mg	-	373	O
/	-	375	O
day	-	376	O
)	-	379	O
and	-	381	O
tetrabenazine	-	385	O
(	-	399	O
12	-	400	O
.	-	402	O
5	-	403	O
mg	-	405	O
/	-	407	O
day	-	408	O
)	-	411	O
for	-	413	O
Huntington	-	417	B
's	-	427	I
disease	-	430	I
.	-	437	O

The	24881749	439	O
patient	-	443	O
had	-	451	O
been	-	455	O
treated	-	460	O
with	-	468	O
tiapride	-	473	O
or	-	482	O
tetrabenazine	-	485	O
alone	-	499	O
without	-	505	O
any	-	513	O
adverse	-	517	O
effects	-	525	O
before	-	533	O
the	-	540	O
administration	-	544	O
of	-	559	O
the	-	562	O
combination	-	566	O
therapy	-	578	O
.	-	585	O

She	24881749	587	O
also	-	591	O
had	-	596	O
advanced	-	600	O
breast	-	609	B
cancer	-	616	I
when	-	623	O
the	-	628	O
combination	-	632	O
therapy	-	644	O
was	-	652	O
initiated	-	656	O
.	-	665	O

To	24881749	667	O
the	-	670	O
best	-	674	O
of	-	679	O
our	-	682	O
knowledge	-	686	O
,	-	695	O
the	-	697	O
occurrence	-	701	O
of	-	712	O
neuroleptic	-	715	B
malignant	-	727	I
syndrome	-	737	I
due	-	746	O
to	-	750	O
combination	-	753	O
therapy	-	765	O
with	-	773	O
tetrabenazine	-	778	O
and	-	792	O
tiapride	-	796	O
has	-	805	O
not	-	809	O
been	-	813	O
previously	-	818	O
reported	-	829	O
.	-	837	O

Tetrabenazine	24881749	839	O
should	-	853	O
be	-	860	O
administered	-	863	O
very	-	876	O
carefully	-	881	O
in	-	891	O
combination	-	894	O
with	-	906	O
other	-	911	O
neuroleptic	-	917	O
drugs	-	929	O
,	-	934	O
particularly	-	936	O
in	-	949	O
patients	-	952	O
with	-	961	O
a	-	966	O
worsening	-	968	O
general	-	978	O
condition	-	986	O
.	-	995	O

A	24894748	0	O
metoprolol	-	2	O
-	-	12	O
terbinafine	-	13	O
combination	-	25	O
induced	-	37	O
bradycardia	-	45	B
.	-	56	O

To	24894748	58	O
report	-	61	O
a	-	68	O
sinus	-	70	B
bradycardia	-	76	I
induced	-	88	O
by	-	96	O
metoprolol	-	99	O
and	-	110	O
terbinafine	-	114	O
drug	-	126	O
-	-	130	O
drug	-	131	O
interaction	-	136	O
and	-	148	O
its	-	152	O
management	-	156	O
.	-	166	O

A	24894748	168	O
63	-	170	O
year	-	173	O
-	-	177	O
old	-	178	O
Caucasian	-	182	O
man	-	192	O
on	-	196	O
metoprolol	-	199	O
200	-	210	O
mg	-	214	O
/	-	216	O
day	-	217	O
for	-	221	O
stable	-	225	O
coronary	-	232	B
artery	-	241	I
disease	-	248	I
was	-	256	O
prescribed	-	260	O
a	-	271	O
90	-	273	O
-	-	275	O
day	-	276	O
course	-	280	O
of	-	287	O
oral	-	290	O
terbinafine	-	295	O
250	-	307	O
mg	-	311	O
/	-	313	O
day	-	314	O
for	-	318	O
onychomycosis	-	322	B
.	-	335	O

On	24894748	337	O
the	-	340	O
49th	-	344	O
day	-	349	O
of	-	353	O
terbinafine	-	356	O
therapy	-	368	O
,	-	375	O
he	-	377	O
was	-	380	O
brought	-	384	O
to	-	392	O
the	-	395	O
emergency	-	399	O
room	-	409	O
for	-	414	O
a	-	418	O
decrease	-	420	O
of	-	429	O
his	-	432	O
global	-	436	O
health	-	443	O
status	-	450	O
,	-	456	O
confusion	-	458	B
and	-	468	O
falls	-	472	O
.	-	477	O

The	24894748	479	O
electrocardiogram	-	483	O
revealed	-	501	O
a	-	510	O
37	-	512	O
beats	-	515	O
/	-	520	O
min	-	521	O
sinus	-	525	B
bradycardia	-	531	I
.	-	542	O

A	24894748	544	O
score	-	546	O
of	-	552	O
7	-	555	O
on	-	557	O
the	-	560	O
Naranjo	-	564	O
adverse	-	572	B
drug	-	580	I
reaction	-	585	I
probability	-	594	O
scale	-	606	O
indicates	-	612	O
a	-	622	O
probable	-	624	O
relationship	-	633	O
between	-	646	O
the	-	654	O
patient	-	658	O
's	-	665	O
sinus	-	668	B
bradycardia	-	674	I
and	-	686	O
the	-	690	O
drug	-	694	O
interaction	-	699	O
between	-	711	O
metoprolol	-	719	O
and	-	730	O
terbinafine	-	734	O
.	-	745	O

The	24894748	747	O
heart	-	751	O
rate	-	757	O
ameliorated	-	762	O
first	-	774	O
with	-	780	O
a	-	785	O
decrease	-	787	O
in	-	796	O
the	-	799	O
dose	-	803	O
of	-	808	O
metoprolol	-	811	O
.	-	821	O

It	24894748	823	O
was	-	826	O
subsequently	-	830	O
changed	-	843	O
to	-	851	O
bisoprolol	-	854	O
and	-	865	O
the	-	869	O
heart	-	873	O
rate	-	879	O
remained	-	884	O
normal	-	893	O
.	-	899	O

By	24894748	901	O
inhibiting	-	904	O
the	-	915	O
cytochrome	-	919	O
P450	-	930	O
2D6	-	935	O
,	-	938	O
terbinafine	-	940	O
had	-	952	O
decreased	-	956	O
metoprolol	-	966	O
's	-	976	O
clearance	-	979	O
,	-	988	O
leading	-	990	O
in	-	998	O
metoprolol	-	1001	O
accumulation	-	1012	O
which	-	1025	O
has	-	1031	O
resulted	-	1035	O
in	-	1044	O
clinically	-	1047	O
significant	-	1058	O
sinus	-	1070	B
bradycardia	-	1076	I
.	-	1087	O

Optochiasmatic	24897009	0	O
and	-	15	O
peripheral	-	19	B
neuropathy	-	30	I
due	-	41	O
to	-	45	O
ethambutol	-	48	O
overtreatment	-	59	O
.	-	72	O

Ethambutol	24897009	74	O
is	-	85	O
known	-	88	O
to	-	94	O
cause	-	97	O
optic	-	103	B
neuropathy	-	109	I
and	-	120	O
,	-	123	O
more	-	125	O
rarely	-	130	O
,	-	136	O
axonal	-	138	O
polyneuropathy	-	145	B
.	-	159	O

We	24897009	161	O
characterize	-	164	O
the	-	177	O
clinical	-	181	O
,	-	189	O
neurophysiological	-	191	O
,	-	209	O
and	-	211	O
neuroimaging	-	215	O
findings	-	228	O
in	-	237	O
a	-	240	O
72	-	242	O
-	-	244	O
year	-	245	O
-	-	249	O
old	-	250	O
man	-	254	O
who	-	258	O
developed	-	262	O
visual	-	272	B
loss	-	279	I
and	-	284	O
paresthesias	-	288	B
after	-	301	O
11	-	307	O
weeks	-	310	O
of	-	316	O
exposure	-	319	O
to	-	328	O
a	-	331	O
supratherapeutic	-	333	O
dose	-	350	O
of	-	355	O
ethambutol	-	358	O
.	-	368	O

This	24897009	370	O
case	-	375	O
demonstrates	-	380	O
the	-	393	O
selective	-	397	O
vulnerability	-	407	O
of	-	421	O
the	-	424	O
anterior	-	428	O
visual	-	437	O
pathways	-	444	O
and	-	453	O
peripheral	-	457	O
nerves	-	468	O
to	-	475	O
ethambutol	-	478	O
toxicity	-	489	B
.	-	497	O

Testosterone	24902786	0	O
ameliorates	-	13	O
streptozotocin	-	25	O
-	-	39	O
induced	-	40	O
memory	-	48	B
impairment	-	55	I
in	-	66	O
male	-	69	O
rats	-	74	O
.	-	78	O

AIM	24902786	80	O
:	-	83	O

To	24902786	85	O
study	-	88	O
the	-	94	O
effects	-	98	O
of	-	106	O
testosterone	-	109	O
on	-	122	O
streptozotocin	-	125	O
(	-	140	O
STZ	-	141	O
)	-	144	O
-	-	145	O
induced	-	146	O
memory	-	154	B
impairment	-	161	I
in	-	172	O
male	-	175	O
rats	-	180	O
.	-	184	O

METHODS	24902786	186	O
:	-	193	O

Adult	24902786	195	O
male	-	201	O
Wistar	-	206	O
rats	-	213	O
were	-	218	O
intracerebroventricularly	-	223	O
(	-	249	O
icv	-	250	O
)	-	253	O
infused	-	255	O
with	-	263	O
STZ	-	268	O
(	-	272	O
750	-	273	O
ug	-	277	O
)	-	279	O
on	-	281	O
d	-	284	O
1	-	286	O
and	-	288	O
d	-	292	O
3	-	294	O
,	-	295	O
and	-	297	O
a	-	301	O
passive	-	303	O
avoidance	-	311	O
task	-	321	O
was	-	326	O
assessed	-	330	O
2	-	339	O
weeks	-	341	O
after	-	347	O
the	-	353	O
first	-	357	O
injection	-	363	O
of	-	373	O
STZ	-	376	O
.	-	379	O

Castration	24902786	381	O
surgery	-	392	O
was	-	400	O
performed	-	404	O
in	-	414	O
another	-	417	O
group	-	425	O
of	-	431	O
rats	-	434	O
,	-	438	O
and	-	440	O
the	-	444	O
passive	-	448	O
avoidance	-	456	O
task	-	466	O
was	-	471	O
assessed	-	475	O
4	-	484	O
weeks	-	486	O
after	-	492	O
the	-	498	O
operation	-	502	O
.	-	511	O

Testosterone	24902786	513	O
(	-	526	O
1	-	527	O
mg	-	529	O
.	-	531	O
kg	-	532	O
(	-	534	O
-	-	535	O
1	-	536	O
)	-	537	O
.	-	538	O
d	-	539	O
(	-	540	O
-	-	541	O
1	-	542	O
)	-	543	O
,	-	544	O
sc	-	546	O
)	-	548	O
,	-	549	O
the	-	551	O
androgen	-	555	O
receptor	-	564	O
antagonist	-	573	O
flutamide	-	584	O
(	-	594	O
10	-	595	O
mg	-	598	O
.	-	600	O
kg	-	601	O
(	-	603	O
-	-	604	O
1	-	605	O
)	-	606	O
.	-	607	O
d	-	608	O
(	-	609	O
-	-	610	O
1	-	611	O
)	-	612	O
,	-	613	O
ip	-	615	O
)	-	617	O
,	-	618	O
the	-	620	O
estrogen	-	624	O
receptor	-	633	O
antagonist	-	642	O
tamoxifen	-	653	O
(	-	663	O
1	-	664	O
mg	-	666	O
.	-	668	O
kg	-	669	O
(	-	671	O
-	-	672	O
1	-	673	O
)	-	674	O
.	-	675	O
d	-	676	O
(	-	677	O
-	-	678	O
1	-	679	O
)	-	680	O
,	-	681	O
ip	-	683	O
)	-	685	O
or	-	687	O
the	-	690	O
aromatase	-	694	O
inhibitor	-	704	O
letrozole	-	714	O
(	-	724	O
4	-	725	O
mg	-	727	O
.	-	729	O
kg	-	730	O
(	-	732	O
-	-	733	O
1	-	734	O
)	-	735	O
.	-	736	O
d	-	737	O
(	-	738	O
-	-	739	O
1	-	740	O
)	-	741	O
,	-	742	O
ip	-	744	O
)	-	746	O
were	-	748	O
administered	-	753	O
for	-	766	O
6	-	770	O
d	-	772	O
after	-	774	O
the	-	780	O
first	-	784	O
injection	-	790	O
of	-	800	O
STZ	-	803	O
.	-	806	O

RESULTS	24902786	808	O
:	-	815	O

STZ	24902786	817	O
administration	-	821	O
and	-	836	O
castration	-	840	O
markedly	-	851	O
decreased	-	860	O
both	-	870	O
STL1	-	875	O
(	-	880	O
the	-	881	O
short	-	885	O
memory	-	891	O
)	-	897	O
and	-	899	O
STL2	-	903	O
(	-	908	O
the	-	909	O
long	-	913	O
memory	-	918	O
)	-	924	O
in	-	926	O
passive	-	929	O
avoidance	-	937	O
tests	-	947	O
.	-	952	O

Testosterone	24902786	954	O
replacement	-	967	O
almost	-	979	O
restored	-	986	O
the	-	995	O
STL1	-	999	O
and	-	1004	O
STL2	-	1008	O
in	-	1013	O
castrated	-	1016	O
rats	-	1026	O
,	-	1030	O
and	-	1032	O
significantly	-	1036	O
prolonged	-	1050	O
the	-	1060	O
STL1	-	1064	O
and	-	1069	O
STL2	-	1073	O
in	-	1078	O
STZ	-	1081	O
-	-	1084	O
treated	-	1085	O
rats	-	1093	O
.	-	1097	O

Administration	24902786	1099	O
of	-	1114	O
flutamide	-	1117	O
,	-	1126	O
letrozole	-	1128	O
or	-	1138	O
tamoxifen	-	1141	O
significantly	-	1151	O
impaired	-	1165	B
the	-	1174	I
memory	-	1178	I
in	-	1185	O
intact	-	1188	O
rats	-	1195	O
,	-	1199	O
and	-	1201	O
significantly	-	1205	O
attenuated	-	1219	O
the	-	1230	O
testosterone	-	1234	O
replacement	-	1247	O
in	-	1259	O
improving	-	1262	O
STZ	-	1272	O
-	-	1275	O
and	-	1277	O
castration	-	1281	O
-	-	1291	O
induced	-	1292	O
memory	-	1300	B
impairment	-	1307	I
.	-	1317	O

CONCLUSION	24902786	1319	O
:	-	1329	O

Testosterone	24902786	1331	O
administration	-	1344	O
ameliorates	-	1359	O
STZ	-	1371	O
-	-	1374	O
and	-	1376	O
castration	-	1380	O
-	-	1390	O
induced	-	1391	O
memory	-	1399	B
impairment	-	1406	I
in	-	1417	O
male	-	1420	O
Wistar	-	1425	O
rats	-	1432	O
.	-	1436	O

Behavioral	24911645	0	O
and	-	11	O
neurochemical	-	15	O
studies	-	29	O
in	-	37	O
mice	-	40	O
pretreated	-	45	O
with	-	56	O
garcinielliptone	-	61	O
FC	-	78	O
in	-	81	O
pilocarpine	-	84	O
-	-	95	O
induced	-	96	O
seizures	-	104	B
.	-	112	O

Garcinielliptone	24911645	114	O
FC	-	131	O
(	-	134	O
GFC	-	135	O
)	-	138	O
isolated	-	140	O
from	-	149	O
hexanic	-	154	O
fraction	-	162	O
seed	-	171	O
extract	-	176	O
of	-	184	O
species	-	187	O
Platonia	-	195	O
insignis	-	204	O
Mart	-	213	O
.	-	217	O

It	24911645	219	O
is	-	222	O
widely	-	225	O
used	-	232	O
in	-	237	O
folk	-	240	O
medicine	-	245	O
to	-	254	O
treat	-	257	O
skin	-	263	B
diseases	-	268	I
in	-	277	O
both	-	280	O
humans	-	285	O
and	-	292	O
animals	-	296	O
as	-	304	O
well	-	307	O
as	-	312	O
the	-	315	O
seed	-	319	O
decoction	-	324	O
has	-	334	O
been	-	338	O
used	-	343	O
to	-	348	O
treat	-	351	O
diarrheas	-	357	B
and	-	367	O
inflammatory	-	371	B
diseases	-	384	I
.	-	392	O

However	24911645	394	O
,	-	401	O
there	-	403	O
is	-	409	O
no	-	412	O
research	-	415	O
on	-	424	O
GFC	-	427	O
effects	-	431	O
in	-	439	O
the	-	442	O
central	-	446	O
nervous	-	454	O
system	-	462	O
of	-	469	O
rodents	-	472	O
.	-	479	O

The	24911645	481	O
present	-	485	O
study	-	493	O
aimed	-	499	O
to	-	505	O
evaluate	-	508	O
the	-	517	O
GFC	-	521	O
effects	-	525	O
at	-	533	O
doses	-	536	O
of	-	542	O
25	-	545	O
,	-	547	O
50	-	549	O
or	-	552	O
75	-	555	O
mg	-	558	O
/	-	560	O
kg	-	561	O
on	-	564	O
seizure	-	567	B
parameters	-	575	O
to	-	586	O
determine	-	589	O
their	-	599	O
anticonvulsant	-	605	O
activity	-	620	O
and	-	629	O
its	-	633	O
effects	-	637	O
on	-	645	O
amino	-	648	O
acid	-	654	O
(	-	659	O
r	-	660	O
-	-	661	O
aminobutyric	-	662	O
acid	-	675	O
(	-	680	O
GABA	-	681	O
)	-	685	O
,	-	686	O
glutamine	-	688	O
,	-	697	O
aspartate	-	699	O
and	-	709	O
glutathione	-	713	O
)	-	724	O
levels	-	726	O
as	-	733	O
well	-	736	O
as	-	741	O
on	-	744	O
acetylcholinesterase	-	747	O
(	-	768	O
AChE	-	769	O
)	-	773	O
activity	-	775	O
in	-	784	O
mice	-	787	O
hippocampus	-	792	O
after	-	804	O
seizures	-	810	B
.	-	818	O

GFC	24911645	820	O
produced	-	824	O
an	-	833	O
increased	-	836	O
latency	-	846	O
to	-	854	O
first	-	857	O
seizure	-	863	B
,	-	870	O
at	-	872	O
doses	-	875	O
25mg	-	881	O
/	-	885	O
kg	-	886	O
(	-	889	O
20	-	890	O
.	-	892	O
12	-	893	O
+	-	896	O
2	-	898	O
.	-	899	O
20	-	900	O
min	-	903	O
)	-	906	O
,	-	907	O
50mg	-	909	O
/	-	913	O
kg	-	914	O
(	-	917	O
20	-	918	O
.	-	920	O
95	-	921	O
+	-	924	O
2	-	926	O
.	-	927	O
21	-	928	O
min	-	931	O
)	-	934	O
or	-	936	O
75	-	939	O
mg	-	942	O
/	-	944	O
kg	-	945	O
(	-	948	O
23	-	949	O
.	-	951	O
43	-	952	O
+	-	955	O
1	-	957	O
.	-	958	O
99	-	959	O
min	-	962	O
)	-	965	O
when	-	967	O
compared	-	972	O
with	-	981	O
seized	-	986	O
mice	-	993	O
.	-	997	O

In	24911645	999	O
addition	-	1002	O
,	-	1010	O
GABA	-	1012	O
content	-	1017	O
of	-	1025	O
mice	-	1028	O
hippocampus	-	1033	O
treated	-	1045	O
with	-	1053	O
GFC75	-	1058	O
plus	-	1064	O
P400	-	1069	O
showed	-	1074	O
an	-	1081	O
increase	-	1084	O
of	-	1093	O
46	-	1096	O
.	-	1098	O
90	-	1099	O
%	-	1101	O
when	-	1103	O
compared	-	1108	O
with	-	1117	O
seized	-	1122	O
mice	-	1129	O
.	-	1133	O

In	24911645	1135	O
aspartate	-	1138	O
,	-	1147	O
glutamine	-	1149	O
and	-	1159	O
glutamate	-	1163	O
levels	-	1173	O
detected	-	1180	O
a	-	1189	O
decrease	-	1191	O
of	-	1200	O
5	-	1203	O
.	-	1204	O
21	-	1205	O
%	-	1207	O
,	-	1208	O
13	-	1210	O
.	-	1212	O
55	-	1213	O
%	-	1215	O
and	-	1217	O
21	-	1221	O
.	-	1223	O
80	-	1224	O
%	-	1226	O
,	-	1227	O
respectively	-	1229	O
in	-	1242	O
mice	-	1245	O
hippocampus	-	1250	O
treated	-	1262	O
with	-	1270	O
GFC75	-	1275	O
plus	-	1281	O
P400	-	1286	O
when	-	1291	O
compared	-	1296	O
with	-	1305	O
seized	-	1310	O
mice	-	1317	O
.	-	1321	O

Hippocampus	24911645	1323	O
mice	-	1335	O
treated	-	1340	O
with	-	1348	O
GFC75	-	1353	O
plus	-	1359	O
P400	-	1364	O
showed	-	1369	O
an	-	1376	O
increase	-	1379	O
in	-	1388	O
AChE	-	1391	O
activity	-	1396	O
(	-	1405	O
63	-	1406	O
.	-	1408	O
30	-	1409	O
%	-	1411	O
)	-	1412	O
when	-	1414	O
compared	-	1419	O
with	-	1428	O
seized	-	1433	O
mice	-	1440	O
.	-	1444	O

The	24911645	1446	O
results	-	1450	O
indicate	-	1458	O
that	-	1467	O
GFC	-	1472	O
can	-	1476	O
exert	-	1480	O
anticonvulsant	-	1486	O
activity	-	1501	O
and	-	1510	O
reduce	-	1514	O
the	-	1521	O
frequency	-	1525	O
of	-	1535	O
installation	-	1538	O
of	-	1551	O
pilocarpine	-	1554	O
-	-	1565	O
induced	-	1566	O
status	-	1574	B
epilepticus	-	1581	I
,	-	1592	O
as	-	1594	O
demonstrated	-	1597	O
by	-	1610	O
increase	-	1613	O
in	-	1622	O
latency	-	1625	O
to	-	1633	O
first	-	1636	O
seizure	-	1642	B
and	-	1650	O
decrease	-	1654	O
in	-	1663	O
mortality	-	1666	O
rate	-	1676	O
of	-	1681	O
animals	-	1684	O
.	-	1691	O

In	24911645	1693	O
conclusion	-	1696	O
,	-	1706	O
our	-	1708	O
data	-	1712	O
suggest	-	1717	O
that	-	1725	O
GFC	-	1730	O
may	-	1734	O
influence	-	1738	O
in	-	1748	O
epileptogenesis	-	1751	O
and	-	1767	O
promote	-	1771	O
anticonvulsant	-	1779	O
actions	-	1794	O
in	-	1802	O
pilocarpine	-	1805	O
model	-	1817	O
by	-	1823	O
modulating	-	1826	O
the	-	1837	O
GABA	-	1841	O
and	-	1846	O
glutamate	-	1850	O
contents	-	1860	O
and	-	1869	O
of	-	1873	O
AChE	-	1876	O
activity	-	1881	O
in	-	1890	O
seized	-	1893	O
mice	-	1900	O
hippocampus	-	1905	O
.	-	1916	O

This	24911645	1918	O
compound	-	1923	O
may	-	1932	O
be	-	1936	O
useful	-	1939	O
to	-	1946	O
produce	-	1949	O
neuronal	-	1957	O
protection	-	1966	O
and	-	1977	O
it	-	1981	O
can	-	1984	O
be	-	1988	O
considered	-	1991	O
as	-	2002	O
an	-	2005	O
anticonvulsant	-	2008	O
agent	-	2023	O
.	-	2028	O

Standard	24923469	0	O
operating	-	9	O
procedures	-	19	O
for	-	30	O
antibiotic	-	34	O
therapy	-	45	O
and	-	53	O
the	-	57	O
occurrence	-	61	O
of	-	72	O
acute	-	75	B
kidney	-	81	I
injury	-	88	I
:	-	94	O
a	-	96	O
prospective	-	98	O
,	-	109	O
clinical	-	111	O
,	-	119	O
non	-	121	O
-	-	124	O
interventional	-	125	O
,	-	139	O
observational	-	141	O
study	-	155	O
.	-	160	O

INTRODUCTION	24923469	162	O
:	-	174	O

Acute	24923469	176	B
kidney	-	182	I
injury	-	189	I
(	-	196	O
AKI	-	197	B
)	-	200	O
occurs	-	202	O
in	-	209	O
7	-	212	O
%	-	213	O
of	-	215	O
hospitalized	-	218	O
and	-	231	O
66	-	235	O
%	-	237	O
of	-	239	O
Intensive	-	242	O
Care	-	252	O
Unit	-	257	O
(	-	262	O
ICU	-	263	O
)	-	266	O
patients	-	268	O
.	-	276	O

It	24923469	278	O
increases	-	281	O
mortality	-	291	O
,	-	300	O
hospital	-	302	O
length	-	311	O
of	-	318	O
stay	-	321	O
,	-	325	O
and	-	327	O
costs	-	331	O
.	-	336	O

The	24923469	338	O
aim	-	342	O
of	-	346	O
this	-	349	O
study	-	354	O
was	-	360	O
to	-	364	O
investigate	-	367	O
,	-	378	O
whether	-	380	O
there	-	388	O
is	-	394	O
an	-	397	O
association	-	400	O
between	-	412	O
adherence	-	420	O
to	-	430	O
guidelines	-	433	O
(	-	444	O
standard	-	445	O
operating	-	454	O
procedures	-	464	O
(	-	475	O
SOP	-	476	O
)	-	479	O
)	-	480	O
for	-	482	O
potentially	-	486	O
nephrotoxic	-	498	B
antibiotics	-	510	O
and	-	522	O
the	-	526	O
occurrence	-	530	O
of	-	541	O
AKI	-	544	B
.	-	547	O

METHODS	24923469	549	O
:	-	556	O

This	24923469	558	O
study	-	563	O
was	-	569	O
carried	-	573	O
out	-	581	O
as	-	585	O
a	-	588	O
prospective	-	590	O
,	-	601	O
clinical	-	603	O
,	-	611	O
non	-	613	O
-	-	616	O
interventional	-	617	O
,	-	631	O
observational	-	633	O
study	-	647	O
.	-	652	O

Data	24923469	654	O
collection	-	659	O
was	-	670	O
performed	-	674	O
over	-	684	O
a	-	689	O
total	-	691	O
of	-	697	O
170	-	700	O
days	-	704	O
in	-	709	O
three	-	712	O
ICUs	-	718	O
at	-	723	O
Charite	-	726	O
-	-	734	O
Universitaetsmedizin	-	736	O
Berlin	-	757	O
.	-	763	O

A	24923469	765	O
total	-	767	O
of	-	773	O
675	-	776	O
patients	-	780	O
were	-	789	O
included	-	794	O
;	-	802	O
163	-	804	O
of	-	808	O
these	-	811	O
had	-	817	O
therapy	-	821	O
with	-	829	O
vancomycin	-	834	O
,	-	844	O
gentamicin	-	846	O
,	-	856	O
or	-	858	O
tobramycin	-	861	O
;	-	871	O
were	-	873	O
>	-	878	O
18	-	879	O
years	-	882	O
;	-	887	O
and	-	889	O
treated	-	893	O
in	-	901	O
the	-	904	O
ICU	-	908	O
for	-	912	O
>	-	916	O
24	-	917	O
hours	-	920	O
.	-	925	O

Patients	24923469	927	O
with	-	936	O
an	-	941	O
adherence	-	944	O
to	-	954	O
SOP	-	957	O
>	-	961	O
70	-	962	O
%	-	964	O
were	-	966	O
classified	-	971	O
into	-	982	O
the	-	987	O
high	-	991	O
adherence	-	996	O
group	-	1006	O
(	-	1012	O
HAG	-	1013	O
)	-	1016	O
and	-	1018	O
patients	-	1022	O
with	-	1031	O
an	-	1036	O
adherence	-	1039	O
of	-	1049	O
<	-	1052	O
70	-	1053	O
%	-	1055	O
into	-	1057	O
the	-	1062	O
low	-	1066	O
adherence	-	1070	O
group	-	1080	O
(	-	1086	O
LAG	-	1087	O
)	-	1090	O
.	-	1091	O

AKI	24923469	1093	B
was	-	1097	O
defined	-	1101	O
according	-	1109	O
to	-	1119	O
RIFLE	-	1122	O
criteria	-	1128	O
.	-	1136	O

Adherence	24923469	1138	O
to	-	1148	O
SOPs	-	1151	O
was	-	1156	O
evaluated	-	1160	O
by	-	1170	O
retrospective	-	1173	O
expert	-	1187	O
audit	-	1194	O
.	-	1199	O

Development	24923469	1201	O
of	-	1213	O
AKI	-	1216	B
was	-	1220	O
compared	-	1224	O
between	-	1233	O
groups	-	1241	O
with	-	1248	O
exact	-	1253	O
Chi2	-	1259	O
-	-	1263	O
test	-	1264	O
and	-	1269	O
multivariate	-	1273	O
logistic	-	1286	O
regression	-	1295	O
analysis	-	1306	O
(	-	1315	O
two	-	1316	O
-	-	1319	O
sided	-	1320	O
P	-	1326	O
<	-	1328	O
0	-	1329	O
.	-	1330	O
05	-	1331	O
)	-	1333	O
.	-	1334	O

RESULTS	24923469	1336	O
:	-	1343	O

LAG	24923469	1345	O
consisted	-	1349	O
of	-	1359	O
75	-	1362	O
patients	-	1365	O
(	-	1374	O
46	-	1375	O
%	-	1377	O
)	-	1378	O
versus	-	1380	O
88	-	1387	O
HAG	-	1390	O
patients	-	1394	O
(	-	1403	O
54	-	1404	O
%	-	1406	O
)	-	1407	O
.	-	1408	O

AKI	24923469	1410	B
occurred	-	1414	O
significantly	-	1423	O
more	-	1437	O
often	-	1442	O
in	-	1448	O
LAG	-	1451	O
with	-	1455	O
36	-	1460	O
%	-	1462	O
versus	-	1464	O
21	-	1471	O
%	-	1473	O
in	-	1475	O
HAG	-	1478	O
(	-	1482	O
P	-	1483	O
=	-	1485	O
0	-	1487	O
.	-	1488	O
035	-	1489	O
)	-	1492	O
.	-	1493	O

Basic	24923469	1495	O
characteristics	-	1501	O
were	-	1517	O
comparable	-	1522	O
,	-	1532	O
except	-	1534	O
an	-	1541	O
increased	-	1544	O
rate	-	1554	O
of	-	1559	O
soft	-	1562	O
tissue	-	1567	O
infections	-	1574	B
in	-	1585	O
LAG	-	1588	O
.	-	1591	O

Multivariate	24923469	1593	O
analysis	-	1606	O
revealed	-	1615	O
an	-	1624	O
odds	-	1627	O
ratio	-	1632	O
of	-	1638	O
2	-	1641	O
.	-	1642	O
5	-	1643	O
-	-	1644	O
fold	-	1645	O
for	-	1650	O
LAG	-	1654	O
to	-	1658	O
develop	-	1661	O
AKI	-	1669	B
compared	-	1673	O
with	-	1682	O
HAG	-	1687	O
(	-	1691	O
95	-	1692	O
%	-	1694	O
confidence	-	1696	O
interval	-	1707	O
1	-	1716	O
.	-	1717	O
195	-	1718	O
to	-	1722	O
5	-	1725	O
.	-	1726	O
124	-	1727	O
,	-	1730	O
P	-	1732	O
=	-	1734	O
0	-	1736	O
.	-	1737	O
039	-	1738	O
)	-	1741	O
.	-	1742	O

CONCLUSION	24923469	1744	O
:	-	1754	O

Low	24923469	1756	O
adherence	-	1760	O
to	-	1770	O
SOPs	-	1773	O
for	-	1778	O
potentially	-	1782	O
nephrotoxic	-	1794	B
antibiotics	-	1806	O
was	-	1818	O
associated	-	1822	O
with	-	1833	O
a	-	1838	O
higher	-	1840	O
occurrence	-	1847	O
of	-	1858	O
AKI	-	1861	B
.	-	1864	O

TRIAL	24923469	1866	O
REGISTRATION	-	1872	O
:	-	1884	O

Current	24923469	1886	O
Controlled	-	1894	O
Trials	-	1905	O
ISRCTN54598675	-	1912	O
.	-	1926	O

Registered	24923469	1928	O
17	-	1939	O
August	-	1942	O
2007	-	1949	O
.	-	1953	O

Rhabdomyolysis	24927617	0	B
in	-	15	O
a	-	18	O
hepatitis	-	20	B
C	-	30	I
virus	-	32	I
infected	-	38	I
patient	-	47	O
treated	-	55	O
with	-	63	O
telaprevir	-	68	O
and	-	79	O
simvastatin	-	83	O
.	-	94	O

A	24927617	96	O
46	-	98	O
-	-	100	O
year	-	101	O
old	-	106	O
man	-	110	O
with	-	114	O
a	-	119	O
chronic	-	121	O
hepatitis	-	129	B
C	-	139	I
virus	-	141	I
infection	-	147	I
received	-	157	O
triple	-	166	O
therapy	-	173	O
with	-	181	O
ribavirin	-	186	O
,	-	195	O
pegylated	-	197	O
interferon	-	207	O
and	-	218	O
telaprevir	-	222	O
.	-	232	O

The	24927617	234	O
patient	-	238	O
also	-	246	O
received	-	251	O
simvastatin	-	260	O
.	-	271	O

One	24927617	273	O
month	-	277	O
after	-	283	O
starting	-	289	O
the	-	298	O
antiviral	-	302	O
therapy	-	312	O
,	-	319	O
the	-	321	O
patient	-	325	O
was	-	333	O
admitted	-	337	O
to	-	346	O
the	-	349	O
hospital	-	353	O
because	-	362	O
he	-	370	O
developed	-	373	O
rhabdomyolysis	-	383	B
.	-	397	O

At	24927617	399	O
admission	-	402	O
simvastatin	-	412	O
and	-	424	O
all	-	428	O
antiviral	-	432	O
drugs	-	442	O
were	-	448	O
discontinued	-	453	O
because	-	466	O
toxicity	-	474	B
due	-	483	O
to	-	487	O
a	-	490	O
drug	-	492	O
-	-	496	O
drug	-	497	O
interaction	-	502	O
was	-	514	O
suspected	-	518	O
.	-	527	O

The	24927617	529	O
creatine	-	533	O
kinase	-	542	O
peaked	-	549	O
at	-	556	O
62	-	559	O
,	-	561	O
246	-	562	O
IU	-	566	O
/	-	568	O
L	-	569	O
and	-	571	O
the	-	575	O
patient	-	579	O
was	-	587	O
treated	-	591	O
with	-	599	O
intravenous	-	604	O
normal	-	616	O
saline	-	623	O
.	-	629	O

The	24927617	631	O
patient	-	635	O
's	-	642	O
renal	-	645	O
function	-	651	O
remained	-	660	O
unaffected	-	669	O
.	-	679	O

Fourteen	24927617	681	O
days	-	690	O
after	-	695	O
hospitalization	-	701	O
,	-	716	O
creatine	-	718	O
kinase	-	727	O
level	-	734	O
had	-	740	O
returned	-	744	O
to	-	753	O
230	-	756	O
IU	-	760	O
/	-	762	O
L	-	763	O
and	-	765	O
the	-	769	O
patient	-	773	O
was	-	781	O
discharged	-	785	O
.	-	795	O

Telaprevir	24927617	797	O
was	-	808	O
considered	-	812	O
the	-	823	O
probable	-	827	O
causative	-	836	O
agent	-	846	O
of	-	852	O
an	-	855	O
interaction	-	858	O
with	-	870	O
simvastatin	-	875	O
according	-	887	O
to	-	897	O
the	-	900	O
Drug	-	904	O
Interaction	-	909	O
Probability	-	921	O
Scale	-	933	O
.	-	938	O

The	24927617	940	O
interaction	-	944	O
is	-	956	O
due	-	959	O
to	-	963	O
inhibition	-	966	O
of	-	977	O
CYP3A4	-	980	O
-	-	986	O
mediated	-	987	O
simvastatin	-	996	O
clearance	-	1008	O
.	-	1017	O

Simvastatin	24927617	1019	O
plasma	-	1031	O
concentration	-	1038	O
increased	-	1052	O
30	-	1062	O
times	-	1065	O
in	-	1071	O
this	-	1074	O
patient	-	1079	O
and	-	1087	O
statin	-	1091	O
induced	-	1098	O
muscle	-	1106	B
toxicity	-	1113	I
is	-	1122	O
related	-	1125	O
to	-	1133	O
the	-	1136	O
concentration	-	1140	O
of	-	1154	O
the	-	1157	O
statin	-	1161	O
in	-	1168	O
blood	-	1171	O
.	-	1176	O

In	24927617	1178	O
conclusion	-	1181	O
,	-	1191	O
with	-	1193	O
this	-	1198	O
case	-	1203	O
we	-	1208	O
illustrate	-	1211	O
that	-	1222	O
telaprevir	-	1227	O
as	-	1238	O
well	-	1241	O
as	-	1246	O
statins	-	1249	O
are	-	1257	O
susceptible	-	1261	O
to	-	1273	O
clinical	-	1276	O
relevant	-	1285	O
drug	-	1294	O
-	-	1298	O
drug	-	1299	O
interactions	-	1304	O
.	-	1316	O

Combination	24928523	0	O
of	-	12	O
bortezomib	-	15	O
,	-	25	O
thalidomide	-	27	O
,	-	38	O
and	-	40	O
dexamethasone	-	44	O
(	-	58	O
VTD	-	59	O
)	-	62	O
as	-	64	O
a	-	67	O
consolidation	-	69	O
therapy	-	83	O
after	-	91	O
autologous	-	97	O
stem	-	108	O
cell	-	113	O
transplantation	-	118	O
for	-	134	O
symptomatic	-	138	O
multiple	-	150	B
myeloma	-	159	I
in	-	167	O
Japanese	-	170	O
patients	-	179	O
.	-	187	O

Consolidation	24928523	189	O
therapy	-	203	O
for	-	211	O
patients	-	215	O
with	-	224	O
multiple	-	229	B
myeloma	-	238	I
(	-	246	O
MM	-	247	B
)	-	249	O
has	-	251	O
been	-	255	O
widely	-	260	O
adopted	-	267	O
to	-	275	O
improve	-	278	O
treatment	-	286	O
response	-	296	O
following	-	305	O
autologous	-	315	O
stem	-	326	O
cell	-	331	O
transplantation	-	336	O
.	-	351	O

In	24928523	353	O
this	-	356	O
study	-	361	O
,	-	366	O
we	-	368	O
retrospectively	-	371	O
analyzed	-	387	O
the	-	396	O
safety	-	400	O
and	-	407	O
efficacy	-	411	O
of	-	420	O
combination	-	423	O
regimen	-	435	O
of	-	443	O
bortezomib	-	446	O
,	-	456	O
thalidomide	-	458	O
,	-	469	O
and	-	471	O
dexamethasone	-	475	O
(	-	489	O
VTD	-	490	O
)	-	493	O
as	-	495	O
consolidation	-	498	O
therapy	-	512	O
in	-	520	O
24	-	523	O
Japanese	-	526	O
patients	-	535	O
with	-	544	O
newly	-	549	O
diagnosed	-	555	O
MM	-	565	B
.	-	567	O

VTD	24928523	569	O
consisted	-	573	O
of	-	583	O
bortezomib	-	586	O
at	-	597	O
a	-	600	O
dose	-	602	O
of	-	607	O
1	-	610	O
.	-	611	O
3	-	612	O
mg	-	614	O
/	-	616	O
m	-	617	O
(	-	618	O
2	-	619	O
)	-	620	O
and	-	622	O
dexamethasone	-	626	O
at	-	640	O
a	-	643	O
dose	-	645	O
of	-	650	O
40	-	653	O
mg	-	656	O
/	-	658	O
day	-	659	O
on	-	663	O
days	-	666	O
1	-	671	O
,	-	672	O
8	-	674	O
,	-	675	O
15	-	677	O
,	-	679	O
and	-	681	O
22	-	685	O
of	-	688	O
a	-	691	O
35	-	693	O
-	-	695	O
day	-	696	O
cycle	-	700	O
,	-	705	O
with	-	707	O
daily	-	712	O
oral	-	718	O
thalidomide	-	723	O
at	-	735	O
a	-	738	O
dose	-	740	O
of	-	745	O
100	-	748	O
mg	-	752	O
/	-	754	O
day	-	755	O
.	-	758	O

Grade	24928523	760	O
3	-	766	O
-	-	767	O
4	-	768	O
neutropenia	-	770	B
and	-	782	O
thrombocytopenia	-	786	B
were	-	803	O
documented	-	808	O
in	-	819	O
four	-	822	O
and	-	827	O
three	-	831	O
patients	-	837	O
(	-	846	O
17	-	847	O
and	-	850	O
13	-	854	O
%	-	857	O
)	-	858	O
,	-	859	O
respectively	-	861	O
,	-	873	O
but	-	875	O
drug	-	879	O
dose	-	884	O
reduction	-	889	O
due	-	899	O
to	-	903	O
cytopenia	-	906	B
was	-	916	O
not	-	920	O
required	-	924	O
in	-	933	O
any	-	936	O
case	-	940	O
.	-	944	O

Peripheral	24928523	946	B
neuropathy	-	957	I
was	-	968	O
common	-	972	O
(	-	979	O
63	-	980	O
%	-	983	O
)	-	984	O
,	-	985	O
but	-	987	O
severe	-	991	O
grade	-	998	O
3	-	1004	O
-	-	1005	O
4	-	1006	O
peripheral	-	1008	B
neuropathy	-	1019	I
was	-	1030	O
not	-	1034	O
observed	-	1038	O
.	-	1046	O

Very	24928523	1048	O
good	-	1053	O
partial	-	1058	O
response	-	1066	O
or	-	1075	O
better	-	1078	O
response	-	1085	O
(	-	1094	O
>	-	1095	O
VGPR	-	1096	O
)	-	1100	O
rates	-	1102	O
before	-	1108	O
and	-	1115	O
after	-	1119	O
consolidation	-	1125	O
therapy	-	1139	O
were	-	1147	O
54	-	1152	O
and	-	1155	O
79	-	1159	O
%	-	1162	O
,	-	1163	O
respectively	-	1165	O
.	-	1177	O

Patients	24928523	1179	O
had	-	1188	O
a	-	1192	O
significant	-	1194	O
probability	-	1206	O
of	-	1218	O
improving	-	1221	O
from	-	1231	O
<	-	1236	O
VGPR	-	1237	O
before	-	1242	O
consolidation	-	1249	O
therapy	-	1263	O
to	-	1271	O
>	-	1274	O
VGPR	-	1275	O
after	-	1280	O
consolidation	-	1286	O
therapy	-	1300	O
(	-	1308	O
p	-	1309	O
=	-	1311	O
0	-	1313	O
.	-	1314	O
041	-	1315	O
)	-	1318	O
.	-	1319	O

The	24928523	1321	O
VTD	-	1325	O
regimen	-	1329	O
may	-	1337	O
be	-	1341	O
safe	-	1344	O
and	-	1349	O
effective	-	1353	O
as	-	1363	O
a	-	1366	O
consolidation	-	1368	O
therapy	-	1382	O
in	-	1390	O
the	-	1393	O
treatment	-	1397	O
of	-	1407	O
MM	-	1410	O
in	-	1413	O
Japanese	-	1416	O
population	-	1425	O
.	-	1435	O

Conversion	24971338	0	O
to	-	11	O
sirolimus	-	14	O
ameliorates	-	24	O
cyclosporine	-	36	O
-	-	48	O
induced	-	49	O
nephropathy	-	57	B
in	-	69	O
the	-	72	O
rat	-	76	O
:	-	79	O
focus	-	81	O
on	-	87	O
serum	-	90	O
,	-	95	O
urine	-	97	O
,	-	102	O
gene	-	104	O
,	-	108	O
and	-	110	O
protein	-	114	O
renal	-	122	O
expression	-	128	O
biomarkers	-	139	O
.	-	149	O

Protocols	24971338	151	O
of	-	161	O
conversion	-	164	O
from	-	175	O
cyclosporin	-	180	O
A	-	192	O
(	-	194	O
CsA	-	195	O
)	-	198	O
to	-	200	O
sirolimus	-	203	O
(	-	213	O
SRL	-	214	O
)	-	217	O
have	-	219	O
been	-	224	O
widely	-	229	O
used	-	236	O
in	-	241	O
immunotherapy	-	244	O
after	-	258	O
transplantation	-	264	O
to	-	280	O
prevent	-	283	O
CsA	-	291	O
-	-	294	O
induced	-	295	O
nephropathy	-	303	B
,	-	314	O
but	-	316	O
the	-	320	O
molecular	-	324	O
mechanisms	-	334	O
underlying	-	345	O
these	-	356	O
protocols	-	362	O
remain	-	372	O
nuclear	-	379	O
.	-	386	O

This	24971338	388	O
study	-	393	O
aimed	-	399	O
to	-	405	O
identify	-	408	O
the	-	417	O
molecular	-	421	O
pathways	-	431	O
and	-	440	O
putative	-	444	O
biomarkers	-	453	O
of	-	464	O
CsA	-	467	O
-	-	470	O
to	-	471	O
-	-	473	O
SRL	-	474	O
conversion	-	478	O
in	-	489	O
a	-	492	O
rat	-	494	O
model	-	498	O
.	-	503	O

Four	24971338	505	O
animal	-	510	O
groups	-	517	O
(	-	524	O
n	-	525	O
=	-	527	O
6	-	529	O
)	-	530	O
were	-	532	O
tested	-	537	O
during	-	544	O
9	-	551	O
weeks	-	553	O
:	-	558	O
control	-	560	O
,	-	567	O
CsA	-	569	O
,	-	572	O
SRL	-	574	O
,	-	577	O
and	-	579	O
conversion	-	583	O
(	-	594	O
CsA	-	595	O
for	-	599	O
3	-	603	O
weeks	-	605	O
followed	-	611	O
by	-	620	O
SRL	-	623	O
for	-	627	O
6	-	631	O
weeks	-	633	O
)	-	638	O
.	-	639	O

Classical	24971338	641	O
and	-	651	O
emergent	-	655	O
serum	-	664	O
,	-	669	O
urinary	-	671	O
,	-	678	O
and	-	680	O
kidney	-	684	O
tissue	-	691	O
(	-	698	O
gene	-	699	O
and	-	704	O
protein	-	708	O
expression	-	716	O
)	-	726	O
markers	-	728	O
were	-	736	O
assessed	-	741	O
.	-	749	O

Renal	24971338	751	B
lesions	-	757	I
were	-	765	O
analyzed	-	770	O
in	-	779	O
hematoxylin	-	782	O
and	-	794	O
eosin	-	798	O
,	-	803	O
periodic	-	805	O
acid	-	814	O
-	-	818	O
Schiff	-	819	O
,	-	825	O
and	-	827	O
Masson	-	831	O
's	-	837	O
trichrome	-	840	O
stains	-	850	O
.	-	856	O

SRL	24971338	858	O
-	-	861	O
treated	-	862	O
rats	-	870	O
presented	-	875	O
proteinuria	-	885	B
and	-	897	O
NGAL	-	901	O
(	-	906	O
serum	-	907	O
and	-	913	O
urinary	-	917	O
)	-	924	O
as	-	926	O
the	-	929	O
best	-	933	O
markers	-	938	O
of	-	946	O
renal	-	949	B
impairment	-	955	I
.	-	965	O

Short	24971338	967	O
CsA	-	973	O
treatment	-	977	O
presented	-	987	O
slight	-	997	O
or	-	1004	O
even	-	1007	O
absent	-	1012	O
kidney	-	1019	B
lesions	-	1026	I
and	-	1034	O
TGF	-	1038	O
-	-	1041	O
b	-	1042	O
,	-	1043	O
NF	-	1045	O
-	-	1047	O
kb	-	1049	O
,	-	1051	O
mTOR	-	1053	O
,	-	1057	O
PCNA	-	1059	O
,	-	1063	O
TP53	-	1065	O
,	-	1069	O
KIM	-	1071	O
-	-	1074	O
1	-	1075	O
,	-	1076	O
and	-	1078	O
CTGF	-	1082	O
as	-	1087	O
relevant	-	1090	O
gene	-	1099	O
and	-	1104	O
protein	-	1108	O
changes	-	1116	O
.	-	1123	O

Prolonged	24971338	1125	O
CsA	-	1135	O
exposure	-	1139	O
aggravated	-	1148	O
renal	-	1159	B
damage	-	1165	I
,	-	1171	O
without	-	1173	O
clear	-	1181	O
changes	-	1187	O
on	-	1195	O
the	-	1198	O
traditional	-	1202	O
markers	-	1214	O
,	-	1221	O
but	-	1223	O
with	-	1227	O
changes	-	1232	O
in	-	1240	O
serums	-	1243	O
TGF	-	1250	O
-	-	1253	O
b	-	1255	O
and	-	1257	O
IL	-	1261	O
-	-	1263	O
7	-	1264	O
,	-	1265	O
TBARs	-	1267	O
clearance	-	1273	O
,	-	1282	O
and	-	1284	O
kidney	-	1288	O
TGF	-	1295	O
-	-	1298	O
b	-	1299	O
and	-	1301	O
mTOR	-	1305	O
.	-	1309	O

Conversion	24971338	1311	O
to	-	1322	O
SRL	-	1325	O
prevented	-	1329	O
CsA	-	1339	O
-	-	1342	O
induced	-	1343	O
renal	-	1351	B
damage	-	1357	I
evolution	-	1364	O
(	-	1374	O
absent	-	1375	O
/	-	1381	O
mild	-	1382	O
grade	-	1387	O
lesions	-	1393	O
)	-	1400	O
,	-	1401	O
while	-	1403	O
NGAL	-	1409	O
(	-	1414	O
serum	-	1415	O
versus	-	1421	O
urine	-	1428	O
)	-	1433	O
seems	-	1435	O
to	-	1441	O
be	-	1444	O
a	-	1447	O
feasible	-	1449	O
biomarker	-	1458	O
of	-	1468	O
CsA	-	1471	O
replacement	-	1475	O
to	-	1487	O
SRL	-	1490	O
.	-	1493	O

Kinin	24975837	0	O
B2	-	6	O
receptor	-	9	O
deletion	-	18	O
and	-	27	O
blockage	-	31	O
ameliorates	-	40	O
cisplatin	-	52	O
-	-	61	O
induced	-	62	O
acute	-	70	B
renal	-	76	I
injury	-	82	I
.	-	88	O

Cisplatin	24975837	90	O
treatment	-	100	O
has	-	110	O
been	-	114	O
adopted	-	119	O
in	-	127	O
some	-	130	O
chemotherapies	-	135	O
;	-	149	O
however	-	151	O
,	-	158	O
this	-	160	O
drug	-	165	O
can	-	170	O
induce	-	174	O
acute	-	181	B
kidney	-	187	I
injury	-	194	I
due	-	201	O
its	-	205	O
ability	-	209	O
to	-	217	O
negatively	-	220	O
affect	-	231	O
renal	-	238	O
function	-	244	O
,	-	252	O
augment	-	254	O
serum	-	262	O
levels	-	268	O
of	-	275	O
creatinine	-	278	O
and	-	289	O
urea	-	293	O
,	-	297	O
increase	-	299	O
the	-	308	O
acute	-	312	B
tubular	-	318	I
necrosis	-	326	I
score	-	335	O
and	-	341	O
up	-	345	O
-	-	347	O
regulate	-	348	O
cytokines	-	357	O
(	-	367	O
e	-	368	O
.	-	369	O
g	-	370	O
.	-	371	O
,	-	372	O
IL	-	374	O
-	-	376	O
1b	-	377	O
and	-	380	O
TNF	-	384	O
-	-	387	O
a	-	388	O
)	-	389	O
.	-	390	O

The	24975837	392	O
kinin	-	396	O
B2	-	402	O
receptor	-	405	O
has	-	414	O
been	-	418	O
associated	-	423	O
with	-	434	O
the	-	439	O
inflammation	-	443	B
process	-	456	O
,	-	463	O
as	-	465	O
well	-	468	O
as	-	473	O
the	-	476	O
regulation	-	480	O
of	-	491	O
cytokine	-	494	O
expression	-	503	O
,	-	513	O
and	-	515	O
its	-	519	O
deletion	-	523	O
resulted	-	532	O
in	-	541	O
an	-	544	O
improvement	-	547	O
in	-	559	O
the	-	562	O
diabetic	-	566	B
nephropathy	-	575	I
status	-	587	O
.	-	593	O

To	24975837	595	O
examine	-	598	O
the	-	606	O
role	-	610	O
of	-	615	O
the	-	618	O
kinin	-	622	O
B2	-	628	O
receptor	-	631	O
in	-	640	O
cisplatin	-	643	O
-	-	652	O
induced	-	653	O
acute	-	661	B
kidney	-	667	I
injury	-	674	I
,	-	680	O
kinin	-	682	O
B2	-	688	O
receptor	-	691	O
knockout	-	700	O
mice	-	709	O
were	-	714	O
challenged	-	719	O
with	-	730	O
cisplatin	-	735	O
.	-	744	O

Additionally	24975837	746	O
,	-	758	O
WT	-	760	O
mice	-	763	O
were	-	768	O
treated	-	773	O
with	-	781	O
a	-	786	O
B2	-	788	O
receptor	-	791	O
antagonist	-	800	O
after	-	811	O
cisplatin	-	817	O
administration	-	827	O
.	-	841	O

B2	24975837	843	O
receptor	-	846	O
-	-	854	O
deficient	-	855	O
mice	-	865	O
were	-	870	O
less	-	875	O
sensitive	-	880	O
to	-	890	O
this	-	893	O
drug	-	898	O
than	-	903	O
the	-	908	O
WT	-	912	O
mice	-	915	O
,	-	919	O
as	-	921	O
shown	-	924	O
by	-	930	O
reduced	-	933	O
weight	-	941	B
loss	-	948	I
,	-	952	O
better	-	954	O
preservation	-	961	O
of	-	974	O
kidney	-	977	O
function	-	984	O
,	-	992	O
down	-	994	O
regulation	-	999	O
of	-	1010	O
inflammatory	-	1013	O
cytokines	-	1026	O
and	-	1036	O
less	-	1040	O
acute	-	1045	B
tubular	-	1051	I
necrosis	-	1059	I
.	-	1067	O

Moreover	24975837	1069	O
,	-	1077	O
treatment	-	1079	O
with	-	1089	O
the	-	1094	O
kinin	-	1098	O
B2	-	1104	O
receptor	-	1107	O
antagonist	-	1116	O
effectively	-	1127	O
reduced	-	1139	O
the	-	1147	O
levels	-	1151	O
of	-	1158	O
serum	-	1161	O
creatinine	-	1167	O
and	-	1178	O
blood	-	1182	O
urea	-	1188	O
after	-	1193	O
cisplatin	-	1199	O
administration	-	1209	O
.	-	1223	O

Thus	24975837	1225	O
,	-	1229	O
our	-	1231	O
data	-	1235	O
suggest	-	1240	O
that	-	1248	O
the	-	1253	O
kinin	-	1257	O
B2	-	1263	O
receptor	-	1266	O
is	-	1275	O
involved	-	1278	O
in	-	1287	O
cisplatin	-	1290	O
-	-	1299	O
induced	-	1300	O
acute	-	1308	B
kidney	-	1314	I
injury	-	1321	I
by	-	1328	O
mediating	-	1331	O
the	-	1341	O
necrotic	-	1345	B
process	-	1354	O
and	-	1362	O
the	-	1366	O
expression	-	1370	O
of	-	1381	O
inflammatory	-	1384	O
cytokines	-	1397	O
,	-	1406	O
thus	-	1408	O
resulting	-	1413	O
in	-	1423	O
declined	-	1426	O
renal	-	1435	O
function	-	1441	O
.	-	1449	O

These	24975837	1451	O
results	-	1457	O
highlight	-	1465	O
the	-	1475	O
kinin	-	1479	O
B2	-	1485	O
receptor	-	1488	O
antagonist	-	1497	O
treatment	-	1508	O
in	-	1518	O
amelioration	-	1521	O
of	-	1534	O
nephrotoxicity	-	1537	B
induced	-	1552	O
by	-	1560	O
cisplatin	-	1563	O
therapy	-	1573	O
.	-	1580	O

Safety	24999722	0	O
and	-	7	O
efficacy	-	11	O
of	-	20	O
fluocinolone	-	23	O
acetonide	-	36	O
intravitreal	-	46	O
implant	-	59	O
(	-	67	O
0	-	68	O
.	-	69	O
59	-	70	O
mg	-	73	O
)	-	75	O
in	-	77	O
birdshot	-	80	B
retinochoroidopathy	-	89	I
.	-	108	O

PURPOSE	24999722	110	O
:	-	117	O

To	24999722	119	O
report	-	122	O
the	-	129	O
treatment	-	133	O
outcomes	-	143	O
of	-	152	O
the	-	155	O
fluocinolone	-	159	O
acetonide	-	172	O
intravitreal	-	182	O
implant	-	195	O
(	-	203	O
0	-	204	O
.	-	205	O
59	-	206	O
mg	-	209	O
)	-	211	O
in	-	213	O
patients	-	216	O
with	-	225	O
birdshot	-	230	B
retinochoroidopathy	-	239	I
whose	-	259	O
disease	-	265	O
is	-	273	O
refractory	-	276	O
or	-	287	O
intolerant	-	290	O
to	-	301	O
conventional	-	304	O
immunomodulatory	-	317	O
therapy	-	334	O
.	-	341	O

METHODS	24999722	343	O
:	-	350	O

A	24999722	352	O
retrospective	-	354	O
case	-	368	O
series	-	373	O
involving	-	380	O
11	-	390	O
birdshot	-	393	B
retinochoroidopathy	-	402	I
patients	-	422	O
(	-	431	O
11	-	432	O
eyes	-	435	O
)	-	439	O
.	-	440	O

Eleven	24999722	442	O
patients	-	449	O
(	-	458	O
11	-	459	O
eyes	-	462	O
)	-	466	O
underwent	-	468	O
surgery	-	478	O
for	-	486	O
fluocinolone	-	490	O
acetonide	-	503	O
implant	-	513	O
(	-	521	O
0	-	522	O
.	-	523	O
59	-	524	O
mg	-	527	O
)	-	529	O
.	-	530	O

Treatment	24999722	532	O
outcomes	-	542	O
of	-	551	O
interest	-	554	O
were	-	563	O
noted	-	568	O
at	-	574	O
baseline	-	577	O
,	-	585	O
before	-	587	O
fluocinolone	-	594	O
acetonide	-	607	O
implant	-	617	O
,	-	624	O
and	-	626	O
then	-	630	O
at	-	635	O
6	-	638	O
months	-	640	O
,	-	646	O
1	-	648	O
year	-	650	O
,	-	654	O
2	-	656	O
years	-	658	O
,	-	663	O
3	-	665	O
years	-	667	O
,	-	672	O
and	-	674	O
beyond	-	678	O
3	-	685	O
years	-	687	O
.	-	692	O

Disease	24999722	694	O
activity	-	702	O
markers	-	711	O
,	-	718	O
including	-	720	O
signs	-	730	O
of	-	736	O
ocular	-	739	O
inflammation	-	746	B
,	-	758	O
evidence	-	760	O
of	-	769	O
retinal	-	772	B
vasculitis	-	780	I
,	-	790	O
Swedish	-	792	O
interactive	-	800	O
threshold	-	812	O
algorithm	-	822	O
-	-	831	O
short	-	832	O
wavelength	-	838	O
automated	-	849	O
perimetry	-	859	O
Humphrey	-	869	O
visual	-	878	O
field	-	885	O
analysis	-	891	O
,	-	899	O
electroretinographic	-	901	O
parameters	-	922	O
,	-	932	O
and	-	934	O
optical	-	938	O
coherence	-	946	O
tomography	-	956	O
were	-	967	O
recorded	-	972	O
.	-	980	O

Data	24999722	982	O
on	-	987	O
occurrence	-	990	O
of	-	1001	O
cataract	-	1004	B
and	-	1013	O
raised	-	1017	B
intraocular	-	1024	I
pressure	-	1036	I
were	-	1045	O
collected	-	1050	O
in	-	1060	O
all	-	1063	O
eyes	-	1067	O
.	-	1071	O

RESULTS	24999722	1073	O
:	-	1080	O

Intraocular	24999722	1082	O
inflammation	-	1094	B
was	-	1107	O
present	-	1111	O
in	-	1119	O
54	-	1122	O
.	-	1124	O
5	-	1125	O
,	-	1126	O
9	-	1128	O
.	-	1129	O
9	-	1130	O
,	-	1131	O
11	-	1133	O
.	-	1135	O
1	-	1136	O
,	-	1137	O
and	-	1139	O
0	-	1143	O
%	-	1144	O
of	-	1146	O
patients	-	1149	O
at	-	1158	O
baseline	-	1161	O
,	-	1169	O
6	-	1171	O
months	-	1173	O
,	-	1179	O
1	-	1181	O
year	-	1183	O
,	-	1187	O
2	-	1189	O
years	-	1191	O
,	-	1196	O
3	-	1198	O
years	-	1200	O
,	-	1205	O
and	-	1207	O
beyond	-	1211	O
3	-	1218	O
years	-	1220	O
after	-	1226	O
receiving	-	1232	O
the	-	1242	O
implant	-	1246	O
,	-	1253	O
respectively	-	1255	O
.	-	1267	O

Active	24999722	1269	O
vasculitis	-	1276	B
was	-	1287	O
noted	-	1291	O
in	-	1297	O
36	-	1300	O
.	-	1302	O
3	-	1303	O
%	-	1304	O
patients	-	1306	O
at	-	1315	O
baseline	-	1318	O
and	-	1327	O
0	-	1331	O
%	-	1332	O
at	-	1334	O
3	-	1337	O
years	-	1339	O
of	-	1345	O
follow	-	1348	O
-	-	1354	O
up	-	1355	O
.	-	1357	O

More	24999722	1359	O
than	-	1364	O
20	-	1369	O
%	-	1371	O
(	-	1373	O
47	-	1374	O
.	-	1376	O
61	-	1377	O
-	-	1379	O
67	-	1380	O
.	-	1382	O
2	-	1383	O
%	-	1384	O
)	-	1385	O
reduction	-	1387	O
in	-	1397	O
central	-	1400	O
retinal	-	1408	O
thickness	-	1416	O
was	-	1426	O
noted	-	1430	O
in	-	1436	O
all	-	1439	O
patients	-	1443	O
with	-	1452	O
cystoid	-	1457	B
macular	-	1465	I
edema	-	1473	I
at	-	1479	O
6	-	1482	O
months	-	1484	O
,	-	1490	O
1	-	1492	O
year	-	1494	O
,	-	1498	O
2	-	1500	O
years	-	1502	O
,	-	1507	O
and	-	1509	O
3	-	1513	O
years	-	1515	O
postimplant	-	1521	O
.	-	1532	O

At	24999722	1534	O
baseline	-	1537	O
,	-	1545	O
54	-	1547	O
.	-	1549	O
5	-	1550	O
%	-	1551	O
patients	-	1553	O
were	-	1562	O
on	-	1567	O
immunomodulatory	-	1570	O
agents	-	1587	O
.	-	1593	O

This	24999722	1595	O
percentage	-	1600	O
decreased	-	1611	O
to	-	1621	O
45	-	1624	O
.	-	1626	O
45	-	1627	O
,	-	1629	O
44	-	1631	O
.	-	1633	O
4	-	1634	O
,	-	1635	O
and	-	1637	O
14	-	1641	O
.	-	1643	O
28	-	1644	O
%	-	1646	O
at	-	1648	O
1	-	1651	O
year	-	1653	O
,	-	1657	O
2	-	1659	O
years	-	1661	O
,	-	1666	O
and	-	1668	O
3	-	1672	O
years	-	1674	O
postimplant	-	1680	O
,	-	1691	O
respectively	-	1693	O
.	-	1705	O

Adverse	24999722	1707	O
events	-	1715	O
included	-	1722	O
increased	-	1731	B
intraocular	-	1741	I
pressure	-	1753	I
(	-	1762	O
54	-	1763	O
.	-	1765	O
5	-	1766	O
%	-	1767	O
)	-	1768	O
and	-	1770	O
cataract	-	1774	B
formation	-	1783	O
(	-	1793	O
100	-	1794	O
%	-	1797	O
)	-	1798	O
.	-	1799	O

CONCLUSION	24999722	1801	O
:	-	1811	O

The	24999722	1813	O
data	-	1817	O
suggest	-	1822	O
that	-	1830	O
fluocinolone	-	1835	O
acetonide	-	1848	O
implant	-	1858	O
(	-	1866	O
0	-	1867	O
.	-	1868	O
59	-	1869	O
mg	-	1872	O
)	-	1874	O
helps	-	1876	O
to	-	1882	O
control	-	1885	O
inflammation	-	1893	B
in	-	1906	O
otherwise	-	1909	O
treatment	-	1919	O
-	-	1928	O
refractory	-	1929	O
cases	-	1940	O
of	-	1946	O
birdshot	-	1949	B
retinochoroidopathy	-	1958	I
.	-	1977	O

It	24999722	1979	O
is	-	1982	O
associated	-	1985	O
with	-	1996	O
significant	-	2001	O
side	-	2013	O
effects	-	2018	O
of	-	2026	O
cataract	-	2029	B
and	-	2038	O
ocular	-	2042	B
hypertension	-	2049	I
requiring	-	2062	O
treatment	-	2072	O
.	-	2081	O

Optimal	25006369	0	O
precurarizing	-	8	O
dose	-	22	O
of	-	27	O
rocuronium	-	30	O
to	-	41	O
decrease	-	44	O
fasciculation	-	53	B
and	-	67	O
myalgia	-	71	B
following	-	79	O
succinylcholine	-	89	O
administration	-	105	O
.	-	119	O

BACKGROUND	25006369	121	O
:	-	131	O
Succinylcholine	-	133	O
commonly	-	149	O
produces	-	158	O
frequent	-	167	O
adverse	-	176	O
effects	-	184	O
,	-	191	O
including	-	193	O
muscle	-	203	B
fasciculation	-	210	I
and	-	224	O
myalgia	-	228	B
.	-	235	O

The	25006369	237	O
current	-	241	O
study	-	249	O
identified	-	255	O
the	-	266	O
optimal	-	270	O
dose	-	278	O
of	-	283	O
rocuronium	-	286	O
to	-	297	O
prevent	-	300	O
succinylcholine	-	308	O
-	-	323	O
induced	-	324	O
fasciculation	-	332	B
and	-	346	O
myalgia	-	350	B
and	-	358	O
evaluated	-	362	O
the	-	372	O
influence	-	376	O
of	-	386	O
rocuronium	-	389	O
on	-	400	O
the	-	403	O
speed	-	407	O
of	-	413	O
onset	-	416	O
produced	-	422	O
by	-	431	O
succinylcholine	-	434	O
.	-	449	O

METHODS	25006369	451	O
:	-	458	O

This	25006369	460	O
randomized	-	465	O
,	-	475	O
double	-	477	O
-	-	483	O
blinded	-	484	O
study	-	492	O
was	-	498	O
conducted	-	502	O
in	-	512	O
100	-	515	O
patients	-	519	O
randomly	-	528	O
allocated	-	537	O
into	-	547	O
five	-	552	O
groups	-	557	O
of	-	564	O
20	-	567	O
patients	-	570	O
each	-	579	O
.	-	583	O

Patients	25006369	585	O
were	-	594	O
randomized	-	599	O
to	-	610	O
receive	-	613	O
0	-	621	O
.	-	622	O
02	-	623	O
,	-	625	O
0	-	627	O
.	-	628	O
03	-	629	O
,	-	631	O
0	-	633	O
.	-	634	O
04	-	635	O
,	-	637	O
0	-	639	O
.	-	640	O
05	-	641	O
and	-	644	O
0	-	648	O
.	-	649	O
06	-	650	O
mg	-	653	O
/	-	655	O
kg	-	656	O
rocuronium	-	659	O
as	-	670	O
a	-	673	O
precurarizing	-	675	O
dose	-	689	O
.	-	693	O

Neuromuscular	25006369	695	O
monitoring	-	709	O
after	-	720	O
each	-	726	O
precurarizing	-	731	O
dose	-	745	O
was	-	750	O
recorded	-	754	O
from	-	763	O
the	-	768	O
adductor	-	772	O
pollicis	-	781	O
muscle	-	790	O
using	-	797	O
acceleromyography	-	803	O
with	-	821	O
train	-	826	O
-	-	831	O
of	-	832	O
-	-	834	O
four	-	835	O
stimulation	-	840	O
of	-	852	O
the	-	855	O
ulnar	-	859	O
nerve	-	865	O
.	-	870	O

All	25006369	872	O
patients	-	876	O
received	-	885	O
succinylcholine	-	894	O
1	-	910	O
.	-	911	O
5	-	912	O
mg	-	914	O
/	-	916	O
kg	-	917	O
at	-	920	O
2	-	923	O
minutes	-	925	O
after	-	933	O
the	-	939	O
precurarization	-	943	O
,	-	958	O
and	-	960	O
were	-	964	O
assessed	-	969	O
the	-	978	O
incidence	-	982	O
and	-	992	O
severity	-	996	O
of	-	1005	O
fasciculations	-	1008	B
,	-	1022	O
while	-	1024	O
myalgia	-	1030	B
was	-	1038	O
assessed	-	1042	O
at	-	1051	O
24	-	1054	O
hours	-	1057	O
after	-	1063	O
surgery	-	1069	O
.	-	1076	O

RESULTS	25006369	1078	O
:	-	1085	O

The	25006369	1087	O
incidence	-	1091	O
and	-	1101	O
severity	-	1105	O
of	-	1114	O
visible	-	1117	O
muscle	-	1125	B
fasciculation	-	1132	I
was	-	1146	O
significantly	-	1150	O
less	-	1164	O
with	-	1169	O
increasing	-	1174	O
the	-	1185	O
amount	-	1189	O
of	-	1196	O
precurarizing	-	1199	O
dose	-	1213	O
of	-	1218	O
rocuronium	-	1221	O
(	-	1232	O
P	-	1233	O
<	-	1235	O
0	-	1237	O
.	-	1238	O
001	-	1239	O
)	-	1242	O
.	-	1243	O

Those	25006369	1245	O
of	-	1251	O
myalgia	-	1254	B
tend	-	1262	O
to	-	1267	O
decrease	-	1270	O
according	-	1279	O
to	-	1289	O
increasing	-	1292	O
the	-	1303	O
amount	-	1307	O
of	-	1314	O
precurarizing	-	1317	O
dose	-	1331	O
of	-	1336	O
rocuronium	-	1339	O
,	-	1349	O
but	-	1351	O
there	-	1355	O
was	-	1361	O
no	-	1365	O
significance	-	1368	O
(	-	1381	O
P	-	1382	O
=	-	1384	O
0	-	1386	O
.	-	1387	O
072	-	1388	O
)	-	1391	O
.	-	1392	O

The	25006369	1394	O
onset	-	1398	O
time	-	1404	O
of	-	1409	O
succinylcholine	-	1412	O
was	-	1428	O
significantly	-	1432	O
longer	-	1446	O
with	-	1453	O
increasing	-	1458	O
the	-	1469	O
amount	-	1473	O
of	-	1480	O
precurarizing	-	1483	O
dose	-	1497	O
of	-	1502	O
rocuronium	-	1505	O
(	-	1516	O
P	-	1517	O
<	-	1519	O
0	-	1521	O
.	-	1522	O
001	-	1523	O
)	-	1526	O
.	-	1527	O

CONCLUSIONS	25006369	1529	O
:	-	1540	O

Precurarization	25006369	1542	O
with	-	1558	O
0	-	1563	O
.	-	1564	O
04	-	1565	O
mg	-	1568	O
/	-	1570	O
kg	-	1571	O
rocuronium	-	1574	O
was	-	1585	O
the	-	1589	O
optimal	-	1593	O
dose	-	1601	O
considering	-	1606	O
the	-	1618	O
reduction	-	1622	O
in	-	1632	O
the	-	1635	O
incidence	-	1639	O
and	-	1649	O
severity	-	1653	O
of	-	1662	O
fasciculation	-	1665	B
and	-	1679	O
myalgia	-	1683	B
with	-	1691	O
acceptable	-	1696	O
onset	-	1707	O
time	-	1713	O
,	-	1717	O
and	-	1719	O
the	-	1723	O
safe	-	1727	O
and	-	1732	O
effective	-	1736	O
precurarization	-	1746	O
.	-	1761	O

Absence	25006961	0	O
of	-	8	O
PKC	-	11	O
-	-	14	O
alpha	-	15	O
attenuates	-	21	O
lithium	-	32	O
-	-	39	O
induced	-	40	O
nephrogenic	-	48	B
diabetes	-	60	I
insipidus	-	69	I
.	-	78	O

Lithium	25006961	80	O
,	-	87	O
an	-	89	O
effective	-	92	O
antipsychotic	-	102	O
,	-	115	O
induces	-	117	O
nephrogenic	-	125	B
diabetes	-	137	I
insipidus	-	146	I
(	-	156	O
NDI	-	157	B
)	-	160	O
in	-	162	O
40	-	166	O
%	-	168	O
of	-	170	O
patients	-	173	O
.	-	181	O

The	25006961	183	O
decreased	-	187	O
capacity	-	197	O
to	-	206	O
concentrate	-	209	O
urine	-	221	O
is	-	227	O
likely	-	230	O
due	-	237	O
to	-	241	O
lithium	-	244	O
acutely	-	252	O
disrupting	-	260	O
the	-	271	O
cAMP	-	275	O
pathway	-	280	O
and	-	288	O
chronically	-	292	O
reducing	-	304	O
urea	-	313	O
transporter	-	318	O
(	-	330	O
UT	-	331	O
-	-	333	O
A1	-	334	O
)	-	336	O
and	-	338	O
water	-	342	O
channel	-	348	O
(	-	356	O
AQP2	-	357	O
)	-	361	O
expression	-	363	O
in	-	374	O
the	-	377	O
inner	-	381	O
medulla	-	387	O
.	-	394	O

Targeting	25006961	396	O
an	-	406	O
alternative	-	409	O
signaling	-	421	O
pathway	-	431	O
,	-	438	O
such	-	440	O
as	-	445	O
PKC	-	448	O
-	-	451	O
mediated	-	452	O
signaling	-	461	O
,	-	470	O
may	-	472	O
be	-	476	O
an	-	479	O
effective	-	482	O
method	-	492	O
of	-	499	O
treating	-	502	O
lithium	-	511	O
-	-	518	O
induced	-	519	O
polyuria	-	527	B
.	-	535	O

PKC	25006961	537	O
-	-	540	O
alpha	-	541	O
null	-	547	O
mice	-	552	O
(	-	557	O
PKCa	-	558	O
KO	-	563	O
)	-	565	O
and	-	567	O
strain	-	571	O
-	-	577	O
matched	-	578	O
wild	-	586	O
type	-	591	O
(	-	596	O
WT	-	597	O
)	-	599	O
controls	-	601	O
were	-	610	O
treated	-	615	O
with	-	623	O
lithium	-	628	O
for	-	636	O
0	-	640	O
,	-	641	O
3	-	643	O
or	-	645	O
5	-	648	O
days	-	650	O
.	-	654	O

WT	25006961	656	O
mice	-	659	O
had	-	664	O
increased	-	668	O
urine	-	678	O
output	-	684	O
and	-	691	O
lowered	-	695	O
urine	-	703	O
osmolality	-	709	O
after	-	720	O
3	-	726	O
and	-	728	O
5	-	732	O
days	-	734	O
of	-	739	O
treatment	-	742	O
whereas	-	752	O
PKCa	-	760	O
KO	-	765	O
mice	-	768	O
had	-	773	O
no	-	777	O
change	-	780	O
in	-	787	O
urine	-	790	O
output	-	796	O
or	-	803	O
concentration	-	806	O
.	-	819	O

Western	25006961	821	O
blot	-	829	O
analysis	-	834	O
revealed	-	843	O
that	-	852	O
AQP2	-	857	O
expression	-	862	O
in	-	873	O
medullary	-	876	O
tissues	-	886	O
was	-	894	O
lowered	-	898	O
after	-	906	O
3	-	912	O
and	-	914	O
5	-	918	O
days	-	920	O
in	-	925	O
WT	-	928	O
mice	-	931	O
;	-	935	O
however	-	937	O
,	-	944	O
AQP2	-	946	O
was	-	951	O
unchanged	-	955	O
in	-	965	O
PKCa	-	968	O
KO	-	973	O
.	-	975	O

Similar	25006961	977	O
results	-	985	O
were	-	993	O
observed	-	998	O
with	-	1007	O
UT	-	1012	O
-	-	1014	O
A1	-	1015	O
expression	-	1018	O
.	-	1028	O

Animals	25006961	1030	O
were	-	1038	O
also	-	1043	O
treated	-	1048	O
with	-	1056	O
lithium	-	1061	O
for	-	1069	O
6	-	1073	O
weeks	-	1075	O
.	-	1080	O

Lithium	25006961	1082	O
-	-	1089	O
treated	-	1090	O
WT	-	1098	O
mice	-	1101	O
had	-	1106	O
19	-	1110	O
-	-	1112	O
fold	-	1113	O
increased	-	1118	O
urine	-	1128	O
output	-	1134	O
whereas	-	1141	O
treated	-	1149	O
PKCa	-	1157	O
KO	-	1162	O
animals	-	1165	O
had	-	1173	O
a	-	1177	O
4	-	1179	O
-	-	1180	O
fold	-	1181	O
increase	-	1186	O
in	-	1195	O
output	-	1198	O
.	-	1204	O

AQP2	25006961	1206	O
and	-	1211	O
UT	-	1215	O
-	-	1217	O
A1	-	1218	O
expression	-	1221	O
was	-	1232	O
lowered	-	1236	O
in	-	1244	O
6	-	1247	O
week	-	1249	O
lithium	-	1254	O
-	-	1261	O
treated	-	1262	O
WT	-	1270	O
animals	-	1273	O
whereas	-	1281	O
in	-	1289	O
treated	-	1292	O
PKCa	-	1300	O
KO	-	1305	O
mice	-	1308	O
,	-	1312	O
AQP2	-	1314	O
was	-	1319	O
only	-	1323	O
reduced	-	1328	O
by	-	1336	O
2	-	1339	O
-	-	1340	O
fold	-	1341	O
and	-	1346	O
UT	-	1350	O
-	-	1352	O
A1	-	1353	O
expression	-	1356	O
was	-	1367	O
unaffected	-	1371	O
.	-	1381	O

Urinary	25006961	1383	O
sodium	-	1391	O
,	-	1397	O
potassium	-	1399	O
and	-	1409	O
calcium	-	1413	O
were	-	1421	O
elevated	-	1426	O
in	-	1435	O
lithium	-	1438	O
-	-	1445	O
fed	-	1446	O
WT	-	1450	O
but	-	1453	O
not	-	1457	O
in	-	1461	O
lithium	-	1464	O
-	-	1471	O
fed	-	1472	O
PKCa	-	1476	O
KO	-	1481	O
mice	-	1484	O
.	-	1488	O

Our	25006961	1490	O
data	-	1494	O
show	-	1499	O
that	-	1504	O
ablation	-	1509	O
of	-	1518	O
PKCa	-	1521	O
preserves	-	1526	O
AQP2	-	1536	O
and	-	1541	O
UT	-	1545	O
-	-	1547	O
A1	-	1548	O
protein	-	1551	O
expression	-	1559	O
and	-	1570	O
localization	-	1574	O
in	-	1587	O
lithium	-	1590	O
-	-	1597	O
induced	-	1598	O
NDI	-	1606	B
,	-	1609	O
and	-	1611	O
prevents	-	1615	O
the	-	1624	O
development	-	1628	O
of	-	1640	O
the	-	1643	O
severe	-	1647	O
polyuria	-	1654	B
associated	-	1663	O
with	-	1674	O
lithium	-	1679	O
therapy	-	1687	O
.	-	1694	O

Is	25031906	0	O
Dysguesia	-	3	B
Going	-	13	O
to	-	19	O
be	-	22	O
a	-	25	O
Rare	-	27	O
or	-	32	O
a	-	35	O
Common	-	37	O
Side	-	44	O
-	-	48	O
effect	-	49	O
of	-	56	O
Amlodipine	-	59	O
?	-	69	O

A	25031906	71	O
very	-	73	O
rare	-	78	O
side	-	83	O
-	-	87	O
effect	-	88	O
of	-	95	O
amlodipine	-	98	O
is	-	109	O
dysguesia	-	112	B
.	-	121	O

A	25031906	123	O
review	-	125	O
of	-	132	O
the	-	135	O
literature	-	139	O
produced	-	150	O
only	-	159	O
one	-	164	O
case	-	168	O
.	-	172	O

We	25031906	174	O
report	-	177	O
a	-	184	O
case	-	186	O
about	-	191	O
a	-	197	O
female	-	199	O
with	-	206	O
essential	-	211	O
hypertension	-	221	B
on	-	234	O
drug	-	237	O
treatment	-	242	O
with	-	252	O
amlodipine	-	257	O
developed	-	268	O
loss	-	278	B
of	-	283	I
taste	-	286	I
sensation	-	292	I
.	-	301	O

Condition	25031906	303	O
moderately	-	313	O
improved	-	324	O
on	-	333	O
stoppage	-	336	O
of	-	345	O
the	-	348	O
drug	-	352	O
for	-	357	O
25	-	361	O
days	-	364	O
.	-	368	O

We	25031906	370	O
conclude	-	373	O
that	-	382	O
amlodipine	-	387	O
can	-	398	O
cause	-	402	O
dysguesia	-	408	B
.	-	417	O

Here	25031906	419	O
,	-	423	O
we	-	425	O
describe	-	428	O
the	-	437	O
clinical	-	441	O
presentation	-	450	O
and	-	463	O
review	-	467	O
the	-	474	O
relevant	-	478	O
literature	-	487	O
on	-	498	O
amlodipine	-	501	O
and	-	512	O
dysguesia	-	516	B
.	-	525	O

Rhabdomyolysis	25041770	0	B
in	-	15	O
association	-	18	O
with	-	30	O
simvastatin	-	35	O
and	-	47	O
dosage	-	51	O
increment	-	58	O
in	-	68	O
clarithromycin	-	71	O
.	-	85	O

Clarithromycin	25041770	87	O
is	-	102	O
the	-	105	O
most	-	109	O
documented	-	114	O
cytochrome	-	125	O
P450	-	136	O
3A4	-	141	O
(	-	145	O
CYP3A4	-	146	O
)	-	152	O
inhibitor	-	154	O
to	-	164	O
cause	-	167	O
an	-	173	O
adverse	-	176	O
interaction	-	184	O
with	-	196	O
simvastatin	-	201	O
.	-	212	O

This	25041770	214	O
particular	-	219	O
case	-	230	O
is	-	235	O
of	-	238	O
interest	-	241	O
as	-	250	O
rhabdomyolysis	-	253	B
only	-	268	O
occurred	-	273	O
after	-	282	O
an	-	288	O
increase	-	291	O
in	-	300	O
the	-	303	O
dose	-	307	O
of	-	312	O
clarithromycin	-	315	O
.	-	329	O

The	25041770	331	O
patient	-	335	O
developed	-	343	O
raised	-	353	O
cardiac	-	360	O
biomarkers	-	368	O
without	-	379	O
any	-	387	O
obvious	-	391	O
cardiac	-	399	O
issues	-	407	O
,	-	413	O
a	-	415	O
phenomenon	-	417	O
that	-	428	O
has	-	433	O
been	-	437	O
linked	-	442	O
to	-	449	O
rhabdomyolysis	-	452	B
previously	-	467	O
.	-	477	O

To	25041770	479	O
date	-	482	O
,	-	486	O
there	-	488	O
has	-	494	O
been	-	498	O
no	-	503	O
reported	-	506	O
effect	-	515	O
of	-	522	O
rhabdomyolysis	-	525	B
on	-	540	O
the	-	543	O
structure	-	547	O
and	-	557	O
function	-	561	O
of	-	570	O
cardiac	-	573	O
muscle	-	581	O
.	-	587	O

Clinicians	25041770	589	O
need	-	600	O
to	-	605	O
be	-	608	O
aware	-	611	O
of	-	617	O
prescribing	-	620	O
concomitant	-	632	O
medications	-	644	O
that	-	656	O
increase	-	661	O
the	-	670	O
risk	-	674	O
of	-	679	O
myopathy	-	682	B
or	-	691	O
inhibit	-	694	O
the	-	702	O
CYP3A4	-	706	O
enzyme	-	713	O
.	-	719	O

Our	25041770	721	O
case	-	725	O
suggests	-	730	O
that	-	739	O
troponin	-	744	O
elevation	-	753	O
could	-	763	O
be	-	769	O
associated	-	772	O
with	-	783	O
statin	-	788	O
induced	-	795	O
rhabdomyolysis	-	803	B
,	-	817	O
which	-	819	O
may	-	825	O
warrant	-	829	O
further	-	837	O
studies	-	845	O
.	-	852	O

Characterization	25054547	0	O
of	-	17	O
a	-	20	O
novel	-	22	O
BCHE	-	28	O
""""	-	33	O
silent	-	34	O
""""	-	40	O
allele	-	42	O
:	-	48	O
point	-	50	O
mutation	-	56	O
(	-	65	O
p	-	66	O
.	-	67	O

Val204Asp	25054547	68	O
)	-	77	O
causes	-	79	O
loss	-	86	O
of	-	91	O
activity	-	94	O
and	-	103	O
prolonged	-	107	O
apnea	-	117	B
with	-	123	O
suxamethonium	-	128	O
.	-	141	O

Butyrylcholinesterase	25054547	143	B
deficiency	-	165	I
is	-	176	O
characterized	-	179	O
by	-	193	O
prolonged	-	196	O
apnea	-	206	B
after	-	212	O
the	-	218	O
use	-	222	O
of	-	226	O
muscle	-	229	O
relaxants	-	236	O
(	-	246	O
suxamethonium	-	247	O
or	-	261	O
mivacurium	-	264	O
)	-	274	O
in	-	276	O
patients	-	279	O
who	-	288	O
have	-	292	O
mutations	-	297	O
in	-	307	O
the	-	310	O
BCHE	-	314	O
gene	-	319	O
.	-	323	O

Here	25054547	325	O
,	-	329	O
we	-	331	O
report	-	334	O
a	-	341	O
case	-	343	O
of	-	348	O
prolonged	-	351	O
neuromuscular	-	361	O
block	-	375	O
after	-	381	O
administration	-	387	O
of	-	402	O
suxamethonium	-	405	O
leading	-	419	O
to	-	427	O
the	-	430	O
discovery	-	434	O
of	-	444	O
a	-	447	O
novel	-	449	O
BCHE	-	455	O
variant	-	460	O
(	-	468	O
c	-	469	O
.	-	470	O
695T	-	471	O
>	-	475	O

A	25054547	476	O
,	-	477	O
p	-	479	O
.	-	480	O

Val204Asp	25054547	481	O
)	-	490	O
.	-	491	O

Inhibition	25054547	493	O
studies	-	504	O
,	-	511	O
kinetic	-	513	O
analysis	-	521	O
and	-	530	O
molecular	-	534	O
dynamics	-	544	O
were	-	553	O
undertaken	-	558	O
to	-	569	O
understand	-	572	O
how	-	583	O
this	-	587	O
mutation	-	592	O
disrupts	-	601	O
the	-	610	O
catalytic	-	614	O
triad	-	624	O
and	-	630	O
determines	-	634	O
a	-	645	O
""""	-	647	O
silent	-	648	O
""""	-	654	O
phenotype	-	656	O
.	-	665	O

Low	25054547	667	O
activity	-	671	O
of	-	680	O
patient	-	683	O
plasma	-	691	O
butyrylcholinesterase	-	698	O
with	-	720	O
butyrylthiocholine	-	725	O
(	-	744	O
BTC	-	745	O
)	-	748	O
and	-	750	O
benzoylcholine	-	754	O
,	-	768	O
and	-	770	O
values	-	774	O
of	-	781	O
dibucaine	-	784	O
and	-	794	O
fluoride	-	798	O
numbers	-	807	O
fit	-	815	O
with	-	819	O
heterozygous	-	824	O
atypical	-	837	O
silent	-	846	O
genotype	-	853	O
.	-	861	O

Electrophoretic	25054547	863	O
analysis	-	879	O
of	-	888	O
plasma	-	891	O
BChE	-	898	O
of	-	903	O
the	-	906	O
proband	-	910	O
and	-	918	O
his	-	922	O
mother	-	926	O
showed	-	933	O
that	-	940	O
patient	-	945	O
has	-	953	O
a	-	957	O
reduced	-	959	O
amount	-	967	O
of	-	974	O
tetrameric	-	977	O
enzyme	-	988	O
in	-	995	O
plasma	-	998	O
and	-	1005	O
that	-	1009	O
minor	-	1014	O
fast	-	1020	O
-	-	1024	O
moving	-	1025	O
BChE	-	1032	O
components	-	1037	O
:	-	1047	O
monomer	-	1049	O
,	-	1056	O
dimer	-	1058	O
,	-	1063	O
and	-	1065	O
monomer	-	1069	O
-	-	1076	O
albumin	-	1077	O
conjugate	-	1085	O
are	-	1095	O
missing	-	1099	O
.	-	1106	O

Kinetic	25054547	1108	O
analysis	-	1116	O
showed	-	1125	O
that	-	1132	O
the	-	1137	O
p	-	1141	O
.	-	1142	O

Val204Asp	25054547	1143	O
/	-	1152	O
p	-	1153	O
.	-	1154	O

Asp70Gly	25054547	1155	O
-	-	1163	O
p	-	1164	O
.	-	1165	O

Ala539Thr	25054547	1166	O
BChE	-	1176	O
displays	-	1181	O
a	-	1190	O
pure	-	1192	O
Michaelian	-	1197	O
behavior	-	1208	O
with	-	1217	O
BTC	-	1222	O
as	-	1226	O
the	-	1229	O
substrate	-	1233	O
.	-	1242	O

Both	25054547	1244	O
catalytic	-	1249	O
parameters	-	1259	O
Km	-	1270	O
=	-	1273	O
265	-	1275	O
uM	-	1279	O
for	-	1282	O
BTC	-	1286	O
,	-	1289	O
two	-	1291	O
times	-	1295	O
higher	-	1301	O
than	-	1308	O
that	-	1313	O
of	-	1318	O
the	-	1321	O
atypical	-	1325	O
enzyme	-	1334	O
,	-	1340	O
and	-	1342	O
a	-	1346	O
low	-	1348	O
Vmax	-	1352	O
are	-	1357	O
consistent	-	1361	O
with	-	1372	O
the	-	1377	O
absence	-	1381	O
of	-	1389	O
activity	-	1392	O
against	-	1401	O
suxamethonium	-	1409	O
.	-	1422	O

Molecular	25054547	1424	O
dynamic	-	1434	O
(	-	1442	O
MD	-	1443	O
)	-	1445	O
simulations	-	1447	O
showed	-	1459	O
that	-	1466	O
the	-	1471	O
overall	-	1475	O
effect	-	1483	O
of	-	1490	O
the	-	1493	O
mutation	-	1497	O
p	-	1506	O
.	-	1507	O

Val204Asp	25054547	1508	O
is	-	1518	O
disruption	-	1521	O
of	-	1532	O
hydrogen	-	1535	O
bonding	-	1544	O
between	-	1552	O
Gln223	-	1560	O
and	-	1567	O
Glu441	-	1571	O
,	-	1577	O
leading	-	1579	O
Ser198	-	1587	O
and	-	1594	O
His438	-	1598	O
to	-	1605	O
move	-	1608	O
away	-	1613	O
from	-	1618	O
each	-	1623	O
other	-	1628	O
with	-	1634	O
subsequent	-	1639	O
disruption	-	1650	O
of	-	1661	O
the	-	1664	O
catalytic	-	1668	O
triad	-	1678	O
functionality	-	1684	O
regardless	-	1698	O
of	-	1709	O
the	-	1712	O
type	-	1716	O
of	-	1721	O
substrate	-	1724	O
.	-	1733	O

MD	25054547	1735	O
also	-	1738	O
showed	-	1743	O
that	-	1750	O
the	-	1755	O
enzyme	-	1759	O
volume	-	1766	O
is	-	1773	O
increased	-	1776	O
,	-	1785	O
suggesting	-	1787	O
a	-	1798	O
pre	-	1800	O
-	-	1803	O
denaturation	-	1804	O
state	-	1817	O
.	-	1822	O

This	25054547	1824	O
fits	-	1829	O
with	-	1834	O
the	-	1839	O
reduced	-	1843	O
concentration	-	1851	O
of	-	1865	O
p	-	1868	O
.	-	1869	O

Ala204Asp	25054547	1870	O
/	-	1879	O
p	-	1880	O
.	-	1881	O

Asp70Gly	25054547	1882	O
-	-	1890	O
p	-	1891	O
.	-	1892	O

Ala539Thr	25054547	1893	O
tetrameric	-	1903	O
enzyme	-	1914	O
in	-	1921	O
the	-	1924	O
plasma	-	1928	O
and	-	1935	O
non	-	1939	O
-	-	1942	O
detectable	-	1943	O
fast	-	1954	O
moving	-	1959	O
-	-	1965	O
bands	-	1966	O
on	-	1972	O
electrophoresis	-	1975	O
gels	-	1991	O
.	-	1995	O

Delayed	25071004	0	O
anemia	-	8	B
after	-	15	O
treatment	-	21	O
with	-	31	O
injectable	-	36	O
artesunate	-	47	O
in	-	58	O
the	-	61	O
Democratic	-	65	O
Republic	-	76	O
of	-	85	O
the	-	88	O
Congo	-	92	O
:	-	97	O
a	-	99	O
manageable	-	101	O
issue	-	112	O
.	-	117	O

Cases	25071004	119	O
of	-	125	O
delayed	-	128	O
hemolytic	-	136	B
anemia	-	146	I
have	-	153	O
been	-	158	O
described	-	163	O
after	-	173	O
treatment	-	179	O
with	-	189	O
injectable	-	194	O
artesunate	-	205	O
,	-	215	O
the	-	217	O
current	-	221	O
World	-	229	O
Health	-	235	O
Organization	-	242	O
(	-	255	O
WHO	-	256	O
)	-	259	O
-	-	260	O
recommended	-	261	O
first	-	273	O
-	-	278	O
line	-	279	O
drug	-	284	O
for	-	289	O
the	-	293	O
treatment	-	297	O
of	-	307	O
severe	-	310	O
malaria	-	317	B
.	-	324	O

A	25071004	326	O
total	-	328	O
of	-	334	O
350	-	337	O
patients	-	341	O
(	-	350	O
215	-	351	O
[	-	355	O
61	-	356	O
.	-	358	O
4	-	359	O
%	-	360	O
]	-	361	O
<	-	363	O
5	-	365	O
years	-	367	O
of	-	373	O
age	-	376	O
and	-	380	O
135	-	384	O
[	-	388	O
38	-	389	O
.	-	391	O
6	-	392	O
%	-	393	O
]	-	394	O
>	-	396	O
5	-	398	O
years	-	400	O
of	-	406	O
age	-	409	O
)	-	412	O
were	-	414	O
followed	-	419	O
-	-	427	O
up	-	428	O
after	-	431	O
treatment	-	437	O
with	-	447	O
injectable	-	452	O
artesunate	-	463	O
for	-	474	O
severe	-	478	O
malaria	-	485	B
in	-	493	O
hospitals	-	496	O
and	-	506	O
health	-	510	O
centers	-	517	O
of	-	525	O
the	-	528	O
Democratic	-	532	O
Republic	-	543	O
of	-	552	O
the	-	555	O
Congo	-	559	O
.	-	564	O

Complete	25071004	566	O
series	-	575	O
of	-	582	O
hemoglobin	-	585	O
(	-	596	O
Hb	-	597	O
)	-	599	O
measurements	-	601	O
were	-	614	O
available	-	619	O
for	-	629	O
201	-	633	O
patients	-	637	O
.	-	645	O

A	25071004	647	O
decrease	-	649	O
in	-	658	O
Hb	-	661	O
levels	-	664	O
between	-	671	O
2	-	679	O
and	-	681	O
5	-	685	O
g	-	687	O
/	-	688	O
dL	-	689	O
was	-	692	O
detected	-	696	O
in	-	705	O
23	-	708	O
(	-	711	O
11	-	712	O
.	-	714	O
4	-	715	O
%	-	716	O
)	-	717	O
patients	-	719	O
during	-	728	O
the	-	735	O
follow	-	739	O
-	-	745	O
up	-	746	O
period	-	749	O
.	-	755	O

For	25071004	757	O
five	-	761	O
patients	-	766	O
,	-	774	O
Hb	-	776	O
levels	-	779	O
decreased	-	786	O
below	-	796	O
5	-	802	O
g	-	804	O
/	-	805	O
dL	-	806	O
during	-	809	O
at	-	816	O
least	-	819	O
one	-	825	O
follow	-	829	O
-	-	835	O
up	-	836	O
visit	-	839	O
.	-	844	O

All	25071004	846	O
cases	-	850	O
of	-	856	O
delayed	-	859	O
anemia	-	867	B
were	-	874	O
clinically	-	879	O
manageable	-	890	O
and	-	901	O
resolved	-	905	O
within	-	914	O
one	-	921	O
month	-	925	O
.	-	930	O

Regulation	25080425	0	O
of	-	11	O
signal	-	14	O
transducer	-	21	O
and	-	32	O
activator	-	36	O
of	-	46	O
transcription	-	49	O
3	-	63	O
and	-	65	O
apoptotic	-	69	O
pathways	-	79	O
by	-	88	O
betaine	-	91	O
attenuates	-	99	O
isoproterenol	-	110	O
-	-	123	O
induced	-	124	O
acute	-	132	O
myocardial	-	138	B
injury	-	149	I
in	-	156	O
rats	-	159	O
.	-	163	O

The	25080425	165	O
present	-	169	O
study	-	177	O
was	-	183	O
designed	-	187	O
to	-	196	O
investigate	-	199	O
the	-	211	O
cardioprotective	-	215	O
effects	-	232	O
of	-	240	O
betaine	-	243	O
on	-	251	O
acute	-	254	O
myocardial	-	260	B
ischemia	-	271	I
induced	-	280	O
experimentally	-	288	O
in	-	303	O
rats	-	306	O
focusing	-	311	O
on	-	320	O
regulation	-	323	O
of	-	334	O
signal	-	337	O
transducer	-	344	O
and	-	355	O
activator	-	359	O
of	-	369	O
transcription	-	372	O
3	-	386	O
(	-	388	O
STAT3	-	389	O
)	-	394	O
and	-	396	O
apoptotic	-	400	O
pathways	-	410	O
as	-	419	O
the	-	422	O
potential	-	426	O
mechanism	-	436	O
underlying	-	446	O
the	-	457	O
drug	-	461	O
effect	-	466	O
.	-	472	O

Male	25080425	474	O
Sprague	-	479	O
Dawley	-	487	O
rats	-	494	O
were	-	499	O
treated	-	504	O
with	-	512	O
betaine	-	517	O
(	-	525	O
100	-	526	O
,	-	529	O
200	-	531	O
,	-	534	O
and	-	536	O
400	-	540	O
mg	-	544	O
/	-	546	O
kg	-	547	O
)	-	549	O
orally	-	551	O
for	-	558	O
40	-	562	O
days	-	565	O
.	-	569	O

Acute	25080425	571	O
myocardial	-	577	B
ischemic	-	588	I
injury	-	597	I
was	-	604	O
induced	-	608	O
in	-	616	O
rats	-	619	O
by	-	624	O
subcutaneous	-	627	O
injection	-	640	O
of	-	650	O
isoproterenol	-	653	O
(	-	667	O
85	-	668	O
mg	-	671	O
/	-	673	O
kg	-	674	O
)	-	676	O
,	-	677	O
for	-	679	O
two	-	683	O
consecutive	-	687	O
days	-	699	O
.	-	703	O

Serum	25080425	705	O
cardiac	-	711	O
marker	-	719	O
enzyme	-	726	O
,	-	732	O
histopathological	-	734	O
variables	-	752	O
and	-	762	O
expression	-	766	O
of	-	777	O
protein	-	780	O
levels	-	788	O
were	-	795	O
analyzed	-	800	O
.	-	808	O

Oral	25080425	810	O
administration	-	815	O
of	-	830	O
betaine	-	833	O
(	-	841	O
200	-	842	O
and	-	846	O
400	-	850	O
mg	-	854	O
/	-	856	O
kg	-	857	O
)	-	859	O
significantly	-	861	O
reduced	-	875	O
the	-	883	O
level	-	887	O
of	-	893	O
cardiac	-	896	O
marker	-	904	O
enzyme	-	911	O
in	-	918	O
the	-	921	O
serum	-	925	O
and	-	931	O
prevented	-	935	O
left	-	945	O
ventricular	-	950	B
remodeling	-	962	I
.	-	972	O

Western	25080425	974	O
blot	-	982	O
analysis	-	987	O
showed	-	996	O
that	-	1003	O
isoproterenol	-	1008	O
-	-	1021	O
induced	-	1022	O
phosphorylation	-	1030	O
of	-	1046	O
STAT3	-	1049	O
was	-	1055	O
maintained	-	1059	O
or	-	1070	O
further	-	1073	O
enhanced	-	1081	O
by	-	1090	O
betaine	-	1093	O
treatment	-	1101	O
in	-	1111	O
myocardium	-	1114	O
.	-	1124	O

Furthermore	25080425	1126	O
,	-	1137	O
betaine	-	1139	O
(	-	1147	O
200	-	1148	O
and	-	1152	O
400	-	1156	O
mg	-	1160	O
/	-	1162	O
kg	-	1163	O
)	-	1165	O
treatment	-	1167	O
increased	-	1177	O
the	-	1187	O
ventricular	-	1191	O
expression	-	1203	O
of	-	1214	O
Bcl	-	1217	O
-	-	1220	O
2	-	1221	O
and	-	1223	O
reduced	-	1227	O
the	-	1235	O
level	-	1239	O
of	-	1245	O
Bax	-	1248	O
,	-	1251	O
therefore	-	1253	O
causing	-	1263	O
a	-	1271	O
significant	-	1273	O
increase	-	1285	O
in	-	1294	O
the	-	1297	O
ratio	-	1301	O
of	-	1307	O
Bcl	-	1310	O
-	-	1313	O
2	-	1314	O
/	-	1315	O
Bax	-	1316	O
.	-	1319	O

The	25080425	1321	O
protective	-	1325	O
role	-	1336	O
of	-	1341	O
betaine	-	1344	O
on	-	1352	O
myocardial	-	1355	B
damage	-	1366	I
was	-	1373	O
further	-	1377	O
confirmed	-	1385	O
by	-	1395	O
histopathological	-	1398	O
examination	-	1416	O
.	-	1427	O

In	25080425	1429	O
summary	-	1432	O
,	-	1439	O
our	-	1441	O
results	-	1445	O
showed	-	1453	O
that	-	1460	O
betaine	-	1465	O
pretreatment	-	1473	O
attenuated	-	1486	O
isoproterenol	-	1497	O
-	-	1510	O
induced	-	1511	O
acute	-	1519	O
myocardial	-	1525	B
ischemia	-	1536	I
via	-	1545	O
the	-	1549	O
regulation	-	1553	O
of	-	1564	O
STAT3	-	1567	O
and	-	1573	O
apoptotic	-	1577	O
pathways	-	1587	O
.	-	1595	O

Quetiapine	25084821	0	O
-	-	10	O
induced	-	11	O
neutropenia	-	19	B
in	-	31	O
a	-	34	O
bipolar	-	36	B
patient	-	44	O
with	-	52	O
hepatocellular	-	57	B
carcinoma	-	72	I
.	-	81	O

OBJECTIVE	25084821	83	O
:	-	92	O
Quetiapine	-	94	O
is	-	105	O
a	-	108	O
dibenzothiazepine	-	110	O
derivative	-	128	O
,	-	138	O
similar	-	140	O
to	-	148	O
clozapine	-	151	O
,	-	160	O
which	-	162	O
has	-	168	O
the	-	172	O
highest	-	176	O
risk	-	184	O
of	-	189	O
causing	-	192	O
blood	-	200	B
dyscrasias	-	206	I
,	-	216	O
especially	-	218	O
neutropenia	-	229	B
.	-	240	O

There	25084821	242	O
are	-	248	O
some	-	252	O
case	-	257	O
reports	-	262	O
about	-	270	O
this	-	276	O
side	-	281	O
effect	-	286	O
of	-	293	O
quetiapine	-	296	O
,	-	306	O
but	-	308	O
possible	-	312	O
risk	-	321	O
factors	-	326	O
are	-	334	O
seldom	-	338	O
discussed	-	345	O
and	-	355	O
identified	-	359	O
.	-	369	O

A	25084821	371	O
case	-	373	O
of	-	378	O
a	-	381	O
patient	-	383	O
with	-	391	O
hepatocellular	-	396	B
carcinoma	-	411	I
that	-	421	O
developed	-	426	O
neutropenia	-	436	B
after	-	448	O
treatment	-	454	O
with	-	464	O
quetiapine	-	469	O
is	-	480	O
described	-	483	O
here	-	493	O
.	-	497	O

CASE	25084821	499	O
REPORT	-	504	O
:	-	510	O

A	25084821	512	O
62	-	514	O
-	-	516	O
year	-	517	O
-	-	521	O
old	-	522	O
Taiwanese	-	526	O
widow	-	536	O
with	-	542	O
bipolar	-	547	B
disorder	-	555	I
was	-	564	O
diagnosed	-	568	O
with	-	578	O
hepatocellular	-	583	B
carcinoma	-	598	I
at	-	608	O
age	-	611	O
60	-	615	O
.	-	617	O

She	25084821	619	O
developed	-	623	O
leucopenia	-	633	B
after	-	644	O
being	-	650	O
treated	-	656	O
with	-	664	O
quetiapine	-	669	O
.	-	679	O

After	25084821	681	O
quetiapine	-	687	O
was	-	698	O
discontinued	-	702	O
,	-	714	O
her	-	716	O
white	-	720	O
blood	-	726	O
cell	-	732	O
count	-	737	O
returned	-	743	O
to	-	752	O
normal	-	755	O
.	-	761	O

CONCLUSIONS	25084821	763	O
:	-	774	O

Although	25084821	776	O
neutropenia	-	785	B
is	-	797	O
not	-	800	O
a	-	804	O
common	-	806	O
side	-	813	O
effect	-	818	O
of	-	825	O
quetiapine	-	828	O
,	-	838	O
physicians	-	840	O
should	-	851	O
be	-	858	O
cautious	-	861	O
about	-	870	O
its	-	876	O
presentation	-	880	O
and	-	893	O
associated	-	897	O
risk	-	908	O
factors	-	913	O
.	-	920	O

Hepatic	25084821	922	B
dysfunction	-	930	I
may	-	942	O
be	-	946	O
one	-	949	O
of	-	953	O
the	-	956	O
possible	-	960	O
risk	-	969	O
factors	-	974	O
,	-	981	O
and	-	983	O
concomitant	-	987	O
fever	-	999	B
may	-	1005	O
be	-	1009	O
a	-	1012	O
diagnostic	-	1014	O
marker	-	1025	O
for	-	1032	O
adverse	-	1036	O
reaction	-	1044	O
to	-	1053	O
quetiapine	-	1056	O
.	-	1066	O

Lateral	25096313	0	O
antebrachial	-	8	O
cutaneous	-	21	O
neuropathy	-	31	B
after	-	42	O
steroid	-	48	O
injection	-	56	O
at	-	66	O
lateral	-	69	O
epicondyle	-	77	O
.	-	87	O

BACKGROUND	25096313	89	O
AND	-	100	O
OBJECTIVES	-	104	O
:	-	114	O

This	25096313	116	O
report	-	121	O
aimed	-	128	O
to	-	134	O
present	-	137	O
a	-	145	O
case	-	147	O
of	-	152	O
lateral	-	155	O
antebrachial	-	163	O
cutaneous	-	176	O
neuropathy	-	186	B
(	-	197	O
LACNP	-	198	O
)	-	203	O
that	-	205	O
occurred	-	210	O
after	-	219	O
a	-	225	O
steroid	-	227	O
injection	-	235	O
in	-	245	O
the	-	248	O
lateral	-	252	O
epicondyle	-	260	O
to	-	271	O
treat	-	274	O
lateral	-	280	B
epicondylitis	-	288	I
in	-	302	O
a	-	305	O
40	-	307	O
-	-	309	O
year	-	310	O
-	-	314	O
old	-	315	O
woman	-	319	O
.	-	324	O

MATERIAL	25096313	326	O
AND	-	335	O
METHOD	-	339	O
:	-	345	O

A	25096313	347	O
40	-	349	O
-	-	351	O
year	-	352	O
-	-	356	O
old	-	357	O
woman	-	361	O
presented	-	367	O
with	-	377	O
decreased	-	382	O
sensation	-	392	O
and	-	402	O
paresthesia	-	406	B
over	-	418	O
her	-	423	O
right	-	427	O
lateral	-	433	O
forearm	-	441	O
;	-	448	O
the	-	450	O
paresthesia	-	454	B
had	-	466	O
occurred	-	470	O
after	-	479	O
a	-	485	O
steroid	-	487	O
injection	-	495	O
in	-	505	O
the	-	508	O
right	-	512	O
lateral	-	518	O
epicondyle	-	526	O
3	-	537	O
months	-	539	O
before	-	546	O
.	-	552	O

Her	25096313	554	O
sensation	-	558	O
of	-	568	O
light	-	571	O
touch	-	577	O
and	-	583	O
pain	-	587	B
was	-	592	O
diminished	-	596	O
over	-	607	O
the	-	612	O
lateral	-	616	O
side	-	624	O
of	-	629	O
the	-	632	O
right	-	636	O
forearm	-	642	O
and	-	650	O
wrist	-	654	O
area	-	660	O
.	-	664	O

RESULTS	25096313	666	O
:	-	673	O

The	25096313	675	O
sensory	-	679	O
action	-	687	O
potential	-	694	O
amplitude	-	704	O
of	-	714	O
the	-	717	O
right	-	721	O
lateral	-	727	O
antebrachial	-	735	O
cutaneous	-	748	O
nerve	-	758	O
(	-	764	O
LACN	-	765	O
)	-	769	O
(	-	771	O
6	-	772	O
.	-	773	O
2	-	774	O
uV	-	776	O
)	-	778	O
was	-	780	O
lower	-	784	O
than	-	790	O
that	-	795	O
of	-	800	O
the	-	803	O
left	-	807	O
(	-	812	O
13	-	813	O
.	-	815	O
1	-	816	O
uV	-	818	O
)	-	820	O
.	-	821	O

The	25096313	823	O
difference	-	827	O
of	-	838	O
amplitude	-	841	O
between	-	851	O
both	-	859	O
sides	-	864	O
was	-	870	O
significant	-	874	O
because	-	886	O
there	-	894	O
was	-	900	O
more	-	904	O
than	-	909	O
a	-	914	O
50	-	916	O
%	-	918	O
reduction	-	920	O
.	-	929	O

She	25096313	931	O
was	-	935	O
diagnosed	-	939	O
with	-	949	O
right	-	954	O
LACNP	-	960	O
(	-	966	O
mainly	-	967	O
axonal	-	974	O
involvement	-	981	O
)	-	992	O
on	-	994	O
the	-	997	O
basis	-	1001	O
of	-	1007	O
the	-	1010	O
clinical	-	1014	O
manifestation	-	1023	O
and	-	1037	O
the	-	1041	O
electrodiagnostic	-	1045	O
findings	-	1063	O
.	-	1071	O

Her	25096313	1073	O
symptoms	-	1077	O
improved	-	1086	O
through	-	1095	O
physical	-	1103	O
therapy	-	1112	O
but	-	1120	O
persisted	-	1124	O
to	-	1134	O
some	-	1137	O
degree	-	1142	O
.	-	1148	O

CONCLUSION	25096313	1150	O
:	-	1160	O

This	25096313	1162	O
report	-	1167	O
describes	-	1174	O
the	-	1184	O
case	-	1188	O
of	-	1193	O
a	-	1196	O
woman	-	1198	O
with	-	1204	O
LACNP	-	1209	O
that	-	1215	O
developed	-	1220	O
after	-	1230	O
a	-	1236	O
steroid	-	1238	O
injection	-	1246	O
for	-	1256	O
the	-	1260	O
treatment	-	1264	O
of	-	1274	O
lateral	-	1277	B
epicondylitis	-	1285	I
.	-	1298	O

An	25096313	1300	O
electrodiagnostic	-	1303	O
study	-	1321	O
,	-	1326	O
including	-	1328	O
a	-	1338	O
nerve	-	1340	O
conduction	-	1346	O
study	-	1357	O
of	-	1363	O
the	-	1366	O
LACN	-	1370	O
,	-	1374	O
was	-	1376	O
helpful	-	1380	O
to	-	1388	O
diagnose	-	1391	O
right	-	1400	O
LACNP	-	1406	O
and	-	1412	O
to	-	1416	O
find	-	1419	O
the	-	1424	O
passage	-	1428	O
of	-	1436	O
the	-	1439	O
LACN	-	1443	O
on	-	1448	O
the	-	1451	O
lateral	-	1455	O
epicondyle	-	1463	O
.	-	1473	O

Curcumin	25119790	0	O
prevents	-	9	O
maleate	-	18	O
-	-	25	O
induced	-	26	O
nephrotoxicity	-	34	B
:	-	48	O
relation	-	50	O
to	-	59	O
hemodynamic	-	62	O
alterations	-	74	O
,	-	85	O
oxidative	-	87	O
stress	-	97	O
,	-	103	O
mitochondrial	-	105	O
oxygen	-	119	O
consumption	-	126	O
and	-	138	O
activity	-	142	O
of	-	151	O
respiratory	-	154	O
complex	-	166	O
I	-	174	O
.	-	175	O

The	25119790	177	O
potential	-	181	O
protective	-	191	O
effect	-	202	O
of	-	209	O
the	-	212	O
dietary	-	216	O
antioxidant	-	224	O
curcumin	-	236	O
(	-	245	O
120	-	246	O
mg	-	250	O
/	-	252	O
Kg	-	253	O
/	-	255	O
day	-	256	O
for	-	260	O
6	-	264	O
days	-	266	O
)	-	270	O
against	-	272	O
the	-	280	O
renal	-	284	B
injury	-	290	I
induced	-	297	O
by	-	305	O
maleate	-	308	O
was	-	316	O
evaluated	-	320	O
.	-	329	O

Tubular	25119790	331	O
proteinuria	-	339	B
and	-	351	O
oxidative	-	355	O
stress	-	365	O
were	-	372	O
induced	-	377	O
by	-	385	O
a	-	388	O
single	-	390	O
injection	-	397	O
of	-	407	O
maleate	-	410	O
(	-	418	O
400	-	419	O
mg	-	423	O
/	-	425	O
kg	-	426	O
)	-	428	O
in	-	430	O
rats	-	433	O
.	-	437	O

Maleate	25119790	439	O
-	-	446	O
induced	-	447	O
renal	-	455	B
injury	-	461	I
included	-	468	O
increase	-	477	O
in	-	486	O
renal	-	489	O
vascular	-	495	O
resistance	-	504	O
and	-	515	O
in	-	519	O
the	-	522	O
urinary	-	526	O
excretion	-	534	O
of	-	544	O
total	-	547	O
protein	-	553	O
,	-	560	O
glucose	-	562	O
,	-	569	O
sodium	-	571	O
,	-	577	O
neutrophil	-	579	O
gelatinase	-	590	O
-	-	600	O
associated	-	601	O
lipocalin	-	612	O
(	-	622	O
NGAL	-	623	O
)	-	627	O
and	-	629	O
N	-	633	O
-	-	634	O
acetyl	-	635	O
b	-	642	O
-	-	643	O
D	-	644	O
-	-	645	O
glucosaminidase	-	646	O
(	-	662	O
NAG	-	663	O
)	-	666	O
,	-	667	O
upregulation	-	669	O
of	-	682	O
kidney	-	685	B
injury	-	692	I
molecule	-	699	O
(	-	708	O
KIM	-	709	O
)	-	712	O
-	-	713	O
1	-	714	O
,	-	715	O
decrease	-	717	O
in	-	726	O
renal	-	729	O
blood	-	735	O
flow	-	741	O
and	-	746	O
claudin	-	750	O
-	-	757	O
2	-	758	O
expression	-	760	O
besides	-	771	O
of	-	779	O
necrosis	-	782	B
and	-	791	O
apoptosis	-	795	O
of	-	805	O
tubular	-	808	O
cells	-	816	O
on	-	822	O
24	-	825	O
h	-	828	O
.	-	829	O
Oxidative	-	831	O
stress	-	841	O
was	-	848	O
determined	-	852	O
by	-	863	O
measuring	-	866	O
the	-	876	O
oxidation	-	880	O
of	-	890	O
lipids	-	893	O
and	-	900	O
proteins	-	904	O
and	-	913	O
diminution	-	917	O
in	-	928	O
renal	-	931	O
Nrf2	-	937	O
levels	-	942	O
.	-	948	O

Studies	25119790	950	O
were	-	958	O
also	-	963	O
conducted	-	968	O
in	-	978	O
renal	-	981	O
epithelial	-	987	O
LLC	-	998	O
-	-	1001	O
PK1	-	1002	O
cells	-	1006	O
and	-	1012	O
in	-	1016	O
mitochondria	-	1019	O
isolated	-	1032	O
from	-	1041	O
kidneys	-	1046	O
of	-	1054	O
all	-	1057	O
the	-	1061	O
experimental	-	1065	O
groups	-	1078	O
.	-	1084	O

Maleate	25119790	1086	O
induced	-	1094	O
cell	-	1102	O
damage	-	1107	O
and	-	1114	O
reactive	-	1118	O
oxygen	-	1127	O
species	-	1134	O
(	-	1142	O
ROS	-	1143	O
)	-	1146	O
production	-	1148	O
in	-	1159	O
LLC	-	1162	O
-	-	1165	O
PK1	-	1166	O
cells	-	1170	O
in	-	1176	O
culture	-	1179	O
.	-	1186	O

In	25119790	1188	O
addition	-	1191	O
,	-	1199	O
maleate	-	1201	O
treatment	-	1209	O
reduced	-	1219	O
oxygen	-	1227	O
consumption	-	1234	O
in	-	1246	O
ADP	-	1249	O
-	-	1252	O
stimulated	-	1253	O
mitochondria	-	1264	O
and	-	1277	O
diminished	-	1281	O
respiratory	-	1292	O
control	-	1304	O
index	-	1312	O
when	-	1318	O
using	-	1323	O
malate	-	1329	O
/	-	1335	O
glutamate	-	1336	O
as	-	1346	O
substrate	-	1349	O
.	-	1358	O

The	25119790	1360	O
activities	-	1364	O
of	-	1375	O
both	-	1378	O
complex	-	1383	O
I	-	1391	O
and	-	1393	O
aconitase	-	1397	O
were	-	1407	O
also	-	1412	O
diminished	-	1417	O
.	-	1427	O

All	25119790	1429	O
the	-	1433	O
above	-	1437	O
-	-	1442	O
described	-	1443	O
alterations	-	1453	O
were	-	1465	O
prevented	-	1470	O
by	-	1480	O
curcumin	-	1483	O
.	-	1491	O

It	25119790	1493	O
is	-	1496	O
concluded	-	1499	O
that	-	1509	O
curcumin	-	1514	O
is	-	1523	O
able	-	1526	O
to	-	1531	O
attenuate	-	1534	O
in	-	1544	O
vivo	-	1547	O
maleate	-	1552	O
-	-	1559	O
induced	-	1560	O
nephropathy	-	1568	B
and	-	1580	O
in	-	1584	O
vitro	-	1587	O
cell	-	1593	O
damage	-	1598	O
.	-	1604	O

The	25119790	1606	O
in	-	1610	O
vivo	-	1613	O
protection	-	1618	O
was	-	1629	O
associated	-	1633	O
to	-	1644	O
the	-	1647	O
prevention	-	1651	O
of	-	1662	O
oxidative	-	1665	O
stress	-	1675	O
and	-	1682	O
preservation	-	1686	O
of	-	1699	O
mitochondrial	-	1702	O
oxygen	-	1716	O
consumption	-	1723	O
and	-	1735	O
activity	-	1739	O
of	-	1748	O
respiratory	-	1751	O
complex	-	1763	O
I	-	1771	O
,	-	1772	O
and	-	1774	O
the	-	1778	O
in	-	1782	O
vitro	-	1785	O
protection	-	1791	O
was	-	1802	O
associated	-	1806	O
to	-	1817	O
the	-	1820	O
prevention	-	1824	O
of	-	1835	O
ROS	-	1838	O
production	-	1842	O
.	-	1852	O

Incidence	25907210	0	O
of	-	10	O
solid	-	13	O
tumours	-	19	B
among	-	27	O
pesticide	-	33	O
applicators	-	43	O
exposed	-	55	O
to	-	63	O
the	-	66	O
organophosphate	-	70	O
insecticide	-	86	O
diazinon	-	98	O
in	-	107	O
the	-	110	O
Agricultural	-	114	O
Health	-	127	O
Study	-	134	O
:	-	139	O
an	-	141	O
updated	-	144	O
analysis	-	152	O
.	-	160	O

OBJECTIVE	25907210	162	O
:	-	171	O
Diazinon	-	173	O
,	-	181	O
a	-	183	O
common	-	185	O
organophosphate	-	192	O
insecticide	-	208	O
with	-	220	O
genotoxic	-	225	O
properties	-	235	O
,	-	245	O
was	-	247	O
previously	-	251	O
associated	-	262	O
with	-	273	O
lung	-	278	B
cancer	-	283	I
in	-	290	O
the	-	293	O
Agricultural	-	297	O
Health	-	310	O
Study	-	317	O
(	-	323	O
AHS	-	324	O
)	-	327	O
cohort	-	329	O
,	-	335	O
but	-	337	O
few	-	341	O
other	-	345	O
epidemiological	-	351	O
studies	-	367	O
have	-	375	O
examined	-	380	O
diazinon	-	389	O
-	-	397	O
associated	-	398	O
cancer	-	409	B
risk	-	416	O
.	-	420	O

We	25907210	422	O
used	-	425	O
updated	-	430	O
diazinon	-	438	O
exposure	-	447	O
and	-	456	O
cancer	-	460	B
incidence	-	467	O
information	-	477	O
to	-	489	O
evaluate	-	492	O
solid	-	501	O
tumour	-	507	B
risk	-	514	O
in	-	519	O
the	-	522	O
AHS	-	526	O
.	-	529	O

METHODS	25907210	531	O
:	-	538	O

Male	25907210	540	O
pesticide	-	545	O
applicators	-	555	O
in	-	567	O
Iowa	-	570	O
and	-	575	O
North	-	579	O
Carolina	-	585	O
reported	-	594	O
lifetime	-	603	O
diazinon	-	612	O
use	-	621	O
at	-	625	O
enrolment	-	628	O
(	-	638	O
1993	-	639	O
-	-	643	O
1997	-	644	O
)	-	648	O
and	-	650	O
follow	-	654	O
-	-	660	O
up	-	661	O
(	-	664	O
1998	-	665	O
-	-	669	O
2005	-	670	O
)	-	674	O
;	-	675	O
cancer	-	677	B
incidence	-	684	O
was	-	694	O
assessed	-	698	O
through	-	707	O
2010	-	715	O
(	-	719	O
North	-	720	O
Carolina	-	726	O
)	-	734	O
/	-	735	O
2011	-	736	O
(	-	740	O
Iowa	-	741	O
)	-	745	O
.	-	746	O

Among	25907210	748	O
applicators	-	754	O
with	-	766	O
usage	-	771	O
information	-	777	O
sufficient	-	789	O
to	-	800	O
evaluate	-	803	O
exposure	-	812	O
-	-	820	O
response	-	821	O
patterns	-	830	O
,	-	838	O
we	-	840	O
used	-	843	O
Poisson	-	848	O
regression	-	856	O
to	-	867	O
estimate	-	870	O
adjusted	-	879	O
rate	-	888	O
ratios	-	893	O
(	-	900	O
RRs	-	901	O
)	-	904	O
and	-	906	O
95	-	910	O
%	-	912	O
CI	-	914	O
for	-	917	O
cancer	-	921	B
sites	-	928	O
with	-	934	O
>	-	939	O
10	-	940	O
exposed	-	943	O
cases	-	951	O
for	-	957	O
both	-	961	O
lifetime	-	966	O
(	-	975	O
LT	-	976	O
)	-	978	O
exposure	-	980	O
days	-	989	O
and	-	994	O
intensity	-	998	O
-	-	1007	O
weighted	-	1008	O
(	-	1017	O
IW	-	1018	O
)	-	1020	O
lifetime	-	1022	O
exposure	-	1031	O
days	-	1040	O
(	-	1045	O
accounting	-	1046	O
for	-	1057	O
factors	-	1061	O
impacting	-	1069	O
exposure	-	1079	O
)	-	1087	O
.	-	1088	O

RESULTS	25907210	1090	O
:	-	1097	O

We	25907210	1099	O
observed	-	1102	O
elevated	-	1111	O
lung	-	1120	B
cancer	-	1125	I
risks	-	1132	O
(	-	1138	O
N	-	1139	O
=	-	1140	O
283	-	1141	O
)	-	1144	O
among	-	1146	O
applicators	-	1152	O
with	-	1164	O
the	-	1169	O
greatest	-	1173	O
number	-	1182	O
of	-	1189	O
LT	-	1192	O
(	-	1195	O
RR	-	1196	O
=	-	1198	O
1	-	1199	O
.	-	1200	O
60	-	1201	O
;	-	1203	O
95	-	1205	O
%	-	1207	O
CI	-	1209	O
1	-	1212	O
.	-	1213	O
11	-	1214	O
to	-	1217	O
2	-	1220	O
.	-	1221	O
31	-	1222	O
;	-	1224	O
Ptrend	-	1226	O
=	-	1232	O
0	-	1233	O
.	-	1234	O
02	-	1235	O
)	-	1237	O
and	-	1239	O
IW	-	1243	O
days	-	1246	O
of	-	1251	O
diazinon	-	1254	O
use	-	1263	O
(	-	1267	O
RR	-	1268	O
=	-	1270	O
1	-	1271	O
.	-	1272	O
41	-	1273	O
;	-	1275	O
95	-	1277	O
%	-	1279	O
CI	-	1281	O
0	-	1284	O
.	-	1285	O
98	-	1286	O
to	-	1289	O
2	-	1292	O
.	-	1293	O
04	-	1294	O
;	-	1296	O
Ptrend	-	1298	O
=	-	1304	O
0	-	1305	O
.	-	1306	O
08	-	1307	O
)	-	1309	O
.	-	1310	O

Kidney	25907210	1312	B
cancer	-	1319	I
(	-	1326	O
N	-	1327	O
=	-	1328	O
94	-	1329	O
)	-	1331	O
risks	-	1333	O
were	-	1339	O
non	-	1344	O
-	-	1347	O
significantly	-	1348	O
elevated	-	1362	O
(	-	1371	O
RRLT	-	1372	O
days	-	1377	O
=	-	1381	O
1	-	1382	O
.	-	1383	O
77	-	1384	O
;	-	1386	O
95	-	1388	O
%	-	1390	O
CI	-	1392	O
0	-	1395	O
.	-	1396	O
90	-	1397	O
to	-	1400	O
3	-	1403	O
.	-	1404	O
51	-	1405	O
;	-	1407	O
Ptrend	-	1409	O
=	-	1415	O
0	-	1416	O
.	-	1417	O
09	-	1418	O
;	-	1420	O
RRIW	-	1422	O
days	-	1427	O
1	-	1432	O
.	-	1433	O
37	-	1434	O
;	-	1436	O
95	-	1438	O
%	-	1440	O
CI	-	1442	O
0	-	1445	O
.	-	1446	O
64	-	1447	O
to	-	1450	O
2	-	1453	O
.	-	1454	O
92	-	1455	O
;	-	1457	O
Ptrend	-	1459	O
=	-	1465	O
0	-	1466	O
.	-	1467	O
50	-	1468	O
)	-	1470	O
,	-	1471	O
as	-	1473	O
were	-	1476	O
risks	-	1481	O
for	-	1487	O
aggressive	-	1491	O
prostate	-	1502	B
cancer	-	1511	I
(	-	1518	O
N	-	1519	O
=	-	1520	O
656	-	1521	O
)	-	1524	O
.	-	1525	O

CONCLUSIONS	25907210	1527	O
:	-	1538	O

Our	25907210	1540	O
updated	-	1544	O
evaluation	-	1552	O
of	-	1563	O
diazinon	-	1566	O
provides	-	1575	O
additional	-	1584	O
evidence	-	1595	O
of	-	1604	O
an	-	1607	O
association	-	1610	O
with	-	1622	O
lung	-	1627	B
cancer	-	1632	I
risk	-	1639	O
.	-	1643	O

Newly	25907210	1645	O
identified	-	1651	O
links	-	1662	O
to	-	1668	O
kidney	-	1671	B
cancer	-	1678	I
and	-	1685	O
associations	-	1689	O
with	-	1702	O
aggressive	-	1707	O
prostate	-	1718	B
cancer	-	1727	I
require	-	1734	O
further	-	1742	O
evaluation	-	1750	O
.	-	1760	O

Associations	25951420	0	O
of	-	13	O
Ozone	-	16	O
and	-	22	O
PM2	-	26	O
.	-	29	O
5	-	30	O
Concentrations	-	32	O
With	-	47	O
Parkinson	-	52	B
's	-	61	I
Disease	-	64	I
Among	-	72	O
Participants	-	78	O
in	-	91	O
the	-	94	O
Agricultural	-	98	O
Health	-	111	O
Study	-	118	O
.	-	123	O

OBJECTIVE	25951420	125	O
:	-	134	O

This	25951420	136	O
study	-	141	O
describes	-	147	O
associations	-	157	O
of	-	170	O
ozone	-	173	O
and	-	179	O
fine	-	183	O
particulate	-	188	O
matter	-	200	O
with	-	207	O
Parkinson	-	212	B
's	-	221	I
disease	-	224	I
observed	-	232	O
among	-	241	O
farmers	-	247	O
in	-	255	O
North	-	258	O
Carolina	-	264	O
and	-	273	O
Iowa	-	277	O
.	-	281	O

METHODS	25951420	283	O
:	-	290	O

We	25951420	292	O
used	-	295	O
logistic	-	300	O
regression	-	309	O
to	-	320	O
determine	-	323	O
the	-	333	O
associations	-	337	O
of	-	350	O
these	-	353	O
pollutants	-	359	O
with	-	370	O
self	-	375	O
-	-	379	O
reported	-	380	O
,	-	388	O
doctor	-	390	O
-	-	396	O
diagnosed	-	397	O
Parkinson	-	407	B
's	-	416	I
disease	-	419	I
.	-	426	O

Daily	25951420	428	O
predicted	-	434	O
pollutant	-	444	O
concentrations	-	454	O
were	-	469	O
used	-	474	O
to	-	479	O
derive	-	482	O
surrogates	-	489	O
of	-	500	O
long	-	503	O
-	-	507	O
term	-	508	O
exposure	-	513	O
and	-	522	O
link	-	526	O
them	-	531	O
to	-	536	O
study	-	539	O
participants	-	545	O
'	-	557	O
geocoded	-	559	O
addresses	-	568	O
.	-	577	O

RESULTS	25951420	579	O
:	-	586	O

We	25951420	588	O
observed	-	591	O
positive	-	600	O
associations	-	609	O
of	-	622	O
Parkinson	-	625	B
's	-	634	I
disease	-	637	I
with	-	645	O
ozone	-	650	O
(	-	656	O
odds	-	657	O
ratio	-	662	O
=	-	668	O
1	-	670	O
.	-	671	O
39	-	672	O
;	-	674	O
95	-	676	O
%	-	678	O
CI	-	680	O
:	-	682	O
0	-	684	O
.	-	685	O
98	-	686	O
to	-	689	O
1	-	692	O
.	-	693	O
98	-	694	O
)	-	696	O
and	-	698	O
fine	-	702	O
particulate	-	707	O
matter	-	719	O
(	-	726	O
odds	-	727	O
ratio	-	732	O
=	-	738	O
1	-	740	O
.	-	741	O
34	-	742	O
;	-	744	O
95	-	746	O
%	-	748	O
CI	-	750	O
:	-	752	O
0	-	754	O
.	-	755	O
93	-	756	O
to	-	759	O
1	-	762	O
.	-	763	O
93	-	764	O
)	-	766	O
in	-	768	O
North	-	771	O
Carolina	-	777	O
but	-	786	O
not	-	790	O
in	-	794	O
Iowa	-	797	O
.	-	801	O

CONCLUSIONS	25951420	803	O
:	-	814	O

The	25951420	816	O
plausibility	-	820	O
of	-	833	O
an	-	836	O
effect	-	839	O
of	-	846	O
ambient	-	849	O
concentrations	-	857	O
of	-	872	O
these	-	875	O
pollutants	-	881	O
on	-	892	O
Parkinson	-	895	B
's	-	904	I
disease	-	907	I
risk	-	915	O
is	-	920	O
supported	-	923	O
by	-	933	O
experimental	-	936	O
data	-	949	O
demonstrating	-	954	O
damage	-	968	O
to	-	975	O
dopaminergic	-	978	O
neurons	-	991	O
at	-	999	O
relevant	-	1002	O
concentrations	-	1011	O
.	-	1025	O

Additional	25951420	1027	O
studies	-	1038	O
are	-	1046	O
needed	-	1050	O
to	-	1057	O
address	-	1060	O
uncertainties	-	1068	O
related	-	1082	O
to	-	1090	O
confounding	-	1093	O
and	-	1105	O
to	-	1109	O
examine	-	1112	O
temporal	-	1120	O
aspects	-	1129	O
of	-	1137	O
the	-	1140	O
associations	-	1144	O
we	-	1157	O
observed	-	1160	O
.	-	1168	O

Low	25986755	0	O
functional	-	4	O
programming	-	15	O
of	-	27	O
renal	-	30	O
AT2R	-	36	O
mediates	-	41	O
the	-	50	O
developmental	-	54	O
origin	-	68	O
of	-	75	O
glomerulosclerosis	-	78	B
in	-	97	O
adult	-	100	O
offspring	-	106	O
induced	-	116	O
by	-	124	O
prenatal	-	127	O
caffeine	-	136	O
exposure	-	145	O
.	-	153	O

UNASSIGNED	25986755	155	O
:	-	165	O

Our	25986755	167	O
previous	-	171	O
study	-	180	O
has	-	186	O
indicated	-	190	O
that	-	200	O
prenatal	-	205	O
caffeine	-	214	O
exposure	-	223	O
(	-	232	O
PCE	-	233	O
)	-	236	O
could	-	238	O
induce	-	244	O
intrauterine	-	251	B
growth	-	264	I
retardation	-	271	I
(	-	283	O
IUGR	-	284	B
)	-	288	O
of	-	290	O
offspring	-	293	O
.	-	302	O

Recent	25986755	304	O
research	-	311	O
suggested	-	320	O
that	-	330	O
IUGR	-	335	B
is	-	340	O
a	-	343	O
risk	-	345	O
factor	-	350	O
for	-	357	O
glomerulosclerosis	-	361	B
.	-	379	O

However	25986755	381	O
,	-	388	O
whether	-	390	O
PCE	-	398	O
could	-	402	O
induce	-	408	O
glomerulosclerosis	-	415	B
and	-	434	O
its	-	438	O
underlying	-	442	O
mechanisms	-	453	O
remain	-	464	O
unknown	-	471	O
.	-	478	O

This	25986755	480	O
study	-	485	O
aimed	-	491	O
to	-	497	O
demonstrate	-	500	O
the	-	512	O
induction	-	516	O
to	-	526	O
glomerulosclerosis	-	529	B
in	-	548	O
adult	-	551	O
offspring	-	557	O
by	-	567	O
PCE	-	570	O
and	-	574	O
its	-	578	O
intrauterine	-	582	O
programming	-	595	O
mechanisms	-	607	O
.	-	617	O

A	25986755	619	O
rat	-	621	O
model	-	625	O
of	-	631	O
IUGR	-	634	B
was	-	639	O
established	-	643	O
by	-	655	O
PCE	-	658	O
,	-	661	O
male	-	663	O
fetuses	-	668	O
and	-	676	O
adult	-	680	O
offspring	-	686	O
at	-	696	O
the	-	699	O
age	-	703	O
of	-	707	O
postnatal	-	710	O
week	-	720	O
24	-	725	O
were	-	728	O
euthanized	-	733	O
.	-	743	O

The	25986755	745	O
results	-	749	O
revealed	-	757	O
that	-	766	O
the	-	771	O
adult	-	775	O
offspring	-	781	O
kidneys	-	791	O
in	-	799	O
the	-	802	O
PCE	-	806	O
group	-	810	O
exhibited	-	816	O
glomerulosclerosis	-	826	B
as	-	845	O
well	-	848	O
as	-	853	O
interstitial	-	856	B
fibrosis	-	869	I
,	-	877	O
accompanied	-	879	O
by	-	891	O
elevated	-	894	O
levels	-	903	O
of	-	910	O
serum	-	913	O
creatinine	-	919	O
and	-	930	O
urine	-	934	O
protein	-	940	O
.	-	947	O

Renal	25986755	949	O
angiotensin	-	955	O
II	-	967	O
receptor	-	970	O
type	-	979	O
2	-	984	O
(	-	986	O
AT2R	-	987	O
)	-	991	O
gene	-	993	O
expression	-	998	O
in	-	1009	O
adult	-	1012	O
offspring	-	1018	O
was	-	1028	O
reduced	-	1032	O
by	-	1040	O
PCE	-	1043	O
,	-	1046	O
whereas	-	1048	O
the	-	1056	O
renal	-	1060	O
angiotensin	-	1066	O
II	-	1078	O
receptor	-	1081	O
type	-	1090	O
1a	-	1095	O
(	-	1098	O
AT1aR	-	1099	O
)	-	1104	O
/	-	1105	O
AT2R	-	1106	O
expression	-	1111	O
ratio	-	1122	O
was	-	1128	O
increased	-	1132	O
.	-	1141	O

The	25986755	1143	O
fetal	-	1147	O
kidneys	-	1153	O
in	-	1161	O
the	-	1164	O
PCE	-	1168	O
group	-	1172	O
displayed	-	1178	O
an	-	1188	O
enlarged	-	1191	O
Bowman	-	1200	O
's	-	1206	O
space	-	1209	O
and	-	1215	O
a	-	1219	O
shrunken	-	1221	O
glomerular	-	1230	O
tuft	-	1241	O
,	-	1245	O
accompanied	-	1247	O
by	-	1259	O
a	-	1262	O
reduced	-	1264	O
cortex	-	1272	O
width	-	1279	O
and	-	1285	O
an	-	1289	O
increase	-	1292	O
in	-	1301	O
the	-	1304	O
nephrogenic	-	1308	O
zone	-	1320	O
/	-	1324	O
cortical	-	1325	O
zone	-	1334	O
ratio	-	1339	O
.	-	1344	O

Observation	25986755	1346	O
by	-	1358	O
electronic	-	1361	O
microscope	-	1372	O
revealed	-	1383	O
structural	-	1392	O
damage	-	1403	O
of	-	1410	O
podocytes	-	1413	O
;	-	1422	O
the	-	1424	O
reduced	-	1428	O
expression	-	1436	O
level	-	1447	O
of	-	1453	O
podocyte	-	1456	O
marker	-	1465	O
genes	-	1472	O
,	-	1477	O
nephrin	-	1479	O
and	-	1487	O
podocin	-	1491	O
,	-	1498	O
was	-	1500	O
also	-	1504	O
detected	-	1509	O
by	-	1518	O
q	-	1521	O
-	-	1522	O
PCR	-	1523	O
.	-	1526	O

Moreover	25986755	1528	O
,	-	1536	O
AT2R	-	1538	O
gene	-	1543	O
and	-	1548	O
protein	-	1552	O
expressions	-	1560	O
in	-	1572	O
fetal	-	1575	O
kidneys	-	1581	O
were	-	1589	O
inhibited	-	1594	O
by	-	1604	O
PCE	-	1607	O
,	-	1610	O
associated	-	1612	O
with	-	1623	O
the	-	1628	O
repression	-	1632	O
of	-	1643	O
the	-	1646	O
gene	-	1650	O
expression	-	1655	O
of	-	1666	O
glial	-	1669	O
-	-	1674	O
cell	-	1675	O
-	-	1679	O
line	-	1680	O
-	-	1684	O
derived	-	1685	O
neurotrophic	-	1693	O
factor	-	1706	O
(	-	1713	O
GDNF	-	1714	O
)	-	1718	O
/	-	1719	O
tyrosine	-	1720	O
kinase	-	1729	O
receptor	-	1736	O
(	-	1745	O
c	-	1746	O
-	-	1747	O
Ret	-	1748	O
)	-	1751	O
signaling	-	1753	O
pathway	-	1763	O
.	-	1770	O

These	25986755	1772	O
results	-	1778	O
demonstrated	-	1786	O
that	-	1799	O
PCE	-	1804	O
could	-	1808	O
induce	-	1814	O
dysplasia	-	1821	B
of	-	1831	I
fetal	-	1834	I
kidneys	-	1840	I
as	-	1848	O
well	-	1851	O
as	-	1856	O
glomerulosclerosis	-	1859	B
of	-	1878	O
adult	-	1881	O
offspring	-	1887	O
,	-	1896	O
and	-	1898	O
the	-	1902	O
low	-	1906	O
functional	-	1910	O
programming	-	1921	O
of	-	1933	O
renal	-	1936	O
AT2R	-	1942	O
might	-	1947	O
mediate	-	1953	O
the	-	1961	O
developmental	-	1965	O
origin	-	1979	O
of	-	1986	O
adult	-	1989	O
glomerulosclerosis	-	1995	B
.	-	2013	O

1	26002693	0	O
,	-	1	O
3	-	2	O
-	-	3	O
Butadiene	-	4	O
,	-	13	O
CML	-	15	B
and	-	19	O
the	-	23	O
t	-	27	O
(	-	28	O
9	-	29	O
:	-	30	O
22	-	31	O
)	-	33	O
translocation	-	35	O
:	-	48	O

A	26002693	50	O
reality	-	52	O
check	-	60	O
.	-	65	O

UNASSIGNED	26002693	67	O
:	-	77	O

Epidemiological	26002693	79	O
studies	-	95	O
of	-	103	O
1	-	106	O
,	-	107	O
3	-	108	O
-	-	109	O
butadiene	-	110	O
have	-	120	O
suggest	-	125	O
that	-	133	O
exposures	-	138	O
to	-	148	O
humans	-	151	O
are	-	158	O
associated	-	162	O
with	-	173	O
chronic	-	178	B
myeloid	-	186	I
leukemia	-	194	I
(	-	203	O
CML	-	204	B
)	-	207	O
.	-	208	O

CML	26002693	210	B
has	-	214	O
a	-	218	O
well	-	220	O
-	-	224	O
documented	-	225	O
association	-	236	O
with	-	248	O
ionizing	-	253	O
radiation	-	262	O
,	-	271	O
but	-	273	O
reports	-	277	O
of	-	285	O
associations	-	288	O
with	-	301	O
chemical	-	306	O
exposures	-	315	O
have	-	325	O
been	-	330	O
questioned	-	335	O
.	-	345	O

Ionizing	26002693	347	O
radiation	-	356	O
is	-	366	O
capable	-	369	O
of	-	377	O
inducing	-	380	O
the	-	389	O
requisite	-	393	O
CML	-	403	B
-	-	406	O
associated	-	407	O
t	-	418	O
(	-	419	O
9	-	420	O
:	-	421	O
22	-	422	O
)	-	424	O
translocation	-	426	O
(	-	440	O
Philadelphia	-	441	B
chromosome	-	454	I
)	-	464	O
in	-	466	O
appropriate	-	469	O
cells	-	481	O
in	-	487	O
vitro	-	490	O
but	-	496	O
,	-	499	O
thus	-	501	O
far	-	506	O
,	-	509	O
chemicals	-	511	O
have	-	521	O
not	-	526	O
shown	-	530	O
this	-	536	O
capacity	-	541	O
.	-	549	O

We	26002693	551	O
have	-	554	O
proposed	-	559	O
that	-	568	O
1	-	573	O
,	-	574	O
3	-	575	O
-	-	576	O
butadiene	-	577	O
metabolites	-	587	O
be	-	599	O
so	-	602	O
tested	-	605	O
as	-	612	O
a	-	615	O
reality	-	617	O
check	-	625	O
on	-	631	O
the	-	634	O
epidemiological	-	638	O
reports	-	654	O
.	-	661	O

In	26002693	663	O
order	-	666	O
to	-	672	O
conduct	-	675	O
reliable	-	683	O
testing	-	692	O
in	-	700	O
this	-	703	O
regard	-	708	O
,	-	714	O
it	-	716	O
is	-	719	O
essential	-	722	O
that	-	732	O
a	-	737	O
positive	-	739	O
control	-	748	O
for	-	756	O
induction	-	760	O
be	-	770	O
available	-	773	O
.	-	782	O

We	26002693	784	O
have	-	787	O
used	-	792	O
ionizing	-	797	O
radiation	-	806	O
to	-	816	O
develop	-	819	O
such	-	827	O
a	-	832	O
control	-	834	O
.	-	841	O

Results	26002693	843	O
described	-	851	O
here	-	861	O
demonstrate	-	866	O
that	-	878	O
this	-	883	O
agent	-	888	O
does	-	894	O
in	-	899	O
fact	-	902	O
induce	-	907	O
pathogenic	-	914	O
t	-	925	O
(	-	926	O
9	-	927	O
:	-	928	O
22	-	929	O
)	-	931	O
translocations	-	933	O
in	-	948	O
a	-	951	O
human	-	953	O
myeloid	-	959	O
cell	-	967	O
line	-	972	O
in	-	977	O
vitro	-	980	O
,	-	985	O
but	-	987	O
does	-	991	O
so	-	996	O
at	-	999	O
low	-	1002	O
frequencies	-	1006	O
.	-	1017	O

Conditions	26002693	1019	O
that	-	1030	O
will	-	1035	O
be	-	1040	O
required	-	1043	O
for	-	1052	O
studies	-	1056	O
of	-	1064	O
1	-	1067	O
,	-	1068	O
3	-	1069	O
-	-	1070	O
butadiene	-	1071	O
are	-	1081	O
discussed	-	1085	O
.	-	1094	O

Cancer	26033014	0	B
incidence	-	7	O
and	-	17	O
metolachlor	-	21	O
use	-	33	O
in	-	37	O
the	-	40	O
Agricultural	-	44	O
Health	-	57	O
Study	-	64	O
:	-	69	O

An	26033014	71	O
update	-	74	O
.	-	80	O

UNASSIGNED	26033014	82	O
:	-	92	O
Metolachlor	-	94	O
,	-	105	O
a	-	107	O
widely	-	109	O
used	-	116	O
herbicide	-	121	O
,	-	130	O
is	-	132	O
classified	-	135	O
as	-	146	O
a	-	149	O
Group	-	151	O
C	-	157	O
carcinogen	-	159	O
by	-	170	O
the	-	173	O
U	-	177	O
.	-	178	O
S	-	179	O
.	-	180	O
Environmental	-	182	O
Protection	-	196	O
Agency	-	207	O
based	-	214	O
on	-	220	O
increased	-	223	O
liver	-	233	B
neoplasms	-	239	I
in	-	249	O
female	-	252	O
rats	-	259	O
.	-	263	O

Epidemiologic	26033014	265	O
studies	-	279	O
of	-	287	O
the	-	290	O
health	-	294	O
effects	-	301	O
of	-	309	O
metolachlor	-	312	O
have	-	324	O
been	-	329	O
limited	-	334	O
.	-	341	O

The	26033014	343	O
Agricultural	-	347	O
Health	-	360	O
Study	-	367	O
(	-	373	O
AHS	-	374	O
)	-	377	O
is	-	379	O
a	-	382	O
prospective	-	384	O
cohort	-	396	O
study	-	403	O
including	-	409	O
licensed	-	419	O
private	-	428	O
and	-	436	O
commercial	-	440	O
pesticide	-	451	O
applicators	-	461	O
in	-	473	O
Iowa	-	476	O
and	-	481	O
North	-	485	O
Carolina	-	491	O
enrolled	-	500	O
1993	-	509	O
-	-	513	O
1997	-	514	O
.	-	518	O

We	26033014	520	O
evaluated	-	523	O
cancer	-	533	B
incidence	-	540	O
through	-	550	O
2010	-	558	O
/	-	562	O
2011	-	563	O
(	-	568	O
NC	-	569	O
/	-	571	O
IA	-	572	O
)	-	574	O
for	-	576	O
49	-	580	O
,	-	582	O
616	-	583	O
applicators	-	587	O
,	-	598	O
53	-	600	O
%	-	602	O
of	-	604	O
whom	-	607	O
reported	-	612	O
ever	-	621	O
using	-	626	O
metolachlor	-	632	O
.	-	643	O

We	26033014	645	O
used	-	648	O
Poisson	-	653	O
regression	-	661	O
to	-	672	O
evaluate	-	675	O
relations	-	684	O
between	-	694	O
two	-	702	O
metrics	-	706	O
of	-	714	O
metolachlor	-	717	O
use	-	729	O
(	-	733	O
lifetime	-	734	O
days	-	743	O
,	-	747	O
intensity	-	749	O
-	-	758	O
weighted	-	759	O
lifetime	-	768	O
days	-	777	O
)	-	781	O
and	-	783	O
cancer	-	787	B
incidence	-	794	O
.	-	803	O

We	26033014	805	O
saw	-	808	O
no	-	812	O
association	-	815	O
between	-	827	O
metolachlor	-	835	O
use	-	847	O
and	-	851	O
incidence	-	855	O
of	-	865	O
all	-	868	O
cancers	-	872	B
combined	-	880	O
(	-	889	O
n	-	890	O
=	-	892	O
5	-	894	O
,	-	895	O
701	-	896	O
with	-	900	O
a	-	905	O
5	-	907	O
-	-	908	O
year	-	909	O
lag	-	914	O
)	-	917	O
or	-	919	O
most	-	922	O
site	-	927	O
-	-	931	O
specific	-	932	O
cancers	-	941	B
.	-	948	O

For	26033014	950	O
liver	-	954	B
cancer	-	960	I
,	-	966	O
in	-	968	O
analyses	-	971	O
restricted	-	980	O
to	-	991	O
exposed	-	994	O
workers	-	1002	O
,	-	1009	O
elevations	-	1011	O
observed	-	1022	O
at	-	1031	O
higher	-	1034	O
categories	-	1041	O
of	-	1052	O
use	-	1055	O
were	-	1059	O
not	-	1064	O
statistically	-	1068	O
significant	-	1082	O
.	-	1093	O

However	26033014	1095	O
,	-	1102	O
trends	-	1104	O
for	-	1111	O
both	-	1115	O
lifetime	-	1120	O
and	-	1129	O
intensity	-	1133	O
-	-	1142	O
weighted	-	1143	O
lifetime	-	1152	O
days	-	1161	O
of	-	1166	O
metolachor	-	1169	O
use	-	1180	O
were	-	1184	O
positive	-	1189	O
and	-	1198	O
statistically	-	1202	O
significant	-	1216	O
with	-	1228	O
an	-	1233	O
unexposed	-	1236	O
reference	-	1246	O
group	-	1256	O
.	-	1261	O

A	26033014	1263	O
similar	-	1265	O
pattern	-	1273	O
was	-	1281	O
observed	-	1285	O
for	-	1294	O
follicular	-	1298	B
cell	-	1309	I
lymphoma	-	1314	I
,	-	1322	O
but	-	1324	O
no	-	1328	O
other	-	1331	O
lymphoma	-	1337	B
subtypes	-	1346	O
.	-	1354	O

An	26033014	1356	O
earlier	-	1359	O
suggestion	-	1367	O
of	-	1378	O
increased	-	1381	O
lung	-	1391	B
cancer	-	1396	I
risk	-	1403	O
at	-	1408	O
high	-	1411	O
levels	-	1416	O
of	-	1423	O
metolachlor	-	1426	O
use	-	1438	O
in	-	1442	O
this	-	1445	O
cohort	-	1450	O
was	-	1457	O
not	-	1461	O
confirmed	-	1465	O
in	-	1475	O
this	-	1478	O
update	-	1483	O
.	-	1489	O

This	26033014	1491	O
suggestion	-	1496	O
of	-	1507	O
an	-	1510	O
association	-	1513	O
between	-	1525	O
metolachlor	-	1533	O
and	-	1545	O
liver	-	1549	B
cancer	-	1555	I
among	-	1562	O
pesticide	-	1568	O
applicators	-	1578	O
is	-	1590	O
a	-	1593	O
novel	-	1595	O
finding	-	1601	O
and	-	1609	O
echoes	-	1613	O
observation	-	1620	O
of	-	1632	O
increased	-	1635	O
liver	-	1645	B
neoplasms	-	1651	I
in	-	1661	O
some	-	1664	O
animal	-	1669	O
studies	-	1676	O
.	-	1683	O

However	26033014	1685	O
,	-	1692	O
our	-	1694	O
findings	-	1698	O
for	-	1707	O
both	-	1711	O
liver	-	1716	B
cancer	-	1722	I
and	-	1729	O
follicular	-	1733	O
cell	-	1744	O
lymphoma	-	1749	B
warrant	-	1758	O
follow	-	1766	O
-	-	1772	O
up	-	1773	O
to	-	1776	O
better	-	1779	O
differentiate	-	1786	O
effects	-	1800	O
of	-	1808	O
metolachlor	-	1811	O
use	-	1823	O
from	-	1827	O
other	-	1832	O
factors	-	1838	O
.	-	1845	O

Mechanisms	26115410	0	O
Underlying	-	11	O
Latent	-	22	O
Disease	-	29	O
Risk	-	37	O
Associated	-	42	O
with	-	53	O
Early	-	58	O
-	-	63	O
Life	-	64	O
Arsenic	-	69	O
Exposure	-	77	O
:	-	85	O
Current	-	87	O
Research	-	95	O
Trends	-	104	O
and	-	111	O
Scientific	-	115	O
Gaps	-	126	O
.	-	130	O

BACKGROUND	26115410	132	O
:	-	142	O

Millions	26115410	144	O
of	-	153	O
individuals	-	156	O
worldwide	-	168	O
,	-	177	O
particularly	-	179	O
those	-	192	O
living	-	198	O
in	-	205	O
rural	-	208	O
and	-	214	O
developing	-	218	O
areas	-	229	O
,	-	234	O
are	-	236	O
exposed	-	240	O
to	-	248	O
harmful	-	251	O
levels	-	259	O
of	-	266	O
inorganic	-	269	O
arsenic	-	279	O
(	-	287	O
iAs	-	288	O
)	-	291	O
in	-	293	O
their	-	296	O
drinking	-	302	O
water	-	311	O
.	-	316	O

Inorganic	26115410	318	O
As	-	328	O
exposure	-	331	O
during	-	340	O
key	-	347	O
developmental	-	351	O
periods	-	365	O
is	-	373	O
associated	-	376	O
with	-	387	O
a	-	392	O
variety	-	394	O
of	-	402	O
adverse	-	405	O
health	-	413	O
effects	-	420	O
including	-	428	O
those	-	438	O
that	-	444	O
are	-	449	O
evident	-	453	O
in	-	461	O
adulthood	-	464	O
.	-	473	O

There	26115410	475	O
is	-	481	O
considerable	-	484	O
interest	-	497	O
in	-	506	O
identifying	-	509	O
the	-	521	O
molecular	-	525	O
mechanisms	-	535	O
that	-	546	O
relate	-	551	O
early	-	558	O
-	-	563	O
life	-	564	O
iAs	-	569	O
exposure	-	573	O
to	-	582	O
the	-	585	O
development	-	589	O
of	-	601	O
these	-	604	O
latent	-	610	O
diseases	-	617	O
,	-	625	O
particularly	-	627	O
in	-	640	O
relationship	-	643	O
to	-	656	O
cancer	-	659	B
.	-	665	O

OBJECTIVES	26115410	667	O
:	-	677	O

This	26115410	679	O
work	-	684	O
summarizes	-	689	O
research	-	700	O
on	-	709	O
the	-	712	O
molecular	-	716	O
mechanisms	-	726	O
that	-	737	O
underlie	-	742	O
the	-	751	O
increased	-	755	O
risk	-	765	O
of	-	770	O
cancer	-	773	B
development	-	780	O
in	-	792	O
adulthood	-	795	O
that	-	805	O
is	-	810	O
associated	-	813	O
with	-	824	O
early	-	829	O
-	-	834	O
life	-	835	O
iAs	-	840	O
exposure	-	844	O
.	-	852	O

DISCUSSION	26115410	854	O
:	-	864	O

Epigenetic	26115410	866	O
reprogramming	-	877	O
that	-	891	O
imparts	-	896	O
functional	-	904	O
changes	-	915	O
in	-	923	O
gene	-	926	O
expression	-	931	O
,	-	941	O
the	-	943	O
development	-	947	O
of	-	959	O
cancer	-	962	B
stem	-	969	O
cells	-	974	O
,	-	979	O
and	-	981	O
immunomodulation	-	985	O
are	-	1002	O
plausible	-	1006	O
underlying	-	1016	O
mechanisms	-	1027	O
by	-	1038	O
which	-	1041	O
early	-	1047	O
-	-	1052	O
life	-	1053	O
iAs	-	1058	O
exposure	-	1062	O
elicits	-	1071	O
latent	-	1079	O
carcinogenic	-	1086	O
effects	-	1099	O
.	-	1106	O

CONCLUSIONS	26115410	1108	O
:	-	1119	O

Evidence	26115410	1121	O
is	-	1130	O
mounting	-	1133	O
that	-	1142	O
relates	-	1147	O
early	-	1155	O
-	-	1160	O
life	-	1161	O
iAs	-	1166	O
exposure	-	1170	O
and	-	1179	O
cancer	-	1183	B
development	-	1190	O
later	-	1202	O
in	-	1208	O
life	-	1211	O
.	-	1215	O

Future	26115410	1217	O
research	-	1224	O
should	-	1233	O
include	-	1240	O
animal	-	1248	O
studies	-	1255	O
that	-	1263	O
address	-	1268	O
mechanistic	-	1276	O
hypotheses	-	1288	O
and	-	1299	O
studies	-	1303	O
of	-	1311	O
human	-	1314	O
populations	-	1320	O
that	-	1332	O
integrate	-	1337	O
early	-	1347	O
-	-	1352	O
life	-	1353	O
exposure	-	1358	O
,	-	1366	O
molecular	-	1368	O
alterations	-	1378	O
,	-	1389	O
and	-	1391	O
latent	-	1395	O
disease	-	1402	O
outcomes	-	1410	O
.	-	1418	O

On	44072	0	O
the	-	3	O
antiarrhythmic	-	7	O
activity	-	22	O
of	-	31	O
one	-	34	O
N	-	38	O
-	-	39	O
substituted	-	40	O
piperazine	-	52	O
derivative	-	63	O
of	-	74	O
trans	-	77	O
-	-	82	O
2	-	83	O
-	-	84	O
amino	-	85	O
-	-	90	O
3	-	91	O
-	-	92	O
hydroxy	-	93	O
-	-	100	O
1	-	101	O
,	-	102	O
2	-	104	O
,	-	105	O
3	-	107	O
,	-	108	O
4	-	110	O
-	-	111	O
tetrahydroanaphthalene	-	112	O
.	-	134	O

The	44072	136	O
antiarrhythmic	-	140	O
activity	-	155	O
of	-	164	O
the	-	167	O
compound	-	171	O
N	-	180	O
-	-	181	O
(	-	182	O
trans	-	183	O
-	-	188	O
3	-	189	O
-	-	190	O
hydroxy	-	191	O
-	-	198	O
1	-	199	O
,	-	200	O
2	-	201	O
,	-	202	O
3	-	203	O
,	-	204	O
4	-	205	O
-	-	206	O
tetrahydro	-	207	O
-	-	217	O
2	-	218	O
-	-	219	O
naphthyl	-	220	O
)	-	228	O
-	-	229	O
N	-	230	O
-	-	231	O
(	-	232	O
3	-	233	O
-	-	234	O
oxo	-	235	O
-	-	238	O
3	-	239	O
-	-	240	O
phenyl	-	241	O
-	-	247	O
2	-	248	O
-	-	249	O
methylpropyl	-	250	O
)	-	262	O
-	-	263	O
piperazine	-	264	O
hydrochloride	-	275	O
,	-	288	O
referred	-	290	O
to	-	299	O
as	-	302	O
P11	-	305	O
,	-	308	O
is	-	310	O
studied	-	313	O
on	-	321	O
anaesthesized	-	324	O
cats	-	338	O
and	-	343	O
Wistar	-	347	O
albino	-	354	O
rats	-	361	O
,	-	365	O
as	-	367	O
well	-	370	O
as	-	375	O
on	-	378	O
non	-	381	O
-	-	384	O
anaesthesized	-	385	O
rabbits	-	399	O
.	-	406	O

Four	44072	408	O
types	-	413	O
of	-	419	O
experimental	-	422	O
arrhythmia	-	435	B
are	-	446	O
used	-	450	O
-	-	454	O
-	-	455	O
with	-	456	O
BaCl2	-	461	O
,	-	466	O
with	-	468	O
chloroform	-	473	O
-	-	483	O
adrenaline	-	484	O
,	-	494	O
with	-	496	O
strophantine	-	501	O
G	-	514	O
and	-	516	O
with	-	520	O
aconitine	-	525	O
.	-	534	O

The	44072	536	O
compound	-	540	O
P11	-	549	O
is	-	553	O
introduced	-	556	O
in	-	567	O
doses	-	570	O
of	-	576	O
0	-	579	O
.	-	580	O
25	-	581	O
and	-	584	O
0	-	588	O
.	-	589	O
50	-	590	O
mg	-	593	O
/	-	595	O
kg	-	596	O
intravenously	-	599	O
and	-	613	O
10	-	617	O
mg	-	620	O
/	-	622	O
kg	-	623	O
orally	-	626	O
.	-	632	O

The	44072	634	O
compound	-	638	O
manifests	-	647	O
antiarrhythmic	-	657	O
activity	-	672	O
in	-	681	O
all	-	684	O
models	-	688	O
of	-	695	O
experimental	-	698	O
arrhythmia	-	711	B
used	-	722	O
,	-	726	O
causing	-	728	O
greatest	-	736	O
inhibition	-	745	O
on	-	756	O
the	-	759	O
arrhythmia	-	763	B
induced	-	774	O
by	-	782	O
chloroform	-	785	O
-	-	795	O
adrenaline	-	796	O
(	-	807	O
in	-	808	O
90	-	811	O
per	-	814	O
cent	-	818	O
)	-	822	O
and	-	824	O
with	-	828	O
BaCl2	-	833	O
(	-	839	O
in	-	840	O
84	-	843	O
per	-	846	O
cent	-	850	O
)	-	854	O
.	-	855	O

The	44072	857	O
results	-	861	O
obtained	-	869	O
are	-	878	O
associated	-	882	O
with	-	893	O
the	-	898	O
beta	-	902	O
-	-	906	O
adrenoblocking	-	907	O
and	-	922	O
with	-	926	O
the	-	931	O
membrane	-	935	O
-	-	943	O
stabilizing	-	944	O
action	-	956	O
of	-	963	O
the	-	966	O
compound	-	970	O
.	-	978	O

Experimental	753803	0	O
progressive	-	13	O
muscular	-	25	B
dystrophy	-	34	I
and	-	44	O
its	-	48	O
treatment	-	52	O
with	-	62	O
high	-	67	O
doses	-	72	O
anabolizing	-	78	O
agents	-	90	O
.	-	96	O

We	753803	98	O
are	-	101	O
still	-	105	O
a	-	111	O
long	-	113	O
way	-	118	O
from	-	122	O
discovering	-	127	O
an	-	139	O
unequivocal	-	142	O
pathogenetic	-	154	O
interpretation	-	167	O
of	-	182	O
progressive	-	185	O
muscular	-	197	B
dystrophy	-	206	I
in	-	216	O
man	-	219	O
.	-	222	O

Noteworthy	753803	224	O
efforts	-	235	O
have	-	243	O
been	-	248	O
made	-	253	O
in	-	258	O
the	-	261	O
experimental	-	265	O
field	-	278	O
;	-	283	O
a	-	285	O
recessive	-	287	O
autosomic	-	297	O
form	-	307	O
found	-	312	O
in	-	318	O
the	-	321	O
mouse	-	325	O
seems	-	331	O
to	-	337	O
bear	-	340	O
the	-	345	O
closest	-	349	O
resemblance	-	357	O
to	-	369	O
the	-	372	O
human	-	376	O
form	-	382	O
from	-	387	O
the	-	392	O
genetic	-	396	O
point	-	404	O
of	-	410	O
view	-	413	O
.	-	417	O

Myopathy	753803	419	B
due	-	428	O
to	-	432	O
lack	-	435	O
of	-	440	O
vitamin	-	443	O
E	-	451	O
and	-	453	O
myopathy	-	457	B
induced	-	466	O
by	-	474	O
certain	-	477	O
viruses	-	485	O
have	-	493	O
much	-	498	O
in	-	503	O
common	-	506	O
anatomically	-	513	O
and	-	526	O
pathologically	-	530	O
with	-	545	O
the	-	550	O
human	-	554	O
form	-	560	O
.	-	564	O

The	753803	566	O
authors	-	570	O
induced	-	578	O
myodystrophy	-	586	B
in	-	599	O
the	-	602	O
rat	-	606	O
by	-	610	O
giving	-	613	O
it	-	620	O
a	-	623	O
diet	-	625	O
lacking	-	630	O
in	-	638	O
vitamin	-	641	O
E	-	649	O
.	-	650	O

The	753803	652	O
pharmacological	-	656	O
characteristics	-	672	O
of	-	688	O
vitamin	-	691	O
E	-	699	O
and	-	701	O
the	-	705	O
degenerative	-	709	O
changes	-	722	O
brought	-	730	O
about	-	738	O
by	-	744	O
its	-	747	O
deficiency	-	751	O
,	-	761	O
especially	-	763	O
in	-	774	O
the	-	777	O
muscles	-	781	O
,	-	788	O
are	-	790	O
illustrated	-	794	O
.	-	805	O

It	753803	807	O
is	-	810	O
thus	-	813	O
confirmed	-	818	O
that	-	828	O
the	-	833	O
histological	-	837	O
characteristics	-	850	O
of	-	866	O
myopathic	-	869	B
rat	-	879	O
muscle	-	883	O
induced	-	890	O
experimentally	-	898	O
are	-	913	O
extraordinarily	-	917	O
similar	-	933	O
to	-	941	O
those	-	944	O
of	-	950	O
human	-	953	O
myopathy	-	959	B
as	-	968	O
confirmed	-	971	O
during	-	981	O
biopsies	-	988	O
performed	-	997	O
at	-	1007	O
the	-	1010	O
Orthopaedic	-	1014	O
Traumatological	-	1026	O
Centre	-	1042	O
,	-	1048	O
Florence	-	1050	O
.	-	1058	O

The	753803	1060	O
encouraging	-	1064	O
results	-	1076	O
obtained	-	1084	O
in	-	1093	O
various	-	1096	O
authoratative	-	1104	O
departments	-	1118	O
in	-	1130	O
myopathic	-	1133	B
patients	-	1143	O
by	-	1152	O
using	-	1155	O
anabolizing	-	1161	O
steroids	-	1173	O
have	-	1182	O
encouraged	-	1187	O
the	-	1198	O
authors	-	1202	O
to	-	1210	O
investigate	-	1213	O
the	-	1225	O
beneficial	-	1229	O
effects	-	1240	O
of	-	1248	O
one	-	1251	O
anabolizing	-	1255	O
agent	-	1267	O
(	-	1273	O
Dianabol	-	1274	O
,	-	1282	O
CIBA	-	1284	O
)	-	1288	O
at	-	1290	O
high	-	1293	O
doses	-	1298	O
in	-	1304	O
rats	-	1307	O
rendered	-	1312	O
myopathic	-	1321	B
by	-	1331	O
a	-	1334	O
diet	-	1336	O
deficient	-	1341	O
in	-	1351	O
vitamin	-	1354	O
E	-	1362	O
.	-	1363	O

In	753803	1365	O
this	-	1368	O
way	-	1373	O
they	-	1377	O
obtained	-	1382	O
appreciable	-	1391	O
changes	-	1403	O
in	-	1411	O
body	-	1414	O
weight	-	1419	O
(	-	1426	O
increased	-	1427	O
from	-	1437	O
50	-	1442	O
to	-	1445	O
70	-	1448	O
g	-	1451	O
after	-	1453	O
forty	-	1459	O
days	-	1465	O
at	-	1470	O
a	-	1473	O
dose	-	1475	O
of	-	1480	O
5	-	1483	O
mg	-	1485	O
per	-	1488	O
day	-	1492	O
of	-	1496	O
anabolizing	-	1499	O
agent	-	1511	O
)	-	1516	O
,	-	1517	O
but	-	1519	O
most	-	1523	O
of	-	1528	O
all	-	1531	O
they	-	1535	O
found	-	1540	O
histological	-	1546	O
changes	-	1559	O
due	-	1567	O
to	-	1571	O
""""	-	1574	O
regenerative	-	1575	O
""""	-	1587	O
changes	-	1589	O
in	-	1597	O
the	-	1600	O
muscle	-	1604	O
tissue	-	1611	O
,	-	1617	O
which	-	1619	O
however	-	1625	O
maintained	-	1633	O
its	-	1644	O
myopathic	-	1648	B
characteristics	-	1658	O
in	-	1674	O
the	-	1677	O
control	-	1681	O
animals	-	1689	O
that	-	1697	O
were	-	1702	O
not	-	1707	O
treated	-	1711	O
with	-	1719	O
the	-	1724	O
anabolizing	-	1728	O
agent	-	1740	O
.	-	1745	O

The	753803	1747	O
authors	-	1751	O
conclude	-	1759	O
by	-	1768	O
affirming	-	1771	O
the	-	1781	O
undoubted	-	1785	O
efficacy	-	1795	O
of	-	1804	O
the	-	1807	O
anabolizing	-	1811	O
steroids	-	1823	O
in	-	1832	O
experimental	-	1835	O
myopathic	-	1848	B
disease	-	1858	I
,	-	1865	O
but	-	1867	O
they	-	1871	O
have	-	1876	O
reservations	-	1881	O
as	-	1894	O
to	-	1897	O
the	-	1900	O
transfer	-	1904	O
of	-	1913	O
the	-	1916	O
results	-	1920	O
into	-	1928	O
the	-	1933	O
human	-	1937	O
field	-	1943	O
,	-	1948	O
where	-	1950	O
high	-	1956	O
dosage	-	1961	O
can	-	1968	O
not	-	1971	O
be	-	1975	O
carried	-	1978	O
out	-	1986	O
continuously	-	1990	O
because	-	2003	O
of	-	2011	O
the	-	2014	O
effects	-	2018	O
of	-	2026	O
the	-	2029	O
drug	-	2033	O
on	-	2038	O
virility	-	2041	O
;	-	2049	O
because	-	2051	O
the	-	2059	O
tissue	-	2063	O
injury	-	2070	O
too	-	2077	O
often	-	2081	O
occurs	-	2087	O
at	-	2094	O
an	-	2097	O
irreversible	-	2100	O
stage	-	2113	O
vis	-	2119	O
-	-	2122	O
a	-	2123	O
-	-	2124	O
vis	-	2125	O
the	-	2129	O
""""	-	2133	O
regeneration	-	2134	O
""""	-	2146	O
of	-	2148	O
the	-	2151	O
muscle	-	2155	O
tissue	-	2162	O
;	-	2168	O
and	-	2170	O
finally	-	2174	O
because	-	2182	O
the	-	2190	O
dystrophic	-	2194	O
injurious	-	2205	O
agent	-	2215	O
is	-	2221	O
certainly	-	2224	O
not	-	2234	O
the	-	2238	O
lack	-	2242	O
of	-	2247	O
vitamin	-	2250	O
E	-	2258	O
but	-	2260	O
something	-	2264	O
as	-	2274	O
yet	-	2277	O
unknown	-	2281	O
.	-	2288	O

Fetal	920167	0	O
risks	-	6	O
due	-	12	O
to	-	16	O
warfarin	-	19	O
therapy	-	28	O
during	-	36	O
pregnancy	-	43	O
.	-	52	O

Two	920167	54	O
mothers	-	58	O
with	-	66	O
heart	-	71	O
valve	-	77	O
prosthesis	-	83	O
were	-	94	O
treated	-	99	O
with	-	107	O
warfarin	-	112	O
during	-	121	O
pregnancy	-	128	O
.	-	137	O

In	920167	139	O
the	-	142	O
first	-	146	O
case	-	152	O
a	-	157	O
caesarean	-	159	O
section	-	169	O
was	-	177	O
done	-	181	O
one	-	186	O
week	-	190	O
after	-	195	O
replacement	-	201	O
of	-	213	O
warfarin	-	216	O
with	-	225	O
heparin	-	230	O
.	-	237	O

The	920167	239	O
baby	-	243	O
died	-	248	O
of	-	253	O
cerebral	-	256	B
and	-	265	I
pulmonary	-	269	I
hemorrhage	-	279	I
.	-	289	O

The	920167	291	O
second	-	295	O
mother	-	302	O
had	-	309	O
a	-	313	O
male	-	315	O
infant	-	320	O
by	-	327	O
caesarean	-	330	O
section	-	340	O
.	-	347	O

The	920167	349	O
baby	-	353	O
showed	-	358	O
warfarin	-	365	O
-	-	373	O
induced	-	374	O
embryopathy	-	382	B
with	-	394	O
nasal	-	399	B
hypoplasia	-	405	I
and	-	416	O
stippled	-	420	B
epiphyses	-	429	I
(	-	439	O
chondrodysplasia	-	440	B
punctata	-	457	I
)	-	465	O
.	-	466	O

Nasal	920167	468	B
hypoplasia	-	474	I
with	-	485	O
or	-	490	O
without	-	493	O
stippled	-	501	B
epiphyses	-	510	I
has	-	520	O
now	-	524	O
been	-	528	O
reported	-	533	O
in	-	542	O
11	-	545	O
infants	-	548	O
born	-	556	O
to	-	561	O
mothers	-	564	O
treated	-	572	O
with	-	580	O
warfarin	-	585	O
during	-	594	O
the	-	601	O
first	-	605	O
trimester	-	611	O
,	-	620	O
and	-	622	O
a	-	626	O
causal	-	628	O
association	-	635	O
is	-	647	O
probable	-	650	O
.	-	658	O

In	920167	660	O
view	-	663	O
of	-	668	O
the	-	671	O
risks	-	675	O
to	-	681	O
both	-	684	O
mother	-	689	O
and	-	696	O
fetus	-	700	O
in	-	706	O
women	-	709	O
with	-	715	O
prosthetic	-	720	O
cardiac	-	731	O
valves	-	739	O
it	-	746	O
is	-	749	O
recommended	-	752	O
that	-	764	O
therapeutic	-	769	O
abortion	-	781	O
be	-	790	O
advised	-	793	O
as	-	801	O
the	-	804	O
first	-	808	O
alternative	-	814	O
.	-	825	O

Isradipine	1451544	0	O
treatment	-	11	O
for	-	21	O
hypertension	-	25	B
in	-	38	O
general	-	41	O
practice	-	49	O
in	-	58	O
Hong	-	61	O
Kong	-	66	O
.	-	70	O

A	1451544	72	O
6	-	74	O
-	-	75	O
week	-	76	O
open	-	81	O
study	-	86	O
of	-	92	O
the	-	95	O
introduction	-	99	O
of	-	112	O
isradipine	-	115	O
treatment	-	126	O
was	-	136	O
conducted	-	140	O
in	-	150	O
general	-	153	O
practice	-	161	O
in	-	170	O
Hong	-	173	O
Kong	-	178	O
.	-	182	O

303	1451544	184	O
Chinese	-	188	O
patients	-	196	O
with	-	205	O
mild	-	210	O
to	-	215	O
moderate	-	218	O
hypertension	-	227	B
entered	-	240	O
the	-	248	O
study	-	252	O
.	-	257	O

Side	1451544	259	O
effects	-	264	O
were	-	272	O
reported	-	277	O
in	-	286	O
21	-	289	O
%	-	291	O
of	-	293	O
patients	-	296	O
and	-	305	O
caused	-	309	O
withdrawal	-	316	O
from	-	327	O
the	-	332	O
study	-	336	O
in	-	342	O
3	-	345	O
patients	-	347	O
.	-	355	O

The	1451544	357	O
main	-	361	O
side	-	366	O
-	-	370	O
effects	-	371	O
were	-	379	O
headache	-	384	B
,	-	392	O
dizziness	-	394	B
,	-	403	O
palpitation	-	405	B
and	-	417	O
flushing	-	421	B
and	-	430	O
these	-	434	O
were	-	440	O
not	-	445	O
more	-	449	O
frequent	-	454	O
than	-	463	O
reported	-	468	O
in	-	477	O
other	-	480	O
studies	-	486	O
with	-	494	O
isradipine	-	499	O
or	-	510	O
with	-	513	O
placebo	-	518	O
.	-	525	O

Supine	1451544	527	O
blood	-	534	O
pressure	-	540	O
was	-	549	O
reduced	-	553	O
(	-	561	O
P	-	562	O
less	-	564	O
than	-	569	O
0	-	574	O
.	-	575	O
01	-	576	O
)	-	578	O
from	-	580	O
170	-	585	O
+	-	589	O
/	-	590	O
-	-	591	O

20	1451544	593	O
/	-	595	O
102	-	596	O
+	-	600	O
/	-	601	O
-	-	602	O

6	1451544	604	O
mmHg	-	606	O
to	-	611	O
153	-	614	O
+	-	618	O
/	-	619	O
-	-	620	O

19	1451544	622	O
/	-	624	O
92	-	625	O
+	-	628	O
/	-	629	O
-	-	630	O

8	1451544	632	O
,	-	633	O
147	-	635	O
+	-	639	O
/	-	640	O
-	-	641	O

18	1451544	643	O
/	-	645	O
88	-	646	O
+	-	649	O
/	-	650	O
-	-	651	O
7	-	653	O
and	-	655	O
144	-	659	O
+	-	663	O
/	-	664	O
-	-	665	O

14	1451544	667	O
/	-	669	O
87	-	670	O
+	-	673	O
/	-	674	O
-	-	675	O

6	1451544	677	O
mmHg	-	679	O
at	-	684	O
2	-	687	O
,	-	688	O
4	-	690	O
and	-	692	O
6	-	696	O
weeks	-	698	O
respectively	-	704	O
in	-	717	O
evaluable	-	720	O
patients	-	730	O
.	-	738	O

Similar	1451544	740	O
reductions	-	748	O
occurred	-	759	O
in	-	768	O
standing	-	771	O
blood	-	780	O
pressure	-	786	O
and	-	795	O
there	-	799	O
was	-	805	O
no	-	809	O
evidence	-	812	O
of	-	821	O
postural	-	824	B
hypotension	-	833	I
.	-	844	O

Normalization	1451544	846	O
and	-	860	O
responder	-	864	O
rates	-	874	O
at	-	880	O
6	-	883	O
weeks	-	885	O
were	-	891	O
86	-	896	O
%	-	898	O
and	-	900	O
69	-	904	O
%	-	906	O
respectively	-	908	O
.	-	920	O

Dosage	1451544	922	O
was	-	929	O
increased	-	933	O
from	-	943	O
2	-	948	O
.	-	949	O
5	-	950	O
mg	-	952	O
b	-	955	O
.	-	956	O
d	-	957	O
.	-	958	O

to	1451544	960	O
5	-	963	O
mg	-	965	O
b	-	968	O
.	-	969	O
d	-	970	O
.	-	971	O

at	1451544	973	O
4	-	976	O
weeks	-	978	O
in	-	984	O
patients	-	987	O
with	-	996	O
diastolic	-	1001	O
blood	-	1011	O
pressure	-	1017	O
greater	-	1026	O
than	-	1034	O
90	-	1039	O
mmHg	-	1042	O
and	-	1047	O
their	-	1051	O
further	-	1057	O
response	-	1065	O
was	-	1074	O
greater	-	1078	O
than	-	1086	O
those	-	1091	O
remaining	-	1097	O
on	-	1107	O
2	-	1110	O
.	-	1111	O
5	-	1112	O
mg	-	1114	O
b	-	1117	O
.	-	1118	O
d	-	1119	O
.	-	1120	O

Tachyphylaxis	2782734	0	O
to	-	14	O
systemic	-	17	O
but	-	26	O
not	-	30	O
to	-	34	O
airway	-	37	O
responses	-	44	O
during	-	54	O
prolonged	-	61	O
therapy	-	71	O
with	-	79	O
high	-	84	O
dose	-	89	O
inhaled	-	94	O
salbutamol	-	102	O
in	-	113	O
asthmatics	-	116	B
.	-	126	O

High	2782734	128	O
doses	-	133	O
of	-	139	O
inhaled	-	142	O
salbutamol	-	150	O
produce	-	161	O
substantial	-	169	O
improvements	-	181	O
in	-	194	O
airway	-	197	O
response	-	204	O
in	-	213	O
patients	-	216	O
with	-	225	O
asthma	-	230	B
,	-	236	O
and	-	238	O
are	-	242	O
associated	-	246	O
with	-	257	O
dose	-	262	O
-	-	266	O
dependent	-	267	O
systemic	-	277	O
beta	-	286	O
-	-	290	O
adrenoceptor	-	291	O
responses	-	304	O
.	-	313	O

The	2782734	315	O
purpose	-	319	O
of	-	327	O
the	-	330	O
present	-	334	O
study	-	342	O
was	-	348	O
to	-	352	O
investigate	-	355	O
whether	-	367	O
tachyphylaxis	-	375	O
occurs	-	389	O
during	-	396	O
prolonged	-	403	O
treatment	-	413	O
with	-	423	O
high	-	428	O
dose	-	433	O
inhaled	-	438	O
salbutamol	-	446	O
.	-	456	O

Twelve	2782734	458	O
asthmatic	-	465	B
patients	-	475	O
(	-	484	O
FEV1	-	485	O
,	-	489	O
81	-	491	O
+	-	494	O
/	-	495	O
-	-	496	O

4	2782734	498	O
%	-	499	O
predicted	-	501	O
)	-	510	O
,	-	511	O
requiring	-	513	O
only	-	523	O
occasional	-	528	O
inhaled	-	539	O
beta	-	547	O
-	-	551	O
agonists	-	552	O
as	-	561	O
their	-	564	O
sole	-	570	O
therapy	-	575	O
,	-	582	O
were	-	584	O
given	-	589	O
a	-	595	O
14	-	597	O
-	-	599	O
day	-	600	O
treatment	-	604	O
with	-	614	O
high	-	619	O
dose	-	624	O
inhaled	-	629	O
salbutamol	-	637	O
(	-	648	O
HDS	-	649	O
)	-	652	O
,	-	653	O
4	-	655	O
,	-	656	O
000	-	657	O
micrograms	-	661	O
daily	-	672	O
,	-	677	O
low	-	679	O
dose	-	683	O
inhaled	-	688	O
salbutamol	-	696	O
(	-	707	O
LDS	-	708	O
)	-	711	O
,	-	712	O
800	-	714	O
micrograms	-	718	O
daily	-	729	O
,	-	734	O
or	-	736	O
placebo	-	739	O
(	-	747	O
PI	-	748	O
)	-	750	O
by	-	752	O
metered	-	755	O
-	-	762	O
dose	-	763	O
inhaler	-	768	O
in	-	776	O
a	-	779	O
double	-	781	O
-	-	787	O
blind	-	788	O
,	-	793	O
randomized	-	795	O
crossover	-	806	O
design	-	816	O
.	-	822	O

During	2782734	824	O
the	-	831	O
14	-	835	O
-	-	837	O
day	-	838	O
run	-	842	O
-	-	845	O
in	-	846	O
and	-	849	O
during	-	853	O
washout	-	860	O
periods	-	868	O
,	-	875	O
inhaled	-	877	O
beta	-	885	O
-	-	889	O
agonists	-	890	O
were	-	899	O
withheld	-	904	O
and	-	913	O
ipratropium	-	917	O
bromide	-	929	O
was	-	937	O
substituted	-	941	O
for	-	953	O
rescue	-	957	O
purposes	-	964	O
.	-	972	O

At	2782734	974	O
the	-	977	O
end	-	981	O
of	-	985	O
each	-	988	O
14	-	993	O
-	-	995	O
day	-	996	O
treatment	-	1000	O
,	-	1009	O
a	-	1011	O
dose	-	1013	O
-	-	1017	O
response	-	1018	O
curve	-	1027	O
(	-	1033	O
DRC	-	1034	O
)	-	1037	O
was	-	1039	O
performed	-	1043	O
,	-	1052	O
and	-	1054	O
airway	-	1058	O
(	-	1065	O
FEV1	-	1066	O
,	-	1070	O
FEF25	-	1072	O
-	-	1077	O
75	-	1078	O
)	-	1080	O
chronotropic	-	1082	O
(	-	1095	O
HR	-	1096	O
)	-	1098	O
,	-	1099	O
tremor	-	1101	B
,	-	1107	O
and	-	1109	O
metabolic	-	1113	O
(	-	1123	O
K	-	1124	O
,	-	1125	O
Glu	-	1127	O
)	-	1130	O
responses	-	1132	O
were	-	1142	O
measured	-	1147	O
at	-	1156	O
each	-	1159	O
step	-	1164	O
(	-	1169	O
from	-	1170	O
100	-	1175	O
to	-	1179	O
4	-	1182	O
,	-	1183	O
000	-	1184	O
micrograms	-	1188	O
)	-	1198	O
.	-	1199	O

Treatment	2782734	1201	O
had	-	1211	O
no	-	1215	O
significant	-	1218	O
effect	-	1230	O
on	-	1237	O
baseline	-	1240	O
values	-	1249	O
.	-	1255	O

There	2782734	1257	O
were	-	1263	O
dose	-	1268	O
-	-	1272	O
dependent	-	1273	O
increases	-	1283	O
in	-	1293	O
FEV1	-	1296	O
and	-	1301	O
FEF25	-	1305	O
-	-	1310	O
75	-	1311	O
(	-	1314	O
p	-	1315	O
less	-	1317	O
than	-	1322	O
0	-	1327	O
.	-	1328	O
001	-	1329	O
)	-	1332	O
,	-	1333	O
and	-	1335	O
pretreatment	-	1339	O
with	-	1352	O
HDS	-	1357	O
did	-	1361	O
not	-	1365	O
displace	-	1369	O
the	-	1378	O
DRC	-	1382	O
to	-	1386	O
the	-	1389	O
right	-	1393	O
.	-	1398	O

DRC	2782734	1400	O
for	-	1404	O
HR	-	1408	O
(	-	1411	O
p	-	1412	O
less	-	1414	O
than	-	1419	O
0	-	1424	O
.	-	1425	O
001	-	1426	O
)	-	1429	O
,	-	1430	O
K	-	1432	O
(	-	1434	O
p	-	1435	O
less	-	1437	O
than	-	1442	O
0	-	1447	O
.	-	1448	O
001	-	1449	O
)	-	1452	O
,	-	1453	O
and	-	1455	O
Glu	-	1459	O
(	-	1463	O
p	-	1464	O
less	-	1466	O
than	-	1471	O
0	-	1476	O
.	-	1477	O
005	-	1478	O
)	-	1481	O
were	-	1483	O
attenuated	-	1488	O
after	-	1499	O
treatment	-	1505	O
with	-	1515	O
HDS	-	1520	O
compared	-	1524	O
with	-	1533	O
PI	-	1538	O
.	-	1540	O

There	2782734	1542	O
were	-	1548	O
also	-	1553	O
differences	-	1558	O
between	-	1570	O
HDS	-	1578	O
and	-	1582	O
LDS	-	1586	O
for	-	1590	O
HR	-	1594	O
(	-	1597	O
p	-	1598	O
less	-	1600	O
than	-	1605	O
0	-	1610	O
.	-	1611	O
001	-	1612	O
)	-	1615	O
and	-	1617	O
Glu	-	1621	O
(	-	1625	O
p	-	1626	O
less	-	1628	O
than	-	1633	O
0	-	1638	O
.	-	1639	O
05	-	1640	O
)	-	1642	O
responses	-	1644	O
.	-	1653	O

Frequency	2782734	1655	O
and	-	1665	O
severity	-	1669	O
of	-	1678	O
subjective	-	1681	O
adverse	-	1692	O
effects	-	1700	O
were	-	1708	O
also	-	1713	O
reduced	-	1718	O
after	-	1726	O
HDS	-	1732	O
:	-	1735	O
tremor	-	1737	B
(	-	1744	O
p	-	1745	O
less	-	1747	O
than	-	1752	O
0	-	1757	O
.	-	1758	O
001	-	1759	O
)	-	1762	O
,	-	1763	O
palpitations	-	1765	B
(	-	1778	O
p	-	1779	O
less	-	1781	O
than	-	1786	O
0	-	1791	O
.	-	1792	O
001	-	1793	O
)	-	1796	O
.	-	1797	O
(	-	1798	O
ABSTRACT	-	1799	O

TRUNCATED	2782734	1808	O
AT	-	1818	O
250	-	1821	O
WORDS	-	1825	O
)	-	1830	O

Increased	2983630	0	O
anxiogenic	-	10	O
effects	-	21	O
of	-	29	O
caffeine	-	32	O
in	-	41	O
panic	-	44	B
disorders	-	50	I
.	-	59	O

The	2983630	61	O
effects	-	65	O
of	-	73	O
oral	-	76	O
administration	-	81	O
of	-	96	O
caffeine	-	99	O
(	-	108	O
10	-	109	O
mg	-	112	O
/	-	114	O
kg	-	115	O
)	-	117	O
on	-	119	O
behavioral	-	122	O
ratings	-	133	O
,	-	140	O
somatic	-	142	O
symptoms	-	150	O
,	-	158	O
blood	-	160	O
pressure	-	166	O
and	-	175	O
plasma	-	179	O
levels	-	186	O
of	-	193	O
3	-	196	O
-	-	197	O
methoxy	-	198	O
-	-	205	O
4	-	206	O
-	-	207	O
hydroxyphenethyleneglycol	-	208	O
(	-	234	O
MHPG	-	235	O
)	-	239	O
and	-	241	O
cortisol	-	245	O
were	-	254	O
determined	-	259	O
in	-	270	O
17	-	273	O
healthy	-	276	O
subjects	-	284	O
and	-	293	O
21	-	297	O
patients	-	300	O
meeting	-	309	O
DSM	-	317	O
-	-	320	O
III	-	321	O
criteria	-	325	O
for	-	334	O
agoraphobia	-	338	B
with	-	350	O
panic	-	355	B
attacks	-	361	I
or	-	369	O
panic	-	372	B
disorder	-	378	I
.	-	386	O

Caffeine	2983630	388	O
produced	-	397	O
significantly	-	406	O
greater	-	420	O
increases	-	428	O
in	-	438	O
subject	-	441	O
-	-	448	O
rated	-	449	O
anxiety	-	455	B
,	-	462	O
nervousness	-	464	O
,	-	475	O
fear	-	477	O
,	-	481	O
nausea	-	483	B
,	-	489	O
palpitations	-	491	B
,	-	503	O
restlessness	-	505	B
,	-	517	O
and	-	519	O
tremors	-	523	B
in	-	531	O
the	-	534	O
patients	-	538	O
compared	-	547	O
with	-	556	O
healthy	-	561	O
subjects	-	569	O
.	-	577	O

In	2983630	579	O
the	-	582	O
patients	-	586	O
,	-	594	O
but	-	596	O
not	-	600	O
the	-	604	O
healthy	-	608	O
subjects	-	616	O
,	-	624	O
these	-	626	O
symptoms	-	632	O
were	-	641	O
significantly	-	646	O
correlated	-	660	O
with	-	671	O
plasma	-	676	O
caffeine	-	683	O
levels	-	692	O
.	-	698	O

Seventy	2983630	700	O
-	-	707	O
one	-	708	O
percent	-	712	O
of	-	720	O
the	-	723	O
patients	-	727	O
reported	-	736	O
that	-	745	O
the	-	750	O
behavioral	-	754	O
effects	-	765	O
of	-	773	O
caffeine	-	776	O
were	-	785	O
similar	-	790	O
to	-	798	O
those	-	801	O
experienced	-	807	O
during	-	819	O
panic	-	826	B
attacks	-	832	I
.	-	839	O

Caffeine	2983630	841	O
did	-	850	O
not	-	854	O
alter	-	858	O
plasma	-	864	O
MHPG	-	871	O
levels	-	876	O
in	-	883	O
either	-	886	O
the	-	893	O
healthy	-	897	O
subjects	-	905	O
or	-	914	O
patients	-	917	O
.	-	925	O

Caffeine	2983630	927	O
increased	-	936	O
plasma	-	946	O
cortisol	-	953	O
levels	-	962	O
equally	-	969	O
in	-	977	O
the	-	980	O
patient	-	984	O
and	-	992	O
healthy	-	996	O
groups	-	1004	O
.	-	1010	O

Because	2983630	1012	O
caffeine	-	1020	O
is	-	1029	O
an	-	1032	O
adenosine	-	1035	O
receptor	-	1045	O
antagonist	-	1054	O
,	-	1064	O
these	-	1066	O
results	-	1072	O
suggest	-	1080	O
that	-	1088	O
some	-	1093	O
panic	-	1098	B
disorder	-	1104	I
patients	-	1113	O
may	-	1122	O
have	-	1126	O
abnormalities	-	1131	B
in	-	1145	I
neuronal	-	1148	I
systems	-	1157	I
involving	-	1165	O
adenosine	-	1175	O
.	-	1184	O

Patients	2983630	1186	O
with	-	1195	O
anxiety	-	1200	B
disorders	-	1208	I
may	-	1218	O
benefit	-	1222	O
by	-	1230	O
avoiding	-	1233	O
caffeine	-	1242	O
-	-	1250	O
containing	-	1251	O
foods	-	1262	O
and	-	1268	O
beverages	-	1272	O
.	-	1281	O

Human	3711722	0	O
and	-	6	O
canine	-	10	O
ventricular	-	17	O
vasoactive	-	29	O
intestinal	-	40	O
polypeptide	-	51	O
:	-	62	O
decrease	-	64	O
with	-	73	O
heart	-	78	B
failure	-	84	I
.	-	91	O

Vasoactive	3711722	93	O
intestinal	-	104	O
polypeptide	-	115	O
(	-	127	O
VIP	-	128	O
)	-	131	O
is	-	133	O
a	-	136	O
systemic	-	138	O
and	-	147	O
coronary	-	151	O
vasodilator	-	160	O
that	-	172	O
may	-	177	O
have	-	181	O
positive	-	186	O
inotropic	-	195	O
properties	-	205	O
.	-	215	O

Myocardial	3711722	217	O
levels	-	228	O
of	-	235	O
VIP	-	238	O
were	-	242	O
assayed	-	247	O
before	-	255	O
and	-	262	O
after	-	266	O
the	-	272	O
development	-	276	O
of	-	288	O
heart	-	291	B
failure	-	297	I
in	-	305	O
two	-	308	O
canine	-	312	O
models	-	319	O
.	-	325	O

In	3711722	327	O
the	-	330	O
first	-	334	O
,	-	339	O
cobalt	-	341	O
cardiomyopathy	-	348	B
was	-	363	O
induced	-	367	O
in	-	375	O
eight	-	378	O
dogs	-	384	O
;	-	388	O
VIP	-	390	O
(	-	394	O
by	-	395	O
radioimmunoassay	-	398	O
)	-	414	O
decreased	-	416	O
from	-	426	O
35	-	431	O
+	-	434	O
/	-	435	O
-	-	436	O

11	3711722	438	O
pg	-	441	O
/	-	443	O
mg	-	444	O
protein	-	447	O
(	-	455	O
mean	-	456	O
+	-	461	O
/	-	462	O
-	-	463	O

SD	3711722	465	O
)	-	467	O
to	-	469	O
5	-	472	O
+	-	474	O
/	-	475	O
-	-	476	O

4	3711722	478	O
pg	-	480	O
/	-	482	O
mg	-	483	O
protein	-	486	O
(	-	494	O
P	-	495	O
less	-	497	O
than	-	502	O
0	-	507	O
.	-	508	O
05	-	509	O
)	-	511	O
.	-	512	O

In	3711722	514	O
six	-	517	O
dogs	-	521	O
with	-	526	O
doxorubicin	-	531	O
-	-	542	O
induced	-	543	O
heart	-	551	B
failure	-	557	I
,	-	564	O
VIP	-	566	O
decreased	-	570	O
from	-	580	O
31	-	585	O
+	-	588	O
/	-	589	O
-	-	590	O

7	3711722	592	O
to	-	594	O
11	-	597	O
+	-	600	O
/	-	601	O
-	-	602	O

4	3711722	604	O
pg	-	606	O
/	-	608	O
mg	-	609	O
protein	-	612	O
(	-	620	O
P	-	621	O
less	-	623	O
than	-	628	O
0	-	633	O
.	-	634	O
05	-	635	O
)	-	637	O
.	-	638	O

In	3711722	640	O
addition	-	643	O
,	-	651	O
VIP	-	653	O
content	-	657	O
of	-	665	O
left	-	668	O
ventricular	-	673	O
muscle	-	685	O
of	-	692	O
resected	-	695	O
failing	-	704	O
hearts	-	712	O
in	-	719	O
10	-	722	O
patients	-	725	O
receiving	-	734	O
a	-	744	O
heart	-	746	O
transplant	-	752	O
was	-	763	O
compared	-	767	O
with	-	776	O
the	-	781	O
papillary	-	785	O
muscles	-	795	O
in	-	803	O
14	-	806	O
patients	-	809	O
(	-	818	O
five	-	819	O
with	-	824	O
rheumatic	-	829	B
disease	-	839	I
,	-	846	O
nine	-	848	O
with	-	853	O
myxomatous	-	858	B
degeneration	-	869	I
)	-	881	O
receiving	-	883	O
mitral	-	893	O
valve	-	900	O
prostheses	-	906	O
.	-	916	O

The	3711722	918	O
lowest	-	922	O
myocardial	-	929	O
VIP	-	940	O
concentration	-	944	O
was	-	958	O
found	-	962	O
in	-	968	O
the	-	971	O
hearts	-	975	O
of	-	982	O
patients	-	985	O
with	-	994	O
coronary	-	999	B
disease	-	1008	I
(	-	1016	O
one	-	1017	O
patient	-	1021	O
receiving	-	1029	O
a	-	1039	O
transplant	-	1041	O
and	-	1052	O
three	-	1056	O
receiving	-	1062	O
mitral	-	1072	O
prostheses	-	1079	O
)	-	1089	O
(	-	1091	O
6	-	1092	O
.	-	1093	O
3	-	1094	O
+	-	1096	O
/	-	1097	O
-	-	1098	O

1	3711722	1100	O
.	-	1101	O
9	-	1102	O
pg	-	1104	O
/	-	1106	O
mg	-	1107	O
protein	-	1110	O
)	-	1117	O
.	-	1118	O

The	3711722	1120	O
other	-	1124	O
patients	-	1130	O
undergoing	-	1139	O
transplantation	-	1150	O
had	-	1166	O
an	-	1170	O
average	-	1173	O
ejection	-	1181	O
fraction	-	1190	O
of	-	1199	O
17	-	1202	O
%	-	1204	O
+	-	1206	O
/	-	1207	O
-	-	1208	O

6	3711722	1210	O
%	-	1211	O
and	-	1213	O
a	-	1217	O
VIP	-	1219	O
level	-	1223	O
of	-	1229	O
8	-	1232	O
.	-	1233	O
8	-	1234	O
+	-	1236	O
/	-	1237	O
-	-	1238	O

3	3711722	1240	O
.	-	1241	O
9	-	1242	O
pg	-	1244	O
/	-	1246	O
mg	-	1247	O
protein	-	1250	O
.	-	1257	O

The	3711722	1259	O
hearts	-	1263	O
without	-	1270	O
coronary	-	1278	B
artery	-	1287	I
disease	-	1294	I
(	-	1302	O
average	-	1303	O
ejection	-	1311	O
fraction	-	1320	O
of	-	1329	O
this	-	1332	O
group	-	1337	O
62	-	1343	O
%	-	1345	O
+	-	1347	O
/	-	1348	O
-	-	1349	O

10	3711722	1351	O
%	-	1353	O
)	-	1354	O
had	-	1356	O
a	-	1360	O
VIP	-	1362	O
concentration	-	1366	O
of	-	1380	O
14	-	1383	O
.	-	1385	O
1	-	1386	O
+	-	1388	O
/	-	1389	O
-	-	1390	O

7	3711722	1392	O
.	-	1393	O
9	-	1394	O
pg	-	1396	O
/	-	1398	O
mg	-	1399	O
protein	-	1402	O
,	-	1409	O
and	-	1411	O
this	-	1415	O
was	-	1420	O
greater	-	1424	O
than	-	1432	O
in	-	1437	O
hearts	-	1440	O
of	-	1447	O
the	-	1450	O
patients	-	1454	O
with	-	1463	O
coronary	-	1468	B
disease	-	1477	I
and	-	1485	O
the	-	1489	O
hearts	-	1493	O
of	-	1500	O
patients	-	1503	O
receiving	-	1512	O
a	-	1522	O
transplant	-	1524	O
(	-	1535	O
P	-	1536	O
less	-	1538	O
than	-	1543	O
0	-	1548	O
.	-	1549	O
05	-	1550	O
)	-	1552	O
.	-	1553	O

Myocardial	3711722	1555	O
catecholamines	-	1566	O
were	-	1581	O
also	-	1586	O
determined	-	1591	O
in	-	1602	O
14	-	1605	O
subjects	-	1608	O
;	-	1616	O
a	-	1618	O
weak	-	1620	O
correlation	-	1625	O
(	-	1637	O
r	-	1638	O
=	-	1640	O
0	-	1642	O
.	-	1643	O
57	-	1644	O
,	-	1646	O
P	-	1648	O
less	-	1650	O
than	-	1655	O
0	-	1660	O
.	-	1661	O
05	-	1662	O
)	-	1664	O
between	-	1666	O
the	-	1674	O
tissue	-	1678	O
concentrations	-	1685	O
of	-	1700	O
VIP	-	1703	O
and	-	1707	O
norepinephrine	-	1711	O
was	-	1726	O
noted	-	1730	O
.	-	1735	O
(	-	1736	O
ABSTRACT	-	1737	O
TRUNCATED	-	1746	O
AT	-	1756	O
250	-	1759	O
WORDS	-	1763	O
)	-	1768	O

Interstrain	6728873	0	O
variation	-	12	O
in	-	22	O
acute	-	25	O
toxic	-	31	O
response	-	37	O
to	-	46	O
caffeine	-	49	O
among	-	58	O
inbred	-	64	O
mice	-	71	O
.	-	75	O

Acute	6728873	77	O
toxic	-	83	O
dosage	-	89	O
-	-	95	O
dependent	-	96	O
behavioral	-	106	O
effects	-	117	O
of	-	125	O
caffeine	-	128	O
were	-	137	O
compared	-	142	O
in	-	151	O
adult	-	154	O
males	-	160	O
from	-	166	O
seven	-	171	O
inbred	-	177	O
mouse	-	184	O
strains	-	190	O
(	-	198	O
A	-	199	O
/	-	200	O
J	-	201	O
,	-	202	O
BALB	-	204	O
/	-	208	O
cJ	-	209	O
,	-	211	O
CBA	-	213	O
/	-	216	O
J	-	217	O
,	-	218	O
C3H	-	220	O
/	-	223	O
HeJ	-	224	O
,	-	227	O
C57BL	-	229	O
/	-	234	O
6J	-	235	O
,	-	237	O
DBA	-	239	O
/	-	242	O
2J	-	243	O
,	-	245	O
SWR	-	247	O
/	-	250	O
J	-	251	O
)	-	252	O
.	-	253	O

C57BL	6728873	255	O
/	-	260	O
6J	-	261	O
,	-	263	O
chosen	-	265	O
as	-	272	O
a	-	275	O
""""	-	277	O
prototypic	-	278	O
""""	-	288	O
mouse	-	290	O
strain	-	296	O
,	-	302	O
was	-	304	O
used	-	308	O
to	-	313	O
determine	-	316	O
behavioral	-	326	O
responses	-	337	O
to	-	347	O
a	-	350	O
broad	-	352	O
range	-	358	O
(	-	364	O
5	-	365	O
-	-	366	O
500	-	367	O
mg	-	371	O
/	-	373	O
kg	-	374	O
)	-	376	O
of	-	378	O
caffeine	-	381	O
doses	-	390	O
.	-	395	O

Five	6728873	397	O
phenotypic	-	402	O
characteristics	-	413	O
-	-	428	O
-	-	429	O
locomotor	-	430	O
activity	-	440	O
,	-	448	O
righting	-	450	O
ability	-	459	O
,	-	466	O
clonic	-	468	B
seizure	-	475	I
induction	-	483	O
,	-	492	O
stress	-	494	O
-	-	500	O
induced	-	501	O
lethality	-	509	O
,	-	518	O
death	-	520	O
without	-	526	O
external	-	534	O
stress	-	543	O
-	-	549	O
-	-	550	O
were	-	551	O
scored	-	556	O
at	-	563	O
various	-	566	O
caffeine	-	574	O
doses	-	583	O
in	-	589	O
drug	-	592	O
-	-	596	O
naive	-	597	O
animals	-	603	O
under	-	611	O
empirically	-	617	O
optimized	-	629	O
,	-	638	O
rigidly	-	640	O
constant	-	648	O
experimental	-	657	O
conditions	-	670	O
.	-	680	O

Mice	6728873	682	O
(	-	687	O
n	-	688	O
=	-	690	O
12	-	692	O
for	-	695	O
each	-	699	O
point	-	704	O
)	-	709	O
received	-	711	O
single	-	720	O
IP	-	727	O
injections	-	730	O
of	-	741	O
a	-	744	O
fixed	-	746	O
volume	-	752	O
/	-	758	O
g	-	759	O
body	-	761	O
weight	-	766	O
of	-	773	O
physiological	-	776	O
saline	-	790	O
carrier	-	797	O
with	-	805	O
or	-	810	O
without	-	813	O
caffeine	-	821	O
in	-	830	O
doses	-	833	O
ranging	-	839	O
from	-	847	O
125	-	852	O
-	-	855	O
500	-	856	O
mg	-	860	O
/	-	862	O
kg	-	863	O
.	-	865	O

Loss	6728873	867	O
of	-	872	O
righting	-	875	O
ability	-	884	O
was	-	892	O
scored	-	896	O
at	-	903	O
1	-	906	O
,	-	907	O
3	-	909	O
,	-	910	O
5	-	912	O
min	-	914	O
post	-	918	O
dosing	-	923	O
and	-	930	O
at	-	934	O
5	-	937	O
min	-	939	O
intervals	-	943	O
thereafter	-	953	O
for	-	964	O
20	-	968	O
min	-	971	O
.	-	974	O

In	6728873	976	O
the	-	979	O
same	-	983	O
animals	-	988	O
the	-	996	O
occurrence	-	1000	O
of	-	1011	O
clonic	-	1014	B
seizures	-	1021	I
was	-	1030	O
scored	-	1034	O
as	-	1041	O
to	-	1044	O
time	-	1047	O
of	-	1052	O
onset	-	1055	O
and	-	1061	O
severity	-	1065	O
for	-	1074	O
20	-	1078	O
min	-	1081	O
after	-	1085	O
drug	-	1091	O
administration	-	1096	O
.	-	1110	O

When	6728873	1112	O
these	-	1117	O
proceeded	-	1123	O
to	-	1133	O
tonic	-	1136	B
seizures	-	1142	I
,	-	1150	O
death	-	1152	O
occurred	-	1158	O
in	-	1167	O
less	-	1170	O
than	-	1175	O
20	-	1180	O
min	-	1183	O
.	-	1186	O

Animals	6728873	1188	O
surviving	-	1196	O
for	-	1206	O
20	-	1210	O
min	-	1213	O
were	-	1217	O
immediately	-	1222	O
stressed	-	1234	O
by	-	1243	O
a	-	1246	O
swim	-	1248	O
test	-	1253	O
in	-	1258	O
25	-	1261	O
degrees	-	1264	O
C	-	1272	O
water	-	1274	O
,	-	1279	O
and	-	1281	O
death	-	1285	O
-	-	1290	O
producing	-	1291	O
tonic	-	1301	B
seizures	-	1307	I
were	-	1316	O
scored	-	1321	O
for	-	1328	O
2	-	1332	O
min	-	1334	O
.	-	1337	O

In	6728873	1339	O
other	-	1342	O
animals	-	1348	O
locomotor	-	1356	O
activity	-	1366	O
was	-	1375	O
measured	-	1379	O
15	-	1388	O
or	-	1391	O
60	-	1394	O
min	-	1397	O
after	-	1401	O
caffeine	-	1407	O
administration	-	1416	O
.	-	1430	O

By	6728873	1432	O
any	-	1435	O
single	-	1439	O
behavioral	-	1446	O
criterion	-	1457	O
or	-	1467	O
a	-	1470	O
combination	-	1472	O
of	-	1484	O
these	-	1487	O
criteria	-	1493	O
,	-	1501	O
marked	-	1503	O
differences	-	1510	O
in	-	1522	O
response	-	1525	O
to	-	1534	O
toxic	-	1537	O
caffeine	-	1543	O
doses	-	1552	O
were	-	1558	O
observed	-	1563	O
between	-	1572	O
strains	-	1580	O
.	-	1587	O

These	6728873	1589	O
results	-	1595	O
indicate	-	1603	O
that	-	1612	O
behavioral	-	1617	O
toxicity	-	1628	B
testing	-	1637	O
of	-	1645	O
alkylxanthines	-	1648	O
in	-	1663	O
a	-	1666	O
single	-	1668	O
mouse	-	1675	O
strain	-	1681	O
may	-	1688	O
be	-	1692	O
misleading	-	1695	O
and	-	1706	O
suggest	-	1710	O
that	-	1718	O
toxic	-	1723	O
responses	-	1729	O
of	-	1739	O
the	-	1742	O
central	-	1746	O
nervous	-	1754	O
system	-	1762	O
to	-	1769	O
this	-	1772	O
class	-	1777	O
of	-	1783	O
compounds	-	1786	O
are	-	1796	O
genetically	-	1800	O
influenced	-	1812	O
in	-	1823	O
mammals	-	1826	O
.	-	1833	O

Invasive	7248895	0	O
carcinoma	-	9	B
of	-	19	I
the	-	22	I
renal	-	26	I
pelvis	-	32	I
following	-	39	O
cyclophosphamide	-	49	O
therapy	-	66	O
for	-	74	O
nonmalignant	-	78	O
disease	-	91	O
.	-	98	O

A	7248895	100	O
47	-	102	O
-	-	104	O
year	-	105	O
-	-	109	O
old	-	110	O
woman	-	114	O
with	-	120	O
right	-	125	O
hydroureteronephrosis	-	131	B
due	-	153	O
to	-	157	O
ureterovesical	-	160	O
junction	-	175	O
obstruction	-	184	O
had	-	196	O
gross	-	200	O
hematuria	-	206	B
after	-	216	O
being	-	222	O
treated	-	228	O
for	-	236	O
five	-	240	O
years	-	245	O
wtih	-	251	O
cyclophosphamide	-	256	O
for	-	273	O
cerebral	-	277	B
vasculitis	-	286	I
.	-	296	O

A	7248895	298	O
right	-	300	O
nephroureterectomy	-	306	O
was	-	325	O
required	-	329	O
for	-	338	O
control	-	342	O
of	-	350	O
bleeding	-	353	B
.	-	361	O

The	7248895	363	O
pathology	-	367	O
specimen	-	377	O
contained	-	386	O
clinically	-	396	O
occult	-	407	O
invasive	-	414	O
carcinoma	-	423	B
of	-	433	I
the	-	436	I
renal	-	440	I
pelvis	-	446	I
.	-	452	O

Although	7248895	454	O
the	-	463	O
ability	-	467	O
of	-	475	O
cyclophosphamide	-	478	O
to	-	495	O
cause	-	498	O
hemorrhagic	-	504	B
cystitis	-	516	I
and	-	525	O
urine	-	529	O
cytologic	-	535	O
abnormalities	-	545	O
indistinguishable	-	559	O
from	-	577	O
high	-	582	O
grade	-	587	O
carcinoma	-	593	B
is	-	603	O
well	-	606	O
known	-	611	O
,	-	616	O
it	-	618	O
is	-	621	O
less	-	624	O
widely	-	629	O
appreciated	-	636	O
that	-	648	O
it	-	653	O
is	-	656	O
also	-	659	O
associated	-	664	O
with	-	675	O
carcinoma	-	680	B
of	-	690	I
the	-	693	I
urinary	-	697	I
tract	-	705	I
.	-	710	O

Twenty	7248895	712	O
carcinomas	-	719	B
of	-	730	I
the	-	733	I
urinary	-	737	I
bladder	-	745	I
and	-	753	O
one	-	757	O
carcinoma	-	761	B
of	-	771	I
the	-	774	I
prostate	-	778	I
have	-	787	O
been	-	792	O
reported	-	797	O
in	-	806	O
association	-	809	O
with	-	821	O
its	-	826	O
use	-	830	O
.	-	833	O

The	7248895	835	O
present	-	839	O
case	-	847	O
is	-	852	O
the	-	855	O
first	-	859	O
carcinoma	-	865	B
of	-	875	I
the	-	878	I
renal	-	882	I
pelvis	-	888	I
reported	-	895	O
in	-	904	O
association	-	907	O
with	-	919	O
cyclophosphamide	-	924	O
treatment	-	941	O
.	-	950	O

It	7248895	952	O
is	-	955	O
the	-	958	O
third	-	962	O
urinary	-	968	B
tract	-	976	I
cancer	-	982	I
reported	-	989	O
in	-	998	O
association	-	1001	O
with	-	1013	O
cyclophosphamide	-	1018	O
treatment	-	1035	O
for	-	1045	O
nonmalignant	-	1049	O
disease	-	1062	O
.	-	1069	O

The	7248895	1071	O
association	-	1075	O
of	-	1087	O
the	-	1090	O
tumor	-	1094	B
with	-	1100	O
preexisting	-	1105	O
hydroureteronephrosis	-	1117	B
suggests	-	1139	O
that	-	1148	O
stasis	-	1153	O
prolonged	-	1160	O
and	-	1170	O
intensified	-	1174	O
exposure	-	1186	O
of	-	1195	O
upper	-	1198	O
urinary	-	1204	O
tract	-	1212	O
epithelium	-	1218	O
to	-	1229	O
cyclophosphamide	-	1232	O
.	-	1248	O

Patients	7248895	1250	O
who	-	1259	O
are	-	1263	O
candidates	-	1267	O
for	-	1278	O
long	-	1282	O
-	-	1286	O
term	-	1287	O
cyclophosphamide	-	1292	O
treatment	-	1309	O
should	-	1319	O
be	-	1326	O
routinely	-	1329	O
evaluated	-	1339	O
for	-	1349	O
obstructive	-	1353	B
uropathy	-	1365	I
.	-	1373	O

Ascending	9578276	0	O
dose	-	10	O
tolerance	-	15	O
study	-	25	O
of	-	31	O
intramuscular	-	34	O
carbetocin	-	48	O
administered	-	59	O
after	-	72	O
normal	-	78	O
vaginal	-	85	O
birth	-	93	O
.	-	98	O

OBJECTIVE	9578276	100	O
:	-	109	O

To	9578276	111	O
determine	-	114	O
the	-	124	O
maximum	-	128	O
tolerated	-	136	O
dose	-	146	O
(	-	151	O
MTD	-	152	O
)	-	155	O
of	-	157	O
carbetocin	-	160	O
(	-	171	O
a	-	172	O
long	-	174	O
-	-	178	O
acting	-	179	O
synthetic	-	186	O
analogue	-	196	O
of	-	205	O
oxytocin	-	208	O
)	-	216	O
,	-	217	O
when	-	219	O
administered	-	224	O
immediately	-	237	O
after	-	249	O
vaginal	-	255	O
delivery	-	263	O
at	-	272	O
term	-	275	O
.	-	279	O

MATERIALS	9578276	281	O
AND	-	291	O
METHODS	-	295	O
:	-	302	O

Carbetocin	9578276	304	O
was	-	315	O
given	-	319	O
as	-	325	O
an	-	328	O
intramuscular	-	331	O
injection	-	345	O
immediately	-	355	O
after	-	367	O
the	-	373	O
birth	-	377	O
of	-	383	O
the	-	386	O
infant	-	390	O
in	-	397	O
45	-	400	O
healthy	-	403	O
women	-	411	O
with	-	417	O
normal	-	422	O
singleton	-	429	O
pregnancies	-	439	O
who	-	451	O
delivered	-	455	O
vaginally	-	465	O
at	-	475	O
term	-	478	O
.	-	482	O

Dosage	9578276	484	O
groups	-	491	O
of	-	498	O
15	-	501	O
,	-	503	O
30	-	505	O
,	-	507	O
50	-	509	O
,	-	511	O
75	-	513	O
,	-	515	O
100	-	517	O
,	-	520	O
125	-	522	O
,	-	525	O
150	-	527	O
,	-	530	O
175	-	532	O
or	-	536	O
200	-	539	O
microg	-	543	O
carbetocin	-	550	O
were	-	561	O
assigned	-	566	O
to	-	575	O
blocks	-	578	O
of	-	585	O
three	-	588	O
women	-	594	O
according	-	600	O
to	-	610	O
the	-	613	O
continual	-	617	O
reassessment	-	627	O
method	-	640	O
(	-	647	O
CRM	-	648	O
)	-	651	O
.	-	652	O

RESULTS	9578276	654	O
:	-	661	O

All	9578276	663	O
dosage	-	667	O
groups	-	674	O
consisted	-	681	O
of	-	691	O
three	-	694	O
women	-	700	O
,	-	705	O
except	-	707	O
those	-	714	O
with	-	720	O
100	-	725	O
microg	-	729	O
(	-	736	O
n	-	737	O
=	-	738	O
6	-	739	O
)	-	740	O
and	-	742	O
200	-	746	O
microg	-	750	O
(	-	757	O
n	-	758	O
=	-	759	O
18	-	760	O
)	-	762	O
.	-	763	O

Recorded	9578276	765	O
were	-	774	O
dose	-	779	O
-	-	783	O
limiting	-	784	O
adverse	-	793	O
events	-	801	O
:	-	807	O
hyper	-	809	B
-	-	814	I
or	-	816	I
hypotension	-	819	I
(	-	831	O
three	-	832	O
)	-	837	O
,	-	838	O
severe	-	840	O
abdominal	-	847	B
pain	-	857	I
(	-	862	O
0	-	863	O
)	-	864	O
,	-	865	O
vomiting	-	867	B
(	-	876	O
0	-	877	O
)	-	878	O
and	-	880	O
retained	-	884	B
placenta	-	893	I
(	-	902	O
four	-	903	O
)	-	907	O
.	-	908	O

Serious	9578276	910	O
adverse	-	918	O
events	-	926	O
occurred	-	933	O
in	-	942	O
seven	-	945	O
women	-	951	O
:	-	956	O
six	-	958	O
cases	-	962	O
with	-	968	O
blood	-	973	B
loss	-	979	I
>	-	984	O
or	-	986	O
=	-	989	O
1000	-	991	O
ml	-	996	O
,	-	998	O
four	-	1000	O
cases	-	1005	O
of	-	1011	O
manual	-	1014	O
placenta	-	1021	O
removal	-	1030	O
,	-	1037	O
five	-	1039	O
cases	-	1044	O
of	-	1050	O
additional	-	1053	O
oxytocics	-	1064	O
administration	-	1074	O
and	-	1089	O
five	-	1093	O
cases	-	1098	O
of	-	1104	O
blood	-	1107	O
transfusion	-	1113	O
.	-	1124	O

Maximum	9578276	1126	O
blood	-	1134	B
loss	-	1140	I
was	-	1145	O
greatest	-	1149	O
at	-	1158	O
the	-	1161	O
upper	-	1165	O
and	-	1171	O
lower	-	1175	O
dose	-	1181	O
levels	-	1186	O
,	-	1192	O
and	-	1194	O
lowest	-	1198	O
in	-	1205	O
the	-	1208	O
70	-	1212	O
-	-	1214	O
125	-	1215	O
microg	-	1219	O
dose	-	1226	O
range	-	1231	O
.	-	1236	O

Four	9578276	1238	O
out	-	1243	O
of	-	1247	O
six	-	1250	O
cases	-	1254	O
with	-	1260	O
blood	-	1265	B
loss	-	1271	I
>	-	1276	O
or	-	1278	O
=	-	1281	O
1000	-	1283	O
ml	-	1288	O
occurred	-	1291	O
in	-	1300	O
the	-	1303	O
200	-	1307	O
microg	-	1311	O
group	-	1318	O
.	-	1323	O

The	9578276	1325	O
majority	-	1329	O
of	-	1338	O
additional	-	1341	O
administration	-	1352	O
of	-	1367	O
oxytocics	-	1370	O
(	-	1380	O
4	-	1381	O
/	-	1382	O
5	-	1383	O
)	-	1384	O
and	-	1386	O
blood	-	1390	O
transfusion	-	1396	O
(	-	1408	O
3	-	1409	O
/	-	1410	O
5	-	1411	O
)	-	1412	O
occurred	-	1414	O
in	-	1423	O
the	-	1426	O
dose	-	1430	O
groups	-	1435	O
of	-	1442	O
200	-	1445	O
microg	-	1449	O
.	-	1455	O

All	9578276	1457	O
retained	-	1461	O
placentae	-	1470	O
were	-	1480	O
found	-	1485	O
in	-	1491	O
the	-	1494	O
group	-	1498	O
of	-	1504	O
200	-	1507	O
microg	-	1511	O
.	-	1517	O

CONCLUSION	9578276	1519	O
:	-	1529	O

The	9578276	1531	O
MTD	-	1535	O
was	-	1539	O
calculated	-	1543	O
to	-	1554	O
be	-	1557	O
at	-	1560	O
200	-	1563	O
microg	-	1567	O
carbetocin	-	1574	O
.	-	1584	O

A	11423811	0	O
pilot	-	2	O
study	-	8	O
to	-	14	O
assess	-	17	O
the	-	24	O
safety	-	28	O
of	-	35	O
dobutamine	-	38	O
stress	-	49	O
echocardiography	-	56	O
in	-	73	O
the	-	76	O
emergency	-	80	O
department	-	90	O
evaluation	-	101	O
of	-	112	O
cocaine	-	115	O
-	-	122	O
associated	-	123	O
chest	-	134	B
pain	-	140	I
.	-	144	O

STUDY	11423811	146	O
OBJECTIVE	-	152	O
:	-	161	O
Chest	-	163	B
pain	-	169	I
in	-	174	O
the	-	177	O
setting	-	181	O
of	-	189	O
cocaine	-	192	O
use	-	200	O
poses	-	204	O
a	-	210	O
diagnostic	-	212	O
dilemma	-	223	O
.	-	230	O

Dobutamine	11423811	232	O
stress	-	243	O
echocardiography	-	250	O
(	-	267	O
DSE	-	268	O
)	-	271	O
is	-	273	O
a	-	276	O
widely	-	278	O
available	-	285	O
and	-	295	O
sensitive	-	299	O
test	-	309	O
for	-	314	O
evaluating	-	318	O
cardiac	-	329	O
ischemia	-	337	B
.	-	345	O

Because	11423811	347	O
of	-	355	O
the	-	358	O
theoretical	-	362	O
concern	-	374	O
regarding	-	382	O
administration	-	392	O
of	-	407	O
dobutamine	-	410	O
in	-	421	O
the	-	424	O
setting	-	428	O
of	-	436	O
cocaine	-	439	O
use	-	447	O
,	-	450	O
we	-	452	O
conducted	-	455	O
a	-	465	O
pilot	-	467	O
study	-	473	O
to	-	479	O
assess	-	482	O
the	-	489	O
safety	-	493	O
of	-	500	O
DSE	-	503	O
in	-	507	O
emergency	-	510	O
department	-	520	O
patients	-	531	O
with	-	540	O
cocaine	-	545	O
-	-	552	O
associated	-	553	O
chest	-	564	B
pain	-	570	I
.	-	574	O

METHODS	11423811	576	O
:	-	583	O

A	11423811	585	O
prospective	-	587	O
case	-	599	O
series	-	604	O
was	-	611	O
conducted	-	615	O
in	-	625	O
the	-	628	O
intensive	-	632	O
diagnostic	-	642	O
and	-	653	O
treatment	-	657	O
unit	-	667	O
in	-	672	O
the	-	675	O
ED	-	679	O
of	-	682	O
an	-	685	O
urban	-	688	O
tertiary	-	694	O
-	-	702	O
care	-	703	O
teaching	-	708	O
hospital	-	717	O
.	-	725	O

Patients	11423811	727	O
were	-	736	O
eligible	-	741	O
for	-	750	O
DSE	-	754	O
if	-	758	O
they	-	761	O
had	-	766	O
used	-	770	O
cocaine	-	775	O
within	-	783	O
24	-	790	O
hours	-	793	O
preceding	-	799	O
the	-	809	O
onset	-	813	O
of	-	819	O
chest	-	822	B
pain	-	828	I
and	-	833	O
had	-	837	O
a	-	841	O
normal	-	843	O
ECG	-	850	O
and	-	854	O
tropinin	-	858	O

I	11423811	867	O
level	-	869	O
.	-	874	O

Patients	11423811	876	O
exhibiting	-	885	O
signs	-	896	O
of	-	902	O
continuing	-	905	O
cocaine	-	916	O
toxicity	-	924	B
were	-	933	O
excluded	-	938	O
from	-	947	O
the	-	952	O
study	-	956	O
.	-	961	O

All	11423811	963	O
patients	-	967	O
were	-	976	O
admitted	-	981	O
to	-	990	O
the	-	993	O
hospital	-	997	O
for	-	1006	O
serial	-	1010	O
testing	-	1017	O
after	-	1025	O
the	-	1031	O
DSE	-	1035	O
testing	-	1039	O
in	-	1047	O
the	-	1050	O
intensive	-	1054	O
diagnostic	-	1064	O
and	-	1075	O
treatment	-	1079	O
unit	-	1089	O
.	-	1093	O

RESULTS	11423811	1095	O
:	-	1102	O

Twenty	11423811	1104	O
-	-	1110	O
four	-	1111	O
patients	-	1116	O
were	-	1125	O
enrolled	-	1130	O
.	-	1138	O

Two	11423811	1140	O
patients	-	1144	O
had	-	1153	O
inadequate	-	1157	O
resting	-	1168	O
images	-	1176	O
,	-	1182	O
one	-	1184	O
DSE	-	1188	O
was	-	1192	O
terminated	-	1196	O
because	-	1207	O
of	-	1215	O
inferior	-	1218	O
hypokinesis	-	1227	B
,	-	1238	O
another	-	1240	O
DSE	-	1248	O
was	-	1252	O
terminated	-	1256	O
because	-	1267	O
of	-	1275	O
a	-	1278	O
rate	-	1280	O
-	-	1284	O
related	-	1285	O
atrial	-	1293	O
conduction	-	1300	O
deficit	-	1311	O
,	-	1318	O
and	-	1320	O
1	-	1324	O
patient	-	1326	O
did	-	1334	O
not	-	1338	O
reach	-	1342	O
the	-	1348	O
target	-	1352	O
heart	-	1359	O
rate	-	1365	O
.	-	1369	O

Thus	11423811	1371	O
,	-	1375	O
19	-	1377	O
patients	-	1380	O
completed	-	1389	O
a	-	1399	O
DSE	-	1401	O
and	-	1405	O
reached	-	1409	O
their	-	1417	O
target	-	1423	O
heart	-	1430	O
rates	-	1436	O
.	-	1441	O

None	11423811	1443	O
of	-	1448	O
the	-	1451	O
patients	-	1455	O
experienced	-	1464	O
signs	-	1476	O
of	-	1482	O
exaggerated	-	1485	O
adrenergic	-	1497	O
response	-	1508	O
,	-	1516	O
which	-	1518	O
was	-	1524	O
defined	-	1528	O
as	-	1536	O
a	-	1539	O
systolic	-	1541	O
blood	-	1550	O
pressure	-	1556	O
of	-	1565	O
greater	-	1568	O
than	-	1576	O
200	-	1581	O
mm	-	1585	O
Hg	-	1588	O
or	-	1591	O
the	-	1594	O
occurrence	-	1598	O
of	-	1609	O
tachydysrhythmias	-	1612	B
(	-	1630	O
excluding	-	1631	O
sinus	-	1641	B
tachycardia	-	1647	I
)	-	1658	O
.	-	1659	O

Further	11423811	1661	O
suggesting	-	1669	O
lack	-	1680	O
of	-	1685	O
exaggerated	-	1688	O
adrenergic	-	1700	O
response	-	1711	O
,	-	1719	O
13	-	1721	O
(	-	1724	O
65	-	1725	O
%	-	1727	O
)	-	1728	O
of	-	1730	O
20	-	1733	O
patients	-	1736	O
required	-	1745	O
supplemental	-	1754	O
atropine	-	1767	O
to	-	1776	O
reach	-	1779	O
their	-	1785	O
target	-	1791	O
heart	-	1798	O
rates	-	1804	O
.	-	1809	O

CONCLUSION	11423811	1811	O
:	-	1821	O

No	11423811	1823	O
exaggerated	-	1826	O
adrenergic	-	1838	O
response	-	1849	O
was	-	1858	O
detected	-	1862	O
when	-	1871	O
dobutamine	-	1876	O
was	-	1887	O
administered	-	1891	O
to	-	1904	O
patients	-	1907	O
with	-	1916	O
cocaine	-	1921	O
-	-	1928	O
related	-	1929	O
chest	-	1937	B
pain	-	1943	I
.	-	1947	O

Amiodarone	12678199	0	O
-	-	10	O
induced	-	11	O
torsade	-	19	B
de	-	27	I
pointes	-	30	I
during	-	38	O
bladder	-	45	O
irrigation	-	53	O
:	-	63	O
an	-	65	O
unusual	-	68	O
presentation	-	76	O
-	-	88	O
-	-	89	O
a	-	90	O
case	-	92	O
report	-	97	O
.	-	103	O

The	12678199	105	O
authors	-	109	O
present	-	117	O
a	-	125	O
case	-	127	O
of	-	132	O
early	-	135	O
(	-	141	O
within	-	142	O
4	-	149	O
days	-	151	O
)	-	155	O
development	-	157	O
of	-	169	O
torsade	-	172	B
de	-	180	I
pointes	-	183	I
(	-	191	O
TdP	-	192	B
)	-	195	O
associated	-	197	O
with	-	208	O
oral	-	213	O
amiodarone	-	218	O
therapy	-	229	O
.	-	236	O

Consistent	12678199	238	O
with	-	249	O
other	-	254	O
reports	-	260	O
this	-	268	O
case	-	273	O
of	-	278	O
TdP	-	281	B
occurred	-	285	O
in	-	294	O
the	-	297	O
context	-	301	O
of	-	309	O
multiple	-	312	O
exacerbating	-	321	O
factors	-	334	O
including	-	342	O
hypokalemia	-	352	B
and	-	364	O
digoxin	-	368	O
excess	-	376	O
.	-	382	O

Transient	12678199	384	O
prolongation	-	394	O
of	-	407	O
the	-	410	O
QT	-	414	O
during	-	417	O
bladder	-	424	O
irrigation	-	432	O
prompted	-	443	O
the	-	452	O
episode	-	456	O
of	-	464	O
TdP	-	467	B
.	-	470	O

It	12678199	472	O
is	-	475	O
well	-	478	O
known	-	483	O
that	-	489	O
bradycardia	-	494	B
exacerbates	-	506	O
acquired	-	518	O
TdP	-	527	B
.	-	530	O

The	12678199	532	O
authors	-	536	O
speculate	-	544	O
that	-	554	O
the	-	559	O
increased	-	563	O
vagal	-	573	O
tone	-	579	O
during	-	584	O
bladder	-	591	O
irrigation	-	599	O
,	-	609	O
a	-	611	O
vagal	-	613	O
maneuver	-	619	O
,	-	627	O
in	-	629	O
the	-	632	O
context	-	636	O
of	-	644	O
amiodarone	-	647	O
therapy	-	658	O
resulted	-	666	O
in	-	675	O
amiodarone	-	678	O
-	-	688	O
induced	-	689	O
proarrhythmia	-	697	B
.	-	710	O

In	12678199	712	O
the	-	715	O
absence	-	719	O
of	-	727	O
amiodarone	-	730	O
therapy	-	741	O
,	-	748	O
a	-	750	O
second	-	752	O
bladder	-	759	O
irrigation	-	767	O
did	-	778	O
not	-	782	O
induce	-	786	O
TdP	-	793	B
despite	-	797	O
hypokalemia	-	805	B
and	-	817	O
hypomagnesemia	-	821	B
.	-	835	O

Acute	15696449	0	B
renal	-	6	I
insufficiency	-	12	I
after	-	26	O
high	-	32	O
-	-	36	O
dose	-	37	O
melphalan	-	42	O
in	-	52	O
patients	-	55	O
with	-	64	O
primary	-	69	B
systemic	-	77	I
amyloidosis	-	86	I
during	-	98	O
stem	-	105	O
cell	-	110	O
transplantation	-	115	O
.	-	130	O

BACKGROUND	15696449	132	O
:	-	142	O

Patients	15696449	144	O
with	-	153	O
primary	-	158	B
systemic	-	166	I
amyloidosis	-	175	I
(	-	187	O
AL	-	188	B
)	-	190	O
have	-	192	O
a	-	197	O
poor	-	199	O
prognosis	-	204	O
.	-	213	O

Median	15696449	215	O
survival	-	222	O
time	-	231	O
from	-	236	O
standard	-	241	O
treatments	-	250	O
is	-	261	O
only	-	264	O
17	-	269	O
months	-	272	O
.	-	278	O

High	15696449	280	O
-	-	284	O
dose	-	285	O
intravenous	-	290	O
melphalan	-	302	O
followed	-	312	O
by	-	321	O
peripheral	-	324	O
blood	-	335	O
stem	-	341	O
cell	-	346	O
transplant	-	351	O
(	-	362	O
PBSCT	-	363	O
)	-	368	O
appears	-	370	O
to	-	378	O
be	-	381	O
the	-	384	O
most	-	388	O
promising	-	393	O
therapy	-	403	O
,	-	410	O
but	-	412	O
treatment	-	416	O
mortality	-	426	O
can	-	436	O
be	-	440	O
high	-	443	O
.	-	447	O

The	15696449	449	O
authors	-	453	O
have	-	461	O
noted	-	466	O
the	-	472	O
development	-	476	O
of	-	488	O
acute	-	491	B
renal	-	497	I
insufficiency	-	503	I
immediately	-	517	O
after	-	529	O
melphalan	-	535	O
conditioning	-	545	O
.	-	557	O

This	15696449	559	O
study	-	564	O
was	-	570	O
undertaken	-	574	O
to	-	585	O
further	-	588	O
examine	-	596	O
its	-	604	O
risk	-	608	O
factors	-	613	O
and	-	621	O
impact	-	625	O
on	-	632	O
posttransplant	-	635	O
mortality	-	650	O
.	-	659	O

METHODS	15696449	661	O
:	-	668	O

Consecutive	15696449	670	O
AL	-	682	B
patients	-	685	O
who	-	694	O
underwent	-	698	O
PBSCT	-	708	O
were	-	714	O
studied	-	719	O
retrospectively	-	727	O
.	-	742	O

Acute	15696449	744	B
renal	-	750	I
insufficiency	-	756	I
(	-	770	O
ARI	-	771	B
)	-	774	O
after	-	776	O
high	-	782	O
-	-	786	O
dose	-	787	O
melphalan	-	792	O
was	-	802	O
defined	-	806	O
by	-	814	O
a	-	817	O
minimum	-	819	O
increase	-	827	O
of	-	836	O
0	-	839	O
.	-	840	O
5	-	841	O
mg	-	843	O
/	-	845	O
dL	-	846	O
(	-	849	O
44	-	850	O
micromol	-	853	O
/	-	861	O
L	-	862	O
)	-	863	O
in	-	865	O
the	-	868	O
serum	-	872	O
creatinine	-	878	O
level	-	889	O
that	-	895	O
is	-	900	O
greater	-	903	O
than	-	911	O
50	-	916	O
%	-	918	O
of	-	920	O
baseline	-	923	O
immediately	-	932	O
after	-	944	O
conditioning	-	950	O
.	-	962	O

Urine	15696449	964	O
sediment	-	970	O
score	-	979	O
was	-	985	O
the	-	989	O
sum	-	993	O
of	-	997	O
the	-	1000	O
individual	-	1004	O
types	-	1015	O
of	-	1021	O
sediment	-	1024	O
identified	-	1033	O
on	-	1044	O
urine	-	1047	O
microscopy	-	1053	O
.	-	1063	O

RESULTS	15696449	1065	O
:	-	1072	O

Of	15696449	1074	O
the	-	1077	O
80	-	1081	O
patients	-	1084	O
studied	-	1093	O
,	-	1100	O
ARI	-	1102	B
developed	-	1106	O
in	-	1116	O
18	-	1119	O
.	-	1121	O
8	-	1122	O
%	-	1123	O
of	-	1125	O
the	-	1128	O
patients	-	1132	O
after	-	1141	O
high	-	1147	O
-	-	1151	O
dose	-	1152	O
melphalan	-	1157	O
.	-	1166	O

Univariate	15696449	1168	O
analysis	-	1179	O
identified	-	1188	O
age	-	1199	O
,	-	1202	O
hypoalbuminemia	-	1204	B
,	-	1219	O
heavy	-	1221	O
proteinuria	-	1227	B
,	-	1238	O
diuretic	-	1240	O
use	-	1249	O
,	-	1252	O
and	-	1254	O
urine	-	1258	O
sediment	-	1264	O
score	-	1273	O
(	-	1279	O
>	-	1280	O
3	-	1281	O
)	-	1282	O
as	-	1284	O
risk	-	1287	O
factors	-	1292	O
.	-	1299	O

Age	15696449	1301	O
and	-	1305	O
urine	-	1309	O
sediment	-	1315	O
score	-	1324	O
remained	-	1330	O
independently	-	1339	O
significant	-	1353	O
risk	-	1365	O
factors	-	1370	O
in	-	1378	O
the	-	1381	O
multivariate	-	1385	O
analysis	-	1398	O
.	-	1406	O

Patients	15696449	1408	O
who	-	1417	O
had	-	1421	O
ARI	-	1425	B
after	-	1429	O
high	-	1435	O
-	-	1439	O
dose	-	1440	O
melphalan	-	1445	O
underwent	-	1455	O
dialysis	-	1465	O
more	-	1474	O
often	-	1479	O
(	-	1485	O
P	-	1486	O
=	-	1488	O
0	-	1490	O
.	-	1491	O
007	-	1492	O
)	-	1495	O
,	-	1496	O
and	-	1498	O
had	-	1502	O
a	-	1506	O
worse	-	1508	O
1	-	1514	O
-	-	1515	O
year	-	1516	O
survival	-	1521	O
(	-	1530	O
P	-	1531	O
=	-	1533	O
0	-	1535	O
.	-	1536	O
03	-	1537	O
)	-	1539	O
.	-	1540	O

CONCLUSION	15696449	1542	O
:	-	1552	O

The	15696449	1554	O
timing	-	1558	O
of	-	1565	O
renal	-	1568	B
injury	-	1574	I
strongly	-	1581	O
suggests	-	1590	O
melphalan	-	1599	O
as	-	1609	O
the	-	1612	O
causative	-	1616	O
agent	-	1626	O
.	-	1631	O

Ongoing	15696449	1633	O
tubular	-	1641	B
injury	-	1649	I
may	-	1656	O
be	-	1660	O
a	-	1663	O
prerequisite	-	1665	O
for	-	1678	O
renal	-	1682	B
injury	-	1688	I
by	-	1695	O
melphalan	-	1698	O
as	-	1708	O
evidenced	-	1711	O
by	-	1721	O
the	-	1724	O
active	-	1728	O
urinary	-	1735	O
sediment	-	1743	O
.	-	1751	O

Development	15696449	1753	O
of	-	1765	O
ARI	-	1768	B
adversely	-	1772	O
affected	-	1782	O
the	-	1791	O
outcome	-	1795	O
after	-	1803	O
PBSCT	-	1809	O
.	-	1814	O

Effective	15696449	1816	O
preventive	-	1826	O
measures	-	1837	O
may	-	1846	O
help	-	1850	O
decrease	-	1855	O
the	-	1864	O
treatment	-	1868	O
mortality	-	1878	O
of	-	1888	O
PBSCT	-	1891	O
in	-	1897	O
AL	-	1900	B
patients	-	1903	O
.	-	1911	O

Impaired	17554526	0	B
fear	-	9	I
recognition	-	14	I
in	-	26	O
regular	-	29	O
recreational	-	37	O
cocaine	-	50	O
users	-	58	O
.	-	63	O

INTRODUCTION	17554526	65	O
:	-	77	O

The	17554526	79	O
ability	-	83	O
to	-	91	O
read	-	94	O
facial	-	99	O
expressions	-	106	O
is	-	118	O
essential	-	121	O
for	-	131	O
normal	-	135	O
human	-	142	O
social	-	148	O
interaction	-	155	O
.	-	166	O

The	17554526	168	O
aim	-	172	O
of	-	176	O
the	-	179	O
present	-	183	O
study	-	191	O
was	-	197	O
to	-	201	O
conduct	-	204	O
the	-	212	O
first	-	216	O
investigation	-	222	O
of	-	236	O
facial	-	239	O
expression	-	246	O
recognition	-	257	O
performance	-	269	O
in	-	281	O
recreational	-	284	O
cocaine	-	297	O
users	-	305	O
.	-	310	O

MATERIALS	17554526	312	O
AND	-	322	O
METHODS	-	326	O
:	-	333	O

Three	17554526	335	O
groups	-	341	O
,	-	347	O
comprised	-	349	O
of	-	359	O
21	-	362	O
cocaine	-	365	O
naive	-	373	O
participants	-	379	O
(	-	392	O
CN	-	393	O
)	-	395	O
,	-	396	O
30	-	399	O
occasional	-	402	O
cocaine	-	413	O
(	-	421	O
OC	-	422	O
)	-	424	O
,	-	425	O
and	-	427	O
48	-	431	O
regular	-	434	O
recreational	-	442	O
cocaine	-	455	O
(	-	463	O
RC	-	464	O
)	-	466	O
users	-	468	O
,	-	473	O
were	-	475	O
compared	-	480	O
.	-	488	O

An	17554526	490	O
emotional	-	493	O
facial	-	503	O
expression	-	510	O
(	-	521	O
EFE	-	522	O
)	-	525	O
task	-	527	O
consisting	-	532	O
of	-	543	O
a	-	546	O
male	-	548	O
and	-	553	O
female	-	557	O
face	-	564	O
expressing	-	569	O
six	-	580	O
basic	-	584	O
emotions	-	590	O
(	-	599	O
happiness	-	600	O
,	-	609	O
surprise	-	611	O
,	-	619	O
sadness	-	621	O
,	-	628	O
anger	-	630	O
,	-	635	O
fear	-	637	O
,	-	641	O
and	-	643	O
disgust	-	647	O
)	-	654	O
was	-	656	O
administered	-	660	O
.	-	672	O

Mean	17554526	674	O
percent	-	679	O
accuracy	-	687	O
and	-	696	O
latencies	-	700	O
for	-	710	O
correct	-	714	O
responses	-	722	O
across	-	732	O
eight	-	739	O
presentations	-	745	O
of	-	759	O
each	-	762	O
basic	-	767	O
emotion	-	773	O
were	-	781	O
derived	-	786	O
.	-	793	O

Participants	17554526	795	O
were	-	808	O
also	-	813	O
assessed	-	818	O
with	-	827	O
the	-	832	O
""""	-	836	O
Eyes	-	837	O
task	-	842	O
""""	-	846	O
to	-	848	O
investigate	-	851	O
their	-	863	O
ability	-	869	O
to	-	877	O
recognize	-	880	O
more	-	890	O
complex	-	895	O
emotional	-	903	O
states	-	913	O
and	-	920	O
the	-	924	O
Symptom	-	928	O
CheckList	-	936	O
-	-	945	O
90	-	946	O
-	-	948	O
Revised	-	949	O
to	-	957	O
measure	-	960	O
psychopathology	-	968	O
.	-	983	O

RESULTS	17554526	985	O
:	-	992	O

There	17554526	994	O
were	-	1000	O
no	-	1005	O
group	-	1008	O
differences	-	1014	O
in	-	1026	O
psychopathology	-	1029	O
or	-	1045	O
""""	-	1048	O
eyes	-	1049	O
task	-	1054	O
""""	-	1058	O
performance	-	1060	O
,	-	1071	O
but	-	1073	O
the	-	1077	O
RC	-	1081	O
group	-	1084	O
,	-	1089	O
who	-	1091	O
otherwise	-	1095	O
had	-	1105	O
similar	-	1109	O
illicit	-	1117	O
substance	-	1125	O
use	-	1135	O
histories	-	1139	O
to	-	1149	O
the	-	1152	O
OC	-	1156	O
group	-	1159	O
,	-	1164	O
exhibited	-	1166	O
impaired	-	1176	B
fear	-	1185	I
recognition	-	1190	I
accuracy	-	1202	O
compared	-	1211	O
to	-	1220	O
the	-	1223	O
OC	-	1227	O
and	-	1230	O
CN	-	1234	O
groups	-	1237	O
.	-	1243	O

The	17554526	1245	O
RC	-	1249	O
group	-	1252	O
also	-	1258	O
correctly	-	1263	O
identified	-	1273	O
anger	-	1284	O
,	-	1289	O
fear	-	1291	O
,	-	1295	O
happiness	-	1297	O
,	-	1306	O
and	-	1308	O
surprise	-	1312	O
,	-	1320	O
more	-	1322	O
slowly	-	1327	O
than	-	1334	O
CN	-	1339	O
,	-	1341	O
but	-	1343	O
not	-	1347	O
OC	-	1351	O
participants	-	1354	O
.	-	1366	O

The	17554526	1368	O
OC	-	1372	O
group	-	1375	O
was	-	1381	O
slower	-	1385	O
than	-	1392	O
CN	-	1397	O
when	-	1400	O
correctly	-	1405	O
identifying	-	1415	O
disgust	-	1427	O
.	-	1434	O

The	17554526	1436	O
selective	-	1440	O
deficit	-	1450	B
in	-	1458	I
fear	-	1461	I
recognition	-	1466	I
accuracy	-	1478	O
manifested	-	1487	O
by	-	1498	O
the	-	1501	O
RC	-	1505	O
group	-	1508	O
can	-	1514	O
not	-	1517	O
be	-	1521	O
explained	-	1524	O
by	-	1534	O
the	-	1537	O
subacute	-	1541	O
effects	-	1550	O
of	-	1558	O
cocaine	-	1561	O
,	-	1568	O
or	-	1570	O
ecstasy	-	1573	O
,	-	1580	O
because	-	1582	O
recent	-	1590	O
and	-	1597	O
less	-	1601	O
recent	-	1606	O
users	-	1613	O
of	-	1619	O
these	-	1622	O
drugs	-	1628	O
within	-	1634	O
this	-	1641	O
group	-	1646	O
were	-	1652	O
similarly	-	1657	O
impaired	-	1667	O
.	-	1675	O

Possible	17554526	1677	O
parallels	-	1686	O
between	-	1696	O
RC	-	1704	O
users	-	1707	O
and	-	1713	O
psychopaths	-	1717	B
with	-	1729	O
respect	-	1734	O
to	-	1742	O
impaired	-	1745	B
fear	-	1754	I
recognition	-	1759	I
,	-	1770	O
amygdala	-	1772	B
dysfunction	-	1781	I
,	-	1792	O
and	-	1794	O
etiology	-	1798	O
are	-	1807	O
discussed	-	1811	O
.	-	1820	O

Corneal	17721298	0	B
ulcers	-	8	I
associated	-	15	O
with	-	26	O
aerosolized	-	31	O
crack	-	43	O
cocaine	-	49	O
use	-	57	O
.	-	60	O

PURPOSE	17721298	62	O
:	-	69	O

We	17721298	71	O
report	-	74	O
4	-	81	O
cases	-	83	O
of	-	89	O
corneal	-	92	B
ulcers	-	100	I
associated	-	107	O
with	-	118	O
drug	-	123	B
abuse	-	128	I
.	-	133	O

The	17721298	135	O
pathogenesis	-	139	O
of	-	152	O
these	-	155	O
ulcers	-	161	B
and	-	168	O
management	-	172	O
of	-	183	O
these	-	186	O
patients	-	192	O
are	-	201	O
also	-	205	O
reviewed	-	210	O
.	-	218	O

METHODS	17721298	220	O
:	-	227	O

Review	17721298	229	O
of	-	236	O
all	-	239	O
cases	-	243	O
of	-	249	O
corneal	-	252	B
ulcers	-	260	I
associated	-	267	O
with	-	278	O
drug	-	283	B
abuse	-	288	I
seen	-	294	O
at	-	299	O
our	-	302	O
institution	-	306	O
from	-	318	O
July	-	323	O
2006	-	328	O
to	-	333	O
December	-	336	O
2006	-	345	O
.	-	349	O

RESULTS	17721298	351	O
:	-	358	O

Four	17721298	360	O
patients	-	365	O
with	-	374	O
corneal	-	379	B
ulcers	-	387	I
associated	-	394	O
with	-	405	O
crack	-	410	O
cocaine	-	416	O
use	-	424	O
were	-	428	O
reviewed	-	433	O
.	-	441	O

All	17721298	443	O
corneal	-	447	B
ulcers	-	455	I
were	-	462	O
cultured	-	467	O
,	-	475	O
and	-	477	O
the	-	481	O
patients	-	485	O
were	-	494	O
admitted	-	499	O
to	-	508	O
the	-	511	O
hospital	-	515	O
for	-	524	O
intensive	-	528	O
topical	-	538	O
antibiotic	-	546	O
treatment	-	557	O
.	-	566	O

Each	17721298	568	O
patient	-	573	O
received	-	581	O
comprehensive	-	590	O
health	-	604	O
care	-	611	O
,	-	615	O
including	-	617	O
medical	-	627	O
and	-	635	O
substance	-	639	B
abuse	-	649	I
consultations	-	655	O
.	-	668	O

Streptococcal	17721298	670	O
organisms	-	684	O
were	-	694	O
found	-	699	O
in	-	705	O
3	-	708	O
cases	-	710	O
and	-	716	O
Capnocytophaga	-	720	O
and	-	735	O
Brevibacterium	-	739	O
casei	-	754	O
in	-	760	O
1	-	763	O
patient	-	765	O
.	-	772	O

The	17721298	774	O
infections	-	778	B
responded	-	789	O
to	-	799	O
antibiotic	-	802	O
treatment	-	813	O
.	-	822	O

Two	17721298	824	O
patients	-	828	O
needed	-	837	O
a	-	844	O
lateral	-	846	O
tarsorrhaphy	-	854	O
for	-	867	O
persistent	-	871	O
epithelial	-	882	B
defects	-	893	I
.	-	900	O

CONCLUSIONS	17721298	902	O
:	-	913	O

Aerosolized	17721298	915	O
crack	-	927	O
cocaine	-	933	O
use	-	941	O
can	-	945	O
be	-	949	O
associated	-	952	O
with	-	963	O
the	-	968	O
development	-	972	O
of	-	984	O
corneal	-	987	B
ulcers	-	995	I
.	-	1001	O

Drug	17721298	1003	B
abuse	-	1008	I
provides	-	1014	O
additional	-	1023	O
challenges	-	1034	O
for	-	1045	O
management	-	1049	O
.	-	1059	O

Not	17721298	1061	O
only	-	1065	O
treatment	-	1070	O
of	-	1080	O
their	-	1083	O
infections	-	1089	B
but	-	1100	O
also	-	1104	O
the	-	1109	O
overall	-	1113	O
poor	-	1121	O
health	-	1126	O
of	-	1133	O
the	-	1136	O
patients	-	1140	O
and	-	1149	O
increased	-	1153	O
risk	-	1163	O
of	-	1168	O
noncompliance	-	1171	O
need	-	1185	O
to	-	1190	O
be	-	1193	O
addressed	-	1196	O
.	-	1205	O

Comprehensive	17721298	1207	O
care	-	1221	O
may	-	1226	O
provide	-	1230	O
the	-	1238	O
patient	-	1242	O
the	-	1250	O
opportunity	-	1254	O
to	-	1266	O
discontinue	-	1269	O
their	-	1281	O
substance	-	1287	B
abuse	-	1297	I
,	-	1302	O
improve	-	1304	O
their	-	1312	O
overall	-	1318	O
health	-	1326	O
,	-	1332	O
and	-	1334	O
prevent	-	1338	O
future	-	1346	O
corneal	-	1353	O
complications	-	1361	O
.	-	1374	O

Levetiracetam	18341442	0	O
as	-	14	O
an	-	17	O
adjunct	-	20	O
to	-	28	O
phenobarbital	-	31	O
treatment	-	45	O
in	-	55	O
cats	-	58	O
with	-	63	O
suspected	-	68	O
idiopathic	-	78	B
epilepsy	-	89	I
.	-	97	O

OBJECTIVE	18341442	99	O
:	-	108	O

To	18341442	110	O
assess	-	113	O
pharmacokinetics	-	120	O
,	-	136	O
efficacy	-	138	O
,	-	146	O
and	-	148	O
tolerability	-	152	O
of	-	165	O
oral	-	168	O
levetiracetam	-	173	O
administered	-	187	O
as	-	200	O
an	-	203	O
adjunct	-	206	O
to	-	214	O
phenobarbital	-	217	O
treatment	-	231	O
in	-	241	O
cats	-	244	O
with	-	249	O
poorly	-	254	O
controlled	-	261	O
suspected	-	272	O
idiopathic	-	282	B
epilepsy	-	293	I
.	-	301	O

DESIGN	18341442	303	O
-	-	309	O
Open	-	310	O
-	-	314	O
label	-	315	O
,	-	320	O
noncomparative	-	322	O
clinical	-	337	O
trial	-	346	O
.	-	351	O

ANIMALS	18341442	353	O
:	-	360	O
12	-	362	O
cats	-	365	O
suspected	-	370	O
to	-	380	O
have	-	383	O
idiopathic	-	388	B
epilepsy	-	399	I
that	-	408	O
was	-	413	O
poorly	-	417	O
controlled	-	424	O
with	-	435	O
phenobarbital	-	440	O
or	-	454	O

that	18341442	457	O
had	-	462	O
unacceptable	-	466	O
adverse	-	479	O
effects	-	487	O
when	-	495	O
treated	-	500	O
with	-	508	O
phenobarbital	-	513	O
.	-	526	O

PROCEDURES	18341442	528	O
:	-	538	O

Cats	18341442	540	O
were	-	545	O
treated	-	550	O
with	-	558	O
levetiracetam	-	563	O
(	-	577	O
20	-	578	O
mg	-	581	O
/	-	583	O
kg	-	584	O

[	18341442	587	O
9	-	588	O
.	-	589	O
1	-	590	O
mg	-	592	O
/	-	594	O
lb	-	595	O
]	-	597	O
,	-	598	O
PO	-	600	O
,	-	602	O
q	-	604	O
8	-	606	O
h	-	608	O
)	-	609	O
.	-	610	O

After	18341442	612	O
a	-	618	O
minimum	-	620	O
of	-	628	O
1	-	631	O
week	-	633	O
of	-	638	O
treatment	-	641	O
,	-	650	O
serum	-	652	O
levetiracetam	-	658	O
concentrations	-	672	O
were	-	687	O
measured	-	692	O
before	-	701	O
and	-	708	O
2	-	712	O
,	-	713	O
4	-	715	O
,	-	716	O
and	-	718	O
6	-	722	O
hours	-	724	O
after	-	730	O
drug	-	736	O
administration	-	741	O
,	-	755	O
and	-	757	O
maximum	-	761	O
and	-	769	O
minimum	-	773	O
serum	-	781	O
concentrations	-	787	O
and	-	802	O
elimination	-	806	O
half	-	818	O
-	-	822	O
life	-	823	O
were	-	828	O
calculated	-	833	O
.	-	843	O

Seizure	18341442	845	B
frequencies	-	853	O
before	-	865	O
and	-	872	O
after	-	876	O
initiation	-	882	O
of	-	893	O
levetiracetam	-	896	O
treatment	-	910	O
were	-	920	O
compared	-	925	O
,	-	933	O
and	-	935	O
adverse	-	939	O
effects	-	947	O
were	-	955	O
recorded	-	960	O
.	-	968	O

RESULTS	18341442	970	O
:	-	977	O

Median	18341442	979	O
maximum	-	986	O
serum	-	994	O
levetiracetam	-	1000	O
concentration	-	1014	O
was	-	1028	O
25	-	1032	O
.	-	1034	O
5	-	1035	O
microg	-	1037	O
/	-	1043	O
mL	-	1044	O
,	-	1046	O
median	-	1048	O
minimum	-	1055	O
serum	-	1063	O
levetiracetam	-	1069	O
concentration	-	1083	O
was	-	1097	O
8	-	1101	O
.	-	1102	O
3	-	1103	O
microg	-	1105	O
/	-	1111	O
mL	-	1112	O
,	-	1114	O
and	-	1116	O
median	-	1120	O
elimination	-	1127	O
half	-	1139	O
-	-	1143	O
life	-	1144	O
was	-	1149	O
2	-	1153	O
.	-	1154	O
9	-	1155	O
hours	-	1157	O
.	-	1162	O

Median	18341442	1164	O
seizure	-	1171	B
frequency	-	1179	O
prior	-	1189	O
to	-	1195	O
treatment	-	1198	O
with	-	1208	O
levetiracetam	-	1213	O
(	-	1227	O
2	-	1228	O
.	-	1229	O
1	-	1230	O
seizures	-	1232	B
/	-	1240	O
mo	-	1241	O
)	-	1243	O
was	-	1245	O
significantly	-	1249	O
higher	-	1263	O
than	-	1270	O
median	-	1275	O
seizure	-	1282	B
frequency	-	1290	O
after	-	1300	O
initiation	-	1306	O
of	-	1317	O
levetiracetam	-	1320	O
treatment	-	1334	O
(	-	1344	O
0	-	1345	O
.	-	1346	O
42	-	1347	O
seizures	-	1350	B
/	-	1358	O
mo	-	1359	O
)	-	1361	O
,	-	1362	O
and	-	1364	O
7	-	1368	O
of	-	1370	O
10	-	1373	O
cats	-	1376	O
were	-	1381	O
classified	-	1386	O
as	-	1397	O
having	-	1400	O
responded	-	1407	O
to	-	1417	O
levetiracetam	-	1420	O
treatment	-	1434	O
(	-	1444	O
ie	-	1445	O
,	-	1447	O
reduction	-	1449	O
in	-	1459	O
seizure	-	1462	B
frequency	-	1470	O
of	-	1480	O
>	-	1483	O

or	18341442	1484	O
=	-	1486	O
50	-	1487	O
%	-	1489	O
)	-	1490	O
.	-	1491	O

Two	18341442	1493	O
cats	-	1497	O
had	-	1502	O
transient	-	1506	O
lethargy	-	1516	B
and	-	1525	O
inappetence	-	1529	B
.	-	1540	O

CONCLUSIONS	18341442	1542	O
AND	-	1554	O
CLINICAL	-	1558	O
RELEVANCE	-	1567	O
:	-	1576	O

Results	18341442	1578	O
suggested	-	1586	O
that	-	1596	O
levetiracetam	-	1601	O
is	-	1615	O
well	-	1618	O
tolerated	-	1623	O
in	-	1633	O
cats	-	1636	O
and	-	1641	O
may	-	1645	O
be	-	1649	O
useful	-	1652	O
as	-	1659	O
an	-	1662	O
adjunct	-	1665	O
to	-	1673	O
phenobarbital	-	1676	O
treatment	-	1690	O
in	-	1700	O
cats	-	1703	O
with	-	1708	O
idiopathic	-	1713	B
epilepsy	-	1724	I
.	-	1732	O

Bilateral	19681452	0	O
haemorrhagic	-	10	B
infarction	-	23	I
of	-	34	I
the	-	37	I
globus	-	41	I
pallidus	-	48	I
after	-	57	O
cocaine	-	63	O
and	-	71	O
alcohol	-	75	O
intoxication	-	83	O
.	-	95	O

Cocaine	19681452	97	O
is	-	105	O
a	-	108	O
risk	-	110	O
factor	-	115	O
for	-	122	O
both	-	126	O
ischemic	-	131	B
and	-	140	I
haemorrhagic	-	144	I
stroke	-	157	I
.	-	163	O

We	19681452	165	O
present	-	168	O
the	-	176	O
case	-	180	O
of	-	185	O
a	-	188	O
31	-	190	O
-	-	192	O
year	-	193	O
-	-	197	O
old	-	198	O
man	-	202	O
with	-	206	O
bilateral	-	211	O
ischemia	-	221	B
of	-	230	I
the	-	233	I
globus	-	237	I
pallidus	-	244	I
after	-	253	O
excessive	-	259	O
alcohol	-	269	O
and	-	277	O
intranasal	-	281	O
cocaine	-	292	O
use	-	300	O
.	-	303	O

Drug	19681452	305	O
-	-	309	O
related	-	310	O
globus	-	318	B
pallidus	-	325	I
infarctions	-	334	I
are	-	346	O
most	-	350	O
often	-	355	O
associated	-	361	O
with	-	372	O
heroin	-	377	O
.	-	383	O

Bilateral	19681452	385	O
basal	-	395	B
ganglia	-	401	I
infarcts	-	409	I
after	-	418	O
the	-	424	O
use	-	428	O
of	-	432	O
cocaine	-	435	O
,	-	442	O
without	-	444	O
concurrent	-	452	O
heroin	-	463	O
use	-	470	O
,	-	473	O
have	-	475	O
never	-	480	O
been	-	486	O
reported	-	491	O
.	-	499	O

In	19681452	501	O
our	-	504	O
patient	-	508	O
,	-	515	O
transient	-	517	O
cardiac	-	527	B
arrhythmia	-	535	I
or	-	546	O
respiratory	-	549	B
dysfunction	-	561	I
related	-	573	O
to	-	581	O
cocaine	-	584	O
and	-	592	O
/	-	595	O
or	-	596	O
ethanol	-	599	O
use	-	607	O
were	-	611	O
the	-	616	O
most	-	620	O
likely	-	625	O
causes	-	632	O
of	-	639	O
cerebral	-	642	B
hypoperfusion	-	651	I
.	-	664	O

Acute	20009434	0	B
renal	-	6	I
failure	-	12	I
after	-	20	O
high	-	26	O
-	-	30	O
dose	-	31	O
methotrexate	-	36	O
therapy	-	49	O
in	-	57	O
a	-	60	O
patient	-	62	O
with	-	70	O
ileostomy	-	75	O
.	-	84	O

High	20009434	86	O
-	-	90	O
dose	-	91	O
methotrexate	-	96	O
(	-	109	O
HD	-	110	O
-	-	112	O
MTX	-	113	O
)	-	116	O
is	-	118	O
an	-	121	O
important	-	124	O
treatment	-	134	O
for	-	144	O
Burkitt	-	148	B
lymphoma	-	156	I
,	-	164	O
but	-	166	O
can	-	170	O
cause	-	174	O
hepatic	-	180	B
and	-	188	I
renal	-	192	I
toxicity	-	198	I
when	-	207	O
its	-	212	O
clearance	-	216	O
is	-	226	O
delayed	-	229	O
.	-	236	O

We	20009434	238	O
report	-	241	O
a	-	248	O
case	-	250	O
of	-	255	O
acute	-	258	B
renal	-	264	I
failure	-	270	I
after	-	278	O
HD	-	284	O
-	-	286	O
MTX	-	287	O
therapy	-	291	O
in	-	299	O
a	-	302	O
patient	-	304	O
with	-	312	O
ileostomy	-	317	O
,	-	326	O
The	-	328	O
patient	-	332	O
was	-	340	O
a	-	344	O
3	-	346	O
-	-	347	O
year	-	348	O
-	-	352	O
old	-	353	O
boy	-	357	O
who	-	361	O
had	-	365	O
received	-	369	O
a	-	378	O
living	-	380	O
-	-	386	O
related	-	387	O
liver	-	395	O
transplantation	-	401	O
for	-	417	O
congenital	-	421	O
biliary	-	432	B
atresia	-	440	I
.	-	447	O

At	20009434	449	O
day	-	452	O
833	-	456	O
after	-	460	O
the	-	466	O
transplantation	-	470	O
,	-	485	O
he	-	487	O
was	-	490	O
diagnosed	-	494	O
with	-	504	O
PTLD	-	509	B
(	-	514	O
post	-	515	B
-	-	519	I
transplantation	-	520	I
lymphoproliferative	-	536	I
disorder	-	556	I
,	-	564	O
Burkitt	-	566	B
-	-	573	I
type	-	574	I
malignant	-	579	I
lymphoma	-	589	I
)	-	597	O
.	-	598	O

During	20009434	600	O
induction	-	607	O
therapy	-	617	O
,	-	624	O
he	-	626	O
suffered	-	629	O
ileal	-	638	O
perforation	-	644	O
and	-	656	O
ileostomy	-	660	O
was	-	670	O
performed	-	674	O
.	-	683	O

Subsequent	20009434	685	O
HD	-	696	O
-	-	698	O
MTX	-	699	O
therapy	-	703	O
caused	-	711	O
acute	-	718	B
renal	-	724	I
failure	-	730	I
that	-	738	O
required	-	743	O
continuous	-	752	O
hemodialysis	-	763	O
.	-	775	O

We	20009434	777	O
supposed	-	780	O
that	-	789	O
intravascular	-	794	O
hypovolemia	-	808	B
due	-	820	O
to	-	824	O
substantial	-	827	O
drainage	-	839	O
from	-	848	O
the	-	853	O
ileostoma	-	857	O
caused	-	867	O
acute	-	874	B
prerenal	-	880	I
failure	-	889	I
.	-	896	O

After	20009434	898	O
recovery	-	904	O
of	-	913	O
his	-	916	O
renal	-	920	O
function	-	926	O
,	-	934	O
we	-	936	O
could	-	939	O
safely	-	945	O
treat	-	952	O
the	-	958	O
patient	-	962	O
with	-	970	O
HD	-	975	O
-	-	977	O
MTX	-	978	O
therapy	-	982	O
by	-	990	O
controlling	-	993	O
drainage	-	1005	O
from	-	1014	O
ileostoma	-	1019	O
with	-	1029	O
total	-	1034	O
parenteral	-	1040	O
nutrition	-	1051	O
.	-	1060	O

Antithrombotic	20431083	0	O
drug	-	15	O
use	-	20	O
,	-	23	O
cerebral	-	25	B
microbleeds	-	34	I
,	-	45	O
and	-	47	O
intracerebral	-	51	B
hemorrhage	-	65	I
:	-	75	O
a	-	77	O
systematic	-	79	O
review	-	90	O
of	-	97	O
published	-	100	O
and	-	110	O
unpublished	-	114	O
studies	-	126	O
.	-	133	O

BACKGROUND	20431083	135	O
AND	-	146	O
PURPOSE	-	150	O
:	-	157	O

Cerebral	20431083	159	B
microbleeds	-	168	I
(	-	180	O
MB	-	181	B
)	-	183	O
are	-	185	O
potential	-	189	O
risk	-	199	O
factors	-	204	O
for	-	212	O
intracerebral	-	216	B
hemorrhage	-	230	I
(	-	241	O
ICH	-	242	B
)	-	245	O
,	-	246	O
but	-	248	O
it	-	252	O
is	-	255	O
unclear	-	258	O
if	-	266	O
they	-	269	O
are	-	274	O
a	-	278	O
contraindication	-	280	O
to	-	297	O
using	-	300	O
antithrombotic	-	306	O
drugs	-	321	O
.	-	326	O

Insights	20431083	328	O
could	-	337	O
be	-	343	O
gained	-	346	O
by	-	353	O
pooling	-	356	O
data	-	364	O
on	-	369	O
MB	-	372	B
frequency	-	375	O
stratified	-	385	O
by	-	396	O
antithrombotic	-	399	O
use	-	414	O
in	-	418	O
cohorts	-	421	O
with	-	429	O
ICH	-	434	B
and	-	438	O
ischemic	-	442	B
stroke	-	451	I
(	-	458	O
IS	-	459	B
)	-	461	O
/	-	462	O
transient	-	463	B
ischemic	-	473	I
attack	-	482	I
(	-	489	O
TIA	-	490	B
)	-	493	O
.	-	494	O

METHODS	20431083	496	O
:	-	503	O

We	20431083	505	O
performed	-	508	O
a	-	518	O
systematic	-	520	O
review	-	531	O
of	-	538	O
published	-	541	O
and	-	551	O
unpublished	-	555	O
data	-	567	O
from	-	572	O
cohorts	-	577	O
with	-	585	O
stroke	-	590	B
or	-	597	O
TIA	-	600	B
to	-	604	O
compare	-	607	O
the	-	615	O
presence	-	619	O
of	-	628	O
MB	-	631	B
in	-	634	O
:	-	636	O
(	-	638	O
1	-	639	O
)	-	640	O
antithrombotic	-	642	O
users	-	657	O
vs	-	663	O
nonantithrombotic	-	666	O
users	-	684	O
with	-	690	O
ICH	-	695	B
;	-	698	O
(	-	700	O
2	-	701	O
)	-	702	O
antithrombotic	-	704	O
users	-	719	O
vs	-	725	O
nonusers	-	728	O
with	-	737	O
IS	-	742	B
/	-	744	O
TIA	-	745	B
;	-	748	O
and	-	750	O
(	-	754	O
3	-	755	O
)	-	756	O
ICH	-	758	B
vs	-	762	O
ischemic	-	765	B
events	-	774	O
stratified	-	781	O
by	-	792	O
antithrombotic	-	795	O
use	-	810	O
.	-	813	O

We	20431083	815	O
also	-	818	O
analyzed	-	823	O
published	-	832	O
and	-	842	O
unpublished	-	846	O
follow	-	858	O
-	-	864	O
up	-	865	O
data	-	868	O
to	-	873	O
determine	-	876	O
the	-	886	O
risk	-	890	O
of	-	895	O
ICH	-	898	B
in	-	902	O
antithrombotic	-	905	O
users	-	920	O
with	-	926	O
MB	-	931	B
.	-	933	O

RESULTS	20431083	935	O
:	-	942	O

In	20431083	944	O
a	-	947	O
pooled	-	949	O
analysis	-	956	O
of	-	965	O
1460	-	968	O
ICH	-	973	B
and	-	977	O
3817	-	981	O
IS	-	986	B
/	-	988	O
TIA	-	989	B
,	-	992	O
MB	-	994	B
were	-	997	O
more	-	1002	O
frequent	-	1007	O
in	-	1016	O
ICH	-	1019	B
vs	-	1023	O
IS	-	1026	B
/	-	1028	O
TIA	-	1029	B
in	-	1033	O
all	-	1036	O
treatment	-	1040	O
groups	-	1050	O
,	-	1056	O
but	-	1058	O
the	-	1062	O
excess	-	1066	O
increased	-	1073	O
from	-	1083	O
2	-	1088	O
.	-	1089	O
8	-	1090	O
(	-	1092	O
odds	-	1093	O
ratio	-	1098	O
;	-	1103	O
range	-	1105	O
,	-	1110	O
2	-	1112	O
.	-	1113	O
3	-	1114	O
-	-	1115	O
3	-	1116	O
.	-	1117	O
5	-	1118	O
)	-	1119	O
in	-	1121	O
nonantithrombotic	-	1124	O
users	-	1142	O
to	-	1148	O
5	-	1151	O
.	-	1152	O
7	-	1153	O
(	-	1155	O
range	-	1156	O
,	-	1161	O
3	-	1163	O
.	-	1164	O
4	-	1165	O
-	-	1166	O
9	-	1167	O
.	-	1168	O
7	-	1169	O
)	-	1170	O
in	-	1172	O
antiplatelet	-	1175	O
users	-	1188	O
and	-	1194	O
8	-	1198	O
.	-	1199	O
0	-	1200	O
(	-	1202	O
range	-	1203	O
,	-	1208	O
3	-	1210	O
.	-	1211	O
5	-	1212	O
-	-	1213	O
17	-	1214	O
.	-	1216	O
8	-	1217	O
)	-	1218	O
in	-	1220	O
warfarin	-	1223	O
users	-	1232	O
(	-	1238	O
P	-	1239	O
difference	-	1241	O
=	-	1251	O
0	-	1252	O
.	-	1253	O
01	-	1254	O
)	-	1256	O
.	-	1257	O

There	20431083	1259	O
was	-	1265	O
also	-	1269	O
an	-	1274	O
excess	-	1277	O
of	-	1284	O
MB	-	1287	B
in	-	1290	O
warfarin	-	1293	O
users	-	1302	O
vs	-	1308	O
nonusers	-	1311	O
with	-	1320	O
ICH	-	1325	B
(	-	1329	O
OR	-	1330	O
,	-	1332	O
2	-	1334	O
.	-	1335	O
7	-	1336	O
;	-	1337	O
95	-	1339	O
%	-	1341	O
CI	-	1343	O
,	-	1345	O
1	-	1347	O
.	-	1348	O
6	-	1349	O
-	-	1350	O
4	-	1351	O
.	-	1352	O
4	-	1353	O
;	-	1354	O
P	-	1356	O
<	-	1357	O
0	-	1358	O
.	-	1359	O
001	-	1360	O
)	-	1363	O
but	-	1365	O
none	-	1369	O
in	-	1374	O
warfarin	-	1377	O
users	-	1386	O
with	-	1392	O
IS	-	1397	B
/	-	1399	O
TIA	-	1400	B
(	-	1404	O

OR	20431083	1405	O

,	20431083	1407	O
1	-	1409	O
.	-	1410	O
3	-	1411	O
;	-	1412	O
95	-	1414	O
%	-	1416	O
CI	-	1418	O
,	-	1420	O
0	-	1422	O
.	-	1423	O
9	-	1424	O
-	-	1425	O
1	-	1426	O
.	-	1427	O
7	-	1428	O
;	-	1429	O
P	-	1431	O
=	-	1432	O
0	-	1433	O
.	-	1434	O
33	-	1435	O
;	-	1437	O
P	-	1439	O
difference	-	1441	O
=	-	1451	O
0	-	1452	O
.	-	1453	O
01	-	1454	O
)	-	1456	O
.	-	1457	O

There	20431083	1459	O
was	-	1465	O
a	-	1469	O
smaller	-	1471	O
excess	-	1479	O
of	-	1486	O
MB	-	1489	B
in	-	1492	O
antiplatelet	-	1495	O
users	-	1508	O
vs	-	1514	O
nonusers	-	1517	O
with	-	1526	O
ICH	-	1531	B
(	-	1535	O
OR	-	1536	O
,	-	1538	O
1	-	1540	O
.	-	1541	O
7	-	1542	O
;	-	1543	O
95	-	1545	O
%	-	1547	O
CI	-	1549	O
,	-	1551	O
1	-	1553	O
.	-	1554	O
3	-	1555	O
-	-	1556	O
2	-	1557	O
.	-	1558	O
3	-	1559	O
;	-	1560	O
P	-	1562	O
<	-	1563	O
0	-	1564	O
.	-	1565	O
001	-	1566	O
)	-	1569	O
,	-	1570	O
but	-	1572	O
findings	-	1576	O
were	-	1585	O
similar	-	1590	O
for	-	1598	O
antiplatelet	-	1602	O
users	-	1615	O
with	-	1621	O
IS	-	1626	B
/	-	1628	O
TIA	-	1629	B
(	-	1633	O

OR	20431083	1634	O
,	-	1636	O
1	-	1638	O
.	-	1639	O
4	-	1640	O
;	-	1641	O
95	-	1643	O
%	-	1645	O
CI	-	1647	O
,	-	1649	O
1	-	1651	O
.	-	1652	O
2	-	1653	O
-	-	1654	O
1	-	1655	O
.	-	1656	O
7	-	1657	O
;	-	1658	O
P	-	1660	O
<	-	1661	O
0	-	1662	O
.	-	1663	O
001	-	1664	O
;	-	1667	O
P	-	1669	O
difference	-	1671	O
=	-	1681	O
0	-	1682	O
.	-	1683	O
25	-	1684	O
)	-	1686	O
.	-	1687	O

In	20431083	1689	O
pooled	-	1692	O
follow	-	1699	O
-	-	1705	O
up	-	1706	O
data	-	1709	O
for	-	1714	O
768	-	1718	O
antithrombotic	-	1722	O
users	-	1737	O
,	-	1742	O
presence	-	1744	O
of	-	1753	O
MB	-	1756	B
at	-	1759	O
baseline	-	1762	O
was	-	1771	O
associated	-	1775	O
with	-	1786	O
a	-	1791	O
substantially	-	1793	O
increased	-	1807	O
risk	-	1817	O
of	-	1822	O
subsequent	-	1825	O
ICH	-	1836	B
(	-	1840	O
OR	-	1841	O
,	-	1843	O
12	-	1845	O
.	-	1847	O
1	-	1848	O
;	-	1849	O
95	-	1851	O
%	-	1853	O
CI	-	1855	O
,	-	1857	O
3	-	1859	O
.	-	1860	O
4	-	1861	O
-	-	1862	O
42	-	1863	O
.	-	1865	O
5	-	1866	O
;	-	1867	O
P	-	1869	O
<	-	1870	O
0	-	1871	O
.	-	1872	O
001	-	1873	O
)	-	1876	O
.	-	1877	O

CONCLUSIONS	20431083	1879	O
:	-	1890	O

The	20431083	1892	O
excess	-	1896	O
of	-	1903	O
MB	-	1906	B
in	-	1909	O
warfarin	-	1912	O
users	-	1921	O
with	-	1927	O
ICH	-	1932	B
compared	-	1936	O
to	-	1945	O
other	-	1948	O
groups	-	1954	O
suggests	-	1961	O
that	-	1970	O
MB	-	1975	B
increase	-	1978	O
the	-	1987	O
risk	-	1991	O
of	-	1996	O
warfarin	-	1999	O
-	-	2007	O
associated	-	2008	O
ICH	-	2019	B
.	-	2022	O

Limited	20431083	2024	O
prospective	-	2032	O
data	-	2044	O
corroborate	-	2049	O
these	-	2061	O
findings	-	2067	O
,	-	2075	O
but	-	2077	O
larger	-	2081	O
prospective	-	2088	O
studies	-	2100	O
are	-	2108	O
urgently	-	2112	O
required	-	2121	O
.	-	2129	O

Verapamil	20595935	0	O
stimulation	-	10	O
test	-	22	O
in	-	27	O
hyperprolactinemia	-	30	B
:	-	48	O
loss	-	50	O
of	-	55	O
prolactin	-	58	O
response	-	68	O
in	-	77	O
anatomic	-	80	O
or	-	89	O
functional	-	92	O
stalk	-	103	O
effect	-	109	O
.	-	115	O

AIM	20595935	117	O
:	-	120	O

Verapamil	20595935	122	O
stimulation	-	132	O
test	-	144	O
was	-	149	O
previously	-	153	O
investigated	-	164	O
as	-	177	O
a	-	180	O
tool	-	182	O
for	-	187	O
differential	-	191	O
diagnosis	-	204	O
of	-	214	O
hyperprolactinemia	-	217	B
,	-	235	O
but	-	237	O
with	-	241	O
conflicting	-	246	O
results	-	258	O
.	-	265	O

Macroprolactinemia	20595935	267	B
was	-	286	O
never	-	290	O
considered	-	296	O
in	-	307	O
those	-	310	O
previous	-	316	O
studies	-	325	O
.	-	332	O

Here	20595935	334	O
,	-	338	O
we	-	340	O
aimed	-	343	O
to	-	349	O
re	-	352	O
-	-	354	O
investigate	-	355	O
the	-	367	O
diagnostic	-	371	O
value	-	382	O
of	-	388	O
verapamil	-	391	O
in	-	401	O
a	-	404	O
population	-	406	O
who	-	417	O
were	-	421	O
all	-	426	O
screened	-	430	O
for	-	439	O
macroprolactinemia	-	443	B
.	-	461	O

Prolactin	20595935	463	O
responses	-	473	O
to	-	483	O
verapamil	-	486	O
in	-	496	O
65	-	499	O
female	-	502	O
patients	-	509	O
(	-	518	O
age	-	519	O
:	-	522	O
29	-	524	O
.	-	526	O
9	-	527	O
+	-	529	O
/	-	530	O
-	-	531	O

8	20595935	533	O
.	-	534	O
1	-	535	O
years	-	537	O
)	-	542	O
with	-	544	O
hyperprolactinemia	-	549	B
were	-	568	O
tested	-	573	O
in	-	580	O
a	-	583	O
descriptive	-	585	O
,	-	596	O
matched	-	598	O
case	-	606	O
-	-	610	O
control	-	611	O
study	-	619	O
.	-	624	O

METHODS	20595935	626	O
:	-	633	O

Verapamil	20595935	635	O
80	-	645	O
mg	-	648	O
,	-	650	O
p	-	652	O
.	-	653	O
o	-	654	O
.	-	655	O
was	-	657	O
administered	-	661	O
,	-	673	O
and	-	675	O
then	-	679	O
PRL	-	684	O
levels	-	688	O
were	-	695	O
measured	-	700	O
at	-	709	O
8th	-	712	O
and	-	716	O
16th	-	720	O
hours	-	725	O
,	-	730	O
by	-	732	O
immunometric	-	735	O
chemiluminescence	-	748	O
.	-	765	O

Verapamil	20595935	767	O
responsiveness	-	777	O
was	-	792	O
determined	-	796	O
by	-	807	O
peak	-	810	O
percent	-	815	O
change	-	823	O
in	-	830	O
basal	-	833	O
prolactin	-	839	O
levels	-	849	O
(	-	856	O
PRL	-	857	O
)	-	860	O
.	-	861	O

RESULTS	20595935	863	O
:	-	870	O

Verapamil	20595935	872	O
significantly	-	882	O
increased	-	896	O
PRL	-	906	O
levels	-	910	O
in	-	917	O
healthy	-	920	O
controls	-	928	O
(	-	937	O
N	-	938	O
.	-	939	O
8	-	941	O
,	-	942	O
PRL	-	944	O
:	-	947	O
183	-	949	O
%	-	952	O
)	-	953	O
,	-	954	O
macroprolactinoma	-	956	B
(	-	974	O
N	-	975	O
.	-	976	O
8	-	978	O
,	-	979	O
PRL	-	981	O
:	-	984	O
7	-	986	O
%	-	987	O
)	-	988	O
,	-	989	O
microprolactinoma	-	991	B
(	-	1009	O
N	-	1010	O
.	-	1011	O
19	-	1013	O
,	-	1015	O
PRL	-	1017	O
:	-	1020	O
21	-	1022	O
%	-	1024	O
)	-	1025	O
,	-	1026	O
macroprolactinemia	-	1028	B
(	-	1047	O
N	-	1048	O
.	-	1049	O
23	-	1051	O
,	-	1053	O
PRL	-	1055	O
:	-	1058	O
126	-	1060	O
%	-	1063	O
)	-	1064	O
,	-	1065	O
but	-	1067	O
not	-	1071	O
in	-	1075	O
pseudoprolactinoma	-	1078	B
(	-	1097	O
N	-	1098	O
.	-	1099	O
8	-	1101	O
,	-	1102	O
PRL	-	1104	O
:	-	1107	O
0	-	1109	O
.	-	1110	O
8	-	1111	O
%	-	1112	O
)	-	1113	O
,	-	1114	O
and	-	1116	O
risperidone	-	1120	O
-	-	1131	O
induced	-	1132	O
hyperprolactinemia	-	1140	B
(	-	1159	O
N	-	1160	O
.	-	1161	O
7	-	1163	O
,	-	1164	O
PRL	-	1166	O
:	-	1169	O
3	-	1171	O
%	-	1172	O
)	-	1173	O
.	-	1174	O

ROC	20595935	1176	O
curve	-	1180	O
analysis	-	1186	O
revealed	-	1195	O
that	-	1204	O
unresponsiveness	-	1209	O
to	-	1226	O
verapamil	-	1229	O
defined	-	1239	O
as	-	1247	O
PRL	-	1250	O
<	-	1254	O
7	-	1255	O
%	-	1256	O
,	-	1257	O
discriminated	-	1259	O
anatomical	-	1273	O
or	-	1284	O
functional	-	1287	O
stalk	-	1298	O
effect	-	1304	O
(	-	1311	O
sensitivity	-	1312	O
:	-	1323	O
74	-	1325	O
%	-	1327	O
,	-	1328	O
specificity	-	1330	O
:	-	1341	O
73	-	1343	O
%	-	1345	O
,	-	1346	O
AUC	-	1348	O
:	-	1351	O
0	-	1353	O
.	-	1354	O
855	-	1355	O
+	-	1358	O
/	-	1359	O
-	-	1360	O
0	-	1361	O
.	-	1362	O
04	-	1363	O
,	-	1365	O
P	-	1367	O
<	-	1369	O
0	-	1370	O
.	-	1371	O
001	-	1372	O
,	-	1375	O
CI	-	1377	O
:	-	1379	O
0	-	1381	O
.	-	1382	O
768	-	1383	O
-	-	1386	O
0	-	1387	O
.	-	1388	O
942	-	1389	O
)	-	1392	O
associated	-	1394	O
with	-	1405	O
pseudoprolactinoma	-	1410	B
or	-	1429	O
risperidone	-	1432	O
-	-	1443	O
induced	-	1444	O
hyperprolactinemia	-	1452	B
,	-	1470	O
respectively	-	1472	O
.	-	1484	O

CONCLUSION	20595935	1486	O
:	-	1496	O

Verapamil	20595935	1498	O
responsiveness	-	1508	O
is	-	1523	O
not	-	1526	O
a	-	1530	O
reliable	-	1532	O
finding	-	1541	O
for	-	1549	O
the	-	1553	O
differential	-	1557	O
diagnosis	-	1570	O
of	-	1580	O
hyperprolactinemia	-	1583	B
.	-	1601	O

However	20595935	1603	O
,	-	1610	O
verapamil	-	1612	O
unresponsiveness	-	1622	O
discriminates	-	1639	O
stalk	-	1653	O
effect	-	1659	O
(	-	1666	O
i	-	1667	O
.	-	1668	O
e	-	1669	O
.	-	1670	O
,	-	1671	O
anatomically	-	1673	O
or	-	1686	O
functionally	-	1689	O
inhibited	-	1702	O
dopaminergic	-	1712	O
tonus	-	1725	O
)	-	1730	O
from	-	1732	O
other	-	1737	O
causes	-	1743	O
of	-	1750	O
hyperprolactinemia	-	1753	B
with	-	1772	O
varying	-	1777	O
degrees	-	1785	O
of	-	1793	O
responsiveness	-	1796	O
.	-	1810	O

Central	35781	0	O
action	-	8	O
of	-	15	O
narcotic	-	18	O
analgesics	-	27	O
.	-	37	O

Part	35781	39	O
IV	-	44	O
.	-	46	O

Noradrenergic	35781	48	O
influences	-	62	O
on	-	73	O
the	-	76	O
activity	-	80	O
of	-	89	O
analgesics	-	92	O
in	-	103	O
rats	-	106	O
.	-	110	O

The	35781	112	O
effect	-	116	O
of	-	123	O
clonidine	-	126	O
,	-	135	O
naphazoline	-	137	O
and	-	149	O
xylometazoline	-	153	O
on	-	168	O
analgesia	-	171	O
induced	-	181	O
by	-	189	O
morphine	-	192	O
,	-	200	O
codeine	-	202	O
,	-	209	O
fentanyl	-	211	O
and	-	220	O
pentazocine	-	224	O
,	-	235	O
and	-	237	O
on	-	241	O
cataleptic	-	244	B
effect	-	255	O
of	-	262	O
morphine	-	265	O
,	-	273	O
codine	-	275	O
and	-	282	O
fentanyl	-	286	O
was	-	295	O
studied	-	299	O
in	-	307	O
rats	-	310	O
.	-	314	O

The	35781	316	O
biochemical	-	320	O
assays	-	332	O
on	-	339	O
the	-	342	O
influence	-	346	O
of	-	356	O
four	-	359	O
analgesics	-	364	O
on	-	375	O
the	-	378	O
brain	-	382	O
concentration	-	388	O
and	-	402	O
turnover	-	406	O
of	-	415	O
noradrenaline	-	418	O
(	-	432	O
NA	-	433	O
)	-	435	O
were	-	437	O
also	-	442	O
performed	-	447	O
.	-	456	O

It	35781	458	O
was	-	461	O
found	-	465	O
that	-	471	O
three	-	476	O
drugs	-	482	O
stimulating	-	488	O
central	-	500	O
NA	-	508	O
receptors	-	511	O
failed	-	521	O
to	-	528	O
affect	-	531	O
the	-	538	O
analgesic	-	542	O
ED50	-	552	O
of	-	557	O
all	-	560	O
antinociceptive	-	564	O
agents	-	580	O
and	-	587	O
they	-	591	O
enhanced	-	596	O
catalepsy	-	605	B
induced	-	615	O
by	-	623	O
morphine	-	626	O
and	-	635	O
fentanyl	-	639	O
.	-	647	O

Codeine	35781	649	O
catalepsy	-	657	B
was	-	667	O
increased	-	671	O
by	-	681	O
clonidine	-	684	O
and	-	694	O
decreased	-	698	O
by	-	708	O
naphazoline	-	711	O
and	-	723	O
xylometazoline	-	727	O
.	-	741	O

The	35781	743	O
brain	-	747	O
concentration	-	753	O
of	-	767	O
NA	-	770	O
was	-	773	O
not	-	777	O
changed	-	781	O
by	-	789	O
morphine	-	792	O
and	-	801	O
fentanyl	-	805	O
,	-	813	O
but	-	815	O
one	-	819	O
of	-	823	O
the	-	826	O
doses	-	830	O
of	-	836	O
codeine	-	839	O
(	-	847	O
45	-	848	O
mg	-	851	O
/	-	853	O
kg	-	854	O
)	-	856	O
slightly	-	858	O
enhanced	-	867	O
it	-	876	O
.	-	878	O

Pentazocine	35781	880	O
dose	-	892	O
-	-	896	O
dependently	-	897	O
decreased	-	909	O
the	-	919	O
brain	-	923	O
level	-	929	O
of	-	935	O
NA	-	938	O
.	-	940	O

The	35781	942	O
rate	-	946	O
of	-	951	O
NA	-	954	O
turnover	-	957	O
was	-	966	O
not	-	970	O
altered	-	974	O
by	-	982	O
analgesics	-	985	O
except	-	996	O
for	-	1003	O
the	-	1007	O
higher	-	1011	O
dose	-	1018	O
of	-	1023	O
fentanyl	-	1026	O
(	-	1035	O
0	-	1036	O
.	-	1037	O
2	-	1038	O
mg	-	1040	O
/	-	1042	O
kg	-	1043	O
)	-	1045	O
following	-	1047	O
which	-	1057	O
the	-	1063	O
disappearance	-	1067	O
of	-	1081	O
NA	-	1084	O
from	-	1087	O
the	-	1092	O
brain	-	1096	O
was	-	1102	O
diminished	-	1106	O
.	-	1116	O

The	35781	1118	O
results	-	1122	O
are	-	1130	O
discussed	-	1134	O
in	-	1144	O
the	-	1147	O
light	-	1151	O
of	-	1157	O
various	-	1160	O
and	-	1168	O
non	-	1172	O
-	-	1175	O
uniform	-	1176	O
data	-	1184	O
from	-	1189	O
the	-	1194	O
literature	-	1198	O
.	-	1208	O

It	35781	1210	O
is	-	1213	O
suggested	-	1216	O
that	-	1226	O
in	-	1231	O
rats	-	1234	O
the	-	1239	O
brain	-	1243	O
NA	-	1249	O
plays	-	1252	O
a	-	1258	O
less	-	1260	O
important	-	1265	O
function	-	1275	O
than	-	1284	O
the	-	1289	O
other	-	1293	O
monoamines	-	1299	O
in	-	1310	O
the	-	1313	O
behavioural	-	1317	O
activity	-	1329	O
of	-	1338	O
potent	-	1341	O
analgesics	-	1348	O
.	-	1358	O

Modification	48835	0	O
by	-	13	O
propranolol	-	16	O
of	-	28	O
cardiovascular	-	31	O
effects	-	46	O
of	-	54	O
induced	-	57	O
hypoglycaemia	-	65	B
.	-	78	O

The	48835	80	O
cardiovascular	-	84	O
effects	-	99	O
of	-	107	O
hypoglycaemia	-	110	B
,	-	123	O
with	-	125	O
and	-	130	O
without	-	134	O
beta	-	142	O
-	-	146	O
blockade	-	147	O
,	-	155	O
were	-	157	O
compared	-	162	O
in	-	171	O
fourteen	-	174	O
healthy	-	183	O
men	-	191	O
.	-	194	O

Eight	48835	196	O
received	-	202	O
insulin	-	211	O
alone	-	219	O
,	-	224	O
and	-	226	O
eight	-	230	O
,	-	235	O
including	-	237	O
two	-	247	O
of	-	251	O
the	-	254	O
original	-	258	O
insulin	-	267	O
-	-	274	O
only	-	275	O
group	-	280	O
,	-	285	O
were	-	287	O
given	-	292	O
propranolol	-	298	O
and	-	310	O
insulin	-	314	O
.	-	321	O

In	48835	323	O
the	-	326	O
insulin	-	330	O
-	-	337	O
group	-	338	O
the	-	344	O
period	-	348	O
of	-	355	O
hypoglycaemia	-	358	B
was	-	372	O
associated	-	376	O
with	-	387	O
an	-	392	O
increase	-	395	O
in	-	404	O
heart	-	407	O
-	-	412	O
rate	-	413	O
and	-	418	O
a	-	422	O
fall	-	424	O
in	-	429	O
diastolic	-	432	O
blood	-	442	O
-	-	447	O
pressure	-	448	O
.	-	456	O

In	48835	458	O
the	-	461	O
propranolol	-	465	O
-	-	476	O
insulin	-	477	O
group	-	485	O
there	-	491	O
was	-	497	O
a	-	501	O
significant	-	503	O
fall	-	515	O
in	-	520	O
heart	-	523	O
-	-	528	O
rate	-	529	O
in	-	534	O
most	-	537	O
subjects	-	542	O
and	-	551	O
an	-	555	O
increase	-	558	O
in	-	567	O
diastolic	-	570	O
pressure	-	580	O
.	-	588	O

Typical	48835	590	O
S	-	598	O
-	-	599	O
T	-	600	O
/	-	601	O
T	-	602	O
changes	-	604	O
occurred	-	612	O
in	-	621	O
the	-	624	O
insulin	-	628	O
-	-	635	O
group	-	636	O
but	-	642	O
in	-	646	O
none	-	649	O
of	-	654	O
the	-	657	O
propranolol	-	661	O
-	-	672	O
insulin	-	673	O
group	-	681	O
.	-	686	O

Hypertension	48835	688	B
in	-	701	O
diabetics	-	704	B
prone	-	714	O
to	-	720	O
hypoglycaemia	-	723	B
attacks	-	737	O
should	-	745	O
not	-	752	O
be	-	756	O
treated	-	759	O
with	-	767	O
beta	-	772	O
-	-	776	O
blockers	-	777	O
because	-	786	O
these	-	794	O
drugs	-	800	O
may	-	806	O
cause	-	810	O
a	-	816	O
sharp	-	818	O
rise	-	824	O
in	-	829	O
blood	-	832	O
-	-	837	O
pressure	-	838	O
in	-	847	O
such	-	850	O
patients	-	855	O
.	-	863	O

Prevention	89511	0	O
and	-	11	O
treatment	-	15	O
of	-	25	O
endometrial	-	28	B
disease	-	40	I
in	-	48	O
climacteric	-	51	O
women	-	63	O
receiving	-	69	O
oestrogen	-	79	O
therapy	-	89	O
.	-	96	O

The	89511	98	O
treatment	-	102	O
regimens	-	112	O
are	-	121	O
described	-	125	O
in	-	135	O
74	-	138	O
patients	-	141	O
with	-	150	O
endometrial	-	155	B
disease	-	167	I
among	-	175	O
850	-	181	O
climacteric	-	185	O
women	-	197	O
receiving	-	203	O
oestrogen	-	213	O
therapy	-	223	O
.	-	230	O

Cystic	89511	232	O
hyperplasia	-	239	B
was	-	251	O
associated	-	255	O
with	-	266	O
unopposed	-	271	O
oestrogen	-	281	O
therapy	-	291	O
without	-	299	O
progestagen	-	307	O
.	-	318	O

Two	89511	320	O
courses	-	324	O
of	-	332	O
21	-	335	O
days	-	338	O
of	-	343	O
5	-	346	O
mg	-	348	O
norethisterone	-	351	O
daily	-	366	O
caused	-	372	O
reversion	-	379	O
to	-	389	O
normal	-	392	O
in	-	399	O
all	-	402	O
57	-	406	O
cases	-	409	O
of	-	415	O
cystic	-	418	O
hyperplasia	-	425	B
and	-	437	O
6	-	441	O
of	-	443	O
the	-	446	O
8	-	450	O
cases	-	452	O
of	-	458	O
atypical	-	461	O
hyperplasia	-	470	B
.	-	481	O

4	89511	483	O
cases	-	485	O
of	-	491	O
endometrial	-	494	B
carcinoma	-	506	I
referred	-	516	O
from	-	525	O
elsewhere	-	530	O
demonstrated	-	540	O
the	-	553	O
problems	-	557	O
of	-	566	O
inappropriate	-	569	O
and	-	583	O
unsupervised	-	587	O
unopposed	-	600	O
oestrogen	-	610	O
therapy	-	620	O
and	-	628	O
the	-	632	O
difficulty	-	636	O
in	-	647	O
distinguishing	-	650	O
severe	-	665	O
hyperplasia	-	672	B
from	-	684	O
malignancy	-	689	B
.	-	699	O

Cyclical	89511	701	O
low	-	710	O
-	-	713	O
dose	-	714	O
oestrogen	-	719	O
therapy	-	729	O
with	-	737	O
7	-	742	O
-	-	743	O
-	-	744	O
13	-	745	O
days	-	748	O
of	-	753	O
progestagen	-	756	O
does	-	768	O
not	-	773	O
seem	-	777	O
to	-	782	O
increase	-	785	O
the	-	794	O
risk	-	798	O
of	-	803	O
endometrial	-	806	B
hyperplasia	-	818	I
or	-	830	O
carcinoma	-	833	B
.	-	842	O

Pure	146391	0	B
red	-	5	I
cell	-	9	I
aplasia	-	14	I
,	-	21	O
toxic	-	23	B
dermatitis	-	29	I
and	-	40	O
lymphadenopathy	-	44	B
in	-	60	O
a	-	63	O
patient	-	65	O
taking	-	73	O
diphenylhydantoin	-	80	O
.	-	97	O

A	146391	99	O
patient	-	101	O
taking	-	109	O
diphenylhydantoin	-	116	O
for	-	134	O
3	-	138	O
weeks	-	140	O
developed	-	146	O
a	-	156	O
generalized	-	158	O
skin	-	170	B
rash	-	175	I
,	-	179	O
lymphadenopathy	-	181	B
and	-	197	O
pure	-	201	B
red	-	206	I
cell	-	210	I
aplasia	-	215	I
.	-	222	O

After	146391	224	O
withdrawal	-	230	O
of	-	241	O
the	-	244	O
pharmacon	-	248	O
all	-	258	O
symptoms	-	262	O
disappeared	-	271	O
spontaneously	-	283	O
.	-	296	O

Skin	146391	298	B
rash	-	303	I
is	-	308	O
a	-	311	O
well	-	313	O
-	-	317	O
known	-	318	O
complication	-	324	O
of	-	337	O
diphenylhydantoin	-	340	O
treatment	-	358	O
as	-	368	O
is	-	371	O
benign	-	374	O
and	-	381	O
malignant	-	385	O
lymphadenopathy	-	395	B
.	-	410	O

Pure	146391	412	B
red	-	417	I
cell	-	421	I
aplasia	-	426	I
associated	-	434	O
with	-	445	O
diphenylhydantoin	-	450	O
medication	-	468	O
has	-	479	O
been	-	483	O
reported	-	488	O
in	-	497	O
3	-	500	O
patients	-	502	O
.	-	510	O

The	146391	512	O
exact	-	516	O
mechanism	-	522	O
by	-	532	O
which	-	535	O
diphenylhydantoin	-	541	O
exerts	-	559	O
its	-	566	O
toxic	-	570	O
effects	-	576	O
is	-	584	O
not	-	587	O
known	-	591	O
.	-	596	O

In	146391	598	O
this	-	601	O
patient	-	606	O
the	-	614	O
time	-	618	O
relation	-	623	O
between	-	632	O
the	-	640	O
ingestion	-	644	O
of	-	654	O
diphenylhydantoin	-	657	O
and	-	675	O
the	-	679	O
occurrence	-	683	O
of	-	694	O
the	-	697	O
skin	-	701	B
rash	-	706	I
,	-	710	O
lymphadenopathy	-	712	B
and	-	728	O
pure	-	732	B
red	-	737	I
cell	-	741	I
aplasia	-	746	I
is	-	754	O
very	-	757	O
suggestive	-	762	O
of	-	773	O
a	-	776	O
direct	-	778	O
connection	-	785	O
.	-	795	O

Continuous	256433	0	O
infusion	-	11	O
tobramycin	-	20	O
combined	-	31	O
with	-	40	O
carbenicillin	-	45	O
for	-	59	O
infections	-	63	B
in	-	74	O
cancer	-	77	B
patients	-	84	O
.	-	92	O

The	256433	94	O
cure	-	98	O
rate	-	103	O
of	-	108	O
infections	-	111	B
in	-	122	O
cancer	-	125	B
patients	-	132	O
is	-	141	O
adversely	-	144	O
affected	-	154	O
by	-	163	O
neutropenia	-	166	B
(	-	178	O
less	-	179	O
than	-	184	O
1	-	189	O
,	-	190	O
000	-	191	O
/	-	194	O
mm3	-	195	O
)	-	198	O
.	-	199	O

In	256433	201	O
particular	-	204	O
,	-	214	O
patients	-	216	O
with	-	225	O
severe	-	230	O
neutropenia	-	237	B
(	-	249	O
less	-	250	O
than	-	255	O
100	-	260	O
/	-	263	O
mm3	-	264	O
)	-	267	O
have	-	269	O
shown	-	274	O
a	-	280	O
poor	-	282	O
response	-	287	O
to	-	296	O
antibiotics	-	299	O
.	-	310	O

To	256433	312	O
overcome	-	315	O
the	-	324	O
adverse	-	328	O
effects	-	336	O
of	-	344	O
neutropenia	-	347	B
,	-	358	O
tobramycin	-	360	O
was	-	371	O
given	-	375	O
by	-	381	O
continuous	-	384	O
infusion	-	395	O
and	-	404	O
combined	-	408	O
with	-	417	O
intermittent	-	422	O
carbenicillin	-	435	O
.	-	448	O

Tobramycin	256433	450	O
was	-	461	O
given	-	465	O
to	-	471	O
a	-	474	O
total	-	476	O
daily	-	482	O
dose	-	488	O
of	-	493	O
300	-	496	O
mg	-	500	O
/	-	502	O
m2	-	503	O
and	-	506	O
carbenicillin	-	510	O
was	-	524	O
given	-	528	O
at	-	534	O
a	-	537	O
dose	-	539	O
of	-	544	O
5	-	547	O
gm	-	549	O
every	-	552	O
four	-	558	O
hours	-	563	O
.	-	568	O

There	256433	570	O
were	-	576	O
125	-	581	O
infectious	-	585	O
episodes	-	596	O
in	-	605	O
116	-	608	O
cancer	-	612	B
patients	-	619	O
receiving	-	628	O
myelosuppressive	-	638	O
chemotherapy	-	655	O
.	-	667	O

The	256433	669	O
overall	-	673	O
cure	-	681	O
rate	-	686	O
was	-	691	O
70	-	695	O
%	-	697	O
.	-	698	O

Pneumonia	256433	700	B
was	-	710	O
the	-	714	O
most	-	718	O
common	-	723	O
infection	-	730	B
and	-	740	O
61	-	744	O
%	-	746	O
of	-	748	O
59	-	751	O
episodes	-	754	O
were	-	763	O
cured	-	768	O
.	-	773	O

Gram	256433	775	O
-	-	779	O
negative	-	780	O
bacilli	-	789	O
were	-	797	O
the	-	802	O
most	-	806	O
common	-	811	O
causative	-	818	O
organisms	-	828	O
and	-	838	O
69	-	842	O
%	-	844	O
of	-	846	O
these	-	849	O
infections	-	855	B
were	-	866	O
cured	-	871	O
.	-	876	O

The	256433	878	O
most	-	882	O
common	-	887	O
pathogen	-	894	O
was	-	903	O
Klebsiella	-	907	O
pneumoniae	-	918	B
and	-	929	O
this	-	933	O
,	-	937	O
together	-	939	O
with	-	948	O
Escherichia	-	953	O
coli	-	965	O
and	-	970	O
Pseudomonas	-	974	O
aeruginosa	-	986	O
,	-	996	O
accounted	-	998	O
for	-	1008	O
74	-	1012	O
%	-	1014	O
of	-	1016	O
all	-	1019	O
gram	-	1023	B
-	-	1027	I
negative	-	1028	I
bacillary	-	1037	I
infections	-	1047	I
.	-	1057	O

Response	256433	1059	O
was	-	1068	O
not	-	1072	O
influenced	-	1076	O
by	-	1087	O
the	-	1090	O
initial	-	1094	O
neutrophil	-	1102	O
count	-	1113	O
,	-	1118	O
with	-	1120	O
a	-	1125	O
62	-	1127	O
%	-	1129	O
cure	-	1131	O
rate	-	1136	O
for	-	1141	O
39	-	1145	O
episodes	-	1148	O
associated	-	1157	O
with	-	1168	O
severe	-	1173	O
neutropenia	-	1180	B
.	-	1191	O

However	256433	1193	O
,	-	1200	O
failure	-	1202	O
of	-	1210	O
the	-	1213	O
neutrophil	-	1217	O
count	-	1228	O
to	-	1234	O
increase	-	1237	O
during	-	1246	O
therapy	-	1253	O
adversely	-	1261	O
affected	-	1271	O
response	-	1280	O
.	-	1288	O

Azotemia	256433	1290	B
was	-	1299	O
the	-	1303	O
major	-	1307	O
side	-	1313	O
effect	-	1318	O
recognized	-	1325	O
,	-	1335	O
and	-	1337	O
it	-	1341	O
occurred	-	1344	O
in	-	1353	O
11	-	1356	O
%	-	1358	O
of	-	1360	O
episodes	-	1363	O
.	-	1371	O

Major	256433	1373	O
azotemia	-	1379	B
(	-	1388	O
serum	-	1389	O
creatinine	-	1395	O
greater	-	1406	O
than	-	1414	O
2	-	1419	O
.	-	1420	O
5	-	1421	O
mg	-	1423	O
/	-	1425	O
dl	-	1426	O
or	-	1429	O
BUN	-	1432	O
greater	-	1436	O
than	-	1444	O
50	-	1449	O
mg	-	1452	O
/	-	1454	O
dl	-	1455	O
)	-	1457	O
occurred	-	1459	O
in	-	1468	O
only	-	1471	O
2	-	1476	O
%	-	1477	O
.	-	1478	O

Azotemia	256433	1480	B
was	-	1489	O
not	-	1493	O
related	-	1497	O
to	-	1505	O
duration	-	1508	O
of	-	1517	O
therapy	-	1520	O
or	-	1528	O
serum	-	1531	O
tobramycin	-	1537	O
concentration	-	1548	O
.	-	1561	O

This	256433	1563	O
antibiotic	-	1568	O
regimen	-	1579	O
showed	-	1587	O
both	-	1594	O
therapeutic	-	1599	O
efficacy	-	1611	O
and	-	1620	O
acceptable	-	1624	O
renal	-	1635	B
toxicity	-	1641	I
for	-	1650	O
these	-	1654	O
patients	-	1660	O
.	-	1668	O

Recurrent	448423	0	O
subarachnoid	-	10	B
hemorrhage	-	23	I
associated	-	34	O
with	-	45	O
aminocaproic	-	50	O
acid	-	63	O
therapy	-	68	O
and	-	76	O
acute	-	80	B
renal	-	86	I
artery	-	92	I
thrombosis	-	99	I
.	-	109	O

Case	448423	111	O
report	-	116	O
.	-	122	O

Epsilon	448423	124	O
aminocaproic	-	132	O
acid	-	145	O
(	-	150	O
EACA	-	151	O
)	-	155	O
has	-	157	O
been	-	161	O
used	-	166	O
to	-	171	O
prevent	-	174	O
rebleeding	-	182	O
in	-	193	O
patients	-	196	O
with	-	205	O
subarachnoid	-	210	B
hemorrhage	-	223	I
(	-	234	O
SAH	-	235	B
)	-	238	O
.	-	239	O

Although	448423	241	O
this	-	250	O
agent	-	255	O
does	-	261	O
decrease	-	266	O
the	-	275	O
frequency	-	279	O
of	-	289	O
rebleeding	-	292	O
,	-	302	O
several	-	304	O
reports	-	312	O
have	-	320	O
described	-	325	O
thrombotic	-	335	B
complications	-	346	O
of	-	360	O
EACA	-	363	O
therapy	-	368	O
.	-	375	O

These	448423	377	O
complications	-	383	O
have	-	397	O
included	-	402	O
clinical	-	411	O
deterioration	-	420	O
and	-	434	O
intracranial	-	438	B
vascular	-	451	I
thrombosis	-	460	I
in	-	471	O
patients	-	474	O
with	-	483	O
SAH	-	488	B
,	-	491	O
arteriolar	-	493	O
and	-	504	O
capillary	-	508	O
fibrin	-	518	O
thrombi	-	525	B
in	-	533	O
patients	-	536	O
with	-	545	O
fibrinolytic	-	550	O
syndromes	-	563	O
treated	-	573	O
with	-	581	O
EACA	-	586	O
,	-	590	O
or	-	592	O
other	-	595	O
thromboembolic	-	601	B
phenomena	-	616	I
.	-	625	O

Since	448423	627	O
intravascular	-	633	O
fibrin	-	647	O
thrombi	-	654	B
are	-	662	O
often	-	666	O
observed	-	672	O
in	-	681	O
patients	-	684	O
with	-	693	O
fibrinolytic	-	698	O
disorders	-	711	O
,	-	720	O
EACA	-	722	O
should	-	727	O
not	-	734	O
be	-	738	O
implicated	-	741	O
in	-	752	O
the	-	755	O
pathogenesis	-	759	O
of	-	772	O
fibrin	-	775	O
thrombi	-	782	B
in	-	790	O
patients	-	793	O
with	-	802	O
disseminated	-	807	B
intravascular	-	820	I
coagulation	-	834	I
or	-	846	O
other	-	849	O
""""	-	855	O
consumption	-	856	B
coagulopathies	-	868	I
.	-	882	O

""""	448423	883	O
This	-	885	O
report	-	890	O
describes	-	897	O
subtotal	-	907	O
infarction	-	916	B
of	-	927	O
the	-	930	O
kidney	-	934	O
due	-	941	O
to	-	945	O
thrombosis	-	948	B
of	-	959	I
a	-	962	I
normal	-	964	I
renal	-	971	I
artery	-	977	I
.	-	983	O

This	448423	985	O
occlusion	-	990	O
occurred	-	1000	O
after	-	1009	O
EACA	-	1015	O
therapy	-	1020	O
in	-	1028	O
a	-	1031	O
patient	-	1033	O
with	-	1041	O
SAH	-	1046	B
and	-	1050	O
histopathological	-	1054	O
documentation	-	1072	O
of	-	1086	O
recurrent	-	1089	O
SAH	-	1099	B
.	-	1102	O

The	448423	1104	O
corresponding	-	1108	O
clinical	-	1122	O
event	-	1131	O
was	-	1137	O
characterized	-	1141	O
by	-	1155	O
marked	-	1158	O
hypertension	-	1165	B
and	-	1178	O
abrupt	-	1182	O
neurological	-	1189	O
deterioration	-	1202	O
.	-	1215	O

Long	573555	0	O
-	-	4	O
term	-	5	O
propranolol	-	10	O
therapy	-	22	O
in	-	30	O
pregnancy	-	33	O
:	-	42	O
maternal	-	44	O
and	-	53	O
fetal	-	57	O
outcome	-	63	O
.	-	70	O

Propranolol	573555	72	O
,	-	83	O
a	-	85	O
beta	-	87	O
-	-	91	O
adrenergic	-	92	O
blocking	-	103	O
agent	-	112	O
,	-	117	O
has	-	119	O
found	-	123	O
an	-	129	O
important	-	132	O
position	-	142	O
in	-	151	O
the	-	154	O
practice	-	158	O
of	-	167	O
medicine	-	170	O
.	-	178	O

Its	573555	180	O
use	-	184	O
in	-	188	O
pregnancy	-	191	O
,	-	200	O
however	-	202	O
,	-	209	O
is	-	211	O
an	-	214	O
open	-	217	O
question	-	222	O
as	-	231	O
a	-	234	O
number	-	236	O
of	-	243	O
detrimental	-	246	O
side	-	258	O
effects	-	263	O
have	-	271	O
been	-	276	O
reported	-	281	O
in	-	290	O
the	-	293	O
fetus	-	297	O
and	-	303	O
neonate	-	307	O
.	-	314	O

Ten	573555	316	O
patients	-	320	O
and	-	329	O
12	-	333	O
pregnancies	-	336	O
are	-	348	O
reported	-	352	O
where	-	361	O
chronic	-	367	O
propranolol	-	375	O
has	-	387	O
been	-	391	O
administered	-	396	O
.	-	408	O

Five	573555	410	O
patients	-	415	O
with	-	424	O
serial	-	429	O
pregnancies	-	436	O
with	-	448	O
and	-	453	O
without	-	457	O
propranolol	-	465	O
therapy	-	477	O
are	-	485	O
also	-	489	O
examined	-	494	O
.	-	502	O

Maternal	573555	504	O
,	-	512	O
fetal	-	514	O
,	-	519	O
and	-	521	O
neonatal	-	525	O
complications	-	534	O
are	-	548	O
examined	-	552	O
.	-	560	O

An	573555	562	O
attempt	-	565	O
is	-	573	O
made	-	576	O
to	-	581	O
differentiate	-	584	O
drug	-	598	O
-	-	602	O
related	-	603	O
complications	-	611	O
from	-	625	O
maternal	-	630	O
disease	-	639	O
-	-	646	O
-	-	647	O
related	-	648	O
complications	-	656	O
.	-	669	O

We	573555	671	O
conclude	-	674	O
that	-	683	O
previously	-	688	O
reported	-	699	O
hypoglycemia	-	708	B
,	-	720	O
hyperbilirubinemia	-	722	B
,	-	740	O
polycythemia	-	742	B
,	-	754	O
neonatal	-	756	B
apnea	-	765	I
,	-	770	O
and	-	772	O
bradycardia	-	776	B
are	-	788	O
not	-	792	O
invariable	-	796	O
and	-	807	O
can	-	811	O
not	-	814	O
be	-	818	O
statistically	-	821	O
correlated	-	835	O
with	-	846	O
chronic	-	851	O
propranolol	-	859	O
therapy	-	871	O
.	-	878	O

Growth	573555	880	B
retardation	-	887	I
,	-	898	O
however	-	900	O
,	-	907	O
appears	-	909	O
to	-	917	O
be	-	920	O
significant	-	923	O
in	-	935	O
both	-	938	O
of	-	943	O
our	-	946	O
series	-	950	O
.	-	956	O

Use	611664	0	O
of	-	4	O
propranolol	-	7	O
in	-	19	O
the	-	22	O
treatment	-	26	O
of	-	36	O
idiopathic	-	39	B
orthostatic	-	50	I
hypotension	-	62	I
.	-	73	O

Five	611664	75	O
patients	-	80	O
with	-	89	O
idiopathic	-	94	B
orthostatic	-	105	I
hypotension	-	117	I
who	-	129	O
had	-	133	O
physiologic	-	137	O
and	-	149	O
biochemical	-	153	O
evidence	-	165	O
of	-	174	O
severe	-	177	O
autonomic	-	184	O
dysfunction	-	194	O
were	-	206	O
included	-	211	O
in	-	220	O
the	-	223	O
study	-	227	O
.	-	232	O

They	611664	234	O
all	-	239	O
exhibited	-	243	O
markedly	-	253	O
reduced	-	262	O
plasma	-	270	O
catecholamines	-	277	O
and	-	292	O
plasma	-	296	O
renin	-	303	O
activity	-	309	O
in	-	318	O
both	-	321	O
recumbent	-	326	O
and	-	336	O
upright	-	340	O
positions	-	348	O
and	-	358	O
had	-	362	O
marked	-	366	O
hypersensitivity	-	373	B
to	-	390	O
the	-	393	O
pressor	-	397	O
effects	-	405	O
of	-	413	O
infused	-	416	O
norepinephrine	-	424	O
.	-	438	O

Treatment	611664	440	O
with	-	450	O
propanolol	-	455	O
administered	-	466	O
intravenously	-	479	O
(	-	493	O
1	-	494	O
-	-	495	O
5	-	496	O
mg	-	498	O
)	-	500	O
produced	-	502	O
increases	-	511	O
in	-	521	O
supine	-	524	O
and	-	531	O
upright	-	535	O
blood	-	543	O
pressure	-	549	O
in	-	558	O
4	-	561	O
of	-	563	O
the	-	566	O
5	-	570	O
individuals	-	572	O
with	-	584	O
rises	-	589	O
ranging	-	595	O
from	-	603	O
11	-	608	O
/	-	610	O
6	-	611	O
to	-	613	O
22	-	616	O
/	-	618	O
11	-	619	O
mmHg	-	622	O
.	-	626	O

Chronic	611664	628	O
oral	-	636	O
administration	-	641	O
of	-	656	O
propranolol	-	659	O
(	-	671	O
40	-	672	O
-	-	674	O
160	-	675	O
mg	-	679	O
/	-	681	O
day	-	682	O
)	-	685	O
also	-	687	O
elevated	-	692	O
the	-	701	O
blood	-	705	O
pressures	-	711	O
of	-	721	O
these	-	724	O
individuals	-	730	O
with	-	742	O
increases	-	747	O
in	-	757	O
the	-	760	O
order	-	764	O
of	-	770	O
20	-	773	O
-	-	775	O
35	-	776	O
/	-	778	O
15	-	779	O
-	-	781	O
25	-	782	O
mmg	-	785	O
being	-	789	O
observed	-	795	O
.	-	803	O

In	611664	805	O
1	-	808	O
patient	-	810	O
,	-	817	O
marked	-	819	O
hypertension	-	826	B
was	-	839	O
induced	-	843	O
by	-	851	O
propranolol	-	854	O
and	-	866	O
the	-	870	O
drug	-	874	O
had	-	879	O
to	-	883	O
be	-	886	O
withdrawn	-	889	O
.	-	898	O

It	611664	900	O
otherwise	-	903	O
was	-	913	O
well	-	917	O
tolerated	-	922	O
and	-	932	O
no	-	936	O
important	-	939	O
side	-	949	O
effects	-	954	O
were	-	962	O
observed	-	967	O
.	-	975	O

Treatment	611664	977	O
has	-	987	O
been	-	991	O
continued	-	996	O
in	-	1006	O
3	-	1009	O
individuals	-	1011	O
for	-	1023	O
6	-	1027	O
-	-	1028	O
13	-	1029	O
months	-	1032	O
with	-	1039	O
persistence	-	1044	O
of	-	1056	O
the	-	1059	O
pressor	-	1063	O
effect	-	1071	O
,	-	1077	O
although	-	1079	O
there	-	1088	O
appears	-	1094	O
to	-	1102	O
have	-	1105	O
been	-	1110	O
some	-	1115	O
decrease	-	1120	O
in	-	1129	O
the	-	1132	O
degree	-	1136	O
of	-	1143	O
response	-	1146	O
with	-	1155	O
time	-	1160	O
.	-	1164	O

Hemodynamic	611664	1166	O
measurements	-	1178	O
in	-	1191	O
1	-	1194	O
of	-	1196	O
the	-	1199	O
patients	-	1203	O
demonstrated	-	1212	O
an	-	1225	O
increase	-	1228	O
in	-	1237	O
total	-	1240	O
peripheral	-	1246	O
resistance	-	1257	O
and	-	1268	O
essentially	-	1272	O
no	-	1284	O
change	-	1287	O
in	-	1294	O
cardiac	-	1297	O
output	-	1305	O
following	-	1312	O
propranolol	-	1322	O
therapy	-	1334	O
.	-	1341	O

The	611664	1343	O
studies	-	1347	O
suggest	-	1355	O
that	-	1363	O
propranolol	-	1368	O
is	-	1380	O
a	-	1383	O
useful	-	1385	O
drug	-	1392	O
in	-	1397	O
selected	-	1400	O
patients	-	1409	O
with	-	1418	O
severe	-	1423	O
idiopathic	-	1430	B
orthostatic	-	1441	I
hypotension	-	1453	I
.	-	1464	O

Total	612112	0	O
intravenous	-	6	O
anesthesia	-	18	O
with	-	29	O
etomidate	-	34	O
.	-	43	O

III	612112	45	O
.	-	48	O

Some	612112	50	O
observations	-	55	O
in	-	68	O
adults	-	71	O
.	-	77	O

An	612112	79	O
investigation	-	82	O
was	-	96	O
undertaken	-	100	O
to	-	111	O
determine	-	114	O
the	-	124	O
dosage	-	128	O
of	-	135	O
etomidate	-	138	O
required	-	148	O
to	-	157	O
maintain	-	160	O
sleep	-	169	O
in	-	175	O
adults	-	178	O
undergoing	-	185	O
surgery	-	196	O
under	-	204	O
regional	-	210	O
local	-	219	O
anesthesia	-	225	O
.	-	235	O

Premedication	612112	237	O
of	-	251	O
diazepam	-	254	O
10	-	263	O
mg	-	266	O
and	-	269	O
atropine	-	273	O
0	-	282	O
.	-	283	O
5	-	284	O
mg	-	286	O
was	-	289	O
given	-	293	O
,	-	298	O
and	-	300	O
sleep	-	304	O
was	-	310	O
induced	-	314	O
and	-	322	O
maintained	-	326	O
by	-	337	O
intermittent	-	340	O
intravenous	-	353	O
injections	-	365	O
of	-	376	O
etomidate	-	379	O
0	-	389	O
.	-	390	O
1	-	391	O
/	-	392	O
mg	-	393	O
/	-	395	O
kg	-	396	O
,	-	398	O
given	-	400	O
whenever	-	406	O
the	-	415	O
patient	-	419	O
would	-	427	O
open	-	433	O
his	-	438	O
eyes	-	442	O
on	-	447	O
request	-	450	O
.	-	457	O

A	612112	459	O
mean	-	461	O
overall	-	466	O
dose	-	474	O
of	-	479	O
etomidate	-	482	O
17	-	492	O
.	-	494	O
4	-	495	O
microgram	-	497	O
/	-	506	O
kg	-	507	O
/	-	509	O
min	-	510	O
.	-	513	O
was	-	515	O
required	-	519	O
to	-	528	O
maintain	-	531	O
sleep	-	540	O
,	-	545	O
but	-	547	O
great	-	551	O
individual	-	557	O
variation	-	568	O
occurred	-	578	O
,	-	586	O
with	-	588	O
older	-	593	O
patients	-	599	O
requiring	-	608	O
less	-	618	O
drug	-	623	O
.	-	627	O

The	612112	629	O
investigation	-	633	O
was	-	647	O
discontinued	-	651	O
after	-	664	O
18	-	670	O
patients	-	673	O
because	-	682	O
of	-	690	O
the	-	693	O
frequency	-	697	O
and	-	707	O
intensity	-	711	O
of	-	721	O
side	-	724	O
-	-	728	O
effects	-	729	O
,	-	736	O
particularly	-	738	O
pain	-	751	B
and	-	756	O
myoclonia	-	760	B
,	-	769	O
which	-	771	O
caused	-	777	O
the	-	784	O
technique	-	788	O
to	-	798	O
be	-	801	O
abandoned	-	804	O
in	-	814	O
two	-	817	O
cases	-	821	O
.	-	826	O

It	612112	828	O
is	-	831	O
considered	-	834	O
unlikely	-	845	O
that	-	854	O
etomidate	-	859	O
will	-	869	O
prove	-	874	O
to	-	880	O
be	-	883	O
the	-	886	O
hypnotic	-	890	O
of	-	899	O
choice	-	902	O
for	-	909	O
a	-	913	O
totally	-	915	O
intravenous	-	923	O
anesthetic	-	935	O
technique	-	946	O
in	-	956	O
adults	-	959	O
because	-	966	O
of	-	974	O
the	-	977	O
high	-	981	O
incidence	-	986	O
of	-	996	O
myoclonia	-	999	B
after	-	1009	O
prolonged	-	1015	O
administration	-	1025	O
.	-	1039	O

In	612112	1041	O
several	-	1044	O
patients	-	1052	O
uncontrollable	-	1061	O
muscle	-	1076	O
movements	-	1083	O
persisted	-	1093	O
for	-	1103	O
many	-	1107	O
minutes	-	1112	O
after	-	1120	O
complete	-	1126	O
recovery	-	1135	O
of	-	1144	O
consciousness	-	1147	O
.	-	1160	O

A	689020	0	O
method	-	2	O
for	-	9	O
the	-	13	O
measurement	-	17	O
of	-	29	O
tremor	-	32	B
,	-	38	O
and	-	40	O
a	-	44	O
comparison	-	46	O
of	-	57	O
the	-	60	O
effects	-	64	O
of	-	72	O
tocolytic	-	75	O
beta	-	85	O
-	-	89	O
mimetics	-	90	O
.	-	98	O

A	689020	100	O
method	-	102	O
permitting	-	109	O
measurement	-	120	O
of	-	132	O
finger	-	135	O
tremor	-	142	B
as	-	149	O
a	-	152	O
displacement	-	154	O
-	-	166	O
time	-	167	O
curve	-	172	O
is	-	178	O
described	-	181	O
,	-	190	O
using	-	192	O
a	-	198	O
test	-	200	O
system	-	205	O
with	-	212	O
simple	-	217	O
amplitude	-	224	O
calibration	-	234	O
.	-	245	O

The	689020	247	O
coordinates	-	251	O
of	-	263	O
the	-	266	O
inversion	-	270	O
points	-	280	O
of	-	287	O
the	-	290	O
displacement	-	294	O
-	-	306	O
time	-	307	O
curves	-	312	O
were	-	319	O
transferred	-	324	O
through	-	336	O
graphical	-	344	O
input	-	354	O
equipment	-	360	O
to	-	370	O
punched	-	373	O
tape	-	381	O
.	-	385	O

By	689020	387	O
means	-	390	O
of	-	396	O
a	-	399	O
computer	-	401	O
program	-	410	O
,	-	417	O
periods	-	419	O
and	-	427	O
amplitudes	-	431	O
of	-	442	O
tremor	-	445	B
oscillations	-	452	O
were	-	465	O
calculated	-	470	O
and	-	481	O
classified	-	485	O
.	-	495	O

The	689020	497	O
event	-	501	O
frequency	-	507	O
for	-	517	O
each	-	521	O
class	-	526	O
of	-	532	O
periods	-	535	O
and	-	543	O
amplitudes	-	547	O
was	-	558	O
determined	-	562	O
.	-	572	O

The	689020	574	O
actions	-	578	O
of	-	586	O
fenoterol	-	589	O
-	-	598	O
hydrobromide	-	599	O
,	-	611	O
ritodrin	-	613	O
-	-	621	O
HCl	-	622	O
and	-	626	O
placebo	-	630	O
given	-	638	O
to	-	644	O
10	-	647	O
healthy	-	650	O
subjects	-	658	O
by	-	667	O
intravenous	-	670	O
infusion	-	682	O
in	-	691	O
a	-	694	O
double	-	696	O
-	-	702	O
blind	-	703	O
crossover	-	709	O
study	-	719	O
were	-	725	O
tested	-	730	O
by	-	737	O
this	-	740	O
method	-	745	O
.	-	751	O

At	689020	753	O
therapeutic	-	756	O
doses	-	768	O
both	-	774	O
substances	-	779	O
raised	-	790	O
the	-	797	O
mean	-	801	O
tremor	-	806	B
amplitude	-	813	O
to	-	823	O
about	-	826	O
three	-	832	O
times	-	838	O
the	-	844	O
control	-	848	O
level	-	856	O
.	-	861	O

At	689020	863	O
the	-	866	O
same	-	870	O
time	-	875	O
,	-	879	O
the	-	881	O
mean	-	885	O
period	-	890	O
within	-	897	O
each	-	904	O
class	-	909	O
of	-	915	O
amplitudes	-	918	O
shortened	-	929	O
by	-	939	O
10	-	942	O
-	-	944	O
-	-	945	O
20	-	946	O
ms	-	949	O
,	-	951	O
whereas	-	953	O
the	-	961	O
mean	-	965	O
periods	-	970	O
calculated	-	978	O
from	-	989	O
all	-	994	O
oscillations	-	998	O
together	-	1011	O
did	-	1020	O
not	-	1024	O
change	-	1028	O
significantly	-	1035	O
.	-	1048	O

After	689020	1050	O
the	-	1056	O
end	-	1060	O
of	-	1064	O
fenoterol	-	1067	O
-	-	1076	O
hydrobromide	-	1077	O
infusion	-	1090	O
,	-	1098	O
tremor	-	1100	B
amplitudes	-	1107	O
decreased	-	1118	O
significantly	-	1128	O
faster	-	1142	O
than	-	1149	O
those	-	1154	O
following	-	1160	O
ritodrin	-	1170	O
-	-	1178	O
HCl	-	1179	O
infusion	-	1183	O
.	-	1191	O

Bilateral	733189	0	O
retinal	-	10	B
artery	-	18	I
and	-	25	I
choriocapillaris	-	29	I
occlusion	-	46	I
following	-	56	O
the	-	66	O
injection	-	70	O
of	-	80	O
long	-	83	O
-	-	87	O
acting	-	88	O
corticosteroid	-	95	O
suspensions	-	110	O
in	-	122	O
combination	-	125	O
with	-	137	O
other	-	142	O
drugs	-	148	O
:	-	153	O
I	-	155	O
.	-	156	O
Clinical	-	158	O
studies	-	167	O
.	-	174	O

Two	733189	176	O
well	-	180	O
-	-	184	O
documented	-	185	O
cases	-	196	O
of	-	202	O
bilateral	-	205	O
retinal	-	215	B
artery	-	223	I
and	-	230	I
choriocapillaris	-	234	I
occlusions	-	251	I
with	-	262	O
blindness	-	267	B
following	-	277	O
head	-	287	O
and	-	292	O
neck	-	296	O
soft	-	301	O
-	-	305	O
tissue	-	306	O
injection	-	313	O
with	-	323	O
methylprednisolone	-	328	O
acetate	-	347	O
in	-	355	O
combination	-	358	O
with	-	370	O
lidocaine	-	375	O
,	-	384	O
epinephrine	-	386	O
,	-	397	O
or	-	399	O
penicillin	-	402	O
are	-	413	O
reported	-	417	O
.	-	425	O

One	733189	427	O
case	-	431	O
had	-	436	O
only	-	440	O
a	-	445	O
unilateral	-	447	O
injection	-	458	O
.	-	467	O

The	733189	469	O
acute	-	473	O
observations	-	479	O
included	-	492	O
hazy	-	501	O
sensorium	-	506	O
,	-	515	O
superior	-	517	O
gaze	-	526	O
palsy	-	531	B
,	-	536	O
pupillary	-	538	B
abnormalities	-	548	I
,	-	561	O
and	-	563	O
conjunctival	-	567	O
hemorrhages	-	580	B
with	-	592	O
edema	-	597	B
.	-	602	O

Follow	733189	604	O
-	-	610	O
up	-	611	O
changes	-	614	O
showed	-	622	O
marked	-	629	O
visual	-	636	B
loss	-	643	I
,	-	647	O
constricted	-	649	O
visual	-	661	O
fields	-	668	O
,	-	674	O
optic	-	676	O
nerve	-	682	O
pallor	-	688	O
,	-	694	O
vascular	-	696	O
attenuation	-	705	O
,	-	716	O
and	-	718	O
chorioretinal	-	722	B
atrophy	-	736	I
.	-	743	O

The	733189	745	O
literature	-	749	O
is	-	760	O
reviewed	-	763	O
,	-	771	O
and	-	773	O
possible	-	777	O
causes	-	786	O
are	-	793	O
discussed	-	797	O
.	-	806	O

Cephalothin	816141	0	O
-	-	11	O
induced	-	12	O
immune	-	20	O
hemolytic	-	27	B
anemia	-	37	I
.	-	43	O

A	816141	45	O
patient	-	47	O
with	-	55	O
renal	-	60	B
disease	-	66	I
developed	-	74	O
Coombs	-	84	O
-	-	90	O
positive	-	91	O
hemolytic	-	100	B
anemia	-	110	I
while	-	117	O
receiving	-	123	O
cephalothin	-	133	O
therapy	-	145	O
.	-	152	O

An	816141	154	O
anti	-	157	O
-	-	161	O
cephalothin	-	162	O
IgG	-	174	O
antibody	-	178	O
was	-	187	O
detected	-	191	O
in	-	200	O
the	-	203	O
patient	-	207	O
's	-	214	O
serum	-	217	O
and	-	223	O
in	-	227	O
the	-	230	O
eluates	-	234	O
from	-	242	O
her	-	247	O
erythrocytes	-	251	O
.	-	263	O

In	816141	265	O
addition	-	268	O
,	-	276	O
nonimmunologic	-	278	O
binding	-	293	O
of	-	301	O
normal	-	304	O
and	-	311	O
patient	-	315	O
's	-	322	O
serum	-	325	O
proteins	-	331	O
to	-	340	O
her	-	343	O
own	-	347	O
and	-	351	O
cephalothin	-	355	O
-	-	366	O
coated	-	367	O
normal	-	374	O
red	-	381	O
cells	-	385	O
was	-	391	O
demonstrated	-	395	O
.	-	407	O

Skin	816141	409	O
tests	-	414	O
and	-	420	O
in	-	424	O
vitro	-	427	O
lymphocyte	-	433	O
stimulation	-	444	O
revealed	-	456	O
that	-	465	O
the	-	470	O
patient	-	474	O
was	-	482	O
sensitized	-	486	O
to	-	497	O
cephalothin	-	500	O
and	-	512	O
also	-	516	O
to	-	521	O
ampicillin	-	524	O
.	-	534	O

Careful	816141	536	O
investigation	-	544	O
of	-	558	O
drug	-	561	O
-	-	565	O
induced	-	566	O
hemolytic	-	574	B
anemias	-	584	I
reveals	-	592	O
the	-	600	O
complexity	-	604	O
of	-	615	O
the	-	618	O
immune	-	622	O
mechanisms	-	629	O
involved	-	640	O
.	-	648	O

Kaliuretic	851038	0	O
effect	-	11	O
of	-	18	O
L	-	21	O
-	-	22	O
dopa	-	23	O
treatment	-	28	O
in	-	38	O
parkinsonian	-	41	B
patients	-	54	O
.	-	62	O

Hypokalemia	851038	64	B
,	-	75	O
sometimes	-	77	O
severe	-	87	O
,	-	93	O
was	-	95	O
observed	-	99	O
in	-	108	O
some	-	111	O
L	-	116	O
-	-	117	O
dopa	-	118	O
-	-	122	O
treated	-	123	O
parkinsonian	-	131	B
patients	-	144	O
.	-	152	O

The	851038	154	O
influence	-	158	O
of	-	168	O
L	-	171	O
-	-	172	O
dopa	-	173	O
on	-	178	O
the	-	181	O
renal	-	185	O
excretion	-	191	O
of	-	201	O
potassium	-	204	O
was	-	214	O
studied	-	218	O
in	-	226	O
3	-	229	O
patients	-	231	O
with	-	240	O
hypokalemia	-	245	B
and	-	257	O
in	-	261	O
5	-	264	O
normokalemic	-	266	O
patients	-	279	O
by	-	288	O
determination	-	291	O
of	-	305	O
renal	-	308	O
plasma	-	314	O
flow	-	321	O
,	-	325	O
glomerular	-	327	O
filtration	-	338	O
rate	-	349	O
,	-	353	O
plasma	-	355	O
concentration	-	362	O
of	-	376	O
potassium	-	379	O
and	-	389	O
sodium	-	393	O
as	-	400	O
well	-	403	O
as	-	408	O
urinary	-	411	O
excretion	-	419	O
of	-	429	O
potassium	-	432	O
,	-	441	O
sodium	-	443	O
and	-	450	O
aldosterone	-	454	O
.	-	465	O

L	851038	467	O
-	-	468	O
Dopa	-	469	O
intake	-	474	O
was	-	481	O
found	-	485	O
to	-	491	O
cause	-	494	O
an	-	500	O
increased	-	503	O
excretion	-	513	O
of	-	523	O
potassium	-	526	O
,	-	535	O
and	-	537	O
sometimes	-	541	O
also	-	551	O
of	-	556	O
sodium	-	559	O
,	-	565	O
in	-	567	O
the	-	570	O
hypokalemic	-	574	O
but	-	586	O
not	-	590	O
in	-	594	O
the	-	597	O
normokalemic	-	601	O
patients	-	614	O
.	-	622	O

This	851038	624	O
effect	-	629	O
on	-	636	O
the	-	639	O
renal	-	643	O
function	-	649	O
could	-	658	O
be	-	664	O
prohibited	-	667	O
by	-	678	O
the	-	681	O
administration	-	685	O
of	-	700	O
a	-	703	O
peripheral	-	705	O
dopa	-	716	O
decarbodylase	-	721	O
inhibitor	-	735	O
.	-	744	O

It	851038	746	O
is	-	749	O
not	-	752	O
known	-	756	O
why	-	762	O
this	-	766	O
effect	-	771	O
occurred	-	778	O
in	-	787	O
some	-	790	O
individuals	-	795	O
but	-	807	O
not	-	811	O
in	-	815	O
others	-	818	O
,	-	824	O
but	-	826	O
our	-	830	O
results	-	834	O
indicate	-	842	O
a	-	851	O
correlation	-	853	O
between	-	865	O
aldosterone	-	873	O
production	-	885	O
and	-	896	O
this	-	900	O
renal	-	905	O
effect	-	911	O
of	-	918	O
L	-	921	O
-	-	922	O
dopa	-	923	O
.	-	927	O

Phenytoin	891494	0	O
encephalopathy	-	10	B
as	-	25	O
probable	-	28	O
idiosyncratic	-	37	O
reaction	-	51	O
:	-	59	O
case	-	61	O
report	-	66	O
.	-	72	O

A	891494	74	O
case	-	76	O
of	-	81	O
phenytoin	-	84	O
(	-	94	O
DPH	-	95	O
)	-	98	O
encephalopathy	-	100	B
with	-	115	O
increasing	-	120	O
seizures	-	131	B
and	-	140	O
EEG	-	144	O
and	-	148	O
mental	-	152	O
changes	-	159	O
is	-	167	O
described	-	170	O
.	-	179	O

Despite	891494	181	O
adequate	-	189	O
oral	-	198	O
dosage	-	203	O
of	-	210	O
DPH	-	213	O
(	-	217	O
5	-	218	O
mg	-	220	O
/	-	222	O
kg	-	223	O
/	-	225	O
daily	-	226	O
)	-	231	O
the	-	233	O
plasma	-	237	O
level	-	244	O
was	-	250	O
very	-	254	O
low	-	259	O
(	-	263	O
2	-	264	O
.	-	265	O
8	-	266	O
microgramg	-	268	O
/	-	278	O
ml	-	279	O
)	-	281	O
.	-	282	O

The	891494	284	O
encephalopathy	-	288	B
was	-	303	O
probably	-	307	O
an	-	316	O
idiosyncratic	-	319	O
and	-	333	O
not	-	337	O
toxic	-	341	O
or	-	347	O
allergic	-	350	O
reaction	-	359	O
.	-	367	O

In	891494	369	O
fact	-	372	O
the	-	377	O
concentration	-	381	O
of	-	395	O
free	-	398	O
DPH	-	403	O
was	-	407	O
normal	-	411	O
,	-	417	O
the	-	419	O
patient	-	423	O
presented	-	431	O
a	-	441	O
retarded	-	443	O
morbilliform	-	452	O
rash	-	465	B
during	-	470	O
DPH	-	477	O
treatment	-	481	O
,	-	490	O
the	-	492	O
protidogram	-	496	O
was	-	508	O
normal	-	512	O
,	-	518	O
and	-	520	O
an	-	524	O
intradermic	-	527	O
DPH	-	539	O
injection	-	543	O
had	-	553	O
no	-	557	O
local	-	560	O
effect	-	566	O
.	-	572	O

The	891494	574	O
authors	-	578	O
conclude	-	586	O
that	-	595	O
in	-	600	O
a	-	603	O
patient	-	605	O
starting	-	613	O
DPH	-	622	O
treatment	-	626	O
an	-	636	O
unexpected	-	639	O
increase	-	650	O
in	-	659	O
seizures	-	662	B
,	-	670	O
with	-	672	O
EEG	-	677	O
and	-	681	O
mental	-	685	O
changes	-	692	O
occurring	-	700	O
simultaneously	-	710	O
,	-	724	O
should	-	726	O
alert	-	733	O
the	-	739	O
physician	-	743	O
to	-	753	O
the	-	756	O
possible	-	760	O
need	-	769	O
for	-	774	O
eliminating	-	778	O
DPH	-	790	O
from	-	794	O
the	-	799	O
therapeutic	-	803	O
regimen	-	815	O
,	-	822	O
even	-	824	O
if	-	829	O
plasma	-	832	O
concentrations	-	839	O
are	-	854	O
low	-	858	O
.	-	861	O

Effects	895432	0	O
of	-	8	O
exercise	-	11	O
on	-	20	O
the	-	23	O
severity	-	27	O
of	-	36	O
isoproterenol	-	39	O
-	-	52	O
induced	-	53	O
myocardial	-	61	B
infarction	-	72	I
.	-	82	O

The	895432	84	O
effect	-	88	O
of	-	95	O
exercise	-	98	O
on	-	107	O
the	-	110	O
severity	-	114	O
of	-	123	O
isoproterenol	-	126	O
-	-	139	O
induced	-	140	O
myocardial	-	148	B
infarction	-	159	I
was	-	170	O
studied	-	174	O
in	-	182	O
male	-	185	O
rats	-	190	O
.	-	194	O

Ninety	895432	196	O
-	-	202	O
three	-	203	O
rats	-	209	O
were	-	214	O
randomly	-	219	O
divided	-	228	O
into	-	236	O
three	-	241	O
groups	-	247	O
.	-	253	O

The	895432	255	O
exercise	-	259	O
-	-	267	O
isoproterenol	-	268	O
(	-	282	O
E	-	283	O
-	-	284	O
1	-	285	O
)	-	286	O
and	-	288	O
exercise	-	292	O
control	-	301	O
(	-	309	O
EC	-	310	O
)	-	312	O
groups	-	314	O
exercised	-	321	O
daily	-	331	O
for	-	337	O
thirty	-	341	O
days	-	348	O
on	-	353	O
a	-	356	O
treadmill	-	358	O
at	-	368	O
1	-	371	O
mph	-	373	O
,	-	376	O
2	-	378	O
%	-	379	O
grade	-	381	O
while	-	387	O
animals	-	393	O
of	-	401	O
the	-	404	O
sedentary	-	408	O
-	-	417	O
isoproterenol	-	418	O
(	-	432	O
S	-	433	O
-	-	434	O
I	-	435	O
)	-	436	O
group	-	438	O
remained	-	444	O
sedentary	-	453	O
.	-	462	O

Eight	895432	464	O
animals	-	470	O
were	-	478	O
assigned	-	483	O
to	-	492	O
the	-	495	O
sedentary	-	499	O
control	-	509	O
(	-	517	O
SC	-	518	O
)	-	520	O
group	-	522	O
which	-	528	O
remained	-	534	O
sedentary	-	543	O
throughout	-	553	O
the	-	564	O
experimental	-	568	O
period	-	581	O
.	-	587	O

Forty	895432	589	O
-	-	594	O
eight	-	595	O
hours	-	601	O
after	-	607	O
the	-	613	O
final	-	617	O
exercise	-	623	O
period	-	632	O
,	-	638	O
S	-	640	O
-	-	641	O
I	-	642	O
and	-	644	O
E	-	648	O
-	-	649	O
I	-	650	O
animals	-	652	O
received	-	660	O
a	-	669	O
single	-	671	O
subcutaneous	-	678	O
injection	-	691	O
of	-	701	O
isoproterenol	-	704	O
(	-	718	O
250	-	719	O
mg	-	723	O
/	-	725	O
kg	-	726	O
body	-	729	O
weight	-	734	O
)	-	740	O
.	-	741	O

Animals	895432	743	O
of	-	751	O
the	-	754	O
S	-	758	O
-	-	759	O
I	-	760	O
group	-	762	O
exhibited	-	768	O
significantly	-	778	O
(	-	792	O
Pp	-	793	O
less	-	796	O
than	-	801	O
0	-	806	O
.	-	807	O
05	-	808	O
)	-	810	O
greater	-	812	O
mortality	-	820	O
from	-	830	O
the	-	835	O
effects	-	839	O
of	-	847	O
isoproterenol	-	850	O
than	-	864	O
animals	-	869	O
of	-	877	O
the	-	880	O
E	-	884	O
-	-	885	O
I	-	886	O
group	-	888	O
.	-	893	O

Serum	895432	895	O
CPK	-	901	O
activity	-	905	O
for	-	914	O
E	-	918	O
-	-	919	O
I	-	920	O
animals	-	922	O
was	-	930	O
significantly	-	934	O
(	-	948	O
p	-	949	O
less	-	951	O
than	-	956	O
0	-	961	O
.	-	962	O
05	-	963	O
)	-	965	O
greater	-	967	O
than	-	975	O
for	-	980	O
animals	-	984	O
in	-	992	O
the	-	995	O
S	-	999	O
-	-	1000	O
I	-	1001	O
and	-	1003	O
EC	-	1007	O
groups	-	1010	O
twenty	-	1017	O
hours	-	1024	O
following	-	1030	O
isoproterenol	-	1040	O
injection	-	1054	O
.	-	1063	O

No	895432	1065	O
statistically	-	1068	O
significant	-	1082	O
differences	-	1094	O
were	-	1106	O
observed	-	1111	O
between	-	1120	O
the	-	1128	O
two	-	1132	O
isoproterenol	-	1136	O
treated	-	1150	O
groups	-	1158	O
for	-	1165	O
severity	-	1169	O
of	-	1178	O
the	-	1181	O
induced	-	1185	O
lesions	-	1193	O
,	-	1200	O
changes	-	1202	O
in	-	1210	O
heart	-	1213	O
weight	-	1219	O
,	-	1225	O
or	-	1227	O
heart	-	1230	O
weight	-	1236	O
to	-	1243	O
body	-	1246	O
weight	-	1251	O
ratios	-	1258	O
.	-	1264	O

The	895432	1266	O
results	-	1270	O
indicated	-	1278	O
that	-	1288	O
exercise	-	1293	O
reduced	-	1302	O
the	-	1310	O
mortality	-	1314	O
associated	-	1324	O
with	-	1335	O
the	-	1340	O
effects	-	1344	O
of	-	1352	O
large	-	1355	O
dosages	-	1361	O
of	-	1369	O
isoproterenol	-	1372	O
but	-	1386	O
had	-	1390	O
little	-	1394	O
on	-	1401	O
the	-	1404	O
severity	-	1408	O
of	-	1417	O
the	-	1420	O
infarction	-	1424	B
.	-	1434	O

Effect	931801	0	O
of	-	7	O
D	-	10	O
-	-	11	O
Glucarates	-	12	O
on	-	23	O
basic	-	26	O
antibiotic	-	32	O
-	-	42	O
induced	-	43	O
renal	-	51	B
damage	-	57	I
in	-	64	O
rats	-	67	O
.	-	71	O

Dehydrated	931801	73	B
rats	-	84	O
regularly	-	89	O
develop	-	99	O
acute	-	107	B
renal	-	113	I
failure	-	119	I
following	-	127	O
single	-	137	O
injection	-	144	O
of	-	154	O
aminoglycoside	-	157	O
antibiotics	-	172	O
combined	-	184	O
with	-	193	O
dextran	-	198	O
or	-	206	O
of	-	209	O
antibiotics	-	212	O
only	-	224	O
.	-	228	O

Oral	931801	230	O
administration	-	235	O
of	-	250	O
2	-	253	O
,	-	254	O
5	-	255	O
-	-	256	O
di	-	257	O
-	-	259	O
O	-	260	O
-	-	261	O
acetyl	-	262	O
-	-	268	O
D	-	269	O
-	-	270	O
glucaro	-	271	O
-	-	278	O
1	-	279	O
,	-	280	O
4	-	281	O
-	-	282	O
6	-	283	O
,	-	284	O
3	-	285	O
-	-	286	O
dilactone	-	287	O
protected	-	297	O
rats	-	307	O
against	-	312	O
renal	-	320	B
failure	-	326	I
induced	-	334	O
by	-	342	O
kanamycin	-	345	O
-	-	354	O
dextran	-	355	O
.	-	362	O

The	931801	364	O
protective	-	368	O
effect	-	379	O
was	-	386	O
prevalent	-	390	O
among	-	400	O
D	-	406	O
-	-	407	O
glucarates	-	408	O
,	-	418	O
and	-	420	O
also	-	424	O
to	-	429	O
other	-	432	O
saccharic	-	438	O
acid	-	448	O
,	-	452	O
hexauronic	-	454	O
acids	-	465	O
and	-	471	O
hexaaldonic	-	475	O
acids	-	487	O
,	-	492	O
although	-	494	O
to	-	503	O
a	-	506	O
lesser	-	508	O
degree	-	515	O
,	-	521	O
but	-	523	O
not	-	527	O
to	-	531	O
a	-	534	O
hexaaldose	-	536	O
,	-	546	O
sugar	-	548	O
alcohols	-	554	O
,	-	562	O
substances	-	564	O
inthe	-	575	O
TCA	-	581	O
cycle	-	585	O
and	-	591	O
other	-	595	O
acidic	-	601	O
compounds	-	608	O
.	-	617	O

D	931801	619	O
-	-	620	O
Glucarates	-	621	O
were	-	632	O
effective	-	637	O
against	-	647	O
renal	-	655	B
damage	-	661	I
induced	-	668	O
by	-	676	O
peptide	-	679	O
antibiotics	-	687	O
as	-	699	O
well	-	702	O
as	-	707	O
various	-	710	O
aminoglycoside	-	718	O
antibitocis	-	733	O
.	-	744	O

Dose	931801	746	O
-	-	750	O
responses	-	751	O
were	-	761	O
observed	-	766	O
in	-	775	O
the	-	778	O
protective	-	782	O
effect	-	793	O
of	-	800	O
D	-	803	O
-	-	804	O
Glucarates	-	805	O
.	-	815	O

With	931801	817	O
a	-	822	O
D	-	824	O
-	-	825	O
glucarate	-	826	O
of	-	836	O
a	-	839	O
fixed	-	841	O
size	-	847	O
of	-	852	O
dose	-	855	O
,	-	859	O
approximately	-	861	O
the	-	875	O
same	-	879	O
degree	-	884	O
of	-	891	O
protection	-	894	O
was	-	905	O
obtained	-	909	O
against	-	918	O
renal	-	926	B
damages	-	932	I
induced	-	940	O
by	-	948	O
different	-	951	O
basic	-	961	O
antibiotics	-	967	O
despite	-	979	O
large	-	987	O
disparities	-	993	O
in	-	1005	O
administration	-	1008	O
doses	-	1023	O
of	-	1029	O
different	-	1032	O
antibiotics	-	1042	O
.	-	1053	O

D	931801	1055	O
-	-	1056	O
Glucarates	-	1057	O
had	-	1068	O
the	-	1072	O
ability	-	1076	O
to	-	1084	O
prevent	-	1087	O
renal	-	1095	B
damage	-	1101	I
but	-	1108	O
not	-	1112	O
to	-	1116	O
cure	-	1119	O
it	-	1124	O
.	-	1126	O

Rats	931801	1128	O
excreted	-	1133	O
acidic	-	1142	O
urine	-	1149	O
when	-	1155	O
they	-	1160	O
were	-	1165	O
spared	-	1170	O
from	-	1177	O
renal	-	1182	B
lesions	-	1188	I
by	-	1196	O
monosaccharides	-	1199	O
.	-	1214	O

The	931801	1216	O
reduction	-	1220	O
effect	-	1230	O
of	-	1237	O
D	-	1240	O
-	-	1241	O
glucarates	-	1242	O
against	-	1253	O
nephrotoxicity	-	1261	B
of	-	1276	O
basic	-	1279	O
antibiotics	-	1285	O
was	-	1297	O
discussed	-	1301	O
.	-	1310	O

Paraplegia	946593	0	B
following	-	11	O
intrathecal	-	21	O
methotrexate	-	33	O
:	-	45	O
report	-	47	O
of	-	54	O
a	-	57	O
case	-	59	O
and	-	64	O
review	-	68	O
of	-	75	O
the	-	78	O
literature	-	82	O
.	-	92	O

A	946593	94	O
patient	-	96	O
who	-	104	O
developed	-	108	O
paraplegia	-	118	B
following	-	129	O
the	-	139	O
intrathecal	-	143	O
instillation	-	155	O
of	-	168	O
methotrexate	-	171	O
is	-	184	O
discribed	-	187	O
.	-	196	O

The	946593	198	O
ten	-	202	O
previously	-	206	O
reported	-	217	O
cases	-	226	O
of	-	232	O
this	-	235	O
unusual	-	240	O
complication	-	248	O
are	-	261	O
reviewed	-	265	O
.	-	273	O

The	946593	275	O
following	-	279	O
factors	-	289	O
appear	-	297	O
to	-	304	O
predispose	-	307	O
to	-	318	O
the	-	321	O
development	-	325	O
of	-	337	O
this	-	340	O
complication	-	345	O
:	-	357	O
abnormal	-	359	O
cerebrospinal	-	368	O
dynamics	-	382	O
related	-	391	O
to	-	399	O
the	-	402	O
presence	-	406	O
of	-	415	O
central	-	418	B
nervous	-	426	I
system	-	434	I
leukemia	-	441	I
,	-	449	O
and	-	451	O
epidural	-	455	O
cerebrospinal	-	464	O
leakage	-	478	O
;	-	485	O
elevated	-	487	O
cerebrospinal	-	496	O
fluid	-	510	O
methothexate	-	516	O
concentration	-	529	O
related	-	543	O
to	-	551	O
abnormal	-	554	O
cerebrospinal	-	563	O
fluid	-	577	O
dynamics	-	583	O
and	-	592	O
to	-	596	O
inappropriately	-	599	O
high	-	615	O
methotrexate	-	620	O
doses	-	633	O
based	-	639	O
on	-	645	O
body	-	648	O
surface	-	653	O
area	-	661	O
calculations	-	666	O
in	-	679	O
older	-	682	O
children	-	688	O
and	-	697	O
adults	-	701	O
;	-	707	O
the	-	709	O
presence	-	713	O
of	-	722	O
neurotoxic	-	725	B
preservatives	-	736	O
in	-	750	O
commercially	-	753	O
available	-	766	O
methotrexate	-	776	O
preparations	-	789	O
and	-	802	O
diluents	-	806	O
;	-	814	O
and	-	816	O
the	-	820	O
use	-	824	O
of	-	828	O
methotrexate	-	831	O
diluents	-	844	O
of	-	853	O
unphysiologic	-	856	O
pH	-	870	O
,	-	872	O
ionic	-	874	O
content	-	880	O
and	-	888	O
osmolarity	-	892	O
.	-	902	O

The	946593	904	O
role	-	908	O
of	-	913	O
methotrexate	-	916	O
contaminants	-	929	O
,	-	941	O
local	-	943	O
folate	-	949	B
deficiency	-	956	I
,	-	966	O
and	-	968	O
cranial	-	972	O
irradiation	-	980	O
in	-	992	O
the	-	995	O
pathogenesis	-	999	O
of	-	1012	O
intrathecal	-	1015	O
methotrexate	-	1027	O
toxicity	-	1040	B
is	-	1049	O
unclear	-	1052	O
.	-	1059	O

The	946593	1061	O
incidence	-	1065	O
of	-	1075	O
neurotoxicity	-	1078	B
may	-	1092	O
be	-	1096	O
reduced	-	1099	O
by	-	1107	O
employing	-	1110	O
lower	-	1120	O
doses	-	1126	O
of	-	1132	O
methotrexate	-	1135	O
in	-	1148	O
the	-	1151	O
presence	-	1155	O
of	-	1164	O
central	-	1167	B
nervous	-	1175	I
system	-	1183	I
leukemia	-	1190	I
,	-	1198	O
in	-	1200	O
older	-	1203	O
children	-	1209	O
and	-	1218	O
adults	-	1222	O
,	-	1228	O
and	-	1230	O
in	-	1234	O
the	-	1237	O
presence	-	1241	O
of	-	1250	O
epidural	-	1253	O
leakage	-	1262	O
.	-	1269	O

Only	946593	1271	O
preservative	-	1276	O
-	-	1288	O
free	-	1289	O
methotrexate	-	1294	O
in	-	1307	O
Elliott	-	1310	O
's	-	1317	O
B	-	1320	O
Solution	-	1322	O
at	-	1331	O
a	-	1334	O
concentration	-	1336	O
of	-	1350	O
not	-	1353	O
more	-	1357	O
than	-	1362	O
1	-	1367	O
mg	-	1369	O
/	-	1371	O
ml	-	1372	O
should	-	1375	O
be	-	1382	O
used	-	1385	O
for	-	1390	O
intrathecal	-	1394	O
administration	-	1406	O
.	-	1420	O

Periodic	946593	1422	O
monitoring	-	1431	O
of	-	1442	O
cerebruspinal	-	1445	O
fluid	-	1459	O
methotrexate	-	1465	O
levels	-	1478	O
may	-	1485	O
be	-	1489	O
predictive	-	1492	O
of	-	1503	O
the	-	1506	O
development	-	1510	O
of	-	1522	O
serious	-	1525	O
neurotoxicity	-	1533	B
.	-	1546	O

Centrally	978847	0	O
mediated	-	10	O
cardiovascular	-	19	O
effects	-	34	O
of	-	42	O
intracisternal	-	45	O
application	-	60	O
of	-	72	O
carbachol	-	75	O
in	-	85	O
anesthetized	-	88	O
rats	-	101	O
.	-	105	O

The	978847	107	O
pressor	-	111	O
response	-	119	O
to	-	128	O
the	-	131	O
intracisternal	-	135	O
(	-	150	O
i	-	151	O
.	-	152	O
c	-	153	O
.	-	154	O
)	-	155	O
injection	-	157	O
of	-	167	O
carbachol	-	170	O
(	-	180	O
1	-	181	O
mug	-	183	O
)	-	186	O
in	-	188	O
anesthetized	-	191	O
rats	-	204	O
was	-	209	O
analyzed	-	213	O
.	-	221	O

This	978847	223	O
response	-	228	O
was	-	237	O
significantly	-	241	O
reduced	-	255	O
by	-	263	O
the	-	266	O
intravenous	-	270	O
(	-	282	O
i	-	283	O
.	-	284	O
v	-	285	O
.	-	286	O
)	-	287	O
injection	-	289	O
of	-	299	O
guanethidine	-	302	O
(	-	315	O
5	-	316	O
mg	-	318	O
)	-	320	O
,	-	321	O
hexamethonium	-	323	O
(	-	337	O
10	-	338	O
mg	-	341	O
)	-	343	O
or	-	345	O
phentolamine	-	348	O
(	-	361	O
5	-	362	O
mg	-	364	O
)	-	366	O
,	-	367	O
and	-	369	O
conversely	-	373	O
,	-	383	O
potentiated	-	385	O
by	-	397	O
i	-	400	O
.	-	401	O
v	-	402	O
.	-	403	O

desmethylimipramine	978847	405	O
(	-	425	O
0	-	426	O
.	-	427	O
3	-	428	O
mg	-	430	O
)	-	432	O
,	-	433	O

while	978847	435	O
propranolol	-	441	O
(	-	453	O
0	-	454	O
.	-	455	O
5	-	456	O
mg	-	458	O
)	-	460	O
i	-	462	O
.	-	463	O
v	-	464	O
.	-	465	O

selectively	978847	467	O
inhibited	-	479	O
the	-	489	O
enlargement	-	493	B
of	-	505	I
pulse	-	508	I
pressure	-	514	I
and	-	523	O
the	-	527	O
tachycardia	-	531	B
following	-	543	O
i	-	553	O
.	-	554	O
c	-	555	O
.	-	556	O

carbachol	978847	558	O
(	-	568	O
1	-	569	O
mug	-	571	O
)	-	574	O
.	-	575	O

On	978847	577	O
the	-	580	O
other	-	584	O
hand	-	590	O
,	-	594	O
the	-	596	O
pressor	-	600	O
response	-	608	O
to	-	617	O
i	-	620	O
.	-	621	O
c	-	622	O
.	-	623	O
carbachol	-	625	O
(	-	635	O
1	-	636	O
mug	-	638	O
)	-	641	O
was	-	643	O
almost	-	647	O
completely	-	654	O
blocked	-	665	O
by	-	673	O
i	-	676	O
.	-	677	O
c	-	678	O
.	-	679	O

atropine	978847	681	O
(	-	690	O
3	-	691	O
mug	-	693	O
)	-	696	O
or	-	698	O
hexamethonium	-	701	O
(	-	715	O
500	-	716	O
mug	-	720	O
)	-	723	O
,	-	724	O
and	-	726	O
significantly	-	730	O
reduced	-	744	O
by	-	752	O
i	-	755	O
.	-	756	O
c	-	757	O
.	-	758	O

chlorpromazine	978847	760	O
(	-	775	O
50	-	776	O
mug	-	779	O
)	-	782	O
but	-	784	O
significantly	-	788	O
potentiated	-	802	O
by	-	814	O
i	-	817	O
.	-	818	O
c	-	819	O
.	-	820	O

desmethylimipramine	978847	822	O
(	-	842	O
30	-	843	O
mug	-	846	O
)	-	849	O
.	-	850	O

The	978847	852	O
pressor	-	856	O
response	-	864	O
to	-	873	O
i	-	876	O
.	-	877	O
c	-	878	O
.	-	879	O
carbachol	-	881	O
(	-	891	O
1	-	892	O
mug	-	894	O
)	-	897	O
remained	-	899	O
unchanged	-	908	O
after	-	918	O
sectioning	-	924	O
of	-	935	O
the	-	938	O
bilateral	-	942	O
cervical	-	952	O
vagal	-	961	O
nerves	-	967	O
but	-	974	O
disappeared	-	978	O
after	-	990	O
sectioning	-	996	O
of	-	1007	O
the	-	1010	O
spinal	-	1014	O
cord	-	1021	O
(	-	1026	O
C7	-	1027	O
-	-	1029	O
C8	-	1030	O
)	-	1032	O
.	-	1033	O

From	978847	1035	O
the	-	1040	O
above	-	1044	O
result	-	1050	O
it	-	1057	O
is	-	1060	O
suggested	-	1063	O
that	-	1073	O
the	-	1078	O
pressor	-	1082	O
response	-	1090	O
to	-	1099	O
i	-	1102	O
.	-	1103	O
c	-	1104	O
.	-	1105	O

carbachol	978847	1107	O
ortral	-	1117	O
and	-	1124	O
peripheral	-	1128	O
adrenergic	-	1139	O
mechanisms	-	1150	O
,	-	1160	O
and	-	1162	O
that	-	1166	O
the	-	1171	O
sympathetic	-	1175	O
trunk	-	1187	O
is	-	1193	O
the	-	1196	O
main	-	1200	O
pathway	-	1205	O
.	-	1212	O

Hyperglycemic	1117341	0	B
effect	-	14	O
of	-	21	O
amino	-	24	O
compounds	-	30	O
structurally	-	40	O
related	-	53	O
to	-	61	O
caproate	-	64	O
in	-	73	O
rats	-	76	O
.	-	80	O

The	1117341	82	O
chronic	-	86	O
feeding	-	94	O
of	-	102	O
small	-	105	O
amounts	-	111	O
(	-	119	O
0	-	120	O
.	-	121	O
3	-	122	O
-	-	123	O
3	-	124	O
%	-	125	O
of	-	127	O
diet	-	130	O
weight	-	135	O
)	-	141	O
of	-	143	O
certain	-	146	O
amino	-	154	O
derivatives	-	160	O
of	-	172	O
caproate	-	175	O
resulted	-	184	O
in	-	193	O
hyperglycemia	-	196	B
,	-	209	O
an	-	211	O
elevated	-	214	O
glucose	-	223	O
tolerance	-	231	O
curve	-	241	O
and	-	247	O
,	-	250	O
occasionally	-	252	O
,	-	264	O
glucosuria	-	266	B
.	-	276	O

Effective	1117341	278	O
compounds	-	288	O
included	-	298	O
norleucine	-	307	O
,	-	317	O
norvaline	-	319	O
,	-	328	O
glutamate	-	330	O
,	-	339	O
epsilon	-	341	O
-	-	348	O
aminocaproate	-	349	O
,	-	362	O
methionine	-	364	O
,	-	374	O
and	-	376	O
leucine	-	380	O
.	-	387	O

Fatty	1158089	0	B
liver	-	6	I
induced	-	12	O
by	-	20	O
tetracycline	-	23	O
in	-	36	O
the	-	39	O
rat	-	43	O
.	-	46	O

Dose	1158089	48	O
-	-	52	O
response	-	53	O
relationships	-	62	O
and	-	76	O
effect	-	80	O
of	-	87	O
sex	-	90	O
.	-	93	O

Dose	1158089	95	O
-	-	99	O
response	-	100	O
relationships	-	109	O
,	-	122	O
biochemical	-	124	O
mechanisms	-	136	O
,	-	146	O
and	-	148	O
sex	-	152	O
differences	-	156	O
in	-	168	O
the	-	171	O
experimental	-	175	O
fatty	-	188	B
liver	-	194	I
induced	-	200	O
by	-	208	O
tetracycline	-	211	O
were	-	224	O
studied	-	229	O
in	-	237	O
the	-	240	O
intact	-	244	O
rat	-	251	O
and	-	255	O
with	-	259	O
the	-	264	O
isolated	-	268	O
perfused	-	277	O
rat	-	286	O
liver	-	290	O
in	-	296	O
vitro	-	299	O
.	-	304	O

In	1158089	306	O
the	-	309	O
intact	-	313	O
male	-	320	O
and	-	325	O
female	-	329	O
rat	-	336	O
,	-	339	O
no	-	341	O
direct	-	344	O
relationship	-	351	O
was	-	364	O
observed	-	368	O
between	-	377	O
dose	-	385	O
of	-	390	O
tetracycline	-	393	O
and	-	406	O
hepatic	-	410	O
accumulation	-	418	O
of	-	431	O
triglyceride	-	434	O
.	-	446	O

With	1158089	448	O
provision	-	453	O
of	-	463	O
adequate	-	466	O
oleic	-	475	O
acid	-	481	O
as	-	486	O
a	-	489	O
substrate	-	491	O
for	-	501	O
the	-	505	O
isolated	-	509	O
perfused	-	518	O
liver	-	527	O
,	-	532	O
a	-	534	O
direct	-	536	O
relationship	-	543	O
was	-	556	O
observed	-	560	O
between	-	569	O
dose	-	577	O
of	-	582	O
tetracycline	-	585	O
and	-	598	O
both	-	602	O
accumulation	-	607	O
of	-	620	O
triglyceride	-	623	O
in	-	636	O
the	-	639	O
liver	-	643	O
and	-	649	O
depression	-	653	B
of	-	664	O
output	-	667	O
of	-	674	O
triglyceride	-	677	O
by	-	690	O
livers	-	693	O
from	-	700	O
male	-	705	O
and	-	710	O
female	-	714	O
rats	-	721	O
.	-	725	O

Marked	1158089	727	O
differences	-	734	O
were	-	746	O
observed	-	751	O
between	-	760	O
female	-	768	O
and	-	775	O
male	-	779	O
rats	-	784	O
with	-	789	O
regard	-	794	O
to	-	801	O
base	-	804	O
line	-	809	O
(	-	814	O
control	-	815	O
)	-	822	O
hepatic	-	824	O
concentration	-	832	O
of	-	846	O
triglyceride	-	849	O
and	-	862	O
output	-	866	O
of	-	873	O
triglyceride	-	876	O
.	-	888	O

Accumulation	1158089	890	O
of	-	903	O
hepatic	-	906	O
triglyceride	-	914	O
,	-	926	O
as	-	928	O
a	-	931	O
per	-	933	O
cent	-	937	O
of	-	942	O
control	-	945	O
values	-	953	O
,	-	959	O
in	-	961	O
response	-	964	O
to	-	973	O
graded	-	976	O
doses	-	983	O
of	-	989	O
tetracycline	-	992	O
,	-	1004	O
did	-	1006	O
not	-	1010	O
differ	-	1014	O
significantly	-	1021	O
between	-	1035	O
male	-	1043	O
,	-	1047	O
female	-	1049	O
and	-	1056	O
pregnant	-	1060	O
rat	-	1069	O
livers	-	1073	O
.	-	1079	O

However	1158089	1081	O
,	-	1088	O
livers	-	1090	O
from	-	1097	O
female	-	1102	O
,	-	1108	O
and	-	1110	O
especially	-	1114	O
pregnant	-	1125	O
female	-	1134	O
rats	-	1141	O
,	-	1145	O
were	-	1147	O
strikingly	-	1152	O
resistant	-	1163	O
to	-	1173	O
the	-	1176	O
effects	-	1180	O
of	-	1188	O
tetracycline	-	1191	O
on	-	1204	O
depression	-	1207	B
of	-	1218	O
output	-	1221	O
of	-	1228	O
triglyceride	-	1231	O
under	-	1244	O
these	-	1250	O
experimental	-	1256	O
conditions	-	1269	O
.	-	1279	O

These	1158089	1281	O
differences	-	1287	O
between	-	1299	O
the	-	1307	O
sexes	-	1311	O
could	-	1317	O
not	-	1323	O
be	-	1327	O
related	-	1330	O
to	-	1338	O
altered	-	1341	O
disposition	-	1349	O
of	-	1361	O
tetracycline	-	1364	O
or	-	1377	O
altered	-	1380	O
uptake	-	1388	O
of	-	1395	O
oleic	-	1398	O
acid	-	1404	O
.	-	1408	O

Depressed	1158089	1410	O
hepatic	-	1420	O
secretion	-	1428	O
of	-	1438	O
triglyceride	-	1441	O
accounted	-	1454	O
only	-	1464	O
for	-	1469	O
30	-	1473	O
to	-	1476	O
50	-	1479	O
%	-	1481	O
of	-	1483	O
accumulated	-	1486	O
hepatic	-	1498	O
triglyceride	-	1506	O
,	-	1518	O
indicating	-	1520	O
that	-	1531	O
additional	-	1536	O
mechanisms	-	1547	O
must	-	1558	O
be	-	1563	O
involved	-	1566	O
in	-	1575	O
the	-	1578	O
production	-	1582	O
of	-	1593	O
the	-	1596	O
triglyceride	-	1600	O
-	-	1612	O
rich	-	1613	O
fatty	-	1618	B
liver	-	1624	I
in	-	1630	O
response	-	1633	O
to	-	1642	O
tetracycline	-	1645	O
.	-	1657	O

Fatal	1280054	0	O
myeloencephalopathy	-	6	B
due	-	26	O
to	-	30	O
intrathecal	-	33	O
vincristine	-	45	O
administration	-	57	O
.	-	71	O

Vincristine	1280054	73	O
was	-	85	O
accidentally	-	89	O
given	-	102	O
intrathecally	-	108	O
to	-	122	O
a	-	125	O
child	-	127	O
with	-	133	O
leukaemia	-	138	B
,	-	147	O
producing	-	149	O
sensory	-	159	B
and	-	167	I
motor	-	171	I
dysfunction	-	177	I
followed	-	189	O
by	-	198	O
encephalopathy	-	201	B
and	-	216	O
death	-	220	O
.	-	225	O

Separate	1280054	227	O
times	-	236	O
for	-	242	O
administering	-	246	O
vincristine	-	260	O
and	-	272	O
intrathecal	-	276	O
therapy	-	288	O
is	-	296	O
recommended	-	299	O
.	-	310	O

Progesterone	1280707	0	O
potentiation	-	13	O
of	-	26	O
bupivacaine	-	29	O
arrhythmogenicity	-	41	O
in	-	59	O
pentobarbital	-	62	O
-	-	75	O
anesthetized	-	76	O
rats	-	89	O
and	-	94	O
beating	-	98	O
rat	-	106	O
heart	-	110	O
cell	-	116	O
cultures	-	121	O
.	-	129	O

The	1280707	131	O
effects	-	135	O
of	-	143	O
progesterone	-	146	O
treatment	-	159	O
on	-	169	O
bupivacaine	-	172	O
arrhythmogenicity	-	184	O
in	-	202	O
beating	-	205	O
rat	-	213	O
heart	-	217	O
myocyte	-	223	O
cultures	-	231	O
and	-	240	O
on	-	244	O
anesthetized	-	247	O
rats	-	260	O
were	-	265	O
determined	-	270	O
.	-	280	O

After	1280707	282	O
determining	-	288	O
the	-	300	O
bupivacaine	-	304	O
AD50	-	316	O
(	-	321	O
the	-	322	O
concentration	-	326	O
of	-	340	O
bupivacaine	-	343	O
that	-	355	O
caused	-	360	O
50	-	367	O
%	-	369	O
of	-	371	O
all	-	374	O
beating	-	378	O
rat	-	386	O
heart	-	390	O
myocyte	-	396	O
cultures	-	404	O
to	-	413	O
become	-	416	O
arrhythmic	-	423	B
)	-	433	O
,	-	434	O
we	-	436	O
determined	-	439	O
the	-	450	O
effect	-	454	O
of	-	461	O
1	-	464	O
-	-	465	O
hour	-	466	O
progesterone	-	471	O
HCl	-	484	O
exposure	-	488	O
on	-	497	O
myocyte	-	500	O
contractile	-	508	O
rhythm	-	520	O
.	-	526	O

Each	1280707	528	O
concentration	-	533	O
of	-	547	O
progesterone	-	550	O
(	-	563	O
6	-	564	O
.	-	565	O
25	-	566	O
,	-	568	O
12	-	570	O
.	-	572	O
5	-	573	O
,	-	574	O
25	-	576	O
,	-	578	O
and	-	580	O
50	-	584	O
micrograms	-	587	O
/	-	597	O
ml	-	598	O
)	-	600	O
caused	-	602	O
a	-	609	O
significant	-	611	O
and	-	623	O
concentration	-	627	O
-	-	640	O
dependent	-	641	O
reduction	-	651	O
in	-	661	O
the	-	664	O
AD50	-	668	O
for	-	673	O
bupivacaine	-	677	O
.	-	688	O

Estradiol	1280707	690	O
treatment	-	700	O
also	-	710	O
increased	-	715	O
the	-	725	O
arrhythmogenicity	-	729	O
of	-	747	O
bupivacaine	-	750	O
in	-	762	O
myocyte	-	765	O
cultures	-	773	O
,	-	781	O
but	-	783	O
was	-	787	O
only	-	791	O
one	-	796	O
fourth	-	800	O
as	-	807	O
potent	-	810	O
as	-	817	O
progesterone	-	820	O
.	-	832	O

Neither	1280707	834	O
progesterone	-	842	O
nor	-	855	O
estradiol	-	859	O
effects	-	869	O
on	-	877	O
bupivacaine	-	880	O
arrhythmogenicity	-	892	O
were	-	910	O
potentiated	-	915	O
by	-	927	O
epinephrine	-	930	O
.	-	941	O

Chronic	1280707	943	O
progesterone	-	951	O
pretreatment	-	964	O
(	-	977	O
5	-	978	O
mg	-	980	O
/	-	982	O
kg	-	983	O
/	-	985	O
day	-	986	O
for	-	990	O
21	-	994	O
days	-	997	O
)	-	1001	O
caused	-	1003	O
a	-	1010	O
significant	-	1012	O
increase	-	1024	O
in	-	1033	O
bupivacaine	-	1036	O
arrhythmogenicity	-	1048	O
in	-	1066	O
intact	-	1069	O
pentobarbital	-	1076	O
-	-	1089	O
anesthetized	-	1090	O
rats	-	1103	O
.	-	1107	O

There	1280707	1109	O
was	-	1115	O
a	-	1119	O
significant	-	1121	O
decrease	-	1133	O
in	-	1142	O
the	-	1145	O
time	-	1149	O
to	-	1154	O
onset	-	1157	O
of	-	1163	O
arrhythmia	-	1166	B
as	-	1177	O
compared	-	1180	O
with	-	1189	O
control	-	1194	O
nonprogesterone	-	1202	O
-	-	1217	O
treated	-	1218	O
rats	-	1226	O
(	-	1231	O
6	-	1232	O
.	-	1233	O
2	-	1234	O
+	-	1236	O
/	-	1237	O
-	-	1238	O

1	1280707	1240	O
.	-	1241	O
3	-	1242	O
vs	-	1244	O
.	-	1246	O
30	-	1248	O
.	-	1250	O
8	-	1251	O
+	-	1253	O
/	-	1254	O
-	-	1255	O

2	1280707	1257	O
.	-	1258	O
5	-	1259	O
min	-	1261	O
,	-	1264	O
mean	-	1266	O
+	-	1271	O
/	-	1272	O
-	-	1273	O

SE	1280707	1275	O
)	-	1277	O
.	-	1278	O

The	1280707	1280	O
results	-	1284	O
of	-	1292	O
this	-	1295	O
study	-	1300	O
indicate	-	1306	O
that	-	1315	O
progesterone	-	1320	O
can	-	1333	O
potentiate	-	1337	O
bupivacaine	-	1348	O
arrhythmogenicity	-	1360	O
both	-	1378	O
in	-	1383	O
vivo	-	1386	O
and	-	1391	O
in	-	1395	O
vitro	-	1398	O
.	-	1403	O

Potentiation	1280707	1405	O
of	-	1418	O
bupivacaine	-	1421	O
arrhythmia	-	1433	B
in	-	1444	O
myocyte	-	1447	O
cultures	-	1455	O
suggests	-	1464	O
that	-	1473	O
this	-	1478	O
effect	-	1483	O
is	-	1490	O
at	-	1493	O
least	-	1496	O
partly	-	1502	O
mediated	-	1509	O
at	-	1518	O
the	-	1521	O
myocyte	-	1525	O
level	-	1533	O
.	-	1538	O

Acute	1289188	0	B
renal	-	6	I
failure	-	12	I
occurring	-	20	O
during	-	30	O
intravenous	-	37	O
desferrioxamine	-	49	O
therapy	-	65	O
:	-	72	O
recovery	-	74	O
after	-	83	O
haemodialysis	-	89	O
.	-	102	O

A	1289188	104	O
patient	-	106	O
with	-	114	O
transfusion	-	119	O
-	-	130	O
dependent	-	131	O
thalassemia	-	141	B
was	-	153	O
undergoing	-	157	O
home	-	168	O
intravenous	-	173	O
desferrioxamine	-	185	O
(	-	201	O
DFX	-	202	O
)	-	205	O
treatment	-	207	O
by	-	217	O
means	-	220	O
of	-	226	O
a	-	229	O
totally	-	231	O
implanted	-	239	O
system	-	249	O
because	-	256	O
of	-	264	O
his	-	267	O
poor	-	271	O
compliance	-	276	O
with	-	287	O
the	-	292	O
nightly	-	296	O
subcutaneous	-	304	O
therapy	-	317	O
.	-	324	O

Due	1289188	326	O
to	-	330	O
an	-	333	O
accidental	-	336	O
malfunctioning	-	347	O
of	-	362	O
the	-	365	O
infusion	-	369	O
pump	-	378	O
,	-	382	O
the	-	384	O
patient	-	388	O
was	-	396	O
inadvertently	-	400	O
administered	-	414	O
a	-	427	O
toxic	-	429	O
dosage	-	435	O
of	-	442	O
the	-	445	O
drug	-	449	O
which	-	454	O
caused	-	460	O
renal	-	467	B
insufficiency	-	473	I
.	-	486	O

Given	1289188	488	O
the	-	494	O
progressive	-	498	O
deterioration	-	510	O
of	-	524	O
the	-	527	O
symptoms	-	531	O
and	-	540	O
of	-	544	O
the	-	547	O
laboratory	-	551	O
values	-	562	O
,	-	568	O
despite	-	570	O
adequate	-	578	O
medical	-	587	O
treatment	-	595	O
,	-	604	O
a	-	606	O
decision	-	608	O
was	-	617	O
made	-	621	O
to	-	626	O
introduce	-	629	O
haemodialytical	-	639	O
therapy	-	655	O
in	-	663	O
order	-	666	O
to	-	672	O
remove	-	675	O
the	-	682	O
drug	-	686	O
and	-	691	O
therapy	-	695	O
reduce	-	703	O
the	-	710	O
nephrotoxicity	-	714	B
.	-	728	O

From	1289188	730	O
the	-	735	O
results	-	739	O
obtained	-	747	O
,	-	755	O
haemodialysis	-	757	O
can	-	771	O
therefore	-	775	O
be	-	785	O
suggested	-	788	O
as	-	798	O
a	-	801	O
useful	-	803	O
therapy	-	810	O
in	-	818	O
rare	-	821	O
cases	-	826	O
of	-	832	O
progressive	-	835	O
acute	-	847	B
renal	-	853	I
failure	-	859	I
caused	-	867	O
by	-	874	O
desferrioxamine	-	877	O
.	-	892	O

Neuroleptic	1359137	0	O
-	-	11	O
associated	-	12	O
hyperprolactinemia	-	23	B
.	-	41	O

Can	1359137	43	O
it	-	47	O
be	-	50	O
treated	-	53	O
with	-	61	O
bromocriptine	-	66	O
?	-	79	O

Six	1359137	81	O
stable	-	85	O
psychiatric	-	92	O
outpatients	-	104	O
with	-	116	O
hyperprolactinemia	-	121	B
and	-	140	O
amenorrhea	-	144	B
/	-	154	O
oligomenorrhea	-	155	B
associated	-	170	O
with	-	181	O
their	-	186	O
neuroleptic	-	192	O
medications	-	204	O
were	-	216	O
treated	-	221	O
with	-	229	O
bromocriptine	-	234	O
.	-	247	O

Daily	1359137	249	O
dosages	-	255	O
of	-	263	O
5	-	266	O
-	-	267	O
10	-	268	O
mg	-	271	O
corrected	-	274	O
the	-	284	O
hyperprolactinemia	-	288	B
and	-	307	O
restored	-	311	O
menstruation	-	320	O
in	-	333	O
four	-	336	O
of	-	341	O
the	-	344	O
six	-	348	O
patients	-	352	O
.	-	360	O

One	1359137	362	O
woman	-	366	O
,	-	371	O
however	-	373	O
,	-	380	O
developed	-	382	O
worsened	-	392	O
psychiatric	-	401	B
symptoms	-	413	I
while	-	422	O
taking	-	428	O
bromocriptine	-	435	O
,	-	448	O
and	-	450	O
it	-	454	O
was	-	457	O
discontinued	-	461	O
.	-	473	O

Thus	1359137	475	O
,	-	479	O
three	-	481	O
of	-	487	O
six	-	490	O
patients	-	494	O
had	-	503	O
their	-	507	O
menstrual	-	513	O
irregularity	-	523	O
successfully	-	536	O
corrected	-	549	O
with	-	559	O
bromocriptine	-	564	O
.	-	577	O

This	1359137	579	O
suggests	-	584	O
that	-	593	O
bromocriptine	-	598	O
should	-	612	O
be	-	619	O
further	-	622	O
evaluated	-	630	O
as	-	640	O
potential	-	643	O
therapy	-	653	O
for	-	661	O
neuroleptic	-	665	O
-	-	676	O
associated	-	677	O
hyperprolactinemia	-	688	B
and	-	707	O
amenorrhea	-	711	B
/	-	721	O
galactorrhea	-	722	B
.	-	734	O

Ethacrynic	1360900	0	O
acid	-	11	O
-	-	15	O
induced	-	16	O
convulsions	-	24	B
and	-	36	O
brain	-	40	O
neurotransmitters	-	46	O
in	-	64	O
mice	-	67	O
.	-	71	O

Intracerebroventricular	1360900	73	O
injection	-	97	O
of	-	107	O
ethacrynic	-	110	O
acid	-	121	O
(	-	126	O
50	-	127	O
%	-	129	O
convulsive	-	131	B
dose	-	142	O
;	-	146	O
50	-	148	O
micrograms	-	151	O
/	-	161	O
mouse	-	162	O
)	-	167	O
accelerated	-	169	O
the	-	181	O
synthesis	-	185	O
/	-	194	O
turnover	-	195	O
of	-	204	O
5	-	207	O
-	-	208	O
hydroxytryptamine	-	209	O
(	-	227	O
5	-	228	O
-	-	229	O
HT	-	230	O
)	-	232	O
but	-	234	O
suppressed	-	238	O
the	-	249	O
synthesis	-	253	O
of	-	263	O
gamma	-	266	O
-	-	271	O
aminobutyric	-	272	O
acid	-	285	O
and	-	290	O
acetylcholine	-	294	O
in	-	308	O
mouse	-	311	O
brain	-	317	O
.	-	322	O

These	1360900	324	O
effects	-	330	O
were	-	338	O
completely	-	343	O
antagonized	-	354	O
by	-	366	O
pretreatment	-	369	O
with	-	382	O
a	-	387	O
glutamate	-	389	O
/	-	398	O
N	-	399	O
-	-	400	O
methyl	-	401	O
-	-	407	O
D	-	408	O
-	-	409	O
aspartate	-	410	O
antagonist	-	420	O
,	-	430	O
aminophosphonovaleric	-	432	O
acid	-	454	O
.	-	458	O

In	1360900	460	O
ethacrynic	-	463	O
acid	-	474	O
-	-	478	O
induced	-	479	O
convulsions	-	487	B
,	-	498	O
these	-	500	O
neurotransmitter	-	506	O
systems	-	523	O
may	-	531	O
be	-	535	O
differentially	-	538	O
modulated	-	553	O
,	-	562	O
probably	-	564	O
through	-	573	O
activation	-	581	O
of	-	592	O
glutaminergic	-	595	O
neurons	-	609	O
in	-	617	O
the	-	620	O
brain	-	624	O
.	-	629	O

Pharmacology	1361574	0	O
of	-	13	O
gamma	-	16	O
-	-	21	O
aminobutyric	-	22	O
acidA	-	35	O
receptor	-	41	O
complex	-	50	O
after	-	58	O
the	-	64	O
in	-	68	O
vivo	-	71	O
administration	-	76	O
of	-	91	O
the	-	94	O
anxioselective	-	98	O
and	-	113	O
anticonvulsant	-	117	O
beta	-	132	O
-	-	136	O
carboline	-	137	O
derivative	-	147	O
abecarnil	-	158	O
.	-	167	O

In	1361574	169	O
rodents	-	172	O
,	-	179	O
the	-	181	O
effect	-	185	O
of	-	192	O
the	-	195	O
beta	-	199	O
-	-	203	O
carboline	-	204	O
derivative	-	214	O
isopropyl	-	225	O
-	-	234	O
6	-	235	O
-	-	236	O
benzyloxy	-	238	O
-	-	247	O
4	-	248	O
-	-	249	O
methoxymethyl	-	250	O
-	-	263	O
beta	-	264	O
-	-	268	O
carboline	-	269	O
-	-	278	O
3	-	279	O
-	-	280	O
carboxylate	-	281	O
(	-	293	O
abecarrnil	-	294	O
)	-	304	O
,	-	305	O
a	-	307	O
new	-	309	O
ligand	-	313	O
for	-	320	O
benzodiazepine	-	324	O
receptors	-	339	O
possessing	-	349	O
anxiolytic	-	360	O
and	-	371	O
anticonvulsant	-	375	O
properties	-	390	O
,	-	400	O
was	-	402	O
evaluated	-	406	O
on	-	416	O
the	-	419	O
function	-	423	O
of	-	432	O
central	-	435	O
gamma	-	443	O
-	-	448	O
aminobutyric	-	449	O
acid	-	462	O
(	-	467	O
GABA	-	468	O
)	-	472	O
A	-	473	O
receptor	-	475	O
complex	-	484	O
,	-	491	O
both	-	493	O
in	-	498	O
vitro	-	501	O
and	-	507	O
in	-	511	O
vivo	-	514	O
.	-	518	O

Added	1361574	520	O
in	-	526	O
vitro	-	529	O
to	-	535	O
rat	-	538	O
cortical	-	542	O
membrane	-	551	O
preparation	-	560	O
,	-	571	O
abecarnil	-	573	O
increased	-	583	O
[	-	593	O
3H	-	594	O
]	-	596	O
GABA	-	597	O
binding	-	602	O
,	-	609	O
enhanced	-	611	O
muscimol	-	620	O
-	-	628	O
stimulated	-	629	O
36Cl	-	640	O
-	-	644	O
uptake	-	646	O
and	-	653	O
reduced	-	657	O
the	-	665	O
binding	-	669	O
of	-	677	O
t	-	680	O
-	-	681	O
[	-	682	O
35S	-	683	O
]	-	686	O
butylbicyclophosphorothionate	-	687	O
(	-	717	O
[	-	718	O
35S	-	719	O
]	-	722	O
TBPS	-	723	O
)	-	727	O
.	-	728	O

These	1361574	730	O
effects	-	736	O
were	-	744	O
similar	-	749	O
to	-	757	O
those	-	760	O
induced	-	766	O
by	-	774	O
diazepam	-	777	O
,	-	785	O
whereas	-	787	O
the	-	795	O
partial	-	799	O
agonist	-	807	O
Ro	-	815	O
16	-	818	O
-	-	820	O
6028	-	821	O
(	-	826	O
tert	-	827	O
-	-	831	O
butyl	-	832	O
-	-	837	O
(	-	838	O
S	-	839	O
)	-	840	O
-	-	841	O
8	-	842	O
-	-	843	O
bromo	-	844	O
-	-	849	O
11	-	850	O
,	-	852	O
12	-	853	O
,	-	855	O
13	-	856	O
,	-	858	O
13a	-	859	O
-	-	862	O
tetrahydro	-	863	O
-	-	873	O
9	-	874	O
-	-	875	O
oxo	-	876	O
-	-	879	O
9H	-	880	O
-	-	882	O
imidazo	-	884	O
[	-	891	O
1	-	892	O
,	-	893	O
5	-	894	O
-	-	895	O
a	-	896	O
]	-	897	O
-	-	898	O
pyrrolo	-	899	O
-	-	906	O
[	-	907	O
2	-	908	O
,	-	909	O
1	-	910	O
-	-	911	O
c	-	912	O
]	-	913	O
[	-	914	O
1	-	915	O
,	-	916	O
4	-	917	O
]	-	918	O
benzodiazepine	-	919	O
-	-	933	O
1	-	934	O
-	-	935	O
carboxylate	-	936	O
)	-	947	O
showed	-	949	O
very	-	956	O
weak	-	961	O
efficacy	-	966	O
in	-	975	O
these	-	978	O
biochemical	-	984	O
tests	-	996	O
.	-	1001	O

After	1361574	1003	O
i	-	1009	O
.	-	1010	O
p	-	1011	O
.	-	1012	O

injection	1361574	1014	O
to	-	1024	O
rats	-	1027	O
,	-	1031	O
abecarnil	-	1033	O
and	-	1043	O
diazepam	-	1047	O
decreased	-	1056	O
in	-	1066	O
a	-	1069	O
time	-	1071	O
-	-	1075	O
dependent	-	1076	O
and	-	1086	O
dose	-	1090	O
-	-	1094	O
related	-	1095	O
(	-	1103	O
0	-	1104	O
.	-	1105	O
25	-	1106	O
-	-	1108	O
20	-	1109	O
mg	-	1112	O
/	-	1114	O
kg	-	1115	O
i	-	1118	O
.	-	1119	O
p	-	1120	O
.	-	1121	O
)	-	1122	O

manner	1361574	1124	O

[	1361574	1131	O
35S	-	1132	O
]	-	1135	O
TBPS	-	1136	O
binding	-	1141	O
measured	-	1149	O
ex	-	1158	O
vivo	-	1161	O
in	-	1166	O
the	-	1169	O
cerebral	-	1173	O
cortex	-	1182	O
.	-	1188	O

Moreover	1361574	1190	O
,	-	1198	O
both	-	1200	O
drugs	-	1205	O
at	-	1211	O
the	-	1214	O
dose	-	1218	O
of	-	1223	O
0	-	1226	O
.	-	1227	O
5	-	1228	O
mg	-	1230	O
/	-	1232	O
kg	-	1233	O
antagonized	-	1236	O
completely	-	1248	O
the	-	1259	O
convulsant	-	1263	O
activity	-	1274	O
and	-	1283	O
the	-	1287	O
increase	-	1291	O
of	-	1300	O
[	-	1303	O
35S	-	1304	O
]	-	1307	O
TBPS	-	1308	O
binding	-	1313	O
induced	-	1321	O
by	-	1329	O
isoniazide	-	1332	O
(	-	1343	O
350	-	1344	O
mg	-	1348	O
/	-	1350	O
kg	-	1351	O
s	-	1354	O
.	-	1355	O
c	-	1356	O
.	-	1357	O
)	-	1358	O
as	-	1360	O
well	-	1363	O
as	-	1368	O
the	-	1371	O
increase	-	1375	O
of	-	1384	O
[	-	1387	O
35S	-	1388	O
]	-	1391	O
TBPS	-	1392	O
binding	-	1397	O
induced	-	1405	O
by	-	1413	O
foot	-	1416	O
-	-	1420	O
shock	-	1421	O
stress	-	1427	O
.	-	1433	O

To	1361574	1435	O
better	-	1438	O
correlate	-	1445	O
the	-	1455	O
biochemical	-	1459	O
and	-	1471	O
the	-	1475	O
pharmacological	-	1479	O
effects	-	1495	O
,	-	1502	O
we	-	1504	O
studied	-	1507	O
the	-	1515	O
action	-	1519	O
of	-	1526	O
abecarnil	-	1529	O
on	-	1539	O
[	-	1542	O
35S	-	1543	O
]	-	1546	O
TBPS	-	1547	O
binding	-	1552	O
,	-	1559	O
exploratory	-	1561	O
motility	-	1573	O
and	-	1582	O
on	-	1586	O
isoniazid	-	1589	O
-	-	1598	O
induced	-	1599	O
biochemical	-	1607	O
and	-	1619	O
pharmacological	-	1623	O
effects	-	1639	O
in	-	1647	O
mice	-	1650	O
.	-	1654	O

In	1361574	1656	O
these	-	1659	O
animals	-	1665	O
,	-	1672	O
abecarnil	-	1674	O
produced	-	1684	O
a	-	1693	O
paralleled	-	1695	O
dose	-	1706	O
-	-	1710	O
dependent	-	1711	O
(	-	1721	O
0	-	1722	O
.	-	1723	O
05	-	1724	O
-	-	1726	O
1	-	1727	O
mg	-	1729	O
/	-	1731	O
kg	-	1732	O
i	-	1735	O
.	-	1736	O
p	-	1737	O
.	-	1738	O
)	-	1739	O
reduction	-	1741	O
of	-	1751	O
both	-	1754	O
motor	-	1759	O
behavior	-	1765	O
and	-	1774	O
cortical	-	1778	O
[	-	1787	O
35S	-	1788	O
]	-	1791	O
TBPS	-	1792	O
binding	-	1797	O
.	-	1804	O

Moreover	1361574	1806	O
,	-	1814	O
0	-	1816	O
.	-	1817	O
05	-	1818	O
mg	-	1821	O
/	-	1823	O
kg	-	1824	O
of	-	1827	O
this	-	1830	O
beta	-	1835	O
-	-	1839	O
carboline	-	1840	O
reduced	-	1850	O
markedly	-	1858	O
the	-	1867	O
increase	-	1871	O
of	-	1880	O
[	-	1883	O
35S	-	1884	O
]	-	1887	O
TBPS	-	1888	O
binding	-	1893	O
and	-	1901	O
the	-	1905	O
convulsions	-	1909	B
induced	-	1921	O
by	-	1929	O
isoniazid	-	1932	O
(	-	1942	O
200	-	1943	O
mg	-	1947	O
/	-	1949	O
kg	-	1950	O
s	-	1953	O
.	-	1954	O
c	-	1955	O
.	-	1956	O
)	-	1957	O
.	-	1958	O
(	-	1959	O
ABSTRACT	-	1960	O
TRUNCATED	-	1969	O
AT	-	1979	O
250	-	1982	O
WORDS	-	1986	O
)	-	1991	O

Recurrent	1395192	0	O
myocardial	-	10	B
infarction	-	21	I
in	-	32	O
a	-	35	O
postpartum	-	37	O
patient	-	48	O
receiving	-	56	O
bromocriptine	-	66	O
.	-	79	O

Myocardial	1395192	81	B
infarction	-	92	I
in	-	103	O
puerperium	-	106	O
is	-	117	O
infrequently	-	120	O
reported	-	133	O
.	-	141	O

Spasm	1395192	143	B
,	-	148	O
coronary	-	150	O
dissection	-	159	O
,	-	169	O
or	-	171	O
atheromatous	-	174	O
etiology	-	187	O
has	-	196	O
been	-	200	O
described	-	205	O
.	-	214	O

Bromocriptine	1395192	216	O
has	-	230	O
been	-	234	O
implicated	-	239	O
in	-	250	O
several	-	253	O
previous	-	261	O
case	-	270	O
reports	-	275	O
of	-	283	O
myocardial	-	286	B
infarction	-	297	I
in	-	308	O
the	-	311	O
puerperium	-	315	O
.	-	325	O

Our	1395192	327	O
case	-	331	O
(	-	336	O
including	-	337	O
an	-	347	O
inadvertent	-	350	O
rechallenge	-	362	O
)	-	373	O
suggests	-	375	O
such	-	384	O
a	-	389	O
relationship	-	391	O
.	-	403	O

Although	1395192	405	O
generally	-	414	O
regarded	-	424	O
as	-	433	O
""""	-	436	O
safe	-	437	O
,	-	441	O
""""	-	442	O
possible	-	444	O
serious	-	453	O
cardiac	-	461	O
effects	-	469	O
of	-	477	O
bromocriptine	-	480	O
should	-	494	O
be	-	501	O
acknowledged	-	504	O
.	-	516	O

Asterixis	1420650	0	B
induced	-	10	O
by	-	18	O
carbamazepine	-	21	O
therapy	-	35	O
.	-	42	O

There	1420650	44	O
are	-	50	O
very	-	54	O
few	-	59	O
reports	-	63	O
about	-	71	O
asterixis	-	77	B
as	-	87	O
a	-	90	O
side	-	92	O
effect	-	97	O
of	-	104	O
treatment	-	107	O
with	-	117	O
psychopharmacologic	-	122	O
agents	-	142	O
.	-	148	O

In	1420650	150	O
this	-	153	O
report	-	158	O
we	-	165	O
present	-	168	O
four	-	176	O
patients	-	181	O
treated	-	190	O
with	-	198	O
a	-	203	O
combination	-	205	O
of	-	217	O
different	-	220	O
psychotropic	-	230	O
drugs	-	243	O
,	-	248	O
in	-	250	O
whom	-	253	O
asterixis	-	258	B
was	-	268	O
triggered	-	272	O
either	-	282	O
by	-	289	O
adding	-	292	O
carbamazepine	-	299	O
(	-	313	O
CBZ	-	314	O
)	-	317	O
to	-	319	O
a	-	322	O
treatment	-	324	O
regimen	-	334	O
,	-	341	O
or	-	343	O
by	-	346	O
increasing	-	349	O
its	-	360	O
dosage	-	364	O
.	-	370	O

Neither	1420650	372	O
dosage	-	380	O
nor	-	387	O
serum	-	391	O
levels	-	397	O
of	-	404	O
CBZ	-	407	O
were	-	411	O
in	-	416	O
a	-	419	O
higher	-	421	O
range	-	428	O
.	-	433	O

We	1420650	435	O
consider	-	438	O
asterixis	-	447	B
to	-	457	O
be	-	460	O
an	-	463	O
easily	-	466	O
overlooked	-	473	O
sign	-	484	O
of	-	489	O
neurotoxicity	-	492	B
,	-	505	O
which	-	507	O
may	-	513	O
occur	-	517	O
even	-	523	O
at	-	528	O
low	-	531	O
or	-	535	O
moderate	-	538	O
dosage	-	547	O
levels	-	554	O
,	-	560	O
if	-	562	O
certain	-	565	O
drugs	-	573	O
as	-	579	O
lithium	-	582	O
or	-	590	O
clozapine	-	593	O
are	-	603	O
used	-	607	O
in	-	612	O
combination	-	615	O
with	-	627	O
CBZ	-	632	O
.	-	635	O

Pharmacodynamics	1423336	0	O
of	-	17	O
the	-	20	O
hypotensive	-	24	B
effect	-	36	O
of	-	43	O
levodopa	-	46	O
in	-	55	O
parkinsonian	-	58	B
patients	-	71	O
.	-	79	O

Blood	1423336	81	O
pressure	-	87	O
effects	-	96	O
of	-	104	O
i	-	107	O
.	-	108	O
v	-	109	O
.	-	110	O

levodopa	1423336	112	O
were	-	121	O
examined	-	126	O
in	-	135	O
parkinsonian	-	138	B
patients	-	151	O
with	-	160	O
stable	-	165	O
and	-	172	O
fluctuating	-	176	O
responses	-	188	O
to	-	198	O
levodopa	-	201	O
.	-	209	O

The	1423336	211	O
magnitude	-	215	O
of	-	225	O
the	-	228	O
hypotensive	-	232	B
effect	-	244	O
of	-	251	O
levodopa	-	254	O
was	-	263	O
concentration	-	267	O
dependent	-	281	O
and	-	291	O
was	-	295	O
fit	-	299	O
to	-	303	O
an	-	306	O
Emax	-	309	O
model	-	314	O
in	-	320	O
fluctuating	-	323	O
responders	-	335	O
.	-	345	O

Stable	1423336	347	O
responders	-	354	O
demonstrated	-	365	O
a	-	378	O
small	-	380	O
hypotensive	-	386	B
response	-	398	O
.	-	406	O

Baseline	1423336	408	O
blood	-	417	O
pressures	-	423	O
were	-	433	O
higher	-	438	O
in	-	445	O
fluctuating	-	448	O
patients	-	460	O
;	-	468	O
a	-	470	O
higher	-	472	O
baseline	-	479	O
blood	-	488	O
pressure	-	494	O
correlated	-	503	O
with	-	514	O
greater	-	519	O
hypotensive	-	527	B
effects	-	539	O
.	-	546	O

Antiparkinsonian	1423336	548	O
effects	-	565	O
of	-	573	O
levodopa	-	576	O
temporally	-	585	O
correlated	-	596	O
with	-	607	O
blood	-	612	O
pressure	-	618	O
changes	-	627	O
.	-	634	O

Phenylalanine	1423336	636	O
,	-	649	O
a	-	651	O
large	-	653	O
neutral	-	659	O
amino	-	667	O
acid	-	673	O
(	-	678	O
LNAA	-	679	O
)	-	683	O
competing	-	685	O
with	-	695	O
levodopa	-	700	O
for	-	709	O
transport	-	713	O
across	-	723	O
the	-	730	O
blood	-	734	O
-	-	739	O
brain	-	740	O
barrier	-	746	O
,	-	753	O
reduced	-	755	O
the	-	763	O
hypotensive	-	767	B
and	-	779	O
antiparkinsonian	-	783	O
effects	-	800	O
of	-	808	O
levodopa	-	811	O
.	-	819	O

We	1423336	821	O
conclude	-	824	O
that	-	833	O
levodopa	-	838	O
has	-	847	O
a	-	851	O
central	-	853	O
hypotensive	-	861	B
action	-	873	O
that	-	880	O
parallels	-	885	O
the	-	895	O
motor	-	899	O
effects	-	905	O
in	-	913	O
fluctuating	-	916	O
patients	-	928	O
.	-	936	O

The	1423336	938	O
hypotensive	-	942	B
effect	-	954	O
appears	-	961	O
to	-	969	O
be	-	972	O
related	-	975	O
to	-	983	O
the	-	986	O
higher	-	990	O
baseline	-	997	O
blood	-	1006	O
pressure	-	1012	O
we	-	1021	O
observed	-	1024	O
in	-	1033	O
fluctuating	-	1036	O
patients	-	1048	O
relative	-	1057	O
to	-	1066	O
stable	-	1069	O
patients	-	1076	O
.	-	1084	O

Syndrome	1424076	0	B
of	-	9	I
inappropriate	-	12	I
secretion	-	26	I
of	-	36	I
antidiuretic	-	39	I
hormone	-	52	I
after	-	60	O
infusional	-	66	O
vincristine	-	77	O
.	-	88	O

A	1424076	90	O
77	-	92	O
-	-	94	O
year	-	95	O
-	-	99	O
old	-	100	O
woman	-	104	O
with	-	110	O
refractory	-	115	O
multiple	-	126	B
myeloma	-	135	I
was	-	143	O
treated	-	147	O
with	-	155	O
a	-	160	O
4	-	162	O
-	-	163	O
day	-	164	O
continuous	-	168	O
intravenous	-	179	O
infusion	-	191	O
of	-	200	O
vincristine	-	203	O
and	-	215	O
doxorubicin	-	219	O
and	-	231	O
4	-	235	O
days	-	237	O
of	-	242	O
oral	-	245	O
dexamethasone	-	250	O
.	-	263	O

Nine	1424076	265	O
days	-	270	O
after	-	275	O
her	-	281	O
second	-	285	O
cycle	-	292	O
she	-	298	O
presented	-	302	O
with	-	312	O
lethargy	-	317	B
and	-	326	O
weakness	-	330	B
associated	-	339	O
with	-	350	O
hyponatremia	-	355	B
.	-	367	O

Evaluation	1424076	369	O
revealed	-	380	O
the	-	389	O
syndrome	-	393	B
of	-	402	I
inappropriate	-	405	I
secretion	-	419	I
of	-	429	I
antidiuretic	-	432	I
hormone	-	445	I
,	-	452	O
which	-	454	O
was	-	460	O
attributed	-	464	O
to	-	475	O
the	-	478	O
vincristine	-	482	O
infusion	-	494	O
.	-	502	O

After	1424076	504	O
normal	-	510	O
serum	-	517	O
sodium	-	523	O
levels	-	530	O
returned	-	537	O
,	-	545	O
further	-	547	O
doxorubicin	-	555	O
and	-	567	O
dexamethasone	-	571	O
chemotherapy	-	585	O
without	-	598	O
vincristine	-	606	O
did	-	618	O
not	-	622	O
produce	-	626	O
this	-	634	O
complication	-	639	O
.	-	651	O

Heart	1449452	0	B
failure	-	6	I
:	-	13	O
to	-	15	O
digitalise	-	18	O
or	-	29	O
not	-	32	O
?	-	35	O

The	1449452	37	O
view	-	41	O
against	-	46	O
.	-	53	O

Despite	1449452	55	O
extensive	-	63	O
clinical	-	73	O
experience	-	82	O
the	-	93	O
role	-	97	O
of	-	102	O
digoxin	-	105	O
is	-	113	O
still	-	116	O
not	-	122	O
well	-	126	O
defined	-	131	O
.	-	138	O

In	1449452	140	O
patients	-	143	O
with	-	152	O
atrial	-	157	B
fibrillation	-	164	I
digoxin	-	177	O
is	-	185	O
beneficial	-	188	O
for	-	199	O
ventricular	-	203	O
rate	-	215	O
control	-	220	O
.	-	227	O

For	1449452	229	O
patients	-	233	O
in	-	242	O
sinus	-	245	O
rhythm	-	251	O
and	-	258	O
heart	-	262	B
failure	-	268	I
the	-	276	O
situation	-	280	O
is	-	290	O
less	-	293	O
clear	-	298	O
.	-	303	O

Digoxin	1449452	305	O
has	-	313	O
a	-	317	O
narrow	-	319	O
therapeutic	-	326	O
:	-	337	O
toxic	-	338	O
ratio	-	344	O
and	-	350	O
concentrations	-	354	O
are	-	369	O
affected	-	373	O
by	-	382	O
a	-	385	O
number	-	387	O
of	-	394	O
drugs	-	397	O
.	-	402	O

Also	1449452	404	O
,	-	408	O
digoxin	-	410	O
has	-	418	O
undesirable	-	422	O
effects	-	434	O
such	-	442	O
as	-	447	O
increasing	-	450	O
peripheral	-	461	O
resistance	-	472	O
and	-	483	O
myocardial	-	487	O
demands	-	498	O
,	-	505	O
and	-	507	O
causing	-	511	O
arrhythmias	-	519	B
.	-	530	O

There	1449452	532	O
is	-	538	O
a	-	541	O
paucity	-	543	O
of	-	551	O
data	-	554	O
from	-	559	O
well	-	564	O
-	-	568	O
designed	-	569	O
trials	-	578	O
.	-	584	O

The	1449452	586	O
trials	-	590	O
that	-	597	O
are	-	602	O
available	-	606	O
are	-	616	O
generally	-	620	O
small	-	630	O
with	-	636	O
limitations	-	641	O
in	-	653	O
design	-	656	O
and	-	663	O
these	-	667	O
show	-	673	O
variation	-	678	O
in	-	688	O
patient	-	691	O
benefit	-	699	O
.	-	706	O

More	1449452	708	O
convincing	-	713	O
evidence	-	724	O
is	-	733	O
required	-	736	O
showing	-	745	O
that	-	753	O
digoxin	-	758	O
improves	-	766	O
symptoms	-	775	O
or	-	784	O
exercise	-	787	O
capacity	-	796	O
.	-	804	O

Furthermore	1449452	806	O
,	-	817	O
no	-	819	O
trial	-	822	O
has	-	828	O
had	-	832	O
sufficient	-	836	O
power	-	847	O
to	-	853	O
evaluate	-	856	O
mortality	-	865	O
.	-	874	O

Pooled	1449452	876	O
analysis	-	883	O
of	-	892	O
the	-	895	O
effects	-	899	O
of	-	907	O
other	-	910	O
inotropic	-	916	O
drugs	-	926	O
shows	-	932	O
an	-	938	O
excess	-	941	O
mortality	-	948	O
and	-	958	O
there	-	962	O
is	-	968	O
a	-	971	O
possibility	-	973	O
that	-	985	O
digoxin	-	990	O
may	-	998	O
increase	-	1002	O
mortality	-	1011	O
after	-	1021	O
myocardial	-	1027	B
infarction	-	1038	I
(	-	1049	O
MI	-	1050	B
)	-	1052	O
.	-	1053	O

Angiotensin	1449452	1055	O
-	-	1066	O
converting	-	1067	O
enzyme	-	1078	O
(	-	1085	O
ACE	-	1086	O
)	-	1089	O
inhibitors	-	1091	O
should	-	1102	O
be	-	1109	O
used	-	1112	O
first	-	1117	O
as	-	1123	O
they	-	1126	O
are	-	1131	O
safer	-	1135	O
,	-	1140	O
do	-	1142	O
not	-	1145	O
require	-	1149	O
blood	-	1157	O
level	-	1163	O
monitoring	-	1169	O
,	-	1179	O
modify	-	1181	O
progression	-	1188	O
of	-	1200	O
disease	-	1203	O
,	-	1210	O
relieve	-	1212	O
symptoms	-	1220	O
,	-	1228	O
improve	-	1230	O
exercise	-	1238	O
tolerance	-	1247	O
and	-	1257	O
reduce	-	1261	O
mortality	-	1268	O
.	-	1277	O

Caution	1449452	1279	O
should	-	1287	O
be	-	1294	O
exercised	-	1297	O
in	-	1307	O
using	-	1310	O
digoxin	-	1316	O
until	-	1324	O
large	-	1330	O
mortality	-	1336	O
trials	-	1346	O
are	-	1353	O
completed	-	1357	O
showing	-	1367	O
either	-	1375	O
benefit	-	1382	O
or	-	1390	O
harm	-	1393	O
.	-	1397	O

Until	1449452	1399	O
then	-	1405	O
digoxin	-	1410	O
should	-	1418	O
be	-	1425	O
considered	-	1428	O
a	-	1439	O
third	-	1441	O
-	-	1446	O
line	-	1447	O
therapy	-	1452	O
.	-	1459	O

Intravascular	1522360	0	O
hemolysis	-	14	B
and	-	24	O
acute	-	28	B
renal	-	34	I
failure	-	40	I
following	-	48	O
intermittent	-	58	O
rifampin	-	71	O
therapy	-	80	O
.	-	87	O

Renal	1522360	89	B
failure	-	95	I
is	-	103	O
a	-	106	O
rare	-	108	O
complication	-	113	O
associated	-	126	O
with	-	137	O
the	-	142	O
use	-	146	O
of	-	150	O
rifampin	-	153	O
.	-	161	O

Intravascular	1522360	163	O
hemolysis	-	177	B
leading	-	187	O
to	-	195	O
acute	-	198	B
renal	-	204	I
failure	-	210	I
following	-	218	O
rifampin	-	228	O
therapy	-	237	O
is	-	245	O
extremely	-	248	O
rare	-	258	O
.	-	262	O

Two	1522360	264	O
patients	-	268	O
with	-	277	O
leprosy	-	282	B
who	-	290	O
developed	-	294	O
hemolysis	-	304	B
and	-	314	O
acute	-	318	B
renal	-	324	I
failure	-	330	I
following	-	338	O
rifampin	-	348	O
are	-	357	O
reported	-	361	O
.	-	369	O

Zidovudine	1556529	0	O
-	-	10	O
induced	-	11	O
hepatitis	-	19	B
.	-	28	O

A	1556529	30	O
case	-	32	O
of	-	37	O
acute	-	40	O
hepatitis	-	46	B
induced	-	56	O
by	-	64	O
zidovudine	-	67	O
in	-	78	O
a	-	81	O
38	-	83	O
-	-	85	O
year	-	86	O
-	-	90	O
old	-	91	O
patient	-	95	O
with	-	103	O
AIDS	-	108	B
is	-	113	O
presented	-	116	O
.	-	125	O

The	1556529	127	O
mechanism	-	131	O
whereby	-	141	O
the	-	149	O
hepatitis	-	153	B
was	-	163	O
induced	-	167	O
is	-	175	O
not	-	178	O
known	-	182	O
.	-	187	O

However	1556529	189	O
,	-	196	O
the	-	198	O
patient	-	202	O
tolerated	-	210	O
well	-	220	O
an	-	225	O
alternative	-	228	O
reverse	-	240	O
transcriptase	-	248	O
inhibitor	-	262	O
,	-	271	O
2'3	-	273	O
'	-	276	O
dideoxyinosine	-	278	O
.	-	292	O

Physicians	1556529	294	O
caring	-	305	O
for	-	312	O
patients	-	316	O
with	-	325	O
AIDS	-	330	B
should	-	335	O
be	-	342	O
aware	-	345	O
of	-	351	O
this	-	354	O
hitherto	-	359	O
rarely	-	368	O
reported	-	375	O
complication	-	384	O
.	-	396	O

Thoracic	1563460	0	B
hematomyelia	-	9	I
secondary	-	22	O
to	-	32	O
coumadin	-	35	O
anticoagulant	-	44	O
therapy	-	58	O
:	-	65	O
a	-	67	O
case	-	69	O
report	-	74	O
.	-	80	O

A	1563460	82	O
case	-	84	O
of	-	89	O
thoracic	-	92	B
hematomyelia	-	101	I
secondary	-	114	O
to	-	124	O
anticoagulant	-	127	O
therapy	-	141	O
is	-	149	O
presented	-	152	O
.	-	161	O

Clinical	1563460	163	O
features	-	172	O
,	-	180	O
similar	-	182	O
to	-	190	O
2	-	193	O
other	-	195	O
previously	-	201	O
reported	-	212	O
cases	-	221	O
,	-	226	O
are	-	228	O
discussed	-	232	O
.	-	241	O

A	1563460	243	O
high	-	245	O
index	-	250	O
of	-	256	O
suspicion	-	259	O
may	-	269	O
lead	-	273	O
to	-	278	O
a	-	281	O
quick	-	283	O
diagnostic	-	289	O
procedure	-	300	O
and	-	310	O
successful	-	314	O
decompressive	-	325	O
surgery	-	339	O
.	-	346	O

Mania	1564030	0	B
associated	-	6	O
with	-	17	O
fluoxetine	-	22	O
treatment	-	33	O
in	-	43	O
adolescents	-	46	O
.	-	57	O

Fluoxetine	1564030	59	O
,	-	69	O
a	-	71	O
selective	-	73	O
serotonin	-	83	O
reuptake	-	93	O
inhibitor	-	102	O
,	-	111	O
is	-	113	O
gaining	-	116	O
increased	-	124	O
acceptance	-	134	O
in	-	145	O
the	-	148	O
treatment	-	152	O
of	-	162	O
adolescent	-	165	O
depression	-	176	B
.	-	186	O

Generally	1564030	188	O
safe	-	198	O
and	-	203	O
well	-	207	O
tolerated	-	212	O
by	-	222	O
adults	-	225	O
,	-	231	O
fluoxetine	-	233	O
has	-	244	O
been	-	248	O
reported	-	253	O
to	-	262	O
induce	-	265	O
mania	-	272	B
.	-	277	O

The	1564030	279	O
cases	-	283	O
of	-	289	O
five	-	292	O
depressed	-	297	B
adolescents	-	307	O
,	-	318	O
14	-	320	O
-	-	322	O
16	-	323	O
years	-	326	O
of	-	332	O
age	-	335	O
,	-	338	O
who	-	340	O
developed	-	344	O
mania	-	354	B
during	-	360	O
pharmacotherapy	-	367	O
with	-	383	O
fluoxetine	-	388	O
,	-	398	O
are	-	400	O
reported	-	404	O
here	-	413	O
.	-	417	O

Apparent	1564030	419	O
risk	-	428	O
factors	-	433	O
for	-	441	O
the	-	445	O
development	-	449	O
of	-	461	O
mania	-	464	B
or	-	470	O
hypomania	-	473	B
during	-	483	O
fluoxetine	-	490	O
pharmacotherapy	-	501	O
in	-	517	O
this	-	520	O
population	-	525	O
were	-	536	O
the	-	541	O
combination	-	545	O
of	-	557	O
attention	-	560	B
-	-	569	I
deficit	-	570	I
hyperactivity	-	578	I
disorder	-	592	I
and	-	601	O
affective	-	605	O
instability	-	615	O
;	-	626	O
major	-	628	O
depression	-	634	B
with	-	645	O
psychotic	-	650	B
features	-	660	O
;	-	668	O
a	-	670	O
family	-	672	O
history	-	679	O
of	-	687	O
affective	-	690	B
disorder	-	700	I
,	-	708	O
especially	-	710	O
bipolar	-	721	B
disorder	-	729	I
;	-	737	O
and	-	739	O
a	-	743	O
diagnosis	-	745	O
of	-	755	O
bipolar	-	758	B
disorder	-	766	I
.	-	774	O

Further	1564030	776	O
study	-	784	O
is	-	790	O
needed	-	793	O
to	-	800	O
determine	-	803	O
the	-	813	O
optimal	-	817	O
dosage	-	825	O
and	-	832	O
to	-	836	O
identify	-	839	O
risk	-	848	O
factors	-	853	O
that	-	861	O
increase	-	866	O
individual	-	875	O
vulnerability	-	886	O
to	-	900	O
fluoxetine	-	903	O
induced	-	914	O
mania	-	922	B
in	-	928	O
adolescents	-	931	O
.	-	942	O

Gemfibrozil	1615846	0	O
-	-	11	O
lovastatin	-	12	O
therapy	-	23	O
for	-	31	O
primary	-	35	O
hyperlipoproteinemias	-	43	B
.	-	64	O

The	1615846	66	O
specific	-	70	O
aim	-	79	O
of	-	83	O
this	-	86	O
retrospective	-	91	O
,	-	104	O
observational	-	106	O
study	-	120	O
was	-	126	O
to	-	130	O
assess	-	133	O
safety	-	140	O
and	-	147	O
efficacy	-	151	O
of	-	160	O
long	-	163	O
-	-	167	O
term	-	168	O
(	-	173	O
21	-	174	O
months	-	177	O
/	-	183	O
patient	-	184	O
)	-	191	O
,	-	192	O
open	-	194	O
-	-	198	O
label	-	199	O
,	-	204	O
gemfibrozil	-	206	O
-	-	217	O
lovastatin	-	218	O
treatment	-	229	O
in	-	239	O
80	-	242	O
patients	-	245	O
with	-	254	O
primary	-	259	O
mixed	-	267	O
hyperlipidemia	-	273	B
(	-	288	O
68	-	289	O
%	-	291	O
of	-	293	O
whom	-	296	O
had	-	301	O
atherosclerotic	-	305	B
vascular	-	321	I
disease	-	330	I
)	-	337	O
.	-	338	O

Because	1615846	340	O
ideal	-	348	O
lipid	-	354	O
targets	-	360	O
were	-	368	O
not	-	373	O
reached	-	377	O
(	-	385	O
low	-	386	O
-	-	389	O
density	-	390	O
lipoprotein	-	398	O
(	-	410	O
LDL	-	411	O
)	-	414	O
cholesterol	-	416	O
less	-	428	O
than	-	433	O
130	-	438	O
mg	-	442	O
/	-	444	O
dl	-	445	O
,	-	447	O
high	-	449	O
-	-	453	O
density	-	454	O
lipoprotein	-	462	O
(	-	474	O
HDL	-	475	O
)	-	478	O
cholesterol	-	480	O
greater	-	492	O
than	-	500	O
35	-	505	O
mg	-	508	O
/	-	510	O
dl	-	511	O
,	-	513	O
or	-	515	O
total	-	518	O
cholesterol	-	524	O
/	-	535	O
HDL	-	536	O
cholesterol	-	540	O
less	-	552	O
than	-	557	O
4	-	562	O
.	-	563	O
5	-	564	O
mg	-	566	O
/	-	568	O
dl	-	569	O
)	-	571	O
with	-	573	O
diet	-	578	O
plus	-	583	O
a	-	588	O
single	-	590	O
drug	-	597	O
,	-	601	O
gemfibrozil	-	603	O
(	-	615	O
1	-	616	O
.	-	617	O
2	-	618	O
g	-	620	O
/	-	621	O
day	-	622	O
)	-	625	O
-	-	626	O
lovastatin	-	627	O
(	-	638	O
primarily	-	639	O
20	-	649	O
or	-	652	O
40	-	655	O
mg	-	658	O
)	-	660	O
treatment	-	662	O
was	-	672	O
given	-	676	O
.	-	681	O

Follow	1615846	683	O
-	-	689	O
up	-	690	O
visits	-	693	O
were	-	700	O
scheduled	-	705	O
with	-	715	O
2	-	720	O
-	-	721	O
drug	-	722	O
therapy	-	727	O
every	-	735	O
6	-	741	O
to	-	743	O
8	-	746	O
weeks	-	748	O
,	-	753	O
an	-	755	O
average	-	758	O
of	-	766	O
10	-	769	O
.	-	771	O
3	-	772	O
visits	-	774	O
per	-	781	O
patient	-	785	O
,	-	792	O
with	-	794	O
741	-	799	O
batteries	-	803	O
of	-	813	O
6	-	816	O
liver	-	818	O
function	-	824	O
tests	-	833	O
and	-	839	O
714	-	843	O
creatine	-	847	O
phosphokinase	-	856	O
levels	-	870	O
measured	-	877	O
.	-	885	O

Only	1615846	887	O
1	-	892	O
of	-	894	O
the	-	897	O
4	-	901	O
,	-	902	O
446	-	903	O
liver	-	907	O
function	-	913	O
tests	-	922	O
(	-	928	O
0	-	929	O
.	-	930	O
02	-	931	O
%	-	933	O
)	-	934	O
,	-	935	O
a	-	937	O
gamma	-	939	O
glutamyl	-	945	O
transferase	-	954	O
,	-	965	O
was	-	967	O
greater	-	971	O
than	-	979	O
or	-	984	O
equal	-	987	O
to	-	993	O
3	-	996	O
times	-	998	O
the	-	1004	O
upper	-	1008	O
normal	-	1014	O
limit	-	1021	O
.	-	1026	O

Of	1615846	1028	O
the	-	1031	O
714	-	1035	O
creatine	-	1039	O
phosphokinase	-	1048	O
levels	-	1062	O
,	-	1068	O
9	-	1070	O
%	-	1071	O
were	-	1073	O
high	-	1078	O
;	-	1082	O
only	-	1084	O
1	-	1089	O
(	-	1091	O
0	-	1092	O
.	-	1093	O
1	-	1094	O
%	-	1095	O
)	-	1096	O
was	-	1098	O
greater	-	1102	O
than	-	1110	O
or	-	1115	O
equal	-	1118	O
to	-	1124	O
3	-	1127	O
times	-	1129	O
the	-	1135	O
upper	-	1139	O
normal	-	1145	O
limit	-	1152	O
.	-	1157	O

With	1615846	1159	O
2	-	1164	O
-	-	1165	O
drug	-	1166	O
therapy	-	1171	O
,	-	1178	O
mean	-	1180	O
total	-	1185	O
cholesterol	-	1191	O
decreased	-	1203	O
22	-	1213	O
%	-	1215	O
from	-	1217	O
255	-	1222	O
to	-	1226	O
200	-	1229	O
mg	-	1233	O
/	-	1235	O
dl	-	1236	O
,	-	1238	O
triglyceride	-	1240	O
levels	-	1253	O
decreased	-	1260	O
35	-	1270	O
%	-	1272	O
from	-	1274	O
236	-	1279	O
to	-	1283	O
154	-	1286	O
mg	-	1290	O
/	-	1292	O
dl	-	1293	O
,	-	1295	O
LDL	-	1297	O
cholesterol	-	1301	O
decreased	-	1313	O
26	-	1323	O
%	-	1325	O
from	-	1327	O
176	-	1332	O
to	-	1336	O
131	-	1339	O
mg	-	1343	O
/	-	1345	O
dl	-	1346	O
,	-	1348	O
and	-	1350	O
the	-	1354	O
total	-	1358	O
cholesterol	-	1364	O
/	-	1375	O
HDL	-	1376	O
cholesterol	-	1380	O
ratio	-	1392	O
decreased	-	1398	O
24	-	1408	O
%	-	1410	O
from	-	1412	O
7	-	1417	O
.	-	1418	O
1	-	1419	O
to	-	1421	O
5	-	1424	O
.	-	1425	O
4	-	1426	O
,	-	1427	O
all	-	1429	O
p	-	1433	O
less	-	1435	O
than	-	1440	O
or	-	1445	O
equal	-	1448	O
to	-	1454	O
0	-	1457	O
.	-	1458	O
0001	-	1459	O
.	-	1463	O

Myositis	1615846	1465	B
,	-	1473	O
attributable	-	1475	O
to	-	1488	O
the	-	1491	O
drug	-	1495	O
combination	-	1500	O
and	-	1512	O
symptomatic	-	1516	O
enough	-	1528	O
to	-	1535	O
discontinue	-	1538	O
it	-	1550	O
,	-	1552	O
occurred	-	1554	O
in	-	1563	O
3	-	1566	O
%	-	1567	O
of	-	1569	O
patients	-	1572	O
,	-	1580	O
and	-	1582	O
in	-	1586	O
1	-	1589	O
%	-	1590	O
with	-	1592	O
concurrent	-	1597	O
high	-	1608	O
creatine	-	1613	O
phosphokinase	-	1622	O
(	-	1636	O
769	-	1637	O
U	-	1641	O
/	-	1642	O
liter	-	1643	O
)	-	1648	O
;	-	1649	O
no	-	1651	O
patients	-	1654	O
had	-	1663	O
rhabdomyolysis	-	1667	B
or	-	1682	O
myoglobinuria	-	1685	B
.	-	1698	O
(	-	1699	O
ABSTRACT	-	1700	O
TRUNCATED	-	1709	O
AT	-	1719	O
250	-	1722	O
WORDS	-	1726	O
)	-	1731	O

Hepatocellular	1655018	0	B
carcinoma	-	15	I
in	-	25	O
Fanconi	-	28	B
's	-	35	I
anemia	-	38	I
treated	-	45	O
with	-	53	O
androgen	-	58	O
and	-	67	O
corticosteroid	-	71	O
.	-	85	O

The	1655018	87	O
case	-	91	O
of	-	96	O
an	-	99	O
11	-	102	O
-	-	104	O
year	-	105	O
-	-	109	O
old	-	110	O
boy	-	114	O
is	-	118	O
reported	-	121	O
who	-	130	O
was	-	134	O
known	-	138	O
to	-	144	O
have	-	147	O
Fanconi	-	152	B
's	-	159	I
anemia	-	162	I
for	-	169	O
3	-	173	O
years	-	175	O
and	-	181	O
was	-	185	O
treated	-	189	O
with	-	197	O
androgens	-	202	O
,	-	211	O
corticosteroids	-	213	O
and	-	229	O
transfusions	-	233	O
.	-	245	O

Two	1655018	247	O
weeks	-	251	O
before	-	257	O
his	-	264	O
death	-	268	O
he	-	274	O
was	-	277	O
readmitted	-	281	O
because	-	292	O
of	-	300	O
aplastic	-	303	O
crisis	-	312	O
with	-	319	O
septicemia	-	324	B
and	-	335	O
marked	-	339	O
abnormalities	-	346	O
in	-	360	O
liver	-	363	O
function	-	369	O
and	-	378	O
died	-	382	O
of	-	387	O
hemorrhagic	-	390	B
bronchopneumonia	-	402	I
.	-	418	O

At	1655018	420	O
autopsy	-	423	O
peliosis	-	431	B
and	-	440	O
multiple	-	444	O
hepatic	-	453	B
tumors	-	461	I
were	-	468	O
found	-	473	O
which	-	479	O
histologically	-	485	O
proved	-	500	O
to	-	507	O
be	-	510	O
well	-	513	O
-	-	517	O
differentiated	-	518	O
hepatocellular	-	533	B
carcinoma	-	548	I
.	-	557	O

This	1655018	559	O
case	-	564	O
contributes	-	569	O
to	-	581	O
the	-	584	O
previous	-	588	O
observations	-	597	O
that	-	610	O
non	-	615	O
-	-	618	O
metastasizing	-	619	O
hepatic	-	633	B
neoplasms	-	641	I
and	-	651	O
peliosis	-	655	B
can	-	664	O
develop	-	668	O
in	-	676	O
patients	-	679	O
with	-	688	O
androgen	-	693	O
-	-	701	O
and	-	703	O
corticosteroid	-	707	O
-	-	721	O
treated	-	722	O
Fanconi	-	730	B
's	-	737	I
anemia	-	740	I
.	-	746	O

Chronic	1735570	0	O
lesion	-	8	O
of	-	15	O
rostral	-	18	O
ventrolateral	-	26	O
medulla	-	40	O
in	-	48	O
spontaneously	-	51	O
hypertensive	-	65	B
rats	-	78	O
.	-	82	O

We	1735570	84	O
studied	-	87	O
the	-	95	O
effects	-	99	O
of	-	107	O
chronic	-	110	O
selective	-	118	O
neuronal	-	128	O
lesion	-	137	O
of	-	144	O
rostral	-	147	O
ventrolateral	-	155	O
medulla	-	169	O
on	-	177	O
mean	-	180	O
arterial	-	185	O
pressure	-	194	O
,	-	202	O
heart	-	204	O
rate	-	210	O
,	-	214	O
and	-	216	O
neurogenic	-	220	O
tone	-	231	O
in	-	236	O
conscious	-	239	O
,	-	248	O
unrestrained	-	250	O
spontaneously	-	263	O
hypertensive	-	277	B
rats	-	290	O
.	-	294	O

The	1735570	296	O
lesions	-	300	O
were	-	308	O
placed	-	313	O
via	-	320	O
bilateral	-	324	O
microinjections	-	334	O
of	-	350	O
30	-	353	O
nmol	-	356	O
/	-	360	O
200	-	361	O
nl	-	365	O
N	-	368	O
-	-	369	O
methyl	-	370	O
-	-	376	O
D	-	377	O
-	-	378	O
aspartic	-	379	O
acid	-	388	O
.	-	392	O

The	1735570	394	O
restimulation	-	398	O
of	-	412	O
this	-	415	O
area	-	420	O
with	-	425	O
N	-	430	O
-	-	431	O
methyl	-	432	O
-	-	438	O
D	-	439	O
-	-	440	O
aspartic	-	441	O
acid	-	450	O
15	-	455	O
days	-	458	O
postlesion	-	463	O
failed	-	474	O
to	-	481	O
produce	-	484	O
a	-	492	O
pressor	-	494	O
response	-	502	O
.	-	510	O

One	1735570	512	O
day	-	516	O
postlesion	-	520	O
,	-	530	O
the	-	532	O
resting	-	536	O
mean	-	544	O
arterial	-	549	O
pressure	-	558	O
was	-	567	O
significantly	-	571	O
decreased	-	585	O
in	-	595	O
lesioned	-	598	O
rats	-	607	O
when	-	612	O
compared	-	617	O
with	-	626	O
sham	-	631	O
rats	-	636	O
(	-	641	O
100	-	642	O
+	-	646	O
/	-	647	O
-	-	648	O
7	-	650	O
versus	-	652	O
173	-	659	O
+	-	663	O
/	-	664	O
-	-	665	O

4	1735570	667	O
mm	-	669	O
Hg	-	672	O
,	-	674	O
p	-	676	O
less	-	678	O
than	-	683	O
0	-	688	O
.	-	689	O
05	-	690	O
)	-	692	O
.	-	693	O

Fifteen	1735570	695	O
days	-	703	O
later	-	708	O
,	-	713	O
the	-	715	O
lesioned	-	719	O
group	-	728	O
still	-	734	O
showed	-	740	O
values	-	747	O
significantly	-	754	O
lower	-	768	O
than	-	774	O
the	-	779	O
sham	-	783	O
group	-	788	O
(	-	794	O
150	-	795	O
+	-	799	O
/	-	800	O
-	-	801	O

6	1735570	803	O
versus	-	805	O
167	-	812	O
+	-	816	O
/	-	817	O
-	-	818	O

5	1735570	820	O
mm	-	822	O
Hg	-	825	O
,	-	827	O
p	-	829	O
less	-	831	O
than	-	836	O
0	-	841	O
.	-	842	O
05	-	843	O
)	-	845	O
.	-	846	O

No	1735570	848	O
significant	-	851	O
heart	-	863	O
rate	-	869	O
differences	-	874	O
were	-	886	O
observed	-	891	O
between	-	900	O
the	-	908	O
sham	-	912	O
and	-	917	O
lesioned	-	921	O
groups	-	930	O
.	-	936	O

The	1735570	938	O
ganglionic	-	942	O
blocker	-	953	O
trimethaphan	-	961	O
(	-	974	O
5	-	975	O
mg	-	977	O
/	-	979	O
kg	-	980	O
i	-	983	O
.	-	984	O
v	-	985	O
.	-	986	O
)	-	987	O

caused	1735570	989	O
similar	-	996	O
reductions	-	1004	O
in	-	1015	O
mean	-	1018	O
arterial	-	1023	O
pressure	-	1032	O
in	-	1041	O
both	-	1044	O
lesioned	-	1049	O
and	-	1058	O
sham	-	1062	O
groups	-	1067	O
.	-	1073	O

The	1735570	1075	O
trimethaphan	-	1079	O
-	-	1091	O
induced	-	1092	O
hypotension	-	1100	B
was	-	1112	O
accompanied	-	1116	O
by	-	1128	O
a	-	1131	O
significant	-	1133	O
bradycardia	-	1145	B
in	-	1157	O
lesioned	-	1160	O
rats	-	1169	O
(	-	1174	O
-	-	1175	O
32	-	1176	O
+	-	1179	O
/	-	1180	O
-	-	1181	O

13	1735570	1183	O
beats	-	1186	O
per	-	1192	O
minute	-	1196	O
)	-	1202	O
but	-	1204	O
a	-	1208	O
tachycardia	-	1210	B
in	-	1222	O
sham	-	1225	O
rats	-	1230	O
(	-	1235	O
+	-	1236	O
33	-	1237	O
+	-	1240	O
/	-	1241	O
-	-	1242	O

12	1735570	1244	O
beats	-	1247	O
per	-	1253	O
minute	-	1257	O
)	-	1263	O
1	-	1265	O
day	-	1267	O
postlesion	-	1271	O
.	-	1281	O

Therefore	1735570	1283	O
,	-	1292	O
rostral	-	1294	O
ventrolateral	-	1302	O
medulla	-	1316	O
neurons	-	1324	O
appear	-	1332	O
to	-	1339	O
play	-	1342	O
a	-	1347	O
significant	-	1349	O
role	-	1361	O
in	-	1366	O
maintaining	-	1369	O
hypertension	-	1381	B
in	-	1394	O
conscious	-	1397	O
spontaneously	-	1407	O
hypertensive	-	1421	B
rats	-	1434	O
.	-	1438	O

Spinal	1735570	1440	O
or	-	1447	O
suprabulbar	-	1450	O
structures	-	1462	O
could	-	1473	O
be	-	1479	O
responsible	-	1482	O
for	-	1494	O
the	-	1498	O
gradual	-	1502	O
recovery	-	1510	O
of	-	1519	O
the	-	1522	O
hypertension	-	1526	B
in	-	1539	O
the	-	1542	O
lesioned	-	1546	O
rats	-	1555	O
.	-	1559	O

Damage	1756784	0	B
of	-	7	I
substantia	-	10	I
nigra	-	21	I
pars	-	27	I
reticulata	-	32	I
during	-	43	O
pilocarpine	-	50	O
-	-	61	O
induced	-	62	O
status	-	70	B
epilepticus	-	77	I
in	-	89	O
the	-	92	O
rat	-	96	O
:	-	99	O
immunohistochemical	-	101	O
study	-	121	O
of	-	127	O
neurons	-	130	O
,	-	137	O
astrocytes	-	139	O
and	-	150	O
serum	-	154	O
-	-	159	O
protein	-	160	O
extravasation	-	168	O
.	-	181	O

The	1756784	183	O
substantia	-	187	O
nigra	-	198	O
has	-	204	O
a	-	208	O
gating	-	210	O
function	-	217	O
controlling	-	226	O
the	-	238	O
spread	-	242	O
of	-	249	O
epileptic	-	252	B
seizure	-	262	I
activity	-	270	O
.	-	278	O

Additionally	1756784	280	O
,	-	292	O
in	-	294	O
models	-	297	O
of	-	304	O
prolonged	-	307	B
status	-	317	I
epilepticus	-	324	I
the	-	336	O
pars	-	340	O
reticulata	-	345	O
of	-	356	O
substantia	-	359	O
nigra	-	370	O
(	-	376	O
SNR	-	377	O
)	-	380	O
suffers	-	382	O
from	-	390	O
a	-	395	O
massive	-	397	O
lesion	-	405	O
which	-	412	O
may	-	418	O
arise	-	422	O
from	-	428	O
a	-	433	O
massive	-	435	O
metabolic	-	443	B
derangement	-	453	I
and	-	465	O
hyperexcitation	-	469	O
developing	-	485	O
in	-	496	O
the	-	499	O
activated	-	503	O
SNR	-	513	O
.	-	516	O

In	1756784	518	O
this	-	521	O
study	-	526	O
,	-	531	O
status	-	533	B
epilepticus	-	540	I
was	-	552	O
induced	-	556	O
by	-	564	O
systemic	-	567	O
injection	-	576	O
of	-	586	O
pilocarpine	-	589	O
in	-	601	O
rats	-	604	O
.	-	608	O

The	1756784	610	O
neuropathology	-	614	O
of	-	629	O
SNR	-	632	O
was	-	636	O
investigated	-	640	O
using	-	653	O
immunohistochemical	-	659	O
techniques	-	679	O
with	-	690	O
the	-	695	O
major	-	699	O
emphasis	-	705	O
on	-	714	O
the	-	717	O
time	-	721	O
-	-	725	O
course	-	726	O
of	-	733	O
changes	-	736	O
in	-	744	O
neurons	-	747	O
and	-	755	O
astrocytes	-	759	O
.	-	769	O

Animals	1756784	771	O
surviving	-	779	O
20	-	789	O
,	-	791	O
30	-	793	O
,	-	795	O
40	-	797	O
,	-	799	O
60	-	801	O
min	-	804	O
,	-	807	O
2	-	809	O
,	-	810	O
3	-	812	O
,	-	813	O
6	-	815	O
hours	-	817	O
,	-	822	O
1	-	824	O
,	-	825	O
2	-	827	O
,	-	828	O
and	-	830	O
3	-	834	O
days	-	836	O
after	-	841	O
induction	-	847	O
of	-	857	O
status	-	860	B
epilepticus	-	867	I
were	-	879	O
perfusion	-	884	O
-	-	893	O
fixed	-	894	O
,	-	899	O
and	-	901	O
brains	-	905	O
processed	-	912	O
for	-	922	O
immunohistochemical	-	926	O
staining	-	946	O
of	-	955	O
SNR	-	958	O
.	-	961	O

Nissl	1756784	963	O
-	-	968	O
staining	-	969	O
and	-	978	O
antibodies	-	982	O
against	-	993	O
the	-	1001	O
neuron	-	1005	O
-	-	1011	O
specific	-	1012	O
calcium	-	1021	O
-	-	1028	O
binding	-	1029	O
protein	-	1037	O
,	-	1044	O
parvalbumin	-	1046	O
,	-	1057	O
served	-	1059	O
to	-	1066	O
detect	-	1069	O
neuronal	-	1076	B
damage	-	1085	I
in	-	1092	O
SNR	-	1095	O
.	-	1098	O

Antibodies	1756784	1100	O
against	-	1111	O
the	-	1119	O
astroglia	-	1123	O
-	-	1132	O
specific	-	1133	O
cytoskeletal	-	1142	O
protein	-	1155	O
,	-	1162	O
glial	-	1164	O
fibrillary	-	1170	O
acidic	-	1181	O
protein	-	1188	O
(	-	1196	O
GFAP	-	1197	O
)	-	1201	O
,	-	1202	O
and	-	1204	O
against	-	1208	O
the	-	1216	O
glial	-	1220	O
calcium	-	1226	O
-	-	1233	O
binding	-	1234	O
protein	-	1242	O
,	-	1249	O
S	-	1251	O
-	-	1252	O
100	-	1253	O
protein	-	1257	O
,	-	1264	O
were	-	1266	O
used	-	1271	O
to	-	1276	O
assess	-	1279	O
the	-	1286	O
status	-	1290	O
of	-	1297	O
astrocytes	-	1300	O
.	-	1310	O

Immunohistochemical	1756784	1312	O
staining	-	1332	O
for	-	1341	O
serum	-	1345	O
-	-	1350	O
albumin	-	1351	O
and	-	1359	O
immunoglobulins	-	1363	O
in	-	1379	O
brain	-	1382	O
tissue	-	1388	O
was	-	1395	O
taken	-	1399	O
as	-	1405	O
indicator	-	1408	O
of	-	1418	O
blood	-	1421	O
-	-	1426	O
brain	-	1427	O
barrier	-	1433	O
disturbances	-	1441	O
and	-	1454	O
vasogenic	-	1458	B
edema	-	1468	I
formation	-	1474	O
.	-	1483	O

Immunohistochemical	1756784	1485	O
staining	-	1505	O
indicated	-	1514	O
loss	-	1524	O
of	-	1529	O
GFAP	-	1532	O
-	-	1536	O
staining	-	1537	O
already	-	1546	O
at	-	1554	O
30	-	1557	O
min	-	1560	O
after	-	1564	O
induction	-	1570	O
of	-	1580	O
seizures	-	1583	B
in	-	1592	O
an	-	1595	O
oval	-	1598	O
focus	-	1603	O
situated	-	1609	O
in	-	1618	O
the	-	1621	O
center	-	1625	O
of	-	1632	O
SNR	-	1635	O
while	-	1639	O
sparing	-	1645	O
medial	-	1653	O
and	-	1660	O
lateral	-	1664	O
aspects	-	1672	O
.	-	1679	O

At	1756784	1681	O
1	-	1684	O
h	-	1686	O
there	-	1688	O
was	-	1694	O
additional	-	1698	O
vacuolation	-	1709	O
in	-	1721	O
S	-	1724	O
-	-	1725	O
100	-	1726	O
protein	-	1730	O
staining	-	1738	O
.	-	1746	O

By	1756784	1748	O
2	-	1751	O
hours	-	1753	O
,	-	1758	O
parvalbumin	-	1760	O
-	-	1771	O
staining	-	1772	O
changed	-	1781	O
in	-	1789	O
the	-	1792	O
central	-	1796	O
SNR	-	1804	O
indicating	-	1808	O
neuronal	-	1819	B
damage	-	1828	I
,	-	1834	O
and	-	1836	O
Nissl	-	1840	O
-	-	1845	O
staining	-	1846	O
visualized	-	1855	O
some	-	1866	O
neuronal	-	1871	O
distortion	-	1880	O
.	-	1890	O

Staining	1756784	1892	O
for	-	1901	O
serum	-	1905	O
-	-	1910	O
proteins	-	1911	O
occurred	-	1920	O
in	-	1929	O
a	-	1932	O
patchy	-	1934	O
manner	-	1941	O
throughout	-	1948	O
the	-	1959	O
forebrain	-	1963	O
during	-	1973	O
the	-	1980	O
first	-	1984	O
hours	-	1990	O
.	-	1995	O

By	1756784	1997	O
6	-	2000	O
h	-	2002	O
,	-	2003	O
vasogenic	-	2005	B
edema	-	2015	I
covered	-	2021	O
the	-	2029	O
lesioned	-	2033	B
SNR	-	2042	I
.	-	2045	O

By	1756784	2047	O
24	-	2050	O
h	-	2053	O
,	-	2054	O
glial	-	2056	O
and	-	2062	O
neuronal	-	2066	O
markers	-	2075	O
indicated	-	2083	O
a	-	2093	O
massive	-	2095	O
lesion	-	2103	O
in	-	2110	O
the	-	2113	O
center	-	2117	O
of	-	2124	O
SNR	-	2127	O
.	-	2130	O

By	1756784	2132	O
48	-	2135	O
-	-	2137	O
72	-	2138	O
h	-	2141	O
,	-	2142	O
astrocytes	-	2144	O
surrounding	-	2155	O
the	-	2167	O
lesion	-	2171	O
increased	-	2178	O
in	-	2188	O
size	-	2191	O
,	-	2195	O
and	-	2197	O
polymorphic	-	2201	O
phagocytotic	-	2213	O
cells	-	2226	O
invaded	-	2232	O
the	-	2240	O
damaged	-	2244	O
area	-	2252	O
.	-	2256	O

In	1756784	2258	O
a	-	2261	O
further	-	2263	O
group	-	2271	O
of	-	2277	O
animals	-	2280	O
surviving	-	2288	O
1	-	2298	O
to	-	2300	O
5	-	2303	O
days	-	2305	O
,	-	2309	O
conventional	-	2311	O
paraffin	-	2324	O
-	-	2332	O
sections	-	2333	O
confirmed	-	2342	O
the	-	2352	O
neuronal	-	2356	O
and	-	2365	O
glial	-	2369	O
damage	-	2375	B
of	-	2382	I
SNR	-	2385	I
.	-	2388	O

Additional	1756784	2390	O
pathology	-	2401	O
of	-	2411	O
similar	-	2414	O
quality	-	2422	O
was	-	2430	O
found	-	2434	O
in	-	2440	O
the	-	2443	O
globus	-	2447	O
pallidus	-	2454	O
.	-	2462	O

Since	1756784	2464	O
astrocytes	-	2470	O
were	-	2481	O
always	-	2486	O
damaged	-	2493	O
in	-	2501	O
parallel	-	2504	O
with	-	2513	O
neurons	-	2518	O
in	-	2526	O
SNR	-	2529	O
it	-	2533	O
is	-	2536	O
proposed	-	2539	O
that	-	2548	O
the	-	2553	O
anatomical	-	2557	O
and	-	2568	O
functional	-	2572	O
interrelationship	-	2583	O
between	-	2601	O
neurons	-	2609	O
and	-	2617	O
astrocytes	-	2621	O
is	-	2632	O
particularly	-	2635	O
tight	-	2648	O
in	-	2654	O
SNR	-	2657	O
.	-	2660	O

Both	1756784	2662	O
cell	-	2667	O
elements	-	2672	O
may	-	2681	O
suffer	-	2685	O
in	-	2692	O
common	-	2695	O
from	-	2702	O
metabolic	-	2707	O
disturbance	-	2717	O
and	-	2729	O
neurotransmitter	-	2733	B
dysfunction	-	2750	I
as	-	2762	O
occur	-	2765	O
during	-	2771	O
massive	-	2778	O
status	-	2786	B
epilepticus	-	2793	I
.	-	2804	O

Reduced	1760851	0	O
cardiotoxicity	-	8	B
of	-	23	O
doxorubicin	-	26	O
given	-	38	O
in	-	44	O
the	-	47	O
form	-	51	O
of	-	56	O
N	-	59	O
-	-	60	O
(	-	61	O
2	-	62	O
-	-	63	O
hydroxypropyl	-	64	O
)	-	77	O
methacrylamide	-	78	O
conjugates	-	93	O
:	-	103	O
and	-	105	O
experimental	-	109	O
study	-	122	O
in	-	128	O
the	-	131	O
rat	-	135	O
.	-	138	O

A	1760851	140	O
rat	-	142	O
model	-	146	O
was	-	152	O
used	-	156	O
to	-	161	O
evaluate	-	164	O
the	-	173	O
general	-	177	O
acute	-	185	O
toxicity	-	191	B
and	-	200	O
the	-	204	O
late	-	208	O
cardiotoxicity	-	213	B
of	-	228	O
4	-	231	O
mg	-	233	O
/	-	235	O
kg	-	236	O
doxorubicin	-	239	O
(	-	251	O
DOX	-	252	O
)	-	255	O
given	-	257	O
either	-	263	O
as	-	270	O
free	-	273	O
drug	-	278	O
or	-	283	O
in	-	286	O
the	-	289	O
form	-	293	O
of	-	298	O
three	-	301	O
N	-	307	O
-	-	308	O
(	-	309	O
2	-	310	O
-	-	311	O
hydroxypropyl	-	312	O
)	-	325	O
methacrylamide	-	326	O
(	-	341	O
HPMA	-	342	O
)	-	346	O
copolymer	-	348	O
conjugates	-	358	O
.	-	368	O

In	1760851	370	O
these	-	373	O
HPMA	-	379	O
copolymers	-	384	O
,	-	394	O
DOX	-	396	O
was	-	400	O
covalently	-	404	O
bound	-	415	O
via	-	421	O
peptide	-	425	O
linkages	-	433	O
that	-	442	O
were	-	447	O
either	-	452	O
non	-	459	O
-	-	462	O
biodegradable	-	463	O
(	-	477	O
Gly	-	478	O
-	-	481	O
Gly	-	482	O
)	-	485	O
or	-	487	O
degradable	-	490	O
by	-	501	O
lysosomal	-	504	O
proteinases	-	514	O
(	-	526	O
Gly	-	527	O
-	-	530	O
Phe	-	531	O
-	-	534	O
Leu	-	535	O
-	-	538	O
Gly	-	539	O
)	-	542	O
.	-	543	O

In	1760851	545	O
addition	-	548	O
,	-	556	O
one	-	558	O
biodegradable	-	562	O
conjugate	-	576	O
containing	-	586	O
galactosamine	-	597	O
was	-	611	O
used	-	615	O
;	-	619	O
this	-	621	O
residue	-	626	O
was	-	634	O
targeted	-	638	O
to	-	647	O
the	-	650	O
liver	-	654	O
.	-	659	O

Over	1760851	661	O
the	-	666	O
first	-	670	O
3	-	676	O
weeks	-	678	O
after	-	684	O
the	-	690	O
i	-	694	O
.	-	695	O
v	-	696	O
.	-	697	O

administration	1760851	699	O
of	-	714	O
free	-	717	O
and	-	722	O
polymer	-	726	O
-	-	733	O
bound	-	734	O
DOX	-	740	O
,	-	743	O
all	-	745	O
animals	-	749	O
showed	-	757	O
a	-	764	O
transient	-	766	O
reduction	-	776	O
in	-	786	O
body	-	789	O
weight	-	794	O
.	-	800	O

However	1760851	802	O
,	-	809	O
the	-	811	O
maximal	-	815	O
reduction	-	823	O
in	-	833	O
body	-	836	O
weight	-	841	O
seen	-	848	O
in	-	853	O
animals	-	856	O
that	-	864	O
received	-	869	O
polymer	-	878	O
-	-	885	O
bound	-	886	O
DOX	-	892	O
(	-	896	O
4	-	897	O
mg	-	899	O
/	-	901	O
kg	-	902	O
)	-	904	O
was	-	906	O
significantly	-	910	O
lower	-	924	O
than	-	930	O
that	-	935	O
observed	-	940	O
in	-	949	O
those	-	952	O
that	-	958	O
received	-	963	O
free	-	972	O
DOX	-	977	O
(	-	981	O
4	-	982	O
mg	-	984	O
/	-	986	O
kg	-	987	O
)	-	989	O
or	-	991	O
a	-	994	O
mixture	-	996	O
of	-	1004	O
the	-	1007	O
unmodified	-	1011	O
parent	-	1022	O
HPMA	-	1029	O
copolymer	-	1034	O
and	-	1044	O
free	-	1048	O
DOX	-	1053	O
(	-	1057	O
4	-	1058	O
mg	-	1060	O
/	-	1062	O
kg	-	1063	O
;	-	1065	O
P	-	1067	O
less	-	1069	O
than	-	1074	O
0	-	1079	O
.	-	1080	O
01	-	1081	O
)	-	1083	O
.	-	1084	O

Throughout	1760851	1086	O
the	-	1097	O
study	-	1101	O
(	-	1107	O
20	-	1108	O
weeks	-	1111	O
)	-	1116	O
,	-	1117	O
deaths	-	1119	O
related	-	1126	O
to	-	1134	O
cardiotoxicity	-	1137	B
were	-	1152	O
observed	-	1157	O
only	-	1166	O
in	-	1171	O
animals	-	1174	O
that	-	1182	O
received	-	1187	O
either	-	1196	O
free	-	1203	O
DOX	-	1208	O
or	-	1212	O
the	-	1215	O
mixture	-	1219	O
of	-	1227	O
HPMA	-	1230	O
copolymer	-	1235	O
and	-	1245	O
free	-	1249	O
DOX	-	1254	O
;	-	1257	O
in	-	1259	O
these	-	1262	O
cases	-	1268	O
,	-	1273	O
histological	-	1275	O
investigations	-	1288	O
revealed	-	1303	O
marked	-	1312	O
changes	-	1319	O
in	-	1327	O
the	-	1330	O
heart	-	1334	O
that	-	1340	O
were	-	1345	O
consistent	-	1350	O
with	-	1361	O
DOX	-	1366	O
-	-	1369	O
induced	-	1370	O
cardiotoxicity	-	1378	B
.	-	1392	O

Sequential	1760851	1394	O
measurements	-	1405	O
of	-	1418	O
cardiac	-	1421	O
output	-	1429	O
in	-	1436	O
surviving	-	1439	O
animals	-	1449	O
that	-	1457	O
received	-	1462	O
either	-	1471	O
free	-	1478	O
DOX	-	1483	O
or	-	1487	O
the	-	1490	O
mixture	-	1494	O
of	-	1502	O
HPMA	-	1505	O
copolymer	-	1510	O
and	-	1520	O
free	-	1524	O
DOX	-	1529	O
showed	-	1533	O
a	-	1540	O
reduction	-	1542	O
of	-	1552	O
approximately	-	1555	O
30	-	1569	O
%	-	1571	O
in	-	1573	O
function	-	1576	O
beginning	-	1585	O
at	-	1595	O
the	-	1598	O
4th	-	1602	O
week	-	1606	O
after	-	1611	O
drug	-	1617	O
administration	-	1622	O
.	-	1636	O

The	1760851	1638	O
heart	-	1642	O
rate	-	1648	O
in	-	1653	O
these	-	1656	O
animals	-	1662	O
was	-	1670	O
approximately	-	1674	O
12	-	1688	O
%	-	1690	O
lower	-	1692	O
than	-	1698	O
that	-	1703	O
measured	-	1708	O
in	-	1717	O
age	-	1720	O
-	-	1723	O
matched	-	1724	O
control	-	1732	O
rats	-	1740	O
(	-	1745	O
P	-	1746	O
less	-	1748	O
than	-	1753	O
0	-	1758	O
.	-	1759	O
05	-	1760	O
)	-	1762	O
.	-	1763	O

Animals	1760851	1765	O
that	-	1773	O
were	-	1778	O
given	-	1783	O
the	-	1789	O
HPMA	-	1793	O
copolymer	-	1798	O
conjugates	-	1808	O
containing	-	1819	O
DOX	-	1830	O
exhibited	-	1834	O
no	-	1844	O
significant	-	1847	O
change	-	1859	O
in	-	1866	O
cardiac	-	1869	O
output	-	1877	O
throughout	-	1884	O
the	-	1895	O
study	-	1899	O
(	-	1905	O
P	-	1906	O
less	-	1908	O
than	-	1913	O
0	-	1918	O
.	-	1919	O
05	-	1920	O
)	-	1922	O
.	-	1923	O

In	1760851	1925	O
addition	-	1928	O
,	-	1936	O
no	-	1938	O
significant	-	1941	O
histological	-	1953	O
change	-	1966	O
was	-	1973	O
observed	-	1977	O
in	-	1986	O
the	-	1989	O
heart	-	1993	O
of	-	1999	O
animals	-	2002	O
that	-	2010	O
received	-	2015	O
DOX	-	2024	O
in	-	2028	O
the	-	2031	O
form	-	2035	O
of	-	2040	O
HPMA	-	2043	O
copolymer	-	2048	O
conjugates	-	2058	O
and	-	2069	O
were	-	2073	O
killed	-	2078	O
at	-	2085	O
the	-	2088	O
end	-	2092	O
of	-	2096	O
the	-	2099	O
study	-	2103	O
.	-	2108	O

However	1760851	2110	O
,	-	2117	O
these	-	2119	O
animals	-	2125	O
had	-	2133	O
shown	-	2137	O
a	-	2143	O
significant	-	2145	O
increase	-	2157	O
in	-	2166	O
heart	-	2169	O
rate	-	2175	O
beginning	-	2180	O
at	-	2190	O
8	-	2193	O
weeks	-	2195	O
after	-	2201	O
drug	-	2207	O
administration	-	2212	O
(	-	2227	O
P	-	2228	O
less	-	2230	O
than	-	2235	O
0	-	2240	O
.	-	2241	O
01	-	2242	O
)	-	2244	O
.	-	2245	O
(	-	2246	O
ABSTRACT	-	2247	O

TRUNCATED	1760851	2256	O
AT	-	2266	O
400	-	2269	O
WORDS	-	2273	O
)	-	2278	O

Topical	1779253	0	O
0	-	8	O
.	-	9	O
025	-	10	O
%	-	13	O
capsaicin	-	15	O
in	-	25	O
chronic	-	28	O
post	-	36	B
-	-	40	I
herpetic	-	41	I
neuralgia	-	50	I
:	-	59	O
efficacy	-	61	O
,	-	69	O
predictors	-	71	O
of	-	82	O
response	-	85	O
and	-	94	O
long	-	98	O
-	-	102	O
term	-	103	O
course	-	108	O
.	-	114	O

In	1779253	116	O
order	-	119	O
to	-	125	O
evaluate	-	128	O
the	-	137	O
efficacy	-	141	O
,	-	149	O
time	-	151	O
-	-	155	O
course	-	156	O
of	-	163	O
action	-	166	O
and	-	173	O
predictors	-	177	O
of	-	188	O
response	-	191	O
to	-	200	O
topical	-	203	O
capsaicin	-	211	O
,	-	220	O
39	-	222	O
patients	-	225	O
with	-	234	O
chronic	-	239	O
post	-	247	B
-	-	251	I
herpetic	-	252	I
neuralgia	-	261	I
(	-	271	O
PHN	-	272	B
)	-	275	O
,	-	276	O
median	-	278	O
duration	-	285	O
24	-	294	O
months	-	297	O
,	-	303	O
were	-	305	O
treated	-	310	O
with	-	318	O
0	-	323	O
.	-	324	O
025	-	325	O
%	-	328	O
capsaicin	-	330	O
cream	-	340	O
for	-	346	O
8	-	350	O
weeks	-	352	O
.	-	357	O

During	1779253	359	O
therapy	-	366	O
the	-	374	O
patients	-	378	O
rated	-	387	O
their	-	393	O
pain	-	399	B
on	-	404	O
a	-	407	O
visual	-	409	O
analogue	-	416	O
scale	-	425	O
(	-	431	O
VAS	-	432	O
)	-	435	O
and	-	437	O
a	-	441	O
verbal	-	443	O
outcome	-	450	O
scale	-	458	O
.	-	463	O

A	1779253	465	O
follow	-	467	O
-	-	473	O
up	-	474	O
investigation	-	477	O
was	-	491	O
performed	-	495	O
10	-	505	O
-	-	507	O
12	-	508	O
months	-	511	O
after	-	518	O
study	-	524	O
onset	-	530	O
on	-	536	O
the	-	539	O
patients	-	543	O
who	-	552	O
had	-	556	O
improved	-	560	O
.	-	568	O

Nineteen	1779253	570	O
patients	-	579	O
(	-	588	O
48	-	589	O
.	-	591	O
7	-	592	O
%	-	593	O
)	-	594	O
substantially	-	596	O
improved	-	610	O
after	-	619	O
the	-	625	O
8	-	629	O
-	-	630	O
week	-	631	O
trial	-	636	O
;	-	641	O
5	-	643	O
(	-	645	O
12	-	646	O
.	-	648	O
8	-	649	O
%	-	650	O
)	-	651	O
discontinued	-	653	O
therapy	-	666	O
due	-	674	O
to	-	678	O
side	-	681	O
-	-	685	O
effects	-	686	O
such	-	694	O
as	-	699	O
intolerable	-	702	O
capsaicin	-	714	O
-	-	723	O
induced	-	724	O
burning	-	732	O
sensations	-	740	O
(	-	751	O
4	-	752	O
)	-	753	O
or	-	755	O
mastitis	-	758	B
(	-	767	O
1	-	768	O
)	-	769	O
;	-	770	O
15	-	772	O
(	-	775	O
38	-	776	O
.	-	778	O
5	-	779	O
%	-	780	O
)	-	781	O
reported	-	783	O
no	-	792	O
benefit	-	795	O
.	-	802	O

The	1779253	804	O
decrease	-	808	O
in	-	817	O
VAS	-	820	O
ratings	-	824	O
was	-	832	O
significant	-	836	O
after	-	848	O
2	-	854	O
weeks	-	856	O
of	-	862	O
continuous	-	865	O
application	-	876	O
.	-	887	O

Of	1779253	889	O
the	-	892	O
responders	-	896	O
72	-	907	O
.	-	909	O
2	-	910	O
%	-	911	O
were	-	913	O
still	-	918	O
improved	-	924	O
at	-	933	O
the	-	936	O
follow	-	940	O
-	-	946	O
up	-	947	O
;	-	949	O
only	-	951	O
one	-	956	O
-	-	959	O
third	-	960	O
of	-	966	O
them	-	969	O
had	-	974	O
continued	-	978	O
application	-	988	O
irregularly	-	1000	O
.	-	1011	O

Treatment	1779253	1013	O
effect	-	1023	O
was	-	1030	O
not	-	1034	O
dependent	-	1038	O
on	-	1048	O
patient	-	1051	O
's	-	1058	O
age	-	1061	O
,	-	1064	O
duration	-	1066	O
or	-	1075	O
localization	-	1078	O
of	-	1091	O
PHN	-	1094	B
(	-	1098	O
trigeminal	-	1099	O
involvement	-	1110	O
was	-	1122	O
excluded	-	1126	O
)	-	1134	O
,	-	1135	O
sensory	-	1137	B
disturbance	-	1145	I
or	-	1157	O
pain	-	1160	B
character	-	1165	O
.	-	1174	O

Treatment	1779253	1176	O
response	-	1186	O
was	-	1195	O
not	-	1199	O
correlated	-	1203	O
with	-	1214	O
the	-	1219	O
incidence	-	1223	O
,	-	1232	O
time	-	1234	O
-	-	1238	O
course	-	1239	O
or	-	1246	O
severity	-	1249	O
of	-	1258	O
capsaicin	-	1261	O
-	-	1270	O
induced	-	1271	O
burning	-	1279	O
.	-	1286	O

If	1779253	1288	O
confirmed	-	1291	O
in	-	1301	O
controlled	-	1304	O
trials	-	1315	O
,	-	1321	O
the	-	1323	O
long	-	1327	O
-	-	1331	O
term	-	1332	O
results	-	1337	O
of	-	1345	O
this	-	1348	O
open	-	1353	O
,	-	1357	O
non	-	1359	O
-	-	1362	O
randomized	-	1363	O
study	-	1374	O
might	-	1380	O
indicate	-	1386	O
that	-	1395	O
the	-	1400	O
analgesic	-	1404	O
effect	-	1414	O
of	-	1421	O
capsaicin	-	1424	O
in	-	1434	O
PHN	-	1437	B
is	-	1441	O
mediated	-	1444	O
by	-	1453	O
both	-	1456	O
interference	-	1461	O
with	-	1474	O
neuropeptide	-	1479	O
metabolism	-	1492	O
and	-	1503	O
morphological	-	1507	O
changes	-	1521	O
(	-	1529	O
perhaps	-	1530	O
degeneration	-	1538	O
)	-	1550	O
of	-	1552	O
nociceptive	-	1555	O
afferents	-	1567	O
.	-	1576	O

Serotonin	1837756	0	O
reuptake	-	10	O
inhibitors	-	19	O
,	-	29	O
paranoia	-	31	B
,	-	39	O
and	-	41	O
the	-	45	O
ventral	-	49	O
basal	-	57	O
ganglia	-	63	O
.	-	70	O

Antidepressants	1837756	72	O
have	-	88	O
previously	-	93	O
been	-	104	O
associated	-	109	O
with	-	120	O
paranoid	-	125	B
reactions	-	134	O
in	-	144	O
psychiatric	-	147	O
patients	-	159	O
.	-	167	O

Five	1837756	169	O
cases	-	174	O
of	-	180	O
paranoid	-	183	B
exacerbation	-	192	O
with	-	205	O
the	-	210	O
serotonin	-	214	O
reuptake	-	224	O
inhibitors	-	233	O
fluoxetine	-	244	O
and	-	255	O
amitriptyline	-	259	O
are	-	273	O
reported	-	277	O
here	-	286	O
.	-	290	O

Elements	1837756	292	O
common	-	301	O
to	-	308	O
these	-	311	O
cases	-	317	O
included	-	323	O
a	-	332	O
history	-	334	O
of	-	342	O
paranoid	-	345	B
symptomatology	-	354	O
and	-	369	O
the	-	373	O
concomitant	-	377	O
occurrence	-	389	O
of	-	400	O
depressive	-	403	B
and	-	414	I
psychotic	-	418	I
symptoms	-	428	I
.	-	436	O

Complicated	1837756	438	O
depressive	-	450	B
disorders	-	461	I
(	-	471	O
including	-	472	O
atypicality	-	482	O
of	-	494	O
course	-	497	O
and	-	504	O
symptomatology	-	508	O
,	-	522	O
chronicity	-	524	O
,	-	534	O
psychosis	-	536	B
,	-	545	O
bipolarity	-	547	O
,	-	557	O
and	-	559	O
secondary	-	563	O
onset	-	573	O
in	-	579	O
the	-	582	O
course	-	586	O
of	-	593	O
a	-	596	O
primary	-	598	O
psychosis	-	606	B
)	-	615	O
may	-	617	O
present	-	621	O
particular	-	629	O
vulnerability	-	640	O
to	-	654	O
paranoid	-	657	B
exacerbations	-	666	O
associated	-	680	O
with	-	691	O
serotonin	-	696	O
reuptake	-	706	O
inhibitors	-	715	O
.	-	725	O

Although	1837756	727	O
the	-	736	O
pharmacology	-	740	O
and	-	753	O
neurobiology	-	757	O
of	-	770	O
paranoia	-	773	B
remain	-	782	O
cryptic	-	789	O
,	-	796	O
several	-	798	O
mechanisms	-	806	O
,	-	816	O
including	-	818	O
5HT3	-	828	O
receptor	-	833	O
-	-	841	O
mediated	-	842	O
dopamine	-	851	O
release	-	860	O
,	-	867	O
beta	-	869	O
-	-	873	O
noradrenergic	-	874	O
receptor	-	888	O
downregulation	-	897	O
,	-	911	O
or	-	913	O
GABAB	-	916	O
receptor	-	922	O
upregulation	-	931	O
acting	-	944	O
in	-	951	O
the	-	954	O
vicinity	-	958	O
of	-	967	O
the	-	970	O
ventral	-	974	O
basal	-	982	O
ganglia	-	988	O
(	-	996	O
possibly	-	997	O
in	-	1006	O
lateral	-	1009	O
orbitofrontal	-	1017	O
or	-	1031	O
anterior	-	1034	O
cingulate	-	1043	O
circuits	-	1053	O
)	-	1061	O
,	-	1062	O
might	-	1064	O
apply	-	1070	O
to	-	1076	O
this	-	1079	O
phenomenon	-	1084	O
.	-	1094	O

These	1837756	1096	O
cases	-	1102	O
call	-	1108	O
attention	-	1113	O
to	-	1123	O
possible	-	1126	O
paranoid	-	1135	B
exacerbations	-	1144	O
with	-	1158	O
serotonin	-	1163	O
reuptake	-	1173	O
blockers	-	1182	O
in	-	1191	O
select	-	1194	O
patients	-	1201	O
and	-	1210	O
raise	-	1214	O
neurobiological	-	1220	O
considerations	-	1236	O
regarding	-	1251	O
paranoia	-	1261	B
.	-	1269	O

Five	1858969	0	O
cases	-	5	O
of	-	11	O
encephalitis	-	14	B
during	-	27	O
treatment	-	34	O
of	-	44	O
loiasis	-	47	B
with	-	55	O
diethylcarbamazine	-	60	O
.	-	78	O

Five	1858969	80	O
cases	-	85	O
of	-	91	O
encephalitis	-	94	B
following	-	107	O
treatment	-	117	O
with	-	127	O
diethylcarbamazine	-	132	O

(	1858969	151	O
DEC	-	152	O
)	-	155	O
were	-	157	O
observed	-	162	O
in	-	171	O
Congolese	-	174	O
patients	-	184	O
with	-	193	O
Loa	-	198	O
loa	-	202	O
filariasis	-	206	B
.	-	216	O

Two	1858969	218	O
cases	-	222	O
had	-	228	O
a	-	232	O
fatal	-	234	O
outcome	-	240	O
and	-	248	O
one	-	252	O
resulted	-	256	O
in	-	265	O
severe	-	268	O
sequelae	-	275	O
.	-	283	O

The	1858969	285	O
notable	-	289	O
fact	-	297	O
was	-	302	O
that	-	306	O
this	-	311	O
complication	-	316	O
occurred	-	329	O
in	-	338	O
three	-	341	O
patients	-	347	O
hospitalized	-	356	O
before	-	369	O
treatment	-	376	O
began	-	386	O
,	-	391	O
with	-	393	O
whom	-	398	O
particularly	-	403	O
strict	-	416	O
therapeutic	-	423	O
precautions	-	435	O
were	-	447	O
taken	-	452	O
,	-	457	O
i	-	459	O
.	-	460	O
e	-	461	O
.	-	462	O
,	-	463	O
initial	-	465	O
dose	-	473	O
less	-	478	O
than	-	483	O
10	-	488	O
mg	-	491	O
of	-	494	O
DEC	-	497	O
,	-	500	O
very	-	502	O
gradual	-	507	O
dose	-	515	O
increases	-	520	O
,	-	529	O
and	-	531	O
associated	-	535	O
anti	-	546	O
-	-	550	O
allergic	-	551	O
treatment	-	560	O
.	-	569	O

This	1858969	571	O
type	-	576	O
of	-	581	O
drug	-	584	O
-	-	588	O
induced	-	589	O
complication	-	597	O
may	-	610	O
not	-	614	O
be	-	618	O
that	-	621	O
uncommon	-	626	O
in	-	635	O
highly	-	638	O
endemic	-	645	O
regions	-	653	O
.	-	660	O

It	1858969	662	O
occurs	-	665	O
primarily	-	672	O
,	-	681	O
but	-	683	O
not	-	687	O
exclusively	-	691	O
,	-	702	O
in	-	704	O
subjects	-	707	O
presenting	-	716	O
with	-	727	O
a	-	732	O
high	-	734	O
microfilarial	-	739	O
load	-	753	O
.	-	757	O

The	1858969	759	O
relationship	-	763	O
between	-	776	O
the	-	784	O
occurrence	-	788	O
of	-	799	O
encephalitis	-	802	B
and	-	815	O
the	-	819	O
decrease	-	823	O
in	-	832	O
microfilaremia	-	835	B
is	-	850	O
evident	-	853	O
.	-	860	O

The	1858969	862	O
pathophysiological	-	866	O
mechanisms	-	885	O
are	-	896	O
discussed	-	900	O
in	-	910	O
the	-	913	O
light	-	917	O
of	-	923	O
these	-	926	O
observations	-	932	O
and	-	945	O
the	-	949	O
few	-	953	O
other	-	957	O
comments	-	963	O
on	-	972	O
this	-	975	O
subject	-	980	O
published	-	988	O
in	-	998	O
the	-	1001	O
literature	-	1005	O
.	-	1015	O

Delirium	1905439	0	B
in	-	9	O
an	-	12	O
elderly	-	15	O
woman	-	23	O
possibly	-	29	O
associated	-	38	O
with	-	49	O
administration	-	54	O
of	-	69	O
misoprostol	-	72	O
.	-	83	O

Misoprostol	1905439	85	O
has	-	97	O
been	-	101	O
associated	-	106	O
with	-	117	O
adverse	-	122	O
reactions	-	130	O
,	-	139	O
including	-	141	O
gastrointestinal	-	151	O
symptoms	-	168	O
,	-	176	O
gynecologic	-	178	O
problems	-	190	O
,	-	198	O
and	-	200	O
headache	-	204	B
.	-	212	O

Changes	1905439	214	O
in	-	222	O
mental	-	225	O
status	-	232	O
,	-	238	O
however	-	240	O
,	-	247	O
have	-	249	O
not	-	254	O
been	-	258	O
reported	-	263	O
.	-	271	O

We	1905439	273	O
present	-	276	O
a	-	284	O
case	-	286	O
in	-	291	O
which	-	294	O
an	-	300	O
89	-	303	O
-	-	305	O
year	-	306	O
-	-	310	O
old	-	311	O
woman	-	315	O
in	-	321	O
a	-	324	O
long	-	326	O
-	-	330	O
term	-	331	O
care	-	336	O
facility	-	341	O
became	-	350	O
confused	-	357	O
after	-	366	O
the	-	372	O
initiation	-	376	O
of	-	387	O
misoprostol	-	390	O
therapy	-	402	O
.	-	409	O

The	1905439	411	O
patient	-	415	O
's	-	422	O
change	-	425	O
in	-	432	O
mental	-	435	O
status	-	442	O
was	-	449	O
first	-	453	O
reported	-	459	O
nine	-	468	O
days	-	473	O
after	-	478	O
the	-	484	O
initiation	-	488	O
of	-	499	O
therapy	-	502	O
.	-	509	O

Her	1905439	511	O
delirium	-	515	B
significantly	-	524	O
improved	-	538	O
after	-	547	O
misoprostol	-	553	O
was	-	565	O
discontinued	-	569	O
and	-	582	O
her	-	586	O
mental	-	590	O
status	-	597	O
returned	-	604	O
to	-	613	O
normal	-	616	O
within	-	623	O
a	-	630	O
week	-	632	O
.	-	636	O

Because	1905439	638	O
no	-	646	O
other	-	649	O
factors	-	655	O
related	-	663	O
to	-	671	O
this	-	674	O
patient	-	679	O
changed	-	687	O
significantly	-	695	O
,	-	708	O
the	-	710	O
delirium	-	714	B
experienced	-	723	O
by	-	735	O
this	-	738	O
patient	-	743	O
possibly	-	751	O
resulted	-	760	O
from	-	769	O
misoprostol	-	774	O
therapy	-	786	O
.	-	793	O

Hepatocellular	1943082	0	O
oxidant	-	15	O
stress	-	23	O
following	-	30	O
intestinal	-	40	O
ischemia	-	51	B
-	-	59	O
reperfusion	-	60	B
injury	-	72	I
.	-	78	O

Reperfusion	1943082	80	O
of	-	92	O
ischemic	-	95	B
intestine	-	104	O
results	-	114	O
in	-	122	O
acute	-	125	O
liver	-	131	B
dysfunction	-	137	I
characterized	-	149	O
by	-	163	O
hepatocellular	-	166	O
enzyme	-	181	O
release	-	188	O
into	-	196	O
plasma	-	201	O
,	-	207	O
reduction	-	209	O
in	-	219	O
bile	-	222	O
flow	-	227	O
rate	-	232	O
,	-	236	O
and	-	238	O
neutrophil	-	242	O
sequestration	-	253	O
within	-	267	O
the	-	274	O
liver	-	278	O
.	-	283	O

The	1943082	285	O
pathophysiology	-	289	O
underlying	-	305	O
this	-	316	O
acute	-	321	O
hepatic	-	327	B
injury	-	335	I
is	-	342	O
unknown	-	345	O
.	-	352	O

This	1943082	354	O
study	-	359	O
was	-	365	O
undertaken	-	369	O
to	-	380	O
determine	-	383	O
whether	-	393	O
oxidants	-	401	O
are	-	410	O
associated	-	414	O
with	-	425	O
the	-	430	O
hepatic	-	434	B
injury	-	442	I
and	-	449	O
to	-	453	O
determine	-	456	O
the	-	466	O
relative	-	470	O
value	-	479	O
of	-	485	O
several	-	488	O
indirect	-	496	O
methods	-	505	O
of	-	513	O
assessing	-	516	O
oxidant	-	526	O
exposure	-	534	O
in	-	543	O
vivo	-	546	O
.	-	550	O

Rats	1943082	552	O
were	-	557	O
subjected	-	562	O
to	-	572	O
a	-	575	O
standardized	-	577	O
intestinal	-	590	O
ischemia	-	601	B
-	-	609	O
reperfusion	-	610	B
injury	-	622	I
.	-	628	O

Hepatic	1943082	630	O
tissue	-	638	O
was	-	645	O
assayed	-	649	O
for	-	657	O
lipid	-	661	O
peroxidation	-	667	O
products	-	680	O
and	-	689	O
oxidized	-	693	O
and	-	702	O
reduced	-	706	O
glutathione	-	714	O
.	-	725	O

There	1943082	727	O
was	-	733	O
no	-	737	O
change	-	740	O
in	-	747	O
hepatic	-	750	O
tissue	-	758	O
total	-	765	O
glutathione	-	771	O
following	-	783	O
intestinal	-	793	O
ischemia	-	804	B
-	-	812	O
reperfusion	-	813	B
injury	-	825	I
.	-	831	O

Oxidized	1943082	833	O
glutathione	-	842	O
(	-	854	O
GSSG	-	855	O
)	-	859	O
increased	-	861	O
significantly	-	871	O
following	-	885	O
30	-	895	O
and	-	898	O
60	-	902	O
min	-	905	O
of	-	909	O
reperfusion	-	912	O
.	-	923	O

There	1943082	925	O
was	-	931	O
no	-	935	O
increase	-	938	O
in	-	947	O
any	-	950	O
of	-	954	O
the	-	957	O
products	-	961	O
of	-	970	O
lipid	-	973	O
peroxidation	-	979	O
associated	-	992	O
with	-	1003	O
this	-	1008	O
injury	-	1013	O
.	-	1019	O

An	1943082	1021	O
increase	-	1024	O
in	-	1033	O
GSSG	-	1036	O
within	-	1041	O
hepatic	-	1048	O
tissue	-	1056	O
during	-	1063	O
intestinal	-	1070	O
reperfusion	-	1081	O
suggests	-	1093	O
exposure	-	1102	O
of	-	1111	O
hepatocytes	-	1114	O
to	-	1126	O
an	-	1129	O
oxidant	-	1132	O
stress	-	1140	O
.	-	1146	O

The	1943082	1148	O
lack	-	1152	O
of	-	1157	O
a	-	1160	O
significant	-	1162	O
increase	-	1174	O
in	-	1183	O
products	-	1186	O
of	-	1195	O
lipid	-	1198	O
peroxidation	-	1204	O
suggests	-	1217	O
that	-	1226	O
the	-	1231	O
oxidant	-	1235	O
stress	-	1243	O
is	-	1250	O
of	-	1253	O
insufficient	-	1256	O
magnitude	-	1269	O
to	-	1279	O
result	-	1282	O
in	-	1289	O
irreversible	-	1292	O
injury	-	1305	O
to	-	1312	O
hepatocyte	-	1315	O
cell	-	1326	O
membranes	-	1331	O
.	-	1340	O

These	1943082	1342	O
data	-	1348	O
also	-	1353	O
suggest	-	1358	O
that	-	1366	O
the	-	1371	O
measurement	-	1375	O
of	-	1387	O
tissue	-	1390	O
GSSG	-	1397	O
may	-	1402	O
be	-	1406	O
a	-	1409	O
more	-	1411	O
sensitive	-	1416	O
indicator	-	1426	O
of	-	1436	O
oxidant	-	1439	O
stress	-	1447	O
than	-	1454	O
measurement	-	1459	O
of	-	1471	O
products	-	1474	O
of	-	1483	O
lipid	-	1486	O
peroxidation	-	1492	O
.	-	1504	O

Diphenhydramine	2021990	0	O
prevents	-	16	O
the	-	25	O
haemodynamic	-	29	O
changes	-	42	O
of	-	50	O
cimetidine	-	53	O
in	-	64	O
ICU	-	67	O
patients	-	71	O
.	-	79	O

Cimetidine	2021990	81	O
,	-	91	O
a	-	93	O
histamine	-	95	O
2	-	105	O
(	-	107	O
H2	-	108	O
)	-	110	O
antagonist	-	112	O
,	-	122	O
produces	-	124	O
a	-	133	O
decrease	-	135	O
in	-	144	O
arterial	-	147	O
pressure	-	156	O
due	-	165	O
to	-	169	O
vasodilatation	-	172	O
,	-	186	O
especially	-	188	O
in	-	199	O
critically	-	202	O
ill	-	213	O
patients	-	217	O
.	-	225	O

This	2021990	227	O
may	-	232	O
be	-	236	O
because	-	239	O
cimetidine	-	247	O
acts	-	258	O
as	-	263	O
a	-	266	O
histamine	-	268	O
agonist	-	278	O
.	-	285	O

We	2021990	287	O
,	-	289	O
therefore	-	291	O
,	-	300	O
investigated	-	302	O
the	-	315	O
effects	-	319	O
of	-	327	O
the	-	330	O
histamine	-	334	O
1	-	344	O
(	-	345	O
H1	-	346	O
)	-	348	O
receptor	-	350	O
antagonist	-	359	O
,	-	369	O
diphenhydramine	-	371	O
,	-	386	O
on	-	388	O
the	-	391	O
haemodynamic	-	395	O
changes	-	408	O
observed	-	416	O
after	-	425	O
cimetidine	-	431	O
in	-	442	O
ICU	-	445	O
patients	-	449	O
.	-	457	O

Each	2021990	459	O
patient	-	464	O
was	-	472	O
studied	-	476	O
on	-	484	O
two	-	487	O
separate	-	491	O
days	-	500	O
.	-	504	O

In	2021990	506	O
a	-	509	O
random	-	511	O
fashion	-	518	O
,	-	525	O
they	-	527	O
received	-	532	O
cimetidine	-	541	O
200	-	552	O
mg	-	556	O
iv	-	559	O
on	-	562	O
one	-	565	O
day	-	569	O
,	-	572	O
and	-	574	O
on	-	578	O
the	-	581	O
other	-	585	O
,	-	590	O
a	-	592	O
pretreatment	-	594	O
of	-	607	O
diphenhydramine	-	610	O
40	-	626	O
mg	-	629	O
iv	-	632	O
with	-	635	O
cimetidine	-	640	O
200	-	651	O
mg	-	655	O
iv	-	658	O
.	-	660	O

In	2021990	662	O
the	-	665	O
non	-	669	O
-	-	672	O
pretreatment	-	673	O
group	-	686	O
,	-	691	O
mean	-	693	O
arterial	-	698	O
pressure	-	707	O
(	-	716	O
MAP	-	717	O
)	-	720	O
decreased	-	722	O
from	-	732	O
107	-	737	O
.	-	740	O
4	-	741	O
+	-	743	O
/	-	744	O
-	-	745	O

8	2021990	747	O
.	-	748	O
4	-	749	O
mmHg	-	751	O
to	-	756	O
86	-	759	O
.	-	761	O
7	-	762	O
+	-	764	O
/	-	765	O
-	-	766	O

11	2021990	768	O
.	-	770	O
4	-	771	O
mmHg	-	773	O
(	-	778	O
P	-	779	O
less	-	781	O
than	-	786	O
0	-	791	O
.	-	792	O
01	-	793	O
)	-	795	O
two	-	797	O
minutes	-	801	O
after	-	809	O
cimetidine	-	815	O
.	-	825	O

Also	2021990	827	O
,	-	831	O
systemic	-	833	O
vascular	-	842	O
resistance	-	851	O
(	-	862	O
SVR	-	863	O
)	-	866	O
decreased	-	868	O
during	-	878	O
the	-	885	O
eight	-	889	O
-	-	894	O
minute	-	895	O
observation	-	902	O
period	-	914	O
(	-	921	O
P	-	922	O
less	-	924	O
than	-	929	O
0	-	934	O
.	-	935	O
01	-	936	O
)	-	938	O
.	-	939	O

In	2021990	941	O
contrast	-	944	O
,	-	952	O
in	-	954	O
the	-	957	O
pretreatment	-	961	O
group	-	974	O
,	-	979	O
little	-	981	O
haemodynamic	-	988	O
change	-	1001	O
was	-	1008	O
seen	-	1012	O
.	-	1016	O

We	2021990	1018	O
conclude	-	1021	O
that	-	1030	O
an	-	1035	O
H1	-	1038	O
antagonist	-	1041	O
may	-	1052	O
be	-	1056	O
useful	-	1059	O
in	-	1066	O
preventing	-	1069	O
hypotension	-	1080	B
caused	-	1092	O
by	-	1099	O
iv	-	1102	O
cimetidine	-	1105	O
,	-	1115	O
since	-	1117	O
the	-	1123	O
vasodilating	-	1127	O
activity	-	1140	O
of	-	1149	O
cimetidine	-	1152	O
is	-	1163	O
mediated	-	1166	O
,	-	1174	O
in	-	1176	O
part	-	1179	O
,	-	1183	O
through	-	1185	O
the	-	1193	O
H1	-	1197	O
receptor	-	1200	O
.	-	1208	O

Acute	2083961	0	B
renal	-	6	I
failure	-	12	I
due	-	20	O
to	-	24	O
rifampicin	-	27	O
.	-	37	O

A	2083961	39	O
23	-	41	O
-	-	43	O
year	-	44	O
-	-	48	O
old	-	49	O
male	-	53	O
patient	-	58	O
with	-	66	O
bacteriologically	-	71	O
proven	-	89	O
pulmonary	-	96	B
tuberculosis	-	106	I
was	-	119	O
treated	-	123	O
with	-	131	O
the	-	136	O
various	-	140	O
regimens	-	148	O
of	-	157	O
antituberculosis	-	160	O
drugs	-	177	O
for	-	183	O
nearly	-	187	O
15	-	194	O
months	-	197	O
.	-	203	O

Rifampicin	2083961	205	O
was	-	216	O
administered	-	220	O
thrice	-	233	O
as	-	240	O
one	-	243	O
of	-	247	O
the	-	250	O
3	-	254	O
-	-	255	O
4	-	256	O
drug	-	258	O
regimen	-	263	O
and	-	271	O
each	-	275	O
time	-	280	O
he	-	285	O
developed	-	288	O
untoward	-	298	O
side	-	307	O
effects	-	312	O
like	-	320	O
nausea	-	325	B
,	-	331	O
vomiting	-	333	B
and	-	342	O
fever	-	346	B
with	-	352	O
chills	-	357	O
and	-	364	O
rigors	-	368	O
.	-	374	O

The	2083961	376	O
last	-	380	O
such	-	385	O
episode	-	390	O
was	-	398	O
of	-	402	O
acute	-	405	O
renal	-	411	O
failure	-	417	O
at	-	425	O
which	-	428	O
stage	-	434	O
the	-	440	O
patient	-	444	O
was	-	452	O
seen	-	456	O
by	-	461	O
the	-	464	O
authors	-	468	O
of	-	476	O
this	-	479	O
report	-	484	O
.	-	490	O

The	2083961	492	O
patient	-	496	O
,	-	503	O
however	-	505	O
,	-	512	O
made	-	514	O
a	-	519	O
full	-	521	O
recovery	-	526	O
.	-	534	O

Severe	2131034	0	O
polyneuropathy	-	7	B
and	-	22	O
motor	-	26	O
loss	-	32	O
after	-	37	O
intrathecal	-	43	O
thiotepa	-	55	O
combination	-	64	O
chemotherapy	-	76	O
:	-	88	O
description	-	90	O
of	-	102	O
two	-	105	O
cases	-	109	O
.	-	114	O

Two	2131034	116	O
cases	-	120	O
of	-	126	O
severe	-	129	O
delayed	-	136	O
neurologic	-	144	B
toxicity	-	155	I
related	-	164	O
to	-	172	O
the	-	175	O
administration	-	179	O
of	-	194	O
intrathecal	-	197	O
(	-	209	O
IT	-	210	O
)	-	212	O
combination	-	214	O
chemotherapy	-	226	O
including	-	239	O
thiotepa	-	249	O
(	-	258	O
TSPA	-	259	O
)	-	263	O
are	-	265	O
presented	-	269	O
.	-	278	O

Both	2131034	280	O
cases	-	285	O
developed	-	291	O
axonal	-	301	B
neuropathy	-	308	I
with	-	319	O
motor	-	324	O
predominance	-	330	O
in	-	343	O
the	-	346	O
lower	-	350	O
extremities	-	356	O
1	-	368	O
and	-	370	O
6	-	374	O
months	-	376	O
after	-	383	O
IT	-	389	O
chemotherapy	-	392	O
was	-	405	O
administered	-	409	O
.	-	421	O

Neurologic	2131034	423	B
toxicities	-	434	I
have	-	445	O
been	-	450	O
described	-	455	O
with	-	465	O
IT	-	470	O
-	-	472	O
methotrexate	-	473	O
,	-	485	O
IT	-	487	O
-	-	489	O
cytosine	-	490	O
arabinoside	-	499	O
and	-	511	O
IT	-	515	O
-	-	517	O
TSPA	-	518	O
.	-	522	O

To	2131034	524	O
our	-	527	O
knowledge	-	531	O
,	-	540	O
however	-	542	O
,	-	549	O
axonal	-	551	B
neuropathy	-	558	I
following	-	569	O
administration	-	579	O
of	-	594	O
these	-	597	O
three	-	603	O
agents	-	609	O
has	-	616	O
not	-	620	O
been	-	624	O
previously	-	629	O
described	-	640	O
.	-	649	O

In	2131034	651	O
spite	-	654	O
of	-	660	O
the	-	663	O
fact	-	667	O
that	-	672	O
TSPA	-	677	O
is	-	682	O
a	-	685	O
useful	-	687	O
IT	-	694	O
agent	-	697	O
,	-	702	O
its	-	704	O
combination	-	708	O
with	-	720	O
MTX	-	725	O
,	-	728	O
ara	-	730	O
-	-	733	O
C	-	734	O
and	-	736	O
radiotherapy	-	740	O
could	-	753	O
cause	-	759	O
severe	-	765	O
neurotoxicity	-	772	B
.	-	785	O

This	2131034	787	O
unexpected	-	792	O
complication	-	803	O
indicates	-	816	O
the	-	826	O
need	-	830	O
for	-	835	O
further	-	839	O
toxicology	-	847	O
research	-	858	O
on	-	867	O
IT	-	870	O
-	-	872	O
TSPA	-	873	O
.	-	877	O

Effects	2173761	0	O
of	-	8	O
cromakalim	-	11	O
and	-	22	O
pinacidil	-	26	O
on	-	36	O
large	-	39	O
epicardial	-	45	O
and	-	56	O
small	-	60	O
coronary	-	66	O
arteries	-	75	O
in	-	84	O
conscious	-	87	O
dogs	-	97	O
.	-	101	O

The	2173761	103	O
effects	-	107	O
of	-	115	O
i	-	118	O
.	-	119	O
v	-	120	O
.	-	121	O

bolus	2173761	123	O
administration	-	129	O
of	-	144	O
cromakalim	-	147	O
(	-	158	O
1	-	159	O
-	-	160	O
10	-	161	O
micrograms	-	164	O
/	-	174	O
kg	-	175	O
)	-	177	O
and	-	179	O
pinacidil	-	183	O
(	-	193	O
3	-	194	O
-	-	195	O
100	-	196	O
micrograms	-	200	O
/	-	210	O
kg	-	211	O
)	-	213	O
on	-	215	O
large	-	218	O
(	-	224	O
circumflex	-	225	O
artery	-	236	O
)	-	242	O
and	-	244	O
small	-	248	O
coronary	-	254	O
arteries	-	263	O
and	-	272	O
on	-	276	O
systemic	-	279	O
hemodynamics	-	288	O
were	-	301	O
investigated	-	306	O
in	-	319	O
chronically	-	322	O
instrumented	-	334	O
conscious	-	347	O
dogs	-	357	O
and	-	362	O
compared	-	366	O
to	-	375	O
those	-	378	O
of	-	384	O
nitroglycerin	-	387	O
(	-	401	O
0	-	402	O
.	-	403	O
03	-	404	O
-	-	406	O
10	-	407	O
micrograms	-	410	O
/	-	420	O
kg	-	421	O
)	-	423	O
.	-	424	O

Nitroglycerin	2173761	426	O
,	-	439	O
up	-	441	O
to	-	444	O
0	-	447	O
.	-	448	O
3	-	449	O
micrograms	-	451	O
/	-	461	O
kg	-	462	O
,	-	464	O
selectively	-	466	O
increased	-	478	O
circumflex	-	488	O
artery	-	499	O
diameter	-	506	O
(	-	515	O
CxAD	-	516	O
)	-	520	O
without	-	522	O
simultaneously	-	530	O
affecting	-	545	O
any	-	555	O
other	-	559	O
cardiac	-	565	O
or	-	573	O
systemic	-	576	O
hemodynamic	-	585	O
parameter	-	597	O
.	-	606	O

In	2173761	608	O
contrast	-	611	O
,	-	619	O
cromakalim	-	621	O
and	-	632	O
pinacidil	-	636	O
at	-	646	O
all	-	649	O
doses	-	653	O
and	-	659	O
nitroglycerin	-	663	O
at	-	677	O
doses	-	680	O
higher	-	686	O
than	-	693	O
0	-	698	O
.	-	699	O
3	-	700	O
micrograms	-	702	O
/	-	712	O
kg	-	713	O
simultaneously	-	716	O
and	-	731	O
dose	-	735	O
-	-	739	O
dependently	-	740	O
increased	-	752	O
CxAD	-	762	O
,	-	766	O
coronary	-	768	O
blood	-	777	O
flow	-	783	O
and	-	788	O
heart	-	792	O
rate	-	798	O
and	-	803	O
decreased	-	807	O
coronary	-	817	O
vascular	-	826	O
resistance	-	835	O
and	-	846	O
aortic	-	850	O
pressure	-	857	O
.	-	865	O

Cromakalim	2173761	867	O
was	-	878	O
approximately	-	882	O

8	2173761	896	O
-	-	897	O

to	2173761	899	O
9	-	902	O
.	-	903	O
5	-	904	O
-	-	905	O
fold	-	906	O
more	-	911	O
potent	-	916	O
than	-	923	O
pinacidil	-	928	O
in	-	938	O
increasing	-	941	O
CxAD	-	952	O
.	-	956	O

Vasodilation	2173761	958	O
of	-	971	O
large	-	974	O
and	-	980	O
small	-	984	O
coronary	-	990	O
vessels	-	999	O
and	-	1007	O
hypotension	-	1011	B
induced	-	1023	O
by	-	1031	O
cromakalim	-	1034	O
and	-	1045	O
pinacidil	-	1049	O
were	-	1059	O
not	-	1064	O
affected	-	1068	O
by	-	1077	O
prior	-	1080	O
combined	-	1086	O
beta	-	1095	O
adrenergic	-	1100	O
and	-	1111	O
muscarinic	-	1115	O
receptors	-	1126	O
blockade	-	1136	O
but	-	1145	O
drug	-	1149	O
-	-	1153	O
induced	-	1154	O
tachycardia	-	1162	B
was	-	1174	O
abolished	-	1178	O
.	-	1187	O

When	2173761	1189	O
circumflex	-	1194	O
artery	-	1205	O
blood	-	1212	O
flow	-	1218	O
was	-	1223	O
maintained	-	1227	O
constant	-	1238	O
,	-	1246	O
the	-	1248	O
increases	-	1252	O
in	-	1262	O
CxAD	-	1265	O
induced	-	1270	O
by	-	1278	O
cromakalim	-	1281	O
(	-	1292	O
10	-	1293	O
micrograms	-	1296	O
/	-	1306	O
kg	-	1307	O
)	-	1309	O
,	-	1310	O
pinacidil	-	1312	O
(	-	1322	O
30	-	1323	O
micrograms	-	1326	O
/	-	1336	O
kg	-	1337	O
)	-	1339	O
and	-	1341	O
nitroglycerin	-	1345	O
(	-	1359	O
10	-	1360	O
micrograms	-	1363	O
/	-	1373	O
kg	-	1374	O
)	-	1376	O
were	-	1378	O
reduced	-	1383	O
by	-	1391	O
68	-	1394	O
+	-	1397	O
/	-	1398	O
-	-	1399	O

7	2173761	1401	O
,	-	1402	O
54	-	1404	O
+	-	1407	O
/	-	1408	O
-	-	1409	O

9	2173761	1411	O
and	-	1413	O
1	-	1417	O
+	-	1419	O
/	-	1420	O
-	-	1421	O

1	2173761	1423	O
%	-	1424	O
,	-	1425	O
respectively	-	1427	O
.	-	1439	O

Thus	2173761	1441	O
,	-	1445	O
whereas	-	1447	O
nitroglycerin	-	1455	O
preferentially	-	1469	O
and	-	1484	O
flow	-	1488	O
-	-	1492	O
independently	-	1493	O
dilates	-	1507	O
large	-	1515	O
coronary	-	1521	O
arteries	-	1530	O
,	-	1538	O
cromakalim	-	1540	O
and	-	1551	O
pinacidil	-	1555	O
dilate	-	1565	O
both	-	1572	O
large	-	1577	O
and	-	1583	O
small	-	1587	O
coronary	-	1593	O
arteries	-	1602	O
and	-	1611	O
this	-	1615	O
effect	-	1620	O
is	-	1627	O
not	-	1630	O
dependent	-	1634	O
upon	-	1644	O
the	-	1649	O
simultaneous	-	1653	O
beta	-	1666	O
adrenoceptors	-	1671	O
-	-	1684	O
mediated	-	1685	O
rise	-	1694	O
in	-	1699	O
myocardial	-	1702	O
metabolic	-	1713	O
demand	-	1723	O
.	-	1729	O

Finally	2173761	1731	O
,	-	1738	O
two	-	1740	O
mechanisms	-	1744	O
at	-	1755	O
least	-	1758	O
,	-	1763	O
direct	-	1765	O
vasodilation	-	1772	O
and	-	1785	O
flow	-	1789	O
dependency	-	1794	O
,	-	1804	O
are	-	1806	O
involved	-	1810	O
in	-	1819	O
the	-	1822	O
cromakalim	-	1826	O
-	-	1836	O
and	-	1838	O
pinacidil	-	1842	O
-	-	1851	O
induced	-	1852	O
increase	-	1860	O
in	-	1869	O
CxAD	-	1872	O
.	-	1876	O

Mefenamic	2217015	0	O
acid	-	10	O
-	-	14	O
induced	-	15	O
neutropenia	-	23	B
and	-	35	O
renal	-	39	B
failure	-	45	I
in	-	53	O
elderly	-	56	O
females	-	64	O
with	-	72	O
hypothyroidism	-	77	B
.	-	91	O

We	2217015	93	O
report	-	96	O
mefenamic	-	103	O
acid	-	113	O
-	-	117	O
induced	-	118	O
non	-	126	O
-	-	129	O
oliguric	-	130	O
renal	-	139	B
failure	-	145	I
and	-	153	O
severe	-	157	O
neutropenia	-	164	B
occurring	-	176	O
simultaneously	-	186	O
in	-	201	O
two	-	204	O
elderly	-	208	O
females	-	216	O
.	-	223	O

The	2217015	225	O
neutropenia	-	229	B
was	-	241	O
due	-	245	O
to	-	249	O
maturation	-	252	O
arrest	-	263	O
of	-	270	O
the	-	273	O
myeloid	-	277	O
series	-	285	O
in	-	292	O
one	-	295	O
patient	-	299	O
.	-	306	O

Both	2217015	308	O
patients	-	313	O
were	-	322	O
also	-	327	O
hypothyroid	-	332	B
,	-	343	O
but	-	345	O
it	-	349	O
is	-	352	O
not	-	355	O
clear	-	359	O
whether	-	365	O
this	-	373	O
was	-	378	O
a	-	382	O
predisposing	-	384	O
factor	-	397	O
to	-	404	O
the	-	407	O
development	-	411	O
of	-	423	O
these	-	426	O
adverse	-	432	O
reactions	-	440	O
.	-	449	O

However	2217015	451	O
,	-	458	O
it	-	460	O
would	-	463	O
seem	-	469	O
prudent	-	474	O
not	-	482	O
to	-	486	O
use	-	489	O
mefenamic	-	493	O
acid	-	503	O
in	-	508	O
hypothyroid	-	511	B
patients	-	523	O
until	-	532	O
the	-	538	O
hypothyroidism	-	542	B
has	-	557	O
been	-	561	O
corrected	-	566	O
.	-	575	O

Etiology	2239937	0	O
of	-	9	O
hypercalcemia	-	12	B
in	-	26	O
hemodialysis	-	29	O
patients	-	42	O
on	-	51	O
calcium	-	54	O
carbonate	-	62	O
therapy	-	72	O
.	-	79	O

Fourteen	2239937	81	O
of	-	90	O
39	-	93	O
dialysis	-	96	O
patients	-	105	O
(	-	114	O
36	-	115	O
%	-	117	O
)	-	118	O
became	-	120	O
hypercalcemic	-	127	B
after	-	141	O
switching	-	147	O
to	-	157	O
calcium	-	160	O
carbonate	-	168	O
as	-	178	O
their	-	181	O
principal	-	187	O
phosphate	-	197	O
binder	-	207	O
.	-	213	O

In	2239937	215	O
order	-	218	O
to	-	224	O
identify	-	227	O
risk	-	236	O
factors	-	241	O
associated	-	249	O
with	-	260	O
the	-	265	O
development	-	269	O
of	-	281	O
hypercalcemia	-	284	B
,	-	297	O
indirect	-	299	O
parameters	-	308	O
of	-	319	O
intestinal	-	322	O
calcium	-	333	O
reabsorption	-	341	O
and	-	354	O
bone	-	358	O
turnover	-	363	O
rate	-	372	O
in	-	377	O
these	-	380	O
14	-	386	O
patients	-	389	O
were	-	398	O
compared	-	403	O
with	-	412	O
results	-	417	O
in	-	425	O
14	-	428	O
eucalcemic	-	431	O
patients	-	442	O
matched	-	451	O
for	-	459	O
age	-	463	O
,	-	466	O
sex	-	468	O
,	-	471	O
length	-	473	O
of	-	480	O
time	-	483	O
on	-	488	O
dialysis	-	491	O
,	-	499	O
and	-	501	O
etiology	-	505	O
of	-	514	O
renal	-	517	B
disease	-	523	I
.	-	530	O

In	2239937	532	O
addition	-	535	O
to	-	544	O
experiencing	-	547	O
hypercalcemic	-	560	B
episodes	-	574	O
with	-	583	O
peak	-	588	O
calcium	-	593	O
values	-	601	O
of	-	608	O
2	-	611	O
.	-	612	O
7	-	613	O
to	-	615	O
3	-	618	O
.	-	619	O
8	-	620	O
mmol	-	622	O
/	-	626	O
L	-	627	O
(	-	629	O
10	-	630	O
.	-	632	O
7	-	633	O
to	-	635	O
15	-	638	O
.	-	640	O
0	-	641	O
mg	-	643	O
/	-	645	O
dL	-	646	O
)	-	648	O
,	-	649	O
patients	-	651	O
in	-	660	O
the	-	663	O
hypercalcemic	-	667	B
group	-	681	O
exhibited	-	687	O
a	-	697	O
significant	-	699	O
increase	-	711	O
in	-	720	O
the	-	723	O
mean	-	727	O
calcium	-	732	O
concentration	-	740	O
obtained	-	754	O
during	-	763	O
6	-	770	O
months	-	772	O
before	-	779	O
the	-	786	O
switch	-	790	O
,	-	796	O
compared	-	798	O
with	-	807	O
the	-	812	O
mean	-	816	O
value	-	821	O
obtained	-	827	O
during	-	836	O
the	-	843	O
7	-	847	O
months	-	849	O
of	-	856	O
observation	-	859	O
after	-	871	O
the	-	877	O
switch	-	881	O
(	-	888	O
2	-	889	O
.	-	890	O
4	-	891	O
+	-	893	O
/	-	894	O
-	-	895	O

0	2239937	897	O
.	-	898	O
03	-	899	O
to	-	902	O
2	-	905	O
.	-	906	O
5	-	907	O
+	-	909	O
/	-	910	O
-	-	911	O

0	2239937	913	O
.	-	914	O
03	-	915	O
mmol	-	918	O
/	-	922	O
L	-	923	O
[	-	925	O
9	-	926	O
.	-	927	O
7	-	928	O
+	-	930	O
/	-	931	O
-	-	932	O

0	2239937	934	O
.	-	935	O
2	-	936	O
to	-	938	O
10	-	941	O
.	-	943	O
2	-	944	O
+	-	946	O
/	-	947	O
-	-	948	O
0	-	950	O
.	-	951	O
1	-	952	O
mg	-	954	O
/	-	956	O
dL	-	957	O
]	-	959	O
,	-	960	O
P	-	962	O
=	-	964	O
0	-	966	O
.	-	967	O
006	-	968	O
)	-	971	O
.	-	972	O

In	2239937	974	O
contrast	-	977	O
,	-	985	O
eucalcemic	-	987	O
patients	-	998	O
exhibited	-	1007	O
no	-	1017	O
change	-	1020	O
in	-	1027	O
mean	-	1030	O
calcium	-	1035	O
values	-	1043	O
over	-	1050	O
the	-	1055	O
same	-	1059	O
time	-	1064	O
period	-	1069	O
(	-	1076	O
2	-	1077	O
.	-	1078	O
3	-	1079	O
+	-	1081	O
/	-	1082	O
-	-	1083	O
0	-	1085	O
.	-	1086	O
05	-	1087	O
to	-	1090	O
2	-	1093	O
.	-	1094	O
3	-	1095	O
+	-	1097	O
/	-	1098	O
-	-	1099	O

0	2239937	1101	O
.	-	1102	O
05	-	1103	O
mmol	-	1106	O
/	-	1110	O
L	-	1111	O
[	-	1113	O
9	-	1114	O
.	-	1115	O
2	-	1116	O
+	-	1118	O
/	-	1119	O
-	-	1120	O

0	2239937	1122	O
.	-	1123	O
2	-	1124	O
to	-	1126	O
9	-	1129	O
.	-	1130	O
2	-	1131	O
+	-	1133	O
/	-	1134	O
-	-	1135	O

0	2239937	1137	O
.	-	1138	O
2	-	1139	O
mg	-	1141	O
/	-	1143	O
dL	-	1144	O
]	-	1146	O
)	-	1147	O
.	-	1148	O

CaCO3	2239937	1150	O
dosage	-	1156	O
,	-	1162	O
calculated	-	1164	O
dietary	-	1175	O
calcium	-	1183	O
intake	-	1191	O
,	-	1197	O
and	-	1199	O
circulating	-	1203	O
levels	-	1215	O
of	-	1222	O
vitamin	-	1225	O
D	-	1233	O
metabolites	-	1235	O
were	-	1247	O
similar	-	1252	O
in	-	1260	O
both	-	1263	O
groups	-	1268	O
.	-	1274	O

Physical	2239937	1276	O
activity	-	1285	O
index	-	1294	O
and	-	1300	O
predialysis	-	1304	O
serum	-	1316	O
bicarbonate	-	1322	O
levels	-	1334	O
also	-	1341	O
were	-	1346	O
similar	-	1351	O
in	-	1359	O
both	-	1362	O
groups	-	1367	O
.	-	1373	O

However	2239937	1375	O
,	-	1382	O
there	-	1384	O
was	-	1390	O
a	-	1394	O
significant	-	1396	O
difference	-	1408	O
in	-	1419	O
parameters	-	1422	O
reflecting	-	1433	O
bone	-	1444	O
turnover	-	1449	O
rates	-	1458	O
between	-	1464	O
groups	-	1472	O
.	-	1478	O
(	-	1479	O
ABSTRACT	-	1480	O
TRUNCATED	-	1489	O
AT	-	1499	O
250	-	1502	O
WORDS	-	1506	O
)	-	1511	O

Methyldopa	2320485	0	O
-	-	10	O
induced	-	11	O
hemolytic	-	19	B
anemia	-	29	I
in	-	36	O
a	-	39	O
15	-	41	O
year	-	44	O
old	-	49	O
presenting	-	53	O
as	-	64	O
near	-	67	O
-	-	71	O
syncope	-	72	B
.	-	79	O

Methyldopa	2320485	81	O
is	-	92	O
an	-	95	O
antihypertensive	-	98	O
medication	-	115	O
which	-	126	O
is	-	132	O
available	-	135	O
generically	-	145	O
and	-	157	O
under	-	161	O
the	-	167	O
trade	-	171	O
name	-	177	O
Aldomet	-	182	O
that	-	190	O
is	-	195	O
widely	-	198	O
prescribed	-	205	O
in	-	216	O
the	-	219	O
adult	-	223	O
population	-	229	O
and	-	240	O
infrequently	-	244	O
used	-	257	O
in	-	262	O
children	-	265	O
.	-	273	O

Methyldopa	2320485	275	O
causes	-	286	O
an	-	293	O
autoimmune	-	296	B
hemolytic	-	307	I
anemia	-	317	I
in	-	324	O
a	-	327	O
small	-	329	O
percentage	-	335	O
of	-	346	O
patients	-	349	O
who	-	358	O
take	-	362	O
the	-	367	O
drug	-	371	O
.	-	375	O

We	2320485	377	O
report	-	380	O
a	-	387	O
case	-	389	O
of	-	394	O
methyldopa	-	397	O
-	-	407	O
induced	-	408	O
hemolytic	-	416	B
anemia	-	426	I
in	-	433	O
a	-	436	O
15	-	438	O
-	-	440	O
year	-	441	O
-	-	445	O
old	-	446	O
boy	-	450	O
who	-	454	O
presented	-	458	O
to	-	468	O
the	-	471	O
emergency	-	475	B
department	-	485	I
with	-	496	O
near	-	501	O
-	-	505	O
syncope	-	506	B
.	-	513	O

The	2320485	515	O
boy	-	519	O
had	-	523	O
been	-	527	O
treated	-	532	O
with	-	540	O
intravenous	-	545	O
methyldopa	-	557	O
during	-	568	O
a	-	575	O
trauma	-	577	B
admission	-	584	O
seven	-	594	O
weeks	-	600	O
prior	-	606	O
to	-	612	O
presentation	-	615	O
.	-	627	O

Evaluation	2320485	629	O
revealed	-	640	O
a	-	649	O
hemoglobin	-	651	O
of	-	662	O
three	-	665	O
grams	-	671	O
,	-	676	O
3	-	678	O
+	-	679	O
Coombs	-	681	O
'	-	687	O
test	-	689	O
with	-	694	O
polyspecific	-	699	O
anti	-	712	O
-	-	716	O
human	-	717	O
globulin	-	723	O
and	-	732	O
monospecific	-	736	O
IgG	-	749	O
reagents	-	753	O
,	-	761	O
and	-	763	O
a	-	767	O
warm	-	769	O
reacting	-	774	O
autoantibody	-	783	O
.	-	795	O

Transfusion	2320485	797	O
and	-	809	O
corticosteroid	-	813	O
therapy	-	828	O
resulted	-	836	O
in	-	845	O
a	-	848	O
complete	-	850	O
recovery	-	859	O
of	-	868	O
the	-	871	O
patient	-	875	O
.	-	882	O

Emergency	2320485	884	O
physicians	-	894	O
treating	-	905	O
children	-	914	O
must	-	923	O
be	-	928	O
aware	-	931	O
of	-	937	O
this	-	940	O
syndrome	-	945	O
in	-	954	O
order	-	957	O
to	-	963	O
diagnose	-	966	O
and	-	975	O
treat	-	979	O
it	-	985	O
correctly	-	988	O
.	-	997	O

A	2320485	999	O
brief	-	1001	O
review	-	1007	O
of	-	1014	O
autoimmune	-	1017	O
and	-	1028	O
drug	-	1032	O
-	-	1036	O
induced	-	1037	O
hemolytic	-	1045	B
anemias	-	1055	I
is	-	1063	O
provided	-	1066	O
.	-	1074	O

The	2358093	0	O
long	-	4	O
-	-	8	O
term	-	9	O
safety	-	14	O
of	-	21	O
danazol	-	24	O
in	-	32	O
women	-	35	O
with	-	41	O
hereditary	-	46	B
angioedema	-	57	I
.	-	67	O

Although	2358093	69	O
the	-	78	O
short	-	82	O
-	-	87	O
term	-	88	O
safety	-	93	O
(	-	100	O
less	-	101	O
than	-	106	O
or	-	111	O
equal	-	114	O
to	-	120	O
6	-	123	O
months	-	125	O
)	-	131	O
of	-	133	O
danazol	-	136	O
has	-	144	O
been	-	148	O
established	-	153	O
in	-	165	O
a	-	168	O
variety	-	170	O
of	-	178	O
settings	-	181	O
,	-	189	O
no	-	191	O
information	-	194	O
exists	-	206	O
as	-	213	O
to	-	216	O
its	-	219	O
long	-	223	O
-	-	227	O
term	-	228	O
safety	-	233	O
.	-	239	O

We	2358093	241	O
therefore	-	244	O
investigated	-	254	O
the	-	267	O
long	-	271	O
-	-	275	O
term	-	276	O
safety	-	281	O
of	-	288	O
danazol	-	291	O
by	-	299	O
performing	-	302	O
a	-	313	O
retrospective	-	315	O
chart	-	329	O
review	-	335	O
of	-	342	O
60	-	345	O
female	-	348	O
patients	-	355	O
with	-	364	O
hereditary	-	369	B
angioedema	-	380	I
treated	-	391	O
with	-	399	O
danazol	-	404	O
for	-	412	O
a	-	416	O
continuous	-	418	O
period	-	429	O
of	-	436	O
6	-	439	O
months	-	441	O
or	-	448	O
longer	-	451	O
.	-	457	O

The	2358093	459	O
mean	-	463	O
age	-	468	O
of	-	472	O
the	-	475	O
patients	-	479	O
was	-	488	O
35	-	492	O
.	-	494	O
2	-	495	O
years	-	497	O
and	-	503	O
the	-	507	O
mean	-	511	O
duration	-	516	O
of	-	525	O
therapy	-	528	O
was	-	536	O
59	-	540	O
.	-	542	O
7	-	543	O
months	-	545	O
.	-	551	O

Virtually	2358093	553	O
all	-	563	O
patients	-	567	O
experienced	-	576	O
one	-	588	O
or	-	592	O
more	-	595	O
adverse	-	600	O
reactions	-	608	O
.	-	617	O

Menstrual	2358093	619	B
abnormalities	-	629	I
(	-	643	O
79	-	644	O
%	-	646	O
)	-	647	O
,	-	648	O
weight	-	650	B
gain	-	657	I
(	-	662	O
60	-	663	O
%	-	665	O
)	-	666	O
,	-	667	O
muscle	-	669	B
cramps	-	676	I
/	-	682	O
myalgias	-	683	B
(	-	692	O
40	-	693	O
%	-	695	O
)	-	696	O
,	-	697	O
and	-	699	O
transaminase	-	703	O
elevations	-	716	O
(	-	727	O
40	-	728	O
%	-	730	O
)	-	731	O
were	-	733	O
the	-	738	O
most	-	742	O
common	-	747	O
adverse	-	754	O
reactions	-	762	O
.	-	771	O

The	2358093	773	O
drug	-	777	O
was	-	782	O
discontinued	-	786	O
due	-	799	O
to	-	803	O
adverse	-	806	O
reactions	-	814	O
in	-	824	O
8	-	827	O
patients	-	829	O
.	-	837	O

No	2358093	839	O
patient	-	842	O
has	-	850	O
died	-	854	O
or	-	859	O
suffered	-	862	O
any	-	871	O
apparent	-	875	O
long	-	884	O
-	-	888	O
term	-	889	O
sequelae	-	894	O
that	-	903	O
were	-	908	O
directly	-	913	O
attributable	-	922	O
to	-	935	O
the	-	938	O
drug	-	942	O
.	-	946	O

We	2358093	948	O
conclude	-	951	O
that	-	960	O
,	-	964	O
despite	-	966	O
a	-	974	O
relatively	-	976	O
high	-	987	O
incidence	-	992	O
of	-	1002	O
adverse	-	1005	O
reactions	-	1013	O
,	-	1022	O
danazol	-	1024	O
has	-	1032	O
proven	-	1036	O
to	-	1043	O
be	-	1046	O
remarkably	-	1049	O
safe	-	1060	O
over	-	1065	O
the	-	1070	O
long	-	1074	O
-	-	1078	O
term	-	1079	O
in	-	1084	O
this	-	1087	O
group	-	1092	O
of	-	1098	O
patients	-	1101	O
.	-	1109	O

Patient	2383364	0	O
tolerance	-	8	O
study	-	18	O
of	-	24	O
topical	-	27	O
chlorhexidine	-	35	O
diphosphanilate	-	49	O
:	-	64	O
a	-	66	O
new	-	68	O
topical	-	72	O
agent	-	80	O
for	-	86	O
burns	-	90	B
.	-	95	O

Effective	2383364	97	O
topical	-	107	O
antimicrobial	-	115	O
agents	-	129	O
decrease	-	136	O
infection	-	145	B
and	-	155	O
mortality	-	159	O
in	-	169	O
burn	-	172	B
patients	-	177	O
.	-	185	O

Chlorhexidine	2383364	187	O
phosphanilate	-	201	O
(	-	215	O
CHP	-	216	O
)	-	219	O
,	-	220	O
a	-	222	O
new	-	224	O
broad	-	228	O
-	-	233	O
spectrum	-	234	O
antimicrobial	-	243	O
agent	-	257	O
,	-	262	O
has	-	264	O
been	-	268	O
evaluated	-	273	O
as	-	283	O
a	-	286	O
topical	-	288	O
burn	-	296	B
wound	-	301	O
dressing	-	307	O
in	-	316	O
cream	-	319	O
form	-	325	O
,	-	329	O
but	-	331	O
preliminary	-	335	O
clinical	-	347	O
trials	-	356	O
reported	-	363	O
that	-	372	O
it	-	377	O
was	-	380	O
painful	-	384	O
upon	-	392	O
application	-	397	O
.	-	408	O

This	2383364	410	O
study	-	415	O
compared	-	421	O
various	-	430	O
concentrations	-	438	O
of	-	453	O
CHP	-	456	O
to	-	460	O
determine	-	463	O
if	-	473	O
a	-	476	O
tolerable	-	478	O
concentration	-	488	O
could	-	502	O
be	-	508	O
identified	-	511	O
with	-	522	O
retention	-	527	O
of	-	537	O
antimicrobial	-	540	O
efficacy	-	554	O
.	-	562	O

Twenty	2383364	564	O
-	-	570	O
nine	-	571	O
burn	-	576	B
patients	-	581	O
,	-	589	O
each	-	591	O
with	-	596	O
two	-	601	O
similar	-	605	O
burns	-	613	B
which	-	619	O
could	-	625	O
be	-	631	O
separately	-	634	O
treated	-	645	O
,	-	652	O
were	-	654	O
given	-	659	O
pairs	-	665	O
of	-	671	O
treatments	-	674	O
at	-	685	O
successive	-	688	O
12	-	699	O
-	-	701	O
h	-	702	O
intervals	-	704	O
over	-	714	O
a	-	719	O
3	-	721	O
-	-	722	O
day	-	723	O
period	-	727	O
.	-	733	O

One	2383364	735	O
burn	-	739	B
site	-	744	O
was	-	749	O
treated	-	753	O
with	-	761	O
each	-	766	O
of	-	771	O
four	-	774	O
different	-	779	O
CHP	-	789	O
concentrations	-	793	O
,	-	807	O
from	-	809	O
0	-	814	O
.	-	815	O
25	-	816	O
per	-	819	O
cent	-	823	O
to	-	828	O
2	-	831	O
per	-	833	O
cent	-	837	O
,	-	841	O
their	-	843	O
vehicle	-	849	O
,	-	856	O
and	-	858	O
1	-	862	O
per	-	864	O
cent	-	868	O
silver	-	873	O
sulphadiazine	-	880	O
(	-	894	O
AgSD	-	895	O
)	-	899	O
cream	-	901	O
,	-	906	O
an	-	908	O
antimicrobial	-	911	O
agent	-	925	O
frequently	-	931	O
used	-	942	O
for	-	947	O
topical	-	951	O
treatment	-	959	O
of	-	969	O
burn	-	972	B
wounds	-	977	O
.	-	983	O

The	2383364	985	O
other	-	989	O
site	-	995	O
was	-	1000	O
always	-	1004	O
treated	-	1011	O
with	-	1019	O
AgSD	-	1024	O
cream	-	1029	O
.	-	1034	O

There	2383364	1036	O
was	-	1042	O
a	-	1046	O
direct	-	1048	O
relationship	-	1055	O
between	-	1068	O
CHP	-	1076	O
concentration	-	1080	O
and	-	1094	O
patients	-	1098	O
'	-	1106	O
ratings	-	1108	O
of	-	1116	O
pain	-	1119	B
on	-	1124	O
an	-	1127	O
analogue	-	1130	O
scale	-	1139	O
.	-	1144	O

The	2383364	1146	O
0	-	1150	O
.	-	1151	O
25	-	1152	O
per	-	1155	O
cent	-	1159	O
CHP	-	1164	O
cream	-	1168	O
was	-	1174	O
closest	-	1178	O
to	-	1186	O
AgSD	-	1189	O
in	-	1194	O
pain	-	1197	B
tolerance	-	1202	O
;	-	1211	O
however	-	1213	O
,	-	1220	O
none	-	1222	O
of	-	1227	O
the	-	1230	O
treatments	-	1234	O
differed	-	1245	O
statistically	-	1254	O
from	-	1268	O
AgSD	-	1273	O
or	-	1278	O
from	-	1281	O
each	-	1286	O
other	-	1291	O
.	-	1296	O

In	2383364	1298	O
addition	-	1301	O
,	-	1309	O
ease	-	1311	O
of	-	1316	O
application	-	1319	O
of	-	1331	O
CHP	-	1334	O
creams	-	1338	O
was	-	1345	O
less	-	1349	O
satisfactory	-	1354	O
than	-	1367	O
that	-	1372	O
of	-	1377	O
AgSD	-	1380	O
.	-	1384	O

It	2383364	1386	O
was	-	1389	O
concluded	-	1393	O
that	-	1403	O
formulations	-	1408	O
at	-	1421	O
or	-	1424	O
below	-	1427	O
0	-	1433	O
.	-	1434	O
5	-	1435	O
per	-	1437	O
cent	-	1441	O
CHP	-	1446	O
may	-	1450	O
prove	-	1454	O
acceptable	-	1460	O
for	-	1471	O
wound	-	1475	O
care	-	1481	O
,	-	1485	O
but	-	1487	O
the	-	1491	O
vehicle	-	1495	O
system	-	1503	O
needs	-	1510	O
pharmaceutical	-	1516	O
improvement	-	1531	O
to	-	1543	O
render	-	1546	O
it	-	1553	O
more	-	1556	O
tolerable	-	1561	O
and	-	1571	O
easier	-	1575	O
to	-	1582	O
use	-	1585	O
.	-	1588	O

Dose	2400986	0	O
-	-	4	O
dependent	-	5	O
neurotoxicity	-	15	B
of	-	29	O
high	-	32	O
-	-	36	O
dose	-	37	O
busulfan	-	42	O
in	-	51	O
children	-	54	O
:	-	62	O
a	-	64	O
clinical	-	66	O
and	-	75	O
pharmacological	-	79	O
study	-	95	O
.	-	100	O

Busulfan	2400986	102	O
is	-	111	O
known	-	114	O
to	-	120	O
be	-	123	O
neurotoxic	-	126	B
in	-	137	O
animals	-	140	O
and	-	148	O
humans	-	152	O
,	-	158	O
but	-	160	O
its	-	164	O
acute	-	168	O
neurotoxicity	-	174	B
remains	-	188	O
poorly	-	196	O
characterized	-	203	O
in	-	217	O
children	-	220	O
.	-	228	O

We	2400986	230	O
report	-	233	O
here	-	240	O
a	-	245	O
retrospective	-	247	O
study	-	261	O
of	-	267	O
123	-	270	O
children	-	274	O
(	-	283	O
median	-	284	O
age	-	291	O
,	-	294	O
6	-	296	O
.	-	297	O
5	-	298	O
years	-	300	O
)	-	305	O
receiving	-	307	O
high	-	317	O
-	-	321	O
dose	-	322	O
busulfan	-	327	O
in	-	336	O
combined	-	339	O
chemotherapy	-	348	O
before	-	361	O
bone	-	368	O
marrow	-	373	O
transplantation	-	380	O
for	-	396	O
malignant	-	400	O
solid	-	410	O
tumors	-	416	B
,	-	422	O
brain	-	424	B
tumors	-	430	I
excluded	-	437	O
.	-	445	O

Busulfan	2400986	447	O
was	-	456	O
given	-	460	O
p	-	466	O
.	-	467	O
o	-	468	O
.	-	469	O
,	-	470	O
every	-	472	O
6	-	478	O
hours	-	480	O
for	-	486	O
16	-	490	O
doses	-	493	O
over	-	499	O
4	-	504	O
days	-	506	O
.	-	510	O

Two	2400986	512	O
total	-	516	O
doses	-	522	O
were	-	528	O
consecutively	-	533	O
used	-	547	O
:	-	551	O
16	-	553	O
mg	-	556	O
/	-	558	O
kg	-	559	O
,	-	561	O
then	-	563	O
600	-	568	O
mg	-	572	O
/	-	574	O
m2	-	575	O
.	-	577	O

The	2400986	579	O
dose	-	583	O
calculation	-	588	O
on	-	600	O
the	-	603	O
basis	-	607	O
of	-	613	O
body	-	616	O
surface	-	621	O
area	-	629	O
results	-	634	O
in	-	642	O
higher	-	645	O
doses	-	652	O
in	-	658	O
young	-	661	O
children	-	667	O
than	-	676	O
in	-	681	O
older	-	684	O
patients	-	690	O
(	-	699	O
16	-	700	O
to	-	703	O
28	-	706	O
mg	-	709	O
/	-	711	O
kg	-	712	O
)	-	714	O
.	-	715	O

Ninety	2400986	717	O
-	-	723	O
six	-	724	O
patients	-	728	O
were	-	737	O
not	-	742	O
given	-	746	O
anticonvulsive	-	752	O
prophylaxis	-	767	O
;	-	778	O
7	-	780	O
(	-	782	O
7	-	783	O
.	-	784	O
5	-	785	O
%	-	786	O
)	-	787	O
developed	-	789	O
seizures	-	799	B
during	-	808	O
the	-	815	O
4	-	819	O
days	-	821	O
of	-	826	O
the	-	829	O
busulfan	-	833	O
course	-	842	O
or	-	849	O
within	-	852	O
24	-	859	O
h	-	862	O
after	-	864	O
the	-	870	O
last	-	874	O
dosing	-	879	O
.	-	885	O

When	2400986	887	O
the	-	892	O
total	-	896	O
busulfan	-	902	O
dose	-	911	O
was	-	916	O
taken	-	920	O
into	-	926	O
account	-	931	O
,	-	938	O
there	-	940	O
was	-	946	O
a	-	950	O
significant	-	952	O
difference	-	964	O
in	-	975	O
terms	-	978	O
of	-	984	O
neurotoxicity	-	987	B
incidence	-	1001	O
among	-	1011	O
patients	-	1017	O
under	-	1026	O
16	-	1032	O
mg	-	1035	O
/	-	1037	O
kg	-	1038	O
(	-	1041	O
1	-	1042	O
of	-	1044	O
57	-	1047	O
,	-	1049	O
1	-	1051	O
.	-	1052	O
7	-	1053	O
%	-	1054	O
)	-	1055	O
and	-	1057	O
patients	-	1061	O
under	-	1070	O
600	-	1076	O
mg	-	1080	O
/	-	1082	O
m2	-	1083	O
(	-	1086	O
6	-	1087	O
of	-	1089	O
39	-	1092	O
,	-	1094	O
15	-	1096	O
.	-	1098	O
4	-	1099	O
%	-	1100	O
)	-	1101	O
(	-	1103	O
P	-	1104	O
less	-	1106	O
than	-	1111	O
0	-	1116	O
.	-	1117	O
02	-	1118	O
)	-	1120	O
.	-	1121	O

Twenty	2400986	1123	O
-	-	1129	O
seven	-	1130	O
patients	-	1136	O
were	-	1145	O
given	-	1150	O
a	-	1156	O
600	-	1158	O
-	-	1161	O
mg	-	1162	O
/	-	1164	O
m2	-	1165	O
busulfan	-	1168	O
total	-	1177	O
dose	-	1183	O
with	-	1188	O
continuous	-	1193	O
i	-	1204	O
.	-	1205	O
v	-	1206	O
.	-	1207	O

infusion	2400986	1209	O
of	-	1218	O
clonazepam	-	1221	O
;	-	1231	O
none	-	1233	O
had	-	1238	O
any	-	1242	O
neurological	-	1246	B
symptoms	-	1259	I
.	-	1267	O

Busulfan	2400986	1269	O
levels	-	1278	O
were	-	1285	O
measured	-	1290	O
by	-	1299	O
a	-	1302	O
gas	-	1304	O
chromatographic	-	1308	O
-	-	1323	O
mass	-	1324	O
spectrometry	-	1329	O
assay	-	1342	O
in	-	1348	O
the	-	1351	O
plasma	-	1355	O
and	-	1362	O
cerebrospinal	-	1366	O
fluid	-	1380	O
of	-	1386	O
9	-	1389	O
children	-	1391	O
without	-	1400	O
central	-	1408	B
nervous	-	1416	I
system	-	1424	I
disease	-	1431	I
under	-	1439	O
600	-	1445	O
mg	-	1449	O
/	-	1451	O
m2	-	1452	O
busulfan	-	1455	O
with	-	1464	O
clonazepam	-	1469	O
:	-	1479	O
busulfan	-	1480	O
cerebrospinal	-	1489	O
fluid	-	1503	O
:	-	1508	O
plasma	-	1509	O
ratio	-	1516	O
was	-	1522	O
1	-	1526	O
.	-	1527	O
39	-	1528	O
.	-	1530	O

This	2400986	1532	O
was	-	1537	O
significantly	-	1541	O
different	-	1555	O
(	-	1565	O
P	-	1566	O
less	-	1568	O
than	-	1573	O
0	-	1578	O
.	-	1579	O
02	-	1580	O
)	-	1582	O
from	-	1584	O
the	-	1589	O
cerebrospinal	-	1593	O
fluid	-	1607	O
:	-	1612	O
plasma	-	1613	O
ratio	-	1620	O
previously	-	1626	O
defined	-	1637	O
in	-	1645	O
children	-	1648	O
receiving	-	1657	O
a	-	1667	O
16	-	1669	O
-	-	1671	O
mg	-	1672	O
/	-	1674	O
kg	-	1675	O
total	-	1678	O
dose	-	1684	O
of	-	1689	O
busulfan	-	1692	O
.	-	1700	O

This	2400986	1702	O
study	-	1707	O
shows	-	1713	O
that	-	1719	O
busulfan	-	1724	O
neurotoxicity	-	1733	B
is	-	1747	O
dose	-	1750	O
-	-	1754	O
dependent	-	1755	O
in	-	1765	O
children	-	1768	O
and	-	1777	O
efficiently	-	1781	O
prevented	-	1793	O
by	-	1803	O
clonazepam	-	1806	O
.	-	1816	O

A	2400986	1818	O
busulfan	-	1820	O
dose	-	1829	O
calculated	-	1834	O
on	-	1845	O
the	-	1848	O
basis	-	1852	O
of	-	1858	O
body	-	1861	O
surface	-	1866	O
area	-	1874	O
,	-	1878	O
resulting	-	1880	O
in	-	1890	O
higher	-	1893	O
doses	-	1900	O
in	-	1906	O
young	-	1909	O
children	-	1915	O
,	-	1923	O
was	-	1925	O
followed	-	1929	O
by	-	1938	O
increased	-	1941	O
neurotoxicity	-	1951	B
,	-	1964	O
close	-	1966	O
to	-	1972	O
neurotoxicity	-	1975	B
incidence	-	1989	O
observed	-	1999	O
in	-	2008	O
adults	-	2011	O
.	-	2017	O

Since	2400986	2019	O
plasma	-	2025	O
pharmacokinetic	-	2032	O
studies	-	2048	O
showed	-	2056	O
a	-	2063	O
faster	-	2065	O
busulfan	-	2072	O
clearance	-	2081	O
in	-	2091	O
children	-	2094	O
than	-	2103	O
in	-	2108	O
adults	-	2111	O
,	-	2117	O
this	-	2119	O
new	-	2124	O
dose	-	2128	O
may	-	2133	O
approximate	-	2137	O
more	-	2149	O
closely	-	2154	O
the	-	2162	O
adult	-	2166	O
systemic	-	2172	O
exposure	-	2181	O
obtained	-	2190	O
after	-	2199	O
the	-	2205	O
usual	-	2209	O
16	-	2215	O
-	-	2217	O
mg	-	2218	O
/	-	2220	O
kg	-	2221	O
total	-	2224	O
dose	-	2230	O
,	-	2234	O
with	-	2236	O
potential	-	2241	O
inferences	-	2251	O
in	-	2262	O
terms	-	2265	O
of	-	2271	O
anticancer	-	2274	O
or	-	2285	O
myeloablative	-	2288	O
effects	-	2302	O
.	-	2309	O

The	2400986	2311	O
busulfan	-	2315	O
dose	-	2324	O
in	-	2329	O
children	-	2332	O
and	-	2341	O
infants	-	2345	O
undergoing	-	2353	O
bone	-	2364	O
marrow	-	2369	O
transplantation	-	2376	O
should	-	2392	O
be	-	2399	O
reconsidered	-	2402	O
on	-	2415	O
the	-	2418	O
basis	-	2422	O
of	-	2428	O
pharmacokinetic	-	2431	O
studies	-	2447	O
.	-	2454	O

Histamine	2429800	0	O
antagonists	-	10	O
and	-	22	O
d	-	26	O
-	-	27	O
tubocurarine	-	28	O
-	-	40	O
induced	-	41	O
hypotension	-	49	B
in	-	61	O
cardiac	-	64	O
surgical	-	72	O
patients	-	81	O
.	-	89	O

Hemodynamic	2429800	91	O
effects	-	103	O
and	-	111	O
histamine	-	115	O
release	-	125	O
by	-	133	O
bolus	-	136	O
injection	-	142	O
of	-	152	O
0	-	155	O
.	-	156	O
35	-	157	O
mg	-	160	O
/	-	162	O
kg	-	163	O
of	-	166	O
d	-	169	O
-	-	170	O
tubocurarine	-	171	O
were	-	184	O
studied	-	189	O
in	-	197	O
24	-	200	O
patients	-	203	O
.	-	211	O

H1	2429800	213	O
-	-	215	O
and	-	217	O
H2	-	221	O
-	-	223	O
histamine	-	224	O
antagonists	-	234	O
or	-	246	O
placebo	-	249	O
were	-	257	O
given	-	262	O
before	-	268	O
dosing	-	275	O
with	-	282	O
d	-	287	O
-	-	288	O
tubocurarine	-	289	O
in	-	302	O
a	-	305	O
randomized	-	307	O
double	-	318	O
-	-	324	O
blind	-	325	O
fashion	-	331	O
to	-	339	O
four	-	342	O
groups	-	347	O
:	-	353	O
group	-	355	O
1	-	361	O
-	-	362	O
-	-	363	O
placebo	-	364	O
;	-	371	O
group	-	373	O
2	-	379	O
-	-	380	O
-	-	381	O
cimetidine	-	382	O
,	-	392	O
4	-	394	O
mg	-	396	O
/	-	398	O
kg	-	399	O
,	-	401	O
plus	-	403	O
placebo	-	408	O
;	-	415	O
group	-	417	O
3	-	423	O
-	-	424	O
-	-	425	O
chlorpheniramine	-	426	O
,	-	442	O
0	-	444	O
.	-	445	O
1	-	446	O
mg	-	448	O
/	-	450	O
kg	-	451	O
,	-	453	O
plus	-	455	O
placebo	-	460	O
;	-	467	O
and	-	469	O
group	-	473	O
4	-	479	O
-	-	480	O
-	-	481	O
cimetidine	-	482	O
plus	-	493	O
chlorpheniramine	-	498	O
.	-	514	O

Histamine	2429800	516	O
release	-	526	O
occurred	-	534	O
in	-	543	O
most	-	546	O
patients	-	551	O
,	-	559	O
the	-	561	O
highest	-	565	O
level	-	573	O
2	-	579	O
minutes	-	581	O
after	-	589	O
d	-	595	O
-	-	596	O
tubocurarine	-	597	O
dosing	-	610	O
.	-	616	O

Group	2429800	618	O
1	-	624	O
had	-	626	O
a	-	630	O
moderate	-	632	O
negative	-	641	O
correlation	-	650	O
between	-	662	O
plasma	-	670	O
histamine	-	677	O
change	-	687	O
and	-	694	O
systemic	-	698	O
vascular	-	707	O
resistance	-	716	O
(	-	727	O
r	-	728	O
=	-	730	O
0	-	732	O
.	-	733	O
58	-	734	O
;	-	736	O
P	-	738	O
less	-	740	O
than	-	745	O
0	-	750	O
.	-	751	O
05	-	752	O
)	-	754	O
not	-	756	O
present	-	760	O
in	-	768	O
group	-	771	O
4	-	777	O
.	-	778	O

Prior	2429800	780	O
dosing	-	786	O
with	-	793	O
antagonists	-	798	O
partially	-	810	O
prevented	-	820	O
the	-	830	O
fall	-	834	O
in	-	839	O
systemic	-	842	O
vascular	-	851	O
resistance	-	860	O
.	-	870	O

These	2429800	872	O
data	-	878	O
demonstrate	-	883	O
that	-	895	O
the	-	900	O
hemodynamic	-	904	O
changes	-	916	O
associated	-	924	O
with	-	935	O
d	-	940	O
-	-	941	O
tubocurarine	-	942	O
dosing	-	955	O
are	-	962	O
only	-	966	O
partially	-	971	O
explained	-	981	O
by	-	991	O
histamine	-	994	O
release	-	1004	O
.	-	1011	O

Thus	2429800	1013	O
prior	-	1018	O
dosing	-	1024	O
with	-	1031	O
H1	-	1036	O
-	-	1038	O
and	-	1040	O
H2	-	1044	O
-	-	1046	O
antagonists	-	1047	O
provides	-	1059	O
only	-	1068	O
partial	-	1073	O
protection	-	1081	O
.	-	1091	O

Convulsant	2453942	0	O
effect	-	11	O
of	-	18	O
lindane	-	21	O
and	-	29	O
regional	-	33	O
brain	-	42	O
concentration	-	48	O
of	-	62	O
GABA	-	65	O
and	-	70	O
dopamine	-	74	O
.	-	82	O

Lindane	2453942	84	O
(	-	92	O
gamma	-	93	O
-	-	98	O
hexachlorocyclohexane	-	99	O
)	-	120	O
is	-	122	O
an	-	125	O
organochlorine	-	128	O
insecticide	-	143	O
with	-	155	O
known	-	160	O
neurotoxic	-	166	B
effects	-	177	O
.	-	184	O

Its	2453942	186	O
mechanism	-	190	O
of	-	200	O
action	-	203	O
is	-	210	O
not	-	213	O
well	-	217	O
understood	-	222	O
although	-	233	O
it	-	242	O
has	-	245	O
been	-	249	O
proposed	-	254	O
that	-	263	O
lindane	-	268	O
acts	-	276	O
as	-	281	O
a	-	284	O
non	-	286	O
-	-	289	O
competitive	-	290	O
antagonist	-	302	O
at	-	313	O
the	-	316	O
gamma	-	320	O
-	-	325	O
aminobutyric	-	326	O
acid	-	339	O
(	-	344	O
GABA	-	345	O
)	-	349	O
-	-	350	O
A	-	351	O
receptor	-	353	O
.	-	361	O

We	2453942	363	O
studied	-	366	O
the	-	374	O
effect	-	378	O
of	-	385	O
lindane	-	388	O
(	-	396	O
150	-	397	O
mg	-	401	O
/	-	403	O
kg	-	404	O
)	-	406	O
on	-	408	O
the	-	411	O
GABAergic	-	415	O
and	-	425	O
dopaminergic	-	429	O
systems	-	442	O
by	-	450	O
measuring	-	453	O
the	-	463	O
concentration	-	467	O
of	-	481	O
GABA	-	484	O
,	-	488	O
dopamine	-	490	O
and	-	499	O
its	-	503	O
metabolites	-	507	O
in	-	519	O
7	-	522	O
brain	-	524	O
areas	-	530	O
at	-	536	O
the	-	539	O
onset	-	543	O
of	-	549	O
seizures	-	552	B
.	-	560	O

All	2453942	562	O
animals	-	566	O
suffered	-	574	O
tonic	-	583	O
convulsions	-	589	B
at	-	601	O
18	-	604	O
.	-	606	O
3	-	607	O
+	-	609	O
/	-	610	O
-	-	611	O

1	2453942	613	O
.	-	614	O
4	-	615	O
min	-	617	O
after	-	621	O
lindane	-	627	O
administration	-	635	O
.	-	649	O

The	2453942	651	O
concentration	-	655	O
of	-	669	O
GABA	-	672	O
was	-	677	O
only	-	681	O
slightly	-	686	O
but	-	695	O
significantly	-	699	O
decreased	-	713	O
in	-	723	O
the	-	726	O
colliculi	-	730	O
without	-	740	O
modifications	-	748	O
in	-	762	O
the	-	765	O
other	-	769	O
areas	-	775	O
.	-	780	O

The	2453942	782	O
concentration	-	786	O
of	-	800	O
dopamine	-	803	O
was	-	812	O
increased	-	816	O
in	-	826	O
the	-	829	O
mesencephalon	-	833	O
and	-	847	O
that	-	851	O
of	-	856	O
its	-	859	O
metabolite	-	863	O
DOPAC	-	874	O
was	-	880	O
also	-	884	O
increased	-	889	O
in	-	899	O
the	-	902	O
mesencephalon	-	906	O
and	-	920	O
the	-	924	O
striatum	-	928	O
.	-	936	O

Unusual	2484903	0	O
complications	-	8	O
of	-	22	O
antithyroid	-	25	O
drug	-	37	O
therapy	-	42	O
:	-	49	O
four	-	51	O
case	-	56	O
reports	-	61	O
and	-	69	O
review	-	73	O
of	-	80	O
literature	-	83	O
.	-	93	O

Two	2484903	95	O
cases	-	99	O
of	-	105	O
propylthiouracil	-	108	O
-	-	124	O
associated	-	125	O
acute	-	136	O
hepatitis	-	142	B
,	-	151	O
one	-	153	O
case	-	157	O
of	-	162	O
fatal	-	165	O
methimazole	-	171	O
-	-	182	O
associated	-	183	O
hepatocellular	-	194	B
necrosis	-	209	I
and	-	218	O
one	-	222	O
case	-	226	O
of	-	231	O
propylthiouracil	-	234	O
-	-	250	O
associated	-	251	O
lupus	-	262	B
-	-	267	I
like	-	268	I
syndrome	-	273	I
are	-	282	O
described	-	286	O
.	-	295	O

The	2484903	297	O
literature	-	301	O
related	-	312	O
to	-	320	O
antithyroid	-	323	O
drug	-	335	O
side	-	340	O
effects	-	345	O
and	-	353	O
the	-	357	O
mechanisms	-	361	O
for	-	372	O
their	-	376	O
occurrence	-	382	O
are	-	393	O
reviewed	-	397	O
and	-	406	O
the	-	410	O
efficacy	-	414	O
and	-	423	O
complications	-	427	O
of	-	441	O
thyroidectomy	-	444	O
and	-	458	O
radioiodine	-	462	O
compared	-	474	O
to	-	483	O
those	-	486	O
of	-	492	O
antithyroid	-	495	O
drugs	-	507	O
.	-	512	O

It	2484903	514	O
is	-	517	O
concluded	-	520	O
that	-	530	O
in	-	535	O
most	-	538	O
circumstances	-	543	O
131I	-	557	O
is	-	562	O
the	-	565	O
therapy	-	569	O
of	-	577	O
choice	-	580	O
for	-	587	O
hyperthyroidism	-	591	B
.	-	606	O

Anticonvulsant	2553470	0	O
actions	-	15	O
of	-	23	O
MK	-	26	O
-	-	28	O
801	-	29	O
on	-	33	O
the	-	36	O
lithium	-	40	O
-	-	47	O
pilocarpine	-	48	O
model	-	60	O
of	-	66	O
status	-	69	B
epilepticus	-	76	I
in	-	88	O
rats	-	91	O
.	-	95	O
MK	-	97	O
-	-	99	O
801	-	100	O
,	-	103	O
a	-	105	O
noncompetitive	-	107	O
N	-	122	O
-	-	123	O
methyl	-	124	O
-	-	130	O
D	-	131	O
-	-	132	O
aspartate	-	133	O
(	-	143	O
NMDA	-	144	O
)	-	148	O
receptor	-	150	O
antagonist	-	159	O
,	-	169	O
was	-	171	O
tested	-	175	O
for	-	182	O
anticonvulsant	-	186	O
effects	-	201	O
in	-	209	O
rats	-	212	O
using	-	217	O
two	-	223	O
seizure	-	227	B
models	-	235	O
,	-	241	O
coadministration	-	243	O
of	-	260	O
lithium	-	263	O
and	-	271	O
pilocarpine	-	275	O
and	-	287	O
administration	-	291	O
of	-	306	O
a	-	309	O
high	-	311	O
dose	-	316	O
of	-	321	O
pilocarpine	-	324	O
alone	-	336	O
.	-	341	O

Three	2553470	343	O
major	-	349	O
results	-	355	O
are	-	363	O
reported	-	367	O
.	-	375	O

First	2553470	377	O
,	-	382	O
pretreatment	-	384	O
with	-	397	O
MK	-	402	O
-	-	404	O
801	-	405	O
produced	-	409	O
an	-	418	O
effective	-	421	O
and	-	431	O
dose	-	435	O
-	-	439	O
dependent	-	440	O
anticonvulsant	-	450	O
action	-	465	O
with	-	472	O
the	-	477	O
lithium	-	481	O
-	-	488	O
pilocarpine	-	489	O
model	-	501	O
but	-	507	O
not	-	511	O
with	-	515	O
rats	-	520	O
treated	-	525	O
with	-	533	O
pilocarpine	-	538	O
alone	-	550	O
,	-	555	O
suggesting	-	557	O
that	-	568	O
different	-	573	O
biochemical	-	583	O
mechanisms	-	595	O
control	-	606	O
seizures	-	614	B
in	-	623	O
these	-	626	O
two	-	632	O
models	-	636	O
.	-	642	O

Second	2553470	644	O
,	-	650	O
the	-	652	O
anticonvulsant	-	656	O
effect	-	671	O
of	-	678	O
MK	-	681	O
-	-	683	O
801	-	684	O
in	-	688	O
the	-	691	O
lithium	-	695	O
-	-	702	O
pilocarpine	-	703	O
model	-	715	O
only	-	721	O
occurred	-	726	O
after	-	735	O
initial	-	741	O
periods	-	749	O
of	-	757	O
seizure	-	760	B
activity	-	768	O
.	-	776	O

This	2553470	778	O
observation	-	783	O
is	-	795	O
suggested	-	798	O
to	-	808	O
be	-	811	O
an	-	814	O
in	-	817	O
vivo	-	820	O
demonstration	-	825	O
of	-	839	O
the	-	842	O
conclusion	-	846	O
derived	-	857	O
from	-	865	O
in	-	870	O
vitro	-	873	O
experiments	-	879	O
that	-	891	O
MK	-	896	O
-	-	898	O
801	-	899	O
binding	-	903	O
requires	-	911	O
agonist	-	920	O
-	-	927	O
induced	-	928	O
opening	-	936	O
of	-	944	O
the	-	947	O
channel	-	951	O
sites	-	959	O
of	-	965	O
the	-	968	O
NMDA	-	972	O
receptor	-	977	O
.	-	985	O

Third	2553470	987	O
,	-	992	O
although	-	994	O
it	-	1003	O
is	-	1006	O
relatively	-	1009	O
easy	-	1020	O
to	-	1025	O
block	-	1028	O
seizures	-	1034	B
induced	-	1043	O
by	-	1051	O
lithium	-	1054	O
and	-	1062	O
pilocarpine	-	1066	O
by	-	1078	O
administration	-	1081	O
of	-	1096	O
anticonvulsants	-	1099	O
prior	-	1115	O
to	-	1121	O
pilocarpine	-	1124	O
,	-	1135	O
it	-	1137	O
is	-	1140	O
more	-	1143	O
difficult	-	1148	O
to	-	1158	O
terminate	-	1161	O
ongoing	-	1171	O
status	-	1179	B
epilepticus	-	1186	I
and	-	1198	O
block	-	1202	O
the	-	1208	O
lethality	-	1212	O
of	-	1222	O
the	-	1225	O
seizures	-	1229	B
.	-	1237	O

Administration	2553470	1239	O
of	-	1254	O
MK	-	1257	O
-	-	1259	O
801	-	1260	O
30	-	1264	O
or	-	1267	O
60	-	1270	O
min	-	1273	O
after	-	1277	O
pilocarpine	-	1283	O
,	-	1294	O
i	-	1296	O
.	-	1297	O
e	-	1298	O
.	-	1299	O
,	-	1300	O
during	-	1302	O
status	-	1309	B
epilepticus	-	1316	I
,	-	1327	O
gradually	-	1329	O
reduced	-	1339	O
electrical	-	1347	O
and	-	1358	O
behavioral	-	1362	O
seizure	-	1373	B
activity	-	1381	O
and	-	1390	O
greatly	-	1394	O
enhanced	-	1402	O
the	-	1411	O
survival	-	1415	O
rate	-	1424	O
.	-	1428	O

These	2553470	1430	O
results	-	1436	O
suggest	-	1444	O
that	-	1452	O
activation	-	1457	O
of	-	1468	O
NMDA	-	1471	O
receptors	-	1476	O
plays	-	1486	O
an	-	1492	O
important	-	1495	O
role	-	1505	O
in	-	1510	O
status	-	1513	B
epilepticus	-	1520	I
and	-	1532	O
brain	-	1536	B
damage	-	1542	I
in	-	1549	O
the	-	1552	O
lithium	-	1556	O
-	-	1563	O
pilocarpine	-	1564	O
model	-	1576	O
.	-	1581	O

This	2553470	1583	O
was	-	1588	O
further	-	1592	O
supported	-	1600	O
by	-	1610	O
results	-	1613	O
showing	-	1621	O
that	-	1629	O
nonconvulsive	-	1634	O
doses	-	1648	O
of	-	1654	O
NMDA	-	1657	O
and	-	1662	O
pilocarpine	-	1666	O
were	-	1678	O
synergistic	-	1683	O
,	-	1694	O
resulting	-	1696	O
in	-	1706	O
status	-	1709	B
epilepticus	-	1716	I
and	-	1728	O
subsequent	-	1732	O
mortality	-	1743	O
.	-	1752	O

Nifedipine	2614930	0	O
induced	-	11	O
bradycardia	-	19	B
in	-	31	O
a	-	34	O
patient	-	36	O
with	-	44	O
autonomic	-	49	B
neuropathy	-	59	I
.	-	69	O

An	2614930	71	O
80	-	74	O
year	-	77	O
old	-	82	O
diabetic	-	86	B
male	-	95	O
with	-	100	O
evidence	-	105	O
of	-	114	O
peripheral	-	117	B
and	-	128	I
autonomic	-	132	I
neuropathy	-	142	I
was	-	153	O
admitted	-	157	O
with	-	166	O
chest	-	171	B
pain	-	177	I
.	-	181	O

He	2614930	183	O
was	-	186	O
found	-	190	O
to	-	196	O
have	-	199	O
atrial	-	204	B
flutter	-	211	I
at	-	219	O
a	-	222	O
ventricular	-	224	O
rate	-	236	O
of	-	241	O
70	-	244	O
/	-	246	O
min	-	247	O
which	-	251	O
slowed	-	257	O
down	-	264	O
to	-	269	O
30	-	272	O
-	-	274	O
40	-	275	O
/	-	277	O
min	-	278	O
when	-	282	O
nifedipine	-	287	O
(	-	298	O
60	-	299	O
mg	-	302	O
)	-	304	O
in	-	306	O
3	-	309	O
divided	-	311	O
doses	-	319	O
,	-	324	O
during	-	326	O
which	-	333	O
he	-	339	O
was	-	342	O
paced	-	346	O
at	-	352	O
a	-	355	O
rate	-	357	O
of	-	362	O
70	-	365	O
/	-	367	O
min	-	368	O
.	-	371	O

This	2614930	373	O
is	-	378	O
inconsistent	-	381	O
with	-	394	O
the	-	399	O
well	-	403	O
-	-	407	O
established	-	408	O
finding	-	420	O
that	-	428	O
nifedipine	-	433	O
induces	-	444	O
tachycardia	-	452	B
in	-	464	O
normally	-	467	O
innervated	-	476	O
hearts	-	487	O
.	-	493	O

However	2614930	495	O
,	-	502	O
in	-	504	O
hearts	-	507	O
deprived	-	514	O
of	-	523	O
compensatory	-	526	O
sympathetic	-	539	O
drive	-	551	O
,	-	556	O
it	-	558	O
may	-	561	O
lead	-	565	O
to	-	570	O
bradycardia	-	573	B
.	-	584	O

The	2625524	0	O
effect	-	4	O
of	-	11	O
haloperidol	-	14	O
in	-	26	O
cocaine	-	29	O
and	-	37	O
amphetamine	-	41	O
intoxication	-	53	O
.	-	65	O

The	2625524	67	O
effectiveness	-	71	O
of	-	85	O
haloperidol	-	88	O
pretreatment	-	100	O
in	-	113	O
preventing	-	116	O
the	-	127	O
toxic	-	131	O
effects	-	137	O
of	-	145	O
high	-	148	O
doses	-	153	O
of	-	159	O
amphetamine	-	162	O
and	-	174	O
cocaine	-	178	O
was	-	186	O
studied	-	190	O
in	-	198	O
rats	-	201	O
.	-	205	O

In	2625524	207	O
this	-	210	O
model	-	215	O
,	-	220	O
toxic	-	222	O
effects	-	228	O
were	-	236	O
induced	-	241	O
by	-	249	O
intraperitoneal	-	252	O
(	-	268	O
i	-	269	O
.	-	270	O
p	-	271	O
.	-	272	O
)	-	273	O
injection	-	275	O
of	-	285	O
amphetamine	-	288	O
75	-	300	O
mg	-	303	O
/	-	305	O
kg	-	306	O
(	-	309	O
100	-	310	O
%	-	313	O
death	-	315	O
rate	-	321	O
)	-	325	O
or	-	327	O
cocaine	-	330	O
70	-	338	O
mg	-	341	O
/	-	343	O
kg	-	344	O
(	-	347	O
82	-	348	O
%	-	350	O
death	-	352	O
rate	-	358	O
)	-	362	O
.	-	363	O

Haloperidol	2625524	365	O
failed	-	377	O
to	-	384	O
prevent	-	387	O
amphetamine	-	395	O
-	-	406	O
induced	-	407	O
seizures	-	415	B
,	-	423	O
but	-	425	O
did	-	429	O
lower	-	433	O
the	-	439	O
mortality	-	443	O
rate	-	453	O
at	-	458	O
most	-	461	O
doses	-	466	O
tested	-	472	O
.	-	478	O

Haloperidol	2625524	480	O
decreased	-	492	O
the	-	502	O
incidence	-	506	O
of	-	516	O
cocaine	-	519	O
-	-	526	O
induced	-	527	O
seizures	-	535	B
at	-	544	O
the	-	547	O
two	-	551	O
highest	-	555	O
doses	-	563	O
,	-	568	O
but	-	570	O
the	-	574	O
lowering	-	578	O
of	-	587	O
the	-	590	O
mortality	-	594	O
rate	-	604	O
did	-	609	O
not	-	613	O
reach	-	617	O
statistical	-	623	O
significance	-	635	O
at	-	648	O
any	-	651	O
dose	-	655	O
.	-	659	O

These	2625524	661	O
data	-	667	O
suggest	-	672	O
a	-	680	O
protective	-	682	O
role	-	693	O
for	-	698	O
the	-	702	O
central	-	706	O
dopamine	-	714	O
blocker	-	723	O
haloperidol	-	731	O
against	-	743	O
death	-	751	O
from	-	757	O
high	-	762	O
-	-	766	O
dose	-	767	O
amphetamine	-	772	O
exposure	-	784	O
without	-	793	O
reducing	-	801	O
the	-	810	O
incidence	-	814	O
of	-	824	O
seizures	-	827	B
.	-	835	O

In	2625524	837	O
contrast	-	840	O
,	-	848	O
haloperidol	-	850	O
demonstrated	-	862	O
an	-	875	O
ability	-	878	O
to	-	886	O
reduce	-	889	O
cocaine	-	896	O
-	-	903	O
induced	-	904	O
seizures	-	912	B
without	-	921	O
significantly	-	929	O
reducing	-	943	O
mortality	-	952	O
.	-	961	O

Autoradiographic	2650911	0	O
evidence	-	17	O
of	-	26	O
estrogen	-	29	O
binding	-	38	O
sites	-	46	O
in	-	52	O
nuclei	-	55	O
of	-	62	O
diethylstilbesterol	-	65	O
induced	-	85	O
hamster	-	93	O
renal	-	101	B
carcinomas	-	107	I
.	-	117	O

Estrogen	2650911	119	O
binding	-	128	O
sites	-	136	O
were	-	142	O
demonstrated	-	147	O
by	-	160	O
autoradiography	-	163	O
in	-	179	O
one	-	182	O
transplantable	-	186	O
and	-	201	O
five	-	205	O
primary	-	210	O
diethylstilbesterol	-	218	O
induced	-	238	O
renal	-	246	B
carcinomas	-	252	I
in	-	263	O
three	-	266	O
hamsters	-	272	O
.	-	280	O

Radiolabelling	2650911	282	O
,	-	296	O
following	-	298	O
the	-	308	O
in	-	312	O
vivo	-	315	O
injection	-	320	O
of	-	330	O
3H	-	333	O
-	-	335	O
17	-	336	O
beta	-	339	O
estradiol	-	344	O
,	-	353	O
was	-	355	O
increased	-	359	O
only	-	369	O
over	-	374	O
the	-	379	O
nuclei	-	383	O
of	-	390	O
tumor	-	393	B
cells	-	399	O
;	-	404	O
stereologic	-	406	O
analysis	-	418	O
revealed	-	427	O
a	-	436	O
4	-	438	O
.	-	439	O
5	-	440	O
-	-	441	O
to	-	443	O
6	-	446	O
.	-	447	O
7	-	448	O
-	-	449	O
times	-	450	O
higher	-	456	O
concentration	-	463	O
of	-	477	O
reduced	-	480	O
silver	-	488	O
grains	-	495	O
over	-	502	O
nuclei	-	507	O
than	-	514	O
cytoplasm	-	519	O
of	-	529	O
these	-	532	O
cells	-	538	O
.	-	543	O

Despite	2650911	545	O
rapid	-	553	O
tubular	-	559	O
excretion	-	567	O
of	-	577	O
estradiol	-	580	O
which	-	590	O
peaked	-	596	O
in	-	603	O
less	-	606	O
than	-	611	O
1	-	616	O
h	-	618	O
,	-	619	O
the	-	621	O
normal	-	625	O
cells	-	632	O
did	-	638	O
not	-	642	O
appear	-	646	O
to	-	653	O
bind	-	656	O
the	-	661	O
ligand	-	665	O
.	-	671	O

This	2650911	673	O
is	-	678	O
the	-	681	O
first	-	685	O
published	-	691	O
report	-	701	O
documenting	-	708	O
the	-	720	O
preferential	-	724	O
in	-	737	O
vivo	-	740	O
binding	-	745	O
of	-	753	O
estrogen	-	756	O
to	-	765	O
nuclei	-	768	O
of	-	775	O
cells	-	778	O
in	-	784	O
estrogen	-	787	O
induced	-	796	O
hamster	-	804	O
renal	-	812	B
carcinomas	-	818	I
.	-	828	O

Bradycardia	2710809	0	B
due	-	12	O
to	-	16	O
biperiden	-	19	O
.	-	28	O

In	2710809	30	O
a	-	33	O
38	-	35	O
-	-	37	O
year	-	38	O
-	-	42	O
old	-	43	O
male	-	47	O
patient	-	52	O
suffering	-	60	O
from	-	70	O
a	-	75	O
severe	-	77	O
postzosteric	-	84	B
trigeminal	-	97	B
neuralgia	-	108	I
,	-	117	O
intravenous	-	119	O
application	-	131	O
of	-	143	O
10	-	146	O
mg	-	149	O
biperiden	-	152	O
lactate	-	162	O
led	-	170	O
to	-	174	O
a	-	177	O
long	-	179	O
-	-	183	O
lasting	-	184	O
paradoxical	-	192	O
reaction	-	204	O
characterized	-	213	O
by	-	227	O
considerable	-	230	O
bradycardia	-	243	B
,	-	254	O
dysarthria	-	256	B
,	-	266	O
and	-	268	O
dysphagia	-	272	B
.	-	281	O

The	2710809	283	O
heart	-	287	O
rate	-	293	O
was	-	298	O
back	-	302	O
to	-	307	O
normal	-	310	O
within	-	317	O
12	-	324	O
hours	-	327	O
upon	-	333	O
administration	-	338	O
of	-	353	O
orciprenaline	-	356	O
under	-	370	O
cardiac	-	376	O
monitoring	-	384	O
in	-	395	O
an	-	398	O
intensive	-	401	O
care	-	411	O
unit	-	416	O
.	-	420	O

Bradycardia	2710809	422	B
induced	-	434	O
by	-	442	O
biperiden	-	445	O
is	-	455	O
attributed	-	458	O
to	-	469	O
the	-	472	O
speed	-	476	O
of	-	482	O
injection	-	485	O
and	-	495	O
to	-	499	O
a	-	502	O
dose	-	504	O
-	-	508	O
related	-	509	O
dual	-	517	O
effect	-	522	O
of	-	529	O
atropine	-	532	O
-	-	540	O
like	-	541	O
drugs	-	546	O
on	-	552	O
muscarine	-	555	O
receptors	-	565	O
.	-	574	O

Deliberate	2718706	0	O
hypotension	-	11	B
induced	-	23	O
by	-	31	O
labetalol	-	34	O
with	-	44	O
halothane	-	49	O
,	-	58	O
enflurane	-	60	O
or	-	70	O
isoflurane	-	73	O
for	-	84	O
middle	-	88	O
-	-	94	O
ear	-	95	O
surgery	-	99	O
.	-	106	O

The	2718706	108	O
feasibility	-	112	O
of	-	124	O
using	-	127	O
labetalol	-	133	O
,	-	142	O
an	-	144	O
alpha	-	147	O
-	-	152	O
and	-	154	O
beta	-	158	O
-	-	162	O
adrenergic	-	163	O
blocking	-	174	O
agent	-	183	O
,	-	188	O
as	-	190	O
a	-	193	O
hypotensive	-	195	B
agent	-	207	O
in	-	213	O
combination	-	216	O
with	-	228	O
inhalation	-	233	O
anaesthetics	-	244	O
(	-	257	O
halothane	-	258	O
,	-	267	O
enflurane	-	269	O
or	-	279	O
isoflurane	-	282	O
)	-	292	O
was	-	294	O
studied	-	298	O
in	-	306	O
23	-	309	O
adult	-	312	O
patients	-	318	O
undergoing	-	327	O
middle	-	338	O
-	-	344	O
ear	-	345	O
surgery	-	349	O
.	-	356	O

The	2718706	358	O
mean	-	362	O
arterial	-	367	O
pressure	-	376	O
was	-	385	O
decreased	-	389	O
from	-	399	O
86	-	404	O
+	-	407	O
/	-	408	O
-	-	409	O

5	2718706	411	O
(	-	413	O
s	-	414	O
.	-	415	O
e	-	416	O
.	-	417	O

mean	2718706	419	O
)	-	423	O

mmHg	2718706	425	O
to	-	430	O
52	-	433	O
+	-	436	O
/	-	437	O
-	-	438	O

1	2718706	440	O
mmHg	-	442	O
(	-	447	O
11	-	448	O
.	-	450	O
5	-	451	O
+	-	453	O
/	-	454	O
-	-	455	O

0	2718706	457	O
.	-	458	O
7	-	459	O
to	-	461	O
6	-	464	O
.	-	465	O
9	-	466	O
+	-	468	O
/	-	469	O
-	-	470	O

0	2718706	472	O
.	-	473	O
1	-	474	O
kPa	-	476	O
)	-	479	O
for	-	481	O
98	-	485	O
+	-	488	O
/	-	489	O
-	-	490	O

10	2718706	492	O
min	-	495	O
in	-	499	O
the	-	502	O
halothane	-	506	O
(	-	516	O
H	-	517	O
)	-	518	O
group	-	520	O
,	-	525	O
from	-	527	O
79	-	532	O
+	-	535	O
/	-	536	O
-	-	537	O

5	2718706	539	O
to	-	541	O
53	-	544	O
+	-	547	O
/	-	548	O
-	-	549	O

1	2718706	551	O
mmHg	-	553	O
(	-	558	O
10	-	559	O
.	-	561	O
5	-	562	O
+	-	564	O
/	-	565	O
-	-	566	O

0	2718706	568	O
.	-	569	O
7	-	570	O
to	-	572	O
7	-	575	O
.	-	576	O
1	-	577	O
+	-	579	O
/	-	580	O
-	-	581	O

0	2718706	583	O
.	-	584	O
1	-	585	O
kPa	-	587	O
)	-	590	O
for	-	592	O
129	-	596	O
+	-	600	O
/	-	601	O
-	-	602	O

11	2718706	604	O
min	-	607	O
in	-	611	O
the	-	614	O
enflurane	-	618	O
(	-	628	O
E	-	629	O
)	-	630	O
group	-	632	O
,	-	637	O
and	-	639	O
from	-	643	O
80	-	648	O
+	-	651	O
/	-	652	O
-	-	653	O

4	2718706	655	O
to	-	657	O
49	-	660	O
+	-	663	O
/	-	664	O
-	-	665	O

1	2718706	667	O
mmHg	-	669	O
(	-	674	O
10	-	675	O
.	-	677	O
7	-	678	O
+	-	680	O
/	-	681	O
-	-	682	O

0	2718706	684	O
.	-	685	O
5	-	686	O
to	-	688	O
6	-	691	O
.	-	692	O
5	-	693	O
+	-	695	O
/	-	696	O
-	-	697	O

0	2718706	699	O
.	-	700	O
1	-	701	O
kPa	-	703	O
)	-	706	O
for	-	708	O
135	-	712	O
+	-	716	O
/	-	717	O
-	-	718	O

15	2718706	720	O
min	-	723	O
in	-	727	O
the	-	730	O
isoflurane	-	734	O
(	-	745	O
I	-	746	O
)	-	747	O
group	-	749	O
.	-	754	O

The	2718706	756	O
mean	-	760	O
H	-	765	O
concentration	-	767	O
during	-	781	O
hypotension	-	788	B
in	-	800	O
the	-	803	O
inspiratory	-	807	O
gas	-	819	O
was	-	823	O
0	-	827	O
.	-	828	O
7	-	829	O
+	-	831	O
/	-	832	O
-	-	833	O
0	-	835	O
.	-	836	O
1	-	837	O
vol	-	839	O
%	-	842	O
,	-	843	O
the	-	845	O
mean	-	849	O
E	-	854	O
concentration	-	856	O
1	-	870	O
.	-	871	O
6	-	872	O
+	-	874	O
/	-	875	O
-	-	876	O

0	2718706	878	O
.	-	879	O
2	-	880	O
vol	-	882	O
%	-	885	O
,	-	886	O
and	-	888	O
the	-	892	O
mean	-	896	O
I	-	901	O
concentration	-	903	O
1	-	917	O
.	-	918	O
0	-	919	O
+	-	921	O
/	-	922	O
-	-	923	O

0	2718706	925	O
.	-	926	O
1	-	927	O
vol	-	929	O
%	-	932	O
.	-	933	O

In	2718706	935	O
addition	-	938	O
,	-	946	O
the	-	948	O
patients	-	952	O
received	-	961	O
fentanyl	-	970	O
and	-	979	O
d	-	983	O
-	-	984	O
tubocurarine	-	985	O
.	-	997	O

The	2718706	999	O
initial	-	1003	O
dose	-	1011	O
of	-	1016	O
labetalol	-	1019	O
for	-	1029	O
lowering	-	1033	O
blood	-	1042	O
pressure	-	1048	O
was	-	1057	O
similar	-	1061	O
,	-	1068	O
0	-	1070	O
.	-	1071	O
52	-	1072	O
-	-	1074	O
0	-	1075	O
.	-	1076	O
59	-	1077	O
mg	-	1080	O
/	-	1082	O
kg	-	1083	O
,	-	1085	O
in	-	1087	O
all	-	1090	O
the	-	1094	O
groups	-	1098	O
.	-	1104	O

During	2718706	1106	O
hypotension	-	1113	B
,	-	1124	O
the	-	1126	O
heart	-	1130	O
rate	-	1136	O
was	-	1141	O
stable	-	1145	O
without	-	1152	O
tachy	-	1160	B
-	-	1165	I
or	-	1167	I
bradycardia	-	1170	I
.	-	1181	O

The	2718706	1183	O
operating	-	1187	O
conditions	-	1197	O
regarding	-	1208	O
bleeding	-	1218	B
were	-	1227	O
estimated	-	1232	O
in	-	1242	O
a	-	1245	O
double	-	1247	O
-	-	1253	O
blind	-	1254	O
manner	-	1260	O
,	-	1266	O
and	-	1268	O
did	-	1272	O
not	-	1276	O
differ	-	1280	O
significantly	-	1287	O
between	-	1301	O
the	-	1309	O
groups	-	1313	O
.	-	1319	O

During	2718706	1321	O
hypotension	-	1328	B
,	-	1339	O
the	-	1341	O
serum	-	1345	O
creatinine	-	1351	O
concentration	-	1362	O
rose	-	1376	O
significantly	-	1381	O
in	-	1395	O
all	-	1398	O
groups	-	1402	O
from	-	1409	O
the	-	1414	O
values	-	1418	O
before	-	1425	O
hypotension	-	1432	B
and	-	1444	O
returned	-	1448	O
postoperatively	-	1457	O
to	-	1473	O
the	-	1476	O
initial	-	1480	O
level	-	1488	O
in	-	1494	O
the	-	1497	O
other	-	1501	O
groups	-	1507	O
,	-	1513	O
except	-	1515	O
the	-	1522	O
isoflurane	-	1526	O
group	-	1537	O
.	-	1542	O

After	2718706	1544	O
hypotension	-	1550	B
there	-	1562	O
was	-	1568	O
no	-	1572	O
rebound	-	1575	O
phenomenon	-	1583	O
in	-	1594	O
either	-	1597	O
blood	-	1604	O
pressure	-	1610	O
or	-	1619	O
heart	-	1622	O
rate	-	1628	O
.	-	1632	O

These	2718706	1634	O
results	-	1640	O
indicate	-	1648	O
that	-	1657	O
labetalol	-	1662	O
induces	-	1672	O
easily	-	1680	O
adjustable	-	1687	O
hypotension	-	1698	B
without	-	1710	O
compensatory	-	1718	O
tachycardia	-	1731	B
and	-	1743	O
rebound	-	1747	O
hypertension	-	1755	B
.	-	1767	O

Convulsion	2765447	0	B
following	-	11	O
intravenous	-	21	O
fluorescein	-	33	O
angiography	-	45	O
.	-	56	O

Tonic	2765447	58	B
-	-	63	I
clonic	-	64	I
seizures	-	71	I
followed	-	80	O
intravenous	-	89	O
fluorescein	-	101	O
injection	-	113	O
for	-	123	O
fundus	-	127	O
angiography	-	134	O
in	-	146	O
a	-	149	O
47	-	151	O
-	-	153	O
year	-	154	O
-	-	158	O
old	-	159	O
male	-	163	O
.	-	167	O

Despite	2765447	169	O
precautions	-	177	O
this	-	189	O
adverse	-	194	O
reaction	-	202	O
recurred	-	211	O
on	-	220	O
re	-	223	O
-	-	225	O
exposure	-	226	O
to	-	235	O
intravenous	-	238	O
fluorescein	-	250	O
.	-	261	O

Pharmacology	2767010	0	O
of	-	13	O
ACC	-	16	O
-	-	19	O
9653	-	20	O
(	-	25	O
phenytoin	-	26	O
prodrug	-	36	O
)	-	43	O
.	-	44	O

ACC	2767010	46	O
-	-	49	O
9653	-	50	O
,	-	54	O
the	-	56	O
disodium	-	60	O
phosphate	-	69	O
ester	-	79	O
of	-	85	O
3	-	88	O
-	-	89	O
hydroxymethyl	-	90	O
-	-	103	O
5	-	104	O
,	-	105	O
5	-	106	O
-	-	107	O
diphenylhydantoin	-	108	O
,	-	125	O
is	-	127	O
a	-	130	O
prodrug	-	132	O
of	-	140	O
phenytoin	-	143	O
with	-	153	O
advantageous	-	158	O
physicochemical	-	171	O
properties	-	187	O
.	-	197	O

ACC	2767010	199	O
-	-	202	O
9653	-	203	O
is	-	208	O
rapidly	-	211	O
converted	-	219	O
enzymatically	-	229	O
to	-	243	O
phenytoin	-	246	O
in	-	256	O
vivo	-	259	O
.	-	263	O

ACC	2767010	265	O
-	-	268	O
9653	-	269	O
and	-	274	O
phenytoin	-	278	O
sodium	-	288	O
have	-	295	O
equivalent	-	300	O
anticonvulsant	-	311	O
activity	-	326	O
against	-	335	O
seizures	-	343	B
induced	-	352	O
by	-	360	O
maximal	-	363	O
electroshock	-	371	O
(	-	384	O
MES	-	385	O
)	-	388	O
in	-	390	O
mice	-	393	O
following	-	398	O
i	-	408	O
.	-	409	O
p	-	410	O
.	-	411	O

,	2767010	412	O
oral	-	414	O
,	-	418	O
or	-	420	O
i	-	423	O
.	-	424	O
v	-	425	O
.	-	426	O

administration	2767010	428	O
.	-	442	O

The	2767010	444	O
ED50	-	448	O
doses	-	453	O
were	-	459	O
16	-	464	O
mg	-	467	O
/	-	469	O
kg	-	470	O
for	-	473	O
i	-	477	O
.	-	478	O
v	-	479	O
.	-	480	O

ACC	2767010	482	O
-	-	485	O
9653	-	486	O
and	-	491	O
8	-	495	O
mg	-	497	O
/	-	499	O
kg	-	500	O
for	-	503	O
i	-	507	O
.	-	508	O
v	-	509	O
.	-	510	O

phenytoin	2767010	512	O
sodium	-	522	O
.	-	528	O

ACC	2767010	530	O
-	-	533	O
9653	-	534	O
and	-	539	O
phenytoin	-	543	O
sodium	-	553	O
have	-	560	O
similar	-	565	O
antiarrhythmic	-	573	O
activity	-	588	O
against	-	597	O
ouabain	-	605	O
-	-	612	O
induced	-	613	O
ventricular	-	621	B
tachycardia	-	633	I
in	-	645	O
anesthetized	-	648	O
dogs	-	661	O
.	-	665	O

The	2767010	667	O
total	-	671	O
doses	-	677	O
of	-	683	O
ACC	-	686	O
-	-	689	O
9653	-	690	O
or	-	695	O
phenytoin	-	698	O
sodium	-	708	O
necessary	-	715	O
to	-	725	O
convert	-	728	O
the	-	736	O
arrhythmia	-	740	B
to	-	751	O
a	-	754	O
normal	-	756	O
sinus	-	763	O
rhythm	-	769	O
were	-	776	O
24	-	781	O
+	-	784	O
/	-	785	O
-	-	786	O

6	2767010	788	O
and	-	790	O
14	-	794	O
+	-	797	O
/	-	798	O
-	-	799	O

3	2767010	801	O
mg	-	803	O
/	-	805	O
kg	-	806	O
,	-	808	O
respectively	-	810	O
.	-	822	O

Only	2767010	824	O
phenytoin	-	829	O
sodium	-	839	O
displayed	-	846	O
in	-	856	O
vitro	-	859	O
antiarrhythmic	-	865	O
activity	-	880	O
against	-	889	O
strophanthidin	-	897	O
-	-	911	O
induced	-	912	O
arrhythmias	-	920	B
in	-	932	O
guinea	-	935	O
pig	-	942	O
right	-	946	O
atria	-	952	O
.	-	957	O

In	2767010	959	O
anesthetized	-	962	O
dogs	-	975	O
,	-	979	O
a	-	981	O
high	-	983	O
dose	-	988	O
of	-	993	O
ACC	-	996	O
-	-	999	O
9653	-	1000	O
(	-	1005	O
31	-	1006	O
mg	-	1009	O
/	-	1011	O
kg	-	1012	O
)	-	1014	O
was	-	1016	O
infused	-	1020	O
over	-	1028	O
15	-	1033	O
,	-	1035	O
20	-	1037	O
,	-	1039	O
and	-	1041	O
30	-	1045	O
min	-	1048	O
and	-	1052	O
the	-	1056	O
responses	-	1060	O
were	-	1070	O
compared	-	1075	O
to	-	1084	O
an	-	1087	O
equimolar	-	1090	O
dose	-	1100	O
of	-	1105	O
phenytoin	-	1108	O
sodium	-	1118	O
(	-	1125	O
21	-	1126	O
mg	-	1129	O
/	-	1131	O
kg	-	1132	O
)	-	1134	O
.	-	1135	O

The	2767010	1137	O
ACC	-	1141	O
-	-	1144	O
9653	-	1145	O
and	-	1150	O
phenytoin	-	1154	O
sodium	-	1164	O
treatments	-	1171	O
produced	-	1182	O
similar	-	1191	O
marked	-	1199	O
reductions	-	1206	O
in	-	1217	O
diastolic	-	1220	O
blood	-	1230	O
pressure	-	1236	O
and	-	1245	O
contractile	-	1249	O
force	-	1261	O
(	-	1267	O
LVdP	-	1268	O
/	-	1272	O
dt	-	1273	O
)	-	1275	O
.	-	1276	O

The	2767010	1278	O
maximum	-	1282	O
effects	-	1290	O
of	-	1298	O
each	-	1301	O
treatment	-	1306	O
occurred	-	1316	O
at	-	1325	O
the	-	1328	O
time	-	1332	O
of	-	1337	O
maximum	-	1340	O
phenytoin	-	1348	O
sodium	-	1358	O
levels	-	1365	O
.	-	1371	O

Acute	2767010	1373	O
toxicity	-	1379	B
studies	-	1388	O
of	-	1396	O
ACC	-	1399	O
-	-	1402	O
9653	-	1403	O
and	-	1408	O
phenytoin	-	1412	O
sodium	-	1422	O
were	-	1429	O
carried	-	1434	O
out	-	1442	O
in	-	1446	O
mice	-	1449	O
,	-	1453	O
rats	-	1455	O
,	-	1459	O
rabbits	-	1461	O
,	-	1468	O
and	-	1470	O
dogs	-	1474	O
by	-	1479	O
i	-	1482	O
.	-	1483	O
v	-	1484	O
.	-	1485	O

,	2767010	1486	O
i	-	1488	O
.	-	1489	O
m	-	1490	O
.	-	1491	O
,	-	1492	O
and	-	1494	O
i	-	1498	O
.	-	1499	O
p	-	1500	O
.	-	1501	O
routes	-	1503	O
of	-	1510	O
administration	-	1513	O
.	-	1527	O

The	2767010	1529	O
systemic	-	1533	O
toxic	-	1542	O
signs	-	1548	O
of	-	1554	O
both	-	1557	O
agents	-	1562	O
were	-	1569	O
similar	-	1574	O
and	-	1582	O
occurred	-	1586	O
at	-	1595	O
approximately	-	1598	O
equivalent	-	1612	O
doses	-	1623	O
.	-	1628	O

Importantly	2767010	1630	O
,	-	1641	O
the	-	1643	O
local	-	1647	O
irritation	-	1653	O
of	-	1664	O
ACC	-	1667	O
-	-	1670	O
9653	-	1671	O
was	-	1676	O
markedly	-	1680	O
less	-	1689	O
than	-	1694	O
phenytoin	-	1699	O
sodium	-	1709	O
following	-	1716	O
i	-	1726	O
.	-	1727	O
m	-	1728	O
.	-	1729	O

administration	2767010	1731	O
.	-	1745	O
(	-	1746	O
ABSTRACT	-	1747	O
TRUNCATED	-	1756	O
AT	-	1766	O
250	-	1769	O
WORDS	-	1773	O
)	-	1778	O

Phenytoin	2818777	0	O
induced	-	10	O
fatal	-	18	O
hepatic	-	24	B
injury	-	32	I
.	-	38	O

A	2818777	40	O
61	-	42	O
year	-	45	O
old	-	50	O
female	-	54	O
developed	-	61	O
fatal	-	71	O
hepatic	-	77	B
failure	-	85	I
after	-	93	O
phenytoin	-	99	O
administration	-	109	O
.	-	123	O

A	2818777	125	O
typical	-	127	O
multisystem	-	135	O
clinical	-	147	O
pattern	-	156	O
precedes	-	164	O
the	-	173	O
manifestations	-	177	O
of	-	192	O
hepatic	-	195	B
injury	-	203	I
.	-	209	O

The	2818777	211	O
hematologic	-	215	O
,	-	226	O
biochemical	-	228	O
and	-	240	O
pathologic	-	244	O
features	-	255	O
indicate	-	264	O
a	-	273	O
mixed	-	275	O
hepatocellular	-	281	B
damage	-	296	I
due	-	303	O
to	-	307	O
drug	-	310	B
hypersensitivity	-	315	I
.	-	331	O

In	2818777	333	O
a	-	336	O
patient	-	338	O
receiving	-	346	O
phenytoin	-	356	O
who	-	366	O
presents	-	370	O
a	-	379	O
viral	-	381	O
-	-	386	O
like	-	387	O
illness	-	392	O
,	-	399	O
early	-	401	O
recognition	-	407	O
and	-	419	O
discontinuation	-	423	O
of	-	439	O
the	-	442	O
drug	-	446	O
are	-	451	O
mandatory	-	455	O
.	-	464	O

Treatment	2884595	0	O
of	-	10	O
lethal	-	13	O
pertussis	-	20	O
vaccine	-	30	O
reaction	-	38	O
with	-	47	O
histamine	-	52	O
H1	-	62	O
antagonists	-	65	O
.	-	76	O

We	2884595	78	O
studied	-	81	O
mortality	-	89	O
after	-	99	O
pertussis	-	105	B
immunization	-	115	O
in	-	128	O
the	-	131	O
mouse	-	135	O
.	-	140	O

Without	2884595	142	O
treatment	-	150	O
,	-	159	O
73	-	161	O
of	-	164	O
92	-	167	O
animals	-	170	O
(	-	178	O
80	-	179	O
%	-	181	O
)	-	182	O
died	-	184	O
after	-	189	O
injection	-	195	O
of	-	205	O
bovine	-	208	O
serum	-	215	O
albumin	-	221	O
(	-	229	O
BSA	-	230	O
)	-	233	O
on	-	235	O
day	-	238	O
+	-	242	O
7	-	243	O
of	-	245	O
pertussis	-	248	B
immunization	-	258	O
.	-	270	O

After	2884595	272	O
pretreatment	-	278	O
with	-	291	O
3	-	296	O
mg	-	298	O
of	-	301	O
cyproheptadine	-	304	O
,	-	318	O
2	-	320	O
mg	-	322	O
mianserin	-	325	O
,	-	334	O
or	-	336	O
2	-	339	O
mg	-	341	O
chlorpheniramine	-	344	O
,	-	360	O
only	-	362	O
5	-	367	O
of	-	369	O
105	-	372	O
animals	-	376	O
(	-	384	O
5	-	385	O
%	-	386	O
)	-	387	O
died	-	389	O
after	-	394	O
receiving	-	400	O
BSA	-	410	O
on	-	414	O
day	-	417	O
+	-	421	O
7	-	422	O
(	-	424	O
p	-	425	O
less	-	427	O
than	-	432	O
0	-	437	O
.	-	438	O
001	-	439	O
)	-	442	O
.	-	443	O

Blockade	2884595	445	O
of	-	454	O
histamine	-	457	O
H1	-	467	O
receptors	-	470	O
may	-	480	O
reduce	-	484	O
mortality	-	491	O
in	-	501	O
pertussis	-	504	B
immunization	-	514	O
-	-	526	O
induced	-	527	O
encephalopathy	-	535	B
in	-	550	O
mice	-	553	O
.	-	557	O

Support	2904523	0	O
for	-	8	O
adrenaline	-	12	O
-	-	22	O
hypertension	-	23	B
hypothesis	-	36	O
:	-	46	O
18	-	48	O
hour	-	51	O
pressor	-	56	O
effect	-	64	O
after	-	71	O
6	-	77	O
hours	-	79	O
adrenaline	-	85	O
infusion	-	96	O
.	-	104	O

In	2904523	106	O
a	-	109	O
double	-	111	O
blind	-	118	O
,	-	123	O
crossover	-	125	O
study	-	135	O
6	-	141	O
h	-	143	O
infusions	-	145	O
of	-	155	O
adrenaline	-	158	O
(	-	169	O
15	-	170	O
ng	-	173	O
/	-	175	O
kg	-	176	O
/	-	178	O
min	-	179	O
;	-	182	O
1	-	184	O
ng	-	186	O
=	-	189	O
5	-	191	O
.	-	192	O
458	-	193	O
pmol	-	197	O
)	-	201	O
,	-	202	O
noradrenaline	-	204	O
(	-	218	O
30	-	219	O
ng	-	222	O
/	-	224	O
kg	-	225	O
/	-	227	O
min	-	228	O
;	-	231	O
1	-	233	O
ng	-	235	O
=	-	238	O
5	-	240	O
.	-	241	O
911	-	242	O
pmol	-	246	O
)	-	250	O
,	-	251	O
and	-	253	O
a	-	257	O
5	-	259	O
%	-	260	O
dextrose	-	262	O
solution	-	271	O
(	-	280	O
5	-	281	O
.	-	282	O
4	-	283	O
ml	-	285	O
/	-	287	O
h	-	288	O
)	-	289	O
,	-	290	O
were	-	292	O
given	-	297	O
to	-	303	O
ten	-	306	O
healthy	-	310	O
volunteers	-	318	O
in	-	329	O
random	-	332	O
order	-	339	O
2	-	345	O
weeks	-	347	O
apart	-	353	O
.	-	358	O

By	2904523	360	O
means	-	363	O
of	-	369	O
intra	-	372	O
-	-	377	O
arterial	-	378	O
ambulatory	-	387	O
monitoring	-	398	O
the	-	409	O
haemodynamic	-	413	O
effects	-	426	O
were	-	434	O
followed	-	439	O
for	-	448	O
18	-	452	O
h	-	455	O
after	-	457	O
the	-	463	O
infusions	-	467	O
were	-	477	O
stopped	-	482	O
.	-	489	O

Adrenaline	2904523	491	O
,	-	501	O
but	-	503	O
not	-	507	O
noradrenaline	-	511	O
,	-	524	O
caused	-	526	O
a	-	533	O
delayed	-	535	O
and	-	543	O
protracted	-	547	O
pressor	-	558	O
effect	-	566	O
.	-	572	O

Over	2904523	574	O
the	-	579	O
total	-	583	O
postinfusion	-	589	O
period	-	602	O
systolic	-	609	O
and	-	618	O
diastolic	-	622	O
arterial	-	632	O
pressure	-	641	O
were	-	650	O
6	-	655	O
(	-	657	O
SEM	-	658	O
2	-	662	O
)	-	663	O
%	-	664	O
and	-	666	O
7	-	670	O
(	-	672	O
2	-	673	O
)	-	674	O
%	-	675	O
,	-	676	O
respectively	-	678	O
,	-	690	O
higher	-	692	O
than	-	699	O
after	-	704	O
dextrose	-	710	O
infusion	-	719	O
(	-	728	O
ANOVA	-	729	O
,	-	734	O
p	-	736	O
less	-	738	O
than	-	743	O
0	-	748	O
.	-	749	O
001	-	750	O
)	-	753	O
.	-	754	O

Thus	2904523	756	O
,	-	760	O
""""	-	762	O
stress	-	763	O
""""	-	769	O
levels	-	771	O
of	-	778	O
adrenaline	-	781	O
(	-	792	O
230	-	793	O
pg	-	797	O
/	-	799	O
ml	-	800	O
)	-	802	O
for	-	804	O
6	-	808	O
h	-	810	O
cause	-	812	O
a	-	818	O
delayed	-	820	O
and	-	828	O
protracted	-	832	O
pressor	-	843	O
effect	-	851	O
.	-	857	O

These	2904523	859	O
findings	-	865	O
are	-	874	O
strong	-	878	O
support	-	885	O
for	-	893	O
the	-	897	O
adrenaline	-	901	O
-	-	911	O
hypertension	-	912	B
hypothesis	-	925	O
in	-	936	O
man	-	939	O
.	-	942	O

Effect	2907577	0	O
of	-	7	O
alkylxanthines	-	10	O
on	-	25	O
gentamicin	-	28	O
-	-	38	O
induced	-	39	O
acute	-	47	B
renal	-	53	I
failure	-	59	I
in	-	67	O
the	-	70	O
rat	-	74	O
.	-	77	O

Adenosine	2907577	79	O
antagonists	-	89	O
have	-	101	O
been	-	106	O
previously	-	111	O
shown	-	122	O
to	-	128	O
be	-	131	O
of	-	134	O
benefit	-	137	O
in	-	145	O
some	-	148	O
ischaemic	-	153	B
and	-	163	O
nephrotoxic	-	167	B
models	-	179	O
of	-	186	O
acute	-	189	B
renal	-	195	I
failure	-	201	I
(	-	209	O
ARF	-	210	B
)	-	213	O
.	-	214	O

In	2907577	216	O
the	-	219	O
present	-	223	O
study	-	231	O
,	-	236	O
the	-	238	O
effects	-	242	O
of	-	250	O
three	-	253	O
alkylxanthines	-	259	O
with	-	274	O
different	-	279	O
potencies	-	289	O
as	-	299	O
adenosine	-	302	O
antagonists	-	312	O
8	-	324	O
-	-	325	O
phenyltheophylline	-	326	O
,	-	344	O
theophylline	-	346	O
and	-	359	O
enprofylline	-	363	O
,	-	375	O
were	-	377	O
examined	-	382	O
in	-	391	O
rats	-	394	O
developing	-	399	O
acute	-	410	B
renal	-	416	I
failure	-	422	I
after	-	430	O
4	-	436	O
daily	-	438	O
injections	-	444	O
of	-	455	O
gentamicin	-	458	O
(	-	469	O
200	-	470	O
mg	-	474	O
kg	-	477	O
-	-	479	O
1	-	480	O
)	-	481	O
.	-	482	O

Renal	2907577	484	O
function	-	490	O
was	-	499	O
assessed	-	503	O
by	-	512	O
biochemical	-	515	O
(	-	527	O
plasma	-	528	O
urea	-	535	O
and	-	540	O
creatinine	-	544	O
)	-	554	O
,	-	555	O
functional	-	557	O
(	-	568	O
urine	-	569	O
analysis	-	575	O
and	-	584	O
[	-	588	O
3H	-	589	O
]	-	591	O
inulin	-	592	O
and	-	599	O
[	-	603	O
14C	-	604	O
]	-	607	O
p	-	608	O
-	-	609	O
aminohippuric	-	610	O
acid	-	624	O
clearances	-	629	O
)	-	639	O
and	-	641	O
morphological	-	645	O
(	-	659	O
degree	-	660	O
of	-	667	O
necrosis	-	670	B
)	-	678	O
indices	-	680	O
.	-	687	O

The	2907577	689	O
various	-	693	O
drug	-	701	O
treatments	-	706	O
produced	-	717	O
improvements	-	726	O
in	-	739	O
some	-	742	O
,	-	746	O
but	-	748	O
not	-	752	O
all	-	756	O
,	-	759	O
measurements	-	761	O
of	-	774	O
renal	-	777	O
function	-	783	O
.	-	791	O

However	2907577	793	O
,	-	800	O
any	-	802	O
improvement	-	806	O
produced	-	818	O
by	-	827	O
drug	-	830	O
treatment	-	835	O
was	-	845	O
largely	-	849	O
a	-	857	O
result	-	859	O
of	-	866	O
a	-	869	O
beneficial	-	871	O
effect	-	882	O
exerted	-	889	O
by	-	897	O
its	-	900	O
vehicle	-	904	O
(	-	912	O
polyethylene	-	913	O
glycol	-	926	O
and	-	933	O
NaOH	-	937	O
)	-	941	O
.	-	942	O

The	2907577	944	O
lack	-	948	O
of	-	953	O
any	-	956	O
consistent	-	960	O
protective	-	971	O
effect	-	982	O
noted	-	989	O
with	-	995	O
the	-	1000	O
alkylxanthines	-	1004	O
tested	-	1019	O
in	-	1026	O
the	-	1029	O
present	-	1033	O
study	-	1041	O
indicates	-	1047	O
that	-	1057	O
adenosine	-	1062	O
plays	-	1072	O
little	-	1078	O
,	-	1084	O
if	-	1086	O
any	-	1089	O
,	-	1092	O
pathophysiological	-	1094	O
role	-	1113	O
in	-	1118	O
gentamicin	-	1121	O
-	-	1131	O
induced	-	1132	O
ARF	-	1140	B
.	-	1143	O

Adverse	2931989	0	O
ocular	-	8	O
reactions	-	15	O
possibly	-	25	O
associated	-	34	O
with	-	45	O
isotretinoin	-	50	O
.	-	62	O

A	2931989	64	O
total	-	66	O
of	-	72	O
261	-	75	O
adverse	-	79	O
ocular	-	87	O
reactions	-	94	O
occurred	-	104	O
in	-	113	O
237	-	116	O
patients	-	120	O
who	-	129	O
received	-	133	O
isotretinoin	-	142	O
,	-	154	O
a	-	156	O
commonly	-	158	O
used	-	167	O
drug	-	172	O
in	-	177	O
the	-	180	O
treatment	-	184	O
of	-	194	O
severe	-	197	O
cystic	-	204	O
acne	-	211	B
.	-	215	O

Blepharoconjunctivitis	2931989	217	B
,	-	239	O
subjective	-	241	O
complaints	-	252	O
of	-	263	O
dry	-	266	B
eyes	-	270	I
,	-	274	O
blurred	-	276	B
vision	-	284	I
,	-	290	O
contact	-	292	O
lens	-	300	O
intolerance	-	305	O
,	-	316	O
and	-	318	O
photodermatitis	-	322	B
are	-	338	O
reversible	-	342	O
side	-	353	O
effects	-	358	O
.	-	365	O

More	2931989	367	O
serious	-	372	O
ocular	-	380	O
adverse	-	387	O
reactions	-	395	O
include	-	405	O
papilledema	-	413	B
,	-	424	O
pseudotumor	-	426	B
cerebri	-	438	I
,	-	445	O
and	-	447	O
white	-	451	O
or	-	457	O
gray	-	460	O
subepithelial	-	465	O
corneal	-	479	B
opacities	-	487	I
;	-	496	O
all	-	498	O
of	-	502	O
these	-	505	O
are	-	511	O
reversible	-	515	O
if	-	526	O
the	-	529	O
drug	-	533	O
is	-	538	O
discontinued	-	541	O
.	-	553	O

Reported	2931989	555	O
cases	-	564	O
of	-	570	O
decreased	-	573	O
dark	-	583	O
adaptation	-	588	O
are	-	599	O
under	-	603	O
investigation	-	609	O
.	-	622	O

Isotretinoin	2931989	624	O
is	-	637	O
contraindicated	-	640	O
in	-	656	O
pregnancy	-	659	O
because	-	669	O
of	-	677	O
the	-	680	O
many	-	684	O
reported	-	689	O
congenital	-	698	B
abnormalities	-	709	I
after	-	723	O
maternal	-	729	O
use	-	738	O
(	-	742	O
including	-	743	O
microphthalmos	-	753	B
,	-	767	O
orbital	-	769	O
hypertelorism	-	777	B
,	-	790	O
and	-	792	O
optic	-	796	B
nerve	-	802	I
hypoplasia	-	808	I
)	-	818	O
.	-	819	O

Procaterol	2933998	0	O
and	-	11	O
terbutaline	-	15	O
in	-	27	O
bronchial	-	30	B
asthma	-	40	I
.	-	46	O

A	2933998	48	O
double	-	50	O
-	-	56	O
blind	-	57	O
,	-	62	O
placebo	-	64	O
-	-	71	O
controlled	-	72	O
,	-	82	O
cross	-	84	O
-	-	89	O
over	-	90	O
study	-	95	O
.	-	100	O

Procaterol	2933998	102	O
,	-	112	O
a	-	114	O
new	-	116	O
beta	-	120	O
-	-	124	O
2	-	125	O
adrenoceptor	-	127	O
stimulant	-	140	O
,	-	149	O
was	-	151	O
studied	-	155	O
in	-	163	O
a	-	166	O
double	-	168	O
-	-	174	O
blind	-	175	O
,	-	180	O
placebo	-	182	O
-	-	189	O
controlled	-	190	O
,	-	200	O
cross	-	202	O
-	-	207	O
over	-	208	O
trial	-	213	O
in	-	219	O
patients	-	222	O
with	-	231	O
bronchial	-	236	B
asthma	-	246	I
.	-	252	O

Oral	2933998	254	O
procaterol	-	259	O
50	-	270	O
micrograms	-	273	O
b	-	284	O
.	-	285	O
d	-	286	O
.	-	287	O
,	-	288	O
procaterol	-	290	O
100	-	301	O
micrograms	-	305	O
b	-	316	O
.	-	317	O
d	-	318	O
.	-	319	O

,	2933998	320	O
and	-	322	O
terbutaline	-	326	O
5	-	338	O
mg	-	340	O
t	-	343	O
.	-	344	O
i	-	345	O
.	-	346	O
d	-	347	O
.	-	348	O
,	-	349	O
were	-	351	O
compared	-	356	O
when	-	365	O
given	-	370	O
randomly	-	376	O
in	-	385	O
1	-	388	O
-	-	389	O
week	-	390	O
treatment	-	395	O
periods	-	405	O
.	-	412	O

The	2933998	414	O
best	-	418	O
clinical	-	423	O
effect	-	432	O
was	-	439	O
found	-	443	O
with	-	449	O
terbutaline	-	454	O
.	-	465	O

Both	2933998	467	O
anti	-	472	O
-	-	476	O
asthmatic	-	477	B
and	-	487	O
tremorgenic	-	491	B
effects	-	503	O
of	-	511	O
procaterol	-	514	O
were	-	525	O
dose	-	530	O
-	-	534	O
related	-	535	O
.	-	542	O

Procaterol	2933998	544	O
appeared	-	555	O
effective	-	564	O
in	-	574	O
the	-	577	O
doses	-	581	O
tested	-	587	O
,	-	593	O
and	-	595	O
a	-	599	O
twice	-	601	O
daily	-	607	O
regimen	-	613	O
would	-	621	O
appear	-	627	O
to	-	634	O
be	-	637	O
suitable	-	640	O
with	-	649	O
this	-	654	O
drug	-	659	O
.	-	663	O

Subacute	2974281	0	O
effects	-	9	O
of	-	17	O
propranolol	-	20	O
and	-	32	O
B	-	36	O
24	-	38	O
/	-	40	O
76	-	41	O
on	-	44	O
isoproterenol	-	47	O
-	-	60	O
induced	-	61	O
rat	-	69	O
heart	-	73	B
hypertrophy	-	79	I
in	-	91	O
correlation	-	94	O
with	-	106	O
blood	-	111	O
pressure	-	117	O
.	-	125	O

We	2974281	127	O
compared	-	130	O
the	-	139	O
potential	-	143	O
beta	-	153	O
-	-	157	O
receptor	-	158	O
blocker	-	167	O
,	-	174	O
B	-	176	O
24	-	178	O
/	-	180	O
76	-	181	O
i	-	184	O
.	-	185	O
e	-	186	O
.	-	187	O
1	-	189	O
-	-	190	O
(	-	191	O
2	-	192	O
,	-	193	O
4	-	194	O
-	-	195	O
dichlorophenoxy	-	196	O
)	-	211	O
-	-	212	O
3	-	213	O
[	-	214	O
2	-	215	O
-	-	216	O
3	-	217	O
,	-	218	O
4	-	219	O
-	-	220	O
dimethoxyphenyl	-	221	O
)	-	236	O
ethanolamino	-	237	O
]	-	249	O
-	-	250	O
prop	-	251	O
an	-	256	O
-	-	258	O
2	-	259	O
-	-	260	O
ol	-	261	O
,	-	263	O
which	-	265	O
is	-	271	O
characterized	-	274	O
by	-	288	O
beta	-	291	O
1	-	296	O
-	-	297	O
adrenoceptor	-	298	O
blocking	-	311	O
and	-	320	O
beta	-	324	O
2	-	329	O
-	-	330	O
adrenoceptor	-	331	O
stimulating	-	344	O
properties	-	356	O
with	-	367	O
propranolol	-	372	O
.	-	383	O

The	2974281	385	O
studies	-	389	O
were	-	397	O
performed	-	402	O
using	-	412	O
an	-	418	O
experimental	-	421	O
model	-	434	O
of	-	440	O
isoproterenol	-	443	O
-	-	456	O
induced	-	457	O
heart	-	465	B
hypertrophy	-	471	I
in	-	483	O
rats	-	486	O
.	-	490	O

A	2974281	492	O
correlation	-	494	O
of	-	506	O
the	-	509	O
blood	-	513	O
pressure	-	519	O
was	-	528	O
neither	-	532	O
found	-	540	O
in	-	546	O
the	-	549	O
development	-	553	O
nor	-	565	O
in	-	569	O
the	-	572	O
attempt	-	576	O
to	-	584	O
suppress	-	587	O
the	-	596	O
development	-	600	O
of	-	612	O
heart	-	615	B
hypertrophy	-	621	I
with	-	633	O
the	-	638	O
two	-	642	O
beta	-	646	O
-	-	650	O
receptor	-	651	O
blockers	-	660	O
.	-	668	O

Both	2974281	670	O
beta	-	675	O
-	-	679	O
blockers	-	680	O
influenced	-	689	O
the	-	700	O
development	-	704	O
of	-	716	O
hypertrophy	-	719	B
to	-	731	O
a	-	734	O
different	-	736	O
,	-	745	O
but	-	747	O
not	-	751	O
reproducible	-	755	O
extent	-	768	O
.	-	774	O

It	2974281	776	O
was	-	779	O
possible	-	783	O
to	-	792	O
suppress	-	795	O
the	-	804	O
increased	-	808	O
ornithine	-	818	O
decarboxylase	-	828	O
activity	-	842	O
with	-	851	O
both	-	856	O
beta	-	861	O
-	-	865	O
blockers	-	866	O
in	-	875	O
hypertrophied	-	878	B
hearts	-	892	I
,	-	898	O
but	-	900	O
there	-	904	O
was	-	910	O
no	-	914	O
effect	-	917	O
on	-	924	O
the	-	927	O
heart	-	931	O
mass	-	937	O
.	-	941	O

Neither	2974281	943	O
propranolol	-	951	O
nor	-	963	O
B	-	967	O
24	-	969	O
/	-	971	O
76	-	972	O
could	-	975	O
stop	-	981	O
the	-	986	O
changes	-	990	O
in	-	998	O
the	-	1001	O
characteristic	-	1005	O
myosin	-	1020	O
isoenzyme	-	1027	O
pattern	-	1037	O
of	-	1045	O
the	-	1048	O
hypertrophied	-	1052	B
rat	-	1066	O
heart	-	1070	O
.	-	1075	O

Thus	2974281	1077	O
,	-	1081	O
the	-	1083	O
investigations	-	1087	O
did	-	1102	O
not	-	1106	O
provide	-	1110	O
any	-	1118	O
evidence	-	1122	O
that	-	1131	O
the	-	1136	O
beta	-	1140	O
-	-	1144	O
receptor	-	1145	O
blockers	-	1154	O
propranolol	-	1163	O
and	-	1175	O
B	-	1179	O
24	-	1181	O
/	-	1183	O
76	-	1184	O
have	-	1187	O
the	-	1192	O
potency	-	1196	O
to	-	1204	O
prevent	-	1207	O
isoproterenol	-	1215	O
from	-	1229	O
producing	-	1234	O
heart	-	1244	B
hypertrophy	-	1250	I
.	-	1261	O

Comparison	3074291	0	O
of	-	11	O
the	-	14	O
effect	-	18	O
of	-	25	O
oxitropium	-	28	O
bromide	-	39	O
and	-	47	O
of	-	51	O
slow	-	54	O
-	-	58	O
release	-	59	O
theophylline	-	67	O
on	-	80	O
nocturnal	-	83	O
asthma	-	93	B
.	-	99	O

The	3074291	101	O
effects	-	105	O
of	-	113	O
a	-	116	O
new	-	118	O
inhaled	-	122	O
antimuscarinic	-	130	O
drug	-	145	O
,	-	149	O
oxitropium	-	151	O
bromide	-	162	O
,	-	169	O
and	-	171	O
of	-	175	O
a	-	178	O
slow	-	180	O
-	-	184	O
release	-	185	O
theophylline	-	193	O
preparation	-	206	O
upon	-	218	O
nocturnal	-	223	O
asthma	-	233	B
were	-	240	O
compared	-	245	O
in	-	254	O
a	-	257	O
placebo	-	259	O
-	-	266	O
controlled	-	267	O
double	-	278	O
-	-	284	O
blind	-	285	O
study	-	291	O
.	-	296	O

Two	3074291	298	O
samples	-	302	O
were	-	310	O
studied	-	315	O
:	-	322	O
12	-	324	O
patients	-	327	O
received	-	336	O
oxitropium	-	345	O
at	-	356	O
600	-	359	O
micrograms	-	363	O
(	-	374	O
6	-	375	O
subjects	-	377	O
)	-	385	O
or	-	387	O
at	-	390	O
400	-	393	O
micrograms	-	397	O
t	-	408	O
.	-	409	O
i	-	410	O
.	-	411	O
d	-	412	O
.	-	413	O

(	3074291	415	O
6	-	416	O
subjects	-	418	O
)	-	426	O
whereas	-	428	O
11	-	436	O
received	-	439	O
theophylline	-	448	O
at	-	461	O
300	-	464	O
mg	-	468	O
b	-	471	O
.	-	472	O
i	-	473	O
.	-	474	O
d	-	475	O
.	-	476	O

Morning	3074291	478	O
dipping	-	486	O
,	-	493	O
assessed	-	495	O
by	-	504	O
the	-	507	O
fall	-	511	O
in	-	516	O
peak	-	519	O
flow	-	524	O
overnight	-	529	O
,	-	538	O
was	-	540	O
significantly	-	544	O
reduced	-	558	O
in	-	566	O
the	-	569	O
periods	-	573	O
when	-	581	O
either	-	586	O
active	-	593	O
drug	-	600	O
was	-	605	O
taken	-	609	O
,	-	614	O
whereas	-	616	O
no	-	624	O
difference	-	627	O
was	-	638	O
noticed	-	642	O
during	-	650	O
the	-	657	O
placebo	-	661	O
administration	-	669	O
.	-	683	O

No	3074291	685	O
significant	-	688	O
difference	-	700	O
was	-	711	O
noticed	-	715	O
between	-	723	O
results	-	731	O
obtained	-	739	O
with	-	748	O
either	-	753	O
active	-	760	O
drug	-	767	O
,	-	771	O
as	-	773	O
well	-	776	O
as	-	781	O
with	-	784	O
either	-	789	O
dosage	-	796	O
of	-	803	O
oxitropium	-	806	O
.	-	816	O

No	3074291	818	O
subject	-	821	O
reported	-	829	O
side	-	838	O
effects	-	843	O
of	-	851	O
oxitropium	-	854	O
,	-	864	O
as	-	866	O
compared	-	869	O
to	-	878	O
three	-	881	O
subjects	-	887	O
reporting	-	896	O
nausea	-	906	B
,	-	912	O
vomiting	-	914	B
and	-	923	O
tremors	-	927	B
after	-	935	O
theophylline	-	941	O
.	-	953	O

Oxitropium	3074291	955	O
proves	-	966	O
to	-	973	O
be	-	976	O
a	-	979	O
valuable	-	981	O
alternative	-	990	O
to	-	1002	O
theophylline	-	1005	O
in	-	1018	O
nocturnal	-	1021	O
asthma	-	1031	B
,	-	1037	O
since	-	1039	O
it	-	1045	O
is	-	1048	O
equally	-	1051	O
potent	-	1059	O
,	-	1065	O
safer	-	1067	O
and	-	1073	O
does	-	1077	O
not	-	1082	O
require	-	1086	O
the	-	1094	O
titration	-	1098	O
of	-	1108	O
dosage	-	1111	O
.	-	1117	O

Penicillin	3083835	0	O
anaphylaxis	-	11	B
.	-	22	O

A	3083835	24	O
case	-	26	O
of	-	31	O
oral	-	34	O
penicillin	-	39	O
anaphylaxis	-	50	B
is	-	62	O
described	-	65	O
,	-	74	O
and	-	76	O
the	-	80	O
terminology	-	84	O
,	-	95	O
occurrence	-	97	O
,	-	107	O
clinical	-	109	O
manifestations	-	118	O
,	-	132	O
pathogenesis	-	134	O
,	-	146	O
prevention	-	148	O
,	-	158	O
and	-	160	O
treatment	-	164	O
of	-	174	O
anaphylaxis	-	177	B
are	-	189	O
reviewed	-	193	O
.	-	201	O

Emergency	3083835	203	O
physicians	-	213	O
should	-	224	O
be	-	231	O
aware	-	234	O
of	-	240	O
oral	-	243	O
penicillin	-	248	O
anaphylaxis	-	259	B
in	-	271	O
order	-	274	O
to	-	280	O
prevent	-	283	O
its	-	291	O
occurrence	-	295	O
by	-	306	O
prescribing	-	309	O
the	-	321	O
antibiotic	-	325	O
judiciously	-	336	O
and	-	348	O
knowledgeably	-	352	O
and	-	366	O
to	-	370	O
offer	-	373	O
optimal	-	379	O
medical	-	387	O
therapy	-	395	O
once	-	403	O
this	-	408	O
life	-	413	O
-	-	417	O
threatening	-	418	O
reaction	-	430	O
has	-	439	O
begun	-	443	O
.	-	448	O

Reversible	3084231	0	O
valproic	-	11	O
acid	-	20	O
-	-	24	O
induced	-	25	O
dementia	-	33	B
:	-	41	O
a	-	43	O
case	-	45	O
report	-	50	O
.	-	56	O

Reversible	3084231	58	O
valproic	-	69	O
acid	-	78	O
-	-	82	O
induced	-	83	O
dementia	-	91	B
was	-	100	O
documented	-	104	O
in	-	115	O
a	-	118	O
21	-	120	O
-	-	122	O
year	-	123	O
-	-	127	O
old	-	128	O
man	-	132	O
with	-	136	O
epilepsy	-	141	B
who	-	150	O
had	-	154	O
a	-	158	O
3	-	160	O
-	-	161	O
year	-	162	O
history	-	167	O
of	-	175	O
insidious	-	178	O
progressive	-	188	O
decline	-	200	O
in	-	208	O
global	-	211	O
cognitive	-	218	O
abilities	-	228	O
documented	-	238	O
by	-	249	O
serial	-	252	O
neuropsychological	-	259	O
studies	-	278	O
.	-	285	O

Repeat	3084231	287	O
neuropsychological	-	294	O
testing	-	313	O
7	-	321	O
weeks	-	323	O
after	-	329	O
discontinuation	-	335	O
of	-	351	O
the	-	354	O
drug	-	358	O
revealed	-	363	O
dramatic	-	372	O
improvement	-	381	O
in	-	393	O
IQ	-	396	O
,	-	398	O
memory	-	400	O
,	-	406	O
naming	-	408	O
,	-	414	O
and	-	416	O
other	-	420	O
tasks	-	426	O
commensurate	-	432	O
with	-	445	O
clinical	-	450	O
recovery	-	459	O
in	-	468	O
his	-	471	O
intellectual	-	475	O
capacity	-	488	O
.	-	496	O

Possible	3084231	498	O
pathophysiological	-	507	O
mechanisms	-	526	O
which	-	537	O
may	-	543	O
have	-	547	O
been	-	552	O
operative	-	557	O
in	-	567	O
this	-	570	O
case	-	575	O
include	-	580	O
:	-	587	O
a	-	589	O
direct	-	591	O
central	-	598	O
nervous	-	606	O
system	-	614	O
(	-	621	O
CNS	-	622	O
)	-	625	O
toxic	-	627	O
effect	-	633	O
of	-	640	O
valproic	-	643	O
acid	-	652	O
;	-	656	O
a	-	658	O
paradoxical	-	660	O
epileptogenic	-	672	O
effect	-	686	O
secondary	-	693	O
to	-	703	O
the	-	706	O
drug	-	710	O
;	-	714	O
and	-	716	O
an	-	720	O
indirect	-	723	O
CNS	-	732	O
toxic	-	736	O
effect	-	742	O
mediated	-	749	O
through	-	758	O
valproic	-	766	O
acid	-	775	O
-	-	779	O
induced	-	780	O
hyperammonemia	-	788	B
.	-	802	O

Reversal	3088653	0	O
of	-	9	O
scopolamine	-	12	O
-	-	23	O
induced	-	24	O
amnesia	-	32	B
of	-	40	O
passive	-	43	O
avoidance	-	51	O
by	-	61	O
pre	-	64	O
-	-	67	O
and	-	69	O
post	-	73	O
-	-	77	O
training	-	78	O
naloxone	-	87	O
.	-	95	O

In	3088653	97	O
a	-	100	O
series	-	102	O
of	-	109	O
five	-	112	O
experiments	-	117	O
,	-	128	O
the	-	130	O
modulating	-	134	O
role	-	145	O
of	-	150	O
naloxone	-	153	O
on	-	162	O
a	-	165	O
scopolamine	-	167	O
-	-	178	O
induced	-	179	O
retention	-	187	B
deficit	-	197	I
in	-	205	O
a	-	208	O
passive	-	210	O
avoidance	-	218	O
paradigm	-	228	O
was	-	237	O
investigated	-	241	O
in	-	254	O
mice	-	257	O
.	-	261	O

Scopolamine	3088653	263	O
,	-	274	O
but	-	276	O
not	-	280	O
methyl	-	284	O
scopolamine	-	291	O
(	-	303	O
1	-	304	O
and	-	306	O
3	-	310	O
mg	-	312	O
/	-	314	O
kg	-	315	O
)	-	317	O
,	-	318	O
induced	-	320	O
an	-	328	O
amnesia	-	331	B
as	-	339	O
measured	-	342	O
by	-	351	O
latency	-	354	O
and	-	362	O
duration	-	366	O
parameters	-	375	O
.	-	385	O

Naloxone	3088653	387	O
(	-	396	O
0	-	397	O
.	-	398	O
3	-	399	O
,	-	400	O
1	-	402	O
,	-	403	O
3	-	405	O
,	-	406	O
and	-	408	O
10	-	412	O
mg	-	415	O
/	-	417	O
kg	-	418	O
)	-	420	O
injected	-	422	O
prior	-	431	O
to	-	437	O
training	-	440	O
attenuated	-	449	O
the	-	460	O
retention	-	464	B
deficit	-	474	I
with	-	482	O
a	-	487	O
peak	-	489	O
of	-	494	O
activity	-	497	O
at	-	506	O
3	-	509	O
mg	-	511	O
/	-	513	O
kg	-	514	O
.	-	516	O

The	3088653	518	O
effect	-	522	O
of	-	529	O
naloxone	-	532	O
could	-	541	O
be	-	547	O
antagonized	-	550	O
with	-	562	O
morphine	-	567	O
(	-	576	O
1	-	577	O
,	-	578	O
3	-	580	O
,	-	581	O
and	-	583	O
10	-	587	O
mg	-	590	O
/	-	592	O
kg	-	593	O
)	-	595	O
,	-	596	O
demonstrating	-	598	O
the	-	612	O
opioid	-	616	O
specificity	-	623	O
of	-	635	O
the	-	638	O
naloxone	-	642	O
effect	-	651	O
.	-	657	O

Post	3088653	659	O
-	-	663	O
training	-	664	O
administration	-	673	O
of	-	688	O
naloxone	-	691	O
(	-	700	O
3	-	701	O
mg	-	703	O
/	-	705	O
kg	-	706	O
)	-	708	O
as	-	710	O
a	-	713	O
single	-	715	O
or	-	722	O
as	-	725	O
a	-	728	O
split	-	730	O
dose	-	736	O
also	-	741	O
attenuated	-	746	O
the	-	757	O
scopolamine	-	761	O
-	-	772	O
induced	-	773	O
amnesia	-	781	B
.	-	788	O

Control	3088653	790	O
experiments	-	798	O
indicated	-	810	O
that	-	820	O
neither	-	825	O
an	-	833	O
increase	-	836	O
in	-	845	O
pain	-	848	B
sensitivity	-	853	O
(	-	865	O
pre	-	866	O
-	-	869	O
training	-	870	O
naloxone	-	879	O
)	-	887	O
nor	-	889	O
an	-	893	O
induced	-	896	O
aversive	-	904	O
state	-	913	O
(	-	919	O
post	-	920	O
-	-	924	O
training	-	925	O
naloxone	-	934	O
)	-	942	O
appear	-	944	O
to	-	951	O
be	-	954	O
responsible	-	957	O
for	-	969	O
the	-	973	O
influence	-	977	O
of	-	987	O
naloxone	-	990	O
on	-	999	O
the	-	1002	O
scopolamine	-	1006	O
-	-	1017	O
induced	-	1018	O
retention	-	1026	B
deficit	-	1036	I
.	-	1043	O

These	3088653	1045	O
results	-	1051	O
extend	-	1059	O
previous	-	1066	O
findings	-	1075	O
implicating	-	1084	O
a	-	1096	O
cholinergic	-	1098	O
-	-	1109	O
opioid	-	1110	O
interaction	-	1117	O
in	-	1129	O
memory	-	1132	O
processes	-	1139	O
.	-	1148	O

A	3088653	1150	O
possible	-	1152	O
mechanism	-	1161	O
for	-	1171	O
this	-	1175	O
interaction	-	1180	O
involving	-	1192	O
the	-	1202	O
septo	-	1206	O
-	-	1211	O
hippocampal	-	1212	O
cholinergic	-	1224	O
pathway	-	1236	O
is	-	1244	O
discussed	-	1247	O
.	-	1256	O

Electron	3109094	0	O
microscopic	-	9	O
investigations	-	21	O
of	-	36	O
the	-	39	O
cyclophosphamide	-	43	O
-	-	59	O
induced	-	60	O
lesions	-	68	B
of	-	76	I
the	-	79	I
urinary	-	83	I
bladder	-	91	I
of	-	99	O
the	-	102	O
rat	-	106	O
and	-	110	O
their	-	114	O
prevention	-	120	O
by	-	131	O
mesna	-	134	O
.	-	139	O

Fully	3109094	141	O
developed	-	147	O
cyclophosphamide	-	157	O
-	-	173	O
induced	-	174	O
cystitis	-	182	B
is	-	191	O
characterized	-	194	O
by	-	208	O
nearly	-	211	O
complete	-	218	O
detachment	-	227	O
of	-	238	O
the	-	241	O
urothelium	-	245	O
,	-	255	O
severe	-	257	O
submucosal	-	264	O
edema	-	275	B
owing	-	281	O
to	-	287	O
damage	-	290	O
to	-	297	O
the	-	300	O
microvascular	-	304	O
bed	-	318	O
and	-	322	O
focal	-	326	O
muscle	-	332	O
necroses	-	339	B
.	-	347	O

The	3109094	349	O
initial	-	353	O
response	-	361	O
to	-	370	O
the	-	373	O
primary	-	377	O
attack	-	385	O
by	-	392	O
the	-	395	O
cyclophosphamide	-	399	O
metabolites	-	416	O
seems	-	428	O
to	-	434	O
be	-	437	O
fragmentation	-	440	O
of	-	454	O
the	-	457	O
luminal	-	461	O
membrane	-	469	O
.	-	477	O

This	3109094	479	O
damages	-	484	O
the	-	492	O
cellular	-	496	O
barrier	-	505	O
against	-	513	O
the	-	521	O
hypertonic	-	525	O
urine	-	536	O
.	-	541	O

Subsequent	3109094	543	O
breaks	-	554	O
in	-	561	O
the	-	564	O
lateral	-	568	O
cell	-	576	O
membranes	-	581	O
of	-	591	O
the	-	594	O
superficial	-	598	O
cells	-	610	O
and	-	616	O
in	-	620	O
all	-	623	O
the	-	627	O
plasma	-	631	O
membranes	-	638	O
of	-	648	O
the	-	651	O
intermediate	-	655	O
and	-	668	O
basal	-	672	O
cells	-	678	O
,	-	683	O
intercellular	-	685	O
and	-	699	O
intracellular	-	703	O
edema	-	717	B
and	-	723	O
disintegration	-	727	O
of	-	742	O
the	-	745	O
desmosomes	-	749	O
and	-	760	O
hemidesmosomes	-	764	O
lead	-	779	O
to	-	784	O
progressive	-	787	O
degeneration	-	799	O
and	-	812	O
detachment	-	816	O
of	-	827	O
the	-	830	O
epithelial	-	834	O
cells	-	845	O
with	-	851	O
exposure	-	856	O
and	-	865	O
splitting	-	869	O
of	-	879	O
the	-	882	O
basal	-	886	O
membrane	-	892	O
.	-	900	O

The	3109094	902	O
morphological	-	906	O
changes	-	920	O
of	-	928	O
the	-	931	O
endothelial	-	935	O
cells	-	947	O
,	-	952	O
which	-	954	O
become	-	960	O
more	-	967	O
pronounced	-	972	O
in	-	983	O
the	-	986	O
later	-	990	O
stages	-	996	O
of	-	1003	O
the	-	1006	O
experiment	-	1010	O
,	-	1020	O
the	-	1022	O
involvement	-	1026	O
of	-	1038	O
blood	-	1041	O
vessels	-	1047	O
regardless	-	1055	O
of	-	1066	O
their	-	1069	O
diameter	-	1075	O
and	-	1084	O
the	-	1088	O
location	-	1092	O
-	-	1100	O
dependent	-	1101	O
extent	-	1111	O
of	-	1118	O
the	-	1121	O
damage	-	1125	O
indicate	-	1132	O
a	-	1141	O
direct	-	1143	O
type	-	1150	O
of	-	1155	O
damage	-	1158	O
which	-	1165	O
is	-	1171	O
preceded	-	1174	O
by	-	1183	O
a	-	1186	O
mediator	-	1188	O
-	-	1196	O
induced	-	1197	O
increase	-	1205	O
in	-	1214	O
permeability	-	1217	O
,	-	1229	O
the	-	1231	O
morphological	-	1235	O
correlate	-	1249	O
of	-	1259	O
which	-	1262	O
is	-	1268	O
the	-	1271	O
formation	-	1275	O
of	-	1285	O
gaps	-	1288	O
in	-	1293	O
the	-	1296	O
interendothelial	-	1300	O
cell	-	1317	O
connections	-	1322	O
on	-	1334	O
the	-	1337	O
venules	-	1341	O
.	-	1348	O

These	3109094	1350	O
changes	-	1356	O
can	-	1364	O
be	-	1368	O
effectively	-	1371	O
prevented	-	1383	O
by	-	1393	O
mesna	-	1396	O
.	-	1401	O

The	3109094	1403	O
only	-	1407	O
sign	-	1412	O
of	-	1417	O
a	-	1420	O
possible	-	1422	O
involvement	-	1431	O
is	-	1443	O
the	-	1446	O
increase	-	1450	O
in	-	1459	O
the	-	1462	O
number	-	1466	O
of	-	1473	O
specific	-	1476	O
granules	-	1485	O
with	-	1494	O
a	-	1499	O
presumed	-	1501	O
lysosomal	-	1510	O
function	-	1520	O
in	-	1529	O
the	-	1532	O
superficial	-	1536	O
cells	-	1548	O
.	-	1553	O

Increase	3125850	0	O
in	-	9	O
intragastric	-	12	O
pressure	-	25	O
during	-	34	O
suxamethonium	-	41	O
-	-	54	O
induced	-	55	O
muscle	-	63	B
fasciculations	-	70	I
in	-	85	O
children	-	88	O
:	-	96	O
inhibition	-	98	O
by	-	109	O
alfentanil	-	112	O
.	-	122	O

Changes	3125850	124	O
in	-	132	O
intragastric	-	135	O
pressure	-	148	O
after	-	157	O
the	-	163	O
administration	-	167	O
of	-	182	O
suxamethonium	-	185	O
1	-	199	O
.	-	200	O
5	-	201	O
mg	-	203	O
kg	-	206	O
-	-	208	O
1	-	209	O
i	-	211	O
.	-	212	O
v	-	213	O
.	-	214	O
were	-	216	O
studied	-	221	O
in	-	229	O
32	-	232	O
children	-	235	O
(	-	244	O
mean	-	245	O
age	-	250	O
6	-	254	O
.	-	255	O
9	-	256	O
yr	-	258	O
)	-	260	O
pretreated	-	262	O
with	-	273	O
either	-	278	O
physiological	-	285	O
saline	-	299	O
or	-	306	O
alfentanil	-	309	O
50	-	320	O
micrograms	-	323	O
kg	-	334	O
-	-	336	O
1	-	337	O
.	-	338	O

Anaesthesia	3125850	340	O
was	-	352	O
induced	-	356	O
with	-	364	O
thiopentone	-	369	O
5	-	381	O
mg	-	383	O
kg	-	386	O
-	-	388	O
1	-	389	O
.	-	390	O

The	3125850	392	O
incidence	-	396	O
and	-	406	O
intensity	-	410	O
of	-	420	O
muscle	-	423	B
fasciculations	-	430	I
caused	-	445	O
by	-	452	O
suxamethonium	-	455	O
were	-	469	O
significantly	-	474	O
greater	-	488	O
in	-	496	O
the	-	499	O
control	-	503	O
than	-	511	O
in	-	516	O
the	-	519	O
alfentanil	-	523	O
group	-	534	O
.	-	539	O

The	3125850	541	O
intragastric	-	545	O
pressure	-	558	O
during	-	567	O
muscle	-	574	B
fasciculations	-	581	I
was	-	596	O
significantly	-	600	O
higher	-	614	O
in	-	621	O
the	-	624	O
control	-	628	O
group	-	636	O
(	-	642	O
16	-	643	O
+	-	646	O
/	-	647	O
-	-	648	O

0	3125850	650	O
.	-	651	O
7	-	652	O

(	3125850	654	O
SEM	-	655	O
)	-	658	O
cm	-	660	O
H2O	-	663	O
)	-	666	O
than	-	668	O
in	-	673	O
the	-	676	O
alfentanil	-	680	O
group	-	691	O
(	-	697	O
7	-	698	O
.	-	699	O
7	-	700	O
+	-	702	O
/	-	703	O
-	-	704	O

1	3125850	706	O
.	-	707	O
5	-	708	O

(	3125850	710	O
SEM	-	711	O
)	-	714	O
cm	-	716	O
H2O	-	719	O
)	-	722	O
.	-	723	O

The	3125850	725	O
increase	-	729	O
in	-	738	O
intragastric	-	741	O
pressure	-	754	O
was	-	763	O
directly	-	767	O
related	-	776	O
to	-	784	O
the	-	787	O
intensity	-	791	O
of	-	801	O
muscle	-	804	B
fasciculations	-	811	I
(	-	826	O
regression	-	827	O
line	-	838	O
:	-	842	O
y	-	844	O
=	-	846	O
0	-	848	O
.	-	849	O
5	-	850	O
+	-	852	O
4	-	854	O
.	-	855	O
78x	-	856	O
with	-	860	O
r	-	865	O
of	-	867	O
0	-	870	O
.	-	871	O
78	-	872	O
)	-	874	O
.	-	875	O

It	3125850	877	O
is	-	880	O
concluded	-	883	O
that	-	893	O
intragastric	-	898	O
pressure	-	911	O
increases	-	920	O
significantly	-	930	O
during	-	944	O
muscle	-	951	B
fasciculations	-	958	I
caused	-	973	O
by	-	980	O
suxamethonium	-	983	O
in	-	997	O
healthy	-	1000	O
children	-	1008	O
.	-	1016	O

Alfentanil	3125850	1018	O
50	-	1029	O
micrograms	-	1032	O
kg	-	1043	O
-	-	1045	O
1	-	1046	O
effectively	-	1048	O
inhibits	-	1060	O
the	-	1069	O
incidence	-	1073	O
and	-	1083	O
intensity	-	1087	O
of	-	1097	O
suxamethonium	-	1100	O
-	-	1113	O
induced	-	1114	O
muscle	-	1122	B
fasciculations	-	1129	I
;	-	1143	O
moreover	-	1145	O
,	-	1153	O
intragastric	-	1155	O
pressure	-	1168	O
remains	-	1177	O
at	-	1185	O
its	-	1188	O
control	-	1192	O
value	-	1200	O
.	-	1205	O

Acute	3155884	0	O
insulin	-	6	O
treatment	-	14	O
normalizes	-	24	O
the	-	35	O
resistance	-	39	O
to	-	50	O
the	-	53	O
cardiotoxic	-	57	B
effect	-	69	O
of	-	76	O
isoproterenol	-	79	O
in	-	93	O
streptozotocin	-	96	O
diabetic	-	111	B
rats	-	120	O
.	-	124	O

A	3155884	126	O
morphometric	-	128	O
study	-	141	O
of	-	147	O
isoproterenol	-	150	O
induced	-	164	O
myocardial	-	172	O
fibrosis	-	183	B
.	-	191	O

The	3155884	193	O
acute	-	197	O
effect	-	203	O
of	-	210	O
insulin	-	213	O
treatment	-	221	O
on	-	231	O
the	-	234	O
earlier	-	238	O
reported	-	246	O
protective	-	255	O
effect	-	266	O
of	-	273	O
streptozotocin	-	276	O
diabetes	-	291	B
against	-	300	O
the	-	308	O
cardiotoxic	-	312	B
effect	-	324	O
of	-	331	O
high	-	334	O
doses	-	339	O
of	-	345	O
isoproterenol	-	348	O
(	-	362	O
ISO	-	363	O
)	-	366	O
was	-	368	O
investigated	-	372	O
in	-	385	O
rats	-	388	O
.	-	392	O

Thirty	3155884	394	O
to	-	401	O
135	-	404	O
min	-	408	O
after	-	412	O
the	-	418	O
injection	-	422	O
of	-	432	O
crystalline	-	435	O
insulin	-	447	O
,	-	454	O
ISO	-	456	O
was	-	460	O
given	-	464	O
subcutaneously	-	470	O
and	-	485	O
when	-	489	O
ISO	-	494	O
induced	-	498	O
fibrosis	-	506	B
in	-	515	O
the	-	518	O
myocardium	-	522	O
was	-	533	O
morphometrically	-	537	O
analyzed	-	554	O
7	-	563	O
days	-	565	O
later	-	570	O
,	-	575	O
a	-	577	O
highly	-	579	O
significant	-	586	O
correlation	-	598	O
(	-	610	O
r	-	611	O
=	-	613	O
0	-	615	O
.	-	616	O
83	-	617	O
,	-	619	O
2	-	621	O
p	-	623	O
=	-	625	O
0	-	627	O
.	-	628	O
006	-	629	O
)	-	632	O
to	-	634	O
the	-	637	O
slope	-	641	O
of	-	647	O
the	-	650	O
fall	-	654	O
in	-	659	O
blood	-	662	O
glucose	-	668	O
after	-	676	O
insulin	-	682	O
treatment	-	690	O
appeared	-	700	O
.	-	708	O

The	3155884	710	O
myocardial	-	714	O
content	-	725	O
of	-	733	O
catecholamines	-	736	O
was	-	751	O
estimated	-	755	O
in	-	765	O
these	-	768	O
8	-	774	O
day	-	776	O
diabetic	-	780	B
rats	-	789	O
.	-	793	O

The	3155884	795	O
norepinephrine	-	799	O
content	-	814	O
was	-	822	O
significantly	-	826	O
increased	-	840	O
while	-	850	O
epinephrine	-	856	O
remained	-	868	O
unchanged	-	877	O
.	-	886	O

An	3155884	888	O
enhanced	-	891	O
sympathetic	-	900	O
nervous	-	912	O
system	-	920	O
activity	-	927	O
with	-	936	O
a	-	941	O
consequent	-	943	O
down	-	954	O
regulation	-	959	O
of	-	970	O
the	-	973	O
myocardial	-	977	O
beta	-	988	O
-	-	992	O
adrenergic	-	993	O
receptors	-	1004	O
could	-	1014	O
,	-	1019	O
therefore	-	1021	O
,	-	1030	O
explain	-	1032	O
this	-	1040	O
catecholamine	-	1045	O
resistance	-	1059	O
.	-	1069	O

The	3155884	1071	O
rapid	-	1075	O
reversion	-	1081	O
after	-	1091	O
insulin	-	1097	O
treatment	-	1105	O
excludes	-	1115	O
the	-	1124	O
possibility	-	1128	O
that	-	1140	O
streptozotocin	-	1145	O
in	-	1160	O
itself	-	1163	O
causes	-	1170	O
the	-	1177	O
ISO	-	1181	O
resistance	-	1185	O
and	-	1196	O
points	-	1200	O
towards	-	1207	O
a	-	1215	O
direct	-	1217	O
insulin	-	1224	O
effect	-	1232	O
on	-	1239	O
myocardial	-	1242	O
catecholamine	-	1253	O
sensitivity	-	1267	O
in	-	1279	O
diabetic	-	1282	B
rats	-	1291	O
.	-	1295	O

The	3155884	1297	O
phenomenon	-	1301	O
described	-	1312	O
might	-	1322	O
elucidate	-	1328	O
pathogenetic	-	1338	O
mechanisms	-	1351	O
behind	-	1362	O
toxic	-	1369	O
myocardial	-	1375	O
cell	-	1386	O
degeneration	-	1391	O
and	-	1404	O
may	-	1408	O
possibly	-	1412	O
have	-	1421	O
relevance	-	1426	O
for	-	1436	O
acute	-	1440	O
cardiovascular	-	1446	O
complications	-	1461	O
in	-	1475	O
diabetic	-	1478	B
patients	-	1487	O
.	-	1495	O

Differential	3191389	0	O
effects	-	13	O
of	-	21	O
non	-	24	O
-	-	27	O
steroidal	-	28	O
anti	-	38	O
-	-	42	O
inflammatory	-	43	O
drugs	-	56	O
on	-	62	O
seizures	-	65	B
produced	-	74	O
by	-	83	O
pilocarpine	-	86	O
in	-	98	O
rats	-	101	O
.	-	105	O

The	3191389	107	O
muscarinic	-	111	O
cholinergic	-	122	O
agonist	-	134	O
pilocarpine	-	142	O
induces	-	154	O
in	-	162	O
rats	-	165	O
seizures	-	170	B
and	-	179	O
status	-	183	B
epilepticus	-	190	I
followed	-	202	O
by	-	211	O
widespread	-	214	O
damage	-	225	O
to	-	232	O
the	-	235	O
forebrain	-	239	O
.	-	248	O

The	3191389	250	O
present	-	254	O
study	-	262	O
was	-	268	O
designed	-	272	O
to	-	281	O
investigate	-	284	O
the	-	296	O
effect	-	300	O
of	-	307	O
5	-	310	O
non	-	312	O
-	-	315	O
steroidal	-	316	O
anti	-	326	O
-	-	330	O
inflammatory	-	331	O
drugs	-	344	O
,	-	349	O
sodium	-	351	O
salicylate	-	358	O
,	-	368	O
phenylbutazone	-	370	O
,	-	384	O
indomethacin	-	386	O
,	-	398	O
ibuprofen	-	400	O
and	-	410	O
mefenamic	-	414	O
acid	-	424	O
,	-	428	O
on	-	430	O
seizures	-	433	B
produced	-	442	O
by	-	451	O
pilocarpine	-	454	O
.	-	465	O

Pretreatment	3191389	467	O
of	-	480	O
rats	-	483	O
with	-	488	O
sodium	-	493	O
salicylate	-	500	O
,	-	510	O
ED50	-	512	O
103	-	517	O
mg	-	521	O
/	-	523	O
kg	-	524	O
(	-	527	O
60	-	528	O
-	-	530	O
174	-	531	O
)	-	534	O
,	-	535	O
and	-	537	O
phenylbutazone	-	541	O
,	-	555	O
59	-	557	O
mg	-	560	O
/	-	562	O
kg	-	563	O
(	-	566	O
50	-	567	O
-	-	569	O
70	-	570	O
)	-	572	O
converted	-	574	O
the	-	584	O
non	-	588	O
-	-	591	O
convulsant	-	592	O
dose	-	603	O
of	-	608	O
pilocarpine	-	611	O
,	-	622	O
200	-	624	O
mg	-	628	O
/	-	630	O
kg	-	631	O
,	-	633	O
to	-	635	O
a	-	638	O
convulsant	-	640	O
one	-	651	O
.	-	654	O

Indomethacin	3191389	656	O
,	-	668	O
1	-	670	O
-	-	671	O
10	-	672	O
mg	-	675	O
/	-	677	O
kg	-	678	O
,	-	680	O
and	-	682	O
ibuprofen	-	686	O
,	-	695	O
10	-	697	O
-	-	699	O
100	-	700	O
mg	-	704	O
/	-	706	O
kg	-	707	O
,	-	709	O
failed	-	711	O
to	-	718	O
modulate	-	721	O
seizures	-	730	B
produced	-	739	O
by	-	748	O
pilocarpine	-	751	O
.	-	762	O

Mefenamic	3191389	764	O
acid	-	774	O
,	-	778	O
26	-	780	O
(	-	783	O
22	-	784	O
-	-	786	O
30	-	787	O
)	-	789	O
mg	-	791	O
/	-	793	O
kg	-	794	O
,	-	796	O
prevented	-	798	O
seizures	-	808	B
and	-	817	O
protected	-	821	O
rats	-	831	O
from	-	836	O
seizure	-	841	B
-	-	848	O
related	-	849	O
brain	-	857	B
damage	-	863	I
induced	-	870	O
by	-	878	O
pilocarpine	-	881	O
,	-	892	O
380	-	894	O
mg	-	898	O
/	-	900	O
kg	-	901	O
.	-	903	O

These	3191389	905	O
results	-	911	O
indicate	-	919	O
that	-	928	O
non	-	933	O
-	-	936	O
steroidal	-	937	O
anti	-	947	O
-	-	951	O
inflammatory	-	952	O
drugs	-	965	O
differentially	-	971	O
modulate	-	986	O
the	-	995	O
threshold	-	999	O
for	-	1009	O
pilocarpine	-	1013	O
-	-	1024	O
induced	-	1025	O
seizures	-	1033	B
.	-	1041	O

Acute	3289726	0	B
neurologic	-	6	I
dysfunction	-	17	I
after	-	29	O
high	-	35	O
-	-	39	O
dose	-	40	O
etoposide	-	45	O
therapy	-	55	O
for	-	63	O
malignant	-	67	B
glioma	-	77	I
.	-	83	O

Etoposide	3289726	85	O
(	-	95	O
VP	-	96	O
-	-	98	O
16	-	99	O
-	-	101	O
213	-	102	O
)	-	105	O
has	-	107	O
been	-	111	O
used	-	116	O
in	-	121	O
the	-	124	O
treatment	-	128	O
of	-	138	O
many	-	141	O
solid	-	146	O
tumors	-	152	B
and	-	159	O
hematologic	-	163	B
malignancies	-	175	I
.	-	187	O

When	3289726	189	O
used	-	194	O
in	-	199	O
high	-	202	O
doses	-	207	O
and	-	213	O
in	-	217	O
conjunction	-	220	O
with	-	232	O
autologous	-	237	O
bone	-	248	O
marrow	-	253	O
transplantation	-	260	O
,	-	275	O
this	-	277	O
agent	-	282	O
has	-	288	O
activity	-	292	O
against	-	301	O
several	-	309	O
treatment	-	317	O
-	-	326	O
resistant	-	327	O
cancers	-	337	B
including	-	345	O
malignant	-	355	B
glioma	-	365	I
.	-	371	O

In	3289726	373	O
six	-	376	O
of	-	380	O
eight	-	383	O
patients	-	389	O
(	-	398	O
75	-	399	O
%	-	401	O
)	-	402	O
who	-	404	O
we	-	408	O
treated	-	411	O
for	-	419	O
recurrent	-	423	O
or	-	433	O
resistant	-	436	O
glioma	-	446	B
,	-	452	O
sudden	-	454	O
severe	-	461	O
neurologic	-	468	B
deterioration	-	479	I
occurred	-	493	O
.	-	501	O

This	3289726	503	O
developed	-	508	O
a	-	518	O
median	-	520	O
of	-	527	O
9	-	530	O
days	-	532	O
after	-	537	O
initiation	-	543	O
of	-	554	O
high	-	557	O
-	-	561	O
dose	-	562	O
etoposide	-	567	O
therapy	-	577	O
.	-	584	O

Significant	3289726	586	O
clinical	-	598	O
manifestations	-	607	O
have	-	622	O
included	-	627	O
confusion	-	636	B
,	-	645	O
papilledema	-	647	B
,	-	658	O
somnolence	-	660	B
,	-	670	O
exacerbation	-	672	O
of	-	685	O
motor	-	688	B
deficits	-	694	I
,	-	702	O
and	-	704	O
sharp	-	708	O
increase	-	714	O
in	-	723	O
seizure	-	726	B
activity	-	734	O
.	-	742	O

These	3289726	744	O
abnormalities	-	750	O
resolved	-	764	O
rapidly	-	773	O
after	-	781	O
initiation	-	787	O
of	-	798	O
high	-	801	O
-	-	805	O
dose	-	806	O
intravenous	-	811	O
dexamethasone	-	823	O
therapy	-	837	O
.	-	844	O

In	3289726	846	O
all	-	849	O
patients	-	853	O
,	-	861	O
computerized	-	863	O
tomographic	-	876	O
(	-	888	O
CT	-	889	O
)	-	891	O
brain	-	893	O
scans	-	899	O
demonstrated	-	905	O
stability	-	918	O
in	-	928	O
tumor	-	931	B
size	-	937	O
and	-	942	O
peritumor	-	946	O
edema	-	956	B
when	-	962	O
compared	-	967	O
with	-	976	O
pretransplant	-	981	O
scans	-	995	O
.	-	1000	O

This	3289726	1002	O
complication	-	1007	O
appears	-	1020	O
to	-	1028	O
represent	-	1031	O
a	-	1041	O
significant	-	1043	O
new	-	1055	O
toxicity	-	1059	B
of	-	1068	O
high	-	1071	O
-	-	1075	O
dose	-	1076	O
etoposide	-	1081	O
therapy	-	1091	O
for	-	1099	O
malignant	-	1103	B
glioma	-	1113	I
.	-	1119	O

Progressive	3297909	0	O
bile	-	12	B
duct	-	17	I
injury	-	22	I
after	-	29	O
thiabendazole	-	35	O
administration	-	49	O
.	-	63	O

A	3297909	65	O
27	-	67	O
-	-	69	O
yr	-	70	O
-	-	72	O
old	-	73	O
man	-	77	O
developed	-	81	O
jaundice	-	91	B
2	-	100	O
wk	-	102	O
after	-	105	O
exposure	-	111	O
to	-	120	O
thiabendazole	-	123	O
.	-	136	O

Cholestasis	3297909	138	B
persisted	-	150	O
for	-	160	O
3	-	164	O
yr	-	166	O
,	-	168	O
at	-	170	O
which	-	173	O
time	-	179	O
a	-	184	O
liver	-	186	O
transplant	-	192	O
was	-	203	O
performed	-	207	O
.	-	216	O

Two	3297909	218	O
liver	-	222	O
biopsy	-	228	O
specimens	-	235	O
and	-	245	O
the	-	249	O
hepatectomy	-	253	O
specimen	-	265	O
were	-	274	O
remarkable	-	279	O
for	-	290	O
almost	-	294	O
complete	-	301	O
disappearance	-	310	O
of	-	324	O
interlobular	-	327	O
bile	-	340	O
ducts	-	345	O
.	-	350	O

Prominent	3297909	352	O
fibrosis	-	362	B
and	-	371	O
hepatocellular	-	375	O
regeneration	-	390	O
were	-	403	O
also	-	408	O
present	-	413	O
;	-	420	O
however	-	422	O
,	-	429	O
the	-	431	O
lobular	-	435	O
architecture	-	443	O
was	-	456	O
preserved	-	460	O
.	-	469	O

This	3297909	471	O
case	-	476	O
represents	-	481	O
an	-	492	O
example	-	495	O
of	-	503	O
""""	-	506	O
idiosyncratic	-	507	O
""""	-	520	O
drug	-	522	B
-	-	526	I
induced	-	527	I
liver	-	535	I
damage	-	541	I
in	-	548	O
which	-	551	O
the	-	557	O
primary	-	561	O
target	-	569	O
of	-	576	O
injury	-	579	O
is	-	586	O
the	-	589	O
bile	-	593	O
duct	-	598	O
.	-	602	O

An	3297909	604	O
autoimmune	-	607	O
pathogenesis	-	618	O
of	-	631	O
the	-	634	O
bile	-	638	B
duct	-	643	I
destruction	-	648	I
is	-	660	O
suggested	-	663	O
.	-	672	O

Differential	3323259	0	O
effects	-	13	O
of	-	21	O
1	-	24	O
,	-	25	O
4	-	26	O
-	-	27	O
dihydropyridine	-	28	O
calcium	-	44	O
channel	-	52	O
blockers	-	60	O
:	-	68	O
therapeutic	-	70	O
implications	-	82	O
.	-	94	O

Increasing	3323259	96	O
recognition	-	107	O
of	-	119	O
the	-	122	O
importance	-	126	O
of	-	137	O
calcium	-	140	O
in	-	148	O
the	-	151	O
pathogenesis	-	155	O
of	-	168	O
cardiovascular	-	171	B
disease	-	186	I
has	-	194	O
stimulated	-	198	O
research	-	209	O
into	-	218	O
the	-	223	O
use	-	227	O
of	-	231	O
calcium	-	234	O
channel	-	242	O
blocking	-	250	O
agents	-	259	O
for	-	266	O
treatment	-	270	O
of	-	280	O
a	-	283	O
variety	-	285	O
of	-	293	O
cardiovascular	-	296	B
diseases	-	311	I
.	-	319	O

The	3323259	321	O
favorable	-	325	O
efficacy	-	335	O
and	-	344	O
tolerability	-	348	O
profiles	-	361	O
of	-	370	O
these	-	373	O
agents	-	379	O
make	-	386	O
them	-	391	O
attractive	-	396	O
therapeutic	-	407	O
modalities	-	419	O
.	-	429	O

Clinical	3323259	431	O
applications	-	440	O
of	-	453	O
calcium	-	456	O
channel	-	464	O
blockers	-	472	O
parallel	-	481	O
their	-	490	O
tissue	-	496	O
selectivity	-	503	O
.	-	514	O

In	3323259	516	O
contrast	-	519	O
to	-	528	O
verapamil	-	531	O
and	-	541	O
diltiazem	-	545	O
,	-	554	O
which	-	556	O
are	-	562	O
roughly	-	566	O
equipotent	-	574	O
in	-	585	O
their	-	588	O
actions	-	594	O
on	-	602	O
the	-	605	O
heart	-	609	O
and	-	615	O
vascular	-	619	O
smooth	-	628	O
muscle	-	635	O
,	-	641	O
the	-	643	O
dihydropyridine	-	647	O
calcium	-	663	O
channel	-	671	O
blockers	-	679	O
are	-	688	O
a	-	692	O
group	-	694	O
of	-	700	O
potent	-	703	O
peripheral	-	710	O
vasodilator	-	721	O
agents	-	733	O
that	-	740	O
exert	-	745	O
minimal	-	751	O
electrophysiologic	-	759	O
effects	-	778	O
on	-	786	O
cardiac	-	789	O
nodal	-	797	O
or	-	803	O
conduction	-	806	O
tissue	-	817	O
.	-	823	O

As	3323259	825	O
the	-	828	O
first	-	832	O
dihydropyridine	-	838	O
available	-	854	O
for	-	864	O
use	-	868	O
in	-	872	O
the	-	875	O
United	-	879	O
States	-	886	O
,	-	892	O
nifedipine	-	894	O
controls	-	905	O
angina	-	914	B
and	-	921	O
hypertension	-	925	B
with	-	938	O
minimal	-	943	O
depression	-	951	O
of	-	962	O
cardiac	-	965	O
function	-	973	O
.	-	981	O

Additional	3323259	983	O
members	-	994	O
of	-	1002	O
this	-	1005	O
group	-	1010	O
of	-	1016	O
calcium	-	1019	O
channel	-	1027	O
blockers	-	1035	O
have	-	1044	O
been	-	1049	O
studied	-	1054	O
for	-	1062	O
a	-	1066	O
variety	-	1068	O
of	-	1076	O
indications	-	1079	O
for	-	1091	O
which	-	1095	O
they	-	1101	O
may	-	1106	O
offer	-	1110	O
advantages	-	1116	O
over	-	1127	O
current	-	1132	O
therapy	-	1140	O
.	-	1147	O

Once	3323259	1149	O
or	-	1154	O
twice	-	1157	O
daily	-	1163	O
dosage	-	1169	O
possible	-	1176	O
with	-	1185	O
nitrendipine	-	1190	O
and	-	1203	O
nisoldipine	-	1207	O
offers	-	1219	O
a	-	1226	O
convenient	-	1228	O
administration	-	1239	O
schedule	-	1254	O
,	-	1262	O
which	-	1264	O
encourages	-	1270	O
patient	-	1281	O
compliance	-	1289	O
in	-	1300	O
long	-	1303	O
-	-	1307	O
term	-	1308	O
therapy	-	1313	O
of	-	1321	O
hypertension	-	1324	B
.	-	1336	O

The	3323259	1338	O
coronary	-	1342	O
vasodilating	-	1351	O
properties	-	1364	O
of	-	1375	O
nisoldipine	-	1378	O
have	-	1390	O
led	-	1395	O
to	-	1399	O
the	-	1402	O
investigation	-	1406	O
of	-	1420	O
this	-	1423	O
agent	-	1428	O
for	-	1434	O
use	-	1438	O
in	-	1442	O
angina	-	1445	B
.	-	1451	O

Selectivity	3323259	1453	O
for	-	1465	O
the	-	1469	O
cerebrovascular	-	1473	O
bed	-	1489	O
makes	-	1493	O
nimodipine	-	1499	O
potentially	-	1510	O
useful	-	1522	O
in	-	1529	O
the	-	1532	O
treatment	-	1536	O
of	-	1546	O
subarachnoid	-	1549	B
hemorrhage	-	1562	I
,	-	1572	O
migraine	-	1574	B
headache	-	1583	I
,	-	1591	O
dementia	-	1593	B
,	-	1601	O
and	-	1603	O
stroke	-	1607	B
.	-	1613	O

In	3323259	1615	O
general	-	1618	O
,	-	1625	O
the	-	1627	O
dihydropyridine	-	1631	O
calcium	-	1647	O
channel	-	1655	O
blockers	-	1663	O
are	-	1672	O
usually	-	1676	O
well	-	1684	O
tolerated	-	1689	O
,	-	1698	O
with	-	1700	O
headache	-	1705	B
,	-	1713	O
facial	-	1715	O
flushing	-	1722	B
,	-	1730	O
palpitations	-	1732	B
,	-	1744	O
edema	-	1746	B
,	-	1751	O
nausea	-	1753	B
,	-	1759	O
anorexia	-	1761	B
,	-	1769	O
and	-	1771	O
dizziness	-	1775	B
being	-	1785	O
the	-	1791	O
more	-	1795	O
common	-	1800	O
adverse	-	1807	O
effects	-	1815	O
.	-	1822	O

The	3323599	0	O
enhancement	-	4	O
of	-	16	O
aminonucleoside	-	19	O
nephrosis	-	35	B
by	-	45	O
the	-	48	O
co	-	52	O
-	-	54	O
administration	-	55	O
of	-	70	O
protamine	-	73	O
.	-	82	O

An	3323599	84	O
experimental	-	87	O
model	-	100	O
of	-	106	O
focal	-	109	B
segmental	-	115	I
glomerular	-	125	I
sclerosis	-	136	I
(	-	146	O
FSGS	-	147	B
)	-	151	O
was	-	153	O
developed	-	157	O
in	-	167	O
rats	-	170	O
by	-	175	O
the	-	178	O
combined	-	182	O
administration	-	191	O
of	-	206	O
puromycin	-	209	O
-	-	218	O
aminonucleoside	-	219	O
(	-	235	O
AMNS	-	236	O
)	-	240	O
and	-	242	O
protamine	-	246	O
sulfate	-	256	O
(	-	264	O
PS	-	265	O
)	-	267	O
.	-	268	O

Male	3323599	270	O
Sprague	-	275	O
-	-	282	O
Dawley	-	283	O
rats	-	290	O
,	-	294	O
uninephrectomized	-	296	O
three	-	314	O
weeks	-	320	O
before	-	326	O
,	-	332	O
received	-	334	O
daily	-	343	O
injections	-	349	O
of	-	360	O
subcutaneous	-	363	O
AMNS	-	376	O
(	-	381	O
1	-	382	O
mg	-	384	O
/	-	386	O
100	-	387	O
g	-	391	O
body	-	393	O
wt	-	398	O
)	-	400	O
and	-	402	O
intravenous	-	406	O
PS	-	418	O
(	-	421	O
2	-	422	O
separated	-	424	O
doses	-	434	O
of	-	440	O
2	-	443	O
.	-	444	O
5	-	445	O
mg	-	447	O
/	-	449	O
100	-	450	O
g	-	454	O
body	-	456	O
wt	-	461	O
)	-	463	O
for	-	465	O
four	-	469	O
days	-	474	O
.	-	478	O

The	3323599	480	O
series	-	484	O
of	-	491	O
injections	-	494	O
were	-	505	O
repeated	-	510	O
another	-	519	O
three	-	527	O
times	-	533	O
at	-	539	O
10	-	542	O
day	-	545	O
intervals	-	549	O
.	-	558	O

The	3323599	560	O
animals	-	564	O
were	-	572	O
sacrificed	-	577	O
on	-	588	O
days	-	591	O
24	-	596	O
,	-	598	O
52	-	600	O
,	-	602	O
and	-	604	O
80	-	608	O
.	-	610	O

They	3323599	612	O
developed	-	617	O
nephrotic	-	627	B
syndrome	-	637	I
and	-	646	O
finally	-	650	O
renal	-	658	B
failure	-	664	I
.	-	671	O

The	3323599	673	O
time	-	677	O
-	-	681	O
course	-	682	O
curve	-	689	O
of	-	695	O
creatinine	-	698	O
clearance	-	709	O
dropped	-	719	O
and	-	727	O
showed	-	731	O
significant	-	738	O
difference	-	750	O
(	-	761	O
P	-	762	O
less	-	764	O
than	-	769	O
0	-	774	O
.	-	775	O
01	-	776	O
)	-	778	O
from	-	780	O
that	-	785	O
of	-	790	O
each	-	793	O
control	-	798	O
group	-	806	O
,	-	811	O
such	-	813	O
as	-	818	O
,	-	820	O
AMNS	-	822	O
alone	-	827	O
,	-	832	O
PS	-	834	O
alone	-	837	O
or	-	843	O
saline	-	846	O
injected	-	853	O
.	-	861	O

Their	3323599	863	O
glomeruli	-	869	O
showed	-	879	O
changes	-	886	O
of	-	894	O
progressive	-	897	O
FSGS	-	909	B
.	-	913	O

The	3323599	915	O
ultrastructural	-	919	O
studies	-	935	O
in	-	943	O
the	-	946	O
initial	-	950	O
stage	-	958	O
revealed	-	964	O
significant	-	973	O
lack	-	985	O
of	-	990	O
particles	-	993	O
of	-	1003	O
perfused	-	1006	O
ruthenium	-	1015	O
red	-	1025	O
on	-	1029	O
the	-	1032	O
lamina	-	1036	O
rara	-	1043	O
externa	-	1048	O
and	-	1056	O
marked	-	1060	O
changes	-	1067	O
in	-	1075	O
epithelial	-	1078	O
cell	-	1089	O
cytoplasm	-	1094	O
.	-	1103	O

Therefore	3323599	1105	O
,	-	1114	O
it	-	1116	O
is	-	1119	O
suggested	-	1122	O
that	-	1132	O
the	-	1137	O
administration	-	1141	O
of	-	1156	O
PS	-	1159	O
enhances	-	1162	O
the	-	1171	O
toxicity	-	1175	B
of	-	1184	O
AMNS	-	1187	O
on	-	1192	O
the	-	1195	O
glomerulus	-	1199	O
and	-	1210	O
readily	-	1214	O
produces	-	1222	O
progressive	-	1231	O
FSGS	-	1243	B
in	-	1248	O
rats	-	1251	O
resulting	-	1256	O
in	-	1266	O
the	-	1269	O
end	-	1273	B
-	-	1276	I
stage	-	1277	I
renal	-	1283	I
disease	-	1289	I
.	-	1296	O

Theophylline	3339945	0	O
neurotoxicity	-	13	B
in	-	27	O
pregnant	-	30	O
rats	-	39	O
.	-	43	O

The	3339945	45	O
purpose	-	49	O
of	-	57	O
this	-	60	O
investigation	-	65	O
was	-	79	O
to	-	83	O
determine	-	86	O
whether	-	96	O
the	-	104	O
neurotoxicity	-	108	B
of	-	122	O
theophylline	-	125	O
is	-	138	O
altered	-	141	O
in	-	149	O
advanced	-	152	O
pregnancy	-	161	O
.	-	170	O

Sprague	3339945	172	O
-	-	179	O
Dawley	-	180	O
rats	-	187	O
that	-	192	O
were	-	197	O
20	-	202	O
days	-	205	O
pregnant	-	210	O
and	-	219	O
nonpregnant	-	223	O
rats	-	235	O
of	-	240	O
the	-	243	O
same	-	247	O
age	-	252	O
and	-	256	O
strain	-	260	O
received	-	267	O
infusions	-	276	O
of	-	286	O
aminophylline	-	289	O
until	-	303	O
onset	-	309	O
of	-	315	O
maximal	-	318	O
seizures	-	326	B
which	-	335	O
occurred	-	341	O
after	-	350	O
28	-	356	O
and	-	359	O
30	-	363	O
minutes	-	366	O
respectively	-	374	O
.	-	386	O

Theophylline	3339945	388	O
concentrations	-	401	O
at	-	416	O
this	-	419	O
endpoint	-	424	O
in	-	433	O
serum	-	436	O
(	-	442	O
total	-	443	O
)	-	448	O
and	-	450	O
CSF	-	454	O
were	-	458	O
similar	-	463	O
but	-	471	O
serum	-	475	O
(	-	481	O
free	-	482	O
)	-	486	O
and	-	488	O
brain	-	492	O
concentrations	-	498	O
were	-	513	O
slightly	-	518	O
different	-	527	O
in	-	537	O
pregnant	-	540	O
rats	-	549	O
.	-	553	O

Theophylline	3339945	555	O
serum	-	568	O
protein	-	574	O
binding	-	582	O
determined	-	590	O
by	-	601	O
equilibrium	-	604	O
dialysis	-	616	O
was	-	625	O
lower	-	629	O
in	-	635	O
pregnant	-	638	O
rats	-	647	O
.	-	651	O

Fetal	3339945	653	O
serum	-	659	O
concentrations	-	665	O
at	-	680	O
onset	-	683	O
of	-	689	O
seizures	-	692	B
in	-	701	O
the	-	704	O
mother	-	708	O
were	-	715	O
similar	-	720	O
to	-	728	O
maternal	-	731	O
brain	-	740	O
and	-	746	O
CSF	-	750	O
concentrations	-	754	O
and	-	769	O
correlated	-	773	O
significantly	-	784	O
with	-	798	O
the	-	803	O
former	-	807	O
.	-	813	O

It	3339945	815	O
is	-	818	O
concluded	-	821	O
that	-	831	O
advanced	-	836	O
pregnancy	-	845	O
has	-	855	O
a	-	859	O
negligible	-	861	O
effect	-	872	O
on	-	879	O
the	-	882	O
neurotoxic	-	886	B
response	-	897	O
to	-	906	O
theophylline	-	909	O
in	-	922	O
rats	-	925	O
.	-	929	O

Hyperkalemia	3375885	0	B
induced	-	13	O
by	-	21	O
indomethacin	-	24	O
and	-	37	O
naproxen	-	41	O
and	-	50	O
reversed	-	54	O
by	-	63	O
fludrocortisone	-	66	O
.	-	81	O

We	3375885	83	O
have	-	86	O
described	-	91	O
a	-	101	O
patient	-	103	O
with	-	111	O
severe	-	116	O
rheumatoid	-	123	B
arthritis	-	134	I
and	-	144	O
a	-	148	O
history	-	150	O
of	-	158	O
mefenamic	-	161	O
acid	-	171	O
nephropathy	-	176	B
in	-	188	O
whom	-	191	O
hyperkalemia	-	196	B
and	-	209	O
inappropriate	-	213	O
hypoaldosteronism	-	227	B
were	-	245	O
caused	-	250	O
by	-	257	O
both	-	260	O
indomethacin	-	265	O
and	-	278	O
naproxen	-	282	O
,	-	290	O
without	-	292	O
major	-	300	O
decline	-	306	O
in	-	314	O
renal	-	317	O
function	-	323	O
.	-	331	O

It	3375885	333	O
is	-	336	O
likely	-	339	O
that	-	346	O
preexisting	-	351	O
renal	-	363	B
disease	-	369	I
predisposed	-	377	O
this	-	389	O
patient	-	394	O
to	-	402	O
type	-	405	B
IV	-	410	I
renal	-	413	I
tubular	-	419	I
acidosis	-	427	I
with	-	436	O
prostaglandin	-	441	O
synthetase	-	455	O
inhibitors	-	466	O
.	-	476	O

Because	3375885	478	O
he	-	486	O
was	-	489	O
unable	-	493	O
to	-	500	O
discontinue	-	503	O
nonsteroidal	-	515	O
anti	-	528	O
-	-	532	O
inflammatory	-	533	O
drug	-	546	O
therapy	-	551	O
,	-	558	O
fludrocortisone	-	560	O
was	-	576	O
added	-	580	O
,	-	585	O
correcting	-	587	O
the	-	598	O
hyperkalemia	-	602	B
and	-	615	O
allowing	-	619	O
indomethacin	-	628	O
therapy	-	641	O
to	-	649	O
be	-	652	O
continued	-	655	O
safely	-	665	O
.	-	671	O

Hypotension	3383127	0	B
as	-	12	O
a	-	15	O
manifestation	-	17	O
of	-	31	O
cardiotoxicity	-	34	B
in	-	49	O
three	-	52	O
patients	-	58	O
receiving	-	67	O
cisplatin	-	77	O
and	-	87	O
5	-	91	O
-	-	92	O
fluorouracil	-	93	O
.	-	105	O

Cardiac	3383127	107	O
symptoms	-	115	O
,	-	123	O
including	-	125	O
hypotension	-	135	B
,	-	146	O
developed	-	148	O
in	-	158	O
three	-	161	O
patients	-	167	O
with	-	176	O
advanced	-	181	O
colorectal	-	190	B
carcinoma	-	201	I
while	-	211	O
being	-	217	O
treated	-	223	O
with	-	231	O
cisplatin	-	236	O
(	-	246	O
CDDP	-	247	O
)	-	251	O
and	-	253	O
5	-	257	O
-	-	258	O
fluorouracil	-	259	O
(	-	272	O
5	-	273	O
-	-	274	O
FU	-	275	O
)	-	277	O
.	-	278	O

In	3383127	280	O
two	-	283	O
patients	-	287	O
,	-	295	O
hypotension	-	297	B
was	-	309	O
associated	-	313	O
with	-	324	O
severe	-	329	O
left	-	336	B
ventricular	-	341	I
dysfunction	-	353	I
.	-	364	O

All	3383127	366	O
three	-	370	O
patients	-	376	O
required	-	385	O
therapy	-	394	O
discontinuation	-	402	O
.	-	417	O

Cardiac	3383127	419	O
enzymes	-	427	O
remained	-	435	O
normal	-	444	O
despite	-	451	O
transient	-	459	O
electrocardiographic	-	469	O
(	-	490	O
EKG	-	491	O
)	-	494	O
changes	-	496	O
.	-	503	O

The	3383127	505	O
presentation	-	509	O
and	-	522	O
cardiac	-	526	O
evaluation	-	534	O
(	-	545	O
hemodynamic	-	546	O
,	-	557	O
echocardiographic	-	559	O
,	-	576	O
and	-	578	O
scintigraphic	-	582	O
)	-	595	O
of	-	597	O
these	-	600	O
patients	-	606	O
suggest	-	615	O
new	-	623	O
manifestations	-	627	O
of	-	642	O
5	-	645	O
-	-	646	O
FU	-	647	O
cardiotoxicity	-	650	B
that	-	665	O
may	-	670	O
be	-	674	O
influenced	-	677	O
by	-	688	O
CDDP	-	691	O
.	-	695	O

The	3383127	697	O
possible	-	701	O
pathophysiologic	-	710	O
mechanisms	-	727	O
are	-	738	O
discussed	-	742	O
.	-	751	O

Fatal	3409843	0	O
aplastic	-	6	B
anemia	-	15	I
in	-	22	O
a	-	25	O
patient	-	27	O
treated	-	35	O
with	-	43	O
carbamazepine	-	48	O
.	-	61	O

A	3409843	63	O
case	-	65	O
of	-	70	O
fatal	-	73	O
aplastic	-	79	B
anemia	-	88	I
due	-	95	O
to	-	99	O
carbamazepine	-	102	O
treatment	-	116	O
in	-	126	O
an	-	129	O
epileptic	-	132	B
woman	-	142	O
is	-	148	O
reported	-	151	O
.	-	159	O

Despite	3409843	161	O
concerns	-	169	O
of	-	178	O
fatal	-	181	O
bone	-	187	B
marrow	-	192	I
toxicity	-	199	I
due	-	208	O
to	-	212	O
carbamazepine	-	215	O
,	-	228	O
this	-	230	O
is	-	235	O
only	-	238	O
the	-	243	O
fourth	-	247	O
documented	-	254	O
and	-	265	O
published	-	269	O
report	-	279	O
.	-	285	O

Carbamazepine	3409843	287	O
is	-	301	O
a	-	304	O
safe	-	306	O
drug	-	311	O
,	-	315	O
but	-	317	O
physicians	-	321	O
and	-	332	O
patients	-	336	O
should	-	345	O
be	-	352	O
aware	-	355	O
of	-	361	O
the	-	364	O
exceedingly	-	368	O
rare	-	380	O
but	-	385	O
potentially	-	389	O
fatal	-	401	O
side	-	407	O
effects	-	412	O
,	-	419	O
better	-	421	O
prevented	-	428	O
by	-	438	O
clinical	-	441	O
than	-	450	O
by	-	455	O
laboratory	-	458	O
monitoring	-	469	O
.	-	479	O

Participation	3423103	0	O
of	-	14	O
a	-	17	O
bulbospinal	-	19	O
serotonergic	-	31	O
pathway	-	44	O
in	-	52	O
the	-	55	O
rat	-	59	O
brain	-	63	O
in	-	69	O
clonidine	-	72	O
-	-	81	O
induced	-	82	O
hypotension	-	90	B
and	-	102	O
bradycardia	-	106	B
.	-	117	O

The	3423103	119	O
effects	-	123	O
of	-	131	O
microinjection	-	134	O
of	-	149	O
clonidine	-	152	O
(	-	162	O
1	-	163	O
-	-	164	O
10	-	165	O
micrograms	-	168	O
in	-	179	O
1	-	182	O
microliter	-	184	O
)	-	194	O
into	-	196	O
a	-	201	O
region	-	203	O
adjacent	-	210	O
to	-	219	O
the	-	222	O
ventrolateral	-	226	O
surface	-	240	O
of	-	248	O
the	-	251	O
medulla	-	255	O
oblongata	-	263	O
on	-	273	O
cardiovascular	-	276	O
function	-	291	O
were	-	300	O
assessed	-	305	O
in	-	314	O
urethane	-	317	O
-	-	325	O
anesthetized	-	326	O
rats	-	339	O
.	-	343	O

Intramedullary	3423103	345	O
administration	-	360	O
of	-	375	O
clonidine	-	378	O
,	-	387	O
but	-	389	O
not	-	393	O
saline	-	397	O
vehicle	-	404	O
,	-	411	O
caused	-	413	O
a	-	420	O
dose	-	422	O
-	-	426	O
dependent	-	427	O
decrease	-	437	O
in	-	446	O
both	-	449	O
the	-	454	O
mean	-	458	O
arterial	-	463	O
pressure	-	472	O
and	-	481	O
the	-	485	O
heart	-	489	O
rate	-	495	O
.	-	499	O

The	3423103	501	O
clonidine	-	505	O
-	-	514	O
induced	-	515	O
hypotension	-	523	B
was	-	535	O
antagonized	-	539	O
by	-	551	O
prior	-	554	O
spinal	-	560	O
transection	-	567	O
,	-	578	O
but	-	580	O
not	-	584	O
bilateral	-	588	O
vagotomy	-	598	O
.	-	606	O

On	3423103	608	O
the	-	611	O
other	-	615	O
hand	-	621	O
,	-	625	O
the	-	627	O
clonidine	-	631	O
-	-	640	O
induced	-	641	O
bradycardia	-	649	B
was	-	661	O
antagonized	-	665	O
by	-	677	O
prior	-	680	O
bilateral	-	686	O
vagotomy	-	696	O
,	-	704	O
but	-	706	O
not	-	710	O
spinal	-	714	O
transection	-	721	O
.	-	732	O

Furthermore	3423103	734	O
,	-	745	O
selective	-	747	O
destruction	-	757	O
of	-	769	O
the	-	772	O
spinal	-	776	O
5	-	783	O
-	-	784	O
HT	-	785	O
nerves	-	788	O
,	-	794	O
produced	-	796	O
by	-	805	O
bilateral	-	808	O
spinal	-	818	O
injection	-	825	O
of	-	835	O
5	-	838	O
,	-	839	O
7	-	840	O
-	-	841	O
dihydroxytryptamine	-	842	O
,	-	861	O
reduced	-	863	O
the	-	871	O
magnitude	-	875	O
of	-	885	O
the	-	888	O
vasodepressor	-	892	O
or	-	906	O
the	-	909	O
bradycardiac	-	913	B
responses	-	926	O
to	-	936	O
clonidine	-	939	O
microinjected	-	949	O
into	-	963	O
the	-	968	O
area	-	972	O
near	-	977	O
the	-	982	O
ventrolateral	-	986	O
surface	-	1000	O
of	-	1008	O
the	-	1011	O
medulla	-	1015	O
oblongata	-	1023	O
in	-	1033	O
rats	-	1036	O
.	-	1040	O

The	3423103	1042	O
data	-	1046	O
indicate	-	1051	O
that	-	1060	O
a	-	1065	O
bulbospinal	-	1067	O
serotonergic	-	1079	O
pathway	-	1092	O
is	-	1100	O
involved	-	1103	O
in	-	1112	O
development	-	1115	O
of	-	1127	O
clonidine	-	1130	O
-	-	1139	O
induced	-	1140	O
hypotension	-	1148	B
and	-	1160	O
bradycardia	-	1164	B
.	-	1175	O

The	3423103	1177	O
induced	-	1181	O
hypotension	-	1189	B
is	-	1201	O
brought	-	1204	O
about	-	1212	O
by	-	1218	O
a	-	1221	O
decrease	-	1223	O
in	-	1232	O
sympathetic	-	1235	O
efferent	-	1247	O
activity	-	1256	O
,	-	1264	O
whereas	-	1266	O
the	-	1274	O
induced	-	1278	O
bradycardia	-	1286	B
was	-	1298	O
due	-	1302	O
to	-	1306	O
an	-	1309	O
increase	-	1312	O
in	-	1321	O
vagal	-	1324	O
efferent	-	1330	O
activity	-	1339	O
.	-	1347	O

Hypertension	3439580	0	B
in	-	13	O
neuroblastoma	-	16	B
induced	-	30	O
by	-	38	O
imipramine	-	41	O
.	-	51	O

Hypertension	3439580	53	B
is	-	66	O
a	-	69	O
well	-	71	O
-	-	75	O
known	-	76	O
finding	-	82	O
in	-	90	O
some	-	93	O
patients	-	98	O
with	-	107	O
neuroblastoma	-	112	B
.	-	125	O

However	3439580	127	O
,	-	134	O
it	-	136	O
has	-	139	O
not	-	143	O
previously	-	147	O
been	-	158	O
described	-	163	O
in	-	173	O
association	-	176	O
with	-	188	O
the	-	193	O
use	-	197	O
of	-	201	O
Imipramine	-	204	O
.	-	214	O

We	3439580	216	O
report	-	219	O
the	-	226	O
occurrence	-	230	O
of	-	241	O
severe	-	244	O
hypertension	-	251	B
(	-	264	O
blood	-	265	O
pressure	-	271	O
190	-	280	O
/	-	283	O
160	-	284	O
)	-	287	O
in	-	289	O
a	-	292	O
4	-	294	O
-	-	295	O
year	-	296	O
-	-	300	O
old	-	301	O
girl	-	305	O
with	-	310	O
neuroblastoma	-	315	B
who	-	329	O
was	-	333	O
given	-	337	O
Imipramine	-	343	O
to	-	354	O
control	-	357	O
a	-	365	O
behavior	-	367	B
disorder	-	376	I
.	-	384	O

It	3439580	386	O
was	-	389	O
determined	-	393	O
later	-	404	O
that	-	410	O
this	-	415	O
patient	-	420	O
's	-	427	O
tumor	-	430	B
was	-	436	O
recurring	-	440	O
at	-	450	O
the	-	453	O
time	-	457	O
of	-	462	O
her	-	465	O
hypertensive	-	469	B
episode	-	482	O
.	-	489	O

Since	3439580	491	O
she	-	497	O
had	-	501	O
no	-	505	O
blood	-	508	O
pressure	-	514	O
elevation	-	523	O
at	-	533	O
initial	-	536	O
diagnosis	-	544	O
and	-	554	O
none	-	558	O
following	-	563	O
discontinuation	-	573	O
of	-	589	O
the	-	592	O
Imipramine	-	596	O
(	-	607	O
when	-	608	O
she	-	613	O
was	-	617	O
in	-	621	O
florid	-	624	O
relapse	-	631	O
)	-	638	O
,	-	639	O
we	-	641	O
believe	-	644	O
that	-	652	O
this	-	657	O
drug	-	662	O
rather	-	667	O
than	-	674	O
her	-	679	O
underlying	-	683	O
disease	-	694	O
alone	-	702	O
caused	-	708	O
her	-	715	O
hypertension	-	719	B
.	-	731	O

The	3439580	733	O
mechanism	-	737	O
for	-	747	O
this	-	751	O
reaction	-	756	O
is	-	765	O
believed	-	768	O
to	-	777	O
be	-	780	O
increased	-	783	O
levels	-	793	O
of	-	800	O
vasoactive	-	803	O
catecholamines	-	814	O
due	-	829	O
to	-	833	O
interference	-	836	O
of	-	849	O
their	-	852	O
physiologic	-	858	O
inactivation	-	870	O
by	-	883	O
Imipramine	-	886	O
.	-	896	O

From	3439580	898	O
this	-	903	O
experience	-	908	O
,	-	918	O
we	-	920	O
urge	-	923	O
extreme	-	928	O
caution	-	936	O
in	-	944	O
the	-	947	O
use	-	951	O
of	-	955	O
tricyclic	-	958	O
antidepressants	-	968	O
in	-	984	O
children	-	987	O
with	-	996	O
active	-	1001	O
neuroblastoma	-	1008	B
.	-	1021	O

Rechallenge	3475563	0	O
of	-	12	O
patients	-	15	O
who	-	24	O
developed	-	28	O
oral	-	38	B
candidiasis	-	43	I
or	-	55	O
hoarseness	-	58	B
with	-	69	O
beclomethasone	-	74	O
dipropionate	-	89	O
.	-	101	O

Of	3475563	103	O
158	-	106	O
asthmatic	-	110	B
patients	-	120	O
who	-	129	O
were	-	133	O
placed	-	138	O
on	-	145	O
inhaled	-	148	O
beclomethasone	-	156	O
,	-	170	O
15	-	172	O
(	-	175	O
9	-	176	O
.	-	177	O
5	-	178	O
%	-	179	O
)	-	180	O
developed	-	182	O
either	-	192	O
hoarseness	-	199	B
(	-	210	O
8	-	211	O
)	-	212	O
,	-	213	O
oral	-	215	O
thrush	-	220	B
(	-	227	O
6	-	228	O
)	-	229	O
,	-	230	O
or	-	232	O
both	-	235	O
(	-	240	O
1	-	241	O
)	-	242	O
.	-	243	O

When	3475563	245	O
their	-	250	O
adverse	-	256	O
reactions	-	264	O
subsided	-	274	O
,	-	282	O
seven	-	284	O
of	-	290	O
these	-	293	O
15	-	299	O
patients	-	302	O
were	-	311	O
rechallenged	-	316	O
with	-	329	O
inhaled	-	334	O
beclomethasone	-	342	O
.	-	356	O

These	3475563	358	O
included	-	364	O
five	-	373	O
cases	-	378	O
who	-	384	O
developed	-	388	O
hoarseness	-	398	B
and	-	409	O
three	-	413	O
who	-	419	O
developed	-	423	O
Candidiasis	-	433	B
.	-	444	O

One	3475563	446	O
patient	-	450	O
had	-	458	O
both	-	462	O
.	-	466	O

Oral	3475563	468	O
thrush	-	473	B
did	-	480	O
not	-	484	O
recur	-	488	O
,	-	493	O
but	-	495	O
60	-	499	O
%	-	501	O
(	-	503	O
3	-	504	O
/	-	505	O
5	-	506	O
)	-	507	O
of	-	509	O
patients	-	512	O
with	-	521	O
hoarseness	-	526	B
had	-	537	O
recurrence	-	541	O
.	-	551	O

We	3475563	553	O
conclude	-	556	O
that	-	565	O
patients	-	570	O
may	-	579	O
be	-	583	O
restarted	-	586	O
on	-	596	O
inhaled	-	599	O
beclomethasone	-	607	O
when	-	622	O
clinically	-	627	O
indicated	-	638	O
;	-	647	O
however	-	649	O
,	-	656	O
because	-	658	O
of	-	666	O
the	-	669	O
high	-	673	O
recurrence	-	678	O
rate	-	689	O
,	-	693	O
patients	-	695	O
who	-	704	O
develop	-	708	O
hoarseness	-	716	B
should	-	727	O
not	-	734	O
be	-	738	O
re	-	741	O
-	-	743	O
challenged	-	744	O
.	-	754	O

Concomitant	3475563	756	O
use	-	768	O
of	-	772	O
oral	-	775	O
prednisone	-	780	O
and	-	791	O
topical	-	795	O
beclomethasone	-	803	O
may	-	818	O
increase	-	822	O
the	-	831	O
risk	-	835	O
of	-	840	O
developing	-	843	O
hoarseness	-	854	B
or	-	865	O
candidiasis	-	868	B
.	-	879	O

Cyclophosphamide	3533179	0	O
cardiotoxicity	-	17	B
:	-	31	O
an	-	33	O
analysis	-	36	O
of	-	45	O
dosing	-	48	O
as	-	55	O
a	-	58	O
risk	-	60	O
factor	-	65	O
.	-	71	O

Patients	3533179	73	O
who	-	82	O
undergo	-	86	O
bone	-	94	O
marrow	-	99	O
transplantation	-	106	O
are	-	122	O
generally	-	126	O
immunosuppressed	-	136	O
with	-	153	O
a	-	158	O
dose	-	160	O
of	-	165	O
cyclophosphamide	-	168	O
(	-	185	O
CYA	-	186	O
)	-	189	O
which	-	191	O
is	-	197	O
usually	-	200	O
calculated	-	208	O
based	-	219	O
on	-	225	O
the	-	228	O
patient	-	232	O
's	-	239	O
weight	-	242	O
.	-	248	O

At	3533179	250	O
these	-	253	O
high	-	259	O
doses	-	264	O
of	-	270	O
CYA	-	273	O
,	-	276	O
serious	-	278	O
cardiotoxicity	-	286	B
may	-	301	O
occur	-	305	O
,	-	310	O
but	-	312	O
definitive	-	316	O
risk	-	327	O
factors	-	332	O
for	-	340	O
the	-	344	O
development	-	348	O
of	-	360	O
such	-	363	O
cardiotoxicity	-	368	B
have	-	383	O
not	-	388	O
been	-	392	O
described	-	397	O
.	-	406	O

Since	3533179	408	O
chemotherapeutic	-	414	O
agent	-	431	O
toxicity	-	437	B
generally	-	446	O
correlates	-	456	O
with	-	467	O
dose	-	472	O
per	-	477	O
body	-	481	O
surface	-	486	O
area	-	494	O
,	-	498	O
we	-	500	O
retrospectively	-	503	O
calculated	-	519	O
the	-	530	O
dose	-	534	O
of	-	539	O
CYA	-	542	O
in	-	546	O
patients	-	549	O
transplanted	-	558	O
at	-	571	O
our	-	574	O
institution	-	578	O
to	-	590	O
determine	-	593	O
whether	-	603	O
the	-	611	O
incidence	-	615	O
of	-	625	O
CYA	-	628	O
cardiotoxicity	-	632	B
correlated	-	647	O
with	-	658	O
the	-	663	O
dose	-	667	O
per	-	672	O
body	-	676	O
surface	-	681	O
area	-	689	O
.	-	693	O

Eighty	3533179	695	O
patients	-	702	O
who	-	711	O
were	-	715	O
to	-	720	O
receive	-	723	O
CYA	-	731	O
50	-	735	O
mg	-	738	O
/	-	740	O
kg	-	741	O
/	-	743	O
d	-	744	O
for	-	746	O
four	-	750	O
days	-	755	O
as	-	760	O
preparation	-	763	O
for	-	775	O
marrow	-	779	O
grafting	-	786	O
underwent	-	795	O
a	-	805	O
total	-	807	O
of	-	813	O
84	-	816	O
transplants	-	819	O
for	-	831	O
aplastic	-	835	B
anemia	-	844	I
,	-	850	O
Wiskott	-	852	B
-	-	859	I
Aldrich	-	860	I
syndrome	-	868	I
,	-	876	O
or	-	878	O
severe	-	881	B
combined	-	888	I
immunodeficiency	-	897	I
syndrome	-	914	I
.	-	922	O

Fourteen	3533179	924	O
of	-	933	O
84	-	936	O
(	-	939	O
17	-	940	O
%	-	942	O
)	-	943	O
patients	-	945	O
had	-	954	O
symptoms	-	958	O
and	-	967	O
signs	-	971	O
consistent	-	977	O
with	-	988	O
CYA	-	993	O
cardiotoxicity	-	997	B
within	-	1012	O
ten	-	1019	O
days	-	1023	O
of	-	1028	O
receiving	-	1031	O
1	-	1041	O
to	-	1043	O
4	-	1046	O
doses	-	1048	O
of	-	1054	O
CYA	-	1057	O
.	-	1060	O

Six	3533179	1062	O
of	-	1066	O
the	-	1069	O
14	-	1073	O
patients	-	1076	O
died	-	1085	O
with	-	1090	O
congestive	-	1095	B
heart	-	1106	I
failure	-	1112	I
.	-	1119	O

The	3533179	1121	O
dose	-	1125	O
of	-	1130	O
CYA	-	1133	O
per	-	1137	O
body	-	1141	O
surface	-	1146	O
area	-	1154	O
was	-	1159	O
calculated	-	1163	O
for	-	1174	O
all	-	1178	O
patients	-	1182	O
and	-	1191	O
the	-	1195	O
patients	-	1199	O
were	-	1208	O
divided	-	1213	O
into	-	1221	O
two	-	1226	O
groups	-	1230	O
based	-	1237	O
on	-	1243	O
daily	-	1246	O
CYA	-	1252	O
dose	-	1256	O
:	-	1260	O
Group	-	1262	O
1	-	1268	O
,	-	1269	O
CYA	-	1271	O
less	-	1275	O
than	-	1280	O
or	-	1285	O
equal	-	1288	O
to	-	1294	O
1	-	1297	O
.	-	1298	O
55	-	1299	O
g	-	1302	O
/	-	1303	O
m2	-	1304	O
/	-	1306	O
d	-	1307	O
;	-	1308	O
Group	-	1310	O
2	-	1316	O
,	-	1317	O
CYA	-	1319	O
greater	-	1323	O
than	-	1331	O
1	-	1336	O
.	-	1337	O
55	-	1338	O
g	-	1341	O
/	-	1342	O
m2	-	1343	O
/	-	1345	O
d	-	1346	O
.	-	1347	O

Cardiotoxicity	3533179	1349	B
that	-	1364	O
was	-	1369	O
thought	-	1373	O
to	-	1381	O
be	-	1384	O
related	-	1387	O
to	-	1395	O
CYA	-	1398	O
occurred	-	1402	O
in	-	1411	O
1	-	1414	O
/	-	1415	O
32	-	1416	O
(	-	1419	O
3	-	1420	O
%	-	1421	O
)	-	1422	O
of	-	1424	O
patients	-	1427	O
in	-	1436	O
Group	-	1439	O
1	-	1445	O
and	-	1447	O
in	-	1451	O
13	-	1454	O
/	-	1456	O
52	-	1457	O
(	-	1460	O
25	-	1461	O
%	-	1463	O
)	-	1464	O
patients	-	1466	O
in	-	1475	O
Group	-	1478	O
2	-	1484	O
(	-	1486	O
P	-	1487	O
less	-	1489	O
than	-	1494	O
0	-	1499	O
.	-	1500	O
025	-	1501	O
)	-	1504	O
.	-	1505	O

Congestive	3533179	1507	B
heart	-	1518	I
failure	-	1524	I
caused	-	1532	O
or	-	1539	O
contributed	-	1542	O
to	-	1554	O
death	-	1557	O
in	-	1563	O
0	-	1566	O
/	-	1567	O
32	-	1568	O
patients	-	1571	O
in	-	1580	O
Group	-	1583	O
1	-	1589	O
v	-	1591	O
6	-	1593	O
/	-	1594	O
52	-	1595	O
(	-	1598	O
12	-	1599	O
%	-	1601	O
)	-	1602	O
of	-	1604	O
patients	-	1607	O
in	-	1616	O
Group	-	1619	O
2	-	1625	O
(	-	1627	O
P	-	1628	O
less	-	1630	O
than	-	1635	O
0	-	1640	O
.	-	1641	O
25	-	1642	O
)	-	1644	O
.	-	1645	O

There	3533179	1647	O
was	-	1653	O
no	-	1657	O
difference	-	1660	O
in	-	1671	O
the	-	1674	O
rate	-	1678	O
of	-	1683	O
engraftment	-	1686	O
of	-	1698	O
evaluable	-	1701	O
patients	-	1711	O
in	-	1720	O
the	-	1723	O
two	-	1727	O
groups	-	1731	O
(	-	1738	O
P	-	1739	O
greater	-	1741	O
than	-	1749	O
0	-	1754	O
.	-	1755	O
5	-	1756	O
)	-	1757	O
.	-	1758	O

We	3533179	1760	O
conclude	-	1763	O
that	-	1772	O
the	-	1777	O
CYA	-	1781	O
cardiotoxicity	-	1785	B
correlates	-	1800	O
with	-	1811	O
CYA	-	1816	O
dosage	-	1820	O
as	-	1827	O
calculated	-	1830	O
by	-	1841	O
body	-	1844	O
surface	-	1849	O
area	-	1857	O
,	-	1861	O
and	-	1863	O
that	-	1867	O
patients	-	1872	O
with	-	1881	O
aplastic	-	1886	B
anemia	-	1895	I
and	-	1902	O
immunodeficiencies	-	1906	B
can	-	1925	O
be	-	1929	O
effectively	-	1932	O
prepared	-	1944	O
for	-	1953	O
bone	-	1957	O
marrow	-	1962	O
grafting	-	1969	O
at	-	1978	O
a	-	1981	O
CYA	-	1983	O
dose	-	1987	O
of	-	1992	O
1	-	1995	O
.	-	1996	O
55	-	1997	O
g	-	2000	O
/	-	2001	O
m2	-	2002	O
/	-	2004	O
d	-	2005	O
for	-	2007	O
four	-	2011	O
days	-	2016	O
with	-	2021	O
a	-	2026	O
lower	-	2028	O
incidence	-	2034	O
of	-	2044	O
cardiotoxicity	-	2047	B
than	-	2062	O
patients	-	2067	O
whose	-	2076	O
CYA	-	2082	O
dosage	-	2086	O
is	-	2093	O
calculated	-	2096	O
based	-	2107	O
on	-	2113	O
weight	-	2116	O
.	-	2122	O

This	3533179	2124	O
study	-	2129	O
reaffirms	-	2135	O
the	-	2145	O
principle	-	2149	O
that	-	2159	O
drug	-	2164	O
toxicity	-	2169	B
correlates	-	2178	O
with	-	2189	O
dose	-	2194	O
per	-	2199	O
body	-	2203	O
surface	-	2208	O
area	-	2216	O
.	-	2220	O

Studies	3538855	0	O
of	-	8	O
risk	-	11	O
factors	-	16	O
for	-	24	O
aminoglycoside	-	28	O
nephrotoxicity	-	43	B
.	-	57	O

The	3538855	59	O
epidemiology	-	63	O
of	-	76	O
aminoglycoside	-	79	O
-	-	93	O
induced	-	94	O
nephrotoxicity	-	102	B
is	-	117	O
not	-	120	O
fully	-	124	O
understood	-	130	O
.	-	140	O

Experimental	3538855	142	O
studies	-	155	O
in	-	163	O
healthy	-	166	O
human	-	174	O
volunteers	-	180	O
indicate	-	191	O
aminoglycosides	-	200	O
cause	-	216	O
proximal	-	222	O
tubular	-	231	O
damage	-	239	O
in	-	246	O
most	-	249	O
patients	-	254	O
,	-	262	O
but	-	264	O
rarely	-	268	O
,	-	274	O
if	-	276	O
ever	-	279	O
,	-	283	O
cause	-	285	O
glomerular	-	291	B
or	-	302	I
tubular	-	305	I
dysfunction	-	313	I
.	-	324	O

Clinical	3538855	326	O
trials	-	335	O
of	-	342	O
aminoglycosides	-	345	O
in	-	361	O
seriously	-	364	O
ill	-	374	O
patients	-	378	O
indicate	-	387	O
that	-	396	O
the	-	401	O
relative	-	405	O
risk	-	414	O
for	-	419	O
developing	-	423	O
acute	-	434	B
renal	-	440	I
failure	-	446	I
during	-	454	O
therapy	-	461	O
ranges	-	469	O
from	-	476	O
8	-	481	O
to	-	483	O
10	-	486	O
and	-	489	O
that	-	493	O
the	-	498	O
attributable	-	502	O
risk	-	515	O
is	-	520	O
70	-	523	O
%	-	525	O
to	-	527	O
80	-	530	O
%	-	532	O
.	-	533	O

Further	3538855	535	O
analysis	-	543	O
of	-	552	O
these	-	555	O
data	-	561	O
suggests	-	566	O
that	-	575	O
the	-	580	O
duration	-	584	O
of	-	593	O
therapy	-	596	O
,	-	603	O
plasma	-	605	O
aminoglycoside	-	612	O
levels	-	627	O
,	-	633	O
liver	-	635	B
disease	-	641	I
,	-	648	O
advanced	-	650	O
age	-	659	O
,	-	662	O
high	-	664	O
initial	-	669	O
estimated	-	677	O
creatinine	-	687	O
clearance	-	698	O
and	-	708	O
,	-	711	O
possibly	-	713	O
,	-	721	O
female	-	723	O
gender	-	730	O
all	-	737	O
increase	-	741	O
the	-	750	O
risk	-	754	O
for	-	759	O
nephrotoxicity	-	763	B
.	-	777	O

Other	3538855	779	O
causes	-	785	O
of	-	792	O
acute	-	795	B
renal	-	801	I
failure	-	807	I
,	-	814	O
such	-	816	O
as	-	821	O
shock	-	824	B
,	-	829	O
appear	-	831	O
to	-	838	O
have	-	841	O
an	-	846	O
additive	-	849	O
effect	-	858	O
.	-	864	O

Predictive	3538855	866	O
models	-	877	O
have	-	884	O
been	-	889	O
developed	-	894	O
from	-	904	O
these	-	909	O
analyses	-	915	O
that	-	924	O
should	-	929	O
be	-	936	O
useful	-	939	O
for	-	946	O
identifying	-	950	O
patients	-	962	O
at	-	971	O
high	-	974	O
risk	-	979	O
.	-	983	O

These	3538855	985	O
models	-	991	O
may	-	998	O
also	-	1002	O
be	-	1007	O
useful	-	1010	O
in	-	1017	O
developing	-	1020	O
insights	-	1031	O
into	-	1040	O
the	-	1045	O
pathophysiology	-	1049	O
of	-	1065	O
aminoglycoside	-	1068	O
-	-	1082	O
induced	-	1083	O
nephrotoxicity	-	1091	B
.	-	1105	O

Flurothyl	3685052	0	O
seizure	-	10	B
thresholds	-	18	O
in	-	29	O
mice	-	32	O
treated	-	37	O
neonatally	-	45	O
with	-	56	O
a	-	61	O
single	-	63	O
injection	-	70	O
of	-	80	O
monosodium	-	83	O
glutamate	-	94	O
(	-	104	O
MSG	-	105	O
)	-	108	O
:	-	109	O
evaluation	-	111	O
of	-	122	O
experimental	-	125	O
parameters	-	138	O
in	-	149	O
flurothyl	-	152	O
seizure	-	162	B
testing	-	170	O
.	-	177	O

Monosodium	3685052	179	O
glutamate	-	190	O
(	-	200	O
MSG	-	201	O
)	-	204	O
administration	-	206	O
to	-	221	O
neonatal	-	224	O
rodents	-	233	O
produces	-	241	O
convulsions	-	250	B
and	-	262	O
results	-	266	O
in	-	274	O
numerous	-	277	O
biochemical	-	286	O
and	-	298	O
behavioral	-	302	O
deficits	-	313	O
.	-	321	O

These	3685052	323	O
studies	-	329	O
were	-	337	O
undertaken	-	342	O
to	-	353	O
determine	-	356	O
if	-	366	O
neonatal	-	369	O
administration	-	378	O
of	-	393	O
MSG	-	396	O
produced	-	400	O
permanent	-	409	O
alterations	-	419	O
in	-	431	O
seizure	-	434	B
susceptibility	-	442	O
,	-	456	O
since	-	458	O
previous	-	464	O
investigations	-	473	O
were	-	488	O
inconclusive	-	493	O
.	-	505	O

A	3685052	507	O
flurothyl	-	509	O
ether	-	519	O
seizure	-	525	B
screening	-	533	O
technique	-	543	O
was	-	553	O
used	-	557	O
to	-	562	O
evaluate	-	565	O
seizure	-	574	B
susceptibility	-	582	O
in	-	597	O
adult	-	600	O
mice	-	606	O
that	-	611	O
received	-	616	O
neonatal	-	625	O
injections	-	634	O
of	-	645	O
MSG	-	648	O
(	-	652	O
4	-	653	O
mg	-	655	O
/	-	657	O
g	-	658	O
and	-	660	O
1	-	664	O
mg	-	666	O
/	-	668	O
g	-	669	O
)	-	670	O
.	-	671	O

MSG	3685052	673	O
treatment	-	677	O
resulted	-	687	O
in	-	696	O
significant	-	699	O
reductions	-	711	O
in	-	722	O
whole	-	725	O
brain	-	731	O
weight	-	737	O
but	-	744	O
did	-	748	O
not	-	752	O
alter	-	756	O
seizure	-	762	B
threshold	-	770	O
.	-	779	O

A	3685052	781	O
naloxone	-	783	O
(	-	792	O
5	-	793	O
mg	-	795	O
/	-	797	O
kg	-	798	O
)	-	800	O
challenge	-	802	O
was	-	812	O
also	-	816	O
ineffective	-	821	O
in	-	833	O
altering	-	836	O
the	-	845	O
seizure	-	849	B
thresholds	-	857	O
of	-	868	O
either	-	871	O
control	-	878	O
of	-	886	O
MSG	-	889	O
-	-	892	O
treated	-	893	O
mice	-	901	O
.	-	905	O

Flurothyl	3685052	907	O
ether	-	917	O
produced	-	923	O
hypothermia	-	932	B
which	-	944	O
was	-	950	O
correlated	-	954	O
with	-	965	O
the	-	970	O
duration	-	974	O
of	-	983	O
flurothyl	-	986	O
exposure	-	996	O
;	-	1004	O
however	-	1006	O
,	-	1013	O
the	-	1015	O
relationship	-	1019	O
of	-	1032	O
hypothermia	-	1035	B
to	-	1047	O
seizure	-	1050	B
induction	-	1058	O
was	-	1068	O
unclear	-	1072	O
.	-	1079	O

Flurothyl	3685052	1081	O
seizure	-	1091	B
testing	-	1099	O
proved	-	1107	O
to	-	1114	O
be	-	1117	O
a	-	1120	O
rapid	-	1122	O
and	-	1128	O
reliable	-	1132	O
technique	-	1141	O
with	-	1151	O
which	-	1156	O
to	-	1162	O
evaluate	-	1165	O
seizure	-	1174	B
susceptibility	-	1182	O
.	-	1196	O

Susceptibility	3708328	0	O
to	-	15	O
seizures	-	18	B
produced	-	27	O
by	-	36	O
pilocarpine	-	39	O
in	-	51	O
rats	-	54	O
after	-	59	O
microinjection	-	65	O
of	-	80	O
isoniazid	-	83	O
or	-	93	O
gamma	-	96	O
-	-	101	O
vinyl	-	102	O
-	-	107	O
GABA	-	108	O
into	-	113	O
the	-	118	O
substantia	-	122	O
nigra	-	133	O
.	-	138	O

Pilocarpine	3708328	140	O
,	-	151	O
given	-	153	O
intraperitoneally	-	159	O
to	-	177	O
rats	-	180	O
,	-	184	O
reproduces	-	186	O
the	-	197	O
neuropathological	-	201	O
sequelae	-	219	O
of	-	228	O
temporal	-	231	B
lobe	-	240	I
epilepsy	-	245	I
and	-	254	O
provides	-	258	O
a	-	267	O
relevant	-	269	O
animal	-	278	O
model	-	285	O
for	-	291	O
studying	-	295	O
mechanisms	-	304	O
of	-	315	O
buildup	-	318	O
of	-	326	O
convulsive	-	329	B
activity	-	340	O
and	-	349	O
pathways	-	353	O
operative	-	362	O
in	-	372	O
the	-	375	O
generalization	-	379	O
and	-	394	O
propagation	-	398	O
of	-	410	O
seizures	-	413	B
within	-	422	O
the	-	429	O
forebrain	-	433	O
.	-	442	O

In	3708328	444	O
the	-	447	O
present	-	451	O
study	-	459	O
,	-	464	O
the	-	466	O
effects	-	470	O
of	-	478	O
manipulating	-	481	O
the	-	494	O
activity	-	498	O
of	-	507	O
the	-	510	O
gamma	-	514	O
-	-	519	O
aminobutyric	-	520	O
acid	-	533	O
(	-	538	O
GABA	-	539	O
)	-	543	O
-	-	544	O
mediated	-	545	O
synaptic	-	554	O
inhibition	-	563	O
within	-	574	O
the	-	581	O
substantia	-	585	O
nigra	-	596	O
on	-	602	O
seizures	-	605	B
produced	-	614	O
by	-	623	O
pilocarpine	-	626	O
in	-	638	O
rats	-	641	O
,	-	645	O
were	-	647	O
investigated	-	652	O
.	-	664	O

In	3708328	666	O
animals	-	669	O
pretreated	-	677	O
with	-	688	O
microinjections	-	693	O
of	-	709	O
isoniazid	-	712	O
,	-	721	O
150	-	723	O
micrograms	-	727	O
,	-	737	O
an	-	739	O
inhibitor	-	742	O
of	-	752	O
activity	-	755	O
of	-	764	O
the	-	767	O
GABA	-	771	O
-	-	775	O
synthesizing	-	776	O
enzyme	-	789	O
,	-	795	O
L	-	797	O
-	-	798	O
glutamic	-	799	O
acid	-	808	O
decarboxylase	-	813	O
,	-	826	O
into	-	828	O
the	-	833	O
substantia	-	837	O
nigra	-	848	O
pars	-	854	O
reticulata	-	859	O
(	-	870	O
SNR	-	871	O
)	-	874	O
,	-	875	O
bilaterally	-	877	O
,	-	888	O
non	-	890	O
-	-	893	O
convulsant	-	894	O
doses	-	905	O
of	-	911	O
pilocarpine	-	914	O
,	-	925	O
100	-	927	O
and	-	931	O
200	-	935	O
mg	-	939	O
/	-	941	O
kg	-	942	O
,	-	944	O
resulted	-	946	O
in	-	955	O
severe	-	958	O
motor	-	965	O
limbic	-	971	O
seizures	-	978	B
and	-	987	O
status	-	991	B
epilepticus	-	998	I
.	-	1009	O

Electroencephalographic	3708328	1011	O
and	-	1035	O
behavioral	-	1039	O
monitoring	-	1050	O
revealed	-	1061	O
a	-	1070	O
profound	-	1072	O
reduction	-	1081	O
of	-	1091	O
the	-	1094	O
threshold	-	1098	O
for	-	1108	O
pilocarpine	-	1112	O
-	-	1123	O
induced	-	1124	O
convulsions	-	1132	B
.	-	1143	O

Morphological	3708328	1145	O
analysis	-	1159	O
of	-	1168	O
frontal	-	1171	O
forebrain	-	1179	O
sections	-	1189	O
with	-	1198	O
light	-	1203	O
microscopy	-	1209	O
revealed	-	1220	O
seizure	-	1229	B
-	-	1236	O
related	-	1237	O
damage	-	1245	O
to	-	1252	O
the	-	1255	O
hippocampal	-	1259	O
formation	-	1271	O
,	-	1280	O
thalamus	-	1282	O
,	-	1290	O
amygdala	-	1292	O
,	-	1300	O
olfactory	-	1302	O
cortex	-	1312	O
,	-	1318	O
substantia	-	1320	O
nigra	-	1331	O
and	-	1337	O
neocortex	-	1341	O
,	-	1350	O
which	-	1352	O
is	-	1358	O
typically	-	1361	O
observed	-	1371	O
with	-	1380	O
pilocarpine	-	1385	O
in	-	1397	O
doses	-	1400	O
exceeding	-	1406	O
350	-	1416	O
mg	-	1420	O
/	-	1422	O
kg	-	1423	O
.	-	1425	O

Bilateral	3708328	1427	O
intrastriatal	-	1437	O
injections	-	1451	O
of	-	1462	O
isoniazid	-	1465	O
did	-	1475	O
not	-	1479	O
augment	-	1483	O
seizures	-	1491	B
produced	-	1500	O
by	-	1509	O
pilocarpine	-	1512	O
,	-	1523	O
200	-	1525	O
mg	-	1529	O
/	-	1531	O
kg	-	1532	O
.	-	1534	O

Application	3708328	1536	O
of	-	1548	O
an	-	1551	O
irreversible	-	1554	O
inhibitor	-	1567	O
of	-	1577	O
GABA	-	1580	O
transaminase	-	1585	O
,	-	1597	O
gamma	-	1599	O
-	-	1604	O
vinyl	-	1605	O
-	-	1610	O
GABA	-	1611	O
(	-	1616	O
D	-	1617	O
,	-	1618	O
L	-	1619	O
-	-	1620	O
4	-	1621	O
-	-	1622	O
amino	-	1623	O
-	-	1628	O
hex	-	1629	O
-	-	1632	O
5	-	1633	O
-	-	1634	O
enoic	-	1635	O
acid	-	1641	O
)	-	1645	O
,	-	1646	O
5	-	1648	O
micrograms	-	1650	O
,	-	1660	O
into	-	1662	O
the	-	1667	O
SNR	-	1671	O
,	-	1674	O
bilaterally	-	1676	O
,	-	1687	O
suppressed	-	1689	O
the	-	1700	O
appearance	-	1704	O
of	-	1715	O
electrographic	-	1718	O
and	-	1733	O
behavioral	-	1737	O
seizures	-	1748	B
produced	-	1757	O
by	-	1766	O
pilocarpine	-	1769	O
,	-	1780	O
380	-	1782	O
mg	-	1786	O
/	-	1788	O
kg	-	1789	O
.	-	1791	O

This	3708328	1793	O
treatment	-	1798	O
was	-	1808	O
also	-	1812	O
sufficient	-	1817	O
to	-	1828	O
protect	-	1831	O
animals	-	1839	O
from	-	1847	O
the	-	1852	O
occurrence	-	1856	O
of	-	1867	O
brain	-	1870	B
damage	-	1876	I
.	-	1882	O

Microinjections	3708328	1884	O
of	-	1900	O
gamma	-	1903	O
-	-	1908	O
vinyl	-	1909	O
-	-	1914	O
GABA	-	1915	O
,	-	1919	O
5	-	1921	O
micrograms	-	1923	O
,	-	1933	O
into	-	1935	O
the	-	1940	O
dorsal	-	1944	O
striatum	-	1951	O
,	-	1959	O
bilaterally	-	1961	O
,	-	1972	O
failed	-	1974	O
to	-	1981	O
prevent	-	1984	O
the	-	1992	O
development	-	1996	O
of	-	2008	O
convulsions	-	2011	B
produced	-	2023	O
by	-	2032	O
pilocarpine	-	2035	O
,	-	2046	O
380	-	2048	O
mg	-	2052	O
/	-	2054	O
kg	-	2055	O
.	-	2057	O

The	3708328	2059	O
results	-	2063	O
demonstrate	-	2071	O
that	-	2083	O
the	-	2088	O
threshold	-	2092	O
for	-	2102	O
pilocarpine	-	2106	O
-	-	2117	O
induced	-	2118	O
seizures	-	2126	B
in	-	2135	O
rats	-	2138	O
is	-	2143	O
subjected	-	2146	O
to	-	2156	O
the	-	2159	O
regulation	-	2163	O
of	-	2174	O
the	-	2177	O
GABA	-	2181	O
-	-	2185	O
mediated	-	2186	O
synaptic	-	2195	O
inhibition	-	2204	O
within	-	2215	O
the	-	2222	O
substantia	-	2226	O
nigra	-	2237	O
.	-	2242	O

Non	3746148	0	O
-	-	3	O
invasive	-	4	O
detection	-	13	O
of	-	23	O
coronary	-	26	B
artery	-	35	I
disease	-	42	I
by	-	50	O
body	-	53	O
surface	-	58	O
electrocardiographic	-	66	O
mapping	-	87	O
after	-	95	O
dipyridamole	-	101	O
infusion	-	114	O
.	-	122	O

Electrocardiographic	3746148	124	O
changes	-	145	O
after	-	153	O
dipyridamole	-	159	O
infusion	-	172	O
(	-	181	O
0	-	182	O
.	-	183	O
568	-	184	O
mg	-	188	O
/	-	190	O
kg	-	191	O
/	-	193	O
4	-	194	O
min	-	196	O
)	-	199	O
were	-	201	O
studied	-	206	O
in	-	214	O
41	-	217	O
patients	-	220	O
with	-	229	O
coronary	-	234	B
artery	-	243	I
disease	-	250	I
and	-	258	O
compared	-	262	O
with	-	271	O
those	-	276	O
after	-	282	O
submaximal	-	288	O
treadmill	-	299	O
exercise	-	309	O
by	-	318	O
use	-	321	O
of	-	325	O
the	-	328	O
body	-	332	O
surface	-	337	O
mapping	-	345	O
technique	-	353	O
.	-	362	O

Patients	3746148	364	O
were	-	373	O
divided	-	378	O
into	-	386	O
three	-	391	O
groups	-	397	O
;	-	403	O
19	-	405	O
patients	-	408	O
without	-	417	O
myocardial	-	425	B
infarction	-	436	I
(	-	447	O
non	-	448	O
-	-	451	O
MI	-	452	B
group	-	455	O
)	-	460	O
,	-	461	O
14	-	463	O
with	-	466	O
anterior	-	471	B
infarction	-	480	I
(	-	491	O
ANT	-	492	B
-	-	495	I
MI	-	496	I
)	-	498	O
and	-	500	O
eight	-	504	O
with	-	510	O
inferior	-	515	B
infarction	-	524	I
(	-	535	O
INF	-	536	B
-	-	539	I
MI	-	540	I
)	-	542	O
.	-	543	O

Eighty	3746148	545	O
-	-	551	O
seven	-	552	O
unipolar	-	558	O
electrocardiograms	-	567	O
(	-	586	O
ECGs	-	587	O
)	-	591	O
distributed	-	593	O
over	-	605	O
the	-	610	O
entire	-	614	O
thoracic	-	621	O
surface	-	630	O
were	-	638	O
simultaneously	-	643	O
recorded	-	658	O
.	-	666	O

After	3746148	668	O
dipyridamole	-	674	O
,	-	686	O
ischemic	-	688	B
ST	-	697	O
-	-	699	O
segment	-	700	O
depression	-	708	B
(	-	719	O
0	-	720	O
.	-	721	O
05	-	722	O
mV	-	725	O
or	-	728	O
more	-	731	O
)	-	735	O
was	-	737	O
observed	-	741	O
in	-	750	O
84	-	753	O
%	-	755	O
of	-	757	O
the	-	760	O
non	-	764	O
-	-	767	O
MI	-	768	B
group	-	771	O
,	-	776	O
29	-	778	O
%	-	780	O
of	-	782	O
the	-	785	O
ANT	-	789	B
-	-	792	I
MI	-	793	I
group	-	796	O
,	-	801	O
63	-	803	O
%	-	805	O
of	-	807	O
the	-	810	O
INF	-	814	B
-	-	817	I
MI	-	818	I
group	-	821	O
and	-	827	O
61	-	831	O
%	-	833	O
of	-	835	O
the	-	838	O
total	-	842	O
population	-	848	O
.	-	858	O

Exercise	3746148	860	O
-	-	868	O
induced	-	869	O
ST	-	877	O
depression	-	880	B
was	-	891	O
observed	-	895	O
in	-	904	O
84	-	907	O
%	-	909	O
of	-	911	O
the	-	914	O
non	-	918	O
-	-	921	O
MI	-	922	B
group	-	925	O
,	-	930	O
43	-	932	O
%	-	934	O
of	-	936	O
the	-	939	O
ANT	-	943	B
-	-	946	I
MI	-	947	I
group	-	950	O
,	-	955	O
38	-	957	O
%	-	959	O
of	-	961	O
the	-	964	O
INF	-	968	B
-	-	971	I
MI	-	972	I
group	-	975	O
and	-	981	O
61	-	985	O
%	-	987	O
of	-	989	O
the	-	992	O
total	-	996	O
.	-	1001	O

For	3746148	1003	O
individual	-	1007	O
patients	-	1018	O
,	-	1026	O
there	-	1028	O
were	-	1034	O
no	-	1039	O
obvious	-	1042	O
differences	-	1050	O
between	-	1062	O
the	-	1070	O
body	-	1074	O
surface	-	1079	O
distribution	-	1087	O
of	-	1100	O
ST	-	1103	O
depression	-	1106	B
in	-	1117	O
both	-	1120	O
tests	-	1125	O
.	-	1130	O

The	3746148	1132	O
increase	-	1136	O
in	-	1145	O
pressure	-	1148	O
rate	-	1157	O
product	-	1162	O
after	-	1170	O
dipyridamole	-	1176	O
was	-	1189	O
significantly	-	1193	O
less	-	1207	O
than	-	1212	O
that	-	1217	O
during	-	1222	O
the	-	1229	O
treadmill	-	1233	O
exercise	-	1243	O
.	-	1251	O

The	3746148	1253	O
data	-	1257	O
suggest	-	1262	O
that	-	1270	O
the	-	1275	O
dipyridamole	-	1279	O
-	-	1291	O
induced	-	1292	O
myocardial	-	1300	B
ischemia	-	1311	I
is	-	1320	O
caused	-	1323	O
by	-	1330	O
the	-	1333	O
inhomogenous	-	1337	O
distribution	-	1350	O
of	-	1363	O
myocardial	-	1366	O
blood	-	1377	O
flow	-	1383	O
.	-	1387	O

We	3746148	1389	O
conclude	-	1392	O
that	-	1401	O
the	-	1406	O
dipyridamole	-	1410	O
ECG	-	1423	O
test	-	1427	O
is	-	1432	O
as	-	1435	O
useful	-	1438	O
as	-	1445	O
the	-	1448	O
exercise	-	1452	O
ECG	-	1461	O
test	-	1465	O
for	-	1470	O
the	-	1474	O
assessment	-	1478	O
of	-	1489	O
coronary	-	1492	B
artery	-	1501	I
disease	-	1508	I
.	-	1515	O

Bradycardia	3798047	0	B
after	-	12	O
high	-	18	O
-	-	22	O
dose	-	23	O
intravenous	-	28	O
methylprednisolone	-	40	O
therapy	-	59	O
.	-	66	O

In	3798047	68	O
5	-	71	O
consecutive	-	73	O
patients	-	85	O
with	-	94	O
rheumatoid	-	99	B
arthritis	-	110	I
who	-	120	O
received	-	124	O
intravenous	-	133	O
high	-	145	O
-	-	149	O
dose	-	150	O
methylprednisolone	-	155	O
(	-	174	O
MP	-	175	O
)	-	177	O
therapy	-	179	O
(	-	187	O
1	-	188	O
g	-	190	O
daily	-	192	O
for	-	198	O
2	-	202	O
or	-	204	O
3	-	207	O
consecutive	-	209	O
days	-	221	O
)	-	225	O
,	-	226	O
a	-	228	O
decline	-	230	O
in	-	238	O
pulse	-	241	O
rate	-	247	O
was	-	252	O
observed	-	256	O
,	-	264	O
most	-	266	O
pronounced	-	271	O
on	-	282	O
day	-	285	O
4	-	289	O
.	-	290	O

In	3798047	292	O
one	-	295	O
of	-	299	O
the	-	302	O
5	-	306	O
patients	-	308	O
the	-	317	O
bradycardia	-	321	B
was	-	333	O
associated	-	337	O
with	-	348	O
complaints	-	353	O
of	-	364	O
substernal	-	367	O
pressure	-	378	O
.	-	386	O

Reversal	3798047	388	O
to	-	397	O
normal	-	400	O
heart	-	407	O
rate	-	413	O
was	-	418	O
found	-	422	O
on	-	428	O
day	-	431	O
7	-	435	O
.	-	436	O

Electrocardiographic	3798047	438	O
registrations	-	459	O
showed	-	473	O
sinus	-	480	B
bradycardia	-	486	I
in	-	498	O
all	-	501	O
cases	-	505	O
.	-	510	O

No	3798047	512	O
significant	-	515	O
changes	-	527	O
in	-	535	O
plasma	-	538	O
concentrations	-	545	O
of	-	560	O
electrolytes	-	563	O
were	-	576	O
found	-	581	O
.	-	586	O

Careful	3798047	588	O
observation	-	596	O
of	-	608	O
patients	-	611	O
receiving	-	620	O
high	-	630	O
-	-	634	O
dose	-	635	O
MP	-	640	O
is	-	643	O
recommended	-	646	O
.	-	657	O

High	3798047	659	O
-	-	663	O
dose	-	664	O
MP	-	669	O
may	-	672	O
be	-	676	O
contraindicated	-	679	O
in	-	695	O
patients	-	698	O
with	-	707	O
known	-	712	O
heart	-	718	B
disease	-	724	I
.	-	731	O

Two	3812624	0	O
cases	-	4	O
of	-	10	O
downbeat	-	13	B
nystagmus	-	22	I
and	-	32	O
oscillopsia	-	36	B
associated	-	48	O
with	-	59	O
carbamazepine	-	64	O
.	-	77	O

Downbeat	3812624	79	B
nystagmus	-	88	I
is	-	98	O
often	-	101	O
associated	-	107	O
with	-	118	O
structural	-	123	O
lesions	-	134	O
at	-	142	O
the	-	145	O
craniocervical	-	149	O
junction	-	164	O
,	-	172	O
but	-	174	O
has	-	178	O
occasionally	-	182	O
been	-	195	O
reported	-	200	O
as	-	209	O
a	-	212	O
manifestation	-	214	O
of	-	228	O
metabolic	-	231	O
imbalance	-	241	O
or	-	251	O
drug	-	254	O
intoxication	-	259	O
.	-	271	O

We	3812624	273	O
recorded	-	276	O
the	-	285	O
eye	-	289	O
movements	-	293	O
of	-	303	O
two	-	306	O
patients	-	310	O
with	-	319	O
reversible	-	324	O
downbeat	-	335	B
nystagmus	-	344	I
related	-	354	O
to	-	362	O
carbamazepine	-	365	O
therapy	-	379	O
.	-	386	O

The	3812624	388	O
nystagmus	-	392	B
of	-	402	O
both	-	405	O
patients	-	410	O
resolved	-	419	O
after	-	428	O
reduction	-	434	O
of	-	444	O
the	-	447	O
serum	-	451	O
carbamazepine	-	457	O
levels	-	471	O
.	-	477	O

Neuroradiologic	3812624	479	O
investigations	-	495	O
including	-	510	O
magnetic	-	520	O
resonance	-	529	O
imaging	-	539	O
scans	-	547	O
in	-	553	O
both	-	556	O
patients	-	561	O
showed	-	570	O
no	-	577	O
evidence	-	580	O
of	-	589	O
intracranial	-	592	O
abnormality	-	605	O
.	-	616	O

In	3812624	618	O
patients	-	621	O
with	-	630	O
downbeat	-	635	B
nystagmus	-	644	I
who	-	654	O
are	-	658	O
taking	-	662	O
anticonvulsant	-	669	O
medications	-	684	O
,	-	695	O
consideration	-	697	O
should	-	711	O
be	-	718	O
given	-	721	O
to	-	727	O
reduction	-	730	O
in	-	740	O
dose	-	743	O
before	-	748	O
further	-	755	O
investigation	-	763	O
is	-	777	O
undertaken	-	780	O
.	-	790	O

Improvement	3831029	0	O
by	-	12	O
denopamine	-	15	O
(	-	26	O
TA	-	27	O
-	-	29	O
064	-	30	O
)	-	33	O
of	-	35	O
pentobarbital	-	38	O
-	-	51	O
induced	-	52	O
cardiac	-	60	B
failure	-	68	I
in	-	76	O
the	-	79	O
dog	-	83	O
heart	-	87	O
-	-	92	O
lung	-	93	O
preparation	-	98	O
.	-	109	O

The	3831029	111	O
efficacy	-	115	O
of	-	124	O
denopamine	-	127	O
,	-	137	O
an	-	139	O
orally	-	142	O
active	-	149	O
beta	-	156	O
1	-	161	O
-	-	162	O
adrenoceptor	-	163	O
agonist	-	176	O
,	-	183	O
in	-	185	O
improving	-	188	O
cardiac	-	198	B
failure	-	206	I
was	-	214	O
assessed	-	218	O
in	-	227	O
dog	-	230	O
heart	-	234	O
-	-	239	O
lung	-	240	O
preparations	-	245	O
.	-	257	O

Cardiac	3831029	259	O
functions	-	267	O
depressed	-	277	O
by	-	287	O
pentobarbital	-	290	O
(	-	304	O
118	-	305	O
+	-	309	O
/	-	310	O
-	-	311	O

28	3831029	313	O
mg	-	316	O
;	-	318	O
mean	-	320	O
value	-	325	O
+	-	331	O
/	-	332	O
-	-	333	O

SD	3831029	335	O
)	-	337	O
such	-	339	O
that	-	344	O
cardiac	-	349	O
output	-	357	O
and	-	364	O
maximum	-	368	O
rate	-	376	O
of	-	381	O
rise	-	384	O
of	-	389	O
left	-	392	O
ventricular	-	397	O
pressure	-	409	O
(	-	418	O
LV	-	419	O
dP	-	422	O
/	-	424	O
dt	-	425	O
max	-	428	O
)	-	431	O
had	-	433	O
been	-	437	O
reduced	-	442	O
by	-	450	O
about	-	453	O
35	-	459	O
%	-	461	O
and	-	463	O
26	-	467	O
%	-	469	O
of	-	471	O
the	-	474	O
respective	-	478	O
controls	-	489	O
were	-	498	O
improved	-	503	O
by	-	512	O
denopamine	-	515	O
(	-	526	O
10	-	527	O
-	-	529	O
300	-	530	O
micrograms	-	534	O
)	-	544	O
in	-	546	O
a	-	549	O
dose	-	551	O
-	-	555	O
dependent	-	556	O
manner	-	566	O
.	-	572	O

With	3831029	574	O
100	-	579	O
micrograms	-	583	O
denopamine	-	594	O
,	-	604	O
almost	-	606	O
complete	-	613	O
restoration	-	622	O
of	-	634	O
cardiac	-	637	O
performance	-	645	O
was	-	657	O
attained	-	661	O
,	-	669	O
associated	-	671	O
with	-	682	O
a	-	687	O
slight	-	689	O
increase	-	696	O
in	-	705	O
heart	-	708	O
rate	-	714	O
.	-	718	O

No	3831029	720	O
arrhythmias	-	723	B
were	-	735	O
induced	-	740	O
by	-	748	O
these	-	751	O
doses	-	757	O
of	-	763	O
denopamine	-	766	O
.	-	776	O

The	3831029	778	O
results	-	782	O
warrant	-	790	O
clinical	-	798	O
trials	-	807	O
of	-	814	O
denopamine	-	817	O
in	-	828	O
the	-	831	O
treatment	-	835	O
of	-	845	O
cardiac	-	848	B
failure	-	856	I
.	-	863	O

Clonazepam	3832950	0	O
monotherapy	-	11	O
for	-	23	O
epilepsy	-	27	B
in	-	36	O
childhood	-	39	O
.	-	48	O

Sixty	3832950	50	O
patients	-	56	O
(	-	65	O
age	-	66	O
-	-	69	O
range	-	70	O
one	-	76	O
month	-	80	O
to	-	86	O
14	-	89	O
years	-	92	O
)	-	97	O
with	-	99	O
other	-	104	O
types	-	110	O
of	-	116	O
epilepsy	-	119	B
than	-	128	O
infantile	-	133	B
spasms	-	143	I
were	-	150	O
treated	-	155	O
with	-	163	O
clonazepam	-	168	O
.	-	178	O

Disappearance	3832950	180	O
of	-	194	O
seizures	-	197	B
and	-	206	O
normalization	-	210	O
of	-	224	O
abnormal	-	227	O
EEG	-	236	O
with	-	240	O
disappearance	-	245	O
of	-	259	O
seizures	-	262	B
were	-	271	O
recognized	-	276	O
in	-	287	O
77	-	290	O
%	-	292	O
and	-	294	O
50	-	298	O
%	-	300	O
,	-	301	O
respectively	-	303	O
.	-	315	O

Seizures	3832950	317	B
disappeared	-	326	O
in	-	338	O
71	-	341	O
%	-	343	O
of	-	345	O
the	-	348	O
patients	-	352	O
with	-	361	O
generalized	-	366	O
seizures	-	378	B
and	-	387	O
89	-	391	O
%	-	393	O
of	-	395	O
partial	-	398	O
seizures	-	406	B
.	-	414	O

Improvement	3832950	416	O
of	-	428	O
abnormal	-	431	O
EEG	-	440	O
was	-	444	O
noticed	-	448	O
in	-	456	O
76	-	459	O
%	-	461	O
of	-	463	O
diffuse	-	466	O
paroxysms	-	474	O
and	-	484	O
in	-	488	O
67	-	491	O
%	-	493	O
of	-	495	O
focal	-	498	O
paroxysms	-	504	O
.	-	513	O

In	3832950	515	O
excellent	-	518	O
cases	-	528	O
,	-	533	O
mean	-	535	O
effective	-	540	O
dosages	-	550	O
were	-	558	O
0	-	563	O
.	-	564	O
086	-	565	O
+	-	569	O
/	-	570	O
-	-	571	O

0	3832950	573	O
.	-	574	O
021	-	575	O
mg	-	579	O
/	-	581	O
kg	-	582	O
/	-	584	O
day	-	585	O
in	-	589	O
infants	-	592	O
and	-	600	O
0	-	604	O
.	-	605	O
057	-	606	O
+	-	610	O
/	-	611	O
-	-	612	O
0	-	614	O
.	-	615	O
022	-	616	O
mg	-	620	O
/	-	622	O
kg	-	623	O
/	-	625	O
day	-	626	O
in	-	630	O
schoolchildren	-	633	O
,	-	647	O
this	-	649	O
difference	-	654	O
was	-	665	O
statistically	-	669	O
significant	-	683	O
(	-	695	O
p	-	696	O
less	-	698	O
than	-	703	O
0	-	708	O
.	-	709	O
005	-	710	O
)	-	713	O
.	-	714	O

The	3832950	716	O
incidence	-	720	O
of	-	730	O
side	-	733	O
effects	-	738	O
such	-	746	O
as	-	751	O
drowsiness	-	754	B
and	-	765	O
ataxia	-	769	B
was	-	776	O
only	-	780	O
5	-	785	O
%	-	786	O
.	-	787	O

Postmarketing	3833372	0	O
study	-	14	O
of	-	20	O
timolol	-	23	O
-	-	30	O
hydrochlorothiazide	-	31	O
antihypertensive	-	51	O
therapy	-	68	O
.	-	75	O

A	3833372	77	O
postmarketing	-	79	O
surveillance	-	93	O
study	-	106	O
was	-	112	O
conducted	-	116	O
to	-	126	O
determine	-	129	O
the	-	139	O
safety	-	143	O
and	-	150	O
efficacy	-	154	O
of	-	163	O
a	-	166	O
fixed	-	168	O
-	-	173	O
ratio	-	174	O
combination	-	180	O
containing	-	192	O
10	-	203	O
mg	-	206	O
of	-	209	O
timolol	-	212	O
maleate	-	220	O
and	-	228	O
25	-	232	O
mg	-	235	O
of	-	238	O
hydrochlorothiazide	-	241	O
,	-	260	O
administered	-	262	O
twice	-	275	O
daily	-	281	O
for	-	287	O
one	-	291	O
month	-	295	O
to	-	301	O
hypertensive	-	304	B
patients	-	317	O
.	-	325	O

Data	3833372	327	O
on	-	332	O
9	-	335	O
,	-	336	O
037	-	337	O
patients	-	341	O
were	-	350	O
collected	-	355	O
by	-	365	O
1	-	368	O
,	-	369	O
455	-	370	O
participating	-	374	O
physicians	-	388	O
.	-	398	O

Mean	3833372	400	O
systolic	-	405	O
blood	-	414	O
pressure	-	420	O
decreased	-	429	O
25	-	439	O
mmHg	-	442	O
and	-	447	O
mean	-	451	O
diastolic	-	456	O
blood	-	466	O
pressure	-	472	O
declined	-	481	O
15	-	490	O
mmHg	-	493	O
after	-	498	O
one	-	504	O
month	-	508	O
of	-	514	O
timolol	-	517	O
-	-	524	O
hydrochlorothiazide	-	525	O
therapy	-	545	O
(	-	553	O
P	-	554	O
less	-	556	O
than	-	561	O
0	-	566	O
.	-	567	O
01	-	568	O
,	-	570	O
both	-	572	O
comparisons	-	577	O
)	-	588	O
.	-	589	O

Age	3833372	591	O
,	-	594	O
race	-	596	O
,	-	600	O
and	-	602	O
sex	-	606	O
appeared	-	610	O
to	-	619	O
have	-	622	O
no	-	627	O
influence	-	630	O
on	-	640	O
the	-	643	O
decrease	-	647	O
in	-	656	O
blood	-	659	O
pressure	-	665	O
.	-	673	O

The	3833372	675	O
antihypertensive	-	679	O
effect	-	696	O
of	-	703	O
the	-	706	O
drug	-	710	O
was	-	715	O
greater	-	719	O
in	-	727	O
patients	-	730	O
with	-	739	O
more	-	744	O
severe	-	749	O
hypertension	-	756	B
.	-	768	O

Overall	3833372	770	O
,	-	777	O
1	-	779	O
,	-	780	O
453	-	781	O
patients	-	785	O
experienced	-	794	O
a	-	806	O
total	-	808	O
of	-	814	O
2	-	817	O
,	-	818	O
658	-	819	O
adverse	-	823	O
events	-	831	O
,	-	837	O
the	-	839	O
most	-	843	O
common	-	848	O
being	-	855	O
fatigue	-	861	B
,	-	868	O
dizziness	-	870	B
,	-	879	O
and	-	881	O
weakness	-	885	B
.	-	893	O

Treatment	3833372	895	O
in	-	905	O
590	-	908	O
patients	-	912	O
was	-	921	O
discontinued	-	925	O
because	-	938	O
of	-	946	O
adverse	-	949	O
events	-	957	O
.	-	963	O

Salicylate	3864191	0	O
nephropathy	-	11	B
in	-	23	O
the	-	26	O
Gunn	-	30	O
rat	-	35	O
:	-	38	O
potential	-	40	O
role	-	50	O
of	-	55	O
prostaglandins	-	58	O
.	-	72	O

We	3864191	74	O
examined	-	77	O
the	-	86	O
potential	-	90	O
role	-	100	O
of	-	105	O
prostaglandins	-	108	O
in	-	123	O
the	-	126	O
development	-	130	O
of	-	142	O
analgesic	-	145	O
nephropathy	-	155	B
in	-	167	O
the	-	170	O
Gunn	-	174	O
strain	-	179	O
of	-	186	O
rat	-	189	O
.	-	192	O

The	3864191	194	O
homozygous	-	198	O
Gunn	-	209	O
rats	-	214	O
have	-	219	O
unconjugated	-	224	O
hyperbilirubinemia	-	237	B
due	-	256	O
to	-	260	O
the	-	263	O
absence	-	267	O
of	-	275	O
glucuronyl	-	278	O
transferase	-	289	O
,	-	300	O
leading	-	302	O
to	-	310	O
marked	-	313	O
bilirubin	-	320	O
deposition	-	330	O
in	-	341	O
renal	-	344	O
medulla	-	350	O
and	-	358	O
papilla	-	362	O
.	-	369	O

These	3864191	371	O
rats	-	377	O
are	-	382	O
also	-	386	O
highly	-	391	O
susceptible	-	398	O
to	-	410	O
develop	-	413	O
papillary	-	421	B
necrosis	-	431	I
with	-	440	O
analgesic	-	445	O
administration	-	455	O
.	-	469	O

We	3864191	471	O
used	-	474	O
homozygous	-	479	O
(	-	490	O
jj	-	491	O
)	-	493	O
and	-	495	O
phenotypically	-	499	O
normal	-	514	O
heterozygous	-	521	O
(	-	534	O
jJ	-	535	O
)	-	537	O
animals	-	539	O
.	-	546	O

Four	3864191	548	O
groups	-	553	O
of	-	560	O
rats	-	563	O
(	-	568	O
n	-	569	O
=	-	571	O
7	-	573	O
)	-	574	O
were	-	576	O
studied	-	581	O
:	-	588	O
jj	-	590	O
and	-	593	O
jJ	-	597	O
rats	-	600	O
treated	-	605	O
either	-	613	O
with	-	620	O
aspirin	-	625	O
300	-	633	O
mg	-	637	O
/	-	639	O
kg	-	640	O
every	-	643	O
other	-	649	O
day	-	655	O
or	-	659	O
sham	-	662	O
-	-	666	O
treated	-	667	O
.	-	674	O

After	3864191	676	O
one	-	682	O
week	-	686	O
,	-	690	O
slices	-	692	O
of	-	699	O
cortex	-	702	O
,	-	708	O
outer	-	710	O
and	-	716	O
inner	-	720	O
medulla	-	726	O
from	-	734	O
one	-	739	O
kidney	-	743	O
were	-	750	O
incubated	-	755	O
in	-	765	O
buffer	-	768	O
and	-	775	O
prostaglandin	-	779	O
synthesis	-	793	O
was	-	803	O
determined	-	807	O
by	-	818	O
radioimmunoassay	-	821	O
.	-	837	O

The	3864191	839	O
other	-	843	O
kidney	-	849	O
was	-	856	O
examined	-	860	O
histologically	-	869	O
.	-	883	O

A	3864191	885	O
marked	-	887	O
corticomedullary	-	894	O
gradient	-	911	O
of	-	920	O
prostaglandin	-	923	O
synthesis	-	937	O
was	-	947	O
observed	-	951	O
in	-	960	O
all	-	963	O
groups	-	967	O
.	-	973	O

PGE2	3864191	975	O
synthesis	-	980	O
was	-	990	O
significantly	-	994	O
higher	-	1008	O
in	-	1015	O
outer	-	1018	O
medulla	-	1024	O
,	-	1031	O
but	-	1033	O
not	-	1037	O
cortex	-	1041	O
or	-	1048	O
inner	-	1051	O
medulla	-	1057	O
,	-	1064	O
of	-	1066	O
jj	-	1069	O
(	-	1072	O
38	-	1073	O
+	-	1076	O
/	-	1077	O
-	-	1078	O

6	3864191	1080	O
ng	-	1082	O
/	-	1084	O
mg	-	1085	O
prot	-	1088	O
)	-	1092	O
than	-	1094	O
jJ	-	1099	O
rats	-	1102	O
(	-	1107	O
15	-	1108	O
+	-	1111	O
/	-	1112	O
-	-	1113	O
3	-	1115	O
)	-	1116	O
(	-	1118	O
p	-	1119	O
less	-	1121	O
than	-	1126	O
0	-	1131	O
.	-	1132	O
01	-	1133	O
)	-	1135	O
.	-	1136	O

Aspirin	3864191	1138	O
treatment	-	1146	O
reduced	-	1156	O
PGE2	-	1164	O
synthesis	-	1169	O
in	-	1179	O
all	-	1182	O
regions	-	1186	O
,	-	1193	O
but	-	1195	O
outer	-	1199	O
medullary	-	1205	O
PGE2	-	1215	O
remained	-	1220	O
higher	-	1229	O
in	-	1236	O
jj	-	1239	O
(	-	1242	O
18	-	1243	O
+	-	1246	O
/	-	1247	O
-	-	1248	O
3	-	1250	O
)	-	1251	O
than	-	1253	O
jJ	-	1258	O
rats	-	1261	O
(	-	1266	O
9	-	1267	O
+	-	1269	O
/	-	1270	O
-	-	1271	O
2	-	1273	O
)	-	1274	O
(	-	1276	O
p	-	1277	O
less	-	1279	O
than	-	1284	O
0	-	1289	O
.	-	1290	O
05	-	1291	O
)	-	1293	O
.	-	1294	O

PGF2	3864191	1296	O
alpha	-	1301	O
was	-	1307	O
also	-	1311	O
significantly	-	1316	O
higher	-	1330	O
in	-	1337	O
the	-	1340	O
outer	-	1344	O
medulla	-	1350	O
of	-	1358	O
jj	-	1361	O
rats	-	1364	O
with	-	1369	O
and	-	1374	O
without	-	1378	O
aspirin	-	1386	O
administration	-	1394	O
(	-	1409	O
p	-	1410	O
less	-	1412	O
than	-	1417	O
0	-	1422	O
.	-	1423	O
05	-	1424	O
)	-	1426	O
.	-	1427	O

The	3864191	1429	O
changes	-	1433	O
in	-	1441	O
renal	-	1444	O
prostaglandin	-	1450	O
synthesis	-	1464	O
were	-	1474	O
accompanied	-	1479	O
by	-	1491	O
evidence	-	1494	O
of	-	1503	O
renal	-	1506	B
damage	-	1512	I
in	-	1519	O
aspirin	-	1522	O
-	-	1529	O
treated	-	1530	O
jj	-	1538	O
but	-	1541	O
not	-	1545	O
jJ	-	1549	O
rats	-	1552	O
as	-	1557	O
evidenced	-	1560	O
by	-	1570	O
:	-	1572	O
increased	-	1574	O
incidence	-	1584	O
and	-	1594	O
severity	-	1598	O
of	-	1607	O
hematuria	-	1610	B
(	-	1620	O
p	-	1621	O
less	-	1623	O
than	-	1628	O
0	-	1633	O
.	-	1634	O
01	-	1635	O
)	-	1637	O
;	-	1638	O
increased	-	1640	O
serum	-	1650	O
creatinine	-	1656	O
(	-	1667	O
p	-	1668	O
less	-	1670	O
than	-	1675	O
0	-	1680	O
.	-	1681	O
05	-	1682	O
)	-	1684	O
;	-	1685	O
and	-	1687	O
increase	-	1691	O
in	-	1700	O
outer	-	1703	O
medullary	-	1709	O
histopathologic	-	1719	O
lesions	-	1735	O
(	-	1743	O
p	-	1744	O
less	-	1746	O
than	-	1751	O
0	-	1756	O
.	-	1757	O
005	-	1758	O
compared	-	1762	O
to	-	1771	O
either	-	1774	O
sham	-	1781	O
-	-	1785	O
treated	-	1786	O
jj	-	1794	O
or	-	1797	O
aspirin	-	1800	O
-	-	1807	O
treated	-	1808	O
jJ	-	1816	O
)	-	1818	O
.	-	1819	O

These	3864191	1821	O
results	-	1827	O
suggest	-	1835	O
that	-	1843	O
enhanced	-	1848	O
prostaglandin	-	1857	O
synthesis	-	1871	O
contributes	-	1881	O
to	-	1893	O
maintenance	-	1896	O
of	-	1908	O
renal	-	1911	O
function	-	1917	O
and	-	1926	O
morphological	-	1930	O
integrity	-	1944	O
,	-	1953	O
and	-	1955	O
that	-	1959	O
inhibition	-	1964	O
of	-	1975	O
prostaglandin	-	1978	O
synthesis	-	1992	O
may	-	2002	O
lead	-	2006	O
to	-	2011	O
pathological	-	2014	B
renal	-	2027	I
medullary	-	2033	I
lesions	-	2043	I
and	-	2051	O
deterioration	-	2055	B
of	-	2069	I
renal	-	2072	I
function	-	2078	I
.	-	2086	O

Prophylactic	3895875	0	O
lidocaine	-	13	O
in	-	23	O
the	-	26	O
early	-	30	O
phase	-	36	O
of	-	42	O
suspected	-	45	O
myocardial	-	55	B
infarction	-	66	I
.	-	76	O

Four	3895875	78	O
hundred	-	83	O
two	-	91	O
patients	-	95	O
with	-	104	O
suspected	-	109	O
myocardial	-	119	B
infarction	-	130	I
seen	-	141	O
within	-	146	O
6	-	153	O
hours	-	155	O
of	-	161	O
the	-	164	O
onset	-	168	O
of	-	174	O
symptoms	-	177	O
entered	-	186	O
a	-	194	O
double	-	196	O
-	-	202	O
blind	-	203	O
randomized	-	209	O
trial	-	220	O
of	-	226	O
lidocaine	-	229	O
vs	-	239	O
placebo	-	242	O
.	-	249	O

During	3895875	251	O
the	-	258	O
1	-	262	O
hour	-	264	O
after	-	269	O
administration	-	275	O
of	-	290	O
the	-	293	O
drug	-	297	O
the	-	302	O
incidence	-	306	O
of	-	316	O
ventricular	-	319	B
fibrillation	-	331	I
or	-	344	O
sustained	-	347	O
ventricular	-	357	B
tachycardia	-	369	I
among	-	381	O
the	-	387	O
204	-	391	O
patients	-	395	O
with	-	404	O
acute	-	409	O
myocardial	-	415	B
infarction	-	426	I
was	-	437	O
low	-	441	O
,	-	444	O
1	-	446	O
.	-	447	O
5	-	448	O
%	-	449	O
.	-	450	O

Lidocaine	3895875	452	O
,	-	461	O
given	-	463	O
in	-	469	O
a	-	472	O
300	-	474	O
mg	-	478	O
dose	-	481	O
intramuscularly	-	486	O
followed	-	502	O
by	-	511	O
100	-	514	O
mg	-	518	O
intravenously	-	521	O
,	-	534	O
did	-	536	O
not	-	540	O
prevent	-	544	O
sustained	-	552	O
ventricular	-	562	B
tachycardia	-	574	I
,	-	585	O
although	-	587	O
there	-	596	O
was	-	602	O
a	-	606	O
significant	-	608	O
reduction	-	620	O
in	-	630	O
the	-	633	O
number	-	637	O
of	-	644	O
patients	-	647	O
with	-	656	O
warning	-	661	O
arrhythmias	-	669	B
between	-	681	O
15	-	689	O
and	-	692	O
45	-	696	O
minutes	-	699	O
after	-	707	O
the	-	713	O
administration	-	717	O
of	-	732	O
lidocaine	-	735	O
(	-	745	O
p	-	746	O
less	-	748	O
than	-	753	O
0	-	758	O
.	-	759	O
05	-	760	O
)	-	762	O
.	-	763	O

The	3895875	765	O
average	-	769	O
plasma	-	777	O
lidocaine	-	784	O
level	-	794	O
10	-	800	O
minutes	-	803	O
after	-	811	O
administration	-	817	O
for	-	832	O
patients	-	836	O
without	-	845	O
a	-	853	O
myocardial	-	855	B
infarction	-	866	I
was	-	877	O
significantly	-	881	O
higher	-	895	O
than	-	902	O
that	-	907	O
for	-	912	O
patients	-	916	O
with	-	925	O
an	-	930	O
acute	-	933	O
infarction	-	939	B
.	-	949	O

The	3895875	951	O
mean	-	955	O
plasma	-	960	O
lidocaine	-	967	O
level	-	977	O
of	-	983	O
patients	-	986	O
on	-	995	O
beta	-	998	O
-	-	1002	O
blocking	-	1003	O
agents	-	1012	O
was	-	1019	O
no	-	1023	O
different	-	1026	O
from	-	1036	O
that	-	1041	O
in	-	1046	O
patients	-	1049	O
not	-	1058	O
on	-	1062	O
beta	-	1065	O
blocking	-	1070	O
agents	-	1079	O
.	-	1085	O

During	3895875	1087	O
the	-	1094	O
1	-	1098	O
-	-	1099	O
hour	-	1100	O
study	-	1105	O
period	-	1111	O
,	-	1117	O
the	-	1119	O
incidence	-	1123	O
of	-	1133	O
central	-	1136	O
nervous	-	1144	O
system	-	1152	O
side	-	1159	O
effects	-	1164	O
was	-	1172	O
significantly	-	1176	O
greater	-	1190	O
in	-	1198	O
the	-	1201	O
lidocaine	-	1205	O
group	-	1215	O
,	-	1220	O
hypotension	-	1222	B
occurred	-	1234	O
in	-	1243	O
11	-	1246	O
patients	-	1249	O
,	-	1257	O
nine	-	1259	O
of	-	1264	O
whom	-	1267	O
had	-	1272	O
received	-	1276	O
lidocaine	-	1285	O
,	-	1294	O
and	-	1296	O
four	-	1300	O
patients	-	1305	O
died	-	1314	O
from	-	1319	O
asystole	-	1324	B
,	-	1332	O
three	-	1334	O
of	-	1340	O
whom	-	1343	O
had	-	1348	O
had	-	1352	O
lidocaine	-	1356	O
.	-	1365	O

We	3895875	1367	O
can	-	1370	O
not	-	1373	O
advocate	-	1377	O
the	-	1386	O
administration	-	1390	O
of	-	1405	O
lidocaine	-	1408	O
prophylactically	-	1418	O
in	-	1435	O
the	-	1438	O
early	-	1442	O
hours	-	1448	O
of	-	1454	O
suspected	-	1457	O
myocardial	-	1467	B
infarction	-	1478	I
.	-	1488	O

Evidence	3925479	0	O
for	-	9	O
a	-	13	O
cholinergic	-	15	O
role	-	27	O
in	-	32	O
haloperidol	-	35	O
-	-	46	O
induced	-	47	O
catalepsy	-	55	B
.	-	64	O

Experiments	3925479	66	O
in	-	78	O
mice	-	81	O
tested	-	86	O
previous	-	93	O
evidence	-	102	O
that	-	111	O
activation	-	116	O
of	-	127	O
cholinergic	-	130	O
systems	-	142	O
promotes	-	150	O
catalepsy	-	159	B
and	-	169	O
that	-	173	O
cholinergic	-	178	O
mechanisms	-	190	O
need	-	201	O
to	-	206	O
be	-	209	O
intact	-	212	O
for	-	219	O
full	-	223	O
expression	-	228	O
of	-	239	O
neuroleptic	-	242	O
-	-	253	O
induced	-	254	O
catalepsy	-	262	B
.	-	271	O

Large	3925479	273	O
doses	-	279	O
of	-	285	O
the	-	288	O
cholinomimetic	-	292	O
,	-	306	O
pilocarpine	-	308	O
,	-	319	O
could	-	321	O
induce	-	327	O
catalepsy	-	334	B
when	-	344	O
peripheral	-	349	O
cholinergic	-	360	O
receptors	-	372	O
were	-	382	O
blocked	-	387	O
.	-	394	O

Low	3925479	396	O
doses	-	400	O
of	-	406	O
pilocarpine	-	409	O
caused	-	421	O
a	-	428	O
pronounced	-	430	O
enhancement	-	441	O
of	-	453	O
the	-	456	O
catalepsy	-	460	B
that	-	470	O
was	-	475	O
induced	-	479	O
by	-	487	O
the	-	490	O
dopaminergic	-	494	O
blocker	-	507	O
,	-	514	O
haloperidol	-	516	O
.	-	527	O

A	3925479	529	O
muscarinic	-	531	O
receptor	-	542	O
blocker	-	551	O
,	-	558	O
atropine	-	560	O
,	-	568	O
disrupted	-	570	O
haloperidol	-	580	O
-	-	591	O
induced	-	592	O
catalepsy	-	600	B
.	-	609	O

Intracranial	3925479	611	O
injection	-	624	O
of	-	634	O
an	-	637	O
acetylcholine	-	640	O
-	-	653	O
synthesis	-	654	O
inhibitor	-	664	O
,	-	673	O
hemicholinium	-	675	O
,	-	688	O
prevented	-	690	O
the	-	700	O
catalepsy	-	704	B
that	-	714	O
is	-	719	O
usually	-	722	O
induced	-	730	O
by	-	738	O
haloperidol	-	741	O
.	-	752	O

These	3925479	754	O
findings	-	760	O
suggest	-	769	O
the	-	777	O
hypothesis	-	781	O
that	-	792	O
the	-	797	O
catalepsy	-	801	B
that	-	811	O
is	-	816	O
produced	-	819	O
by	-	828	O
neuroleptics	-	831	O
such	-	844	O
as	-	849	O
haloperidol	-	852	O
is	-	864	O
actually	-	867	O
mediated	-	876	O
by	-	885	O
intrinsic	-	888	O
central	-	898	O
cholinergic	-	906	O
systems	-	918	O
.	-	925	O

Alternatively	3925479	927	O
,	-	940	O
activation	-	942	O
of	-	953	O
central	-	956	O
cholinergic	-	964	O
systems	-	976	O
could	-	984	O
promote	-	990	O
catalepsy	-	998	B
by	-	1008	O
suppression	-	1011	O
of	-	1023	O
dopaminergic	-	1026	O
systems	-	1039	O
.	-	1046	O

Cardiovascular	3975902	0	B
dysfunction	-	15	I
and	-	27	O
hypersensitivity	-	31	B
to	-	48	O
sodium	-	51	O
pentobarbital	-	58	O
induced	-	72	O
by	-	80	O
chronic	-	83	O
barium	-	91	O
chloride	-	98	O
ingestion	-	107	O
.	-	116	O

Barium	3975902	118	O
-	-	124	O
supplemented	-	125	O
Long	-	138	O
-	-	142	O
Evans	-	143	O
hooded	-	149	O
rats	-	156	O
were	-	161	O
characterized	-	166	O
by	-	180	O
a	-	183	O
persistent	-	185	O
hypertension	-	196	B
that	-	209	O
was	-	214	O
evident	-	218	O
after	-	226	O
1	-	232	O
month	-	234	O
of	-	240	O
barium	-	243	O
(	-	250	O
100	-	251	O
micrograms	-	255	O
/	-	265	O
ml	-	266	O
mineral	-	269	O
fortified	-	277	O
water	-	287	O
)	-	292	O
treatment	-	294	O
.	-	303	O

Analysis	3975902	305	O
of	-	314	O
in	-	317	O
vivo	-	320	O
myocardial	-	325	O
excitability	-	336	O
,	-	348	O
contractility	-	350	O
,	-	363	O
and	-	365	O
metabolic	-	369	O
characteristics	-	379	O
at	-	395	O
16	-	398	O
months	-	401	O
revealed	-	408	O
other	-	417	O
significant	-	423	O
barium	-	435	O
-	-	441	O
induced	-	442	O
disturbances	-	450	B
within	-	463	I
the	-	470	I
cardiovascular	-	474	I
system	-	489	I
.	-	495	O

The	3975902	497	O
most	-	501	O
distinctive	-	506	O
aspect	-	518	O
of	-	525	O
the	-	528	O
barium	-	532	O
effect	-	539	O
was	-	546	O
a	-	550	O
demonstrated	-	552	O
hypersensitivity	-	565	B
of	-	582	O
the	-	585	O
cardiovascular	-	589	O
system	-	604	O
to	-	611	O
sodium	-	614	O
pentobarbital	-	621	O
.	-	634	O

Under	3975902	636	O
barbiturate	-	642	O
anesthesia	-	654	O
,	-	664	O
virtually	-	666	O
all	-	676	O
of	-	680	O
the	-	683	O
myocardial	-	687	O
contractile	-	698	O
indices	-	710	O
were	-	718	O
depressed	-	723	O
significantly	-	733	O
in	-	747	O
barium	-	750	O
-	-	756	O
exposed	-	757	O
rats	-	765	O
relative	-	770	O
to	-	779	O
the	-	782	O
corresponding	-	786	O
control	-	800	O
-	-	807	O
fed	-	808	O
rats	-	812	O
.	-	816	O

The	3975902	818	O
lack	-	822	O
of	-	827	O
a	-	830	O
similar	-	832	O
response	-	840	O
to	-	849	O
ketamine	-	852	O
and	-	861	O
xylazine	-	865	O
anesthesia	-	874	O
revealed	-	885	O
that	-	894	O
the	-	899	O
cardiovascular	-	903	O
actions	-	918	O
of	-	926	O
sodium	-	929	O
pentobarbital	-	936	O
in	-	950	O
barium	-	953	O
-	-	959	O
treated	-	960	O
rats	-	968	O
were	-	973	O
linked	-	978	O
specifically	-	985	O
to	-	998	O
this	-	1001	O
anesthetic	-	1006	O
,	-	1016	O
and	-	1018	O
were	-	1022	O
not	-	1027	O
representative	-	1031	O
of	-	1046	O
a	-	1049	O
generalized	-	1051	O
anesthetic	-	1063	O
response	-	1074	O
.	-	1082	O

Other	3975902	1084	O
myocardial	-	1090	O
pathophysiologic	-	1101	O
and	-	1118	O
metabolic	-	1122	O
changes	-	1132	O
induced	-	1140	O
by	-	1148	O
barium	-	1151	O
were	-	1158	O
manifest	-	1163	O
,	-	1171	O
irrespective	-	1173	O
of	-	1186	O
the	-	1189	O
anesthetic	-	1193	O
employed	-	1204	O
.	-	1212	O

The	3975902	1214	O
contractile	-	1218	O
element	-	1230	O
shortening	-	1238	O
velocity	-	1249	O
of	-	1258	O
the	-	1261	O
cardiac	-	1265	O
muscle	-	1273	O
fibers	-	1280	O
was	-	1287	O
significantly	-	1291	O
slower	-	1305	O
in	-	1312	O
both	-	1315	O
groups	-	1320	O
of	-	1327	O
barium	-	1330	O
-	-	1336	O
treated	-	1337	O
rats	-	1345	O
relative	-	1350	O
to	-	1359	O
the	-	1362	O
control	-	1366	O
groups	-	1374	O
,	-	1380	O
irrespective	-	1382	O
of	-	1395	O
the	-	1398	O
anesthetic	-	1402	O
regimen	-	1413	O
.	-	1420	O

Similarly	3975902	1422	O
,	-	1431	O
significant	-	1433	O
disturbances	-	1445	O
in	-	1458	O
myocardial	-	1461	O
energy	-	1472	O
metabolism	-	1479	O
were	-	1490	O
detected	-	1495	O
in	-	1504	O
the	-	1507	O
barium	-	1511	O
-	-	1517	O
exposed	-	1518	O
rats	-	1526	O
which	-	1531	O
were	-	1537	O
consistent	-	1542	O
with	-	1553	O
the	-	1558	O
reduced	-	1562	O
contractile	-	1570	O
element	-	1582	O
shortening	-	1590	O
velocity	-	1601	O
.	-	1609	O

In	3975902	1611	O
addition	-	1614	O
,	-	1622	O
the	-	1624	O
excitability	-	1628	O
of	-	1641	O
the	-	1644	O
cardiac	-	1648	O
conduction	-	1656	O
system	-	1667	O
was	-	1674	O
depressed	-	1678	O
preferentially	-	1688	O
in	-	1703	O
the	-	1706	O
atrioventricular	-	1710	O
nodal	-	1727	O
region	-	1733	O
of	-	1740	O
hearts	-	1743	O
from	-	1750	O
barium	-	1755	O
-	-	1761	O
exposed	-	1762	O
rats	-	1770	O
.	-	1774	O

Overall	3975902	1776	O
,	-	1783	O
the	-	1785	O
altered	-	1789	O
cardiac	-	1797	O
contractility	-	1805	O
and	-	1819	O
excitability	-	1823	O
characteristics	-	1836	O
,	-	1851	O
the	-	1853	O
myocardial	-	1857	O
metabolic	-	1868	B
disturbances	-	1878	I
,	-	1890	O
and	-	1892	O
the	-	1896	O
hypersensitivity	-	1900	B
of	-	1917	O
the	-	1920	O
cardiovascular	-	1924	O
system	-	1939	O
to	-	1946	O
sodium	-	1949	O
pentobarbital	-	1956	O
suggest	-	1970	O
the	-	1978	O
existence	-	1982	O
of	-	1992	O
a	-	1995	O
heretofore	-	1997	O
undescribed	-	2008	O
cardiomyopathic	-	2020	B
disorder	-	2036	I
induced	-	2045	O
by	-	2053	O
chronic	-	2056	O
barium	-	2064	O
exposure	-	2071	O
.	-	2079	O

These	3975902	2081	O
experimental	-	2087	O
findings	-	2100	O
represent	-	2109	O
the	-	2119	O
first	-	2123	O
indication	-	2129	O
that	-	2140	O
life	-	2145	O
-	-	2149	O
long	-	2150	O
barium	-	2155	O
ingestion	-	2162	O
may	-	2172	O
have	-	2176	O
significant	-	2181	O
adverse	-	2193	O
effects	-	2201	O
on	-	2209	O
the	-	2212	O
mammalian	-	2216	O
cardiovascular	-	2226	O
system	-	2241	O
.	-	2247	O

Propranolol	3987172	0	O
antagonism	-	12	O
of	-	23	O
phenylpropanolamine	-	26	O
-	-	45	O
induced	-	46	O
hypertension	-	54	B
.	-	66	O

Phenylpropanolamine	3987172	68	O
(	-	88	O
PPA	-	89	O
)	-	92	O
overdose	-	94	B
can	-	103	O
cause	-	107	O
severe	-	113	O
hypertension	-	120	B
,	-	132	O
intracerebral	-	134	B
hemorrhage	-	148	I
,	-	158	O
and	-	160	O
death	-	164	O
.	-	169	O

We	3987172	171	O
studied	-	174	O
the	-	182	O
efficacy	-	186	O
and	-	195	O
safety	-	199	O
of	-	206	O
propranolol	-	209	O
in	-	221	O
the	-	224	O
treatment	-	228	O
of	-	238	O
PPA	-	241	O
-	-	244	O
induced	-	245	O
hypertension	-	253	B
.	-	265	O

Subjects	3987172	267	O
received	-	276	O
propranolol	-	285	O
either	-	297	O
by	-	304	O
mouth	-	307	O
for	-	313	O
48	-	317	O
hours	-	320	O
before	-	326	O
PPA	-	333	O
or	-	337	O
as	-	340	O
a	-	343	O
rapid	-	345	O
intravenous	-	351	O
infusion	-	363	O
after	-	372	O
PPA	-	378	O
.	-	381	O

PPA	3987172	383	O
,	-	386	O
75	-	388	O
mg	-	391	O
alone	-	394	O
,	-	399	O
increased	-	401	O
blood	-	411	O
pressure	-	417	O
(	-	426	O
31	-	427	O
+	-	430	O
/	-	431	O
-	-	432	O

14	3987172	434	O
mm	-	437	O
Hg	-	440	O
systolic	-	443	O
,	-	451	O
20	-	453	O
+	-	456	O
/	-	457	O
-	-	458	O

5	3987172	460	O
mm	-	462	O
Hg	-	465	O
diastolic	-	468	O
)	-	477	O
,	-	478	O
and	-	480	O
propranolol	-	484	O
pretreatment	-	496	O
antagonized	-	509	O
this	-	521	O
increase	-	526	O
(	-	535	O
12	-	536	O
+	-	539	O
/	-	540	O
-	-	541	O

10	3987172	543	O
mm	-	546	O

Hg	3987172	549	O
systolic	-	552	O
,	-	560	O
10	-	562	O
+	-	565	O
/	-	566	O
-	-	567	O
7	-	569	O
mm	-	571	O
Hg	-	574	O
diastolic	-	577	O
)	-	586	O
.	-	587	O

Intravenous	3987172	589	O
propranolol	-	601	O
after	-	613	O
PPA	-	619	O
also	-	623	O
decreased	-	628	O
blood	-	638	O
pressure	-	644	O
.	-	652	O

Left	3987172	654	O
ventricular	-	659	O
function	-	671	O
(	-	680	O
assessed	-	681	O
by	-	690	O
echocardiography	-	693	O
)	-	709	O
showed	-	711	O
that	-	718	O
PPA	-	723	O
increased	-	727	O
the	-	737	O
stroke	-	741	B
volume	-	748	O
30	-	755	O
%	-	757	O
(	-	759	O
from	-	760	O
62	-	765	O
.	-	767	O
5	-	768	O
+	-	770	O
/	-	771	O
-	-	772	O

20	3987172	774	O
.	-	776	O
9	-	777	O
to	-	779	O
80	-	782	O
.	-	784	O
8	-	785	O
+	-	787	O
/	-	788	O
-	-	789	O

22	3987172	791	O
.	-	793	O
4	-	794	O
ml	-	796	O
)	-	798	O
,	-	799	O
the	-	801	O
ejection	-	805	O
fraction	-	814	O
9	-	823	O
%	-	824	O
(	-	826	O
from	-	827	O
64	-	832	O
%	-	834	O
+	-	836	O
/	-	837	O
-	-	838	O

10	3987172	840	O
%	-	842	O
to	-	844	O
70	-	847	O
%	-	849	O
+	-	851	O
/	-	852	O
-	-	853	O

7	3987172	855	O
%	-	856	O
)	-	857	O
,	-	858	O
and	-	860	O
cardiac	-	864	O
output	-	872	O
14	-	879	O
%	-	881	O
(	-	883	O
from	-	884	O
3	-	889	O
.	-	890	O
6	-	891	O
+	-	893	O
/	-	894	O
-	-	895	O

0	3987172	897	O
.	-	898	O
6	-	899	O
to	-	901	O
4	-	904	O
.	-	905	O
1	-	906	O
+	-	908	O
/	-	909	O
-	-	910	O

1	3987172	912	O
.	-	913	O
0	-	914	O
L	-	916	O
/	-	917	O
min	-	918	O
)	-	921	O
.	-	922	O

Intravenous	3987172	924	O
propranolol	-	936	O
reversed	-	948	O
these	-	957	O
effects	-	963	O
.	-	970	O

Systemic	3987172	972	O
vascular	-	981	O
resistance	-	990	O
was	-	1001	O
increased	-	1005	O
by	-	1015	O
PPA	-	1018	O
28	-	1022	O
%	-	1024	O
(	-	1026	O
from	-	1027	O
1710	-	1032	O
+	-	1037	O
/	-	1038	O
-	-	1039	O

200	3987172	1041	O
to	-	1045	O
2190	-	1048	O
+	-	1053	O
/	-	1054	O
-	-	1055	O
700	-	1057	O
dyne	-	1061	O
X	-	1066	O
sec	-	1068	O
/	-	1071	O
cm5	-	1072	O
)	-	1075	O

and	3987172	1077	O
was	-	1081	O
further	-	1085	O
increased	-	1093	O
by	-	1103	O
propranolol	-	1106	O
22	-	1118	O
%	-	1120	O
(	-	1122	O
to	-	1123	O
2660	-	1126	O
+	-	1131	O
/	-	1132	O
-	-	1133	O

1200	3987172	1135	O
dyne	-	1140	O
X	-	1145	O
sec	-	1147	O
/	-	1150	O
cm5	-	1151	O
)	-	1154	O
.	-	1155	O

We	3987172	1157	O
conclude	-	1160	O
that	-	1169	O
PPA	-	1174	O
increases	-	1178	O
blood	-	1188	O
pressure	-	1194	O
by	-	1203	O
increasing	-	1206	O
systemic	-	1217	O
vascular	-	1226	O
resistance	-	1235	O
and	-	1246	O
cardiac	-	1250	O
output	-	1258	O
,	-	1264	O
and	-	1266	O
that	-	1270	O
propranolol	-	1275	O
antagonizes	-	1287	O
this	-	1299	O
increase	-	1304	O
by	-	1313	O
reversing	-	1316	O
the	-	1326	O
effect	-	1330	O
of	-	1337	O
PPA	-	1340	O
on	-	1344	O
cardiac	-	1347	O
output	-	1355	O
.	-	1361	O

That	3987172	1363	O
propranolol	-	1368	O
antagonizes	-	1380	O
the	-	1392	O
pressor	-	1396	O
effect	-	1404	O
of	-	1411	O
PPA	-	1414	O
is	-	1418	O
in	-	1421	O
contrast	-	1424	O
to	-	1433	O
the	-	1436	O
interaction	-	1440	O
in	-	1452	O
which	-	1455	O
propranolol	-	1461	O
enhances	-	1473	O
the	-	1482	O
pressor	-	1486	O
effect	-	1494	O
of	-	1501	O
norepinephrine	-	1504	O
.	-	1518	O

This	3987172	1520	O
is	-	1525	O
probably	-	1528	O
because	-	1537	O
PPA	-	1545	O
has	-	1549	O
less	-	1553	O
beta	-	1558	O
2	-	1563	O
activity	-	1565	O
than	-	1574	O
does	-	1579	O
norepinephrine	-	1584	O
.	-	1598	O

Mesangial	3990093	0	O
function	-	10	O
and	-	19	O
glomerular	-	23	B
sclerosis	-	34	I
in	-	44	O
rats	-	47	O
with	-	52	O
aminonucleoside	-	57	O
nephrosis	-	73	B
.	-	82	O

The	3990093	84	O
possible	-	88	O
relationship	-	97	O
between	-	110	O
mesangial	-	118	B
dysfunction	-	128	I
and	-	140	O
development	-	144	O
of	-	156	O
glomerular	-	159	B
sclerosis	-	170	I
was	-	180	O
studied	-	184	O
in	-	192	O
the	-	195	O
puromycin	-	199	O
aminonucleoside	-	209	O
(	-	225	O
PAN	-	226	O
)	-	229	O
model	-	231	O
.	-	236	O

Five	3990093	238	O
male	-	243	O
Wistar	-	248	O
rats	-	255	O
received	-	260	O
repeated	-	269	O
subcutaneous	-	278	O
PAN	-	291	O
injections	-	295	O
;	-	305	O
five	-	307	O
controls	-	312	O
received	-	321	O
saline	-	330	O
only	-	337	O
.	-	341	O

After	3990093	343	O
4	-	349	O
weeks	-	351	O
the	-	357	O
PAN	-	361	O
rats	-	365	O
were	-	370	O
severely	-	375	O
proteinuric	-	384	B
(	-	396	O
190	-	397	O
+	-	401	O
/	-	402	O
-	-	403	O

80	3990093	405	O
mg	-	408	O
/	-	410	O
24	-	411	O
hr	-	414	O
)	-	416	O
,	-	417	O
and	-	419	O
all	-	423	O
rats	-	427	O
were	-	432	O
given	-	437	O
colloidal	-	443	O
carbon	-	453	O
(	-	460	O
CC	-	461	O
)	-	463	O
intravenously	-	465	O
.	-	478	O

At	3990093	480	O
5	-	483	O
months	-	485	O
glomerular	-	492	B
sclerosis	-	503	I
was	-	513	O
found	-	517	O
in	-	523	O
7	-	526	O
.	-	527	O
6	-	528	O
+	-	530	O
/	-	531	O
-	-	532	O

3	3990093	534	O
.	-	535	O
4	-	536	O
%	-	537	O
of	-	539	O
the	-	542	O
glomeruli	-	546	O
of	-	556	O
PAN	-	559	O
rats	-	563	O
;	-	567	O
glomeruli	-	569	O
of	-	579	O
the	-	582	O
controls	-	586	O
were	-	595	O
normal	-	600	O
.	-	606	O

Glomeruli	3990093	608	O
of	-	618	O
PAN	-	621	O
rats	-	625	O
contained	-	630	O
significantly	-	640	O
more	-	654	O
CC	-	659	O
than	-	662	O
glomeruli	-	667	O
of	-	677	O
controls	-	680	O
.	-	688	O

Glomeruli	3990093	690	O
with	-	700	O
sclerosis	-	705	B
contained	-	715	O
significantly	-	725	O
more	-	739	O
CC	-	744	O
than	-	747	O
non	-	752	O
-	-	755	O
sclerotic	-	756	O
glomeruli	-	766	O
in	-	776	O
the	-	779	O
same	-	783	O
kidneys	-	788	O
.	-	795	O

CC	3990093	797	O
was	-	800	O
preferentially	-	804	O
localized	-	819	O
within	-	829	O
the	-	836	O
sclerotic	-	840	O
areas	-	850	O
of	-	856	O
the	-	859	O
affected	-	863	O
glomeruli	-	872	O
.	-	881	O

Since	3990093	883	O
mesangial	-	889	O
CC	-	899	O
clearance	-	902	O
from	-	912	O
the	-	917	O
mesangium	-	921	O
did	-	931	O
not	-	935	O
change	-	939	O
during	-	946	O
chronic	-	953	O
PAN	-	961	O
treatment	-	965	O
,	-	974	O
we	-	976	O
conclude	-	979	O
that	-	988	O
this	-	993	O
preferential	-	998	O
CC	-	1011	O
localization	-	1014	O
within	-	1027	O
the	-	1034	O
lesions	-	1038	O
is	-	1046	O
caused	-	1049	O
by	-	1056	O
an	-	1059	O
increased	-	1062	O
CC	-	1072	O
uptake	-	1075	O
shortly	-	1082	O
after	-	1090	O
injection	-	1096	O
in	-	1106	O
apparent	-	1109	O
vulnerable	-	1118	O
areas	-	1129	O
where	-	1135	O
sclerosis	-	1141	B
will	-	1151	O
develop	-	1156	O
subsequently	-	1164	O
.	-	1176	O

Cluster	3990093	1178	O
analysis	-	1186	O
showed	-	1195	O
a	-	1202	O
random	-	1204	O
distribution	-	1211	O
of	-	1224	O
lesions	-	1227	O
in	-	1235	O
the	-	1238	O
PAN	-	1242	O
glomeruli	-	1246	O
in	-	1256	O
concordance	-	1259	O
with	-	1271	O
the	-	1276	O
random	-	1280	O
localization	-	1287	O
of	-	1300	O
mesangial	-	1303	O
areas	-	1313	O
with	-	1319	O
dysfunction	-	1324	O
in	-	1336	O
this	-	1339	O
model	-	1344	O
.	-	1349	O

Similar	3990093	1351	O
to	-	1359	O
the	-	1362	O
remnant	-	1366	O
kidney	-	1374	O
model	-	1381	O
in	-	1387	O
PAN	-	1390	O
nephrosis	-	1394	B
the	-	1404	O
development	-	1408	O
of	-	1420	O
glomerular	-	1423	B
sclerosis	-	1434	I
may	-	1444	O
be	-	1448	O
related	-	1451	O
to	-	1459	O
""""	-	1462	O
mesangial	-	1463	O
overloading	-	1473	O
.	-	1484	O
""""	-	1485	O

Relationship	4010471	0	O
between	-	13	O
nicotine	-	21	O
-	-	29	O
induced	-	30	O
seizures	-	38	B
and	-	47	O
hippocampal	-	51	O
nicotinic	-	63	O
receptors	-	73	O
.	-	82	O

A	4010471	84	O
controversy	-	86	O
has	-	98	O
existed	-	102	O
for	-	110	O
several	-	114	O
years	-	122	O
concerning	-	128	O
the	-	139	O
physiological	-	143	O
relevance	-	157	O
of	-	167	O
the	-	170	O
nicotinic	-	174	O
receptor	-	184	O
measured	-	193	O
by	-	202	O
alpha	-	205	O
-	-	210	O
bungarotoxin	-	211	O
binding	-	224	O
.	-	231	O

Using	4010471	233	O
mice	-	239	O
derived	-	244	O
from	-	252	O
a	-	257	O
classical	-	259	O
F2	-	269	O
and	-	272	O
backcross	-	276	O
genetic	-	286	O
design	-	294	O
,	-	300	O
a	-	302	O
relationship	-	304	O
between	-	317	O
nicotine	-	325	O
-	-	333	O
induced	-	334	O
seizures	-	342	B
and	-	351	O
alpha	-	355	O
-	-	360	O
bungarotoxin	-	361	O
nicotinic	-	374	O
receptor	-	384	O
concentration	-	393	O
was	-	407	O
found	-	411	O
.	-	416	O

Mice	4010471	418	O
sensitive	-	423	O
to	-	433	O
the	-	436	O
convulsant	-	440	O
effects	-	451	O
of	-	459	O
nicotine	-	462	O
had	-	471	O
greater	-	475	O
alpha	-	483	O
-	-	488	O
bungarotoxin	-	489	O
binding	-	502	O
in	-	510	O
the	-	513	O
hippocampus	-	517	O
than	-	529	O
seizure	-	534	B
insensitive	-	542	O
mice	-	554	O
.	-	558	O

The	4010471	560	O
binding	-	564	O
sites	-	572	O
from	-	578	O
seizure	-	583	B
sensitive	-	591	O
and	-	601	O
resistant	-	605	O
mice	-	615	O
were	-	620	O
equally	-	625	O
affected	-	633	O
by	-	642	O
treatment	-	645	O
with	-	655	O
dithiothreitol	-	660	O
,	-	674	O
trypsin	-	676	O
or	-	684	O
heat	-	687	O
.	-	691	O

Thus	4010471	693	O
it	-	698	O
appears	-	701	O
that	-	709	O
the	-	714	O
difference	-	718	O
between	-	729	O
seizure	-	737	B
sensitive	-	745	O
and	-	755	O
insensitive	-	759	O
animals	-	771	O
may	-	779	O
be	-	783	O
due	-	786	O
to	-	790	O
a	-	793	O
difference	-	795	O
in	-	806	O
hippocampal	-	809	O
nicotinic	-	821	O
receptor	-	831	O
concentration	-	840	O
as	-	854	O
measured	-	857	O
with	-	866	O
alpha	-	871	O
-	-	876	O
bungarotoxin	-	877	O
binding	-	890	O
.	-	897	O

The	4082192	0	O
role	-	4	O
of	-	9	O
p	-	12	O
-	-	13	O
aminophenol	-	14	O
in	-	26	O
acetaminophen	-	29	O
-	-	42	O
induced	-	43	O
nephrotoxicity	-	51	B
:	-	65	O
effect	-	67	O
of	-	74	O
bis	-	77	O
(	-	80	O
p	-	81	O
-	-	82	O
nitrophenyl	-	83	O
)	-	94	O
phosphate	-	96	O
on	-	106	O
acetaminophen	-	109	O
and	-	123	O
p	-	127	O
-	-	128	O
aminophenol	-	129	O
nephrotoxicity	-	141	B
and	-	156	O
metabolism	-	160	O
in	-	171	O
Fischer	-	174	O
344	-	182	O
rats	-	186	O
.	-	190	O

Acetaminophen	4082192	192	O
(	-	206	O
APAP	-	207	O
)	-	211	O
produces	-	213	O
proximal	-	222	O
tubular	-	231	B
necrosis	-	239	I
in	-	248	O
Fischer	-	251	O
344	-	259	O
(	-	263	O
F344	-	264	O
)	-	268	O
rats	-	270	O
.	-	274	O

Recently	4082192	276	O
,	-	284	O
p	-	286	O
-	-	287	O
aminophenol	-	288	O
(	-	300	O
PAP	-	301	O
)	-	304	O
,	-	305	O
a	-	307	O
known	-	309	O
potent	-	315	O
nephrotoxicant	-	322	O
,	-	336	O
was	-	338	O
identified	-	342	O
as	-	353	O
a	-	356	O
metabolite	-	358	O
of	-	369	O
APAP	-	372	O
in	-	377	O
F344	-	380	O
rats	-	385	O
.	-	389	O

The	4082192	391	O
purpose	-	395	O
of	-	403	O
this	-	406	O
study	-	411	O
was	-	417	O
to	-	421	O
determine	-	424	O
if	-	434	O
PAP	-	437	O
formation	-	441	O
is	-	451	O
a	-	454	O
requisite	-	456	O
step	-	466	O
in	-	471	O
APAP	-	474	O
-	-	478	O
induced	-	479	O
nephrotoxicity	-	487	B
.	-	501	O

Therefore	4082192	503	O
,	-	512	O
the	-	514	O
effect	-	518	O
of	-	525	O
bis	-	528	O
(	-	531	O
p	-	532	O
-	-	533	O
nitrophenyl	-	534	O
)	-	545	O
phosphate	-	547	O
(	-	557	O
BNPP	-	558	O
)	-	562	O
,	-	563	O
an	-	565	O
acylamidase	-	568	O
inhibitor	-	580	O
,	-	589	O
on	-	591	O
APAP	-	594	O
and	-	599	O
PAP	-	603	O
nephrotoxicity	-	607	B
and	-	622	O
metabolism	-	626	O
was	-	637	O
determined	-	641	O
.	-	651	O

BNPP	4082192	653	O
(	-	658	O
1	-	659	O
to	-	661	O
8	-	664	O
mM	-	666	O
)	-	668	O
reduced	-	670	O
APAP	-	678	O
deacetylation	-	683	O
and	-	697	O
covalent	-	701	O
binding	-	710	O
in	-	718	O
F344	-	721	O
renal	-	726	O
cortical	-	732	O
homogenates	-	741	O
in	-	753	O
a	-	756	O
concentration	-	758	O
-	-	771	O
dependent	-	772	O
manner	-	782	O
.	-	788	O

Pretreatment	4082192	790	O
of	-	803	O
animals	-	806	O
with	-	814	O
BNPP	-	819	O
prior	-	824	O
to	-	830	O
APAP	-	833	O
or	-	838	O
PAP	-	841	O
administration	-	845	O
resulted	-	860	O
in	-	869	O
marked	-	872	O
reduction	-	879	O
of	-	889	O
APAP	-	892	O
(	-	897	O
900	-	898	O
mg	-	902	O
/	-	904	O
kg	-	905	O
)	-	907	O
nephrotoxicity	-	909	B
but	-	924	O
not	-	928	O
PAP	-	932	O
nephrotoxicity	-	936	B
.	-	950	O

This	4082192	952	O
result	-	957	O
was	-	964	O
not	-	968	O
due	-	972	O
to	-	976	O
altered	-	979	O
disposition	-	987	O
of	-	999	O
either	-	1002	O
APAP	-	1009	O
or	-	1014	O
acetylated	-	1017	O
metabolites	-	1028	O
in	-	1040	O
plasma	-	1043	O
or	-	1050	O
renal	-	1053	O
cortical	-	1059	O
and	-	1068	O
hepatic	-	1072	O
tissue	-	1080	O
.	-	1086	O

Rather	4082192	1088	O
,	-	1094	O
BNPP	-	1096	O
pretreatment	-	1101	O
reduced	-	1114	O
the	-	1122	O
fraction	-	1126	O
of	-	1135	O
APAP	-	1138	O
excreted	-	1143	O
as	-	1152	O
PAP	-	1155	O
by	-	1159	O
64	-	1162	O
and	-	1165	O
75	-	1169	O
%	-	1171	O
after	-	1173	O
APAP	-	1179	O
doses	-	1184	O
of	-	1190	O
750	-	1193	O
and	-	1197	O
900	-	1201	O
mg	-	1205	O
/	-	1207	O
kg	-	1208	O
.	-	1210	O

BNPP	4082192	1212	O
did	-	1217	O
not	-	1221	O
alter	-	1225	O
the	-	1231	O
excretion	-	1235	O
of	-	1245	O
APAP	-	1248	O
or	-	1253	O
any	-	1256	O
of	-	1260	O
its	-	1263	O
non	-	1267	O
-	-	1270	O
deacetylated	-	1271	O
metabolites	-	1284	O
nor	-	1296	O
did	-	1300	O
BNPP	-	1304	O
alter	-	1309	O
excretion	-	1315	O
of	-	1325	O
PAP	-	1328	O
or	-	1332	O
its	-	1335	O
metabolites	-	1339	O
after	-	1351	O
PAP	-	1357	O
doses	-	1361	O
of	-	1367	O
150	-	1370	O
and	-	1374	O
300	-	1378	O
mg	-	1382	O
/	-	1384	O
kg	-	1385	O
.	-	1387	O

Therefore	4082192	1389	O
,	-	1398	O
the	-	1400	O
BNPP	-	1404	O
-	-	1408	O
induced	-	1409	O
reduction	-	1417	O
in	-	1427	O
APAP	-	1430	O
-	-	1434	O
induced	-	1435	O
nephrotoxicity	-	1443	B
appears	-	1458	O
to	-	1466	O
be	-	1469	O
due	-	1472	O
to	-	1476	O
inhibition	-	1479	O
of	-	1490	O
APAP	-	1493	O
deacetylation	-	1498	O
.	-	1511	O

It	4082192	1513	O
is	-	1516	O
concluded	-	1519	O
that	-	1529	O
PAP	-	1534	O
formation	-	1538	O
,	-	1547	O
in	-	1549	O
vivo	-	1552	O
,	-	1556	O
accounts	-	1558	O
,	-	1566	O
at	-	1568	O
least	-	1571	O
in	-	1577	O
part	-	1580	O
,	-	1584	O
for	-	1586	O
APAP	-	1590	O
-	-	1594	O
induced	-	1595	O
renal	-	1603	B
tubular	-	1609	I
necrosis	-	1617	I
.	-	1625	O

Morphine	4082466	0	O
-	-	8	O
induced	-	9	O
seizures	-	17	B
in	-	26	O
newborn	-	29	O
infants	-	37	O
.	-	44	O

Two	4082466	46	O
neonates	-	50	O
suffered	-	59	O
from	-	68	O
generalized	-	73	O
seizures	-	85	B
during	-	94	O
the	-	101	O
course	-	105	O
of	-	112	O
intravenous	-	115	O
morphine	-	127	O
sulfate	-	136	O
for	-	144	O
post	-	148	O
-	-	152	O
operative	-	153	O
analgesia	-	163	O
.	-	172	O

They	4082466	174	O
received	-	179	O
morphine	-	188	O
in	-	197	O
doses	-	200	O
of	-	206	O
32	-	209	O
micrograms	-	212	O
/	-	222	O
kg	-	223	O
/	-	225	O
hr	-	226	O
and	-	229	O
40	-	233	O
micrograms	-	236	O
/	-	246	O
kg	-	247	O
/	-	249	O
hr	-	250	O
larger	-	253	O
than	-	260	O
a	-	265	O
group	-	267	O
of	-	273	O
10	-	276	O
neonates	-	279	O
who	-	288	O
received	-	292	O
6	-	301	O
-	-	302	O
24	-	303	O
micrograms	-	306	O
/	-	316	O
kg	-	317	O
/	-	319	O
hr	-	320	O
and	-	323	O
had	-	327	O
no	-	331	O
seizures	-	334	B
.	-	342	O

Plasma	4082466	344	O
concentrations	-	351	O
of	-	366	O
morphine	-	369	O
in	-	378	O
these	-	381	O
neonates	-	387	O
was	-	396	O
excessive	-	400	O
(	-	410	O
60	-	411	O
and	-	414	O
90	-	418	O
mg	-	421	O
/	-	423	O
ml	-	424	O
)	-	426	O
.	-	427	O

Other	4082466	429	O
known	-	435	O
reasons	-	441	O
for	-	449	O
seizures	-	453	B
were	-	462	O
ruled	-	467	O
out	-	473	O
and	-	477	O
the	-	481	O
convulsions	-	485	B
stopped	-	497	O
a	-	505	O
few	-	507	O
hours	-	511	O
after	-	517	O
cessation	-	523	O
of	-	533	O
morphine	-	536	O
and	-	545	O
did	-	549	O
not	-	553	O
reoccur	-	557	O
in	-	565	O
the	-	568	O
subsequent	-	572	O
8	-	583	O
months	-	585	O
.	-	591	O

It	4082466	593	O
is	-	596	O
suggested	-	599	O
that	-	609	O
post	-	614	O
-	-	618	O
operative	-	619	O
intravenous	-	629	O
morphine	-	641	O
should	-	650	O
not	-	657	O
exceed	-	661	O
20	-	668	O
micrograms	-	671	O
/	-	681	O
kg	-	682	O
/	-	684	O
ml	-	685	O
in	-	688	O
neonates	-	691	O
.	-	699	O

Effect	4631913	0	O
of	-	7	O
vincristine	-	10	O
sulfate	-	22	O
on	-	30	O
Pseudomonas	-	33	B
infections	-	45	I
in	-	56	O
monkeys	-	59	O
.	-	66	O

In	4631913	68	O
rhesus	-	71	O
monkeys	-	78	O
,	-	85	O
intravenous	-	87	O
challenge	-	99	O
with	-	109	O
0	-	114	O
.	-	115	O
6	-	116	O
x	-	118	O
10	-	120	O
(	-	122	O
10	-	123	O
)	-	125	O
to	-	127	O
2	-	130	O
.	-	131	O
2	-	132	O
x	-	134	O
10	-	136	O
(	-	138	O
10	-	139	O
)	-	141	O
Pseudomonas	-	142	O
aeruginosa	-	154	O
organisms	-	165	O
caused	-	175	O
acute	-	182	O
illness	-	188	O
of	-	196	O
4	-	199	O
to	-	201	O
5	-	204	O
days	-	206	O
'	-	210	O
duration	-	212	O
with	-	221	O
spontaneous	-	226	O
recovery	-	238	O
in	-	247	O
13	-	250	O
of	-	253	O
15	-	256	O
monkeys	-	259	O
;	-	266	O
blood	-	268	O
cultures	-	274	O
became	-	283	O
negative	-	290	O
3	-	299	O
to	-	301	O
17	-	304	O
days	-	307	O
after	-	312	O
challenge	-	318	O
.	-	327	O

Leukocytosis	4631913	329	B
was	-	342	O
observed	-	346	O
in	-	355	O
all	-	358	O
monkeys	-	362	O
.	-	369	O

Intravenous	4631913	371	O
or	-	383	O
intratracheal	-	386	O
inoculation	-	400	O
of	-	412	O
2	-	415	O
.	-	416	O
0	-	417	O
to	-	419	O
2	-	422	O
.	-	423	O
5	-	424	O
mg	-	426	O
of	-	429	O
vincristine	-	432	O
sulfate	-	444	O
was	-	452	O
followed	-	456	O
by	-	465	O
leukopenia	-	468	B
in	-	479	O
4	-	482	O
to	-	484	O
5	-	487	O
days	-	489	O
.	-	493	O

Intravenous	4631913	495	O
inoculation	-	507	O
of	-	519	O
4	-	522	O
.	-	523	O
2	-	524	O
x	-	526	O
10	-	528	O
(	-	530	O
10	-	531	O
)	-	533	O
to	-	535	O
7	-	538	O
.	-	539	O
8	-	540	O
x	-	542	O
10	-	544	O
(	-	546	O
10	-	547	O
)	-	549	O
pyocin	-	551	O
type	-	558	O
6	-	563	O
Pseudomonas	-	565	O
organisms	-	577	O
in	-	587	O
monkeys	-	590	O
given	-	598	O
vincristine	-	604	O
sulfate	-	616	O
4	-	624	O
days	-	626	O
previously	-	631	O
resulted	-	642	O
in	-	651	O
fatal	-	654	O
infection	-	660	B
in	-	670	O
11	-	673	O
of	-	676	O
14	-	679	O
monkeys	-	682	O
,	-	689	O
whereas	-	691	O
none	-	699	O
of	-	704	O
four	-	707	O
receiving	-	712	O
Pseudomonas	-	722	O
alone	-	734	O
died	-	740	O
.	-	744	O

These	4631913	746	O
studies	-	752	O
suggest	-	760	O
that	-	768	O
an	-	773	O
antimetabolite	-	776	O
-	-	790	O
induced	-	791	O
leukopenia	-	799	B
predisposes	-	810	O
to	-	822	O
severe	-	825	O
Pseudomonas	-	832	O
sepsis	-	844	B
and	-	851	O
that	-	855	O
such	-	860	O
monkeys	-	865	O
may	-	873	O
serve	-	877	O
as	-	883	O
a	-	886	O
biological	-	888	O
model	-	899	O
for	-	905	O
study	-	909	O
of	-	915	O
comparative	-	918	O
efficacy	-	930	O
of	-	939	O
antimicrobial	-	942	O
agents	-	956	O
.	-	962	O

Central	6106951	0	O
excitatory	-	8	O
actions	-	19	O
of	-	27	O
flurazepam	-	30	O
.	-	40	O

Toxic	6106951	42	O
actions	-	48	O
of	-	56	O
flurazepam	-	59	O
(	-	70	O
FZP	-	71	O
)	-	74	O
were	-	76	O
studied	-	81	O
in	-	89	O
cats	-	92	O
,	-	96	O
mice	-	98	O
and	-	103	O
rats	-	107	O
.	-	111	O

High	6106951	113	O
doses	-	118	O
caused	-	124	O
an	-	131	O
apparent	-	134	O
central	-	143	O
excitation	-	151	O
,	-	161	O
most	-	163	O
clearly	-	168	O
seen	-	176	O
as	-	181	O
clonic	-	184	O
convulsions	-	191	B
,	-	202	O
superimposed	-	204	O
on	-	217	O
general	-	220	O
depression	-	228	B
.	-	238	O

Following	6106951	240	O
a	-	250	O
lethal	-	252	O
dose	-	259	O
,	-	263	O
death	-	265	O
was	-	271	O
always	-	275	O
associated	-	282	O
with	-	293	O
convulsions	-	298	B
.	-	309	O

Comparing	6106951	311	O
the	-	321	O
relative	-	325	O
sensitivity	-	334	O
to	-	346	O
central	-	349	O
depression	-	357	B
and	-	368	O
excitation	-	372	O
revealed	-	383	O
that	-	392	O
rats	-	397	O
were	-	402	O
least	-	407	O
likely	-	413	O
to	-	420	O
have	-	423	O
convulsions	-	428	B
at	-	440	O
doses	-	443	O
that	-	449	O
did	-	454	O
not	-	458	O
first	-	462	O
cause	-	468	O
loss	-	474	B
of	-	479	I
consciousness	-	482	I
,	-	495	O
while	-	497	O
cats	-	503	O
most	-	508	O
clearly	-	513	O
showed	-	521	O
marked	-	528	O
central	-	535	O
excitatory	-	543	O
actions	-	554	O
.	-	561	O

Signs	6106951	563	O
of	-	569	O
FZP	-	572	O
toxocity	-	576	B
in	-	585	O
cats	-	588	O
included	-	593	O
excessive	-	602	O
salivation	-	612	B
,	-	622	O
extreme	-	624	O
apprehensive	-	632	O
behavior	-	645	O
,	-	653	O
retching	-	655	O
,	-	663	O
muscle	-	665	B
tremors	-	672	I
and	-	680	O
convulsions	-	684	B
.	-	695	O

An	6106951	697	O
interaction	-	700	O
between	-	712	O
FZP	-	720	O
and	-	724	O
pentylenetetrazol	-	728	O
(	-	746	O
PTZ	-	747	O
)	-	750	O
was	-	752	O
shown	-	756	O
by	-	762	O
pretreating	-	765	O
mice	-	777	O
with	-	782	O
FZP	-	787	O
before	-	791	O
PTZ	-	798	O
challenge	-	802	O
.	-	811	O

As	6106951	813	O
a	-	816	O
function	-	818	O
of	-	827	O
dose	-	830	O
,	-	834	O
FZP	-	836	O
first	-	840	O
protected	-	846	O
against	-	856	O
convulsions	-	864	B
and	-	876	O
death	-	880	O
.	-	885	O

At	6106951	887	O
higher	-	890	O
doses	-	897	O
,	-	902	O
however	-	904	O
,	-	911	O
convulsions	-	913	B
again	-	925	O
emerged	-	931	O
.	-	938	O

These	6106951	940	O
doses	-	946	O
of	-	952	O
FZP	-	955	O
were	-	959	O
lower	-	964	O
than	-	970	O
those	-	975	O
that	-	981	O
would	-	986	O
alone	-	992	O
cause	-	998	O
convulsions	-	1004	B
.	-	1015	O

These	6106951	1017	O
results	-	1023	O
may	-	1031	O
be	-	1035	O
relevant	-	1038	O
to	-	1047	O
the	-	1050	O
use	-	1054	O
of	-	1058	O
FZP	-	1061	O
in	-	1065	O
clinical	-	1068	O
situations	-	1077	O
in	-	1088	O
which	-	1091	O
there	-	1097	O
is	-	1103	O
increased	-	1106	O
neural	-	1116	O
excitability	-	1123	O
,	-	1135	O
such	-	1137	O
as	-	1142	O
epilepsy	-	1145	B
or	-	1154	O
sedative	-	1157	O
-	-	1165	O
hypnotic	-	1166	O
drug	-	1175	O
withdrawal	-	1180	O
.	-	1190	O

Evidence	6299641	0	O
for	-	9	O
cardiac	-	13	O
beta	-	21	O
2	-	26	O
-	-	27	O
adrenoceptors	-	28	O
in	-	42	O
man	-	45	O
.	-	48	O

We	6299641	50	O
compared	-	53	O
the	-	62	O
effects	-	66	O
of	-	74	O
single	-	77	O
doses	-	84	O
of	-	90	O
50	-	93	O
mg	-	96	O
atenolol	-	99	O
(	-	108	O
cardioselective	-	109	O
)	-	124	O
,	-	125	O
40	-	127	O
mg	-	130	O
propranolol	-	133	O
(	-	145	O
nonselective	-	146	O
)	-	158	O
,	-	159	O
and	-	161	O
placebo	-	165	O
on	-	173	O
both	-	176	O
exercise	-	181	O
-	-	189	O
and	-	191	O
isoproterenol	-	195	O
-	-	208	O
induced	-	209	O
tachycardia	-	217	B
in	-	229	O
two	-	232	O
experiments	-	236	O
involving	-	248	O
nine	-	258	O
normal	-	263	O
subjects	-	270	O
.	-	278	O

Maximal	6299641	280	O
exercise	-	288	O
heart	-	297	O
rate	-	303	O
was	-	308	O
reduced	-	312	O
from	-	320	O
187	-	325	O
+	-	329	O
/	-	330	O
-	-	331	O

4	6299641	333	O
(	-	334	O
SEM	-	335	O
)	-	338	O
after	-	340	O
placebo	-	346	O
to	-	354	O
146	-	357	O
+	-	361	O
/	-	362	O
-	-	363	O

7	6299641	365	O
bpm	-	367	O
after	-	371	O
atenolol	-	377	O
and	-	386	O
138	-	390	O
+	-	394	O
/	-	395	O
-	-	396	O

6	6299641	398	O
bpm	-	400	O
after	-	404	O
propranolol	-	410	O
,	-	421	O
but	-	423	O
there	-	427	O
were	-	433	O
no	-	438	O
differences	-	441	O
between	-	453	O
the	-	461	O
drugs	-	465	O
.	-	470	O

The	6299641	472	O
effects	-	476	O
on	-	484	O
isoproterenol	-	487	O
tachycardia	-	501	B
were	-	513	O
determined	-	518	O
before	-	529	O
and	-	536	O
after	-	540	O
atropine	-	546	O
(	-	555	O
0	-	556	O
.	-	557	O
04	-	558	O
mg	-	561	O
/	-	563	O
kg	-	564	O
IV	-	567	O
)	-	569	O
.	-	570	O

Isoproterenol	6299641	572	O
sensitivity	-	586	O
was	-	598	O
determined	-	602	O
as	-	613	O
the	-	616	O
intravenous	-	620	O
dose	-	632	O
that	-	637	O
increased	-	642	O
heart	-	652	O
rate	-	658	O
by	-	663	O
25	-	666	O
bpm	-	669	O
(	-	673	O
CD25	-	674	O
)	-	678	O
and	-	680	O
this	-	684	O
was	-	689	O
increased	-	693	O
from	-	703	O
1	-	708	O
.	-	709	O
8	-	710	O
+	-	712	O
/	-	713	O
-	-	714	O

0	6299641	716	O
.	-	717	O
3	-	718	O
micrograms	-	720	O
after	-	731	O
placebo	-	737	O
to	-	745	O
38	-	748	O
.	-	750	O
9	-	751	O
+	-	753	O
/	-	754	O
-	-	755	O

8	6299641	757	O
.	-	758	O
3	-	759	O
micrograms	-	761	O
after	-	772	O
propranolol	-	778	O
and	-	790	O
8	-	794	O
.	-	795	O
3	-	796	O
+	-	798	O
/	-	799	O
-	-	800	O

1	6299641	802	O
.	-	803	O
7	-	804	O
micrograms	-	806	O
after	-	817	O
atenolol	-	823	O
.	-	831	O

The	6299641	833	O
difference	-	837	O
in	-	848	O
the	-	851	O
effects	-	855	O
of	-	863	O
the	-	866	O
two	-	870	O
was	-	874	O
significant	-	878	O
.	-	889	O

After	6299641	891	O
atropine	-	897	O
the	-	906	O
CD25	-	910	O
was	-	915	O
unchanged	-	919	O
after	-	929	O
placebo	-	935	O
(	-	943	O
2	-	944	O
.	-	945	O
3	-	946	O
+	-	948	O
/	-	949	O
-	-	950	O
0	-	952	O
.	-	953	O
3	-	954	O
micrograms	-	956	O
)	-	966	O
and	-	968	O
atenolol	-	972	O
(	-	981	O
7	-	982	O
.	-	983	O
7	-	984	O
+	-	986	O
/	-	987	O
-	-	988	O

1	6299641	990	O
.	-	991	O
3	-	992	O
micrograms	-	994	O
)	-	1004	O
;	-	1005	O
it	-	1007	O
was	-	1010	O
reduced	-	1014	O
after	-	1022	O
propranolol	-	1028	O
(	-	1040	O
24	-	1041	O
.	-	1043	O
8	-	1044	O
+	-	1046	O
/	-	1047	O
-	-	1048	O

5	6299641	1050	O
.	-	1051	O
0	-	1052	O
micrograms	-	1054	O
)	-	1064	O
,	-	1065	O
but	-	1067	O
remained	-	1071	O
different	-	1080	O
from	-	1090	O
atenolol	-	1095	O
.	-	1103	O

This	6299641	1105	O
change	-	1110	O
with	-	1117	O
propranolol	-	1122	O
sensitivity	-	1134	O
was	-	1146	O
calculated	-	1150	O
as	-	1161	O
the	-	1164	O
apparent	-	1168	O
Ka	-	1177	O
,	-	1179	O
this	-	1181	O
was	-	1186	O
unchanged	-	1190	O
by	-	1200	O
atropine	-	1203	O
(	-	1212	O
11	-	1213	O
.	-	1215	O
7	-	1216	O
+	-	1218	O
/	-	1219	O
-	-	1220	O

2	6299641	1222	O
.	-	1223	O
1	-	1224	O
and	-	1226	O
10	-	1230	O
.	-	1232	O
1	-	1233	O
+	-	1235	O
/	-	1236	O
-	-	1237	O

2	6299641	1239	O
.	-	1240	O
5	-	1241	O
ml	-	1243	O
/	-	1245	O
ng	-	1246	O
)	-	1248	O
.	-	1249	O

These	6299641	1251	O
data	-	1257	O
are	-	1262	O
consistent	-	1266	O
with	-	1277	O
the	-	1282	O
hypothesis	-	1286	O
that	-	1297	O
exercise	-	1302	O
-	-	1310	O
induced	-	1311	O
tachycardia	-	1319	B
results	-	1331	O
largely	-	1339	O
from	-	1347	O
beta	-	1352	O
1	-	1357	O
-	-	1358	O
receptor	-	1359	O
activation	-	1368	O
that	-	1379	O
is	-	1384	O
blocked	-	1387	O
by	-	1395	O
both	-	1398	O
cardioselective	-	1403	O
and	-	1419	O
nonselective	-	1423	O
drugs	-	1436	O
,	-	1441	O
whereas	-	1443	O
isoproterenol	-	1451	O
activates	-	1465	O
both	-	1475	O
beta	-	1480	O

1	6299641	1485	O
-	-	1486	O
and	-	1488	O
beta	-	1492	O
2	-	1497	O
-	-	1498	O
receptors	-	1499	O

so	6299641	1509	O
that	-	1512	O
after	-	1517	O
cardioselective	-	1523	O
blockade	-	1539	O
there	-	1548	O
remains	-	1554	O
a	-	1562	O
beta	-	1564	O
2	-	1569	O
-	-	1570	O
component	-	1571	O
that	-	1581	O
can	-	1586	O
be	-	1590	O
blocked	-	1593	O
with	-	1601	O
a	-	1606	O
nonselective	-	1608	O
drug	-	1621	O
.	-	1625	O

While	6299641	1627	O
there	-	1633	O
appear	-	1639	O
to	-	1646	O
be	-	1649	O
beta	-	1652	O
2	-	1657	O
-	-	1658	O
receptors	-	1659	O
in	-	1669	O
the	-	1672	O
human	-	1676	O
heart	-	1682	O
,	-	1687	O
their	-	1689	O
physiologic	-	1695	O
or	-	1707	O
pathologic	-	1710	O
roles	-	1721	O
remain	-	1727	O
to	-	1734	O
be	-	1737	O
defined	-	1740	O
.	-	1747	O

Hormones	6305660	0	O
and	-	9	O
risk	-	13	O
of	-	18	O
breast	-	21	B
cancer	-	28	I
.	-	34	O

This	6305660	36	O
paper	-	41	O
reports	-	47	O
the	-	55	O
results	-	59	O
of	-	67	O
a	-	70	O
study	-	72	O
of	-	78	O
50	-	81	O
menopausal	-	84	O
women	-	95	O
receiving	-	101	O
hormonal	-	111	O
replacement	-	120	O
therapy	-	132	O
.	-	139	O

The	6305660	141	O
majority	-	145	O
(	-	154	O
29	-	155	O
)	-	157	O
had	-	159	O
surgical	-	163	O
menopause	-	172	O
;	-	181	O
their	-	183	O
mean	-	189	O
age	-	194	O
was	-	198	O
45	-	202	O
.	-	204	O
7	-	205	O
years	-	207	O
.	-	212	O

It	6305660	214	O
was	-	217	O
hypothesized	-	221	O
that	-	234	O
progestins	-	239	O
could	-	250	O
equilibrate	-	256	O
the	-	268	O
effects	-	272	O
of	-	280	O
the	-	283	O
estrogenic	-	287	O
stimulation	-	298	O
on	-	310	O
the	-	313	O
mammary	-	317	O
and	-	325	O
endometrial	-	329	O
target	-	341	O
tissues	-	348	O
of	-	356	O
women	-	359	O
on	-	365	O
hormonal	-	368	O
replacement	-	377	O
therapy	-	389	O
.	-	396	O

The	6305660	398	O
treatment	-	402	O
schedule	-	412	O
consisted	-	421	O
of	-	431	O
conjugated	-	434	O
estrogens	-	445	O
(	-	455	O
Premarin	-	456	O
)	-	464	O
1	-	466	O
.	-	467	O
25	-	468	O
mg	-	471	O
/	-	473	O
day	-	474	O
for	-	478	O
21	-	482	O
days	-	485	O
and	-	490	O
Medroxyprogesterone	-	494	O
acetate	-	514	O
10	-	522	O
mg	-	525	O
/	-	527	O
day	-	528	O
for	-	532	O
10	-	536	O
days	-	539	O
in	-	544	O
each	-	547	O
month	-	552	O
.	-	557	O

The	6305660	559	O
mean	-	563	O
treatment	-	568	O
period	-	578	O
was	-	585	O
18	-	589	O
months	-	592	O
.	-	598	O

During	6305660	600	O
the	-	607	O
follow	-	611	O
-	-	617	O
up	-	618	O
period	-	621	O
,	-	627	O
attention	-	629	O
was	-	639	O
paid	-	643	O
to	-	648	O
breast	-	651	O
modifications	-	658	O
as	-	672	O
evidenced	-	675	O
by	-	685	O
symptomatology	-	688	O
,	-	702	O
physical	-	704	O
examination	-	713	O
,	-	724	O
and	-	726	O
plate	-	730	O
thermography	-	736	O
.	-	748	O

Mastodynia	6305660	750	B
was	-	761	O
reported	-	765	O
by	-	774	O
21	-	777	O
patients	-	780	O
,	-	788	O
and	-	790	O
physical	-	794	O
examination	-	803	O
revealed	-	815	O
a	-	824	O
light	-	826	O
increase	-	832	O
in	-	841	O
breast	-	844	O
firmness	-	851	O
in	-	860	O
12	-	863	O
women	-	866	O
and	-	872	O
a	-	876	O
moderate	-	878	O
increase	-	887	O
in	-	896	O
breast	-	899	O
nodularity	-	906	O
in	-	917	O
2	-	920	O
women	-	922	O
.	-	927	O

Themography	6305660	929	O
confirmed	-	941	O
the	-	951	O
existence	-	955	O
of	-	965	O
an	-	968	O
excessive	-	971	O
breast	-	981	O
stimulation	-	988	O
in	-	1000	O
1	-	1003	O
women	-	1005	O
who	-	1011	O
complained	-	1015	O
of	-	1026	O
moderate	-	1029	O
mastodynia	-	1038	B
and	-	1049	O
in	-	1053	O
5	-	1056	O
of	-	1058	O
the	-	1061	O
7	-	1065	O
women	-	1067	O
who	-	1073	O
complained	-	1077	O
of	-	1088	O
severe	-	1091	O
mastodynia	-	1098	B
.	-	1108	O

Normalization	6305660	1110	O
was	-	1124	O
obtained	-	1128	O
by	-	1137	O
halving	-	1140	O
the	-	1148	O
estrogen	-	1152	O
dose	-	1161	O
.	-	1165	O

These	6305660	1167	O
results	-	1173	O
suggest	-	1181	O
that	-	1189	O
hormonal	-	1194	O
replacement	-	1203	O
therapy	-	1215	O
can	-	1223	O
be	-	1227	O
safely	-	1230	O
prescribed	-	1237	O
if	-	1248	O
the	-	1251	O
following	-	1255	O
criteria	-	1265	O
are	-	1274	O
satisfied	-	1278	O
:	-	1287	O
1	-	1289	O
)	-	1290	O
preliminary	-	1292	O
evaluation	-	1304	O
of	-	1315	O
patients	-	1318	O
from	-	1327	O
a	-	1332	O
clinical	-	1334	O
,	-	1342	O
metabolic	-	1344	O
,	-	1353	O
cytologic	-	1355	O
,	-	1364	O
and	-	1366	O
mammographic	-	1370	O
perspective	-	1383	O
;	-	1394	O
2	-	1396	O
)	-	1397	O
cyclic	-	1399	O
treatment	-	1406	O
schedule	-	1416	O
,	-	1424	O
with	-	1426	O
a	-	1431	O
progestative	-	1433	O
phase	-	1446	O
of	-	1452	O
10	-	1455	O
days	-	1458	O
;	-	1462	O
and	-	1464	O
3	-	1468	O
)	-	1469	O
periodic	-	1471	O
complete	-	1480	O
follow	-	1489	O
-	-	1495	O
up	-	1496	O
,	-	1498	O
with	-	1500	O
accurate	-	1505	O
thermographic	-	1514	O
evaluation	-	1528	O
of	-	1539	O
the	-	1542	O
breast	-	1546	O
target	-	1553	O
tissues	-	1560	O
.	-	1567	O

Early	6310832	0	O
infections	-	6	B
in	-	17	O
kidney	-	20	O
,	-	26	O
heart	-	28	O
,	-	33	O
and	-	35	O
liver	-	39	O
transplant	-	45	O
recipients	-	56	O
on	-	67	O
cyclosporine	-	70	O
.	-	82	O

Eighty	6310832	84	O
-	-	90	O
one	-	91	O
renal	-	95	O
,	-	100	O
seventeen	-	102	O
heart	-	112	O
,	-	117	O
and	-	119	O
twenty	-	123	O
-	-	129	O
four	-	130	O
liver	-	135	O
transplant	-	141	O
patients	-	152	O
were	-	161	O
followed	-	166	O
for	-	175	O
infection	-	179	B
.	-	188	O

Seventeen	6310832	190	O
renal	-	200	O
patients	-	206	O
received	-	215	O
azathioprine	-	224	O
(	-	237	O
Aza	-	238	O
)	-	241	O
and	-	243	O
prednisone	-	247	O
as	-	258	O
part	-	261	O
of	-	266	O
a	-	269	O
randomized	-	271	O
trial	-	282	O
of	-	288	O
immunosuppression	-	291	O
with	-	309	O
21	-	314	O
cyclosporine	-	317	O
-	-	329	O
and	-	330	O
-	-	333	O
prednisone	-	334	O
-	-	344	O
treated	-	345	O
renal	-	353	O
transplant	-	359	O
patients	-	370	O
.	-	378	O

All	6310832	380	O
others	-	384	O
received	-	391	O
cyclosporine	-	400	O
and	-	413	O
prednisone	-	417	O
.	-	427	O

The	6310832	429	O
randomized	-	433	O
Aza	-	444	O
patients	-	448	O
had	-	457	O
more	-	461	O
overall	-	466	O
infections	-	474	B
(	-	485	O
P	-	486	O
less	-	488	O
than	-	493	O
0	-	498	O
.	-	499	O
05	-	500	O
)	-	502	O
and	-	504	O
more	-	508	O
nonviral	-	513	O
infections	-	522	B
(	-	533	O
P	-	534	O
less	-	536	O
than	-	541	O
0	-	546	O
.	-	547	O
02	-	548	O
)	-	550	O
than	-	552	O
the	-	557	O
randomized	-	561	O
cyclosporine	-	572	O
patients	-	585	O
.	-	593	O

Heart	6310832	595	O
and	-	601	O
liver	-	605	O
patients	-	611	O
had	-	620	O
more	-	624	O
infections	-	629	B
than	-	640	O
cyclosporine	-	645	O
renal	-	658	O
patients	-	664	O
but	-	673	O
fewer	-	677	O
infections	-	683	B
than	-	694	O
the	-	699	O
Aza	-	703	O
renal	-	707	O
patients	-	713	O
.	-	721	O

There	6310832	723	O
were	-	729	O
no	-	734	O
infectious	-	737	O
deaths	-	748	O
in	-	755	O
renal	-	758	O
transplant	-	764	O
patients	-	775	O
on	-	784	O
cyclosporine	-	787	O
or	-	800	O
Aza	-	803	O
,	-	806	O
but	-	808	O
infection	-	812	B
played	-	822	O
a	-	829	O
major	-	831	O
role	-	837	O
in	-	842	O
3	-	845	O
out	-	847	O
of	-	851	O
6	-	854	O
cardiac	-	856	O
transplant	-	864	O
deaths	-	875	O
and	-	882	O
in	-	886	O
8	-	889	O
out	-	891	O
of	-	895	O
9	-	898	O
liver	-	900	O
transplant	-	906	O
deaths	-	917	O
.	-	923	O

Renal	6310832	925	O
patients	-	931	O
on	-	940	O
cyclosporine	-	943	O
had	-	956	O
the	-	960	O
fewest	-	964	O
bacteremias	-	971	B
.	-	982	O

Analysis	6310832	984	O
of	-	993	O
site	-	996	O
of	-	1001	O
infection	-	1004	B
showed	-	1014	O
a	-	1021	O
preponderance	-	1023	O
of	-	1037	O
abdominal	-	1040	B
infections	-	1050	I
in	-	1061	O
liver	-	1064	O
patients	-	1070	O
,	-	1078	O
intrathoracic	-	1080	O
infections	-	1094	B
in	-	1105	O
heart	-	1108	O
patients	-	1114	O
,	-	1122	O
and	-	1124	O
urinary	-	1128	B
tract	-	1136	I
infections	-	1142	I
in	-	1153	O
renal	-	1156	O
patients	-	1162	O
.	-	1170	O

Pulmonary	6310832	1172	O
infections	-	1182	B
were	-	1193	O
less	-	1198	O
common	-	1203	O
in	-	1210	O
cyclosporine	-	1213	O
-	-	1225	O
treated	-	1226	O
renal	-	1234	O
patients	-	1240	O
than	-	1249	O
in	-	1254	O
Aza	-	1257	O
-	-	1260	O
treated	-	1261	O
patients	-	1269	O
(	-	1278	O
P	-	1279	O
less	-	1281	O
than	-	1286	O
0	-	1291	O
.	-	1292	O
05	-	1293	O
)	-	1295	O
.	-	1296	O

Aza	6310832	1298	O
patients	-	1302	O
had	-	1311	O
significantly	-	1315	O
more	-	1329	O
staphylococcal	-	1334	B
infections	-	1349	I
than	-	1360	O
all	-	1365	O
other	-	1369	O
transplant	-	1375	O
groups	-	1386	O
(	-	1393	O
P	-	1394	O
less	-	1396	O
than	-	1401	O
0	-	1406	O
.	-	1407	O
005	-	1408	O
)	-	1411	O
,	-	1412	O
and	-	1414	O
systemic	-	1418	O
fungal	-	1427	B
infections	-	1434	I
occurred	-	1445	O
only	-	1454	O
in	-	1459	O
the	-	1462	O
liver	-	1466	O
transplant	-	1472	O
group	-	1483	O
.	-	1488	O

Cytomegalovirus	6310832	1490	O
(	-	1506	O
CMV	-	1507	O
)	-	1510	O
shedding	-	1512	O
or	-	1521	O
serological	-	1524	O
rises	-	1536	O
in	-	1542	O
antibody	-	1545	O
titer	-	1554	O
,	-	1559	O
or	-	1561	O
both	-	1564	O
occurred	-	1569	O
in	-	1578	O
78	-	1581	O
%	-	1583	O
of	-	1585	O
cyclosporine	-	1588	O
patients	-	1601	O
and	-	1610	O
76	-	1614	O
%	-	1616	O
of	-	1618	O
Aza	-	1621	O
patients	-	1625	O
.	-	1633	O

Of	6310832	1635	O
the	-	1638	O
cyclosporine	-	1642	O
patients	-	1655	O
,	-	1663	O
15	-	1665	O
%	-	1667	O
had	-	1669	O
symptoms	-	1673	O
related	-	1682	O
to	-	1690	O
CMV	-	1693	B
infection	-	1697	I
.	-	1706	O

Serological	6310832	1708	O
evidence	-	1720	O
for	-	1729	O
Epstein	-	1733	B
Barr	-	1741	I
Virus	-	1746	I
infection	-	1752	I
was	-	1762	O
found	-	1766	O
in	-	1772	O
20	-	1775	O
%	-	1777	O
of	-	1779	O
65	-	1782	O
cyclosporine	-	1785	O
patients	-	1798	O
studied	-	1807	O
.	-	1814	O

Three	6310832	1816	O
had	-	1822	O
associated	-	1826	O
symptoms	-	1837	O
,	-	1845	O
and	-	1847	O
one	-	1851	O
developed	-	1855	O
a	-	1865	O
lymphoma	-	1867	B
.	-	1875	O

Structure	6316193	0	O
-	-	9	O
activity	-	10	O
and	-	19	O
dose	-	23	O
-	-	27	O
effect	-	28	O
relationships	-	35	O
of	-	49	O
the	-	52	O
antagonism	-	56	O
of	-	67	O
picrotoxin	-	70	O
-	-	80	O
induced	-	81	O
seizures	-	89	B
by	-	98	O
cholecystokinin	-	101	O
,	-	116	O
fragments	-	118	O
and	-	128	O
analogues	-	132	O
of	-	142	O
cholecystokinin	-	145	O
in	-	161	O
mice	-	164	O
.	-	168	O

Intraperitoneal	6316193	170	O
administration	-	186	O
of	-	201	O
cholecystokinin	-	204	O
octapeptide	-	220	O
sulphate	-	232	O
ester	-	241	O
(	-	247	O
CCK	-	248	O
-	-	251	O
8	-	252	O
-	-	253	O
SE	-	254	O
)	-	256	O
and	-	258	O
nonsulphated	-	262	O
cholecystokinin	-	275	O
octapeptide	-	291	O
(	-	303	O
CCK	-	304	O
-	-	307	O
8	-	308	O
-	-	309	O
NS	-	310	O
)	-	312	O
enhanced	-	314	O
the	-	323	O
latency	-	327	O
of	-	335	O
seizures	-	338	B
induced	-	347	O
by	-	355	O
picrotoxin	-	358	O
in	-	369	O
mice	-	372	O
.	-	376	O

Experiments	6316193	378	O
with	-	390	O
N	-	395	O
-	-	396	O
and	-	398	O
C	-	402	O
-	-	403	O
terminal	-	404	O
fragments	-	413	O
revealed	-	423	O
that	-	432	O
the	-	437	O
C	-	441	O
-	-	442	O
terminal	-	443	O
tetrapeptide	-	452	O
(	-	465	O
CCK	-	466	O
-	-	469	O
5	-	470	O
-	-	471	O
8	-	472	O
)	-	473	O
was	-	475	O
the	-	479	O
active	-	483	O
centre	-	490	O
of	-	497	O
the	-	500	O
CCK	-	504	O
octapeptide	-	508	O
molecule	-	520	O
.	-	528	O

The	6316193	530	O
analogues	-	534	O
CCK	-	544	O
-	-	547	O
8	-	548	O
-	-	549	O
SE	-	550	O
and	-	553	O
CCK	-	557	O
-	-	560	O
8	-	561	O
-	-	562	O
NS	-	563	O
(	-	566	O
dose	-	567	O
range	-	572	O
0	-	578	O
.	-	579	O
2	-	580	O
-	-	581	O
6	-	582	O
.	-	583	O
4	-	584	O
mumol	-	586	O
/	-	591	O
kg	-	592	O
)	-	594	O
and	-	596	O
caerulein	-	600	O
dose	-	610	O
range	-	615	O
0	-	621	O
.	-	622	O
1	-	623	O
-	-	624	O
0	-	625	O
.	-	626	O
8	-	627	O
mumol	-	629	O
/	-	634	O
kg	-	635	O
)	-	637	O
showed	-	639	O
bell	-	646	O
-	-	650	O
shaped	-	651	O
dose	-	658	O
-	-	662	O
effect	-	663	O
curves	-	670	O
,	-	676	O
with	-	678	O
the	-	683	O
greatest	-	687	O
maximum	-	696	O
inhibition	-	704	O
for	-	715	O
CCK	-	719	O
-	-	722	O
8	-	723	O
-	-	724	O
NS	-	725	O
.	-	727	O

The	6316193	729	O
peptide	-	733	O
CCK	-	741	O
-	-	744	O
5	-	745	O
-	-	746	O
8	-	747	O
had	-	749	O
weak	-	753	O
anticonvulsant	-	758	O
activity	-	773	O
in	-	782	O
comparison	-	785	O
to	-	796	O
the	-	799	O
octapeptides	-	803	O
,	-	815	O
3	-	817	O
.	-	818	O
2	-	819	O
mumol	-	821	O
/	-	826	O
kg	-	827	O
and	-	830	O
larger	-	834	O
doses	-	841	O
of	-	847	O
the	-	850	O
reference	-	854	O
drug	-	864	O
,	-	868	O
diazepam	-	870	O
,	-	878	O
totally	-	880	O
prevented	-	888	O
picrotoxin	-	898	O
-	-	908	O
induced	-	909	O
seizures	-	917	B
and	-	926	O
mortality	-	930	O
.	-	939	O

The	6316193	941	O
maximum	-	945	O
effect	-	953	O
of	-	960	O
the	-	963	O
peptides	-	967	O
tested	-	976	O
was	-	983	O
less	-	987	O
than	-	992	O
that	-	997	O
of	-	1002	O
diazepam	-	1005	O
.	-	1013	O

Experiments	6316193	1015	O
with	-	1027	O
analogues	-	1032	O
and	-	1042	O
derivatives	-	1046	O
of	-	1058	O
CCK	-	1061	O
-	-	1064	O
5	-	1065	O
-	-	1066	O
8	-	1067	O
demonstrated	-	1069	O
that	-	1082	O
the	-	1087	O
effectiveness	-	1091	O
of	-	1105	O
the	-	1108	O
beta	-	1112	O
-	-	1116	O
alanyl	-	1117	O
derivatives	-	1124	O
of	-	1136	O
CCK	-	1139	O
-	-	1142	O
5	-	1143	O
-	-	1144	O
8	-	1145	O
were	-	1147	O
enhanced	-	1152	O
and	-	1161	O
that	-	1165	O
they	-	1170	O
were	-	1175	O
equipotent	-	1180	O
with	-	1191	O
CCK	-	1196	O
-	-	1199	O
8	-	1200	O
-	-	1201	O
SE	-	1202	O
.	-	1204	O

Of	6316193	1206	O
the	-	1209	O
CCK	-	1213	O
-	-	1216	O
2	-	1217	O
-	-	1218	O
8	-	1219	O
analogues	-	1221	O
,	-	1230	O
Ser	-	1232	O
(	-	1235	O
SO3H	-	1236	O
)	-	1240	O
7	-	1241	O
-	-	1242	O
Ac	-	1243	O
-	-	1245	O
CCK	-	1246	O
-	-	1249	O
2	-	1250	O
-	-	1251	O
8	-	1252	O
-	-	1253	O
SE	-	1254	O
and	-	1257	O
Thr	-	1261	O
(	-	1264	O
SO3H	-	1265	O
)	-	1269	O
7	-	1270	O
-	-	1271	O
Ac	-	1272	O
-	-	1274	O
CCK	-	1275	O
-	-	1278	O
2	-	1279	O
-	-	1280	O
8	-	1281	O
-	-	1282	O
SE	-	1283	O
and	-	1286	O
Hyp	-	1290	O
(	-	1293	O
SO3H	-	1294	O
)	-	1298	O
-	-	1299	O
Ac	-	1300	O
-	-	1302	O
CCK	-	1303	O
-	-	1306	O
2	-	1307	O
-	-	1308	O
8	-	1309	O
-	-	1310	O
SE	-	1311	O
were	-	1314	O
slightly	-	1319	O
more	-	1328	O
active	-	1333	O
than	-	1340	O
CCK	-	1345	O
-	-	1348	O
8	-	1349	O
-	-	1350	O
SE	-	1351	O
.	-	1353	O

Vasopressin	6321816	0	O
as	-	12	O
a	-	15	O
possible	-	17	O
contributor	-	26	O
to	-	38	O
hypertension	-	41	B
.	-	53	O

The	6321816	55	O
role	-	59	O
of	-	64	O
vasopressin	-	67	O
as	-	79	O
a	-	82	O
pressor	-	84	O
agent	-	92	O
to	-	98	O
the	-	101	O
hypertensive	-	105	B
process	-	118	O
was	-	126	O
examined	-	130	O
.	-	138	O

Vasopressin	6321816	140	O
plays	-	152	O
a	-	158	O
major	-	160	O
role	-	166	O
in	-	171	O
the	-	174	O
pathogenesis	-	178	O
of	-	191	O
DOCA	-	194	O
-	-	198	O
salt	-	199	O
hypertension	-	204	B
,	-	216	O
since	-	218	O
the	-	224	O
elevation	-	228	O
of	-	238	O
blood	-	241	O
pressure	-	247	O
was	-	256	O
not	-	260	O
substantial	-	264	O
in	-	276	O
the	-	279	O
rats	-	283	O
with	-	288	O
lithium	-	293	O
-	-	300	O
treated	-	301	O
diabetes	-	309	B
insipidus	-	318	I
after	-	328	O
DOCA	-	334	O
-	-	338	O
salt	-	339	O
treatment	-	344	O
.	-	353	O

Administration	6321816	355	O
of	-	370	O
DDAVP	-	373	O
which	-	379	O
has	-	385	O
antidiuretic	-	389	O
action	-	402	O
but	-	409	O
minimal	-	413	O
vasopressor	-	421	O
effect	-	433	O
failed	-	440	O
to	-	447	O
increase	-	450	O
blood	-	459	O
pressure	-	465	O
to	-	474	O
the	-	477	O
levels	-	481	O
observed	-	488	O
after	-	497	O
administration	-	503	O
of	-	518	O
AVP	-	521	O
.	-	524	O

Furthermore	6321816	526	O
,	-	537	O
the	-	539	O
pressor	-	543	O
action	-	551	O
of	-	558	O
vasopressin	-	561	O
appears	-	573	O
to	-	581	O
be	-	584	O
important	-	587	O
in	-	597	O
the	-	600	O
development	-	604	O
of	-	616	O
this	-	619	O
model	-	624	O
of	-	630	O
hypertension	-	633	B
,	-	645	O
since	-	647	O
the	-	653	O
enhanced	-	657	O
pressor	-	666	O
responsiveness	-	674	O
to	-	689	O
the	-	692	O
hormone	-	696	O
was	-	704	O
observed	-	708	O
in	-	717	O
the	-	720	O
initial	-	724	O
stage	-	732	O
of	-	738	O
hypertension	-	741	B
.	-	753	O

Increased	6321816	755	O
secretion	-	765	O
of	-	775	O
vasopressin	-	778	O
from	-	790	O
neurohypophysis	-	795	O
also	-	811	O
promotes	-	816	O
the	-	825	O
function	-	829	O
of	-	838	O
the	-	841	O
hormone	-	845	O
as	-	853	O
a	-	856	O
pathogenetic	-	858	O
factor	-	871	O
in	-	878	O
hypertension	-	881	B
.	-	893	O

An	6321816	895	O
unproportional	-	898	O
release	-	913	O
of	-	921	O
vasopressin	-	924	O
compared	-	936	O
to	-	945	O
plasma	-	948	O
osmolality	-	955	O
may	-	966	O
be	-	970	O
induced	-	973	O
by	-	981	O
the	-	984	O
absence	-	988	O
of	-	996	O
an	-	999	O
adjusting	-	1002	O
control	-	1012	O
of	-	1020	O
angiotensin	-	1023	O
II	-	1035	O
forming	-	1038	O
and	-	1046	O
receptor	-	1050	O
binding	-	1059	O
capacity	-	1067	O
for	-	1076	O
sodium	-	1080	O
balance	-	1087	O
in	-	1095	O
the	-	1098	O
brain	-	1102	O
.	-	1107	O

However	6321816	1109	O
,	-	1116	O
the	-	1118	O
role	-	1122	O
of	-	1127	O
vasopressin	-	1130	O
remains	-	1142	O
to	-	1150	O
be	-	1153	O
determined	-	1156	O
in	-	1167	O
human	-	1170	O
essential	-	1176	O
hypertension	-	1186	B
.	-	1198	O

Toxic	6453500	0	B
hepatitis	-	6	I
induced	-	16	O
by	-	24	O
disulfiram	-	27	O
in	-	38	O
a	-	41	O
non	-	43	O
-	-	46	O
alcoholic	-	47	O
.	-	56	O

A	6453500	58	O
reversible	-	60	O
toxic	-	71	B
liver	-	77	I
damage	-	83	I
was	-	90	O
observed	-	94	O
in	-	103	O
a	-	106	O
non	-	108	O
-	-	111	O
alcoholic	-	112	O
woman	-	122	O
treated	-	128	O
with	-	136	O
disulfiram	-	141	O
.	-	151	O

The	6453500	153	O
causative	-	157	O
relationship	-	167	O
was	-	180	O
proven	-	184	O
by	-	191	O
challenge	-	194	O
.	-	203	O

Atrial	6517710	0	B
thrombosis	-	7	I
involving	-	18	O
the	-	28	O
heart	-	32	O
of	-	38	O
F	-	41	O
-	-	42	O
344	-	43	O
rats	-	47	O
ingesting	-	52	O
quinacrine	-	62	O
hydrochloride	-	73	O
.	-	86	O

Quinacrine	6517710	88	O
hydrochloride	-	99	O
is	-	113	O
toxic	-	116	O
for	-	122	O
the	-	126	O
heart	-	130	O
of	-	136	O
F	-	139	O
-	-	140	O
344	-	141	O
rats	-	145	O
.	-	149	O

Rats	6517710	151	O
treated	-	156	O
with	-	164	O
500	-	169	O
ppm	-	173	O
quinacrine	-	177	O
hydrochloride	-	188	O
in	-	202	O
the	-	205	O
diet	-	209	O
all	-	214	O
developed	-	218	O
a	-	228	O
high	-	230	O
incidence	-	235	O
of	-	245	O
left	-	248	O
atrial	-	253	B
thrombosis	-	260	I
.	-	270	O

The	6517710	272	O
lesion	-	276	O
was	-	283	O
associated	-	287	O
with	-	298	O
cardiac	-	303	B
hypertrophy	-	311	I
and	-	323	O
dilatation	-	327	O
and	-	338	O
focal	-	342	O
myocardial	-	348	B
degeneration	-	359	I
.	-	371	O

Rats	6517710	373	O
died	-	378	O
from	-	383	O
cardiac	-	388	B
hypertrophy	-	396	I
with	-	408	O
severe	-	413	O
acute	-	420	O
and	-	426	O
chronic	-	430	O
congestion	-	438	O
of	-	449	O
the	-	452	O
lungs	-	456	O
,	-	461	O
liver	-	463	O
,	-	468	O
and	-	470	O
other	-	474	O
organs	-	480	O
.	-	486	O

Seventy	6517710	488	O
percent	-	496	O
of	-	504	O
rats	-	507	O
given	-	512	O
250	-	518	O
ppm	-	522	O
quinacrine	-	526	O
hydrochloride	-	537	O
and	-	551	O
1	-	555	O
,	-	556	O
000	-	557	O
ppm	-	561	O
sodium	-	565	O
nitrite	-	572	O
simultaneously	-	580	O
in	-	595	O
the	-	598	O
diet	-	602	O
had	-	607	O
thrombosis	-	611	B
of	-	622	O
the	-	625	O
atria	-	629	O
of	-	635	O
the	-	638	O
heart	-	642	O
,	-	647	O
while	-	649	O
untreated	-	655	O
control	-	665	O
rats	-	673	O
in	-	678	O
this	-	681	O
laboratory	-	686	O
did	-	697	O
not	-	701	O
have	-	705	O
atrial	-	710	B
thrombosis	-	717	I
.	-	727	O

Sodium	6517710	729	O
nitrite	-	736	O
in	-	744	O
combination	-	747	O
with	-	759	O
quinacrine	-	764	O
hydrochloride	-	775	O
appeared	-	789	O
to	-	798	O
have	-	801	O
no	-	806	O
additional	-	809	O
effect	-	820	O
.	-	826	O

Alternating	6529939	0	B
sinus	-	12	I
rhythm	-	18	I
and	-	25	O
intermittent	-	29	O
sinoatrial	-	42	B
block	-	53	I
induced	-	59	O
by	-	67	O
propranolol	-	70	O
.	-	81	O

Alternating	6529939	83	B
sinus	-	95	I
rhythm	-	101	I
and	-	108	O
intermittent	-	112	O
sinoatrial	-	125	B
(	-	136	I
S	-	137	I
-	-	138	I
A	-	139	I
)	-	140	I
block	-	142	I
was	-	148	O
observed	-	152	O
in	-	161	O
a	-	164	O
57	-	166	O
-	-	168	O
year	-	169	O
-	-	173	O
old	-	174	O
woman	-	178	O
,	-	183	O
under	-	185	O
treatment	-	191	O
for	-	201	O
angina	-	205	B
with	-	212	O
80	-	217	O
mg	-	220	O
propranolol	-	223	O
daily	-	235	O
.	-	240	O

The	6529939	242	O
electrocardiogram	-	246	O
showed	-	264	O
alternation	-	271	O
of	-	283	O
long	-	286	O
and	-	291	O
short	-	295	O
P	-	301	O
-	-	302	O
P	-	303	O
intervals	-	305	O
and	-	315	O
occasional	-	319	O
pauses	-	330	O
.	-	336	O

These	6529939	338	O
pauses	-	344	O
were	-	351	O
always	-	356	O
preceded	-	363	O
by	-	372	O
the	-	375	O
short	-	379	O
P	-	385	O
-	-	386	O
P	-	387	O
intervals	-	389	O
and	-	399	O
were	-	403	O
usually	-	408	O
followed	-	416	O
by	-	425	O
one	-	428	O
or	-	432	O
two	-	435	O
P	-	439	O
-	-	440	O
P	-	441	O
intervals	-	443	O
of	-	453	O
0	-	456	O
.	-	457	O
92	-	458	O
-	-	460	O
0	-	461	O
.	-	462	O
95	-	463	O
s	-	466	O
representing	-	468	O
the	-	481	O
basic	-	485	O
sinus	-	491	O
cycle	-	497	O
.	-	502	O

Following	6529939	504	O
these	-	514	O
basic	-	520	O
sinus	-	526	O
cycles	-	532	O
,	-	538	O
alternating	-	540	B
rhythm	-	552	I
started	-	559	O
with	-	567	O
the	-	572	O
longer	-	576	O
P	-	583	O
-	-	584	O
P	-	585	O
interval	-	587	O
.	-	595	O

The	6529939	597	O
long	-	601	O
P	-	606	O
-	-	607	O
P	-	608	O
intervals	-	610	O
ranged	-	620	O
between	-	627	O
1	-	635	O
.	-	636	O
04	-	637	O
-	-	639	O
1	-	640	O
.	-	641	O
12	-	642	O
s	-	645	O
and	-	647	O
the	-	651	O
short	-	655	O
P	-	661	O
-	-	662	O
P	-	663	O
intervals	-	665	O
between	-	675	O
0	-	683	O
.	-	684	O
80	-	685	O
-	-	687	O
0	-	688	O
.	-	689	O
84	-	690	O
s	-	693	O
,	-	694	O
respectively	-	696	O
.	-	708	O

The	6529939	710	O
duration	-	714	O
of	-	723	O
the	-	726	O
pauses	-	730	O
were	-	737	O
equal	-	742	O
or	-	748	O
almost	-	751	O
equal	-	758	O
to	-	764	O
one	-	767	O
short	-	771	O
plus	-	777	O
one	-	782	O
long	-	786	O
P	-	791	O
-	-	792	O
P	-	793	O
interval	-	795	O
or	-	804	O
to	-	807	O
twice	-	810	O
the	-	816	O
basic	-	820	O
sinus	-	826	O
cycle	-	832	O
.	-	837	O

In	6529939	839	O
one	-	842	O
recording	-	846	O
a	-	856	O
short	-	858	O
period	-	864	O
of	-	871	O
regular	-	874	O
sinus	-	882	O
rhythm	-	888	O
with	-	895	O
intermittent	-	900	O
2	-	913	O
/	-	914	O
1	-	915	O
S	-	917	B
-	-	918	I
A	-	919	I
block	-	921	I
was	-	927	O
observed	-	931	O
.	-	939	O

This	6529939	941	O
short	-	946	O
period	-	952	O
of	-	959	O
sinus	-	962	O
rhythm	-	968	O
was	-	975	O
interrupted	-	979	O
by	-	991	O
sudden	-	994	O
prolongation	-	1001	O
of	-	1014	O
the	-	1017	O
P	-	1021	O
-	-	1022	O
P	-	1023	O
interval	-	1025	O
starting	-	1034	O
the	-	1043	O
alternative	-	1047	O
rhythm	-	1059	O
.	-	1065	O

There	6529939	1067	O
were	-	1073	O
small	-	1078	O
changes	-	1084	O
in	-	1092	O
the	-	1095	O
shape	-	1099	O
of	-	1105	O
the	-	1108	O
P	-	1112	O
waves	-	1114	O
and	-	1120	O
P	-	1124	O
-	-	1125	O
R	-	1126	O
intervals	-	1128	O
.	-	1137	O

S	6529939	1139	O
-	-	1140	O

A	6529939	1141	O
conduction	-	1143	O
through	-	1154	O
two	-	1162	O
pathways	-	1166	O
,	-	1174	O
the	-	1176	O
first	-	1180	O
with	-	1186	O
2	-	1191	O
/	-	1192	O
1	-	1193	O
block	-	1195	O
the	-	1201	O
second	-	1205	O
having	-	1212	O
0	-	1219	O
.	-	1220	O
12	-	1221	O
-	-	1223	O
0	-	1224	O
.	-	1225	O
14	-	1226	O
s	-	1229	O
longer	-	1231	O
conduction	-	1238	O
time	-	1249	O
and	-	1254	O
with	-	1258	O
occasional	-	1263	O
2	-	1274	O
/	-	1275	O
1	-	1276	O
block	-	1278	O
was	-	1284	O
proposed	-	1288	O
for	-	1297	O
the	-	1301	O
explanation	-	1305	O
of	-	1317	O
the	-	1320	O
alternating	-	1324	O
P	-	1336	O
-	-	1337	O
P	-	1338	O
interval	-	1340	O
and	-	1349	O
other	-	1353	O
electrocardiographic	-	1359	O
features	-	1380	O
seen	-	1389	O
.	-	1393	O

Atropine	6529939	1395	O
1	-	1404	O
mg	-	1406	O
given	-	1409	O
intravenously	-	1415	O
resulted	-	1429	O
in	-	1438	O
shortening	-	1441	O
of	-	1452	O
all	-	1455	O
P	-	1459	O
-	-	1460	O
P	-	1461	O
intervals	-	1463	O
without	-	1473	O
changing	-	1481	O
the	-	1490	O
rhythm	-	1494	O
.	-	1500	O

The	6529939	1502	O
abnormal	-	1506	O
rhythm	-	1515	O
disappeared	-	1522	O
with	-	1534	O
the	-	1539	O
withdrawal	-	1543	O
of	-	1554	O
propranolol	-	1557	O
and	-	1569	O
when	-	1573	O
the	-	1578	O
drug	-	1582	O
was	-	1587	O
restarted	-	1591	O
a	-	1601	O
2	-	1603	O
/	-	1604	O
1	-	1605	O
S	-	1607	B
-	-	1608	I
A	-	1609	I
block	-	1611	I
was	-	1617	O
seen	-	1621	O
.	-	1625	O

This	6529939	1627	O
was	-	1632	O
accepted	-	1636	O
as	-	1645	O
evidence	-	1648	O
for	-	1657	O
propranolol	-	1661	O
being	-	1673	O
the	-	1679	O
cause	-	1683	O
of	-	1689	O
this	-	1692	O
conduction	-	1697	B
disorder	-	1708	I
.	-	1716	O

Antitumor	6585590	0	O
effect	-	10	O
,	-	16	O
cardiotoxicity	-	18	B
,	-	32	O
and	-	34	O
nephrotoxicity	-	38	B
of	-	53	O
doxorubicin	-	56	O
in	-	68	O
the	-	71	O
IgM	-	75	O
solid	-	79	O
immunocytoma	-	85	B
-	-	97	O
bearing	-	98	O
LOU	-	106	O
/	-	109	O
M	-	110	O
/	-	111	O
WSL	-	112	O
rat	-	116	O
.	-	119	O

Antitumor	6585590	121	O
activity	-	131	O
,	-	139	O
cardiotoxicity	-	141	B
,	-	155	O
and	-	157	O
nephrotoxicity	-	161	B
induced	-	176	O
by	-	184	O
doxorubicin	-	187	O
were	-	199	O
studied	-	204	O
in	-	212	O
LOU	-	215	O
/	-	218	O
M	-	219	O
/	-	220	O
WSL	-	221	O
inbred	-	225	O
rats	-	232	O
each	-	237	O
bearing	-	242	O
a	-	250	O
transplantable	-	252	O
solid	-	267	O
IgM	-	273	O
immunocytoma	-	277	B
.	-	289	O

Animals	6585590	291	O
with	-	299	O
a	-	304	O
tumor	-	306	B
(	-	312	O
diameter	-	313	O
,	-	321	O
15	-	323	O
.	-	325	O
8	-	326	O
+	-	328	O
/	-	329	O
-	-	330	O

3	6585590	332	O
.	-	333	O
3	-	334	O
mm	-	336	O
)	-	338	O
were	-	340	O
treated	-	345	O
with	-	353	O
iv	-	358	O
injections	-	361	O
of	-	372	O
doxorubicin	-	375	O
on	-	387	O
5	-	390	O
consecutive	-	392	O
days	-	404	O
,	-	408	O
followed	-	410	O
by	-	419	O
1	-	422	O
weekly	-	424	O
injection	-	431	O
for	-	441	O
7	-	445	O
weeks	-	447	O
(	-	453	O
dose	-	454	O
range	-	459	O
,	-	464	O
0	-	466	O
.	-	467	O
015	-	468	O
-	-	471	O
4	-	472	O
.	-	473	O
0	-	474	O
mg	-	476	O
/	-	478	O
kg	-	479	O
body	-	482	O
wt	-	487	O
)	-	489	O
.	-	490	O

Tumor	6585590	492	B
regression	-	498	O
was	-	509	O
observed	-	513	O
with	-	522	O
0	-	527	O
.	-	528	O
5	-	529	O
mg	-	531	O
doxorubicin	-	534	O
/	-	545	O
kg	-	546	O
.	-	548	O

Complete	6585590	550	O
disappearance	-	559	O
of	-	573	O
the	-	576	O
tumor	-	580	B
was	-	586	O
induced	-	590	O
with	-	598	O
1	-	603	O
.	-	604	O
0	-	605	O
mg	-	607	O
doxorubicin	-	610	O
/	-	621	O
kg	-	622	O
.	-	624	O

Histologic	6585590	626	O
evidence	-	637	O
of	-	646	O
cardiotoxicity	-	649	B
scored	-	664	O
as	-	671	O
grade	-	674	O
III	-	680	O
was	-	684	O
only	-	688	O
observed	-	693	O
at	-	702	O
a	-	705	O
dose	-	707	O
of	-	712	O
1	-	715	O
.	-	716	O
0	-	717	O
mg	-	719	O
doxorubicin	-	722	O
/	-	733	O
kg	-	734	O
.	-	736	O

Light	6585590	738	O
microscopic	-	744	O
evidence	-	756	O
of	-	765	O
renal	-	768	B
damage	-	774	I
was	-	781	O
seen	-	785	O
above	-	790	O
a	-	796	O
dose	-	798	O
of	-	803	O
0	-	806	O
.	-	807	O
5	-	808	O
mg	-	810	O
doxorubicin	-	813	O
/	-	824	O
kg	-	825	O
,	-	827	O
which	-	829	O
resulted	-	835	O
in	-	844	O
albuminuria	-	847	B
and	-	859	O
very	-	863	O
low	-	868	O
serum	-	872	O
albumin	-	878	O
levels	-	886	O
.	-	892	O

In	6585590	894	O
the	-	897	O
group	-	901	O
that	-	907	O
received	-	912	O
1	-	921	O
.	-	922	O
0	-	923	O
mg	-	925	O
doxorubicin	-	928	O
/	-	939	O
kg	-	940	O
,	-	942	O
the	-	944	O
serum	-	948	O
albumin	-	954	O
level	-	962	O
decreased	-	968	O
from	-	978	O
33	-	983	O
.	-	985	O
6	-	986	O
+	-	988	O
/	-	989	O
-	-	990	O

4	6585590	992	O
.	-	993	O
1	-	994	O
to	-	996	O
1	-	999	O
.	-	1000	O
5	-	1001	O
+	-	1003	O
/	-	1004	O
-	-	1005	O
0	-	1007	O
.	-	1008	O
5	-	1009	O
g	-	1011	O
/	-	1012	O
liter	-	1013	O
.	-	1018	O

Ascites	6585590	1020	B
and	-	1028	O
hydrothorax	-	1032	B
were	-	1044	O
observed	-	1049	O
simultaneously	-	1058	O
.	-	1072	O

The	6585590	1074	O
same	-	1078	O
experiments	-	1083	O
were	-	1095	O
performed	-	1100	O
with	-	1110	O
non	-	1115	O
-	-	1118	O
tumor	-	1119	B
-	-	1124	O
bearing	-	1125	O
rats	-	1133	O
,	-	1137	O
in	-	1139	O
which	-	1142	O
no	-	1148	O
major	-	1151	O
differences	-	1157	O
were	-	1169	O
observed	-	1174	O
.	-	1182	O

In	6585590	1184	O
conclusion	-	1187	O
,	-	1197	O
antitumor	-	1199	O
activity	-	1209	O
,	-	1217	O
cardiotoxicity	-	1219	B
,	-	1233	O
and	-	1235	O
nephrotoxicity	-	1239	B
were	-	1254	O
studied	-	1259	O
simultaneously	-	1267	O
in	-	1282	O
the	-	1285	O
same	-	1289	O
LOU	-	1294	O
/	-	1297	O
M	-	1298	O
/	-	1299	O
WSL	-	1300	O
rat	-	1304	O
.	-	1307	O

Albuminuria	6585590	1309	B
due	-	1321	O
to	-	1325	O
renal	-	1328	B
damage	-	1334	I
led	-	1341	O
to	-	1345	O
extremely	-	1348	O
low	-	1358	O
serum	-	1362	O
albumin	-	1368	O
levels	-	1376	O
,	-	1382	O
so	-	1384	O
ascites	-	1387	B
and	-	1395	O
hydrothorax	-	1399	B
were	-	1411	O
not	-	1416	O
necessarily	-	1420	O
a	-	1432	O
consequence	-	1434	O
of	-	1446	O
the	-	1449	O
observed	-	1453	O
cardiomyopathy	-	1462	B
.	-	1476	O

Intraoperative	6615679	0	O
bradycardia	-	15	B
and	-	27	O
hypotension	-	31	B
associated	-	43	O
with	-	54	O
timolol	-	59	O
and	-	67	O
pilocarpine	-	71	O
eye	-	83	O
drops	-	87	O
.	-	92	O

A	6615679	94	O
69	-	96	O
-	-	98	O
yr	-	99	O
-	-	101	O
old	-	102	O
man	-	106	O
,	-	109	O
who	-	111	O
was	-	115	O
concurrently	-	119	O
being	-	132	O
treated	-	138	O
with	-	146	O
pilocarpine	-	151	O
nitrate	-	163	O
and	-	171	O
timolol	-	175	O
maleate	-	183	O
eye	-	191	O
drops	-	195	O
,	-	200	O
developed	-	202	O
a	-	212	O
bradycardia	-	214	B
and	-	226	O
became	-	230	O
hypotensive	-	237	B
during	-	249	O
halothane	-	256	O
anaesthesia	-	266	O
.	-	277	O

Both	6615679	279	O
timolol	-	284	O
and	-	292	O
pilocarpine	-	296	O
were	-	308	O
subsequently	-	313	O
identified	-	326	O
in	-	337	O
a	-	340	O
24	-	342	O
-	-	344	O
h	-	345	O
collection	-	347	O
of	-	358	O
urine	-	361	O
.	-	366	O

Timolol	6615679	368	O
(	-	376	O
but	-	377	O
not	-	381	O
pilocarpine	-	385	O
)	-	396	O
was	-	398	O
detected	-	402	O
in	-	411	O
a	-	414	O
sample	-	416	O
of	-	423	O
plasma	-	426	O
removed	-	433	O
during	-	441	O
surgery	-	448	O
;	-	455	O
the	-	457	O
plasma	-	461	O
concentration	-	468	O
of	-	482	O
timolol	-	485	O
(	-	493	O
2	-	494	O
.	-	495	O
6	-	496	O
ng	-	498	O
ml	-	501	O
-	-	503	O
1	-	504	O
)	-	505	O
was	-	507	O
consistent	-	511	O
with	-	522	O
partial	-	527	O
beta	-	535	O
-	-	539	O
adrenoceptor	-	540	O
blockade	-	553	O
.	-	561	O

It	6615679	563	O
is	-	566	O
postulated	-	569	O
that	-	580	O
this	-	585	O
action	-	590	O
may	-	597	O
have	-	601	O
been	-	606	O
enhanced	-	611	O
during	-	620	O
halothane	-	627	O
anaesthesia	-	637	O
with	-	649	O
resultant	-	654	O
bradycardia	-	664	B
and	-	676	O
hypotension	-	680	B
.	-	691	O

Pilocarpine	6615679	693	O
may	-	705	O
have	-	709	O
had	-	714	O
a	-	718	O
contributory	-	720	O
effect	-	733	O
.	-	739	O

Succinylcholine	6627074	0	O
apnoea	-	16	B
:	-	22	O
attempted	-	24	O
reversal	-	34	O
with	-	43	O
anticholinesterases	-	48	O
.	-	67	O

Anticholinesterases	6627074	69	O
were	-	89	O
administered	-	94	O
in	-	107	O
an	-	110	O
attempt	-	113	O
to	-	121	O
antagonize	-	124	O
prolonged	-	135	O
neuromuscular	-	145	B
blockade	-	159	I
following	-	168	O
the	-	178	O
administration	-	182	O
of	-	197	O
succinylcholine	-	200	O
in	-	216	O
a	-	219	O
patient	-	221	O
later	-	229	O
found	-	235	O
to	-	241	O
be	-	244	O
homozygous	-	247	O
for	-	258	O
atypical	-	262	O
plasma	-	271	O
cholinesterase	-	278	O
.	-	292	O

Edrophonium	6627074	294	O
10	-	306	O
mg	-	309	O
,	-	311	O
given	-	313	O
74	-	319	O
min	-	322	O
after	-	326	O
succinylcholine	-	332	O
,	-	347	O
when	-	349	O
train	-	354	O
-	-	359	O
of	-	360	O
-	-	362	O
four	-	363	O
stimulation	-	368	O
was	-	380	O
characteristic	-	384	O
of	-	399	O
phase	-	402	O
II	-	408	O
block	-	411	O
,	-	416	O
produced	-	418	O
partial	-	427	O
antagonism	-	435	O
which	-	446	O
was	-	452	O
not	-	456	O
sustained	-	460	O
.	-	469	O

Repeated	6627074	471	O
doses	-	480	O
of	-	486	O
edrophonium	-	489	O
to	-	501	O
70	-	504	O
mg	-	507	O
and	-	510	O
neostigmine	-	514	O
to	-	526	O
2	-	529	O
.	-	530	O
5	-	531	O
mg	-	533	O
did	-	536	O
not	-	540	O
antagonize	-	544	O
or	-	555	O
augment	-	558	O
the	-	566	O
block	-	570	O
.	-	575	O

Spontaneous	6627074	577	O
respiration	-	589	O
recommenced	-	601	O
200	-	613	O
min	-	617	O
after	-	621	O
succinylcholine	-	627	O
administration	-	643	O
.	-	657	O

It	6627074	659	O
is	-	662	O
concluded	-	665	O
that	-	675	O
anticholinesterases	-	680	O
are	-	700	O
only	-	704	O
partially	-	709	O
effective	-	719	O
in	-	729	O
restoring	-	732	O
neuromuscular	-	742	O
function	-	756	O
in	-	765	O
succinylcholine	-	768	O
apnoea	-	784	B
despite	-	791	O
muscle	-	799	O
twitch	-	806	O
activity	-	813	O
typical	-	822	O
of	-	830	O
phase	-	833	O
II	-	839	O
block	-	842	O
.	-	847	O

Effect	6631522	0	O
of	-	7	O
doxorubicin	-	10	O
on	-	22	O
[	-	25	O
omega	-	26	O
-	-	31	O
I	-	32	O
-	-	33	O
131	-	34	O
]	-	37	O
heptadecanoic	-	38	O
acid	-	52	O
myocardial	-	57	O
scintigraphy	-	68	O
and	-	81	O
echocardiography	-	85	O
in	-	102	O
dogs	-	105	O
.	-	109	O

The	6631522	111	O
effects	-	115	O
of	-	123	O
serial	-	126	O
treatment	-	133	O
with	-	143	O
doxorubicin	-	148	O
on	-	160	O
dynamic	-	163	O
myocardial	-	171	O
scintigraphy	-	182	O
with	-	195	O
[	-	200	O
omega	-	201	O
-	-	206	O
I	-	207	O
-	-	208	O
131	-	209	O
]	-	212	O
heptadecanoic	-	213	O
acid	-	227	O
(	-	232	O
I	-	233	O
-	-	234	O
131	-	235	O
HA	-	239	O
)	-	241	O
,	-	242	O
and	-	244	O
on	-	248	O
global	-	251	O
left	-	258	O
-	-	262	O
ventricular	-	263	O
function	-	275	O
determined	-	284	O
echocardiographically	-	295	O
,	-	316	O
were	-	318	O
studied	-	323	O
in	-	331	O
a	-	334	O
group	-	336	O
of	-	342	O
nine	-	345	O
mongrel	-	350	O
dogs	-	358	O
.	-	362	O

Total	6631522	364	O
extractable	-	370	O
myocardial	-	382	O
lipid	-	393	O
was	-	399	O
compared	-	403	O
postmortem	-	412	O
between	-	423	O
a	-	431	O
group	-	433	O
of	-	439	O
control	-	442	O
dogs	-	450	O
and	-	455	O
doxorubicin	-	459	O
-	-	470	O
treated	-	471	O
dogs	-	479	O
.	-	483	O

A	6631522	485	O
significant	-	487	O
and	-	499	O
then	-	503	O
progressive	-	508	O
fall	-	520	O
in	-	525	O
global	-	528	O
LV	-	535	O
function	-	538	O
was	-	547	O
observed	-	551	O
at	-	560	O
a	-	563	O
cumulative	-	565	O
doxorubicin	-	576	O
dose	-	588	O
of	-	593	O
4	-	596	O
mg	-	598	O
/	-	600	O
kg	-	601	O
.	-	603	O

A	6631522	605	O
significant	-	607	O
increase	-	619	O
in	-	628	O
the	-	631	O
myocardial	-	635	O
t1	-	646	O
/	-	648	O
2	-	649	O
of	-	651	O
the	-	654	O
I	-	658	O
-	-	659	O
131	-	660	O
HA	-	664	O
was	-	667	O
observed	-	671	O
only	-	680	O
at	-	685	O
a	-	688	O
higher	-	690	O
cumulative	-	697	O
dose	-	708	O
,	-	712	O
10	-	714	O
mg	-	717	O
/	-	719	O
kg	-	720	O
.	-	722	O

No	6631522	724	O
significant	-	727	O
alteration	-	739	O
in	-	750	O
total	-	753	O
extractable	-	759	O
myocardial	-	771	O
lipids	-	782	O
was	-	789	O
observed	-	793	O
between	-	802	O
control	-	810	O
dogs	-	818	O
and	-	823	O
those	-	827	O
treated	-	833	O
with	-	841	O
doxorubicin	-	846	O
.	-	857	O

Our	6631522	859	O
findings	-	863	O
suggest	-	872	O
that	-	880	O
the	-	885	O
changes	-	889	O
leading	-	897	O
to	-	905	O
an	-	908	O
alteration	-	911	O
of	-	922	O
myocardial	-	925	O
dynamic	-	936	O
imaging	-	944	O
with	-	952	O
I	-	957	O
-	-	958	O
131	-	959	O
HA	-	963	O
are	-	966	O
not	-	970	O
the	-	974	O
initiating	-	978	O
factor	-	989	O
in	-	996	O
doxorubicin	-	999	O
cardiotoxicity	-	1011	B
.	-	1025	O

Hemodynamics	6673474	0	O
and	-	13	O
myocardial	-	17	O
metabolism	-	28	O
under	-	39	O
deliberate	-	45	O
hypotension	-	56	B
.	-	67	O

An	6673474	69	O
experimental	-	72	O
study	-	85	O
in	-	91	O
dogs	-	94	O
.	-	98	O

Coronary	6673474	100	O
blood	-	109	O
flow	-	115	O
,	-	119	O
cardiac	-	121	O
work	-	129	O
and	-	134	O
metabolism	-	138	O
were	-	149	O
studied	-	154	O
in	-	162	O
dogs	-	165	O
under	-	170	O
sodium	-	176	O
nitroprusside	-	183	O
(	-	197	O
SNP	-	198	O
)	-	201	O
and	-	203	O
trimetaphan	-	207	O
(	-	219	O
TMP	-	220	O
)	-	223	O
deliberate	-	225	O
hypotension	-	236	B
(	-	248	O
20	-	249	O
%	-	251	O
and	-	253	O
40	-	257	O
%	-	259	O
mean	-	261	O
pressure	-	266	O
decrease	-	275	O
from	-	284	O
baseline	-	289	O
)	-	297	O
.	-	298	O

Regarding	6673474	300	O
the	-	310	O
effects	-	314	O
of	-	322	O
drug	-	325	O
-	-	329	O
induced	-	330	O
hypotension	-	338	B
on	-	350	O
coronary	-	353	O
blood	-	362	O
flow	-	368	O
,	-	372	O
aortic	-	374	O
and	-	381	O
coronary	-	385	O
sinus	-	394	O
metabolic	-	400	O
data	-	410	O
(	-	415	O
pH	-	416	O
,	-	418	O
pO2	-	420	O
,	-	423	O
pCO2	-	425	O
)	-	429	O
we	-	431	O
could	-	434	O
confirm	-	440	O
that	-	448	O
nitroprusside	-	453	O
hypotension	-	467	B
could	-	479	O
be	-	485	O
safely	-	488	O
used	-	495	O
to	-	500	O
30	-	503	O
%	-	505	O
mean	-	507	O
blood	-	512	O
pressure	-	518	O
decrease	-	527	O
from	-	536	O
control	-	541	O
,	-	548	O
trimetaphan	-	550	O
hypotension	-	562	B
to	-	574	O
20	-	577	O
%	-	579	O
mean	-	581	O
blood	-	586	O
pressure	-	592	O
decrease	-	601	O
.	-	609	O

Cardiac	6673474	611	O
work	-	619	O
was	-	624	O
significantly	-	628	O
reduced	-	642	O
during	-	650	O
SNP	-	657	O
hypotension	-	661	B
.	-	672	O

Myocardial	6673474	674	O
O2	-	685	O
consumption	-	688	O
and	-	700	O
O2	-	704	O
availability	-	707	O
were	-	720	O
directly	-	725	O
dependent	-	734	O
on	-	744	O
the	-	747	O
coronary	-	751	O
perfusion	-	760	O
.	-	769	O

Careful	6673474	771	O
invasive	-	779	O
monitoring	-	788	O
of	-	799	O
the	-	802	O
blood	-	806	O
pressure	-	812	O
,	-	820	O
blood	-	822	O
gases	-	828	O
and	-	834	O
of	-	838	O
the	-	841	O
ECG	-	845	O
ST	-	849	O
-	-	851	O
T	-	852	O
segment	-	854	O
is	-	862	O
mandatory	-	865	O
.	-	874	O

Evidence	6687006	0	O
for	-	9	O
a	-	13	O
selective	-	15	O
brain	-	25	O
noradrenergic	-	31	O
involvement	-	45	O
in	-	57	O
the	-	60	O
locomotor	-	64	O
stimulant	-	74	O
effects	-	84	O
of	-	92	O
amphetamine	-	95	O
in	-	107	O
the	-	110	O
rat	-	114	O
.	-	117	O

Male	6687006	119	O
rats	-	124	O
received	-	129	O
the	-	138	O
noradrenaline	-	142	O
neurotoxin	-	156	O
DSP4	-	167	O
(	-	172	O
50	-	173	O
mg	-	176	O
/	-	178	O
kg	-	179	O
)	-	181	O
7	-	183	O
days	-	185	O
prior	-	190	O
to	-	196	O
injection	-	199	O
of	-	209	O
D	-	212	O
-	-	213	O
amphetamine	-	214	O
(	-	226	O
10	-	227	O
or	-	230	O
40	-	233	O
mumol	-	236	O
/	-	241	O
kg	-	242	O
i	-	245	O
.	-	246	O
p	-	247	O
.	-	248	O
)	-	249	O
.	-	250	O

The	6687006	252	O
hyperactivity	-	256	B
induced	-	270	O
by	-	278	O
D	-	281	O
-	-	282	O
amphetamine	-	283	O
(	-	295	O
10	-	296	O
mumol	-	299	O
/	-	304	O
kg	-	305	O
)	-	307	O
was	-	309	O
significantly	-	313	O
reduced	-	327	O
by	-	335	O
DSP4	-	338	O
pretreatment	-	343	O
.	-	355	O

However	6687006	357	O
,	-	364	O
the	-	366	O
increased	-	370	O
rearings	-	380	O
and	-	389	O
the	-	393	O
amphetamine	-	397	O
-	-	408	O
induced	-	409	O
stereotypies	-	417	B
were	-	430	O
not	-	435	O
blocked	-	439	O
by	-	447	O
pretreatment	-	450	O
with	-	463	O
DSP4	-	468	O
.	-	472	O

The	6687006	474	O
reduction	-	478	O
of	-	488	O
amphetamine	-	491	O
hyperactivity	-	503	B
induced	-	517	O
by	-	525	O
DSP4	-	528	O
was	-	533	O
blocked	-	537	O
by	-	545	O
pretreatment	-	548	O
with	-	561	O
the	-	566	O
noradrenaline	-	570	O
-	-	583	O
uptake	-	584	O
blocking	-	591	O
agent	-	600	O
,	-	605	O
desipramine	-	607	O
,	-	618	O
which	-	620	O
prevents	-	626	O
the	-	635	O
neurotoxic	-	639	B
action	-	650	O
of	-	657	O
DSP4	-	660	O
.	-	664	O

The	6687006	666	O
present	-	670	O
results	-	678	O
suggest	-	686	O
a	-	694	O
selective	-	696	O
involvement	-	706	O
of	-	718	O
central	-	721	O
noradrenergic	-	729	O
neurones	-	743	O
in	-	752	O
the	-	755	O
locomotor	-	759	O
stimulant	-	769	O
effect	-	779	O
of	-	786	O
amphetamine	-	789	O
in	-	801	O
the	-	804	O
rat	-	808	O
.	-	811	O

Accelerated	6695685	0	B
junctional	-	12	I
rhythms	-	23	I
during	-	31	O
oral	-	38	O
verapamil	-	43	O
therapy	-	53	O
.	-	60	O

This	6695685	62	O
study	-	67	O
examined	-	73	O
the	-	82	O
frequency	-	86	O
of	-	96	O
atrioventricular	-	99	O
(	-	116	O
AV	-	117	O
)	-	119	O
dissociation	-	121	O
and	-	134	O
accelerated	-	138	B
junctional	-	150	I
rhythms	-	161	I
in	-	169	O
59	-	172	O
patients	-	175	O
receiving	-	184	O
oral	-	194	O
verapamil	-	199	O
.	-	208	O

Accelerated	6695685	210	B
junctional	-	222	I
rhythms	-	233	I
and	-	241	O
AV	-	245	O
dissociation	-	248	O
were	-	261	O
frequent	-	266	O
in	-	275	O
patients	-	278	O
with	-	287	O
supraventricular	-	292	B
tachyarrhythmias	-	309	I
,	-	325	O
particularly	-	327	O
AV	-	340	O
nodal	-	343	O
reentry	-	349	O
.	-	356	O

Verapamil	6695685	358	O
administration	-	368	O
to	-	383	O
these	-	386	O
patients	-	392	O
led	-	401	O
to	-	405	O
an	-	408	O
asymptomatic	-	411	O
increase	-	424	O
in	-	433	O
activity	-	436	O
of	-	445	O
these	-	448	O
junctional	-	454	O
pacemakers	-	465	O
.	-	475	O

In	6695685	477	O
patients	-	480	O
with	-	489	O
various	-	494	O
chest	-	502	B
pain	-	508	I
syndromes	-	513	O
,	-	522	O
verapamil	-	524	O
neither	-	534	O
increased	-	542	O
the	-	552	O
frequency	-	556	O
of	-	566	O
junctional	-	569	O
rhythms	-	580	O
nor	-	588	O
suppressed	-	592	O
their	-	603	O
role	-	609	O
as	-	614	O
escape	-	617	O
rhythms	-	624	O
under	-	632	O
physiologically	-	638	O
appropriate	-	654	O
circumstances	-	666	O
.	-	679	O

Treatment	6806735	0	O
of	-	10	O
ovarian	-	13	B
cancer	-	21	I
with	-	28	O
a	-	33	O
combination	-	35	O
of	-	47	O
cis	-	50	O
-	-	53	O
platinum	-	54	O
,	-	62	O
adriamycin	-	64	O
,	-	74	O
cyclophosphamide	-	76	O
and	-	93	O
hexamethylmelamine	-	97	O
.	-	115	O

During	6806735	117	O
the	-	124	O
last	-	128	O
2	-	133	O
1	-	135	O
/	-	136	O
2	-	137	O
years	-	139	O
,	-	144	O
38	-	146	O
patients	-	149	O
with	-	158	O
ovarian	-	163	B
cancer	-	171	I
were	-	178	O
treated	-	183	O
with	-	191	O
a	-	196	O
combination	-	198	O
of	-	210	O
cisplatinum	-	213	O
(	-	225	O
CPDD	-	226	O
)	-	230	O
,	-	231	O
50	-	233	O
mg	-	236	O
/	-	238	O
m2	-	239	O
,	-	241	O
adriamycin	-	243	O
,	-	253	O
30	-	255	O
mg	-	258	O
/	-	260	O
m2	-	261	O
,	-	263	O
cyclophosphamide	-	265	O
,	-	281	O
300	-	283	O
mg	-	287	O
/	-	289	O
m2	-	290	O
,	-	292	O
on	-	294	O
day	-	297	O
1	-	301	O
;	-	302	O
and	-	304	O
hexamethylmelamine	-	308	O
(	-	327	O
HMM	-	328	O
)	-	331	O
,	-	332	O
6	-	334	O
mg	-	336	O
/	-	338	O
kg	-	339	O
daily	-	342	O
,	-	347	O
for	-	349	O
14	-	353	O
days	-	356	O
.	-	360	O

Each	6806735	362	O
course	-	367	O
was	-	374	O
repeated	-	378	O
monthly	-	387	O
.	-	394	O

2	6806735	396	O
patients	-	398	O
had	-	407	O
stage	-	411	O
II	-	417	O
,	-	419	O
14	-	421	O
stage	-	424	O
III	-	430	O
and	-	434	O
22	-	438	O
stage	-	441	O
IV	-	447	O
disease	-	450	O
.	-	457	O

14	6806735	459	O
of	-	462	O
the	-	465	O
38	-	469	O
patients	-	472	O
were	-	481	O
previously	-	486	O
treated	-	497	O
with	-	505	O
chemotherapy	-	510	O
,	-	522	O
1	-	524	O
with	-	526	O
radiation	-	531	O
,	-	540	O
6	-	542	O
with	-	544	O
both	-	549	O
chemotherapy	-	554	O
and	-	567	O
radiation	-	571	O
,	-	580	O
and	-	582	O
17	-	586	O
did	-	589	O
not	-	593	O
have	-	597	O
any	-	602	O
treatment	-	606	O
before	-	616	O
CPDD	-	623	O
combination	-	628	O
.	-	639	O

31	6806735	641	O
of	-	644	O
the	-	647	O
38	-	651	O
cases	-	654	O
(	-	660	O
81	-	661	O
.	-	663	O
5	-	664	O
%	-	665	O
)	-	666	O
demonstrated	-	668	O
objective	-	681	O
responses	-	691	O
lasting	-	701	O
for	-	709	O
2	-	713	O
months	-	715	O
or	-	722	O
more	-	725	O
.	-	729	O

These	6806735	731	O
responses	-	737	O
were	-	747	O
partial	-	752	O
in	-	760	O
19	-	763	O
and	-	766	O
complete	-	770	O
in	-	779	O
12	-	782	O
cases	-	785	O
.	-	790	O

Hematologic	6806735	792	B
toxicity	-	804	I
was	-	813	O
moderate	-	817	O
and	-	826	O
with	-	830	O
reversible	-	835	O
anemia	-	846	B
developing	-	853	O
in	-	864	O
71	-	867	O
%	-	869	O
of	-	871	O
patients	-	874	O
.	-	882	O

Gastrointestinal	6806735	884	O
side	-	901	O
effects	-	906	O
from	-	914	O
CPDD	-	919	O
were	-	924	O
universal	-	929	O
.	-	938	O

HMM	6806735	940	O
gastrointestinal	-	944	B
toxicity	-	961	I
necessitated	-	970	O
discontinuation	-	983	O
of	-	999	O
the	-	1002	O
drug	-	1006	O
in	-	1011	O
5	-	1014	O
patients	-	1016	O
.	-	1024	O

Severe	6806735	1026	O
nephrotoxicity	-	1033	B
was	-	1048	O
observed	-	1052	O
in	-	1061	O
2	-	1064	O
patients	-	1066	O
but	-	1075	O
was	-	1079	O
reversible	-	1083	O
.	-	1093	O

There	6806735	1095	O
were	-	1101	O
no	-	1106	O
drug	-	1109	O
-	-	1113	O
related	-	1114	O
deaths	-	1122	O
.	-	1128	O

Nontraumatic	6884395	0	O
dissecting	-	13	B
aneurysm	-	24	I
of	-	33	O
the	-	36	O
basilar	-	40	O
artery	-	48	O
.	-	54	O

A	6884395	56	O
case	-	58	O
of	-	63	O
nontraumatic	-	66	O
dissecting	-	79	B
aneurysm	-	90	I
of	-	99	O
the	-	102	O
basilar	-	106	O
artery	-	114	O
in	-	121	O
association	-	124	O
with	-	136	O
hypertension	-	141	B
,	-	153	O
smoke	-	155	O
,	-	160	O
and	-	162	O
oral	-	166	O
contraceptives	-	171	O
is	-	186	O
reported	-	189	O
in	-	198	O
a	-	201	O
young	-	203	O
female	-	209	O
patient	-	216	O
with	-	224	O
a	-	229	O
locked	-	231	B
-	-	237	I
in	-	238	I
syndrome	-	241	I
.	-	249	O

Propylthiouracil	6893265	0	O
-	-	16	O
induced	-	17	O
hepatic	-	25	B
damage	-	33	I
.	-	39	O

Two	6893265	41	O
cases	-	45	O
of	-	51	O
propylthiouracil	-	54	O
-	-	70	O
induced	-	71	O
liver	-	79	B
damage	-	85	I
have	-	92	O
been	-	97	O
observed	-	102	O
.	-	110	O

The	6893265	112	O
first	-	116	O
case	-	122	O
is	-	127	O
of	-	130	O
an	-	133	O
acute	-	136	O
type	-	142	O
of	-	147	O
damage	-	150	O
,	-	156	O
proven	-	158	O
by	-	165	O
rechallenge	-	168	O
;	-	179	O
the	-	181	O
second	-	185	O
presents	-	192	O
a	-	201	O
clinical	-	203	O
and	-	212	O
histologic	-	216	O
picture	-	227	O
resembling	-	235	O
chronic	-	246	B
active	-	254	I
hepatitis	-	261	I
,	-	270	O
with	-	272	O
spontaneous	-	277	O
remission	-	289	O
.	-	298	O

Studies	6985297	0	O
on	-	8	O
the	-	11	O
bradycardia	-	15	B
induced	-	27	O
by	-	35	O
bepridil	-	38	O
.	-	46	O

Bepridil	6985297	48	O
,	-	56	O
a	-	58	O
novel	-	60	O
active	-	66	O
compound	-	73	O
for	-	82	O
prophylactic	-	86	O
treatment	-	99	O
of	-	109	O
anginal	-	112	B
attacks	-	120	I
,	-	127	O
induced	-	129	O
persistent	-	137	O
bradycardia	-	148	B
and	-	160	O
a	-	164	O
non	-	166	O
-	-	169	O
specific	-	170	O
anti	-	179	O
-	-	183	O
tachycardial	-	184	B
effect	-	197	O
,	-	203	O
the	-	205	O
mechanisms	-	209	O
of	-	220	O
which	-	223	O
were	-	229	O
investigated	-	234	O
in	-	247	O
vitro	-	250	O
and	-	256	O
in	-	260	O
vivo	-	263	O
.	-	267	O

In	6985297	269	O
vitro	-	272	O
perfusion	-	278	O
of	-	288	O
bepridil	-	291	O
in	-	300	O
the	-	303	O
life	-	307	O
-	-	311	O
support	-	312	O
medium	-	320	O
for	-	327	O
isolated	-	331	O
sino	-	340	O
-	-	344	O
atrial	-	345	O
tissue	-	352	O
from	-	359	O
rabbit	-	364	O
heart	-	371	O
,	-	376	O
caused	-	378	O
a	-	385	O
reduction	-	387	O
in	-	397	O
action	-	400	O
potential	-	407	O
(	-	417	O
AP	-	418	O
)	-	420	O
spike	-	422	O
frequency	-	428	O
(	-	438	O
recorded	-	439	O
by	-	448	O
KCl	-	451	O
microelectrodes	-	455	O
)	-	470	O
starting	-	472	O
at	-	481	O
doses	-	484	O
of	-	490	O
5	-	493	O
X	-	495	O
10	-	497	O
(	-	499	O
-	-	500	O
6	-	501	O
)	-	502	O
M	-	504	O
.	-	505	O

This	6985297	507	O
effect	-	512	O
was	-	519	O
dose	-	523	O
-	-	527	O
dependent	-	528	O
up	-	538	O
to	-	541	O
concentrations	-	544	O
of	-	559	O
5	-	562	O
X	-	564	O
10	-	566	O
(	-	568	O
-	-	569	O
5	-	570	O
)	-	571	O

M	6985297	573	O
,	-	574	O
whereupon	-	576	O
blockade	-	586	O
of	-	595	O
sinus	-	598	O
activity	-	604	O
set	-	613	O
in	-	617	O
.	-	619	O

Bepridil	6985297	621	O
at	-	630	O
a	-	633	O
dose	-	635	O
of	-	640	O
5	-	643	O
X	-	645	O
10	-	647	O
(	-	649	O
-	-	650	O
6	-	651	O
)	-	652	O
M	-	654	O
,	-	655	O
induced	-	657	O
a	-	665	O
concomitant	-	667	O
reduction	-	679	O
in	-	689	O
AP	-	692	O
amplitude	-	695	O
(	-	705	O
falling	-	706	O
from	-	714	O
71	-	719	O
+	-	722	O
/	-	723	O
-	-	724	O

8	6985297	726	O
mV	-	728	O
to	-	731	O
47	-	734	O
+	-	737	O
/	-	738	O
-	-	739	O

6	6985297	741	O
mV	-	743	O
)	-	745	O
,	-	746	O
maximum	-	748	O
systolic	-	756	O
depolarization	-	765	O
velocity	-	780	O
(	-	789	O
phase	-	790	O
0	-	796	O
)	-	797	O
which	-	799	O
fell	-	805	O
from	-	810	O
1	-	815	O
.	-	816	O
85	-	817	O
+	-	820	O
/	-	821	O
-	-	822	O

0	6985297	824	O
.	-	825	O
35	-	826	O
V	-	829	O
/	-	830	O
s	-	831	O
to	-	833	O
0	-	836	O
.	-	837	O
84	-	838	O
+	-	841	O
/	-	842	O
-	-	843	O

0	6985297	845	O
.	-	846	O
28	-	847	O
V	-	850	O
/	-	851	O
s	-	852	O
,	-	853	O
together	-	855	O
with	-	864	O
maximum	-	869	O
diastolic	-	877	O
depolarization	-	887	O
velocity	-	902	O
(	-	911	O
phase	-	912	O
4	-	918	O
)	-	919	O
which	-	921	O
fell	-	927	O
from	-	932	O
38	-	937	O
+	-	940	O
/	-	941	O
-	-	942	O

3	6985297	944	O
mV	-	946	O
/	-	948	O
s	-	949	O
to	-	951	O
24	-	954	O
+	-	957	O
/	-	958	O
-	-	959	O

5	6985297	961	O
mV	-	963	O
/	-	965	O
s	-	966	O
.	-	967	O

In	6985297	969	O
vivo	-	972	O
injection	-	977	O
of	-	987	O
bepridil	-	990	O
at	-	999	O
a	-	1002	O
dose	-	1004	O
of	-	1009	O
5	-	1012	O
mg	-	1014	O
/	-	1016	O
kg	-	1017	O
(	-	1020	O
i	-	1021	O
.	-	1022	O
v	-	1023	O
.	-	1024	O
)	-	1025	O
into	-	1027	O
6	-	1032	O
anaesthetized	-	1034	O
dogs	-	1048	O
which	-	1053	O
had	-	1059	O
undergone	-	1063	O
ablation	-	1073	O
of	-	1082	O
all	-	1085	O
the	-	1089	O
extrinsic	-	1093	O
cardiac	-	1103	O
afferent	-	1111	O
nerve	-	1120	O
supply	-	1126	O
,	-	1132	O
together	-	1134	O
with	-	1143	O
a	-	1148	O
bilateral	-	1150	O
medullo	-	1160	O
-	-	1167	O
adrenalectomy	-	1168	O
,	-	1181	O
caused	-	1183	O
a	-	1190	O
marked	-	1192	O
reduction	-	1199	O
in	-	1209	O
heart	-	1212	O
rate	-	1218	O
which	-	1223	O
fell	-	1229	O
from	-	1234	O
98	-	1239	O
.	-	1241	O
7	-	1242	O
+	-	1244	O
/	-	1245	O
-	-	1246	O

4	6985297	1248	O
.	-	1249	O
2	-	1250	O
beats	-	1252	O
/	-	1257	O
min	-	1258	O
to	-	1262	O
76	-	1265	O
+	-	1268	O
/	-	1269	O
-	-	1270	O

5	6985297	1272	O
.	-	1273	O
3	-	1274	O
beats	-	1276	O
/	-	1281	O
min	-	1282	O
sustained	-	1286	O
for	-	1296	O
more	-	1300	O
than	-	1305	O
45	-	1310	O
min	-	1313	O
.	-	1316	O

It	6985297	1318	O
is	-	1321	O
concluded	-	1324	O
that	-	1334	O
bepridil	-	1339	O
reduces	-	1348	O
heart	-	1356	O
rate	-	1362	O
by	-	1367	O
acting	-	1370	O
directly	-	1377	O
on	-	1386	O
the	-	1389	O
sinus	-	1393	O
node	-	1399	O
.	-	1403	O

This	6985297	1405	O
effect	-	1410	O
,	-	1416	O
which	-	1418	O
results	-	1424	O
in	-	1432	O
a	-	1435	O
flattening	-	1437	O
of	-	1448	O
the	-	1451	O
phase	-	1455	O
0	-	1461	O
and	-	1463	O
phase	-	1467	O
4	-	1473	O
slope	-	1475	O
,	-	1480	O
together	-	1482	O
with	-	1491	O
a	-	1496	O
longer	-	1498	O
AP	-	1505	O
duration	-	1508	O
,	-	1516	O
may	-	1518	O
be	-	1522	O
due	-	1525	O
to	-	1529	O
an	-	1532	O
increase	-	1535	O
in	-	1544	O
the	-	1547	O
time	-	1551	O
constants	-	1556	O
of	-	1566	O
slow	-	1569	O
inward	-	1574	O
ionic	-	1581	O
currents	-	1587	O
(	-	1596	O
already	-	1597	O
demonstrated	-	1605	O
elsewhere	-	1618	O
)	-	1627	O
,	-	1628	O
but	-	1630	O
also	-	1634	O
to	-	1639	O
an	-	1642	O
increased	-	1645	O
time	-	1655	O
constant	-	1660	O
for	-	1669	O
deactivation	-	1673	O
of	-	1686	O
the	-	1689	O
outward	-	1693	O
potassium	-	1701	O
current	-	1711	O
(	-	1719	O
Ip	-	1720	O
)	-	1722	O
.	-	1723	O

Hepatitis	6985498	0	B
and	-	10	O
renal	-	14	B
tubular	-	20	I
acidosis	-	28	I
after	-	37	O
anesthesia	-	43	O
with	-	54	O
methoxyflurane	-	59	O
.	-	73	O

A	6985498	75	O
69	-	77	O
-	-	79	O
year	-	80	O
-	-	84	O
old	-	85	O
man	-	89	O
operated	-	93	O
for	-	102	O
acute	-	106	B
cholecystitis	-	112	I
under	-	126	O
methoxyflurane	-	132	O
anesthesia	-	147	O
developed	-	158	O
postoperatively	-	168	O
a	-	184	O
hepatic	-	186	B
insufficiency	-	194	I
syndrome	-	208	I
and	-	217	O
renal	-	221	B
tubular	-	227	I
acidosis	-	235	I
.	-	243	O

Massive	6985498	245	O
bleeding	-	253	B
appeared	-	262	O
during	-	271	O
surgery	-	278	O
which	-	286	O
lasted	-	292	O
for	-	299	O
six	-	303	O
hours	-	307	O
.	-	312	O

Postoperative	6985498	314	O
evolution	-	328	O
under	-	338	O
supportive	-	344	O
therapy	-	355	O
was	-	363	O
favourable	-	367	O
.	-	377	O

Complete	6985498	379	O
recovery	-	388	O
was	-	397	O
confirmed	-	401	O
by	-	411	O
repeated	-	414	O
controls	-	423	O
performed	-	432	O
over	-	442	O
a	-	447	O
period	-	449	O
of	-	456	O
one	-	459	O
year	-	463	O
after	-	468	O
surgery	-	474	O
.	-	481	O

Pituitary	7018927	0	O
response	-	10	O
to	-	19	O
luteinizing	-	22	O
hormone	-	34	O
-	-	41	O
releasing	-	42	O
hormone	-	52	O
during	-	60	O
haloperidol	-	67	O
-	-	78	O
induced	-	79	O
hyperprolactinemia	-	87	B
.	-	105	O

The	7018927	107	O
effects	-	111	O
of	-	119	O
a	-	122	O
6	-	124	O
-	-	125	O
hour	-	126	O
infusion	-	131	O
with	-	140	O
haloperidol	-	145	O
on	-	157	O
serum	-	160	O
prolactin	-	166	O
and	-	176	O
luteinizing	-	180	O
hormone	-	192	O
(	-	200	O
LH	-	201	O
)	-	203	O
levels	-	205	O
was	-	212	O
studied	-	216	O
in	-	224	O
a	-	227	O
group	-	229	O
of	-	235	O
male	-	238	O
subjects	-	243	O
.	-	251	O

Five	7018927	253	O
hours	-	258	O
after	-	264	O
starting	-	270	O
the	-	279	O
infusions	-	283	O
,	-	292	O
a	-	294	O
study	-	296	O
of	-	302	O
the	-	305	O
pituitary	-	309	O
responses	-	319	O
to	-	329	O
LH	-	332	O
-	-	334	O
releasing	-	335	O
hormone	-	345	O
(	-	353	O
LH	-	354	O
-	-	356	O
RH	-	357	O
)	-	359	O
was	-	361	O
carried	-	365	O
out	-	373	O
.	-	376	O

Control	7018927	378	O
patients	-	386	O
received	-	395	O
infusions	-	404	O
of	-	414	O
0	-	417	O
.	-	418	O
9	-	419	O
%	-	420	O
NaCl	-	422	O
solution	-	427	O
.	-	435	O

During	7018927	437	O
the	-	444	O
course	-	448	O
of	-	455	O
haloperidol	-	458	O
infusions	-	470	O
,	-	479	O
significant	-	481	O
hyperprolactinemia	-	493	B
was	-	512	O
found	-	516	O
,	-	521	O
together	-	523	O
with	-	532	O
an	-	537	O
abolished	-	540	O
pituitary	-	550	O
response	-	560	O
to	-	569	O
LH	-	572	O
-	-	574	O
RH	-	575	O
,	-	577	O
as	-	579	O
compared	-	582	O
with	-	591	O
responses	-	596	O
of	-	606	O
control	-	609	O
subjects	-	617	O
.	-	625	O

Antirifampicin	7121659	0	O
antibodies	-	15	O
in	-	26	O
acute	-	29	O
rifampicin	-	35	O
-	-	45	O
associated	-	46	O
renal	-	57	B
failure	-	63	I
.	-	70	O

5	7121659	72	O
patients	-	74	O
with	-	83	O
acute	-	88	B
renal	-	94	I
failure	-	100	I
(	-	108	O
3	-	109	O
with	-	111	O
thrombopenia	-	116	B
and	-	129	O
hemolysis	-	133	B
)	-	142	O
induced	-	144	O
by	-	152	O
the	-	155	O
reintroduction	-	159	O
of	-	174	O
rifampicin	-	177	O
are	-	188	O
described	-	192	O
.	-	201	O

No	7121659	203	O
correlation	-	206	O
was	-	218	O
found	-	222	O
between	-	228	O
the	-	236	O
severity	-	240	O
of	-	249	O
clinical	-	252	O
manifestations	-	261	O
and	-	276	O
the	-	280	O
total	-	284	O
dose	-	290	O
taken	-	295	O
by	-	301	O
the	-	304	O
patients	-	308	O
.	-	316	O

In	7121659	318	O
all	-	321	O
but	-	325	O
1	-	329	O
patient	-	331	O
,	-	338	O
antirifampicin	-	340	O
antibodies	-	355	O
were	-	366	O
detected	-	371	O
.	-	379	O

Antibodies	7121659	381	O
suggested	-	392	O
to	-	402	O
be	-	405	O
of	-	408	O
the	-	411	O
IgM	-	415	O
class	-	419	O
were	-	425	O
detected	-	430	O
in	-	439	O
all	-	442	O
3	-	446	O
patients	-	448	O
with	-	457	O
hematological	-	462	B
disorders	-	476	I
.	-	485	O

The	7121659	487	O
pattern	-	491	O
of	-	499	O
non	-	502	O
-	-	505	O
specific	-	506	O
acute	-	515	B
tubular	-	521	I
necrosis	-	529	I
found	-	538	O
in	-	544	O
the	-	547	O
2	-	551	O
biopsied	-	553	O
patients	-	562	O
,	-	570	O
indistinguishable	-	572	O
from	-	590	O
that	-	595	O
of	-	600	O
ischemic	-	603	O
origin	-	612	O
,	-	618	O
raised	-	620	O
the	-	627	O
possibility	-	631	O
of	-	643	O
a	-	646	O
vascular	-	648	O
-	-	656	O
mediated	-	657	O
damage	-	666	O
.	-	672	O

In	7121659	674	O
3	-	677	O
patients	-	679	O
,	-	687	O
the	-	689	O
possibility	-	693	O
of	-	705	O
a	-	708	O
triggering	-	710	O
immunoallergic	-	721	O
mechanism	-	736	O
is	-	746	O
discussed	-	749	O
.	-	758	O

Cardiovascular	7147232	0	O
effects	-	15	O
of	-	23	O
hypotension	-	26	B
induced	-	38	O
by	-	46	O
adenosine	-	49	O
triphosphate	-	59	O
and	-	72	O
sodium	-	76	O
nitroprusside	-	83	O
on	-	97	O
dogs	-	100	O
with	-	105	O
denervated	-	110	O
hearts	-	121	O
.	-	127	O

Adenosine	7147232	129	O
triphosphate	-	139	O
(	-	152	O
ATP	-	153	O
)	-	156	O
and	-	158	O
sodium	-	162	O
nitroprusside	-	169	O
(	-	183	O
SNP	-	184	O
)	-	187	O
are	-	189	O
administered	-	193	O
to	-	206	O
patients	-	209	O
to	-	218	O
induce	-	221	O
and	-	228	O
control	-	232	O
hypotension	-	240	B
during	-	252	O
anesthesia	-	259	O
.	-	269	O

SNP	7147232	271	O
is	-	275	O
authorized	-	278	O
for	-	289	O
clinical	-	293	O
use	-	302	O
in	-	306	O
USA	-	309	O
and	-	313	O
UK	-	317	O
,	-	319	O
and	-	321	O
ATP	-	325	O
is	-	329	O
clinically	-	332	O
used	-	343	O
in	-	348	O
other	-	351	O
countries	-	357	O
such	-	367	O
as	-	372	O
Japan	-	375	O
.	-	380	O

We	7147232	382	O
investigated	-	385	O
how	-	398	O
these	-	402	O
two	-	408	O
drugs	-	412	O
act	-	418	O
on	-	422	O
the	-	425	O
cardiovascular	-	429	O
systems	-	444	O
of	-	452	O
20	-	455	O
dogs	-	458	O
whose	-	463	O
hearts	-	469	O
had	-	476	O
been	-	480	O
denervated	-	485	O
by	-	496	O
a	-	499	O
procedure	-	501	O
we	-	511	O
had	-	514	O
devised	-	518	O
.	-	525	O

ATP	7147232	527	O
(	-	531	O
10	-	532	O
dogs	-	535	O
)	-	539	O
or	-	541	O
SNP	-	544	O
(	-	548	O
10	-	549	O
dogs	-	552	O
)	-	556	O
was	-	558	O
administered	-	562	O
to	-	575	O
reduce	-	578	O
mean	-	585	O
arterial	-	590	O
pressure	-	599	O
by	-	608	O
30	-	611	O
%	-	613	O
to	-	615	O
70	-	618	O
%	-	620	O
of	-	622	O
control	-	625	O
.	-	632	O

Before	7147232	634	O
,	-	640	O
during	-	642	O
and	-	649	O
after	-	653	O
induced	-	659	O
hypotension	-	667	B
,	-	678	O
we	-	680	O
measured	-	683	O
major	-	692	O
cardiovascular	-	698	O
parameters	-	713	O
.	-	723	O

Hypotension	7147232	725	B
induced	-	737	O
by	-	745	O
ATP	-	748	O
was	-	752	O
accompanied	-	756	O
by	-	768	O
significant	-	771	O
decreases	-	783	O
in	-	793	O
mean	-	796	O
pulmonary	-	801	O
arterial	-	811	O
pressure	-	820	O
(	-	829	O
p	-	830	O
less	-	832	O
than	-	837	O
0	-	842	O
.	-	843	O
001	-	844	O
)	-	847	O
,	-	848	O
central	-	850	O
venous	-	858	O
pressure	-	865	O
(	-	874	O
p	-	875	O
less	-	877	O
than	-	882	O
0	-	887	O
.	-	888	O
001	-	889	O
)	-	892	O
,	-	893	O
left	-	895	O
ventricular	-	900	O
end	-	912	O
-	-	915	O
diastolic	-	916	O
pressure	-	926	O
(	-	935	O
p	-	936	O
less	-	938	O
than	-	943	O
0	-	948	O
.	-	949	O
001	-	950	O
)	-	953	O
,	-	954	O
total	-	956	O
peripheral	-	962	O
resistance	-	973	O
(	-	984	O
p	-	985	O
less	-	987	O
than	-	992	O
0	-	997	O
.	-	998	O
001	-	999	O
)	-	1002	O
,	-	1003	O
rate	-	1005	O
pressure	-	1010	O
product	-	1019	O
(	-	1027	O
p	-	1028	O
less	-	1030	O
than	-	1035	O
0	-	1040	O
.	-	1041	O
001	-	1042	O
)	-	1045	O
,	-	1046	O
total	-	1048	O
body	-	1054	O
oxygen	-	1059	O
consumption	-	1066	O
(	-	1078	O
p	-	1079	O
less	-	1081	O
than	-	1086	O
0	-	1091	O
.	-	1092	O
05	-	1093	O
)	-	1095	O
,	-	1096	O
and	-	1098	O
heart	-	1102	O
rate	-	1108	O
(	-	1113	O
p	-	1114	O
less	-	1116	O
than	-	1121	O
0	-	1126	O
.	-	1127	O
001	-	1128	O
)	-	1131	O
;	-	1132	O
all	-	1134	O
these	-	1138	O
variables	-	1144	O
returned	-	1154	O
normal	-	1163	O
within	-	1170	O
30	-	1177	O
min	-	1180	O
after	-	1184	O
ATP	-	1190	O
was	-	1194	O
stopped	-	1198	O
.	-	1205	O

Cardiac	7147232	1207	O
output	-	1215	O
did	-	1222	O
not	-	1226	O
change	-	1230	O
.	-	1236	O

During	7147232	1238	O
hypotension	-	1245	B
produced	-	1257	O
by	-	1266	O
SNP	-	1269	O
similar	-	1273	O
decreases	-	1281	O
were	-	1291	O
observed	-	1296	O
in	-	1305	O
mean	-	1308	O
pulmonary	-	1313	O
arterial	-	1323	O
pressure	-	1332	O
(	-	1341	O
p	-	1342	O
less	-	1344	O
than	-	1349	O
0	-	1354	O
.	-	1355	O
01	-	1356	O
)	-	1358	O
,	-	1359	O
central	-	1361	O
venous	-	1369	O
pressure	-	1376	O
(	-	1385	O
p	-	1386	O
less	-	1388	O
than	-	1393	O
0	-	1398	O
.	-	1399	O
001	-	1400	O
)	-	1403	O
,	-	1404	O
left	-	1406	O
ventricular	-	1411	O
end	-	1423	O
-	-	1426	O
diastolic	-	1427	O
pressure	-	1437	O
(	-	1446	O
p	-	1447	O
less	-	1449	O
than	-	1454	O
0	-	1459	O
.	-	1460	O
01	-	1461	O
)	-	1463	O
,	-	1464	O
total	-	1466	O
peripheral	-	1472	O
resistance	-	1483	O
(	-	1494	O
p	-	1495	O
less	-	1497	O
than	-	1502	O
0	-	1507	O
.	-	1508	O
001	-	1509	O
)	-	1512	O
,	-	1513	O
rate	-	1515	O
pressure	-	1520	O
product	-	1529	O
(	-	1537	O
p	-	1538	O
less	-	1540	O
than	-	1545	O
0	-	1550	O
.	-	1551	O
001	-	1552	O
)	-	1555	O
,	-	1556	O
and	-	1558	O
oxygen	-	1562	O
content	-	1569	O
difference	-	1577	O
between	-	1588	O
arterial	-	1596	O
and	-	1605	O
mixed	-	1609	O
venous	-	1615	O
blood	-	1622	O
(	-	1628	O
p	-	1629	O
less	-	1631	O
than	-	1636	O
0	-	1641	O
.	-	1642	O
05	-	1643	O
)	-	1645	O
,	-	1646	O
while	-	1648	O
heart	-	1654	O
rate	-	1660	O
(	-	1665	O
p	-	1666	O
less	-	1668	O
than	-	1673	O
0	-	1678	O
.	-	1679	O
001	-	1680	O
)	-	1683	O
and	-	1685	O
cardiac	-	1689	O
output	-	1697	O
(	-	1704	O
p	-	1705	O
less	-	1707	O
than	-	1712	O
0	-	1717	O
.	-	1718	O
05	-	1719	O
)	-	1721	O
were	-	1723	O
increased	-	1728	O
.	-	1737	O

Recoveries	7147232	1739	O
of	-	1750	O
heart	-	1753	O
rate	-	1759	O
and	-	1764	O
left	-	1768	O
ventricular	-	1773	O
end	-	1785	O
-	-	1788	O
diastolic	-	1789	O
pressure	-	1799	O
were	-	1808	O
not	-	1813	O
shown	-	1817	O
within	-	1823	O
60	-	1830	O
min	-	1833	O
after	-	1837	O
SNP	-	1843	O
had	-	1847	O
been	-	1851	O
stopped	-	1856	O
.	-	1863	O

Both	7147232	1865	O
ATP	-	1870	O
and	-	1874	O
SNP	-	1878	O
should	-	1882	O
act	-	1889	O
on	-	1893	O
the	-	1896	O
pacemaker	-	1900	O
tissue	-	1910	O
of	-	1917	O
the	-	1920	O
heart	-	1924	O
.	-	1929	O

Comparative	7173007	0	O
study	-	12	O
:	-	17	O
Endografine	-	19	O
(	-	31	O
diatrizoate	-	32	O
)	-	43	O
,	-	44	O
Vasurix	-	46	O
polyvidone	-	54	O
(	-	65	O
acetrizoate	-	66	O
)	-	77	O
,	-	78	O
Dimer	-	80	O
-	-	85	O
X	-	86	O
(	-	88	O
iocarmate	-	89	O
)	-	98	O
and	-	100	O
Hexabrix	-	104	O
(	-	113	O
ioxaglate	-	114	O
)	-	123	O
in	-	125	O
hysterosalpingography	-	128	O
.	-	149	O

Side	7173007	151	O
effects	-	156	O
of	-	164	O
hysterosalpingography	-	167	O
with	-	189	O
Dimer	-	194	O
-	-	199	O
X	-	200	O
,	-	201	O
Hexabrix	-	203	O
,	-	211	O
Vasurix	-	213	O
polyvidone	-	221	O
and	-	232	O
Endografine	-	236	O
in	-	248	O
142	-	251	O
consecutive	-	255	O
patients	-	267	O
,	-	275	O
receiving	-	277	O
one	-	287	O
of	-	291	O
the	-	294	O
four	-	298	O
tested	-	303	O
media	-	310	O
were	-	316	O
evaluated	-	321	O
from	-	331	O
replies	-	336	O
to	-	344	O
postal	-	347	O
questionnaires	-	354	O
.	-	368	O

The	7173007	370	O
Dimer	-	374	O
-	-	379	O
X	-	380	O
group	-	382	O
had	-	388	O
a	-	392	O
higher	-	394	O
incidence	-	401	O
of	-	411	O
nausea	-	414	B
and	-	421	O
dizziness	-	425	B
.	-	434	O

The	7173007	436	O
Endografine	-	440	O
group	-	452	O
had	-	458	O
a	-	462	O
higher	-	464	O
incidence	-	471	O
of	-	481	O
abdominal	-	484	B
pain	-	494	I
.	-	498	O

These	7173007	500	O
differences	-	506	O
occur	-	518	O
especially	-	524	O
in	-	535	O
the	-	538	O
age	-	542	O
groups	-	546	O
under	-	553	O
30	-	559	O
years	-	562	O
.	-	567	O

Hexabrix	7173007	569	O
and	-	578	O
Vasurix	-	582	O
polyvidone	-	590	O
are	-	601	O
considered	-	605	O
the	-	616	O
best	-	620	O
contrast	-	625	O
media	-	634	O
for	-	640	O
hysterosalpingography	-	644	O
and	-	666	O
perhaps	-	670	O
because	-	678	O
of	-	686	O
its	-	689	O
low	-	693	O
toxicity	-	697	B
Hexabrix	-	706	O
should	-	715	O
be	-	722	O
preferred	-	725	O
.	-	734	O

Post	7176945	0	O
-	-	4	O
suxamethonium	-	5	O
pains	-	19	B
in	-	25	O
Nigerian	-	28	O
surgical	-	37	O
patients	-	46	O
.	-	54	O

Contrary	7176945	56	O
to	-	65	O
an	-	68	O
earlier	-	71	O
report	-	79	O
by	-	86	O
Coxon	-	89	O
,	-	94	O
scoline	-	96	O
pain	-	104	B
occurs	-	109	O
in	-	116	O
African	-	119	O
negroes	-	127	O
.	-	134	O

Its	7176945	136	O
incidence	-	140	O
was	-	150	O
determined	-	154	O
in	-	165	O
a	-	168	O
prospective	-	170	O
study	-	182	O
involving	-	188	O
a	-	198	O
total	-	200	O
of	-	206	O
100	-	209	O
Nigerian	-	213	O
patients	-	222	O
(	-	231	O
50	-	232	O
out	-	235	O
-	-	238	O
patients	-	239	O
and	-	248	O
50	-	252	O
in	-	255	O
-	-	257	O
patients	-	258	O
)	-	266	O
.	-	267	O

About	7176945	269	O
62	-	275	O
%	-	277	O
of	-	279	O
the	-	282	O
out	-	286	O
-	-	289	O
patients	-	290	O
developed	-	299	O
scoline	-	309	O
pain	-	317	B
as	-	322	O
compared	-	325	O
with	-	334	O
about	-	339	O
26	-	345	O
%	-	347	O
among	-	349	O
the	-	355	O
in	-	359	O
-	-	361	O
patients	-	362	O
.	-	370	O

The	7176945	372	O
abolition	-	376	O
of	-	386	O
muscle	-	389	O
fasciculations	-	396	B
(	-	411	O
by	-	412	O
0	-	415	O
.	-	416	O
075mg	-	417	O
/	-	422	O
kg	-	423	O
dose	-	426	O
of	-	431	O
Fazadinium	-	434	O
)	-	444	O
did	-	446	O
not	-	450	O
influence	-	454	O
the	-	464	O
occurrence	-	468	O
of	-	479	O
scoline	-	482	O
pain	-	490	B
.	-	494	O

Neither	7176945	496	O
the	-	504	O
type	-	508	O
of	-	513	O
induction	-	516	O
agent	-	526	O
(	-	532	O
Althesin	-	533	O
or	-	542	O
Thiopentone	-	545	O
)	-	556	O
nor	-	558	O
the	-	562	O
salt	-	566	O
preparation	-	571	O
of	-	583	O
suxamethonium	-	586	O
used	-	600	O
(	-	605	O
chloride	-	606	O
or	-	615	O
bromide	-	618	O
)	-	625	O
,	-	626	O
affected	-	628	O
the	-	637	O
incidence	-	641	O
of	-	651	O
scoline	-	654	O
pain	-	662	B
.	-	666	O

Medial	7315949	0	O
changes	-	7	O
in	-	15	O
arterial	-	18	O
spasm	-	27	B
induced	-	33	O
by	-	41	O
L	-	44	O
-	-	45	O
norepinephrine	-	46	O
.	-	60	O

In	7315949	62	O
normal	-	65	O
rats	-	72	O
,	-	76	O
the	-	78	O
media	-	82	O
of	-	88	O
small	-	91	O
arteries	-	97	O
(	-	106	O
0	-	107	O
.	-	108	O
4	-	109	O
-	-	110	O
-	-	111	O
0	-	112	O
.	-	113	O
2	-	114	O
mm	-	116	O
in	-	119	O
diameter	-	122	O
)	-	130	O
previously	-	132	O
was	-	143	O
shown	-	147	O
to	-	153	O
contain	-	156	O
intracellular	-	164	O
vacuoles	-	178	O
,	-	186	O
identified	-	188	O
ultrastructurally	-	199	O
as	-	217	O
herniations	-	220	O
of	-	232	O
one	-	235	O
smooth	-	239	O
muscle	-	246	O
cell	-	253	O
into	-	258	O
another	-	263	O
.	-	270	O

The	7315949	272	O
hypothesis	-	276	O
that	-	287	O
intense	-	292	O
vasoconstriction	-	300	O
would	-	317	O
increase	-	323	O
the	-	332	O
number	-	336	O
of	-	343	O
such	-	346	O
vacuoles	-	351	O
has	-	360	O
been	-	364	O
tested	-	369	O
.	-	375	O

In	7315949	377	O
the	-	380	O
media	-	384	O
of	-	390	O
the	-	393	O
saphenous	-	397	O
artery	-	407	O
and	-	414	O
its	-	418	O
distal	-	422	O
branch	-	429	O
,	-	435	O
vasoconstriction	-	437	O
induced	-	454	O
by	-	462	O
L	-	465	O
-	-	466	O
norepinephrine	-	467	O
produced	-	482	O
many	-	491	O
cell	-	496	O
-	-	500	O
to	-	501	O
-	-	503	O
cell	-	504	O
hernias	-	509	B
within	-	517	O
15	-	524	O
minutes	-	527	O
.	-	534	O

At	7315949	536	O
1	-	539	O
day	-	541	O
their	-	545	O
number	-	551	O
was	-	558	O
reduced	-	562	O
to	-	570	O
about	-	573	O
1	-	579	O
/	-	580	O
10	-	581	O
of	-	584	O
the	-	587	O
original	-	591	O
number	-	600	O
.	-	606	O

By	7315949	608	O
7	-	611	O
days	-	613	O
the	-	618	O
vessel	-	622	O
was	-	629	O
almost	-	633	O
restored	-	640	O
to	-	649	O
normal	-	652	O
.	-	658	O

Triple	7315949	660	O
stimulation	-	667	O
over	-	679	O
1	-	684	O
day	-	686	O
induced	-	690	O
more	-	698	O
severe	-	703	O
changes	-	710	O
in	-	718	O
the	-	721	O
media	-	725	O
.	-	730	O

These	7315949	732	O
findings	-	738	O
suggest	-	747	O
that	-	755	O
smooth	-	760	O
muscle	-	767	O
cells	-	774	O
are	-	780	O
susceptible	-	784	O
to	-	796	O
damage	-	799	O
in	-	806	O
the	-	809	O
course	-	813	O
of	-	820	O
their	-	823	O
specific	-	829	O
function	-	838	O
.	-	846	O

The	7315949	848	O
experimental	-	852	O
data	-	865	O
are	-	870	O
discussed	-	874	O
in	-	884	O
relation	-	887	O
to	-	896	O
medial	-	899	O
changes	-	906	O
observed	-	914	O
in	-	923	O
other	-	926	O
instances	-	932	O
of	-	942	O
arterial	-	945	O
spasm	-	954	B
.	-	959	O

Endothelial	7315949	961	O
changes	-	973	O
that	-	981	O
developed	-	986	O
in	-	996	O
the	-	999	O
same	-	1003	O
experimental	-	1008	O
model	-	1021	O
were	-	1027	O
described	-	1032	O
in	-	1042	O
a	-	1045	O
previous	-	1047	O
paper	-	1056	O
.	-	1061	O

Abnormalities	7369302	0	O
of	-	14	O
the	-	17	O
pupil	-	21	O
and	-	27	O
visual	-	31	O
-	-	37	O
evoked	-	38	O
potential	-	45	O
in	-	55	O
quinine	-	58	O
amblyopia	-	66	B
.	-	75	O

Total	7369302	77	O
blindness	-	83	B
with	-	93	O
a	-	98	O
transient	-	100	O
tonic	-	110	B
pupillary	-	116	I
response	-	126	O
,	-	134	O
denervation	-	136	O
supersensitivity	-	148	O
,	-	164	O
and	-	166	O
abnormal	-	170	O
visual	-	179	O
-	-	185	O
evoked	-	186	O
potentials	-	193	O
developed	-	204	O
in	-	214	O
a	-	217	O
54	-	219	O
-	-	221	O
year	-	222	O
-	-	226	O
old	-	227	O
man	-	231	O
after	-	235	O
the	-	241	O
use	-	245	O
of	-	249	O
quinine	-	252	O
sulfate	-	260	O
for	-	268	O
leg	-	272	B
cramps	-	276	I
.	-	282	O

He	7369302	284	O
later	-	287	O
recovered	-	293	O
normal	-	303	O
visual	-	310	O
acuity	-	317	O
.	-	323	O

A	7369302	325	O
transient	-	327	O
tonic	-	337	B
pupillary	-	343	I
response	-	353	O
,	-	361	O
denervation	-	363	O
supersensitivity	-	375	O
,	-	391	O
and	-	393	O
abnormal	-	397	O
visual	-	406	O
-	-	412	O
evoked	-	413	O
potentials	-	420	O
in	-	431	O
quinine	-	434	O
toxicity	-	442	B
,	-	450	O
to	-	452	O
our	-	455	O
knowledge	-	459	O
,	-	468	O
have	-	470	O
not	-	475	O
been	-	479	O
previously	-	484	O
reported	-	495	O
.	-	503	O

Suxamethonium	7378868	0	O
-	-	13	O
induced	-	14	O
jaw	-	22	B
stiffness	-	26	I
and	-	36	O
myalgia	-	40	B
associated	-	48	O
with	-	59	O
atypical	-	64	O
cholinesterase	-	73	O
:	-	87	O
case	-	89	O
report	-	94	O
.	-	100	O

An	7378868	102	O
11	-	105	O
-	-	107	O
year	-	108	O
-	-	112	O
old	-	113	O
boy	-	117	O
was	-	121	O
given	-	125	O
halothane	-	131	O
,	-	140	O
nitrous	-	142	O
oxide	-	150	O
and	-	156	O
oxygen	-	160	O
,	-	166	O
pancuronium	-	168	O
0	-	180	O
.	-	181	O
4	-	182	O
mg	-	184	O
and	-	187	O
suxamethonium	-	191	O
100	-	205	O
mg	-	209	O
for	-	212	O
induction	-	216	O
of	-	226	O
anaesthesia	-	229	O
.	-	240	O

In	7378868	242	O
response	-	245	O
to	-	254	O
this	-	257	O
a	-	262	O
marked	-	264	O
jaw	-	271	B
stiffness	-	275	I
occurred	-	285	O
which	-	294	O
lasted	-	300	O
for	-	307	O
two	-	311	O
minutes	-	315	O
and	-	323	O
the	-	327	O
anaesthesia	-	331	O
were	-	343	O
terminated	-	348	O
.	-	358	O

Four	7378868	360	O
hours	-	365	O
of	-	371	O
apnoea	-	374	B
ensued	-	381	O
and	-	388	O
he	-	392	O
suffered	-	395	O
generalized	-	404	O
severe	-	416	O
myalgia	-	423	B
lasting	-	431	O
for	-	439	O
one	-	443	O
week	-	447	O
.	-	451	O

He	7378868	453	O
was	-	456	O
found	-	460	O
to	-	466	O
have	-	469	O
atypical	-	474	O
plasma	-	483	O
cholinesterase	-	490	O
with	-	505	O
a	-	510	O
dibucaine	-	512	O
number	-	522	O
of	-	529	O
12	-	532	O
,	-	534	O
indicating	-	536	O
homozygocity	-	547	O
.	-	559	O

This	7378868	561	O
was	-	566	O
verified	-	570	O
by	-	579	O
study	-	582	O
of	-	588	O
the	-	591	O
family	-	595	O
.	-	601	O

The	7378868	603	O
case	-	607	O
shows	-	612	O
that	-	618	O
prolonged	-	623	B
jaw	-	633	I
rigidity	-	637	I
and	-	646	O
myalgia	-	650	B
may	-	658	O
occur	-	662	O
after	-	668	O
suxamethonium	-	674	O
in	-	688	O
patients	-	691	O
with	-	700	O
atypical	-	705	O
cholinesterase	-	714	O
despite	-	729	O
pretreatment	-	737	O
with	-	750	O
pancuronium	-	755	O
.	-	766	O

Indomethacin	7411769	0	O
-	-	12	O
induced	-	13	O
hyperkalemia	-	21	B
in	-	34	O
three	-	37	O
patients	-	43	O
with	-	52	O
gouty	-	57	B
arthritis	-	63	I
.	-	72	O

We	7411769	74	O
describe	-	77	O
three	-	86	O
patients	-	92	O
in	-	101	O
whom	-	104	O
severe	-	109	O
,	-	115	O
life	-	117	O
-	-	121	O
threatening	-	122	O
hyperkalemia	-	134	B
and	-	147	O
renal	-	151	B
insufficiency	-	157	I
developed	-	171	O
after	-	181	O
treatment	-	187	O
of	-	197	O
acute	-	200	O
gouty	-	206	B
arthritis	-	212	I
with	-	222	O
indomethacin	-	227	O
.	-	239	O

This	7411769	241	O
complication	-	246	O
may	-	259	O
result	-	263	O
from	-	270	O
an	-	275	O
inhibition	-	278	O
of	-	289	O
prostaglandin	-	292	O
synthesis	-	306	O
and	-	316	O
consequent	-	320	O
hyporeninemic	-	331	B
hypoaidosteronism	-	345	I
.	-	362	O

Careful	7411769	364	O
attention	-	372	O
to	-	382	O
renal	-	385	O
function	-	391	O
and	-	400	O
potassium	-	404	O
balance	-	414	O
in	-	422	O
patients	-	425	O
receiving	-	434	O
indomethacin	-	444	O
or	-	457	O
other	-	460	O
nonsteroidal	-	466	O
anti	-	479	O
-	-	483	O
inflammatory	-	484	O
agents	-	497	O
,	-	503	O
particularly	-	505	O
in	-	518	O
those	-	521	O
patients	-	527	O
with	-	536	O
diabetes	-	541	B
mellitus	-	550	I
or	-	559	O
preexisting	-	562	O
renal	-	574	B
disease	-	580	I
,	-	587	O
will	-	589	O
help	-	594	O
prevent	-	599	O
this	-	607	O
potentially	-	612	O
serious	-	624	O
complication	-	632	O
.	-	644	O

Etomidate	7457821	0	O
:	-	9	O
a	-	11	O
foreshortened	-	13	O
clinical	-	27	O
trial	-	36	O
.	-	41	O

A	7457821	43	O
clinical	-	45	O
evaluation	-	54	O
of	-	65	O
etomidate	-	68	O
for	-	78	O
outpatient	-	82	O
cystoscopy	-	93	O
was	-	104	O
embarked	-	108	O
upon	-	117	O
.	-	121	O

Unpremedicated	7457821	123	O
patients	-	138	O
were	-	147	O
given	-	152	O
fentanyl	-	158	O
1	-	167	O
microgram	-	169	O
/	-	178	O
kg	-	179	O
followed	-	182	O
by	-	191	O
etomidate	-	194	O
0	-	204	O
.	-	205	O
3	-	206	O
mg	-	208	O
/	-	210	O
kg	-	211	O
.	-	213	O

Anaesthesia	7457821	215	O
was	-	227	O
maintained	-	231	O
with	-	242	O
intermittent	-	247	O
etomidate	-	260	O
in	-	270	O
2	-	273	O
-	-	274	O
4	-	275	O
mg	-	277	O
doses	-	280	O
.	-	285	O

Patients	7457821	287	O
were	-	296	O
interviewed	-	301	O
personally	-	313	O
later	-	324	O
the	-	330	O
same	-	334	O
day	-	339	O
,	-	342	O
and	-	344	O
by	-	348	O
questionnaire	-	351	O
three	-	365	O
to	-	371	O
four	-	374	O
weeks	-	379	O
later	-	385	O
.	-	390	O

The	7457821	392	O
trial	-	396	O
was	-	402	O
discontinued	-	406	O
after	-	419	O
20	-	425	O
cases	-	428	O
because	-	434	O
of	-	442	O
an	-	445	O
unacceptable	-	448	O
incidence	-	461	O
of	-	471	O
side	-	474	O
effects	-	479	O
.	-	486	O

Venous	7457821	488	O
pain	-	495	B
occurred	-	500	O
in	-	509	O
68	-	512	O
%	-	514	O
of	-	516	O
patients	-	519	O
and	-	528	O
50	-	532	O
%	-	534	O
had	-	536	O
redness	-	540	O
,	-	547	O
pain	-	549	B
or	-	554	O
swelling	-	557	B
related	-	566	O
to	-	574	O
the	-	577	O
injection	-	581	O
site	-	591	O
,	-	595	O
in	-	597	O
some	-	600	O
cases	-	605	O
lasting	-	611	O
up	-	619	O
to	-	622	O
three	-	625	O
weeks	-	631	O
after	-	637	O
anaesthesia	-	643	O
.	-	654	O

Skeletal	7457821	656	O
movements	-	665	O
occurred	-	675	O
in	-	684	O
50	-	687	O
%	-	689	O
of	-	691	O
patients	-	694	O
;	-	702	O
30	-	704	O
%	-	706	O
experienced	-	708	O
respiratory	-	720	B
upset	-	732	I
,	-	737	O
one	-	739	O
sufficiently	-	743	O
severe	-	756	O
to	-	763	O
necessitate	-	766	O
abandoning	-	778	O
the	-	789	O
technique	-	793	O
.	-	802	O

Nausea	7457821	804	B
and	-	811	O
vomiting	-	815	B
occurred	-	824	O
in	-	833	O
40	-	836	O
%	-	838	O
and	-	840	O
25	-	844	O
%	-	846	O
had	-	848	O
disturbing	-	852	O
emergence	-	863	O
psychoses	-	873	B
.	-	882	O

Levodopa	7477981	0	O
-	-	8	O
induced	-	9	O
dyskinesias	-	17	B
are	-	29	O
improved	-	33	O
by	-	42	O
fluoxetine	-	45	O
.	-	55	O

We	7477981	57	O
evaluated	-	60	O
the	-	70	O
severity	-	74	O
of	-	83	O
motor	-	86	B
disability	-	92	I
and	-	103	O
dyskinesias	-	107	B
in	-	119	O
seven	-	122	O
levodopa	-	128	O
-	-	136	O
responsive	-	137	O
patients	-	148	O
with	-	157	O
Parkinson	-	162	B
's	-	171	I
disease	-	174	I
after	-	182	O
an	-	188	O
acute	-	191	O
challenge	-	197	O
with	-	207	O
the	-	212	O
mixed	-	216	O
dopamine	-	222	O
agonist	-	231	O
,	-	238	O
apomorphine	-	240	O
,	-	251	O
before	-	253	O
and	-	260	O
after	-	264	O
the	-	270	O
administration	-	274	O
of	-	289	O
fluoxetine	-	292	O
(	-	303	O
20	-	304	O
mg	-	307	O
twice	-	310	O
per	-	316	O
day	-	320	O
)	-	323	O
for	-	325	O
11	-	329	O
+	-	332	O
/	-	333	O
-	-	334	O

1	7477981	336	O
days	-	338	O
.	-	342	O

After	7477981	344	O
fluoxetine	-	350	O
treatment	-	361	O
,	-	370	O
there	-	372	O
was	-	378	O
a	-	382	O
significant	-	384	O
47	-	396	O
%	-	398	O
improvement	-	400	O
(	-	412	O
p	-	413	O
<	-	415	O
0	-	417	O
.	-	418	O
05	-	419	O
)	-	421	O
of	-	423	O
apomorphine	-	426	O
-	-	437	O
induced	-	438	O
dyskinesias	-	446	B
without	-	458	O
modification	-	466	O
of	-	479	O
parkinsonian	-	482	B
motor	-	495	B
disability	-	501	I
.	-	511	O

The	7477981	513	O
dyskinesias	-	517	B
were	-	529	O
reduced	-	534	O
predominantly	-	542	O
in	-	556	O
the	-	559	O
lower	-	563	O
limbs	-	569	O
during	-	575	O
the	-	582	O
onset	-	586	O
and	-	592	O
disappearance	-	596	O
of	-	610	O
dystonic	-	613	B
dyskinesias	-	622	I
(	-	634	O
onset	-	635	O
-	-	640	O
and	-	642	O
end	-	646	O
-	-	649	O
of	-	650	O
-	-	652	O
dose	-	653	O
dyskinesias	-	658	B
)	-	669	O
and	-	671	O
in	-	675	O
the	-	678	O
upper	-	682	O
limbs	-	688	O
during	-	694	O
choreic	-	701	B
mid	-	709	I
-	-	712	I
dose	-	713	I
dyskinesias	-	718	I
.	-	729	O

The	7477981	731	O
results	-	735	O
suggest	-	743	O
that	-	751	O
increased	-	756	O
brain	-	766	O
serotoninergic	-	772	O
transmission	-	787	O
with	-	800	O
fluoxetine	-	805	O
may	-	816	O
reduce	-	820	O
levodopa	-	827	O
-	-	835	O
or	-	837	O
dopamine	-	840	O
agonist	-	849	O
-	-	856	O
induced	-	857	O
dyskinesias	-	865	B
without	-	877	O
aggravating	-	885	O
parkinsonian	-	897	B
motor	-	910	B
disability	-	916	I
.	-	926	O

A	7479194	0	O
large	-	2	O
population	-	8	O
-	-	18	O
based	-	19	O
follow	-	25	O
-	-	31	O
up	-	32	O
study	-	35	O
of	-	41	O
trimethoprim	-	44	O
-	-	56	O
sulfamethoxazole	-	57	O
,	-	73	O
trimethoprim	-	75	O
,	-	87	O
and	-	89	O
cephalexin	-	93	O
for	-	104	O
uncommon	-	108	O
serious	-	117	O
drug	-	125	B
toxicity	-	130	I
.	-	138	O

We	7479194	140	O
conducted	-	143	O
a	-	153	O
population	-	155	O
-	-	165	O
based	-	166	O
45	-	172	O
-	-	174	O
day	-	175	O
follow	-	179	O
-	-	185	O
up	-	186	O
study	-	189	O
of	-	195	O
232	-	198	O
,	-	201	O
390	-	202	O
people	-	206	O
who	-	213	O
were	-	217	O
prescribed	-	222	O
trimethoprim	-	233	O
-	-	245	O
sulfamethoxazole	-	246	O
(	-	263	O
TMP	-	264	O
-	-	267	O
SMZ	-	268	O
)	-	271	O
,	-	272	O
266	-	274	O
,	-	277	O
951	-	278	O
prescribed	-	282	O
trimethoprim	-	293	O
alone	-	306	O
,	-	311	O
and	-	313	O
196	-	317	O
,	-	320	O
397	-	321	O
prescribed	-	325	O
cephalexin	-	336	O
,	-	346	O
to	-	348	O
estimate	-	351	O
the	-	360	O
risk	-	364	O
of	-	369	O
serious	-	372	O
liver	-	380	B
,	-	385	I
blood	-	387	I
,	-	392	I
skin	-	394	I
,	-	398	I
and	-	400	I
renal	-	404	I
disorders	-	410	I
resulting	-	420	O
in	-	430	O
referral	-	433	O
or	-	442	O
hospitalization	-	445	O
associated	-	461	O
with	-	472	O
these	-	477	O
drugs	-	483	O
.	-	488	O

The	7479194	490	O
results	-	494	O
were	-	502	O
based	-	507	O
on	-	513	O
information	-	516	O
recorded	-	528	O
on	-	537	O
office	-	540	O
computers	-	547	O
by	-	557	O
selected	-	560	O
general	-	569	O
practitioners	-	577	O
in	-	591	O
the	-	594	O
United	-	598	O
Kingdom	-	605	O
,	-	612	O
together	-	614	O
with	-	623	O
a	-	628	O
review	-	630	O
of	-	637	O
clinical	-	640	O
records	-	649	O
.	-	656	O

The	7479194	658	O
risk	-	662	O
of	-	667	O
clinically	-	670	O
important	-	681	O
idiopathic	-	691	O
liver	-	702	B
disease	-	708	I
was	-	716	O
similar	-	720	O
for	-	728	O
persons	-	732	O
prescribed	-	740	O
TMP	-	751	O
-	-	754	O
SMZ	-	755	O
(	-	759	O
5	-	760	O
.	-	761	O
2	-	762	O
/	-	763	O
100	-	764	O
,	-	767	O
000	-	768	O
)	-	771	O
and	-	773	O
those	-	777	O
prescribed	-	783	O
trimethoprim	-	794	O
alone	-	807	O
(	-	813	O
3	-	814	O
.	-	815	O
8	-	816	O
/	-	817	O
100	-	818	O
,	-	821	O
000	-	822	O
)	-	825	O
.	-	826	O

The	7479194	828	O
risk	-	832	O
for	-	837	O
those	-	841	O
prescribed	-	847	O
cephalexin	-	858	O
was	-	869	O
somewhat	-	873	O
lower	-	882	O
(	-	888	O
2	-	889	O
.	-	890	O
0	-	891	O
/	-	892	O
100	-	893	O
,	-	896	O
000	-	897	O
)	-	900	O
.	-	901	O

Only	7479194	903	O
five	-	908	O
patients	-	913	O
experienced	-	922	O
blood	-	934	O
disorders	-	940	O
,	-	949	O
one	-	951	O
of	-	955	O
whom	-	958	O
was	-	963	O
exposed	-	967	O
to	-	975	O
TMP	-	978	O
-	-	981	O
SMZ	-	982	O
;	-	985	O
of	-	987	O
seven	-	990	O
with	-	996	O
erythema	-	1001	B
multiforme	-	1010	I
and	-	1021	O
Stevens	-	1025	B
-	-	1032	I
Johnson	-	1033	I
syndrome	-	1041	I
,	-	1049	O
four	-	1051	O
were	-	1056	O
exposed	-	1061	O
to	-	1069	O
TMP	-	1072	O
-	-	1075	O
SMZ	-	1076	O
.	-	1079	O

The	7479194	1081	O
one	-	1085	O
case	-	1089	O
of	-	1094	O
toxic	-	1097	B
epidermal	-	1103	I
necrolysis	-	1113	I
occurred	-	1124	O
in	-	1133	O
a	-	1136	O
patient	-	1138	O
who	-	1146	O
took	-	1150	O
cephalexin	-	1155	O
.	-	1165	O

Finally	7479194	1167	O
,	-	1174	O
only	-	1176	O
five	-	1181	O
cases	-	1186	O
of	-	1192	O
acute	-	1195	O
parenchymal	-	1201	O
renal	-	1213	B
disease	-	1219	I
occurred	-	1227	O
,	-	1235	O
none	-	1237	O
likely	-	1242	O
to	-	1249	O
be	-	1252	O
caused	-	1255	O
by	-	1262	O
a	-	1265	O
study	-	1267	O
drug	-	1273	O
.	-	1277	O

We	7479194	1279	O
conclude	-	1282	O
that	-	1291	O
the	-	1296	O
risk	-	1300	O
of	-	1305	O
the	-	1308	O
serious	-	1312	O
diseases	-	1320	O
studied	-	1329	O
is	-	1337	O
small	-	1340	O
for	-	1346	O
the	-	1350	O
three	-	1354	O
agents	-	1360	O
,	-	1366	O
and	-	1368	O
compares	-	1372	O
reasonably	-	1381	O
with	-	1392	O
the	-	1397	O
risk	-	1401	O
for	-	1406	O
many	-	1410	O
other	-	1415	O
antibiotics	-	1421	O
.	-	1432	O

Clinical	7492040	0	O
safety	-	9	O
of	-	16	O
lidocaine	-	19	O
in	-	29	O
patients	-	32	O
with	-	41	O
cocaine	-	46	O
-	-	53	O
associated	-	54	O
myocardial	-	65	B
infarction	-	76	I
.	-	86	O

STUDY	7492040	88	O
OBJECTIVE	-	94	O
:	-	103	O

To	7492040	105	O
evaluate	-	108	O
the	-	117	O
safety	-	121	O
of	-	128	O
lidocaine	-	131	O
in	-	141	O
the	-	144	O
setting	-	148	O
of	-	156	O
cocaine	-	159	O
-	-	166	O
induced	-	167	O
myocardial	-	175	B
infarction	-	186	I
(	-	197	O
MI	-	198	B
)	-	200	O
.	-	201	O

DESIGN	7492040	203	O
:	-	209	O

A	7492040	211	O
retrospective	-	213	O
,	-	226	O
multicenter	-	228	O
study	-	240	O
.	-	245	O

SETTING	7492040	247	O
:	-	254	O

Twenty	7492040	256	O
-	-	262	O
nine	-	263	O
university	-	268	O
,	-	278	O
university	-	280	O
-	-	290	O
affiliated	-	291	O
,	-	301	O
or	-	303	O
community	-	306	O
hospitals	-	316	O
during	-	326	O
a	-	333	O
6	-	335	O
-	-	336	O
year	-	337	O
period	-	342	O
(	-	349	O
total	-	350	O
of	-	356	O
117	-	359	O
cumulative	-	363	O
hospital	-	374	O
-	-	382	O
years	-	383	O
)	-	388	O
.	-	389	O

PARTICIPANTS	7492040	391	O
:	-	403	O
Patients	-	405	O
with	-	414	O
cocaine	-	419	O
-	-	426	O
associated	-	427	O
MI	-	438	B
who	-	441	O
received	-	445	O
lidocaine	-	454	O
in	-	464	O
the	-	467	O
emergency	-	471	O
department	-	481	O
.	-	491	O

RESULTS	7492040	493	O
:	-	500	O

Of	7492040	502	O
29	-	505	O
patients	-	508	O
who	-	517	O
received	-	521	O
lidocaine	-	530	O
in	-	540	O
the	-	543	O
setting	-	547	O
of	-	555	O
cocaine	-	558	O
-	-	565	O
associated	-	566	O
MI	-	577	B
,	-	579	O
no	-	581	O
patient	-	584	O
died	-	592	O
;	-	596	O
exhibited	-	598	O
bradydysrhythmias	-	608	B
,	-	625	O
ventricular	-	627	B
tachycardia	-	639	I
,	-	650	O
or	-	652	O
ventricular	-	655	B
fibrillation	-	667	I
;	-	679	O
or	-	681	O
experienced	-	684	O
seizures	-	696	B
after	-	705	O
administration	-	711	O
of	-	726	O
lidocaine	-	729	O
(	-	739	O
95	-	740	O
%	-	742	O
confidence	-	744	O
interval	-	755	O
,	-	763	O
0	-	765	O
%	-	766	O
to	-	768	O
11	-	771	O
%	-	773	O
)	-	774	O
.	-	775	O

CONCLUSION	7492040	777	O
:	-	787	O

Despite	7492040	789	O
theoretical	-	797	O
concerns	-	809	O
that	-	818	O
lidocaine	-	823	O
may	-	833	O
enhance	-	837	O
cocaine	-	845	O
toxicity	-	853	B
,	-	861	O
the	-	863	O
use	-	867	O
of	-	871	O
lidocaine	-	874	O
in	-	884	O
patients	-	887	O
with	-	896	O
cocaine	-	901	O
-	-	908	O
associated	-	909	O
MI	-	920	B
was	-	923	O
not	-	927	O
associated	-	931	O
with	-	942	O
significant	-	947	O
cardiovascular	-	959	B
or	-	974	I
central	-	977	I
nervous	-	985	I
system	-	993	I
toxicity	-	1000	I
.	-	1008	O

Paclitaxel	7644931	0	O
3	-	11	O
-	-	12	O
hour	-	13	O
infusion	-	18	O
given	-	27	O
alone	-	33	O
and	-	39	O
combined	-	43	O
with	-	52	O
carboplatin	-	57	O
:	-	68	O
preliminary	-	70	O
results	-	82	O
of	-	90	O
dose	-	93	O
-	-	97	O
escalation	-	98	O
trials	-	109	O
.	-	115	O

Paclitaxel	7644931	117	O

(	7644931	128	O
Taxol	-	129	O
;	-	134	O
Bristol	-	136	O
-	-	143	O
Myers	-	144	O
Squibb	-	150	O
Company	-	157	O
,	-	164	O
Princeton	-	166	O
,	-	175	O
NJ	-	177	O
)	-	179	O
by	-	181	O
3	-	184	O
-	-	185	O
hour	-	186	O
infusion	-	191	O
was	-	200	O
combined	-	204	O
with	-	213	O
carboplatin	-	218	O
in	-	230	O
a	-	233	O
phase	-	235	O
I	-	241	O
/	-	242	O
II	-	243	O
study	-	246	O
directed	-	252	O
to	-	261	O
patients	-	264	O
with	-	273	O
non	-	278	B
-	-	281	I
small	-	282	I
cell	-	288	I
lung	-	293	I
cancer	-	298	I
.	-	304	O

Carboplatin	7644931	306	O
was	-	318	O
given	-	322	O
at	-	328	O
a	-	331	O
fixed	-	333	O
target	-	339	O
area	-	346	O
under	-	351	O
the	-	357	O
concentration	-	361	O
-	-	374	O
time	-	375	O
curve	-	380	O
of	-	386	O
6	-	389	O
.	-	390	O
0	-	391	O
by	-	393	O
the	-	396	O
Calvert	-	400	O
formula	-	408	O
,	-	415	O
whereas	-	417	O
paclitaxel	-	425	O
was	-	436	O
escalated	-	440	O
in	-	450	O
patient	-	453	O
cohorts	-	461	O
from	-	469	O
150	-	474	O
mg	-	478	O
/	-	480	O
m2	-	481	O
(	-	484	O
dose	-	485	O
level	-	490	O
I	-	496	O
)	-	497	O
to	-	499	O
175	-	502	O
,	-	505	O
200	-	507	O
,	-	510	O
225	-	512	O
,	-	515	O
and	-	517	O
250	-	521	O
mg	-	525	O
/	-	527	O
m2	-	528	O
.	-	530	O

The	7644931	532	O
225	-	536	O
mg	-	540	O
/	-	542	O
m2	-	543	O
level	-	546	O
was	-	552	O
expanded	-	556	O
for	-	565	O
the	-	569	O
phase	-	573	O
II	-	579	O
study	-	582	O
since	-	588	O
the	-	594	O
highest	-	598	O
level	-	606	O
achieved	-	612	O
(	-	621	O
250	-	622	O
mg	-	626	O
/	-	628	O
m2	-	629	O
)	-	631	O
required	-	633	O
modification	-	642	O
because	-	655	O
of	-	663	O
nonhematologic	-	666	O
toxicities	-	681	B
(	-	692	O
arthralgia	-	693	B
and	-	704	O
sensory	-	708	B
neuropathy	-	716	I
)	-	726	O
.	-	727	O

Therapeutic	7644931	729	O
effects	-	741	O
were	-	749	O
noted	-	754	O
at	-	760	O
all	-	763	O
dose	-	767	O
levels	-	772	O
,	-	778	O
with	-	780	O
objective	-	785	O
responses	-	795	O
in	-	805	O
17	-	808	O
(	-	811	O
two	-	812	O
complete	-	816	O
and	-	825	O
15	-	829	O
partial	-	832	O
regressions	-	840	O
)	-	851	O
of	-	853	O
41	-	856	O
previously	-	859	O
untreated	-	870	O
patients	-	880	O
.	-	888	O

Toxicities	7644931	890	B
were	-	901	O
compared	-	906	O
with	-	915	O
a	-	920	O
cohort	-	922	O
of	-	929	O
patients	-	932	O
in	-	941	O
a	-	944	O
phase	-	946	O
I	-	952	O
trial	-	954	O
of	-	960	O
paclitaxel	-	963	O
alone	-	974	O
at	-	980	O
identical	-	983	O
dose	-	993	O
levels	-	998	O
.	-	1004	O

Carboplatin	7644931	1006	O
did	-	1018	O
not	-	1022	O
appear	-	1026	O
to	-	1033	O
add	-	1036	O
to	-	1040	O
the	-	1043	O
hematologic	-	1047	B
toxicities	-	1059	I
observed	-	1070	O
,	-	1078	O
and	-	1080	O
the	-	1084	O
paclitaxel	-	1088	O
/	-	1098	O
carboplatin	-	1099	O
combination	-	1111	O
could	-	1123	O
be	-	1129	O
dosed	-	1132	O
every	-	1138	O
3	-	1144	O
weeks	-	1146	O
.	-	1151	O

The	7661171	0	O
dose	-	4	O
-	-	8	O
dependent	-	9	O
effect	-	19	O
of	-	26	O
misoprostol	-	29	O
on	-	41	O
indomethacin	-	44	O
-	-	56	O
induced	-	57	O
renal	-	65	B
dysfunction	-	71	I
in	-	83	O
well	-	86	O
compensated	-	91	O
cirrhosis	-	103	B
.	-	112	O

Misoprostol	7661171	114	O
(	-	126	O
200	-	127	O
micrograms	-	131	O
)	-	141	O
has	-	143	O
been	-	147	O
shown	-	152	O
to	-	158	O
acutely	-	161	O
counteract	-	169	O
the	-	180	O
indomethacin	-	184	O
-	-	196	O
induced	-	197	O
renal	-	205	B
dysfunction	-	211	I
in	-	223	O
well	-	226	O
compensated	-	231	O
cirrhotic	-	243	B
patients	-	253	O
.	-	261	O

The	7661171	263	O
aim	-	267	O
of	-	271	O
this	-	274	O
study	-	279	O
was	-	285	O
to	-	289	O
determine	-	292	O
if	-	302	O
the	-	305	O
prophylactic	-	309	O
value	-	322	O
of	-	328	O
misoprostol	-	331	O
was	-	343	O
dose	-	347	O
-	-	351	O
dependent	-	352	O
.	-	361	O

Parameters	7661171	363	O
of	-	374	O
renal	-	377	O
hemodynamics	-	383	O
and	-	396	O
tubular	-	400	O
sodium	-	408	O
and	-	415	O
water	-	419	O
handling	-	425	O
were	-	434	O
assessed	-	439	O
by	-	448	O
clearance	-	451	O
techniques	-	461	O
in	-	472	O
26	-	475	O
well	-	478	O
compensated	-	483	O
cirrhotic	-	495	B
patients	-	505	O
before	-	514	O
and	-	521	O
after	-	525	O
an	-	531	O
oral	-	534	O
combination	-	539	O
of	-	551	O
50	-	554	O
mg	-	557	O
of	-	560	O
indomethacin	-	563	O
and	-	576	O
various	-	580	O
doses	-	588	O
of	-	594	O
misoprostol	-	597	O
.	-	608	O

The	7661171	610	O
200	-	614	O
-	-	617	O
micrograms	-	618	O
dose	-	629	O
was	-	634	O
able	-	638	O
to	-	643	O
totally	-	646	O
abolish	-	654	O
the	-	662	O
deleterious	-	666	O
renal	-	678	O
effects	-	684	O
of	-	692	O
indomethacin	-	695	O
,	-	707	O
whereas	-	709	O
the	-	717	O
800	-	721	O
-	-	724	O
micrograms	-	725	O
dose	-	736	O
resulted	-	741	O
in	-	750	O
significant	-	753	O
worsening	-	765	O
of	-	775	O
renal	-	778	O
hemodynamics	-	784	O
and	-	797	O
sodium	-	801	O
retention	-	808	O
.	-	817	O

These	7661171	819	O
changes	-	825	O
were	-	833	O
maximal	-	838	O
in	-	846	O
the	-	849	O
hour	-	853	O
immediately	-	858	O
after	-	870	O
medications	-	876	O
and	-	888	O
slowly	-	892	O
returned	-	899	O
toward	-	908	O
base	-	915	O
-	-	919	O
line	-	920	O
levels	-	925	O
thereafter	-	932	O
.	-	942	O

These	7661171	944	O
results	-	950	O
suggest	-	958	O
that	-	966	O
the	-	971	O
renal	-	975	O
protective	-	981	O
effects	-	992	O
of	-	1000	O
misoprostol	-	1003	O
is	-	1015	O
dose	-	1018	O
-	-	1022	O
dependent	-	1023	O
.	-	1032	O

However	7661171	1034	O
,	-	1041	O
until	-	1043	O
this	-	1049	O
apparent	-	1054	O
ability	-	1063	O
of	-	1071	O
200	-	1074	O
micrograms	-	1078	O
of	-	1089	O
misoprostol	-	1092	O
to	-	1104	O
prevent	-	1107	O
the	-	1115	O
adverse	-	1119	O
effects	-	1127	O
of	-	1135	O
indomethacin	-	1138	O
on	-	1151	O
renal	-	1154	O
function	-	1160	O
is	-	1169	O
confirmed	-	1172	O
with	-	1182	O
chronic	-	1187	O
frequent	-	1195	O
dosing	-	1204	O
,	-	1210	O
it	-	1212	O
would	-	1215	O
be	-	1221	O
prudent	-	1224	O
to	-	1232	O
avoid	-	1235	O
nonsteroidal	-	1241	O
anti	-	1254	O
-	-	1258	O
inflammatory	-	1259	O
therapy	-	1272	O
in	-	1280	O
patients	-	1283	O
with	-	1292	O
cirrhosis	-	1297	B
.	-	1306	O

Increased	7671401	0	O
frequency	-	10	O
and	-	20	O
severity	-	24	O
of	-	33	O
angio	-	36	B
-	-	41	I
oedema	-	42	I
related	-	49	O
to	-	57	O
long	-	60	O
-	-	64	O
term	-	65	O
therapy	-	70	O
with	-	78	O
angiotensin	-	83	O
-	-	94	O
converting	-	95	O
enzyme	-	106	O
inhibitor	-	113	O
in	-	123	O
two	-	126	O
patients	-	130	O
.	-	138	O

Adverse	7671401	140	O
reactions	-	148	O
to	-	158	O
drugs	-	161	O
are	-	167	O
well	-	171	O
recognized	-	176	O
as	-	187	O
a	-	190	O
cause	-	192	O
of	-	198	O
acute	-	201	O
or	-	207	O
chronic	-	210	O
urticaria	-	218	B
,	-	227	O
and	-	229	O
angio	-	233	B
-	-	238	I
oedema	-	239	I
.	-	245	O

Angiotensin	7671401	247	O
-	-	258	O
converting	-	259	O
enzyme	-	270	O
(	-	277	O
ACE	-	278	O
)	-	281	O
inhibitors	-	283	O
,	-	293	O
used	-	295	O
to	-	300	O
treat	-	303	O
hypertension	-	309	B
and	-	322	O
congestive	-	326	B
heart	-	337	I
failure	-	343	I
,	-	350	O
were	-	352	O
introduced	-	357	O
in	-	368	O
Europe	-	371	O
in	-	378	O
the	-	381	O
middle	-	385	O
of	-	392	O
the	-	395	O
eighties	-	399	O
,	-	407	O
and	-	409	O
the	-	413	O
use	-	417	O
of	-	421	O
these	-	424	O
drugs	-	430	O
has	-	436	O
increased	-	440	O
progressively	-	450	O
.	-	463	O

Soon	7671401	465	O
after	-	470	O
the	-	476	O
introduction	-	480	O
of	-	493	O
ACE	-	496	O
inhibitors	-	500	O
,	-	510	O
acute	-	512	O
bouts	-	518	O
of	-	524	O
angio	-	527	B
-	-	532	I
oedema	-	533	I
were	-	540	O
reported	-	545	O
in	-	554	O
association	-	557	O
with	-	569	O
the	-	574	O
use	-	578	O
of	-	582	O
these	-	585	O
drugs	-	591	O
.	-	596	O

We	7671401	598	O
wish	-	601	O
to	-	606	O
draw	-	609	O
attention	-	614	O
to	-	624	O
the	-	627	O
possibility	-	631	O
of	-	643	O
adverse	-	646	O
reactions	-	654	O
to	-	664	O
ACE	-	667	O
inhibitors	-	671	O
after	-	682	O
long	-	688	O
-	-	692	O
term	-	693	O
use	-	698	O
and	-	702	O
in	-	706	O
patients	-	709	O
with	-	718	O
pre	-	723	O
-	-	726	O
existing	-	727	O
angio	-	736	B
-	-	741	I
oedema	-	742	I
.	-	748	O

Myoclonus	7727612	0	B
associated	-	10	O
with	-	21	O
lorazepam	-	26	O
therapy	-	36	O
in	-	44	O
very	-	47	O
-	-	51	O
low	-	52	O
-	-	55	O
birth	-	56	O
-	-	61	O
weight	-	62	O
infants	-	69	O
.	-	76	O

Lorazepam	7727612	78	O
is	-	88	O
being	-	91	O
used	-	97	O
with	-	102	O
increasing	-	107	O
frequency	-	118	O
as	-	128	O
a	-	131	O
sedative	-	133	O
in	-	142	O
the	-	145	O
newborn	-	149	O
and	-	157	O
the	-	161	O
young	-	165	O
infant	-	171	O
.	-	177	O

Concern	7727612	179	O
has	-	187	O
been	-	191	O
raised	-	196	O
with	-	203	O
regard	-	208	O
to	-	215	O
the	-	218	O
safety	-	222	O
of	-	229	O
lorazepam	-	232	O
in	-	242	O
this	-	245	O
age	-	250	O
group	-	254	O
,	-	259	O
especially	-	261	O
in	-	272	O
very	-	275	O
-	-	279	O
low	-	280	O
-	-	283	O
birth	-	284	O
-	-	289	O
weight	-	290	O
(	-	297	O
VLBW	-	298	O
;	-	302	O
<	-	304	O
1	-	306	O
,	-	307	O
500	-	308	O
g	-	312	O
)	-	313	O
infants	-	315	O
.	-	322	O

Three	7727612	324	O
young	-	330	O
infants	-	336	O
,	-	343	O
all	-	345	O
of	-	349	O
birth	-	352	O
weight	-	358	O
<	-	365	O
1	-	367	O
,	-	368	O
500	-	369	O
g	-	373	O
,	-	374	O
experienced	-	376	O
myoclonus	-	388	B
following	-	398	O
the	-	408	O
intravenous	-	412	O
administration	-	424	O
of	-	439	O
lorazepam	-	442	O
.	-	451	O

The	7727612	453	O
potential	-	457	O
neurotoxic	-	467	B
effects	-	478	O
of	-	486	O
the	-	489	O
drug	-	493	O
(	-	498	O
and	-	499	O
its	-	503	O
vehicle	-	507	O
)	-	514	O
in	-	516	O
this	-	519	O
population	-	524	O
are	-	535	O
discussed	-	539	O
.	-	548	O

Injectable	7727612	550	O
lorazepam	-	561	O
should	-	571	O
be	-	578	O
used	-	581	O
with	-	586	O
caution	-	591	O
in	-	599	O
VLBW	-	602	O
infants	-	607	O
.	-	614	O

Transvenous	7739955	0	O
right	-	12	O
ventricular	-	18	O
pacing	-	30	O
during	-	37	O
cardiopulmonary	-	44	O
resuscitation	-	60	O
of	-	74	O
pediatric	-	77	O
patients	-	87	O
with	-	96	O
acute	-	101	O
cardiomyopathy	-	107	B
.	-	121	O

We	7739955	123	O
describe	-	126	O
the	-	135	O
cardiopulmonary	-	139	O
resuscitation	-	155	O
efforts	-	169	O
on	-	177	O
five	-	180	O
patients	-	185	O
who	-	194	O
presented	-	198	O
in	-	208	O
acute	-	211	O
circulatory	-	217	B
failure	-	229	I
from	-	237	O
myocardial	-	242	B
dysfunction	-	253	I
.	-	264	O

Three	7739955	266	O
patients	-	272	O
had	-	281	O
acute	-	285	O
viral	-	291	O
myocarditis	-	297	B
,	-	308	O
one	-	310	O
had	-	314	O
a	-	318	O
carbamazepine	-	320	O
-	-	333	O
induced	-	334	O
acute	-	342	O
eosinophilic	-	348	B
myocarditis	-	361	I
,	-	372	O
and	-	374	O
one	-	378	O
had	-	382	O
cardiac	-	386	O
hemosiderosis	-	394	O
resulting	-	408	O
in	-	418	O
acute	-	421	O
cardiogenic	-	427	B
shock	-	439	I
.	-	444	O

All	7739955	446	O
patients	-	450	O
were	-	459	O
continuously	-	464	O
monitored	-	477	O
with	-	487	O
central	-	492	O
venous	-	500	O
and	-	507	O
arterial	-	511	O
catheters	-	520	O
in	-	530	O
addition	-	533	O
to	-	542	O
routine	-	545	O
noninvasive	-	553	O
monitoring	-	565	O
.	-	575	O

An	7739955	577	O
introducer	-	580	O
sheath	-	591	O
,	-	597	O
a	-	599	O
pacemaker	-	601	O
,	-	610	O
and	-	612	O
sterile	-	616	O
pacing	-	624	O
wires	-	631	O
were	-	637	O
made	-	642	O
readily	-	647	O
available	-	655	O
for	-	665	O
the	-	669	O
patients	-	673	O
,	-	681	O
should	-	683	O
the	-	690	O
need	-	694	O
arise	-	699	O
to	-	705	O
terminate	-	708	O
resistant	-	718	O
cardiac	-	728	O
dysrhythmias	-	736	B
.	-	748	O

All	7739955	750	O
patients	-	754	O
developed	-	763	O
cardiocirculatory	-	773	O
arrest	-	791	O
associated	-	798	O
with	-	809	O
extreme	-	814	O
hypotension	-	822	B
and	-	834	O
dysrhythmias	-	838	B
within	-	851	O
the	-	858	O
first	-	862	O
48	-	868	O
hours	-	871	O
of	-	877	O
their	-	880	O
admission	-	886	O
to	-	896	O
the	-	899	O
pediatric	-	903	O
intensive	-	913	O
care	-	923	O
unit	-	928	O
(	-	933	O
PICU	-	934	O
)	-	938	O
.	-	939	O

Right	7739955	941	O
ventricular	-	947	O
pacemaker	-	959	O
wires	-	969	O
were	-	975	O
inserted	-	980	O
in	-	989	O
all	-	992	O
of	-	996	O
them	-	999	O
during	-	1004	O
cardiopulmonary	-	1011	O
resuscitation	-	1027	O
(	-	1041	O
CPR	-	1042	O
)	-	1045	O
.	-	1046	O

In	7739955	1048	O
four	-	1051	O
patients	-	1056	O
,	-	1064	O
cardiac	-	1066	O
pacing	-	1074	O
was	-	1081	O
used	-	1085	O
,	-	1089	O
resulting	-	1091	O
in	-	1101	O
a	-	1104	O
temporary	-	1106	O
captured	-	1116	O
rhythm	-	1125	O
and	-	1132	O
restoration	-	1136	O
of	-	1148	O
their	-	1151	O
cardiac	-	1157	O
output	-	1165	O
.	-	1171	O

These	7739955	1173	O
patients	-	1179	O
had	-	1188	O
a	-	1192	O
second	-	1194	O
event	-	1201	O
of	-	1207	O
cardiac	-	1210	B
arrest	-	1218	I
,	-	1224	O
resulting	-	1226	O
in	-	1236	O
death	-	1239	O
,	-	1244	O
within	-	1246	O
10	-	1253	O
to	-	1256	O
60	-	1259	O
minutes	-	1262	O
.	-	1269	O

In	7739955	1271	O
one	-	1274	O
patient	-	1278	O
,	-	1285	O
cardiac	-	1287	O
pacing	-	1295	O
was	-	1302	O
not	-	1306	O
used	-	1310	O
,	-	1314	O
because	-	1316	O
he	-	1324	O
converted	-	1327	O
to	-	1337	O
normal	-	1340	O
sinus	-	1347	O
rhythm	-	1353	O
by	-	1360	O
electrical	-	1363	O
defibrillation	-	1374	O
within	-	1389	O
three	-	1396	O
minutes	-	1402	O
of	-	1410	O
initiating	-	1413	O
CPR	-	1424	O
.	-	1427	O

We	7739955	1429	O
conclude	-	1432	O
that	-	1441	O
cardiac	-	1446	O
pacing	-	1454	O
during	-	1461	O
resuscitative	-	1468	O
efforts	-	1482	O
in	-	1490	O
pediatric	-	1493	O
patients	-	1503	O
suffering	-	1512	O
from	-	1522	O
acute	-	1527	O
myocardial	-	1533	B
dysfunction	-	1544	I
may	-	1556	O
not	-	1560	O
have	-	1564	O
long	-	1569	O
-	-	1573	O
term	-	1574	O
value	-	1579	O
in	-	1585	O
and	-	1588	O
of	-	1592	O
itself	-	1595	O
;	-	1601	O
however	-	1603	O
,	-	1610	O
if	-	1612	O
temporary	-	1615	O
hemodynamic	-	1625	O
stability	-	1637	O
is	-	1647	O
achieved	-	1650	O
by	-	1659	O
this	-	1662	O
procedure	-	1667	O
,	-	1676	O
it	-	1678	O
may	-	1681	O
provide	-	1685	O
additional	-	1693	O
time	-	1704	O
needed	-	1709	O
to	-	1716	O
institute	-	1719	O
other	-	1729	O
therapeutic	-	1735	O
modalities	-	1747	O
.	-	1757	O

Efficacy	7931490	0	O
and	-	9	O
safety	-	13	O
of	-	20	O
granisetron	-	23	O
,	-	34	O
a	-	36	O
selective	-	38	O
5	-	48	O
-	-	49	O
hydroxytryptamine	-	50	O
-	-	67	O
3	-	68	O
receptor	-	70	O
antagonist	-	79	O
,	-	89	O
in	-	91	O
the	-	94	O
prevention	-	98	O
of	-	109	O
nausea	-	112	B
and	-	119	O
vomiting	-	123	B
induced	-	132	O
by	-	140	O
high	-	143	O
-	-	147	O
dose	-	148	O
cisplatin	-	153	O
.	-	162	O

PURPOSE	7931490	164	O
:	-	171	O

To	7931490	173	O
assess	-	176	O
the	-	183	O
antiemetic	-	187	O
effects	-	198	O
and	-	206	O
safety	-	210	O
profile	-	217	O
of	-	225	O
four	-	228	O
different	-	233	O
doses	-	243	O
of	-	249	O
granisetron	-	252	O
(	-	264	O
Kytril	-	265	O
;	-	271	O
SmithKline	-	273	O
Beecham	-	284	O
Pharmaceuticals	-	292	O
,	-	307	O
Philadelphia	-	309	O
,	-	321	O
PA	-	323	O
)	-	325	O
when	-	327	O
administered	-	332	O
as	-	345	O
a	-	348	O
single	-	350	O
intravenous	-	357	O
(	-	369	O
IV	-	370	O
)	-	372	O
dose	-	374	O
for	-	379	O
prophylaxis	-	383	O
of	-	395	O
cisplatin	-	398	O
-	-	407	O
induced	-	408	O
nausea	-	416	B
and	-	423	O
vomiting	-	427	B
.	-	435	O

PATIENTS	7931490	437	O
AND	-	446	O
METHODS	-	450	O
:	-	457	O

One	7931490	459	O
hundred	-	463	O
eighty	-	471	O
-	-	477	O
four	-	478	O
chemotherapy	-	483	O
-	-	495	O
naive	-	496	O
patients	-	502	O
receiving	-	511	O
high	-	521	O
-	-	525	O
dose	-	526	O
cisplatin	-	531	O
(	-	541	O
81	-	542	O
to	-	545	O
120	-	548	O
mg	-	552	O
/	-	554	O
m2	-	555	O
)	-	557	O
were	-	559	O
randomized	-	564	O
to	-	575	O
receive	-	578	O
one	-	586	O
of	-	590	O
four	-	593	O
granisetron	-	598	O
doses	-	610	O
(	-	616	O
5	-	617	O
,	-	618	O
10	-	620	O
,	-	622	O
20	-	624	O
,	-	626	O
or	-	628	O
40	-	631	O
micrograms	-	634	O
/	-	644	O
kg	-	645	O
)	-	647	O
administered	-	649	O
before	-	662	O
chemotherapy	-	669	O
.	-	681	O

Patients	7931490	683	O
were	-	692	O
observed	-	697	O
on	-	706	O
an	-	709	O
inpatient	-	712	O
basis	-	722	O
for	-	728	O
18	-	732	O
to	-	735	O
24	-	738	O
hours	-	741	O
,	-	746	O
and	-	748	O
vital	-	752	O
signs	-	758	O
,	-	763	O
nausea	-	765	B
,	-	771	O
vomiting	-	773	B
,	-	781	O
retching	-	783	O
,	-	791	O
and	-	793	O
appetite	-	797	O
were	-	806	O
assessed	-	811	O
.	-	819	O

Safety	7931490	821	O
analyses	-	828	O
included	-	837	O
incidence	-	846	O
of	-	856	O
adverse	-	859	O
experiences	-	867	O
and	-	879	O
laboratory	-	883	O
parameter	-	894	O
changes	-	904	O
.	-	911	O

RESULTS	7931490	913	O
:	-	920	O

After	7931490	922	O
granisetron	-	928	O
doses	-	940	O
of	-	946	O
5	-	949	O
,	-	950	O
10	-	952	O
,	-	954	O
20	-	956	O
,	-	958	O
and	-	960	O
40	-	964	O
micrograms	-	967	O
/	-	977	O
kg	-	978	O
,	-	980	O
a	-	982	O
major	-	984	O
response	-	990	O
(	-	999	O
<	-	1000	O
or	-	1002	O
=	-	1005	O
two	-	1007	O
vomiting	-	1011	B
or	-	1020	O
retching	-	1023	O
episodes	-	1032	O
,	-	1040	O
and	-	1042	O
no	-	1046	O
antiemetic	-	1049	O
rescue	-	1060	O
)	-	1066	O
was	-	1068	O
recorded	-	1072	O
in	-	1081	O
23	-	1084	O
%	-	1086	O
,	-	1087	O
57	-	1089	O
%	-	1091	O
,	-	1092	O
58	-	1094	O
%	-	1096	O
,	-	1097	O
and	-	1099	O
60	-	1103	O
%	-	1105	O
of	-	1107	O
patients	-	1110	O
,	-	1118	O
respectively	-	1120	O
,	-	1132	O
and	-	1134	O
a	-	1138	O
complete	-	1140	O
response	-	1149	O
(	-	1158	O
no	-	1159	O
vomiting	-	1162	B
or	-	1171	O
retching	-	1174	O
,	-	1182	O
and	-	1184	O
no	-	1188	O
antiemetic	-	1191	O
rescue	-	1202	O
)	-	1208	O
in	-	1210	O
18	-	1213	O
%	-	1215	O
,	-	1216	O
41	-	1218	O
%	-	1220	O
,	-	1221	O
40	-	1223	O
%	-	1225	O
,	-	1226	O
and	-	1228	O
47	-	1232	O
%	-	1234	O
of	-	1236	O
patients	-	1239	O
,	-	1247	O
respectively	-	1249	O
.	-	1261	O

There	7931490	1263	O
was	-	1269	O
a	-	1273	O
statistically	-	1275	O
longer	-	1289	O
time	-	1296	O
to	-	1301	O
first	-	1304	O
episode	-	1310	O
of	-	1318	O
nausea	-	1321	B
(	-	1328	O
P	-	1329	O
=	-	1331	O
.	-	1333	O
0015	-	1334	O
)	-	1338	O
and	-	1340	O
vomiting	-	1344	B
(	-	1353	O
P	-	1354	O
=	-	1356	O
.	-	1358	O
0001	-	1359	O
)	-	1363	O
,	-	1364	O
and	-	1366	O
fewer	-	1370	O
patients	-	1376	O
were	-	1385	O
administered	-	1390	O
additional	-	1403	O
antiemetic	-	1414	O
medication	-	1425	O
in	-	1436	O
the	-	1439	O
10	-	1443	O
-	-	1445	O
micrograms	-	1446	O
/	-	1456	O
kg	-	1457	O
dosing	-	1460	O
groups	-	1467	O
than	-	1474	O
in	-	1479	O
the	-	1482	O
5	-	1486	O
-	-	1487	O
micrograms	-	1488	O
/	-	1498	O
kg	-	1499	O
dosing	-	1502	O
group	-	1509	O
.	-	1514	O

As	7931490	1516	O
granisetron	-	1519	O
dose	-	1531	O
increased	-	1536	O
,	-	1545	O
appetite	-	1547	O
return	-	1556	O
increased	-	1563	O
(	-	1573	O
P	-	1574	O
=	-	1576	O
.	-	1578	O
040	-	1579	O
)	-	1582	O
.	-	1583	O

Headache	7931490	1585	B
was	-	1594	O
the	-	1598	O
most	-	1602	O
frequently	-	1607	O
reported	-	1618	O
adverse	-	1627	O
event	-	1635	O
(	-	1641	O
20	-	1642	O
%	-	1644	O
)	-	1645	O
.	-	1646	O

CONCLUSION	7931490	1648	O
:	-	1658	O

A	7931490	1660	O
single	-	1662	O
10	-	1669	O
-	-	1671	O
,	-	1672	O
20	-	1674	O
-	-	1676	O
,	-	1677	O
or	-	1679	O
40	-	1682	O
-	-	1684	O
micrograms	-	1685	O
/	-	1695	O
kg	-	1696	O
dose	-	1699	O
of	-	1704	O
granisetron	-	1707	O
was	-	1719	O
effective	-	1723	O
in	-	1733	O
controlling	-	1736	O
vomiting	-	1748	B
in	-	1757	O
57	-	1760	O
%	-	1762	O
to	-	1764	O
60	-	1767	O
%	-	1769	O
of	-	1771	O
patients	-	1774	O
who	-	1783	O
received	-	1787	O
cisplatin	-	1796	O
at	-	1806	O
doses	-	1809	O
greater	-	1815	O
than	-	1823	O
81	-	1828	O
mg	-	1831	O
/	-	1833	O
m2	-	1834	O
and	-	1837	O
totally	-	1841	O
prevented	-	1849	O
vomiting	-	1859	B
in	-	1868	O
40	-	1871	O
%	-	1873	O
to	-	1875	O
47	-	1878	O
%	-	1880	O
of	-	1882	O
patients	-	1885	O
.	-	1893	O

There	7931490	1895	O
were	-	1901	O
no	-	1906	O
statistically	-	1909	O
significant	-	1923	O
differences	-	1935	O
in	-	1947	O
efficacy	-	1950	O
between	-	1959	O
the	-	1967	O
10	-	1971	O
-	-	1973	O
micrograms	-	1974	O
/	-	1984	O
kg	-	1985	O
dose	-	1988	O
and	-	1993	O
the	-	1997	O
20	-	2001	O
-	-	2003	O
and	-	2005	O
40	-	2009	O
-	-	2011	O
micrograms	-	2012	O
/	-	2022	O
kg	-	2023	O
doses	-	2026	O
.	-	2031	O

Granisetron	7931490	2033	O
was	-	2045	O
well	-	2049	O
tolerated	-	2054	O
at	-	2064	O
all	-	2067	O
doses	-	2071	O
.	-	2076	O

Adverse	7949506	0	O
interaction	-	8	O
between	-	20	O
clonidine	-	28	O
and	-	38	O
verapamil	-	42	O
.	-	51	O

OBJECTIVE	7949506	53	O
:	-	62	O

To	7949506	64	O
report	-	67	O
two	-	74	O
cases	-	78	O
of	-	84	O
a	-	87	O
possible	-	89	O
adverse	-	98	O
interaction	-	106	O
between	-	118	O
clonidine	-	126	O
and	-	136	O
verapamil	-	140	O
resulting	-	150	O
in	-	160	O
atrioventricular	-	163	B
(	-	180	I
AV	-	181	I
)	-	183	I
block	-	185	I
in	-	191	O
both	-	194	O
patients	-	199	O
and	-	208	O
severe	-	212	O
hypotension	-	219	B
in	-	231	O
one	-	234	O
patient	-	238	O
.	-	245	O

CASE	7949506	247	O

SUMMARIES	7949506	252	O
:	-	261	O

A	7949506	263	O
54	-	265	O
-	-	267	O
year	-	268	O
-	-	272	O
old	-	273	O
woman	-	277	O
with	-	283	O
hyperaldosteronism	-	288	B
was	-	307	O
treated	-	311	O
with	-	319	O
verapamil	-	324	O
480	-	334	O
mg	-	338	O
/	-	340	O
d	-	341	O
and	-	343	O
spironolactone	-	347	O
100	-	362	O
mg	-	366	O
/	-	368	O
d	-	369	O
.	-	370	O

After	7949506	372	O
the	-	378	O
addition	-	382	O
of	-	391	O
a	-	394	O
minimal	-	396	O
dose	-	404	O
of	-	409	O
clonidine	-	412	O
(	-	422	O
0	-	423	O
.	-	424	O
15	-	425	O
mg	-	428	O
bid	-	431	O
)	-	434	O
,	-	435	O
she	-	437	O
developed	-	441	O
complete	-	451	O
AV	-	460	B
block	-	463	I
and	-	469	O
severe	-	473	O
hypotension	-	480	B
,	-	491	O
which	-	493	O
resolved	-	499	O
upon	-	508	O
cessation	-	513	O
of	-	523	O
all	-	526	O
medications	-	530	O
.	-	541	O

A	7949506	543	O
65	-	545	O
-	-	547	O
year	-	548	O
-	-	552	O
old	-	553	O
woman	-	557	O
was	-	563	O
treated	-	567	O
with	-	575	O
extended	-	580	O
-	-	588	O
release	-	589	O
verapamil	-	597	O
240	-	607	O
mg	-	611	O
/	-	613	O
d	-	614	O
.	-	615	O

After	7949506	617	O
the	-	623	O
addition	-	627	O
of	-	636	O
clonidine	-	639	O
0	-	649	O
.	-	650	O
15	-	651	O
mg	-	654	O
bid	-	657	O
she	-	661	O
developed	-	665	O
complete	-	675	O
AV	-	684	B
block	-	687	I
,	-	692	O
which	-	694	O
resolved	-	700	O
after	-	709	O
all	-	715	O
therapy	-	719	O
was	-	727	O
stopped	-	731	O
.	-	738	O

DISCUSSION	7949506	740	O
:	-	750	O

An	7949506	752	O
adverse	-	755	O
interaction	-	763	O
between	-	775	O
clonidine	-	783	O
and	-	793	O
verapamil	-	797	O
has	-	807	O
not	-	811	O
been	-	815	O
reported	-	820	O
previously	-	829	O
.	-	839	O

We	7949506	841	O
describe	-	844	O
two	-	853	O
such	-	857	O
cases	-	862	O
and	-	868	O
discuss	-	872	O
the	-	880	O
various	-	884	O
mechanisms	-	892	O
that	-	903	O
might	-	908	O
cause	-	914	O
such	-	920	O
an	-	925	O
interaction	-	928	O
.	-	939	O

Clinicians	7949506	941	O
should	-	952	O
be	-	959	O
acquainted	-	962	O
with	-	973	O
this	-	978	O
possibly	-	983	O
fatal	-	992	O
interaction	-	998	O
between	-	1010	O
two	-	1018	O
commonly	-	1022	O
used	-	1031	O
antihypertensive	-	1036	O
drugs	-	1053	O
.	-	1058	O

CONCLUSIONS	7949506	1060	O
:	-	1071	O

Caution	7949506	1073	O
is	-	1081	O
recommended	-	1084	O
in	-	1096	O
combining	-	1099	O
clonidine	-	1109	O
and	-	1119	O
verapamil	-	1123	O
therapy	-	1133	O
,	-	1140	O
even	-	1142	O
in	-	1147	O
patients	-	1150	O
who	-	1159	O
do	-	1163	O
not	-	1166	O
have	-	1170	O
sinus	-	1175	O
or	-	1181	O
AV	-	1184	O
node	-	1187	O
dysfunction	-	1192	O
.	-	1203	O

The	7949506	1205	O
two	-	1209	O
drugs	-	1213	O
may	-	1219	O
act	-	1223	O
synergistically	-	1227	O
on	-	1243	O
both	-	1246	O
the	-	1251	O
AV	-	1255	O
node	-	1258	O
and	-	1263	O
the	-	1267	O
peripheral	-	1271	O
circulation	-	1282	O
.	-	1293	O

Pharmacological	7967231	0	O
studies	-	16	O
on	-	24	O
a	-	27	O
new	-	29	O
dihydrothienopyridine	-	33	O
calcium	-	55	O
antagonist	-	63	O
,	-	73	O
S	-	75	O
-	-	76	O
312	-	77	O
-	-	80	O
d	-	81	O
.	-	82	O

5th	7967231	84	O
communication	-	88	O
:	-	101	O
anticonvulsant	-	103	O
effects	-	118	O
in	-	126	O
mice	-	129	O
.	-	133	O

S	7967231	135	O
-	-	136	O
312	-	137	O
,	-	140	O
S	-	142	O
-	-	143	O
312	-	144	O
-	-	147	O
d	-	148	O
,	-	149	O
but	-	151	O
not	-	155	O
S	-	159	O
-	-	160	O
312	-	161	O
-	-	164	O
l	-	165	O
,	-	166	O
L	-	168	O
-	-	169	O
type	-	170	O
calcium	-	175	O
channel	-	183	O
antagonists	-	191	O
,	-	202	O
showed	-	204	O
anticonvulsant	-	211	O
effects	-	226	O
on	-	234	O
the	-	237	O
audiogenic	-	241	B
tonic	-	252	I
convulsions	-	258	I
in	-	270	O
DBA	-	273	O
/	-	276	O
2	-	277	O
mice	-	279	O
;	-	283	O
and	-	285	O
their	-	289	O
ED50	-	295	O
values	-	300	O
were	-	307	O
18	-	312	O
.	-	314	O
4	-	315	O
(	-	317	O
12	-	318	O
.	-	320	O
8	-	321	O
-	-	322	O
27	-	323	O
.	-	325	O
1	-	326	O
)	-	327	O
mg	-	329	O
/	-	331	O
kg	-	332	O
,	-	334	O
p	-	336	O
.	-	337	O
o	-	338	O
.	-	339	O
and	-	341	O
15	-	345	O
.	-	347	O
0	-	348	O
(	-	350	O
10	-	351	O
.	-	353	O
2	-	354	O
-	-	355	O
23	-	356	O
.	-	358	O
7	-	359	O
)	-	360	O
mg	-	362	O
/	-	364	O
kg	-	365	O
,	-	367	O
p	-	369	O
.	-	370	O
o	-	371	O
.	-	372	O
,	-	373	O
respectively	-	375	O
,	-	387	O
while	-	389	O
that	-	395	O
of	-	400	O
flunarizine	-	403	O
was	-	415	O
34	-	419	O
.	-	421	O
0	-	422	O
(	-	424	O
26	-	425	O
.	-	427	O
0	-	428	O
-	-	429	O
44	-	430	O
.	-	432	O
8	-	433	O
)	-	434	O
mg	-	436	O
/	-	438	O
kg	-	439	O
,	-	441	O
p	-	443	O
.	-	444	O
o	-	445	O
.	-	446	O

Although	7967231	448	O
moderate	-	457	O
anticonvulsant	-	466	O
effects	-	481	O
of	-	489	O
S	-	492	O
-	-	493	O
312	-	494	O
-	-	497	O
d	-	498	O
in	-	500	O
higher	-	503	O
doses	-	510	O
were	-	516	O
observed	-	521	O
against	-	530	O
the	-	538	O
clonic	-	542	O
convulsions	-	549	B
induced	-	561	O
by	-	569	O
pentylenetetrazole	-	572	O
(	-	591	O
85	-	592	O
mg	-	595	O
/	-	597	O
kg	-	598	O
,	-	600	O
s	-	602	O
.	-	603	O
c	-	604	O
.	-	605	O
)	-	606	O
or	-	608	O
bemegride	-	611	O
(	-	621	O
40	-	622	O
mg	-	625	O
/	-	627	O
kg	-	628	O
,	-	630	O
s	-	632	O
.	-	633	O
c	-	634	O
.	-	635	O
)	-	636	O
,	-	637	O
no	-	639	O
effects	-	642	O
were	-	650	O
observed	-	655	O
in	-	664	O
convulsions	-	667	B
induced	-	679	O
by	-	687	O
N	-	690	O
-	-	691	O
methyl	-	692	O
-	-	698	O
D	-	699	O
-	-	700	O
aspartate	-	701	O
,	-	710	O
picrotoxin	-	712	O
,	-	722	O
or	-	724	O
electroshock	-	727	O
in	-	740	O
Slc	-	743	O
:	-	746	O
ddY	-	747	O
mice	-	751	O
.	-	755	O

S	7967231	757	O
-	-	758	O
312	-	759	O
-	-	762	O
d	-	763	O
may	-	765	O
be	-	769	O
useful	-	772	O
in	-	779	O
the	-	782	O
therapy	-	786	O
of	-	794	O
certain	-	797	O
types	-	805	O
of	-	811	O
human	-	814	O
epilepsy	-	820	B
.	-	828	O

Transmural	8096565	0	O
myocardial	-	11	B
infarction	-	22	I
with	-	33	O
sumatriptan	-	38	O
.	-	49	O

For	8096565	51	O
sumatriptan	-	55	O
,	-	66	O
tightness	-	68	O
in	-	78	O
the	-	81	O
chest	-	85	O
caused	-	91	O
by	-	98	O
an	-	101	O
unknown	-	104	O
mechanism	-	112	O
has	-	122	O
been	-	126	O
reported	-	131	O
in	-	140	O
3	-	143	O
-	-	144	O
5	-	145	O
%	-	146	O
of	-	148	O
users	-	151	O
.	-	156	O

We	8096565	158	O
describe	-	161	O
a	-	170	O
47	-	172	O
-	-	174	O
year	-	175	O
-	-	179	O
old	-	180	O
woman	-	184	O
with	-	190	O
an	-	195	O
acute	-	198	O
myocardial	-	204	B
infarction	-	215	I
after	-	226	O
administration	-	232	O
of	-	247	O
sumatriptan	-	250	O
6	-	262	O
mg	-	264	O
subcutaneously	-	267	O
for	-	282	O
cluster	-	286	B
headache	-	294	I
.	-	302	O

The	8096565	304	O
patient	-	308	O
had	-	316	O
no	-	320	O
history	-	323	O
of	-	331	O
underlying	-	334	O
ischaemic	-	345	B
heart	-	355	I
disease	-	361	I
or	-	369	O
Prinzmetal	-	372	B
's	-	382	I
angina	-	385	I
.	-	391	O

She	8096565	393	O
recovered	-	397	O
without	-	407	O
complications	-	415	O
.	-	428	O

Flumazenil	8135424	0	O
induces	-	11	O
seizures	-	19	B
and	-	28	O
death	-	32	O
in	-	38	O
mixed	-	41	O
cocaine	-	47	O
-	-	54	O
diazepam	-	55	O
intoxications	-	64	O
.	-	77	O

STUDY	8135424	79	O

HYPOTHESIS	8135424	85	O
:	-	95	O

Administration	8135424	97	O
of	-	112	O
the	-	115	O
benzodiazepine	-	119	O
antagonist	-	134	O
flumazenil	-	145	O
may	-	156	O
unmask	-	160	O
seizures	-	167	B
in	-	176	O
mixed	-	179	O
cocaine	-	185	O
-	-	192	O
benzodiazepine	-	193	O
intoxication	-	208	O
.	-	220	O

DESIGN	8135424	222	O
:	-	228	O

Male	8135424	230	O
Sprague	-	235	O
-	-	242	O
Dawley	-	243	O
rats	-	250	O
received	-	255	O
100	-	264	O
mg	-	268	O
/	-	270	O
kg	-	271	O
cocaine	-	274	O
IP	-	282	O
alone	-	285	O
,	-	290	O
5	-	292	O
mg	-	294	O
/	-	296	O
kg	-	297	O
diazepam	-	300	O
alone	-	309	O
,	-	314	O
or	-	316	O
a	-	319	O
combination	-	321	O
of	-	333	O
diazepam	-	336	O
and	-	345	O
cocaine	-	349	O
.	-	356	O

Three	8135424	358	O
minutes	-	364	O
later	-	372	O
,	-	377	O
groups	-	379	O
were	-	386	O
challenged	-	391	O
with	-	402	O
vehicle	-	407	O
or	-	415	O
flumazenil	-	418	O
5	-	429	O
or	-	431	O
10	-	434	O
mg	-	437	O
/	-	439	O
kg	-	440	O
IP	-	443	O
.	-	445	O

Animal	8135424	447	O
behavior	-	454	O
,	-	462	O
seizures	-	464	B
(	-	473	O
time	-	474	O
to	-	479	O
and	-	482	O
incidence	-	486	O
)	-	495	O
,	-	496	O
death	-	498	O
(	-	504	O
time	-	505	O
to	-	510	O
and	-	513	O
incidence	-	517	O
)	-	526	O
,	-	527	O
and	-	529	O
cortical	-	533	O
EEG	-	542	O
tracings	-	546	O
were	-	555	O
recorded	-	560	O
.	-	568	O

INTERVENTIONS	8135424	570	O
:	-	583	O

Administration	8135424	585	O
of	-	600	O
flumazenil	-	603	O
to	-	614	O
animals	-	617	O
after	-	625	O
they	-	631	O
had	-	636	O
received	-	640	O
a	-	649	O
combination	-	651	O
dose	-	663	O
of	-	668	O
cocaine	-	671	O
and	-	679	O
diazepam	-	683	O
.	-	691	O

RESULTS	8135424	693	O
:	-	700	O

In	8135424	702	O
group	-	705	O
1	-	711	O
,	-	712	O
animals	-	714	O
received	-	722	O
cocaine	-	731	O
followed	-	739	O
by	-	748	O
vehicle	-	751	O
.	-	758	O

This	8135424	760	O
resulted	-	765	O
in	-	774	O
100	-	777	O
%	-	780	O
developing	-	782	O
seizures	-	793	B
and	-	802	O
death	-	806	O
.	-	811	O

Group	8135424	813	O
2	-	819	O
received	-	821	O
diazepam	-	830	O
alone	-	839	O
followed	-	845	O
by	-	854	O
vehicle	-	857	O
.	-	864	O

Animals	8135424	866	O
became	-	874	O
somnolent	-	881	O
and	-	891	O
none	-	895	O
died	-	900	O
.	-	904	O

Group	8135424	906	O
3	-	912	O
received	-	914	O
diazepam	-	923	O
followed	-	932	O
by	-	941	O
5	-	944	O
mg	-	946	O
/	-	948	O
kg	-	949	O
flumazenil	-	952	O
.	-	962	O

Animals	8135424	964	O
became	-	972	O
somnolent	-	979	O
after	-	989	O
diazepam	-	995	O
and	-	1004	O
then	-	1008	O
active	-	1013	O
after	-	1020	O
flumazenil	-	1026	O
administration	-	1037	O
.	-	1051	O

In	8135424	1053	O
group	-	1056	O
4	-	1062	O
,	-	1063	O
a	-	1065	O
combination	-	1067	O
of	-	1079	O
cocaine	-	1082	O
and	-	1090	O
diazepam	-	1094	O
was	-	1103	O
administered	-	1107	O
simultaneously	-	1120	O
.	-	1134	O

This	8135424	1136	O
resulted	-	1141	O
in	-	1150	O
no	-	1153	O
overt	-	1156	O
or	-	1162	O
EEG	-	1165	O
-	-	1168	O
detectable	-	1169	O
seizures	-	1180	B
and	-	1189	O
a	-	1193	O
50	-	1195	O
%	-	1197	O
incidence	-	1199	O
of	-	1209	O
death	-	1212	O
.	-	1217	O

Group	8135424	1219	O
5	-	1225	O
received	-	1227	O
a	-	1236	O
similar	-	1238	O
combination	-	1246	O
of	-	1258	O
cocaine	-	1261	O
and	-	1269	O
diazepam	-	1273	O
,	-	1281	O
followed	-	1283	O
later	-	1292	O
by	-	1298	O
5	-	1301	O
mg	-	1303	O
/	-	1305	O
kg	-	1306	O
flumazenil	-	1309	O
.	-	1319	O

This	8135424	1321	O
resulted	-	1326	O
in	-	1335	O
an	-	1338	O
increased	-	1341	O
incidence	-	1351	O
of	-	1361	O
seizures	-	1364	B
,	-	1372	O
90	-	1374	O
%	-	1376	O
(	-	1378	O
P	-	1379	O
<	-	1381	O
.	-	1383	O
01	-	1384	O
)	-	1386	O
,	-	1387	O
and	-	1389	O
death	-	1393	O
,	-	1398	O
100	-	1400	O
%	-	1403	O
(	-	1405	O
P	-	1406	O
<	-	1408	O
or	-	1410	O
=	-	1413	O
.	-	1415	O
01	-	1416	O
)	-	1418	O
,	-	1419	O
compared	-	1421	O
with	-	1430	O
group	-	1435	O
4	-	1441	O
.	-	1442	O

Group	8135424	1444	O
6	-	1450	O
received	-	1452	O
cocaine	-	1461	O
and	-	1469	O
diazepam	-	1473	O
followed	-	1482	O
by	-	1491	O
10	-	1494	O
mg	-	1497	O
/	-	1499	O
kg	-	1500	O
flumazenil	-	1503	O
.	-	1513	O

This	8135424	1515	O
also	-	1520	O
resulted	-	1525	O
in	-	1534	O
an	-	1537	O
increased	-	1540	O
incidence	-	1550	O
of	-	1560	O
seizures	-	1563	B
,	-	1571	O
90	-	1573	O
%	-	1575	O
(	-	1577	O
P	-	1578	O
<	-	1580	O
or	-	1582	O
=	-	1585	O
.	-	1587	O
01	-	1588	O
)	-	1590	O
,	-	1591	O
and	-	1593	O
death	-	1597	O
,	-	1602	O
90	-	1604	O
%	-	1606	O
(	-	1608	O
P	-	1609	O
<	-	1611	O
or	-	1613	O
=	-	1616	O
.	-	1618	O
05	-	1619	O
)	-	1621	O
,	-	1622	O
compared	-	1624	O
with	-	1633	O
group	-	1638	O
4	-	1644	O
.	-	1645	O

CONCLUSION	8135424	1647	O
:	-	1657	O

Flumazenil	8135424	1659	O
can	-	1670	O
unmask	-	1674	O
seizures	-	1681	B
and	-	1690	O
increase	-	1694	O
the	-	1703	O
incidence	-	1707	O
of	-	1717	O
death	-	1720	O
in	-	1726	O
a	-	1729	O
model	-	1731	O
of	-	1737	O
combined	-	1740	O
cocaine	-	1749	O
-	-	1756	O
diazepam	-	1757	O
intoxications	-	1766	O
.	-	1779	O

Mechanisms	8160791	0	O
for	-	11	O
protective	-	15	O
effects	-	26	O
of	-	34	O
free	-	37	O
radical	-	42	O
scavengers	-	50	O
on	-	61	O
gentamicin	-	64	O
-	-	74	O
mediated	-	75	O
nephropathy	-	84	B
in	-	96	O
rats	-	99	O
.	-	103	O

Studies	8160791	105	O
were	-	113	O
performed	-	118	O
to	-	128	O
examine	-	131	O
the	-	139	O
mechanisms	-	143	O
for	-	154	O
the	-	158	O
protective	-	162	O
effects	-	173	O
of	-	181	O
free	-	184	O
radical	-	189	O
scavengers	-	197	O
on	-	208	O
gentamicin	-	211	O
(	-	222	O
GM	-	223	O
)	-	225	O
-	-	226	O
mediated	-	227	O
nephropathy	-	236	B
.	-	247	O

Administration	8160791	249	O
of	-	264	O
GM	-	267	O
at	-	270	O
40	-	273	O
mg	-	276	O
/	-	278	O
kg	-	279	O
sc	-	282	O
for	-	285	O
13	-	289	O
days	-	292	O
to	-	297	O
rats	-	300	O
induced	-	305	O
a	-	313	O
significant	-	315	O
reduction	-	327	O
in	-	337	O
renal	-	340	O
blood	-	346	O
flow	-	352	O
(	-	357	O
RBF	-	358	O
)	-	361	O
and	-	363	O
inulin	-	367	O
clearance	-	374	O
(	-	384	O
CIn	-	385	O
)	-	388	O
as	-	390	O
well	-	393	O
as	-	398	O
marked	-	401	O
tubular	-	408	B
damage	-	416	I
.	-	422	O

A	8160791	424	O
significant	-	426	O
reduction	-	438	O
in	-	448	O
urinary	-	451	O
guanosine	-	459	O
3'	-	469	O
,	-	471	O
5'	-	472	O
-	-	474	O
cyclic	-	475	O
monophosphate	-	482	O
(	-	496	O
cGMP	-	497	O
)	-	501	O
excretion	-	503	O
and	-	513	O
a	-	517	O
significant	-	519	O
increase	-	531	O
in	-	540	O
renal	-	543	O
cortical	-	549	O
renin	-	558	O
and	-	564	O
endothelin	-	568	O
-	-	578	O
1	-	579	O
contents	-	581	O
were	-	590	O
also	-	595	O
observed	-	600	O
in	-	609	O
GM	-	612	O
-	-	614	O
mediated	-	615	O
nephropathy	-	624	B
.	-	635	O

Superoxide	8160791	637	O
dismutase	-	648	O
(	-	658	O
SOD	-	659	O
)	-	662	O
or	-	664	O
dimethylthiourea	-	667	O
(	-	684	O
DMTU	-	685	O
)	-	689	O
significantly	-	691	O
lessened	-	705	O
the	-	714	O
GM	-	718	O
-	-	720	O
induced	-	721	O
decrement	-	729	O
in	-	739	O
CIn	-	742	O
.	-	745	O

The	8160791	747	O
SOD	-	751	O
-	-	754	O
induced	-	755	O
increase	-	763	O
in	-	772	O
glomerular	-	775	O
filtration	-	786	O
rate	-	797	O
was	-	802	O
associated	-	806	O
with	-	817	O
a	-	822	O
marked	-	824	O
improvement	-	831	O
in	-	843	O
RBF	-	846	O
,	-	849	O
an	-	851	O
increase	-	854	O
in	-	863	O
urinary	-	866	O
cGMP	-	874	O
excretion	-	879	O
,	-	888	O
and	-	890	O
a	-	894	O
decrease	-	896	O
in	-	905	O
renal	-	908	O
renin	-	914	O
and	-	920	O
endothelin	-	924	O
-	-	934	O
1	-	935	O
content	-	937	O
.	-	944	O

SOD	8160791	946	O
did	-	950	O
not	-	954	O
attenuate	-	958	O
the	-	968	O
tubular	-	972	B
damage	-	980	I
.	-	986	O

In	8160791	988	O
contrast	-	991	O
,	-	999	O
DMTU	-	1001	O
significantly	-	1006	O
reduced	-	1020	O
the	-	1028	O
tubular	-	1032	B
damage	-	1040	I
and	-	1047	O
lipid	-	1051	O
peroxidation	-	1057	O
,	-	1069	O
but	-	1071	O
it	-	1075	O
did	-	1078	O
not	-	1082	O
affect	-	1086	O
renal	-	1093	O
hemodynamics	-	1099	O
and	-	1112	O
vasoactive	-	1116	O
substances	-	1127	O
.	-	1137	O

Neither	8160791	1139	O
SOD	-	1147	O
nor	-	1151	O
DMTU	-	1155	O
affected	-	1160	O
the	-	1169	O
renal	-	1173	O
cortical	-	1179	O
GM	-	1188	O
content	-	1191	O
in	-	1199	O
GM	-	1202	O
-	-	1204	O
treated	-	1205	O
rats	-	1213	O
.	-	1217	O

These	8160791	1219	O
results	-	1225	O
suggest	-	1233	O
that	-	1241	O
1	-	1246	O
)	-	1247	O
both	-	1249	O
SOD	-	1254	O
and	-	1258	O
DMTU	-	1262	O
have	-	1267	O
protective	-	1272	O
effects	-	1283	O
on	-	1291	O
GM	-	1294	O
-	-	1296	O
mediated	-	1297	O
nephropathy	-	1306	B
,	-	1317	O
2	-	1319	O
)	-	1320	O
the	-	1322	O
mechanisms	-	1326	O
for	-	1337	O
the	-	1341	O
protective	-	1345	O
effects	-	1356	O
differ	-	1364	O
for	-	1371	O
SOD	-	1375	O
and	-	1379	O
DMTU	-	1383	O
,	-	1387	O
and	-	1389	O
3	-	1393	O
)	-	1394	O
superoxide	-	1396	O
anions	-	1407	O
play	-	1414	O
a	-	1419	O
critical	-	1421	O
role	-	1430	O
in	-	1435	O
GM	-	1438	O
-	-	1440	O
induced	-	1441	O
renal	-	1449	O
vasoconstriction	-	1455	O
.	-	1471	O

Assessment	8184922	0	O
of	-	11	O
cardiomyocyte	-	14	O
DNA	-	28	O
synthesis	-	32	O
during	-	42	O
hypertrophy	-	49	B
in	-	61	O
adult	-	64	O
mice	-	70	O
.	-	74	O

The	8184922	76	O
ability	-	80	O
of	-	88	O
cardiomyocytes	-	91	O
to	-	106	O
synthesize	-	109	O
DNA	-	120	O
in	-	124	O
response	-	127	O
to	-	136	O
experimentally	-	139	O
induced	-	154	O
cardiac	-	162	B
hypertrophy	-	170	I
was	-	182	O
assessed	-	186	O
in	-	195	O
adult	-	198	O
mice	-	204	O
.	-	208	O

Isoproterenol	8184922	210	O
delivered	-	224	O
by	-	234	O
osmotic	-	237	O
minipump	-	245	O
implantation	-	254	O
in	-	267	O
adult	-	270	O
C3Heb	-	276	O
/	-	281	O
FeJ	-	282	O
mice	-	286	O
resulted	-	291	O
in	-	300	O
a	-	303	O
46	-	305	O
%	-	307	O
increase	-	309	O
in	-	318	O
heart	-	321	O
weight	-	327	O
and	-	334	O
a	-	338	O
19	-	340	O
.	-	342	O
3	-	343	O
%	-	344	O
increase	-	346	O
in	-	355	O
cardiomyocyte	-	358	O
area	-	372	O
.	-	376	O

No	8184922	378	O
DNA	-	381	O
synthesis	-	385	O
,	-	394	O
as	-	396	O
assessed	-	399	O
by	-	408	O
autoradiographic	-	411	O
analysis	-	428	O
of	-	437	O
isolated	-	440	O
cardiomyocytes	-	449	O
,	-	463	O
was	-	465	O
observed	-	469	O
in	-	478	O
control	-	481	O
or	-	489	O
hypertrophic	-	492	B
hearts	-	505	I
.	-	511	O

A	8184922	513	O
survey	-	515	O
of	-	522	O
15	-	525	O
independent	-	528	O
inbred	-	540	O
strains	-	547	O
of	-	555	O
mice	-	558	O
revealed	-	563	O
that	-	572	O
ventricular	-	577	O
cardiomyocyte	-	589	O
nuclear	-	603	O
number	-	611	O
ranged	-	618	O
from	-	625	O
3	-	630	O
to	-	632	O
13	-	635	O
%	-	637	O
mononucleate	-	639	O
,	-	651	O
suggesting	-	653	O
that	-	664	O
cardiomyocyte	-	669	O
terminal	-	683	O
differentiation	-	692	O
is	-	708	O
influenced	-	711	O
directly	-	722	O
or	-	731	O
indirectly	-	734	O
by	-	745	O
genetic	-	748	O
background	-	756	O
.	-	766	O

To	8184922	768	O
determine	-	771	O
whether	-	781	O
the	-	789	O
capacity	-	793	O
for	-	802	O
reactive	-	806	O
DNA	-	815	O
synthesis	-	819	O
was	-	829	O
also	-	833	O
subject	-	838	O
to	-	846	O
genetic	-	849	O
regulation	-	857	O
,	-	867	O
cardiac	-	869	B
hypertrophy	-	877	I
was	-	889	O
induced	-	893	O
in	-	901	O
the	-	904	O
strains	-	908	O
of	-	916	O
mice	-	919	O
comprising	-	924	O
the	-	935	O
extremes	-	939	O
of	-	948	O
the	-	951	O
nuclear	-	955	O
number	-	963	O
survey	-	970	O
.	-	976	O

These	8184922	978	O
data	-	984	O
indicate	-	989	O
that	-	998	O
adult	-	1003	O
mouse	-	1009	O
atrial	-	1015	O
and	-	1022	O
ventricular	-	1026	O
cardiomyocytes	-	1038	O
do	-	1053	O
not	-	1056	O
synthesize	-	1060	O
DNA	-	1071	O
in	-	1075	O
response	-	1078	O
to	-	1087	O
isoproterenol	-	1090	O
-	-	1103	O
induced	-	1104	O
cardiac	-	1112	B
hypertrophy	-	1120	I
.	-	1131	O

Central	8188982	0	O
cardiovascular	-	8	O
effects	-	23	O
of	-	31	O
AVP	-	34	O
and	-	38	O
ANP	-	42	O
in	-	46	O
normotensive	-	49	O
and	-	62	O
spontaneously	-	66	O
hypertensive	-	80	B
rats	-	93	O
.	-	97	O

The	8188982	99	O
purpose	-	103	O
of	-	111	O
the	-	114	O
present	-	118	O
study	-	126	O
was	-	132	O
to	-	136	O
compare	-	139	O
influence	-	147	O
of	-	157	O
central	-	160	O
arginine	-	168	O
vasopressin	-	177	O
(	-	189	O
AVP	-	190	O
)	-	193	O
and	-	195	O
of	-	199	O
atrial	-	202	O
natriuretic	-	209	O
peptide	-	221	O
(	-	229	O
ANP	-	230	O
)	-	233	O
on	-	235	O
control	-	238	O
of	-	246	O
arterial	-	249	O
blood	-	258	O
pressure	-	264	O
(	-	273	O
MAP	-	274	O
)	-	277	O
and	-	279	O
heart	-	283	O
rate	-	289	O
(	-	294	O
HR	-	295	O
)	-	297	O
in	-	299	O
normotensive	-	302	O
(	-	315	O
WKY	-	316	O
)	-	319	O
and	-	321	O
spontaneously	-	325	O
hypertensive	-	339	B
(	-	352	O
SHR	-	353	O
)	-	356	O
rats	-	358	O
.	-	362	O

Three	8188982	364	O
series	-	370	O
of	-	377	O
experiments	-	380	O
were	-	392	O
performed	-	397	O
on	-	407	O
30	-	410	O
WKY	-	413	O
and	-	417	O
30	-	421	O
SHR	-	424	O
,	-	427	O
chronically	-	429	O
instrumented	-	441	O
with	-	454	O
guide	-	459	O
tubes	-	465	O
in	-	471	O
the	-	474	O
lateral	-	478	O
ventricle	-	486	O
(	-	496	O
LV	-	497	O
)	-	499	O
and	-	501	O
arterial	-	505	O
and	-	514	O
venous	-	518	O
catheters	-	525	O
.	-	534	O

MAP	8188982	536	O
and	-	540	O
HR	-	544	O
were	-	547	O
monitored	-	552	O
before	-	562	O
and	-	569	O
after	-	573	O
i	-	579	O
.	-	580	O
v	-	581	O
.	-	582	O

injections	8188982	584	O
of	-	595	O
either	-	598	O
vehicle	-	605	O
or	-	613	O
1	-	616	O
,	-	617	O
10	-	619	O
and	-	622	O
50	-	626	O
ng	-	629	O
of	-	632	O
AVP	-	635	O
and	-	639	O
25	-	643	O
,	-	645	O
125	-	647	O
and	-	651	O
500	-	655	O
ng	-	659	O
of	-	662	O
ANP	-	665	O
.	-	668	O

Sensitivity	8188982	670	O
of	-	682	O
cardiac	-	685	O
component	-	693	O
of	-	703	O
baroreflex	-	706	O
(	-	717	O
CCB	-	718	O
)	-	721	O
,	-	722	O
expressed	-	724	O
as	-	734	O
a	-	737	O
slope	-	739	O
of	-	745	O
the	-	748	O
regression	-	752	O
line	-	763	O
was	-	768	O
determined	-	772	O
from	-	783	O
relationships	-	788	O
between	-	802	O
systolic	-	810	O
arterial	-	819	O
pressure	-	828	O
(	-	837	O
SAP	-	838	O
)	-	841	O
and	-	843	O
HR	-	847	O
period	-	850	O
(	-	857	O
HRp	-	858	O
)	-	861	O
during	-	863	O
phenylephrine	-	870	O
(	-	884	O
Phe	-	885	O
)	-	888	O
-	-	889	O
induced	-	890	O
hypertension	-	898	B
and	-	911	O
sodium	-	915	O
nitroprusside	-	922	O
(	-	936	O
SN	-	937	O
)	-	939	O
-	-	940	O
induced	-	941	O
hypotension	-	949	B
.	-	960	O

CCB	8188982	962	O
was	-	966	O
measured	-	970	O
before	-	979	O
and	-	986	O
after	-	990	O
administration	-	996	O
of	-	1011	O
either	-	1014	O
vehicle	-	1021	O
,	-	1028	O
AVP	-	1030	O
,	-	1033	O
ANP	-	1035	O
,	-	1038	O
or	-	1040	O
both	-	1043	O
peptides	-	1048	O
together	-	1057	O
.	-	1065	O

Increases	8188982	1067	O
of	-	1077	O
MAP	-	1080	O
occurred	-	1084	O
after	-	1093	O
LV	-	1099	O
administration	-	1102	O
of	-	1117	O
1	-	1120	O
,	-	1121	O
10	-	1123	O
and	-	1126	O
50	-	1130	O
ng	-	1133	O
of	-	1136	O
AVP	-	1139	O
in	-	1143	O
WKY	-	1146	O
and	-	1150	O
of	-	1154	O
10	-	1157	O
and	-	1160	O
50	-	1164	O
ng	-	1167	O
in	-	1170	O
SHR	-	1173	O
.	-	1176	O

ANP	8188982	1178	O
did	-	1182	O
not	-	1186	O
cause	-	1190	O
significant	-	1196	O
changes	-	1208	O
in	-	1216	O
MAP	-	1219	O
in	-	1223	O
both	-	1226	O
strains	-	1231	O
as	-	1239	O
compared	-	1242	O
to	-	1251	O
vehicle	-	1254	O
,	-	1261	O
but	-	1263	O
it	-	1267	O
abolished	-	1270	O
AVP	-	1280	O
-	-	1283	O
induced	-	1284	O
MAP	-	1292	O
increase	-	1296	O
in	-	1305	O
WKY	-	1308	O
and	-	1312	O
SHR	-	1316	O
.	-	1319	O

CCB	8188982	1321	O
was	-	1325	O
reduced	-	1329	O
in	-	1337	O
WKY	-	1340	O
and	-	1344	O
SHR	-	1348	O
after	-	1352	O
LV	-	1358	O
administration	-	1361	O
of	-	1376	O
AVP	-	1379	O
during	-	1383	O
SN	-	1390	O
-	-	1392	O
induced	-	1393	O
hypotension	-	1401	B
.	-	1412	O

In	8188982	1414	O
SHR	-	1417	O
but	-	1421	O
not	-	1425	O
in	-	1429	O
WKY	-	1432	O
administration	-	1436	O
of	-	1451	O
ANP	-	1454	O
,	-	1457	O
AVP	-	1459	O
and	-	1463	O
ANP	-	1467	O
+	-	1471	O
AVP	-	1473	O
decreased	-	1477	O
CCB	-	1487	O
during	-	1491	O
Phe	-	1498	O
-	-	1501	O
induced	-	1502	O
MAP	-	1510	O
elevation	-	1514	O
.	-	1523	O

The	8188982	1525	O
results	-	1529	O
indicate	-	1537	O
that	-	1546	O
centrally	-	1551	O
applied	-	1561	O
AVP	-	1569	O
and	-	1573	O
ANP	-	1577	O
exert	-	1581	O
differential	-	1587	O
effects	-	1600	O
on	-	1608	O
blood	-	1611	O
pressure	-	1617	O
and	-	1626	O
baroreflex	-	1630	O
control	-	1641	O
of	-	1649	O
heart	-	1652	O
rate	-	1658	O
in	-	1663	O
WKY	-	1666	O
and	-	1670	O
SHR	-	1674	O
and	-	1678	O
suggest	-	1682	O
interaction	-	1690	O
of	-	1702	O
these	-	1705	O
two	-	1711	O
peptides	-	1715	O
in	-	1724	O
blood	-	1727	O
pressure	-	1733	O
regulation	-	1742	O
at	-	1753	O
the	-	1756	O
level	-	1760	O
of	-	1766	O
central	-	1769	O
nervous	-	1777	O
system	-	1785	O
.	-	1791	O

Cutaneous	8308951	0	O
exposure	-	10	O
to	-	19	O
warfarin	-	22	O
-	-	30	O
like	-	31	O
anticoagulant	-	36	O
causing	-	50	O
an	-	58	O
intracerebral	-	61	B
hemorrhage	-	75	I
:	-	85	O
a	-	87	O
case	-	89	O
report	-	94	O
.	-	100	O

A	8308951	102	O
case	-	104	O
of	-	109	O
intercerebral	-	112	O
hematoma	-	126	B
due	-	135	O
to	-	139	O
warfarin	-	142	O
-	-	150	O
induced	-	151	O
coagulopathy	-	159	B
is	-	172	O
presented	-	175	O
.	-	184	O

The	8308951	186	O
39	-	190	O
-	-	192	O
year	-	193	O
-	-	197	O
old	-	198	O
woman	-	202	O
had	-	208	O
spread	-	212	O
a	-	219	O
warfarin	-	221	O
-	-	229	O
type	-	230	O
rat	-	235	O
poison	-	239	O
around	-	246	O
her	-	253	O
house	-	257	O
weekly	-	263	O
using	-	270	O
her	-	276	O
bare	-	280	O
hands	-	285	O
,	-	290	O
with	-	292	O
no	-	297	O
washing	-	300	O
post	-	308	O
application	-	313	O
.	-	324	O

Percutaneous	8308951	326	O
absorption	-	339	O
of	-	350	O
warfarin	-	353	O
causing	-	362	O
coagulopathy	-	370	B
,	-	382	O
reported	-	384	O
three	-	393	O
times	-	399	O
in	-	405	O
the	-	408	O
past	-	412	O
,	-	416	O
is	-	418	O
a	-	421	O
significant	-	423	O
risk	-	435	O
if	-	440	O
protective	-	443	O
measures	-	454	O
,	-	462	O
such	-	464	O
as	-	469	O
gloves	-	472	O
,	-	478	O
are	-	480	O
not	-	484	O
used	-	488	O
.	-	492	O

An	8308951	494	O
adverse	-	497	O
drug	-	505	O
interaction	-	510	O
with	-	522	O
piroxicam	-	527	O
,	-	536	O
which	-	538	O
she	-	544	O
took	-	548	O
occasionally	-	553	O
,	-	565	O
may	-	567	O
have	-	571	O
exacerbated	-	576	O
the	-	588	O
coagulopathy	-	592	B
.	-	604	O

Pediatric	8312343	0	O
heart	-	10	O
transplantation	-	16	O
without	-	32	O
chronic	-	40	O
maintenance	-	48	O
steroids	-	60	O
.	-	68	O

From	8312343	70	O
1986	-	75	O
to	-	80	O
February	-	83	O
1993	-	92	O
,	-	96	O
40	-	98	O
children	-	101	O
aged	-	110	O
2	-	115	O
months	-	117	O
to	-	124	O
18	-	127	O
years	-	130	O
(	-	136	O
average	-	137	O
age	-	145	O
10	-	149	O
.	-	151	O
4	-	152	O
+	-	154	O
/	-	155	O
-	-	156	O

5	8312343	158	O
.	-	159	O
8	-	160	O
years	-	162	O
)	-	167	O
underwent	-	169	O
heart	-	179	O
transplantation	-	185	O
.	-	200	O

Indications	8312343	202	O
for	-	214	O
transplantation	-	218	O
were	-	234	O
idiopathic	-	239	B
cardiomyopathy	-	250	I
(	-	265	O
52	-	266	O
%	-	268	O
)	-	269	O
,	-	270	O
congenital	-	272	B
heart	-	283	I
disease	-	289	I
(	-	297	O
35	-	298	O
%	-	300	O
)	-	301	O
with	-	303	O
and	-	308	O
without	-	312	O
prior	-	320	O
repair	-	326	O
(	-	333	O
71	-	334	O
%	-	336	O
and	-	338	O
29	-	342	O
%	-	344	O
,	-	345	O
respectively	-	347	O
)	-	359	O
,	-	360	O
hypertrophic	-	362	B
cardiomyopathy	-	375	I
(	-	390	O
5	-	391	O
%	-	392	O
)	-	393	O
,	-	394	O
valvular	-	396	B
heart	-	405	I
disease	-	411	I
(	-	419	O
3	-	420	O
%	-	421	O
)	-	422	O
,	-	423	O
and	-	425	O
doxorubicin	-	429	O
cardiomyopathy	-	441	B
(	-	456	O
5	-	457	O
%	-	458	O
)	-	459	O
.	-	460	O

Patients	8312343	462	O
were	-	471	O
managed	-	476	O
with	-	484	O
cyclosporine	-	489	O
and	-	502	O
azathioprine	-	506	O
.	-	518	O

No	8312343	520	O
prophylaxis	-	523	O
with	-	535	O
antilymphocyte	-	540	O
globulin	-	555	O
was	-	564	O
used	-	568	O
.	-	572	O

Steroids	8312343	574	O
were	-	583	O
given	-	588	O
to	-	594	O
39	-	597	O
%	-	599	O
of	-	601	O
patients	-	604	O
for	-	613	O
refractory	-	617	O
rejection	-	628	O
,	-	637	O
but	-	639	O
weaning	-	643	O
was	-	651	O
always	-	655	O
attempted	-	662	O
and	-	672	O
generally	-	676	O
successful	-	686	O
(	-	697	O
64	-	698	O
%	-	700	O
)	-	701	O
.	-	702	O

Five	8312343	704	O
patients	-	709	O
(	-	718	O
14	-	719	O
%	-	721	O
)	-	722	O
received	-	724	O
maintenance	-	733	O
steroids	-	745	O
.	-	753	O

Four	8312343	755	O
patients	-	760	O
died	-	769	O
in	-	774	O
the	-	777	O
perioperative	-	781	O
period	-	795	O
and	-	802	O
one	-	806	O
died	-	810	O
4	-	815	O
months	-	817	O
later	-	824	O
.	-	829	O

There	8312343	831	O
have	-	837	O
been	-	842	O
no	-	847	O
deaths	-	850	O
related	-	857	O
to	-	865	O
rejection	-	868	O
or	-	878	O
infection	-	881	B
.	-	890	O

Average	8312343	892	O
follow	-	900	O
-	-	906	O
up	-	907	O
was	-	910	O
36	-	914	O
+	-	917	O
/	-	918	O
-	-	919	O

19	8312343	921	O
months	-	924	O
(	-	931	O
range	-	932	O
1	-	938	O
to	-	940	O
65	-	943	O
months	-	946	O
)	-	952	O
.	-	953	O

Cumulative	8312343	955	O
survival	-	966	O
is	-	975	O
88	-	978	O
%	-	980	O
at	-	982	O
5	-	985	O
years	-	987	O
.	-	992	O

In	8312343	994	O
patients	-	997	O
less	-	1006	O
than	-	1011	O
7	-	1016	O
years	-	1018	O
of	-	1024	O
age	-	1027	O
,	-	1030	O
rejection	-	1032	O
was	-	1042	O
monitored	-	1046	O
noninvasively	-	1056	O
.	-	1069	O

In	8312343	1071	O
the	-	1074	O
first	-	1078	O
postoperative	-	1084	O
month	-	1098	O
,	-	1103	O
89	-	1105	O
%	-	1107	O
of	-	1109	O
patients	-	1112	O
were	-	1121	O
treated	-	1126	O
for	-	1134	O
rejection	-	1138	O
.	-	1147	O

Freedom	8312343	1149	O
from	-	1157	O
serious	-	1162	O
infections	-	1170	B
was	-	1181	O
83	-	1185	O
%	-	1187	O
at	-	1189	O
1	-	1192	O
month	-	1194	O
and	-	1200	O
65	-	1204	O
%	-	1206	O
at	-	1208	O
1	-	1211	O
year	-	1213	O
.	-	1217	O

Cytomegalovirus	8312343	1219	B
infections	-	1235	I
were	-	1246	O
treated	-	1251	O
successfully	-	1259	O
with	-	1272	O
ganciclovir	-	1277	O
in	-	1289	O
11	-	1292	O
patients	-	1295	O
.	-	1303	O

No	8312343	1305	O
impairment	-	1308	O
of	-	1319	O
growth	-	1322	O
was	-	1329	O
observed	-	1333	O
in	-	1342	O
children	-	1345	O
who	-	1354	O
underwent	-	1358	O
transplantation	-	1368	O
compared	-	1384	O
with	-	1393	O
a	-	1398	O
control	-	1400	O
population	-	1408	O
.	-	1418	O

Twenty	8312343	1420	O
-	-	1426	O
one	-	1427	O
patients	-	1431	O
(	-	1440	O
60	-	1441	O
%	-	1443	O
)	-	1444	O
have	-	1446	O
undergone	-	1451	O
annual	-	1461	O
catheterizations	-	1468	O
and	-	1485	O
no	-	1489	O
sign	-	1492	O
of	-	1497	O
graft	-	1500	O
atherosclerosis	-	1506	B
has	-	1522	O
been	-	1526	O
observed	-	1531	O
.	-	1539	O

Seizures	8312343	1541	B
occurred	-	1550	O
in	-	1559	O
five	-	1562	O
patients	-	1567	O
(	-	1576	O
14	-	1577	O
%	-	1579	O
)	-	1580	O
and	-	1582	O
hypertension	-	1586	B
was	-	1599	O
treated	-	1603	O
in	-	1611	O
10	-	1614	O
patients	-	1617	O
(	-	1626	O
28	-	1627	O
%	-	1629	O
)	-	1630	O
.	-	1631	O

No	8312343	1633	O
patient	-	1636	O
was	-	1644	O
disabled	-	1648	O
and	-	1657	O
no	-	1661	O
lymphoproliferative	-	1664	B
disorder	-	1684	I
was	-	1693	O
observed	-	1697	O
.	-	1705	O
(	-	1706	O
ABSTRACT	-	1707	O
TRUNCATED	-	1716	O
AT	-	1726	O
250	-	1729	O
WORDS	-	1733	O
)	-	1738	O

Delirium	8312983	0	B
during	-	9	O
fluoxetine	-	16	O
treatment	-	27	O
.	-	36	O

A	8312983	38	O
case	-	40	O
report	-	45	O
.	-	51	O

The	8312983	53	O
correlation	-	57	O
between	-	69	O
high	-	77	O
serum	-	82	O
tricyclic	-	88	O
antidepressant	-	98	O
concentrations	-	113	O
and	-	128	O
central	-	132	O
nervous	-	140	O
system	-	148	O
side	-	155	O
effects	-	160	O
has	-	168	O
been	-	172	O
well	-	177	O
established	-	182	O
.	-	193	O

Only	8312983	195	O
a	-	200	O
few	-	202	O
reports	-	206	O
exist	-	214	O
,	-	219	O
however	-	221	O
,	-	228	O
on	-	230	O
the	-	233	O
relationship	-	237	O
between	-	250	O
the	-	258	O
serum	-	262	O
concentrations	-	268	O
of	-	283	O
selective	-	286	O
serotonin	-	296	O
reuptake	-	306	O
inhibitors	-	315	O
(	-	326	O
SSRIs	-	327	O
)	-	332	O
and	-	334	O
their	-	338	O
toxic	-	344	O
effects	-	350	O
.	-	357	O

In	8312983	359	O
some	-	362	O
cases	-	367	O
,	-	372	O
a	-	374	O
high	-	376	O
serum	-	381	O
concentration	-	387	O
of	-	401	O
citalopram	-	404	O
(	-	415	O
>	-	416	O
600	-	418	O
nmol	-	422	O
/	-	426	O
L	-	427	O
)	-	428	O
in	-	430	O
elderly	-	433	O
patients	-	441	O
has	-	450	O
been	-	454	O
associated	-	459	O
with	-	470	O
increased	-	475	O
somnolence	-	485	B
and	-	496	O
movement	-	500	B
difficulties	-	509	I
.	-	521	O

Widespread	8312983	523	O
cognitive	-	534	B
disorders	-	544	I
,	-	553	O
such	-	555	O
as	-	560	O
delirium	-	563	B
,	-	571	O
have	-	573	O
not	-	578	O
been	-	582	O
previously	-	587	O
linked	-	598	O
with	-	605	O
high	-	610	O
blood	-	615	O
levels	-	621	O
of	-	628	O
SSRIs	-	631	O
.	-	636	O

In	8312983	638	O
this	-	641	O
report	-	646	O
,	-	652	O
we	-	654	O
describe	-	657	O
a	-	666	O
patient	-	668	O
with	-	676	O
acute	-	681	O
hyperkinetic	-	687	B
delirium	-	700	B
connected	-	709	O
with	-	719	O
a	-	724	O
high	-	726	O
serum	-	731	O
total	-	737	O
fluoxetine	-	743	O
(	-	754	O
fluoxetine	-	755	O
plus	-	766	O
desmethylfluoxetine	-	771	O
)	-	790	O
concentration	-	792	O
.	-	805	O

Pulmonary	8318674	0	B
edema	-	10	I
and	-	16	O
shock	-	20	B
after	-	26	O
high	-	32	O
-	-	36	O
dose	-	37	O
aracytine	-	42	O
-	-	51	O
C	-	52	O
for	-	54	O
lymphoma	-	58	B
;	-	66	O
possible	-	68	O
role	-	77	O
of	-	82	O
TNF	-	85	O
-	-	88	O
alpha	-	89	O
and	-	95	O
PAF	-	99	O
.	-	102	O

Four	8318674	104	O
out	-	109	O
of	-	113	O
23	-	116	O
consecutive	-	119	O
patients	-	131	O
treated	-	140	O
with	-	148	O
high	-	153	O
-	-	157	O
dose	-	158	O
Ara	-	163	O
-	-	166	O
C	-	167	O
for	-	169	O
lymphomas	-	173	B
in	-	183	O
our	-	186	O
institution	-	190	O
developed	-	202	O
a	-	212	O
strikingly	-	214	O
similar	-	225	O
syndrome	-	233	O
during	-	242	O
the	-	249	O
perfusion	-	253	O
.	-	262	O

It	8318674	264	O
was	-	267	O
characterized	-	271	O
by	-	285	O
the	-	288	O
onset	-	292	O
of	-	298	O
fever	-	301	B
,	-	306	O
diarrhea	-	308	B
,	-	316	O
shock	-	318	B
,	-	323	O
pulmonary	-	325	B
edema	-	335	I
,	-	340	O
acute	-	342	B
renal	-	348	I
failure	-	354	I
,	-	361	O
metabolic	-	363	B
acidosis	-	373	I
,	-	381	O
weight	-	383	B
gain	-	390	I
and	-	395	O
leukocytosis	-	399	B
.	-	411	O

Thorough	8318674	413	O
bacteriological	-	422	O
screening	-	438	O
failed	-	448	O
to	-	455	O
provide	-	458	O
evidence	-	466	O
of	-	475	O
infection	-	478	B
.	-	487	O

Sequential	8318674	489	O
biological	-	500	O
assays	-	511	O
of	-	518	O
IL	-	521	O
-	-	523	O
1	-	524	O
,	-	525	O
IL	-	527	O
-	-	529	O
2	-	530	O
,	-	531	O
TNF	-	533	O
and	-	537	O
PAF	-	541	O
were	-	545	O
performed	-	550	O
during	-	560	O
Ara	-	567	O
-	-	570	O
C	-	571	O
infusion	-	573	O
to	-	582	O
ten	-	585	O
patients	-	589	O
,	-	597	O
including	-	599	O
the	-	609	O
four	-	613	O
who	-	618	O
developed	-	622	O
the	-	632	O
syndrome	-	636	O
.	-	644	O

TNF	8318674	646	O
and	-	650	O
PAF	-	654	O
activity	-	658	O
was	-	667	O
found	-	671	O
in	-	677	O
the	-	680	O
serum	-	684	O
of	-	690	O
respectively	-	693	O
two	-	706	O
and	-	710	O
four	-	714	O
of	-	719	O
the	-	722	O
cases	-	726	O
,	-	731	O
but	-	733	O
not	-	737	O
in	-	741	O
the	-	744	O
six	-	748	O
controls	-	752	O
.	-	760	O

As	8318674	762	O
TNF	-	765	O
and	-	769	O
PAF	-	773	O
are	-	777	O
thought	-	781	O
to	-	789	O
be	-	792	O
involved	-	795	O
in	-	804	O
the	-	807	O
development	-	811	O
of	-	823	O
septic	-	826	O
shock	-	833	B
and	-	839	O
adult	-	843	B
respiratory	-	849	I
distress	-	861	I
syndrome	-	870	I
,	-	878	O
we	-	880	O
hypothesize	-	883	O
that	-	895	O
high	-	900	O
-	-	904	O
dose	-	905	O
Ara	-	910	O
-	-	913	O
C	-	914	O
may	-	916	O
be	-	920	O
associated	-	923	O
with	-	934	O
cytokine	-	939	O
release	-	948	O
.	-	955	O

Protective	8392553	0	O
effect	-	11	O
of	-	18	O
clentiazem	-	21	O
against	-	32	O
epinephrine	-	40	O
-	-	51	O
induced	-	52	O
cardiac	-	60	B
injury	-	68	I
in	-	75	O
rats	-	78	O
.	-	82	O

We	8392553	84	O
investigated	-	87	O
the	-	100	O
effects	-	104	O
of	-	112	O
clentiazem	-	115	O
,	-	125	O
a	-	127	O
1	-	129	O
,	-	130	O
5	-	131	O
-	-	132	O
benzothiazepine	-	133	O
calcium	-	149	O
antagonist	-	157	O
,	-	167	O
on	-	169	O
epinephrine	-	172	O
-	-	183	O
induced	-	184	O
cardiomyopathy	-	192	B
in	-	207	O
rats	-	210	O
.	-	214	O

With	8392553	216	O
2	-	221	O
-	-	222	O
week	-	223	O
chronic	-	228	O
epinephrine	-	236	O
infusion	-	248	O
,	-	256	O
16	-	258	O
of	-	261	O
30	-	264	O
rats	-	267	O
died	-	272	O
within	-	277	O
4	-	284	O
days	-	286	O
,	-	290	O
and	-	292	O
severe	-	296	O
ischemic	-	303	B
lesions	-	312	I
and	-	320	O
fibrosis	-	324	B
of	-	333	O
the	-	336	O
left	-	340	O
ventricles	-	345	O
were	-	356	O
observed	-	361	O
.	-	369	O

In	8392553	371	O
epinephrine	-	374	O
-	-	385	O
treated	-	386	O
rats	-	394	O
,	-	398	O
left	-	400	O
atrial	-	405	O
and	-	412	O
left	-	416	O
ventricular	-	421	O
papillary	-	433	O
muscle	-	443	O
contractile	-	450	O
responses	-	462	O
to	-	472	O
isoproterenol	-	475	O
were	-	489	O
reduced	-	494	O
,	-	501	O
but	-	503	O
responses	-	507	O
to	-	517	O
calcium	-	520	O
were	-	528	O
normal	-	533	O
or	-	540	O
enhanced	-	543	O
compared	-	552	O
to	-	561	O
controls	-	564	O
.	-	572	O

Left	8392553	574	O
ventricular	-	579	O
alpha	-	591	O
and	-	597	O
beta	-	601	O
adrenoceptor	-	606	O
densities	-	619	O
were	-	629	O
also	-	634	O
reduced	-	639	O
compared	-	647	O
to	-	656	O
controls	-	659	O
.	-	667	O

Treatment	8392553	669	O
with	-	679	O
clentiazem	-	684	O
prevented	-	695	O
epinephrine	-	705	O
-	-	716	O
induced	-	717	O
death	-	725	O
(	-	731	O
P	-	732	O
<	-	734	O
.	-	736	O
05	-	737	O
)	-	739	O
,	-	740	O
and	-	742	O
attenuated	-	746	O
the	-	757	O
ventricular	-	761	O
ischemic	-	773	B
lesions	-	782	I
and	-	790	O
fibrosis	-	794	B
,	-	802	O
in	-	804	O
a	-	807	O
dose	-	809	O
-	-	813	O
dependent	-	814	O
manner	-	824	O
.	-	830	O

Left	8392553	832	O
atrial	-	837	O
and	-	844	O
left	-	848	O
ventricular	-	853	O
papillary	-	865	O
muscle	-	875	O
contractile	-	882	O
responses	-	894	O
to	-	904	O
isoproterenol	-	907	O
were	-	921	O
reduced	-	926	O
compared	-	934	O
to	-	943	O
controls	-	946	O
in	-	955	O
groups	-	958	O
treated	-	965	O
with	-	973	O
clentiazem	-	978	O
alone	-	989	O
,	-	994	O
but	-	996	O
combined	-	1000	O
with	-	1009	O
epinephrine	-	1014	O
,	-	1025	O
clentiazem	-	1027	O
restored	-	1038	O
left	-	1047	O
atrial	-	1052	O
responses	-	1059	O
and	-	1069	O
enhanced	-	1073	O
left	-	1082	O
ventricular	-	1087	O
papillary	-	1099	O
responses	-	1109	O
to	-	1119	O
isoproterenol	-	1122	O
.	-	1135	O

On	8392553	1137	O
the	-	1140	O
other	-	1144	O
hand	-	1150	O
clentiazem	-	1155	O
did	-	1166	O
not	-	1170	O
prevent	-	1174	O
epinephrine	-	1182	O
-	-	1193	O
induced	-	1194	O
down	-	1202	O
-	-	1206	O
regulation	-	1207	O
of	-	1218	O
alpha	-	1221	O
and	-	1227	O
beta	-	1231	O
adrenoceptors	-	1236	O
.	-	1249	O

Interestingly	8392553	1251	O
,	-	1264	O
clentiazem	-	1266	O
,	-	1276	O
infused	-	1278	O
alone	-	1286	O
,	-	1291	O
resulted	-	1293	O
in	-	1302	O
decreased	-	1305	O
adrenergic	-	1315	O
receptor	-	1326	O
densities	-	1335	O
in	-	1345	O
the	-	1348	O
left	-	1352	O
ventricle	-	1357	O
.	-	1366	O

Clentiazem	8392553	1368	O
also	-	1379	O
did	-	1384	O
not	-	1388	O
prevent	-	1392	O
the	-	1400	O
enhanced	-	1404	O
responses	-	1413	O
to	-	1423	O
calcium	-	1426	O
seen	-	1434	O
in	-	1439	O
the	-	1442	O
epinephrine	-	1446	O
-	-	1457	O
treated	-	1458	O
animals	-	1466	O
,	-	1473	O
although	-	1475	O
the	-	1484	O
high	-	1488	O
dose	-	1493	O
of	-	1498	O
clentiazem	-	1501	O
partially	-	1512	O
attenuated	-	1522	O
the	-	1533	O
maximal	-	1537	O
response	-	1545	O
to	-	1554	O
calcium	-	1557	O
compared	-	1565	O
to	-	1574	O
epinephrine	-	1577	O
-	-	1588	O
treated	-	1589	O
animals	-	1597	O
.	-	1604	O

In	8392553	1606	O
conclusion	-	1609	O
,	-	1619	O
clentiazem	-	1621	O
attenuated	-	1632	O
epinephrine	-	1643	O
-	-	1654	O
induced	-	1655	O
cardiac	-	1663	B
injury	-	1671	I
,	-	1677	O
possibly	-	1679	O
through	-	1688	O
its	-	1696	O
effect	-	1700	O
on	-	1707	O
the	-	1710	O
adrenergic	-	1714	O
pathway	-	1725	O
.	-	1732	O

Cocaine	8511251	0	O
induced	-	8	O
myocardial	-	16	B
ischemia	-	27	I
.	-	35	O

We	8511251	37	O
report	-	40	O
a	-	47	O
case	-	49	O
of	-	54	O
myocardial	-	57	B
ischemia	-	68	I
induced	-	77	O
by	-	85	O
cocaine	-	88	O
.	-	95	O

The	8511251	97	O
ischemia	-	101	B
probably	-	110	O
induced	-	119	O
by	-	127	O
coronary	-	130	B
artery	-	139	I
spasm	-	146	I
was	-	152	O
reversed	-	156	O
by	-	165	O
nitroglycerin	-	168	O
and	-	182	O
calcium	-	186	O
blocking	-	194	O
agents	-	203	O
.	-	209	O

Doxorubicin	8603459	0	O
-	-	11	O
induced	-	12	O
cardiotoxicity	-	20	B
monitored	-	35	O
by	-	45	O
ECG	-	48	O
in	-	52	O
freely	-	55	O
moving	-	62	O
mice	-	69	O
.	-	73	O

A	8603459	75	O
new	-	77	O
model	-	81	O
to	-	87	O
test	-	90	O
potential	-	95	O
protectors	-	105	O
.	-	115	O

In	8603459	117	O
laboratory	-	120	O
animals	-	131	O
,	-	138	O
histology	-	140	O
is	-	150	O
most	-	153	O
commonly	-	158	O
used	-	167	O
to	-	172	O
study	-	175	O
doxorubicin	-	181	O
-	-	192	O
induced	-	193	O
cardiotoxicity	-	201	B
.	-	215	O

However	8603459	217	O
,	-	224	O
for	-	226	O
monitoring	-	230	O
during	-	241	O
treatment	-	248	O
,	-	257	O
large	-	259	O
numbers	-	265	O
of	-	273	O
animals	-	276	O
are	-	284	O
needed	-	288	O
.	-	294	O

Recently	8603459	296	O
we	-	305	O
developed	-	308	O
a	-	318	O
new	-	320	O
method	-	324	O
to	-	331	O
measure	-	334	O
ECG	-	342	O
values	-	346	O
in	-	353	O
freely	-	356	O
moving	-	363	O
mice	-	370	O
by	-	375	O
telemetry	-	378	O
.	-	387	O

With	8603459	389	O
this	-	394	O
model	-	399	O
we	-	405	O
investigated	-	408	O
the	-	421	O
effect	-	425	O
of	-	432	O
chronic	-	435	O
doxorubicin	-	443	O
administration	-	455	O
on	-	470	O
the	-	473	O
ECG	-	477	O
of	-	481	O
freely	-	484	O
moving	-	491	O
BALB	-	498	O
/	-	502	O

c	8603459	503	O
mice	-	505	O
and	-	510	O
the	-	514	O
efficacy	-	518	O
of	-	527	O
ICRF	-	530	O
-	-	534	O
187	-	535	O
as	-	539	O
a	-	542	O
protective	-	544	O
agent	-	555	O
.	-	560	O

The	8603459	562	O
ST	-	566	O
interval	-	569	O
significantly	-	578	O
widened	-	592	O
from	-	600	O
15	-	605	O
.	-	607	O
0	-	608	O
+	-	610	O
/	-	611	O
-	-	612	O

1	8603459	614	O
.	-	615	O
5	-	616	O
to	-	618	O
56	-	621	O
.	-	623	O
8	-	624	O
+	-	626	O
/	-	627	O
-	-	628	O

11	8603459	630	O
.	-	632	O
8	-	633	O
ms	-	635	O
in	-	638	O
week	-	641	O
10	-	646	O
(	-	649	O
7	-	650	O
weekly	-	652	O
doses	-	659	O
of	-	665	O
4	-	668	O
mg	-	670	O
/	-	672	O
kg	-	673	O
doxorubicin	-	676	O
given	-	688	O
i	-	694	O
.	-	695	O
v	-	696	O
.	-	697	O

plus	8603459	699	O
3	-	704	O
weeks	-	706	O
of	-	712	O
observation	-	715	O
)	-	726	O
.	-	727	O

The	8603459	729	O
ECG	-	733	O
of	-	737	O
the	-	740	O
control	-	744	O
animals	-	752	O
did	-	760	O
not	-	764	O
change	-	768	O
during	-	775	O
the	-	782	O
entire	-	786	O
study	-	793	O
.	-	798	O

After	8603459	800	O
sacrifice	-	806	O
the	-	816	O
hearts	-	820	O
of	-	827	O
doxorubicin	-	830	O
-	-	841	O
treated	-	842	O
animals	-	850	O
were	-	858	O
enlarged	-	863	O
and	-	872	O
the	-	876	O
atria	-	880	O
were	-	886	O
hypertrophic	-	891	B
.	-	903	O

As	8603459	905	O
this	-	908	O
schedule	-	913	O
exerted	-	922	O
more	-	930	O
toxicity	-	935	B
than	-	944	O
needed	-	949	O
to	-	956	O
investigate	-	959	O
protective	-	971	O
agents	-	982	O
,	-	988	O
the	-	990	O
protection	-	994	O
of	-	1005	O
ICRF	-	1008	O
-	-	1012	O
187	-	1013	O
was	-	1017	O
determined	-	1021	O
using	-	1032	O
a	-	1038	O
dose	-	1040	O
schedule	-	1045	O
with	-	1054	O
lower	-	1059	O
general	-	1065	O
toxicity	-	1073	B
(	-	1082	O
6	-	1083	O
weekly	-	1085	O
doses	-	1092	O
of	-	1098	O
4	-	1101	O
mg	-	1103	O
/	-	1105	O
kg	-	1106	O
doxorubicin	-	1109	O
given	-	1121	O
i	-	1127	O
.	-	1128	O
v	-	1129	O
.	-	1130	O

plus	8603459	1132	O
2	-	1137	O
weeks	-	1139	O
of	-	1145	O
observation	-	1148	O
)	-	1159	O
.	-	1160	O

On	8603459	1162	O
this	-	1165	O
schedule	-	1170	O
,	-	1178	O
the	-	1180	O
animals	-	1184	O
'	-	1191	O
hearts	-	1193	O
appeared	-	1200	O
normal	-	1209	O
after	-	1216	O
sacrifice	-	1222	O
and	-	1232	O
ICRF	-	1236	O
-	-	1240	O
187	-	1241	O
(	-	1245	O
50	-	1246	O
mg	-	1249	O
/	-	1251	O
kg	-	1252	O
given	-	1255	O
i	-	1261	O
.	-	1262	O
p	-	1263	O
.	-	1264	O

1	8603459	1266	O
h	-	1268	O
before	-	1270	O
doxorubicin	-	1277	O
)	-	1288	O
provided	-	1290	O
almost	-	1299	O
full	-	1306	O
protection	-	1311	O
.	-	1321	O

These	8603459	1323	O
data	-	1329	O
were	-	1334	O
confirmed	-	1339	O
by	-	1349	O
histology	-	1352	O
.	-	1361	O

The	8603459	1363	O
results	-	1367	O
indicate	-	1375	O
that	-	1384	O
this	-	1389	O
new	-	1394	O
model	-	1398	O
is	-	1404	O
very	-	1407	O
sensitive	-	1412	O
and	-	1422	O
enables	-	1426	O
monitoring	-	1434	O
of	-	1445	O
the	-	1448	O
development	-	1452	O
of	-	1464	O
cardiotoxicity	-	1467	B
with	-	1482	O
time	-	1487	O
.	-	1491	O

These	8603459	1493	O
findings	-	1499	O
result	-	1508	O
in	-	1515	O
a	-	1518	O
model	-	1520	O
that	-	1526	O
allows	-	1531	O
the	-	1538	O
testing	-	1542	O
of	-	1550	O
protectors	-	1553	O
against	-	1564	O
doxorubicin	-	1572	O
-	-	1583	O
induced	-	1584	O
cardiotoxicity	-	1592	B
as	-	1607	O
demonstrated	-	1610	O
by	-	1623	O
the	-	1626	O
protection	-	1630	O
provided	-	1641	O
by	-	1650	O
ICRF	-	1653	O
-	-	1657	O
187	-	1658	O
.	-	1661	O

Epinephrine	8659767	0	O
dysrhythmogenicity	-	12	O
is	-	31	O
not	-	34	O
enhanced	-	38	O
by	-	47	O
subtoxic	-	50	O
bupivacaine	-	59	O
in	-	71	O
dogs	-	74	O
.	-	78	O

Since	8659767	80	O
bupivacaine	-	86	O
and	-	98	O
epinephrine	-	102	O
may	-	114	O
both	-	118	O
precipitate	-	123	O
dysrhythmias	-	135	B
,	-	147	O
circulating	-	149	O
bupivacaine	-	161	O
during	-	173	O
regional	-	180	O
anesthesia	-	189	O
could	-	200	O
potentiate	-	206	O
dysrhythmogenic	-	217	O
effects	-	233	O
of	-	241	O
epinephrine	-	244	O
.	-	255	O

We	8659767	257	O
therefore	-	260	O
examined	-	270	O
whether	-	279	O
bupivacaine	-	287	O
alters	-	299	O
the	-	306	O
dysrhythmogenicity	-	310	O
of	-	329	O
subsequent	-	332	O
administration	-	343	O
of	-	358	O
epinephrine	-	361	O
in	-	373	O
conscious	-	376	O
,	-	385	O
healthy	-	387	O
dogs	-	395	O
and	-	400	O
in	-	404	O
anesthetized	-	407	O
dogs	-	420	O
with	-	425	O
myocardial	-	430	B
infarction	-	441	I
.	-	451	O

Forty	8659767	453	O
-	-	458	O
one	-	459	O
conscious	-	463	O
dogs	-	473	O
received	-	478	O
10	-	487	O
micrograms	-	490	O
.	-	500	O
kg	-	501	O
-	-	503	O
1	-	504	O
.	-	505	O
min	-	506	O
-	-	509	O
1	-	510	O
epinephrine	-	512	O
.	-	523	O

Seventeen	8659767	525	O
animals	-	535	O
responded	-	543	O
with	-	553	O
ventricular	-	558	B
tachycardia	-	570	I
(	-	582	O
VT	-	583	B
)	-	585	O
within	-	587	O
3	-	594	O
min	-	596	O
.	-	599	O

After	8659767	601	O
3	-	607	O
h	-	609	O
,	-	610	O
these	-	612	O
responders	-	618	O
randomly	-	629	O
received	-	638	O
1	-	647	O
or	-	649	O
2	-	652	O
mg	-	654	O
/	-	656	O
kg	-	657	O
bupivacaine	-	660	O
or	-	672	O
saline	-	675	O
over	-	682	O
5	-	687	O
min	-	689	O
,	-	692	O
followed	-	694	O
by	-	703	O
10	-	706	O
micrograms	-	709	O
.	-	719	O
kg	-	720	O
-	-	722	O
1	-	723	O
.	-	724	O
min	-	725	O
-	-	728	O
1	-	729	O
epinephrine	-	731	O
.	-	742	O

In	8659767	744	O
the	-	747	O
bupivacaine	-	751	O
groups	-	763	O
,	-	769	O
epinephrine	-	771	O
caused	-	783	O
fewer	-	790	O
prodysrhythmic	-	796	O
effects	-	811	O
than	-	819	O
without	-	824	O
bupivacaine	-	832	O
.	-	843	O

VT	8659767	845	B
appeared	-	848	O
in	-	857	O
fewer	-	860	O
dogs	-	866	O
and	-	871	O
at	-	875	O
a	-	878	O
later	-	880	O
time	-	886	O
,	-	890	O
and	-	892	O
there	-	896	O
were	-	902	O
more	-	907	O
sinoatrial	-	912	O
beats	-	923	O
and	-	929	O
less	-	933	O
ectopies	-	938	O
.	-	946	O

Epinephrine	8659767	948	O
shortened	-	960	O
QT	-	970	O
less	-	973	O
after	-	978	O
bupivacaine	-	984	O
than	-	996	O
in	-	1001	O
control	-	1004	O
animals	-	1012	O
.	-	1019	O

One	8659767	1021	O
day	-	1025	O
after	-	1029	O
experimental	-	1035	O
myocardial	-	1048	B
infarction	-	1059	I
,	-	1069	O
six	-	1071	O
additional	-	1075	O
halothane	-	1086	O
-	-	1095	O
anesthetized	-	1096	O
dogs	-	1109	O
received	-	1114	O
4	-	1123	O
micrograms	-	1125	O
.	-	1135	O
kg	-	1136	O
-	-	1138	O
1	-	1139	O
.	-	1140	O
min	-	1141	O
-	-	1144	O
1	-	1145	O
epinephrine	-	1147	O
until	-	1159	O
VT	-	1165	B
appeared	-	1168	O
.	-	1176	O

After	8659767	1178	O
45	-	1184	O
min	-	1187	O
,	-	1190	O
1	-	1192	O
mg	-	1194	O
/	-	1196	O
kg	-	1197	O
bupivacaine	-	1200	O
was	-	1212	O
injected	-	1216	O
over	-	1225	O
5	-	1230	O
min	-	1232	O
,	-	1235	O
again	-	1237	O
followed	-	1243	O
by	-	1252	O
4	-	1255	O
micrograms	-	1257	O
.	-	1267	O
kg	-	1268	O
-	-	1270	O
1	-	1271	O
.	-	1272	O
min	-	1273	O
-	-	1276	O
1	-	1277	O
epinephrine	-	1279	O
.	-	1290	O

In	8659767	1292	O
these	-	1295	O
dogs	-	1301	O
,	-	1305	O
the	-	1307	O
prodysrhythmic	-	1311	O
response	-	1326	O
to	-	1335	O
epinephrine	-	1338	O
was	-	1350	O
also	-	1354	O
mitigated	-	1359	O
by	-	1369	O
preceding	-	1372	O
bupivacaine	-	1382	O
.	-	1393	O

Bupivacaine	8659767	1395	O
antagonizes	-	1407	O
epinephrine	-	1419	O
dysrhythmogenicity	-	1431	O
in	-	1450	O
conscious	-	1453	O
dogs	-	1463	O
susceptible	-	1468	O
to	-	1480	O
VT	-	1483	B
and	-	1486	O
in	-	1490	O
anesthetized	-	1493	O
dogs	-	1506	O
with	-	1511	O
spontaneous	-	1516	O
postinfarct	-	1528	O
dysrhythmias	-	1540	B
.	-	1552	O

There	8659767	1554	O
is	-	1560	O
no	-	1563	O
evidence	-	1566	O
that	-	1575	O
systemic	-	1580	O
subtoxic	-	1589	O
bupivacaine	-	1598	O
administration	-	1610	O
enhances	-	1625	O
the	-	1634	O
dysrhythmogenicity	-	1638	O
of	-	1657	O
subsequent	-	1660	O
epinephrine	-	1671	O
.	-	1682	O

Milk	8667442	0	B
-	-	4	I
alkali	-	5	I
syndrome	-	12	I
induced	-	21	O
by	-	29	O
1	-	32	O
,	-	33	O
25	-	34	O
(	-	36	O
OH	-	37	O
)	-	39	O
2D	-	40	O
in	-	43	O
a	-	46	O
patient	-	48	O
with	-	56	O
hypoparathyroidism	-	61	B
.	-	79	O

Milk	8667442	81	B
-	-	85	I
alkali	-	86	I
syndrome	-	93	I
was	-	102	O
first	-	106	O
described	-	112	O
70	-	122	O
years	-	125	O
ago	-	131	O
in	-	135	O
the	-	138	O
context	-	142	O
of	-	150	O
the	-	153	O
treatment	-	157	O
of	-	167	O
peptic	-	170	B
ulcer	-	177	I
disease	-	183	I
with	-	191	O
large	-	196	O
amounts	-	202	O
of	-	210	O
calcium	-	213	O
and	-	221	O
alkali	-	225	O
.	-	231	O

Although	8667442	233	O
with	-	242	O
current	-	247	O
ulcer	-	255	B
therapy	-	261	O
(	-	269	O
H	-	270	O
-	-	271	O
2	-	272	O
blockers	-	274	O
,	-	282	O
omeprazole	-	284	O
,	-	294	O
and	-	296	O
sucralfate	-	300	O
)	-	310	O
,	-	311	O
the	-	313	O
frequency	-	317	O
of	-	327	O
milk	-	330	B
-	-	334	I
alkali	-	335	I
syndrome	-	342	I
has	-	351	O
decreased	-	355	O
significantly	-	365	O
,	-	378	O
the	-	380	O
classic	-	384	O
triad	-	392	O
of	-	398	O
hypercalcemia	-	401	B
,	-	414	O
alkalosis	-	416	B
,	-	425	O
and	-	427	O
renal	-	431	B
impairment	-	437	I
remains	-	448	O
the	-	456	O
hallmark	-	460	O
of	-	469	O
the	-	472	O
syndrome	-	476	O
.	-	484	O

Milk	8667442	486	B
-	-	490	I
alkali	-	491	I
syndrome	-	498	I
can	-	507	O
present	-	511	O
serious	-	519	O
and	-	527	O
occasionally	-	531	O
life	-	544	O
-	-	548	O
threatening	-	549	O
illness	-	561	O
unless	-	569	O
diagnosed	-	576	O
and	-	586	O
treated	-	590	O
appropriately	-	598	O
.	-	611	O

This	8667442	613	O
article	-	618	O
presents	-	626	O
a	-	635	O
patient	-	637	O
with	-	645	O
hypoparathyroidism	-	650	B
who	-	669	O
was	-	673	O
treated	-	677	O
with	-	685	O
calcium	-	690	O
carbonate	-	698	O
and	-	708	O
calcitriol	-	712	O
resulting	-	723	O
in	-	733	O
two	-	736	O
admissions	-	740	O
to	-	751	O
the	-	754	O
hospital	-	758	O
for	-	767	O
milk	-	771	B
-	-	775	I
alkali	-	776	I
syndrome	-	783	I
.	-	791	O

The	8667442	793	O
patient	-	797	O
was	-	805	O
successfully	-	809	O
treated	-	822	O
with	-	830	O
intravenous	-	835	O
pamidronate	-	847	O
on	-	859	O
his	-	862	O
first	-	866	O
admission	-	872	O
and	-	882	O
with	-	886	O
hydrocortisone	-	891	O
on	-	906	O
the	-	909	O
second	-	913	O
.	-	919	O

This	8667442	921	O
illustrates	-	926	O
intravenous	-	938	O
pamidronate	-	950	O
as	-	962	O
a	-	965	O
valuable	-	967	O
therapeutic	-	976	O
tool	-	988	O
when	-	993	O
milk	-	998	B
-	-	1002	I
alkali	-	1003	I
syndrome	-	1010	I
presents	-	1019	O
as	-	1028	O
hypercalcemic	-	1031	B
emergency	-	1045	I
.	-	1054	O

Encephalopathy	8748050	0	B
during	-	15	O
amitriptyline	-	22	O
therapy	-	36	O
:	-	43	O
are	-	45	O
neuroleptic	-	49	B
malignant	-	61	I
syndrome	-	71	I
and	-	80	O
serotonin	-	84	B
syndrome	-	94	I
spectrum	-	103	O
disorders	-	112	O
?	-	121	O

This	8748050	123	O
report	-	128	O
describes	-	135	O
a	-	145	O
case	-	147	O
of	-	152	O
encephalopathy	-	155	B
developed	-	170	O
in	-	180	O
the	-	183	O
course	-	187	O
of	-	194	O
amitriptyline	-	197	O
therapy	-	211	O
,	-	218	O
during	-	220	O
a	-	227	O
remission	-	229	O
of	-	239	O
unipolar	-	242	B
depression	-	251	I
.	-	261	O

This	8748050	263	O
patient	-	268	O
could	-	276	O
have	-	282	O
been	-	287	O
diagnosed	-	292	O
as	-	302	O
having	-	305	O
either	-	312	O
neuroleptic	-	319	B
malignant	-	331	I
syndrome	-	341	I
(	-	350	O
NMS	-	351	B
)	-	354	O
or	-	356	O
serotonin	-	359	B
syndrome	-	369	I
(	-	378	O
SS	-	379	B
)	-	381	O
.	-	382	O

The	8748050	384	O
major	-	388	O
determinant	-	394	O
of	-	406	O
the	-	409	O
symptoms	-	413	O
may	-	422	O
have	-	426	O
been	-	431	O
dopamine	-	436	O
/	-	444	O
serotonin	-	445	O
imbalance	-	455	O
in	-	465	O
the	-	468	O
central	-	472	O
nervous	-	480	O
system	-	488	O
.	-	494	O

The	8748050	496	O
NMS	-	500	B
-	-	503	O
like	-	504	O
encephalopathy	-	509	B
that	-	524	O
develops	-	529	O
in	-	538	O
association	-	541	O
with	-	553	O
the	-	558	O
use	-	562	O
of	-	566	O
antidepressants	-	569	O
indicates	-	585	O
that	-	595	O
NMS	-	600	B
and	-	604	O
SS	-	608	B
are	-	611	O
spectrum	-	615	O
disorders	-	624	O
induced	-	634	O
by	-	642	O
drugs	-	645	O
with	-	651	O
both	-	656	O
antidopaminergic	-	661	O
and	-	678	O
serotonergic	-	682	O
effects	-	695	O
.	-	702	O

Genetic	8755612	0	O
separation	-	8	O
of	-	19	O
tumor	-	22	B
growth	-	28	O
and	-	35	O
hemorrhagic	-	39	B
phenotypes	-	51	O
in	-	62	O
an	-	65	O
estrogen	-	68	O
-	-	76	O
induced	-	77	O
tumor	-	85	B
.	-	90	O

Chronic	8755612	92	O
administration	-	100	O
of	-	115	O
estrogen	-	118	O
to	-	127	O
the	-	130	O
Fischer	-	134	O
344	-	142	O
(	-	146	O
F344	-	147	O
)	-	151	O
rat	-	153	O
induces	-	157	O
growth	-	165	O
of	-	172	O
large	-	175	O
,	-	180	O
hemorrhagic	-	182	B
pituitary	-	194	B
tumors	-	204	I
.	-	210	O

Ten	8755612	212	O
weeks	-	216	O
of	-	222	O
diethylstilbestrol	-	225	O
(	-	244	O
DES	-	245	O
)	-	248	O
treatment	-	250	O
caused	-	260	O
female	-	267	O
F344	-	274	O
rat	-	279	O
pituitaries	-	283	O
to	-	295	O
grow	-	298	O
to	-	303	O
an	-	306	O
average	-	309	O
of	-	317	O
109	-	320	O
.	-	323	O
2	-	324	O
+	-	326	O
/	-	327	O
-	-	328	O

6	8755612	330	O
.	-	331	O
3	-	332	O
mg	-	334	O
(	-	337	O
mean	-	338	O
+	-	343	O
/	-	344	O
-	-	345	O

SE	8755612	347	O
)	-	349	O
versus	-	351	O
11	-	358	O
.	-	360	O
3	-	361	O
+	-	363	O
/	-	364	O
-	-	365	O

1	8755612	367	O
.	-	368	O
4	-	369	O
mg	-	371	O
for	-	374	O
untreated	-	378	O
rats	-	388	O
,	-	392	O
and	-	394	O
to	-	398	O
become	-	401	O
highly	-	408	O
hemorrhagic	-	415	B
.	-	426	O

The	8755612	428	O
same	-	432	O
DES	-	437	O
treatment	-	441	O
produced	-	451	O
no	-	460	O
significant	-	463	O
growth	-	475	O
(	-	482	O
8	-	483	O
.	-	484	O
9	-	485	O
+	-	487	O
/	-	488	O
-	-	489	O
0	-	491	O
.	-	492	O
5	-	493	O
mg	-	495	O
for	-	498	O
treated	-	502	O
females	-	510	O
versus	-	518	O
8	-	525	O
.	-	526	O
7	-	527	O
+	-	529	O
/	-	530	O
-	-	531	O

1	8755612	533	O
.	-	534	O
1	-	535	O
for	-	537	O
untreated	-	541	O
females	-	551	O
)	-	558	O
or	-	560	O
morphological	-	563	O
changes	-	577	O
in	-	585	O
Brown	-	588	O
Norway	-	594	O
(	-	601	O
BN	-	602	O
)	-	604	O
rat	-	606	O
pituitaries	-	610	O
.	-	621	O

An	8755612	623	O
F1	-	626	O
hybrid	-	629	O
of	-	636	O
F344	-	639	O
and	-	644	O
BN	-	648	O
exhibited	-	651	O
significant	-	661	O
pituitary	-	673	O
growth	-	683	O
after	-	690	O
10	-	696	O
weeks	-	699	O
of	-	705	O
DES	-	708	O
treatment	-	712	O
with	-	722	O
an	-	727	O
average	-	730	O
mass	-	738	O
of	-	743	O
26	-	746	O
.	-	748	O
3	-	749	O
+	-	751	O
/	-	752	O
-	-	753	O

0	8755612	755	O
.	-	756	O
7	-	757	O
mg	-	759	O
compared	-	762	O
with	-	771	O
8	-	776	O
.	-	777	O
6	-	778	O
+	-	780	O
/	-	781	O
-	-	782	O
0	-	784	O
.	-	785	O
9	-	786	O
mg	-	788	O
for	-	791	O
untreated	-	795	O
rats	-	805	O
.	-	809	O

Surprisingly	8755612	811	O
,	-	823	O
the	-	825	O
F1	-	829	O
hybrid	-	832	O
tumors	-	839	B
were	-	846	O
not	-	851	O
hemorrhagic	-	855	B
and	-	867	O
had	-	871	O
hemoglobin	-	875	O
content	-	886	O
and	-	894	O
outward	-	898	O
appearance	-	906	O
identical	-	917	O
to	-	927	O
that	-	930	O
of	-	935	O
BN	-	938	O
.	-	940	O

Expression	8755612	942	O
of	-	953	O
both	-	956	O
growth	-	961	O
and	-	968	O
morphological	-	972	O
changes	-	986	O
is	-	994	O
due	-	997	O
to	-	1001	O
multiple	-	1004	O
genes	-	1013	O
.	-	1018	O

However	8755612	1020	O
,	-	1027	O
while	-	1029	O
DES	-	1035	O
-	-	1038	O
induced	-	1039	O
pituitary	-	1047	O
growth	-	1057	O
exhibited	-	1064	O
quantitative	-	1074	O
,	-	1086	O
additive	-	1088	O
inheritance	-	1097	O
,	-	1108	O
the	-	1110	O
hemorrhagic	-	1114	B
phenotype	-	1126	O
exhibited	-	1136	O
recessive	-	1146	O
,	-	1155	O
epistatic	-	1157	O
inheritance	-	1167	O
.	-	1178	O

Only	8755612	1180	O
5	-	1185	O
of	-	1187	O
the	-	1190	O
160	-	1194	O
F2	-	1198	O
pituitaries	-	1201	O
exhibited	-	1213	O
the	-	1223	O
hemorrhagic	-	1227	B
phenotype	-	1239	O
;	-	1248	O
36	-	1250	O
of	-	1253	O
the	-	1256	O
160	-	1260	O
F2	-	1264	O
pituitaries	-	1267	O
were	-	1279	O
in	-	1284	O
the	-	1287	O
F344	-	1291	O
range	-	1296	O
of	-	1302	O
mass	-	1305	O
,	-	1309	O
but	-	1311	O
31	-	1315	O
of	-	1318	O
these	-	1321	O
were	-	1327	O
not	-	1332	O
hemorrhagic	-	1336	B
,	-	1347	O
indicating	-	1349	O
that	-	1360	O
the	-	1365	O
hemorrhagic	-	1369	B
phenotype	-	1381	O
is	-	1391	O
not	-	1394	O
merely	-	1398	O
a	-	1405	O
consequence	-	1407	O
of	-	1419	O
extensive	-	1422	O
growth	-	1432	O
.	-	1438	O

The	8755612	1440	O
hemorrhagic	-	1444	B
F2	-	1456	O
pituitaries	-	1459	O
were	-	1471	O
all	-	1476	O
among	-	1480	O
the	-	1486	O
most	-	1490	O
massive	-	1495	O
,	-	1502	O
indicating	-	1504	O
that	-	1515	O
some	-	1520	O
of	-	1525	O
the	-	1528	O
genes	-	1532	O
regulate	-	1538	O
both	-	1547	O
phenotypes	-	1552	O
.	-	1562	O

Increased	8808730	0	O
expression	-	10	O
of	-	21	O
neuronal	-	24	O
nitric	-	33	O
oxide	-	40	O
synthase	-	46	O
in	-	55	O
bladder	-	58	O
afferent	-	66	O
pathways	-	75	O
following	-	84	O
chronic	-	94	O
bladder	-	102	B
irritation	-	110	I
.	-	120	O

Immunocytochemical	8808730	122	O
techniques	-	141	O
were	-	152	O
used	-	157	O
to	-	162	O
examine	-	165	O
alterations	-	173	O
in	-	185	O
the	-	188	O
expression	-	192	O
of	-	203	O
neuronal	-	206	O
nitric	-	215	O
oxide	-	222	O
synthase	-	228	O
(	-	237	O
NOS	-	238	O
)	-	241	O
in	-	243	O
bladder	-	246	O
pathways	-	254	O
following	-	263	O
acute	-	273	O
and	-	279	O
chronic	-	283	O
irritation	-	291	B
of	-	302	I
the	-	305	I
urinary	-	309	I
tract	-	317	I
of	-	323	O
the	-	326	O
rat	-	330	O
.	-	333	O

Chemical	8808730	335	O
cystitis	-	344	B
was	-	353	O
induced	-	357	O
by	-	365	O
cyclophosphamide	-	368	O
(	-	385	O
CYP	-	386	O
)	-	389	O
which	-	391	O
is	-	397	O
metabolized	-	400	O
to	-	412	O
acrolein	-	415	O
,	-	423	O
an	-	425	O
irritant	-	428	O
eliminated	-	437	O
in	-	448	O
the	-	451	O
urine	-	455	O
.	-	460	O

Injection	8808730	462	O
of	-	472	O
CYP	-	475	O
(	-	479	O
n	-	480	O
=	-	482	O
10	-	484	O
,	-	486	O
75	-	488	O
mg	-	491	O
/	-	493	O
kg	-	494	O
,	-	496	O
i	-	498	O
.	-	499	O
p	-	500	O
.	-	501	O
)	-	502	O

2	8808730	504	O
hours	-	506	O
prior	-	512	O
to	-	518	O
perfusion	-	521	O
(	-	531	O
acute	-	532	O
treatment	-	538	O
)	-	547	O
of	-	549	O
the	-	552	O
animals	-	556	O
increased	-	564	O
Fos	-	574	O
-	-	577	O
immunoreactivity	-	578	O
(	-	595	O
IR	-	596	O
)	-	598	O
in	-	600	O
neurons	-	603	O
in	-	611	O
the	-	614	O
dorsal	-	618	O
commissure	-	625	O
,	-	635	O
dorsal	-	637	O
horn	-	644	O
,	-	648	O
and	-	650	O
autonomic	-	654	O
regions	-	664	O
of	-	672	O
spinal	-	675	O
segments	-	682	O
(	-	691	O
L1	-	692	O
-	-	694	O
L2	-	695	O
and	-	698	O
L6	-	702	O
-	-	704	O
S1	-	705	O
)	-	707	O
which	-	709	O
receive	-	715	O
afferent	-	723	O
inputs	-	732	O
from	-	739	O
the	-	744	O
bladder	-	748	O
,	-	755	O
urethra	-	757	O
,	-	764	O
and	-	766	O
ureter	-	770	O
.	-	776	O

Fos	8808730	778	O
-	-	781	O
IR	-	782	O
in	-	785	O
the	-	788	O
spinal	-	792	O
cord	-	799	O
was	-	804	O
not	-	808	O
changed	-	812	O
in	-	820	O
rats	-	823	O
receiving	-	828	O
chronic	-	838	O
CYP	-	846	O
treatment	-	850	O
(	-	860	O
n	-	861	O
=	-	863	O
15	-	865	O
,	-	867	O
75	-	869	O
mg	-	872	O
/	-	874	O
kg	-	875	O
,	-	877	O
i	-	879	O
.	-	880	O
p	-	881	O
.	-	882	O

,	8808730	883	O
every	-	885	O
3rd	-	891	O
day	-	895	O
for	-	899	O
2	-	903	O
weeks	-	905	O
)	-	910	O
.	-	911	O

In	8808730	913	O
control	-	916	O
animals	-	924	O
and	-	932	O
in	-	936	O
animals	-	939	O
treated	-	947	O
acutely	-	955	O
with	-	963	O
CYP	-	968	O
,	-	971	O
only	-	973	O
small	-	978	O
numbers	-	984	O
of	-	992	O
NOS	-	995	O
-	-	998	O
IR	-	999	O
cells	-	1002	O
(	-	1008	O
0	-	1009	O
.	-	1010	O
5	-	1011	O
-	-	1012	O
0	-	1013	O
.	-	1014	O
7	-	1015	O
cell	-	1017	O
profiles	-	1022	O
/	-	1030	O
sections	-	1031	O
)	-	1039	O
were	-	1041	O
detected	-	1046	O
in	-	1055	O
the	-	1058	O
L6	-	1062	O
-	-	1064	O
S1	-	1065	O
dorsal	-	1068	O
root	-	1075	O
ganglia	-	1080	O
(	-	1088	O
DRG	-	1089	O
)	-	1092	O
.	-	1093	O

Chronic	8808730	1095	O
CYP	-	1103	O
administration	-	1107	O
significantly	-	1122	O
(	-	1136	O
P	-	1137	O
<	-	1139	O
or	-	1141	O
=	-	1144	O
.	-	1146	O
002	-	1147	O
)	-	1150	O
increased	-	1152	O
bladder	-	1162	O
weight	-	1170	O
by	-	1177	O
60	-	1180	O
%	-	1182	O
and	-	1184	O
increased	-	1188	O

(	8808730	1198	O
7	-	1199	O
-	-	1200	O
to	-	1202	O
11	-	1205	O
-	-	1207	O
fold	-	1208	O
)	-	1212	O
the	-	1214	O
numbers	-	1218	O
of	-	1226	O
NOS	-	1229	O
-	-	1232	O
immunoreactive	-	1233	O
(	-	1248	O
IR	-	1249	O
)	-	1251	O
afferent	-	1253	O
neurons	-	1262	O
in	-	1270	O
the	-	1273	O
L6	-	1277	O
-	-	1279	O
S1	-	1280	O
DRG	-	1283	O
.	-	1286	O

A	8808730	1288	O
small	-	1290	O
increase	-	1296	O
(	-	1305	O
1	-	1306	O
.	-	1307	O
5	-	1308	O
-	-	1309	O
fold	-	1310	O
)	-	1314	O
also	-	1316	O
occurred	-	1321	O
in	-	1330	O
the	-	1333	O
L1	-	1337	O
DRG	-	1340	O
,	-	1343	O
but	-	1345	O
no	-	1349	O
change	-	1352	O
was	-	1359	O
detected	-	1363	O
in	-	1372	O
the	-	1375	O
L2	-	1379	O
and	-	1382	O
L5	-	1386	O
DRG	-	1389	O
.	-	1392	O

Bladder	8808730	1394	O
afferent	-	1402	O
cells	-	1411	O
in	-	1417	O
the	-	1420	O
L6	-	1424	O
-	-	1426	O
S1	-	1427	O
DRG	-	1430	O
labeled	-	1434	O
by	-	1442	O
Fluorogold	-	1445	O
(	-	1456	O
40	-	1457	O
microliters	-	1460	O
)	-	1471	O
injected	-	1473	O
into	-	1482	O
the	-	1487	O
bladder	-	1491	O
wall	-	1499	O
did	-	1504	O
not	-	1508	O
exhibit	-	1512	O
NOS	-	1520	O
-	-	1523	O
IR	-	1524	O
in	-	1527	O
control	-	1530	O
animals	-	1538	O
;	-	1545	O
however	-	1547	O
,	-	1554	O
following	-	1556	O
chronic	-	1566	O
CYP	-	1574	O
administration	-	1578	O
,	-	1592	O
a	-	1594	O
significant	-	1596	O
percentage	-	1608	O
of	-	1619	O
bladder	-	1622	O
afferent	-	1630	O
neurons	-	1639	O
were	-	1647	O
NOS	-	1652	O
-	-	1655	O
IR	-	1656	O
:	-	1658	O
L6	-	1660	O
(	-	1663	O
19	-	1664	O
.	-	1666	O
8	-	1667	O
+	-	1669	O
/	-	1670	O
-	-	1671	O

4	8808730	1673	O
.	-	1674	O
6	-	1675	O
%	-	1676	O
)	-	1677	O
and	-	1679	O
S1	-	1683	O
(	-	1686	O
25	-	1687	O
.	-	1689	O
3	-	1690	O
+	-	1692	O
/	-	1693	O
-	-	1694	O

2	8808730	1696	O
.	-	1697	O
9	-	1698	O
%	-	1699	O
)	-	1700	O
.	-	1701	O

These	8808730	1703	O
results	-	1709	O
indicate	-	1717	O
that	-	1726	O
neuronal	-	1731	O
gene	-	1740	O
expression	-	1745	O
in	-	1756	O
visceral	-	1759	O
sensory	-	1768	O
pathways	-	1776	O
can	-	1785	O
be	-	1789	O
upregulated	-	1792	O
by	-	1804	O
chemical	-	1807	O
irritation	-	1816	O
of	-	1827	O
afferent	-	1830	O
receptors	-	1839	O
in	-	1849	O
the	-	1852	O
urinary	-	1856	O
tract	-	1864	O
and	-	1870	O
/	-	1873	O
or	-	1874	O
that	-	1877	O
pathological	-	1882	O
changes	-	1895	O
in	-	1903	O
the	-	1906	O
urinary	-	1910	O
tract	-	1918	O
can	-	1924	O
initiate	-	1928	O
chemical	-	1937	O
signals	-	1946	O
that	-	1954	O
alter	-	1959	O
the	-	1965	O
chemical	-	1969	O
properties	-	1978	O
of	-	1989	O
visceral	-	1992	O
afferent	-	2001	O
neurons	-	2010	O
.	-	2017	O

Effects	8819482	0	O
of	-	8	O
a	-	11	O
new	-	13	O
calcium	-	17	O
antagonist	-	25	O
,	-	35	O
CD	-	37	O
-	-	39	O
832	-	40	O
,	-	43	O
on	-	45	O
isoproterenol	-	48	O
-	-	61	O
induced	-	62	O
myocardial	-	70	B
ischemia	-	81	I
in	-	90	O
dogs	-	93	O
with	-	98	O
partial	-	103	O
coronary	-	111	B
stenosis	-	120	I
.	-	128	O

Effects	8819482	130	O
of	-	138	O
CD	-	141	O
-	-	143	O
832	-	144	O
on	-	148	O
isoproterenol	-	151	O
(	-	165	O
ISO	-	166	O
)	-	169	O
-	-	170	O
induced	-	171	O
myocardial	-	179	B
ischemia	-	190	I
were	-	199	O
studied	-	204	O
in	-	212	O
dogs	-	215	O
with	-	220	O
partial	-	225	O
coronary	-	233	B
stenosis	-	242	I
of	-	251	O
the	-	254	O
left	-	258	O
circumflex	-	263	O
coronary	-	274	O
artery	-	283	O
and	-	290	O
findings	-	294	O
were	-	303	O
compared	-	308	O
with	-	317	O
those	-	322	O
for	-	328	O
nifedipine	-	332	O
or	-	343	O
diltiazem	-	346	O
.	-	355	O

In	8819482	357	O
the	-	360	O
presence	-	364	O
of	-	373	O
coronary	-	376	B
artery	-	385	I
stenosis	-	392	I
,	-	400	O
3	-	402	O
-	-	403	O
min	-	404	O
periods	-	408	O
of	-	416	O
intracoronary	-	419	O
ISO	-	433	O
infusion	-	437	O
(	-	446	O
10	-	447	O
ng	-	450	O
/	-	452	O
kg	-	453	O
/	-	455	O
min	-	456	O
)	-	459	O
increased	-	461	O
heart	-	471	O
rate	-	477	O
and	-	482	O
maximal	-	486	O
rate	-	494	O
of	-	499	O
left	-	502	O
ventricular	-	507	O
pressure	-	519	O
rise	-	528	O
,	-	532	O
which	-	534	O
resulted	-	540	O
in	-	549	O
a	-	552	O
decrease	-	554	O
in	-	563	O
percentage	-	566	O
segmental	-	577	O
shortening	-	587	O
and	-	598	O
ST	-	602	O
-	-	604	O
segment	-	605	O
elevation	-	613	O
of	-	623	O
the	-	626	O
epicardial	-	630	O
electrocardiogram	-	641	O
.	-	658	O

After	8819482	660	O
the	-	666	O
control	-	670	O
ISO	-	678	O
infusion	-	682	O
with	-	691	O
stenosis	-	696	B
was	-	705	O
performed	-	709	O
,	-	718	O
equihypotensive	-	720	O
doses	-	736	O
of	-	742	O
CD	-	745	O
-	-	747	O
832	-	748	O
(	-	752	O
3	-	753	O
and	-	755	O
10	-	759	O
micrograms	-	762	O
/	-	772	O
kg	-	773	O
/	-	775	O
min	-	776	O
,	-	779	O
n	-	781	O
=	-	783	O
7	-	785	O
)	-	786	O
,	-	787	O
nifedipine	-	789	O
(	-	800	O
1	-	801	O
and	-	803	O
3	-	807	O
micrograms	-	809	O
/	-	819	O
kg	-	820	O
/	-	822	O
min	-	823	O
,	-	826	O
n	-	828	O
=	-	830	O
9	-	832	O
)	-	833	O
or	-	835	O
diltiazem	-	838	O
(	-	848	O
10	-	849	O
and	-	852	O
30	-	856	O
micrograms	-	859	O
/	-	869	O
kg	-	870	O
/	-	872	O
min	-	873	O
,	-	876	O
n	-	878	O
=	-	880	O
7	-	882	O
)	-	883	O
were	-	885	O
infused	-	890	O
5	-	898	O
min	-	900	O
before	-	904	O
and	-	911	O
during	-	915	O
the	-	922	O
second	-	926	O
and	-	933	O
third	-	937	O
ISO	-	943	O
infusion	-	947	O
.	-	955	O

Both	8819482	957	O
CD	-	962	O
-	-	964	O
832	-	965	O
and	-	969	O
diltiazem	-	973	O
,	-	982	O
but	-	984	O
not	-	988	O
nifedipine	-	992	O
,	-	1002	O
significantly	-	1004	O
reduced	-	1018	O
the	-	1026	O
increase	-	1030	O
in	-	1039	O
heart	-	1042	O
rate	-	1048	O
induced	-	1053	O
by	-	1061	O
ISO	-	1064	O
infusion	-	1068	O
.	-	1076	O

In	8819482	1078	O
contrast	-	1081	O
to	-	1090	O
nifedipine	-	1093	O
,	-	1103	O
CD	-	1105	O
-	-	1107	O
832	-	1108	O
(	-	1112	O
10	-	1113	O
micrograms	-	1116	O
/	-	1126	O
kg	-	1127	O
/	-	1129	O
min	-	1130	O
)	-	1133	O
prevented	-	1135	O
the	-	1145	O
decrease	-	1149	O
in	-	1158	O
percentage	-	1161	O
segmental	-	1172	O
shortening	-	1182	O
from	-	1193	O
32	-	1198	O
+	-	1201	O
/	-	1202	O
-	-	1203	O

12	8819482	1205	O
%	-	1207	O
to	-	1209	O
115	-	1212	O
+	-	1216	O
/	-	1217	O
-	-	1218	O

26	8819482	1220	O
%	-	1222	O
of	-	1224	O
the	-	1227	O
control	-	1231	O
value	-	1239	O
(	-	1245	O
P	-	1246	O
<	-	1248	O
.	-	1250	O
01	-	1251	O
)	-	1253	O
and	-	1255	O
ST	-	1259	O
-	-	1261	O
segment	-	1262	O
elevation	-	1270	O
from	-	1280	O
5	-	1285	O
.	-	1286	O
6	-	1287	O
+	-	1289	O
/	-	1290	O
-	-	1291	O

1	8819482	1293	O
.	-	1294	O
0	-	1295	O
mV	-	1297	O
to	-	1300	O
1	-	1303	O
.	-	1304	O
6	-	1305	O
+	-	1307	O
/	-	1308	O
-	-	1309	O

1	8819482	1311	O
.	-	1312	O
3	-	1313	O
mV	-	1315	O
(	-	1318	O
P	-	1319	O
<	-	1321	O
.	-	1323	O
01	-	1324	O
)	-	1326	O
at	-	1328	O
3	-	1331	O
min	-	1333	O
after	-	1337	O
ISO	-	1343	O
infusion	-	1347	O
with	-	1356	O
stenosis	-	1361	B
.	-	1369	O

Diltiazem	8819482	1371	O
(	-	1381	O
30	-	1382	O
micrograms	-	1385	O
/	-	1395	O
kg	-	1396	O
/	-	1398	O
min	-	1399	O
)	-	1402	O
also	-	1404	O
prevented	-	1409	O
the	-	1419	O
decrease	-	1423	O
in	-	1432	O
percentage	-	1435	O
segmental	-	1446	O
shortening	-	1456	O
from	-	1467	O
34	-	1472	O
+	-	1475	O
/	-	1476	O
-	-	1477	O

14	8819482	1479	O
%	-	1481	O
to	-	1483	O
63	-	1486	O
+	-	1489	O
/	-	1490	O
-	-	1491	O

18	8819482	1493	O
%	-	1495	O
of	-	1497	O
the	-	1500	O
control	-	1504	O
value	-	1512	O
(	-	1518	O
P	-	1519	O
<	-	1521	O
.	-	1523	O
05	-	1524	O
)	-	1526	O
and	-	1528	O
ST	-	1532	O
-	-	1534	O
segment	-	1535	O
elevation	-	1543	O
from	-	1553	O
4	-	1558	O
.	-	1559	O
7	-	1560	O
+	-	1562	O
/	-	1563	O
-	-	1564	O

0	8819482	1566	O
.	-	1567	O
7	-	1568	O
mV	-	1570	O
to	-	1573	O
2	-	1576	O
.	-	1577	O
1	-	1578	O
+	-	1580	O
/	-	1581	O
-	-	1582	O

0	8819482	1584	O
.	-	1585	O
7	-	1586	O
mV	-	1588	O
(	-	1591	O
P	-	1592	O
<	-	1594	O
.	-	1596	O
01	-	1597	O
)	-	1599	O
at	-	1601	O
3	-	1604	O
min	-	1606	O
after	-	1610	O
ISO	-	1616	O
infusion	-	1620	O
with	-	1629	O
stenosis	-	1634	B
.	-	1642	O

These	8819482	1644	O
data	-	1650	O
show	-	1655	O
that	-	1660	O
CD	-	1665	O
-	-	1667	O
832	-	1668	O
improves	-	1672	O
myocardial	-	1681	B
ischemia	-	1692	I
during	-	1701	O
ISO	-	1708	O
infusion	-	1712	O
with	-	1721	O
stenosis	-	1726	B
and	-	1735	O
suggest	-	1739	O
that	-	1747	O
the	-	1752	O
negative	-	1756	O
chronotropic	-	1765	O
property	-	1778	O
of	-	1787	O
CD	-	1790	O
-	-	1792	O
832	-	1793	O
plays	-	1797	O
a	-	1803	O
major	-	1805	O
role	-	1811	O
in	-	1816	O
the	-	1819	O
beneficial	-	1823	O
effects	-	1834	O
of	-	1842	O
CD	-	1845	O
-	-	1847	O
832	-	1848	O
.	-	1851	O

The	8825380	0	O
effect	-	4	O
of	-	11	O
recombinant	-	14	O
human	-	26	O
insulin	-	32	O
-	-	39	O
like	-	40	O
growth	-	45	O
factor	-	52	O
-	-	58	O
I	-	59	O
on	-	61	O
chronic	-	64	O
puromycin	-	72	O
aminonucleoside	-	82	O
nephropathy	-	98	B
in	-	110	O
rats	-	113	O
.	-	117	O

We	8825380	119	O
recently	-	122	O
demonstrated	-	131	O
that	-	144	O
recombinant	-	149	O
hGH	-	161	O
exacerbates	-	165	O
renal	-	177	O
functional	-	183	O
and	-	194	O
structural	-	198	O
injury	-	209	O
in	-	216	O
chronic	-	219	O
puromycin	-	227	O
aminonucleoside	-	237	O
(	-	253	O
PAN	-	254	O
)	-	257	O
nephropathy	-	259	B
,	-	270	O
an	-	272	O
experimental	-	275	O
model	-	288	O
of	-	294	O
glomerular	-	297	B
disease	-	308	I
.	-	315	O

Therefore	8825380	317	O
,	-	326	O
we	-	328	O
examined	-	331	O
whether	-	340	O
recombinant	-	348	O
human	-	360	O
(	-	366	O
rh	-	367	O
)	-	369	O
IGF	-	371	O
-	-	374	O

I	8825380	375	O
is	-	377	O
a	-	380	O
safer	-	382	O
alternative	-	388	O
for	-	400	O
the	-	404	O
treatment	-	408	O
of	-	418	O
growth	-	421	B
failure	-	428	I
in	-	436	O
rats	-	439	O
with	-	444	O
chronic	-	449	O
PAN	-	457	O
nephropathy	-	461	B
.	-	472	O

The	8825380	474	O
glomerulopathy	-	478	B
was	-	493	O
induced	-	497	O
by	-	505	O
seven	-	508	O
serial	-	514	O
injections	-	521	O
of	-	532	O
PAN	-	535	O
over	-	539	O
12	-	544	O
wk	-	547	O
.	-	549	O

Experimental	8825380	551	O
animals	-	564	O
(	-	572	O
n	-	573	O
=	-	575	O
6	-	577	O
)	-	578	O
received	-	580	O
rhIGF	-	589	O
-	-	594	O
I	-	595	O
,	-	596	O
400	-	598	O
micrograms	-	602	O
/	-	612	O
d	-	613	O
,	-	614	O
whereas	-	616	O
control	-	624	O
rats	-	632	O
(	-	637	O
n	-	638	O
=	-	640	O
6	-	642	O
)	-	643	O
received	-	645	O
the	-	654	O
vehicle	-	658	O
.	-	665	O

rhIGF	8825380	667	O
-	-	672	O
I	-	673	O
improved	-	675	O
weight	-	684	O
gain	-	691	O
by	-	696	O
14	-	699	O
%	-	701	O
(	-	703	O
p	-	704	O
<	-	706	O
0	-	708	O
.	-	709	O
05	-	710	O
)	-	712	O
,	-	713	O
without	-	715	O
altering	-	723	O
hematocrit	-	732	O
or	-	743	O
blood	-	746	O
pressure	-	752	O
in	-	761	O
rats	-	764	O
with	-	769	O
renal	-	774	B
disease	-	780	I
.	-	787	O

Urinary	8825380	789	O
protein	-	797	O
excretion	-	805	O
was	-	815	O
unaltered	-	819	O
by	-	829	O
rhIGF	-	832	O
-	-	837	O
I	-	838	O
treatment	-	840	O
in	-	850	O
rats	-	853	O
with	-	858	O
chronic	-	863	O
PAN	-	871	O
nephropathy	-	875	B
.	-	886	O

After	8825380	888	O
12	-	894	O
wk	-	897	O
,	-	899	O
the	-	901	O
inulin	-	905	O
clearance	-	912	O
was	-	922	O
higher	-	926	O
in	-	933	O
rhIGF	-	936	O
-	-	941	O
I	-	942	O
-	-	943	O
treated	-	944	O
rats	-	952	O
,	-	956	O
0	-	958	O
.	-	959	O
48	-	960	O
+	-	963	O
/	-	964	O
-	-	965	O

0	8825380	967	O
.	-	968	O
08	-	969	O
versus	-	972	O
0	-	979	O
.	-	980	O
24	-	981	O
+	-	984	O
/	-	985	O
-	-	986	O

0	8825380	988	O
.	-	989	O
06	-	990	O
mL	-	993	O
/	-	995	O
min	-	996	O
/	-	999	O
100	-	1000	O
g	-	1004	O
of	-	1006	O
body	-	1009	O
weight	-	1014	O
in	-	1021	O
untreated	-	1024	O
PAN	-	1034	O
nephropathy	-	1038	B
animals	-	1050	O
,	-	1057	O
p	-	1059	O
<	-	1061	O
0	-	1063	O
.	-	1064	O
05	-	1065	O
.	-	1067	O

The	8825380	1069	O
improvement	-	1073	O
in	-	1085	O
GFR	-	1088	O
was	-	1092	O
not	-	1096	O
associated	-	1100	O
with	-	1111	O
enhanced	-	1116	O
glomerular	-	1125	B
hypertrophy	-	1136	I
or	-	1148	O
increased	-	1151	O
segmental	-	1161	O
glomerulosclerosis	-	1171	B
,	-	1189	O
tubulointerstitial	-	1191	B
injury	-	1210	I
,	-	1216	O
or	-	1218	O
renal	-	1221	O
cortical	-	1227	O
malondialdehyde	-	1236	O
content	-	1252	O
.	-	1259	O

In	8825380	1261	O
rats	-	1264	O
with	-	1269	O
PAN	-	1274	O
nephropathy	-	1278	B
,	-	1289	O
administration	-	1291	O
of	-	1306	O
rhIGF	-	1309	O
-	-	1314	O
I	-	1315	O
increased	-	1317	O
IGF	-	1327	O
-	-	1330	O
I	-	1331	O
and	-	1333	O
GH	-	1337	O
receptor	-	1340	O
gene	-	1349	O
expression	-	1354	O
,	-	1364	O
without	-	1366	O
altering	-	1374	O
the	-	1383	O
steady	-	1387	O
state	-	1394	O
level	-	1400	O
of	-	1406	O
IGF	-	1409	O
-	-	1412	O
I	-	1413	O
receptor	-	1415	O
mRNA	-	1424	O
.	-	1428	O

In	8825380	1430	O
normal	-	1433	O
rats	-	1440	O
with	-	1445	O
intact	-	1450	O
kidneys	-	1457	O
,	-	1464	O
rhIGF	-	1466	O
-	-	1471	O
I	-	1472	O
administration	-	1474	O
(	-	1489	O
n	-	1490	O
=	-	1492	O
4	-	1494	O
)	-	1495	O
did	-	1497	O
not	-	1501	O
alter	-	1505	O
weight	-	1511	O
gain	-	1518	O
,	-	1522	O
blood	-	1524	O
pressure	-	1530	O
,	-	1538	O
proteinuria	-	1540	B
,	-	1551	O
GFR	-	1553	O
,	-	1556	O
glomerular	-	1558	O
planar	-	1569	O
area	-	1576	O
,	-	1580	O
renal	-	1582	O
cortical	-	1588	O
malondialdehyde	-	1597	O
content	-	1613	O
,	-	1620	O
or	-	1622	O
glomerular	-	1625	O
or	-	1636	O
tubulointerstitial	-	1639	B
damage	-	1658	I
,	-	1664	O
compared	-	1666	O
with	-	1675	O
untreated	-	1680	O
animals	-	1690	O
(	-	1698	O
n	-	1699	O
=	-	1701	O
4	-	1703	O
)	-	1704	O
.	-	1705	O

rhIGF	8825380	1707	O
-	-	1712	O

I	8825380	1713	O
treatment	-	1715	O
reduced	-	1725	O
the	-	1733	O
steady	-	1737	O
state	-	1744	O
renal	-	1750	O
IGF	-	1756	O
-	-	1759	O
I	-	1760	O
mRNA	-	1762	O
level	-	1767	O
but	-	1773	O
did	-	1777	O
not	-	1781	O
modify	-	1785	O
gene	-	1792	O
expression	-	1797	O
of	-	1808	O
the	-	1811	O
IGF	-	1815	O
-	-	1818	O
I	-	1819	O
or	-	1821	O
GH	-	1824	O
receptors	-	1827	O
.	-	1836	O

We	8825380	1838	O
conclude	-	1841	O
that	-	1850	O
:	-	1854	O
1	-	1856	O
)	-	1857	O
administration	-	1859	O
of	-	1874	O
rhIGF	-	1877	O
-	-	1882	O
I	-	1883	O
improves	-	1885	O
growth	-	1894	O
and	-	1901	O
GFR	-	1905	O
in	-	1909	O
rats	-	1912	O
with	-	1917	O
chronic	-	1922	O
PAN	-	1930	O
nephropathy	-	1934	B
and	-	1946	O
2	-	1950	O
)	-	1951	O
unlike	-	1953	O
rhGH	-	1960	O
,	-	1964	O
long	-	1966	O
-	-	1970	O
term	-	1971	O
use	-	1976	O
of	-	1980	O
rhIGF	-	1983	O
-	-	1988	O
I	-	1989	O
does	-	1991	O
not	-	1996	O
worsen	-	2000	O
renal	-	2007	O
functional	-	2013	O
and	-	2024	O
structural	-	2028	O
injury	-	2039	O
in	-	2046	O
this	-	2049	O
disease	-	2054	O
model	-	2062	O
.	-	2067	O

Nefiracetam	8829135	0	O
(	-	12	O
DM	-	13	O
-	-	15	O
9384	-	16	O
)	-	20	O
reverses	-	22	O
apomorphine	-	31	O
-	-	42	O
induced	-	43	O
amnesia	-	51	B
of	-	59	O
a	-	62	O
passive	-	64	O
avoidance	-	72	O
response	-	82	O
:	-	90	O
delayed	-	92	O
emergence	-	100	O
of	-	110	O
the	-	113	O
memory	-	117	O
retention	-	124	O
effects	-	134	O
.	-	141	O

Nefiracetam	8829135	143	O
is	-	155	O
a	-	158	O
novel	-	160	O
pyrrolidone	-	166	O
derivative	-	178	O
which	-	189	O
attenuates	-	195	O
scopolamine	-	206	O
-	-	217	O
induced	-	218	O
learning	-	226	B
and	-	235	I
post	-	239	I
-	-	243	I
training	-	244	I
consolidation	-	253	I
deficits	-	267	I
.	-	275	O

Given	8829135	277	O
that	-	283	O
apomorphine	-	288	O
inhibits	-	300	O
passive	-	309	O
avoidance	-	317	O
retention	-	327	O
when	-	337	O
given	-	342	O
during	-	348	O
training	-	355	O
or	-	364	O
in	-	367	O
a	-	370	O
defined	-	372	O
10	-	380	O
-	-	382	O
12h	-	383	O
post	-	387	O
-	-	391	O
training	-	392	O
period	-	401	O
,	-	407	O
we	-	409	O
evaluated	-	412	O
the	-	422	O
ability	-	426	O
of	-	434	O
nefiracetam	-	437	O
to	-	449	O
attenuate	-	452	O
amnesia	-	462	B
induced	-	470	O
by	-	478	O
dopaminergic	-	481	O
agonism	-	494	O
.	-	501	O

A	8829135	503	O
step	-	505	O
-	-	509	O
down	-	510	O
passive	-	515	O
avoidance	-	523	O
paradigm	-	533	O
was	-	542	O
employed	-	546	O
and	-	555	O
nefiracetam	-	559	O
(	-	571	O
3	-	572	O
mg	-	574	O
/	-	576	O
kg	-	577	O
)	-	579	O
and	-	581	O
apomorphine	-	585	O
(	-	597	O
0	-	598	O
.	-	599	O
5	-	600	O
mg	-	602	O
/	-	604	O
kg	-	605	O
)	-	607	O
were	-	609	O
given	-	614	O
alone	-	620	O
or	-	626	O
in	-	629	O
combination	-	632	O
during	-	644	O
training	-	651	O
and	-	660	O
at	-	664	O
the	-	667	O
10	-	671	O
-	-	673	O
12h	-	674	O
post	-	678	O
-	-	682	O
training	-	683	O
period	-	692	O
of	-	699	O
consolidation	-	702	O
.	-	715	O

Co	8829135	717	O
-	-	719	O
administration	-	720	O
of	-	735	O
nefiracetam	-	738	O
and	-	750	O
apomorphine	-	754	O
during	-	766	O
training	-	773	O
or	-	782	O
10h	-	785	O
thereafter	-	789	O
produced	-	800	O
no	-	809	O
significant	-	812	O
anti	-	824	O
-	-	828	O
amnesic	-	829	O
effect	-	837	O
.	-	843	O

However	8829135	845	O
,	-	852	O
administration	-	854	O
of	-	869	O
nefiracetam	-	872	O
during	-	884	O
training	-	891	O
completely	-	900	O
reversed	-	911	O
the	-	920	O
amnesia	-	924	B
induced	-	932	O
by	-	940	O
apomorphine	-	943	O
at	-	955	O
the	-	958	O
10h	-	962	O
post	-	966	O
-	-	970	O
training	-	971	O
time	-	980	O
and	-	985	O
the	-	989	O
converse	-	993	O
was	-	1002	O
also	-	1006	O
true	-	1011	O
.	-	1015	O

These	8829135	1017	O
effects	-	1023	O
were	-	1031	O
not	-	1036	O
mediated	-	1040	O
by	-	1049	O
a	-	1052	O
dopaminergic	-	1054	O
mechanism	-	1067	O
as	-	1077	O
nefiracetam	-	1080	O
,	-	1091	O
at	-	1093	O
millimolar	-	1096	O
concentrations	-	1107	O
,	-	1121	O
failed	-	1123	O
to	-	1130	O
displace	-	1133	O
either	-	1142	O
[	-	1149	O
3H	-	1150	O
]	-	1152	O
SCH	-	1153	O
23390	-	1157	O
or	-	1163	O
[	-	1166	O
3H	-	1167	O
]	-	1169	O
spiperone	-	1170	O
binding	-	1180	O
from	-	1188	O
D1	-	1193	O
or	-	1196	O
D2	-	1199	O
dopamine	-	1202	O
receptor	-	1211	O
subtypes	-	1220	O
,	-	1228	O
respectively	-	1230	O
.	-	1242	O

It	8829135	1244	O
is	-	1247	O
suggested	-	1250	O
that	-	1260	O
nefiracetam	-	1265	O
augments	-	1277	O
molecular	-	1286	O
processes	-	1296	O
in	-	1306	O
the	-	1309	O
early	-	1313	O
stages	-	1319	O
of	-	1326	O
events	-	1329	O
which	-	1336	O
ultimately	-	1342	O
lead	-	1353	O
to	-	1358	O
consolidation	-	1361	O
of	-	1375	O
memory	-	1378	O
.	-	1384	O

Human	8957205	0	O
corticotropin	-	6	O
-	-	19	O
releasing	-	20	O
hormone	-	30	O
and	-	38	O
thyrotropin	-	42	O
-	-	53	O
releasing	-	54	O
hormone	-	64	O
modulate	-	72	O
the	-	81	O
hypercapnic	-	85	B
ventilatory	-	97	O
response	-	109	O
in	-	118	O
humans	-	121	O
.	-	127	O

Human	8957205	129	O
corticotropin	-	135	O
-	-	148	O
releasing	-	149	O
hormone	-	159	O
(	-	167	O
hCRH	-	168	O
)	-	172	O
and	-	174	O
thyrotropin	-	178	O
-	-	189	O
releasing	-	190	O
hormone	-	200	O
(	-	208	O
TRH	-	209	O
)	-	212	O
are	-	214	O
known	-	218	O
to	-	224	O
stimulate	-	227	O
ventilation	-	237	O
after	-	249	O
i	-	255	O
.	-	256	O
v	-	257	O
.	-	258	O

administration	8957205	260	O
in	-	275	O
humans	-	278	O
.	-	284	O

In	8957205	286	O
a	-	289	O
placebo	-	291	O
-	-	298	O
controlled	-	299	O
,	-	309	O
single	-	311	O
-	-	317	O
blind	-	318	O
study	-	324	O
we	-	330	O
aimed	-	333	O
to	-	339	O
clarify	-	342	O
if	-	350	O
both	-	353	O
peptides	-	358	O
act	-	367	O
by	-	371	O
altering	-	374	O
central	-	383	O
chemosensitivity	-	391	O
.	-	407	O

Two	8957205	409	O
subsequent	-	413	O
CO2	-	424	O
-	-	427	O
rebreathing	-	428	O
tests	-	440	O
were	-	446	O
performed	-	451	O
in	-	461	O
healthy	-	464	O
young	-	472	O
volunteers	-	478	O
.	-	488	O

During	8957205	490	O
the	-	497	O
first	-	501	O
test	-	507	O
0	-	512	O
.	-	513	O
9	-	514	O
%	-	515	O
NaCl	-	517	O
was	-	522	O
given	-	526	O
i	-	532	O
.	-	533	O
v	-	534	O
.	-	535	O
;	-	536	O
during	-	538	O
the	-	545	O
second	-	549	O
test	-	556	O
200	-	561	O
micrograms	-	565	O
of	-	576	O
hCRH	-	579	O
(	-	584	O
n	-	585	O
=	-	587	O
12	-	589	O
)	-	591	O
or	-	593	O
400	-	596	O
micrograms	-	600	O
of	-	611	O
TRH	-	614	O
(	-	618	O
n	-	619	O
=	-	621	O
6	-	623	O
)	-	624	O
was	-	626	O
administered	-	630	O
i	-	643	O
.	-	644	O
v	-	645	O
.	-	646	O

Nine	8957205	648	O
subjects	-	653	O
received	-	662	O
0	-	671	O
.	-	672	O
9	-	673	O
%	-	674	O
NaCl	-	676	O
i	-	681	O
.	-	682	O
v	-	683	O
.	-	684	O

during	8957205	686	O
both	-	693	O
rebreathing	-	698	O
manoeuvres	-	710	O
.	-	720	O

The	8957205	722	O
CO2	-	726	O
-	-	729	O
response	-	730	O
curves	-	739	O
for	-	746	O
the	-	750	O
two	-	754	O
tests	-	758	O
were	-	764	O
compared	-	769	O
within	-	778	O
the	-	785	O
same	-	789	O
subject	-	794	O
.	-	801	O

In	8957205	803	O
the	-	806	O
hCRH	-	810	O
group	-	815	O
a	-	821	O
marked	-	823	O
parallel	-	830	O
shift	-	839	O
of	-	845	O
the	-	848	O
CO2	-	852	O
-	-	855	O
response	-	856	O
curve	-	865	O
to	-	871	O
the	-	874	O
left	-	878	O
was	-	883	O
observed	-	887	O
after	-	896	O
hCRH	-	902	O
(	-	907	O
P	-	908	O
<	-	910	O
0	-	912	O
.	-	913	O
01	-	914	O
)	-	916	O
.	-	917	O

The	8957205	919	O
same	-	923	O
effect	-	928	O
occurred	-	935	O
following	-	944	O
TRH	-	954	O
but	-	958	O
was	-	962	O
less	-	966	O
striking	-	971	O
(	-	980	O
P	-	981	O
=	-	983	O
0	-	985	O
.	-	986	O
05	-	987	O
)	-	989	O
.	-	990	O

hCRH	8957205	992	O
and	-	997	O
TRH	-	1001	O
caused	-	1005	O
a	-	1012	O
reduction	-	1014	O
in	-	1024	O
the	-	1027	O
CO2	-	1031	O
threshold	-	1035	O
.	-	1044	O

The	8957205	1046	O
CO2	-	1050	O
-	-	1053	O
response	-	1054	O
curves	-	1063	O
in	-	1070	O
the	-	1073	O
control	-	1077	O
group	-	1085	O
were	-	1091	O
nearly	-	1096	O
identical	-	1103	O
.	-	1112	O

The	8957205	1114	O
results	-	1118	O
indicate	-	1126	O
an	-	1135	O
additive	-	1138	O
effect	-	1147	O
of	-	1154	O
both	-	1157	O
releasing	-	1162	O
hormones	-	1172	O
on	-	1181	O
the	-	1184	O
hypercapnic	-	1188	B
ventilatory	-	1200	O
response	-	1212	O
in	-	1221	O
humans	-	1224	O
,	-	1230	O
presumably	-	1232	O
independent	-	1243	O
of	-	1255	O
central	-	1258	O
chemosensitivity	-	1266	O
.	-	1282	O

Lamivudine	8985298	0	O
is	-	11	O
effective	-	14	O
in	-	24	O
suppressing	-	27	O
hepatitis	-	39	B
B	-	49	I
virus	-	51	O
DNA	-	57	O
in	-	61	O
Chinese	-	64	O
hepatitis	-	72	O
B	-	82	O
surface	-	84	O
antigen	-	92	O
carriers	-	100	O
:	-	108	O
a	-	110	O
placebo	-	112	O
-	-	119	O
controlled	-	120	O
trial	-	131	O
.	-	136	O

Lamivudine	8985298	138	O
is	-	149	O
a	-	152	O
novel	-	154	O
2'	-	160	O
,	-	162	O
3'	-	163	O
-	-	165	O
dideoxy	-	166	O
cytosine	-	174	O
analogue	-	183	O
that	-	192	O
has	-	197	O
potent	-	201	O
inhibitory	-	208	O
effects	-	219	O
on	-	227	O
hepatitis	-	230	B
B	-	240	I
virus	-	242	O
replication	-	248	O
in	-	260	O
vitro	-	263	O
and	-	269	O
in	-	273	O
vivo	-	276	O
.	-	280	O

We	8985298	282	O
performed	-	285	O
a	-	295	O
single	-	297	O
-	-	303	O
blind	-	304	O
,	-	309	O
placebo	-	311	O
-	-	318	O
controlled	-	319	O
study	-	330	O
to	-	336	O
assess	-	339	O
its	-	346	O
effectiveness	-	350	O
and	-	364	O
safety	-	368	O
in	-	375	O
Chinese	-	378	O
hepatitis	-	386	O
B	-	396	O
surface	-	398	O
antigen	-	406	O
(	-	414	O
HBsAg	-	415	O
)	-	420	O
carriers	-	422	O
.	-	430	O

Forty	8985298	432	O
-	-	437	O
two	-	438	O
Chinese	-	442	O
HBsAg	-	450	O
carriers	-	456	O
were	-	465	O
randomized	-	470	O
to	-	481	O
receive	-	484	O
placebo	-	492	O
(	-	500	O
6	-	501	O
patients	-	503	O
)	-	511	O
or	-	513	O
lamivudine	-	516	O
orally	-	527	O
in	-	534	O
dosages	-	537	O
of	-	545	O
25	-	548	O
mg	-	551	O
,	-	553	O
100	-	555	O
mg	-	559	O
,	-	561	O
or	-	563	O
300	-	566	O
mg	-	570	O
daily	-	573	O
(	-	579	O
12	-	580	O
patients	-	583	O
for	-	592	O
each	-	596	O
dosage	-	601	O
)	-	607	O
.	-	608	O

The	8985298	610	O
drug	-	614	O
was	-	619	O
given	-	623	O
for	-	629	O
4	-	633	O
weeks	-	635	O
.	-	640	O

The	8985298	642	O
patients	-	646	O
were	-	655	O
closely	-	660	O
monitored	-	668	O
clinically	-	678	O
,	-	688	O
biochemically	-	690	O
,	-	703	O
and	-	705	O
serologically	-	709	O
up	-	723	O
to	-	726	O
4	-	729	O
weeks	-	731	O
after	-	737	O
drug	-	743	O
treatment	-	748	O
.	-	757	O

All	8985298	759	O
36	-	763	O
patients	-	766	O
receiving	-	775	O
lamivudine	-	785	O
had	-	796	O
a	-	800	O
decrease	-	802	O
in	-	811	O
hepatitis	-	814	B
B	-	824	I
virus	-	826	O
(	-	832	O
HBV	-	833	O
)	-	836	O
DNA	-	838	O
values	-	842	O
of	-	849	O
>	-	852	O
90	-	853	O
%	-	855	O
(	-	857	O
P	-	858	O
<	-	860	O
.	-	862	O
001	-	863	O
compared	-	867	O
with	-	876	O
placebo	-	881	O
)	-	888	O
.	-	889	O

Although	8985298	891	O
25	-	900	O
mg	-	903	O
of	-	906	O
lamivudine	-	909	O
was	-	920	O
slightly	-	924	O
less	-	933	O
effective	-	938	O
than	-	948	O
100	-	953	O
mg	-	957	O
(	-	960	O
P	-	961	O
=	-	963	O
.	-	965	O
011	-	966	O
)	-	969	O
and	-	971	O
300	-	975	O
mg	-	979	O
(	-	982	O
P	-	983	O
=	-	985	O
.	-	987	O
005	-	988	O
)	-	991	O
,	-	992	O
it	-	994	O
still	-	997	O
induced	-	1003	O
94	-	1011	O
%	-	1013	O
suppression	-	1015	O
of	-	1027	O
HBV	-	1030	O
DNA	-	1034	O
after	-	1038	O
the	-	1044	O
fourth	-	1048	O
week	-	1055	O
of	-	1060	O
therapy	-	1063	O
.	-	1070	O

HBV	8985298	1072	O
DNA	-	1076	O
values	-	1080	O
returned	-	1087	O
to	-	1096	O
pretreatment	-	1099	O
levels	-	1112	O
within	-	1119	O
4	-	1126	O
weeks	-	1128	O
of	-	1134	O
cessation	-	1137	O
of	-	1147	O
therapy	-	1150	O
.	-	1157	O

There	8985298	1159	O
was	-	1165	O
no	-	1169	O
change	-	1172	O
in	-	1179	O
the	-	1182	O
hepatitis	-	1186	B
B	-	1196	I
e	-	1198	O
antigen	-	1200	O
status	-	1208	O
or	-	1215	O
in	-	1218	O
aminotransferase	-	1221	O
levels	-	1238	O
.	-	1244	O

No	8985298	1246	O
serious	-	1249	O
adverse	-	1257	O
events	-	1265	O
were	-	1272	O
observed	-	1277	O
.	-	1285	O

In	8985298	1287	O
conclusion	-	1290	O
,	-	1300	O
a	-	1302	O
4	-	1304	O
-	-	1305	O
week	-	1306	O
course	-	1311	O
of	-	1318	O
lamivudine	-	1321	O
was	-	1332	O
safe	-	1336	O
and	-	1341	O
effective	-	1345	O
in	-	1355	O
suppression	-	1358	O
of	-	1370	O
HBV	-	1373	O
DNA	-	1377	O
in	-	1381	O
Chinese	-	1384	O
HBsAg	-	1392	O
carriers	-	1398	O
.	-	1406	O

The	8985298	1408	O
suppression	-	1412	O
was	-	1424	O
>	-	1428	O
90	-	1429	O
%	-	1431	O
but	-	1433	O
reversible	-	1437	O
.	-	1447	O

Studies	8985298	1449	O
with	-	1457	O
long	-	1462	O
-	-	1466	O
term	-	1467	O
lamivudine	-	1472	O
administration	-	1483	O
should	-	1498	O
be	-	1505	O
performed	-	1508	O
to	-	1518	O
determine	-	1521	O
if	-	1531	O
prolonged	-	1534	O
suppression	-	1544	O
of	-	1556	O
HBV	-	1559	O
DNA	-	1563	O
can	-	1567	O
be	-	1571	O
achieved	-	1574	O
.	-	1582	O

Population	8996419	0	O
-	-	10	O
based	-	11	O
study	-	17	O
of	-	23	O
risk	-	26	O
of	-	31	O
venous	-	34	B
thromboembolism	-	41	I
associated	-	57	O
with	-	68	O
various	-	73	O
oral	-	81	O
contraceptives	-	86	O
.	-	100	O

BACKGROUND	8996419	102	O
:	-	112	O

Four	8996419	114	O
studies	-	119	O
published	-	127	O
since	-	137	O
December	-	143	O
,	-	151	O
1995	-	153	O
,	-	157	O
reported	-	159	O
that	-	168	O
the	-	173	O
incidence	-	177	O
of	-	187	O
venous	-	190	B
thromboembolism	-	197	I
(	-	213	O
VTE	-	214	B
)	-	217	O
was	-	219	O
higher	-	223	O
in	-	230	O
women	-	233	O
who	-	239	O
used	-	243	O
oral	-	248	O
contraceptives	-	253	O
(	-	268	O
OCs	-	269	O
)	-	272	O
containing	-	274	O
the	-	285	O
third	-	289	O
-	-	294	O
generation	-	295	O
progestagens	-	306	O
gestodene	-	319	O
or	-	329	O
desogestrel	-	332	O
than	-	344	O
in	-	349	O
users	-	352	O
of	-	358	O
OCs	-	361	O
containing	-	365	O
second	-	376	O
-	-	382	O
generation	-	383	O
progestagens	-	394	O
.	-	406	O

However	8996419	408	O
,	-	415	O
confounding	-	417	O
and	-	429	O
bias	-	433	O
in	-	438	O
the	-	441	O
design	-	445	O
of	-	452	O
these	-	455	O
studies	-	461	O
may	-	469	O
have	-	473	O
affected	-	478	O
the	-	487	O
findings	-	491	O
.	-	499	O

The	8996419	501	O
aim	-	505	O
of	-	509	O
our	-	512	O
study	-	516	O
was	-	522	O
to	-	526	O
re	-	529	O
-	-	531	O
examine	-	532	O
the	-	540	O
association	-	544	O
between	-	556	O
risk	-	564	O
of	-	569	O
VTE	-	572	B
and	-	576	O
OC	-	580	O
use	-	583	O
with	-	587	O
a	-	592	O
different	-	594	O
study	-	604	O
design	-	610	O
and	-	617	O
analysis	-	621	O
to	-	630	O
avoid	-	633	O
some	-	639	O
of	-	644	O
the	-	647	O
bias	-	651	O
and	-	656	O
confounding	-	660	O
of	-	672	O
the	-	675	O
earlier	-	679	O
studies	-	687	O
.	-	694	O

METHODS	8996419	696	O
:	-	703	O

We	8996419	705	O
used	-	708	O
computer	-	713	O
records	-	722	O
of	-	730	O
patients	-	733	O
from	-	742	O
143	-	747	O
general	-	751	O
practices	-	759	O
in	-	769	O
the	-	772	O
UK	-	776	O
.	-	778	O

The	8996419	780	O
study	-	784	O
was	-	790	O
based	-	794	O
on	-	800	O
the	-	803	O
medical	-	807	O
records	-	815	O
of	-	823	O
about	-	826	O
540	-	832	O
,	-	835	O
000	-	836	O
women	-	840	O
born	-	846	O
between	-	851	O
1941	-	859	O
and	-	864	O
1981	-	868	O
.	-	872	O

All	8996419	874	O
women	-	878	O
who	-	884	O
had	-	888	O
a	-	892	O
recorded	-	894	O
diagnosis	-	903	O
of	-	913	O
deep	-	916	B
-	-	920	I
vein	-	921	I
thrombosis	-	926	I
,	-	936	O
venous	-	938	B
thrombosis	-	945	I
not	-	956	O
otherwise	-	960	O
specified	-	970	O
,	-	979	O
or	-	981	O
pulmonary	-	984	O
embolus	-	994	O
during	-	1002	O
the	-	1009	O
study	-	1013	O
period	-	1019	O
,	-	1025	O
and	-	1027	O
who	-	1031	O
had	-	1035	O
been	-	1039	O
treated	-	1044	O
with	-	1052	O
an	-	1057	O
anticoagulant	-	1060	O
were	-	1074	O
identified	-	1079	O
as	-	1090	O
potential	-	1093	O
cases	-	1103	O
of	-	1109	O
VTE	-	1112	B
.	-	1115	O

We	8996419	1117	O
did	-	1120	O
a	-	1124	O
cohort	-	1126	O
analysis	-	1133	O
to	-	1142	O
estimate	-	1145	O
and	-	1154	O
compare	-	1158	O
incidence	-	1166	O
of	-	1176	O
VTE	-	1179	B
in	-	1183	O
users	-	1186	O
of	-	1192	O
the	-	1195	O
main	-	1199	O
OC	-	1204	O
preparations	-	1207	O
,	-	1219	O
and	-	1221	O
a	-	1225	O
nested	-	1227	O
case	-	1234	O
-	-	1238	O
control	-	1239	O
study	-	1247	O
to	-	1253	O
calculate	-	1256	O
the	-	1266	O
odds	-	1270	O
ratios	-	1275	O
of	-	1282	O
VTE	-	1285	B
associated	-	1289	O
with	-	1300	O
use	-	1305	O
of	-	1309	O
different	-	1312	O
types	-	1322	O
of	-	1328	O
OC	-	1331	O
,	-	1333	O
after	-	1335	O
adjustment	-	1341	O
for	-	1352	O
potential	-	1356	O
confounding	-	1366	O
factors	-	1378	O
.	-	1385	O

In	8996419	1387	O
the	-	1390	O
case	-	1394	O
-	-	1398	O
control	-	1399	O
study	-	1407	O
,	-	1412	O
we	-	1414	O
matched	-	1417	O
cases	-	1425	O
to	-	1431	O
controls	-	1434	O
by	-	1443	O
exact	-	1446	O
year	-	1452	O
of	-	1457	O
birth	-	1460	O
,	-	1465	O
practice	-	1467	O
,	-	1475	O
and	-	1477	O
current	-	1481	O
use	-	1489	O
of	-	1493	O
OCs	-	1496	O
.	-	1499	O

We	8996419	1501	O
used	-	1504	O
a	-	1509	O
multiple	-	1511	O
logistic	-	1520	O
regression	-	1529	O
model	-	1540	O
that	-	1546	O
included	-	1551	O
body	-	1560	O
-	-	1564	O
mass	-	1565	O
index	-	1570	O
,	-	1575	O
number	-	1577	O
of	-	1584	O
cycles	-	1587	O
,	-	1593	O
change	-	1595	O
in	-	1602	O
type	-	1605	O
of	-	1610	O
OC	-	1613	O
prescribed	-	1616	O
within	-	1627	O
3	-	1634	O
months	-	1636	O
of	-	1643	O
the	-	1646	O
event	-	1650	O
,	-	1655	O
previous	-	1657	O
pregnancy	-	1666	O
,	-	1675	O
and	-	1677	O
concurrent	-	1681	O
disease	-	1692	O
.	-	1699	O

FINDINGS	8996419	1701	O
:	-	1709	O

85	8996419	1711	O
women	-	1714	O
met	-	1720	O
the	-	1724	O
inclusion	-	1728	O
criteria	-	1738	O
for	-	1747	O
VTE	-	1751	B
,	-	1754	O
two	-	1756	O
of	-	1760	O
whom	-	1763	O
were	-	1768	O
users	-	1773	O
of	-	1779	O
progestagen	-	1782	O
-	-	1793	O
only	-	1794	O
OCs	-	1799	O
.	-	1802	O

Of	8996419	1804	O
the	-	1807	O
83	-	1811	O
cases	-	1814	O
of	-	1820	O
VTE	-	1823	B
associated	-	1827	O
with	-	1838	O
use	-	1843	O
of	-	1847	O
combined	-	1850	O
OCs	-	1859	O
,	-	1862	O
43	-	1864	O
were	-	1867	O
recorded	-	1872	O
as	-	1881	O
deep	-	1884	B
-	-	1888	I
vein	-	1889	I
thrombosis	-	1894	I
,	-	1904	O
35	-	1906	O
as	-	1909	O
pulmonary	-	1912	O
thrombosis	-	1922	B
,	-	1932	O
and	-	1934	O
five	-	1938	O
as	-	1943	O
venous	-	1946	B
thrombosis	-	1953	I
not	-	1964	O
otherwise	-	1968	O
specified	-	1978	O
.	-	1987	O

The	8996419	1989	O
crude	-	1993	O
rate	-	1999	O
of	-	2004	O
VTE	-	2007	B
per	-	2011	O
10	-	2015	O
,	-	2017	O
000	-	2018	O
woman	-	2022	O
-	-	2027	O
years	-	2028	O
was	-	2034	O
4	-	2038	O
.	-	2039	O
10	-	2040	O
in	-	2043	O
current	-	2046	O
users	-	2054	O
of	-	2060	O
any	-	2063	O
OC	-	2067	O
,	-	2069	O
3	-	2071	O
.	-	2072	O
10	-	2073	O
in	-	2076	O
users	-	2079	O
of	-	2085	O
second	-	2088	O
-	-	2094	O
generation	-	2095	O
OCs	-	2106	O
,	-	2109	O
and	-	2111	O
4	-	2115	O
.	-	2116	O
96	-	2117	O
in	-	2120	O
users	-	2123	O
of	-	2129	O
third	-	2132	O
-	-	2137	O
generation	-	2138	O
preparations	-	2149	O
.	-	2161	O

After	8996419	2163	O
adjustment	-	2169	O
for	-	2180	O
age	-	2184	O
,	-	2187	O
the	-	2189	O
rate	-	2193	O
ratio	-	2198	O
of	-	2204	O
VTE	-	2207	B
in	-	2211	O
users	-	2214	O
of	-	2220	O
third	-	2223	O
-	-	2228	O
generation	-	2229	O
relative	-	2240	O
to	-	2249	O
second	-	2252	O
-	-	2258	O
generation	-	2259	O
OCs	-	2270	O
was	-	2274	O
1	-	2278	O
.	-	2279	O
68	-	2280	O
(	-	2283	O
95	-	2284	O
%	-	2286	O
CI	-	2288	O
1	-	2291	O
.	-	2292	O
04	-	2293	O
-	-	2295	O
2	-	2296	O
.	-	2297	O
75	-	2298	O
)	-	2300	O
.	-	2301	O

Logistic	8996419	2303	O
regression	-	2312	O
showed	-	2323	O
no	-	2330	O
significant	-	2333	O
difference	-	2345	O
in	-	2356	O
the	-	2359	O
risk	-	2363	O
of	-	2368	O
VTE	-	2371	B
between	-	2375	O
users	-	2383	O
of	-	2389	O
third	-	2392	O
-	-	2397	O
generation	-	2398	O
and	-	2409	O
second	-	2413	O
-	-	2419	O
generation	-	2420	O
OCs	-	2431	O
.	-	2434	O

Among	8996419	2436	O
users	-	2442	O
of	-	2448	O
third	-	2451	O
-	-	2456	O
generation	-	2457	O
progestagens	-	2468	O
,	-	2480	O
the	-	2482	O
risk	-	2486	O
of	-	2491	O
VTE	-	2494	B
was	-	2498	O
higher	-	2502	O
in	-	2509	O
users	-	2512	O
of	-	2518	O
desogestrel	-	2521	O
with	-	2533	O
20	-	2538	O
g	-	2541	O
ethinyloestradiol	-	2543	O
than	-	2561	O
in	-	2566	O
users	-	2569	O
of	-	2575	O
gestodene	-	2578	O
or	-	2588	O
desogestrel	-	2591	O
with	-	2603	O
30	-	2608	O
g	-	2611	O
ethinyloestradiol	-	2613	O
.	-	2630	O

With	8996419	2632	O
all	-	2637	O
second	-	2641	O
-	-	2647	O
generation	-	2648	O
OCs	-	2659	O
as	-	2663	O
the	-	2666	O
reference	-	2670	O
,	-	2679	O
the	-	2681	O
odds	-	2685	O
ratios	-	2690	O
for	-	2697	O
VTE	-	2701	B
were	-	2705	O
3	-	2710	O
.	-	2711	O
49	-	2712	O
(	-	2715	O
1	-	2716	O
.	-	2717	O
21	-	2718	O
-	-	2720	O
10	-	2721	O
.	-	2723	O
12	-	2724	O
)	-	2726	O
for	-	2728	O
desogestrel	-	2732	O
plus	-	2744	O
20	-	2749	O
g	-	2752	O
ethinyloestradiol	-	2754	O
and	-	2772	O
1	-	2776	O
.	-	2777	O
18	-	2778	O
(	-	2781	O
0	-	2782	O
.	-	2783	O
66	-	2784	O
-	-	2786	O
2	-	2787	O
.	-	2788	O
17	-	2789	O
)	-	2791	O
for	-	2793	O
the	-	2797	O
other	-	2801	O
third	-	2807	O
-	-	2812	O
generation	-	2813	O
progestagens	-	2824	O
.	-	2836	O

INTERPRETATION	8996419	2838	O
:	-	2852	O

The	8996419	2854	O
previously	-	2858	O
reported	-	2869	O
increase	-	2878	O
in	-	2887	O
odds	-	2890	O
ratio	-	2895	O
associated	-	2901	O
with	-	2912	O
third	-	2917	O
-	-	2922	O
generation	-	2923	O
OCs	-	2934	O
when	-	2938	O
compared	-	2943	O
with	-	2952	O
second	-	2957	O
-	-	2963	O
generation	-	2964	O
products	-	2975	O
is	-	2984	O
likely	-	2987	O
to	-	2994	O
have	-	2997	O
been	-	3002	O
the	-	3007	O
result	-	3011	O
of	-	3018	O
residual	-	3021	O
confounding	-	3030	O
by	-	3042	O
age	-	3045	O
.	-	3048	O

The	8996419	3050	O
increased	-	3054	O
odds	-	3064	O
ratio	-	3069	O
associated	-	3075	O
with	-	3086	O
products	-	3091	O
containing	-	3100	O
20	-	3111	O
micrograms	-	3114	O
ethinyloestradiol	-	3125	O
and	-	3143	O
desogestrel	-	3147	O
compared	-	3159	O
with	-	3168	O
the	-	3173	O
30	-	3177	O
micrograms	-	3180	O
product	-	3191	O
is	-	3199	O
biologically	-	3202	O
implausible	-	3215	O
,	-	3226	O
and	-	3228	O
is	-	3232	O
likely	-	3235	O
to	-	3242	O
be	-	3245	O
the	-	3248	O
result	-	3252	O
of	-	3259	O
preferential	-	3262	O
prescribing	-	3275	O
and	-	3287	O
,	-	3290	O
thus	-	3292	O
,	-	3296	O
confounding	-	3298	O
.	-	3309	O

MK	9061777	0	O
-	-	2	O
801	-	3	O
augments	-	7	O
pilocarpine	-	16	O
-	-	27	O
induced	-	28	O
electrographic	-	36	O
seizure	-	51	B
but	-	59	O
protects	-	63	O
against	-	72	O
brain	-	80	B
damage	-	86	I
in	-	93	O
rats	-	96	O
.	-	100	O

1	9061777	102	O
.	-	103	O

The	9061777	105	O
authors	-	109	O
examined	-	117	O
the	-	126	O
anticonvulsant	-	130	O
effects	-	145	O
of	-	153	O
MK	-	156	O
-	-	158	O
801	-	159	O
on	-	163	O
the	-	166	O
pilocarpine	-	170	O
-	-	181	O
induced	-	182	O
seizure	-	190	B
model	-	198	O
.	-	203	O

Intraperitoneal	9061777	205	O
injection	-	221	O
of	-	231	O
pilocarpine	-	234	O
(	-	246	O
400	-	247	O
mg	-	251	O
/	-	253	O
kg	-	254	O
)	-	256	O
induced	-	258	O
tonic	-	266	B
and	-	272	I
clonic	-	276	I
seizure	-	283	I
.	-	290	O

Scopolamine	9061777	292	O
(	-	304	O
10	-	305	O
mg	-	308	O
/	-	310	O
kg	-	311	O
)	-	313	O
and	-	315	O
pentobarbital	-	319	O
(	-	333	O
5	-	334	O
mg	-	336	O
/	-	338	O
kg	-	339	O
)	-	341	O
prevented	-	343	O
development	-	353	O
of	-	365	O
pilocarpine	-	368	O
-	-	379	O
induced	-	380	O
behavioral	-	388	O
seizure	-	399	B
but	-	407	O
MK	-	411	O
-	-	413	O
801	-	414	O
(	-	418	O
0	-	419	O
.	-	420	O
5	-	421	O
mg	-	423	O
/	-	425	O
kg	-	426	O
)	-	428	O
did	-	430	O
not	-	434	O
.	-	437	O

2	9061777	439	O
.	-	440	O

An	9061777	442	O
electrical	-	445	O
seizure	-	456	B
measured	-	464	O
with	-	473	O
hippocampal	-	478	O
EEG	-	490	O
appeared	-	494	O
in	-	503	O
the	-	506	O
pilocarpine	-	510	O
-	-	521	O
treated	-	522	O
group	-	530	O
.	-	535	O

Scopolamine	9061777	537	O
and	-	549	O
pentobarbital	-	553	O
blocked	-	567	O
the	-	575	O
pilocarpine	-	579	O
-	-	590	O
induced	-	591	O
electrographic	-	599	O
seizure	-	614	B
,	-	621	O
MK	-	623	O
-	-	625	O
801	-	626	O
treatment	-	630	O
augmented	-	640	O
the	-	650	O
electrographic	-	654	O
seizure	-	669	B
induced	-	677	O
by	-	685	O
pilocarpine	-	688	O
.	-	699	O

3	9061777	701	O
.	-	702	O

Brain	9061777	704	B
damage	-	710	I
was	-	717	O
assessed	-	721	O
by	-	730	O
examining	-	733	O
the	-	743	O
hippocampus	-	747	O
microscopically	-	759	O
.	-	774	O

Pilocarpine	9061777	776	O
produced	-	788	O
neuronal	-	797	B
death	-	806	I
in	-	812	O
the	-	815	O
hippocampus	-	819	O
,	-	830	O
which	-	832	O
showed	-	838	O
pyknotic	-	845	O
changes	-	854	O
.	-	861	O

Pentobarbital	9061777	863	O
,	-	876	O
scopolamine	-	878	O
and	-	890	O
MK	-	894	O
-	-	896	O
801	-	897	O
protected	-	901	O
the	-	911	O
brain	-	915	B
damage	-	921	I
by	-	928	O
pilocarpine	-	931	O
,	-	942	O
though	-	944	O
in	-	951	O
the	-	954	O
MK	-	958	O
-	-	960	O
801	-	961	O
-	-	964	O
treated	-	965	O
group	-	973	O
,	-	978	O
the	-	980	O
pyramidal	-	984	O
cells	-	994	O
of	-	1000	O
hippocampus	-	1003	O
appeared	-	1015	O
darker	-	1024	O
than	-	1031	O
normal	-	1036	O
.	-	1042	O

In	9061777	1044	O
all	-	1047	O
treatments	-	1051	O
,	-	1061	O
granule	-	1063	O
cells	-	1071	O
of	-	1077	O
the	-	1080	O
dentate	-	1084	O
gyrus	-	1092	O
were	-	1098	O
not	-	1103	O
affected	-	1107	O
.	-	1115	O

4	9061777	1117	O
.	-	1118	O

These	9061777	1120	O
results	-	1126	O
indicate	-	1134	O
that	-	1143	O
status	-	1148	B
epilepticus	-	1155	I
induced	-	1167	O
by	-	1175	O
pilocarpine	-	1178	O
is	-	1190	O
initiated	-	1193	O
by	-	1203	O
cholinergic	-	1206	O
overstimulation	-	1218	O
and	-	1234	O
propagated	-	1238	O
by	-	1249	O
glutamatergic	-	1252	O
transmission	-	1266	O
,	-	1278	O
the	-	1280	O
elevation	-	1284	O
of	-	1294	O
which	-	1297	O
may	-	1303	O
cause	-	1307	O
brain	-	1313	B
damage	-	1319	I
through	-	1326	O
an	-	1334	O
excitatory	-	1337	O
NMDA	-	1348	O
receptor	-	1353	O
-	-	1361	O
mediated	-	1362	O
mechanism	-	1371	O
.	-	1380	O

Paclitaxel	9071336	0	O
,	-	10	O
5	-	12	O
-	-	13	O
fluorouracil	-	14	O
,	-	26	O
and	-	28	O
folinic	-	32	O
acid	-	40	O
in	-	45	O
metastatic	-	48	O
breast	-	59	B
cancer	-	66	I
:	-	72	O
BRE	-	74	O
-	-	77	O
26	-	78	O
,	-	80	O
a	-	82	O
phase	-	84	O
II	-	90	O
trial	-	93	O
.	-	98	O

5	9071336	100	O
-	-	101	O
Fluorouracil	-	102	O
plus	-	115	O
folinic	-	120	O
acid	-	128	O
and	-	133	O
paclitaxel	-	137	O
(	-	148	O
Taxol	-	149	O
;	-	154	O
Bristol	-	156	O
-	-	163	O
Myers	-	164	O
Squibb	-	170	O
Company	-	177	O
,	-	184	O
Princeton	-	186	O
,	-	195	O
NJ	-	197	O
)	-	199	O
are	-	201	O
effective	-	205	O
salvage	-	215	O
therapies	-	223	O
for	-	233	O
metastatic	-	237	O
breast	-	248	B
cancer	-	255	I
patients	-	262	O
.	-	270	O

Paclitaxel	9071336	272	O
and	-	283	O
5	-	287	O
-	-	288	O
fluorouracil	-	289	O
have	-	302	O
additive	-	307	O
cytotoxicity	-	316	B
in	-	329	O
MCF	-	332	O
-	-	335	O
7	-	336	O
cell	-	338	O
lines	-	343	O
.	-	348	O

We	9071336	350	O
performed	-	353	O
a	-	363	O
phase	-	365	O
II	-	371	O
trial	-	374	O
of	-	380	O
paclitaxel	-	383	O
175	-	394	O
mg	-	398	O
/	-	400	O
m2	-	401	O
over	-	404	O
3	-	409	O
hours	-	411	O
on	-	417	O
day	-	420	O
I	-	424	O
followed	-	426	O
by	-	435	O
folinic	-	438	O
acid	-	446	O
300	-	451	O
mg	-	455	O
over	-	458	O
1	-	463	O
hour	-	465	O
before	-	470	O
5	-	477	O
-	-	478	O
fluorouracil	-	479	O
350	-	492	O
mg	-	496	O
/	-	498	O
m2	-	499	O
on	-	502	O
days	-	505	O
1	-	510	O
to	-	512	O
3	-	515	O
every	-	517	O
28	-	523	O
days	-	526	O
(	-	531	O
TFL	-	532	O
)	-	535	O
in	-	537	O
women	-	540	O
with	-	546	O
metastatic	-	551	O
breast	-	562	B
cancer	-	569	I
.	-	575	O

Analysis	9071336	577	O
is	-	586	O
reported	-	589	O
on	-	598	O
37	-	601	O
patients	-	604	O
with	-	613	O
a	-	618	O
minimum	-	620	O
of	-	628	O
6	-	631	O
months	-	633	O
follow	-	640	O
-	-	646	O
up	-	647	O
who	-	650	O
received	-	654	O
a	-	663	O
total	-	665	O
of	-	671	O
192	-	674	O
cycles	-	678	O
of	-	685	O
TFL	-	688	O
:	-	691	O
nine	-	693	O
cycles	-	698	O
(	-	705	O
5	-	706	O
%	-	707	O
)	-	708	O
were	-	710	O
associated	-	715	O
with	-	726	O
grade	-	731	O
3	-	737	O
/	-	738	O
4	-	739	O
neutropenia	-	741	B
requiring	-	753	O
hospitalization	-	763	O
;	-	778	O
seven	-	780	O
(	-	786	O
4	-	787	O
%	-	788	O
)	-	789	O
cycles	-	791	O
in	-	798	O
two	-	801	O
patients	-	805	O
required	-	814	O
granulocyte	-	823	O
colony	-	835	O
-	-	841	O
stimulating	-	842	O
factor	-	854	O
due	-	861	O
to	-	865	O
neutropenia	-	868	B
;	-	879	O
no	-	881	O
patient	-	884	O
required	-	892	O
platelet	-	901	O
transfusions	-	910	O
.	-	922	O

Grade	9071336	924	O
3	-	930	O
/	-	931	O
4	-	932	O
nonhematologic	-	934	O
toxicities	-	949	B
were	-	960	O
uncommon	-	965	O
.	-	973	O

Among	9071336	975	O
the	-	981	O
34	-	985	O
patients	-	988	O
evaluable	-	997	O
for	-	1007	O
response	-	1011	O
,	-	1019	O
there	-	1021	O
were	-	1027	O
three	-	1032	O
complete	-	1038	O
responses	-	1047	O
(	-	1057	O
9	-	1058	O
%	-	1059	O
)	-	1060	O
and	-	1062	O
18	-	1066	O
partial	-	1069	O
responses	-	1077	O
(	-	1087	O
53	-	1088	O
%	-	1090	O
)	-	1091	O
for	-	1093	O
an	-	1097	O
overall	-	1100	O
response	-	1108	O
rate	-	1117	O
of	-	1122	O
62	-	1125	O
%	-	1127	O
.	-	1128	O

Of	9071336	1130	O
the	-	1133	O
19	-	1137	O
evaluable	-	1140	O
patients	-	1150	O
with	-	1159	O
prior	-	1164	O
doxorubicin	-	1170	O
exposure	-	1182	O
,	-	1190	O
11	-	1192	O
(	-	1195	O
58	-	1196	O
%	-	1198	O
)	-	1199	O
responded	-	1201	O
compared	-	1211	O
with	-	1220	O
nine	-	1225	O
of	-	1230	O
15	-	1233	O
(	-	1236	O
60	-	1237	O
%	-	1239	O
)	-	1240	O
without	-	1242	O
prior	-	1250	O
doxorubicin	-	1256	O
.	-	1267	O

Plasma	9071336	1269	O
paclitaxel	-	1276	O
concentrations	-	1287	O
were	-	1302	O
measured	-	1307	O
at	-	1316	O
the	-	1319	O
completion	-	1323	O
of	-	1334	O
paclitaxel	-	1337	O
infusion	-	1348	O
and	-	1357	O
at	-	1361	O
24	-	1364	O
hours	-	1367	O
in	-	1373	O
19	-	1376	O
patients	-	1379	O
.	-	1387	O

TFL	9071336	1389	O
is	-	1393	O
an	-	1396	O
active	-	1399	O
,	-	1405	O
well	-	1407	O
-	-	1411	O
tolerated	-	1412	O
regimen	-	1422	O
in	-	1430	O
metastatic	-	1433	O
breast	-	1444	B
cancer	-	1451	I
.	-	1457	O

Efficacy	9125676	0	O
and	-	9	O
proarrhythmia	-	13	B
with	-	27	O
the	-	32	O
use	-	36	O
of	-	40	O
d	-	43	O
,	-	44	O
l	-	45	O
-	-	46	O
sotalol	-	47	O
for	-	55	O
sustained	-	59	O
ventricular	-	69	B
tachyarrhythmias	-	81	I
.	-	97	O

This	9125676	99	O
study	-	104	O
prospectively	-	110	O
evaluated	-	124	O
the	-	134	O
clinical	-	138	O
efficacy	-	147	O
,	-	155	O
the	-	157	O
incidence	-	161	O
of	-	171	O
torsades	-	174	B
de	-	183	I
pointes	-	186	I
,	-	193	O
and	-	195	O
the	-	199	O
presumable	-	203	O
risk	-	214	O
factors	-	219	O
for	-	227	O
torsades	-	231	B
de	-	240	I
pointes	-	243	I
in	-	251	O
patients	-	254	O
treated	-	263	O
with	-	271	O
d	-	276	O
,	-	277	O
l	-	278	O
-	-	279	O
sotalol	-	280	O
for	-	288	O
sustained	-	292	O
ventricular	-	302	B
tachyarrhythmias	-	314	I
.	-	330	O

Eighty	9125676	332	O
-	-	338	O
one	-	339	O
consecutive	-	343	O
patients	-	355	O
(	-	364	O
54	-	365	O
with	-	368	O
coronary	-	373	B
artery	-	382	I
disease	-	389	I
,	-	396	O
and	-	398	O
20	-	402	O
with	-	405	O
dilated	-	410	B
cardiomyopathy	-	418	I
)	-	432	O
with	-	434	O
inducible	-	439	O
sustained	-	449	O
ventricular	-	459	B
tachycardia	-	471	I
or	-	483	O
ventricular	-	486	B
fibrillation	-	498	I
received	-	511	O
oral	-	520	O
d	-	525	O
,	-	526	O
l	-	527	O
-	-	528	O
sotalol	-	529	O
to	-	537	O
prevent	-	540	O
induction	-	548	O
of	-	558	O
the	-	561	O
ventricular	-	565	B
tachyarrhythmia	-	577	I
.	-	592	O

During	9125676	594	O
oral	-	601	O
loading	-	606	O
with	-	614	O
d	-	619	O
,	-	620	O
l	-	621	O
-	-	622	O
sotalol	-	623	O
,	-	630	O
continuous	-	632	O
electrocardiographic	-	643	O
(	-	664	O
ECG	-	665	O
)	-	668	O
monitoring	-	670	O
was	-	681	O
performed	-	685	O
.	-	694	O

Those	9125676	696	O
patients	-	702	O
in	-	711	O
whom	-	714	O
d	-	719	O
,	-	720	O
l	-	721	O
-	-	722	O
sotalol	-	723	O
prevented	-	731	O
induction	-	741	O
of	-	751	O
ventricular	-	754	B
tachycardia	-	766	I
or	-	778	O
ventricular	-	781	B
fibrillation	-	793	I
were	-	806	O
discharged	-	811	O
with	-	822	O
the	-	827	O
drug	-	831	O
and	-	836	O
followed	-	840	O
up	-	849	O
on	-	852	O
an	-	855	O
outpatient	-	858	O
basis	-	869	O
for	-	875	O
21	-	879	O
+	-	882	O
/	-	883	O
-	-	884	O

18	9125676	886	O
months	-	889	O
.	-	895	O

Induction	9125676	897	O
of	-	907	O
the	-	910	O
ventricular	-	914	B
tachyarrhythmia	-	926	I
was	-	942	O
prevented	-	946	O
by	-	956	O
oral	-	959	O
d	-	964	O
,	-	965	O
l	-	966	O
-	-	967	O
sotalol	-	968	O
in	-	976	O
35	-	979	O
(	-	982	O
43	-	983	O
%	-	985	O
)	-	986	O
patients	-	988	O
;	-	996	O
the	-	998	O
ventricular	-	1002	B
tachyarrhythmia	-	1014	I
remained	-	1030	O
inducible	-	1039	O
in	-	1049	O
40	-	1052	O
(	-	1055	O
49	-	1056	O
%	-	1058	O
)	-	1059	O
patients	-	1061	O
;	-	1069	O
and	-	1071	O
two	-	1075	O
(	-	1079	O
2	-	1080	O
.	-	1081	O
5	-	1082	O
%	-	1083	O
)	-	1084	O
patients	-	1086	O
did	-	1095	O
not	-	1099	O
tolerate	-	1103	O
even	-	1112	O
40	-	1117	O
mg	-	1120	O
of	-	1123	O
d	-	1126	O
,	-	1127	O
l	-	1128	O
-	-	1129	O
sotalol	-	1130	O
once	-	1138	O
daily	-	1143	O
.	-	1148	O

Four	9125676	1150	O
(	-	1155	O
5	-	1156	O
%	-	1157	O
)	-	1158	O
patients	-	1160	O
had	-	1169	O
from	-	1173	O
torsades	-	1178	B
de	-	1187	I
pointes	-	1190	I
during	-	1198	O
the	-	1205	O
initial	-	1209	O
oral	-	1217	O
treatment	-	1222	O
with	-	1232	O
d	-	1237	O
,	-	1238	O
l	-	1239	O
-	-	1240	O
sotalol	-	1241	O
.	-	1248	O

Neither	9125676	1250	O
ECG	-	1258	O
[	-	1262	O
sinus	-	1263	O
-	-	1268	O
cycle	-	1269	O
length	-	1275	O
(	-	1282	O
SCL	-	1283	O
)	-	1286	O
,	-	1287	O
QT	-	1289	O
or	-	1292	O
QTc	-	1295	O
interval	-	1299	O
,	-	1307	O
or	-	1309	O
U	-	1312	O
wave	-	1314	O
]	-	1318	O
nor	-	1320	O
clinical	-	1324	O
parameters	-	1333	O
identified	-	1344	O
patients	-	1355	O
at	-	1364	O
risk	-	1367	O
for	-	1372	O
torsades	-	1376	B
de	-	1385	I
pointes	-	1388	I
.	-	1395	O

However	9125676	1397	O
,	-	1404	O
the	-	1406	O
oral	-	1410	O
dose	-	1415	O
of	-	1420	O
d	-	1423	O
,	-	1424	O
l	-	1425	O
-	-	1426	O
sotalol	-	1427	O
was	-	1435	O
significantly	-	1439	O
lower	-	1453	O
in	-	1459	O
patients	-	1462	O
with	-	1471	O
torsades	-	1476	B
de	-	1485	I
pointes	-	1488	I
(	-	1496	O
200	-	1497	O
+	-	1501	O
/	-	1502	O
-	-	1503	O

46	9125676	1505	O
vs	-	1508	O
.	-	1510	O
328	-	1512	O
+	-	1516	O
/	-	1517	O
-	-	1518	O

53	9125676	1520	O
mg	-	1523	O
/	-	1525	O
day	-	1526	O
;	-	1529	O
p	-	1531	O
=	-	1533	O
0	-	1535	O
.	-	1536	O
0017	-	1537	O
)	-	1541	O
.	-	1542	O

Risk	9125676	1544	O
factors	-	1549	O
associated	-	1557	O
with	-	1568	O
the	-	1573	O
development	-	1577	O
of	-	1589	O
torsades	-	1592	B
de	-	1601	I
pointes	-	1604	I
were	-	1612	O
the	-	1617	O
appearance	-	1621	O
of	-	1632	O
an	-	1635	O
U	-	1638	O
wave	-	1640	O
(	-	1645	O
p	-	1646	O
=	-	1648	O
0	-	1650	O
.	-	1651	O
049	-	1652	O
)	-	1655	O
,	-	1656	O
female	-	1658	O
gender	-	1665	O
(	-	1672	O
p	-	1673	O
=	-	1675	O
0	-	1677	O
.	-	1678	O
015	-	1679	O
)	-	1682	O
,	-	1683	O
and	-	1685	O
significant	-	1689	O
dose	-	1701	O
-	-	1705	O
corrected	-	1706	O
changes	-	1716	O
of	-	1724	O
SCL	-	1727	O
,	-	1730	O
QT	-	1732	O
interval	-	1735	O
,	-	1743	O
and	-	1745	O
QTc	-	1749	O
interval	-	1753	O
(	-	1762	O
p	-	1763	O
<	-	1765	O
0	-	1767	O
.	-	1768	O
05	-	1769	O
)	-	1771	O
.	-	1772	O

During	9125676	1774	O
follow	-	1781	O
-	-	1787	O
up	-	1788	O
,	-	1790	O
seven	-	1792	O
(	-	1798	O
20	-	1799	O
%	-	1801	O
)	-	1802	O
patients	-	1804	O
had	-	1813	O
a	-	1817	O
nonfatal	-	1819	O
ventricular	-	1828	B
tachycardia	-	1840	I
recurrence	-	1852	O
,	-	1862	O
and	-	1864	O
two	-	1868	O
(	-	1872	O
6	-	1873	O
%	-	1874	O
)	-	1875	O
patients	-	1877	O
died	-	1886	O
suddenly	-	1891	O
.	-	1899	O

One	9125676	1901	O
female	-	1905	O
patient	-	1912	O
with	-	1920	O
stable	-	1925	O
cardiac	-	1932	B
disease	-	1940	I
had	-	1948	O
recurrent	-	1952	O
torsades	-	1962	B
de	-	1971	I
pointes	-	1974	I
after	-	1982	O
2	-	1988	O
years	-	1990	O
of	-	1996	O
successful	-	1999	O
treatment	-	2010	O
with	-	2020	O
d	-	2025	O
,	-	2026	O
l	-	2027	O
-	-	2028	O
sotalol	-	2029	O
.	-	2036	O

Torsades	9125676	2038	B
de	-	2047	I
pointes	-	2050	I
occurred	-	2058	O
early	-	2067	O
during	-	2073	O
treatment	-	2080	O
even	-	2090	O
with	-	2095	O
low	-	2100	O
doses	-	2104	O
of	-	2110	O
oral	-	2113	O
d	-	2118	O
,	-	2119	O
l	-	2120	O
-	-	2121	O
sotalol	-	2122	O
.	-	2129	O

Pronounced	9125676	2131	O
changes	-	2142	O
in	-	2150	O
the	-	2153	O
surface	-	2157	O
ECG	-	2165	O
(	-	2169	O
cycle	-	2170	O
length	-	2176	O
,	-	2182	O
QT	-	2184	O
,	-	2186	O
and	-	2188	O
QTc	-	2192	O
)	-	2195	O
in	-	2197	O
relation	-	2200	O
to	-	2209	O
the	-	2212	O
dose	-	2216	O
of	-	2221	O
oral	-	2224	O
d	-	2229	O
,	-	2230	O
l	-	2231	O
-	-	2232	O
sotalol	-	2233	O
might	-	2241	O
identify	-	2247	O
a	-	2256	O
subgroup	-	2258	O
of	-	2267	O
patients	-	2270	O
with	-	2279	O
an	-	2284	O
increased	-	2287	O
risk	-	2297	O
for	-	2302	O
torsades	-	2306	B
de	-	2315	I
pointes	-	2318	I
.	-	2325	O

Other	9125676	2327	O
ECG	-	2333	O
parameters	-	2337	O
before	-	2348	O
the	-	2355	O
application	-	2359	O
of	-	2371	O
d	-	2374	O
,	-	2375	O
l	-	2376	O
-	-	2377	O
sotalol	-	2378	O
did	-	2386	O
not	-	2390	O
identify	-	2394	O
patients	-	2403	O
at	-	2412	O
increased	-	2415	O
risk	-	2425	O
for	-	2430	O
torsades	-	2434	B
de	-	2443	I
pointes	-	2446	I
.	-	2453	O

Recurrence	9125676	2455	O
rates	-	2466	O
of	-	2472	O
ventricular	-	2475	B
tachyarrhythmias	-	2487	I
are	-	2504	O
high	-	2508	O
despite	-	2513	O
complete	-	2521	O
suppression	-	2530	O
of	-	2542	O
the	-	2545	O
arrhythmia	-	2549	B
during	-	2560	O
programmed	-	2567	O
stimulation	-	2578	O
.	-	2589	O

Therefore	9125676	2591	O
programmed	-	2601	O
electrical	-	2612	O
stimulation	-	2623	O
in	-	2635	O
the	-	2638	O
case	-	2642	O
of	-	2647	O
d	-	2650	O
,	-	2651	O
l	-	2652	O
-	-	2653	O
sotalol	-	2654	O
seems	-	2662	O
to	-	2668	O
be	-	2671	O
of	-	2674	O
limited	-	2677	O
prognostic	-	2685	O
value	-	2696	O
.	-	2701	O

Chronic	9128918	0	O
hyperprolactinemia	-	8	B
and	-	27	O
changes	-	31	O
in	-	39	O
dopamine	-	42	O
neurons	-	51	O
.	-	58	O

The	9128918	60	O
tuberoinfundibular	-	64	O
dopaminergic	-	83	O
(	-	96	O
TIDA	-	97	O
)	-	101	O
system	-	103	O
is	-	110	O
known	-	113	O
to	-	119	O
inhibit	-	122	O
prolactin	-	130	O
(	-	140	O
PRL	-	141	O
)	-	144	O
secretion	-	146	O
.	-	155	O

In	9128918	157	O
young	-	160	O
animals	-	166	O
this	-	174	O
system	-	179	O
responds	-	186	O
to	-	195	O
acute	-	198	O
elevations	-	204	O
in	-	215	O
serum	-	218	O
PRL	-	224	O
by	-	228	O
increasing	-	231	O
its	-	242	O
activity	-	246	O
.	-	254	O

However	9128918	256	O
,	-	263	O
this	-	265	O
responsiveness	-	270	O
is	-	285	O
lost	-	288	O
in	-	293	O
aging	-	296	O
rats	-	302	O
with	-	307	O
chronically	-	312	O
high	-	324	O
serum	-	329	O
PRL	-	335	O
levels	-	339	O
.	-	345	O

The	9128918	347	O
purpose	-	351	O
of	-	359	O
this	-	362	O
study	-	367	O
was	-	373	O
to	-	377	O
induce	-	380	O
hyperprolactinemia	-	387	B
in	-	406	O
rats	-	409	O
for	-	414	O
extended	-	418	O
periods	-	427	O
of	-	435	O
time	-	438	O
and	-	443	O
examine	-	447	O
its	-	455	O
effects	-	459	O
on	-	467	O
dopaminergic	-	470	O
systems	-	483	O
in	-	491	O
the	-	494	O
brain	-	498	O
.	-	503	O

Hyperprolactinemia	9128918	505	B
was	-	524	O
induced	-	528	O
by	-	536	O
treatment	-	539	O
with	-	549	O
haloperidol	-	554	O
,	-	565	O
a	-	567	O
dopamine	-	569	O
receptor	-	578	O
antagonist	-	587	O
,	-	597	O
and	-	599	O
Palkovits	-	603	O
'	-	612	O
microdissection	-	614	O
technique	-	630	O
in	-	640	O
combination	-	643	O
with	-	655	O
high	-	660	O
-	-	664	O
performance	-	665	O
liquid	-	677	O
chromatography	-	684	O
was	-	699	O
used	-	703	O
to	-	708	O
measure	-	711	O
neurotransmitter	-	719	O
concentrations	-	736	O
in	-	751	O
several	-	754	O
areas	-	762	O
of	-	768	O
the	-	771	O
brain	-	775	O
.	-	780	O

After	9128918	782	O
6	-	788	O
months	-	790	O
of	-	797	O
hyperprolactinemia	-	800	B
,	-	818	O
dopamine	-	820	O
(	-	829	O
DA	-	830	O
)	-	832	O
concentrations	-	834	O
in	-	849	O
the	-	852	O
median	-	856	O
eminence	-	863	O
(	-	872	O
ME	-	873	O
)	-	875	O
increased	-	877	O
by	-	887	O
84	-	890	O
%	-	892	O
over	-	894	O
the	-	899	O
control	-	903	O
group	-	911	O
.	-	916	O

Nine	9128918	918	O
months	-	923	O
of	-	930	O
hyperprolactinemia	-	933	B
produced	-	952	O
a	-	961	O
50	-	963	O
%	-	965	O
increase	-	967	O
in	-	976	O
DA	-	979	O
concentrations	-	982	O
in	-	997	O
the	-	1000	O
ME	-	1004	O
over	-	1007	O
the	-	1012	O
control	-	1016	O
group	-	1024	O
.	-	1029	O

However	9128918	1031	O
,	-	1038	O
DA	-	1040	O
response	-	1043	O
was	-	1052	O
lost	-	1056	O
if	-	1061	O
a	-	1064	O
9	-	1066	O
-	-	1067	O
month	-	1068	O
long	-	1074	O
haloperidol	-	1079	O
-	-	1090	O
induced	-	1091	O
hyperprolactinemia	-	1099	B
was	-	1118	O
followed	-	1122	O
by	-	1131	O
a	-	1134	O
1	-	1136	O
1	-	1138	O
/	-	1139	O
2	-	1140	O
month	-	1142	O
-	-	1147	O
long	-	1148	O
extremely	-	1153	O
high	-	1163	O
increase	-	1168	O
in	-	1177	O
serum	-	1180	O
PRL	-	1186	O
levels	-	1190	O
produced	-	1197	O
by	-	1206	O
implantation	-	1209	O
of	-	1222	O
MMQ	-	1225	O
cells	-	1229	O
under	-	1235	O
the	-	1241	O
kidney	-	1245	O
capsule	-	1252	O
.	-	1259	O

There	9128918	1261	O
was	-	1267	O
no	-	1271	O
change	-	1274	O
in	-	1281	O
the	-	1284	O
levels	-	1288	O
of	-	1295	O
DA	-	1298	O
,	-	1300	O
norepinephrine	-	1302	O
(	-	1317	O
NE	-	1318	O
)	-	1320	O
,	-	1321	O
serotonin	-	1323	O
(	-	1333	O
5	-	1334	O
-	-	1335	O
HT	-	1336	O
)	-	1338	O
,	-	1339	O
or	-	1341	O
their	-	1344	O
metabolites	-	1350	O
in	-	1362	O
the	-	1365	O
arcuate	-	1369	O
nucleus	-	1377	O
(	-	1385	O
AN	-	1386	O
)	-	1388	O
,	-	1389	O
medial	-	1391	O
preoptic	-	1398	O
area	-	1407	O
(	-	1412	O
MPA	-	1413	O
)	-	1416	O
,	-	1417	O
caudate	-	1419	O
putamen	-	1427	O
(	-	1435	O
CP	-	1436	O
)	-	1438	O
,	-	1439	O
substantia	-	1441	O
nigra	-	1452	O
(	-	1458	O
SN	-	1459	O
)	-	1461	O
,	-	1462	O
and	-	1464	O
zona	-	1468	O
incerta	-	1473	O
(	-	1481	O
ZI	-	1482	O
)	-	1484	O
,	-	1485	O
except	-	1487	O
for	-	1494	O
a	-	1498	O
decrease	-	1500	O
in	-	1509	O
5	-	1512	O
-	-	1513	O
hydroxyindoleacetic	-	1514	O
acid	-	1534	O
(	-	1539	O
5	-	1540	O
-	-	1541	O
HIAA	-	1542	O
)	-	1546	O
in	-	1548	O
the	-	1551	O
AN	-	1555	O
after	-	1558	O
6	-	1564	O
-	-	1565	O
months	-	1566	O
of	-	1573	O
hyperprolactinemia	-	1576	B
and	-	1595	O
an	-	1599	O
increase	-	1602	O
in	-	1611	O
DA	-	1614	O
concentrations	-	1617	O
in	-	1632	O
the	-	1635	O
AN	-	1639	O
after	-	1642	O
9	-	1648	O
-	-	1649	O
months	-	1650	O
of	-	1657	O
hyperprolactinemia	-	1660	B
.	-	1678	O

These	9128918	1680	O
results	-	1686	O
demonstrate	-	1694	O
that	-	1706	O
hyperprolactinemia	-	1711	B
specifically	-	1730	O
affects	-	1743	O
TIDA	-	1751	O
neurons	-	1756	O
and	-	1764	O
these	-	1768	O
effects	-	1774	O
vary	-	1782	O
,	-	1786	O
depending	-	1788	O
on	-	1798	O
the	-	1801	O
duration	-	1805	O
and	-	1814	O
intensity	-	1818	O
of	-	1828	O
hyperprolactinemia	-	1831	B
.	-	1849	O

The	9128918	1851	O
age	-	1855	O
-	-	1858	O
related	-	1859	O
decrease	-	1867	O
in	-	1876	O
hypothalamic	-	1879	O
dopamine	-	1892	O
function	-	1901	O
may	-	1910	O
be	-	1914	O
associated	-	1917	O
with	-	1928	O
increases	-	1933	O
in	-	1943	O
PRL	-	1946	O
secretion	-	1950	O
.	-	1959	O

Treatment	9132810	0	O
-	-	9	O
related	-	10	O
disseminated	-	18	O
necrotizing	-	31	O
leukoencephalopathy	-	43	B
with	-	63	O
characteristic	-	68	O
contrast	-	83	O
enhancement	-	92	O
of	-	104	O
the	-	107	O
white	-	111	O
matter	-	117	O
.	-	123	O

This	9132810	125	O
report	-	130	O
describes	-	137	O
unique	-	147	O
contrast	-	154	O
enhancement	-	163	O
of	-	175	O
the	-	178	O
white	-	182	O
matter	-	188	O
on	-	195	O
T1	-	198	O
-	-	200	O
weighted	-	201	O
magnetic	-	210	O
resonance	-	219	O
images	-	229	O
of	-	236	O
two	-	239	O
patients	-	243	O
with	-	252	O
disseminated	-	257	O
necrotizing	-	270	O
leukoencephalopathy	-	282	B
,	-	301	O
which	-	303	O
developed	-	309	O
from	-	319	O
acute	-	324	B
lymphoblastic	-	330	I
leukemia	-	344	I
treated	-	353	O
with	-	361	O
high	-	366	O
-	-	370	O
dose	-	371	O
methotrexate	-	376	O
.	-	388	O

In	9132810	390	O
both	-	393	O
patients	-	398	O
,	-	406	O
the	-	408	O
enhancement	-	412	O
was	-	424	O
more	-	428	O
pronounced	-	433	O
near	-	444	O
the	-	449	O
base	-	453	O
of	-	458	O
the	-	461	O
brain	-	465	O
than	-	471	O
at	-	476	O
the	-	479	O
vertex	-	483	O
.	-	489	O

Necropsy	9132810	491	O
of	-	500	O
the	-	503	O
first	-	507	O
case	-	513	O
revealed	-	518	O
loss	-	527	B
of	-	532	I
myelination	-	535	I
and	-	547	O
necrosis	-	551	B
of	-	560	O
the	-	563	O
white	-	567	O
matter	-	573	O
.	-	579	O

Possible	9132810	581	O
mechanisms	-	590	O
causing	-	601	O
such	-	609	O
a	-	614	O
leukoencephalopathy	-	616	B
are	-	636	O
discussed	-	640	O
.	-	649	O

Thrombotic	9158667	0	B
complications	-	11	O
in	-	25	O
acute	-	28	B
promyelocytic	-	34	I
leukemia	-	48	I
during	-	57	O
all	-	64	O
-	-	67	O
trans	-	68	O
-	-	73	O
retinoic	-	74	O
acid	-	83	O
therapy	-	88	O
.	-	95	O

A	9158667	97	O
case	-	99	O
of	-	104	O
acute	-	107	B
renal	-	113	I
failure	-	119	I
,	-	126	O
due	-	128	O
to	-	132	O
occlusion	-	135	B
of	-	145	I
renal	-	148	I
vessels	-	154	I
in	-	162	O
a	-	165	O
patient	-	167	O
with	-	175	O
acute	-	180	B
promyelocytic	-	186	I
leukemia	-	200	I
(	-	209	O
APL	-	210	B
)	-	213	O
treated	-	215	O
with	-	223	O
all	-	228	O
-	-	231	O
trans	-	232	O
-	-	237	O
retinoic	-	238	O
acid	-	247	O
(	-	252	O
ATRA	-	253	O
)	-	257	O
and	-	259	O
tranexamic	-	263	O
acid	-	274	O
has	-	279	O
been	-	283	O
described	-	288	O
recently	-	298	O
.	-	306	O

We	9158667	308	O
report	-	311	O
a	-	318	O
case	-	320	O
of	-	325	O
acute	-	328	B
renal	-	334	I
failure	-	340	I
in	-	348	O
an	-	351	O
APL	-	354	B
patient	-	358	O
treated	-	366	O
with	-	374	O
ATRA	-	379	O
alone	-	384	O
.	-	389	O

This	9158667	391	O
case	-	396	O
further	-	401	O
supports	-	409	O
the	-	418	O
concern	-	422	O
about	-	430	O
thromboembolic	-	436	B
complications	-	451	O
associated	-	465	O
with	-	476	O
ATRA	-	481	O
therapy	-	486	O
in	-	494	O
APL	-	497	B
patients	-	501	O
.	-	509	O

The	9158667	511	O
patients	-	515	O
,	-	523	O
a	-	525	O
43	-	527	O
-	-	529	O
year	-	530	O
-	-	534	O
old	-	535	O
man	-	539	O
,	-	542	O
presented	-	544	O
all	-	554	O
the	-	558	O
signs	-	562	O
and	-	568	O
symptoms	-	572	O
of	-	581	O
APL	-	584	B
and	-	588	O
was	-	592	O
included	-	596	O
in	-	605	O
a	-	608	O
treatment	-	610	O
protocol	-	620	O
with	-	629	O
ATRA	-	634	O
.	-	638	O

After	9158667	640	O
10	-	646	O
days	-	649	O
of	-	654	O
treatment	-	657	O
,	-	666	O
he	-	668	O
developed	-	671	O
acute	-	681	B
renal	-	687	I
failure	-	693	I
that	-	701	O
was	-	706	O
completely	-	710	O
reversible	-	721	O
after	-	732	O
complete	-	738	O
remission	-	747	O
of	-	757	O
APL	-	760	B
was	-	764	O
achieved	-	768	O
and	-	777	O
therapy	-	781	O
discontinued	-	789	O
.	-	801	O

We	9158667	803	O
conclude	-	806	O
that	-	815	O
ATRA	-	820	O
is	-	825	O
a	-	828	O
valid	-	830	O
therapeutic	-	836	O
choice	-	848	O
for	-	855	O
patients	-	859	O
with	-	868	O
APL	-	873	B
,	-	876	O
although	-	878	O
the	-	887	O
procoagulant	-	891	O
tendency	-	904	O
is	-	913	O
not	-	916	O
completely	-	920	O
corrected	-	931	O
.	-	940	O

Thrombotic	9158667	942	B
events	-	953	O
,	-	959	O
however	-	961	O
,	-	968	O
could	-	970	O
be	-	976	O
avoided	-	979	O
by	-	987	O
using	-	990	O
low	-	996	O
-	-	999	O
dose	-	1000	O
heparin	-	1005	O
.	-	1012	O

Pupillary	9197951	0	O
changes	-	10	O
associated	-	18	O
with	-	29	O
the	-	34	O
development	-	38	O
of	-	50	O
stimulant	-	53	O
-	-	62	O
induced	-	63	O
mania	-	71	B
:	-	76	O
a	-	78	O
case	-	80	O
report	-	85	O
.	-	91	O

A	9197951	93	O
30	-	95	O
-	-	97	O
year	-	98	O
-	-	102	O
old	-	103	O
cocaine	-	107	O
-	-	114	O
dependent	-	115	O
man	-	125	O
who	-	129	O
was	-	133	O
a	-	137	O
subject	-	139	O
in	-	147	O
a	-	150	O
study	-	152	O
evaluating	-	158	O
the	-	169	O
anticraving	-	173	O
efficacy	-	185	O
of	-	194	O
the	-	197	O
stimulant	-	201	O
medication	-	211	O
diethylpropion	-	222	O
(	-	237	O
DEP	-	238	O
)	-	241	O
became	-	243	O
manic	-	250	B
during	-	256	O
his	-	263	O
second	-	267	O
week	-	274	O
on	-	279	O
the	-	282	O
study	-	286	O
drug	-	292	O
.	-	296	O

Pupillometric	9197951	298	O
changes	-	312	O
while	-	320	O
on	-	326	O
DEP	-	329	O
,	-	332	O
especially	-	334	O
changes	-	345	O
in	-	353	O
the	-	356	O
total	-	360	O
power	-	366	O
of	-	372	O
pupillary	-	375	B
oscillation	-	385	I
,	-	396	O
were	-	398	O
dramatically	-	403	O
different	-	416	O
than	-	426	O
those	-	431	O
observed	-	437	O
in	-	446	O
the	-	449	O
eight	-	453	O
other	-	459	O
study	-	465	O
subjects	-	471	O
who	-	480	O
did	-	484	O
not	-	488	O
become	-	492	O
manic	-	499	B
.	-	504	O

The	9197951	506	O
large	-	510	O
changes	-	516	O
in	-	524	O
total	-	527	O
power	-	533	O
of	-	539	O
pupillary	-	542	B
oscillation	-	552	I
occurred	-	564	O
a	-	573	O
few	-	575	O
days	-	579	O
before	-	584	O
the	-	591	O
patient	-	595	O
became	-	603	O
fully	-	610	O
manic	-	616	B
.	-	621	O

Such	9197951	623	O
medication	-	628	O
-	-	638	O
associated	-	639	O
changes	-	650	O
in	-	658	O
the	-	661	O
total	-	665	O
power	-	671	O
of	-	677	O
pupillary	-	680	B
oscillation	-	690	I
might	-	702	O
be	-	708	O
of	-	711	O
utility	-	714	O
in	-	722	O
identifying	-	725	O
persons	-	737	O
at	-	745	O
risk	-	748	O
for	-	753	O
manic	-	757	B
-	-	762	O
like	-	763	O
adverse	-	768	O
effects	-	776	O
during	-	784	O
the	-	791	O
medical	-	795	O
use	-	803	O
of	-	807	O
psychomotor	-	810	O
stimulants	-	822	O
or	-	833	O
sympathomimetic	-	836	O
agents	-	852	O
.	-	858	O

The	9272404	0	O
negative	-	4	O
mucosal	-	13	O
potential	-	21	O
:	-	30	O
separating	-	32	O
central	-	43	O
and	-	51	O
peripheral	-	55	O
effects	-	66	O
of	-	74	O
NSAIDs	-	77	O
in	-	84	O
man	-	87	O
.	-	90	O

OBJECTIVE	9272404	92	O
:	-	101	O
We	-	103	O
wanted	-	106	O
to	-	113	O
test	-	116	O
whether	-	121	O
assessment	-	129	O
of	-	140	O
both	-	143	O
a	-	148	O
central	-	150	O
pain	-	158	B
-	-	162	O
related	-	163	O
signal	-	171	O
(	-	178	O
chemo	-	179	O
-	-	184	O
somatosensory	-	185	O
evoked	-	199	O
potential	-	206	O
,	-	215	O
CSSEP	-	217	O
)	-	222	O
and	-	224	O
a	-	228	O
concomitantly	-	230	O
recorded	-	244	O
peripheral	-	253	O
signal	-	264	O
(	-	271	O
negative	-	272	O
mucosal	-	281	O
potential	-	289	O
,	-	298	O
NMP	-	300	O
)	-	303	O
allows	-	305	O
for	-	312	O
separation	-	316	O
of	-	327	O
central	-	330	O
and	-	338	O
peripheral	-	342	O
effects	-	353	O
of	-	361	O
NSAIDs	-	364	O
.	-	370	O

For	9272404	372	O
this	-	376	O
purpose	-	381	O
,	-	388	O
experimental	-	390	O
conditions	-	403	O
were	-	414	O
created	-	419	O
in	-	427	O
which	-	430	O
NSAIDs	-	436	O
had	-	443	O
previously	-	447	O
been	-	458	O
observed	-	463	O
to	-	472	O
produce	-	475	O
effects	-	483	O
on	-	491	O
phasic	-	494	O
and	-	501	O
tonic	-	505	O
pain	-	511	B
by	-	516	O
either	-	519	O
central	-	526	O
or	-	534	O
peripheral	-	537	O
mechanisms	-	548	O
.	-	558	O

METHODS	9272404	560	O
:	-	567	O

According	9272404	569	O
to	-	579	O
a	-	582	O
double	-	584	O
-	-	590	O
blind	-	591	O
,	-	596	O
randomised	-	598	O
,	-	608	O
controlled	-	610	O
,	-	620	O
threefold	-	622	O
cross	-	632	O
-	-	637	O
over	-	638	O
design	-	643	O
,	-	649	O
18	-	651	O
healthy	-	654	O
subjects	-	662	O
(	-	671	O
11	-	672	O
males	-	675	O
,	-	680	O
7	-	682	O
females	-	684	O
;	-	691	O
mean	-	693	O
age	-	698	O
26	-	702	O
years	-	705	O
)	-	710	O
received	-	712	O
either	-	721	O
placebo	-	728	O
,	-	735	O
400	-	737	O
mg	-	741	O
ibuprofen	-	744	O
,	-	753	O
or	-	755	O
800	-	758	O
mg	-	762	O
ibuprofen	-	765	O
.	-	774	O

Phasic	9272404	776	O
pain	-	783	B
was	-	788	O
applied	-	792	O
by	-	800	O
means	-	803	O
of	-	809	O
short	-	812	O
pulses	-	818	O
of	-	825	O
CO2	-	828	O
to	-	832	O
the	-	835	O
nasal	-	839	O
mucosa	-	845	O
(	-	852	O
stimulus	-	853	O
duration	-	862	O
500	-	871	O
ms	-	875	O
,	-	877	O
interval	-	879	O
approximately	-	888	O
60	-	902	O
s	-	905	O
)	-	906	O
,	-	907	O
and	-	909	O
tonic	-	913	O
pain	-	919	B
was	-	924	O
induced	-	928	O
in	-	936	O
the	-	939	O
nasal	-	943	O
cavity	-	949	O
by	-	956	O
means	-	959	O
of	-	965	O
dry	-	968	O
air	-	972	O
of	-	976	O
controlled	-	979	O
temperature	-	990	O
,	-	1001	O
humidity	-	1003	O
and	-	1012	O
flow	-	1016	O
rate	-	1021	O
(	-	1026	O
22	-	1027	O
degrees	-	1030	O
C	-	1038	O
,	-	1039	O
0	-	1041	O
%	-	1042	O
relative	-	1044	O
humidity	-	1053	O
,	-	1061	O
145	-	1063	O
ml	-	1067	O
.	-	1069	O
s	-	1070	O
-	-	1071	O
1	-	1072	O
)	-	1073	O
.	-	1074	O

Both	9272404	1076	O
CSSEPs	-	1081	O
as	-	1088	O
central	-	1091	O
and	-	1099	O
NMPs	-	1103	O
as	-	1108	O
peripheral	-	1111	O
correlates	-	1122	O
of	-	1133	O
pain	-	1136	B
were	-	1141	O
obtained	-	1146	O
in	-	1155	O
response	-	1158	O
to	-	1167	O
the	-	1170	O
CO2	-	1174	O
stimuli	-	1178	O
.	-	1185	O

Additionally	9272404	1187	O
,	-	1199	O
the	-	1201	O
subjects	-	1205	O
rated	-	1214	O
the	-	1220	O
intensity	-	1224	O
of	-	1234	O
both	-	1237	O
phasic	-	1242	O
and	-	1249	O
tonic	-	1253	O
pain	-	1259	B
by	-	1264	O
means	-	1267	O
of	-	1273	O
visual	-	1276	O
analogue	-	1283	O
scales	-	1292	O
.	-	1298	O

RESULTS	9272404	1300	O
:	-	1307	O

As	9272404	1309	O
described	-	1312	O
earlier	-	1322	O
,	-	1329	O
administration	-	1331	O
of	-	1346	O
ibuprofen	-	1349	O
was	-	1359	O
followed	-	1363	O
by	-	1372	O
a	-	1375	O
decrease	-	1377	O
in	-	1386	O
tonic	-	1389	O
pain	-	1395	B
but	-	1400	O
-	-	1403	O
relative	-	1404	O
to	-	1413	O
placebo	-	1416	O
-	-	1423	O
an	-	1424	O
increase	-	1427	O
in	-	1436	O
correlates	-	1439	O
of	-	1450	O
phasic	-	1453	O
pain	-	1460	B
,	-	1464	O
indicating	-	1466	O
a	-	1477	O
specific	-	1479	O
effect	-	1488	O
of	-	1495	O
ibuprofen	-	1498	O
on	-	1508	O
the	-	1511	O
interaction	-	1515	O
between	-	1527	O
the	-	1535	O
pain	-	1539	B
stimuli	-	1544	O
under	-	1552	O
these	-	1558	O
special	-	1564	O
experimental	-	1572	O
conditions	-	1585	O
.	-	1595	O

Based	9272404	1597	O
on	-	1603	O
the	-	1606	O
similar	-	1610	O
behaviour	-	1618	O
of	-	1628	O
CSSEP	-	1631	O
and	-	1637	O
NMP	-	1641	O
,	-	1644	O
it	-	1646	O
was	-	1649	O
concluded	-	1653	O
that	-	1663	O
the	-	1668	O
pharmacological	-	1672	O
process	-	1688	O
underlying	-	1696	O
this	-	1707	O
phenomenon	-	1712	O
was	-	1723	O
localised	-	1727	O
in	-	1737	O
the	-	1740	O
periphery	-	1744	O
.	-	1753	O

By	9272404	1755	O
means	-	1758	O
of	-	1764	O
the	-	1767	O
simultaneous	-	1771	O
recording	-	1784	O
of	-	1794	O
interrelated	-	1797	O
peripheral	-	1810	O
and	-	1821	O
central	-	1825	O
electrophysiologic	-	1833	O
correlates	-	1852	O
of	-	1863	O
nociception	-	1866	O
,	-	1877	O
it	-	1879	O
was	-	1882	O
possible	-	1886	O
to	-	1895	O
separate	-	1898	O
central	-	1907	O
and	-	1915	O
peripheral	-	1919	O
effects	-	1930	O
of	-	1938	O
an	-	1941	O
NSAID	-	1944	O
.	-	1949	O

The	9272404	1951	O
major	-	1955	O
advantage	-	1961	O
of	-	1971	O
this	-	1974	O
pain	-	1979	B
model	-	1984	O
is	-	1990	O
the	-	1993	O
possibility	-	1997	O
of	-	2009	O
obtaining	-	2012	O
peripheral	-	2022	O
pain	-	2033	B
-	-	2037	O
related	-	2038	O
activity	-	2046	O
directly	-	2055	O
using	-	2064	O
a	-	2070	O
non	-	2072	O
-	-	2075	O
invasive	-	2076	O
technique	-	2085	O
in	-	2095	O
humans	-	2098	O
.	-	2104	O

Acute	9323412	0	O
severe	-	6	O
depression	-	13	B
following	-	24	O
peri	-	34	O
-	-	38	O
operative	-	39	O
ondansetron	-	49	O
.	-	60	O

A	9323412	62	O
41	-	64	O
-	-	66	O
year	-	67	O
-	-	71	O
old	-	72	O
woman	-	76	O
with	-	82	O
a	-	87	O
strong	-	89	O
history	-	96	O
of	-	104	O
postoperative	-	107	B
nausea	-	121	I
and	-	128	I
vomiting	-	132	I
presented	-	141	O
for	-	151	O
abdominal	-	155	O
hysterectomy	-	165	O
3	-	178	O
months	-	180	O
after	-	187	O
a	-	193	O
previous	-	195	O
anaesthetic	-	204	O
where	-	216	O
ondansetron	-	222	O
prophylaxis	-	234	O
had	-	246	O
been	-	250	O
used	-	255	O
.	-	259	O

She	9323412	261	O
had	-	265	O
developed	-	269	O
a	-	279	O
severe	-	281	O
acute	-	288	O
major	-	294	B
depression	-	300	I
disorder	-	311	I
almost	-	320	O
immediately	-	327	O
thereafter	-	339	O
,	-	349	O
possibly	-	351	O
related	-	360	O
to	-	368	O
the	-	371	O
use	-	375	O
of	-	379	O
a	-	382	O
serotonin	-	384	O
antagonist	-	394	O
.	-	404	O

Nine	9323412	406	O
years	-	411	O
before	-	417	O
she	-	424	O
had	-	428	O
experienced	-	432	O
a	-	444	O
self	-	446	O
-	-	450	O
limited	-	451	O
puerperal	-	459	O
depressive	-	469	B
episode	-	480	I
.	-	487	O

Anaesthesia	9323412	489	O
with	-	501	O
a	-	506	O
propofol	-	508	O
infusion	-	517	O
and	-	526	O
avoidance	-	530	O
of	-	540	O
serotonin	-	543	O
antagonists	-	553	O
provided	-	565	O
a	-	574	O
nausea	-	576	B
-	-	582	O
free	-	583	O
postoperative	-	588	O
course	-	602	O
without	-	609	O
exacerbation	-	617	O
of	-	630	O
the	-	633	O
depression	-	637	B
disorder	-	648	I
.	-	656	O

Hypertensive	9382023	0	B
response	-	13	O
during	-	22	O
dobutamine	-	29	O
stress	-	40	O
echocardiography	-	47	O
.	-	63	O

Among	9382023	65	O
3	-	71	O
,	-	72	O
129	-	73	O
dobutamine	-	77	O
stress	-	88	O
echocardiographic	-	95	O
studies	-	113	O
,	-	120	O
a	-	122	O
hypertensive	-	124	B
response	-	137	O
,	-	145	O
defined	-	147	O
as	-	155	O
systolic	-	158	O
blood	-	167	O
pressure	-	173	O
(	-	182	O
BP	-	183	O
)	-	185	O
>	-	187	O
or	-	189	O
=	-	192	O
220	-	194	O
mm	-	198	O
Hg	-	201	O
and	-	204	O
/	-	207	O
or	-	208	O
diastolic	-	211	O
BP	-	221	O
>	-	224	O
or	-	226	O
=	-	229	O
110	-	231	O
mm	-	235	O
Hg	-	238	O
,	-	240	O
occurred	-	242	O
in	-	251	O
30	-	254	O
patients	-	257	O
(	-	266	O
1	-	267	O
%	-	268	O
)	-	269	O
.	-	270	O

Patients	9382023	272	O
with	-	281	O
this	-	286	O
response	-	291	O
more	-	300	O
often	-	305	O
had	-	311	O
a	-	315	O
history	-	317	O
of	-	325	O
hypertension	-	328	B
and	-	341	O
had	-	345	O
higher	-	349	O
resting	-	356	O
systolic	-	364	O
and	-	373	O
diastolic	-	377	O
BP	-	387	O
before	-	390	O
dobutamine	-	397	O
infusion	-	408	O
.	-	416	O

Continuously	9428298	0	O
nebulized	-	13	O
albuterol	-	23	O
in	-	33	O
severe	-	36	O
exacerbations	-	43	O
of	-	57	O
asthma	-	60	B
in	-	67	O
adults	-	70	O
:	-	76	O
a	-	78	O
case	-	80	O
-	-	84	O
controlled	-	85	O
study	-	96	O
.	-	101	O

A	9428298	103	O
retrospective	-	105	O
,	-	118	O
case	-	120	O
-	-	124	O
controlled	-	125	O
analysis	-	136	O
comparing	-	145	O
patients	-	155	O
admitted	-	164	O
to	-	173	O
a	-	176	O
medical	-	178	O
intensive	-	186	O
care	-	196	O
unit	-	201	O
with	-	206	O
severe	-	211	O
exacerbations	-	218	O
of	-	232	O
asthma	-	235	B
who	-	242	O
received	-	246	O
continuously	-	255	O
nebulized	-	268	O
albuterol	-	278	O
(	-	288	O
CNA	-	289	O
)	-	292	O
versus	-	294	O
intermittent	-	301	O
albuterol	-	314	O
(	-	324	O
INA	-	325	O
)	-	328	O
treatments	-	330	O
is	-	341	O
reported	-	344	O
.	-	352	O

Forty	9428298	354	O
matched	-	360	O
pairs	-	368	O
of	-	374	O
patients	-	377	O
with	-	386	O
asthma	-	391	B
are	-	398	O
compared	-	402	O
.	-	410	O

CNA	9428298	412	O
was	-	416	O
administered	-	420	O
for	-	433	O
a	-	437	O
mean	-	439	O
of	-	444	O
11	-	447	O
+	-	450	O
/	-	451	O
-	-	452	O

10	9428298	454	O
hr	-	457	O
.	-	459	O

The	9428298	461	O
incidence	-	465	O
of	-	475	O
cardiac	-	478	B
dysrhythmias	-	486	I
was	-	499	O
similar	-	503	O
between	-	511	O
groups	-	519	O
.	-	525	O

Symptomatic	9428298	527	O
hypokalemia	-	539	B
did	-	551	O
not	-	555	O
occur	-	559	O
.	-	564	O

CNA	9428298	566	O
patients	-	570	O
had	-	579	O
higher	-	583	O
heart	-	590	O
rates	-	596	O
during	-	602	O
treatment	-	609	O
,	-	618	O
which	-	620	O
may	-	626	O
reflect	-	630	O
severity	-	638	O
of	-	647	O
illness	-	650	O
.	-	657	O

The	9428298	659	O
incidence	-	663	O
of	-	673	O
intubation	-	676	O
was	-	687	O
similar	-	691	O
.	-	698	O

We	9428298	700	O
conclude	-	703	O
that	-	712	O
CNA	-	717	O
and	-	721	O
INA	-	725	O
demonstrated	-	729	O
similar	-	742	O
profiles	-	750	O
with	-	759	O
regard	-	764	O
to	-	771	O
safety	-	774	O
,	-	780	O
morbidity	-	782	O
,	-	791	O
and	-	793	O
mortality	-	797	O
.	-	806	O

Hyperosmolar	9538487	0	B
nonketotic	-	13	I
coma	-	24	I
precipitated	-	29	O
by	-	42	O
lithium	-	45	O
-	-	52	O
induced	-	53	O
nephrogenic	-	61	B
diabetes	-	73	I
insipidus	-	82	I
.	-	91	O

A	9538487	93	O
45	-	95	O
-	-	97	O
year	-	98	O
-	-	102	O
old	-	103	O
man	-	107	O
,	-	110	O
with	-	112	O
a	-	117	O
10	-	119	O
-	-	121	O
year	-	122	O
history	-	127	O
of	-	135	O
manic	-	138	B
depression	-	144	I
treated	-	155	O
with	-	163	O
lithium	-	168	O
,	-	175	O
was	-	177	O
admitted	-	181	O
with	-	190	O
hyperosmolar	-	195	B
,	-	207	I
nonketotic	-	209	I
coma	-	220	I
.	-	224	O

He	9538487	226	O
gave	-	229	O
a	-	234	O
five	-	236	O
-	-	240	O
year	-	241	O
history	-	246	O
of	-	254	O
polyuria	-	257	B
and	-	266	O
polydipsia	-	270	B
,	-	280	O
during	-	282	O
which	-	289	O
time	-	295	O
urinalysis	-	300	O
had	-	311	O
been	-	315	O
negative	-	320	O
for	-	329	O
glucose	-	333	O
.	-	340	O

After	9538487	342	O
recovery	-	348	O
from	-	357	O
hyperglycaemia	-	362	B
,	-	376	O
he	-	378	O
remained	-	381	O
polyuric	-	390	B
despite	-	399	O
normal	-	407	O
blood	-	414	O
glucose	-	420	O
concentrations	-	428	O
;	-	442	O
water	-	444	O
deprivation	-	450	O
testing	-	462	O
indicated	-	470	O
nephrogenic	-	480	B
diabetes	-	492	I
insipidus	-	501	I
,	-	510	O
likely	-	512	O
to	-	519	O
be	-	522	O
lithium	-	525	O
-	-	532	O
induced	-	533	O
.	-	540	O

We	9538487	542	O
hypothesize	-	545	O
that	-	557	O
when	-	562	O
this	-	567	O
man	-	572	O
developed	-	576	O
type	-	586	B
2	-	591	I
diabetes	-	593	I
,	-	601	O
chronic	-	603	O
polyuria	-	611	B
due	-	620	O
to	-	624	O
nephrogenic	-	627	B
diabetes	-	639	I
insipidus	-	648	I
was	-	658	O
sufficient	-	662	O
to	-	673	O
precipitate	-	676	O
hyperosmolar	-	688	O
dehydration	-	701	B
.	-	712	O

Effects	9570197	0	O
of	-	8	O
the	-	11	O
intracoronary	-	15	O
infusion	-	29	O
of	-	38	O
cocaine	-	41	O
on	-	49	O
left	-	52	O
ventricular	-	57	O
systolic	-	69	O
and	-	78	O
diastolic	-	82	O
function	-	92	O
in	-	101	O
humans	-	104	O
.	-	110	O

BACKGROUND	9570197	112	O
:	-	122	O

In	9570197	124	O
dogs	-	127	O
,	-	131	O
a	-	133	O
large	-	135	O
amount	-	141	O
of	-	148	O
intravenous	-	151	O
cocaine	-	163	O
causes	-	171	O
a	-	178	O
profound	-	180	O
deterioration	-	189	B
of	-	203	I
left	-	206	I
ventricular	-	211	I
(	-	223	I
LV	-	224	I
)	-	226	I
systolic	-	228	I
function	-	237	I
and	-	246	O
an	-	250	O
increase	-	253	O
in	-	262	O
LV	-	265	O
end	-	268	O
-	-	271	O
diastolic	-	272	O
pressure	-	282	O
.	-	290	O

This	9570197	292	O
study	-	297	O
was	-	303	O
done	-	307	O
to	-	312	O
assess	-	315	O
the	-	322	O
influence	-	326	O
of	-	336	O
a	-	339	O
high	-	341	O
intracoronary	-	346	O
cocaine	-	360	O
concentration	-	368	O
on	-	382	O
LV	-	385	O
systolic	-	388	O
and	-	397	O
diastolic	-	401	O
function	-	411	O
in	-	420	O
humans	-	423	O
.	-	429	O

METHODS	9570197	431	O
AND	-	439	O
RESULTS	-	443	O
:	-	450	O

In	9570197	452	O
20	-	455	O
patients	-	458	O
(	-	467	O
14	-	468	O
men	-	471	O
and	-	475	O
6	-	479	O
women	-	481	O
aged	-	487	O
39	-	492	O
to	-	495	O
72	-	498	O
years	-	501	O
)	-	506	O
referred	-	508	O
for	-	517	O
cardiac	-	521	O
catheterization	-	529	O
for	-	545	O
the	-	549	O
evaluation	-	553	O
of	-	564	O
chest	-	567	B
pain	-	573	I
,	-	577	O
we	-	579	O
measured	-	582	O
heart	-	591	O
rate	-	597	O
,	-	601	O
systemic	-	603	O
arterial	-	612	O
pressure	-	621	O
,	-	629	O
LV	-	631	O
pressure	-	634	O
and	-	643	O
its	-	647	O
first	-	651	O
derivative	-	657	O
(	-	668	O
dP	-	669	O
/	-	671	O
dt	-	672	O
)	-	674	O
,	-	675	O
and	-	677	O
LV	-	681	O
volumes	-	684	O
and	-	692	O
ejection	-	696	O
fraction	-	705	O
before	-	714	O
and	-	721	O
during	-	725	O
the	-	732	O
final	-	736	O
2	-	742	O
to	-	744	O
3	-	747	O
minutes	-	749	O
of	-	757	O
a	-	760	O
15	-	762	O
-	-	764	O
minute	-	765	O
intracoronary	-	772	O
infusion	-	786	O
of	-	795	O
saline	-	798	O
(	-	805	O
n	-	806	O
=	-	807	O
10	-	808	O
,	-	810	O
control	-	812	O
subjects	-	820	O
)	-	828	O
or	-	830	O
cocaine	-	833	O
hydrochloride	-	841	O
1	-	855	O
mg	-	857	O
/	-	859	O
min	-	860	O
(	-	864	O
n	-	865	O
=	-	866	O
10	-	867	O
)	-	869	O
.	-	870	O

No	9570197	872	O
variable	-	875	O
changed	-	884	O
with	-	892	O
saline	-	897	O
.	-	903	O

With	9570197	905	O
cocaine	-	910	O
,	-	917	O
the	-	919	O
drug	-	923	O
concentration	-	928	O
in	-	942	O
blood	-	945	O
obtained	-	951	O
from	-	960	O
the	-	965	O
coronary	-	969	O
sinus	-	978	O
was	-	984	O
3	-	988	O
.	-	989	O
0	-	990	O
+	-	991	O
/	-	992	O
-	-	993	O
0	-	994	O
.	-	995	O
4	-	996	O
(	-	998	O
mean	-	999	O
+	-	1003	O
/	-	1004	O
-	-	1005	O
SD	-	1006	O
)	-	1008	O
mg	-	1010	O
/	-	1012	O
L	-	1013	O
,	-	1014	O
similar	-	1016	O
in	-	1024	O
magnitude	-	1027	O
to	-	1037	O
the	-	1040	O
blood	-	1044	O
cocaine	-	1050	O
concentration	-	1058	O
reported	-	1072	O
in	-	1081	O
abusers	-	1084	O
dying	-	1092	O
of	-	1098	O
cocaine	-	1101	O
intoxication	-	1109	O
.	-	1121	O

Cocaine	9570197	1123	O
induced	-	1131	O
no	-	1139	O
significant	-	1142	O
change	-	1154	O
in	-	1161	O
heart	-	1164	O
rate	-	1170	O
,	-	1174	O
LV	-	1176	O
dP	-	1179	O
/	-	1181	O
dt	-	1182	O
(	-	1185	O
positive	-	1186	O
or	-	1195	O
negative	-	1198	O
)	-	1206	O
,	-	1207	O
or	-	1209	O
LV	-	1212	O
end	-	1215	O
-	-	1218	O
diastolic	-	1219	O
volume	-	1229	O
,	-	1235	O
but	-	1237	O
it	-	1241	O
caused	-	1244	O
an	-	1251	O
increase	-	1254	O
in	-	1263	O
systolic	-	1266	O
and	-	1275	O
mean	-	1279	O
arterial	-	1284	O
pressures	-	1293	O
,	-	1302	O
LV	-	1304	O
end	-	1307	O
-	-	1310	O
diastolic	-	1311	O
pressure	-	1321	O
,	-	1329	O
and	-	1331	O
LV	-	1335	O
end	-	1338	O
-	-	1341	O
systolic	-	1342	O
volume	-	1351	O
,	-	1357	O
as	-	1359	O
well	-	1362	O
as	-	1367	O
a	-	1370	O
decrease	-	1372	O
in	-	1381	O
LV	-	1384	O
ejection	-	1387	O
fraction	-	1396	O
.	-	1404	O

CONCLUSIONS	9570197	1406	O
:	-	1417	O

In	9570197	1419	O
humans	-	1422	O
,	-	1428	O
the	-	1430	O
intracoronary	-	1434	O
infusion	-	1448	O
of	-	1457	O
cocaine	-	1460	O
sufficient	-	1468	O
in	-	1479	O
amount	-	1482	O
to	-	1489	O
achieve	-	1492	O
a	-	1500	O
high	-	1502	O
drug	-	1507	O
concentration	-	1512	O
in	-	1526	O
coronary	-	1529	O
sinus	-	1538	O
blood	-	1544	O
causes	-	1550	O
a	-	1557	O
deterioration	-	1559	B
of	-	1573	I
LV	-	1576	I
systolic	-	1579	I
and	-	1588	I
diastolic	-	1592	I
performance	-	1602	I
.	-	1613	O

Heparin	9646784	0	O
-	-	7	O
induced	-	8	O
thrombocytopenia	-	16	B
,	-	32	O
paradoxical	-	34	O
thromboembolism	-	46	B
,	-	61	O
and	-	63	O
other	-	67	O
side	-	73	O
effects	-	78	O
of	-	86	O
heparin	-	89	O
therapy	-	97	O
.	-	104	O

Although	9646784	106	O
several	-	115	O
new	-	123	O
anticoagulant	-	127	O
drugs	-	141	O
are	-	147	O
in	-	151	O
development	-	154	O
,	-	165	O
heparin	-	167	O
remains	-	175	O
the	-	183	O
drug	-	187	O
of	-	192	O
choice	-	195	O
for	-	202	O
most	-	206	O
anticoagulation	-	211	O
needs	-	227	O
.	-	232	O

The	9646784	234	O
clinical	-	238	O
effects	-	247	O
of	-	255	O
heparin	-	258	O
are	-	266	O
meritorious	-	270	O
,	-	281	O
but	-	283	O
side	-	287	O
effects	-	292	O
do	-	300	O
exist	-	303	O
.	-	308	O

Important	9646784	310	O
untoward	-	320	O
effects	-	329	O
of	-	337	O
heparin	-	340	O
therapy	-	348	O
including	-	356	O
heparin	-	366	O
-	-	373	O
induced	-	374	O
thrombocytopenia	-	382	B
,	-	398	O
heparin	-	400	O
-	-	407	O
associated	-	408	O
osteoporosis	-	419	B
,	-	431	O
eosinophilia	-	433	B
,	-	445	O
skin	-	447	B
reactions	-	452	I
,	-	461	O
allergic	-	463	B
reactions	-	472	I
other	-	482	O
than	-	488	O
thrombocytopenia	-	493	B
and	-	510	O
alopecia	-	514	B
will	-	523	O
be	-	528	O
discussed	-	531	O
in	-	541	O
this	-	544	O
article	-	549	O
.	-	556	O

Nonopaque	9725303	0	O
crystal	-	10	O
deposition	-	18	O
causing	-	29	O
ureteric	-	37	B
obstruction	-	46	I
in	-	58	O
patients	-	61	O
with	-	70	O
HIV	-	75	O
undergoing	-	79	O
indinavir	-	90	O
therapy	-	100	O
.	-	107	O

OBJECTIVE	9725303	109	O
:	-	118	O
We	-	120	O
describe	-	123	O
the	-	132	O
unique	-	136	O
CT	-	143	O
features	-	146	O
of	-	155	O
ureteric	-	158	B
calculi	-	167	I
in	-	175	O
six	-	178	O
HIV	-	182	B
-	-	185	I
infected	-	186	I
patients	-	195	O
receiving	-	204	O
indinavir	-	214	O
,	-	223	O
the	-	225	O
most	-	229	O
commonly	-	234	O
used	-	243	O
HIV	-	248	O
protease	-	252	O
inhibitor	-	261	O
,	-	270	O
which	-	272	O
is	-	278	O
associated	-	281	O
with	-	292	O
an	-	297	O
increased	-	300	O
incidence	-	310	O
of	-	320	O
urolithiasis	-	323	B
.	-	335	O

CONCLUSION	9725303	337	O
:	-	347	O

Ureteric	9725303	349	B
obstruction	-	358	I
caused	-	370	O
by	-	377	O
precipitated	-	380	O
indinavir	-	393	O
crystals	-	403	O
may	-	412	O
be	-	416	O
difficult	-	419	O
to	-	429	O
diagnose	-	432	O
with	-	441	O
unenhanced	-	446	O
CT	-	457	O
.	-	459	O

The	9725303	461	O
calculi	-	465	O
are	-	473	O
not	-	477	O
opaque	-	481	O
,	-	487	O
and	-	489	O
secondary	-	493	O
signs	-	503	O
of	-	509	O
obstruction	-	512	O
may	-	524	O
be	-	528	O
absent	-	531	O
or	-	538	O
minimal	-	541	O
and	-	549	O
should	-	553	O
be	-	560	O
sought	-	563	O
carefully	-	570	O
.	-	579	O

Images	9725303	581	O
may	-	588	O
need	-	592	O
to	-	597	O
be	-	600	O
obtained	-	603	O
using	-	612	O
i	-	618	O
.	-	619	O
v	-	620	O
.	-	621	O

contrast	9725303	623	O
material	-	632	O
to	-	641	O
enable	-	644	O
diagnosis	-	651	O
of	-	661	O
ureteric	-	664	B
stones	-	673	I
or	-	680	I
obstruction	-	683	I
in	-	695	O
patients	-	698	O
with	-	707	O
HIV	-	712	B
infection	-	716	I
who	-	726	O
receive	-	730	O
indinavir	-	738	O
therapy	-	748	O
.	-	755	O

Ischemic	9759693	0	B
colitis	-	9	I
and	-	17	O
sumatriptan	-	21	O
use	-	33	O
.	-	36	O

Sumatriptan	9759693	38	O
succinate	-	50	O
,	-	59	O
a	-	61	O
serotonin	-	63	O
-	-	72	O
1	-	73	O
(	-	75	O
5	-	76	O
-	-	77	O
hydroxytryptamine	-	78	O
-	-	95	O
1	-	96	O
)	-	97	O
receptor	-	99	O
agonist	-	108	O
,	-	115	O
is	-	117	O
an	-	120	O
antimigraine	-	123	O
drug	-	136	O
that	-	141	O
is	-	146	O
reported	-	149	O
to	-	158	O
act	-	161	O
by	-	165	O
selectively	-	168	O
constricting	-	180	O
intracranial	-	193	O
arteries	-	206	O
.	-	214	O

Recently	9759693	216	O
,	-	224	O
vasopressor	-	226	O
responses	-	238	O
that	-	248	O
are	-	253	O
distinct	-	257	O
from	-	266	O
the	-	271	O
cranial	-	275	O
circulation	-	283	O
have	-	295	O
been	-	300	O
demonstrated	-	305	O
to	-	318	O
occur	-	321	O
in	-	327	O
the	-	330	O
systemic	-	334	O
,	-	342	O
pulmonary	-	344	O
,	-	353	O
and	-	355	O
coronary	-	359	O
circulations	-	368	O
.	-	380	O

Cases	9759693	382	O
have	-	388	O
been	-	393	O
published	-	398	O
of	-	408	O
coronary	-	411	B
vasospasm	-	420	I
,	-	429	O
myocardial	-	431	B
ischemia	-	442	I
,	-	450	O
and	-	452	O
myocardial	-	456	B
infarction	-	467	I
occurring	-	478	O
after	-	488	O
sumatriptan	-	494	O
use	-	506	O
.	-	509	O

We	9759693	511	O
report	-	514	O
on	-	521	O
the	-	524	O
development	-	528	O
of	-	540	O
8	-	543	O
serious	-	545	O
cases	-	553	O
of	-	559	O
ischemic	-	562	B
colitis	-	571	I
in	-	579	O
patients	-	582	O
with	-	591	O
migraine	-	596	B
treated	-	605	O
with	-	613	O
sumatriptan	-	618	O
.	-	629	O

Pallidotomy	9782254	0	O
with	-	12	O
the	-	17	O
gamma	-	21	O
knife	-	27	O
:	-	32	O
a	-	34	O
positive	-	36	O
experience	-	45	O
.	-	55	O

51	9782254	57	O
patients	-	60	O
with	-	69	O
medically	-	74	O
refractory	-	84	O
Parkinson	-	95	B
's	-	104	I
disease	-	107	I
underwent	-	115	O
stereotactic	-	125	O
posteromedial	-	138	O
pallidotomy	-	152	O
between	-	164	O
August	-	172	O
1993	-	179	O
and	-	184	O
February	-	188	O
1997	-	197	O
for	-	202	O
treatment	-	206	O
of	-	216	O
bradykinesia	-	219	B
,	-	231	O
rigidity	-	233	B
,	-	241	O
and	-	243	O
L	-	247	O
-	-	248	O
DOPA	-	249	O
-	-	253	O
induced	-	254	O
dyskinesias	-	262	B
.	-	273	O

In	9782254	275	O
29	-	278	O
patients	-	281	O
,	-	289	O
the	-	291	O
pallidotomies	-	295	O
were	-	309	O
performed	-	314	O
with	-	324	O
the	-	329	O
Leksell	-	333	O
Gamma	-	341	O
Knife	-	347	O
and	-	353	O
in	-	357	O
22	-	360	O
they	-	363	O
were	-	368	O
performed	-	373	O
with	-	383	O
the	-	388	O
standard	-	392	O
radiofrequency	-	401	O
(	-	416	O
RF	-	417	O
)	-	419	O
method	-	421	O
.	-	427	O

Clinical	9782254	429	O
assessment	-	438	O
as	-	449	O
well	-	452	O
as	-	457	O
blinded	-	460	O
ratings	-	468	O
of	-	476	O
Unified	-	479	O
Parkinson	-	487	B
's	-	496	I
Disease	-	499	I
Rating	-	507	O
Scale	-	514	O
(	-	520	O
UPDRS	-	521	O
)	-	526	O
scores	-	528	O
were	-	535	O
carried	-	540	O
out	-	548	O
pre	-	552	O
-	-	555	O
and	-	557	O
postoperatively	-	561	O
.	-	576	O

Mean	9782254	578	O
follow	-	583	O
-	-	589	O
up	-	590	O
time	-	593	O
is	-	598	O
20	-	601	O
.	-	603	O
6	-	604	O
months	-	606	O
(	-	613	O
range	-	614	O
6	-	620	O
-	-	621	O
48	-	622	O
)	-	624	O
and	-	626	O
all	-	630	O
except	-	634	O
4	-	641	O
patients	-	643	O
have	-	652	O
been	-	657	O
followed	-	662	O
more	-	671	O
than	-	676	O
one	-	681	O
year	-	685	O
.	-	689	O

85	9782254	691	O
percent	-	694	O
of	-	702	O
patients	-	705	O
with	-	714	O
dyskinesias	-	719	B
were	-	731	O
relieved	-	736	O
of	-	745	O
symptoms	-	748	O
,	-	756	O
regardless	-	758	O
of	-	769	O
whether	-	772	O
the	-	780	O
pallidotomies	-	784	O
were	-	798	O
performed	-	803	O
with	-	813	O
the	-	818	O
Gamma	-	822	O
Knife	-	828	O
or	-	834	O
radiofrequency	-	837	O
methods	-	852	O
.	-	859	O

About	9782254	861	O
2	-	867	O
/	-	868	O
3	-	869	O
of	-	871	O
the	-	874	O
patients	-	878	O
in	-	887	O
both	-	890	O
Gamma	-	895	O
Knife	-	901	O
and	-	907	O
radiofrequency	-	911	O
groups	-	926	O
showed	-	933	O
improvements	-	940	O
in	-	953	O
bradykinesia	-	956	B
and	-	969	O
rigidity	-	973	B
,	-	981	O
although	-	983	O
when	-	992	O
considered	-	997	O
as	-	1008	O
a	-	1011	O
group	-	1013	O
neither	-	1019	O
the	-	1027	O
Gamma	-	1031	O
Knife	-	1037	O
nor	-	1043	O
the	-	1047	O
radiofrequency	-	1051	O
group	-	1066	O
showed	-	1072	O
statistically	-	1079	O
significant	-	1093	O
improvements	-	1105	O
in	-	1118	O
UPDRS	-	1121	O
scores	-	1127	O
.	-	1133	O

One	9782254	1135	O
patient	-	1139	O
in	-	1147	O
the	-	1150	O
Gamma	-	1154	O
Knife	-	1160	O
group	-	1166	O
(	-	1172	O
3	-	1173	O
.	-	1174	O
4	-	1175	O
%	-	1176	O
)	-	1177	O
developed	-	1179	O
a	-	1189	O
homonymous	-	1191	B
hemianopsia	-	1202	I
9	-	1214	O
months	-	1216	O
following	-	1223	O
treatment	-	1233	O
and	-	1243	O
5	-	1247	O
patients	-	1249	O
(	-	1258	O
27	-	1259	O
.	-	1261	O
7	-	1262	O
%	-	1263	O
)	-	1264	O
in	-	1266	O
the	-	1269	O
radiofrequency	-	1273	O
group	-	1288	O
became	-	1294	O
transiently	-	1301	O
confused	-	1313	O
postoperatively	-	1322	O
.	-	1337	O

No	9782254	1339	O
other	-	1342	O
complications	-	1348	O
were	-	1362	O
seen	-	1367	O
.	-	1371	O

Gamma	9782254	1373	O
Knife	-	1379	O
pallidotomy	-	1385	O
is	-	1397	O
as	-	1400	O
effective	-	1403	O
as	-	1413	O
radiofrequency	-	1416	O
pallidotomy	-	1431	O
in	-	1443	O
controlling	-	1446	O
certain	-	1458	O
of	-	1466	O
the	-	1469	O
symptoms	-	1473	O
of	-	1482	O
Parkinson	-	1485	B
's	-	1494	I
disease	-	1497	I
.	-	1504	O

It	9782254	1506	O
may	-	1509	O
be	-	1513	O
the	-	1516	O
only	-	1520	O
practical	-	1525	O
technique	-	1535	O
available	-	1545	O
in	-	1555	O
certain	-	1558	O
patients	-	1566	O
,	-	1574	O
such	-	1576	O
as	-	1581	O
those	-	1584	O
who	-	1590	O
take	-	1594	O
anticoagulants	-	1599	O
,	-	1613	O
have	-	1615	O
bleeding	-	1620	B
diatheses	-	1629	O
or	-	1639	O
serious	-	1642	O
systemic	-	1650	O
medical	-	1659	O
illnesses	-	1667	O
.	-	1676	O

It	9782254	1678	O
is	-	1681	O
a	-	1684	O
viable	-	1686	O
option	-	1693	O
for	-	1700	O
other	-	1704	O
patients	-	1710	O
as	-	1719	O
well	-	1722	O
.	-	1726	O

Neuroleptic	9831002	0	B
malignant	-	12	I
syndrome	-	22	I
and	-	31	O
methylphenidate	-	35	O
.	-	50	O

A	9831002	52	O
1	-	54	O
-	-	55	O
year	-	56	O
-	-	60	O
old	-	61	O
female	-	65	O
presented	-	72	O
with	-	82	O
neuroleptic	-	87	B
malignant	-	99	I
syndrome	-	109	I
probably	-	118	O
caused	-	127	O
by	-	134	O
methylphenidate	-	137	O
.	-	152	O

She	9831002	154	O
had	-	158	O
defects	-	162	O
in	-	170	O
the	-	173	O
supratentorial	-	177	O
brain	-	192	O
including	-	198	O
the	-	208	O
basal	-	212	O
ganglia	-	218	O
and	-	226	O
the	-	230	O
striatum	-	234	O
(	-	243	O
multicystic	-	244	B
encephalomalacia	-	256	I
)	-	272	O
due	-	274	O
to	-	278	O
severe	-	281	O
perinatal	-	288	O
hypoxic	-	298	B
-	-	305	I
ischemic	-	306	I
encephalopathy	-	315	I
,	-	329	O
which	-	331	O
was	-	337	O
considered	-	341	O
to	-	352	O
be	-	355	O
a	-	358	O
possible	-	360	O
predisposing	-	369	O
factor	-	382	O
causing	-	389	O
neuroleptic	-	397	B
malignant	-	409	I
syndrome	-	419	I
.	-	427	O

A	9831002	429	O
dopaminergic	-	431	O
blockade	-	444	O
mechanism	-	453	O
generally	-	463	O
is	-	473	O
accepted	-	476	O
as	-	485	O
the	-	488	O
pathogenesis	-	492	O
of	-	505	O
this	-	508	O
syndrome	-	513	O
.	-	521	O

However	9831002	523	O
,	-	530	O
methylphenidate	-	532	O
is	-	548	O
a	-	551	O
dopamine	-	553	O
agonist	-	562	O
via	-	570	O
the	-	574	O
inhibition	-	578	O
of	-	589	O
uptake	-	592	O
of	-	599	O
dopamine	-	602	O
,	-	610	O
and	-	612	O
therefore	-	616	O
dopaminergic	-	626	O
systems	-	639	O
in	-	647	O
the	-	650	O
brainstem	-	654	O
(	-	664	O
mainly	-	665	O
the	-	672	O
midbrain	-	676	O
)	-	684	O
and	-	686	O
the	-	690	O
spinal	-	694	O
cord	-	701	O
were	-	706	O
unlikely	-	711	O
to	-	720	O
participate	-	723	O
in	-	735	O
the	-	738	O
onset	-	742	O
of	-	748	O
this	-	751	O
syndrome	-	756	O
.	-	764	O

A	9831002	766	O
relative	-	768	O
gamma	-	777	O
-	-	782	O
aminobutyric	-	783	O
acid	-	796	O
-	-	800	O
ergic	-	801	O
deficiency	-	807	O
might	-	818	O
occur	-	824	O
because	-	830	O
diazepam	-	838	O
,	-	846	O
a	-	848	O
gamma	-	850	O
-	-	855	O
aminobutyric	-	856	O
acid	-	869	O
-	-	873	O
mimetic	-	874	O
agent	-	882	O
,	-	887	O
was	-	889	O
strikingly	-	893	O
effective	-	904	O
.	-	913	O

This	9831002	915	O
is	-	920	O
the	-	923	O
first	-	927	O
reported	-	933	O
patient	-	942	O
with	-	950	O
neuroleptic	-	955	B
malignant	-	967	I
syndrome	-	977	I
probably	-	986	O
caused	-	995	O
by	-	1002	O
methylphenidate	-	1005	O
.	-	1020	O

Differential	9869655	0	O
effects	-	13	O
of	-	21	O
17alpha	-	24	O
-	-	31	O
ethinylestradiol	-	32	O
on	-	49	O
the	-	52	O
neutral	-	56	O
and	-	64	O
acidic	-	68	O
pathways	-	75	O
of	-	84	O
bile	-	87	O
salt	-	92	O
synthesis	-	97	O
in	-	107	O
the	-	110	O
rat	-	114	O
.	-	117	O

Effects	9869655	119	O
of	-	127	O
17alpha	-	130	O
-	-	137	O
ethinylestradiol	-	138	O
(	-	155	O
EE	-	156	O
)	-	158	O
on	-	160	O
the	-	163	O
neutral	-	167	O
and	-	175	O
acidic	-	179	O
biosynthetic	-	186	O
pathways	-	199	O
of	-	208	O
bile	-	211	O
salt	-	216	O
(	-	221	O
BS	-	222	O
)	-	224	O
synthesis	-	226	O
were	-	236	O
evaluated	-	241	O
in	-	251	O
rats	-	254	O
with	-	259	O
an	-	264	O
intact	-	267	O
enterohepatic	-	274	O
circulation	-	288	O
and	-	300	O
in	-	304	O
rats	-	307	O
with	-	312	O
long	-	317	O
-	-	321	O
term	-	322	O
bile	-	327	O
diversion	-	332	O
to	-	342	O
induce	-	345	O
BS	-	352	O
synthesis	-	355	O
.	-	364	O

For	9869655	366	O
this	-	370	O
purpose	-	375	O
,	-	382	O
bile	-	384	O
salt	-	389	O
pool	-	394	O
composition	-	399	O
,	-	410	O
synthesis	-	412	O
of	-	422	O
individual	-	425	O
BS	-	436	O
in	-	439	O
vivo	-	442	O
,	-	446	O
hepatic	-	448	O
activities	-	456	O
,	-	466	O
and	-	468	O
expression	-	472	O
levels	-	483	O
of	-	490	O
cholesterol	-	493	O
7alpha	-	505	O
-	-	511	O
hydroxylase	-	512	O
(	-	524	O
CYP7A	-	525	O
)	-	530	O
,	-	531	O
and	-	533	O
sterol	-	537	O
27	-	544	O
-	-	546	O
hydroxylase	-	547	O
(	-	559	O
CYP27	-	560	O
)	-	565	O
,	-	566	O
as	-	568	O
well	-	571	O
as	-	576	O
of	-	579	O
other	-	582	O
enzymes	-	588	O
involved	-	596	O
in	-	605	O
BS	-	608	O
synthesis	-	611	O
,	-	620	O
were	-	622	O
analyzed	-	627	O
in	-	636	O
rats	-	639	O
treated	-	644	O
with	-	652	O
EE	-	657	O
(	-	660	O
5	-	661	O
mg	-	663	O
/	-	665	O
kg	-	666	O
,	-	668	O
3	-	670	O
days	-	672	O
)	-	676	O
or	-	678	O
its	-	681	O
vehicle	-	685	O
.	-	692	O

BS	9869655	694	O
pool	-	697	O
size	-	702	O
was	-	707	O
decreased	-	711	O
by	-	721	O
27	-	724	O
%	-	726	O
but	-	728	O
total	-	732	O
BS	-	738	O
synthesis	-	741	O
was	-	751	O
not	-	755	O
affected	-	759	O
by	-	768	O
EE	-	771	O
in	-	774	O
intact	-	777	O
rats	-	784	O
.	-	788	O

Synthesis	9869655	790	O
of	-	800	O
cholate	-	803	O
was	-	811	O
reduced	-	815	O
by	-	823	O
68	-	826	O
%	-	828	O
in	-	830	O
EE	-	833	O
-	-	835	O
treated	-	836	O
rats	-	844	O
,	-	848	O
while	-	850	O
that	-	856	O
of	-	861	O
chenodeoxycholate	-	864	O
was	-	882	O
increased	-	886	O
by	-	896	O
60	-	899	O
%	-	901	O
.	-	902	O

The	9869655	904	O
recently	-	908	O
identified	-	917	O
Delta22	-	928	O
-	-	935	O
isomer	-	936	O
of	-	943	O
beta	-	946	O
-	-	950	O
muricholate	-	951	O
contributed	-	963	O
for	-	975	O
5	-	979	O
.	-	980	O
4	-	981	O
%	-	982	O
and	-	984	O
18	-	988	O
.	-	990	O
3	-	991	O
%	-	993	O
(	-	995	O
P	-	996	O
<	-	998	O
0	-	1000	O
.	-	1001	O
01	-	1002	O
)	-	1004	O
to	-	1006	O
the	-	1009	O
pool	-	1013	O
in	-	1018	O
control	-	1021	O
and	-	1029	O
EE	-	1033	O
-	-	1035	O
treated	-	1036	O
rats	-	1044	O
,	-	1048	O
respectively	-	1050	O
,	-	1062	O
but	-	1064	O
could	-	1068	O
not	-	1074	O
be	-	1078	O
detected	-	1081	O
in	-	1090	O
bile	-	1093	O
after	-	1098	O
exhaustion	-	1104	O
of	-	1115	O
the	-	1118	O
pool	-	1122	O
.	-	1126	O

A	9869655	1128	O
clear	-	1130	O
reduction	-	1136	O
of	-	1146	O
BS	-	1149	O
synthesis	-	1152	O
was	-	1162	O
found	-	1166	O
in	-	1172	O
bile	-	1175	O
-	-	1179	O
diverted	-	1180	O
rats	-	1189	O
treated	-	1194	O
with	-	1202	O
EE	-	1207	O
,	-	1209	O
yet	-	1211	O
biliary	-	1215	O
BS	-	1223	O
composition	-	1226	O
was	-	1238	O
only	-	1242	O
minimally	-	1247	O
affected	-	1257	O
.	-	1265	O

Activity	9869655	1267	O
of	-	1276	O
CYP7A	-	1279	O
was	-	1285	O
decreased	-	1289	O
by	-	1299	O
EE	-	1302	O
in	-	1305	O
both	-	1308	O
intact	-	1313	O
and	-	1320	O
bile	-	1324	O
-	-	1328	O
diverted	-	1329	O
rats	-	1338	O
,	-	1342	O
whereas	-	1344	O
the	-	1352	O
activity	-	1356	O
of	-	1365	O
the	-	1368	O
CYP27	-	1372	O
was	-	1378	O
not	-	1382	O
affected	-	1386	O
.	-	1394	O

Hepatic	9869655	1396	O
mRNA	-	1404	O
levels	-	1409	O
of	-	1416	O
CYP7A	-	1419	O
were	-	1425	O
significantly	-	1430	O
reduced	-	1444	O
by	-	1452	O
EE	-	1455	O
in	-	1458	O
bile	-	1461	O
-	-	1465	O
diverted	-	1466	O
rats	-	1475	O
only	-	1480	O
;	-	1484	O
CYP27	-	1486	O
mRNA	-	1492	O
levels	-	1497	O
were	-	1504	O
not	-	1509	O
affected	-	1513	O
by	-	1522	O
EE	-	1525	O
.	-	1527	O

In	9869655	1529	O
addition	-	1532	O
,	-	1540	O
mRNA	-	1542	O
levels	-	1547	O
of	-	1554	O
sterol	-	1557	O
12alpha	-	1564	O
-	-	1571	O
hydroxylase	-	1572	O
and	-	1584	O
lithocholate	-	1588	O
6beta	-	1601	O
-	-	1606	O
hydroxylase	-	1607	O
were	-	1619	O
increased	-	1624	O
by	-	1634	O
bile	-	1637	O
diversion	-	1642	O
and	-	1652	O
suppressed	-	1656	O
by	-	1667	O
EE	-	1670	O
.	-	1672	O

This	9869655	1674	O
study	-	1679	O
shows	-	1685	O
that	-	1691	O
17alpha	-	1696	O
-	-	1703	O
ethinylestradiol	-	1704	O
(	-	1721	O
EE	-	1722	O
)	-	1724	O
-	-	1725	O
induced	-	1726	O
intrahepatic	-	1734	B
cholestasis	-	1747	I
in	-	1759	O
rats	-	1762	O
is	-	1767	O
associated	-	1770	O
with	-	1781	O
selective	-	1786	O
inhibition	-	1796	O
of	-	1807	O
the	-	1810	O
neutral	-	1814	O
pathway	-	1822	O
of	-	1830	O
bile	-	1833	O
salt	-	1838	O
(	-	1843	O
BS	-	1844	O
)	-	1846	O
synthesis	-	1848	O
.	-	1857	O

Simultaneous	9869655	1859	O
impairment	-	1872	O
of	-	1883	O
other	-	1886	O
enzymes	-	1892	O
in	-	1900	O
the	-	1903	O
BS	-	1907	O
biosynthetic	-	1910	O
pathways	-	1923	O
may	-	1932	O
contribute	-	1936	O
to	-	1947	O
overall	-	1950	O
effects	-	1958	O
of	-	1966	O
EE	-	1969	O
on	-	1972	O
BS	-	1975	O
synthesis	-	1978	O
.	-	1987	O

Glibenclamide	9881641	0	O
-	-	13	O
sensitive	-	14	O
hypotension	-	24	B
produced	-	36	O
by	-	45	O
helodermin	-	48	O
assessed	-	59	O
in	-	68	O
the	-	71	O
rat	-	75	O
.	-	78	O

The	9881641	80	O
effects	-	84	O
of	-	92	O
helodermin	-	95	O
,	-	105	O
a	-	107	O
basic	-	109	O
35	-	115	O
-	-	117	O
amino	-	118	O
acid	-	124	O
peptide	-	129	O
isolated	-	137	O
from	-	146	O
the	-	151	O
venom	-	155	O
of	-	161	O
a	-	164	O
lizard	-	166	O
salivary	-	173	O
gland	-	182	O
,	-	187	O
on	-	189	O
arterial	-	192	O
blood	-	201	O
pressure	-	207	O
and	-	216	O
heart	-	220	O
rate	-	226	O
were	-	231	O
examined	-	236	O
in	-	245	O
the	-	248	O
rat	-	252	O
,	-	255	O
focusing	-	257	O
on	-	266	O
the	-	269	O
possibility	-	273	O
that	-	285	O
activation	-	290	O
of	-	301	O
ATP	-	304	O
sensitive	-	308	O
K	-	318	O
+	-	319	O
(	-	321	O
K	-	322	O
(	-	323	O
ATP	-	324	O
)	-	327	O
)	-	328	O
channels	-	330	O
is	-	339	O
involved	-	342	O
in	-	351	O
the	-	354	O
responses	-	358	O
.	-	367	O

The	9881641	369	O
results	-	373	O
were	-	381	O
also	-	386	O
compared	-	391	O
with	-	400	O
those	-	405	O
of	-	411	O
vasoactive	-	414	O
intestinal	-	425	O
polypeptide	-	436	O
(	-	448	O
VIP	-	449	O
)	-	452	O
.	-	453	O

Helodermin	9881641	455	O
produced	-	466	O
hypotension	-	475	B
in	-	487	O
a	-	490	O
dose	-	492	O
-	-	496	O
dependent	-	497	O
manner	-	507	O
with	-	514	O
approximately	-	519	O
similar	-	533	O
potency	-	541	O
and	-	549	O
duration	-	553	O
to	-	562	O
VIP	-	565	O
.	-	568	O

Hypotension	9881641	570	B
induced	-	582	O
by	-	590	O
both	-	593	O
peptides	-	598	O
was	-	607	O
significantly	-	611	O
attenuated	-	625	O
by	-	636	O
glibenclamide	-	639	O
,	-	652	O
which	-	654	O
abolished	-	660	O
a	-	670	O
levcromakalim	-	672	O
-	-	685	O
produced	-	686	O
decrease	-	695	O
in	-	704	O
arterial	-	707	O
blood	-	716	O
pressure	-	722	O
.	-	730	O

Oxyhemoglobin	9881641	732	O
did	-	746	O
not	-	750	O
affect	-	754	O
helodermin	-	761	O
-	-	771	O
induced	-	772	O
hypotension	-	780	B
,	-	791	O
whereas	-	793	O
it	-	801	O
shortened	-	804	O
the	-	814	O
duration	-	818	O
of	-	827	O
acetylcholine	-	830	O
(	-	844	O
ACh	-	845	O
)	-	848	O
-	-	849	O
produced	-	850	O
hypotension	-	859	B
.	-	870	O

These	9881641	872	O
findings	-	878	O
suggest	-	887	O
that	-	895	O
helodermin	-	900	O
-	-	910	O
produced	-	911	O
hypotension	-	920	B
is	-	932	O
partly	-	935	O
attributable	-	942	O
to	-	955	O
the	-	958	O
activation	-	962	O
of	-	973	O
glibenclamide	-	976	O
-	-	989	O
sensitive	-	990	O
K	-	1000	O
+	-	1001	O
channels	-	1003	O
(	-	1012	O
K	-	1013	O
(	-	1014	O
ATP	-	1015	O
)	-	1018	O
channels	-	1020	O
)	-	1028	O
,	-	1029	O
which	-	1031	O
presumably	-	1037	O
exist	-	1048	O
on	-	1054	O
arterial	-	1057	O
smooth	-	1066	O
muscle	-	1073	O
cells	-	1080	O
.	-	1085	O

EDRF	9881641	1087	O
(	-	1092	O
endothelium	-	1093	O
-	-	1104	O
derived	-	1105	O
relaxing	-	1113	O
factor	-	1122	O
)	-	1128	O
/	-	1129	O
nitric	-	1130	O
oxide	-	1137	O
does	-	1143	O
not	-	1148	O
seem	-	1152	O
to	-	1157	O
play	-	1160	O
an	-	1165	O
important	-	1168	O
role	-	1178	O
in	-	1183	O
the	-	1186	O
peptide	-	1190	O
-	-	1197	O
produced	-	1198	O
hypotension	-	1207	B
.	-	1218	O

Long	9889429	0	O
-	-	4	O
term	-	5	O
efficacy	-	10	O
and	-	19	O
adverse	-	23	O
event	-	31	O
of	-	37	O
nifedipine	-	40	O
sustained	-	51	O
-	-	60	O
release	-	61	O
tablets	-	69	O
for	-	77	O
cyclosporin	-	81	O
A	-	93	O
-	-	94	O
induced	-	95	O
hypertension	-	103	B
in	-	116	O
patients	-	119	O
with	-	128	O
psoriasis	-	133	B
.	-	142	O

Thirteen	9889429	144	O
psoriatic	-	153	B
patients	-	163	O
with	-	172	O
hypertension	-	177	B
during	-	190	O
the	-	197	O
course	-	201	O
of	-	208	O
cyclosporin	-	211	O
A	-	223	O
therapy	-	225	O
were	-	233	O
treated	-	238	O
for	-	246	O
25	-	250	O
months	-	253	O
with	-	260	O
a	-	265	O
calcium	-	267	O
channel	-	275	O
blocker	-	283	O
,	-	290	O
sustained	-	292	O
-	-	301	O
release	-	302	O
nifedipine	-	310	O
,	-	320	O
to	-	322	O
study	-	325	O
the	-	331	O
clinical	-	335	O
antihypertensive	-	344	O
effects	-	361	O
and	-	369	O
adverse	-	373	O
events	-	381	O
during	-	388	O
treatment	-	395	O
with	-	405	O
both	-	410	O
drugs	-	415	O
.	-	420	O

Seven	9889429	422	O
of	-	428	O
the	-	431	O
13	-	435	O
patients	-	438	O
had	-	447	O
exhibited	-	451	O
a	-	461	O
subclinical	-	463	O
hypertensive	-	475	B
state	-	488	O
before	-	494	O
cyclosporin	-	501	O
A	-	513	O
therapy	-	515	O
.	-	522	O

Both	9889429	524	O
systolic	-	529	O
and	-	538	O
diastolic	-	542	O
blood	-	552	O
pressures	-	558	O
of	-	568	O
these	-	571	O
13	-	577	O
patients	-	580	O
were	-	589	O
decreased	-	594	O
significantly	-	604	O
after	-	618	O
4	-	624	O
weeks	-	626	O
of	-	632	O
nifedipine	-	635	O
therapy	-	646	O
,	-	653	O
and	-	655	O
blood	-	659	O
pressure	-	665	O
was	-	674	O
maintained	-	678	O
within	-	689	O
the	-	696	O
normal	-	700	O
range	-	707	O
thereafter	-	713	O
for	-	724	O
25	-	728	O
months	-	731	O
.	-	737	O

The	9889429	739	O
adverse	-	743	O
events	-	751	O
during	-	758	O
combined	-	765	O
therapy	-	774	O
with	-	782	O
cyclosporin	-	787	O
A	-	799	O
and	-	801	O
nifedipine	-	805	O
included	-	816	O
an	-	825	O
increase	-	828	O
in	-	837	O
blood	-	840	O
urea	-	846	O
nitrogen	-	851	O
levels	-	860	O
in	-	867	O
9	-	870	O
of	-	872	O
the	-	875	O
13	-	879	O
patients	-	882	O
and	-	891	O
development	-	895	O
of	-	907	O
gingival	-	910	B
hyperplasia	-	919	I
in	-	931	O
2	-	934	O
of	-	936	O
the	-	939	O
13	-	943	O
patients	-	946	O
.	-	954	O

Our	9889429	956	O
findings	-	960	O
indicate	-	969	O
that	-	978	O
sustained	-	983	O
-	-	992	O
release	-	993	O
nifedipine	-	1001	O
is	-	1012	O
useful	-	1015	O
for	-	1022	O
hypertensive	-	1026	B
psoriatic	-	1039	B
patients	-	1049	O
under	-	1058	O
long	-	1064	O
-	-	1068	O
term	-	1069	O
treatment	-	1074	O
with	-	1084	O
cyclosporin	-	1089	O
A	-	1101	O
,	-	1102	O
but	-	1104	O
that	-	1108	O
these	-	1113	O
patients	-	1119	O
should	-	1128	O
be	-	1135	O
monitored	-	1138	O
for	-	1148	O
gingival	-	1152	B
hyperplasia	-	1161	I
.	-	1172	O

Torsade	10087562	0	B
de	-	8	I
pointes	-	11	I
ventricular	-	19	B
tachycardia	-	31	I
during	-	43	O
low	-	50	O
dose	-	54	O
intermittent	-	59	O
dobutamine	-	72	O
treatment	-	83	O
in	-	93	O
a	-	96	O
patient	-	98	O
with	-	106	O
dilated	-	111	B
cardiomyopathy	-	119	I
and	-	134	O
congestive	-	138	B
heart	-	149	I
failure	-	155	I
.	-	162	O

The	10087562	164	O
authors	-	168	O
describe	-	176	O
the	-	185	O
case	-	189	O
of	-	194	O
a	-	197	O
56	-	199	O
-	-	201	O
year	-	202	O
-	-	206	O
old	-	207	O
woman	-	211	O
with	-	217	O
chronic	-	222	O
,	-	229	O
severe	-	231	O
heart	-	238	B
failure	-	244	I
secondary	-	252	O
to	-	262	O
dilated	-	265	B
cardiomyopathy	-	273	I
and	-	288	O
absence	-	292	O
of	-	300	O
significant	-	303	O
ventricular	-	315	B
arrhythmias	-	327	I
who	-	339	O
developed	-	343	O
QT	-	353	B
prolongation	-	356	I
and	-	369	O
torsade	-	373	B
de	-	381	I
pointes	-	384	I
ventricular	-	392	B
tachycardia	-	404	I
during	-	416	O
one	-	423	O
cycle	-	427	O
of	-	433	O
intermittent	-	436	O
low	-	449	O
dose	-	453	O
(	-	458	O
2	-	459	O
.	-	460	O
5	-	461	O
mcg	-	463	O
/	-	466	O
kg	-	467	O
per	-	470	O
min	-	474	O
)	-	477	O
dobutamine	-	479	O
.	-	489	O

This	10087562	491	O
report	-	496	O
of	-	503	O
torsade	-	506	B
de	-	514	I
pointes	-	517	I
ventricular	-	525	B
tachycardia	-	537	I
during	-	549	O
intermittent	-	556	O
dobutamine	-	569	O
supports	-	580	O
the	-	589	O
hypothesis	-	593	O
that	-	604	O
unpredictable	-	609	O
fatal	-	623	O
arrhythmias	-	629	B
may	-	641	O
occur	-	645	O
even	-	651	O
with	-	656	O
low	-	661	O
doses	-	665	O
and	-	671	O
in	-	675	O
patients	-	678	O
with	-	687	O
no	-	692	O
history	-	695	O
of	-	703	O
significant	-	706	O
rhythm	-	718	O
disturbances	-	725	O
.	-	737	O

The	10087562	739	O
mechanisms	-	743	O
of	-	754	O
proarrhythmic	-	757	O
effects	-	771	O
of	-	779	O
Dubutamine	-	782	O
are	-	793	O
discussed	-	797	O
.	-	806	O

Positive	10219427	0	O
skin	-	9	O
tests	-	14	O
in	-	20	O
late	-	23	O
reactions	-	28	O
to	-	38	O
radiographic	-	41	O
contrast	-	54	O
media	-	63	O
.	-	68	O

In	10219427	70	O
the	-	73	O
last	-	77	O
few	-	82	O
years	-	86	O
delayed	-	92	O
reactions	-	100	O
several	-	110	O
hours	-	118	O
after	-	124	O
the	-	130	O
injection	-	134	O
of	-	144	O
radiographic	-	147	O
and	-	160	O
contrast	-	164	O
materials	-	173	O

(	10219427	183	O
PRC	-	184	O
)	-	187	O
have	-	189	O
been	-	194	O
described	-	199	O
with	-	209	O
increasing	-	214	O
frequency	-	225	O
.	-	234	O

The	10219427	236	O
authors	-	240	O
report	-	248	O
two	-	255	O
observations	-	259	O
on	-	272	O
patients	-	275	O
with	-	284	O
delayed	-	289	O
reactions	-	297	O
in	-	307	O
whom	-	310	O
intradermoreactions	-	315	O
(	-	335	O
IDR	-	336	O
)	-	339	O
and	-	341	O
patch	-	345	O
tests	-	351	O
to	-	357	O
a	-	360	O
series	-	362	O
of	-	369	O
ionic	-	372	O
and	-	378	O
non	-	382	O
ionic	-	386	O
PRC	-	392	O
were	-	396	O
studied	-	401	O
.	-	408	O

After	10219427	410	O
angiography	-	416	O
by	-	428	O
the	-	431	O
venous	-	435	O
route	-	442	O
in	-	448	O
patient	-	451	O
n	-	459	O
degree	-	461	O
1	-	468	O
a	-	470	O
biphasic	-	472	O
reaction	-	481	O
with	-	490	O
an	-	495	O
immediate	-	498	O
reaction	-	508	O
(	-	517	O
dyspnea	-	518	B
,	-	525	O
loss	-	527	B
of	-	532	I
consciousness	-	535	I
)	-	548	O
and	-	550	O
delayed	-	554	O
macro	-	562	B
-	-	567	I
papular	-	568	I
rash	-	576	I
appeared	-	581	O
,	-	589	O
whilst	-	591	O
patient	-	598	O
n	-	606	O
degree	-	608	O
2	-	615	O
developed	-	617	O
a	-	627	O
generalised	-	629	O
sensation	-	641	O
of	-	651	O
heat	-	654	O
,	-	658	O
persistent	-	660	O
pain	-	671	B
at	-	676	O
the	-	679	O
site	-	683	O
of	-	688	O
injection	-	691	O
immediately	-	701	O
and	-	713	O
a	-	717	O
generalised	-	719	O
macro	-	731	O
-	-	736	O
papular	-	737	O
reaction	-	745	O
after	-	754	O
24	-	760	O
hours	-	763	O
.	-	768	O

The	10219427	770	O
skin	-	774	O
tests	-	779	O
revealed	-	785	O
positive	-	794	O
delayed	-	803	O
reactions	-	811	O
of	-	821	O
24	-	824	O
hours	-	827	O
and	-	833	O
48	-	837	O
hours	-	840	O
by	-	846	O
IDR	-	849	O
and	-	853	O
patch	-	857	O
tests	-	863	O
to	-	869	O
only	-	872	O
some	-	877	O
PRC	-	882	O
with	-	886	O
common	-	891	O
chains	-	898	O
in	-	905	O
their	-	908	O
structures	-	914	O
.	-	924	O

The	10219427	926	O
positive	-	930	O
skin	-	939	O
tests	-	944	O
are	-	950	O
in	-	954	O
favour	-	957	O
of	-	964	O
immunological	-	967	O
reactions	-	981	O
and	-	991	O
may	-	995	O
help	-	999	O
in	-	1004	O
diagnosis	-	1007	O
of	-	1017	O
allergy	-	1020	B
in	-	1028	O
the	-	1031	O
patients	-	1035	O
.	-	1043	O

Risk	10327032	0	O
of	-	5	O
transient	-	8	O
hyperammonemic	-	18	B
encephalopathy	-	33	I
in	-	48	O
cancer	-	51	B
patients	-	58	O
who	-	67	O
received	-	71	O
continuous	-	80	O
infusion	-	91	O
of	-	100	O
5	-	103	O
-	-	104	O
fluorouracil	-	105	O
with	-	118	O
the	-	123	O
complication	-	127	O
of	-	140	O
dehydration	-	143	B
and	-	155	O
infection	-	159	B
.	-	168	O

From	10327032	170	O
1986	-	175	O
to	-	180	O
1998	-	183	O
,	-	187	O
29	-	189	O
cancer	-	192	B
patients	-	199	O
who	-	208	O
had	-	212	O
32	-	216	O
episodes	-	219	O
of	-	228	O
transient	-	231	O
hyperammonemic	-	241	B
encephalopathy	-	256	I
related	-	271	O
to	-	279	O
continuous	-	282	O
infusion	-	293	O
of	-	302	O
5	-	305	O
-	-	306	O
fluorouracil	-	307	O
(	-	320	O
5	-	321	O
-	-	322	O
FU	-	323	O
)	-	325	O
were	-	327	O
identified	-	332	O
.	-	342	O

None	10327032	344	O
of	-	349	O
the	-	352	O
patients	-	356	O
had	-	365	O
decompensated	-	369	O
liver	-	383	B
disease	-	389	I
.	-	396	O

Onset	10327032	398	O
of	-	404	O
hyperammonemic	-	407	B
encephalopathy	-	422	I
varied	-	437	O
from	-	444	O
0	-	449	O
.	-	450	O
5	-	451	O
to	-	453	O
5	-	456	O
days	-	458	O
(	-	463	O
mean	-	464	O
:	-	468	O
2	-	470	O
.	-	471	O
6	-	472	O
+	-	474	O
/	-	475	O
-	-	476	O

1	10327032	478	O
.	-	479	O
3	-	480	O
days	-	482	O
)	-	486	O
after	-	488	O
the	-	494	O
initiation	-	498	O
of	-	509	O
chemotherapy	-	512	O
.	-	524	O

Plasma	10327032	526	O
ammonium	-	533	O
level	-	542	O
ranged	-	548	O
from	-	555	O
248	-	560	O
to	-	564	O
2387	-	567	O
microg	-	572	O
%	-	578	O
(	-	580	O
mean	-	581	O
:	-	585	O
626	-	587	O
+	-	591	O
/	-	592	O
-	-	593	O

431	10327032	595	O
microg	-	599	O
%	-	605	O
)	-	606	O
.	-	607	O

Among	10327032	609	O
the	-	615	O
32	-	619	O
episodes	-	622	O
,	-	630	O
26	-	632	O
(	-	635	O
81	-	636	O
%	-	638	O
)	-	639	O
had	-	641	O
various	-	645	O
degrees	-	653	O
of	-	661	O
azotemia	-	664	B
,	-	672	O
18	-	674	O
(	-	677	O
56	-	678	O
%	-	680	O
)	-	681	O
occurred	-	683	O
during	-	692	O
bacterial	-	699	B
infections	-	709	I
and	-	720	O
14	-	724	O
(	-	727	O
44	-	728	O
%	-	730	O
)	-	731	O
without	-	733	O
infection	-	741	B
occurred	-	751	O
during	-	760	O
periods	-	767	O
of	-	775	O
dehydration	-	778	B
.	-	789	O

Higher	10327032	791	O
plasma	-	798	O
ammonium	-	805	O
levels	-	814	O
and	-	821	O
more	-	825	O
rapid	-	830	O
onset	-	836	O
of	-	842	O
hyperammonemia	-	845	B
were	-	860	O
seen	-	865	O
in	-	870	O
18	-	873	O
patients	-	876	O
with	-	885	O
bacterial	-	890	B
infections	-	900	I
(	-	911	O
p	-	912	O
=	-	913	O
0	-	914	O
.	-	915	O
003	-	916	O
and	-	920	O
0	-	924	O
.	-	925	O
0006	-	926	O
,	-	930	O
respectively	-	932	O
)	-	944	O
and	-	946	O
in	-	950	O
nine	-	953	O
patients	-	958	O
receiving	-	967	O
high	-	977	O
daily	-	982	O
doses	-	988	O
(	-	994	O
2600	-	995	O
or	-	1000	O
1800	-	1003	O
mg	-	1008	O
/	-	1010	O
m2	-	1011	O
)	-	1013	O
of	-	1015	O
5	-	1018	O
-	-	1019	O
FU	-	1020	O
(	-	1023	O
p	-	1024	O
=	-	1025	O
0	-	1026	O
.	-	1027	O
0001	-	1028	O
and	-	1033	O
<	-	1037	O
0	-	1039	O
.	-	1040	O
0001	-	1041	O
,	-	1045	O
respectively	-	1047	O
)	-	1059	O
.	-	1060	O

In	10327032	1062	O
25	-	1065	O
out	-	1068	O
of	-	1072	O
32	-	1075	O
episodes	-	1078	O
(	-	1087	O
78	-	1088	O
%	-	1090	O
)	-	1091	O
,	-	1092	O
plasma	-	1094	O
ammonium	-	1101	O
levels	-	1110	O
and	-	1117	O
mental	-	1121	O
status	-	1128	O
returned	-	1135	O
to	-	1144	O
normal	-	1147	O
within	-	1154	O
2	-	1161	O
days	-	1163	O
after	-	1168	O
adequate	-	1174	O
management	-	1183	O
.	-	1193	O

In	10327032	1195	O
conclusion	-	1198	O
,	-	1208	O
hyperammonemic	-	1210	B
encephalopathy	-	1225	I
can	-	1240	O
occur	-	1244	O
in	-	1250	O
patients	-	1253	O
receiving	-	1262	O
continuous	-	1272	O
infusion	-	1283	O
of	-	1292	O
5	-	1295	O
-	-	1296	O
FU	-	1297	O
.	-	1299	O

Azotemia	10327032	1301	B
,	-	1309	O
body	-	1311	O
fluid	-	1316	O
insufficiency	-	1322	O
and	-	1336	O
bacterial	-	1340	B
infections	-	1350	I
were	-	1361	O
frequently	-	1366	O
found	-	1377	O
in	-	1383	O
these	-	1386	O
patients	-	1392	O
.	-	1400	O

It	10327032	1402	O
is	-	1405	O
therefore	-	1408	O
important	-	1418	O
to	-	1428	O
recognize	-	1431	O
this	-	1441	O
condition	-	1446	O
in	-	1456	O
patients	-	1459	O
receiving	-	1468	O
continuous	-	1478	O
infusion	-	1489	O
of	-	1498	O
5	-	1501	O
-	-	1502	O
FU	-	1503	O
.	-	1505	O

The	10390729	0	O
effects	-	4	O
of	-	12	O
quinine	-	15	O
and	-	23	O
4	-	27	O
-	-	28	O
aminopyridine	-	29	O
on	-	43	O
conditioned	-	46	O
place	-	58	O
preference	-	64	O
and	-	75	O
changes	-	79	O
in	-	87	O
motor	-	90	O
activity	-	96	O
induced	-	105	O
by	-	113	O
morphine	-	116	O
in	-	125	O
rats	-	128	O
.	-	132	O

1	10390729	134	O
.	-	135	O

The	10390729	137	O
effects	-	141	O
of	-	149	O
two	-	152	O
unselective	-	156	O
potassium	-	168	O
(	-	178	O
K	-	179	O
(	-	180	O
+	-	181	O
)	-	182	O
-	-	183	O
)	-	184	O
channel	-	186	O
blockers	-	194	O
,	-	202	O
quinine	-	204	O
(	-	212	O
12	-	213	O
.	-	215	O
5	-	216	O
,	-	217	O
25	-	219	O
and	-	222	O
50	-	226	O
mg	-	229	O
/	-	231	O
kg	-	232	O
)	-	234	O
and	-	236	O
4	-	240	O
-	-	241	O
aminopyridine	-	242	O
(	-	256	O
1	-	257	O
and	-	259	O
2	-	263	O
mg	-	265	O
/	-	267	O
kg	-	268	O
)	-	270	O
,	-	271	O
on	-	273	O
conditioned	-	276	O
place	-	288	O
preference	-	294	O
and	-	305	O
biphasic	-	309	O
changes	-	318	O
in	-	326	O
motor	-	329	O
activity	-	335	O
induced	-	344	O
by	-	352	O
morphine	-	355	O
(	-	364	O
10	-	365	O
mg	-	368	O
/	-	370	O
kg	-	371	O
)	-	373	O
were	-	375	O
tested	-	380	O
in	-	387	O
Wistar	-	390	O
rats	-	397	O
.	-	401	O

Quinine	10390729	403	O
is	-	411	O
known	-	414	O
to	-	420	O
block	-	423	O
voltage	-	429	O
-	-	436	O
,	-	437	O
calcium	-	439	O
-	-	446	O
and	-	448	O
ATP	-	452	O
-	-	455	O
sensitive	-	456	O
K	-	466	O
(	-	467	O
+	-	468	O
)	-	469	O
-	-	470	O
channels	-	471	O
while	-	480	O
4	-	486	O
-	-	487	O
aminopyridine	-	488	O
is	-	502	O
known	-	505	O
to	-	511	O
block	-	514	O
voltage	-	520	O
-	-	527	O
sensitive	-	528	O
K	-	538	O
(	-	539	O
+	-	540	O
)	-	541	O
-	-	542	O
channels	-	543	O
.	-	551	O

2	10390729	553	O
.	-	554	O

In	10390729	556	O
the	-	559	O
counterbalanced	-	563	O
method	-	579	O
,	-	585	O
quinine	-	587	O
attenuated	-	595	O
morphine	-	606	O
-	-	614	O
induced	-	615	O
place	-	623	O
preference	-	629	O
,	-	639	O
whereas	-	641	O
4	-	649	O
-	-	650	O
aminopyridine	-	651	O
was	-	665	O
ineffective	-	669	O
.	-	680	O

In	10390729	682	O
the	-	685	O
motor	-	689	O
activity	-	695	O
test	-	704	O
measured	-	709	O
with	-	718	O
an	-	723	O
Animex	-	726	O
-	-	732	O
activity	-	733	O
meter	-	742	O
neither	-	748	O
of	-	756	O
the	-	759	O
K	-	763	O
(	-	764	O
+	-	765	O
)	-	766	O
-	-	767	O
channel	-	768	O
blockers	-	776	O
affected	-	785	O
morphine	-	794	O
-	-	802	O
induced	-	803	O
hypoactivity	-	811	B
,	-	823	O
but	-	825	O
both	-	829	O
K	-	834	O
(	-	835	O
+	-	836	O
)	-	837	O
-	-	838	O
channel	-	839	O
blockers	-	847	O
prevented	-	856	O
morphine	-	866	O
-	-	874	O
induced	-	875	O
secondary	-	883	O
hyperactivity	-	893	B
.	-	906	O

3	10390729	908	O
.	-	909	O

These	10390729	911	O
results	-	917	O
suggest	-	925	O
the	-	933	O
involvement	-	937	O
of	-	949	O
quinine	-	952	O
-	-	959	O
sensitive	-	960	O
but	-	970	O
not	-	974	O
4	-	978	O
-	-	979	O
aminopyridine	-	980	O
-	-	993	O
sensitive	-	994	O
K	-	1004	O
(	-	1005	O
+	-	1006	O
)	-	1007	O
-	-	1008	O
channels	-	1009	O
in	-	1018	O
morphine	-	1021	O
reward	-	1030	O
.	-	1036	O

It	10390729	1038	O
is	-	1041	O
also	-	1044	O
suggested	-	1049	O
that	-	1059	O
the	-	1064	O
blockade	-	1068	O
of	-	1077	O
K	-	1080	O
(	-	1081	O
+	-	1082	O
)	-	1083	O
-	-	1084	O
channels	-	1085	O
sensitive	-	1094	O
to	-	1104	O
these	-	1107	O
blockers	-	1113	O
is	-	1122	O
not	-	1125	O
sufficient	-	1129	O
to	-	1140	O
prevent	-	1143	O
morphine	-	1151	O
-	-	1159	O
induced	-	1160	O
hypoactivity	-	1168	B
whereas	-	1181	O
morphine	-	1189	O
-	-	1197	O
induced	-	1198	O
hyperactivity	-	1206	B
seems	-	1220	O
to	-	1226	O
be	-	1229	O
connected	-	1232	O
to	-	1242	O
both	-	1245	O
quinine	-	1250	O
-	-	1257	O
and	-	1259	O
4	-	1263	O
-	-	1264	O
aminopyridine	-	1265	O
-	-	1278	O
sensitive	-	1279	O
K	-	1289	O
(	-	1290	O
+	-	1291	O
)	-	1292	O
-	-	1293	O
channels	-	1294	O
.	-	1302	O

Nociceptin	10401555	0	O
/	-	10	O
orphanin	-	11	O
FQ	-	20	O
and	-	23	O
nocistatin	-	27	O
on	-	38	O
learning	-	41	B
and	-	50	I
memory	-	54	I
impairment	-	61	I
induced	-	72	O
by	-	80	O
scopolamine	-	83	O
in	-	95	O
mice	-	98	O
.	-	102	O

1	10401555	104	O
.	-	105	O

Nociceptin	10401555	107	O
,	-	117	O
also	-	119	O
known	-	124	O
as	-	130	O
orphanin	-	133	O
FQ	-	142	O
,	-	144	O
is	-	146	O
an	-	149	O
endogenous	-	152	O
ligand	-	163	O
for	-	170	O
the	-	174	O
orphan	-	178	O
opioid	-	185	O
receptor	-	192	O
-	-	200	O
like	-	201	O
receptor	-	206	O
1	-	215	O
(	-	217	O
ORL1	-	218	O
)	-	222	O
and	-	224	O
involves	-	228	O
in	-	237	O
various	-	240	O
functions	-	248	O
in	-	258	O
the	-	261	O
central	-	265	O
nervous	-	273	O
system	-	281	O
(	-	288	O
CNS	-	289	O
)	-	292	O
.	-	293	O

On	10401555	295	O
the	-	298	O
other	-	302	O
hand	-	308	O
,	-	312	O
nocistatin	-	314	O
is	-	325	O
recently	-	328	O
isolated	-	337	O
from	-	346	O
the	-	351	O
same	-	355	O
precursor	-	360	O
as	-	370	O
nociceptin	-	373	O
and	-	384	O
blocks	-	388	O
nociceptin	-	395	O
-	-	405	O
induced	-	406	O
allodynia	-	414	B
and	-	424	O
hyperalgesia	-	428	B
.	-	440	O

2	10401555	442	O
.	-	443	O

Although	10401555	445	O
ORL1	-	454	O
receptors	-	459	O
which	-	469	O
display	-	475	O
a	-	483	O
high	-	485	O
degree	-	490	O
of	-	497	O
sequence	-	500	O
homology	-	509	O
with	-	518	O
classical	-	523	O
opioid	-	533	O
receptors	-	540	O
are	-	550	O
abundant	-	554	O
in	-	563	O
the	-	566	O
hippocampus	-	570	O
,	-	581	O
little	-	583	O
is	-	590	O
known	-	593	O
regarding	-	599	O
their	-	609	O
role	-	615	O
in	-	620	O
learning	-	623	O
and	-	632	O
memory	-	636	O
.	-	642	O

3	10401555	644	O
.	-	645	O

The	10401555	647	O
present	-	651	O
study	-	659	O
was	-	665	O
designed	-	669	O
to	-	678	O
investigate	-	681	O
whether	-	693	O
nociceptin	-	701	O
/	-	711	O
orphanin	-	712	O
FQ	-	721	O
and	-	724	O
nocistatin	-	728	O
could	-	739	O
modulate	-	745	O
impairment	-	754	B
of	-	765	I
learning	-	768	I
and	-	777	I
memory	-	781	I
induced	-	788	O
by	-	796	O
scopolamine	-	799	O
,	-	810	O
a	-	812	O
muscarinic	-	814	O
cholinergic	-	825	O
receptor	-	837	O
antagonist	-	846	O
,	-	856	O
using	-	858	O
spontaneous	-	864	O
alternation	-	876	O
of	-	888	O
Y	-	891	O
-	-	892	O
maze	-	893	O
and	-	898	O
step	-	902	O
-	-	906	O
down	-	907	O
type	-	912	O
passive	-	917	O
avoidance	-	925	O
tasks	-	935	O
in	-	941	O
mice	-	944	O
.	-	948	O

4	10401555	950	O
.	-	951	O

While	10401555	953	O
nocistatin	-	959	O
(	-	970	O
0	-	971	O
.	-	972	O
5	-	973	O
-	-	974	O
5	-	975	O
.	-	976	O
0	-	977	O
nmol	-	979	O
mouse	-	984	O
-	-	989	O
1	-	990	O
,	-	991	O
i	-	993	O
.	-	994	O
c	-	995	O
.	-	996	O
v	-	997	O
.	-	998	O
)	-	999	O

administered	10401555	1001	O
30	-	1014	O
min	-	1017	O
before	-	1021	O
spontaneous	-	1028	O
alternation	-	1040	O
performance	-	1052	O
or	-	1064	O
the	-	1067	O
training	-	1071	O
session	-	1080	O
of	-	1088	O
the	-	1091	O
passive	-	1095	O
avoidance	-	1103	O
task	-	1113	O
,	-	1117	O
had	-	1119	O
no	-	1123	O
effect	-	1126	O
on	-	1133	O
spontaneous	-	1136	O
alternation	-	1148	O
or	-	1160	O
passive	-	1163	O
avoidance	-	1171	O
behaviours	-	1181	O
,	-	1191	O
a	-	1193	O
lower	-	1195	O
per	-	1201	O
cent	-	1205	O
alternation	-	1210	O
and	-	1222	O
shorter	-	1226	O
median	-	1234	O
step	-	1241	O
-	-	1245	O
down	-	1246	O
latency	-	1251	O
in	-	1259	O
the	-	1262	O
retention	-	1266	O
test	-	1276	O
were	-	1281	O
obtained	-	1286	O
in	-	1295	O
nociceptin	-	1298	O
(	-	1309	O
1	-	1310	O
.	-	1311	O
5	-	1312	O
and	-	1314	O
/	-	1317	O
or	-	1318	O
5	-	1321	O
.	-	1322	O
0	-	1323	O
nmol	-	1325	O
mouse	-	1330	O
-	-	1335	O
1	-	1336	O
,	-	1337	O
i	-	1339	O
.	-	1340	O
c	-	1341	O
.	-	1342	O
v	-	1343	O
.	-	1344	O
)	-	1345	O
-	-	1346	O
treated	-	1347	O
normal	-	1355	O
mice	-	1362	O
.	-	1366	O

5	10401555	1368	O
.	-	1369	O

Administration	10401555	1371	O
of	-	1386	O
nocistatin	-	1389	O
(	-	1400	O
1	-	1401	O
.	-	1402	O
5	-	1403	O
and	-	1405	O
/	-	1408	O
or	-	1409	O
5	-	1412	O
.	-	1413	O
0	-	1414	O
nmol	-	1416	O
mouse	-	1421	O
-	-	1426	O
1	-	1427	O
,	-	1428	O
i	-	1430	O
.	-	1431	O
c	-	1432	O
.	-	1433	O
v	-	1434	O
.	-	1435	O
)	-	1436	O

30	10401555	1438	O
min	-	1441	O
before	-	1445	O
spontaneous	-	1452	O
alternation	-	1464	O
performance	-	1476	O
or	-	1488	O
the	-	1491	O
training	-	1495	O
session	-	1504	O
of	-	1512	O
the	-	1515	O
passive	-	1519	O
avoidance	-	1527	O
task	-	1537	O
,	-	1541	O
attenuated	-	1543	O
the	-	1554	O
scopolamine	-	1558	O
-	-	1569	O
induced	-	1570	O
impairment	-	1578	O
of	-	1589	O
spontaneous	-	1592	O
alternation	-	1604	O
and	-	1616	O
passive	-	1620	O
avoidance	-	1628	O
behaviours	-	1638	O
.	-	1648	O

6	10401555	1650	O
.	-	1651	O

These	10401555	1653	O
results	-	1659	O
indicated	-	1667	O
that	-	1677	O
nocistatin	-	1682	O
,	-	1692	O
a	-	1694	O
new	-	1696	O
biologically	-	1700	O
active	-	1713	O
peptide	-	1720	O
,	-	1727	O
ameliorates	-	1729	O
impairments	-	1741	O
of	-	1753	O
spontaneous	-	1756	O
alternation	-	1768	O
and	-	1780	O
passive	-	1784	O
avoidance	-	1792	O
induced	-	1802	O
by	-	1810	O
scopolamine	-	1813	O
,	-	1824	O
and	-	1826	O
suggested	-	1830	O
that	-	1840	O
these	-	1845	O
peptides	-	1851	O
play	-	1860	O
opposite	-	1865	O
roles	-	1874	O
in	-	1880	O
learning	-	1883	O
and	-	1892	O
memory	-	1896	O
.	-	1902	O

Meloxicam	10427794	0	O
-	-	9	O
induced	-	10	O
liver	-	18	B
toxicity	-	24	I
.	-	32	O

We	10427794	34	O
report	-	37	O
the	-	44	O
case	-	48	O
of	-	53	O
a	-	56	O
female	-	58	O
patient	-	65	O
with	-	73	O
rheumatoid	-	78	B
arthritis	-	89	I
who	-	99	O
developed	-	103	O
acute	-	113	O
cytolytic	-	119	O
hepatitis	-	129	B
due	-	139	O
to	-	143	O
meloxicam	-	146	O
.	-	155	O

Recently	10427794	157	O
introduced	-	166	O
in	-	177	O
Belgium	-	180	O
,	-	187	O
meloxicam	-	189	O
is	-	199	O
the	-	202	O
first	-	206	O
nonsteroidal	-	212	O
antiinflammatory	-	225	O
drug	-	242	O
with	-	247	O
selective	-	252	O
action	-	262	O
on	-	269	O
the	-	272	O
inducible	-	276	O
form	-	286	O
of	-	291	O
cyclooxygenase	-	294	O
2	-	309	O
.	-	310	O

The	10427794	312	O
acute	-	316	O
cytolytic	-	322	O
hepatitis	-	332	B
occurred	-	342	O
rapidly	-	351	O
after	-	359	O
meloxicam	-	365	O
administration	-	375	O
and	-	390	O
was	-	394	O
associated	-	398	O
with	-	409	O
the	-	414	O
development	-	418	O
of	-	430	O
antinuclear	-	433	O
antibodies	-	445	O
suggesting	-	456	O
a	-	467	O
hypersensitivity	-	469	B
mechanism	-	486	O
.	-	495	O

This	10427794	497	O
first	-	502	O
case	-	508	O
of	-	513	O
meloxicam	-	516	O
related	-	526	O
liver	-	534	B
toxicity	-	540	I
demonstrates	-	549	O
the	-	562	O
potential	-	566	O
of	-	576	O
this	-	579	O
drug	-	584	O
to	-	589	O
induce	-	592	O
hepatic	-	599	B
damage	-	607	I
.	-	613	O

Induction	10462057	0	O
of	-	10	O
apoptosis	-	13	O
by	-	23	O
remoxipride	-	26	O
metabolites	-	38	O
in	-	50	O
HL60	-	53	O
and	-	58	O
CD34	-	62	O
+	-	66	O
/	-	67	O
CD19	-	68	O
-	-	72	O
human	-	74	O
bone	-	80	O
marrow	-	85	O
progenitor	-	92	O
cells	-	103	O
:	-	108	O
potential	-	110	O
relevance	-	120	O
to	-	130	O
remoxipride	-	133	O
-	-	144	O
induced	-	145	O
aplastic	-	153	B
anemia	-	162	I
.	-	168	O

The	10462057	170	O
antipsychotic	-	174	O
agent	-	188	O
,	-	193	O
remoxipride	-	195	O
[	-	207	O
(	-	208	O
S	-	209	O
)	-	210	O
-	-	211	O
(	-	212	O
-	-	213	O
)	-	214	O
-	-	215	O
3	-	216	O
-	-	217	O
bromo	-	218	O
-	-	223	O
N	-	224	O
-	-	225	O
[	-	226	O
(	-	227	O
1	-	228	O
-	-	229	O
ethyl	-	230	O
-	-	235	O
2	-	236	O
-	-	237	O
pyrrolidinyl	-	238	O
)	-	250	O
methyl	-	251	O
]	-	257	O
-	-	258	O
2	-	259	O
,	-	260	O
6	-	261	O
-	-	262	O
dimethoxybenz	-	263	O
amide	-	277	O
]	-	282	O
has	-	284	O
been	-	288	O
associated	-	293	O
with	-	304	O
acquired	-	309	O
aplastic	-	318	B
anemia	-	327	I
.	-	333	O

We	10462057	335	O
have	-	338	O
examined	-	343	O
the	-	352	O
ability	-	356	O
of	-	364	O
remoxipride	-	367	O
,	-	378	O
three	-	380	O
pyrrolidine	-	386	O
ring	-	398	O
metabolites	-	403	O
and	-	415	O
five	-	419	O
aromatic	-	424	O
ring	-	433	O
metabolites	-	438	O
of	-	450	O
the	-	453	O
parent	-	457	O
compound	-	464	O
to	-	473	O
induce	-	476	O
apoptosis	-	483	O
in	-	493	O
HL60	-	496	O
cells	-	501	O
and	-	507	O
human	-	511	O
bone	-	517	O
marrow	-	522	O
progenitor	-	529	O
(	-	540	O
HBMP	-	541	O
)	-	545	O
cells	-	547	O
.	-	552	O

Cells	10462057	554	O
were	-	560	O
treated	-	565	O
for	-	573	O
0	-	577	O
-	-	578	O
24	-	579	O
h	-	582	O
with	-	584	O
each	-	589	O
compound	-	594	O
(	-	603	O
0	-	604	O
-	-	605	O
200	-	606	O
microM	-	610	O
)	-	616	O
.	-	617	O

Apoptosis	10462057	619	O
was	-	629	O
assessed	-	633	O
by	-	642	O
fluorescence	-	645	O
microscopy	-	658	O
in	-	669	O
Hoechst	-	672	O
33342	-	680	O
-	-	685	O
and	-	687	O
propidium	-	691	O
iodide	-	701	O
stained	-	708	O
cell	-	716	O
samples	-	721	O
.	-	728	O

Results	10462057	730	O
were	-	738	O
confirmed	-	743	O
by	-	753	O
determination	-	756	O
of	-	770	O
internucleosomal	-	773	O
DNA	-	790	O
fragmentation	-	794	O
using	-	808	O
gel	-	814	O
electrophoresis	-	818	O
for	-	834	O
HL60	-	838	O
cell	-	843	O
samples	-	848	O
and	-	856	O
terminal	-	860	O
deoxynucleotidyl	-	869	O
transferase	-	886	O
assay	-	898	O
in	-	904	O
HBMP	-	907	O
cells	-	912	O
.	-	917	O

The	10462057	919	O
catechol	-	923	O
and	-	932	O
hydroquinone	-	936	O
metabolites	-	949	O
,	-	960	O
NCQ436	-	962	O
and	-	969	O
NCQ344	-	973	O
,	-	979	O
induced	-	981	O
apoptosis	-	989	O
in	-	999	O
HL60	-	1002	O
and	-	1007	O
HBMP	-	1011	O
cells	-	1016	O
in	-	1022	O
a	-	1025	O
time	-	1027	O
-	-	1031	O
and	-	1033	O
concentration	-	1037	O
dependent	-	1051	O
manner	-	1061	O
,	-	1067	O
while	-	1069	O
the	-	1075	O
phenols	-	1079	O
,	-	1086	O
NCR181	-	1088	O
,	-	1094	O
FLA873	-	1096	O
,	-	1102	O
and	-	1104	O
FLA797	-	1108	O
,	-	1114	O
and	-	1116	O
the	-	1120	O
derivatives	-	1124	O
formed	-	1136	O
by	-	1143	O
oxidation	-	1146	O
of	-	1156	O
the	-	1159	O
pyrrolidine	-	1163	O
ring	-	1175	O
,	-	1179	O
FLA838	-	1181	O
,	-	1187	O
NCM001	-	1189	O
,	-	1195	O
and	-	1197	O
NCL118	-	1201	O
,	-	1207	O
had	-	1209	O
no	-	1213	O
effect	-	1216	O
.	-	1222	O

No	10462057	1224	O
necrosis	-	1227	B
was	-	1236	O
observed	-	1240	O
in	-	1249	O
cells	-	1252	O
treated	-	1258	O
with	-	1266	O
NCQ436	-	1271	O
but	-	1278	O
NCQ344	-	1282	O
had	-	1289	O
a	-	1293	O
biphasic	-	1295	O
effect	-	1304	O
in	-	1311	O
both	-	1314	O
cell	-	1319	O
types	-	1324	O
,	-	1329	O
inducing	-	1331	O
apoptosis	-	1340	O
at	-	1350	O
lower	-	1353	O
concentrations	-	1359	O
and	-	1374	O
necrosis	-	1378	B
at	-	1387	O
higher	-	1390	O
concentrations	-	1397	O
.	-	1411	O

These	10462057	1413	O
data	-	1419	O
show	-	1424	O
that	-	1429	O
the	-	1434	O
catechol	-	1438	O
and	-	1447	O
hydroquinone	-	1451	O
metabolites	-	1464	O
of	-	1476	O
remoxipride	-	1479	O
have	-	1491	O
direct	-	1496	O
toxic	-	1503	O
effects	-	1509	O
in	-	1517	O
HL60	-	1520	O
and	-	1525	O
HBMP	-	1529	O
cells	-	1534	O
,	-	1539	O
leading	-	1541	O
to	-	1549	O
apoptosis	-	1552	O
,	-	1561	O
while	-	1563	O
the	-	1569	O
phenol	-	1573	O
metabolites	-	1580	O
were	-	1592	O
inactive	-	1597	O
.	-	1605	O

Similarly	10462057	1607	O
,	-	1616	O
benzene	-	1618	O
-	-	1625	O
derived	-	1626	O
catechol	-	1634	O
and	-	1643	O
hydroquinone	-	1647	O
,	-	1659	O
but	-	1661	O
not	-	1665	O
phenol	-	1669	O
,	-	1675	O
induce	-	1677	O
apoptosis	-	1684	O
in	-	1694	O
HBMP	-	1697	O
cells	-	1702	O
[	-	1708	O
Moran	-	1709	O
et	-	1715	O
al	-	1718	O
.	-	1720	O
,	-	1721	O
Mol	-	1723	O
.	-	1726	O

Pharmacol	10462057	1728	O
.	-	1737	O

,	10462057	1738	O
50	-	1740	O
(	-	1743	O
1996	-	1744	O
)	-	1748	O
610	-	1750	O
-	-	1753	O
615	-	1754	O
]	-	1757	O
.	-	1758	O

We	10462057	1760	O
propose	-	1763	O
that	-	1771	O
remoxipride	-	1776	O
and	-	1788	O
benzene	-	1792	O
may	-	1800	O
induce	-	1804	O
aplastic	-	1811	B
anemia	-	1820	I
via	-	1827	O
production	-	1831	O
of	-	1842	O
similar	-	1845	O
reactive	-	1853	O
metabolites	-	1862	O
and	-	1874	O
that	-	1878	O
the	-	1883	O
ability	-	1887	O
of	-	1895	O
NCQ436	-	1898	O
and	-	1905	O
NCQ344	-	1909	O
to	-	1916	O
induce	-	1919	O
apoptosis	-	1926	O
in	-	1936	O
HBMP	-	1939	O
cells	-	1944	O
may	-	1950	O
contribute	-	1954	O
to	-	1965	O
the	-	1968	O
mechanism	-	1972	O
underlying	-	1982	O
acquired	-	1993	O
aplastic	-	2002	B
anemia	-	2011	I
that	-	2018	O
has	-	2023	O
been	-	2027	O
associated	-	2032	O
with	-	2043	O
remoxipride	-	2048	O
.	-	2059	O

Synthesis	10510854	0	O
and	-	10	O
preliminary	-	14	O
pharmacological	-	26	O
investigations	-	42	O
of	-	57	O
1	-	60	O
-	-	61	O
(	-	62	O
1	-	63	O
,	-	64	O
2	-	65	O
-	-	66	O
dihydro	-	67	O
-	-	74	O
2	-	75	O
-	-	76	O
acenaphthylenyl	-	77	O
)	-	92	O
piperazine	-	93	O
derivatives	-	104	O
as	-	116	O
potential	-	119	O
atypical	-	129	O
antipsychotic	-	138	O
agents	-	152	O
in	-	159	O
mice	-	162	O
.	-	166	O

In	10510854	168	O
research	-	171	O
towards	-	180	O
the	-	188	O
development	-	192	O
of	-	204	O
new	-	207	O
atypical	-	211	O
antipsychotic	-	220	O
agents	-	234	O
,	-	240	O
one	-	242	O
strategy	-	246	O
is	-	255	O
that	-	258	O
the	-	263	O
dopaminergic	-	267	O
system	-	280	O
can	-	287	O
be	-	291	O
modulated	-	294	O
through	-	304	O
manipulation	-	312	O
of	-	325	O
the	-	328	O
serotonergic	-	332	O
system	-	345	O
.	-	351	O

The	10510854	353	O
synthesis	-	357	O
and	-	367	O
preliminary	-	371	O
pharmacological	-	383	O
evaluation	-	399	O
of	-	410	O
a	-	413	O
series	-	415	O
of	-	422	O
potential	-	425	O
atypical	-	435	O
antipsychotic	-	444	O
agents	-	458	O
based	-	465	O
on	-	471	O
the	-	474	O
structure	-	478	O
of	-	488	O
1	-	491	O
-	-	492	O
(	-	493	O
1	-	494	O
,	-	495	O
2	-	496	O
-	-	497	O
dihydro	-	498	O
-	-	505	O
2	-	506	O
-	-	507	O
acenaphthylenyl	-	508	O
)	-	523	O
piperazine	-	524	O
(	-	535	O
7	-	536	O
)	-	537	O
is	-	539	O
described	-	542	O
.	-	551	O

Compound	10510854	553	O
7e	-	562	O
,	-	564	O
5	-	566	O
-	-	567	O
{	-	568	O
2	-	569	O
-	-	570	O
[	-	571	O
4	-	572	O
-	-	573	O
(	-	574	O
1	-	575	O
,	-	576	O
2	-	577	O
-	-	578	O
dihydro	-	579	O
-	-	586	O
2	-	587	O
-	-	588	O
acenaphthylenyl	-	589	O
)	-	604	O
piperazinyl	-	605	O
]	-	616	O
ethyl	-	617	O
}	-	622	O
-	-	623	O
2	-	624	O
,	-	625	O
3	-	626	O
-	-	627	O
dihy	-	628	O
dro	-	633	O
-	-	636	O
1H	-	637	O
-	-	639	O

indol	10510854	641	O
-	-	646	O
2	-	647	O
-	-	648	O
one	-	649	O
,	-	652	O
from	-	654	O
this	-	659	O
series	-	664	O
showed	-	671	O
significant	-	678	O
affinities	-	690	O
at	-	701	O
the	-	704	O
5	-	708	O
-	-	709	O
HT1A	-	710	O
and	-	715	O
5	-	719	O
-	-	720	O
HT2A	-	721	O
receptors	-	726	O
and	-	736	O
moderate	-	740	O
affinity	-	749	O
at	-	758	O
the	-	761	O
D2	-	765	O
receptor	-	768	O
.	-	776	O

7e	10510854	778	O
exhibits	-	781	O
a	-	790	O
high	-	792	O
reversal	-	797	O
of	-	806	O
catalepsy	-	809	B
induced	-	819	O
by	-	827	O
haloperidol	-	830	O
indicating	-	842	O
its	-	853	O
atypical	-	857	O
antipsychotic	-	866	O
nature	-	880	O
.	-	886	O

Sub	10672628	0	O
-	-	3	O
chronic	-	4	O
inhibition	-	12	O
of	-	23	O
nitric	-	26	O
-	-	32	O
oxide	-	33	O
synthesis	-	39	O
modifies	-	49	O
haloperidol	-	58	O
-	-	69	O
induced	-	70	O
catalepsy	-	78	B
and	-	88	O
the	-	92	O
number	-	96	O
of	-	103	O
NADPH	-	106	O
-	-	111	O
diaphorase	-	112	O
neurons	-	123	O
in	-	131	O
mice	-	134	O
.	-	138	O

RATIONALE	10672628	140	O
:	-	149	O
NG	-	151	O
-	-	153	O
nitro	-	154	O
-	-	159	O
L	-	160	O
-	-	161	O
arginine	-	162	O
(	-	171	O
L	-	172	O
-	-	173	O
NOARG	-	174	O
)	-	179	O
,	-	180	O
an	-	182	O
inhibitor	-	185	O
of	-	195	O
nitric	-	198	O
-	-	204	O
oxide	-	205	O
synthase	-	211	O
(	-	220	O
NOS	-	221	O
)	-	224	O
,	-	225	O
induces	-	227	O
catalepsy	-	235	B
in	-	245	O
mice	-	248	O
.	-	252	O

This	10672628	254	O
effect	-	259	O
undergoes	-	266	O
rapid	-	276	O
tolerance	-	282	O
,	-	291	O
showing	-	293	O
a	-	301	O
significant	-	303	O
decrease	-	315	O
after	-	324	O
2	-	330	O
days	-	332	O
of	-	337	O
sub	-	340	O
-	-	343	O
chronic	-	344	O
L	-	352	O
-	-	353	O
NOARG	-	354	O
treatment	-	360	O
.	-	369	O

Nitric	10672628	371	O
oxide	-	378	O
(	-	384	O
NO	-	385	O
)	-	387	O
has	-	389	O
been	-	393	O
shown	-	398	O
to	-	404	O
influence	-	407	O
dopaminergic	-	417	O
neurotransmission	-	430	O
in	-	448	O
the	-	451	O
striatum	-	455	O
.	-	463	O

Neuroleptic	10672628	465	O
drugs	-	477	O
such	-	483	O
as	-	488	O
haloperidol	-	491	O
,	-	502	O
which	-	504	O
block	-	510	O
dopamine	-	516	O
receptors	-	525	O
,	-	534	O
also	-	536	O
cause	-	541	O
catalepsy	-	547	B
in	-	557	O
rodents	-	560	O
.	-	567	O

OBJECTIVES	10672628	569	O
:	-	579	O

To	10672628	581	O
investigate	-	584	O
the	-	596	O
effects	-	600	O
of	-	608	O
subchronic	-	611	O
L	-	622	O
-	-	623	O
NOARG	-	624	O
treatment	-	630	O
in	-	640	O
haloperidol	-	643	O
-	-	654	O
induced	-	655	O
catalepsy	-	663	B
and	-	673	O
the	-	677	O
number	-	681	O
of	-	688	O
NOS	-	691	O
neurons	-	695	O
in	-	703	O
areas	-	706	O
related	-	712	O
to	-	720	O
motor	-	723	O
control	-	729	O
.	-	736	O

METHODS	10672628	738	O
:	-	745	O

Male	10672628	747	O
albino	-	752	O
Swiss	-	759	O
mice	-	765	O
were	-	770	O
treated	-	775	O
sub	-	783	O
-	-	786	O
chronically	-	787	O
(	-	799	O
twice	-	800	O
a	-	806	O
day	-	808	O
for	-	812	O
4	-	816	O
days	-	818	O
)	-	822	O
with	-	824	O
L	-	829	O
-	-	830	O
NOARG	-	831	O
(	-	837	O
40	-	838	O
mg	-	841	O
/	-	843	O
kg	-	844	O
i	-	847	O
.	-	848	O
p	-	849	O
.	-	850	O
)	-	851	O
or	-	853	O
haloperidol	-	856	O
(	-	868	O
1	-	869	O
mg	-	871	O
/	-	873	O
kg	-	874	O
i	-	877	O
.	-	878	O
p	-	879	O
.	-	880	O
)	-	881	O
.	-	882	O

Catalepsy	10672628	884	B
was	-	894	O
evaluated	-	898	O
at	-	908	O
the	-	911	O
beginning	-	915	O
and	-	925	O
the	-	929	O
end	-	933	O
of	-	937	O
the	-	940	O
treatments	-	944	O
.	-	954	O

Reduced	10672628	956	O
nicotinamide	-	964	O
adenine	-	977	O
dinucleotide	-	985	O
phosphate	-	998	O
-	-	1007	O
diaphorase	-	1008	O
(	-	1019	O
NADPH	-	1020	O
-	-	1025	O
d	-	1026	O
)	-	1027	O
histochemistry	-	1029	O
was	-	1044	O
also	-	1048	O
employed	-	1053	O
to	-	1062	O
visualize	-	1065	O
NOS	-	1075	O
as	-	1079	O
an	-	1082	O
index	-	1085	O
of	-	1091	O
enzyme	-	1094	O
expression	-	1101	O
in	-	1112	O
mice	-	1115	O
brain	-	1120	O
regions	-	1126	O
related	-	1134	O
to	-	1142	O
motor	-	1145	O
control	-	1151	O
.	-	1158	O

RESULTS	10672628	1160	O
:	-	1167	O

L	10672628	1169	O
-	-	1170	O
NOARG	-	1171	O
sub	-	1177	O
-	-	1180	O
chronic	-	1181	O
administration	-	1189	O
produced	-	1204	O
tolerance	-	1213	O
of	-	1223	O
L	-	1226	O
-	-	1227	O
NOARG	-	1228	O
and	-	1234	O
of	-	1238	O
haloperidol	-	1241	O
-	-	1252	O
induced	-	1253	O
catalepsy	-	1261	B
.	-	1270	O

It	10672628	1272	O
also	-	1275	O
induced	-	1280	O
an	-	1288	O
increase	-	1291	O
in	-	1300	O
the	-	1303	O
number	-	1307	O
of	-	1314	O
NADPH	-	1317	O
-	-	1322	O
d	-	1323	O
-	-	1324	O
positive	-	1325	O
cells	-	1334	O
in	-	1340	O
the	-	1343	O
dorsal	-	1347	O
part	-	1354	O
of	-	1359	O
the	-	1362	O
caudate	-	1366	O
and	-	1374	O
accumbens	-	1378	O
nuclei	-	1388	O
compared	-	1395	O
with	-	1404	O
haloperidol	-	1409	O
and	-	1421	O
in	-	1425	O
the	-	1428	O
pedunculopontine	-	1432	O
tegmental	-	1449	O
nucleus	-	1459	O
compared	-	1467	O
with	-	1476	O
saline	-	1481	O
.	-	1487	O

In	10672628	1489	O
contrast	-	1492	O
,	-	1500	O
there	-	1502	O
was	-	1508	O
a	-	1512	O
decrease	-	1514	O
in	-	1523	O
NADPH	-	1526	O
-	-	1531	O
d	-	1532	O
neuron	-	1534	O
number	-	1541	O
in	-	1548	O
the	-	1551	O
substantia	-	1555	O
nigra	-	1566	O
,	-	1571	O
pars	-	1573	O
compacta	-	1578	O
in	-	1587	O
both	-	1590	O
haloperidol	-	1595	O
-	-	1606	O
treated	-	1607	O
and	-	1615	O
L	-	1619	O
-	-	1620	O
NOARG	-	1621	O
-	-	1626	O
treated	-	1627	O
animals	-	1635	O
.	-	1642	O

CONCLUSIONS	10672628	1644	O
:	-	1655	O

The	10672628	1657	O
results	-	1661	O
give	-	1669	O
further	-	1674	O
support	-	1682	O
to	-	1690	O
the	-	1693	O
hypothesis	-	1697	O
that	-	1708	O
NO	-	1713	O
plays	-	1716	O
a	-	1722	O
role	-	1724	O
in	-	1729	O
motor	-	1732	O
behavior	-	1738	O
control	-	1747	O
and	-	1755	O
suggest	-	1759	O
that	-	1767	O
it	-	1772	O
may	-	1775	O
take	-	1779	O
part	-	1784	O
in	-	1789	O
the	-	1792	O
synaptic	-	1796	O
changes	-	1805	O
produced	-	1813	O
by	-	1822	O
antipsychotic	-	1825	O
treatment	-	1839	O
.	-	1848	O

Prolonged	10677406	0	O
left	-	10	B
ventricular	-	15	I
dysfunction	-	27	I
occurs	-	39	O
in	-	46	O
patients	-	49	O
with	-	58	O
coronary	-	63	B
artery	-	72	I
disease	-	79	I
after	-	87	O
both	-	93	O
dobutamine	-	98	O
and	-	109	O
exercise	-	113	O
induced	-	122	O
myocardial	-	130	B
ischaemia	-	141	I
.	-	150	O

OBJECTIVE	10677406	152	O
:	-	161	O

To	10677406	163	O
determine	-	166	O
whether	-	176	O
pharmacological	-	184	O
stress	-	200	O
leads	-	207	O
to	-	213	O
prolonged	-	216	O
but	-	226	O
reversible	-	230	O
left	-	241	B
ventricular	-	246	I
dysfunction	-	258	I
in	-	270	O
patients	-	273	O
with	-	282	O
coronary	-	287	B
artery	-	296	I
disease	-	303	I
,	-	310	O
similar	-	312	O
to	-	320	O
that	-	323	O
seen	-	328	O
after	-	333	O
exercise	-	339	O
.	-	347	O

DESIGN	10677406	349	O
:	-	355	O

A	10677406	357	O
randomised	-	359	O
crossover	-	370	O
study	-	380	O
of	-	386	O
recovery	-	389	O
time	-	398	O
of	-	403	O
systolic	-	406	O
and	-	415	O
diastolic	-	419	O
left	-	429	O
ventricular	-	434	O
function	-	446	O
after	-	455	O
exercise	-	461	O
and	-	470	O
dobutamine	-	474	O
induced	-	485	O
ischaemia	-	493	B
.	-	502	O

SUBJECTS	10677406	504	O
:	-	512	O
10	-	514	O
patients	-	517	O
with	-	526	O
stable	-	531	B
angina	-	538	I
,	-	544	O

angiographically	10677406	546	O
proven	-	563	O
coronary	-	570	B
artery	-	579	I
disease	-	586	I
,	-	593	O
and	-	595	O
normal	-	599	O
left	-	606	O
ventricular	-	611	O
function	-	623	O
.	-	631	O

INTERVENTIONS	10677406	633	O
:	-	646	O

Treadmill	10677406	648	O
exercise	-	658	O
and	-	667	O
dobutamine	-	671	O
stress	-	682	O
were	-	689	O
performed	-	694	O
on	-	704	O
different	-	707	O
days	-	717	O
.	-	721	O

Quantitative	10677406	723	O
assessment	-	736	O
of	-	747	O
systolic	-	750	O
and	-	759	O
diastolic	-	763	O
left	-	773	O
ventricular	-	778	O
function	-	790	O
was	-	799	O
performed	-	803	O
using	-	813	O
transthoracic	-	819	O
echocardiography	-	833	O
at	-	850	O
baseline	-	853	O
and	-	862	O
at	-	866	O
regular	-	869	O
intervals	-	877	O
after	-	887	O
each	-	893	O
test	-	898	O
.	-	902	O

RESULTS	10677406	904	O
:	-	911	O

Both	10677406	913	O
forms	-	918	O
of	-	924	O
stress	-	927	O
led	-	934	O
to	-	938	O
prolonged	-	941	O
but	-	951	O
reversible	-	955	O
systolic	-	966	O
and	-	975	O
diastolic	-	979	O
dysfunction	-	989	O
.	-	1000	O

There	10677406	1002	O
was	-	1008	O
no	-	1012	O
difference	-	1015	O
in	-	1026	O
the	-	1029	O
maximum	-	1033	O
double	-	1041	O
product	-	1048	O
(	-	1056	O
p	-	1057	O
=	-	1059	O
0	-	1061	O
.	-	1062	O
53	-	1063	O
)	-	1065	O
or	-	1067	O
ST	-	1070	O
depression	-	1073	B
(	-	1084	O
p	-	1085	O
=	-	1087	O
0	-	1089	O
.	-	1090	O
63	-	1091	O
)	-	1093	O
with	-	1095	O
either	-	1100	O
form	-	1107	O
of	-	1112	O
stress	-	1115	O
.	-	1121	O

After	10677406	1123	O
exercise	-	1129	O
,	-	1137	O
ejection	-	1139	O
fraction	-	1148	O
was	-	1157	O
reduced	-	1161	O
at	-	1169	O
15	-	1172	O
and	-	1175	O
30	-	1179	O
minutes	-	1182	O
compared	-	1190	O
with	-	1199	O
baseline	-	1204	O
(	-	1213	O
mean	-	1214	O
(	-	1219	O
SEM	-	1220	O
)	-	1223	O
,	-	1224	O
-	-	1226	O
5	-	1227	O
.	-	1228	O
6	-	1229	O
(	-	1231	O
1	-	1232	O
.	-	1233	O
5	-	1234	O
)	-	1235	O
%	-	1236	O
,	-	1237	O
p	-	1239	O
<	-	1241	O
0	-	1243	O
.	-	1244	O
05	-	1245	O
;	-	1247	O
and	-	1249	O
-	-	1253	O
6	-	1254	O
.	-	1255	O
1	-	1256	O
(	-	1258	O
2	-	1259	O
.	-	1260	O
2	-	1261	O
)	-	1262	O
%	-	1263	O
,	-	1264	O
p	-	1266	O
<	-	1268	O
0	-	1270	O
.	-	1271	O
01	-	1273	O
)	-	1275	O
,	-	1276	O
and	-	1278	O
at	-	1282	O
30	-	1285	O
and	-	1288	O
45	-	1292	O
minutes	-	1295	O
after	-	1303	O
dobutamine	-	1309	O
(	-	1320	O
-	-	1321	O
10	-	1322	O
.	-	1324	O
8	-	1325	O
(	-	1327	O
1	-	1328	O
.	-	1329	O
8	-	1330	O
)	-	1331	O
%	-	1332	O
and	-	1334	O
-	-	1338	O
5	-	1339	O
.	-	1340	O
5	-	1342	O
(	-	1344	O
1	-	1345	O
.	-	1346	O
8	-	1347	O
)	-	1348	O
%	-	1349	O
,	-	1350	O
both	-	1352	O
p	-	1357	O
<	-	1359	O
0	-	1361	O
.	-	1362	O
01	-	1363	O
)	-	1365	O
.	-	1366	O

Regional	10677406	1368	O
analysis	-	1377	O
showed	-	1386	O
a	-	1393	O
reduction	-	1395	O
in	-	1405	O
the	-	1408	O
worst	-	1412	O
affected	-	1418	O
segment	-	1427	O
15	-	1435	O
and	-	1438	O
30	-	1442	O
minutes	-	1445	O
after	-	1453	O
exercise	-	1459	O
(	-	1468	O
-	-	1469	O
27	-	1470	O
.	-	1472	O
9	-	1473	O
(	-	1475	O
7	-	1476	O
.	-	1477	O
2	-	1478	O
)	-	1479	O
%	-	1480	O
and	-	1482	O
-	-	1486	O
28	-	1487	O
.	-	1489	O
6	-	1490	O
(	-	1492	O
5	-	1493	O
.	-	1494	O
7	-	1495	O
)	-	1496	O
%	-	1497	O
,	-	1498	O
both	-	1500	O
p	-	1505	O
<	-	1507	O
0	-	1509	O
.	-	1510	O
01	-	1511	O
)	-	1513	O
,	-	1514	O
and	-	1516	O
at	-	1520	O
30	-	1523	O
minutes	-	1526	O
after	-	1534	O
dobutamine	-	1540	O
(	-	1551	O
-	-	1552	O
32	-	1553	O
(	-	1556	O
5	-	1557	O
.	-	1558	O
3	-	1559	O
)	-	1560	O
%	-	1561	O
,	-	1562	O
p	-	1564	O
<	-	1566	O
0	-	1568	O
.	-	1569	O
01	-	1570	O
)	-	1572	O
.	-	1573	O

The	10677406	1575	O
isovolumic	-	1579	O
relaxation	-	1590	O
period	-	1601	O
was	-	1608	O
prolonged	-	1612	O
45	-	1622	O
minutes	-	1625	O
after	-	1633	O
each	-	1639	O
form	-	1644	O
of	-	1649	O
stress	-	1652	O
(	-	1659	O
p	-	1660	O
<	-	1662	O
0	-	1664	O
.	-	1665	O
05	-	1666	O
)	-	1668	O
.	-	1669	O

CONCLUSIONS	10677406	1671	O
:	-	1682	O

In	10677406	1684	O
patients	-	1687	O
with	-	1696	O
coronary	-	1701	B
artery	-	1710	I
disease	-	1717	I
,	-	1724	O
dobutamine	-	1726	O
induced	-	1737	O
ischaemia	-	1745	B
results	-	1755	O
in	-	1763	O
prolonged	-	1766	O
reversible	-	1776	O
left	-	1787	B
ventricular	-	1792	I
dysfunction	-	1804	I
,	-	1815	O
presumed	-	1817	O
to	-	1826	O
be	-	1829	O
myocardial	-	1832	B
stunning	-	1843	I
,	-	1851	O
similar	-	1853	O
to	-	1861	O
that	-	1864	O
seen	-	1869	O
after	-	1874	O
exercise	-	1880	O
.	-	1888	O

Dobutamine	10677406	1890	O
induced	-	1901	O
ischaemia	-	1909	B
could	-	1919	O
therefore	-	1925	O
be	-	1935	O
used	-	1938	O
to	-	1943	O
study	-	1946	O
the	-	1952	O
pathophysiology	-	1956	O
of	-	1972	O
this	-	1975	O
phenomenon	-	1980	O
further	-	1991	O
in	-	1999	O
patients	-	2002	O
with	-	2011	O
coronary	-	2016	B
artery	-	2025	I
disease	-	2032	I
.	-	2039	O

Anorexigens	10713017	0	O
and	-	12	O
pulmonary	-	16	B
hypertension	-	26	I
in	-	39	O
the	-	42	O
United	-	46	O
States	-	53	O
:	-	59	O
results	-	61	O
from	-	69	O
the	-	74	O
surveillance	-	78	O
of	-	91	O
North	-	94	O
American	-	100	O
pulmonary	-	109	B
hypertension	-	119	I
.	-	131	O

BACKGROUND	10713017	133	O
:	-	143	O

The	10713017	145	O
use	-	149	O
of	-	153	O
appetite	-	156	O
suppressants	-	165	O
in	-	178	O
Europe	-	181	O
has	-	188	O
been	-	192	O
associated	-	197	O
with	-	208	O
the	-	213	O
development	-	217	O
of	-	229	O
primary	-	232	B
pulmonary	-	240	I
hypertension	-	250	I
(	-	263	O
PPH	-	264	B
)	-	267	O
.	-	268	O

Recently	10713017	270	O
,	-	278	O
fenfluramine	-	280	O
appetite	-	293	O
suppressants	-	302	O
became	-	315	O
widely	-	322	O
used	-	329	O
in	-	334	O
the	-	337	O
United	-	341	O
States	-	348	O
but	-	355	O
were	-	359	O
withdrawn	-	364	O
in	-	374	O
September	-	377	O
1997	-	387	O
because	-	392	O
of	-	400	O
concerns	-	403	O
over	-	412	O
adverse	-	417	O
effects	-	425	O
.	-	432	O

MATERIALS	10713017	434	O
AND	-	444	O
METHODS	-	448	O
:	-	455	O

We	10713017	457	O
conducted	-	460	O
a	-	470	O
prospective	-	472	O
surveillance	-	484	O
study	-	497	O
on	-	503	O
patients	-	506	O
diagnosed	-	515	O
with	-	525	O
pulmonary	-	530	B
hypertension	-	540	I
at	-	553	O
12	-	556	O
large	-	559	O
referral	-	565	O
centers	-	574	O
in	-	582	O
North	-	585	O
America	-	591	O
.	-	598	O

Data	10713017	600	O
collected	-	605	O
on	-	615	O
patients	-	618	O
seen	-	627	O
from	-	632	O
September	-	637	O
1	-	647	O
,	-	648	O
1996	-	650	O
,	-	654	O
to	-	656	O
December	-	659	O
31	-	668	O
,	-	670	O
1997	-	672	O
,	-	676	O
included	-	678	O
the	-	687	O
cause	-	691	O
of	-	697	O
the	-	700	O
pulmonary	-	704	B
hypertension	-	714	I
and	-	727	O
its	-	731	O
severity	-	735	O
.	-	743	O

Patients	10713017	745	O
with	-	754	O
no	-	759	O
identifiable	-	762	O
cause	-	775	O
of	-	781	O
pulmonary	-	784	B
hypertension	-	794	I
were	-	807	O
classed	-	812	O
as	-	820	O
PPH	-	823	B
.	-	826	O

A	10713017	828	O
history	-	830	O
of	-	838	O
drug	-	841	O
exposure	-	846	O
also	-	855	O
was	-	860	O
taken	-	864	O
with	-	870	O
special	-	875	O
attention	-	883	O
on	-	893	O
the	-	896	O
use	-	900	O
of	-	904	O
antidepressants	-	907	O
,	-	922	O
anorexigens	-	924	O
,	-	935	O
and	-	937	O
amphetamines	-	941	O
.	-	953	O

RESULTS	10713017	955	O
:	-	962	O

Five	10713017	964	O
hundred	-	969	O
seventy	-	977	O
-	-	984	O
nine	-	985	O
patients	-	990	O
were	-	999	O
studied	-	1004	O
,	-	1011	O
205	-	1013	O
with	-	1017	O
PPH	-	1022	B
and	-	1026	O
374	-	1030	O
with	-	1034	O
pulmonary	-	1039	B
hypertension	-	1049	I
from	-	1062	O
other	-	1067	O
causes	-	1073	O
(	-	1080	O
secondary	-	1081	O
pulmonary	-	1091	B
hypertension	-	1101	I
[	-	1114	O
SPH	-	1115	O
]	-	1118	O
)	-	1119	O
.	-	1120	O

The	10713017	1122	O
use	-	1126	O
of	-	1130	O
anorexigens	-	1133	O
was	-	1145	O
common	-	1149	O
in	-	1156	O
both	-	1159	O
groups	-	1164	O
.	-	1170	O

However	10713017	1172	O
,	-	1179	O
of	-	1181	O
the	-	1184	O
medications	-	1188	O
surveyed	-	1200	O
,	-	1208	O
only	-	1210	O
the	-	1215	O
fenfluramines	-	1219	O
had	-	1233	O
a	-	1237	O
significant	-	1239	O
preferential	-	1251	O
association	-	1264	O
with	-	1276	O
PPH	-	1281	B
as	-	1285	O
compared	-	1288	O
with	-	1297	O
SPH	-	1302	O
(	-	1306	O
adjusted	-	1307	O
odds	-	1316	O
ratio	-	1321	O
for	-	1327	O
use	-	1331	O
>	-	1335	O
6	-	1337	O
months	-	1339	O
,	-	1345	O
7	-	1347	O
.	-	1348	O
5	-	1349	O
;	-	1350	O
95	-	1352	O
%	-	1354	O
confidence	-	1356	O
interval	-	1367	O
,	-	1375	O
1	-	1377	O
.	-	1378	O
7	-	1379	O
to	-	1381	O
32	-	1384	O
.	-	1386	O
4	-	1387	O
)	-	1388	O
.	-	1389	O

The	10713017	1391	O
association	-	1395	O
was	-	1407	O
stronger	-	1411	O
with	-	1420	O
longer	-	1425	O
duration	-	1432	O
of	-	1441	O
use	-	1444	O
when	-	1448	O
compared	-	1453	O
to	-	1462	O
shorter	-	1465	O
duration	-	1473	O
of	-	1482	O
use	-	1485	O
and	-	1489	O
was	-	1493	O
more	-	1497	O
pronounced	-	1502	O
in	-	1513	O
recent	-	1516	O
users	-	1523	O
than	-	1529	O
in	-	1534	O
remote	-	1537	O
users	-	1544	O
.	-	1549	O

An	10713017	1551	O
unexpectedly	-	1554	O
high	-	1567	O
(	-	1572	O
11	-	1573	O
.	-	1575	O
4	-	1576	O
%	-	1577	O
)	-	1578	O
number	-	1580	O
of	-	1587	O
patients	-	1590	O
with	-	1599	O
SPH	-	1604	O
had	-	1608	O
used	-	1612	O
anorexigens	-	1617	O
.	-	1628	O

CONCLUSION	10713017	1630	O
:	-	1640	O

The	10713017	1642	O
magnitude	-	1646	O
of	-	1656	O
the	-	1659	O
association	-	1663	O
with	-	1675	O
PPH	-	1680	B
,	-	1683	O
the	-	1685	O
increase	-	1689	O
of	-	1698	O
association	-	1701	O
with	-	1713	O
increasing	-	1718	O
duration	-	1729	O
of	-	1738	O
use	-	1741	O
,	-	1744	O
and	-	1746	O
the	-	1750	O
specificity	-	1754	O
for	-	1766	O
fenfluramines	-	1770	O
are	-	1784	O
consistent	-	1788	O
with	-	1799	O
previous	-	1804	O
studies	-	1813	O
indicating	-	1821	O
that	-	1832	O
fenfluramines	-	1837	O
are	-	1851	O
causally	-	1855	O
related	-	1864	O
to	-	1872	O
PPH	-	1875	B
.	-	1878	O

The	10713017	1880	O
high	-	1884	O
prevalence	-	1889	O
of	-	1900	O
anorexigen	-	1903	O
use	-	1914	O
in	-	1918	O
patients	-	1921	O
with	-	1930	O
SPH	-	1935	O
also	-	1939	O
raises	-	1944	O
the	-	1951	O
possibility	-	1955	O
that	-	1967	O
these	-	1972	O
drugs	-	1978	O
precipitate	-	1984	O
pulmonary	-	1996	B
hypertension	-	2006	I
in	-	2019	O
patients	-	2022	O
with	-	2031	O
underlying	-	2036	O
conditions	-	2047	O
associated	-	2058	O
with	-	2069	O
SPH	-	2074	O
.	-	2077	O

Clinical	10726030	0	O
aspects	-	9	O
of	-	17	O
heparin	-	20	O
-	-	27	O
induced	-	28	O
thrombocytopenia	-	36	B
and	-	53	O
thrombosis	-	57	B
and	-	68	O
other	-	72	O
side	-	78	O
effects	-	83	O
of	-	91	O
heparin	-	94	O
therapy	-	102	O
.	-	109	O

Heparin	10726030	111	O
,	-	118	O
first	-	120	O
used	-	126	O
to	-	131	O
prevent	-	134	O
the	-	142	O
clotting	-	146	O
of	-	155	O
blood	-	158	O
in	-	164	O
vitro	-	167	O
,	-	172	O
has	-	174	O
been	-	178	O
clinically	-	183	O
used	-	194	O
to	-	199	O
treat	-	202	O
thrombosis	-	208	B
for	-	219	O
more	-	223	O
than	-	228	O
50	-	233	O
years	-	236	O
.	-	241	O

Although	10726030	243	O
several	-	252	O
new	-	260	O
anticoagulant	-	264	O
drugs	-	278	O
are	-	284	O
in	-	288	O
development	-	291	O
,	-	302	O
heparin	-	304	O
remains	-	312	O
the	-	320	O
anticoagulant	-	324	O
of	-	338	O
choice	-	341	O
to	-	348	O
treat	-	351	O
acute	-	357	O
thrombotic	-	363	B
episodes	-	374	O
.	-	382	O

The	10726030	384	O
clinical	-	388	O
effects	-	397	O
of	-	405	O
heparin	-	408	O
are	-	416	O
meritorious	-	420	O
,	-	431	O
but	-	433	O
side	-	437	O
effects	-	442	O
do	-	450	O
exist	-	453	O
.	-	458	O

Bleeding	10726030	460	B
is	-	469	O
the	-	472	O
primary	-	476	O
untoward	-	484	O
effect	-	493	O
of	-	500	O
heparin	-	503	O
.	-	510	O

Major	10726030	512	O
bleeding	-	518	B
is	-	527	O
of	-	530	O
primary	-	533	O
concern	-	541	O
in	-	549	O
patients	-	552	O
receiving	-	561	O
heparin	-	571	O
therapy	-	579	O
.	-	586	O

However	10726030	588	O
,	-	595	O
additional	-	597	O
important	-	608	O
untoward	-	618	O
effects	-	627	O
of	-	635	O
heparin	-	638	O
therapy	-	646	O
include	-	654	O
heparin	-	662	O
-	-	669	O
induced	-	670	O
thrombocytopenia	-	678	B
,	-	694	O
heparin	-	696	O
-	-	703	O
associated	-	704	O
osteoporosis	-	715	B
,	-	727	O
eosinophilia	-	729	B
,	-	741	O
skin	-	743	B
reactions	-	748	I
,	-	757	O
allergic	-	759	B
reactions	-	768	I
other	-	778	O
than	-	784	O
thrombocytopenia	-	789	B
,	-	805	O
alopecia	-	807	B
,	-	815	O
transaminasemia	-	817	O
,	-	832	O
hyperkalemia	-	834	B
,	-	846	O
hypoaldosteronism	-	848	B
,	-	865	O
and	-	867	O
priapism	-	871	B
.	-	879	O

These	10726030	881	O
side	-	887	O
effects	-	892	O
are	-	900	O
relatively	-	904	O
rare	-	915	O
in	-	920	O
a	-	923	O
given	-	925	O
individual	-	931	O
,	-	941	O
but	-	943	O
given	-	947	O
the	-	953	O
extremely	-	957	O
widespread	-	967	O
use	-	978	O
of	-	982	O
heparin	-	985	O
,	-	992	O
some	-	994	O
are	-	999	O
quite	-	1003	O
common	-	1009	O
,	-	1015	O
particularly	-	1017	O
HITT	-	1030	B
and	-	1035	O
osteoporosis	-	1039	B
.	-	1051	O

Although	10726030	1053	O
reasonable	-	1062	O
incidences	-	1073	O
of	-	1084	O
many	-	1087	O
of	-	1092	O
these	-	1095	O
side	-	1101	O
effects	-	1106	O
can	-	1114	O
be	-	1118	O
""""	-	1121	O
softly	-	1122	O
""""	-	1128	O
deduced	-	1130	O
from	-	1138	O
current	-	1143	O
reports	-	1151	O
dealing	-	1159	O
with	-	1167	O
unfractionated	-	1172	O
heparin	-	1187	O
,	-	1194	O
at	-	1196	O
present	-	1199	O
the	-	1207	O
incidences	-	1211	O
of	-	1222	O
these	-	1225	O
side	-	1231	O
effects	-	1236	O
with	-	1244	O
newer	-	1249	O
low	-	1255	O
molecular	-	1259	O
weight	-	1269	O
heparins	-	1276	O
appear	-	1285	O
to	-	1292	O
be	-	1295	O
much	-	1298	O
less	-	1303	O
common	-	1308	O
.	-	1314	O

However	10726030	1316	O
,	-	1323	O
only	-	1325	O
longer	-	1330	O
experience	-	1337	O
will	-	1348	O
more	-	1353	O
clearly	-	1358	O
define	-	1366	O
the	-	1373	O
incidence	-	1377	O
of	-	1387	O
each	-	1390	O
side	-	1395	O
effect	-	1400	O
with	-	1407	O
low	-	1412	O
molecular	-	1416	O
weight	-	1426	O
preparations	-	1433	O
.	-	1445	O

A	10764869	0	O
case	-	2	O
of	-	7	O
bilateral	-	10	O
optic	-	20	B
neuropathy	-	26	I
in	-	37	O
a	-	40	O
patient	-	42	O
on	-	50	O
tacrolimus	-	53	O
(	-	64	O
FK506	-	65	O
)	-	70	O
therapy	-	72	O
after	-	80	O
liver	-	86	O
transplantation	-	92	O
.	-	107	O

PURPOSE	10764869	109	O
:	-	116	O

To	10764869	118	O
report	-	121	O
a	-	128	O
case	-	130	O
of	-	135	O
bilateral	-	138	O
optic	-	148	B
neuropathy	-	154	I
in	-	165	O
a	-	168	O
patient	-	170	O
receiving	-	178	O
tacrolimus	-	188	O
(	-	199	O
FK	-	200	O
506	-	203	O
,	-	206	O
Prograf	-	208	O
;	-	215	O
Fujisawa	-	217	O
USA	-	226	O
,	-	229	O
Inc	-	231	O
,	-	234	O
Deerfield	-	236	O
,	-	245	O
Illinois	-	247	O
)	-	255	O
for	-	257	O
immunosuppression	-	261	O
after	-	279	O
orthotropic	-	285	O
liver	-	297	O
transplantation	-	303	O
.	-	318	O

METHOD	10764869	320	O
:	-	326	O

Case	10764869	328	O
report	-	333	O
.	-	339	O

In	10764869	341	O
a	-	344	O
58	-	346	O
-	-	348	O
year	-	349	O
-	-	353	O
old	-	354	O
man	-	358	O
receiving	-	362	O
tacrolimus	-	372	O
after	-	383	O
orthotropic	-	389	O
liver	-	401	O
transplantation	-	407	O
,	-	422	O
serial	-	424	O
neuro	-	431	O
-	-	436	O
ophthalmologic	-	437	O
examinations	-	452	O
and	-	465	O
laboratory	-	469	O
studies	-	480	O
were	-	488	O
performed	-	493	O
.	-	502	O

RESULTS	10764869	504	O
:	-	511	O

The	10764869	513	O
patient	-	517	O
had	-	525	O
episodic	-	529	O
deterioration	-	538	O
of	-	552	O
vision	-	555	O
in	-	562	O
both	-	565	O
eyes	-	570	O
,	-	574	O
with	-	576	O
clinical	-	581	O
features	-	590	O
resembling	-	599	O
ischemic	-	610	B
optic	-	619	I
neuropathies	-	625	I
.	-	637	O

Deterioration	10764869	639	B
of	-	653	I
vision	-	656	I
occurred	-	663	O
despite	-	672	O
discontinuation	-	680	O
of	-	696	O
the	-	699	O
tacrolimus	-	703	O
.	-	713	O

CONCLUSION	10764869	715	O
:	-	725	O

Tacrolimus	10764869	727	O
and	-	738	O
other	-	742	O
immunosuppressive	-	748	O
agents	-	766	O
may	-	773	O
be	-	777	O
associated	-	780	O
with	-	791	O
optic	-	796	B
nerve	-	802	I
toxicity	-	808	I
.	-	816	O

Hypercalcemia	10770468	0	B
,	-	13	O
arrhythmia	-	15	B
,	-	25	O
and	-	27	O
mood	-	31	O
stabilizers	-	36	O
.	-	47	O

Recent	10770468	49	O
findings	-	56	O
in	-	65	O
a	-	68	O
bipolar	-	70	B
patient	-	78	O
receiving	-	86	O
maintenance	-	96	O
lithium	-	108	O
therapy	-	116	O
who	-	124	O
developed	-	128	O
hypercalcemia	-	138	B
and	-	152	O
severe	-	156	O
bradyarrhythmia	-	163	B
prompted	-	179	O
the	-	188	O
authors	-	192	O
to	-	200	O
conduct	-	203	O
a	-	211	O
retrospective	-	213	O
study	-	227	O
of	-	233	O
bipolar	-	236	B
patients	-	244	O
with	-	253	O
lithium	-	258	O
-	-	265	O
associated	-	266	O
hypercalcemia	-	277	B
.	-	290	O

A	10770468	292	O
printout	-	294	O
of	-	303	O
all	-	306	O
cases	-	310	O
of	-	316	O
hypercalcemia	-	319	B
that	-	333	O
presented	-	338	O
during	-	348	O
a	-	355	O
1	-	357	O
-	-	358	O
year	-	359	O
period	-	364	O
was	-	371	O
generated	-	375	O
.	-	384	O

After	10770468	386	O
eliminating	-	392	O
spurious	-	404	O
hypercalcemias	-	413	B
or	-	428	O
those	-	431	O
associated	-	437	O
with	-	448	O
intravenous	-	453	O
fluids	-	465	O
,	-	471	O
the	-	473	O
authors	-	477	O
identified	-	485	O
18	-	496	O
non	-	499	O
-	-	502	O
lithium	-	503	O
-	-	510	O
treated	-	511	O
patients	-	519	O
with	-	528	O
hypercalcemias	-	533	B
related	-	548	O
to	-	556	O
malignancies	-	559	B
and	-	572	O
other	-	576	O
medical	-	582	O
conditions	-	590	O
(	-	601	O
group	-	602	O
A	-	608	O
)	-	609	O
and	-	611	O
12	-	615	O
patients	-	618	O
with	-	627	O
lithium	-	632	O
-	-	639	O
associated	-	640	O
hypercalcemia	-	651	B
(	-	665	O
group	-	666	O
B	-	672	O
)	-	673	O
.	-	674	O

Patients	10770468	676	O
in	-	685	O
group	-	688	O
B	-	694	O
were	-	696	O
not	-	701	O
comparable	-	705	O
to	-	716	O
those	-	719	O
in	-	725	O
group	-	728	O
A	-	734	O
,	-	735	O
as	-	737	O
the	-	740	O
latter	-	744	O
were	-	751	O
medically	-	756	O
compromised	-	766	O
and	-	778	O
were	-	782	O
receiving	-	787	O
multiple	-	797	O
pharmacotherapies	-	806	O
.	-	823	O

Thus	10770468	825	O
,	-	829	O
two	-	831	O
control	-	835	O
groups	-	843	O
were	-	850	O
generated	-	855	O
:	-	864	O
group	-	866	O
C1	-	872	O
,	-	874	O
which	-	876	O
included	-	882	O
age	-	891	O
-	-	894	O
and	-	896	O
sex	-	900	O
-	-	903	O
comparable	-	904	O
lithium	-	915	O
-	-	922	O
treated	-	923	O
bipolar	-	931	B
normocalcemic	-	939	O
patients	-	953	O
,	-	961	O
and	-	963	O
group	-	967	O
C2	-	973	O
,	-	975	O
which	-	977	O
included	-	983	O
bipolar	-	992	B
normocalcemic	-	1000	O
patients	-	1014	O
treated	-	1023	O
with	-	1031	O
anticonvulsant	-	1036	O
mood	-	1051	O
stabilizers	-	1056	O
.	-	1067	O

The	10770468	1069	O
electrocardiographic	-	1073	O
(	-	1094	O
ECG	-	1095	O
)	-	1098	O
findings	-	1100	O
for	-	1109	O
patients	-	1113	O
in	-	1122	O
group	-	1125	O
B	-	1131	O
were	-	1133	O
compared	-	1138	O
with	-	1147	O
those	-	1152	O
of	-	1158	O
patients	-	1161	O
in	-	1170	O
groups	-	1173	O
C1	-	1180	O
and	-	1183	O
C2	-	1187	O
.	-	1189	O

It	10770468	1191	O
was	-	1194	O
found	-	1198	O
that	-	1204	O
these	-	1209	O
groups	-	1215	O
did	-	1222	O
not	-	1226	O
differ	-	1230	O
in	-	1237	O
their	-	1240	O
overall	-	1246	O
frequency	-	1254	O
of	-	1264	O
ECG	-	1267	O
abnormalities	-	1271	O
;	-	1284	O
however	-	1286	O
,	-	1293	O
there	-	1295	O
were	-	1301	O
significant	-	1306	O
differences	-	1318	O
in	-	1330	O
the	-	1333	O
frequency	-	1337	O
of	-	1347	O
conduction	-	1350	O
defects	-	1361	O
.	-	1368	O

Patients	10770468	1370	O
with	-	1379	O
hypercalcemia	-	1384	B
resulting	-	1398	O
from	-	1408	O
medical	-	1413	O
diseases	-	1421	O
and	-	1430	O
bipolar	-	1434	B
patients	-	1442	O
with	-	1451	O
lithium	-	1456	O
-	-	1463	O
associated	-	1464	O
hypercalcemia	-	1475	B
had	-	1489	O
significantly	-	1493	O
higher	-	1507	O
frequencies	-	1514	O
of	-	1526	O
conduction	-	1529	O
defects	-	1540	O
.	-	1547	O

Patients	10770468	1549	O
in	-	1558	O
group	-	1561	O
A	-	1567	O
had	-	1569	O
significant	-	1573	O
mortality	-	1585	O
at	-	1595	O
2	-	1598	O
-	-	1599	O
year	-	1600	O
follow	-	1605	O
-	-	1611	O
up	-	1612	O
(	-	1615	O
28	-	1616	O
%	-	1618	O
)	-	1619	O
,	-	1620	O
in	-	1622	O
contrast	-	1625	O
to	-	1634	O
zero	-	1637	O
mortality	-	1642	O
in	-	1652	O
the	-	1655	O
other	-	1659	O
three	-	1665	O
groups	-	1671	O
.	-	1677	O

The	10770468	1679	O
clinical	-	1683	O
implications	-	1692	O
of	-	1705	O
these	-	1708	O
findings	-	1714	O
are	-	1723	O
discussed	-	1727	O
.	-	1736	O

Attenuation	10933650	0	O
of	-	12	O
nephrotoxicity	-	15	B
by	-	30	O
a	-	33	O
novel	-	35	O
lipid	-	41	O
nanosphere	-	47	O

(	10933650	58	O
NS	-	59	O
-	-	61	O
718	-	62	O
)	-	65	O
incorporating	-	67	O
amphotericin	-	81	O
B	-	94	O
.	-	95	O
NS	-	97	O
-	-	99	O
718	-	100	O
,	-	103	O
a	-	105	O
lipid	-	107	O
nanosphere	-	113	O
incorporating	-	124	O
amphotericin	-	138	O
B	-	151	O
,	-	152	O
is	-	154	O
effective	-	157	O
against	-	167	O
pathogenic	-	175	O
fungi	-	186	O
and	-	192	O
has	-	196	O
low	-	200	O
toxicity	-	204	B
.	-	212	O

We	10933650	214	O
compared	-	217	O
the	-	226	O
toxicity	-	230	B
of	-	239	O
NS	-	242	O
-	-	244	O
718	-	245	O
with	-	249	O
that	-	254	O
of	-	259	O
Fungizone	-	262	O
(	-	272	O
amphotericin	-	273	O
B	-	286	O
-	-	287	O
sodium	-	288	O
deoxycholate	-	295	O
;	-	307	O
D	-	309	O
-	-	310	O
AmB	-	311	O
)	-	314	O
in	-	316	O
vitro	-	319	O
using	-	325	O
renal	-	331	O
cell	-	337	O
cultures	-	342	O
and	-	351	O
in	-	355	O
vivo	-	358	O
by	-	363	O
biochemical	-	366	O
analysis	-	378	O
,	-	386	O
histopathological	-	388	O
study	-	406	O
of	-	412	O
the	-	415	O
kidney	-	419	O
and	-	426	O
pharmacokinetic	-	430	O
study	-	446	O
of	-	452	O
amphotericin	-	455	O
B	-	468	O
following	-	470	O
intravenous	-	480	O
infusion	-	492	O
of	-	501	O
the	-	504	O
formulation	-	508	O
in	-	520	O
rats	-	523	O
.	-	527	O

Incubation	10933650	529	O
with	-	540	O
NS	-	545	O
-	-	547	O
718	-	548	O
resulted	-	552	O
in	-	561	O
significantly	-	564	O
less	-	578	O
damage	-	583	O
of	-	590	O
cultured	-	593	O
human	-	602	O
renal	-	608	O
proximal	-	614	O
tubular	-	623	O
epithelial	-	631	O
cells	-	642	O
compared	-	648	O
with	-	657	O
D	-	662	O
-	-	663	O
AmB	-	664	O
.	-	667	O
Serum	-	669	O
blood	-	675	O
urea	-	681	O
and	-	686	O
creatinine	-	690	O
concentrations	-	701	O
increased	-	716	O
significantly	-	726	O
in	-	740	O
rats	-	743	O
given	-	748	O
an	-	754	O
iv	-	757	O
infusion	-	760	O
of	-	769	O
D	-	772	O
-	-	773	O
AmB	-	774	O
3	-	778	O
mg	-	780	O
/	-	782	O
kg	-	783	O
but	-	786	O
not	-	790	O
in	-	794	O
those	-	797	O
given	-	803	O
the	-	809	O
same	-	813	O
dose	-	818	O
of	-	823	O
NS	-	826	O
-	-	828	O
718	-	829	O
.	-	832	O

Histopathological	10933650	834	O
examination	-	852	O
of	-	864	O
the	-	867	O
kidney	-	871	O
showed	-	878	O
tubular	-	885	B
necrosis	-	893	I
in	-	902	O
D	-	905	O
-	-	906	O
AmB	-	907	O
-	-	910	O
treated	-	911	O
rats	-	919	O
but	-	924	O
no	-	928	O
change	-	931	O
in	-	938	O
NS	-	941	O
-	-	943	O
718	-	944	O
-	-	947	O
treated	-	948	O
rats	-	956	O
.	-	960	O

Amphotericin	10933650	962	O
B	-	975	O
concentrations	-	977	O
in	-	992	O
the	-	995	O
kidney	-	999	O
in	-	1006	O
NS	-	1009	O
-	-	1011	O
718	-	1012	O
-	-	1015	O
treated	-	1016	O
rats	-	1024	O
were	-	1029	O
higher	-	1034	O
than	-	1041	O
those	-	1046	O
in	-	1052	O
D	-	1055	O
-	-	1056	O
AmB	-	1057	O
-	-	1060	O
treated	-	1061	O
rats	-	1069	O
.	-	1073	O

Our	10933650	1075	O
in	-	1079	O
vitro	-	1082	O
and	-	1088	O
in	-	1092	O
vivo	-	1095	O
results	-	1100	O
suggest	-	1108	O
that	-	1116	O
incorporation	-	1121	O
of	-	1135	O
amphotericin	-	1138	O
B	-	1151	O
into	-	1153	O
lipid	-	1158	O
nanospheres	-	1164	O
of	-	1176	O
NS	-	1179	O
-	-	1181	O
718	-	1182	O
attenuates	-	1186	O
the	-	1197	O
nephrotoxicity	-	1201	B
of	-	1216	O
amphotericin	-	1219	O
B	-	1232	O
.	-	1233	O

Patterns	10939760	0	O
of	-	9	O
sulfadiazine	-	12	O
acute	-	25	B
nephrotoxicity	-	31	I
.	-	45	O

Sulfadiazine	10939760	47	O
acute	-	60	B
nephrotoxicity	-	66	I
is	-	81	O
reviving	-	84	O
specially	-	93	O
because	-	103	O
of	-	111	O
its	-	114	O
use	-	118	O
in	-	122	O
toxoplasmosis	-	125	B
in	-	139	O
HIV	-	142	O
-	-	145	O
positive	-	146	O
patients	-	155	O
.	-	163	O

We	10939760	165	O
report	-	168	O
4	-	175	O
cases	-	177	O
,	-	182	O
one	-	184	O
of	-	188	O
them	-	191	O
in	-	196	O
a	-	199	O
previously	-	201	O
healthy	-	212	O
person	-	220	O
.	-	226	O

Under	10939760	228	O
treatment	-	234	O
with	-	244	O
sulfadiazine	-	249	O
they	-	262	O
developed	-	267	O
oliguria	-	277	B
,	-	285	O
abdominal	-	287	B
pain	-	297	I
,	-	301	O
renal	-	303	B
failure	-	309	I
and	-	317	O
showed	-	321	O
multiple	-	328	O
radiolucent	-	337	O
renal	-	349	B
calculi	-	355	I
in	-	363	O
echography	-	366	O
.	-	376	O

All	10939760	378	O
patients	-	382	O
recovered	-	391	O
their	-	401	O
previous	-	407	O
normal	-	416	O
renal	-	423	O
function	-	429	O
after	-	438	O
adequate	-	444	O
hydration	-	453	O
and	-	463	O
alcalinization	-	467	O
.	-	481	O

A	10939760	483	O
nephrostomy	-	485	O
tube	-	497	O
had	-	502	O
to	-	506	O
be	-	509	O
placed	-	512	O
in	-	519	O
one	-	522	O
of	-	526	O
the	-	529	O
patients	-	533	O
for	-	542	O
ureteral	-	546	B
lithiasis	-	555	I
in	-	565	O
a	-	568	O
single	-	570	O
functional	-	577	O
kidney	-	588	O
.	-	594	O

None	10939760	596	O
of	-	601	O
them	-	604	O
needed	-	609	O
dialysis	-	616	O
or	-	625	O
a	-	628	O
renal	-	630	O
biopsy	-	636	O
because	-	643	O
of	-	651	O
a	-	654	O
typical	-	656	O
benign	-	664	O
course	-	671	O
.	-	677	O

Treatment	10939760	679	O
with	-	689	O
sulfadiazine	-	694	O
requires	-	707	O
exquisite	-	716	O
control	-	726	O
of	-	734	O
renal	-	737	O
function	-	743	O
,	-	751	O
an	-	753	O
increase	-	756	O
in	-	765	O
water	-	768	O
ingestion	-	774	O
and	-	784	O
possibly	-	788	O
the	-	797	O
alcalinization	-	801	O
of	-	816	O
the	-	819	O
urine	-	823	O
.	-	828	O

We	10939760	830	O
communicate	-	833	O
a	-	845	O
case	-	847	O
in	-	852	O
a	-	855	O
previously	-	857	O
healthy	-	868	O
person	-	876	O
,	-	882	O
a	-	884	O
fact	-	886	O
not	-	891	O
found	-	895	O
in	-	901	O
the	-	904	O
recent	-	908	O
literature	-	915	O
.	-	925	O

Probably	10939760	927	O
many	-	936	O
more	-	941	O
cases	-	946	O
are	-	952	O
not	-	956	O
detected	-	960	O
.	-	968	O

We	10939760	970	O
think	-	973	O
that	-	979	O
a	-	984	O
prospective	-	986	O
study	-	998	O
would	-	1004	O
be	-	1010	O
useful	-	1013	O
.	-	1019	O

Downbeat	10960401	0	B
nystagmus	-	9	I
associated	-	19	O
with	-	30	O
intravenous	-	35	O
patient	-	47	O
-	-	54	O
controlled	-	55	O
administration	-	66	O
of	-	81	O
morphine	-	84	O
.	-	92	O

IMPLICATIONS	10960401	94	O
:	-	106	O

This	10960401	108	O
case	-	113	O
documents	-	118	O
a	-	128	O
patient	-	130	O
who	-	138	O
developed	-	142	O
dizziness	-	152	B
with	-	162	O
downbeating	-	167	B
nystagmus	-	179	I
while	-	189	O
receiving	-	195	O
a	-	205	O
relatively	-	207	O
large	-	218	O
dose	-	224	O
of	-	229	O
IV	-	232	O
patient	-	235	O
-	-	242	O
controlled	-	243	O
analgesia	-	254	O
morphine	-	264	O
.	-	272	O

Although	10960401	274	O
there	-	283	O
have	-	289	O
been	-	294	O
case	-	299	O
reports	-	304	O
of	-	312	O
epidural	-	315	O
morphine	-	324	O
with	-	333	O
these	-	338	O
symptoms	-	344	O
and	-	353	O
signs	-	357	O
,	-	362	O
this	-	364	O
has	-	369	O
not	-	373	O
been	-	377	O
previously	-	382	O
documented	-	393	O
with	-	404	O
IV	-	409	O
or	-	412	O
patient	-	415	O
-	-	422	O
controlled	-	423	O
analgesia	-	434	O
morphine	-	444	O
.	-	452	O

Hemodynamic	10975596	0	O
and	-	12	O
antiadrenergic	-	16	O
effects	-	31	O
of	-	39	O
dronedarone	-	42	O
and	-	54	O
amiodarone	-	58	O
in	-	69	O
animals	-	72	O
with	-	80	O
a	-	85	O
healed	-	87	O
myocardial	-	94	B
infarction	-	105	I
.	-	115	O

The	10975596	117	O
hemodynamic	-	121	O
and	-	133	O
antiadrenergic	-	137	O
effects	-	152	O
of	-	160	O
dronedarone	-	163	O
,	-	174	O
a	-	176	O
noniodinated	-	178	O
compound	-	191	O
structurally	-	200	O
related	-	213	O
to	-	221	O
amiodarone	-	224	O
,	-	234	O
were	-	236	O
compared	-	241	O
with	-	250	O
those	-	255	O
of	-	261	O
amiodarone	-	264	O
after	-	275	O
prolonged	-	281	O
oral	-	291	O
administration	-	296	O
,	-	310	O
both	-	312	O
at	-	317	O
rest	-	320	O
and	-	325	O
during	-	329	O
sympathetic	-	336	O
stimulation	-	348	O
in	-	360	O
conscious	-	363	O
dogs	-	373	O
with	-	378	O
a	-	383	O
healed	-	385	O
myocardial	-	392	B
infarction	-	403	I
.	-	413	O

All	10975596	415	O
dogs	-	419	O
(	-	424	O
n	-	425	O
=	-	427	O
6	-	429	O
)	-	430	O
randomly	-	432	O
received	-	441	O
orally	-	450	O
dronedarone	-	457	O
(	-	469	O
10	-	470	O
and	-	473	O
30	-	477	O
mg	-	480	O
/	-	482	O
kg	-	483	O
)	-	485	O
,	-	486	O
amiodarone	-	488	O
(	-	499	O
10	-	500	O
and	-	503	O
30	-	507	O
mg	-	510	O
/	-	512	O
kg	-	513	O
)	-	515	O
,	-	516	O
and	-	518	O
placebo	-	522	O
twice	-	530	O
daily	-	536	O
for	-	542	O
7	-	546	O
days	-	548	O
,	-	552	O
with	-	554	O
a	-	559	O
3	-	561	O
-	-	562	O
week	-	563	O
washout	-	568	O
between	-	576	O
consecutive	-	584	O
treatments	-	596	O
.	-	606	O

Heart	10975596	608	O
rate	-	614	O
(	-	619	O
HR	-	620	O
)	-	622	O
,	-	623	O
mean	-	625	O
arterial	-	630	O
pressure	-	639	O
(	-	648	O
MBP	-	649	O
)	-	652	O
,	-	653	O
positive	-	655	O
rate	-	664	O
of	-	669	O
increase	-	672	O
of	-	681	O
left	-	684	O
ventricular	-	689	O
pressure	-	701	O
(	-	710	O
+	-	711	O
LVdP	-	712	O
/	-	716	O
dt	-	717	O
)	-	719	O
,	-	720	O
echocardiographically	-	722	O
assessed	-	744	O
left	-	753	O
ventricular	-	758	O
ejection	-	770	O
fraction	-	779	O
(	-	788	O
LVEF	-	789	O
)	-	793	O
,	-	794	O
and	-	796	O
fractional	-	800	O
shortening	-	811	O
(	-	822	O
FS	-	823	O
)	-	825	O
,	-	826	O
as	-	828	O
well	-	831	O
as	-	836	O
chronotropic	-	839	O
response	-	852	O
to	-	861	O
isoproterenol	-	864	O
and	-	878	O
exercise	-	882	O
-	-	890	O
induced	-	891	O
sympathetic	-	899	O
stimulation	-	911	O
were	-	923	O
evaluated	-	928	O
under	-	938	O
baseline	-	944	O
and	-	953	O
posttreatment	-	957	O
conditions	-	971	O
.	-	981	O

Resting	10975596	983	O
values	-	991	O
of	-	998	O
LVEF	-	1001	O
,	-	1005	O
FS	-	1007	O
,	-	1009	O
+	-	1011	O
LVdP	-	1012	O
/	-	1016	O
dt	-	1017	O
,	-	1019	O
and	-	1021	O
MBP	-	1025	O
remained	-	1029	O
unchanged	-	1038	O
whatever	-	1048	O
the	-	1057	O
drug	-	1061	O
and	-	1066	O
the	-	1070	O
dosing	-	1074	O
regimen	-	1081	O
,	-	1088	O
whereas	-	1090	O
resting	-	1098	O
HR	-	1106	O
was	-	1109	O
significantly	-	1113	O
and	-	1127	O
dose	-	1131	O
-	-	1135	O
dependently	-	1136	O
lowered	-	1148	O
after	-	1156	O
dronedarone	-	1162	O
and	-	1174	O
to	-	1178	O
a	-	1181	O
lesser	-	1183	O
extent	-	1190	O
after	-	1197	O
amiodarone	-	1203	O
.	-	1213	O

Both	10975596	1215	O
dronedarone	-	1220	O
and	-	1232	O
amiodarone	-	1236	O
significantly	-	1247	O
reduced	-	1261	O
the	-	1269	O
exercise	-	1273	O
-	-	1281	O
induced	-	1282	O
tachycardia	-	1290	B
and	-	1302	O
,	-	1305	O
at	-	1307	O
the	-	1310	O
highest	-	1314	O
dose	-	1322	O
,	-	1326	O
decreased	-	1328	O
the	-	1338	O
isoproterenol	-	1342	O
-	-	1355	O
induced	-	1356	O
tachycardia	-	1364	B
.	-	1375	O

Thus	10975596	1377	O
,	-	1381	O
dronedarone	-	1383	O
and	-	1395	O
amiodarone	-	1399	O
displayed	-	1410	O
a	-	1420	O
similar	-	1422	O
level	-	1430	O
of	-	1436	O
antiadrenergic	-	1439	O
effect	-	1454	O
and	-	1461	O
did	-	1465	O
not	-	1469	O
impair	-	1473	O
the	-	1480	O
resting	-	1484	O
left	-	1492	O
ventricular	-	1497	O
function	-	1509	O
.	-	1517	O

Consequently	10975596	1519	O
,	-	1531	O
dronedarone	-	1533	O
might	-	1545	O
be	-	1551	O
particularly	-	1554	O
suitable	-	1567	O
for	-	1576	O
the	-	1580	O
treatment	-	1584	O
and	-	1594	O
prevention	-	1598	O
of	-	1609	O
various	-	1612	O
clinical	-	1620	O
arrhythmias	-	1629	B
,	-	1640	O
without	-	1642	O
compromising	-	1650	O
the	-	1663	O
left	-	1667	O
ventricular	-	1672	O
function	-	1684	O
.	-	1692	O

Phase	10985896	0	O
2	-	6	O
trial	-	8	O
of	-	14	O
liposomal	-	17	O
doxorubicin	-	27	O
(	-	39	O
40	-	40	O
mg	-	43	O
/	-	45	O
m	-	46	O
(	-	47	O
2	-	48	O
)	-	49	O
)	-	50	O
in	-	52	O
platinum	-	55	O
/	-	63	O
paclitaxel	-	64	O
-	-	74	O
refractory	-	75	O
ovarian	-	86	B
and	-	94	I
fallopian	-	98	I
tube	-	108	I
cancers	-	113	I
and	-	121	O
primary	-	125	O
carcinoma	-	133	B
of	-	143	I
the	-	146	I
peritoneum	-	150	I
.	-	160	O

BACKGROUND	10985896	162	O
:	-	172	O
Several	-	174	O
studies	-	182	O
have	-	190	O
demonstrated	-	195	O
liposomal	-	208	O
doxorubicin	-	218	O
(	-	230	O
Doxil	-	231	O
)	-	236	O
to	-	238	O
be	-	241	O
an	-	244	O
active	-	247	O
antineoplastic	-	254	O
agent	-	269	O
in	-	275	O
platinum	-	278	O
-	-	286	O
resistant	-	287	O
ovarian	-	297	B
cancer	-	305	I
,	-	311	O
with	-	313	O
dose	-	318	O
limiting	-	323	O
toxicity	-	332	B
of	-	341	O
the	-	344	O
standard	-	348	O
dosing	-	357	O
regimen	-	364	O
(	-	372	O
50	-	373	O
mg	-	376	O
/	-	378	O
m	-	379	O
(	-	380	O
2	-	381	O
)	-	382	O
q	-	384	O
4	-	386	O
weeks	-	388	O
)	-	393	O
being	-	395	O
severe	-	401	O
erythrodysesthesia	-	408	B
(	-	427	O
""""	-	428	O
hand	-	429	B
-	-	433	I
foot	-	434	I
syndrome	-	439	I
""""	-	447	O
)	-	448	O
and	-	450	O
stomatitis	-	454	B
.	-	464	O

We	10985896	466	O
wished	-	469	O
to	-	476	O
develop	-	479	O
a	-	487	O
more	-	489	O
tolerable	-	494	O
liposomal	-	504	O
doxorubicin	-	514	O
treatment	-	526	O
regimen	-	536	O
and	-	544	O
document	-	548	O
its	-	557	O
level	-	561	O
of	-	567	O
activity	-	570	O
in	-	579	O
a	-	582	O
well	-	584	O
-	-	588	O
defined	-	589	O
patient	-	597	O
population	-	605	O
with	-	616	O
platinum	-	621	O
/	-	629	O
paclitaxel	-	630	O
-	-	640	O
refractory	-	641	O
disease	-	652	O
.	-	659	O

METHODS	10985896	661	O
AND	-	669	O
MATERIALS	-	673	O
:	-	682	O

Patients	10985896	684	O
with	-	693	O
ovarian	-	698	B
or	-	706	I
fallopian	-	709	I
tube	-	719	I
cancers	-	724	I
or	-	732	O
primary	-	735	O
peritoneal	-	743	B
carcinoma	-	754	I
with	-	764	O
platinum	-	769	O
/	-	777	O
paclitaxel	-	778	O
-	-	788	O
refractory	-	789	O
disease	-	800	O
(	-	808	O
stable	-	809	O
or	-	816	O
progressive	-	819	O
disease	-	831	O
following	-	839	O
treatment	-	849	O
with	-	859	O
these	-	864	O
agents	-	870	O
or	-	877	O
previous	-	880	O
objective	-	889	O
response	-	899	O
<	-	908	O
3	-	909	O
months	-	911	O
in	-	918	O
duration	-	921	O
)	-	929	O
were	-	931	O
treated	-	936	O
with	-	944	O
liposomal	-	949	O
doxorubicin	-	959	O
at	-	971	O
a	-	974	O
dose	-	976	O
of	-	981	O
40	-	984	O
mg	-	987	O
/	-	989	O
m	-	990	O
(	-	991	O
2	-	992	O
)	-	993	O
q	-	995	O
4	-	997	O
weeks	-	999	O
.	-	1004	O

RESULTS	10985896	1006	O
:	-	1013	O

A	10985896	1015	O
total	-	1017	O
of	-	1023	O
49	-	1026	O
patients	-	1029	O
(	-	1038	O
median	-	1039	O
age	-	1046	O
:	-	1049	O
60	-	1051	O
;	-	1053	O
range	-	1055	O
41	-	1061	O
-	-	1063	O
81	-	1064	O
)	-	1066	O
entered	-	1068	O
this	-	1076	O
phase	-	1081	O
2	-	1087	O
trial	-	1089	O
.	-	1094	O

The	10985896	1096	O
median	-	1100	O
number	-	1107	O
of	-	1114	O
prior	-	1117	O
regimens	-	1123	O
was	-	1132	O
2	-	1136	O
(	-	1138	O
range	-	1139	O
:	-	1144	O
1	-	1146	O
-	-	1147	O
6	-	1148	O
)	-	1149	O
.	-	1150	O

Six	10985896	1152	O
(	-	1156	O
12	-	1157	O
%	-	1159	O
)	-	1160	O
and	-	1162	O
4	-	1166	O
(	-	1168	O
8	-	1169	O
%	-	1170	O
)	-	1171	O
patients	-	1173	O
experienced	-	1182	O
grade	-	1194	O
2	-	1200	O
hand	-	1202	B
-	-	1206	I
foot	-	1207	I
syndrome	-	1212	I
and	-	1221	O
stomatitis	-	1225	B
,	-	1235	O
respectively	-	1237	O
(	-	1250	O
no	-	1251	O
episodes	-	1254	O
of	-	1263	O
grade	-	1266	O
3	-	1272	O
)	-	1273	O
.	-	1274	O

One	10985896	1276	O
patient	-	1280	O
developed	-	1288	O
grade	-	1298	O
3	-	1304	O
diarrhea	-	1306	B
requiring	-	1315	O
hospitalization	-	1325	O
for	-	1341	O
hydration	-	1345	O
.	-	1354	O

Six	10985896	1356	O
(	-	1360	O
12	-	1361	O
%	-	1363	O
)	-	1364	O
individuals	-	1366	O
required	-	1378	O
dose	-	1387	O
reductions	-	1392	O
.	-	1402	O

The	10985896	1404	O
median	-	1408	O
number	-	1415	O
of	-	1422	O
courses	-	1425	O
of	-	1433	O
liposomal	-	1436	O
doxorubicin	-	1446	O
administered	-	1458	O
on	-	1471	O
this	-	1474	O
protocol	-	1479	O
was	-	1488	O
2	-	1492	O
(	-	1494	O
range	-	1495	O
:	-	1500	O
1	-	1502	O
-	-	1503	O
12	-	1504	O
)	-	1506	O
.	-	1507	O

Four	10985896	1509	O
of	-	1514	O
44	-	1517	O
patients	-	1520	O
(	-	1529	O
9	-	1530	O
%	-	1531	O
)	-	1532	O
evaluable	-	1534	O
for	-	1544	O
response	-	1548	O
exhibited	-	1557	O
objective	-	1567	O
and	-	1577	O
subjective	-	1581	O
evidence	-	1592	O
of	-	1601	O
an	-	1604	O
antineoplastic	-	1607	O
effect	-	1622	O
of	-	1629	O
therapy	-	1632	O
.	-	1639	O

CONCLUSION	10985896	1641	O
:	-	1651	O

This	10985896	1653	O
modified	-	1658	O
liposomal	-	1667	O
doxorubicin	-	1677	O
regimen	-	1689	O
results	-	1697	O
in	-	1705	O
less	-	1708	O
toxicity	-	1713	B
(	-	1722	O
stomatitis	-	1723	B
,	-	1733	O
hand	-	1735	B
-	-	1739	I
foot	-	1740	I
syndrome	-	1745	I
)	-	1753	O
than	-	1755	O
the	-	1760	O
standard	-	1764	O
FDA	-	1773	O
-	-	1776	O
approved	-	1777	O
dose	-	1786	O
schedule	-	1791	O
.	-	1799	O

Definite	10985896	1801	O
,	-	1809	O
although	-	1811	O
limited	-	1820	O
,	-	1827	O
antineoplastic	-	1829	O
activity	-	1844	O
is	-	1853	O
observed	-	1856	O
in	-	1865	O
patients	-	1868	O
with	-	1877	O
well	-	1882	O
-	-	1886	O
defined	-	1887	O
platinum	-	1895	O
-	-	1903	O
and	-	1905	O
paclitaxel	-	1909	O
-	-	1919	O
refractory	-	1920	O
ovarian	-	1931	B
cancer	-	1939	I
.	-	1945	O

Efficacy	10986547	0	O
of	-	9	O
olanzapine	-	12	O
in	-	23	O
acute	-	26	O
bipolar	-	32	B
mania	-	40	I
:	-	45	O
a	-	47	O
double	-	49	O
-	-	55	O
blind	-	56	O
,	-	61	O
placebo	-	63	O
-	-	70	O
controlled	-	71	O
study	-	82	O
.	-	87	O

The	10986547	89	O
Olanzipine	-	93	O
HGGW	-	104	O
Study	-	109	O
Group	-	115	O
.	-	120	O

BACKGROUND	10986547	122	O
:	-	132	O

We	10986547	134	O
compared	-	137	O
the	-	146	O
efficacy	-	150	O
and	-	159	O
safety	-	163	O
of	-	170	O
olanzapine	-	173	O
vs	-	184	O
placebo	-	187	O
for	-	195	O
the	-	199	O
treatment	-	203	O
of	-	213	O
acute	-	216	O
bipolar	-	222	B
mania	-	230	I
.	-	235	O

METHODS	10986547	237	O
:	-	244	O

Four	10986547	246	O
-	-	250	O
week	-	251	O
,	-	255	O
randomized	-	257	O
,	-	267	O
double	-	269	O
-	-	275	O
blind	-	276	O
,	-	281	O
parallel	-	283	O
study	-	292	O
.	-	297	O

A	10986547	299	O
total	-	301	O
of	-	307	O
115	-	310	O
patients	-	314	O
with	-	323	O
a	-	328	O
DSM	-	330	O
-	-	333	O
IV	-	334	O
diagnosis	-	337	O
of	-	347	O
bipolar	-	350	B
disorder	-	358	I
,	-	366	O
manic	-	368	B
or	-	374	O
mixed	-	377	O
,	-	382	O
were	-	384	O
randomized	-	389	O
to	-	400	O
olanzapine	-	403	O
,	-	413	O
5	-	415	O
to	-	417	O
20	-	420	O
mg	-	423	O
/	-	425	O
d	-	426	O
(	-	428	O
n	-	429	O
=	-	431	O
55	-	433	O
)	-	435	O
,	-	436	O
or	-	438	O
placebo	-	441	O
(	-	449	O
n	-	450	O
=	-	452	O
60	-	454	O
)	-	456	O
.	-	457	O

The	10986547	459	O
primary	-	463	O
efficacy	-	471	O
measure	-	480	O
was	-	488	O
the	-	492	O
Young	-	496	O
-	-	501	O
Mania	-	502	B
Rating	-	508	O
Scale	-	515	O
(	-	521	O
Y	-	522	O
-	-	523	O
MRS	-	524	O
)	-	527	O
total	-	529	O
score	-	535	O
.	-	540	O

Response	10986547	542	O
and	-	551	O
euthymia	-	555	O
were	-	564	O
defined	-	569	O
,	-	576	O
a	-	578	O
priori	-	580	O
,	-	586	O
as	-	588	O
at	-	591	O
least	-	594	O
a	-	600	O
50	-	602	O
%	-	604	O
improvement	-	606	O
from	-	618	O
baseline	-	623	O
to	-	632	O
end	-	635	O
point	-	639	O
and	-	645	O
as	-	649	O
a	-	652	O
score	-	654	O
of	-	660	O
no	-	663	O
less	-	666	O
than	-	671	O
12	-	676	O
at	-	679	O
end	-	682	O
point	-	686	O
in	-	692	O
the	-	695	O
Y	-	699	O
-	-	700	O
MRS	-	701	O
total	-	705	O
score	-	711	O
,	-	716	O
respectively	-	718	O
.	-	730	O

Safety	10986547	732	O
was	-	739	O
assessed	-	743	O
using	-	752	O
adverse	-	758	O
events	-	766	O
,	-	772	O
Extrapyramidal	-	774	B
Symptom	-	789	I
(	-	797	O
EPS	-	798	B
)	-	801	O
rating	-	803	O
scales	-	810	O
,	-	816	O
laboratory	-	818	O
values	-	829	O
,	-	835	O
electrocardiograms	-	837	O
,	-	855	O
vital	-	857	O
signs	-	863	O
,	-	868	O
and	-	870	O
weight	-	874	O
change	-	881	O
.	-	887	O

RESULTS	10986547	889	O
:	-	896	O

Olanzapine	10986547	898	O
-	-	908	O
treated	-	909	O
patients	-	917	O
demonstrated	-	926	O
a	-	939	O
statistically	-	941	O
significant	-	955	O
greater	-	967	O
mean	-	975	O
(	-	980	O
+	-	981	O
/	-	982	O
-	-	983	O

SD	10986547	985	O
)	-	987	O
improvement	-	989	O
in	-	1001	O
Y	-	1004	O
-	-	1005	O
MRS	-	1006	O
total	-	1010	O
score	-	1016	O
than	-	1022	O
placebo	-	1027	O
-	-	1034	O
treated	-	1035	O
patients	-	1043	O
(	-	1052	O
-	-	1053	O
14	-	1054	O
.	-	1056	O
8	-	1057	O
+	-	1059	O
/	-	1060	O
-	-	1061	O

12	10986547	1063	O
.	-	1065	O
5	-	1066	O
and	-	1068	O
-	-	1072	O
8	-	1073	O
.	-	1074	O
1	-	1075	O
+	-	1077	O
/	-	1078	O
-	-	1079	O

12	10986547	1081	O
.	-	1083	O
7	-	1084	O
,	-	1085	O
respectively	-	1087	O
;	-	1099	O
P	-	1101	O
<	-	1102	O
.	-	1103	O
001	-	1104	O
)	-	1107	O
,	-	1108	O
which	-	1110	O
was	-	1116	O
evident	-	1120	O
at	-	1128	O
the	-	1131	O
first	-	1135	O
postbaseline	-	1141	O
observation	-	1154	O
1	-	1166	O
week	-	1168	O
after	-	1173	O
randomization	-	1179	O
and	-	1193	O
was	-	1197	O
maintained	-	1201	O
throughout	-	1212	O
the	-	1223	O
study	-	1227	O
(	-	1233	O
last	-	1234	O
observation	-	1239	O
carried	-	1251	O
forward	-	1259	O
)	-	1266	O
.	-	1267	O

Olanzapine	10986547	1269	O
-	-	1279	O
treated	-	1280	O
patients	-	1288	O
demonstrated	-	1297	O
a	-	1310	O
higher	-	1312	O
rate	-	1319	O
of	-	1324	O
response	-	1327	O
(	-	1336	O
65	-	1337	O
%	-	1339	O
vs	-	1341	O
43	-	1344	O
%	-	1346	O
,	-	1347	O
respectively	-	1349	O
;	-	1361	O
P	-	1363	O
=	-	1365	O
.	-	1366	O
02	-	1367	O
)	-	1369	O
and	-	1371	O
euthymia	-	1375	O
(	-	1384	O
61	-	1385	O
%	-	1387	O
vs	-	1389	O
36	-	1392	O
%	-	1394	O
,	-	1395	O
respectively	-	1397	O
;	-	1409	O
P	-	1411	O
=	-	1413	O
.	-	1414	O

01	10986547	1416	O
)	-	1418	O
than	-	1420	O
placebo	-	1425	O
-	-	1432	O
treated	-	1433	O
patients	-	1441	O
.	-	1449	O

There	10986547	1451	O
were	-	1457	O
no	-	1462	O
statistically	-	1465	O
significant	-	1479	O
differences	-	1491	O
in	-	1503	O
EPSs	-	1506	B
between	-	1511	O
groups	-	1519	O
.	-	1525	O

However	10986547	1527	O
,	-	1534	O
olanzapine	-	1536	O
-	-	1546	O
treated	-	1547	O
patients	-	1555	O
had	-	1564	O
a	-	1568	O
statistically	-	1570	O
significant	-	1584	O
greater	-	1596	O
mean	-	1604	O
(	-	1609	O
+	-	1610	O
/	-	1611	O
-	-	1612	O

SD	10986547	1614	O
)	-	1616	O
weight	-	1618	B
gain	-	1625	I
than	-	1630	O
placebo	-	1635	O
-	-	1642	O
treated	-	1643	O
patients	-	1651	O
(	-	1660	O
2	-	1661	O
.	-	1662	O
1	-	1663	O
+	-	1665	O
/	-	1666	O
-	-	1667	O

2	10986547	1669	O
.	-	1670	O
8	-	1671	O
vs	-	1673	O
0	-	1676	O
.	-	1677	O
45	-	1678	O
+	-	1681	O
/	-	1682	O
-	-	1683	O
2	-	1685	O
.	-	1686	O
3	-	1687	O
kg	-	1689	O
,	-	1691	O
respectively	-	1693	O
)	-	1705	O
and	-	1707	O
also	-	1711	O
experienced	-	1716	O
more	-	1728	O
treatment	-	1733	O
-	-	1742	O
emergent	-	1743	O
somnolence	-	1752	B
(	-	1763	O
21	-	1764	O
patients	-	1767	O
[	-	1776	O
38	-	1777	O
.	-	1779	O
2	-	1780	O
%	-	1781	O
]	-	1782	O
vs	-	1784	O
5	-	1787	O
[	-	1789	O
8	-	1790	O
.	-	1791	O
3	-	1792	O
%	-	1793	O
]	-	1795	O
,	-	1796	O
respectively	-	1798	O
)	-	1810	O
.	-	1811	O

CONCLUSION	10986547	1813	O
:	-	1823	O

Olanzapine	10986547	1825	O
demonstrated	-	1836	O
greater	-	1849	O
efficacy	-	1857	O
than	-	1866	O
placebo	-	1871	O
in	-	1879	O
the	-	1882	O
treatment	-	1886	O
of	-	1896	O
acute	-	1899	O
bipolar	-	1905	B
mania	-	1913	I
and	-	1919	O
was	-	1923	O
generally	-	1927	O
well	-	1937	O
tolerated	-	1942	O
.	-	1951	O

The	11026989	0	O
effect	-	4	O
of	-	11	O
pupil	-	14	B
dilation	-	20	I
with	-	29	O
tropicamide	-	34	O
on	-	46	O
vision	-	49	O
and	-	56	O
driving	-	60	O
simulator	-	68	O
performance	-	78	O
.	-	89	O

PURPOSE	11026989	91	O
:	-	98	O

To	11026989	100	O
assess	-	103	O
the	-	110	O
effect	-	114	O
of	-	121	O
pupil	-	124	B
dilation	-	130	I
on	-	139	O
vision	-	142	O
and	-	149	O
driving	-	153	O
ability	-	161	O
.	-	168	O

METHODS	11026989	170	O
:	-	177	O

A	11026989	179	O
series	-	181	O
of	-	188	O
tests	-	191	O
on	-	197	O
various	-	200	O
parameters	-	208	O
of	-	219	O
visual	-	222	O
function	-	229	O
and	-	238	O
driving	-	242	O
simulator	-	250	O
performance	-	260	O
were	-	272	O
performed	-	277	O
on	-	287	O
12	-	290	O
healthy	-	293	O
drivers	-	301	O
,	-	308	O
before	-	310	O
and	-	317	O
after	-	321	O
pupil	-	327	B
dilation	-	333	I
using	-	342	O
guttae	-	348	O
tropicamide	-	355	O
1	-	367	O
%	-	368	O
.	-	369	O

A	11026989	371	O
driving	-	373	O
simulator	-	381	O
(	-	391	O
Transport	-	392	O
Research	-	402	O
Laboratory	-	411	O
)	-	421	O
was	-	423	O
used	-	427	O
to	-	432	O
measure	-	435	O
reaction	-	443	O
time	-	452	O
(	-	457	O
RT	-	458	O
)	-	460	O
,	-	461	O
speed	-	463	O
maintenance	-	469	O
and	-	481	O
steering	-	485	O
accuracy	-	494	O
.	-	502	O

Tests	11026989	504	O
of	-	510	O
basic	-	513	O
visual	-	519	O
function	-	526	O
included	-	535	O
high	-	544	O
-	-	548	O
and	-	550	O
low	-	554	O
-	-	557	O
contrast	-	558	O
visual	-	567	O
acuity	-	574	O
(	-	581	O
HCVA	-	582	O
and	-	587	O
LCVA	-	591	O
)	-	595	O
,	-	596	O
Pelli	-	598	O
-	-	603	O
Robson	-	604	O
contrast	-	611	O
threshold	-	620	O
(	-	630	O
CT	-	631	O
)	-	633	O
and	-	635	O
Goldmann	-	639	O
perimetry	-	648	O
(	-	658	O
FIELDS	-	659	O
)	-	665	O
.	-	666	O

Useful	11026989	668	O
Field	-	675	O
of	-	681	O
View	-	684	O

(	11026989	689	O
UFOV	-	690	O
-	-	694	O
-	-	695	O
a	-	696	O
test	-	698	O
of	-	703	O
visual	-	706	O
attention	-	713	O
)	-	722	O
was	-	724	O
also	-	728	O
undertaken	-	733	O
.	-	743	O

The	11026989	745	O
mean	-	749	O
differences	-	754	O
in	-	766	O
the	-	769	O
pre	-	773	O
-	-	776	O
and	-	778	O
post	-	782	O
-	-	786	O
dilatation	-	787	O
measurements	-	798	O
were	-	811	O
tested	-	816	O
for	-	823	O
statistical	-	827	O
significance	-	839	O
at	-	852	O
the	-	855	O
95	-	859	O
%	-	861	O
level	-	863	O
using	-	869	O
one	-	875	O
-	-	878	O
tail	-	879	O
paired	-	884	O
t	-	891	O
-	-	892	O
tests	-	893	O
.	-	898	O

RESULTS	11026989	900	O
:	-	907	O

Pupillary	11026989	909	B
dilation	-	919	I
resulted	-	928	O
in	-	937	O
a	-	940	O
statistically	-	942	O
significant	-	956	O
deterioration	-	968	O
in	-	982	O
CT	-	985	O
and	-	988	O
HCVA	-	992	O
only	-	997	O
.	-	1001	O

Five	11026989	1003	O
of	-	1008	O
12	-	1011	O
drivers	-	1014	O
also	-	1022	O
exhibited	-	1027	O
deterioration	-	1037	O
in	-	1051	O
LCVA	-	1054	O
,	-	1058	O
CT	-	1060	O
and	-	1063	O
RT	-	1067	O
.	-	1069	O

Little	11026989	1071	O
evidence	-	1078	O
emerged	-	1087	O
for	-	1095	O
deterioration	-	1099	O
in	-	1113	O
FIELDS	-	1116	O
and	-	1123	O
UFOV	-	1127	O
.	-	1131	O

Also	11026989	1133	O
,	-	1137	O
7	-	1139	O
of	-	1141	O
12	-	1144	O
drivers	-	1147	O
appeared	-	1155	O
to	-	1164	O
adjust	-	1167	O
their	-	1174	O
driving	-	1180	O
behaviour	-	1188	O
by	-	1198	O
reducing	-	1201	O
their	-	1210	O
speed	-	1216	O
on	-	1222	O
the	-	1225	O
driving	-	1229	O
simulator	-	1237	O
,	-	1246	O
leading	-	1248	O
to	-	1256	O
improved	-	1259	O
steering	-	1268	O
accuracy	-	1277	O
.	-	1285	O

CONCLUSIONS	11026989	1287	O
:	-	1298	O

Pupillary	11026989	1300	B
dilation	-	1310	I
may	-	1319	O
lead	-	1323	O
to	-	1328	O
a	-	1331	O
decrease	-	1333	O
in	-	1342	O
vision	-	1345	O
and	-	1352	O
daylight	-	1356	O
driving	-	1365	O
performance	-	1373	O
in	-	1385	O
young	-	1388	O
people	-	1394	O
.	-	1400	O

A	11026989	1402	O
larger	-	1404	O
study	-	1411	O
,	-	1416	O
including	-	1418	O
a	-	1428	O
broader	-	1430	O
spectrum	-	1438	O
of	-	1447	O
subjects	-	1450	O
,	-	1458	O
is	-	1460	O
warranted	-	1463	O
before	-	1473	O
guidelines	-	1480	O
can	-	1491	O
be	-	1495	O
recommended	-	1498	O
.	-	1509	O

A	11105626	0	O
case	-	2	O
of	-	7	O
isotretinoin	-	10	B
embryopathy	-	23	I
with	-	35	O
bilateral	-	40	O
anotia	-	50	B
and	-	57	O
Taussig	-	61	B
-	-	68	I
Bing	-	69	I
malformation	-	74	I
.	-	86	O

We	11105626	88	O
report	-	91	O
a	-	98	O
newborn	-	100	O
infant	-	108	O
with	-	115	O
multiple	-	120	O
congenital	-	129	O
anomalies	-	140	O
(	-	150	O
anotia	-	151	B
and	-	158	O
Taussig	-	162	B
-	-	169	I
Bing	-	170	I
malformation	-	175	I
)	-	187	O
due	-	189	O
to	-	193	O
exposure	-	196	O
to	-	205	O
isotretinoin	-	208	O
within	-	221	O
the	-	228	O
first	-	232	O
trimester	-	238	O
.	-	247	O

In	11105626	249	O
this	-	252	O
paper	-	257	O
we	-	263	O
aim	-	266	O
to	-	270	O
draw	-	273	O
to	-	278	O
the	-	281	O
fact	-	285	O
that	-	290	O
caution	-	295	O
is	-	303	O
needed	-	306	O
when	-	313	O
prescribing	-	318	O
vitamin	-	330	O
A	-	338	O
-	-	339	O
containing	-	340	O
drugs	-	351	O
to	-	357	O
women	-	360	O
of	-	366	O
childbearing	-	369	O
years	-	382	O
.	-	387	O

Effect	11135381	0	O
of	-	7	O
methoxamine	-	10	O
on	-	22	O
maximum	-	25	O
urethral	-	33	O
pressure	-	42	O
in	-	51	O
women	-	54	O
with	-	60	O
genuine	-	65	O
stress	-	73	B
incontinence	-	80	I
:	-	92	O
a	-	94	O
placebo	-	96	O
-	-	103	O
controlled	-	104	O
,	-	114	O
double	-	116	O
-	-	122	O
blind	-	123	O
crossover	-	129	O
study	-	139	O
.	-	144	O

The	11135381	146	O
aim	-	150	O
of	-	154	O
the	-	157	O
study	-	161	O
was	-	167	O
to	-	171	O
evaluate	-	174	O
the	-	183	O
potential	-	187	O
role	-	197	O
for	-	202	O
a	-	206	O
selective	-	208	O
alpha1	-	218	O
-	-	224	O
adrenoceptor	-	225	O
agonist	-	238	O
in	-	246	O
the	-	249	O
treatment	-	253	O
of	-	263	O
urinary	-	266	B
stress	-	274	I
incontinence	-	281	I
.	-	293	O

A	11135381	295	O
randomised	-	297	O
,	-	307	O
double	-	309	O
-	-	315	O
blind	-	316	O
,	-	321	O
placebo	-	323	O
-	-	330	O
controlled	-	331	O
,	-	341	O
crossover	-	343	O
study	-	353	O
design	-	359	O
was	-	366	O
employed	-	370	O
.	-	378	O

Half	11135381	380	O
log	-	385	O
incremental	-	389	O
doses	-	401	O
of	-	407	O
intravenous	-	410	O
methoxamine	-	422	O
or	-	434	O
placebo	-	437	O
(	-	445	O
saline	-	446	O
)	-	452	O
were	-	454	O
administered	-	459	O
to	-	472	O
a	-	475	O
group	-	477	O
of	-	483	O
women	-	486	O
with	-	492	O
genuine	-	497	O
stress	-	505	B
incontinence	-	512	I
while	-	525	O
measuring	-	531	O
maximum	-	541	O
urethral	-	549	O
pressure	-	558	O
(	-	567	O
MUP	-	568	O
)	-	571	O
,	-	572	O
blood	-	574	O
pressure	-	580	O
,	-	588	O
heart	-	590	O
rate	-	596	O
,	-	600	O
and	-	602	O
symptomatic	-	606	O
side	-	618	O
effects	-	623	O
.	-	630	O

Methoxamine	11135381	632	O
evoked	-	644	O
non	-	651	O
-	-	654	O
significant	-	655	O
increases	-	667	O
in	-	677	O
MUP	-	680	O
and	-	684	O
diastolic	-	688	O
blood	-	698	O
pressure	-	704	O
but	-	713	O
caused	-	717	O
a	-	724	B
significant	-	726	I
rise	-	738	I
in	-	743	I
systolic	-	746	I
blood	-	755	I
pressure	-	761	I
and	-	770	O
significant	-	774	O
fall	-	786	O
in	-	791	O
heart	-	794	O
rate	-	800	O
at	-	805	O
maximum	-	808	O
dosage	-	816	O
.	-	822	O

Systemic	11135381	824	O
side	-	833	O
effects	-	838	O
including	-	846	O
piloerection	-	856	O
,	-	868	O
headache	-	870	B
,	-	878	O
and	-	880	O
cold	-	884	O
extremities	-	889	O
were	-	901	O
experienced	-	906	O
in	-	918	O
all	-	921	O
subjects	-	925	O
.	-	933	O

The	11135381	935	O
results	-	939	O
indicate	-	947	O
that	-	956	O
the	-	961	O
clinical	-	965	O
usefulness	-	974	O
of	-	985	O
direct	-	988	O
,	-	994	O
peripherally	-	996	O
acting	-	1009	O
sub	-	1016	O
-	-	1019	O
type	-	1020	O
-	-	1024	O
selective	-	1025	O
alpha1	-	1035	O
-	-	1041	O
adrenoceptor	-	1042	O
agonists	-	1055	O
in	-	1064	O
the	-	1067	O
medical	-	1071	O
treatment	-	1079	O
of	-	1089	O
stress	-	1092	B
incontinence	-	1099	I
may	-	1112	O
be	-	1116	O
limited	-	1119	O
by	-	1127	O
associated	-	1130	O
piloerection	-	1141	O
and	-	1154	O
cardiovascular	-	1158	O
side	-	1173	O
effects	-	1178	O
.	-	1185	O

Toleration	11176729	0	O
of	-	11	O
high	-	14	O
doses	-	19	O
of	-	25	O
angiotensin	-	28	O
-	-	39	O
converting	-	40	O
enzyme	-	51	O
inhibitors	-	58	O
in	-	69	O
patients	-	72	O
with	-	81	O
chronic	-	86	O
heart	-	94	B
failure	-	100	I
:	-	107	O
results	-	109	O
from	-	117	O
the	-	122	O
ATLAS	-	126	O
trial	-	132	O
.	-	137	O

The	11176729	139	O
Assessment	-	143	O
of	-	154	O
Treatment	-	157	O
with	-	167	O
Lisinopril	-	172	O
and	-	183	O
Survival	-	187	O
.	-	195	O

BACKGROUND	11176729	197	O
:	-	207	O
Treatment	-	209	O
with	-	219	O
angiotensin	-	224	O
-	-	235	O
converting	-	236	O
enzyme	-	247	O
(	-	254	O
ACE	-	255	O
)	-	258	O
inhibitors	-	260	O
reduces	-	271	O
mortality	-	279	O
and	-	289	O
morbidity	-	293	O
in	-	303	O
patients	-	306	O
with	-	315	O
chronic	-	320	O
heart	-	328	B
failure	-	334	I
(	-	342	O
CHF	-	343	B
)	-	346	O
,	-	347	O
but	-	349	O
most	-	353	O
affected	-	358	O
patients	-	367	O
are	-	376	O
not	-	380	O
receiving	-	384	O
these	-	394	O
agents	-	400	O
or	-	407	O
are	-	410	O
being	-	414	O
treated	-	420	O
with	-	428	O
doses	-	433	O
lower	-	439	O
than	-	445	O
those	-	450	O
found	-	456	O
to	-	462	O
be	-	465	O
efficacious	-	468	O
in	-	480	O
trials	-	483	O
,	-	489	O
primarily	-	491	O
because	-	501	O
of	-	509	O
concerns	-	512	O
about	-	521	O
the	-	527	O
safety	-	531	O
and	-	538	O
tolerability	-	542	O
of	-	555	O
these	-	558	O
agents	-	564	O
,	-	570	O
especially	-	572	O
at	-	583	O
the	-	586	O
recommended	-	590	O
doses	-	602	O
.	-	607	O

The	11176729	609	O
present	-	613	O
study	-	621	O
examines	-	627	O
the	-	636	O
safety	-	640	O
and	-	647	O
tolerability	-	651	O
of	-	664	O
high	-	667	O
-	-	671	O
compared	-	673	O
with	-	682	O
low	-	687	O
-	-	690	O
dose	-	691	O
lisinopril	-	696	O
in	-	707	O
CHF	-	710	B
.	-	713	O

METHODS	11176729	715	O
:	-	722	O

The	11176729	724	O
Assessment	-	728	O
of	-	739	O
Lisinopril	-	742	O
and	-	753	O
Survival	-	757	O
study	-	766	O
was	-	772	O
a	-	776	O
multicenter	-	778	O
,	-	789	O
randomized	-	791	O
,	-	801	O
double	-	803	O
-	-	809	O
blind	-	810	O
trial	-	816	O
in	-	822	O
which	-	825	O
patients	-	831	O
with	-	840	O
or	-	845	O
without	-	848	O
previous	-	856	O
ACE	-	865	O
inhibitor	-	869	O
treatment	-	879	O
were	-	889	O
stabilized	-	894	O
receiving	-	905	O
medium	-	915	O
-	-	921	O
dose	-	922	O
lisinopril	-	927	O
(	-	938	O
12	-	939	O
.	-	941	O
5	-	942	O
or	-	944	O
15	-	947	O
.	-	949	O
0	-	950	O
mg	-	952	O
once	-	955	O
daily	-	960	O
[	-	966	O
OD	-	967	O
]	-	969	O
)	-	970	O
for	-	972	O
2	-	976	O
to	-	978	O
4	-	981	O
weeks	-	983	O
and	-	989	O
then	-	993	O
randomized	-	998	O
to	-	1009	O
high	-	1012	O
-	-	1016	O
(	-	1018	O
35	-	1019	O
.	-	1021	O
0	-	1022	O
or	-	1024	O
32	-	1027	O
.	-	1029	O
5	-	1030	O
mg	-	1032	O
OD	-	1035	O
)	-	1037	O
or	-	1039	O
low	-	1042	O
-	-	1045	O
dose	-	1046	O
(	-	1051	O
5	-	1052	O
.	-	1053	O
0	-	1054	O
or	-	1056	O
2	-	1059	O
.	-	1060	O
5	-	1061	O
mg	-	1063	O
OD	-	1066	O
)	-	1068	O
groups	-	1070	O
.	-	1076	O

Patients	11176729	1078	O
with	-	1087	O
New	-	1092	O
York	-	1096	O
Heart	-	1101	O
Association	-	1107	O
classes	-	1119	O
II	-	1127	O
to	-	1130	O
IV	-	1133	O
CHF	-	1136	B
and	-	1140	O
left	-	1144	O
ventricular	-	1149	O
ejection	-	1161	O
fractions	-	1170	O
of	-	1180	O
no	-	1183	O
greater	-	1186	O
than	-	1194	O
0	-	1199	O
.	-	1200	O
30	-	1201	O

(	11176729	1204	O
n	-	1205	O
=	-	1207	O
3164	-	1209	O
)	-	1213	O
were	-	1215	O
randomized	-	1220	O
and	-	1231	O
followed	-	1235	O
up	-	1244	O
for	-	1247	O
a	-	1251	O
median	-	1253	O
of	-	1260	O
46	-	1263	O
months	-	1266	O
.	-	1272	O

We	11176729	1274	O
examined	-	1277	O
the	-	1286	O
occurrence	-	1290	O
of	-	1301	O
adverse	-	1304	O
events	-	1312	O
and	-	1319	O
the	-	1323	O
need	-	1327	O
for	-	1332	O
discontinuation	-	1336	O
and	-	1352	O
dose	-	1356	O
reduction	-	1361	O
during	-	1371	O
treatment	-	1378	O
,	-	1387	O
with	-	1389	O
a	-	1394	O
focus	-	1396	O
on	-	1402	O
hypotension	-	1405	B
and	-	1417	O
renal	-	1421	B
dysfunction	-	1427	I
.	-	1438	O

RESULTS	11176729	1440	O
:	-	1447	O

Of	11176729	1449	O
405	-	1452	O
patients	-	1456	O
not	-	1465	O
previously	-	1469	O
receiving	-	1480	O
an	-	1490	O
ACE	-	1493	O
inhibitor	-	1497	O
,	-	1506	O
doses	-	1508	O
in	-	1514	O
only	-	1517	O
4	-	1522	O
.	-	1523	O
2	-	1524	O
%	-	1525	O
could	-	1527	O
not	-	1533	O
be	-	1537	O
titrated	-	1540	O
to	-	1549	O
the	-	1552	O
medium	-	1556	O
doses	-	1563	O
required	-	1569	O
for	-	1578	O
randomization	-	1582	O
because	-	1596	O
of	-	1604	O
symptoms	-	1607	O
possibly	-	1616	O
related	-	1625	O
to	-	1633	O
hypotension	-	1636	B
(	-	1648	O
2	-	1649	O
.	-	1650	O
0	-	1651	O
%	-	1652	O
)	-	1653	O
or	-	1655	O
because	-	1658	O
of	-	1666	O
renal	-	1669	B
dysfunction	-	1675	I
or	-	1687	O
hyperkalemia	-	1690	B
(	-	1703	O
2	-	1704	O
.	-	1705	O
3	-	1706	O
%	-	1707	O
)	-	1708	O
.	-	1709	O

Doses	11176729	1711	O
in	-	1717	O
more	-	1720	O
than	-	1725	O
90	-	1730	O
%	-	1732	O
of	-	1734	O
randomized	-	1737	O
patients	-	1748	O
in	-	1757	O
the	-	1760	O
high	-	1764	O
-	-	1768	O
and	-	1770	O
low	-	1774	O
-	-	1777	O
dose	-	1778	O
groups	-	1783	O
were	-	1790	O
titrated	-	1795	O
to	-	1804	O
their	-	1807	O
assigned	-	1813	O
target	-	1822	O
,	-	1828	O
and	-	1830	O
the	-	1834	O
mean	-	1838	O
doses	-	1843	O
of	-	1849	O
blinded	-	1852	O
medication	-	1860	O
in	-	1871	O
both	-	1874	O
groups	-	1879	O
remained	-	1886	O
similar	-	1895	O
throughout	-	1903	O
the	-	1914	O
study	-	1918	O
.	-	1923	O

Withdrawals	11176729	1925	O
occurred	-	1937	O
in	-	1946	O
27	-	1949	O
.	-	1951	O
1	-	1952	O
%	-	1953	O
of	-	1955	O
the	-	1958	O
high	-	1962	O
-	-	1966	O
and	-	1968	O
30	-	1972	O
.	-	1974	O
7	-	1975	O
%	-	1976	O
of	-	1978	O
the	-	1981	O
low	-	1985	O
-	-	1988	O
dose	-	1989	O
groups	-	1994	O
.	-	2000	O

Subgroups	11176729	2002	O
presumed	-	2012	O
to	-	2021	O
be	-	2024	O
at	-	2027	O
higher	-	2030	O
risk	-	2037	O
for	-	2042	O
ACE	-	2046	O
inhibitor	-	2050	O
intolerance	-	2060	O
(	-	2072	O
blood	-	2073	O
pressure	-	2079	O
,	-	2087	O

<	11176729	2089	O
120	-	2090	O
mm	-	2094	O
Hg	-	2097	O
;	-	2099	O
creatinine	-	2101	O
,	-	2111	O
>	-	2113	O
or	-	2115	O
=	-	2118	O
132	-	2119	O
.	-	2122	O
6	-	2123	O
micromol	-	2125	O
/	-	2133	O
L	-	2134	O
[	-	2136	O
>	-	2137	O
or	-	2139	O
=	-	2142	O
1	-	2143	O
.	-	2144	O
5	-	2145	O
mg	-	2147	O
/	-	2149	O
dL	-	2150	O
]	-	2152	O
;	-	2153	O
age	-	2155	O
,	-	2158	O
>	-	2160	O
or	-	2162	O
=	-	2165	O
70	-	2166	O
years	-	2169	O
;	-	2174	O
and	-	2176	O
patients	-	2180	O
with	-	2189	O
diabetes	-	2194	B
)	-	2202	O
generally	-	2204	O
tolerated	-	2214	O
the	-	2224	O
high	-	2228	O
-	-	2232	O
dose	-	2233	O
strategy	-	2238	O
.	-	2246	O

CONCLUSIONS	11176729	2248	O
:	-	2259	O

These	11176729	2261	O
findings	-	2267	O
demonstrate	-	2276	O
that	-	2288	O
ACE	-	2293	O
inhibitor	-	2297	O
therapy	-	2307	O
in	-	2315	O
most	-	2318	O
patients	-	2323	O
with	-	2332	O
CHF	-	2337	B
can	-	2341	O
be	-	2345	O
successfully	-	2348	O
titrated	-	2361	O
to	-	2370	O
and	-	2373	O
maintained	-	2377	O
at	-	2388	O
high	-	2391	O
doses	-	2396	O
,	-	2401	O
and	-	2403	O
that	-	2407	O
more	-	2412	O
aggressive	-	2417	O
use	-	2428	O
of	-	2432	O
these	-	2435	O
agents	-	2441	O
is	-	2448	O
warranted	-	2451	O
.	-	2460	O

Cocaine	11229942	0	O
,	-	7	O
ethanol	-	9	O
,	-	16	O
and	-	18	O
cocaethylene	-	22	O
cardiotoxity	-	35	B
in	-	48	O
an	-	51	O
animal	-	54	O
model	-	61	O
of	-	67	O
cocaine	-	70	B
and	-	78	I
ethanol	-	82	I
abuse	-	90	I
.	-	95	O

OBJECTIVES	11229942	97	O
:	-	107	O

Simultaneous	11229942	109	O
abuse	-	122	B
of	-	128	I
cocaine	-	131	I
and	-	139	I
ethanol	-	143	I
affects	-	151	O
12	-	159	O
million	-	162	O
Americans	-	170	O
annually	-	180	O
.	-	188	O

In	11229942	190	O
combination	-	193	O
,	-	204	O
these	-	206	O
substances	-	212	O
are	-	223	O
substantially	-	227	O
more	-	241	O
toxic	-	246	O
than	-	252	O
either	-	257	O
drug	-	264	O
alone	-	269	O
.	-	274	O

Their	11229942	276	O
combined	-	282	O
cardiac	-	291	B
toxicity	-	299	I
may	-	308	O
be	-	312	O
due	-	315	O
to	-	319	O
independent	-	322	O
effects	-	334	O
of	-	342	O
each	-	345	O
drug	-	350	O
;	-	354	O
however	-	356	O
,	-	363	O
they	-	365	O
may	-	370	O
also	-	374	O
be	-	379	O
due	-	382	O
to	-	386	O
cocaethylene	-	389	O
(	-	402	O
CE	-	403	O
)	-	405	O
,	-	406	O
a	-	408	O
cocaine	-	410	O
metabolite	-	418	O
formed	-	429	O
only	-	436	O
in	-	441	O
the	-	444	O
presence	-	448	O
of	-	457	O
ethanol	-	460	O
.	-	467	O

The	11229942	469	O
purpose	-	473	O
of	-	481	O
this	-	484	O
study	-	489	O
was	-	495	O
to	-	499	O
delineate	-	502	O
the	-	512	O
role	-	516	O
of	-	521	O
CE	-	524	O
in	-	527	O
the	-	530	O
combined	-	534	O
cardiotoxicity	-	543	B
of	-	558	O
cocaine	-	561	O
and	-	569	O
ethanol	-	573	O
in	-	581	O
a	-	584	O
model	-	586	O
simulating	-	592	O
their	-	603	O
abuse	-	609	O
.	-	614	O

METHODS	11229942	616	O
:	-	623	O

Twenty	11229942	625	O
-	-	631	O
three	-	632	O
dogs	-	638	O
were	-	643	O
randomized	-	648	O
to	-	659	O
receive	-	662	O
either	-	670	O
1	-	677	O
)	-	678	O
three	-	680	O
intravenous	-	686	O
(	-	698	O
IV	-	699	O
)	-	701	O
boluses	-	703	O
of	-	711	O
cocaine	-	714	O
7	-	722	O
.	-	723	O
5	-	724	O
mg	-	726	O
/	-	728	O
kg	-	729	O
with	-	732	O
ethanol	-	737	O
(	-	745	O
1	-	746	O
g	-	748	O
/	-	749	O
kg	-	750	O
)	-	752	O
as	-	754	O
an	-	757	O
IV	-	760	O
infusion	-	763	O
(	-	772	O
C	-	773	O
+	-	774	O
E	-	775	O
,	-	776	O
n	-	778	O
=	-	780	O
8	-	782	O
)	-	783	O
,	-	784	O
2	-	786	O
)	-	787	O
three	-	789	O
cocaine	-	795	O
boluses	-	803	O
only	-	811	O
(	-	816	O
C	-	817	O
,	-	818	O
n	-	820	O
=	-	822	O
6	-	824	O
)	-	825	O
,	-	826	O
3	-	828	O
)	-	829	O
ethanol	-	831	O
infusion	-	839	O
only	-	848	O
(	-	853	O
E	-	854	O
,	-	855	O
n	-	857	O
=	-	859	O
5	-	861	O
)	-	862	O
,	-	863	O
or	-	865	O
4	-	868	O
)	-	869	O
placebo	-	871	O
boluses	-	879	O
and	-	887	O
infusion	-	891	O
(	-	900	O
n	-	901	O
=	-	903	O
4	-	905	O
)	-	906	O
.	-	907	O

Hemodynamic	11229942	909	O
measurements	-	921	O
,	-	933	O
electrocardiograms	-	935	O
,	-	953	O
and	-	955	O
serum	-	959	O
drug	-	965	O
concentrations	-	970	O
were	-	985	O
obtained	-	990	O
at	-	999	O
baseline	-	1002	O
,	-	1010	O
and	-	1012	O
then	-	1016	O
at	-	1021	O
fixed	-	1024	O
time	-	1030	O
intervals	-	1035	O
after	-	1045	O
each	-	1051	O
drug	-	1056	O
was	-	1061	O
administered	-	1065	O
.	-	1077	O

RESULTS	11229942	1079	O
:	-	1086	O

Two	11229942	1088	O
of	-	1092	O
eight	-	1095	O
dogs	-	1101	O
in	-	1106	O
the	-	1109	O
C	-	1113	O
+	-	1114	O
E	-	1115	O
group	-	1117	O
experienced	-	1123	O
cardiovascular	-	1135	B
collapse	-	1150	I
.	-	1158	O

The	11229942	1160	O
most	-	1164	O
dramatic	-	1169	O
hemodynamic	-	1178	O
changes	-	1190	O
occurred	-	1198	O
after	-	1207	O
each	-	1213	O
cocaine	-	1218	O
bolus	-	1226	O
in	-	1232	O
the	-	1235	O
C	-	1239	O
+	-	1240	O
E	-	1241	O
and	-	1243	O
C	-	1247	O
only	-	1249	O
groups	-	1254	O
;	-	1260	O
however	-	1262	O
,	-	1269	O
persistent	-	1271	O
hemodynamic	-	1282	O
changes	-	1294	O
occurred	-	1302	O
in	-	1311	O
the	-	1314	O
C	-	1318	O
+	-	1319	O
E	-	1320	O
group	-	1322	O
.	-	1327	O

Peak	11229942	1329	O
CE	-	1334	O
levels	-	1337	O
were	-	1344	O
associated	-	1349	O
with	-	1360	O
a	-	1365	O
45	-	1367	O
%	-	1369	O
(	-	1371	O
SD	-	1372	O
+	-	1375	O
/	-	1376	O
-	-	1377	O

22	11229942	1379	O
%	-	1381	O
,	-	1382	O
95	-	1384	O
%	-	1386	O
CI	-	1388	O
=	-	1391	O
22	-	1393	O
%	-	1395	O
to	-	1397	O
69	-	1400	O
%	-	1402	O
)	-	1403	O
decrease	-	1405	B
in	-	1414	I
cardiac	-	1417	I
output	-	1425	I
(	-	1432	O
p	-	1433	O
<	-	1435	O
0	-	1437	O
.	-	1438	O
05	-	1439	O
)	-	1441	O
,	-	1442	O
a	-	1444	O
56	-	1446	O
%	-	1448	O
(	-	1450	O
SD	-	1451	O
+	-	1454	O
/	-	1455	O
-	-	1456	O

23	11229942	1458	O
%	-	1460	O
,	-	1461	O
95	-	1463	O
%	-	1465	O
CI	-	1467	O
=	-	1470	O
32	-	1472	O
%	-	1474	O
to	-	1476	O
80	-	1479	O
%	-	1481	O
)	-	1482	O
decrease	-	1484	O
in	-	1493	O
dP	-	1496	O
/	-	1498	O
dt	-	1499	O
(	-	1501	O
max	-	1502	O
)	-	1505	O
(	-	1507	O
p	-	1508	O
<	-	1510	O
.	-	1511	O
006	-	1512	O
)	-	1515	O
,	-	1516	O
and	-	1518	O
a	-	1522	O
23	-	1524	O
%	-	1526	O
(	-	1528	O
SD	-	1529	O
+	-	1532	O
/	-	1533	O
-	-	1534	O

15	11229942	1536	O
%	-	1538	O
,	-	1539	O
95	-	1541	O
%	-	1543	O
CI	-	1545	O
=	-	1548	O
7	-	1550	O
%	-	1551	O
to	-	1553	O
49	-	1556	O
%	-	1558	O
)	-	1559	O
decrease	-	1561	O
in	-	1570	O
SVO	-	1573	O
(	-	1576	O
2	-	1577	O
)	-	1578	O
(	-	1580	O
p	-	1581	O
<	-	1583	O
0	-	1585	O
.	-	1586	O
025	-	1587	O
)	-	1590	O
.	-	1591	O

Ventricular	11229942	1593	B
arrhythmias	-	1605	I
were	-	1617	O
primarily	-	1622	O
observed	-	1632	O
in	-	1641	O
the	-	1644	O
C	-	1648	O
+	-	1649	O
E	-	1650	O
group	-	1652	O
,	-	1657	O
in	-	1659	O
which	-	1662	O
four	-	1668	O
of	-	1673	O
eight	-	1676	O
dogs	-	1682	O
experienced	-	1687	O
ventricular	-	1699	B
tachycardia	-	1711	I
.	-	1722	O

CONCLUSIONS	11229942	1724	O
:	-	1735	O

Cocaine	11229942	1737	O
and	-	1745	O
ethanol	-	1749	O
in	-	1757	O
combination	-	1760	O
were	-	1772	O
more	-	1777	O
toxic	-	1782	O
than	-	1788	O
either	-	1793	O
substance	-	1800	O
alone	-	1810	O
.	-	1815	O

Co	11229942	1817	O
-	-	1819	O
administration	-	1820	O
resulted	-	1835	O
in	-	1844	O
prolonged	-	1847	O
cardiac	-	1857	B
toxicity	-	1865	I
and	-	1874	O
was	-	1878	O
dysrhythmogenic	-	1882	O
.	-	1897	O

Peak	11229942	1899	O
serum	-	1904	O
cocaethylene	-	1910	O
concentrations	-	1923	O
were	-	1938	O
associated	-	1943	O
with	-	1954	O
prolonged	-	1959	O
myocardial	-	1969	B
depression	-	1980	I
.	-	1990	O

Worsening	11299446	0	O
of	-	10	O
Parkinsonism	-	13	B
after	-	26	O
the	-	32	O
use	-	36	O
of	-	40	O
veralipride	-	43	O
for	-	55	O
treatment	-	59	O
of	-	69	O
menopause	-	72	O
:	-	81	O
case	-	83	O
report	-	88	O
.	-	94	O

We	11299446	96	O
describe	-	99	O
a	-	108	O
female	-	110	O
patient	-	117	O
with	-	125	O
stable	-	130	O
Parkinson	-	137	B
's	-	146	I
disease	-	149	I
who	-	157	O
has	-	161	O
shown	-	165	O
a	-	171	O
marked	-	173	O
worsening	-	180	O
of	-	190	O
her	-	193	O
motor	-	197	O
functions	-	203	O
following	-	213	O
therapy	-	223	O
of	-	231	O
menopause	-	234	O
related	-	244	O
symptoms	-	252	O
with	-	261	O
veralipride	-	266	O
,	-	277	O
as	-	279	O
well	-	282	O
as	-	287	O
the	-	290	O
improvement	-	294	O
of	-	306	O
her	-	309	O
symptoms	-	313	O
back	-	322	O
to	-	327	O
baseline	-	330	O
after	-	339	O
discontinuation	-	345	O
of	-	361	O
the	-	364	O
drug	-	368	O
.	-	372	O

We	11299446	374	O
emphasize	-	377	O
the	-	387	O
anti	-	391	O
-	-	395	O
dopaminergic	-	396	O
effect	-	409	O
of	-	416	O
veralipride	-	419	O
.	-	430	O

Viracept	11366874	0	O
and	-	9	O
irregular	-	13	B
heartbeat	-	23	I
warning	-	33	O
.	-	40	O

A	11366874	42	O
group	-	44	O
of	-	50	O
doctors	-	53	O
in	-	61	O
Boston	-	64	O
warn	-	71	O
that	-	76	O
the	-	81	O
protease	-	85	O
inhibitor	-	94	O
Viracept	-	104	O
may	-	113	O
cause	-	117	O
an	-	123	O
irregular	-	126	B
heart	-	136	I
beat	-	142	I
,	-	146	O
known	-	148	O
as	-	154	O
bradycardia	-	157	B
,	-	168	O
in	-	170	O
people	-	173	O
with	-	180	O
HIV	-	185	O
.	-	188	O

Bradycardia	11366874	190	B
occurred	-	202	O
in	-	211	O
a	-	214	O
45	-	216	O
-	-	218	O
year	-	219	O
-	-	223	O
old	-	224	O
male	-	228	O
patient	-	233	O
who	-	241	O
was	-	245	O
Viracept	-	249	O
in	-	258	O
combination	-	261	O
with	-	273	O
other	-	278	O
anti	-	284	O
-	-	288	O
HIV	-	289	O
drugs	-	293	O
.	-	298	O

The	11366874	300	O
symptoms	-	304	O
ceased	-	313	O
after	-	320	O
switching	-	326	O
to	-	336	O
another	-	339	O
drug	-	347	O
combination	-	352	O
.	-	363	O

Frequency	11380496	0	O
of	-	10	O
appearance	-	13	O
of	-	24	O
myeloperoxidase	-	27	O
-	-	42	O
antineutrophil	-	43	O
cytoplasmic	-	58	O
antibody	-	70	O
(	-	79	O
MPO	-	80	O
-	-	83	O
ANCA	-	84	O
)	-	88	O
in	-	90	O
Graves	-	93	B
'	-	99	I
disease	-	101	I
patients	-	109	O
treated	-	118	O
with	-	126	O
propylthiouracil	-	131	O
and	-	148	O
the	-	152	O
relationship	-	156	O
between	-	169	O
MPO	-	177	O
-	-	180	O
ANCA	-	181	O
and	-	186	O
clinical	-	190	O
manifestations	-	199	O
.	-	213	O

OBJECTIVE	11380496	215	O
:	-	224	O
Myeloperoxidase	-	226	O
antineutrophil	-	242	O
cytoplasmic	-	257	O
antibody	-	269	O
(	-	278	O
MPO	-	279	O
-	-	282	O
ANCA	-	283	O
)	-	287	O
-	-	288	O
positive	-	289	O
vasculitis	-	298	B
has	-	309	O
been	-	313	O
reported	-	318	O
in	-	327	O
patients	-	330	O
with	-	339	O
Graves	-	344	B
'	-	350	I
disease	-	352	I
who	-	360	O
were	-	364	O
treated	-	369	O
with	-	377	O
propylthiouracil	-	382	O
(	-	399	O
PTU	-	400	O
)	-	403	O
.	-	404	O

The	11380496	406	O
appearance	-	410	O
of	-	421	O
MPO	-	424	O
-	-	427	O
ANCA	-	428	O
in	-	433	O
these	-	436	O
cases	-	442	O
was	-	448	O
suspected	-	452	O
of	-	462	O
being	-	465	O
related	-	471	O
to	-	479	O
PTU	-	482	O
because	-	486	O
the	-	494	O
titres	-	498	O
of	-	505	O
MPO	-	508	O
-	-	511	O
ANCA	-	512	O
decreased	-	517	O
when	-	527	O
PTU	-	532	O
was	-	536	O
stopped	-	540	O
.	-	547	O

Nevertheless	11380496	549	O
,	-	561	O
there	-	563	O
have	-	569	O
been	-	574	O
no	-	579	O
studies	-	582	O
on	-	590	O
the	-	593	O
temporal	-	597	O
relationship	-	606	O
between	-	619	O
the	-	627	O
appearance	-	631	O
of	-	642	O
MPO	-	645	O
-	-	648	O
ANCA	-	649	O
and	-	654	O
vasculitis	-	658	B
during	-	669	O
PTU	-	676	O
therapy	-	680	O
,	-	687	O
or	-	689	O
on	-	692	O
the	-	695	O
incidence	-	699	O
of	-	709	O
MPO	-	712	O
-	-	715	O
ANCA	-	716	O
in	-	721	O
untreated	-	724	O
Graves	-	734	B
'	-	740	I
disease	-	742	I
patients	-	750	O
.	-	758	O

Therefore	11380496	760	O
,	-	769	O
we	-	771	O
sought	-	774	O
to	-	781	O
address	-	784	O
these	-	792	O
parameters	-	798	O
in	-	809	O
patients	-	812	O
with	-	821	O
Graves	-	826	B
'	-	832	I
disease	-	834	I
.	-	841	O

PATIENTS	11380496	843	O
:	-	851	O

We	11380496	853	O
investigated	-	856	O
102	-	869	O
untreated	-	873	O
patients	-	883	O
with	-	892	O
hyperthyroidism	-	897	B
due	-	913	O
to	-	917	O
Graves	-	920	B
'	-	926	I
disease	-	928	I
for	-	936	O
the	-	940	O
presence	-	944	O
of	-	953	O
MPO	-	956	O
-	-	959	O
ANCA	-	960	O
,	-	964	O
and	-	966	O
for	-	970	O
the	-	974	O
development	-	978	O
vasculitis	-	990	B
after	-	1001	O
starting	-	1007	O
PTU	-	1016	O
therapy	-	1020	O
.	-	1027	O

Twenty	11380496	1029	O
-	-	1035	O
nine	-	1036	O
of	-	1041	O
them	-	1044	O
were	-	1049	O
later	-	1054	O
excluded	-	1060	O
because	-	1069	O
of	-	1077	O
adverse	-	1080	O
effects	-	1088	O
of	-	1096	O
PTU	-	1099	O
or	-	1103	O
because	-	1106	O
the	-	1114	O
observation	-	1118	O
period	-	1130	O
was	-	1137	O
less	-	1141	O
than	-	1146	O
3	-	1151	O
months	-	1153	O
.	-	1159	O

The	11380496	1161	O
remaining	-	1165	O
73	-	1175	O
patients	-	1178	O
(	-	1187	O
55	-	1188	O
women	-	1191	O
and	-	1197	O
18	-	1201	O
men	-	1204	O
)	-	1207	O
,	-	1208	O
all	-	1210	O
of	-	1214	O
whom	-	1217	O
were	-	1222	O
examined	-	1227	O
for	-	1236	O
more	-	1240	O
than	-	1245	O
3	-	1250	O
months	-	1252	O
,	-	1258	O
were	-	1260	O
adopted	-	1265	O
as	-	1273	O
the	-	1276	O
subjects	-	1280	O
of	-	1289	O
the	-	1292	O
investigation	-	1296	O
.	-	1309	O

The	11380496	1311	O
median	-	1315	O
observation	-	1322	O
period	-	1334	O
was	-	1341	O
23	-	1345	O
.	-	1347	O
6	-	1348	O
months	-	1350	O
(	-	1357	O
range	-	1358	O
:	-	1363	O
3	-	1365	O
-	-	1366	O
37	-	1367	O
months	-	1370	O
)	-	1376	O
.	-	1377	O

MEASUREMENTS	11380496	1379	O
:	-	1391	O

MPO	11380496	1393	O
-	-	1396	O
ANCA	-	1397	O
was	-	1402	O
measured	-	1406	O
at	-	1415	O
intervals	-	1418	O
of	-	1428	O
2	-	1431	O
-	-	1432	O
6	-	1433	O
months	-	1435	O
.	-	1441	O

RESULTS	11380496	1443	O
:	-	1450	O

Before	11380496	1452	O
treatment	-	1459	O
,	-	1468	O
the	-	1470	O
MPO	-	1474	O
-	-	1477	O
ANCA	-	1478	O
titres	-	1483	O
of	-	1490	O
all	-	1493	O
102	-	1497	O
untreated	-	1501	O
Graves	-	1511	B
'	-	1517	I
disease	-	1519	I
patients	-	1527	O
were	-	1536	O
within	-	1541	O
the	-	1548	O
reference	-	1552	O
range	-	1562	O
(	-	1568	O
below	-	1569	O
10	-	1575	O
U	-	1578	O
/	-	1579	O
ml	-	1580	O
)	-	1582	O
.	-	1583	O

Three	11380496	1585	O
(	-	1591	O
4	-	1592	O
.	-	1593	O
1	-	1594	O
%	-	1595	O
)	-	1596	O
of	-	1598	O
the	-	1601	O
73	-	1605	O
patients	-	1608	O
were	-	1617	O
positive	-	1622	O
for	-	1631	O
MPO	-	1635	O
-	-	1638	O
ANCA	-	1639	O
at	-	1644	O
13	-	1647	O
,	-	1649	O
16	-	1651	O
and	-	1654	O
17	-	1658	O
months	-	1661	O
,	-	1667	O
respectively	-	1669	O
,	-	1681	O
after	-	1683	O
the	-	1689	O
start	-	1693	O
of	-	1699	O
PTU	-	1702	O
therapy	-	1706	O
.	-	1713	O

In	11380496	1715	O
two	-	1718	O
of	-	1722	O
them	-	1725	O
,	-	1729	O
the	-	1731	O
MPO	-	1735	O
-	-	1738	O
ANCA	-	1739	O
titres	-	1744	O
transiently	-	1751	O
increased	-	1763	O
to	-	1773	O
12	-	1776	O
.	-	1778	O
8	-	1779	O
and	-	1781	O
15	-	1785	O
.	-	1787	O
0	-	1788	O
U	-	1790	O
/	-	1791	O
ml	-	1792	O
,	-	1794	O
respectively	-	1796	O
,	-	1808	O
despite	-	1810	O
continued	-	1818	O
PTU	-	1828	O
therapy	-	1832	O
,	-	1839	O
but	-	1841	O
no	-	1845	O
vasculitic	-	1848	B
disorders	-	1859	I
developed	-	1869	O
.	-	1878	O

In	11380496	1880	O
the	-	1883	O
third	-	1887	O
patient	-	1893	O
,	-	1900	O
the	-	1902	O
MPO	-	1906	O
-	-	1909	O
ANCA	-	1910	O
titre	-	1915	O
increased	-	1921	O
to	-	1931	O
204	-	1934	O
U	-	1938	O
/	-	1939	O
ml	-	1940	O
and	-	1943	O
she	-	1947	O
developed	-	1951	O
a	-	1961	O
higher	-	1963	O
fever	-	1970	B
,	-	1975	O
oral	-	1977	B
ulcers	-	1982	I
and	-	1989	O
polyarthralgia	-	1993	B
,	-	2007	O
but	-	2009	O
the	-	2013	O
symptoms	-	2017	O
resolved	-	2026	O
2	-	2035	O
weeks	-	2037	O
after	-	2043	O
stopping	-	2049	O
PTU	-	2058	O
therapy	-	2062	O
,	-	2069	O
and	-	2071	O
the	-	2075	O
MPO	-	2079	O
-	-	2082	O
ANCA	-	2083	O
titre	-	2088	O
decreased	-	2094	O
to	-	2104	O
20	-	2107	O
.	-	2109	O
7	-	2110	O
U	-	2112	O
/	-	2113	O
ml	-	2114	O
by	-	2117	O
4	-	2120	O
months	-	2122	O
after	-	2129	O
discontinuing	-	2135	O
PTU	-	2149	O
.	-	2152	O

CONCLUSIONS	11380496	2154	O
:	-	2165	O

PTU	11380496	2167	O
therapy	-	2171	O
may	-	2179	O
be	-	2183	O
related	-	2186	O
to	-	2194	O
the	-	2197	O
appearance	-	2201	O
of	-	2212	O
MPO	-	2215	O
-	-	2218	O
ANCA	-	2219	O
,	-	2223	O
but	-	2225	O
MPO	-	2229	O
-	-	2232	O
ANCA	-	2233	O
does	-	2238	O
not	-	2243	O
appear	-	2247	O
to	-	2254	O
be	-	2257	O
closely	-	2260	O
related	-	2268	O
to	-	2276	O
vasculitis	-	2279	B
.	-	2289	O

Prevalence	11385188	0	O
of	-	11	O
heart	-	14	B
disease	-	20	I
in	-	28	O
asymptomatic	-	31	O
chronic	-	44	O
cocaine	-	52	O
users	-	60	O
.	-	65	O

To	11385188	67	O
determine	-	70	O
the	-	80	O
prevalence	-	84	O
of	-	95	O
heart	-	98	B
disease	-	104	I
in	-	112	O
outpatient	-	115	O
young	-	126	O
asymptomatic	-	132	O
chronic	-	145	O
cocaine	-	153	O
users	-	161	O
,	-	166	O
35	-	168	O
cocaine	-	171	O
users	-	179	O
and	-	185	O
32	-	189	O
age	-	192	O
-	-	195	O
matched	-	196	O
controls	-	204	O
underwent	-	213	O
resting	-	223	O
and	-	231	O
exercise	-	235	O
electrocardiography	-	244	O
(	-	264	O
ECG	-	265	O
)	-	268	O
and	-	270	O
Doppler	-	274	O
echocardiography	-	282	O
.	-	298	O

Findings	11385188	300	O
consistent	-	309	O
with	-	320	O
coronary	-	325	B
artery	-	334	I
disease	-	341	I
were	-	349	O
detected	-	354	O
in	-	363	O
12	-	366	O
(	-	369	O
34	-	370	O
%	-	372	O
)	-	373	O
patients	-	375	O
and	-	384	O
3	-	388	O
(	-	390	O
9	-	391	O
%	-	392	O
)	-	393	O
controls	-	395	O
(	-	404	O
p	-	405	O
=	-	407	O
0	-	409	O
.	-	410	O
01	-	411	O
)	-	413	O
.	-	414	O

Decreased	11385188	416	O
left	-	426	O
ventricular	-	431	O
systolic	-	443	O
function	-	452	O
was	-	461	O
demonstrated	-	465	O
in	-	478	O
5	-	481	O
(	-	483	O
14	-	484	O
%	-	486	O
)	-	487	O
patients	-	489	O
,	-	497	O
but	-	499	O
in	-	503	O
none	-	506	O
of	-	511	O
the	-	514	O
controls	-	518	O
(	-	527	O
p	-	528	O
=	-	530	O
0	-	532	O
.	-	533	O
055	-	534	O
)	-	537	O
.	-	538	O

Finally	11385188	540	O
,	-	547	O
resting	-	549	O
and	-	557	O
peak	-	561	O
exercise	-	566	O
abnormal	-	575	B
left	-	584	I
ventricular	-	589	I
filling	-	601	I
was	-	609	O
detected	-	613	O
in	-	622	O
38	-	625	O
and	-	628	O
35	-	632	O
%	-	634	O
of	-	636	O
patients	-	639	O
as	-	648	O
compared	-	651	O
to	-	660	O
19	-	663	O
and	-	666	O
9	-	670	O
%	-	671	O
of	-	673	O
controls	-	676	O
,	-	684	O
respectively	-	686	O
(	-	699	O
p	-	700	O
=	-	702	O
0	-	704	O
.	-	705	O
11	-	706	O
and	-	709	O
0	-	713	O
.	-	714	O
02	-	715	O
,	-	717	O
respectively	-	719	O
)	-	731	O
.	-	732	O

We	11385188	734	O
conclude	-	737	O
that	-	746	O
coronary	-	751	B
artery	-	760	I
or	-	767	I
myocardial	-	770	I
disease	-	781	I
is	-	789	O
common	-	792	O
(	-	799	O
38	-	800	O
%	-	802	O
)	-	803	O
in	-	805	O
young	-	808	O
asymptomatic	-	814	O
chronic	-	827	O
cocaine	-	835	O
users	-	843	O
.	-	848	O

Therefore	11385188	850	O
,	-	859	O
screening	-	861	O
ECG	-	871	O
and	-	875	O
echocardiography	-	879	O
may	-	896	O
be	-	900	O
warranted	-	903	O
in	-	913	O
these	-	916	O
patients	-	922	O
.	-	930	O

Cardioprotective	11395263	0	O
effects	-	17	O
of	-	25	O
Picrorrhiza	-	28	O
kurroa	-	40	O
against	-	47	O
isoproterenol	-	55	O
-	-	68	O
induced	-	69	O
myocardial	-	77	O
stress	-	88	O
in	-	95	O
rats	-	98	O
.	-	102	O

The	11395263	104	O
cardioprotective	-	108	O
effect	-	125	O
of	-	132	O
the	-	135	O
ethanol	-	139	O
extract	-	147	O
of	-	155	O
Picrorrhiza	-	158	O
kurroa	-	170	O
rhizomes	-	177	O
and	-	186	O
roots	-	190	O
(	-	196	O
PK	-	197	O
)	-	199	O
on	-	201	O
isoproterenol	-	204	O
-	-	217	O
induced	-	218	O
myocardial	-	226	B
infarction	-	237	I
in	-	248	O
rats	-	251	O
with	-	256	O
respect	-	261	O
to	-	269	O
lipid	-	272	O
metabolism	-	278	O
in	-	289	O
serum	-	292	O
and	-	298	O
heart	-	302	O
tissue	-	308	O
has	-	315	O
been	-	319	O
investigated	-	324	O
.	-	336	O

Oral	11395263	338	O
pre	-	343	O
-	-	346	O
treatment	-	347	O
with	-	357	O
PK	-	362	O
(	-	365	O
80	-	366	O
mg	-	369	O
kg	-	372	O
(	-	374	O
-	-	375	O
1	-	376	O
)	-	377	O

day	11395263	379	O
(	-	382	O
-	-	383	O
1	-	384	O
)	-	385	O
for	-	387	O
15	-	391	O
days	-	394	O
)	-	398	O
significantly	-	400	O
prevented	-	414	O
the	-	424	O
isoproterenol	-	428	O
-	-	441	O
induced	-	442	O
myocardial	-	450	B
infarction	-	461	I
and	-	472	O
maintained	-	476	O
the	-	487	O
rats	-	491	O
at	-	496	O
near	-	499	O
normal	-	504	O
status	-	511	O
.	-	517	O

Phase	11401944	0	O
2	-	6	O
early	-	8	O
afterdepolarization	-	14	O
as	-	34	O
a	-	37	O
trigger	-	39	O
of	-	47	O
polymorphic	-	50	O
ventricular	-	62	B
tachycardia	-	74	I
in	-	86	O
acquired	-	89	O
long	-	98	B
-	-	102	I
QT	-	103	I
syndrome	-	106	I
:	-	115	O
direct	-	117	O
evidence	-	124	O
from	-	133	O
intracellular	-	138	O
recordings	-	152	O
in	-	163	O
the	-	166	O
intact	-	170	O
left	-	177	O
ventricular	-	182	O
wall	-	194	O
.	-	198	O

BACKGROUND	11401944	200	O
:	-	210	O

This	11401944	212	O
study	-	217	O
examined	-	223	O
the	-	232	O
role	-	236	O
of	-	241	O
phase	-	244	O
2	-	250	O
early	-	252	O
afterdepolarization	-	258	O
(	-	278	O
EAD	-	279	O
)	-	282	O
in	-	284	O
producing	-	287	O
a	-	297	O
trigger	-	299	O
to	-	307	O
initiate	-	310	O
torsade	-	319	B
de	-	327	I
pointes	-	330	I
(	-	338	O
TdP	-	339	B
)	-	342	O
with	-	344	O
QT	-	349	B
prolongation	-	352	I
induced	-	365	O
by	-	373	O
dl	-	376	O
-	-	378	O
sotalol	-	379	O
and	-	387	O
azimilide	-	391	O
.	-	400	O

The	11401944	402	O
contribution	-	406	O
of	-	419	O
transmural	-	422	O
dispersion	-	433	O
of	-	444	O
repolarization	-	447	O
(	-	462	O
TDR	-	463	O
)	-	466	O
to	-	468	O
transmural	-	471	O
propagation	-	482	O
of	-	494	O
EAD	-	497	O
and	-	501	O
the	-	505	O
maintenance	-	509	O
of	-	521	O
TdP	-	524	B
was	-	528	O
also	-	532	O
evaluated	-	537	O
.	-	546	O

METHODS	11401944	548	O
AND	-	556	O
RESULTS	-	560	O
:	-	567	O

Transmembrane	11401944	569	O
action	-	583	O
potentials	-	590	O
from	-	601	O
epicardium	-	606	O
,	-	616	O
midmyocardium	-	618	O
,	-	631	O
and	-	633	O
endocardium	-	637	O
were	-	649	O
recorded	-	654	O
simultaneously	-	663	O
,	-	677	O
together	-	679	O
with	-	688	O
a	-	693	O
transmural	-	695	O
ECG	-	706	O
,	-	709	O
in	-	711	O
arterially	-	714	O
perfused	-	725	O
canine	-	734	O
and	-	741	O
rabbit	-	745	O
left	-	752	O
ventricular	-	757	O
preparations	-	769	O
.	-	781	O

dl	11401944	783	O
-	-	785	O
Sotalol	-	786	O
preferentially	-	794	O
prolonged	-	809	O
action	-	819	O
potential	-	826	O
duration	-	836	O
(	-	845	O
APD	-	846	O
)	-	849	O
in	-	851	O
M	-	854	O
cells	-	856	O
dose	-	862	O
-	-	866	O
dependently	-	867	O
(	-	879	O
1	-	880	O
to	-	882	O
100	-	885	O
micromol	-	889	O
/	-	897	O
L	-	898	O
)	-	899	O
,	-	900	O
leading	-	902	O
to	-	910	O
QT	-	913	B
prolongation	-	916	I
and	-	929	O
an	-	933	O
increase	-	936	O
in	-	945	O
TDR	-	948	O
.	-	951	O

Azimilide	11401944	953	O
,	-	962	O
however	-	964	O
,	-	971	O
significantly	-	973	O
prolonged	-	987	O
APD	-	997	O
and	-	1001	O
QT	-	1005	O
interval	-	1008	O
at	-	1017	O
concentrations	-	1020	O
from	-	1035	O
0	-	1040	O
.	-	1041	O
1	-	1042	O
to	-	1044	O
10	-	1047	O
micromol	-	1050	O
/	-	1058	O
L	-	1059	O
but	-	1061	O
shortened	-	1065	O
them	-	1075	O
at	-	1080	O
30	-	1083	O
micromol	-	1086	O
/	-	1094	O
L	-	1095	O
.	-	1096	O

Unlike	11401944	1098	O
dl	-	1105	O
-	-	1107	O
sotalol	-	1108	O
,	-	1115	O
azimilide	-	1117	O
(	-	1127	O
>	-	1128	O
3	-	1129	O
micromol	-	1131	O
/	-	1139	O
L	-	1140	O
)	-	1141	O

increased	11401944	1143	O
epicardial	-	1153	O
APD	-	1164	O
markedly	-	1168	O
,	-	1176	O
causing	-	1178	O
a	-	1186	O
diminished	-	1188	O
TDR	-	1199	O
.	-	1202	O

Although	11401944	1204	O
both	-	1213	O
dl	-	1218	O
-	-	1220	O
sotalol	-	1221	O
and	-	1229	O
azimilide	-	1233	O
rarely	-	1243	O
induced	-	1250	O
EADs	-	1258	O
in	-	1263	O
canine	-	1266	O
left	-	1273	O
ventricles	-	1278	O
,	-	1288	O
they	-	1290	O
produced	-	1295	O
frequent	-	1304	O
EADs	-	1313	O
in	-	1318	O
rabbits	-	1321	O
,	-	1328	O
in	-	1330	O
which	-	1333	O
more	-	1339	O
pronounced	-	1344	O
QT	-	1355	B
prolongation	-	1358	I
was	-	1371	O
seen	-	1375	O
.	-	1379	O

An	11401944	1381	O
increase	-	1384	O
in	-	1393	O
TDR	-	1396	O
by	-	1400	O
dl	-	1403	O
-	-	1405	O
sotalol	-	1406	O
facilitated	-	1414	O
transmural	-	1426	O
propagation	-	1437	O
of	-	1449	O
EADs	-	1452	O
that	-	1457	O
initiated	-	1462	O
multiple	-	1472	O
episodes	-	1481	O
of	-	1490	O
spontaneous	-	1493	O
TdP	-	1505	B
in	-	1509	O
3	-	1512	O
of	-	1514	O
6	-	1517	O
rabbit	-	1519	O
left	-	1526	O
ventricles	-	1531	O
.	-	1541	O

Of	11401944	1543	O
note	-	1546	O
,	-	1550	O
although	-	1552	O
azimilide	-	1561	O
(	-	1571	O
3	-	1572	O
to	-	1574	O
10	-	1577	O
micromol	-	1580	O
/	-	1588	O
L	-	1589	O
)	-	1590	O
increased	-	1592	O
APD	-	1602	O
more	-	1606	O
than	-	1611	O
dl	-	1616	O
-	-	1618	O
sotalol	-	1619	O
,	-	1626	O
its	-	1628	O
EADs	-	1632	O
often	-	1637	O
failed	-	1643	O
to	-	1650	O
propagate	-	1653	O
transmurally	-	1663	O
,	-	1675	O
probably	-	1677	O
because	-	1686	O
of	-	1694	O
a	-	1697	O
diminished	-	1699	O
TDR	-	1710	O
.	-	1713	O

CONCLUSIONS	11401944	1715	O
:	-	1726	O

This	11401944	1728	O
study	-	1733	O
provides	-	1739	O
the	-	1748	O
first	-	1752	O
direct	-	1758	O
evidence	-	1765	O
from	-	1774	O
intracellular	-	1779	O
action	-	1793	O
potential	-	1800	O
recordings	-	1810	O
that	-	1821	O
phase	-	1826	O
2	-	1832	O
EAD	-	1834	O
can	-	1838	O
be	-	1842	O
generated	-	1845	O
from	-	1855	O
intact	-	1860	O
ventricular	-	1867	O
wall	-	1879	O
and	-	1884	O
produce	-	1888	O
a	-	1896	O
trigger	-	1898	O
to	-	1906	O
initiate	-	1909	O
the	-	1918	O
onset	-	1922	O
of	-	1928	O
TdP	-	1931	B
under	-	1935	O
QT	-	1941	B
prolongation	-	1944	I
.	-	1956	O

Prenatal	11425091	0	O
cocaine	-	9	O
exposure	-	17	O
and	-	26	O
cranial	-	30	O
sonographic	-	38	O
findings	-	50	O
in	-	59	O
preterm	-	62	B
infants	-	70	I
.	-	77	O

PURPOSE	11425091	79	O
:	-	86	O

Prenatal	11425091	88	O
cocaine	-	97	O
exposure	-	105	O
has	-	114	O
been	-	118	O
linked	-	123	O
with	-	130	O
subependymal	-	135	O
hemorrhage	-	148	B
and	-	159	O
the	-	163	O
formation	-	167	O
of	-	177	O
cysts	-	180	B
that	-	186	O
are	-	191	O
detectable	-	195	O
on	-	206	O
cranial	-	209	O
sonography	-	217	O
in	-	228	O
neonates	-	231	O
born	-	240	O
at	-	245	O
term	-	248	O
.	-	252	O

We	11425091	254	O
sought	-	257	O
to	-	264	O
determine	-	267	O
if	-	277	O
prenatal	-	280	O
cocaine	-	289	O
exposure	-	297	O
increases	-	306	O
the	-	316	O
incidence	-	320	O
of	-	330	O
subependymal	-	333	B
cysts	-	346	I
in	-	352	O
preterm	-	355	B
infants	-	363	I
.	-	370	O

METHODS	11425091	372	O
:	-	379	O

We	11425091	381	O
retrospectively	-	384	O
reviewed	-	400	O
the	-	409	O
medical	-	413	O
records	-	421	O
and	-	429	O
cranial	-	433	O
sonograms	-	441	O
obtained	-	451	O
during	-	460	O
a	-	467	O
1	-	469	O
-	-	470	O
year	-	471	O
period	-	476	O
on	-	483	O
122	-	486	O
premature	-	490	B
(	-	500	I
<	-	501	I
36	-	503	I
weeks	-	506	I
of	-	512	I
gestation	-	515	I
)	-	524	I
infants	-	526	I
.	-	533	O

Infants	11425091	535	O
were	-	543	O
categorized	-	548	O
into	-	560	O
1	-	565	O
of	-	567	O
2	-	570	O
groups	-	572	O
:	-	578	O
those	-	580	O
exposed	-	586	O
to	-	594	O
cocaine	-	597	O
and	-	605	O
those	-	609	O
not	-	615	O
exposed	-	619	O
to	-	627	O
cocaine	-	630	O
.	-	637	O

Infants	11425091	639	O
were	-	647	O
assigned	-	652	O
to	-	661	O
the	-	664	O
cocaine	-	668	O
-	-	675	O
exposed	-	676	O
group	-	684	O
if	-	690	O
there	-	693	O
was	-	699	O
a	-	703	O
maternal	-	705	O
history	-	714	O
of	-	722	O
cocaine	-	725	B
abuse	-	733	I
during	-	739	O
pregnancy	-	746	O
or	-	756	O
if	-	759	O
maternal	-	762	O
or	-	771	O
neonatal	-	774	O
urine	-	783	O
toxicology	-	789	O
results	-	800	O
were	-	808	O
positive	-	813	O
at	-	822	O
the	-	825	O
time	-	829	O
of	-	834	O
delivery	-	837	O
.	-	845	O

RESULTS	11425091	847	O
:	-	854	O

Five	11425091	856	O
of	-	861	O
the	-	864	O
122	-	868	O
infants	-	872	O
were	-	880	O
excluded	-	885	O
from	-	894	O
the	-	899	O
study	-	903	O
because	-	909	O
of	-	917	O
insufficient	-	920	O
medical	-	933	O
and	-	941	O
drug	-	945	O
histories	-	950	O
.	-	959	O

The	11425091	961	O
incidence	-	965	O
of	-	975	O
subependymal	-	978	B
cysts	-	991	I
in	-	997	O
the	-	1000	O
117	-	1004	O
remaining	-	1008	O
infants	-	1018	O
was	-	1026	O
14	-	1030	O
%	-	1032	O
(	-	1034	O
16	-	1035	O
of	-	1038	O
117	-	1041	O
)	-	1044	O
.	-	1045	O

The	11425091	1047	O
incidence	-	1051	O
of	-	1061	O
subependymal	-	1064	B
cysts	-	1077	I
in	-	1083	O
infants	-	1086	O
exposed	-	1094	O
to	-	1102	O
cocaine	-	1105	O
prenatally	-	1113	O
was	-	1124	O
44	-	1128	O
%	-	1130	O
(	-	1132	O
8	-	1133	O
of	-	1135	O
18	-	1138	O
)	-	1140	O
compared	-	1142	O
with	-	1151	O
8	-	1156	O
%	-	1157	O
(	-	1159	O
8	-	1160	O
of	-	1162	O
99	-	1165	O
)	-	1167	O
in	-	1169	O
the	-	1172	O
unexposed	-	1176	O
group	-	1186	O
(	-	1192	O
p	-	1193	O
<	-	1195	O
0	-	1197	O
.	-	1198	O
01	-	1199	O
)	-	1201	O
.	-	1202	O

CONCLUSIONS	11425091	1204	O
:	-	1215	O

We	11425091	1217	O
found	-	1220	O
an	-	1226	O
increased	-	1229	O
incidence	-	1239	O
of	-	1249	O
subependymal	-	1252	B
cyst	-	1265	I
formation	-	1270	O
in	-	1280	O
preterm	-	1283	B
infants	-	1291	I
who	-	1299	O
were	-	1303	O
exposed	-	1308	O
to	-	1316	O
cocaine	-	1319	O
prenatally	-	1327	O
.	-	1337	O

This	11425091	1339	O
result	-	1344	O
is	-	1351	O
consistent	-	1354	O
with	-	1365	O
results	-	1370	O
of	-	1378	O
similar	-	1381	O
studies	-	1389	O
in	-	1397	O
term	-	1400	O
infants	-	1405	O
.	-	1412	O

Thalidomide	11439380	0	O
neuropathy	-	12	B
in	-	23	O
patients	-	26	O
treated	-	35	O
for	-	43	O
metastatic	-	47	O
prostate	-	58	B
cancer	-	67	I
.	-	73	O

We	11439380	75	O
prospectively	-	78	O
evaluated	-	92	O
thalidomide	-	102	O
-	-	113	O
induced	-	114	O
neuropathy	-	122	B
using	-	133	O
electrodiagnostic	-	139	O
studies	-	157	O
.	-	164	O

Sixty	11439380	166	O
-	-	171	O
seven	-	172	O
men	-	178	O
with	-	182	O
metastatic	-	187	O
androgen	-	198	O
-	-	206	O
independent	-	207	O
prostate	-	219	B
cancer	-	228	I
in	-	235	O
an	-	238	O
open	-	241	O
-	-	245	O
label	-	246	O
trial	-	252	O
of	-	258	O
oral	-	261	O
thalidomide	-	266	O
underwent	-	278	O
neurologic	-	288	O
examinations	-	299	O
and	-	312	O
nerve	-	316	O
conduction	-	322	O
studies	-	333	O
(	-	341	O
NCS	-	342	O
)	-	345	O
prior	-	347	O
to	-	353	O
and	-	356	O
at	-	360	O
3	-	363	O
-	-	364	O
month	-	365	O
intervals	-	371	O
during	-	381	O
treatment	-	388	O
.	-	397	O

NCS	11439380	399	O
included	-	403	O
recording	-	412	O
of	-	422	O
sensory	-	425	O
nerve	-	433	O
action	-	439	O
potentials	-	446	O
(	-	457	O
SNAPs	-	458	O
)	-	463	O
from	-	465	O
median	-	470	O
,	-	476	O
radial	-	478	O
,	-	484	O
ulnar	-	486	O
,	-	491	O
and	-	493	O
sural	-	497	O
nerves	-	503	O
.	-	509	O

SNAP	11439380	511	O
amplitudes	-	516	O
for	-	527	O
each	-	531	O
nerve	-	536	O
were	-	542	O
expressed	-	547	O
as	-	557	O
the	-	560	O
percentage	-	564	O
of	-	575	O
its	-	578	O
baseline	-	582	O
,	-	590	O
and	-	592	O
the	-	596	O
mean	-	600	O
of	-	605	O
the	-	608	O
four	-	612	O
was	-	617	O
termed	-	621	O
the	-	628	O
SNAP	-	632	O
index	-	637	O
.	-	642	O

A	11439380	644	O
40	-	646	O
%	-	648	O
decline	-	650	O
in	-	658	O
the	-	661	O
SNAP	-	665	O
index	-	670	O
was	-	676	O
considered	-	680	O
clinically	-	691	O
significant	-	702	O
.	-	713	O

Thalidomide	11439380	715	O
was	-	727	O
discontinued	-	731	O
in	-	744	O
55	-	747	O
patients	-	750	O
for	-	759	O
lack	-	763	O
of	-	768	O
therapeutic	-	771	O
response	-	783	O
.	-	791	O

Of	11439380	793	O
67	-	796	O
patients	-	799	O
initially	-	808	O
enrolled	-	818	O
,	-	826	O
24	-	828	O
remained	-	831	O
on	-	840	O
thalidomide	-	843	O
for	-	855	O
3	-	859	O
months	-	861	O
,	-	867	O
8	-	869	O
remained	-	871	O
at	-	880	O
6	-	883	O
months	-	885	O
,	-	891	O
and	-	893	O
3	-	897	O
remained	-	899	O
at	-	908	O
9	-	911	O
months	-	913	O
.	-	919	O

Six	11439380	921	O
patients	-	925	O
developed	-	934	O
neuropathy	-	944	B
.	-	954	O

Clinical	11439380	956	O
symptoms	-	965	O
and	-	974	O
a	-	978	O
decline	-	980	O
in	-	988	O
the	-	991	O
SNAP	-	995	O
index	-	1000	O
occurred	-	1006	O
concurrently	-	1015	O
.	-	1027	O

Older	11439380	1029	O
age	-	1035	O
and	-	1039	O
cumulative	-	1043	O
dose	-	1054	O
were	-	1059	O
possible	-	1064	O
contributing	-	1073	O
factors	-	1086	O
.	-	1093	O

Neuropathy	11439380	1095	B
may	-	1106	O
thus	-	1110	O
be	-	1115	O
a	-	1118	O
common	-	1120	O
complication	-	1127	O
of	-	1140	O
thalidomide	-	1143	O
in	-	1155	O
older	-	1158	O
patients	-	1164	O
.	-	1172	O

The	11439380	1174	O
SNAP	-	1178	O
index	-	1183	O
can	-	1189	O
be	-	1193	O
used	-	1196	O
to	-	1201	O
monitor	-	1204	O
peripheral	-	1212	B
neuropathy	-	1223	I
,	-	1233	O
but	-	1235	O
not	-	1239	O
for	-	1243	O
early	-	1247	O
detection	-	1253	O
.	-	1262	O

Overexpression	11474137	0	O
of	-	15	O
copper	-	18	O
/	-	24	O
zinc	-	25	O
-	-	29	O
superoxide	-	30	O
dismutase	-	41	O
protects	-	51	O
from	-	60	O
kanamycin	-	65	O
-	-	74	O
induced	-	75	O
hearing	-	83	B
loss	-	91	I
.	-	95	O

The	11474137	97	O
participation	-	101	O
of	-	115	O
reactive	-	118	O
oxygen	-	127	O
species	-	134	O
in	-	142	O
aminoglycoside	-	145	O
-	-	159	O
induced	-	160	O
ototoxicity	-	168	B
has	-	180	O
been	-	184	O
deduced	-	189	O
from	-	197	O
observations	-	202	O
that	-	215	O
aminoglycoside	-	220	O
-	-	234	O
iron	-	235	O
complexes	-	240	O
catalyze	-	250	O
the	-	259	O
formation	-	263	O
of	-	273	O
superoxide	-	276	O
radicals	-	287	O
in	-	296	O
vitro	-	299	O
and	-	305	O
that	-	309	O
antioxidants	-	314	O
attenuate	-	327	O
ototoxicity	-	337	B
in	-	349	O
vivo	-	352	O
.	-	356	O

We	11474137	358	O
therefore	-	361	O
hypothesized	-	371	O
that	-	384	O
overexpression	-	389	O
of	-	404	O
Cu	-	407	O
/	-	409	O
Zn	-	410	O
-	-	412	O
superoxide	-	413	O
dismutase	-	424	O
(	-	434	O
h	-	435	O
-	-	436	O
SOD1	-	437	O
)	-	441	O
should	-	443	O
protect	-	450	O
transgenic	-	458	O
mice	-	469	O
from	-	474	O
ototoxicity	-	479	B
.	-	490	O

Immunocytochemistry	11474137	492	O
confirmed	-	512	O
expression	-	522	O
of	-	533	O
h	-	536	O
-	-	537	O
SOD1	-	538	O
in	-	543	O
inner	-	546	O
ear	-	552	O
tissues	-	556	O
of	-	564	O
transgenic	-	567	O
C57BL	-	578	O
/	-	583	O
6	-	584	O
-	-	585	O
TgN	-	586	O
[	-	589	O
SOD1	-	590	O
]	-	594	O
3Cje	-	595	O
mice	-	600	O
.	-	604	O

Transgenic	11474137	606	O
and	-	617	O
nontransgenic	-	621	O
littermates	-	635	O
received	-	647	O
kanamycin	-	656	O
(	-	666	O
400	-	667	O
mg	-	671	O
/	-	673	O
kg	-	674	O
body	-	677	O
weight	-	682	O
/	-	688	O
day	-	689	O
)	-	692	O
for	-	694	O
10	-	698	O
days	-	701	O
beginning	-	706	O
on	-	716	O
day	-	719	O
10	-	723	O
after	-	726	O
birth	-	732	O
.	-	737	O

Auditory	11474137	739	O
thresholds	-	748	O
were	-	759	O
tested	-	764	O
by	-	771	O
evoked	-	774	O
auditory	-	781	O
brain	-	790	O
stem	-	796	O
responses	-	801	O
at	-	811	O
1	-	814	O
month	-	816	O
after	-	822	O
birth	-	828	O
.	-	833	O

In	11474137	835	O
nontransgenic	-	838	O
animals	-	852	O
,	-	859	O
the	-	861	O
threshold	-	865	O
in	-	875	O
the	-	878	O
kanamycin	-	882	O
-	-	891	O
treated	-	892	O
group	-	900	O
was	-	906	O
45	-	910	O
-	-	912	O
50	-	913	O
dB	-	916	O
higher	-	919	O
than	-	926	O
in	-	931	O
saline	-	934	O
-	-	940	O
injected	-	941	O
controls	-	950	O
.	-	958	O

In	11474137	960	O
the	-	963	O
transgenic	-	967	O
group	-	978	O
,	-	983	O
kanamycin	-	985	O
increased	-	995	O
the	-	1005	O
threshold	-	1009	O
by	-	1019	O
only	-	1022	O
15	-	1027	O
dB	-	1030	O
over	-	1033	O
the	-	1038	O
respective	-	1042	O
controls	-	1053	O
.	-	1061	O

The	11474137	1063	O
effects	-	1067	O
were	-	1075	O
similar	-	1080	O
at	-	1088	O
12	-	1091	O
and	-	1094	O
24	-	1098	O
kHz	-	1101	O
.	-	1104	O

The	11474137	1106	O
protection	-	1110	O
by	-	1121	O
overexpression	-	1124	O
of	-	1139	O
superoxide	-	1142	O
dismutase	-	1153	O
supports	-	1163	O
the	-	1172	O
hypothesis	-	1176	O
that	-	1187	O
oxidant	-	1192	O
stress	-	1200	O
plays	-	1207	O
a	-	1213	O
significant	-	1215	O
role	-	1227	O
in	-	1232	O
aminoglycoside	-	1235	O
-	-	1249	O
induced	-	1250	O
ototoxicity	-	1258	B
.	-	1269	O

The	11474137	1271	O
results	-	1275	O
also	-	1283	O
suggest	-	1288	O
transgenic	-	1296	O
animals	-	1307	O
as	-	1315	O
suitable	-	1318	O
models	-	1327	O
to	-	1334	O
investigate	-	1337	O
the	-	1349	O
underlying	-	1353	O
mechanisms	-	1364	O
and	-	1375	O
possible	-	1379	O
strategies	-	1388	O
for	-	1399	O
prevention	-	1403	O
.	-	1413	O

Prednisone	11708428	0	O
induces	-	11	O
anxiety	-	19	B
and	-	27	O
glial	-	31	O
cerebral	-	37	O
changes	-	46	O
in	-	54	O
rats	-	57	O
.	-	61	O

OBJECTIVE	11708428	63	O
:	-	72	O
To	-	74	O
assess	-	77	O
whether	-	84	O
prednisone	-	92	O
(	-	103	O
PDN	-	104	O
)	-	107	O
produces	-	109	O
anxiety	-	118	B
and	-	126	O
/	-	129	O
or	-	130	O
cerebral	-	133	O
glial	-	142	O
changes	-	148	O
in	-	156	O
rats	-	159	O
.	-	163	O

METHODS	11708428	165	O
:	-	172	O

Male	11708428	174	O
Wistar	-	179	O
rats	-	186	O
were	-	191	O
studied	-	196	O
and	-	204	O
3	-	208	O
groups	-	210	O
were	-	217	O
formed	-	222	O
(	-	229	O
8	-	230	O
rats	-	232	O
per	-	237	O
group	-	241	O
)	-	246	O
.	-	247	O

The	11708428	249	O
moderate	-	253	O
-	-	261	O
dose	-	262	O
group	-	267	O
received	-	273	O
5	-	282	O
mg	-	284	O
/	-	286	O
kg	-	287	O
/	-	289	O
day	-	290	O
PDN	-	294	O
released	-	298	O
from	-	307	O
a	-	312	O
subcutaneous	-	314	O
implant	-	327	O
.	-	334	O

In	11708428	336	O
the	-	339	O
high	-	343	O
-	-	347	O
dose	-	348	O
group	-	353	O
,	-	358	O
implants	-	360	O
containing	-	369	O
PDN	-	380	O
equivalent	-	384	O
to	-	395	O
60	-	398	O
mg	-	401	O
/	-	403	O
kg	-	404	O
/	-	406	O
day	-	407	O
were	-	411	O
applied	-	416	O
.	-	423	O

In	11708428	425	O
the	-	428	O
control	-	432	O
group	-	440	O
implants	-	446	O
contained	-	455	O
no	-	465	O
PDN	-	468	O
.	-	471	O

Anxiety	11708428	473	B
was	-	481	O
assessed	-	485	O
using	-	494	O
an	-	500	O
open	-	503	O
field	-	508	O
and	-	514	O
elevated	-	518	O
plus	-	527	O
-	-	531	O
maze	-	532	O
devices	-	537	O
.	-	544	O

The	11708428	546	O
number	-	550	O
of	-	557	O
cells	-	560	O
and	-	566	O
cytoplasmic	-	570	O
transformation	-	582	O
of	-	597	O
astrocytes	-	600	O
and	-	611	O
microglia	-	615	O
cells	-	625	O
were	-	631	O
assessed	-	636	O
by	-	645	O
immunohistochemical	-	648	O
analyses	-	668	O
.	-	676	O

RESULTS	11708428	678	O
:	-	685	O

Anxiety	11708428	687	B
was	-	695	O
documented	-	699	O
in	-	710	O
both	-	713	O
groups	-	718	O
of	-	725	O
PDN	-	728	O
treated	-	732	O
rats	-	740	O
compared	-	745	O
with	-	754	O
controls	-	759	O
.	-	767	O

The	11708428	769	O
magnitude	-	773	O
of	-	783	O
transformation	-	786	O
of	-	801	O
the	-	804	O
microglia	-	808	O
assessed	-	818	O
by	-	827	O
the	-	830	O
number	-	834	O
of	-	841	O
intersections	-	844	O
was	-	858	O
significantly	-	862	O
higher	-	876	O
in	-	883	O
the	-	886	O
PDN	-	890	O
groups	-	894	O
than	-	901	O
in	-	906	O
controls	-	909	O
in	-	918	O
the	-	921	O
prefrontal	-	925	O
cortex	-	936	O
(	-	943	O
moderate	-	944	O
-	-	952	O
dose	-	953	O
,	-	957	O
24	-	959	O
.	-	961	O
1	-	962	O
;	-	963	O
high	-	965	O
-	-	969	O
dose	-	970	O
,	-	974	O
23	-	976	O
.	-	978	O
6	-	979	O
;	-	980	O
controls	-	982	O
18	-	991	O
.	-	993	O
7	-	994	O
;	-	995	O
p	-	997	O
<	-	999	O
0	-	1001	O
.	-	1002	O
01	-	1003	O
)	-	1005	O
and	-	1007	O
striatum	-	1011	O
(	-	1020	O
moderate	-	1021	O
-	-	1029	O
dose	-	1030	O
25	-	1035	O
.	-	1037	O
6	-	1038	O
;	-	1039	O
high	-	1041	O
-	-	1045	O
dose	-	1046	O
26	-	1051	O
.	-	1053	O
3	-	1054	O
;	-	1055	O
controls	-	1057	O
18	-	1066	O
.	-	1068	O
9	-	1069	O
;	-	1070	O
p	-	1072	O
<	-	1074	O
0	-	1076	O
.	-	1077	O
01	-	1078	O
)	-	1080	O
,	-	1081	O
but	-	1083	O
not	-	1087	O
in	-	1091	O
hippocampus	-	1094	O
.	-	1105	O

The	11708428	1107	O
number	-	1111	O
of	-	1118	O
stained	-	1121	O
microglia	-	1129	O
cells	-	1139	O
was	-	1145	O
significantly	-	1149	O
higher	-	1163	O
in	-	1170	O
the	-	1173	O
PDN	-	1177	O
treated	-	1181	O
groups	-	1189	O
in	-	1196	O
the	-	1199	O
prefrontal	-	1203	O
cortex	-	1214	O
than	-	1221	O
in	-	1226	O
controls	-	1229	O
(	-	1238	O
moderate	-	1239	O
-	-	1247	O
dose	-	1248	O
,	-	1252	O
29	-	1254	O
.	-	1256	O
1	-	1257	O
;	-	1258	O
high	-	1260	O
-	-	1264	O
dose	-	1265	O
,	-	1269	O
28	-	1271	O
.	-	1273	O
4	-	1274	O
;	-	1275	O
control	-	1277	O
,	-	1284	O
17	-	1286	O
.	-	1288	O
7	-	1289	O
cells	-	1291	O
per	-	1297	O
field	-	1301	O
;	-	1306	O
p	-	1308	O
<	-	1310	O
0	-	1312	O
.	-	1313	O
01	-	1314	O
)	-	1316	O
.	-	1317	O

Stained	11708428	1319	O
microglia	-	1327	O
cells	-	1337	O
were	-	1343	O
significantly	-	1348	O
more	-	1362	O
numerous	-	1367	O
striatum	-	1376	O
and	-	1385	O
hippocampus	-	1389	O
in	-	1401	O
the	-	1404	O
high	-	1408	O
-	-	1412	O
dose	-	1413	O
group	-	1418	O
compared	-	1424	O
to	-	1433	O
controls	-	1436	O
.	-	1444	O

CONCLUSION	11708428	1446	O
:	-	1456	O

Subacute	11708428	1458	O
exposure	-	1467	O
to	-	1476	O
PDN	-	1479	O
induced	-	1483	O
anxiety	-	1491	B
and	-	1499	O
reactivity	-	1503	O
of	-	1514	O
microglia	-	1517	O
.	-	1526	O

The	11708428	1528	O
relevance	-	1532	O
of	-	1542	O
these	-	1545	O
features	-	1551	O
for	-	1560	O
patients	-	1564	O
using	-	1573	O
PDN	-	1579	O
remains	-	1583	O
to	-	1591	O
be	-	1594	O
elucidated	-	1597	O
.	-	1607	O

Phase	11745287	0	O
II	-	6	O
study	-	9	O
of	-	15	O
carboplatin	-	18	O
and	-	30	O
liposomal	-	34	O
doxorubicin	-	44	O
in	-	56	O
patients	-	59	O
with	-	68	O
recurrent	-	73	O
squamous	-	83	B
cell	-	92	I
carcinoma	-	97	I
of	-	107	I
the	-	110	I
cervix	-	114	I
.	-	120	O

BACKGROUND	11745287	122	O
:	-	132	O

The	11745287	134	O
activity	-	138	O
of	-	147	O
the	-	150	O
combination	-	154	O
of	-	166	O
carboplatin	-	169	O
and	-	181	O
liposomal	-	185	O
doxorubicin	-	195	O
was	-	207	O
tested	-	211	O
in	-	218	O
a	-	221	O
Phase	-	223	O
II	-	229	O
study	-	232	O
of	-	238	O
patients	-	241	O
with	-	250	O
recurrent	-	255	O
cervical	-	265	B
carcinoma	-	274	I
.	-	283	O

METHODS	11745287	285	O
:	-	292	O

The	11745287	294	O
combination	-	298	O
of	-	310	O
carboplatin	-	313	O
(	-	325	O
area	-	326	O
under	-	331	O
the	-	337	O
concentration	-	341	O
curve	-	355	O
[	-	361	O
AUC	-	362	O
]	-	365	O
,	-	366	O
5	-	368	O
)	-	369	O
and	-	371	O
liposomal	-	375	O
doxorubicin	-	385	O

(	11745287	397	O
Doxil	-	398	O
;	-	403	O
starting	-	405	O
dose	-	414	O
,	-	418	O
40	-	420	O
mg	-	423	O
/	-	425	O
m	-	426	O
(	-	427	O
2	-	428	O
)	-	429	O
)	-	430	O
was	-	432	O
administered	-	436	O
intravenously	-	449	O
every	-	463	O
28	-	469	O
days	-	472	O
to	-	477	O
37	-	480	O
patients	-	483	O
with	-	492	O
recurrent	-	497	O
squamous	-	507	B
cell	-	516	I
cervical	-	521	I
carcinoma	-	530	I
to	-	540	O
determine	-	543	O
antitumor	-	553	O
activity	-	563	O
and	-	572	O
toxicity	-	576	B
profile	-	585	O
.	-	592	O

RESULTS	11745287	594	O
:	-	601	O

Twenty	11745287	603	O
-	-	609	O
nine	-	610	O
patients	-	615	O
were	-	624	O
assessable	-	629	O
for	-	640	O
response	-	644	O
,	-	652	O
and	-	654	O
35	-	658	O
patients	-	661	O
were	-	670	O
assessable	-	675	O
for	-	686	O
toxicity	-	690	B
.	-	698	O

The	11745287	700	O
overall	-	704	O
response	-	712	O
rate	-	721	O
was	-	726	O
38	-	730	O
%	-	732	O
,	-	733	O
the	-	735	O
median	-	739	O
time	-	746	O
to	-	751	O
response	-	754	O
was	-	763	O
10	-	767	O
weeks	-	770	O
,	-	775	O
the	-	777	O
median	-	781	O
duration	-	788	O
of	-	797	O
response	-	800	O
was	-	809	O
26	-	813	O
weeks	-	816	O
,	-	821	O
and	-	823	O
the	-	827	O
median	-	831	O
survival	-	838	O
was	-	847	O
37	-	851	O
weeks	-	854	O
.	-	859	O

The	11745287	861	O
main	-	865	O
toxic	-	870	O
effect	-	876	O
was	-	883	O
myelosuppression	-	887	B
,	-	903	O
with	-	905	O
Grade	-	910	O
3	-	916	O
and	-	918	O
4	-	922	O
neutropenia	-	924	B
in	-	936	O
16	-	939	O
patients	-	942	O
,	-	950	O
anemia	-	952	B
in	-	959	O
12	-	962	O
patients	-	965	O
,	-	973	O
thrombocytopenia	-	975	B
in	-	992	O
11	-	995	O
patients	-	998	O
,	-	1006	O
and	-	1008	O
neutropenic	-	1012	B
fever	-	1024	I
in	-	1030	O
3	-	1033	O
patients	-	1035	O
.	-	1043	O

Four	11745287	1045	O
patients	-	1050	O
had	-	1059	O
five	-	1063	O
infusion	-	1068	O
-	-	1076	O
related	-	1077	O
reactions	-	1085	O
during	-	1095	O
the	-	1102	O
infusion	-	1106	O
of	-	1115	O
liposomal	-	1118	O
doxorubicin	-	1128	O
,	-	1139	O
leading	-	1141	O
to	-	1149	O
treatment	-	1152	O
discontinuation	-	1162	O
in	-	1178	O
three	-	1181	O
patients	-	1187	O
.	-	1195	O

Grade	11745287	1197	O
>	-	1203	O
or	-	1205	O
=	-	1208	O
2	-	1210	O
nonhematologic	-	1212	O
toxicity	-	1227	B
included	-	1236	O
nausea	-	1245	B
in	-	1252	O
17	-	1255	O
patients	-	1258	O
,	-	1266	O
emesis	-	1268	B
in	-	1275	O
14	-	1278	O
patients	-	1281	O
,	-	1289	O
fatigue	-	1291	B
in	-	1299	O
9	-	1302	O
patients	-	1304	O
,	-	1312	O
mucositis	-	1314	B
and	-	1324	O
/	-	1327	O
or	-	1328	O
stomatitis	-	1331	B
in	-	1342	O
8	-	1345	O
patients	-	1347	O
,	-	1355	O
constipation	-	1357	B
in	-	1370	O
6	-	1373	O
patients	-	1375	O
,	-	1383	O
weight	-	1385	B
loss	-	1392	I
in	-	1397	O
5	-	1400	O
patients	-	1402	O
,	-	1410	O
hand	-	1412	B
-	-	1416	I
foot	-	1417	I
syndrome	-	1422	I
in	-	1431	O
2	-	1434	O
patients	-	1436	O
,	-	1444	O
and	-	1446	O
skin	-	1450	B
reactions	-	1455	I
in	-	1465	O
3	-	1468	O
patients	-	1470	O
.	-	1478	O

CONCLUSIONS	11745287	1480	O
:	-	1491	O

The	11745287	1493	O
combination	-	1497	O
of	-	1509	O
carboplatin	-	1512	O
and	-	1524	O
liposomal	-	1528	O
doxorubicin	-	1538	O
has	-	1550	O
modest	-	1554	O
activity	-	1561	O
in	-	1570	O
patients	-	1573	O
with	-	1582	O
recurrent	-	1587	O
cervical	-	1597	B
carcinoma	-	1606	I
.	-	1615	O

Antimicrobial	11799346	0	O
-	-	13	O
induced	-	14	O
mania	-	22	B
(	-	28	O
antibiomania	-	29	B
)	-	41	O
:	-	42	O
a	-	44	O
review	-	46	O
of	-	53	O
spontaneous	-	56	O
reports	-	68	O
.	-	75	O

The	11799346	77	O
authors	-	81	O
reviewed	-	89	O
reported	-	98	O
cases	-	107	O
of	-	113	O
antibiotic	-	116	O
-	-	126	O
induced	-	127	O
manic	-	135	B
episodes	-	141	O
by	-	150	O
means	-	153	O
of	-	159	O
a	-	162	O
MEDLINE	-	164	O
and	-	172	O
PsychLit	-	176	O
search	-	185	O
for	-	192	O
reports	-	196	O
of	-	204	O
antibiotic	-	207	O
-	-	217	O
induced	-	218	O
mania	-	226	B
.	-	231	O

Unpublished	11799346	233	O
reports	-	245	O
were	-	253	O
requested	-	258	O
from	-	268	O
the	-	273	O
World	-	277	O
Health	-	283	O
Organization	-	290	O
(	-	303	O
WHO	-	304	O
)	-	307	O
and	-	309	O
the	-	313	O
Food	-	317	O
and	-	322	O
Drug	-	326	O
Administration	-	331	O
(	-	346	O
FDA	-	347	O
)	-	350	O
.	-	351	O

Twenty	11799346	353	O
-	-	359	O
one	-	360	O
reports	-	364	O
of	-	372	O
antimicrobial	-	375	O
-	-	388	O
induced	-	389	O
mania	-	397	B
were	-	403	O
found	-	408	O
in	-	414	O
the	-	417	O
literature	-	421	O
.	-	431	O

There	11799346	433	O
were	-	439	O
6	-	444	O
cases	-	446	O
implicating	-	452	O
clarithromycin	-	464	O
,	-	478	O
13	-	480	O
implicating	-	483	O
isoniazid	-	495	O
,	-	504	O
and	-	506	O
1	-	510	O
case	-	512	O
each	-	517	O
implicating	-	522	O
erythromycin	-	534	O
and	-	547	O
amoxicillin	-	551	O
.	-	562	O

The	11799346	564	O
WHO	-	568	O
reported	-	572	O
82	-	581	O
cases	-	584	O
.	-	589	O

Of	11799346	591	O
these	-	594	O
,	-	599	O
clarithromycin	-	601	O
was	-	616	O
implicated	-	620	O
in	-	631	O
23	-	634	O
(	-	637	O
27	-	638	O
.	-	640	O
6	-	641	O
%	-	642	O
)	-	643	O
cases	-	645	O
,	-	650	O
ciprofloxacin	-	652	O
in	-	666	O
12	-	669	O
(	-	672	O
14	-	673	O
.	-	675	O
4	-	676	O
%	-	677	O
)	-	678	O
cases	-	680	O
,	-	685	O
and	-	687	O
ofloxacin	-	691	O
in	-	701	O
10	-	704	O
(	-	707	O
12	-	708	O
%	-	710	O
)	-	711	O
cases	-	713	O
.	-	718	O

Cotrimoxazole	11799346	720	O
,	-	733	O
metronidazole	-	735	O
,	-	748	O
and	-	750	O
erythromycin	-	754	O
were	-	767	O
involved	-	772	O
in	-	781	O
15	-	784	O
reported	-	787	O
manic	-	796	B
episodes	-	802	O
.	-	810	O

Cases	11799346	812	O
reported	-	818	O
by	-	827	O
the	-	830	O
FDA	-	834	O
showed	-	838	O
clarithromycin	-	845	O
and	-	860	O
ciprofloxacin	-	864	O
to	-	878	O
be	-	881	O
the	-	884	O
most	-	888	O
frequently	-	893	O
associated	-	904	O
with	-	915	O
the	-	920	O
development	-	924	O
of	-	936	O
mania	-	939	B
.	-	944	O

Statistical	11799346	946	O
analysis	-	958	O
of	-	967	O
the	-	970	O
data	-	974	O
would	-	979	O
not	-	985	O
have	-	989	O
demonstrated	-	994	O
a	-	1007	O
significant	-	1009	O
statistical	-	1021	O
correlative	-	1033	O
risk	-	1045	O
and	-	1050	O
was	-	1054	O
therefore	-	1058	O
not	-	1068	O
undertaken	-	1072	O
.	-	1082	O

Patients	11799346	1084	O
have	-	1093	O
an	-	1098	O
increased	-	1101	O
risk	-	1111	O
of	-	1116	O
developing	-	1119	O
mania	-	1130	B
while	-	1136	O
being	-	1142	O
treated	-	1148	O
with	-	1156	O
antimicrobials	-	1161	O
.	-	1175	O

Although	11799346	1177	O
this	-	1186	O
is	-	1191	O
not	-	1194	O
a	-	1198	O
statistically	-	1200	O
significant	-	1214	O
risk	-	1226	O
,	-	1230	O
physicians	-	1232	O
must	-	1243	O
be	-	1248	O
aware	-	1251	O
of	-	1257	O
the	-	1260	O
effect	-	1264	O
and	-	1271	O
reversibility	-	1275	O
.	-	1288	O

Further	11799346	1290	O
research	-	1298	O
clearly	-	1307	O
is	-	1315	O
required	-	1318	O
to	-	1327	O
determine	-	1330	O
the	-	1340	O
incidence	-	1344	O
of	-	1354	O
antimicrobial	-	1357	O
-	-	1370	O
induced	-	1371	O
mania	-	1379	B
,	-	1384	O
the	-	1386	O
relative	-	1390	O
risk	-	1399	O
factors	-	1404	O
of	-	1412	O
developing	-	1415	O
an	-	1426	O
antimicrobial	-	1429	O
-	-	1442	O
induced	-	1443	O
manic	-	1451	B
episode	-	1457	O
among	-	1465	O
various	-	1471	O
demographic	-	1479	O
populations	-	1491	O
,	-	1502	O
and	-	1504	O
the	-	1508	O
incidence	-	1512	O
of	-	1522	O
patients	-	1525	O
who	-	1534	O
continue	-	1538	O
to	-	1547	O
have	-	1550	O
persistent	-	1555	O
affective	-	1566	O
disorders	-	1576	O
once	-	1586	O
the	-	1591	O
initial	-	1595	O
episode	-	1603	O
,	-	1610	O
which	-	1612	O
occurs	-	1618	O
while	-	1625	O
the	-	1631	O
patient	-	1635	O
is	-	1643	O
taking	-	1646	O
antibiotics	-	1653	O
,	-	1664	O
subsides	-	1666	O
.	-	1674	O

The	11799346	1676	O
authors	-	1680	O
elected	-	1688	O
to	-	1696	O
name	-	1699	O
this	-	1704	O
syndrome	-	1709	O
""""	-	1718	O
antibiomania	-	1719	B
.	-	1731	O
""""	-	1732	O

Levodopa	11835460	0	O
-	-	8	O
induced	-	9	O
ocular	-	17	B
dyskinesias	-	24	I
in	-	36	O
Parkinson	-	39	B
's	-	48	I
disease	-	51	I
.	-	58	O

Levodopa	11835460	60	O
-	-	68	O
induced	-	69	O
ocular	-	77	B
dyskinesias	-	84	I
are	-	96	O
very	-	100	O
uncommon	-	105	O
.	-	113	O

Usually	11835460	115	O
they	-	123	O
occur	-	128	O
simultaneously	-	134	O
with	-	149	O
limb	-	154	O
peak	-	159	O
-	-	163	O
dose	-	164	O
choreatic	-	169	B
dyskinesias	-	179	I
.	-	190	O

We	11835460	192	O
report	-	195	O
on	-	202	O
a	-	205	O
patient	-	207	O
with	-	215	O
leftward	-	220	O
and	-	229	O
upward	-	233	O
deviations	-	240	O
of	-	251	O
gaze	-	254	O
during	-	259	O
the	-	266	O
peak	-	270	O
effect	-	275	O
of	-	282	O
levodopa	-	285	O
,	-	293	O
and	-	295	O
hypothesize	-	299	O
that	-	311	O
a	-	316	O
severe	-	318	O
dopaminergic	-	325	O
denervation	-	338	O
in	-	350	O
the	-	353	O
caudate	-	357	O
nucleus	-	365	O
is	-	373	O
needed	-	376	O
for	-	383	O
the	-	387	O
appearance	-	391	O
of	-	402	O
these	-	405	O
levodopa	-	411	O
-	-	419	O
induce	-	420	O
ocular	-	427	B
dyskinesias	-	434	I
.	-	445	O

A	11915580	0	O
comparison	-	2	O
of	-	13	O
glyceryl	-	16	O
trinitrate	-	25	O
with	-	36	O
diclofenac	-	41	O
for	-	52	O
the	-	56	O
treatment	-	60	O
of	-	70	O
primary	-	73	O
dysmenorrhea	-	81	B
:	-	93	O
an	-	95	O
open	-	98	O
,	-	102	O
randomized	-	104	O
,	-	114	O
cross	-	116	O
-	-	121	O
over	-	122	O
trial	-	127	O
.	-	132	O

Primary	11915580	134	O
dysmenorrhea	-	142	B
is	-	155	O
a	-	158	O
syndrome	-	160	O
characterized	-	169	O
by	-	183	O
painful	-	186	O
uterine	-	194	O
contractility	-	202	O
caused	-	216	O
by	-	223	O
a	-	226	O
hypersecretion	-	228	O
of	-	243	O
endometrial	-	246	O
prostaglandins	-	258	O
;	-	272	O
non	-	274	O
-	-	277	O
steroidal	-	278	O
anti	-	288	O
-	-	292	O
inflammatory	-	293	O
drugs	-	306	O
are	-	312	O
the	-	316	O
first	-	320	O
choice	-	326	O
for	-	333	O
its	-	337	O
treatment	-	341	O
.	-	350	O

However	11915580	352	O
,	-	359	O
in	-	361	O
vivo	-	364	O
and	-	369	O
in	-	373	O
vitro	-	376	O
studies	-	382	O
have	-	390	O
demonstrated	-	395	O
that	-	408	O
myometrial	-	413	O
cells	-	424	O
are	-	430	O
also	-	434	O
targets	-	439	O
of	-	447	O
the	-	450	O
relaxant	-	454	O
effects	-	463	O
of	-	471	O
nitric	-	474	O
oxide	-	481	O
(	-	487	O
NO	-	488	O
)	-	490	O
.	-	491	O

The	11915580	493	O
aim	-	497	O
of	-	501	O
the	-	504	O
present	-	508	O
study	-	516	O
was	-	522	O
to	-	526	O
determine	-	529	O
the	-	539	O
efficacy	-	543	O
of	-	552	O
glyceryl	-	555	O
trinitrate	-	564	O
(	-	575	O
GTN	-	576	O
)	-	579	O
,	-	580	O
an	-	582	O
NO	-	585	O
donor	-	588	O
,	-	593	O
in	-	595	O
the	-	598	O
resolution	-	602	O
of	-	613	O
primary	-	616	O
dysmenorrhea	-	624	B
in	-	637	O
comparison	-	640	O
with	-	651	O
diclofenac	-	656	O
(	-	667	O
DCF	-	668	O
)	-	671	O
.	-	672	O

A	11915580	674	O
total	-	676	O
of	-	682	O
24	-	685	O
patients	-	688	O
with	-	697	O
the	-	702	O
diagnosis	-	706	O
of	-	716	O
severe	-	719	O
primary	-	726	O
dysmenorrhea	-	734	B
were	-	747	O
studied	-	752	O
during	-	760	O
two	-	767	O
consecutive	-	771	O
menstrual	-	783	O
cycles	-	793	O
.	-	799	O

In	11915580	801	O
an	-	804	O
open	-	807	O
,	-	811	O
cross	-	813	O
-	-	818	O
over	-	819	O
,	-	823	O
controlled	-	825	O
design	-	836	O
,	-	842	O
patients	-	844	O
were	-	853	O
randomized	-	858	O
to	-	869	O
receive	-	872	O
either	-	880	O
DCF	-	887	O
per	-	891	O
os	-	895	O
or	-	898	O
GTN	-	901	O
patches	-	905	O
the	-	913	O
first	-	917	O
days	-	923	O
of	-	928	O
menses	-	931	O
,	-	937	O
when	-	939	O
menstrual	-	944	O
cramps	-	954	O
became	-	961	O
unendurable	-	968	O
.	-	979	O

In	11915580	981	O
the	-	984	O
subsequent	-	988	O
cycle	-	999	O
the	-	1005	O
other	-	1009	O
treatment	-	1015	O
was	-	1025	O
used	-	1029	O
.	-	1033	O

Patients	11915580	1035	O
received	-	1044	O
up	-	1053	O
to	-	1056	O
3	-	1059	O
doses	-	1061	O
/	-	1066	O
day	-	1067	O
of	-	1071	O
50	-	1074	O
mg	-	1077	O
DCF	-	1080	O
or	-	1084	O
2	-	1087	O
.	-	1088	O
5	-	1089	O
mg	-	1091	O
/	-	1093	O
24	-	1094	O
h	-	1097	O
transdermal	-	1099	O
GTN	-	1111	O
for	-	1115	O
the	-	1119	O
first	-	1123	O
3	-	1129	O
days	-	1131	O
of	-	1136	O
the	-	1139	O
cycle	-	1143	O
,	-	1148	O
according	-	1150	O
to	-	1160	O
their	-	1163	O
needs	-	1169	O
.	-	1174	O

The	11915580	1176	O
participants	-	1180	O
recorded	-	1193	O
menstrual	-	1202	O
symptoms	-	1212	O
and	-	1221	O
possible	-	1225	O
side	-	1234	O
-	-	1238	O
effects	-	1239	O
at	-	1247	O
different	-	1250	O
times	-	1260	O
(	-	1266	O
0	-	1267	O
,	-	1268	O
30	-	1270	O
,	-	1272	O
60	-	1274	O
,	-	1276	O
120	-	1278	O
minutes	-	1282	O
)	-	1289	O
after	-	1291	O
the	-	1297	O
first	-	1301	O
dose	-	1307	O
of	-	1312	O
medication	-	1315	O
on	-	1326	O
the	-	1329	O
first	-	1333	O
day	-	1339	O
of	-	1343	O
the	-	1346	O
cycle	-	1350	O
,	-	1355	O
with	-	1357	O
both	-	1362	O
drugs	-	1367	O
.	-	1372	O

The	11915580	1374	O
difference	-	1378	O
in	-	1389	O
pain	-	1392	B
intensity	-	1397	O
score	-	1407	O
(	-	1413	O
DPI	-	1414	O
)	-	1417	O
was	-	1419	O
the	-	1423	O
main	-	1427	O
outcome	-	1432	O
variable	-	1440	O
.	-	1448	O

Both	11915580	1450	O
treatments	-	1455	O
significantly	-	1466	O
reduced	-	1480	O
DPI	-	1488	O
by	-	1492	O
the	-	1495	O
30th	-	1499	O
minute	-	1504	O
(	-	1511	O
GTN	-	1512	O
,	-	1515	O
-	-	1517	O
12	-	1518	O
.	-	1520	O
8	-	1521	O
+	-	1523	O
/	-	1524	O
-	-	1525	O

17	11915580	1527	O
.	-	1529	O
9	-	1530	O
;	-	1531	O
DCF	-	1533	O
,	-	1536	O
-	-	1538	O
18	-	1539	O
.	-	1541	O
9	-	1542	O
+	-	1544	O
/	-	1545	O
-	-	1546	O

16	11915580	1548	O
.	-	1550	O
6	-	1551	O
)	-	1552	O
.	-	1553	O

However	11915580	1555	O
,	-	1562	O
DCF	-	1564	O
continued	-	1568	O
to	-	1578	O
be	-	1581	O
effective	-	1584	O
in	-	1594	O
reducing	-	1597	O
pelvic	-	1606	B
pain	-	1613	I
for	-	1618	O
two	-	1622	O
hours	-	1626	O
,	-	1631	O
whereas	-	1633	O
GTN	-	1641	O
scores	-	1645	O
remained	-	1652	O
more	-	1661	O
or	-	1666	O
less	-	1669	O
stable	-	1674	O
after	-	1681	O
30	-	1687	O
min	-	1690	O
and	-	1694	O
significantly	-	1698	O
higher	-	1712	O
than	-	1719	O
those	-	1724	O
for	-	1730	O
DFC	-	1734	O
(	-	1738	O
after	-	1739	O
one	-	1745	O
hour	-	1749	O
:	-	1753	O
GTN	-	1755	O
,	-	1758	O
-	-	1760	O
12	-	1761	O
.	-	1763	O
8	-	1764	O
+	-	1766	O
/	-	1767	O
-	-	1768	O

17	11915580	1770	O
.	-	1772	O
9	-	1773	O
;	-	1774	O
DFC	-	1776	O
,	-	1779	O
-	-	1781	O
18	-	1782	O
.	-	1784	O
9	-	1785	O
+	-	1787	O
/	-	1788	O
-	-	1789	O

16	11915580	1791	O
.	-	1793	O
6	-	1794	O
and	-	1796	O
after	-	1800	O
two	-	1806	O
hours	-	1810	O
:	-	1815	O
GTN	-	1817	O
,	-	1820	O
-	-	1822	O
23	-	1823	O
.	-	1825	O
7	-	1826	O
+	-	1828	O
/	-	1829	O
-	-	1830	O

20	11915580	1832	O
.	-	1834	O
5	-	1835	O
;	-	1836	O
DFC	-	1838	O
,	-	1841	O
-	-	1843	O
59	-	1844	O
.	-	1846	O
7	-	1847	O
+	-	1849	O
/	-	1850	O
-	-	1851	O

17	11915580	1853	O
.	-	1855	O
9	-	1856	O
,	-	1857	O
p	-	1859	O
=	-	1861	O
0	-	1863	O
.	-	1864	O
0001	-	1865	O
)	-	1869	O
.	-	1870	O

Low	11915580	1872	B
back	-	1876	I
pain	-	1881	I
was	-	1886	O
also	-	1890	O
relieved	-	1895	O
by	-	1904	O
both	-	1907	O
drugs	-	1912	O
.	-	1917	O

Headache	11915580	1919	B
was	-	1928	O
significantly	-	1932	O
increased	-	1946	O
by	-	1956	O
GTN	-	1959	O
but	-	1963	O
not	-	1967	O
by	-	1971	O
DCF	-	1974	O
.	-	1977	O

Eight	11915580	1979	O
patients	-	1985	O
stopped	-	1994	O
using	-	2002	O
GTN	-	2008	O
because	-	2012	O
headache	-	2020	B
-	-	2028	O
-	-	2029	O
attributed	-	2030	O
to	-	2041	O
its	-	2044	O
use	-	2048	O
-	-	2051	O
-	-	2052	O
became	-	2053	O
intolerable	-	2060	O
.	-	2071	O

These	11915580	2073	O
findings	-	2079	O
indicate	-	2088	O
that	-	2097	O
GTN	-	2102	O
has	-	2106	O
a	-	2110	O
reduced	-	2112	O
efficacy	-	2120	O
and	-	2129	O
tolerability	-	2133	O
by	-	2146	O
comparison	-	2149	O
with	-	2160	O
DCF	-	2165	O
in	-	2169	O
the	-	2172	O
treatment	-	2176	O
of	-	2186	O
primary	-	2189	O
dysmenorrhea	-	2197	B
.	-	2209	O

Temocapril	11936424	0	O
,	-	10	O
a	-	12	O
long	-	14	O
-	-	18	O
acting	-	19	O
non	-	26	O
-	-	29	O
SH	-	30	O
group	-	33	O
angiotensin	-	39	O
converting	-	51	O
enzyme	-	62	O
inhibitor	-	69	O
,	-	78	O
modulates	-	80	O
glomerular	-	90	B
injury	-	101	I
in	-	108	O
chronic	-	111	O
puromycin	-	119	O
aminonucleoside	-	129	O
nephrosis	-	145	B
.	-	154	O

The	11936424	156	O
purpose	-	160	O
of	-	168	O
the	-	171	O
present	-	175	O
study	-	183	O
was	-	189	O
to	-	193	O
determine	-	196	O
whether	-	206	O
chronic	-	214	O
administration	-	222	O
of	-	237	O
temocapril	-	240	O
,	-	250	O
a	-	252	O
long	-	254	O
-	-	258	O
acting	-	259	O
non	-	266	O
-	-	269	O
SH	-	270	O
group	-	273	O
angiotensin	-	279	O
converting	-	291	O
enzyme	-	302	O
(	-	309	O
ACE	-	310	O
)	-	313	O
inhibitor	-	315	O
,	-	324	O
reduced	-	326	O
proteinuria	-	334	B
,	-	345	O
inhibited	-	347	O
glomerular	-	357	O
hypertrophy	-	368	B
and	-	380	O
prevented	-	384	O
glomerulosclerosis	-	394	B
in	-	413	O
chronic	-	416	O
puromycin	-	424	O
aminonucleoside	-	434	O
(	-	450	O
PAN	-	451	O
)	-	454	O
-	-	456	O
induced	-	458	O
nephrotic	-	466	B
rats	-	476	O
.	-	480	O

Nephrosis	11936424	482	B
was	-	492	O
induced	-	496	O
by	-	504	O
injection	-	507	O
of	-	517	O
PAN	-	520	O
(	-	524	O
15mg	-	525	O
/	-	529	O
100	-	530	O
g	-	533	O
body	-	535	O
weight	-	540	O
)	-	546	O
in	-	548	O
male	-	551	O
Sprague	-	556	O
-	-	563	O
Dawley	-	564	O
(	-	571	O
SD	-	572	O
)	-	574	O
rats	-	576	O
.	-	580	O

Four	11936424	582	O
groups	-	587	O
were	-	594	O
used	-	599	O
,	-	603	O
i	-	605	O
)	-	606	O
the	-	608	O
PAN	-	612	O
group	-	616	O
(	-	622	O
14	-	623	O
)	-	625	O
,	-	626	O
ii	-	628	O
)	-	630	O
PAN	-	632	O
/	-	635	O
temocapril	-	636	O
(	-	647	O
13	-	648	O
)	-	650	O
,	-	651	O
iii	-	653	O
)	-	656	O
temocapril	-	658	O
(	-	669	O
14	-	670	O
)	-	672	O
and	-	674	O
iv	-	678	O
)	-	680	O
untreated	-	682	O
controls	-	692	O
(	-	701	O
15	-	702	O
)	-	704	O
.	-	705	O

Temocapril	11936424	707	O
(	-	718	O
8	-	719	O
mg	-	721	O
/	-	723	O
kg	-	724	O
/	-	726	O
day	-	727	O
)	-	730	O
was	-	732	O
administered	-	736	O
to	-	749	O
the	-	752	O
rats	-	756	O
which	-	761	O
were	-	767	O
killed	-	772	O
at	-	779	O
weeks	-	782	O
4	-	788	O
,	-	789	O
14	-	791	O
or	-	794	O
20	-	797	O
.	-	799	O

At	11936424	801	O
each	-	804	O
time	-	809	O
point	-	814	O
,	-	819	O
systolic	-	821	O
blood	-	830	O
pressure	-	836	O
(	-	845	O
BP	-	846	O
)	-	848	O
,	-	849	O
urinary	-	851	O
protein	-	859	O
excretion	-	867	O
and	-	877	O
renal	-	881	O
histopathological	-	887	O
findings	-	905	O
were	-	914	O
evaluated	-	919	O
,	-	928	O
and	-	930	O
morphometric	-	934	O
image	-	947	O
analysis	-	953	O
was	-	962	O
done	-	966	O
.	-	970	O

Systolic	11936424	972	O
BP	-	981	O
in	-	984	O
the	-	987	O
PAN	-	991	O
group	-	995	O
was	-	1001	O
significantly	-	1005	O
high	-	1019	O
at	-	1024	O
4	-	1027	O
,	-	1028	O
14	-	1030	O
and	-	1033	O
20	-	1037	O
weeks	-	1040	O
,	-	1045	O
but	-	1047	O
was	-	1051	O
normal	-	1055	O
in	-	1062	O
the	-	1065	O
PAN	-	1069	O
/	-	1072	O
temocapril	-	1073	O
group	-	1084	O
.	-	1089	O

Urinary	11936424	1091	O
protein	-	1099	O
excretion	-	1107	O
in	-	1117	O
the	-	1120	O
PAN	-	1124	O
group	-	1128	O
increased	-	1134	O
significantly	-	1144	O
,	-	1157	O
peaking	-	1159	O
at	-	1167	O
8	-	1170	O
days	-	1172	O
,	-	1176	O
then	-	1178	O
decreased	-	1183	O
at	-	1193	O
4	-	1196	O
weeks	-	1198	O
,	-	1203	O
but	-	1205	O
rose	-	1209	O
again	-	1214	O
significantly	-	1220	O
at	-	1234	O
14	-	1237	O
and	-	1240	O
20	-	1244	O
weeks	-	1247	O
.	-	1252	O

Temocapril	11936424	1254	O
did	-	1265	O
not	-	1269	O
attenuate	-	1273	O
proteinuria	-	1283	B
at	-	1295	O
8	-	1298	O
days	-	1300	O
,	-	1304	O
but	-	1306	O
it	-	1310	O
did	-	1313	O
markedly	-	1317	O
lower	-	1326	O
it	-	1332	O
from	-	1335	O
weeks	-	1340	O
4	-	1346	O
to	-	1348	O
20	-	1351	O
.	-	1353	O

The	11936424	1355	O
glomerulosclerosis	-	1359	B
index	-	1378	O
(	-	1384	O
GSI	-	1385	O
)	-	1388	O
was	-	1390	O
6	-	1394	O
.	-	1395	O
21	-	1396	O
%	-	1399	O
at	-	1401	O
4	-	1404	O
weeks	-	1406	O
and	-	1412	O
respectively	-	1416	O
25	-	1429	O
.	-	1431	O
35	-	1432	O
%	-	1435	O
and	-	1437	O
30	-	1441	O
.	-	1443	O
49	-	1444	O
%	-	1447	O
at	-	1449	O
14	-	1452	O
and	-	1455	O
20	-	1459	O
weeks	-	1462	O
in	-	1468	O
the	-	1471	O
PAN	-	1475	O
group	-	1479	O
.	-	1484	O

There	11936424	1486	O
was	-	1492	O
a	-	1496	O
significant	-	1498	O
correlation	-	1510	O
between	-	1522	O
urinary	-	1530	O
protein	-	1538	O
excretion	-	1546	O
and	-	1556	O
GSI	-	1560	O
(	-	1564	O
r	-	1565	O
=	-	1567	O
0	-	1569	O
.	-	1570	O
808	-	1571	O
,	-	1574	O
p	-	1576	O
<	-	1578	O
0	-	1580	O
.	-	1581	O
0001	-	1582	O
)	-	1586	O
.	-	1587	O

The	11936424	1589	O
ratio	-	1593	O
of	-	1599	O
glomerular	-	1602	O
tuft	-	1613	O
area	-	1618	O
to	-	1623	O
the	-	1626	O
area	-	1630	O
of	-	1635	O
Bowman	-	1638	O
's	-	1644	O
capsules	-	1647	O
(	-	1656	O
GT	-	1657	O
/	-	1659	O
BC	-	1660	O
)	-	1662	O
in	-	1664	O
the	-	1667	O
PAN	-	1671	O
group	-	1675	O
was	-	1681	O
significantly	-	1685	O
increased	-	1699	O
,	-	1708	O
but	-	1710	O
it	-	1714	O
was	-	1717	O
significantly	-	1721	O
lower	-	1735	O
in	-	1741	O
the	-	1744	O
PAN	-	1748	O
/	-	1751	O
temocapril	-	1752	O
group	-	1763	O
.	-	1768	O

It	11936424	1770	O
appears	-	1773	O
that	-	1781	O
temocapril	-	1786	O
was	-	1797	O
effective	-	1801	O
in	-	1811	O
retarding	-	1814	O
renal	-	1824	O
progression	-	1830	O
and	-	1842	O
protected	-	1846	O
renal	-	1856	O
function	-	1862	O
in	-	1871	O
PAN	-	1874	O
neprotic	-	1878	B
rats	-	1887	O
.	-	1891	O

Pulmonary	11988250	0	B
hypertension	-	10	I
after	-	23	O
ibuprofen	-	29	O
prophylaxis	-	39	O
in	-	51	O
very	-	54	O
preterm	-	59	O
infants	-	67	O
.	-	74	O

We	11988250	76	O
report	-	79	O
three	-	86	O
cases	-	92	O
of	-	98	O
severe	-	101	O
hypoxaemia	-	108	B
after	-	119	O
ibuprofen	-	125	O
administration	-	135	O
during	-	150	O
a	-	157	O
randomised	-	159	O
controlled	-	170	O
trial	-	181	O
of	-	187	O
prophylactic	-	190	O
treatment	-	203	O
of	-	213	O
patent	-	216	B
ductus	-	223	I
arteriosus	-	230	I
with	-	241	O
ibuprofen	-	246	O
in	-	256	O
premature	-	259	O
infants	-	269	O
born	-	277	O
at	-	282	O
less	-	285	O
than	-	290	O
28	-	295	O
weeks	-	298	O
of	-	304	O
gestation	-	307	O
.	-	316	O

Echocardiography	11988250	318	O
showed	-	335	O
severely	-	342	O
decreased	-	351	O
pulmonary	-	361	O
blood	-	371	O
flow	-	377	O
.	-	381	O

Hypoxaemia	11988250	383	B
resolved	-	394	O
quickly	-	403	O
on	-	411	O
inhaled	-	414	O
nitric	-	422	O
oxide	-	429	O
therapy	-	435	O
.	-	442	O

We	11988250	444	O
suggest	-	447	O
that	-	455	O
investigators	-	460	O
involved	-	474	O
in	-	483	O
similar	-	486	O
trials	-	494	O
pay	-	501	O
close	-	505	O
attention	-	511	O
to	-	521	O
pulmonary	-	524	O
pressure	-	534	O
if	-	543	O
hypoxaemia	-	546	B
occurs	-	557	O
after	-	564	O
prophylactic	-	570	O
administration	-	583	O
of	-	598	O
ibuprofen	-	601	O
.	-	610	O

Hyponatremia	12051122	0	B
and	-	13	O
syndrome	-	17	B
of	-	26	I
inappropriate	-	29	I
anti	-	43	I
-	-	47	I
diuretic	-	48	I
hormone	-	57	I
reported	-	65	O
with	-	74	O
the	-	79	O
use	-	83	O
of	-	87	O
Vincristine	-	90	O
:	-	101	O
an	-	103	O
over	-	106	O
-	-	110	O
representation	-	111	O
of	-	126	O
Asians	-	129	O
?	-	135	O

PURPOSE	12051122	137	O
:	-	144	O

This	12051122	146	O
retrospective	-	151	O
study	-	165	O
used	-	171	O
a	-	176	O
pharmaceutical	-	178	O
company	-	193	O
's	-	200	O
global	-	203	O
safety	-	210	O
database	-	217	O
to	-	226	O
determine	-	229	O
the	-	239	O
reporting	-	243	O
rate	-	253	O
of	-	258	O
hyponatremia	-	261	B
and	-	274	O
/	-	277	O
or	-	278	O
syndrome	-	281	B
of	-	290	I
inappropriate	-	293	I
secretion	-	307	I
of	-	317	I
anti	-	320	I
-	-	324	I
diuretic	-	325	I
hormone	-	334	I
(	-	342	O
SIADH	-	343	B
)	-	348	O
among	-	350	O
vincristine	-	356	O
-	-	367	O
treated	-	368	O
patients	-	376	O
and	-	385	O
to	-	389	O
explore	-	392	O
the	-	400	O
possibility	-	404	O
of	-	416	O
at	-	419	O
-	-	421	O
risk	-	422	O
population	-	427	O
subgroups	-	438	O
.	-	447	O

METHOD	12051122	449	O
:	-	455	O

We	12051122	457	O
searched	-	460	O
the	-	469	O
Eli	-	473	O
Lilly	-	477	O
and	-	483	O
Company	-	487	O
's	-	494	O
computerized	-	497	O
adverse	-	510	O
event	-	518	O
database	-	524	O
for	-	533	O
all	-	537	O
reported	-	541	O
cases	-	550	O
of	-	556	O
hyponatremia	-	559	B
and	-	572	O
/	-	575	O
or	-	576	O
SIADH	-	579	B
as	-	585	O
of	-	588	O
1	-	591	O
November	-	593	O
1999	-	602	O
that	-	607	O
had	-	612	O
been	-	616	O
reported	-	621	O
during	-	630	O
the	-	637	O
use	-	641	O
of	-	645	O
vincristine	-	648	O
.	-	659	O

RESULTS	12051122	661	O
:	-	668	O

A	12051122	670	O
total	-	672	O
of	-	678	O
76	-	681	O
cases	-	684	O
of	-	690	O
hyponatremia	-	693	B
and	-	706	O
/	-	709	O
or	-	710	O
SIADH	-	713	B
associated	-	719	O
with	-	730	O
vincristine	-	735	O
use	-	747	O
were	-	751	O
identified	-	756	O
.	-	766	O

The	12051122	768	O
overall	-	772	O
reporting	-	780	O
rate	-	790	O
was	-	795	O
estimated	-	799	O
to	-	809	O
be	-	812	O
1	-	815	O
.	-	816	O
3	-	817	O
/	-	818	O
100	-	819	O
,	-	822	O
000	-	823	O
treated	-	827	O
patients	-	835	O
.	-	843	O

The	12051122	845	O
average	-	849	O
age	-	857	O
of	-	861	O
patients	-	864	O
was	-	873	O
35	-	877	O
.	-	879	O
6	-	880	O
+	-	882	O
/	-	883	O
-	-	884	O

28	12051122	886	O
.	-	888	O
3	-	889	O
years	-	891	O
,	-	896	O
and	-	898	O
62	-	902	O
%	-	904	O
were	-	906	O
males	-	911	O
.	-	916	O

Approximately	12051122	918	O
75	-	932	O
%	-	934	O
of	-	936	O
the	-	939	O
patients	-	943	O
were	-	952	O
receiving	-	957	O
treatment	-	967	O
for	-	977	O
leukemia	-	981	B
or	-	990	O
lymphoma	-	993	B
.	-	1001	O

Among	12051122	1003	O
the	-	1009	O
39	-	1013	O
reports	-	1016	O
that	-	1024	O
included	-	1029	O
information	-	1038	O
on	-	1050	O
race	-	1053	O
,	-	1057	O
the	-	1059	O
racial	-	1063	O
distribution	-	1070	O
was	-	1083	O
:	-	1086	O
1	-	1088	O
Black	-	1090	O
,	-	1095	O
3	-	1097	O
Caucasian	-	1099	O
,	-	1108	O
and	-	1110	O
35	-	1114	O
Asian	-	1117	O
.	-	1122	O

CONCLUSION	12051122	1124	O
:	-	1134	O

Our	12051122	1136	O
data	-	1140	O
suggest	-	1145	O
that	-	1153	O
Asian	-	1158	O
patients	-	1164	O
may	-	1173	O
be	-	1177	O
at	-	1180	O
increased	-	1183	O
risk	-	1193	O
of	-	1198	O
hyponatremia	-	1201	B
and	-	1214	O
/	-	1217	O
or	-	1218	O
SIADH	-	1221	B
associated	-	1227	O
with	-	1238	O
vincristine	-	1243	O
use	-	1255	O
.	-	1258	O

Although	12051122	1260	O
the	-	1269	O
overall	-	1273	O
reported	-	1281	O
rate	-	1290	O
of	-	1295	O
SIADH	-	1298	B
associated	-	1304	O
with	-	1315	O
vincristine	-	1320	O
is	-	1332	O
very	-	1335	O
low	-	1340	O
,	-	1343	O
physicians	-	1345	O
caring	-	1356	O
for	-	1363	O
Asian	-	1367	O
oncology	-	1373	O
patients	-	1382	O
should	-	1391	O
be	-	1398	O
aware	-	1401	O
of	-	1407	O
this	-	1410	O
potential	-	1415	O
serious	-	1425	O
but	-	1433	O
reversible	-	1437	O
adverse	-	1448	O
event	-	1456	O
.	-	1461	O

Delayed	12059909	0	O
toxicity	-	8	B
of	-	17	O
cyclophosphamide	-	20	O
on	-	37	O
the	-	40	O
bladder	-	44	O
of	-	52	O
DBA	-	55	O
/	-	58	O
2	-	59	O
and	-	61	O
C57BL	-	65	O
/	-	70	O
6	-	71	O
female	-	73	O
mouse	-	80	O
.	-	85	O

The	12059909	87	O
present	-	91	O
study	-	99	O
describes	-	105	O
the	-	115	O
delayed	-	119	O
development	-	127	O
of	-	139	O
a	-	142	O
severe	-	144	O
bladder	-	151	O
pathology	-	159	O
in	-	169	O
a	-	172	O
susceptible	-	174	O
strain	-	186	O
of	-	193	O
mice	-	196	O
(	-	201	O
DBA	-	202	O
/	-	205	O
2	-	206	O
)	-	207	O
but	-	209	O
not	-	213	O
in	-	217	O
a	-	220	O
resistant	-	222	O
strain	-	232	O
(	-	239	O
C57BL	-	240	O
/	-	245	O
6	-	246	O
)	-	247	O
when	-	249	O
both	-	254	O
were	-	259	O
treated	-	264	O
with	-	272	O
a	-	277	O
single	-	279	O
300	-	286	O
mg	-	290	O
/	-	292	O
kg	-	293	O
dose	-	296	O
of	-	301	O
cyclophosphamide	-	304	O
(	-	321	O
CY	-	322	O
)	-	324	O
.	-	325	O

Inbred	12059909	327	O
DBA	-	334	O
/	-	337	O
2	-	338	O
and	-	340	O
C57BL	-	344	O
/	-	349	O
6	-	350	O
female	-	352	O
mice	-	359	O
were	-	364	O
injected	-	369	O
with	-	378	O
CY	-	383	O
,	-	385	O
and	-	387	O
the	-	391	O
effect	-	395	O
of	-	402	O
the	-	405	O
drug	-	409	O
on	-	414	O
the	-	417	O
bladder	-	421	O
was	-	429	O
assessed	-	433	O
during	-	442	O
100	-	449	O
days	-	453	O
by	-	458	O
light	-	461	O
microscopy	-	467	O
using	-	478	O
different	-	484	O
staining	-	494	O
procedures	-	503	O
,	-	513	O
and	-	515	O
after	-	519	O
30	-	525	O
days	-	528	O
by	-	533	O
conventional	-	536	O
electron	-	549	O
microscopy	-	558	O
.	-	568	O

Early	12059909	570	O
CY	-	576	O
toxicity	-	579	B
caused	-	588	O
a	-	595	O
typical	-	597	O
haemorrhagic	-	605	B
cystitis	-	618	B
in	-	627	O
both	-	630	O
strains	-	635	O
that	-	643	O
was	-	648	O
completely	-	652	O
repaired	-	663	O
in	-	672	O
about	-	675	O
7	-	681	O
-	-	682	O
10	-	683	O
days	-	686	O
.	-	690	O

After	12059909	692	O
30	-	698	O
days	-	701	O
of	-	706	O
CY	-	709	O
injection	-	712	O
ulcerous	-	722	O
and	-	731	O
non	-	735	O
-	-	738	O
ulcerous	-	739	O
forms	-	748	O
of	-	754	O
chronic	-	757	O
cystitis	-	765	B
appeared	-	774	O
in	-	783	O
86	-	786	O
%	-	788	O
of	-	790	O
DBA	-	793	O
/	-	796	O
2	-	797	O
mice	-	799	O
but	-	804	O
only	-	808	O
in	-	813	O
4	-	816	O
%	-	817	O
of	-	819	O
C57BL	-	822	O
/	-	827	O
6	-	828	O
mice	-	830	O
.	-	834	O

Delayed	12059909	836	O
cystitis	-	844	B
was	-	853	O
characterized	-	857	O
by	-	871	O
infiltration	-	874	O
and	-	887	O
transepithelial	-	891	O
passage	-	907	O
into	-	915	O
the	-	920	O
lumen	-	924	O
of	-	930	O
inflammatory	-	933	O
cells	-	946	O
and	-	952	O
by	-	956	O
frequent	-	959	O
exfoliation	-	968	O
of	-	980	O
the	-	983	O
urothelium	-	987	O
.	-	997	O

Mast	12059909	999	O
cells	-	1004	O
appeared	-	1010	O
in	-	1019	O
the	-	1022	O
connective	-	1026	O
and	-	1037	O
muscular	-	1041	O
layers	-	1050	O
of	-	1057	O
the	-	1060	O
bladder	-	1064	O
at	-	1072	O
a	-	1075	O
much	-	1077	O
higher	-	1082	O
number	-	1089	O
in	-	1096	O
DBA	-	1099	O
/	-	1102	O
2	-	1103	O
mice	-	1105	O
than	-	1110	O
in	-	1115	O
C57BL	-	1118	O
/	-	1123	O
6	-	1124	O
mice	-	1126	O
or	-	1131	O
untreated	-	1134	O
controls	-	1144	O
.	-	1152	O

Electron	12059909	1154	O
microscopy	-	1163	O
disclosed	-	1174	O
the	-	1184	O
absence	-	1188	O
of	-	1196	O
the	-	1199	O
typical	-	1203	O
discoidal	-	1211	O
vesicles	-	1221	O
normally	-	1230	O
present	-	1239	O
in	-	1247	O
the	-	1250	O
cytoplasm	-	1254	O
of	-	1264	O
surface	-	1267	O
cells	-	1275	O
.	-	1280	O

Instead	12059909	1282	O
,	-	1289	O
numerous	-	1291	O
abnormal	-	1300	O
vesicles	-	1309	O
containing	-	1318	O
one	-	1329	O
or	-	1333	O
several	-	1336	O
dark	-	1344	O
granules	-	1349	O
were	-	1358	O
observed	-	1363	O
in	-	1372	O
the	-	1375	O
cytoplasm	-	1379	O
of	-	1389	O
cells	-	1392	O
from	-	1398	O
all	-	1403	O
the	-	1407	O
epithelial	-	1411	O
layers	-	1422	O
.	-	1428	O

Delayed	12059909	1430	O
cystitis	-	1438	B
still	-	1447	O
persisted	-	1453	O
in	-	1463	O
DBA	-	1466	O
/	-	1469	O
2	-	1470	O
mice	-	1472	O
100	-	1477	O
days	-	1481	O
after	-	1486	O
treatment	-	1492	O
.	-	1501	O

These	12059909	1503	O
results	-	1509	O
indicate	-	1517	O
that	-	1526	O
delayed	-	1531	O
toxicity	-	1539	B
of	-	1548	O
CY	-	1551	O
in	-	1554	O
female	-	1557	O
DBA	-	1564	O
/	-	1567	O
2	-	1568	O
mice	-	1570	O
causes	-	1575	O
a	-	1582	O
bladder	-	1584	O
pathology	-	1592	O
that	-	1602	O
is	-	1607	O
not	-	1610	O
observed	-	1614	O
in	-	1623	O
C57BL	-	1626	O
/	-	1631	O
6	-	1632	O
mice	-	1634	O
.	-	1638	O

This	12059909	1640	O
pathology	-	1645	O
resembles	-	1655	O
interstitial	-	1665	B
cystitis	-	1678	I
in	-	1687	O
humans	-	1690	O
and	-	1697	O
could	-	1701	O
perhaps	-	1707	O
be	-	1715	O
used	-	1718	O
as	-	1723	O
an	-	1726	O
animal	-	1729	O
model	-	1736	O
for	-	1742	O
studies	-	1746	O
on	-	1754	O
the	-	1757	O
disease	-	1761	O
.	-	1768	O

High	12119460	0	O
-	-	4	O
dose	-	5	O
5	-	10	O
-	-	11	O
fluorouracil	-	12	O
/	-	25	O
folinic	-	27	O
acid	-	35	O
in	-	40	O
combination	-	43	O
with	-	55	O
three	-	60	O
-	-	65	O
weekly	-	66	O
mitomycin	-	73	O
C	-	83	O
in	-	85	O
the	-	88	O
treatment	-	92	O
of	-	102	O
advanced	-	105	O
gastric	-	114	B
cancer	-	122	I
.	-	128	O

A	12119460	130	O
phase	-	132	O
II	-	138	O
study	-	141	O
.	-	146	O

BACKGROUND	12119460	148	O
:	-	158	O

The	12119460	160	O
24	-	164	O
-	-	166	O
hour	-	167	O
continuous	-	172	O
infusion	-	183	O
of	-	192	O
5	-	195	O
-	-	196	O
fluorouracil	-	197	O
(	-	210	O
5	-	211	O
-	-	212	O
FU	-	213	O
)	-	215	O
and	-	217	O
folinic	-	221	O
acid	-	229	O
(	-	234	O
FA	-	235	O
)	-	237	O
as	-	239	O
part	-	242	O
of	-	247	O
several	-	250	O
new	-	258	O
multidrug	-	262	O
chemotherapy	-	272	O
regimens	-	285	O
in	-	294	O
advanced	-	297	O
gastric	-	306	B
cancer	-	314	I
(	-	321	O
AGC	-	322	B
)	-	325	O
has	-	327	O
shown	-	331	O
to	-	337	O
be	-	340	O
effective	-	343	O
,	-	352	O
with	-	354	O
low	-	359	O
toxicity	-	363	B
.	-	371	O

In	12119460	373	O
a	-	376	O
previous	-	378	O
phase	-	387	O
II	-	393	O
study	-	396	O
with	-	402	O
3	-	407	O
-	-	408	O
weekly	-	409	O
bolus	-	416	O
5	-	422	O
-	-	423	O
FU	-	424	O
,	-	426	O
FA	-	428	O
and	-	431	O
mitomycin	-	435	O
C	-	445	O
(	-	447	O
MMC	-	448	O
)	-	451	O
we	-	453	O
found	-	456	O
a	-	462	O
low	-	464	O
toxicity	-	468	B
rate	-	477	O
and	-	482	O
response	-	486	O
rates	-	495	O
comparable	-	501	O
to	-	512	O
those	-	515	O
of	-	521	O
regimens	-	524	O
such	-	533	O
as	-	538	O
ELF	-	541	O
,	-	544	O
FAM	-	546	O
or	-	550	O
FAMTX	-	553	O
,	-	558	O
and	-	560	O
a	-	564	O
promising	-	566	O
median	-	576	O
overall	-	583	O
survival	-	591	O
.	-	599	O

In	12119460	601	O
order	-	604	O
to	-	610	O
improve	-	613	O
this	-	621	O
MMC	-	626	O
-	-	629	O
dependent	-	630	O
schedule	-	640	O
we	-	649	O
initiated	-	652	O
a	-	662	O
phase	-	664	O
II	-	670	O
study	-	673	O
with	-	679	O
high	-	684	O
-	-	688	O
dose	-	689	O
5	-	694	O
-	-	695	O
FU	-	696	O
/	-	698	O
FA	-	699	O
and	-	702	O
3	-	706	O
-	-	707	O
weekly	-	708	O
bolus	-	715	O
MMC	-	721	O
.	-	724	O

PATIENTS	12119460	726	O
AND	-	735	O
METHODS	-	739	O
:	-	746	O

From	12119460	748	O
February	-	753	O
,	-	761	O
1998	-	763	O
to	-	768	O
September	-	771	O
,	-	780	O
2000	-	782	O
we	-	787	O
recruited	-	790	O
33	-	800	O
patients	-	803	O
with	-	812	O
AGC	-	817	B
to	-	821	O
receive	-	824	O
weekly	-	832	O
24	-	839	O
-	-	841	O
hour	-	842	O
5	-	847	O
-	-	848	O
FU	-	849	O
2	-	852	O
,	-	853	O
600	-	854	O
mg	-	858	O
/	-	860	O
m	-	861	O
(	-	862	O
2	-	863	O
)	-	864	O
preceded	-	866	O
by	-	875	O
2	-	878	O
-	-	879	O
hour	-	880	O
FA	-	885	O
500	-	888	O
mg	-	892	O
/	-	894	O
m	-	895	O
(	-	896	O
2	-	897	O
)	-	898	O
for	-	900	O
6	-	904	O
weeks	-	906	O
,	-	911	O
followed	-	913	O
by	-	922	O
a	-	925	O
2	-	927	O
-	-	928	O
week	-	929	O
rest	-	934	O
period	-	939	O
.	-	945	O

Bolus	12119460	947	O
MMC	-	953	O
10	-	957	O
mg	-	960	O
/	-	962	O
m	-	963	O
(	-	964	O
2	-	965	O
)	-	966	O
was	-	968	O
added	-	972	O
in	-	978	O
3	-	981	O
-	-	982	O
weekly	-	983	O
intervals	-	990	O
.	-	999	O

Treatment	12119460	1001	O
given	-	1011	O
on	-	1017	O
an	-	1020	O
outpatient	-	1023	O
basis	-	1034	O
,	-	1039	O
using	-	1041	O
portable	-	1047	O
pump	-	1056	O
systems	-	1061	O
,	-	1068	O
was	-	1070	O
repeated	-	1074	O
on	-	1083	O
day	-	1086	O
57	-	1090	O
.	-	1092	O

Patients	12119460	1094	O
'	-	1102	O
characteristics	-	1104	O
were	-	1120	O
:	-	1124	O
male	-	1126	O
/	-	1130	O
female	-	1131	O
ratio	-	1138	O
20	-	1144	O
/	-	1146	O
13	-	1147	O
;	-	1149	O
median	-	1151	O
age	-	1158	O
57	-	1162	O
(	-	1165	O
27	-	1166	O
-	-	1168	O
75	-	1169	O
)	-	1171	O
years	-	1173	O
;	-	1178	O
median	-	1180	O
WHO	-	1187	O
status	-	1191	O
1	-	1198	O
(	-	1200	O
0	-	1201	O
-	-	1202	O
2	-	1203	O
)	-	1204	O
.	-	1205	O

18	12119460	1207	O
patients	-	1210	O
had	-	1219	O
a	-	1223	O
primary	-	1225	O
AGC	-	1233	B
,	-	1236	O
and	-	1238	O
15	-	1242	O
showed	-	1245	O
a	-	1252	O
relapsed	-	1254	O
AGC	-	1263	B
.	-	1266	O

Median	12119460	1268	O
follow	-	1275	O
-	-	1281	O
up	-	1282	O
was	-	1285	O
11	-	1289	O
.	-	1291	O
8	-	1292	O
months	-	1294	O
(	-	1301	O
range	-	1302	O
of	-	1308	O
those	-	1311	O
surviving	-	1317	O
:	-	1326	O
2	-	1328	O
.	-	1329	O
7	-	1330	O
-	-	1331	O
11	-	1332	O
.	-	1334	O
8	-	1335	O
months	-	1337	O
)	-	1343	O
.	-	1344	O

RESULTS	12119460	1346	O
:	-	1353	O

32	12119460	1355	O
patients	-	1358	O
were	-	1367	O
evaluable	-	1372	O
for	-	1382	O
response	-	1386	O
-	-	1395	O
complete	-	1397	O
remission	-	1406	O
9	-	1416	O
.	-	1417	O
1	-	1418	O
%	-	1419	O
(	-	1421	O
n	-	1422	O
=	-	1424	O
3	-	1426	O
)	-	1427	O
,	-	1428	O
partial	-	1430	O
remission	-	1438	O
45	-	1448	O
.	-	1450	O
5	-	1451	O
%	-	1452	O
(	-	1454	O
n	-	1455	O
=	-	1457	O
15	-	1459	O
)	-	1461	O
,	-	1462	O
no	-	1464	O
change	-	1467	O
27	-	1474	O
.	-	1476	O
3	-	1477	O
%	-	1478	O
(	-	1480	O
n	-	1481	O
=	-	1483	O
9	-	1485	O
)	-	1486	O
,	-	1487	O
progressive	-	1489	O
disease	-	1501	O
15	-	1509	O
.	-	1511	O
1	-	1512	O
%	-	1513	O
(	-	1515	O
n	-	1516	O
=	-	1518	O
5	-	1520	O
)	-	1521	O
.	-	1522	O

Median	12119460	1524	O
overall	-	1531	O
survival	-	1539	O
time	-	1548	O
was	-	1553	O
10	-	1557	O
.	-	1559	O
2	-	1560	O
months	-	1562	O
[	-	1569	O
95	-	1570	O
%	-	1572	O
confidence	-	1574	O
interval	-	1585	O
(	-	1594	O
CI	-	1595	O
)	-	1597	O
:	-	1598	O
8	-	1600	O
.	-	1601	O
7	-	1602	O
-	-	1603	O
11	-	1604	O
.	-	1606	O
6	-	1607	O
]	-	1608	O
,	-	1609	O
and	-	1611	O
median	-	1615	O
progression	-	1622	O
-	-	1633	O
free	-	1634	O
survival	-	1639	O
time	-	1648	O
was	-	1653	O
7	-	1657	O
.	-	1658	O
6	-	1659	O
months	-	1661	O
(	-	1668	O
95	-	1669	O
%	-	1671	O
CI	-	1673	O
:	-	1675	O
4	-	1677	O
.	-	1678	O
4	-	1679	O
-	-	1680	O
10	-	1681	O
.	-	1683	O
9	-	1684	O
)	-	1685	O
.	-	1686	O

The	12119460	1688	O
worst	-	1692	O
toxicities	-	1698	B
(	-	1709	O
%	-	1710	O
)	-	1711	O
observed	-	1713	O
were	-	1722	O
(	-	1727	O
CTC	-	1728	O
-	-	1731	O
NCI	-	1732	O
1	-	1736	O
/	-	1737	O
2	-	1738	O
/	-	1739	O
3	-	1740	O
)	-	1741	O
:	-	1742	O

leukopenia	12119460	1744	B
45	-	1755	O
.	-	1757	O
5	-	1758	O
/	-	1759	O
18	-	1760	O
.	-	1762	O
2	-	1763	O
/	-	1764	O
6	-	1765	O
.	-	1766	O
1	-	1767	O
,	-	1768	O
thrombocytopenia	-	1770	B
33	-	1787	O
.	-	1789	O
3	-	1790	O
/	-	1791	O
9	-	1792	O
.	-	1793	O
1	-	1794	O
/	-	1795	O
6	-	1796	O
.	-	1797	O
1	-	1798	O
,	-	1799	O
vomitus	-	1801	B
24	-	1809	O
.	-	1811	O
2	-	1812	O
/	-	1813	O
9	-	1814	O
.	-	1815	O
1	-	1816	O
/	-	1817	O
0	-	1818	O
,	-	1819	O
diarrhea	-	1821	B
36	-	1830	O
.	-	1832	O
4	-	1833	O
/	-	1834	O
6	-	1835	O
.	-	1836	O
1	-	1837	O
/	-	1838	O
3	-	1839	O
.	-	1840	O
0	-	1841	O
,	-	1842	O
stomatitis	-	1844	B
18	-	1855	O
.	-	1857	O
2	-	1858	O
/	-	1859	O
9	-	1860	O
.	-	1861	O
1	-	1862	O
/	-	1863	O
0	-	1864	O
,	-	1865	O
hand	-	1867	B
-	-	1871	I
foot	-	1872	I
syndrome	-	1877	I
12	-	1886	O
.	-	1888	O
1	-	1889	O
/	-	1890	O
0	-	1891	O
/	-	1892	O
0	-	1893	O
.	-	1894	O

Two	12119460	1896	O
patients	-	1900	O
developed	-	1909	O
hemolytic	-	1919	B
-	-	1928	I
uremic	-	1929	I
syndrome	-	1936	I
(	-	1945	O
HUS	-	1946	B
)	-	1949	O
.	-	1950	O

CONCLUSIONS	12119460	1952	O
:	-	1963	O

High	12119460	1965	O
-	-	1969	O
dose	-	1970	O
5	-	1975	O
-	-	1976	O
FU	-	1977	O
/	-	1979	O
FA	-	1980	O
/	-	1982	O
MMC	-	1983	O
is	-	1987	O
an	-	1990	O
effective	-	1993	O
and	-	2003	O
well	-	2007	O
-	-	2011	O
tolerated	-	2012	O
outpatient	-	2022	O
regimen	-	2033	O
for	-	2041	O
AGC	-	2045	B
(	-	2049	O
objective	-	2050	O
response	-	2060	O
rate	-	2069	O
54	-	2074	O
.	-	2076	O
6	-	2077	O
%	-	2078	O
)	-	2079	O
.	-	2080	O

It	12119460	2082	O
may	-	2085	O
serve	-	2089	O
as	-	2095	O
an	-	2098	O
alternative	-	2101	O
to	-	2113	O
cisplatin	-	2116	O
-	-	2125	O
containing	-	2126	O
regimens	-	2137	O
;	-	2145	O
however	-	2147	O
,	-	2154	O
it	-	2156	O
has	-	2159	O
to	-	2163	O
be	-	2166	O
considered	-	2169	O
that	-	2180	O
possibly	-	2185	O
HUS	-	2194	B
may	-	2198	O
occur	-	2202	O
.	-	2207	O

Persistent	12165618	0	O
sterile	-	11	O
leukocyturia	-	19	B
is	-	32	O
associated	-	35	O
with	-	46	O
impaired	-	51	B
renal	-	60	I
function	-	66	I
in	-	75	O
human	-	78	B
immunodeficiency	-	84	I
virus	-	101	I
type	-	107	I
1	-	112	I
-	-	113	I
infected	-	114	I
children	-	123	O
treated	-	132	O
with	-	140	O
indinavir	-	145	O
.	-	154	O

BACKGROUND	12165618	156	O
:	-	166	O

Prolonged	12165618	168	O
administration	-	178	O
of	-	193	O
indinavir	-	196	O
is	-	206	O
associated	-	209	O
with	-	220	O
the	-	225	O
occurrence	-	229	O
of	-	240	O
a	-	243	O
variety	-	245	O
of	-	253	O
renal	-	256	O
complications	-	262	O
in	-	276	O
adults	-	279	O
.	-	285	O

These	12165618	287	O
well	-	293	O
-	-	297	O
documented	-	298	O
side	-	309	O
effects	-	314	O
have	-	322	O
restricted	-	327	O
the	-	338	O
use	-	342	O
of	-	346	O
this	-	349	O
potent	-	354	O
protease	-	361	O
inhibitor	-	370	O
in	-	380	O
children	-	383	O
.	-	391	O

DESIGN	12165618	393	O
:	-	399	O

A	12165618	401	O
prospective	-	403	O
study	-	415	O
to	-	421	O
monitor	-	424	O
indinavir	-	432	O
-	-	441	O
related	-	442	O
nephrotoxicity	-	450	B
in	-	465	O
a	-	468	O
cohort	-	470	O
of	-	477	O
30	-	480	O
human	-	483	B
immunodeficiency	-	489	I
virus	-	506	I
type	-	512	I
1	-	517	I
-	-	518	I
infected	-	519	I
children	-	528	O
treated	-	537	O
with	-	545	O
indinavir	-	550	O
.	-	559	O

METHODS	12165618	561	O
:	-	568	O

Urinary	12165618	570	O
pH	-	578	O
,	-	580	O
albumin	-	582	O
,	-	589	O
creatinine	-	591	O
,	-	601	O
the	-	603	O
presence	-	607	O
of	-	616	O
erythrocytes	-	619	O
,	-	631	O
leukocytes	-	633	O
,	-	643	O
bacteria	-	645	O
and	-	654	O
crystals	-	658	O
,	-	666	O
and	-	668	O
culture	-	672	O
were	-	680	O
analyzed	-	685	O
every	-	694	O
3	-	700	O
months	-	702	O
for	-	709	O
96	-	713	O
weeks	-	716	O
.	-	721	O

Serum	12165618	723	O
creatinine	-	729	O
levels	-	740	O
were	-	747	O
routinely	-	752	O
determined	-	762	O
at	-	773	O
the	-	776	O
same	-	780	O
time	-	785	O
points	-	790	O
.	-	796	O

Steady	12165618	798	O
-	-	804	O
state	-	805	O
pharmacokinetics	-	811	O
of	-	828	O
indinavir	-	831	O
were	-	841	O
done	-	846	O
at	-	851	O
week	-	854	O
4	-	859	O
after	-	861	O
the	-	867	O
initiation	-	871	O
of	-	882	O
indinavir	-	885	O
.	-	894	O

RESULTS	12165618	896	O
:	-	903	O

The	12165618	905	O
cumulative	-	909	O
incidence	-	920	O
of	-	930	O
persistent	-	933	O
sterile	-	944	O
leukocyturia	-	952	B
(	-	965	O
>	-	966	O
or	-	968	O
=	-	971	O
75	-	972	O
cells	-	975	O
/	-	980	O
micro	-	982	O
L	-	988	O
in	-	990	O
at	-	993	O
least	-	996	O
2	-	1002	O
consecutive	-	1004	O
visits	-	1016	O
)	-	1022	O
after	-	1024	O
96	-	1030	O
weeks	-	1033	O
was	-	1039	O
53	-	1043	O
%	-	1045	O
.	-	1046	O

Persistent	12165618	1048	O
sterile	-	1059	O
leukocyturia	-	1067	B
was	-	1080	O
frequently	-	1084	O
associated	-	1095	O
with	-	1106	O
a	-	1111	O
mild	-	1113	O
increase	-	1118	O
in	-	1127	O
the	-	1130	O
urine	-	1134	O
albumin	-	1140	O
/	-	1147	O
creatinine	-	1148	O
ratio	-	1159	O
and	-	1165	O
by	-	1169	O
microscopic	-	1172	O
hematuria	-	1184	B
.	-	1193	O

The	12165618	1195	O
cumulative	-	1199	O
incidence	-	1210	O
of	-	1220	O
serum	-	1223	O
creatinine	-	1229	O
levels	-	1240	O
>	-	1247	O
50	-	1248	O
%	-	1250	O
above	-	1252	O
normal	-	1258	O
was	-	1265	O
33	-	1269	O
%	-	1271	O
after	-	1273	O
96	-	1279	O
weeks	-	1282	O
.	-	1287	O

Children	12165618	1289	O
with	-	1298	O
persistent	-	1303	O
sterile	-	1314	O
leukocyturia	-	1322	B
more	-	1335	O
frequently	-	1340	O
had	-	1351	O
serum	-	1355	O
creatinine	-	1361	O
levels	-	1372	O
of	-	1379	O
50	-	1382	O
%	-	1384	O
above	-	1386	O
normal	-	1392	O
than	-	1399	O
those	-	1404	O
children	-	1410	O
without	-	1419	O
persistent	-	1427	O
sterile	-	1438	O
leukocyturia	-	1446	B
.	-	1458	O

In	12165618	1460	O
children	-	1463	O
younger	-	1472	O
than	-	1480	O
5	-	1485	O
.	-	1486	O
6	-	1487	O
years	-	1489	O
,	-	1494	O
persistent	-	1496	O
sterile	-	1507	O
leukocyturia	-	1515	B
was	-	1528	O
significantly	-	1532	O
more	-	1546	O
frequent	-	1551	O
than	-	1560	O
in	-	1565	O
older	-	1568	O
children	-	1574	O
.	-	1582	O

A	12165618	1584	O
higher	-	1586	O
cumulative	-	1593	O
incidence	-	1604	O
of	-	1614	O
persistent	-	1617	O
leukocyturia	-	1628	B
was	-	1641	O
found	-	1645	O
in	-	1651	O
children	-	1654	O
with	-	1663	O
an	-	1668	O
area	-	1671	O
under	-	1676	O
the	-	1682	O
curve	-	1686	O
>	-	1692	O

19	12165618	1693	O
mg	-	1696	O
/	-	1698	O
L	-	1699	O
x	-	1701	O
h	-	1703	O
or	-	1705	O
a	-	1708	O
peak	-	1710	O
serum	-	1715	O
level	-	1721	O
of	-	1727	O
indinavir	-	1730	O
>	-	1740	O

12	12165618	1741	O
mg	-	1744	O
/	-	1746	O
L	-	1747	O
.	-	1748	O

In	12165618	1750	O
4	-	1753	O
children	-	1755	O
,	-	1763	O
indinavir	-	1765	O
was	-	1775	O
discontinued	-	1779	O
because	-	1792	O
of	-	1800	O
nephrotoxicity	-	1803	B
.	-	1817	O

Subsequently	12165618	1819	O
,	-	1831	O
the	-	1833	O
serum	-	1837	O
creatinine	-	1843	O
levels	-	1854	O
decreased	-	1861	O
,	-	1870	O
the	-	1872	O
urine	-	1876	O
albumin	-	1882	O
/	-	1889	O
creatinine	-	1890	O
ratios	-	1901	O
returned	-	1908	O
to	-	1917	O
zero	-	1920	O
,	-	1924	O
and	-	1926	O
the	-	1930	O
leukocyturia	-	1934	B
disappeared	-	1947	O
within	-	1959	O
3	-	1966	O
months	-	1968	O
.	-	1974	O

CONCLUSIONS	12165618	1976	O
:	-	1987	O

Children	12165618	1989	O
treated	-	1998	O
with	-	2006	O
indinavir	-	2011	O
have	-	2021	O
a	-	2026	O
high	-	2028	O
cumulative	-	2033	O
incidence	-	2044	O
of	-	2054	O
persistent	-	2057	O
sterile	-	2068	O
leukocyturia	-	2076	B
.	-	2088	O

Children	12165618	2090	O
with	-	2099	O
persistent	-	2104	O
sterile	-	2115	O
leukocyturia	-	2123	B
more	-	2136	O
frequently	-	2141	O
had	-	2152	O
an	-	2156	O
increase	-	2159	O
in	-	2168	O
serum	-	2171	O
creatinine	-	2177	O
levels	-	2188	O
of	-	2195	O
>	-	2198	O
50	-	2199	O
%	-	2201	O
above	-	2203	O
normal	-	2209	O
.	-	2215	O

Younger	12165618	2217	O
children	-	2225	O
have	-	2234	O
an	-	2239	O
additional	-	2242	O
risk	-	2253	O
for	-	2258	O
renal	-	2262	O
complications	-	2268	O
.	-	2281	O

The	12165618	2283	O
impairment	-	2287	B
of	-	2298	I
the	-	2301	I
renal	-	2305	I
function	-	2311	I
in	-	2320	O
these	-	2323	O
children	-	2329	O
occurred	-	2338	O
in	-	2347	O
the	-	2350	O
absence	-	2354	O
of	-	2362	O
clinical	-	2365	O
symptoms	-	2374	O
of	-	2383	O
nephrolithiasis	-	2386	B
.	-	2401	O

Indinavir	12165618	2403	O
-	-	2412	O
associated	-	2413	O
nephrotoxicity	-	2424	B
must	-	2439	O
be	-	2444	O
monitored	-	2447	O
closely	-	2457	O
,	-	2464	O
especially	-	2466	O
in	-	2477	O
children	-	2480	O
with	-	2489	O
risk	-	2494	O
factors	-	2499	O
such	-	2507	O
as	-	2512	O
persistent	-	2515	O
sterile	-	2526	O
leukocyturia	-	2534	B
,	-	2546	O
age	-	2548	O
<	-	2552	O
5	-	2553	O
.	-	2554	O
6	-	2555	O
years	-	2557	O
,	-	2562	O
an	-	2564	O
area	-	2567	O
under	-	2572	O
the	-	2578	O
curve	-	2582	O
of	-	2588	O
indinavir	-	2591	O
>	-	2601	O
19	-	2602	O
mg	-	2605	O
/	-	2607	O
L	-	2608	O
x	-	2610	O
h	-	2612	O
,	-	2613	O
and	-	2615	O
a	-	2619	O
C	-	2621	O
(	-	2622	O
max	-	2623	O
)	-	2626	O
>	-	2628	O
12	-	2629	O
mg	-	2632	O
/	-	2634	O
L	-	2635	O
.	-	2636	O

Utility	12359538	0	O
of	-	8	O
troponin	-	11	O
I	-	20	O
in	-	22	O
patients	-	25	O
with	-	34	O
cocaine	-	39	O
-	-	46	O
associated	-	47	O
chest	-	58	B
pain	-	64	I
.	-	68	O

Baseline	12359538	70	O
electrocardiogram	-	79	O
abnormalities	-	97	O
and	-	111	O
market	-	115	O
elevations	-	122	O
not	-	133	O
associated	-	137	O
with	-	148	O
myocardial	-	153	B
necrosis	-	164	I
make	-	173	O
accurate	-	178	O
diagnosis	-	187	O
of	-	197	O
myocardial	-	200	B
infarction	-	211	I
(	-	222	O
MI	-	223	B
)	-	225	O
difficult	-	227	O
in	-	237	O
patients	-	240	O
with	-	249	O
cocaine	-	254	O
-	-	261	O
associated	-	262	O
chest	-	273	B
pain	-	279	I
.	-	283	O

Troponin	12359538	285	O
sampling	-	294	O
may	-	303	O
offer	-	307	O
greater	-	313	O
diagnostic	-	321	O
utility	-	332	O
in	-	340	O
these	-	343	O
patients	-	349	O
.	-	357	O

OBJECTIVE	12359538	359	O
:	-	368	O

To	12359538	370	O
assess	-	373	O
outcomes	-	380	O
based	-	389	O
on	-	395	O
troponin	-	398	O
positivity	-	407	O
in	-	418	O
patients	-	421	O
with	-	430	O
cocaine	-	435	O
chest	-	443	B
pain	-	449	I
admitted	-	454	O
for	-	463	O
exclusion	-	467	O
of	-	477	O
MI	-	480	B
.	-	482	O

METHODS	12359538	484	O
:	-	491	O

Outcomes	12359538	493	O
were	-	502	O
examined	-	507	O
in	-	516	O
patients	-	519	O
admitted	-	528	O
for	-	537	O
possible	-	541	O
MI	-	550	B
after	-	553	O
cocaine	-	559	O
use	-	567	O
.	-	570	O

All	12359538	572	O
patients	-	576	O
underwent	-	585	O
a	-	595	O
rapid	-	597	O
rule	-	603	O
-	-	607	O
in	-	608	O
protocol	-	611	O
that	-	620	O
included	-	625	O
serial	-	634	O
sampling	-	641	O
of	-	650	O
creatine	-	653	O
kinase	-	662	O
(	-	669	O
CK	-	670	O
)	-	672	O
,	-	673	O
CK	-	675	O
-	-	677	O
MB	-	678	O
,	-	680	O
and	-	682	O
cardiac	-	686	O
troponin	-	694	O

I	12359538	703	O
(	-	705	O
cTnI	-	706	O
)	-	710	O
over	-	712	O
eight	-	717	O
hours	-	723	O
.	-	728	O

Outcomes	12359538	730	O
included	-	739	O
CK	-	748	O
-	-	750	O
MB	-	751	O
MI	-	754	B
(	-	757	O
CK	-	758	O
-	-	760	O
MB	-	761	O

>	12359538	764	O

or	12359538	765	O
=	-	767	O
8	-	769	O
ng	-	771	O
/	-	773	O
mL	-	774	O
with	-	777	O
a	-	782	O
relative	-	784	O
index	-	793	O
[	-	799	O
(	-	800	O
CK	-	801	O
-	-	803	O
MB	-	804	O
x	-	807	O
100	-	809	O
)	-	812	O
/	-	813	O
total	-	814	O
CK	-	820	O
]	-	822	O

>	12359538	824	O
or	-	825	O
=	-	827	O
4	-	829	O
,	-	830	O
cardiac	-	832	B
death	-	840	I
,	-	845	O
and	-	847	O
significant	-	851	O
coronary	-	863	B
disease	-	872	I
(	-	880	O
>	-	881	O
or	-	882	O
=	-	884	O
50	-	885	O
%	-	887	O
)	-	888	O
.	-	889	O

RESULTS	12359538	891	O
:	-	898	O

Of	12359538	900	O
the	-	903	O
246	-	907	O
admitted	-	911	O
patients	-	920	O
,	-	928	O
34	-	930	O
(	-	933	O
14	-	934	O
%	-	936	O
)	-	937	O
met	-	939	O
CK	-	943	O
-	-	945	O
MB	-	946	O
criteria	-	949	O
for	-	958	O
MI	-	962	B
and	-	965	O
38	-	969	O
(	-	972	O
16	-	973	O
%	-	975	O
)	-	976	O
had	-	978	O
cTnI	-	982	O
elevations	-	987	O
.	-	997	O

Angiography	12359538	999	O
was	-	1011	O
performed	-	1015	O
in	-	1025	O
29	-	1028	O
of	-	1031	O
38	-	1034	O
patients	-	1037	O
who	-	1046	O
were	-	1050	O
cTnI	-	1055	O
-	-	1059	O
positive	-	1060	O
,	-	1068	O
with	-	1070	O
significant	-	1075	O
disease	-	1087	O
present	-	1095	O
in	-	1103	O
25	-	1106	O
(	-	1109	O
86	-	1110	O
%	-	1112	O
)	-	1113	O
.	-	1114	O

Three	12359538	1116	O
of	-	1122	O
the	-	1125	O
four	-	1129	O
patients	-	1134	O
without	-	1143	O
significant	-	1151	O
disease	-	1163	O
who	-	1171	O
had	-	1175	O
cTnI	-	1179	O
elevations	-	1184	O
met	-	1195	O
CK	-	1199	O
-	-	1201	O
MB	-	1202	O
criteria	-	1205	O
for	-	1214	O
MI	-	1218	B
,	-	1220	O
and	-	1222	O
the	-	1226	O
other	-	1230	O
had	-	1236	O
a	-	1240	O
peak	-	1242	O
CK	-	1247	O
-	-	1249	O
MB	-	1250	O
level	-	1253	O
of	-	1259	O
13	-	1262	O
ng	-	1265	O
/	-	1267	O
mL	-	1268	O
.	-	1270	O
Sensitivities	-	1272	O
,	-	1285	O
specificities	-	1287	O
,	-	1300	O
and	-	1302	O
positive	-	1306	O
and	-	1315	O
negative	-	1319	O
likelihood	-	1328	O
ratios	-	1339	O
for	-	1346	O
predicting	-	1350	O
cardiac	-	1361	B
death	-	1369	I
or	-	1375	O
significant	-	1378	O
disease	-	1390	O
were	-	1398	O
high	-	1403	O
for	-	1408	O
both	-	1412	O
CK	-	1417	O
-	-	1419	O
MB	-	1420	O
MI	-	1423	B
and	-	1426	O
cTnI	-	1430	O
and	-	1435	O
were	-	1439	O
not	-	1444	O
significantly	-	1448	O
different	-	1462	O
.	-	1471	O

CONCLUSIONS	12359538	1473	O
:	-	1484	O

Most	12359538	1486	O
patients	-	1491	O
with	-	1500	O
cTnI	-	1505	O
elevations	-	1510	O
meet	-	1521	O
CK	-	1526	O
-	-	1528	O
MB	-	1529	O
criteria	-	1532	O
for	-	1541	O
MI	-	1545	B
,	-	1547	O
as	-	1549	O
well	-	1552	O
as	-	1557	O
have	-	1560	O
a	-	1565	O
high	-	1567	O
incidence	-	1572	O
of	-	1582	O
underlying	-	1585	O
significant	-	1596	O
disease	-	1608	O
.	-	1615	O

Troponin	12359538	1617	O
appears	-	1626	O
to	-	1634	O
have	-	1637	O
an	-	1642	O
equivalent	-	1645	O
diagnostic	-	1656	O
accuracy	-	1667	O
compared	-	1676	O
with	-	1685	O
CK	-	1690	O
-	-	1692	O
MB	-	1693	O
for	-	1696	O
diagnosing	-	1700	O
necrosis	-	1711	B
in	-	1720	O
patients	-	1723	O
with	-	1732	O
cocaine	-	1737	O
-	-	1744	O
associated	-	1745	O
chest	-	1756	B
pain	-	1762	I
and	-	1767	O
suspected	-	1771	O
MI	-	1781	B
.	-	1783	O

Acute	12372954	0	O
interstitial	-	6	B
nephritis	-	19	I
due	-	29	O
to	-	33	O
nicergoline	-	36	O
(	-	48	O
Sermion	-	49	O
)	-	56	O
.	-	57	O

We	12372954	59	O
report	-	62	O
a	-	69	O
case	-	71	O
of	-	76	O
acute	-	79	O
interstitial	-	85	B
nephritis	-	98	I
(	-	108	O
AIN	-	109	B
)	-	112	O
due	-	114	O
to	-	118	O
nicergoline	-	121	O
(	-	133	O
Sermion	-	134	O
)	-	141	O
.	-	142	O

A	12372954	144	O
50	-	146	O
-	-	148	O
year	-	149	O
-	-	153	O
old	-	154	O
patient	-	158	O
admitted	-	166	O
to	-	175	O
our	-	178	O
hospital	-	182	O
for	-	191	O
fever	-	195	B
and	-	201	O
acute	-	205	B
renal	-	211	I
failure	-	217	I
.	-	224	O

Before	12372954	226	O
admission	-	233	O
,	-	242	O
he	-	244	O
had	-	247	O
been	-	251	O
taking	-	256	O
nicergoline	-	263	O
and	-	275	O
bendazac	-	279	O
lysine	-	288	O
due	-	295	O
to	-	299	O
retinal	-	302	B
vein	-	310	I
occlusion	-	315	I
at	-	325	O
ophthalmologic	-	328	O
department	-	343	O
.	-	353	O

Thereafter	12372954	355	O
,	-	365	O
he	-	367	O
experienced	-	370	O
intermittent	-	382	O
fever	-	395	B
and	-	401	O
skin	-	405	B
rash	-	410	I
.	-	414	O

On	12372954	416	O
admission	-	419	O
,	-	428	O
clinical	-	430	O
symptoms	-	439	O
(	-	448	O
i	-	449	O
.	-	450	O
e	-	451	O
.	-	452	O
arthralgia	-	454	B
and	-	465	O
fever	-	469	B
)	-	474	O
and	-	476	O
laboratory	-	480	O
findings	-	491	O
(	-	500	O
i	-	501	O
.	-	502	O
e	-	503	O
.	-	504	O
eosinophilia	-	506	B
and	-	519	O
renal	-	523	B
failure	-	529	I
)	-	536	O
suggested	-	538	O
AIN	-	548	B
,	-	551	O
and	-	553	O
which	-	557	O
was	-	563	O
confirmed	-	567	O
by	-	577	O
pathologic	-	580	O
findings	-	591	O
on	-	600	O
renal	-	603	O
biopsy	-	609	O
.	-	615	O

A	12372954	617	O
lymphocyte	-	619	O
transformation	-	630	O
test	-	645	O
demonstrated	-	650	O
a	-	663	O
positive	-	665	O
result	-	674	O
against	-	681	O
nicergoline	-	689	O
.	-	700	O

Treatment	12372954	702	O
was	-	712	O
consisted	-	716	O
of	-	726	O
withdrawal	-	729	O
of	-	740	O
nicergoline	-	743	O
and	-	755	O
intravenous	-	759	O
methylprednisolone	-	771	O
,	-	789	O
and	-	791	O
his	-	795	O
renal	-	799	O
function	-	805	O
was	-	814	O
completely	-	818	O
recovered	-	829	O
.	-	838	O

To	12372954	840	O
our	-	843	O
knowledge	-	847	O
,	-	856	O
this	-	858	O
is	-	863	O
the	-	866	O
first	-	870	O
report	-	876	O
of	-	883	O
nicergoline	-	886	O
-	-	897	O
associated	-	898	O
AIN	-	909	B
.	-	912	O

Neuroleptic	12452552	0	B
malignant	-	12	I
syndrome	-	22	I
complicated	-	31	O
by	-	43	O
massive	-	46	O
intestinal	-	54	O
bleeding	-	65	B
in	-	74	O
a	-	77	O
patient	-	79	O
with	-	87	O
chronic	-	92	B
renal	-	100	I
failure	-	106	I
.	-	113	O

A	12452552	115	O
patient	-	117	O
with	-	125	O
chronic	-	130	B
renal	-	138	I
failure	-	144	I
(	-	152	O
CRF	-	153	B
)	-	156	O
developed	-	158	O
neuroleptic	-	168	B
malignant	-	180	I
syndrome	-	190	I
(	-	199	O
NMS	-	200	B
)	-	203	O
after	-	205	O
administration	-	211	O
of	-	226	O
risperidone	-	229	O
and	-	241	O
levomepromazine	-	245	O
.	-	260	O

In	12452552	262	O
addition	-	265	O
to	-	274	O
the	-	277	O
typical	-	281	O
symptoms	-	289	O
of	-	298	O
NMS	-	301	B
,	-	304	O
massive	-	306	O
intestinal	-	314	O
bleeding	-	325	B
was	-	334	O
observed	-	338	O
during	-	347	O
the	-	354	O
episode	-	358	O
.	-	365	O

This	12452552	367	O
report	-	372	O
suggests	-	379	O
that	-	388	O
NMS	-	393	B
in	-	397	O
a	-	400	O
patient	-	402	O
with	-	410	O
CRF	-	415	B
may	-	419	O
be	-	423	O
complicated	-	426	O
by	-	438	O
intestinal	-	441	O
bleeding	-	452	B
and	-	461	O
needs	-	465	O
special	-	471	O
caution	-	479	O
for	-	487	O
this	-	491	O
complication	-	496	O
.	-	508	O

Blood	12487093	0	O
brain	-	6	O
barrier	-	12	O
in	-	20	O
right	-	23	O
-	-	28	O
and	-	30	O
left	-	34	O
-	-	38	O
pawed	-	39	O
female	-	45	O
rats	-	52	O
assessed	-	57	O
by	-	66	O
a	-	69	O
new	-	71	O
staining	-	75	O
method	-	84	O
.	-	90	O

The	12487093	92	O
asymmetrical	-	96	O
breakdown	-	109	O
of	-	119	O
the	-	122	O
blood	-	126	O
-	-	131	O
brain	-	132	O
barrier	-	138	O
(	-	146	O
BBB	-	147	O
)	-	150	O
was	-	152	O
studied	-	156	O
in	-	164	O
female	-	167	O
rats	-	174	O
.	-	178	O

Paw	12487093	180	O
preference	-	184	O
was	-	195	O
assessed	-	199	O
by	-	208	O
a	-	211	O
food	-	213	O
reaching	-	218	O
test	-	227	O
.	-	231	O

Adrenaline	12487093	233	O
-	-	243	O
induced	-	244	O
hypertension	-	252	B
was	-	265	O
used	-	269	O
to	-	274	O
destroy	-	277	O
the	-	285	O
BBB	-	289	O
,	-	292	O
which	-	294	O
was	-	300	O
evaluated	-	304	O
using	-	314	O
triphenyltetrazolium	-	320	O
(	-	341	O
TTC	-	342	O
)	-	345	O
staining	-	347	O
of	-	356	O
the	-	359	O
brain	-	363	O
slices	-	369	O
just	-	376	O
after	-	381	O
giving	-	387	O
adrenaline	-	394	O
for	-	405	O
30	-	409	O
s	-	412	O
.	-	413	O

In	12487093	415	O
normal	-	418	O
rats	-	425	O
,	-	429	O
the	-	431	O
whole	-	435	O
brain	-	441	O
sections	-	447	O
exhibited	-	456	O
complete	-	466	O
staining	-	475	O
with	-	484	O
TTC	-	489	O
.	-	492	O

After	12487093	494	O
adrenaline	-	500	O
infusion	-	511	O
for	-	520	O
30	-	524	O
s	-	527	O
,	-	528	O
there	-	530	O
were	-	536	O
large	-	541	O
unstained	-	547	O
areas	-	557	O
in	-	563	O
the	-	566	O
left	-	570	O
brain	-	575	O
in	-	581	O
right	-	584	O
-	-	589	O
pawed	-	590	O
animals	-	596	O
,	-	603	O
and	-	605	O
vice	-	609	O
versa	-	614	O
in	-	620	O
left	-	623	O
-	-	627	O
pawed	-	628	O
animals	-	634	O
.	-	641	O

Similar	12487093	643	O
results	-	651	O
were	-	659	O
obtained	-	664	O
in	-	673	O
seizure	-	676	B
-	-	683	O
induced	-	684	O
breakdown	-	692	O
of	-	702	O
BBB	-	705	O
.	-	708	O

These	12487093	710	O
results	-	716	O
were	-	724	O
explained	-	729	O
by	-	739	O
an	-	742	O
asymmetric	-	745	O
cerebral	-	756	O
blood	-	765	O
flow	-	771	O
depending	-	776	O
upon	-	786	O
the	-	791	O
paw	-	795	O
preference	-	799	O
in	-	810	O
rats	-	813	O
.	-	817	O

It	12487093	819	O
was	-	822	O
suggested	-	826	O
that	-	836	O
this	-	841	O
new	-	846	O
method	-	850	O
and	-	857	O
the	-	861	O
results	-	865	O
are	-	873	O
consistent	-	877	O
with	-	888	O
contralateral	-	893	O
motor	-	907	O
control	-	913	O
that	-	921	O
may	-	926	O
be	-	930	O
important	-	933	O
in	-	943	O
determining	-	946	O
the	-	958	O
dominant	-	962	O
cerebral	-	971	O
hemisphere	-	980	O
in	-	991	O
animals	-	994	O
.	-	1001	O

Carvedilol	12498738	0	O
protects	-	11	O
against	-	20	O
doxorubicin	-	28	O
-	-	39	O
induced	-	40	O
mitochondrial	-	48	O
cardiomyopathy	-	62	B
.	-	76	O

Several	12498738	78	O
cytopathic	-	86	O
mechanisms	-	97	O
have	-	108	O
been	-	113	O
suggested	-	118	O
to	-	128	O
mediate	-	131	O
the	-	139	O
dose	-	143	O
-	-	147	O
limiting	-	148	O
cumulative	-	157	O
and	-	168	O
irreversible	-	172	O
cardiomyopathy	-	185	B
caused	-	200	O
by	-	207	O
doxorubicin	-	210	O
.	-	221	O

Recent	12498738	223	O
evidence	-	230	O
indicates	-	239	O
that	-	249	O
oxidative	-	254	O
stress	-	264	O
and	-	271	O
mitochondrial	-	275	B
dysfunction	-	289	I
are	-	301	O
key	-	305	O
factors	-	309	O
in	-	317	O
the	-	320	O
pathogenic	-	324	O
process	-	335	O
.	-	342	O

The	12498738	344	O
objective	-	348	O
of	-	358	O
this	-	361	O
investigation	-	366	O
was	-	380	O
to	-	384	O
test	-	387	O
the	-	392	O
hypothesis	-	396	O
that	-	407	O
carvedilol	-	412	O
,	-	422	O
a	-	424	O
nonselective	-	426	O
beta	-	439	O
-	-	443	O
adrenergic	-	444	O
receptor	-	455	O
antagonist	-	464	O
with	-	475	O
potent	-	480	O
antioxidant	-	487	O
properties	-	499	O
,	-	509	O
protects	-	511	O
against	-	520	O
the	-	528	O
cardiac	-	532	O
and	-	540	O
hepatic	-	544	O
mitochondrial	-	552	O
bioenergetic	-	566	O
dysfunction	-	579	O
associated	-	591	O
with	-	602	O
subchronic	-	607	O
doxorubicin	-	618	O
toxicity	-	630	B
.	-	638	O

Heart	12498738	640	O
and	-	646	O
liver	-	650	O
mitochondria	-	656	O
were	-	669	O
isolated	-	674	O
from	-	683	O
rats	-	688	O
treated	-	693	O
for	-	701	O
7	-	705	O
weeks	-	707	O
with	-	713	O
doxorubicin	-	718	O
(	-	730	O
2	-	731	O
mg	-	733	O
/	-	735	O
kg	-	736	O
sc	-	739	O
/	-	741	O
week	-	742	O
)	-	746	O
,	-	747	O
carvedilol	-	749	O
(	-	760	O
1	-	761	O
mg	-	763	O
/	-	765	O
kg	-	766	O
ip	-	769	O
/	-	771	O
week	-	772	O
)	-	776	O
,	-	777	O
or	-	779	O
the	-	782	O
combination	-	786	O
of	-	798	O
the	-	801	O
two	-	805	O
drugs	-	809	O
.	-	814	O

Heart	12498738	816	O
mitochondria	-	822	O
isolated	-	835	O
from	-	844	O
doxorubicin	-	849	O
-	-	860	O
treated	-	861	O
rats	-	869	O
exhibited	-	874	O
depressed	-	884	O
rates	-	894	O
for	-	900	O
state	-	904	O
3	-	910	O
respiration	-	912	O
(	-	924	O
336	-	925	O
+	-	929	O
/	-	930	O
-	-	931	O

26	12498738	933	O
versus	-	936	O
425	-	943	O
+	-	947	O
/	-	948	O
-	-	949	O

53	12498738	951	O
natom	-	954	O
O	-	960	O
/	-	961	O
min	-	962	O
/	-	965	O
mg	-	966	O
protein	-	969	O
)	-	976	O
and	-	978	O
a	-	982	O
lower	-	984	O
respiratory	-	990	O
control	-	1002	O
ratio	-	1010	O
(	-	1016	O
RCR	-	1017	O
)	-	1020	O
(	-	1022	O
4	-	1023	O
.	-	1024	O
3	-	1025	O
+	-	1027	O
/	-	1028	O
-	-	1029	O

0	12498738	1031	O
.	-	1032	O
6	-	1033	O
versus	-	1035	O
5	-	1042	O
.	-	1043	O
8	-	1044	O
+	-	1046	O
/	-	1047	O
-	-	1048	O
0	-	1050	O
.	-	1051	O
4	-	1052	O
)	-	1053	O
compared	-	1055	O
with	-	1064	O
cardiac	-	1069	O
mitochondria	-	1077	O
isolated	-	1090	O
from	-	1099	O
saline	-	1104	O
-	-	1110	O
treated	-	1111	O
rats	-	1119	O
.	-	1123	O

Mitochondrial	12498738	1125	O
calcium	-	1139	O
-	-	1146	O
loading	-	1147	O
capacity	-	1155	O
and	-	1164	O
the	-	1168	O
activity	-	1172	O
of	-	1181	O
NADH	-	1184	O
-	-	1188	O
dehydrogenase	-	1189	O
were	-	1203	O
also	-	1208	O
suppressed	-	1213	O
in	-	1224	O
cardiac	-	1227	O
mitochondria	-	1235	O
from	-	1248	O
doxorubicin	-	1253	O
-	-	1264	O
treated	-	1265	O
rats	-	1273	O
.	-	1277	O

Doxorubicin	12498738	1279	O
treatment	-	1291	O
also	-	1301	O
caused	-	1306	O
a	-	1313	O
decrease	-	1315	O
in	-	1324	O
RCR	-	1327	O
for	-	1331	O
liver	-	1335	O
mitochondria	-	1341	O
(	-	1354	O
3	-	1355	O
.	-	1356	O
9	-	1357	O
+	-	1359	O
/	-	1360	O
-	-	1361	O

0	12498738	1363	O
.	-	1364	O
9	-	1365	O
versus	-	1367	O
5	-	1374	O
.	-	1375	O
6	-	1376	O
+	-	1378	O
/	-	1379	O
-	-	1380	O

0	12498738	1382	O
.	-	1383	O
7	-	1384	O
for	-	1386	O
control	-	1390	O
rats	-	1398	O
)	-	1402	O
and	-	1404	O
inhibition	-	1408	O
of	-	1419	O
hepatic	-	1422	O
cytochrome	-	1430	O
oxidase	-	1441	O
activity	-	1449	O
.	-	1457	O

Coadministration	12498738	1459	O
of	-	1476	O
carvedilol	-	1479	O
decreased	-	1490	O
the	-	1500	O
extent	-	1504	O
of	-	1511	O
cellular	-	1514	O
vacuolization	-	1523	O
in	-	1537	O
cardiac	-	1540	O
myocytes	-	1548	O
and	-	1557	O
prevented	-	1561	O
the	-	1571	O
inhibitory	-	1575	O
effect	-	1586	O
of	-	1593	O
doxorubicin	-	1596	O
on	-	1608	O
mitochondrial	-	1611	O
respiration	-	1625	O
in	-	1637	O
both	-	1640	O
heart	-	1645	O
and	-	1651	O
liver	-	1655	O
.	-	1660	O

Carvedilol	12498738	1662	O
also	-	1673	O
prevented	-	1678	O
the	-	1688	O
decrease	-	1692	O
in	-	1701	O
mitochondrial	-	1704	O
Ca	-	1718	O
(	-	1720	O
2	-	1721	O
+	-	1722	O
)	-	1723	O
loading	-	1725	O
capacity	-	1733	O
and	-	1742	O
the	-	1746	O
inhibition	-	1750	O
of	-	1761	O
the	-	1764	O
respiratory	-	1768	O
complexes	-	1780	O
of	-	1790	O
heart	-	1793	O
mitochondria	-	1799	O
caused	-	1812	O
by	-	1819	O
doxorubicin	-	1822	O
.	-	1833	O

Carvedilol	12498738	1835	O
by	-	1846	O
itself	-	1849	O
did	-	1856	O
not	-	1860	O
affect	-	1864	O
any	-	1871	O
of	-	1875	O
the	-	1878	O
parameters	-	1882	O
measured	-	1893	O
for	-	1902	O
heart	-	1906	O
or	-	1912	O
liver	-	1915	O
mitochondria	-	1921	O
.	-	1933	O

It	12498738	1935	O
is	-	1938	O
concluded	-	1941	O
that	-	1951	O
this	-	1956	O
protection	-	1961	O
by	-	1972	O
carvedilol	-	1975	O
against	-	1986	O
both	-	1994	O
the	-	1999	O
structural	-	2003	O
and	-	2014	O
functional	-	2018	O
cardiac	-	2029	O
tissue	-	2037	O
damage	-	2044	O
may	-	2051	O
afford	-	2055	O
significant	-	2062	O
clinical	-	2074	O
advantage	-	2083	O
in	-	2093	O
minimizing	-	2096	O
the	-	2107	O
dose	-	2111	O
-	-	2115	O
limiting	-	2116	O
mitochondrial	-	2125	B
dysfunction	-	2139	I
and	-	2151	O
cardiomyopathy	-	2155	B
that	-	2170	O
accompanies	-	2175	O
long	-	2187	O
-	-	2191	O
term	-	2192	O
doxorubicin	-	2197	O
therapy	-	2209	O
in	-	2217	O
cancer	-	2220	B
patients	-	2227	O
.	-	2235	O

Cocaine	12523489	0	O
-	-	7	O
induced	-	8	O
hyperactivity	-	16	B
is	-	30	O
more	-	33	O
influenced	-	38	O
by	-	49	O
adenosine	-	52	O
receptor	-	62	O
agonists	-	71	O
than	-	80	O
amphetamine	-	85	O
-	-	96	O
induced	-	97	O
hyperactivity	-	105	B
.	-	118	O

The	12523489	120	O
influence	-	124	O
of	-	134	O
adenosine	-	137	O
receptor	-	147	O
agonists	-	156	O
and	-	165	O
antagonists	-	169	O
on	-	181	O
cocaine	-	184	O
-	-	191	O
and	-	192	O
amphetamine	-	196	O
-	-	207	O
induced	-	208	O
hyperactivity	-	216	B
was	-	230	O
examined	-	234	O
in	-	243	O
mice	-	246	O
.	-	250	O

All	12523489	252	O
adenosine	-	256	O
receptor	-	266	O
agonists	-	275	O
significantly	-	284	O
decreased	-	298	B
the	-	308	I
locomotor	-	312	I
activity	-	322	I
in	-	331	O
mice	-	334	O
,	-	338	O
and	-	340	O
the	-	344	O
effects	-	348	O
were	-	356	O
dose	-	361	O
-	-	365	O
dependent	-	366	O
.	-	375	O

It	12523489	377	O
seems	-	380	O
that	-	386	O
adenosine	-	391	O
A1	-	401	O
and	-	404	O
A2	-	408	O
receptors	-	411	O
might	-	421	O
be	-	427	O
involved	-	430	O
in	-	439	O
this	-	442	O
reaction	-	447	O
.	-	455	O

Moreover	12523489	457	O
,	-	465	O
all	-	467	O
adenosine	-	471	O
receptor	-	481	O
agonists	-	490	O
:	-	498	O
2	-	500	O
-	-	501	O
p	-	502	O
-	-	503	O
(	-	504	O
2	-	505	O
-	-	506	O
carboxyethyl	-	507	O
)	-	519	O
phenethylamino	-	520	O
-	-	534	O
5'	-	535	O
-	-	537	O
N	-	538	O
-	-	539	O
ethylcarboxamidoadenosine	-	540	O
(	-	566	O
CGS	-	567	O
21680	-	571	O
)	-	576	O
,	-	577	O
A2A	-	579	O
receptor	-	583	O
agonist	-	592	O
,	-	599	O
N6	-	601	O
-	-	603	O
cyclopentyladenosine	-	604	O
(	-	625	O
CPA	-	626	O
)	-	629	O
,	-	630	O
A1	-	632	O
receptor	-	635	O
agonist	-	644	O
,	-	651	O
and	-	653	O
5'	-	657	O
-	-	659	O
N	-	660	O
-	-	661	O
ethylcarboxamidoadenosine	-	662	O
(	-	688	O
NECA	-	689	O
)	-	693	O
,	-	694	O
A2	-	696	O
/	-	698	O
A1	-	699	O
receptor	-	702	O
agonist	-	711	O
significantly	-	719	O
and	-	733	O
dose	-	737	O
-	-	741	O
dependently	-	742	O
decreased	-	754	O
cocaine	-	764	O
-	-	771	O
induced	-	772	O
locomotor	-	780	O
activity	-	790	O
.	-	798	O

CPA	12523489	800	O
reduced	-	804	O
cocaine	-	812	O
action	-	820	O
at	-	827	O
the	-	830	O
doses	-	834	O
which	-	840	O
,	-	845	O
given	-	847	O
alone	-	853	O
,	-	858	O
did	-	860	O
not	-	864	O
influence	-	868	O
motility	-	878	O
,	-	886	O
while	-	888	O
CGS	-	894	O
21680	-	898	O
and	-	904	O
NECA	-	908	O
decreased	-	913	O
the	-	923	O
action	-	927	O
of	-	934	O
cocaine	-	937	O
at	-	945	O
the	-	948	O
doses	-	952	O
which	-	958	O
,	-	963	O
given	-	965	O
alone	-	971	O
,	-	976	O
decreased	-	978	O
locomotor	-	988	O
activity	-	998	O
in	-	1007	O
animals	-	1010	O
.	-	1017	O

These	12523489	1019	O
results	-	1025	O
suggest	-	1033	O
the	-	1041	O
involvement	-	1045	O
of	-	1057	O
both	-	1060	O
adenosine	-	1065	O
receptors	-	1075	O
in	-	1085	O
the	-	1088	O
action	-	1092	O
of	-	1099	O
cocaine	-	1102	O
although	-	1110	O
agonists	-	1119	O
of	-	1128	O
A1	-	1131	O
receptors	-	1134	O
seem	-	1144	O
to	-	1149	O
have	-	1152	O
stronger	-	1157	O
influence	-	1166	O
on	-	1176	O
it	-	1179	O
.	-	1181	O

The	12523489	1183	O
selective	-	1187	O
blockade	-	1197	O
of	-	1206	O
A2	-	1209	O
adenosine	-	1212	O
receptor	-	1222	O
by	-	1231	O
DMPX	-	1234	O
(	-	1239	O
3	-	1240	O
,	-	1241	O
7	-	1242	O
-	-	1243	O
dimethyl	-	1244	O
-	-	1252	O
1	-	1253	O
-	-	1254	O
propargylxanthine	-	1255	O
)	-	1272	O
significantly	-	1274	O
enhanced	-	1288	O
cocaine	-	1297	O
-	-	1304	O
induced	-	1305	O
locomotor	-	1313	O
activity	-	1323	O
of	-	1332	O
animals	-	1335	O
.	-	1342	O

Caffeine	12523489	1344	O
had	-	1353	O
similar	-	1357	O
action	-	1365	O
but	-	1372	O
the	-	1376	O
effect	-	1380	O
was	-	1387	O
not	-	1391	O
significant	-	1395	O
.	-	1406	O

CPT	12523489	1408	O
(	-	1412	O
8	-	1413	O
-	-	1414	O
cyclopentyltheophylline	-	1415	O
)	-	1438	O
-	-	1439	O
-	-	1440	O
A1	-	1441	O
receptor	-	1444	O
antagonist	-	1453	O
,	-	1463	O
did	-	1465	O
not	-	1469	O
show	-	1473	O
any	-	1478	O
influence	-	1482	O
in	-	1492	O
this	-	1495	O
test	-	1500	O
.	-	1504	O

Similarly	12523489	1506	O
,	-	1515	O
all	-	1517	O
adenosine	-	1521	O
receptor	-	1531	O
agonists	-	1540	O
decreased	-	1549	O
amphetamine	-	1559	O
-	-	1570	O
induced	-	1571	O
hyperactivity	-	1579	B
,	-	1592	O
but	-	1594	O
at	-	1598	O
the	-	1601	O
higher	-	1605	O
doses	-	1612	O
than	-	1618	O
those	-	1623	O
which	-	1629	O
were	-	1635	O
active	-	1640	O
in	-	1647	O
cocaine	-	1650	O
-	-	1657	O
induced	-	1658	O
hyperactivity	-	1666	B
.	-	1679	O

The	12523489	1681	O
selective	-	1685	O
blockade	-	1695	O
of	-	1704	O
A2	-	1707	O
adenosine	-	1710	O
receptors	-	1720	O
(	-	1730	O
DMPX	-	1731	O
)	-	1735	O
and	-	1737	O
non	-	1741	O
-	-	1744	O
selective	-	1745	O
blockade	-	1755	O
of	-	1764	O
adenosine	-	1767	O
receptors	-	1777	O
(	-	1787	O
caffeine	-	1788	O
)	-	1796	O
significantly	-	1798	O
increased	-	1812	O
the	-	1822	O
action	-	1826	O
of	-	1833	O
amphetamine	-	1836	O
in	-	1848	O
the	-	1851	O
locomotor	-	1855	O
activity	-	1865	O
test	-	1874	O
.	-	1878	O

Our	12523489	1880	O
results	-	1884	O
have	-	1892	O
shown	-	1897	O
that	-	1903	O
all	-	1908	O
adenosine	-	1912	O
receptor	-	1922	O
agonists	-	1931	O
(	-	1940	O
A1	-	1941	O
and	-	1944	O
A2	-	1948	O
)	-	1950	O
reduce	-	1952	O
cocaine	-	1959	O
-	-	1966	O
and	-	1968	O
amphetamine	-	1972	O
-	-	1983	O
induced	-	1984	O
locomotor	-	1992	O
activity	-	2002	O
and	-	2011	O
indicate	-	2015	O
that	-	2024	O
cocaine	-	2029	O
-	-	2036	O
induced	-	2037	O
hyperactivity	-	2045	B
is	-	2059	O
more	-	2062	O
influenced	-	2067	O
by	-	2078	O
adenosine	-	2081	O
receptor	-	2091	O
agonists	-	2100	O
(	-	2109	O
particularly	-	2110	O
A1	-	2123	O
receptors	-	2126	O
)	-	2135	O
than	-	2137	O
amphetamine	-	2142	O
-	-	2153	O
induced	-	2154	O
hyperactivity	-	2162	B
.	-	2175	O

Amiodarone	12535818	0	O
and	-	11	O
the	-	15	O
risk	-	19	O
of	-	24	O
bradyarrhythmia	-	27	B
requiring	-	43	O
permanent	-	53	O
pacemaker	-	63	O
in	-	73	O
elderly	-	76	O
patients	-	84	O
with	-	93	O
atrial	-	98	B
fibrillation	-	105	I
and	-	118	O
prior	-	122	O
myocardial	-	128	B
infarction	-	139	I
.	-	149	O

OBJECTIVES	12535818	151	O
:	-	161	O

The	12535818	163	O
aim	-	167	O
of	-	171	O
this	-	174	O
study	-	179	O
was	-	185	O
to	-	189	O
determine	-	192	O
whether	-	202	O
the	-	210	O
use	-	214	O
of	-	218	O
amiodarone	-	221	O
in	-	232	O
patients	-	235	O
with	-	244	O
atrial	-	249	B
fibrillation	-	256	I
(	-	269	O
AF	-	270	B
)	-	272	O
increases	-	274	O
the	-	284	O
risk	-	288	O
of	-	293	O
bradyarrhythmia	-	296	B
requiring	-	312	O
a	-	322	O
permanent	-	324	O
pacemaker	-	334	O
.	-	343	O

BACKGROUND	12535818	345	O
:	-	355	O
Reports	-	357	O
of	-	365	O
severe	-	368	O
bradyarrhythmia	-	375	B
during	-	391	O
amiodarone	-	398	O
therapy	-	409	O
are	-	417	O
infrequent	-	421	O
and	-	432	O
limited	-	436	O
to	-	444	O
studies	-	447	O
assessing	-	455	O
the	-	465	O
therapy	-	469	O
's	-	476	O
use	-	479	O
in	-	483	O
the	-	486	O
management	-	490	O
of	-	501	O
patients	-	504	O
with	-	513	O
ventricular	-	518	B
arrhythmias	-	530	I
.	-	541	O

METHODS	12535818	543	O
:	-	550	O

A	12535818	552	O
study	-	554	O
cohort	-	560	O
of	-	567	O
8	-	570	O
,	-	571	O
770	-	572	O
patients	-	576	O
age	-	585	O
>	-	589	O
or	-	591	O
=	-	594	O
65	-	595	O
years	-	598	O
with	-	604	O
a	-	609	O
new	-	611	O
diagnosis	-	615	O
of	-	625	O
AF	-	628	B
was	-	631	O
identified	-	635	O
from	-	646	O
a	-	651	O
provincewide	-	653	O
database	-	666	O
of	-	675	O
Quebec	-	678	O
residents	-	685	O
with	-	695	O
a	-	700	O
myocardial	-	702	B
infarction	-	713	I
(	-	724	O
MI	-	725	B
)	-	727	O
between	-	729	O
1991	-	737	O
and	-	742	O
1999	-	746	O
.	-	750	O

Using	12535818	752	O
a	-	758	O
nested	-	760	O
case	-	767	O
-	-	771	O
control	-	772	O
design	-	780	O
,	-	786	O
477	-	788	O
cases	-	792	O
of	-	798	O
bradyarrhythmia	-	801	B
requiring	-	817	O
a	-	827	O
permanent	-	829	O
pacemaker	-	839	O
were	-	849	O
matched	-	854	O
(	-	862	O
1	-	863	O
:	-	864	O
4	-	865	O
)	-	866	O
to	-	868	O
1	-	871	O
,	-	872	O
908	-	873	O
controls	-	877	O
.	-	885	O

Multivariable	12535818	887	O
logistic	-	901	O
regression	-	910	O
was	-	921	O
used	-	925	O
to	-	930	O
estimate	-	933	O
the	-	942	O
odds	-	946	O
ratio	-	951	O
(	-	957	O
OR	-	958	O
)	-	960	O
of	-	962	O
pacemaker	-	965	O
insertion	-	975	O
associated	-	985	O
with	-	996	O
amiodarone	-	1001	O
use	-	1012	O
,	-	1015	O
controlling	-	1017	O
for	-	1029	O
baseline	-	1033	O
risk	-	1042	O
factors	-	1047	O
and	-	1055	O
exposure	-	1059	O
to	-	1068	O
sotalol	-	1071	O
,	-	1078	O
Class	-	1080	O
I	-	1086	O
antiarrhythmic	-	1088	O
agents	-	1103	O
,	-	1109	O
beta	-	1111	O
-	-	1115	O
blockers	-	1116	O
,	-	1124	O
calcium	-	1126	O
channel	-	1134	O
blockers	-	1142	O
,	-	1150	O
and	-	1152	O
digoxin	-	1156	O
.	-	1163	O

RESULTS	12535818	1165	O
:	-	1172	O

amiodarone	12535818	1174	O
use	-	1185	O
was	-	1189	O
associated	-	1193	O
with	-	1204	O
an	-	1209	O
increased	-	1212	O
risk	-	1222	O
of	-	1227	O
pacemaker	-	1230	O
insertion	-	1240	O
(	-	1250	O
OR	-	1251	O
:	-	1253	O
2	-	1255	O
.	-	1256	O
14	-	1257	O
,	-	1259	O
95	-	1261	O
%	-	1263	O
confidence	-	1265	O
interval	-	1276	O
[	-	1285	O
CI	-	1286	O
]	-	1288	O
:	-	1289	O
1	-	1291	O
.	-	1292	O
30	-	1293	O
to	-	1296	O
3	-	1299	O
.	-	1300	O
54	-	1301	O
)	-	1303	O
.	-	1304	O

This	12535818	1306	O
effect	-	1311	O
was	-	1318	O
modified	-	1322	O
by	-	1331	O
gender	-	1334	O
,	-	1340	O
with	-	1342	O
a	-	1347	O
greater	-	1349	O
risk	-	1357	O
in	-	1362	O
women	-	1365	O
versus	-	1371	O
men	-	1378	O
(	-	1382	O
OR	-	1383	O
:	-	1385	O
3	-	1387	O
.	-	1388	O
86	-	1389	O
,	-	1391	O
95	-	1393	O
%	-	1395	O
CI	-	1397	O
:	-	1399	O
1	-	1401	O
.	-	1402	O
70	-	1403	O
to	-	1406	O
8	-	1409	O
.	-	1410	O
75	-	1411	O
vs	-	1414	O
.	-	1416	O
OR	-	1418	O
:	-	1420	O
1	-	1422	O
.	-	1423	O
52	-	1424	O
,	-	1426	O
95	-	1428	O
%	-	1430	O
CI	-	1432	O
:	-	1434	O
0	-	1436	O
.	-	1437	O
80	-	1438	O
to	-	1441	O
2	-	1444	O
.	-	1445	O
89	-	1446	O
)	-	1448	O
.	-	1449	O

Digoxin	12535818	1451	O
was	-	1459	O
the	-	1463	O
only	-	1467	O
other	-	1472	O
medication	-	1478	O
associated	-	1489	O
with	-	1500	O
an	-	1505	O
increased	-	1508	O
risk	-	1518	O
of	-	1523	O
pacemaker	-	1526	O
insertion	-	1536	O
(	-	1546	O
OR	-	1547	O
:	-	1549	O
1	-	1551	O
.	-	1552	O
78	-	1553	O
,	-	1555	O
95	-	1557	O
%	-	1559	O
CI	-	1561	O
:	-	1563	O
1	-	1565	O
.	-	1566	O
37	-	1567	O
to	-	1570	O
2	-	1573	O
.	-	1574	O
31	-	1575	O
)	-	1577	O
.	-	1578	O

CONCLUSIONS	12535818	1580	O
:	-	1591	O

This	12535818	1593	O
study	-	1598	O
suggests	-	1604	O
that	-	1613	O
the	-	1618	O
use	-	1622	O
of	-	1626	O
amiodarone	-	1629	O
in	-	1640	O
elderly	-	1643	O
patients	-	1651	O
with	-	1660	O
AF	-	1665	B
and	-	1668	O
a	-	1672	O
previous	-	1674	O
MI	-	1683	B
increases	-	1686	O
the	-	1696	O
risk	-	1700	O
of	-	1705	O
bradyarrhythmia	-	1708	B
requiring	-	1724	O
a	-	1734	O
permanent	-	1736	O
pacemaker	-	1746	O
.	-	1755	O

The	12535818	1757	O
finding	-	1761	O
of	-	1769	O
an	-	1772	O
augmented	-	1775	O
risk	-	1785	O
of	-	1790	O
pacemaker	-	1793	O
insertion	-	1803	O
in	-	1813	O
elderly	-	1816	O
women	-	1824	O
receiving	-	1830	O
amiodarone	-	1840	O
requires	-	1851	O
further	-	1860	O
investigation	-	1868	O
.	-	1881	O

Indomethacin	12559315	0	O
-	-	12	O
induced	-	13	O
morphologic	-	21	O
changes	-	33	O
in	-	41	O
the	-	44	O
rat	-	48	O
urinary	-	52	O
bladder	-	60	O
epithelium	-	68	O
.	-	78	O

OBJECTIVES	12559315	80	O
:	-	90	O

To	12559315	92	O
evaluate	-	95	O
the	-	104	O
morphologic	-	108	O
changes	-	120	O
in	-	128	O
rat	-	131	O
urothelium	-	135	O
induced	-	146	O
by	-	154	O
indomethacin	-	157	O
.	-	169	O

Nonsteroidal	12559315	171	O
anti	-	184	O
-	-	188	O
inflammatory	-	189	O
drug	-	202	O
-	-	206	O
induced	-	207	O
cystitis	-	215	B
is	-	224	O
a	-	227	O
poorly	-	229	O
recognized	-	236	O
and	-	247	O
under	-	251	O
-	-	256	O
reported	-	257	O
condition	-	266	O
.	-	275	O

In	12559315	277	O
addition	-	280	O
to	-	289	O
tiaprofenic	-	292	O
acid	-	304	O
,	-	308	O
indomethacin	-	310	O
has	-	323	O
been	-	327	O
reported	-	332	O
to	-	341	O
be	-	344	O
associated	-	347	O
with	-	358	O
this	-	363	O
condition	-	368	O
.	-	377	O

METHODS	12559315	379	O
:	-	386	O

Three	12559315	388	O
groups	-	394	O
were	-	401	O
established	-	406	O
:	-	417	O
a	-	419	O
control	-	421	O
group	-	429	O
(	-	435	O
n	-	436	O
=	-	438	O
10	-	440	O
)	-	442	O
,	-	443	O
a	-	445	O
high	-	447	O
-	-	451	O
dose	-	452	O
group	-	457	O
(	-	463	O
n	-	464	O
=	-	466	O
10	-	468	O
)	-	470	O
,	-	471	O
treated	-	473	O
with	-	481	O
one	-	486	O
intraperitoneal	-	490	O
injection	-	506	O
of	-	516	O
indomethacin	-	519	O
20	-	532	O
mg	-	535	O
/	-	537	O
kg	-	538	O
,	-	540	O
and	-	542	O
a	-	546	O
therapeutic	-	548	O
dose	-	560	O
group	-	565	O
(	-	571	O
n	-	572	O
=	-	574	O
10	-	576	O
)	-	578	O
in	-	580	O
which	-	583	O
oral	-	589	O
indomethacin	-	594	O
was	-	607	O
administered	-	611	O
3	-	624	O
.	-	625	O
25	-	626	O
mg	-	629	O
/	-	631	O
kg	-	632	O
body	-	635	O
weight	-	640	O
daily	-	647	O
for	-	653	O
3	-	657	O
weeks	-	659	O
.	-	664	O

The	12559315	666	O
animals	-	670	O
were	-	678	O
then	-	683	O
killed	-	688	O
and	-	695	O
the	-	699	O
bladders	-	703	O
removed	-	712	O
for	-	720	O
light	-	724	O
and	-	730	O
electron	-	734	O
microscopic	-	743	O
studies	-	755	O
.	-	762	O

RESULTS	12559315	764	O
:	-	771	O

The	12559315	773	O
light	-	777	O
microscopic	-	783	O
findings	-	795	O
showed	-	804	O
some	-	811	O
focal	-	816	O
epithelial	-	822	O
degeneration	-	833	O
that	-	846	O
was	-	851	O
more	-	855	O
prominent	-	860	O
in	-	870	O
the	-	873	O
high	-	877	O
-	-	881	O
dose	-	882	O
group	-	887	O
.	-	892	O

When	12559315	894	O
compared	-	899	O
with	-	908	O
the	-	913	O
control	-	917	O
group	-	925	O
,	-	930	O
both	-	932	O
indomethacin	-	937	O
groups	-	950	O
revealed	-	957	O
statistically	-	966	O
increased	-	980	O
numbers	-	990	O
of	-	998	O
mast	-	1001	O
cells	-	1006	O
in	-	1012	O
the	-	1015	O
mucosa	-	1019	O
(	-	1026	O
P	-	1027	O
<	-	1029	O
0	-	1030	O
.	-	1031	O
0001	-	1032	O
)	-	1036	O
and	-	1038	O
penetration	-	1042	O
of	-	1054	O
lanthanum	-	1057	O
nitrate	-	1067	O
through	-	1075	O
intercellular	-	1083	O
areas	-	1097	O
of	-	1103	O
the	-	1106	O
epithelium	-	1110	O
.	-	1120	O

Furthermore	12559315	1122	O
,	-	1133	O
the	-	1135	O
difference	-	1139	O
in	-	1150	O
mast	-	1153	O
cell	-	1158	O
counts	-	1163	O
between	-	1170	O
the	-	1178	O
high	-	1182	O
and	-	1187	O
therapeutic	-	1191	O
dose	-	1203	O
groups	-	1208	O
was	-	1215	O
also	-	1219	O
statistically	-	1224	O
significant	-	1238	O
(	-	1250	O
P	-	1251	O
<	-	1253	O
0	-	1254	O
.	-	1255	O
0001	-	1256	O
)	-	1260	O
.	-	1261	O

CONCLUSIONS	12559315	1263	O
:	-	1274	O

Indomethacin	12559315	1276	O
resulted	-	1289	O
in	-	1298	O
histopathologic	-	1301	O
findings	-	1317	O
typical	-	1326	O
of	-	1334	O
interstitial	-	1337	B
cystitis	-	1350	I
,	-	1358	O
such	-	1360	O
as	-	1365	O
leaky	-	1368	O
bladder	-	1374	O
epithelium	-	1382	O
and	-	1393	O
mucosal	-	1397	O
mastocytosis	-	1405	B
.	-	1417	O

The	12559315	1419	O
true	-	1423	O
incidence	-	1428	O
of	-	1438	O
nonsteroidal	-	1441	O
anti	-	1454	O
-	-	1458	O
inflammatory	-	1459	O
drug	-	1472	O
-	-	1476	O
induced	-	1477	O
cystitis	-	1485	B
in	-	1494	O
humans	-	1497	O
must	-	1504	O
be	-	1509	O
clarified	-	1512	O
by	-	1522	O
prospective	-	1525	O
clinical	-	1537	O
trials	-	1546	O
.	-	1552	O

An	12644816	0	O
open	-	3	O
-	-	7	O
label	-	8	O
phase	-	14	O
II	-	20	O
study	-	23	O
of	-	29	O
low	-	32	O
-	-	35	O
dose	-	36	O
thalidomide	-	41	O
in	-	53	O
androgen	-	56	O
-	-	64	O
independent	-	65	O
prostate	-	77	B
cancer	-	86	I
.	-	92	O

The	12644816	94	O
antiangiogenic	-	98	O
effects	-	113	O
of	-	121	O
thalidomide	-	124	O
have	-	136	O
been	-	141	O
assessed	-	146	O
in	-	155	O
clinical	-	158	O
trials	-	167	O
in	-	174	O
patients	-	177	O
with	-	186	O
various	-	191	O
solid	-	199	O
and	-	205	O
haematological	-	209	B
malignancies	-	224	I
.	-	236	O

Thalidomide	12644816	238	O
blocks	-	250	O
the	-	257	O
activity	-	261	O
of	-	270	O
angiogenic	-	273	O
agents	-	284	O
including	-	291	O
bFGF	-	301	O
,	-	305	O
VEGF	-	307	O
and	-	312	O
IL	-	316	O
-	-	318	O
6	-	319	O
.	-	320	O

We	12644816	322	O
undertook	-	325	O
an	-	335	O
open	-	338	O
-	-	342	O
label	-	343	O
study	-	349	O
using	-	355	O
thalidomide	-	361	O
100	-	373	O
mg	-	377	O
once	-	380	O
daily	-	385	O
for	-	391	O
up	-	395	O
to	-	398	O
6	-	401	O
months	-	403	O
in	-	410	O
20	-	413	O
men	-	416	O
with	-	420	O
androgen	-	425	O
-	-	433	O
independent	-	434	O
prostate	-	446	B
cancer	-	455	I
.	-	461	O

The	12644816	463	O
mean	-	467	O
time	-	472	O
of	-	477	O
study	-	480	O
was	-	486	O
109	-	490	O
days	-	494	O
(	-	499	O
median	-	500	O
107	-	507	O
,	-	510	O
range	-	512	O
4	-	518	O
-	-	519	O
184	-	520	O
days	-	524	O
)	-	528	O
.	-	529	O

Patients	12644816	531	O
underwent	-	540	O
regular	-	550	O
measurement	-	558	O
of	-	570	O
prostate	-	573	O
-	-	581	O
specific	-	582	O
antigen	-	591	O
(	-	599	O
PSA	-	600	O
)	-	603	O
,	-	604	O
urea	-	606	O
and	-	611	O
electrolytes	-	615	O
,	-	627	O
serum	-	629	O
bFGF	-	635	O
and	-	640	O
VEGF	-	644	O
.	-	648	O

Three	12644816	650	O
men	-	656	O
(	-	660	O
15	-	661	O
%	-	663	O
)	-	664	O
showed	-	666	O
a	-	673	O
decline	-	675	O
in	-	683	O
serum	-	686	O
PSA	-	692	O
of	-	696	O
at	-	699	O
least	-	702	O
50	-	708	O
%	-	710	O
,	-	711	O
sustained	-	713	O
throughout	-	723	O
treatment	-	734	O
.	-	743	O

Of	12644816	745	O
16	-	748	O
men	-	751	O
treated	-	755	O
for	-	763	O
at	-	767	O
least	-	770	O
2	-	776	O
months	-	778	O
,	-	784	O
six	-	786	O
(	-	790	O
37	-	791	O
.	-	793	O
5	-	794	O
%	-	795	O
)	-	796	O
showed	-	798	O
a	-	805	O
fall	-	807	O
in	-	812	O
absolute	-	815	O
PSA	-	824	O
by	-	828	O
a	-	831	O
median	-	833	O
of	-	840	O
48	-	843	O
%	-	845	O
.	-	846	O

Increasing	12644816	848	O
levels	-	859	O
of	-	866	O
serum	-	869	O
bFGF	-	875	O
and	-	880	O
VEGF	-	884	O
were	-	889	O
associated	-	894	O
with	-	905	O
progressive	-	910	O
disease	-	922	O
;	-	929	O
five	-	931	O
of	-	936	O
six	-	939	O
men	-	943	O
who	-	947	O
demonstrated	-	951	O
a	-	964	O
fall	-	966	O
in	-	971	O
PSA	-	974	O
also	-	978	O
showed	-	983	O
a	-	990	O
decline	-	992	O
in	-	1000	O
bFGF	-	1003	O
and	-	1008	O
VEGF	-	1012	O
levels	-	1017	O
,	-	1023	O
and	-	1025	O
three	-	1029	O
of	-	1035	O
four	-	1038	O
men	-	1043	O
with	-	1047	O
a	-	1052	O
rising	-	1054	O
PSA	-	1061	O
showed	-	1065	O
an	-	1072	O
increase	-	1075	O
in	-	1084	O
both	-	1087	O
growth	-	1092	O
factors	-	1099	O
.	-	1106	O

Adverse	12644816	1108	O
effects	-	1116	O
included	-	1124	O
constipation	-	1133	B
,	-	1145	O
morning	-	1147	O
drowsiness	-	1155	B
,	-	1165	O
dizziness	-	1167	B
and	-	1177	O
rash	-	1181	B
,	-	1185	O
and	-	1187	O
resulted	-	1191	O
in	-	1200	O
withdrawal	-	1203	O
from	-	1214	O
the	-	1219	O
study	-	1223	O
by	-	1229	O
three	-	1232	O
men	-	1238	O
.	-	1241	O

Evidence	12644816	1243	O
of	-	1252	O
peripheral	-	1255	B
sensory	-	1266	I
neuropathy	-	1274	I
was	-	1285	O
found	-	1289	O
in	-	1295	O
nine	-	1298	O
of	-	1303	O
13	-	1306	O
men	-	1309	O
before	-	1313	O
treatment	-	1320	O
.	-	1329	O

In	12644816	1331	O
the	-	1334	O
seven	-	1338	O
men	-	1344	O
who	-	1348	O
completed	-	1352	O
six	-	1362	O
months	-	1366	O
on	-	1373	O
thalidomide	-	1376	O
,	-	1387	O
subclinical	-	1389	O
evidence	-	1401	O
of	-	1410	O
peripheral	-	1413	B
neuropathy	-	1424	I
was	-	1435	O
found	-	1439	O
in	-	1445	O
four	-	1448	O
before	-	1453	O
treatment	-	1460	O
,	-	1469	O
but	-	1471	O
in	-	1475	O
all	-	1478	O
seven	-	1482	O
at	-	1488	O
repeat	-	1491	O
testing	-	1498	O
.	-	1505	O

The	12644816	1507	O
findings	-	1511	O
indicate	-	1520	O
that	-	1529	O
thalidomide	-	1534	O
may	-	1546	O
be	-	1550	O
an	-	1553	O
option	-	1556	O
for	-	1563	O
patients	-	1567	O
who	-	1576	O
have	-	1580	O
failed	-	1585	O
other	-	1592	O
forms	-	1598	O
of	-	1604	O
therapy	-	1607	O
,	-	1614	O
provided	-	1616	O
close	-	1625	O
follow	-	1631	O
-	-	1637	O
up	-	1638	O
is	-	1641	O
maintained	-	1644	O
for	-	1655	O
development	-	1659	O
of	-	1671	O
peripheral	-	1674	B
neuropathy	-	1685	I
.	-	1695	O

Central	12677626	0	B
nervous	-	8	I
system	-	16	I
toxicity	-	23	I
following	-	32	O
the	-	42	O
administration	-	46	O
of	-	61	O
levobupivacaine	-	64	O
for	-	80	O
lumbar	-	84	O
plexus	-	91	O
block	-	98	O
:	-	103	O
A	-	105	O
report	-	107	O
of	-	114	O
two	-	117	O
cases	-	121	O
.	-	126	O

BACKGROUND	12677626	128	O
AND	-	139	O
OBJECTIVES	-	143	O
:	-	153	O

Central	12677626	155	B
nervous	-	163	I
system	-	171	I
and	-	178	I
cardiac	-	182	I
toxicity	-	190	I
following	-	199	O
the	-	209	O
administration	-	213	O
of	-	228	O
local	-	231	O
anesthetics	-	237	O
is	-	249	O
a	-	252	O
recognized	-	254	O
complication	-	265	O
of	-	278	O
regional	-	281	O
anesthesia	-	290	O
.	-	300	O

Levobupivacaine	12677626	302	O
,	-	317	O
the	-	319	O
pure	-	323	O
S	-	328	O
(	-	329	O
-	-	330	O
)	-	331	O
enantiomer	-	333	O
of	-	344	O
bupivacaine	-	347	O
,	-	358	O
was	-	360	O
developed	-	364	O
to	-	374	O
improve	-	377	O
the	-	385	O
cardiac	-	389	O
safety	-	397	O
profile	-	404	O
of	-	412	O
bupivacaine	-	415	O
.	-	426	O

We	12677626	428	O
describe	-	431	O
2	-	440	O
cases	-	442	O
of	-	448	O
grand	-	451	B
mal	-	457	I
seizures	-	461	I
following	-	470	O
accidental	-	480	O
intravascular	-	491	O
injection	-	505	O
of	-	515	O
levobupivacaine	-	518	O
.	-	533	O

CASE	12677626	535	O
REPORT	-	540	O
:	-	546	O

Two	12677626	548	O
patients	-	552	O
presenting	-	561	O
for	-	572	O
elective	-	576	O
orthopedic	-	585	O
surgery	-	596	O
of	-	604	O
the	-	607	O
lower	-	611	O
limb	-	617	O
underwent	-	622	O
blockade	-	632	O
of	-	641	O
the	-	644	O
lumbar	-	648	O
plexus	-	655	O
via	-	662	O
the	-	666	O
posterior	-	670	O
approach	-	680	O
.	-	688	O

Immediately	12677626	690	O
after	-	702	O
the	-	708	O
administration	-	712	O
of	-	727	O
levobupivacaine	-	730	O
0	-	746	O
.	-	747	O
5	-	748	O
%	-	749	O
with	-	751	O
epinephrine	-	756	O
2	-	768	O
.	-	769	O
5	-	770	O
microgram	-	772	O
/	-	781	O
mL	-	782	O
,	-	784	O
the	-	786	O
patients	-	790	O
developed	-	799	O
grand	-	809	B
mal	-	815	I
seizures	-	819	I
,	-	827	O
despite	-	829	O
negative	-	837	O
aspiration	-	846	O
for	-	857	O
blood	-	861	O
and	-	867	O
no	-	871	O
clinical	-	874	O
signs	-	883	O
of	-	889	O
intravenous	-	892	O
epinephrine	-	904	O
administration	-	916	O
.	-	930	O

The	12677626	932	O
seizures	-	936	B
were	-	945	O
successfully	-	950	O
treated	-	963	O
with	-	971	O
sodium	-	976	O
thiopental	-	983	O
in	-	994	O
addition	-	997	O
to	-	1006	O
succinylcholine	-	1009	O
in	-	1025	O
1	-	1028	O
patient	-	1030	O
.	-	1037	O

Neither	12677626	1039	O
patient	-	1047	O
developed	-	1055	O
signs	-	1065	O
of	-	1071	O
cardiovascular	-	1074	B
toxicity	-	1089	I
.	-	1097	O

Both	12677626	1099	O
patients	-	1104	O
were	-	1113	O
treated	-	1118	O
preoperatively	-	1126	O
with	-	1141	O
beta	-	1146	O
-	-	1150	O
adrenergic	-	1151	O
antagonist	-	1162	O
medications	-	1173	O
,	-	1184	O
which	-	1186	O
may	-	1192	O
have	-	1196	O
masked	-	1201	O
the	-	1208	O
cardiovascular	-	1212	O
signs	-	1227	O
of	-	1233	O
the	-	1236	O
unintentional	-	1240	O
intravascular	-	1254	O
administration	-	1268	O
of	-	1283	O
levobupivacaine	-	1286	O
with	-	1302	O
epinephrine	-	1307	O
.	-	1318	O

CONCLUSIONS	12677626	1320	O
:	-	1331	O

Although	12677626	1333	O
levobupivacaine	-	1342	O
may	-	1358	O
have	-	1362	O
a	-	1367	O
safer	-	1369	O
cardiac	-	1375	B
toxicity	-	1383	I
profile	-	1392	O
than	-	1400	O
racemic	-	1405	O
bupivacaine	-	1413	O
,	-	1424	O
if	-	1426	O
adequate	-	1429	O
amounts	-	1438	O
of	-	1446	O
levobupivacaine	-	1449	O
reach	-	1465	O
the	-	1471	O
circulation	-	1475	O
,	-	1486	O
it	-	1488	O
will	-	1491	O
result	-	1496	O
in	-	1503	O
convulsions	-	1506	B
.	-	1517	O

Plasma	12677626	1519	O
concentrations	-	1526	O
sufficient	-	1541	O
to	-	1552	O
result	-	1555	O
in	-	1562	O
central	-	1565	B
nervous	-	1573	I
system	-	1581	I
toxicity	-	1588	I
did	-	1597	O
not	-	1601	O
produce	-	1605	O
manifestations	-	1613	O
of	-	1628	O
cardiac	-	1631	B
toxicity	-	1639	I
in	-	1648	O
these	-	1651	O
2	-	1657	O
patients	-	1659	O
.	-	1667	O

Anaesthetic	12699527	0	O
complications	-	12	O
associated	-	26	O
with	-	37	O
myotonia	-	42	B
congenita	-	51	I
:	-	60	O
case	-	62	O
study	-	67	O
and	-	73	O
comparison	-	77	O
with	-	88	O
other	-	93	O
myotonic	-	99	B
disorders	-	108	I
.	-	117	O

Myotonia	12699527	119	B
congenita	-	128	I
(	-	138	O
MC	-	139	B
)	-	141	O
is	-	143	O
caused	-	146	O
by	-	153	O
a	-	156	O
defect	-	158	O
in	-	165	O
the	-	168	O
skeletal	-	172	O
muscle	-	181	O
chloride	-	188	O
channel	-	197	O
function	-	205	O
,	-	213	O
which	-	215	O
may	-	221	O
cause	-	225	O
sustained	-	231	B
membrane	-	241	I
depolarisation	-	250	I
.	-	264	O

We	12699527	266	O
describe	-	269	O
a	-	278	O
previously	-	280	O
healthy	-	291	O
32	-	299	O
-	-	301	O
year	-	302	O
-	-	306	O
old	-	307	O
woman	-	311	O
who	-	317	O
developed	-	321	O
a	-	331	O
life	-	333	O
-	-	337	O
threatening	-	338	O
muscle	-	350	B
spasm	-	357	I
and	-	363	O
secondary	-	367	O
ventilation	-	377	O
difficulties	-	389	O
following	-	402	O
a	-	412	O
preoperative	-	414	O
injection	-	427	O
of	-	437	O
suxamethonium	-	440	O
.	-	453	O

The	12699527	455	O
muscle	-	459	B
spasms	-	466	I
disappeared	-	473	O
spontaneously	-	485	O
and	-	499	O
the	-	503	O
surgery	-	507	O
proceeded	-	515	O
without	-	525	O
further	-	533	O
problems	-	541	O
.	-	549	O

When	12699527	551	O
subsequently	-	556	O
questioned	-	569	O
,	-	579	O
she	-	581	O
reported	-	585	O
minor	-	594	O
symptoms	-	600	O
suggesting	-	609	O
a	-	620	O
myotonic	-	622	B
condition	-	631	I
.	-	640	O

Myotonia	12699527	642	B
was	-	651	O
found	-	655	O
on	-	661	O
clinical	-	664	O
examination	-	673	O
and	-	685	O
EMG	-	689	O
.	-	692	O

The	12699527	694	O
diagnosis	-	698	O
MC	-	708	B
was	-	711	O
confirmed	-	715	O
genetically	-	725	O
.	-	736	O

Neither	12699527	738	O
the	-	746	O
patient	-	750	O
nor	-	758	O
the	-	762	O
anaesthetist	-	766	O
were	-	779	O
aware	-	784	O
of	-	790	O
the	-	793	O
diagnosis	-	797	O
before	-	807	O
this	-	814	O
potentially	-	819	O
lethal	-	831	O
complication	-	838	O
occurred	-	851	O
.	-	859	O

We	12699527	861	O
give	-	864	O
a	-	869	O
brief	-	871	O
overview	-	877	O
of	-	886	O
ion	-	889	B
channel	-	893	I
disorders	-	901	I
including	-	911	O
malignant	-	921	B
hyperthermia	-	931	I
and	-	944	O
their	-	948	O
anaesthetic	-	954	O
considerations	-	966	O
.	-	980	O

Respiratory	12752472	0	O
pattern	-	12	O
in	-	20	O
a	-	23	O
rat	-	25	O
model	-	29	O
of	-	35	O
epilepsy	-	38	B
.	-	46	O

PURPOSE	12752472	48	O
:	-	55	O

Apnea	12752472	57	B
is	-	63	O
known	-	66	O
to	-	72	O
occur	-	75	O
during	-	81	O
seizures	-	88	B
,	-	96	O
but	-	98	O
systematic	-	102	O
studies	-	113	O
of	-	121	O
ictal	-	124	O
respiratory	-	130	O
changes	-	142	O
in	-	150	O
adults	-	153	O
are	-	160	O
few	-	164	O
.	-	167	O

Data	12752472	169	O
regarding	-	174	O
respiratory	-	184	O
pattern	-	196	O
defects	-	204	O
during	-	212	O
interictal	-	219	O
periods	-	230	O
also	-	238	O
are	-	243	O
scarce	-	247	O
.	-	253	O

Here	12752472	255	O
we	-	260	O
sought	-	263	O
to	-	270	O
generate	-	273	O
information	-	282	O
with	-	294	O
regard	-	299	O
to	-	306	O
the	-	309	O
interictal	-	313	O
period	-	324	O
in	-	331	O
animals	-	334	O
with	-	342	O
pilocarpine	-	347	O
-	-	358	O
induced	-	359	O
epilepsy	-	367	B
.	-	375	O

METHODS	12752472	377	O
:	-	384	O

Twelve	12752472	386	O
rats	-	393	O
(	-	398	O
six	-	399	O
chronically	-	403	O
epileptic	-	415	B
animals	-	425	O
and	-	433	O
six	-	437	O
controls	-	441	O
)	-	449	O
were	-	451	O
anesthetized	-	456	O
,	-	468	O
given	-	470	O
tracheotomies	-	476	O
,	-	489	O
and	-	491	O
subjected	-	495	O
to	-	505	O
hyperventilation	-	508	B
or	-	525	O
hypoventilation	-	528	O
conditions	-	544	O
.	-	554	O

Breathing	12752472	556	O
movements	-	566	O
caused	-	576	O
changes	-	583	O
in	-	591	O
thoracic	-	594	O
volume	-	603	O
and	-	610	O
forced	-	614	O
air	-	621	O
to	-	625	O
flow	-	628	O
tidally	-	633	O
through	-	641	O
a	-	649	O
pneumotachograph	-	651	O
.	-	667	O

This	12752472	669	O
flow	-	674	O
was	-	679	O
measured	-	683	O
by	-	692	O
using	-	695	O
a	-	701	O
differential	-	703	O
pressure	-	716	O
transducer	-	725	O
,	-	735	O
passed	-	737	O
through	-	744	O
a	-	752	O
polygraph	-	754	O
,	-	763	O
and	-	765	O
from	-	769	O
this	-	774	O
to	-	779	O
a	-	782	O
computer	-	784	O
with	-	793	O
custom	-	798	O
software	-	805	O
that	-	814	O
derived	-	819	O
ventilation	-	827	O
(	-	839	O
VE	-	840	O
)	-	842	O
,	-	843	O
tidal	-	845	O
volume	-	851	O
(	-	858	O
VT	-	859	O
)	-	861	O
,	-	862	O
inspiratory	-	864	O
time	-	876	O
(	-	881	O
TI	-	882	O
)	-	884	O
,	-	885	O
expiratory	-	887	O
time	-	898	O
(	-	903	O
TE	-	904	O
)	-	906	O
,	-	907	O
breathing	-	909	O
frequency	-	919	O
(	-	929	O
f	-	930	O
)	-	931	O
,	-	932	O
and	-	934	O
mean	-	938	O
inspiratory	-	943	O
flow	-	955	O
(	-	960	O
VT	-	961	O
/	-	963	O
TI	-	964	O
)	-	966	O
on	-	968	O
a	-	971	O
breath	-	973	O
-	-	979	O
by	-	980	O
-	-	982	O
breath	-	983	O
basis	-	990	O
.	-	995	O

RESULTS	12752472	997	O
:	-	1004	O

The	12752472	1006	O
hyperventilation	-	1010	B
maneuver	-	1027	O
caused	-	1036	O
a	-	1043	O
decrease	-	1045	O
in	-	1054	O
spontaneous	-	1057	O
ventilation	-	1069	O
in	-	1081	O
pilocarpine	-	1084	O
-	-	1095	O
treated	-	1096	O
and	-	1104	O
control	-	1108	O
rats	-	1116	O
.	-	1120	O

Although	12752472	1122	O
VE	-	1131	O
had	-	1134	O
a	-	1138	O
similar	-	1140	O
decrease	-	1148	O
in	-	1157	O
both	-	1160	O
groups	-	1165	O
,	-	1171	O
in	-	1173	O
the	-	1176	O
epileptic	-	1180	B
group	-	1190	O
,	-	1195	O
the	-	1197	O
decrease	-	1201	O
in	-	1210	O
VE	-	1213	O
was	-	1216	O
due	-	1220	O
to	-	1224	O
a	-	1227	O
significant	-	1229	O
(	-	1241	O
p	-	1242	O
<	-	1244	O
0	-	1246	O
.	-	1247	O
05	-	1248	O
)	-	1250	O
increase	-	1252	O
in	-	1261	O
TE	-	1264	O
peak	-	1267	O
in	-	1272	O
relation	-	1275	O
to	-	1284	O
that	-	1287	O
of	-	1292	O
the	-	1295	O
control	-	1299	O
animals	-	1307	O
.	-	1314	O

The	12752472	1316	O
hypoventilation	-	1320	O
maneuver	-	1336	O
led	-	1345	O
to	-	1349	O
an	-	1352	O
increase	-	1355	O
in	-	1364	O
the	-	1367	O
arterial	-	1371	O
Paco2	-	1380	O
,	-	1385	O
followed	-	1387	O
by	-	1396	O
an	-	1399	O
increase	-	1402	O
in	-	1411	O
VE	-	1414	O
.	-	1416	O

In	12752472	1418	O
the	-	1421	O
epileptic	-	1425	B
group	-	1435	O
,	-	1440	O
the	-	1442	O
increase	-	1446	O
in	-	1455	O
VE	-	1458	O
was	-	1461	O
mediated	-	1465	O
by	-	1474	O
a	-	1477	O
significant	-	1479	O
(	-	1491	O
p	-	1492	O
<	-	1494	O
0	-	1496	O
.	-	1497	O
05	-	1498	O
)	-	1500	O
decrease	-	1502	O
in	-	1511	O
TE	-	1514	O
peak	-	1517	O
compared	-	1522	O
with	-	1531	O
the	-	1536	O
control	-	1540	O
group	-	1548	O
.	-	1553	O

Systemic	12752472	1555	O
application	-	1564	O
of	-	1576	O
KCN	-	1579	O
,	-	1582	O
to	-	1584	O
evaluate	-	1587	O
the	-	1596	O
effects	-	1600	O
of	-	1608	O
peripheral	-	1611	O
chemoreception	-	1622	O
activation	-	1637	O
on	-	1648	O
ventilation	-	1651	O
,	-	1662	O
led	-	1664	O
to	-	1668	O
a	-	1671	O
similar	-	1673	O
increase	-	1681	O
in	-	1690	O
VE	-	1693	O
for	-	1696	O
both	-	1700	O
groups	-	1705	O
.	-	1711	O

CONCLUSIONS	12752472	1713	O
:	-	1724	O

The	12752472	1726	O
data	-	1730	O
indicate	-	1735	O
that	-	1744	O
pilocarpine	-	1749	O
-	-	1760	O
treated	-	1761	O
animals	-	1769	O
have	-	1777	O
an	-	1782	O
altered	-	1785	O
ability	-	1793	O
to	-	1801	O
react	-	1804	O
to	-	1810	O
(	-	1813	O
or	-	1814	O
compensate	-	1817	O
for	-	1828	O
)	-	1831	O
blood	-	1833	O
gas	-	1839	O
changes	-	1843	O
with	-	1851	O
changes	-	1856	O
in	-	1864	O
ventilation	-	1867	O
and	-	1879	O
suggest	-	1883	O
that	-	1891	O
it	-	1896	O
is	-	1899	O
centrally	-	1902	O
determined	-	1912	O
.	-	1922	O

We	12752472	1924	O
speculate	-	1927	O
on	-	1937	O
the	-	1940	O
possible	-	1944	O
relation	-	1953	O
of	-	1962	O
the	-	1965	O
current	-	1969	O
findings	-	1977	O
on	-	1986	O
treating	-	1989	O
different	-	1998	O
epilepsy	-	2008	B
-	-	2016	O
associated	-	2017	O
conditions	-	2028	O
.	-	2038	O

Increased	12828076	0	O
serum	-	10	O
soluble	-	16	O
Fas	-	24	O
in	-	28	O
patients	-	31	O
with	-	40	O
acute	-	45	B
liver	-	51	I
failure	-	57	I
due	-	65	O
to	-	69	O
paracetamol	-	72	O
overdose	-	84	B
.	-	92	O

BACKGROUND	12828076	94	O
/	-	104	O
AIMS	-	105	O
:	-	109	O

Experimental	12828076	111	O
studies	-	124	O
have	-	132	O
suggested	-	137	O
that	-	147	O
apoptosis	-	152	O
via	-	162	O
the	-	166	O
Fas	-	170	O
/	-	173	O
Fas	-	174	O
Ligand	-	178	O
signaling	-	185	O
system	-	195	O
may	-	202	O
play	-	206	O
an	-	211	O
important	-	214	O
role	-	224	O
in	-	229	O
the	-	232	O
development	-	236	O
of	-	248	O
acute	-	251	B
liver	-	257	I
failure	-	263	I
.	-	270	O

The	12828076	272	O
aim	-	276	O
of	-	280	O
the	-	283	O
study	-	287	O
was	-	293	O
to	-	297	O
investigate	-	300	O
the	-	312	O
soluble	-	316	O
form	-	324	O
of	-	329	O
Fas	-	332	O
in	-	336	O
patients	-	339	O
with	-	348	O
acute	-	353	B
liver	-	359	I
failure	-	365	I
.	-	372	O

METHODOLOGY	12828076	374	O
:	-	385	O

Serum	12828076	387	O
levels	-	393	O
of	-	400	O
sFas	-	403	O
(	-	408	O
soluble	-	409	O
Fas	-	417	O
)	-	420	O
were	-	422	O
measured	-	427	O
by	-	436	O
ELISA	-	439	O
in	-	445	O
24	-	448	O
patients	-	451	O
with	-	460	O
acute	-	465	B
liver	-	471	I
failure	-	477	I
and	-	485	O
10	-	489	O
normal	-	492	O
control	-	499	O
subjects	-	507	O
.	-	515	O

Serum	12828076	517	O
levels	-	523	O
of	-	530	O
tumor	-	533	B
necrosis	-	539	B
factor	-	548	O
-	-	554	O
alpha	-	555	O
and	-	561	O
interferon	-	565	O
-	-	575	O
gamma	-	576	O
were	-	582	O
also	-	587	O
determined	-	592	O
by	-	603	O
ELISA	-	606	O
.	-	611	O

RESULTS	12828076	613	O
:	-	620	O

Serum	12828076	622	O
sFas	-	628	O
was	-	633	O
significantly	-	637	O
increased	-	651	O
in	-	661	O
patients	-	664	O
with	-	673	O
acute	-	678	B
liver	-	684	I
failure	-	690	I
(	-	698	O
median	-	699	O
,	-	705	O
26	-	707	O
.	-	709	O
8	-	710	O
U	-	712	O
/	-	713	O
mL	-	714	O
;	-	716	O
range	-	718	O
,	-	723	O
6	-	725	O
.	-	726	O
9	-	727	O
-	-	728	O
52	-	729	O
.	-	731	O
7	-	732	O
U	-	734	O
/	-	735	O
mL	-	736	O
)	-	738	O
compared	-	740	O
to	-	749	O
the	-	752	O
normal	-	756	O
controls	-	763	O
(	-	772	O
median	-	773	O
,	-	779	O
8	-	781	O
.	-	782	O
6	-	783	O
U	-	785	O
/	-	786	O
mL	-	787	O
;	-	789	O
range	-	791	O
,	-	796	O
6	-	798	O
.	-	799	O
5	-	800	O
-	-	801	O
12	-	802	O
.	-	804	O
0	-	805	O
U	-	807	O
/	-	808	O
mL	-	809	O
,	-	811	O
P	-	813	O
<	-	815	O
0	-	817	O
.	-	818	O
0001	-	819	O
)	-	823	O
.	-	824	O

Levels	12828076	826	O
were	-	833	O
significantly	-	838	O
greater	-	852	O
in	-	860	O
patients	-	863	O
with	-	872	O
acute	-	877	B
liver	-	883	I
failure	-	889	I
due	-	897	O
to	-	901	O
paracetamol	-	904	O
overdose	-	916	B
(	-	925	O
median	-	926	O
,	-	932	O
28	-	934	O
.	-	936	O
7	-	937	O
U	-	939	O
/	-	940	O
mL	-	941	O
;	-	943	O
range	-	945	O
,	-	950	O
12	-	952	O
.	-	954	O
8	-	955	O
-	-	956	O
52	-	957	O
.	-	959	O
7	-	960	O
U	-	962	O
/	-	963	O
mL	-	964	O
,	-	966	O
n	-	968	O
=	-	970	O
17	-	972	O
)	-	974	O
than	-	976	O
those	-	981	O
due	-	987	O
to	-	991	O
non	-	994	O
-	-	997	O
A	-	998	O
to	-	1000	O
E	-	1003	O
hepatitis	-	1005	B
(	-	1015	O
median	-	1016	O
,	-	1022	O
12	-	1024	O
.	-	1026	O
5	-	1027	O
U	-	1029	O
/	-	1030	O
mL	-	1031	O
;	-	1033	O
range	-	1035	O
,	-	1040	O
6	-	1042	O
.	-	1043	O
9	-	1044	O
-	-	1045	O
46	-	1046	O
.	-	1048	O
0	-	1049	O
U	-	1051	O
/	-	1052	O
mL	-	1053	O
,	-	1055	O
n	-	1057	O
=	-	1059	O
7	-	1061	O
,	-	1062	O
P	-	1064	O
<	-	1066	O
0	-	1068	O
.	-	1069	O
01	-	1070	O
)	-	1072	O
.	-	1073	O

There	12828076	1075	O
was	-	1081	O
no	-	1085	O
relationship	-	1088	O
of	-	1101	O
sFas	-	1104	O
to	-	1109	O
eventual	-	1112	O
outcome	-	1121	O
in	-	1129	O
the	-	1132	O
patients	-	1136	O
.	-	1144	O

A	12828076	1146	O
significant	-	1148	O
correlation	-	1160	O
was	-	1172	O
observed	-	1176	O
between	-	1185	O
serum	-	1193	O
sFas	-	1199	O
levels	-	1204	O
and	-	1211	O
aspartate	-	1215	O
aminotransferase	-	1225	O
(	-	1242	O
r	-	1243	O
=	-	1245	O
0	-	1247	O
.	-	1248	O
613	-	1249	O
,	-	1252	O
P	-	1254	O
<	-	1256	O
0	-	1258	O
.	-	1259	O
01	-	1260	O
)	-	1262	O
.	-	1263	O

CONCLUSIONS	12828076	1265	O
:	-	1276	O

The	12828076	1278	O
increased	-	1282	O
concentration	-	1292	O
of	-	1306	O
sFas	-	1309	O
in	-	1314	O
serum	-	1317	O
of	-	1323	O
patients	-	1326	O
with	-	1335	O
acute	-	1340	B
liver	-	1346	I
failure	-	1352	I
may	-	1360	O
reflect	-	1364	O
activation	-	1372	O
of	-	1383	O
Fas	-	1386	O
-	-	1389	O
mediated	-	1390	O
apoptosis	-	1399	O
in	-	1409	O
the	-	1412	O
liver	-	1416	O
and	-	1422	O
this	-	1426	O
together	-	1431	O
with	-	1440	O
increased	-	1445	O
tumor	-	1455	B
necrosis	-	1461	B
factor	-	1470	O
-	-	1476	O
alpha	-	1477	O
may	-	1483	O
be	-	1487	O
an	-	1490	O
important	-	1493	O
factor	-	1503	O
in	-	1510	O
liver	-	1513	O
cell	-	1519	O
loss	-	1524	O
.	-	1528	O

Bilateral	12865514	0	O
subthalamic	-	10	O
nucleus	-	22	O
stimulation	-	30	O
for	-	42	O
Parkinson	-	46	B
's	-	55	I
disease	-	58	I
.	-	65	O

High	12865514	67	O
frequency	-	72	O
stimulation	-	82	O
of	-	94	O
the	-	97	O
subthalamic	-	101	O
nucleus	-	113	O
(	-	121	O
STN	-	122	O
)	-	125	O
is	-	127	O
known	-	130	O
to	-	136	O
ameliorate	-	139	O
the	-	150	O
signs	-	154	O
and	-	160	O
symptoms	-	164	O
of	-	173	O
advanced	-	176	O
Parkinson	-	185	B
's	-	194	I
disease	-	197	I
.	-	204	O

AIM	12865514	206	O
:	-	209	O

We	12865514	211	O
studied	-	214	O
the	-	222	O
effect	-	226	O
of	-	233	O
high	-	236	O
frequency	-	241	O
STN	-	251	O
stimulation	-	255	O
in	-	267	O
23	-	270	O
patients	-	273	O
.	-	281	O

METHOD	12865514	283	O
:	-	289	O

Twenty	12865514	291	O
-	-	297	O
three	-	298	O
patients	-	304	O
suffering	-	313	O
from	-	323	O
severe	-	328	O
Parkinson	-	335	B
's	-	344	I
disease	-	347	I
(	-	355	O
Stages	-	356	O
III	-	363	O
-	-	366	O
V	-	367	O
on	-	369	O
Hoehn	-	372	O
and	-	378	O
Yahr	-	382	O
scale	-	387	O
)	-	392	O
and	-	394	O
,	-	397	O
particularly	-	399	O
bradykinesia	-	412	B
,	-	424	O
rigidity	-	426	B
,	-	434	O
and	-	436	O
levodopa	-	440	O
-	-	448	O
induced	-	449	O
dyskinesias	-	457	B
underwent	-	469	O
bilateral	-	479	O
implantation	-	489	O
of	-	502	O
electrodes	-	505	O
in	-	516	O
the	-	519	O
STN	-	523	O
.	-	526	O

Preoperative	12865514	528	O
and	-	541	O
postoperative	-	545	O
assessments	-	559	O
of	-	571	O
these	-	574	O
patients	-	580	O
at	-	589	O
1	-	592	O
,	-	593	O
3	-	595	O
,	-	596	O
6	-	598	O
and	-	600	O
12	-	604	O
months	-	607	O
follow	-	614	O
-	-	620	O
up	-	621	O
,	-	623	O
in	-	625	O
""""	-	628	O
on	-	629	O
""""	-	631	O
and	-	633	O
""""	-	637	O
off	-	638	O
""""	-	641	O
drug	-	643	O
conditions	-	648	O
,	-	658	O
was	-	660	O
carried	-	664	O
out	-	672	O
using	-	676	O
Unified	-	682	O
Parkinson	-	690	B
's	-	699	I
Disease	-	702	I
Rating	-	710	O
Scale	-	717	O
,	-	722	O
Hoehn	-	724	O
and	-	730	O
Yahr	-	734	O
staging	-	739	O
,	-	746	O
England	-	748	O
activities	-	756	O
of	-	767	O
daily	-	770	O
living	-	776	O
score	-	783	O
and	-	789	O
video	-	793	O
recordings	-	799	O
.	-	809	O

RESULTS	12865514	811	O
:	-	818	O

After	12865514	820	O
one	-	826	O
year	-	830	O
of	-	835	O
electrical	-	838	O
stimulation	-	849	O
of	-	861	O
the	-	864	O
STN	-	868	O
,	-	871	O
the	-	873	O
patients	-	877	O
'	-	885	O
scores	-	887	O
for	-	894	O
activities	-	898	O
of	-	909	O
daily	-	912	O
living	-	918	O
and	-	925	O
motor	-	929	O
examination	-	935	O
scores	-	947	O
(	-	954	O
Unified	-	955	O
Parkinson	-	963	B
's	-	972	I
Disease	-	975	I
Rating	-	983	O
Scale	-	990	O
parts	-	996	O
II	-	1002	O
and	-	1005	O
III	-	1009	O
)	-	1012	O
off	-	1014	O
medication	-	1018	O
improved	-	1029	O
by	-	1038	O
62	-	1041	O
%	-	1043	O
and	-	1045	O
61	-	1049	O
%	-	1051	O
respectively	-	1053	O
(	-	1066	O
p	-	1067	O
<	-	1068	O
0	-	1069	O
.	-	1070	O
0005	-	1071	O
)	-	1075	O
.	-	1076	O

The	12865514	1078	O
subscores	-	1082	O
for	-	1092	O
the	-	1096	O
akinesia	-	1100	B
,	-	1108	O
rigidity	-	1110	B
,	-	1118	O
tremor	-	1120	B
and	-	1127	O
gait	-	1131	O
also	-	1136	O
improved	-	1141	O
.	-	1149	O

(	12865514	1151	O
p	-	1152	O
<	-	1153	O
0	-	1154	O
.	-	1155	O
0005	-	1156	O
)	-	1160	O
.	-	1161	O

The	12865514	1163	O
average	-	1167	O
levodopa	-	1175	O
dose	-	1184	O
decreased	-	1189	O
from	-	1199	O
813	-	1204	O
mg	-	1208	O
to	-	1211	O
359	-	1214	O
mg	-	1218	O
.	-	1220	O

The	12865514	1222	O
cognitive	-	1226	O
functions	-	1236	O
remained	-	1246	O
unchanged	-	1255	O
.	-	1264	O

Two	12865514	1266	O
patients	-	1270	O
developed	-	1279	O
device	-	1289	O
-	-	1295	O
related	-	1296	O
complications	-	1304	O
and	-	1318	O
two	-	1322	O
patients	-	1326	O
experienced	-	1335	O
abnormal	-	1347	O
weight	-	1356	O
gain	-	1363	O
.	-	1367	O

CONCLUSION	12865514	1369	O
:	-	1379	O

Bilateral	12865514	1381	O
subthalamic	-	1391	O
nucleus	-	1403	O
stimulation	-	1411	O
is	-	1423	O
an	-	1426	O
effective	-	1429	O
treatment	-	1439	O
for	-	1449	O
advanced	-	1453	O
Parkinson	-	1462	B
's	-	1471	I
disease	-	1474	I
.	-	1481	O

It	12865514	1483	O
reduces	-	1486	O
the	-	1494	O
severity	-	1498	O
of	-	1507	O
""""	-	1510	O
off	-	1511	O
""""	-	1514	O
phase	-	1516	O
symptoms	-	1522	O
,	-	1530	O
improves	-	1532	O
the	-	1541	O
axial	-	1545	O
symptoms	-	1551	O
and	-	1560	O
reduces	-	1564	O
levodopa	-	1572	O
requirements	-	1581	O
.	-	1593	O

The	12865514	1595	O
reduction	-	1599	O
in	-	1609	O
the	-	1612	O
levodopa	-	1616	O
dose	-	1625	O
is	-	1630	O
useful	-	1633	O
in	-	1640	O
controlling	-	1643	O
drug	-	1655	B
-	-	1659	I
induced	-	1660	I
dyskinesias	-	1668	I
.	-	1679	O

Ocular	12912689	0	O
motility	-	7	O
changes	-	16	O
after	-	24	O
subtenon	-	30	O
carboplatin	-	39	O
chemotherapy	-	51	O
for	-	64	O
retinoblastoma	-	68	B
.	-	82	O

BACKGROUND	12912689	84	O
:	-	94	O
Focal	-	96	O
subtenon	-	102	O
carboplatin	-	111	O
injections	-	123	O
have	-	134	O
recently	-	139	O
been	-	148	O
used	-	153	O
as	-	158	O
a	-	161	O
presumably	-	163	O
toxicity	-	174	B
-	-	182	O
free	-	183	O
adjunct	-	188	O
to	-	196	O
systemic	-	199	O
chemotherapy	-	208	O
for	-	221	O
intraocular	-	225	O
retinoblastoma	-	237	B
.	-	251	O

OBJECTIVE	12912689	253	O
:	-	262	O

To	12912689	264	O
report	-	267	O
our	-	274	O
clinical	-	278	O
experience	-	287	O
with	-	298	O
abnormal	-	303	B
ocular	-	312	I
motility	-	319	I
in	-	328	O
patients	-	331	O
treated	-	340	O
with	-	348	O
subtenon	-	353	O
carboplatin	-	362	O
chemotherapy	-	374	O
.	-	386	O

METHODS	12912689	388	O
:	-	395	O

We	12912689	397	O
noted	-	400	O
abnormal	-	406	B
ocular	-	415	I
motility	-	422	I
in	-	431	O
10	-	434	O
consecutive	-	437	O
patients	-	449	O
with	-	458	O
retinoblastoma	-	463	B
who	-	478	O
had	-	482	O
received	-	486	O
subtenon	-	495	O
carboplatin	-	504	O
.	-	515	O

During	12912689	517	O
ocular	-	524	O
manipulation	-	531	O
under	-	544	O
general	-	550	O
anesthesia	-	558	O
,	-	568	O
we	-	570	O
assessed	-	573	O
their	-	582	O
eyes	-	588	O
by	-	593	O
forced	-	596	O
duction	-	603	O
testing	-	611	O
,	-	618	O
comparing	-	620	O
ocular	-	630	O
motility	-	637	O
after	-	646	O
tumor	-	652	B
control	-	658	O
with	-	666	O
ocular	-	671	O
motility	-	678	O
at	-	687	O
diagnosis	-	690	O
.	-	699	O

Eyes	12912689	701	O
subsequently	-	706	O
enucleated	-	719	O
because	-	730	O
of	-	738	O
treatment	-	741	O
failure	-	751	O
(	-	759	O
n	-	760	O
=	-	762	O
4	-	764	O
)	-	765	O
were	-	767	O
examined	-	772	O
histologically	-	781	O
.	-	795	O

RESULTS	12912689	797	O
:	-	804	O

Limitation	12912689	806	O
of	-	817	O
ocular	-	820	O
motility	-	827	O
was	-	836	O
detected	-	840	O
in	-	849	O
all	-	852	O
12	-	856	O
eyes	-	859	O
of	-	864	O
10	-	867	O
patients	-	870	O
treated	-	879	O
for	-	887	O
intraocular	-	891	O
retinoblastoma	-	903	B
with	-	918	O
1	-	923	O
to	-	925	O
6	-	928	O
injections	-	930	O
of	-	941	O
subtenon	-	944	O
carboplatin	-	953	O
as	-	965	O
part	-	968	O
of	-	973	O
multimodality	-	976	O
therapy	-	990	O
.	-	997	O

Histopathological	12912689	999	O
examination	-	1017	O
revealed	-	1029	O
many	-	1038	O
lipophages	-	1043	O
in	-	1054	O
the	-	1057	O
periorbital	-	1061	O
fat	-	1073	O
surrounding	-	1077	O
the	-	1089	O
optic	-	1093	O
nerve	-	1099	O
in	-	1105	O
1	-	1108	O
eye	-	1110	O
,	-	1113	O
indicative	-	1115	O
of	-	1126	O
phagocytosis	-	1129	O
of	-	1142	O
previously	-	1145	O
existing	-	1156	O
fat	-	1165	O
cells	-	1169	O
and	-	1175	O
suggesting	-	1179	O
prior	-	1190	O
fat	-	1196	O
necrosis	-	1200	B
.	-	1208	O

The	12912689	1210	O
enucleations	-	1214	O
were	-	1227	O
technically	-	1232	O
difficult	-	1244	O
and	-	1254	O
hazardous	-	1258	O
for	-	1268	O
globe	-	1272	O
rupture	-	1278	B
because	-	1286	O
of	-	1294	O
extensive	-	1297	O
orbital	-	1307	O
soft	-	1315	O
tissue	-	1320	O
adhesions	-	1327	O
.	-	1336	O

CONCLUSIONS	12912689	1338	O
:	-	1349	O

Subtenon	12912689	1351	O
carboplatin	-	1360	O
chemotherapy	-	1372	O
is	-	1385	O
associated	-	1388	O
with	-	1399	O
significant	-	1404	O
fibrosis	-	1416	B
of	-	1425	O
orbital	-	1428	O
soft	-	1436	O
tissues	-	1441	O
,	-	1448	O
leading	-	1450	O
to	-	1458	O
mechanical	-	1461	O
restriction	-	1472	O
of	-	1484	O
eye	-	1487	O
movements	-	1491	O
and	-	1501	O
making	-	1505	O
subsequent	-	1512	O
enucleation	-	1523	O
difficult	-	1535	O
.	-	1544	O

Subtenon	12912689	1546	O
carboplatin	-	1555	O
is	-	1567	O
not	-	1570	O
free	-	1574	O
of	-	1579	O
toxicity	-	1582	B
,	-	1590	O
and	-	1592	O
its	-	1596	O
use	-	1600	O
is	-	1604	O
best	-	1607	O
restricted	-	1612	O
to	-	1623	O
specific	-	1626	O
indications	-	1635	O
.	-	1646	O

Ethambutol	12948256	0	O
and	-	11	O
optic	-	15	B
neuropathy	-	21	I
.	-	31	O

PURPOSE	12948256	33	O
:	-	40	O

To	12948256	42	O
demonstrate	-	45	O
the	-	57	O
association	-	61	O
between	-	73	O
ethambutol	-	81	O
and	-	92	O
optic	-	96	B
neuropathy	-	102	I
.	-	112	O

METHOD	12948256	114	O
:	-	120	O

Thirteen	12948256	122	O
patients	-	131	O
who	-	140	O
developed	-	144	O
optic	-	154	B
neuropathy	-	160	I
after	-	171	O
being	-	177	O
treated	-	183	O
with	-	191	O
ethambutol	-	196	O
for	-	207	O
tuberculosis	-	211	B
of	-	224	I
the	-	227	I
lung	-	231	I
or	-	236	I
lymph	-	239	I
node	-	245	I
at	-	250	O
Siriraj	-	253	O
Hospital	-	261	O
between	-	270	O
1997	-	278	O
and	-	283	O
2001	-	287	O
were	-	292	O
retrospectively	-	297	O
reviewed	-	313	O
.	-	321	O

The	12948256	323	O
clinical	-	327	O
characteristics	-	336	O
and	-	352	O
initial	-	356	O
and	-	364	O
final	-	368	O
visual	-	374	O
acuity	-	381	O
were	-	388	O
analyzed	-	393	O
to	-	402	O
determine	-	405	O
visual	-	415	O
outcome	-	422	O
.	-	429	O

RESULTS	12948256	431	O
:	-	438	O

All	12948256	440	O
patients	-	444	O
had	-	453	O
optic	-	457	B
neuropathy	-	463	I
between	-	474	O
1	-	482	O
to	-	484	O
6	-	487	O
months	-	489	O
(	-	496	O
mean	-	497	O
=	-	502	O
2	-	504	O
.	-	505	O
9	-	506	O
months	-	508	O
)	-	514	O
after	-	516	O
starting	-	522	O
ethambutol	-	531	O
therapy	-	542	O
at	-	550	O
a	-	553	O
dosage	-	555	O
ranging	-	562	O
from	-	570	O
13	-	575	O
to	-	578	O
20	-	581	O
mg	-	584	O
/	-	586	O
kg	-	587	O
/	-	589	O
day	-	590	O
(	-	594	O
mean	-	595	O
=	-	600	O
17	-	602	O
mg	-	605	O
/	-	607	O
kg	-	608	O
/	-	610	O
day	-	611	O
)	-	614	O
.	-	615	O

Seven	12948256	617	O
(	-	623	O
54	-	624	O
%	-	626	O
)	-	627	O
of	-	629	O
the	-	632	O
13	-	636	O
patients	-	639	O
experienced	-	648	O
visual	-	660	O
recovery	-	667	O
after	-	676	O
stopping	-	682	O
the	-	691	O
drug	-	695	O
.	-	699	O

Of	12948256	701	O
6	-	704	O
patients	-	706	O
with	-	715	O
irreversible	-	720	O
visual	-	733	B
impairment	-	740	I
,	-	750	O
4	-	752	O
patients	-	754	O
had	-	763	O
diabetes	-	767	B
mellitus	-	776	I
,	-	784	O
glaucoma	-	786	B
and	-	795	O
a	-	799	O
history	-	801	O
of	-	809	O
heavy	-	812	O
smoking	-	818	O
.	-	825	O

CONCLUSION	12948256	827	O
:	-	837	O

Early	12948256	839	O
recognition	-	845	O
of	-	857	O
optic	-	860	B
neuropathy	-	866	I
should	-	877	O
be	-	884	O
considered	-	887	O
in	-	898	O
patients	-	901	O
with	-	910	O
ethambutol	-	915	O
therapy	-	926	O
.	-	933	O

A	12948256	935	O
low	-	937	O
dose	-	941	O
and	-	946	O
prompt	-	950	O
discontinuation	-	957	O
of	-	973	O
the	-	976	O
drug	-	980	O
is	-	985	O
recommended	-	988	O
particularly	-	1000	O
in	-	1013	O
individuals	-	1016	O
with	-	1028	O
diabetes	-	1033	B
mellitus	-	1042	I
,	-	1050	O
glaucoma	-	1052	B
or	-	1061	O
who	-	1064	O
are	-	1068	O
heavy	-	1072	O
smokers	-	1078	O
.	-	1085	O

Treatment	12950111	0	O
of	-	10	O
compensatory	-	13	O
gustatory	-	26	B
hyperhidrosis	-	36	I
with	-	50	O
topical	-	55	O
glycopyrrolate	-	63	O
.	-	77	O

Gustatory	12950111	79	B
hyperhidrosis	-	89	I
is	-	103	O
facial	-	106	O
sweating	-	113	B
usually	-	122	O
associated	-	130	O
with	-	141	O
the	-	146	O
eating	-	150	O
of	-	157	O
hot	-	160	O
spicy	-	164	O
food	-	170	O
or	-	175	O
even	-	178	O
smelling	-	183	O
this	-	192	O
food	-	197	O
.	-	201	O

Current	12950111	203	O
options	-	211	O
of	-	219	O
treatment	-	222	O
include	-	232	O
oral	-	240	O
anticholinergic	-	245	O
drugs	-	261	O
,	-	266	O
the	-	268	O
topical	-	272	O
application	-	280	O
of	-	292	O
anticholinergics	-	295	O
or	-	312	O
aluminum	-	315	O
chloride	-	324	O
,	-	332	O
and	-	334	O
the	-	338	O
injection	-	342	O
of	-	352	O
botulinum	-	355	O
toxin	-	365	O
.	-	370	O

Thirteen	12950111	372	O
patients	-	381	O
have	-	390	O
been	-	395	O
treated	-	400	O
to	-	408	O
date	-	411	O
with	-	416	O
1	-	421	O
.	-	422	O
5	-	423	O
%	-	424	O
or	-	426	O
2	-	429	O
%	-	430	O
topical	-	432	O
glycopyrrolate	-	440	O
.	-	454	O

All	12950111	456	O
patients	-	460	O
had	-	469	O
gustatory	-	473	B
hyperhidrosis	-	483	I
,	-	496	O
which	-	498	O
interfered	-	504	O
with	-	515	O
their	-	520	O
social	-	526	O
activities	-	533	O
,	-	543	O
after	-	545	O
transthroacic	-	551	O
endoscopic	-	565	O
sympathectomy	-	576	O
,	-	589	O
and	-	591	O
which	-	595	O
was	-	601	O
associated	-	605	O
with	-	616	O
compensatory	-	621	O
focal	-	634	O
hyperhidrosis	-	640	B
.	-	653	O

After	12950111	655	O
applying	-	661	O
topical	-	670	O
glycopyrrolate	-	678	O
,	-	692	O
the	-	694	O
subjective	-	698	O
effect	-	709	O
was	-	716	O
excellent	-	720	O
(	-	730	O
no	-	731	O
sweating	-	734	B
after	-	743	O
eating	-	749	O
hot	-	756	O
spicy	-	760	O
food	-	766	O
)	-	770	O
in	-	772	O
10	-	775	O
patients	-	778	O
(	-	787	O
77	-	788	O
%	-	790	O
)	-	791	O
,	-	792	O
and	-	794	O
fair	-	798	O
(	-	803	O
clearly	-	804	O
reduced	-	812	O
sweating	-	820	B
)	-	828	O
in	-	830	O
3	-	833	O
patients	-	835	O
(	-	844	O
23	-	845	O
%	-	847	O
)	-	848	O
.	-	849	O

All	12950111	851	O
had	-	855	O
reported	-	859	O
incidents	-	868	O
of	-	878	O
being	-	881	O
very	-	887	O
embarrassed	-	892	O
whilst	-	904	O
eating	-	911	O
hot	-	918	O
spicy	-	922	O
foods	-	928	O
.	-	933	O

Adverse	12950111	935	O
effects	-	943	O
included	-	951	O
a	-	960	O
mildly	-	962	O
dry	-	969	B
mouth	-	973	I
and	-	979	O
a	-	983	O
sore	-	985	B
throat	-	990	I
in	-	997	O
2	-	1000	O
patients	-	1002	O
(	-	1011	O
2	-	1012	O
%	-	1013	O
glycopyrrolate	-	1015	O
)	-	1029	O
,	-	1030	O
a	-	1032	O
light	-	1034	O
headache	-	1040	B
in	-	1049	O
1	-	1052	O
patient	-	1054	O
(	-	1062	O
1	-	1063	O
.	-	1064	O
5	-	1065	O
%	-	1066	O
glycopyrrolate	-	1068	O
)	-	1082	O
.	-	1083	O

The	12950111	1085	O
topical	-	1089	O
application	-	1097	O
of	-	1109	O
a	-	1112	O
glycopyrrolate	-	1114	O
pad	-	1129	O
appeared	-	1133	O
to	-	1142	O
be	-	1145	O
safe	-	1148	O
,	-	1152	O
efficacious	-	1154	O
,	-	1165	O
well	-	1167	O
tolerated	-	1172	O
,	-	1181	O
and	-	1183	O
a	-	1187	O
convenient	-	1189	O
method	-	1200	O
of	-	1207	O
treatment	-	1210	O
for	-	1220	O
moderate	-	1224	O
to	-	1233	O
severe	-	1236	O
symptoms	-	1243	O
of	-	1252	O
gustatory	-	1255	B
hyperhidrosis	-	1265	I
in	-	1279	O
post	-	1282	O
transthoracic	-	1287	O
endoscopic	-	1301	O
sympathectomy	-	1312	O
or	-	1326	O
sympathicotomy	-	1329	O
patients	-	1344	O
,	-	1352	O
with	-	1354	O
few	-	1359	O
side	-	1363	O
effects	-	1368	O
.	-	1375	O

Pharmacological	14616590	0	O
characteristics	-	16	O
and	-	32	O
side	-	36	O
effects	-	41	O
of	-	49	O
a	-	52	O
new	-	54	O
galenic	-	58	O
formulation	-	66	O
of	-	78	O
propofol	-	81	O
without	-	90	O
soyabean	-	98	O
oil	-	107	O
.	-	110	O

We	14616590	112	O
compared	-	115	O
the	-	124	O
pharmacokinetics	-	128	O
,	-	144	O
pharmacodynamics	-	146	O
and	-	163	O
safety	-	167	O
profile	-	174	O
of	-	182	O
a	-	185	O
new	-	187	O
galenic	-	191	O
formulation	-	199	O
of	-	211	O
propofol	-	214	O
(	-	223	O
AM149	-	224	O
1	-	230	O
%	-	231	O
)	-	232	O
,	-	233	O
which	-	235	O
does	-	241	O
not	-	246	O
contain	-	250	O
soyabean	-	258	O
oil	-	267	O
,	-	270	O
with	-	272	O
a	-	277	O
standard	-	279	O
formulation	-	288	O
of	-	300	O
propofol	-	303	O
(	-	312	O
Disoprivan	-	313	O
1	-	324	O
%	-	325	O
)	-	326	O
.	-	327	O

In	14616590	329	O
a	-	332	O
randomised	-	334	O
,	-	344	O
double	-	346	O
-	-	352	O
blind	-	353	O
,	-	358	O
cross	-	360	O
-	-	365	O
over	-	366	O
study	-	371	O
,	-	376	O
30	-	378	O
healthy	-	381	O
volunteers	-	389	O
received	-	400	O
a	-	409	O
single	-	411	O
intravenous	-	418	O
bolus	-	430	O
injection	-	436	O
of	-	446	O
2	-	449	O
.	-	450	O
5	-	451	O
mg	-	453	O
.	-	455	O
kg	-	456	O
-	-	458	O
1	-	459	O
propofol	-	461	O
.	-	469	O

Plasma	14616590	471	O
propofol	-	478	O
levels	-	487	O
were	-	494	O
measured	-	499	O
for	-	508	O
48	-	512	O
h	-	515	O
following	-	517	O
drug	-	527	O
administration	-	532	O
and	-	547	O
evaluated	-	551	O
according	-	561	O
to	-	571	O
a	-	574	O
three	-	576	O
-	-	581	O
compartment	-	582	O
model	-	594	O
.	-	599	O

The	14616590	601	O
pharmacodynamic	-	605	O
parameters	-	621	O
assessed	-	632	O
included	-	641	O
induction	-	650	O
and	-	660	O
emergence	-	664	O
times	-	674	O
,	-	679	O
respiratory	-	681	O
and	-	693	O
cardiovascular	-	697	O
effects	-	712	O
,	-	719	O
and	-	721	O
pain	-	725	B
on	-	730	O
injection	-	733	O
.	-	742	O

Patients	14616590	744	O
were	-	753	O
monitored	-	758	O
for	-	768	O
side	-	772	O
effects	-	777	O
over	-	785	O
48	-	790	O
h	-	793	O
.	-	794	O

Owing	14616590	796	O
to	-	802	O
a	-	805	O
high	-	807	O
incidence	-	812	O
of	-	822	O
thrombophlebitis	-	825	B
,	-	841	O
the	-	843	O
study	-	847	O
was	-	853	O
terminated	-	857	O
prematurely	-	868	O
and	-	880	O
only	-	884	O
the	-	889	O
data	-	893	O
of	-	898	O
the	-	901	O
two	-	905	O
parallel	-	909	O
treatment	-	918	O
groups	-	928	O
(	-	935	O
15	-	936	O
patients	-	939	O
in	-	948	O
each	-	951	O
group	-	956	O
)	-	961	O
were	-	963	O
analysed	-	968	O
.	-	976	O

Plasma	14616590	978	O
concentrations	-	985	O
did	-	1000	O
not	-	1004	O
differ	-	1008	O
significantly	-	1015	O
between	-	1029	O
the	-	1037	O
two	-	1041	O
formulations	-	1045	O
.	-	1057	O

Anaesthesia	14616590	1059	O
induction	-	1071	O
and	-	1081	O
emergence	-	1085	O
times	-	1095	O
,	-	1100	O
respiratory	-	1102	O
and	-	1114	O
cardiovascular	-	1118	O
variables	-	1133	O
showed	-	1143	O
no	-	1150	O
significant	-	1153	O
differences	-	1165	O
between	-	1177	O
the	-	1185	O
two	-	1189	O
treatment	-	1193	O
groups	-	1203	O
.	-	1209	O

Pain	14616590	1211	B
on	-	1216	O
injection	-	1219	O
(	-	1229	O
80	-	1230	O
vs	-	1233	O
.	-	1235	O
20	-	1237	O
%	-	1239	O
,	-	1240	O
p	-	1242	O
<	-	1244	O
0	-	1246	O
.	-	1247	O
01	-	1248	O
)	-	1250	O
and	-	1252	O
thrombophlebitis	-	1256	B
(	-	1273	O
93	-	1274	O
.	-	1276	O
3	-	1277	O
vs	-	1279	O
.	-	1281	O
6	-	1283	O
.	-	1284	O
6	-	1285	O
%	-	1286	O
,	-	1287	O
p	-	1289	O
<	-	1291	O
0	-	1293	O
.	-	1294	O
001	-	1295	O
)	-	1298	O
occurred	-	1300	O
more	-	1309	O
frequently	-	1314	O
with	-	1325	O
AM149	-	1330	O
than	-	1336	O
with	-	1341	O
Disoprivan	-	1346	O
.	-	1356	O

Although	14616590	1358	O
both	-	1367	O
formulations	-	1372	O
had	-	1385	O
similar	-	1389	O
pharmacokinetic	-	1397	O
and	-	1413	O
pharmacodynamic	-	1417	O
profiles	-	1433	O
the	-	1442	O
new	-	1446	O
formulation	-	1450	O
is	-	1462	O
not	-	1465	O
suitable	-	1469	O
for	-	1478	O
clinical	-	1482	O
use	-	1491	O
due	-	1495	O
to	-	1499	O
the	-	1502	O
high	-	1506	O
incidence	-	1511	O
of	-	1521	O
thrombophlebitis	-	1524	B
produced	-	1541	O
.	-	1549	O

Vinorelbine	14748761	0	O
-	-	11	O
related	-	12	O
cardiac	-	20	O
events	-	28	O
:	-	34	O
a	-	36	O
meta	-	38	O
-	-	42	O
analysis	-	43	O
of	-	52	O
randomized	-	55	O
clinical	-	66	O
trials	-	75	O
.	-	81	O

Several	14748761	83	O
cases	-	91	O
of	-	97	O
cardiac	-	100	O
adverse	-	108	O
reactions	-	116	O
related	-	126	O
to	-	134	O
vinorelbine	-	137	O
(	-	149	O
VNR	-	150	O
)	-	153	O
have	-	155	O
been	-	160	O
reported	-	165	O
in	-	174	O
the	-	177	O
literature	-	181	O
.	-	191	O

In	14748761	193	O
order	-	196	O
to	-	202	O
quantify	-	205	O
the	-	214	O
incidence	-	218	O
of	-	228	O
these	-	231	O
cardiac	-	237	O
events	-	245	O
,	-	251	O
we	-	253	O
performed	-	256	O
a	-	266	O
meta	-	268	O
-	-	272	O
analysis	-	273	O
of	-	282	O
clinical	-	285	O
trials	-	294	O
comparing	-	301	O
VNR	-	311	O
with	-	315	O
other	-	320	O
chemotherapeutic	-	326	O
agents	-	343	O
in	-	350	O
the	-	353	O
treatment	-	357	O
of	-	367	O
various	-	370	O
malignancies	-	378	B
.	-	390	O

Randomized	14748761	392	O
clinical	-	403	O
trials	-	412	O
comparing	-	419	O
VNR	-	429	O
with	-	433	O
other	-	438	O
drugs	-	444	O
in	-	450	O
the	-	453	O
treatment	-	457	O
of	-	467	O
cancer	-	470	B
were	-	477	O
searched	-	482	O
in	-	491	O
Medline	-	494	O
,	-	501	O
Embase	-	503	O
,	-	509	O
Evidence	-	511	O
-	-	519	O
based	-	520	O
Medicine	-	526	O
Reviews	-	535	O
databases	-	543	O
and	-	553	O
the	-	557	O
Cochrane	-	561	O
library	-	570	O
from	-	578	O
1987	-	583	O
to	-	588	O
2002	-	591	O
.	-	595	O

Outcomes	14748761	597	O
of	-	606	O
interest	-	609	O
were	-	618	O
severe	-	623	O
cardiac	-	630	O
events	-	638	O
,	-	644	O
toxic	-	646	O
deaths	-	652	O
and	-	659	O
cardiac	-	663	O
event	-	671	O
-	-	676	O
related	-	677	O
deaths	-	685	O
reported	-	692	O
in	-	701	O
each	-	704	O
publication	-	709	O
.	-	720	O

We	14748761	722	O
found	-	725	O
19	-	731	O
trials	-	734	O
,	-	740	O
involving	-	742	O
2441	-	752	O
patients	-	757	O
treated	-	766	O
by	-	774	O
VNR	-	777	O
and	-	781	O
2050	-	785	O
control	-	790	O
patients	-	798	O
.	-	806	O

The	14748761	808	O
incidence	-	812	O
of	-	822	O
cardiac	-	825	O
events	-	833	O
with	-	840	O
VNR	-	845	O
was	-	849	O
1	-	853	O
.	-	854	O
19	-	855	O
%	-	857	O
[	-	859	O
95	-	860	O
%	-	862	O
confidence	-	864	O
interval	-	875	O
(	-	884	O
CI	-	885	O
)	-	887	O
(	-	889	O
0	-	890	O
.	-	891	O
75	-	892	O
;	-	894	O
1	-	896	O
.	-	897	O
67	-	898	O
)	-	900	O
]	-	901	O
.	-	902	O

There	14748761	904	O
was	-	910	O
no	-	914	O
difference	-	917	O
in	-	928	O
the	-	931	O
risk	-	935	O
of	-	940	O
cardiac	-	943	O
events	-	951	O
between	-	958	O
VNR	-	966	O
and	-	970	O
other	-	974	O
drugs	-	980	O
[	-	986	O
odds	-	987	O
ratio	-	992	O
:	-	997	O
0	-	999	O
.	-	1000	O
92	-	1001	O
,	-	1003	O
95	-	1005	O
%	-	1007	O
CI	-	1009	O
(	-	1012	O
0	-	1013	O
.	-	1014	O
54	-	1015	O
;	-	1017	O
1	-	1019	O
.	-	1020	O
55	-	1021	O
)	-	1023	O
]	-	1024	O
.	-	1025	O

The	14748761	1027	O
risk	-	1031	O
of	-	1036	O
VNR	-	1039	O
cardiac	-	1043	O
events	-	1051	O
was	-	1058	O
similar	-	1062	O
to	-	1070	O
vindesine	-	1073	O
(	-	1083	O
VDS	-	1084	O
)	-	1087	O
and	-	1089	O
other	-	1093	O
cardiotoxic	-	1099	B
drugs	-	1111	O
[	-	1117	O
fluorouracil	-	1118	O
,	-	1130	O
anthracyclines	-	1132	O
,	-	1146	O
gemcitabine	-	1148	O
(	-	1160	O
GEM	-	1161	O
)	-	1164	O
em	-	1166	O
leader	-	1169	O
]	-	1176	O
.	-	1177	O

Even	14748761	1179	O
if	-	1184	O
it	-	1187	O
did	-	1190	O
not	-	1194	O
reach	-	1198	O
statistical	-	1204	O
significance	-	1216	O
because	-	1229	O
of	-	1237	O
a	-	1240	O
few	-	1242	O
number	-	1246	O
of	-	1253	O
cases	-	1256	O
,	-	1261	O
the	-	1263	O
risk	-	1267	O
was	-	1272	O
lower	-	1276	O
in	-	1282	O
trials	-	1285	O
excluding	-	1292	O
patients	-	1302	O
with	-	1311	O
cardiac	-	1316	O
history	-	1324	O
,	-	1331	O
and	-	1333	O
seemed	-	1337	O
to	-	1344	O
be	-	1347	O
higher	-	1350	O
in	-	1357	O
trials	-	1360	O
including	-	1367	O
patients	-	1377	O
with	-	1386	O
pre	-	1391	O
-	-	1394	O
existing	-	1395	O
cardiac	-	1404	B
diseases	-	1412	I
.	-	1420	O

Vinorelbine	14748761	1422	O
-	-	1433	O
related	-	1434	O
cardiac	-	1442	O
events	-	1450	O
concern	-	1457	O
about	-	1465	O
1	-	1471	O
%	-	1472	O
of	-	1474	O
treated	-	1477	O
patients	-	1485	O
in	-	1494	O
clinical	-	1497	O
trials	-	1506	O
.	-	1512	O

However	14748761	1514	O
,	-	1521	O
the	-	1523	O
risk	-	1527	O
associated	-	1532	O
with	-	1543	O
VNR	-	1548	O
seems	-	1552	O
to	-	1558	O
be	-	1561	O
similar	-	1564	O
to	-	1572	O
that	-	1575	O
of	-	1580	O
other	-	1583	O
chemotherapeutic	-	1589	O
agents	-	1606	O
in	-	1613	O
the	-	1616	O
same	-	1620	O
indications	-	1625	O
.	-	1636	O

MRI	15018178	0	O
findings	-	4	O
of	-	13	O
hypoxic	-	16	O
cortical	-	24	O
laminar	-	33	O
necrosis	-	41	B
in	-	50	O
a	-	53	O
child	-	55	O
with	-	61	O
hemolytic	-	66	B
anemia	-	76	I
crisis	-	83	O
.	-	89	O

We	15018178	91	O
present	-	94	O
magnetic	-	102	O
resonance	-	111	O
imaging	-	121	O
findings	-	129	O
of	-	138	O
a	-	141	O
5	-	143	O
-	-	144	O
year	-	145	O
-	-	149	O
old	-	150	O
girl	-	154	O
who	-	159	O
had	-	163	O
a	-	167	O
rapidly	-	169	O
installing	-	177	O
hemolytic	-	188	B
anemia	-	198	I
crisis	-	205	O
induced	-	212	O
by	-	220	O
trimethoprim	-	223	O
-	-	235	O
sulfomethoxazole	-	236	O
,	-	252	O
resulting	-	254	O
in	-	264	O
cerebral	-	267	B
anoxia	-	276	I
leading	-	283	O
to	-	291	O
permanent	-	294	O
damage	-	304	O
.	-	310	O

Magnetic	15018178	312	O
Resonance	-	321	O
imaging	-	331	O
revealed	-	339	O
cortical	-	348	O
laminar	-	357	O
necrosis	-	365	B
in	-	374	O
arterial	-	377	O
border	-	386	O
zones	-	393	O
in	-	399	O
both	-	402	O
cerebral	-	407	O
hemispheres	-	416	O
,	-	427	O
ischemic	-	429	O
changes	-	438	O
in	-	446	O
subcortical	-	449	O
white	-	461	O
matter	-	467	O
of	-	474	O
left	-	477	O
cerebral	-	482	O
hemisphere	-	491	O
,	-	501	O
and	-	503	O
in	-	507	O
the	-	510	O
left	-	514	O
putamen	-	519	O
.	-	526	O

Although	15018178	528	O
cortical	-	537	O
laminar	-	546	O
necrosis	-	554	B
is	-	563	O
a	-	566	O
classic	-	568	O
entity	-	576	O
in	-	583	O
adulthood	-	586	O
related	-	596	O
to	-	604	O
conditions	-	607	O
of	-	618	O
energy	-	621	O
depletions	-	628	O
,	-	638	O
there	-	640	O
are	-	646	O
few	-	650	O
reports	-	654	O
available	-	662	O
in	-	672	O
children	-	675	O
.	-	683	O

A	15018178	685	O
wide	-	687	O
review	-	692	O
of	-	699	O
the	-	702	O
literature	-	706	O
is	-	717	O
also	-	720	O
presented	-	725	O
.	-	734	O

The	15094729	0	O
natural	-	4	O
history	-	12	O
of	-	20	O
Vigabatrin	-	23	O
associated	-	34	O
visual	-	45	B
field	-	52	I
defects	-	58	I
in	-	66	O
patients	-	69	O
electing	-	78	O
to	-	87	O
continue	-	90	O
their	-	99	O
medication	-	105	O
.	-	115	O

PURPOSE	15094729	117	O
:	-	124	O

To	15094729	126	O
determine	-	129	O
the	-	139	O
natural	-	143	O
history	-	151	O
of	-	159	O
visual	-	162	B
field	-	169	I
defects	-	175	I
in	-	183	O
a	-	186	O
group	-	188	O
of	-	194	O
patients	-	197	O
known	-	206	O
to	-	212	O
have	-	215	O
Vigabatrin	-	220	O
-	-	230	O
associated	-	231	O
changes	-	242	O
who	-	250	O
elected	-	254	O
to	-	262	O
continue	-	265	O
the	-	274	O
medication	-	278	O
because	-	289	O
of	-	297	O
good	-	300	O
seizure	-	305	B
control	-	313	O
.	-	320	O

METHODS	15094729	322	O
:	-	329	O

All	15094729	331	O
patients	-	335	O
taking	-	344	O
Vigabatrin	-	351	O
alone	-	362	O
or	-	368	O
in	-	371	O
combination	-	374	O
with	-	386	O
other	-	391	O
antiepileptic	-	397	O
drugs	-	411	O
for	-	417	O
at	-	421	O
least	-	424	O
5	-	430	O
years	-	432	O
(	-	438	O
range	-	439	O
5	-	445	O
-	-	446	O
12	-	447	O
years	-	450	O
)	-	455	O
were	-	457	O
entered	-	462	O
into	-	470	O
a	-	475	O
visual	-	477	O
surveillance	-	484	O
programme	-	497	O
.	-	506	O

Patients	15094729	508	O
were	-	517	O
followed	-	522	O
up	-	531	O
at	-	534	O
6	-	537	O
-	-	538	O
monthly	-	539	O
intervals	-	547	O
for	-	557	O
not	-	561	O
less	-	565	O
than	-	570	O
18	-	575	O
months	-	578	O
(	-	585	O
range	-	586	O
18	-	592	O
-	-	594	O
43	-	595	O
months	-	598	O
)	-	604	O
.	-	605	O

In	15094729	607	O
all	-	610	O
,	-	613	O
16	-	615	O
patients	-	618	O
with	-	627	O
unequivocal	-	632	O
defects	-	644	O
continued	-	652	O
the	-	662	O
medication	-	666	O
.	-	676	O

Following	15094729	678	O
already	-	688	O
published	-	696	O
methodology	-	706	O
(	-	718	O
Eye	-	719	O
2002	-	723	O
;	-	727	O
16	-	729	O
;	-	731	O
567	-	732	O
-	-	735	O
571	-	736	O
)	-	739	O
monocular	-	741	O
mean	-	751	O
radial	-	756	O
degrees	-	763	O
(	-	771	O
MRDs	-	772	O
)	-	776	O
to	-	778	O
the	-	781	O
I	-	785	O
/	-	786	O
4e	-	787	O
isopter	-	790	O
on	-	798	O
Goldmann	-	801	O
perimetry	-	810	O
was	-	820	O
calculated	-	824	O
for	-	835	O
the	-	839	O
right	-	843	O
eye	-	849	O
at	-	853	O
the	-	856	O
time	-	860	O
of	-	865	O
discovery	-	868	O
of	-	878	O
a	-	881	O
visual	-	883	B
field	-	890	I
defect	-	896	I
and	-	903	O
again	-	907	O
after	-	913	O
not	-	919	O
less	-	923	O
than	-	928	O
18	-	933	O
months	-	936	O
follow	-	943	O
-	-	949	O
up	-	950	O
.	-	952	O

RESULTS	15094729	954	O
:	-	961	O

Mean	15094729	963	O
right	-	968	O
eye	-	974	O
MRD	-	978	O
at	-	982	O
presentation	-	985	O
was	-	998	O
36	-	1002	O
.	-	1004	O
98	-	1005	O
degrees	-	1008	O
(	-	1016	O
range	-	1017	O
22	-	1023	O
.	-	1025	O
25	-	1026	O
-	-	1028	O
51	-	1029	O
.	-	1031	O
0	-	1032	O
)	-	1033	O
,	-	1034	O
compared	-	1036	O
to	-	1045	O
38	-	1048	O
.	-	1050	O
40	-	1051	O
degrees	-	1054	O
(	-	1062	O
range	-	1063	O
22	-	1069	O
.	-	1071	O
5	-	1072	O
-	-	1073	O
49	-	1074	O
.	-	1076	O
75	-	1077	O
)	-	1079	O
after	-	1081	O
follow	-	1087	O
-	-	1093	O
up	-	1094	O
;	-	1096	O
P	-	1098	O
=	-	1099	O
0	-	1100	O
.	-	1101	O
338	-	1102	O
unpaired	-	1106	O
t	-	1115	O
-	-	1116	O
test	-	1117	O
.	-	1121	O

Only	15094729	1123	O
one	-	1128	O
patient	-	1132	O
demonstrated	-	1140	O
a	-	1153	O
deterioration	-	1155	B
in	-	1169	I
visual	-	1172	I
field	-	1179	I
during	-	1185	O
the	-	1192	O
study	-	1196	O
period	-	1202	O
and	-	1209	O
discontinued	-	1213	O
treatment	-	1226	O
.	-	1235	O

CONCLUSION	15094729	1237	O
:	-	1247	O

Established	15094729	1249	O
visual	-	1261	B
field	-	1268	I
defects	-	1274	I
presumed	-	1282	O
to	-	1291	O
be	-	1294	O
due	-	1297	O
to	-	1301	O
Vigabatrin	-	1304	O
therapy	-	1315	O
did	-	1323	O
not	-	1327	O
usually	-	1331	O
progress	-	1339	O
in	-	1348	O
spite	-	1351	O
of	-	1357	O
continuing	-	1360	O
use	-	1371	O
of	-	1375	O
the	-	1378	O
medication	-	1382	O
.	-	1392	O

These	15094729	1394	O
data	-	1400	O
give	-	1405	O
support	-	1410	O
to	-	1418	O
the	-	1421	O
hypothesis	-	1425	O
that	-	1436	O
the	-	1441	O
pathogenesis	-	1445	O
of	-	1458	O
Vigabatrin	-	1461	O
-	-	1471	O
associated	-	1472	O
visual	-	1483	B
field	-	1490	I
defects	-	1496	I
may	-	1504	O
be	-	1508	O
an	-	1511	O
idiosyncratic	-	1514	O
adverse	-	1528	O
drug	-	1536	O
reaction	-	1541	O
rather	-	1550	O
than	-	1557	O
dose	-	1562	O
-	-	1566	O
dependent	-	1567	O
toxicity	-	1577	B
.	-	1585	O

Induction	15096374	0	O
of	-	10	O
rosaceiform	-	13	O
dermatitis	-	25	B
during	-	36	O
treatment	-	43	O
of	-	53	O
facial	-	56	B
inflammatory	-	63	I
dermatoses	-	76	I
with	-	87	O
tacrolimus	-	92	O
ointment	-	103	O
.	-	111	O

BACKGROUND	15096374	113	O
:	-	123	O

Tacrolimus	15096374	125	O
ointment	-	136	O
is	-	145	O
increasingly	-	148	O
used	-	161	O
for	-	166	O
anti	-	170	O
-	-	174	O
inflammatory	-	175	O
treatment	-	188	O
of	-	198	O
sensitive	-	201	O
areas	-	211	O
such	-	217	O
as	-	222	O
the	-	225	O
face	-	229	O
,	-	233	O
and	-	235	O
recent	-	239	O
observations	-	246	O
indicate	-	259	O
that	-	268	O
the	-	273	O
treatment	-	277	O
is	-	287	O
effective	-	290	O
in	-	300	O
steroid	-	303	O
-	-	310	O
aggravated	-	311	O
rosacea	-	322	B
and	-	330	O
perioral	-	334	B
dermatitis	-	343	I
.	-	353	O

We	15096374	355	O
report	-	358	O
on	-	365	O
rosaceiform	-	368	O
dermatitis	-	380	B
as	-	391	O
a	-	394	O
complication	-	396	O
of	-	409	O
treatment	-	412	O
with	-	422	O
tacrolimus	-	427	O
ointment	-	438	O
.	-	446	O

OBSERVATIONS	15096374	448	O
:	-	460	O

Six	15096374	462	O
adult	-	466	O
patients	-	472	O
with	-	481	O
inflammatory	-	486	B
facial	-	499	I
dermatoses	-	506	I
were	-	517	O
treated	-	522	O
with	-	530	O
tacrolimus	-	535	O
ointment	-	546	O
because	-	555	O
of	-	563	O
the	-	566	O
ineffectiveness	-	570	O
of	-	586	O
standard	-	589	O
treatments	-	598	O
.	-	608	O

Within	15096374	610	O
2	-	617	O
to	-	619	O
3	-	622	O
weeks	-	624	O
of	-	630	O
initially	-	633	O
effective	-	643	O
and	-	653	O
well	-	657	O
-	-	661	O
tolerated	-	662	O
treatment	-	672	O
,	-	681	O
3	-	683	O
patients	-	685	O
with	-	694	O
a	-	699	O
history	-	701	O
of	-	709	O
rosacea	-	712	B
and	-	720	O
1	-	724	O
with	-	726	O
a	-	731	O
history	-	733	O
of	-	741	O
acne	-	744	B
experienced	-	749	O
sudden	-	761	O
worsening	-	768	O
with	-	778	O
pustular	-	783	O
rosaceiform	-	792	O
lesions	-	804	O
.	-	811	O

Biopsy	15096374	813	O
revealed	-	820	O
an	-	829	O
abundance	-	832	O
of	-	842	O
Demodex	-	845	O
mites	-	853	O
in	-	859	O
2	-	862	O
of	-	864	O
these	-	867	O
patients	-	873	O
.	-	881	O

In	15096374	883	O
1	-	886	O
patient	-	888	O
with	-	896	O
eyelid	-	901	O
eczema	-	908	B
,	-	914	O
rosaceiform	-	916	O
periocular	-	928	B
dermatitis	-	939	I
gradually	-	950	O
appeared	-	960	O
after	-	969	O
3	-	975	O
weeks	-	977	O
of	-	983	O
treatment	-	986	O
.	-	995	O

In	15096374	997	O
1	-	1000	O
patient	-	1002	O
with	-	1010	O
atopic	-	1015	B
dermatitis	-	1022	I
,	-	1032	O
telangiectatic	-	1034	O
and	-	1049	O
papular	-	1053	B
rosacea	-	1061	I
insidiously	-	1069	O
appeared	-	1081	O
after	-	1090	O
5	-	1096	O
months	-	1098	O
of	-	1105	O
treatment	-	1108	O
.	-	1117	O

CONCLUSIONS	15096374	1119	O
:	-	1130	O

Our	15096374	1132	O
observations	-	1136	O
suggest	-	1149	O
that	-	1157	O
the	-	1162	O
spectrum	-	1166	O
of	-	1175	O
rosaceiform	-	1178	O
dermatitis	-	1190	B
as	-	1201	O
a	-	1204	O
complication	-	1206	O
of	-	1219	O
treatment	-	1222	O
with	-	1232	O
tacrolimus	-	1237	O
ointment	-	1248	O
is	-	1257	O
heterogeneous	-	1260	O
.	-	1273	O

A	15096374	1275	O
variety	-	1277	O
of	-	1285	O
factors	-	1288	O
,	-	1295	O
such	-	1297	O
as	-	1302	O
vasoactive	-	1305	O
properties	-	1316	O
of	-	1327	O
tacrolimus	-	1330	O
,	-	1340	O
proliferation	-	1342	O
of	-	1356	O
Demodex	-	1359	O
due	-	1367	O
to	-	1371	O
local	-	1374	O
immunosuppression	-	1380	O
,	-	1397	O
and	-	1399	O
the	-	1403	O
occlusive	-	1407	O
properties	-	1417	O
of	-	1428	O
the	-	1431	O
ointment	-	1435	O
,	-	1443	O
may	-	1445	O
be	-	1449	O
involved	-	1452	O
in	-	1461	O
the	-	1464	O
observed	-	1468	O
phenomena	-	1477	O
.	-	1486	O

Future	15096374	1488	O
studies	-	1495	O
are	-	1503	O
needed	-	1507	O
to	-	1514	O
identify	-	1517	O
individual	-	1526	O
risk	-	1537	O
factors	-	1542	O
.	-	1549	O

Structural	15229250	0	O
abnormalities	-	11	O
in	-	25	O
the	-	28	O
brains	-	32	O
of	-	39	O
human	-	42	O
subjects	-	48	O
who	-	57	O
use	-	61	O
methamphetamine	-	65	O
.	-	80	O

We	15229250	82	O
visualize	-	85	O
,	-	94	O
for	-	96	O
the	-	100	O
first	-	104	O
time	-	110	O
,	-	114	O
the	-	116	O
profile	-	120	O
of	-	128	O
structural	-	131	B
deficits	-	142	I
in	-	151	I
the	-	154	I
human	-	158	I
brain	-	164	I
associated	-	170	O
with	-	181	O
chronic	-	186	O
methamphetamine	-	194	O
(	-	210	O
MA	-	211	O
)	-	213	O
abuse	-	215	O
.	-	220	O

Studies	15229250	222	O
of	-	230	O
human	-	233	O
subjects	-	239	O
who	-	248	O
have	-	252	O
used	-	257	O
MA	-	262	O
chronically	-	265	O
have	-	277	O
revealed	-	282	O
deficits	-	291	O
in	-	300	O
dopaminergic	-	303	O
and	-	316	O
serotonergic	-	320	O
systems	-	333	O
and	-	341	O
cerebral	-	345	O
metabolic	-	354	B
abnormalities	-	364	I
.	-	377	O

Using	15229250	379	O
magnetic	-	385	O
resonance	-	394	O
imaging	-	404	O
(	-	412	O
MRI	-	413	O
)	-	416	O
and	-	418	O
new	-	422	O
computational	-	426	O
brain	-	440	O
-	-	445	O
mapping	-	446	O
techniques	-	454	O
,	-	464	O
we	-	466	O
determined	-	469	O
the	-	480	O
pattern	-	484	O
of	-	492	O
structural	-	495	O
brain	-	506	O
alterations	-	512	O
associated	-	524	O
with	-	535	O
chronic	-	540	O
MA	-	548	O
abuse	-	551	O
in	-	557	O
human	-	560	O
subjects	-	566	O
and	-	575	O
related	-	579	O
these	-	587	O
deficits	-	593	O
to	-	602	O
cognitive	-	605	B
impairment	-	615	I
.	-	625	O

We	15229250	627	O
used	-	630	O
high	-	635	O
-	-	639	O
resolution	-	640	O
MRI	-	651	O
and	-	655	O
surface	-	659	O
-	-	666	O
based	-	667	O
computational	-	673	O
image	-	687	O
analyses	-	693	O
to	-	702	O
map	-	705	O
regional	-	709	O
abnormalities	-	718	B
in	-	732	I
the	-	735	I
cortex	-	739	I
,	-	745	I
hippocampus	-	747	I
,	-	758	I
white	-	760	I
matter	-	766	I
,	-	772	I
and	-	774	I
ventricles	-	778	I
in	-	789	O
22	-	792	O
human	-	795	O
subjects	-	801	O
who	-	810	O
used	-	814	O
MA	-	819	O
and	-	822	O
21	-	826	O
age	-	829	O
-	-	832	O
matched	-	833	O
,	-	840	O
healthy	-	842	O
controls	-	850	O
.	-	858	O

Cortical	15229250	860	O
maps	-	869	O
revealed	-	874	O
severe	-	883	O
gray	-	890	O
-	-	894	O
matter	-	895	O
deficits	-	902	O
in	-	911	O
the	-	914	O
cingulate	-	918	O
,	-	927	O
limbic	-	929	O
,	-	935	O
and	-	937	O
paralimbic	-	941	O
cortices	-	952	O
of	-	961	O
MA	-	964	O
abusers	-	967	O
(	-	975	O
averaging	-	976	O
11	-	986	O
.	-	988	O
3	-	989	O
%	-	990	O
below	-	992	O
control	-	998	O
;	-	1005	O
p	-	1007	O
<	-	1009	O
0	-	1011	O
.	-	1012	O
05	-	1013	O
)	-	1015	O
.	-	1016	O

On	15229250	1018	O
average	-	1021	O
,	-	1028	O
MA	-	1030	O
abusers	-	1033	O
had	-	1041	O
7	-	1045	O
.	-	1046	O
8	-	1047	O
%	-	1048	O
smaller	-	1050	O
hippocampal	-	1058	O
volumes	-	1070	O
than	-	1078	O
control	-	1083	O
subjects	-	1091	O
(	-	1100	O
p	-	1101	O
<	-	1103	O
0	-	1105	O
.	-	1106	O
01	-	1107	O
;	-	1109	O
left	-	1111	O
,	-	1115	O
p	-	1117	O
=	-	1119	O
0	-	1121	O
.	-	1122	O
01	-	1123	O
;	-	1125	O
right	-	1127	O
,	-	1132	O
p	-	1134	O
<	-	1136	O
0	-	1138	O
.	-	1139	O
05	-	1140	O
)	-	1142	O
and	-	1144	O
significant	-	1148	O
white	-	1160	O
-	-	1165	O
matter	-	1166	O
hypertrophy	-	1173	B
(	-	1185	O
7	-	1186	O
.	-	1187	O
0	-	1188	O
%	-	1189	O
;	-	1190	O
p	-	1192	O
<	-	1194	O
0	-	1196	O
.	-	1197	O
01	-	1198	O
)	-	1200	O
.	-	1201	O

Hippocampal	15229250	1203	O
deficits	-	1215	O
were	-	1224	O
mapped	-	1229	O
and	-	1236	O
correlated	-	1240	O
with	-	1251	O
memory	-	1256	O
performance	-	1263	O
on	-	1275	O
a	-	1278	O
word	-	1280	O
-	-	1284	O
recall	-	1285	O
test	-	1292	O
(	-	1297	O
p	-	1298	O
<	-	1300	O
0	-	1302	O
.	-	1303	O
05	-	1304	O
)	-	1306	O
.	-	1307	O

MRI	15229250	1309	O
-	-	1312	O
based	-	1313	O
maps	-	1319	O
suggest	-	1324	O
that	-	1332	O
chronic	-	1337	O
methamphetamine	-	1345	O
abuse	-	1361	O
causes	-	1367	O
a	-	1374	O
selective	-	1376	O
pattern	-	1386	O
of	-	1394	O
cerebral	-	1397	O
deterioration	-	1406	O
that	-	1420	O
contributes	-	1425	O
to	-	1437	O
impaired	-	1440	B
memory	-	1449	I
performance	-	1456	I
.	-	1467	O

MA	15229250	1469	O
may	-	1472	O
selectively	-	1476	O
damage	-	1488	O
the	-	1495	O
medial	-	1499	O
temporal	-	1506	O
lobe	-	1515	O
and	-	1520	O
,	-	1523	O
consistent	-	1525	O
with	-	1536	O
metabolic	-	1541	O
studies	-	1551	O
,	-	1558	O
the	-	1560	O
cingulate	-	1564	O
-	-	1573	O
limbic	-	1574	O
cortex	-	1581	O
,	-	1587	O
inducing	-	1589	O
neuroadaptation	-	1598	O
,	-	1613	O
neuropil	-	1615	O
reduction	-	1624	O
,	-	1633	O
or	-	1635	O
cell	-	1638	O
death	-	1643	O
.	-	1648	O

Prominent	15229250	1650	O
white	-	1660	O
-	-	1665	O
matter	-	1666	O
hypertrophy	-	1673	B
may	-	1685	O
result	-	1689	O
from	-	1696	O
altered	-	1701	O
myelination	-	1709	O
and	-	1721	O
adaptive	-	1725	O
glial	-	1734	O
changes	-	1740	O
,	-	1747	O
including	-	1749	O
gliosis	-	1759	B
secondary	-	1767	O
to	-	1777	O
neuronal	-	1780	B
damage	-	1789	I
.	-	1795	O

These	15229250	1797	O
brain	-	1803	O
substrates	-	1809	O
may	-	1820	O
help	-	1824	O
account	-	1829	O
for	-	1837	O
the	-	1841	O
symptoms	-	1845	O
of	-	1854	O
MA	-	1857	O
abuse	-	1860	O
,	-	1865	O
providing	-	1867	O
therapeutic	-	1877	O
targets	-	1889	O
for	-	1897	O
drug	-	1901	O
-	-	1905	O
induced	-	1906	O
brain	-	1914	B
injury	-	1920	I
.	-	1926	O

Disruption	15265979	0	O
of	-	11	O
hepatic	-	14	O
lipid	-	22	O
homeostasis	-	28	O
in	-	40	O
mice	-	43	O
after	-	48	O
amiodarone	-	54	O
treatment	-	65	O
is	-	75	O
associated	-	78	O
with	-	89	O
peroxisome	-	94	O
proliferator	-	105	O
-	-	117	O
activated	-	118	O
receptor	-	128	O
-	-	136	O
alpha	-	137	O
target	-	143	O
gene	-	150	O
activation	-	155	O
.	-	165	O

Amiodarone	15265979	167	O
,	-	177	O
an	-	179	O
efficacious	-	182	O
and	-	194	O
widely	-	198	O
used	-	205	O
antiarrhythmic	-	210	O
agent	-	225	O
,	-	230	O
has	-	232	O
been	-	236	O
reported	-	241	O
to	-	250	O
cause	-	253	O
hepatotoxicity	-	259	B
in	-	274	O
some	-	277	O
patients	-	282	O
.	-	290	O

To	15265979	292	O
gain	-	295	O
insight	-	300	O
into	-	308	O
the	-	313	O
mechanism	-	317	O
of	-	327	O
this	-	330	O
unwanted	-	335	O
effect	-	344	O
,	-	350	O
mice	-	352	O
were	-	357	O
administered	-	362	O
various	-	375	O
doses	-	383	O
of	-	389	O
amiodarone	-	392	O
and	-	403	O
examined	-	407	O
for	-	416	O
changes	-	420	O
in	-	428	O
hepatic	-	431	O
histology	-	439	O
and	-	449	O
gene	-	453	O
regulation	-	458	O
.	-	468	O

Amiodarone	15265979	470	O
induced	-	481	O
hepatomegaly	-	489	B
,	-	501	O
hepatocyte	-	503	O
microvesicular	-	514	O
lipid	-	529	O
accumulation	-	535	O
,	-	547	O
and	-	549	O
a	-	553	O
significant	-	555	O
decrease	-	567	O
in	-	576	O
serum	-	579	O
triglycerides	-	585	O
and	-	599	O
glucose	-	603	O
.	-	610	O

Northern	15265979	612	O
blot	-	621	O
analysis	-	626	O
of	-	635	O
hepatic	-	638	O
RNA	-	646	O
revealed	-	650	O
a	-	659	O
dose	-	661	O
-	-	665	O
dependent	-	666	O
increase	-	676	O
in	-	685	O
the	-	688	O
expression	-	692	O
of	-	703	O
a	-	706	O
number	-	708	O
of	-	715	O
genes	-	718	O
critical	-	724	O
for	-	733	O
fatty	-	737	O
acid	-	743	O
oxidation	-	748	O
,	-	757	O
lipoprotein	-	759	O
assembly	-	771	O
,	-	779	O
and	-	781	O
lipid	-	785	O
transport	-	791	O
.	-	800	O

Many	15265979	802	O
of	-	807	O
these	-	810	O
genes	-	816	O
are	-	822	O
regulated	-	826	O
by	-	836	O
the	-	839	O
peroxisome	-	843	O
proliferator	-	854	O
-	-	866	O
activated	-	867	O
receptor	-	877	O
-	-	885	O
alpha	-	886	O
(	-	892	O
PPARalpha	-	893	O
)	-	902	O
,	-	903	O
a	-	905	O
ligand	-	907	O
-	-	913	O
activated	-	914	O
nuclear	-	924	O
hormone	-	932	O
receptor	-	940	O
transcription	-	949	O
factor	-	963	O
.	-	969	O

The	15265979	971	O
absence	-	975	O
of	-	983	O
induction	-	986	O
of	-	996	O
these	-	999	O
genes	-	1005	O
as	-	1011	O
well	-	1014	O
as	-	1019	O
hepatomegaly	-	1022	B
in	-	1035	O
PPARalpha	-	1038	O
knockout	-	1048	O
[	-	1057	O
PPARalpha	-	1058	O
-	-	1067	O
/	-	1068	O
-	-	1069	O
]	-	1070	O
mice	-	1072	O
indicated	-	1077	O
that	-	1087	O
the	-	1092	O
effects	-	1096	O
of	-	1104	O
amiodarone	-	1107	O
were	-	1118	O
dependent	-	1123	O
upon	-	1133	O
the	-	1138	O
presence	-	1142	O
of	-	1151	O
a	-	1154	O
functional	-	1156	O
PPARalpha	-	1167	O
gene	-	1177	O
.	-	1181	O

Compared	15265979	1183	O
to	-	1192	O
wild	-	1195	O
-	-	1199	O
type	-	1200	O
mice	-	1205	O
,	-	1209	O
treatment	-	1211	O
of	-	1221	O
PPARalpha	-	1224	O
-	-	1233	O
/	-	1234	O
-	-	1235	O
mice	-	1237	O
with	-	1242	O
amiodarone	-	1247	O
resulted	-	1258	O
in	-	1267	O
an	-	1270	O
increased	-	1273	O
rate	-	1283	O
and	-	1288	O
extent	-	1292	O
of	-	1299	O
total	-	1302	O
body	-	1308	O
weight	-	1313	B
loss	-	1320	I
.	-	1324	O

The	15265979	1326	O
inability	-	1330	O
of	-	1340	O
amiodarone	-	1343	O
to	-	1354	O
directly	-	1357	O
activate	-	1366	O
either	-	1375	O
human	-	1382	O
or	-	1388	O
mouse	-	1391	O
PPARalpha	-	1397	O
transiently	-	1407	O
expressed	-	1419	O
in	-	1429	O
human	-	1432	O
HepG2	-	1438	O
hepatoma	-	1444	B
cells	-	1453	O
indicates	-	1459	O
that	-	1469	O
the	-	1474	O
effects	-	1478	O
of	-	1486	O
amiodarone	-	1489	O
on	-	1500	O
the	-	1503	O
function	-	1507	O
of	-	1516	O
this	-	1519	O
receptor	-	1524	O
were	-	1533	O
indirect	-	1538	O
.	-	1546	O

Based	15265979	1548	O
upon	-	1554	O
these	-	1559	O
results	-	1565	O
,	-	1572	O
we	-	1574	O
conclude	-	1577	O
that	-	1586	O
amiodarone	-	1591	O
disrupts	-	1602	O
hepatic	-	1611	O
lipid	-	1619	O
homeostasis	-	1625	O
and	-	1637	O
that	-	1641	O
the	-	1646	O
increased	-	1650	O
expression	-	1660	O
of	-	1671	O
PPARalpha	-	1674	O
target	-	1684	O
genes	-	1691	O
is	-	1697	O
secondary	-	1700	O
to	-	1710	O
this	-	1713	O
toxic	-	1718	O
effect	-	1724	O
.	-	1730	O

These	15265979	1732	O
results	-	1738	O
provide	-	1746	O
important	-	1754	O
new	-	1764	O
mechanistic	-	1768	O
information	-	1780	O
regarding	-	1792	O
the	-	1802	O
hepatotoxic	-	1806	B
effects	-	1818	O
of	-	1826	O
amiodarone	-	1829	O
and	-	1840	O
indicate	-	1844	O
that	-	1853	O
PPARalpha	-	1858	O
protects	-	1868	O
against	-	1877	O
amiodarone	-	1885	O
-	-	1895	O
induced	-	1896	O
hepatotoxicity	-	1904	B
.	-	1918	O

Safety	15276093	0	O
and	-	7	O
compliance	-	11	O
with	-	22	O
once	-	27	O
-	-	31	O
daily	-	32	O
niacin	-	38	O
extended	-	45	O
-	-	53	O
release	-	54	O
/	-	61	O
lovastatin	-	62	O
as	-	73	O
initial	-	76	O
therapy	-	84	O
in	-	92	O
the	-	95	O
Impact	-	99	O
of	-	106	O
Medical	-	109	O
Subspecialty	-	117	O
on	-	130	O
Patient	-	133	O
Compliance	-	141	O
to	-	152	O
Treatment	-	155	O
(	-	165	O
IMPACT	-	166	O
)	-	172	O
study	-	174	O
.	-	179	O

Niacin	15276093	181	O
extended	-	188	O
-	-	196	O
release	-	197	O
/	-	204	O
lovastatin	-	205	O
is	-	216	O
a	-	219	O
new	-	221	O
combination	-	225	O
product	-	237	O
approved	-	245	O
for	-	254	O
treatment	-	258	O
of	-	268	O
primary	-	271	O
hypercholesterolemia	-	279	B
and	-	300	O
mixed	-	304	O
dyslipidemia	-	310	B
.	-	322	O

This	15276093	324	O
open	-	329	O
-	-	333	O
labeled	-	334	O
,	-	341	O
multicenter	-	343	O
study	-	355	O
evaluated	-	361	O
the	-	371	O
safety	-	375	O
of	-	382	O
bedtime	-	385	O
niacin	-	393	O
extended	-	400	O
-	-	408	O
release	-	409	O
/	-	416	O
lovastatin	-	417	O
when	-	428	O
dosed	-	433	O
as	-	439	O
initial	-	442	O
therapy	-	450	O
and	-	458	O
patient	-	462	O
compliance	-	470	O
to	-	481	O
treatment	-	484	O
in	-	494	O
various	-	497	O
clinical	-	505	O
practice	-	514	O
settings	-	523	O
.	-	531	O

A	15276093	533	O
total	-	535	O
of	-	541	O
4	-	544	O
,	-	545	O
499	-	546	O
patients	-	550	O
with	-	559	O
dyslipidemia	-	564	B
requiring	-	577	O
drug	-	587	O
intervention	-	592	O
was	-	605	O
enrolled	-	609	O
at	-	618	O
1	-	621	O
,	-	622	O
081	-	623	O
sites	-	627	O
.	-	632	O

Patients	15276093	634	O
were	-	643	O
treated	-	648	O
with	-	656	O
1	-	661	O
tablet	-	663	O
(	-	670	O
500	-	671	O
mg	-	675	O
of	-	678	O
niacin	-	681	O
extended	-	688	O
-	-	696	O
release	-	697	O
/	-	704	O
20	-	705	O
mg	-	708	O
of	-	711	O
lovastatin	-	714	O
)	-	724	O
once	-	726	O
nightly	-	731	O
for	-	739	O
4	-	743	O
weeks	-	745	O
and	-	751	O
then	-	755	O
2	-	760	O
tablets	-	762	O
for	-	770	O
8	-	774	O
weeks	-	776	O
.	-	781	O

Patients	15276093	783	O
also	-	792	O
received	-	797	O
dietary	-	806	O
counseling	-	814	O
,	-	824	O
educational	-	826	O
materials	-	838	O
,	-	847	O
and	-	849	O
reminders	-	853	O
to	-	863	O
call	-	866	O
a	-	871	O
toll	-	873	O
-	-	877	O
free	-	878	O
number	-	883	O
that	-	890	O
provided	-	895	O
further	-	904	O
education	-	912	O
about	-	922	O
dyslipidemia	-	928	B
and	-	941	O
niacin	-	945	O
extended	-	952	O
-	-	960	O
release	-	961	O
/	-	968	O
lovastatin	-	969	O
.	-	979	O

Primary	15276093	981	O
end	-	989	O
points	-	993	O
were	-	1000	O
study	-	1005	O
compliance	-	1011	O
,	-	1021	O
increases	-	1023	O
in	-	1033	O
liver	-	1036	O
transaminases	-	1042	O
to	-	1056	O
>	-	1059	O
3	-	1060	O
times	-	1062	O
the	-	1068	O
upper	-	1072	O
limit	-	1078	O
of	-	1084	O
normal	-	1087	O
,	-	1093	O
and	-	1095	O
clinical	-	1099	O
myopathy	-	1108	B
.	-	1116	O

Final	15276093	1118	O
study	-	1124	O
status	-	1130	O
was	-	1137	O
available	-	1141	O
for	-	1151	O
4	-	1155	O
,	-	1156	O
217	-	1157	O
patients	-	1161	O
(	-	1170	O
94	-	1171	O
%	-	1173	O
)	-	1174	O
.	-	1175	O

Compliance	15276093	1177	O
to	-	1188	O
niacin	-	1191	O
extended	-	1198	O
-	-	1206	O
release	-	1207	O
/	-	1214	O
lovastatin	-	1215	O
was	-	1226	O
77	-	1230	O
%	-	1232	O
,	-	1233	O
with	-	1235	O
3	-	1240	O
,	-	1241	O
245	-	1242	O
patients	-	1246	O
completing	-	1255	O
the	-	1266	O
study	-	1270	O
.	-	1275	O

Patients	15276093	1277	O
in	-	1286	O
the	-	1289	O
southeast	-	1293	O
and	-	1303	O
those	-	1307	O
enrolled	-	1313	O
by	-	1322	O
endocrinologists	-	1325	O
had	-	1342	O
the	-	1346	O
lowest	-	1350	O
compliance	-	1357	O
and	-	1368	O
highest	-	1372	O
adverse	-	1380	O
event	-	1388	O
rates	-	1394	O
.	-	1399	O

Flushing	15276093	1401	B
was	-	1410	O
the	-	1414	O
most	-	1418	O
common	-	1423	O
adverse	-	1430	O
event	-	1438	O
,	-	1443	O
reported	-	1445	O
by	-	1454	O
18	-	1457	O
%	-	1459	O
of	-	1461	O
patients	-	1464	O
and	-	1473	O
leading	-	1477	O
to	-	1485	O
discontinuation	-	1488	O
by	-	1504	O
6	-	1507	O
%	-	1508	O
.	-	1509	O

Incidence	15276093	1511	O
of	-	1521	O
increased	-	1524	O
aspartate	-	1534	O
aminotransferase	-	1544	O
and	-	1561	O
/	-	1564	O
or	-	1565	O
alanine	-	1568	O
aminotransferase	-	1576	O
>	-	1593	O
3	-	1594	O
times	-	1596	O
the	-	1602	O
upper	-	1606	O
limit	-	1612	O
of	-	1618	O
normal	-	1621	O
was	-	1628	O
<	-	1632	O
0	-	1633	O
.	-	1634	O
3	-	1635	O
%	-	1636	O
.	-	1637	O

An	15276093	1639	O
increase	-	1642	O
of	-	1651	O
creatine	-	1654	O
phosphokinase	-	1663	O
to	-	1677	O
>	-	1680	O
5	-	1681	O
times	-	1683	O
the	-	1689	O
upper	-	1693	O
limit	-	1699	O
of	-	1705	O
normal	-	1708	O
occurred	-	1715	O
in	-	1724	O
0	-	1727	O
.	-	1728	O
24	-	1729	O
%	-	1731	O
of	-	1733	O
patients	-	1736	O
,	-	1744	O
and	-	1746	O
no	-	1750	O
cases	-	1753	O
of	-	1759	O
drug	-	1762	O
-	-	1766	O
induced	-	1767	O
myopathy	-	1775	B
were	-	1784	O
observed	-	1789	O
.	-	1797	O

Niacin	15276093	1799	O
extended	-	1806	O
-	-	1814	O
release	-	1815	O
/	-	1822	O
lovastatin	-	1823	O
1	-	1834	O
,	-	1835	O
000	-	1836	O
/	-	1839	O
40	-	1840	O
mg	-	1843	O
,	-	1845	O
dosed	-	1847	O
as	-	1853	O
initial	-	1856	O
therapy	-	1864	O
,	-	1871	O
was	-	1873	O
associated	-	1877	O
with	-	1888	O
good	-	1893	O
compliance	-	1898	O
and	-	1909	O
safety	-	1913	O
and	-	1920	O
had	-	1924	O
very	-	1928	O
low	-	1933	O
incidences	-	1937	O
of	-	1948	O
increased	-	1951	O
liver	-	1961	O
and	-	1967	O
muscle	-	1971	O
enzymes	-	1978	O
.	-	1985	O

Protective	15282950	0	O
effect	-	11	O
of	-	18	O
Terminalia	-	21	O
chebula	-	32	O
against	-	40	O
experimental	-	48	O
myocardial	-	61	B
injury	-	72	I
induced	-	79	O
by	-	87	O
isoproterenol	-	90	O
.	-	103	O

Cardioprotective	15282950	105	O
effect	-	122	O
of	-	129	O
ethanolic	-	132	O
extract	-	142	O
of	-	150	O
Terminalia	-	153	O
chebula	-	164	O
fruits	-	172	O
(	-	179	O
500	-	180	O
mg	-	184	O
/	-	186	O
kg	-	187	O
body	-	190	O
wt	-	195	O
)	-	197	O
was	-	199	O
examined	-	203	O
in	-	212	O
isoproterenol	-	215	O
(	-	229	O
200	-	230	O
mg	-	234	O
/	-	236	O
kg	-	237	O
body	-	240	O
wt	-	245	O
)	-	247	O
induced	-	249	O
myocardial	-	257	B
damage	-	268	I
in	-	275	O
rats	-	278	O
.	-	282	O

In	15282950	284	O
isoproterenol	-	287	O
administered	-	301	O
rats	-	314	O
,	-	318	O
the	-	320	O
level	-	324	O
of	-	330	O
lipid	-	333	O
peroxides	-	339	O
increased	-	349	O
significantly	-	359	O
in	-	373	O
the	-	376	O
serum	-	380	O
and	-	386	O
heart	-	390	O
.	-	395	O

A	15282950	397	O
significant	-	399	O
decrease	-	411	O
was	-	420	O
observed	-	424	O
in	-	433	O
the	-	436	O
activity	-	440	O
of	-	449	O
the	-	452	O
myocardial	-	456	O
marker	-	467	O
enzymes	-	474	O
with	-	482	O
a	-	487	O
concomitant	-	489	O
increase	-	501	O
in	-	510	O
their	-	513	O
activity	-	519	O
in	-	528	O
serum	-	531	O
.	-	536	O

Histopathological	15282950	538	O
examination	-	556	O
was	-	568	O
carried	-	572	O
out	-	580	O
to	-	584	O
confirm	-	587	O
the	-	595	O
myocardial	-	599	O
necrosis	-	610	B
.	-	618	O

T	15282950	620	O
.	-	621	O
chebula	-	623	O
extract	-	631	O
pretreatment	-	639	O
was	-	652	O
found	-	656	O
to	-	662	O
ameliorate	-	665	O
the	-	676	O
effect	-	680	O
of	-	687	O
isoproterenol	-	690	O
on	-	704	O
lipid	-	707	O
peroxide	-	713	O
formation	-	722	O
and	-	732	O
retained	-	736	O
the	-	745	O
activities	-	749	O
of	-	760	O
the	-	763	O
diagnostic	-	767	O
marker	-	778	O
enzymes	-	785	O
.	-	792	O

A	15321332	0	O
case	-	2	O
of	-	7	O
postoperative	-	10	O
anxiety	-	24	B
due	-	32	O
to	-	36	O
low	-	39	O
dose	-	43	O
droperidol	-	48	O
used	-	59	O
with	-	64	O
patient	-	69	O
-	-	76	O
controlled	-	77	O
analgesia	-	88	O
.	-	97	O

A	15321332	99	O
multiparous	-	101	O
woman	-	113	O
in	-	119	O
good	-	122	O
psychological	-	127	O
health	-	141	O
underwent	-	148	O
urgent	-	158	O
caesarean	-	165	O
section	-	175	O
in	-	183	O
labour	-	186	O
.	-	192	O

Postoperatively	15321332	194	O
,	-	209	O
she	-	211	O
was	-	215	O
given	-	219	O
a	-	225	O
patient	-	227	O
-	-	234	O
controlled	-	235	O
analgesia	-	246	O
device	-	256	O
delivering	-	263	O
boluses	-	274	O
of	-	282	O
diamorphine	-	285	O
0	-	297	O
.	-	298	O
5	-	299	O
mg	-	301	O
and	-	304	O
droperidol	-	308	O
0	-	319	O
.	-	320	O
025	-	321	O
mg	-	325	O
.	-	327	O

Whilst	15321332	329	O
using	-	336	O
the	-	342	O
device	-	346	O
she	-	353	O
gradually	-	357	O
became	-	367	O
anxious	-	374	O
,	-	381	O
the	-	383	O
feeling	-	387	O
worsening	-	395	O
after	-	405	O
each	-	411	O
bolus	-	416	O
.	-	421	O

The	15321332	423	O
diagnosis	-	427	O
of	-	437	O
droperidol	-	440	O
-	-	450	O
induced	-	451	O
psychological	-	459	B
disturbance	-	473	I
was	-	485	O
not	-	489	O
made	-	493	O
straight	-	498	O
away	-	507	O
although	-	512	O
on	-	521	O
subsequent	-	524	O
close	-	535	O
questioning	-	541	O
the	-	553	O
patient	-	557	O
gave	-	565	O
a	-	570	O
very	-	572	O
clear	-	577	O
history	-	583	O
.	-	590	O

After	15321332	592	O
she	-	598	O
had	-	602	O
received	-	606	O
a	-	615	O
total	-	617	O
of	-	623	O
only	-	626	O
0	-	631	O
.	-	632	O
9	-	633	O
mg	-	635	O
droperidol	-	638	O
,	-	648	O
a	-	650	O
syringe	-	652	O
containing	-	660	O
diamorphine	-	671	O
only	-	683	O
was	-	688	O
substituted	-	692	O
and	-	704	O
her	-	708	O
unease	-	712	O
resolved	-	719	O
completely	-	728	O
.	-	738	O

We	15321332	740	O
feel	-	743	O
that	-	748	O
,	-	752	O
although	-	754	O
the	-	763	O
dramatic	-	767	O
extrapyramidal	-	776	O
side	-	791	O
effects	-	796	O
of	-	804	O
dopaminergic	-	807	O
antiemetics	-	820	O
are	-	832	O
well	-	836	O
known	-	841	O
,	-	846	O
more	-	848	O
subtle	-	853	O
manifestations	-	860	O
may	-	875	O
easily	-	879	O
be	-	886	O
overlooked	-	889	O
.	-	899	O

Accurate	15366550	0	O
patient	-	9	O
history	-	17	O
contributes	-	25	O
to	-	37	O
differentiating	-	40	O
diabetes	-	56	B
insipidus	-	65	I
:	-	74	O
a	-	76	O
case	-	78	O
study	-	83	O
.	-	88	O

This	15366550	90	O
case	-	95	O
study	-	100	O
highlights	-	106	O
the	-	117	O
important	-	121	O
contribution	-	131	O
of	-	144	O
nursing	-	147	O
in	-	155	O
obtaining	-	158	O
an	-	168	O
accurate	-	171	O
health	-	180	O
history	-	187	O
.	-	194	O

The	15366550	196	O
case	-	200	O
discussed	-	205	O
herein	-	215	O
initially	-	222	O
appeared	-	232	O
to	-	241	O
be	-	244	O
neurogenic	-	247	B
diabetes	-	258	I
insipidus	-	267	I
(	-	277	O
DI	-	278	B
)	-	280	O
secondary	-	282	O
to	-	292	O
a	-	295	O
traumatic	-	297	B
brain	-	307	I
injury	-	313	I
.	-	319	O

The	15366550	321	O
nursing	-	325	O
staff	-	333	O
,	-	338	O
by	-	340	O
reviewing	-	343	O
the	-	353	O
patient	-	357	O
's	-	364	O
health	-	367	O
history	-	374	O
with	-	382	O
his	-	387	O
family	-	391	O
,	-	397	O
discovered	-	399	O
a	-	410	O
history	-	412	O
of	-	420	O
polydipsia	-	423	B
and	-	434	O
long	-	438	O
-	-	442	O
standing	-	443	O
lithium	-	452	O
use	-	460	O
.	-	463	O

Lithium	15366550	465	O
is	-	473	O
implicated	-	476	O
in	-	487	O
drug	-	490	O
-	-	494	O
induced	-	495	O
nephrogenic	-	503	B
DI	-	515	I
,	-	517	O
and	-	519	O
because	-	523	O
the	-	531	O
patient	-	535	O
had	-	543	O
not	-	547	O
received	-	551	O
lithium	-	560	O
since	-	568	O
being	-	574	O
admitted	-	580	O
to	-	589	O
the	-	592	O
hospital	-	596	O
,	-	604	O
his	-	606	O
treatment	-	610	O
changed	-	620	O
to	-	628	O
focus	-	631	O
on	-	637	O
nephrogenic	-	640	B
DI	-	652	I
.	-	654	O

By	15366550	656	O
combining	-	659	O
information	-	669	O
from	-	681	O
the	-	686	O
patient	-	690	O
history	-	698	O
,	-	705	O
the	-	707	O
physical	-	711	O
examination	-	720	O
,	-	731	O
and	-	733	O
radiologic	-	737	O
and	-	748	O
laboratory	-	752	O
studies	-	763	O
,	-	770	O
the	-	772	O
critical	-	776	O
care	-	785	O
team	-	790	O
demonstrated	-	795	O
that	-	808	O
the	-	813	O
patient	-	817	O
had	-	825	O
been	-	829	O
self	-	834	O
-	-	838	O
treating	-	839	O
his	-	848	O
lithium	-	852	O
-	-	859	O
induced	-	860	O
nephrogenic	-	868	B
DI	-	880	I
and	-	883	O
developed	-	887	O
neurogenic	-	897	B
DI	-	908	I
secondary	-	911	O
to	-	921	O
brain	-	924	B
trauma	-	930	I
.	-	936	O

Thus	15366550	938	O
successful	-	943	O
treatment	-	954	O
required	-	964	O
that	-	973	O
nephrogenic	-	978	O
and	-	990	O
neurogenic	-	994	B
DI	-	1005	I
be	-	1008	O
treated	-	1011	O
concomitantly	-	1019	O
.	-	1032	O

Factors	15482540	0	O
contributing	-	8	O
to	-	21	O
ribavirin	-	24	O
-	-	33	O
induced	-	34	O
anemia	-	42	B
.	-	48	O

BACKGROUND	15482540	50	O
AND	-	61	O
AIM	-	65	O
:	-	68	O

Interferon	15482540	70	O
and	-	81	O
ribavirin	-	85	O
combination	-	95	O
therapy	-	107	O
for	-	115	O
chronic	-	119	B
hepatitis	-	127	I
C	-	137	I
produces	-	139	O
hemolytic	-	148	B
anemia	-	158	I
.	-	164	O

This	15482540	166	O
study	-	171	O
was	-	177	O
conducted	-	181	O
to	-	191	O
identify	-	194	O
the	-	203	O
factors	-	207	O
contributing	-	215	O
to	-	228	O
ribavirin	-	231	O
-	-	240	O
induced	-	241	O
anemia	-	249	B
.	-	255	O

METHODS	15482540	257	O
:	-	264	O

Eighty	15482540	266	O
-	-	272	O
eight	-	273	O
patients	-	279	O
with	-	288	O
chronic	-	293	B
hepatitis	-	301	I
C	-	311	I
who	-	313	O
received	-	317	O
interferon	-	326	O
-	-	336	O
alpha	-	337	O
-	-	342	O
2b	-	343	O
at	-	346	O
a	-	349	O
dose	-	351	O
of	-	356	O
6	-	359	O
MU	-	361	O
administered	-	364	O
intramuscularly	-	377	O
for	-	393	O
24	-	397	O
weeks	-	400	O
in	-	406	O
combination	-	409	O
with	-	421	O
ribavirin	-	426	O
administered	-	436	O
orally	-	449	O
at	-	456	O
a	-	459	O
dose	-	461	O
of	-	466	O
600	-	469	O
mg	-	473	O
or	-	476	O
800	-	479	O
mg	-	483	O
participated	-	486	O
in	-	499	O
the	-	502	O
study	-	506	O
.	-	511	O

A	15482540	513	O
hemoglobin	-	515	O
concentration	-	526	O
of	-	540	O
<	-	543	O
10	-	544	O
g	-	547	O
/	-	548	O
dL	-	549	O
was	-	552	O
defined	-	556	O
as	-	564	O
ribavirin	-	567	O
-	-	576	O
induced	-	577	O
anemia	-	585	B
.	-	591	O

RESULTS	15482540	593	O
:	-	600	O

Ribavirin	15482540	602	O
-	-	611	O
induced	-	612	O
anemia	-	620	B
occurred	-	627	O
in	-	636	O
18	-	639	O
(	-	642	O
20	-	643	O
.	-	645	O
5	-	646	O
%	-	647	O
)	-	648	O
patients	-	650	O
during	-	659	O
treatment	-	666	O
.	-	675	O

A	15482540	677	O
2	-	679	O
g	-	681	O
/	-	682	O
dL	-	683	O
decrease	-	686	O
in	-	695	O
hemoglobin	-	698	O
concentrations	-	709	O
in	-	724	O
patients	-	727	O
with	-	736	O
anemia	-	741	B
was	-	748	O
observed	-	752	O
at	-	761	O
week	-	764	O
2	-	769	O
after	-	771	O
the	-	777	O
start	-	781	O
of	-	787	O
treatment	-	790	O
.	-	799	O

The	15482540	801	O
hemoglobin	-	805	O
concentration	-	816	O
in	-	830	O
patients	-	833	O
with	-	842	O
>	-	847	O
or	-	849	O
=	-	852	O
2	-	853	O
g	-	855	O
/	-	856	O
dL	-	857	O
decrease	-	860	O
at	-	869	O
week	-	872	O
2	-	877	O
was	-	879	O
observed	-	883	O
to	-	892	O
be	-	895	O
significantly	-	898	O
lower	-	912	O
even	-	918	O
after	-	923	O
week	-	929	O
2	-	934	O
than	-	936	O
in	-	941	O
patients	-	944	O
with	-	953	O
<	-	958	O
2	-	959	O
g	-	961	O
/	-	962	O
dL	-	963	O
decrease	-	966	O
(	-	975	O
P	-	976	O
<	-	978	O
0	-	980	O
.	-	981	O
01	-	982	O
)	-	984	O
.	-	985	O

A	15482540	987	O
significant	-	989	O
relationship	-	1001	O
was	-	1014	O
observed	-	1018	O
between	-	1027	O
the	-	1035	O
rate	-	1039	O
of	-	1044	O
reduction	-	1047	O
of	-	1057	O
hemoglobin	-	1060	O
concentrations	-	1071	O
at	-	1086	O
week	-	1089	O
2	-	1094	O
and	-	1096	O
the	-	1100	O
severity	-	1104	O
of	-	1113	O
anemia	-	1116	B
(	-	1123	O
P	-	1124	O
<	-	1126	O
0	-	1128	O
.	-	1129	O
01	-	1130	O
)	-	1132	O
.	-	1133	O

Such	15482540	1135	O
factors	-	1140	O
as	-	1148	O
sex	-	1151	O
(	-	1155	O
female	-	1156	O
)	-	1162	O
,	-	1163	O
age	-	1165	O
(	-	1169	O
>	-	1170	O
or	-	1172	O
=	-	1175	O
60	-	1176	O
years	-	1179	O
old	-	1185	O
)	-	1188	O
,	-	1189	O
and	-	1191	O
the	-	1195	O
ribavirin	-	1199	O
dose	-	1209	O
by	-	1214	O
body	-	1217	O
weight	-	1222	O
(	-	1229	O
12	-	1230	O
mg	-	1233	O
/	-	1235	O
kg	-	1236	O
or	-	1239	O
more	-	1242	O
)	-	1246	O
were	-	1248	O
significant	-	1253	O
by	-	1265	O
univariate	-	1268	O
analysis	-	1279	O
.	-	1287	O

CONCLUSIONS	15482540	1289	O
:	-	1300	O

Careful	15482540	1302	O
administration	-	1310	O
is	-	1325	O
necessary	-	1328	O
in	-	1338	O
patients	-	1341	O
>	-	1350	O
or	-	1352	O
=	-	1355	O
60	-	1356	O
years	-	1359	O
old	-	1365	O
,	-	1368	O
in	-	1370	O
female	-	1373	O
patients	-	1380	O
,	-	1388	O
and	-	1390	O
in	-	1394	O
patients	-	1397	O
receiving	-	1406	O
a	-	1416	O
ribavirin	-	1418	O
dose	-	1428	O
of	-	1433	O
12	-	1436	O
mg	-	1439	O
/	-	1441	O
kg	-	1442	O
or	-	1445	O
more	-	1448	O
.	-	1452	O

Patients	15482540	1454	O
who	-	1463	O
experience	-	1467	O
a	-	1478	O
fall	-	1480	O
in	-	1485	O
hemoglobin	-	1488	O
concentrations	-	1499	O
of	-	1514	O
2	-	1517	O
g	-	1519	O
/	-	1520	O
dL	-	1521	O
or	-	1524	O
more	-	1527	O
at	-	1532	O
week	-	1535	O
2	-	1540	O
after	-	1542	O
the	-	1548	O
start	-	1552	O
of	-	1558	O
treatment	-	1561	O
should	-	1571	O
be	-	1578	O
monitored	-	1581	O
with	-	1591	O
particular	-	1596	O
care	-	1607	O
.	-	1611	O

Oxidative	15605432	0	O
damage	-	10	O
precedes	-	17	O
nitrative	-	26	O
damage	-	36	O
in	-	43	O
adriamycin	-	46	O
-	-	56	O
induced	-	57	O
cardiac	-	65	O
mitochondrial	-	73	B
injury	-	87	I
.	-	93	O

The	15605432	95	O
purpose	-	99	O
of	-	107	O
the	-	110	O
present	-	114	O
study	-	122	O
was	-	128	O
to	-	132	O
determine	-	135	O
if	-	145	O
elevated	-	148	O
reactive	-	157	O
oxygen	-	166	O
(	-	173	O
ROS	-	174	O
)	-	177	O
/	-	178	O
nitrogen	-	179	O
species	-	188	O
(	-	196	O
RNS	-	197	O
)	-	200	O
reported	-	202	O
to	-	211	O
be	-	214	O
present	-	217	O
in	-	225	O
adriamycin	-	228	O
(	-	239	O
ADR	-	240	O
)	-	243	O
-	-	244	O
induced	-	245	O
cardiotoxicity	-	253	B
actually	-	268	O
resulted	-	277	O
in	-	286	O
cardiomyocyte	-	289	O
oxidative	-	303	O
/	-	312	O
nitrative	-	313	O
damage	-	323	O
,	-	329	O
and	-	331	O
to	-	335	O
quantitatively	-	338	O
determine	-	353	O
the	-	363	O
time	-	367	O
course	-	372	O
and	-	379	O
subcellular	-	383	O
localization	-	395	O
of	-	408	O
these	-	411	O
postulated	-	417	O
damage	-	428	O
products	-	435	O
using	-	444	O
an	-	450	O
in	-	453	O
vivo	-	456	O
approach	-	461	O
.	-	469	O

B6C3	15605432	471	O
mice	-	476	O
were	-	481	O
treated	-	486	O
with	-	494	O
a	-	499	O
single	-	501	O
dose	-	508	O
of	-	513	O
20	-	516	O
mg	-	519	O
/	-	521	O
kg	-	522	O
ADR	-	525	O
.	-	528	O

Ultrastructural	15605432	530	O
damage	-	546	O
and	-	553	O
levels	-	557	O
of	-	564	O
4	-	567	O
-	-	568	O
hydroxy	-	569	O
-	-	576	O
2	-	577	O
-	-	578	O
nonenal	-	579	O
(	-	587	O
4HNE	-	588	O
)	-	592	O
-	-	593	O
protein	-	594	O
adducts	-	602	O
and	-	610	O
3	-	614	O
-	-	615	O
nitrotyrosine	-	616	O
(	-	630	O
3NT	-	631	O
)	-	634	O
were	-	636	O
analyzed	-	641	O
.	-	649	O

Quantitative	15605432	651	O
ultrastructural	-	664	O
damage	-	680	O
using	-	687	O
computerized	-	693	O
image	-	706	O
techniques	-	712	O
showed	-	723	O
cardiomyocyte	-	730	O
injury	-	744	O
as	-	751	O
early	-	754	O
as	-	760	O
3	-	763	O
hours	-	765	O
,	-	770	O
with	-	772	O
mitochondria	-	777	O
being	-	790	O
the	-	796	O
most	-	800	O
extensively	-	805	O
and	-	817	O
progressively	-	821	O
injured	-	835	O
subcellular	-	843	O
organelle	-	855	O
.	-	864	O

Analysis	15605432	866	O
of	-	875	O
4HNE	-	878	O
protein	-	883	O
adducts	-	891	O
by	-	899	O
immunogold	-	902	O
electron	-	913	O
microscopy	-	922	O
showed	-	933	O
appearance	-	940	O
of	-	951	O
4HNE	-	954	O
protein	-	959	O
adducts	-	967	O
in	-	975	O
mitochondria	-	978	O
as	-	991	O
early	-	994	O
as	-	1000	O
3	-	1003	O
hours	-	1005	O
,	-	1010	O
with	-	1012	O
a	-	1017	O
peak	-	1019	O
at	-	1024	O
6	-	1027	O
hours	-	1029	O
and	-	1035	O
subsequent	-	1039	O
decline	-	1050	O
at	-	1058	O
24	-	1061	O
hours	-	1064	O
.	-	1069	O

3NT	15605432	1071	O
levels	-	1075	O
were	-	1082	O
significantly	-	1087	O
increased	-	1101	O
in	-	1111	O
all	-	1114	O
subcellular	-	1118	O
compartments	-	1130	O
at	-	1143	O
6	-	1146	O
hours	-	1148	O
and	-	1154	O
subsequently	-	1158	O
declined	-	1171	O
at	-	1180	O
24	-	1183	O
hours	-	1186	O
.	-	1191	O

Our	15605432	1193	O
data	-	1197	O
showed	-	1202	O
ADR	-	1209	O
induced	-	1213	O
4HNE	-	1221	O
-	-	1225	O
protein	-	1226	O
adducts	-	1234	O
in	-	1242	O
mitochondria	-	1245	O
at	-	1258	O
the	-	1261	O
same	-	1265	O
time	-	1270	O
point	-	1275	O
as	-	1281	O
when	-	1284	O
mitochondrial	-	1289	B
injury	-	1303	I
initially	-	1310	O
appeared	-	1320	O
.	-	1328	O

These	15605432	1330	O
results	-	1336	O
document	-	1344	O
for	-	1353	O
the	-	1357	O
first	-	1361	O
time	-	1367	O
in	-	1372	O
vivo	-	1375	O
that	-	1380	O
mitochondrial	-	1385	B
oxidative	-	1399	I
damage	-	1409	I
precedes	-	1416	O
nitrative	-	1425	O
damage	-	1435	O
.	-	1441	O

The	15605432	1443	O
progressive	-	1447	O
nature	-	1459	O
of	-	1466	O
mitochondrial	-	1469	B
injury	-	1483	I
suggests	-	1490	O
that	-	1499	O
mitochondria	-	1504	O
,	-	1516	O
not	-	1518	O
other	-	1522	O
subcellular	-	1528	O
organelles	-	1540	O
,	-	1550	O
are	-	1552	O
the	-	1556	O
major	-	1560	O
site	-	1566	O
of	-	1571	O
intracellular	-	1574	O
injury	-	1588	O
.	-	1594	O

Sotalol	15609701	0	O
-	-	7	O
induced	-	8	O
coronary	-	16	B
spasm	-	25	I
in	-	31	O
a	-	34	O
patient	-	36	O
with	-	44	O
dilated	-	49	B
cardiomyopathy	-	57	I
associated	-	72	O
with	-	83	O
sustained	-	88	O
ventricular	-	98	B
tachycardia	-	110	I
.	-	121	O

A	15609701	123	O
54	-	125	O
-	-	127	O
year	-	128	O
-	-	132	O
old	-	133	O
man	-	137	O
with	-	141	O
severe	-	146	O
left	-	153	O
ventricular	-	158	B
dysfunction	-	170	I
due	-	182	O
to	-	186	O
dilated	-	189	B
cardiomyopathy	-	197	I
was	-	212	O
referred	-	216	O
to	-	225	O
our	-	228	O
hospital	-	232	O
for	-	241	O
symptomatic	-	245	O
incessant	-	257	O
sustained	-	267	O
ventricular	-	277	B
tachycardia	-	289	I
(	-	301	O
VT	-	302	B
)	-	304	O
.	-	305	O

After	15609701	307	O
the	-	313	O
administration	-	317	O
of	-	332	O
nifekalant	-	335	O
hydrochloride	-	346	O
,	-	359	O
sustained	-	361	O
VT	-	371	B
was	-	374	O
terminated	-	378	O
.	-	388	O

An	15609701	390	O
alternate	-	393	O
class	-	403	O
III	-	409	O
agent	-	413	O
,	-	418	O
sotalol	-	420	O
,	-	427	O
was	-	429	O
also	-	433	O
effective	-	438	O
for	-	448	O
the	-	452	O
prevention	-	456	O
of	-	467	O
VT	-	470	B
.	-	472	O

However	15609701	474	O
,	-	481	O
one	-	483	O
month	-	487	O
after	-	493	O
switching	-	499	O
over	-	509	O
nifekalant	-	514	O
to	-	525	O
sotalol	-	528	O
,	-	535	O
a	-	537	O
short	-	539	O
duration	-	545	O
of	-	554	O
ST	-	557	O
elevation	-	560	O
was	-	570	O
documented	-	574	O
in	-	585	O
ECG	-	588	O
monitoring	-	592	O
at	-	603	O
almost	-	606	O
the	-	613	O
same	-	617	O
time	-	622	O
for	-	627	O
three	-	631	O
consecutive	-	637	O
days	-	649	O
.	-	653	O

ST	15609701	655	O
elevation	-	658	O
with	-	668	O
chest	-	673	O
discomfort	-	679	O
disappeared	-	690	O
since	-	702	O
he	-	708	O
began	-	711	O
taking	-	717	O
long	-	724	O
-	-	728	O
acting	-	729	O
diltiazem	-	736	O
.	-	745	O

Coronary	15609701	747	B
vasospasm	-	756	I
may	-	766	O
be	-	770	O
induced	-	773	O
by	-	781	O
the	-	784	O
non	-	788	O
-	-	791	O
selective	-	792	O
beta	-	802	O
-	-	806	O
blocking	-	807	O
properties	-	816	O
of	-	827	O
sotalol	-	830	O
.	-	837	O

Effects	15614572	0	O
of	-	8	O
the	-	11	O
antidepressant	-	15	O
trazodone	-	30	O
,	-	39	O
a	-	41	O
5	-	43	O
-	-	44	O
HT	-	45	O
2A	-	48	O
/	-	50	O
2C	-	51	O
receptor	-	54	O
antagonist	-	63	O
,	-	73	O
on	-	75	O
dopamine	-	78	O
-	-	86	O
dependent	-	87	O
behaviors	-	97	O
in	-	107	O
rats	-	110	O
.	-	114	O

RATIONALE	15614572	116	O
:	-	125	O
5	-	127	O
-	-	128	O
Hydroxytryptamine	-	129	O
,	-	146	O
via	-	148	O
stimulation	-	152	O
of	-	164	O
5	-	167	O
-	-	168	O
HT	-	169	O
2C	-	172	O
receptors	-	175	O
,	-	184	O
exerts	-	186	O
a	-	193	O
tonic	-	195	O
inhibitory	-	201	O
influence	-	212	O
on	-	222	O
dopaminergic	-	225	O
neurotransmission	-	238	O
,	-	255	O
whereas	-	257	O
activation	-	265	O
of	-	276	O
5	-	279	O
-	-	280	O
HT	-	281	O
2A	-	284	O
receptors	-	287	O
enhances	-	297	O
stimulated	-	306	O
DAergic	-	317	O
neurotransmission	-	325	O
.	-	342	O

The	15614572	344	O
antidepressant	-	348	O
trazodone	-	363	O
is	-	373	O
a	-	376	O
5	-	378	O
-	-	379	O
HT	-	380	O
2A	-	383	O
/	-	385	O
2C	-	386	O
receptor	-	389	O
antagonist	-	398	O
.	-	408	O

OBJECTIVES	15614572	410	O
:	-	420	O

To	15614572	422	O
evaluate	-	425	O
the	-	434	O
effect	-	438	O
of	-	445	O
trazodone	-	448	O
treatment	-	458	O
on	-	468	O
behaviors	-	471	O
dependent	-	481	O
on	-	491	O
the	-	494	O
functional	-	498	O
status	-	509	O
of	-	516	O
the	-	519	O
nigrostriatal	-	523	O
DAergic	-	537	O
system	-	545	O
.	-	551	O

METHODS	15614572	553	O
:	-	560	O

The	15614572	562	O
effect	-	566	O
of	-	573	O
pretreatment	-	576	O
with	-	589	O
trazodone	-	594	O
on	-	604	O
dexamphetamine	-	607	O
-	-	621	O
and	-	623	O
apomorphine	-	627	O
-	-	638	O
induced	-	639	O
oral	-	647	B
stereotypies	-	652	I
,	-	664	O
on	-	666	O
catalepsy	-	669	B
induced	-	679	O
by	-	687	O
haloperidol	-	690	O
and	-	702	O
apomorphine	-	706	O
(	-	718	O
0	-	719	O
.	-	720	O
05	-	721	O
mg	-	724	O
/	-	726	O
kg	-	727	O
,	-	729	O
i	-	731	O
.	-	732	O
p	-	733	O
.	-	734	O
)	-	735	O
,	-	736	O
on	-	738	O
ergometrine	-	741	O
-	-	752	O
induced	-	753	O
wet	-	761	O
dog	-	765	O
shake	-	769	O
(	-	775	O
WDS	-	776	O
)	-	779	O
behavior	-	781	O
and	-	790	O
fluoxetine	-	794	O
-	-	804	O
induced	-	805	O
penile	-	813	O
erections	-	820	O
was	-	830	O
studied	-	834	O
in	-	842	O
rats	-	845	O
.	-	849	O

We	15614572	851	O
also	-	854	O
investigated	-	859	O
whether	-	872	O
trazodone	-	880	O
induces	-	890	O
catalepsy	-	898	B
in	-	908	O
rats	-	911	O
.	-	915	O

RESULTS	15614572	917	O
:	-	924	O

Trazodone	15614572	926	O
at	-	936	O
2	-	939	O
.	-	940	O
5	-	941	O
-	-	942	O
20	-	943	O
mg	-	946	O
/	-	948	O
kg	-	949	O
i	-	952	O
.	-	953	O
p	-	954	O
.	-	955	O
did	-	957	O
not	-	961	O
induce	-	965	O
catalepsy	-	972	B
,	-	981	O
and	-	983	O
did	-	987	O
not	-	991	O
antagonize	-	995	O
apomorphine	-	1006	O
(	-	1018	O
1	-	1019	O
.	-	1020	O
5	-	1021	O
and	-	1023	O
3	-	1027	O
mg	-	1029	O
/	-	1031	O
kg	-	1032	O
)	-	1034	O
stereotypy	-	1036	O
and	-	1047	O
apomorphine	-	1051	O
(	-	1063	O
0	-	1064	O
.	-	1065	O
05	-	1066	O
mg	-	1069	O
/	-	1071	O
kg	-	1072	O
)	-	1074	O
-	-	1075	O
induced	-	1076	O
catalepsy	-	1084	B
.	-	1093	O

However	15614572	1095	O
,	-	1102	O
pretreatment	-	1104	O
with	-	1117	O
5	-	1122	O
,	-	1123	O
10	-	1125	O
and	-	1128	O
20	-	1132	O
mg	-	1135	O
/	-	1137	O
kg	-	1138	O
i	-	1141	O
.	-	1142	O
p	-	1143	O
.	-	1144	O

trazodone	15614572	1146	O
enhanced	-	1156	O
dexamphetamine	-	1165	O
stereotypy	-	1180	O
,	-	1190	O
and	-	1192	O
antagonized	-	1196	O
haloperidol	-	1208	O
catalepsy	-	1220	B
,	-	1229	O
ergometrine	-	1231	O
-	-	1242	O
induced	-	1243	O
WDS	-	1251	O
behavior	-	1255	O
and	-	1264	O
fluoxetine	-	1268	O
-	-	1278	O
induced	-	1279	O
penile	-	1287	O
erections	-	1294	O
.	-	1303	O

Trazodone	15614572	1305	O
at	-	1315	O
30	-	1318	O
,	-	1320	O
40	-	1322	O
and	-	1325	O
50	-	1329	O
mg	-	1332	O
/	-	1334	O
kg	-	1335	O
i	-	1338	O
.	-	1339	O
p	-	1340	O
.	-	1341	O

induced	15614572	1343	O
catalepsy	-	1351	B
and	-	1361	O
antagonized	-	1365	O
apomorphine	-	1377	O
and	-	1389	O
dexamphetamine	-	1393	O
stereotypies	-	1408	O
.	-	1420	O

CONCLUSIONS	15614572	1422	O
:	-	1433	O

Our	15614572	1435	O
results	-	1439	O
indicate	-	1447	O
that	-	1456	O
trazodone	-	1461	O
at	-	1471	O
2	-	1474	O
.	-	1475	O
5	-	1476	O
-	-	1477	O
20	-	1478	O
mg	-	1481	O
/	-	1483	O
kg	-	1484	O
does	-	1487	O
not	-	1492	O
block	-	1496	O
pre	-	1502	O
-	-	1505	O
and	-	1507	O
postsynaptic	-	1511	O
striatal	-	1524	O
D2	-	1533	O
DA	-	1536	O
receptors	-	1539	O
,	-	1548	O
while	-	1550	O
at	-	1556	O
30	-	1559	O
,	-	1561	O
40	-	1563	O
and	-	1566	O
50	-	1570	O
mg	-	1573	O
/	-	1575	O
kg	-	1576	O
it	-	1579	O
blocks	-	1582	O
postsynaptic	-	1589	O
striatal	-	1602	O
D2	-	1611	O
DA	-	1614	O
receptors	-	1617	O
.	-	1626	O

Furthermore	15614572	1628	O
,	-	1639	O
at	-	1641	O
5	-	1644	O
,	-	1645	O
10	-	1647	O
and	-	1650	O
20	-	1654	O
mg	-	1657	O
/	-	1659	O
kg	-	1660	O
,	-	1662	O
trazodone	-	1664	O
blocks	-	1674	O
5	-	1681	O
-	-	1682	O
HT	-	1683	O
2A	-	1686	O
and	-	1689	O
5	-	1693	O
-	-	1694	O
HT	-	1695	O
2C	-	1698	O
receptors	-	1701	O
.	-	1710	O

We	15614572	1712	O
suggest	-	1715	O
that	-	1723	O
trazodone	-	1728	O
(	-	1738	O
5	-	1739	O
,	-	1740	O
10	-	1742	O
and	-	1745	O
20	-	1749	O
mg	-	1752	O
/	-	1754	O
kg	-	1755	O
)	-	1757	O
,	-	1758	O
by	-	1760	O
blocking	-	1763	O
the	-	1772	O
5	-	1776	O
-	-	1777	O
HT	-	1778	O
2C	-	1781	O
receptors	-	1784	O
,	-	1793	O
releases	-	1795	O
the	-	1804	O
nigrostriatal	-	1808	O
DAergic	-	1822	O
neurons	-	1830	O
from	-	1838	O
tonic	-	1843	O
inhibition	-	1849	O
caused	-	1860	O
by	-	1867	O
5	-	1870	O
-	-	1871	O
HT	-	1872	O
,	-	1874	O
and	-	1876	O
thereby	-	1880	O
potentiates	-	1888	O
dexamphetamine	-	1900	O
stereotypy	-	1915	O
and	-	1926	O
antagonizes	-	1930	O
haloperidol	-	1942	O
catalepsy	-	1954	B
.	-	1963	O

Swallowing	15625689	0	B
abnormalities	-	11	I
and	-	25	O
dyskinesia	-	29	B
in	-	40	O
Parkinson	-	43	B
's	-	52	I
disease	-	55	I
.	-	62	O

Gastrointestinal	15625689	64	B
abnormalities	-	81	I
in	-	95	O
Parkinson	-	98	B
's	-	107	I
disease	-	110	I
(	-	118	O
PD	-	119	B
)	-	121	O
have	-	123	O
been	-	128	O
known	-	133	O
for	-	139	O
almost	-	143	O
two	-	150	O
centuries	-	154	O
,	-	163	O
but	-	165	O
many	-	169	O
aspects	-	174	O
concerning	-	182	O
their	-	193	O
pathophysiology	-	199	O
have	-	215	O
not	-	220	O
been	-	224	O
completely	-	229	O
clarified	-	240	O
.	-	249	O

The	15625689	251	O
aim	-	255	O
of	-	259	O
this	-	262	O
study	-	267	O
was	-	273	O
to	-	277	O
characterize	-	280	O
the	-	293	O
oropharyngeal	-	297	O
dynamics	-	311	O
in	-	320	O
PD	-	323	B
patients	-	326	O
with	-	335	O
and	-	340	O
without	-	344	O
levodopa	-	352	O
-	-	360	O
induced	-	361	O
dyskinesia	-	369	B
.	-	379	O

Fifteen	15625689	381	O
dyskinetic	-	389	B
,	-	399	O
12	-	401	O
nondyskinetic	-	404	O
patients	-	418	O
,	-	426	O
and	-	428	O
a	-	432	O
control	-	434	O
group	-	442	O
were	-	448	O
included	-	453	O
.	-	461	O

Patients	15625689	463	O
were	-	472	O
asked	-	477	O
about	-	483	O
dysphagia	-	489	B
and	-	499	O
evaluated	-	503	O
with	-	513	O
the	-	518	O
Unified	-	522	O
Parkinson	-	530	B
's	-	539	I
Disease	-	542	I
Rating	-	550	O
Scale	-	557	O
Parts	-	563	O
II	-	569	O
and	-	572	O
III	-	576	O
and	-	580	O
the	-	584	O
Hoehn	-	588	O
and	-	594	O
Yahr	-	598	O
scale	-	603	O
.	-	608	O

Deglutition	15625689	610	O
was	-	622	O
assessed	-	626	O
using	-	635	O
modified	-	641	O
barium	-	650	O
swallow	-	657	O
with	-	665	O
videofluoroscopy	-	670	O
.	-	686	O

Nondyskinetic	15625689	688	O
patients	-	702	O
,	-	710	O
but	-	712	O
not	-	716	O
the	-	720	O
dyskinetic	-	724	B
ones	-	735	O
,	-	739	O
showed	-	741	O
less	-	748	O
oropharyngeal	-	753	O
swallowing	-	767	O
efficiency	-	778	O
(	-	789	O
OPSE	-	790	O
)	-	794	O
for	-	796	O
liquid	-	800	O
food	-	807	O
than	-	812	O
controls	-	817	O
(	-	826	O
Dunnett	-	827	O
,	-	834	O
P	-	836	O
=	-	838	O
0	-	840	O
.	-	841	O
02	-	842	O
)	-	844	O
.	-	845	O

Dyskinetic	15625689	847	B
patients	-	858	O
tended	-	867	O
to	-	874	O
have	-	877	O
a	-	882	O
greater	-	884	O
OPSE	-	892	O
than	-	897	O
nondyskinetic	-	902	O
(	-	916	O
Dunnett	-	917	O
,	-	924	O
P	-	926	O
=	-	928	O
0	-	930	O
.	-	931	O
06	-	932	O
)	-	934	O
.	-	935	O

Patients	15625689	937	O
who	-	946	O
were	-	950	O
using	-	955	O
a	-	961	O
higher	-	963	O
dose	-	970	O
of	-	975	O
levodopa	-	978	O
had	-	987	O
a	-	991	O
greater	-	993	O
OPSE	-	1001	O
and	-	1006	O
a	-	1010	O
trend	-	1012	O
toward	-	1018	O
a	-	1025	O
smaller	-	1027	O
oral	-	1035	O
transit	-	1040	O
time	-	1048	O
(	-	1053	O
Pearson	-	1054	O
's	-	1061	O
correlation	-	1064	O
,	-	1075	O
P	-	1077	O
=	-	1079	O
0	-	1081	O
.	-	1082	O
01	-	1083	O
and	-	1086	O
0	-	1090	O
.	-	1091	O
08	-	1092	O
,	-	1094	O
respectively	-	1096	O
)	-	1108	O
.	-	1109	O

Neither	15625689	1111	O
the	-	1119	O
report	-	1123	O
of	-	1130	O
dysphagia	-	1133	B
nor	-	1143	O
any	-	1147	O
of	-	1151	O
the	-	1154	O
PD	-	1158	B
severity	-	1161	O
parameters	-	1170	O
correlated	-	1181	O
to	-	1192	O
the	-	1195	O
videofluoroscopic	-	1199	O
variables	-	1217	O
.	-	1226	O

In	15625689	1228	O
the	-	1231	O
current	-	1235	O
study	-	1243	O
,	-	1248	O
dyskinetic	-	1250	B
patients	-	1261	O
performed	-	1270	O
better	-	1280	O
in	-	1287	O
swallowing	-	1290	O
function	-	1301	O
,	-	1309	O
which	-	1311	O
could	-	1317	O
be	-	1323	O
explained	-	1326	O
on	-	1336	O
the	-	1339	O
basis	-	1343	O
of	-	1349	O
a	-	1352	O
greater	-	1354	O
levodopa	-	1362	O
dose	-	1371	O
.	-	1375	O

Our	15625689	1377	O
results	-	1381	O
suggest	-	1389	O
a	-	1397	O
role	-	1399	O
for	-	1404	O
levodopa	-	1408	O
in	-	1417	O
the	-	1420	O
oral	-	1424	O
phase	-	1429	O
of	-	1435	O
deglutition	-	1438	O
and	-	1450	O
confirm	-	1454	O
that	-	1462	O
dysphagia	-	1467	B
is	-	1477	O
not	-	1480	O
a	-	1484	O
good	-	1486	O
predictor	-	1491	O
of	-	1501	O
deglutition	-	1504	O
alterations	-	1516	O
in	-	1528	O
PD	-	1531	B
.	-	1533	O

Inhibition	15627798	0	O
of	-	11	O
nuclear	-	14	O
factor	-	22	O
-	-	28	O
kappaB	-	29	O
activation	-	36	O
attenuates	-	47	O
tubulointerstitial	-	58	B
nephritis	-	77	I
induced	-	87	O
by	-	95	O
gentamicin	-	98	O
.	-	108	O

BACKGROUND	15627798	110	O
:	-	120	O

Animals	15627798	122	O
treated	-	130	O
with	-	138	O
gentamicin	-	143	O
can	-	154	O
show	-	158	O
residual	-	163	O
areas	-	172	O
of	-	178	O
interstitial	-	181	O
fibrosis	-	194	B
in	-	203	O
the	-	206	O
renal	-	210	O
cortex	-	216	O
.	-	222	O

This	15627798	224	O
study	-	229	O
investigated	-	235	O
the	-	248	O
expression	-	252	O
of	-	263	O
nuclear	-	266	O
factor	-	274	O
-	-	280	O
kappaB	-	281	O
(	-	288	O
NF	-	289	O
-	-	291	O
kappaB	-	292	O
)	-	298	O
,	-	299	O
mitogen	-	301	O
-	-	308	O
activated	-	309	O
protein	-	319	O
(	-	327	O
MAP	-	328	O
)	-	331	O
kinases	-	333	O
and	-	341	O
macrophages	-	345	O
in	-	357	O
the	-	360	O
renal	-	364	O
cortex	-	370	O
and	-	377	O
structural	-	381	O
and	-	392	O
functional	-	396	O
renal	-	407	O
changes	-	413	O
of	-	421	O
rats	-	424	O
treated	-	429	O
with	-	437	O
gentamicin	-	442	O
or	-	453	O
gentamicin	-	456	O
+	-	467	O
pyrrolidine	-	469	O
dithiocarbamate	-	481	O
(	-	497	O
PDTC	-	498	O
)	-	502	O
,	-	503	O
an	-	505	O
NF	-	508	O
-	-	510	O
kappaB	-	511	O
inhibitor	-	518	O
.	-	527	O

METHODS	15627798	529	O
:	-	536	O

38	15627798	538	O
female	-	541	O
Wistar	-	548	O
rats	-	555	O
were	-	560	O
injected	-	565	O
with	-	574	O
gentamicin	-	579	O
,	-	589	O
40	-	591	O
mg	-	594	O
/	-	596	O
kg	-	597	O
,	-	599	O
twice	-	601	O
a	-	607	O
day	-	609	O
for	-	613	O
9	-	617	O
days	-	619	O
,	-	623	O
38	-	625	O
with	-	628	O
gentamicin	-	633	O
+	-	644	O
PDTC	-	646	O
,	-	650	O
and	-	652	O
28	-	656	O
with	-	659	O
0	-	664	O
.	-	665	O
15	-	666	O
M	-	669	O
NaCl	-	671	O
solution	-	676	O
.	-	684	O

The	15627798	686	O
animals	-	690	O
were	-	698	O
killed	-	703	O
5	-	710	O
and	-	712	O
30	-	716	O
days	-	719	O
after	-	724	O
these	-	730	O
injections	-	736	O
and	-	747	O
the	-	751	O
kidneys	-	755	O
were	-	763	O
removed	-	768	O
for	-	776	O
histological	-	780	O
and	-	793	O
immunohistochemical	-	797	O
studies	-	817	O
.	-	824	O

The	15627798	826	O
results	-	830	O
of	-	838	O
the	-	841	O
immunohistochemical	-	845	O
studies	-	865	O
were	-	873	O
scored	-	878	O
according	-	885	O
to	-	895	O
the	-	898	O
extent	-	902	O
of	-	909	O
staining	-	912	O
.	-	920	O

The	15627798	922	O
fractional	-	926	O
interstitial	-	937	O
area	-	950	O
was	-	955	O
determined	-	959	O
by	-	970	O
morphometry	-	973	O
.	-	984	O

RESULTS	15627798	986	O
:	-	993	O

Gentamicin	15627798	995	O
-	-	1005	O
treated	-	1006	O
rats	-	1014	O
presented	-	1019	O
a	-	1029	O
transitory	-	1031	O
increase	-	1042	O
in	-	1051	O
plasma	-	1054	O
creatinine	-	1061	O
levels	-	1072	O
.	-	1078	O

Increased	15627798	1080	O
ED	-	1090	O
-	-	1092	O
1	-	1093	O
,	-	1094	O
MAP	-	1096	O
kinases	-	1100	O
and	-	1108	O
NF	-	1112	O
-	-	1114	O
kappaB	-	1115	O
staining	-	1122	O
were	-	1131	O
also	-	1136	O
observed	-	1141	O
in	-	1150	O
the	-	1153	O
renal	-	1157	O
cortex	-	1163	O
from	-	1170	O
all	-	1175	O
gentamicin	-	1179	O
-	-	1189	O
treated	-	1190	O
rats	-	1198	O
compared	-	1203	O
to	-	1212	O
control	-	1215	O
(	-	1223	O
p	-	1224	O
<	-	1226	O
0	-	1228	O
.	-	1229	O
05	-	1230	O
)	-	1232	O
.	-	1233	O

The	15627798	1235	O
animals	-	1239	O
killed	-	1247	O
on	-	1254	O
day	-	1257	O
30	-	1261	O
also	-	1264	O
presented	-	1269	O
fibrosis	-	1279	B
in	-	1288	O
the	-	1291	O
renal	-	1295	O
cortex	-	1301	O
despite	-	1308	O
the	-	1316	O
recovery	-	1320	O
of	-	1329	O
renal	-	1332	O
function	-	1338	O
.	-	1346	O

Treatment	15627798	1348	O
with	-	1358	O
PDTC	-	1363	O
reduced	-	1368	O
the	-	1376	O
functional	-	1380	O
and	-	1391	O
structural	-	1395	O
changes	-	1406	O
induced	-	1414	O
by	-	1422	O
gentamicin	-	1425	O
.	-	1435	O

CONCLUSIONS	15627798	1437	O
:	-	1448	O

These	15627798	1450	O
data	-	1456	O
show	-	1461	O
that	-	1466	O
inhibition	-	1471	O
of	-	1482	O
NF	-	1485	O
-	-	1487	O
kappaB	-	1488	O
activation	-	1495	O
attenuates	-	1506	O
tubulointerstitial	-	1517	B
nephritis	-	1536	I
induced	-	1546	O
by	-	1554	O
gentamicin	-	1557	O
.	-	1567	O

Glucose	15630069	0	O
metabolism	-	8	O
in	-	19	O
patients	-	22	O
with	-	31	O
schizophrenia	-	36	B
treated	-	50	O
with	-	58	O
atypical	-	63	O
antipsychotic	-	72	O
agents	-	86	O
:	-	92	O
a	-	94	O
frequently	-	96	O
sampled	-	107	O
intravenous	-	115	O
glucose	-	127	O
tolerance	-	135	O
test	-	145	O
and	-	150	O
minimal	-	154	O
model	-	162	O
analysis	-	168	O
.	-	176	O

BACKGROUND	15630069	178	O
:	-	188	O
While	-	190	O
the	-	196	O
incidence	-	200	O
of	-	210	O
new	-	213	O
-	-	216	O
onset	-	217	O
diabetes	-	223	B
mellitus	-	232	I
may	-	241	O
be	-	245	O
increasing	-	248	O
in	-	259	O
patients	-	262	O
with	-	271	O
schizophrenia	-	276	B
treated	-	290	O
with	-	298	O
certain	-	303	O
atypical	-	311	O
antipsychotic	-	320	O
agents	-	334	O
,	-	340	O
it	-	342	O
remains	-	345	O
unclear	-	353	O
whether	-	361	O
atypical	-	369	O
agents	-	378	O
are	-	385	O
directly	-	389	O
affecting	-	398	O
glucose	-	408	O
metabolism	-	416	O
or	-	427	O
simply	-	430	O
increasing	-	437	O
known	-	448	O
risk	-	454	O
factors	-	459	O
for	-	467	O
diabetes	-	471	B
.	-	479	O

OBJECTIVE	15630069	481	O
:	-	490	O

To	15630069	492	O
study	-	495	O
the	-	501	O
2	-	505	O
drugs	-	507	O
most	-	513	O
clearly	-	518	O
implicated	-	526	O
(	-	537	O
clozapine	-	538	O
and	-	548	O
olanzapine	-	552	O
)	-	562	O
and	-	564	O
risperidone	-	568	O
using	-	580	O
a	-	586	O
frequently	-	588	O
sampled	-	599	O
intravenous	-	607	O
glucose	-	619	O
tolerance	-	627	O
test	-	637	O
.	-	641	O

DESIGN	15630069	643	O
:	-	649	O

A	15630069	651	O
cross	-	653	O
-	-	658	O
sectional	-	659	O
design	-	669	O
in	-	676	O
stable	-	679	O
,	-	685	O
treated	-	687	O
patients	-	695	O
with	-	704	O
schizophrenia	-	709	B
evaluated	-	723	O
using	-	733	O
a	-	739	O
frequently	-	741	O
sampled	-	752	O
intravenous	-	760	O
glucose	-	772	O
tolerance	-	780	O
test	-	790	O
and	-	795	O
the	-	799	O
Bergman	-	803	O
minimal	-	811	O
model	-	819	O
analysis	-	825	O
.	-	833	O

SETTING	15630069	835	O
:	-	842	O

Subjects	15630069	844	O
were	-	853	O
recruited	-	858	O
from	-	868	O
an	-	873	O
urban	-	876	O
community	-	882	O
mental	-	892	O
health	-	899	O
clinic	-	906	O
and	-	913	O
were	-	917	O
studied	-	922	O
at	-	930	O
a	-	933	O
general	-	935	O
clinical	-	943	O
research	-	952	O
center	-	961	O
.	-	967	O

Patients	15630069	969	O
Fifty	-	978	O
subjects	-	984	O
signed	-	993	O
informed	-	1000	O
consent	-	1009	O
and	-	1017	O
41	-	1021	O
underwent	-	1024	O
the	-	1034	O
frequently	-	1038	O
sampled	-	1049	O
intravenous	-	1057	O
glucose	-	1069	O
tolerance	-	1077	O
test	-	1087	O
.	-	1091	O

Thirty	15630069	1093	O
-	-	1099	O
six	-	1100	O
nonobese	-	1104	O
subjects	-	1113	O
with	-	1122	O
schizophrenia	-	1127	B
or	-	1141	O
schizoaffective	-	1144	B
disorder	-	1160	I
,	-	1168	O
matched	-	1170	O
by	-	1178	O
body	-	1181	O
mass	-	1186	O
index	-	1191	O
and	-	1197	O
treated	-	1201	O
with	-	1209	O
either	-	1214	O
clozapine	-	1221	O
,	-	1230	O
olanzapine	-	1232	O
,	-	1242	O
or	-	1244	O
risperidone	-	1247	O
,	-	1258	O
were	-	1260	O
included	-	1265	O
in	-	1274	O
the	-	1277	O
analysis	-	1281	O
.	-	1289	O

MAIN	15630069	1291	O
OUTCOME	-	1296	O
MEASURES	-	1304	O
:	-	1312	O

Fasting	15630069	1314	O
plasma	-	1322	O
glucose	-	1329	O
and	-	1337	O
fasting	-	1341	O
serum	-	1349	O
insulin	-	1355	O
levels	-	1363	O
,	-	1369	O
insulin	-	1371	B
sensitivity	-	1379	I
index	-	1391	O
,	-	1396	O
homeostasis	-	1398	O
model	-	1410	O
assessment	-	1416	O
of	-	1427	O
insulin	-	1430	B
resistance	-	1438	I
,	-	1448	O
and	-	1450	O
glucose	-	1454	O
effectiveness	-	1462	O
.	-	1475	O

RESULTS	15630069	1477	O
:	-	1484	O

The	15630069	1486	O
mean	-	1490	O
+	-	1495	O
/	-	1496	O
-	-	1497	O

SD	15630069	1499	O
duration	-	1502	O
of	-	1511	O
treatment	-	1514	O
with	-	1524	O
the	-	1529	O
identified	-	1533	O
atypical	-	1544	O
antipsychotic	-	1553	O
agent	-	1567	O
was	-	1573	O
68	-	1577	O
.	-	1579	O
3	-	1580	O
+	-	1582	O
/	-	1583	O
-	-	1584	O

28	15630069	1586	O
.	-	1588	O
9	-	1589	O
months	-	1591	O
(	-	1598	O
clozapine	-	1599	O
)	-	1608	O
,	-	1609	O
29	-	1611	O
.	-	1613	O
5	-	1614	O
+	-	1616	O
/	-	1617	O
-	-	1618	O

17	15630069	1620	O
.	-	1622	O
5	-	1623	O
months	-	1625	O
(	-	1632	O
olanzapine	-	1633	O
)	-	1643	O
,	-	1644	O
and	-	1646	O
40	-	1650	O
.	-	1652	O
9	-	1653	O
+	-	1655	O
/	-	1656	O
-	-	1657	O

33	15630069	1659	O
.	-	1661	O
7	-	1662	O
(	-	1664	O
risperidone	-	1665	O
)	-	1676	O
.	-	1677	O

Fasting	15630069	1679	O
serum	-	1687	O
insulin	-	1693	O
concentrations	-	1701	O
differed	-	1716	O
among	-	1725	O
groups	-	1731	O
(	-	1738	O
F	-	1739	O
(	-	1740	O
33	-	1741	O
)	-	1743	O
=	-	1745	O
3	-	1747	O
.	-	1748	O
35	-	1749	O
;	-	1751	O
P	-	1753	O
=	-	1755	O
.	-	1757	O
047	-	1758	O
)	-	1761	O

(	15630069	1763	O
clozapine	-	1764	O
>	-	1773	O
olanzapine	-	1774	O
>	-	1784	O
risperidone	-	1785	O
)	-	1796	O
with	-	1798	O
significant	-	1803	O
differences	-	1815	O
between	-	1827	O
clozapine	-	1835	O
and	-	1845	O
risperidone	-	1849	O
(	-	1861	O
t	-	1862	O
(	-	1863	O
33	-	1864	O
)	-	1866	O
=	-	1868	O
2	-	1870	O
.	-	1871	O
32	-	1872	O
;	-	1874	O
P	-	1876	O
=	-	1878	O
.	-	1880	O
03	-	1881	O
)	-	1883	O
and	-	1885	O
olanzapine	-	1889	O
and	-	1900	O
risperidone	-	1904	O
(	-	1916	O
t	-	1917	O
(	-	1918	O
33	-	1919	O
)	-	1921	O
=	-	1923	O

2	15630069	1925	O
.	-	1926	O
15	-	1927	O
;	-	1929	O
P	-	1931	O
=	-	1933	O
.	-	1935	O
04	-	1936	O
)	-	1938	O
.	-	1939	O

There	15630069	1941	O
was	-	1947	O
a	-	1951	O
significant	-	1953	O
difference	-	1965	O
in	-	1976	O
insulin	-	1979	B
sensitivity	-	1987	I
index	-	1999	O
among	-	2005	O
groups	-	2011	O
(	-	2018	O
F	-	2019	O
(	-	2020	O
33	-	2021	O
)	-	2023	O
=	-	2025	O

10	15630069	2027	O
.	-	2029	O
66	-	2030	O
;	-	2032	O
P	-	2034	O
<	-	2035	O
.	-	2036	O
001	-	2037	O
)	-	2040	O
(	-	2042	O
clozapine	-	2043	O
<	-	2052	O
olanzapine	-	2053	O
<	-	2063	O
risperidone	-	2064	O
)	-	2075	O
,	-	2076	O
with	-	2078	O
subjects	-	2083	O
who	-	2092	O
received	-	2096	O
clozapine	-	2105	O
and	-	2115	O
olanzapine	-	2119	O
exhibiting	-	2130	O
significant	-	2141	O
insulin	-	2153	B
resistance	-	2161	I
compared	-	2172	O
with	-	2181	O
subjects	-	2186	O
who	-	2195	O
were	-	2199	O
treated	-	2204	O
with	-	2212	O
risperidone	-	2217	O
(	-	2229	O
clozapine	-	2230	O
vs	-	2240	O
risperidone	-	2243	O
,	-	2254	O
t	-	2256	O
(	-	2257	O
33	-	2258	O
)	-	2260	O
=	-	2262	O

-	15630069	2264	O
4	-	2265	O
.	-	2266	O
29	-	2267	O
;	-	2269	O
P	-	2271	O
<	-	2272	O
.	-	2273	O
001	-	2274	O
;	-	2277	O
olanzapine	-	2279	O
vs	-	2290	O
risperidone	-	2293	O
,	-	2304	O
t	-	2306	O
(	-	2307	O
33	-	2308	O
)	-	2310	O
=	-	2312	O
-	-	2314	O
3	-	2315	O
.	-	2316	O
62	-	2317	O
;	-	2319	O
P	-	2321	O
=	-	2323	O
.	-	2325	O
001	-	2326	O
[	-	2330	O
P	-	2331	O
<	-	2332	O
.	-	2333	O
001	-	2334	O
]	-	2337	O
)	-	2338	O
.	-	2339	O

The	15630069	2341	O
homeostasis	-	2345	O
model	-	2357	O
assessment	-	2363	O
of	-	2374	O
insulin	-	2377	B
resistance	-	2385	I
also	-	2396	O
differed	-	2401	O
significantly	-	2410	O
among	-	2424	O
groups	-	2430	O
(	-	2437	O
F	-	2438	O
(	-	2439	O
33	-	2440	O
)	-	2442	O
=	-	2444	O

4	15630069	2446	O
.	-	2447	O
92	-	2448	O
;	-	2450	O
P	-	2452	O
=	-	2454	O
.	-	2456	O
01	-	2457	O
)	-	2459	O
(	-	2461	O
clozapine	-	2462	O
>	-	2471	O
olanzapine	-	2472	O
>	-	2482	O
risperidone	-	2483	O
)	-	2494	O
(	-	2496	O
clozapine	-	2497	O
vs	-	2507	O
risperidone	-	2510	O
,	-	2521	O
t	-	2523	O
(	-	2524	O
33	-	2525	O
)	-	2527	O
=	-	2529	O
2	-	2531	O
.	-	2532	O
94	-	2533	O
;	-	2535	O

P	15630069	2537	O
=	-	2539	O
.	-	2541	O
006	-	2542	O
;	-	2545	O
olanzapine	-	2547	O
vs	-	2558	O
risperidone	-	2561	O
,	-	2572	O
t	-	2574	O
(	-	2575	O
33	-	2576	O
)	-	2578	O
=	-	2580	O

2	15630069	2582	O
.	-	2583	O
42	-	2584	O
;	-	2586	O
P	-	2588	O
=	-	2590	O
.	-	2592	O
02	-	2593	O
)	-	2595	O
.	-	2596	O

There	15630069	2598	O
was	-	2604	O
a	-	2608	O
significant	-	2610	O
difference	-	2622	O
among	-	2633	O
groups	-	2639	O
in	-	2646	O
glucose	-	2649	O
effectiveness	-	2657	O
(	-	2671	O
F	-	2672	O
(	-	2673	O
30	-	2674	O
)	-	2676	O
=	-	2678	O

4	15630069	2680	O
.	-	2681	O
18	-	2682	O
;	-	2684	O
P	-	2686	O
=	-	2688	O
.	-	2690	O
02	-	2691	O
)	-	2693	O

(	15630069	2695	O
clozapine	-	2696	O
<	-	2705	O
olanzapine	-	2706	O
<	-	2716	O
risperidone	-	2717	O
)	-	2728	O
with	-	2730	O
significant	-	2735	O
differences	-	2747	O
between	-	2759	O
clozapine	-	2767	O
and	-	2777	O
risperidone	-	2781	O
(	-	2793	O
t	-	2794	O
(	-	2795	O
30	-	2796	O
)	-	2798	O
=	-	2800	O

-	15630069	2802	O
2	-	2803	O
.	-	2804	O
59	-	2805	O
;	-	2807	O
P	-	2809	O
=	-	2811	O
.	-	2813	O
02	-	2814	O
)	-	2816	O
and	-	2818	O
olanzapine	-	2822	O
and	-	2833	O
risperidone	-	2837	O
(	-	2849	O
t	-	2850	O
(	-	2851	O
30	-	2852	O
)	-	2854	O
=	-	2856	O

-	15630069	2858	O
2	-	2859	O
.	-	2860	O
34	-	2861	O
,	-	2863	O
P	-	2865	O
=	-	2867	O
.	-	2869	O
03	-	2870	O
)	-	2872	O
.	-	2873	O

CONCLUSIONS	15630069	2875	O
:	-	2886	O

Both	15630069	2888	O
nonobese	-	2893	O
clozapine	-	2902	O
-	-	2911	O
and	-	2913	O
olanzapine	-	2917	O
-	-	2927	O
treated	-	2928	O
groups	-	2936	O
displayed	-	2943	O
significant	-	2953	O
insulin	-	2965	B
resistance	-	2973	I
and	-	2984	O
impairment	-	2988	O
of	-	2999	O
glucose	-	3002	O
effectiveness	-	3010	O
compared	-	3024	O
with	-	3033	O
risperidone	-	3038	O
-	-	3049	O
treated	-	3050	O
subjects	-	3058	O
.	-	3066	O

Patients	15630069	3068	O
taking	-	3077	O
clozapine	-	3084	O
and	-	3094	O
olanzapine	-	3098	O
must	-	3109	O
be	-	3114	O
examined	-	3117	O
for	-	3126	O
insulin	-	3130	B
resistance	-	3138	I
and	-	3149	O
its	-	3153	O
consequences	-	3157	O
.	-	3169	O

Focal	15815446	0	O
cerebral	-	6	B
ischemia	-	15	I
in	-	24	O
rats	-	27	O
:	-	31	O
effect	-	33	O
of	-	40	O
phenylephrine	-	43	O
-	-	56	O
induced	-	57	O
hypertension	-	65	B
during	-	78	O
reperfusion	-	85	O
.	-	96	O

After	15815446	98	O
180	-	104	O
min	-	108	O
of	-	112	O
temporary	-	115	O
middle	-	125	B
cerebral	-	132	I
artery	-	141	I
occlusion	-	148	I
in	-	158	O
spontaneously	-	161	O
hypertensive	-	175	B
rats	-	188	O
,	-	192	O
the	-	194	O
effect	-	198	O
of	-	205	O
phenylephrine	-	208	O
-	-	221	O
induced	-	222	O
hypertension	-	230	B
on	-	243	O
ischemic	-	246	B
brain	-	255	I
injury	-	261	I
and	-	268	O
blood	-	272	O
-	-	277	O
brain	-	278	O
barrier	-	284	O
permeability	-	292	O
was	-	305	O
determined	-	309	O
.	-	319	O

Blood	15815446	321	O
pressure	-	327	O
was	-	336	O
manipulated	-	340	O
by	-	352	O
one	-	355	O
of	-	359	O
the	-	362	O
following	-	366	O
schedules	-	376	O
during	-	386	O
120	-	393	O
min	-	397	O
of	-	401	O
reperfusion	-	404	O
:	-	415	O
Control	-	417	O
,	-	424	O
normotensive	-	426	O
reperfusion	-	439	O
;	-	450	O
90	-	452	O
/	-	454	O
hypertension	-	455	B
(	-	468	O
90	-	469	O
/	-	471	O
HTN	-	472	B
)	-	475	O
,	-	476	O
blood	-	478	O
pressure	-	484	O
was	-	493	O
increased	-	497	O
by	-	507	O
35	-	510	O
mm	-	513	O
Hg	-	516	O
during	-	519	O
the	-	526	O
initial	-	530	O
90	-	538	O
min	-	541	O
of	-	545	O
reperfusion	-	548	O
only	-	560	O
;	-	564	O
15	-	566	O
/	-	568	O
hypertension	-	569	B
(	-	582	O
15	-	583	O
/	-	585	O
HTN	-	586	B
)	-	589	O
,	-	590	O
normotensive	-	592	O
reperfusion	-	605	O
for	-	617	O
30	-	621	O
min	-	624	O
followed	-	628	O
by	-	637	O
15	-	640	O
min	-	643	O
of	-	647	O
hypertension	-	650	B
and	-	663	O
75	-	667	O
min	-	670	O
of	-	674	O
normotension	-	677	O
.	-	689	O

Part	15815446	691	O
A	-	696	O
,	-	697	O
for	-	699	O
eight	-	703	O
rats	-	709	O
in	-	714	O
each	-	717	O
group	-	722	O
brain	-	728	B
injury	-	734	I
was	-	741	O
evaluated	-	745	O
by	-	755	O
staining	-	758	O
tissue	-	767	O
using	-	774	O
2	-	780	O
,	-	781	O
3	-	782	O
,	-	783	O
5	-	784	O
-	-	785	O
triphenyltetrazolium	-	786	O
chloride	-	807	O
and	-	816	O
edema	-	820	B
was	-	826	O
evaluated	-	830	O
by	-	840	O
microgravimetry	-	843	O
.	-	858	O

Part	15815446	860	O
B	-	865	O
,	-	866	O
for	-	868	O
eight	-	872	O
different	-	878	O
rats	-	888	O
in	-	893	O
each	-	896	O
group	-	901	O
blood	-	907	O
-	-	912	O
brain	-	913	O
barrier	-	919	O
permeability	-	927	O
was	-	940	O
evaluated	-	944	O
by	-	954	O
measuring	-	957	O
the	-	967	O
amount	-	971	O
and	-	978	O
extent	-	982	O
of	-	989	O
extravasation	-	992	O
of	-	1006	O
Evans	-	1009	O
Blue	-	1015	O
dye	-	1020	O
.	-	1023	O

Brain	15815446	1025	B
injury	-	1031	I
(	-	1038	O
percentage	-	1039	O
of	-	1050	O
the	-	1053	O
ischemic	-	1057	B
hemisphere	-	1066	I
)	-	1076	O
was	-	1078	O
less	-	1082	O
in	-	1087	O
the	-	1090	O
15	-	1094	O
/	-	1096	O
HTN	-	1097	B
group	-	1101	O
(	-	1107	O
16	-	1108	O
+	-	1111	O
/	-	1112	O
-	-	1113	O

6	15815446	1115	O
,	-	1116	O
mean	-	1118	O
+	-	1123	O
/	-	1124	O
-	-	1125	O
SD	-	1127	O
)	-	1129	O
versus	-	1131	O
the	-	1138	O
90	-	1142	O
/	-	1144	O
HTN	-	1145	B
group	-	1149	O
(	-	1155	O
30	-	1156	O
+	-	1159	O
/	-	1160	O
-	-	1161	O
6	-	1163	O
)	-	1164	O
,	-	1165	O
which	-	1167	O
was	-	1173	O
in	-	1177	O
turn	-	1180	O
less	-	1185	O
than	-	1190	O
the	-	1195	O
control	-	1199	O
group	-	1207	O
(	-	1213	O
42	-	1214	O
+	-	1217	O
/	-	1218	O
-	-	1219	O
5	-	1221	O
)	-	1222	O
.	-	1223	O

Specific	15815446	1225	O
gravity	-	1234	O
was	-	1242	O
greater	-	1246	O
in	-	1254	O
the	-	1257	O
15	-	1261	O
/	-	1263	O
HTN	-	1264	B
group	-	1268	O
(	-	1274	O
1	-	1275	O
.	-	1276	O
043	-	1277	O
+	-	1281	O
/	-	1282	O
-	-	1283	O
0	-	1285	O
.	-	1286	O
002	-	1287	O
)	-	1290	O
versus	-	1292	O
the	-	1299	O
90	-	1303	O
/	-	1305	O
HTN	-	1306	B
(	-	1310	O
1	-	1311	O
.	-	1312	O
036	-	1313	O
+	-	1317	O
/	-	1318	O
-	-	1319	O

0	15815446	1321	O
.	-	1322	O
003	-	1323	O
)	-	1326	O
and	-	1328	O
control	-	1332	O
(	-	1340	O
1	-	1341	O
.	-	1342	O
037	-	1343	O
+	-	1347	O
/	-	1348	O
-	-	1349	O

0	15815446	1351	O
.	-	1352	O
003	-	1353	O
)	-	1356	O
groups	-	1358	O
.	-	1364	O

Evans	15815446	1366	O
Blue	-	1372	O
(	-	1377	O
mug	-	1378	O
g	-	1382	O
-	-	1383	O
1	-	1384	O
of	-	1386	O
brain	-	1389	O
tissue	-	1395	O
)	-	1401	O
was	-	1403	O
greater	-	1407	O
in	-	1415	O
the	-	1418	O
90	-	1422	O
/	-	1424	O
HTN	-	1425	B
group	-	1429	O
(	-	1435	O
24	-	1436	O
.	-	1438	O
4	-	1439	O
+	-	1441	O
/	-	1442	O
-	-	1443	O

6	15815446	1445	O
.	-	1446	O
0	-	1447	O
)	-	1448	O
versus	-	1450	O
the	-	1457	O
control	-	1461	O
group	-	1469	O
(	-	1475	O
12	-	1476	O
.	-	1478	O
3	-	1479	O
+	-	1481	O
/	-	1482	O
-	-	1483	O

4	15815446	1485	O
.	-	1486	O
1	-	1487	O
)	-	1488	O
,	-	1489	O
which	-	1491	O
was	-	1497	O
in	-	1501	O
turn	-	1504	O
greater	-	1509	O
than	-	1517	O
the	-	1522	O
15	-	1526	O
/	-	1528	O
HTN	-	1529	B
group	-	1533	O
(	-	1539	O
7	-	1540	O
.	-	1541	O
3	-	1542	O
+	-	1544	O
/	-	1545	O
-	-	1546	O
3	-	1548	O
.	-	1549	O
2	-	1550	O
)	-	1551	O
.	-	1552	O

This	15815446	1554	O
study	-	1559	O
supports	-	1565	O
a	-	1574	O
hypothesis	-	1576	O
that	-	1587	O
during	-	1592	O
reperfusion	-	1599	O
,	-	1610	O
a	-	1612	O
short	-	1614	O
interval	-	1620	O
of	-	1629	O
hypertension	-	1632	B
decreases	-	1645	O
brain	-	1655	B
injury	-	1661	I
and	-	1668	O
edema	-	1672	B
;	-	1677	O
and	-	1679	O
that	-	1683	O
sustained	-	1688	O
hypertension	-	1698	B
increases	-	1711	O
the	-	1721	O
risk	-	1725	O
of	-	1730	O
vasogenic	-	1733	B
edema	-	1743	I
.	-	1748	O

People	15817013	0	O
aged	-	7	O
over	-	12	O
75	-	17	O
in	-	20	O
atrial	-	23	B
fibrillation	-	30	I
on	-	43	O
warfarin	-	46	O
:	-	54	O
the	-	56	O
rate	-	60	O
of	-	65	O
major	-	68	O
hemorrhage	-	74	B
and	-	85	O
stroke	-	89	B
in	-	96	O
more	-	99	O
than	-	104	O
500	-	109	O
patient	-	113	O
-	-	120	O
years	-	121	O
of	-	127	O
follow	-	130	O
-	-	136	O
up	-	137	O
.	-	139	O

OBJECTIVES	15817013	141	O
:	-	151	O

To	15817013	153	O
determine	-	156	O
the	-	166	O
incidence	-	170	O
of	-	180	O
major	-	183	O
hemorrhage	-	189	B
and	-	200	O
stroke	-	204	B
in	-	211	O
people	-	214	O
aged	-	221	O
76	-	226	O
and	-	229	O
older	-	233	O
with	-	239	O
atrial	-	244	B
fibrillation	-	251	I
on	-	264	O
adjusted	-	267	O
-	-	275	O
dose	-	276	O
warfarin	-	281	O
who	-	290	O
had	-	294	O
been	-	298	O
recently	-	303	O
been	-	312	O
admitted	-	317	O
to	-	326	O
hospital	-	329	O
.	-	337	O

DESIGN	15817013	339	O
:	-	345	O

A	15817013	347	O
retrospective	-	349	O
observational	-	363	O
cohort	-	377	O
study	-	384	O
.	-	389	O

SETTING	15817013	391	O
:	-	398	O

A	15817013	400	O
major	-	402	O
healthcare	-	408	O
network	-	419	O
involving	-	427	O
four	-	437	O
tertiary	-	442	O
hospitals	-	451	O
.	-	460	O

PARTICIPANTS	15817013	462	O
:	-	474	O
Two	-	476	O
hundred	-	480	O
thirty	-	488	O
-	-	494	O
five	-	495	O
patients	-	500	O
aged	-	509	O
76	-	514	O
and	-	517	O
older	-	521	O
admitted	-	527	O
to	-	536	O
a	-	539	O
major	-	541	O
healthcare	-	547	O
network	-	558	O
between	-	566	O
July	-	574	O
1	-	579	O
,	-	580	O
2001	-	582	O
,	-	586	O
and	-	588	O
June	-	592	O
30	-	597	O
,	-	599	O
2002	-	601	O
,	-	605	O
with	-	607	O
atrial	-	612	B
fibrillation	-	619	I
on	-	632	O
warfarin	-	635	O
were	-	644	O
enrolled	-	649	O
.	-	657	O

MEASUREMENTS	15817013	659	O
:	-	671	O

Information	15817013	673	O
regarding	-	685	O
major	-	695	O
bleeding	-	701	B
episodes	-	710	O
,	-	718	O
strokes	-	720	B
,	-	727	O
and	-	729	O
warfarin	-	733	O
use	-	742	O
was	-	746	O
obtained	-	750	O
from	-	759	O
patients	-	764	O
,	-	772	O
relatives	-	774	O
,	-	783	O
primary	-	785	O
physicians	-	793	O
,	-	803	O
and	-	805	O
medical	-	809	O
records	-	817	O
.	-	824	O

RESULTS	15817013	826	O
:	-	833	O

Two	15817013	835	O
hundred	-	839	O
twenty	-	847	O
-	-	853	O
eight	-	854	O
patients	-	860	O
(	-	869	O
42	-	870	O
%	-	872	O
men	-	874	O
)	-	877	O
with	-	879	O
a	-	884	O
mean	-	886	O
age	-	891	O
of	-	895	O
81	-	898	O
.	-	900	O
1	-	901	O
(	-	903	O
range	-	904	O
76	-	910	O
-	-	912	O
94	-	913	O
)	-	915	O
were	-	917	O
included	-	922	O
in	-	931	O
the	-	934	O
analysis	-	938	O
.	-	946	O

Total	15817013	948	O
follow	-	954	O
-	-	960	O
up	-	961	O
on	-	964	O
warfarin	-	967	O
was	-	976	O
530	-	980	O
years	-	984	O
(	-	990	O
mean	-	991	O
28	-	996	O
months	-	999	O
)	-	1005	O
.	-	1006	O

There	15817013	1008	O
were	-	1014	O
53	-	1019	O
major	-	1022	O
hemorrhages	-	1028	B
,	-	1039	O
for	-	1041	O
an	-	1045	O
annual	-	1048	O
rate	-	1055	O
of	-	1060	O
10	-	1063	O
.	-	1065	O
0	-	1066	O
%	-	1067	O
,	-	1068	O
including	-	1070	O
24	-	1080	O
(	-	1083	O
45	-	1084	O
.	-	1086	O
3	-	1087	O
%	-	1088	O
)	-	1089	O
life	-	1091	O
-	-	1095	O
threatening	-	1096	O
and	-	1108	O
five	-	1112	O
(	-	1117	O
9	-	1118	O
.	-	1119	O
4	-	1120	O
%	-	1121	O
)	-	1122	O
fatal	-	1124	O
bleeds	-	1130	O
.	-	1136	O

The	15817013	1138	O
annual	-	1142	O
stroke	-	1149	B
rate	-	1156	O
after	-	1161	O
initiation	-	1167	O
of	-	1178	O
warfarin	-	1181	O
was	-	1190	O
2	-	1194	O
.	-	1195	O
6	-	1196	O
%	-	1197	O
.	-	1198	O

CONCLUSION	15817013	1200	O
:	-	1210	O

The	15817013	1212	O
rate	-	1216	O
of	-	1221	O
major	-	1224	O
hemorrhage	-	1230	B
was	-	1241	O
high	-	1245	O
in	-	1250	O
this	-	1253	O
old	-	1258	O
,	-	1261	O
frail	-	1263	O
group	-	1269	O
,	-	1274	O
but	-	1276	O
excluding	-	1280	O
fatalities	-	1290	O
,	-	1300	O
resulted	-	1302	O
in	-	1311	O
no	-	1314	O
long	-	1317	O
-	-	1321	O
term	-	1322	O
sequelae	-	1327	O
,	-	1335	O
and	-	1337	O
the	-	1341	O
stroke	-	1345	B
rate	-	1352	O
on	-	1357	O
warfarin	-	1360	O
was	-	1369	O
low	-	1373	O
,	-	1376	O
demonstrating	-	1378	O
how	-	1392	O
effective	-	1396	O
warfarin	-	1406	O
treatment	-	1415	O
is	-	1425	O
.	-	1427	O

Safety	15859361	0	O
of	-	7	O
celecoxib	-	10	O
in	-	20	O
patients	-	23	O
with	-	32	O
adverse	-	37	O
skin	-	45	B
reactions	-	50	I
to	-	60	O
acetaminophen	-	63	O
(	-	77	O
paracetamol	-	78	O
)	-	89	O
and	-	91	O
nimesulide	-	95	O
associated	-	106	O
or	-	117	O
not	-	120	O
with	-	124	O
common	-	129	O
non	-	136	O
-	-	139	O
steroidal	-	140	O
anti	-	150	O
-	-	154	O
inflammatory	-	155	O
drugs	-	168	O
.	-	173	O

BACKGROUND	15859361	175	O
:	-	185	O

Acetaminophen	15859361	187	O
(	-	201	O
paracetamol	-	202	O
-	-	213	O
-	-	214	O
P	-	215	O
)	-	216	O
and	-	218	O
Nimesulide	-	222	O
(	-	233	O
N	-	234	O
)	-	235	O
are	-	237	O
widely	-	241	O
used	-	248	O
analgesic	-	253	O
-	-	262	O
antipyretic	-	263	O
/	-	274	O
anti	-	275	O
-	-	279	O
inflammatory	-	280	O
drugs	-	293	O
.	-	298	O

The	15859361	300	O
rate	-	304	O
of	-	309	O
adverse	-	312	O
hypersensitivity	-	320	B
reactions	-	337	O
to	-	347	O
these	-	350	O
agents	-	356	O
is	-	363	O
generally	-	366	O
low	-	376	O
.	-	379	O

On	15859361	381	O
the	-	384	O
contrary	-	388	O
non	-	397	O
-	-	400	O
steroidal	-	401	O
anti	-	411	O
-	-	415	O
inflammatory	-	416	O
drugs	-	429	O
(	-	435	O
NSAIDs	-	436	O
)	-	442	O
are	-	444	O
commonly	-	448	O
involved	-	457	O
in	-	466	O
such	-	469	O
reactions	-	474	O
.	-	483	O

Celecoxib	15859361	485	O
(	-	495	O
CE	-	496	O
)	-	498	O
is	-	500	O
a	-	503	O
novel	-	505	O
drug	-	511	O
,	-	515	O
with	-	517	O
high	-	522	O
selectivity	-	527	O
and	-	539	O
affinity	-	543	O
for	-	552	O
COX	-	556	O
-	-	559	O
2	-	560	O
enzyme	-	562	O
.	-	568	O

OBJECTIVE	15859361	570	O
:	-	579	O
We	-	581	O
evaluated	-	584	O
the	-	594	O
tolerability	-	598	O
of	-	611	O
CE	-	614	O
in	-	617	O
a	-	620	O
group	-	622	O
of	-	628	O
patients	-	631	O
with	-	640	O
documented	-	645	O
history	-	656	O
of	-	664	O
adverse	-	667	O
cutaneous	-	675	B
reactions	-	685	I
to	-	695	O
P	-	698	O
and	-	700	O
N	-	704	O
associated	-	706	O
or	-	717	O
not	-	720	O
to	-	724	O
classic	-	727	O
NSAIDs	-	735	O
.	-	741	O

METHODS	15859361	743	O
:	-	750	O

We	15859361	752	O
studied	-	755	O
9	-	763	O
patients	-	765	O
with	-	774	O
hypersensitivity	-	779	B
to	-	796	O
P	-	799	O
and	-	801	O
N	-	805	O
with	-	807	O
or	-	812	O
without	-	815	O
associated	-	823	O
reactions	-	834	O
to	-	844	O
classic	-	847	O
NSAIDs	-	855	O
.	-	861	O

The	15859361	863	O
diagnosis	-	867	O
of	-	877	O
P	-	880	O
and	-	882	O
N	-	886	O
-	-	887	O
induced	-	888	O
skin	-	896	B
reactions	-	901	I
was	-	911	O
based	-	915	O
in	-	921	O
vivo	-	924	O
challenge	-	929	O
.	-	938	O

The	15859361	940	O
placebo	-	944	O
was	-	952	O
blindly	-	956	O
administered	-	964	O
at	-	977	O
the	-	980	O
beginning	-	984	O
of	-	994	O
each	-	997	O
challenge	-	1002	O
.	-	1011	O

After	15859361	1013	O
three	-	1019	O
days	-	1025	O
,	-	1029	O
a	-	1031	O
cumulative	-	1033	O
dosage	-	1044	O
of	-	1051	O
200	-	1054	O
mg	-	1058	O
of	-	1061	O
CE	-	1064	O
in	-	1067	O
refracted	-	1070	O
doses	-	1080	O
were	-	1086	O
given	-	1091	O
.	-	1096	O

After	15859361	1098	O
2	-	1104	O
-	-	1105	O
3	-	1106	O
days	-	1108	O
,	-	1112	O
a	-	1114	O
single	-	1116	O
dose	-	1123	O
of	-	1128	O
200	-	1131	O
mg	-	1135	O
was	-	1138	O
administered	-	1142	O
.	-	1154	O

All	15859361	1156	O
patients	-	1160	O
were	-	1169	O
observed	-	1174	O
for	-	1183	O
6	-	1187	O
hours	-	1189	O
after	-	1195	O
each	-	1201	O
challenge	-	1206	O
,	-	1215	O
and	-	1217	O
controlled	-	1221	O
again	-	1232	O
after	-	1238	O
24	-	1244	O
hours	-	1247	O
to	-	1253	O
exclude	-	1256	O
delayed	-	1264	O
reactions	-	1272	O
.	-	1281	O

The	15859361	1283	O
challenge	-	1287	O
was	-	1297	O
considered	-	1301	O
positive	-	1312	O
if	-	1321	O
one	-	1324	O
or	-	1328	O
more	-	1331	O
of	-	1336	O
the	-	1339	O
following	-	1343	O
appeared	-	1353	O
:	-	1361	O
erythema	-	1363	B
,	-	1371	O
rush	-	1373	O
or	-	1378	O
urticaria	-	1381	B
-	-	1390	O
angioedema	-	1391	B
.	-	1401	O

RESULTS	15859361	1403	O
:	-	1410	O

No	15859361	1412	O
reaction	-	1415	O
was	-	1424	O
observed	-	1428	O
with	-	1437	O
placebo	-	1442	O
and	-	1450	O
eight	-	1454	O
patients	-	1460	O
(	-	1469	O
88	-	1470	O
.	-	1472	O
8	-	1473	O
%	-	1474	O
)	-	1475	O
tolerated	-	1477	O
CE	-	1487	O
.	-	1489	O

Only	15859361	1491	O
one	-	1496	O
patient	-	1500	O
developed	-	1508	O
a	-	1518	O
moderate	-	1520	O
angioedema	-	1529	B
of	-	1540	O
the	-	1543	O
lips	-	1547	O
.	-	1551	O

CONCLUSION	15859361	1553	O
:	-	1563	O

Only	15859361	1565	O
one	-	1570	O
hypersensitivity	-	1574	B
reaction	-	1591	O
to	-	1600	O
CE	-	1603	O
was	-	1606	O
documented	-	1610	O
among	-	1621	O
9	-	1627	O
P	-	1629	O
and	-	1631	O
N	-	1635	O
-	-	1636	O
highly	-	1637	O
NSAIDs	-	1644	O
intolerant	-	1651	O
patients	-	1662	O
.	-	1670	O

Thus	15859361	1672	O
,	-	1676	O
we	-	1678	O
conclude	-	1681	O
that	-	1690	O
CE	-	1695	O
is	-	1698	O
a	-	1701	O
reasonably	-	1703	O
safe	-	1714	O
alternative	-	1719	O
to	-	1731	O
be	-	1734	O
used	-	1737	O
in	-	1742	O
subjects	-	1745	O
who	-	1754	O
do	-	1758	O
not	-	1761	O
tolerate	-	1765	O
P	-	1774	O
and	-	1776	O
N	-	1780	O
.	-	1781	O

Case	15882284	0	O
-	-	4	O
control	-	5	O
study	-	13	O
of	-	19	O
regular	-	22	O
analgesic	-	30	O
and	-	40	O
nonsteroidal	-	44	O
anti	-	57	O
-	-	61	O
inflammatory	-	62	O
use	-	75	O
and	-	79	O
end	-	83	B
-	-	86	I
stage	-	87	I
renal	-	93	I
disease	-	99	I
.	-	106	O

BACKGROUND	15882284	108	O
:	-	118	O

Studies	15882284	120	O
on	-	128	O
the	-	131	O
association	-	135	O
between	-	147	O
the	-	155	O
long	-	159	O
-	-	163	O
term	-	164	O
use	-	169	O
of	-	173	O
aspirin	-	176	O
and	-	184	O
other	-	188	O
analgesic	-	194	O
and	-	204	O
nonsteroidal	-	208	O
anti	-	221	O
-	-	225	O
inflammatory	-	226	O
drugs	-	239	O
(	-	245	O
NSAIDs	-	246	O
)	-	252	O
and	-	254	O
end	-	258	B
-	-	261	I
stage	-	262	I
renal	-	268	I
disease	-	274	I
(	-	282	O
ESRD	-	283	B
)	-	287	O
have	-	289	O
given	-	294	O
conflicting	-	300	O
results	-	312	O
.	-	319	O

In	15882284	321	O
order	-	324	O
to	-	330	O
examine	-	333	O
this	-	341	O
association	-	346	O
,	-	357	O
a	-	359	O
case	-	361	O
-	-	365	O
control	-	366	O
study	-	374	O
with	-	380	O
incident	-	385	O
cases	-	394	O
of	-	400	O
ESRD	-	403	B
was	-	408	O
carried	-	412	O
out	-	420	O
.	-	423	O

METHODS	15882284	425	O
:	-	432	O

The	15882284	434	O
cases	-	438	O
were	-	444	O
all	-	449	O
patients	-	453	O
entering	-	462	O
the	-	471	O
local	-	475	O
dialysis	-	481	O
program	-	490	O
because	-	498	O
of	-	506	O
ESRD	-	509	B
in	-	514	O
the	-	517	O
study	-	521	O
area	-	527	O
between	-	532	O
June	-	540	O
1	-	545	O
,	-	546	O
1995	-	548	O
and	-	553	O
November	-	557	O
30	-	566	O
,	-	568	O
1997	-	570	O
.	-	574	O

They	15882284	576	O
were	-	581	O
classified	-	586	O
according	-	597	O
to	-	607	O
the	-	610	O
underlying	-	614	O
disease	-	625	O
,	-	632	O
which	-	634	O
had	-	640	O
presumably	-	644	O
led	-	655	O
them	-	659	O
to	-	664	O
ESRD	-	667	B
.	-	671	O

Controls	15882284	673	O
were	-	682	O
patients	-	687	O
admitted	-	696	O
to	-	705	O
the	-	708	O
same	-	712	O
hospitals	-	717	O
from	-	727	O
where	-	732	O
the	-	738	O
cases	-	742	O
arose	-	748	O
,	-	753	O
also	-	755	O
matched	-	760	O
by	-	768	O
age	-	771	O
and	-	775	O
sex	-	779	O
.	-	782	O

Odds	15882284	784	O
ratios	-	789	O
were	-	796	O
calculated	-	801	O
using	-	812	O
a	-	818	O
conditional	-	820	O
logistic	-	832	O
model	-	841	O
,	-	846	O
including	-	848	O
potential	-	858	O
confounding	-	868	O
factors	-	880	O
,	-	887	O
both	-	889	O
for	-	894	O
the	-	898	O
whole	-	902	O
study	-	908	O
population	-	914	O
and	-	925	O
for	-	929	O
the	-	933	O
various	-	937	O
underlying	-	945	O
diseases	-	956	O
.	-	964	O

RESULTS	15882284	966	O
:	-	973	O

Five	15882284	975	O
hundred	-	980	O
and	-	988	O
eighty	-	992	O
-	-	998	O
three	-	999	O
cases	-	1005	O
and	-	1011	O
1190	-	1015	O
controls	-	1020	O
were	-	1029	O
included	-	1034	O
in	-	1043	O
the	-	1046	O
analysis	-	1050	O
.	-	1058	O

Long	15882284	1060	O
-	-	1064	O
term	-	1065	O
use	-	1070	O
of	-	1074	O
any	-	1077	O
analgesic	-	1081	O
was	-	1091	O
associated	-	1095	O
with	-	1106	O
an	-	1111	O
overall	-	1114	O
odds	-	1122	O
ratio	-	1127	O
of	-	1133	O
1	-	1136	O
.	-	1137	O
22	-	1138	O
(	-	1141	O
95	-	1142	O
%	-	1144	O
CI	-	1146	O
,	-	1148	O
0	-	1150	O
.	-	1151	O
89	-	1152	O
-	-	1154	O
1	-	1155	O
.	-	1156	O
66	-	1157	O
)	-	1159	O
.	-	1160	O

For	15882284	1162	O
specific	-	1166	O
groups	-	1175	O
of	-	1182	O
drugs	-	1185	O
,	-	1190	O
the	-	1192	O
risks	-	1196	O
were	-	1202	O
1	-	1207	O
.	-	1208	O
56	-	1209	O
(	-	1212	O
1	-	1213	O
.	-	1214	O
05	-	1215	O
-	-	1217	O
2	-	1218	O
.	-	1219	O
30	-	1220	O
)	-	1222	O
for	-	1224	O
aspirin	-	1228	O
,	-	1235	O
1	-	1237	O
.	-	1238	O
03	-	1239	O
(	-	1242	O
0	-	1243	O
.	-	1244	O
60	-	1245	O
-	-	1247	O
1	-	1248	O
.	-	1249	O
76	-	1250	O
)	-	1252	O
for	-	1254	O
pyrazolones	-	1258	O
,	-	1269	O
0	-	1271	O
.	-	1272	O
80	-	1273	O
(	-	1276	O
0	-	1277	O
.	-	1278	O
39	-	1279	O
-	-	1281	O
1	-	1282	O
.	-	1283	O
63	-	1284	O
)	-	1286	O
for	-	1288	O
paracetamol	-	1292	O
,	-	1303	O
and	-	1305	O
0	-	1309	O
.	-	1310	O
94	-	1311	O
(	-	1314	O
0	-	1315	O
.	-	1316	O
57	-	1317	O
-	-	1319	O
1	-	1320	O
.	-	1321	O
56	-	1322	O
)	-	1324	O
for	-	1326	O
nonaspirin	-	1330	O
NSAIDs	-	1341	O
.	-	1347	O

The	15882284	1349	O
risk	-	1353	O
of	-	1358	O
ESRD	-	1361	B
associated	-	1366	O
with	-	1377	O
aspirin	-	1382	O
was	-	1390	O
related	-	1394	O
to	-	1402	O
the	-	1405	O
cumulated	-	1409	O
dose	-	1419	O
and	-	1424	O
duration	-	1428	O
of	-	1437	O
use	-	1440	O
,	-	1443	O
and	-	1445	O
it	-	1449	O
was	-	1452	O
particularly	-	1456	O
high	-	1469	O
among	-	1474	O
the	-	1480	O
subset	-	1484	O
of	-	1491	O
patients	-	1494	O
with	-	1503	O
vascular	-	1508	O
nephropathy	-	1517	B
as	-	1529	O
underlying	-	1532	O
disease	-	1543	O
[	-	1551	O
2	-	1552	O
.	-	1553	O
35	-	1554	O
(	-	1557	O
1	-	1558	O
.	-	1559	O
17	-	1560	O
-	-	1562	O
4	-	1563	O
.	-	1564	O
72	-	1565	O
)	-	1567	O
]	-	1568	O
.	-	1569	O

CONCLUSION	15882284	1571	O
:	-	1581	O

Our	15882284	1583	O
data	-	1587	O
indicate	-	1592	O
that	-	1601	O
long	-	1606	O
-	-	1610	O
term	-	1611	O
use	-	1616	O
of	-	1620	O
nonaspirin	-	1623	O
analgesic	-	1634	O
drugs	-	1644	O
and	-	1650	O
NSAIDs	-	1654	O
is	-	1661	O
not	-	1664	O
associated	-	1668	O
with	-	1679	O
an	-	1684	O
increased	-	1687	O
risk	-	1697	O
of	-	1702	O
ESRD	-	1705	B
.	-	1709	O

However	15882284	1711	O
,	-	1718	O
the	-	1720	O
chronic	-	1724	O
use	-	1732	O
of	-	1736	O
aspirin	-	1739	O
may	-	1747	O
increase	-	1751	O
the	-	1760	O
risk	-	1764	O
of	-	1769	O
ESRD	-	1772	B
.	-	1776	O

Two	15953230	0	O
cases	-	4	O
of	-	10	O
amisulpride	-	13	O
overdose	-	25	B
:	-	33	O
a	-	35	O
cause	-	37	O
for	-	43	O
prolonged	-	47	B
QT	-	57	I
syndrome	-	60	I
.	-	68	O

Two	15953230	70	O
cases	-	74	O
of	-	80	O
deliberate	-	83	O
self	-	94	O
-	-	98	O
poisoning	-	99	B
with	-	109	O
5	-	114	O
g	-	116	O
and	-	118	O
3	-	122	O
.	-	123	O
6	-	124	O
g	-	126	O
of	-	128	O
amisulpride	-	131	O
,	-	142	O
respectively	-	144	O
,	-	156	O
are	-	158	O
reported	-	162	O
.	-	170	O

In	15953230	172	O
both	-	175	O
cases	-	180	O
,	-	185	O
QT	-	187	B
prolongation	-	190	I
and	-	203	O
hypocalcaemia	-	207	B
were	-	221	O
noted	-	226	O
.	-	231	O

The	15953230	233	O
QT	-	237	B
prolongation	-	240	I
appeared	-	253	O
to	-	262	O
respond	-	265	O
to	-	273	O
administration	-	276	O
of	-	291	O
i	-	294	O
.	-	295	O
v	-	296	O
.	-	297	O

calcium	15953230	299	O
gluconate	-	307	O
.	-	316	O

Growth	15987266	0	O
-	-	6	O
associated	-	7	O
protein	-	18	O
43	-	26	O
expression	-	29	O
in	-	40	O
hippocampal	-	43	O
molecular	-	55	O
layer	-	65	O
of	-	71	O
chronic	-	74	O
epileptic	-	82	B
rats	-	92	O
treated	-	97	O
with	-	105	O
cycloheximide	-	110	O
.	-	123	O

PURPOSE	15987266	125	O
:	-	132	O

GAP43	15987266	134	O
has	-	140	O
been	-	144	O
thought	-	149	O
to	-	157	O
be	-	160	O
linked	-	163	O
with	-	170	O
mossy	-	175	O
fiber	-	181	O
sprouting	-	187	O
(	-	197	O
MFS	-	198	O
)	-	201	O
in	-	203	O
various	-	206	O
experimental	-	214	O
models	-	227	O
of	-	234	O
epilepsy	-	237	B
.	-	245	O

To	15987266	247	O
investigate	-	250	O
how	-	262	O
GAP43	-	266	O
expression	-	272	O
(	-	283	O
GAP43	-	284	O
-	-	289	O
ir	-	290	O
)	-	292	O
correlates	-	294	O
with	-	305	O
MFS	-	310	O
,	-	313	O
we	-	315	O
assessed	-	318	O
the	-	327	O
intensity	-	331	O
(	-	341	O
densitometry	-	342	O
)	-	354	O
and	-	356	O
extension	-	360	O
(	-	370	O
width	-	371	O
)	-	376	O
of	-	378	O
GAP43	-	381	O
-	-	386	O
ir	-	387	O
in	-	390	O
the	-	393	O
inner	-	397	O
molecular	-	403	O
layer	-	413	O
of	-	419	O
the	-	422	O
dentate	-	426	O
gyrus	-	434	O
(	-	440	O
IML	-	441	O
)	-	444	O
of	-	446	O
rats	-	449	O
subject	-	454	O
to	-	462	O
status	-	465	B
epilepticus	-	472	I
induced	-	484	O
by	-	492	O
pilocarpine	-	495	O
(	-	507	O
Pilo	-	508	O
)	-	512	O
,	-	513	O
previously	-	515	O
injected	-	526	O
or	-	535	O
not	-	538	O
with	-	542	O
cycloheximide	-	547	O
(	-	561	O
CHX	-	562	O
)	-	565	O
,	-	566	O
which	-	568	O
has	-	574	O
been	-	578	O
shown	-	583	O
to	-	589	O
inhibit	-	592	O
MFS	-	600	O
.	-	603	O

METHODS	15987266	605	O
:	-	612	O

CHX	15987266	614	O
was	-	618	O
injected	-	622	O
before	-	631	O
the	-	638	O
Pilo	-	642	O
injection	-	647	O
in	-	657	O
adult	-	660	O
Wistar	-	666	O
rats	-	673	O
.	-	677	O

The	15987266	679	O
Pilo	-	683	O
group	-	688	O
was	-	694	O
injected	-	698	O
with	-	707	O
the	-	712	O
same	-	716	O
drugs	-	721	O
,	-	726	O
except	-	728	O
for	-	735	O
CHX	-	739	O
.	-	742	O

Animals	15987266	744	O
were	-	752	O
killed	-	757	O
between	-	764	O
30	-	772	O
and	-	775	O
60	-	779	O
days	-	782	O
later	-	787	O
,	-	792	O
and	-	794	O
brain	-	798	O
sections	-	804	O
were	-	813	O
processed	-	818	O
for	-	828	O
GAP43	-	832	O
immunohistochemistry	-	838	O
.	-	858	O

RESULTS	15987266	860	O
:	-	867	O

Densitometry	15987266	869	O
showed	-	882	O
no	-	889	O
significant	-	892	O
difference	-	904	O
regarding	-	915	O
GAP43	-	925	O
-	-	930	O
ir	-	931	O
in	-	934	O
the	-	937	O
IML	-	941	O
between	-	945	O
Pilo	-	953	O
,	-	957	O
CHX	-	959	O
+	-	962	O
Pilo	-	963	O
,	-	967	O
and	-	969	O
control	-	973	O
groups	-	981	O
.	-	987	O

However	15987266	989	O
,	-	996	O
the	-	998	O
results	-	1002	O
of	-	1010	O
the	-	1013	O
width	-	1017	O
of	-	1023	O
the	-	1026	O
GAP43	-	1030	O
-	-	1035	O
ir	-	1036	O
band	-	1039	O
in	-	1044	O
the	-	1047	O
IML	-	1051	O
showed	-	1055	O
that	-	1062	O
CHX	-	1067	O
+	-	1070	O
Pilo	-	1071	O
and	-	1076	O
control	-	1080	O
animals	-	1088	O
had	-	1096	O
a	-	1100	O
significantly	-	1102	O
larger	-	1116	O
band	-	1123	O
(	-	1128	O
p	-	1129	O
=	-	1131	O
0	-	1133	O
.	-	1134	O
03	-	1135	O
)	-	1137	O
as	-	1139	O
compared	-	1142	O
with	-	1151	O
that	-	1156	O
in	-	1161	O
the	-	1164	O
Pilo	-	1168	O
group	-	1173	O
.	-	1178	O

CONCLUSIONS	15987266	1180	O
:	-	1191	O

Our	15987266	1193	O
current	-	1197	O
finding	-	1205	O
that	-	1213	O
animals	-	1218	O
in	-	1226	O
the	-	1229	O
CHX	-	1233	O
+	-	1236	O
Pilo	-	1237	O
group	-	1242	O
have	-	1248	O
a	-	1253	O
GAP43	-	1255	O
-	-	1260	O
ir	-	1261	O
band	-	1264	O
in	-	1269	O
the	-	1272	O
IML	-	1276	O
,	-	1279	O
similar	-	1281	O
to	-	1289	O
that	-	1292	O
of	-	1297	O
controls	-	1300	O
,	-	1308	O
reinforces	-	1310	O
prior	-	1321	O
data	-	1327	O
on	-	1332	O
the	-	1335	O
blockade	-	1339	O
of	-	1348	O
MFS	-	1351	O
in	-	1355	O
these	-	1358	O
animals	-	1364	O
.	-	1371	O

The	15987266	1373	O
change	-	1377	O
in	-	1384	O
GAP43	-	1387	O
-	-	1392	O
ir	-	1393	O
present	-	1396	O
in	-	1404	O
Pilo	-	1407	O
-	-	1411	O
treated	-	1412	O
animals	-	1420	O
was	-	1428	O
a	-	1432	O
thinning	-	1434	O
of	-	1443	O
the	-	1446	O
band	-	1450	O
to	-	1455	O
a	-	1458	O
very	-	1460	O
narrow	-	1465	O
layer	-	1472	O
just	-	1478	O
above	-	1483	O
the	-	1489	O
granule	-	1493	O
cell	-	1501	O
layer	-	1506	O
that	-	1512	O
is	-	1517	O
likely	-	1520	O
to	-	1527	O
be	-	1530	O
associated	-	1533	O
with	-	1544	O
the	-	1549	O
loss	-	1553	O
of	-	1558	O
hilar	-	1561	O
cell	-	1567	O
projections	-	1572	O
that	-	1584	O
express	-	1589	O
GAP	-	1597	O
-	-	1600	O
43	-	1601	O
.	-	1603	O

Nicotine	15991002	0	O
antagonizes	-	9	O
caffeine	-	21	O
-	-	29	O
but	-	31	O
not	-	35	O
pentylenetetrazole	-	39	O
-	-	57	O
induced	-	58	O
anxiogenic	-	66	O
effect	-	77	O
in	-	84	O
mice	-	87	O
.	-	91	O

RATIONALE	15991002	93	O
:	-	102	O
Nicotine	-	104	O
and	-	113	O
caffeine	-	117	O
are	-	126	O
widely	-	130	O
consumed	-	137	O
licit	-	146	O
psychoactive	-	152	O
drugs	-	165	O
worldwide	-	171	O
.	-	180	O

Epidemiological	15991002	182	O
studies	-	198	O
showed	-	206	O
that	-	213	O
they	-	218	O
were	-	223	O
generally	-	228	O
used	-	238	O
concurrently	-	243	O
.	-	255	O

Although	15991002	257	O
some	-	266	O
studies	-	271	O
in	-	279	O
experimental	-	282	O
animals	-	295	O
indicate	-	303	O
clear	-	312	O
pharmacological	-	318	O
interactions	-	334	O
between	-	347	O
them	-	355	O
,	-	359	O
no	-	361	O
studies	-	364	O
have	-	372	O
shown	-	377	O
a	-	383	O
specific	-	385	O
interaction	-	394	O
on	-	406	O
anxiety	-	409	B
responses	-	417	O
.	-	426	O

OBJECTIVES	15991002	428	O
:	-	438	O

The	15991002	440	O
present	-	444	O
study	-	452	O
investigates	-	458	O
the	-	471	O
effects	-	475	O
of	-	483	O
nicotine	-	486	O
on	-	495	O
anxiety	-	498	B
induced	-	506	O
by	-	514	O
caffeine	-	517	O
and	-	526	O
another	-	530	O
anxiogenic	-	538	O
drug	-	549	O
,	-	553	O
pentylenetetrazole	-	555	O
,	-	573	O
in	-	575	O
mice	-	578	O
.	-	582	O

The	15991002	584	O
elevated	-	588	O
plus	-	597	O
-	-	601	O
maze	-	602	O
(	-	607	O
EPM	-	608	O
)	-	611	O
test	-	613	O
was	-	618	O
used	-	622	O
to	-	627	O
evaluate	-	630	O
the	-	639	O
effects	-	643	O
of	-	651	O
drugs	-	654	O
on	-	660	O
anxiety	-	663	B
.	-	670	O

METHODS	15991002	672	O
:	-	679	O

Adult	15991002	681	O
male	-	687	O
Swiss	-	692	O
Webster	-	698	O
mice	-	706	O
(	-	711	O
25	-	712	O
-	-	714	O
32	-	715	O
g	-	718	O
)	-	719	O
were	-	721	O
given	-	726	O
nicotine	-	732	O
(	-	741	O
0	-	742	O
.	-	743	O
05	-	744	O
-	-	746	O
0	-	747	O
.	-	748	O
25	-	749	O
mg	-	752	O
/	-	754	O
kg	-	755	O
s	-	758	O
.	-	759	O
c	-	760	O
.	-	761	O
)	-	762	O
or	-	764	O
saline	-	767	O
10	-	774	O
min	-	777	O
before	-	781	O
caffeine	-	788	O
(	-	797	O
70	-	798	O
mg	-	801	O
/	-	803	O
kg	-	804	O

i	15991002	807	O
.	-	808	O
p	-	809	O
.	-	810	O
)	-	811	O
or	-	813	O
pentylenetetrazole	-	816	O
(	-	835	O
15	-	836	O
and	-	839	O
30	-	843	O
mg	-	846	O
/	-	848	O
kg	-	849	O

i	15991002	852	O
.	-	853	O
p	-	854	O
.	-	855	O
)	-	856	O

injections	15991002	858	O
.	-	868	O

After	15991002	870	O
15	-	876	O
min	-	879	O
,	-	882	O
mice	-	884	O
were	-	889	O
evaluated	-	894	O
for	-	904	O
their	-	908	O
open	-	914	O
-	-	918	O
and	-	920	O
closed	-	924	O
-	-	930	O
arm	-	931	O
time	-	935	O
and	-	940	O
entries	-	944	O
on	-	952	O
the	-	955	O
EPM	-	959	O
for	-	963	O
a	-	967	O
10	-	969	O
-	-	971	O
min	-	972	O
session	-	976	O
.	-	983	O

Locomotor	15991002	985	O
activity	-	995	O
was	-	1004	O
recorded	-	1008	O
for	-	1017	O
individual	-	1021	O
groups	-	1032	O
by	-	1039	O
using	-	1042	O
the	-	1048	O
same	-	1052	O
treatment	-	1057	O
protocol	-	1067	O
with	-	1076	O
the	-	1081	O
EPM	-	1085	O
test	-	1089	O
.	-	1093	O

RESULTS	15991002	1095	O
:	-	1102	O
Nicotine	-	1104	O
(	-	1113	O
0	-	1114	O
.	-	1115	O
05	-	1116	O
-	-	1118	O
0	-	1119	O
.	-	1120	O
25	-	1121	O
mg	-	1124	O
/	-	1126	O
kg	-	1127	O
)	-	1129	O
itself	-	1131	O

did	15991002	1138	O
not	-	1142	O
produce	-	1146	O
any	-	1154	O
significant	-	1158	O
effect	-	1170	O
in	-	1177	O
the	-	1180	O
EPM	-	1184	O
test	-	1188	O
,	-	1192	O
whereas	-	1194	O
caffeine	-	1202	O
(	-	1211	O
70	-	1212	O
mg	-	1215	O
/	-	1217	O
kg	-	1218	O
)	-	1220	O
and	-	1222	O
pentylenetetrazole	-	1226	O
(	-	1245	O
30	-	1246	O
mg	-	1249	O
/	-	1251	O
kg	-	1252	O
)	-	1254	O
produced	-	1256	O
an	-	1265	O
anxiogenic	-	1268	O
effect	-	1279	O
,	-	1285	O
apparent	-	1287	O
with	-	1296	O
decreases	-	1301	O
in	-	1311	O
open	-	1314	O
-	-	1318	O
arm	-	1319	O
time	-	1323	O
and	-	1328	O
entry	-	1332	O
.	-	1337	O

Nicotine	15991002	1339	O
(	-	1348	O
0	-	1349	O
.	-	1350	O
25	-	1351	O
mg	-	1354	O
/	-	1356	O
kg	-	1357	O
)	-	1359	O
pretreatment	-	1361	O
blocked	-	1374	O
the	-	1382	O
caffeine	-	1386	O
-	-	1394	O
but	-	1396	O
not	-	1400	O
pentylenetetrazole	-	1404	O
-	-	1422	O
induced	-	1423	O
anxiety	-	1431	B
.	-	1438	O

Administration	15991002	1440	O
of	-	1455	O
each	-	1458	O
drug	-	1463	O
and	-	1468	O
their	-	1472	O
combinations	-	1478	O
did	-	1491	O
not	-	1495	O
produce	-	1499	O
any	-	1507	O
effect	-	1511	O
on	-	1518	O
locomotor	-	1521	O
activity	-	1531	O
.	-	1539	O

CONCLUSIONS	15991002	1541	O
:	-	1552	O

Our	15991002	1554	O
results	-	1558	O
suggest	-	1566	O
that	-	1574	O
the	-	1579	O
antagonistic	-	1583	O
effect	-	1596	O
of	-	1603	O
nicotine	-	1606	O
on	-	1615	O
caffeine	-	1618	O
-	-	1626	O
induced	-	1627	O
anxiety	-	1635	B
is	-	1643	O
specific	-	1646	O
to	-	1655	O
caffeine	-	1658	O
,	-	1666	O
instead	-	1668	O
of	-	1676	O
a	-	1679	O
non	-	1681	O
-	-	1684	O
specific	-	1685	O
anxiolytic	-	1694	O
effect	-	1705	O
.	-	1711	O

Thus	15991002	1713	O
,	-	1717	O
it	-	1719	O
may	-	1722	O
extend	-	1726	O
the	-	1733	O
current	-	1737	O
findings	-	1745	O
on	-	1754	O
the	-	1757	O
interaction	-	1761	O
between	-	1773	O
nicotine	-	1781	O
and	-	1790	O
caffeine	-	1794	O
.	-	1802	O

Long	16034922	0	O
term	-	5	O
hormone	-	10	O
therapy	-	18	O
for	-	26	O
perimenopausal	-	30	O
and	-	45	O
postmenopausal	-	49	O
women	-	64	O
.	-	69	O

BACKGROUND	16034922	71	O
:	-	81	O

Hormone	16034922	83	O
therapy	-	91	O
(	-	99	O
HT	-	100	O
)	-	102	O
is	-	104	O
widely	-	107	O
used	-	114	O
for	-	119	O
controlling	-	123	O
menopausal	-	135	B
symptoms	-	146	I
.	-	154	O

It	16034922	156	O
has	-	159	O
also	-	163	O
been	-	168	O
used	-	173	O
for	-	178	O
the	-	182	O
management	-	186	O
and	-	197	O
prevention	-	201	O
of	-	212	O
cardiovascular	-	215	B
disease	-	230	I
,	-	237	O
osteoporosis	-	239	B
and	-	252	O
dementia	-	256	B
in	-	265	O
older	-	268	O
women	-	274	O
but	-	280	O
the	-	284	O
evidence	-	288	O
supporting	-	297	O
its	-	308	O
use	-	312	O
for	-	316	O
these	-	320	O
indications	-	326	O
is	-	338	O
largely	-	341	O
observational	-	349	O
.	-	362	O

OBJECTIVES	16034922	364	O
:	-	374	O

To	16034922	376	O
assess	-	379	O
the	-	386	O
effect	-	390	O
of	-	397	O
long	-	400	O
-	-	404	O
term	-	405	O
HT	-	410	O
on	-	413	O
mortality	-	416	O
,	-	425	O
heart	-	427	B
disease	-	433	I
,	-	440	O
venous	-	442	B
thromboembolism	-	449	I
,	-	464	O
stroke	-	466	B
,	-	472	O
transient	-	474	B
ischaemic	-	484	I
attacks	-	494	I
,	-	501	O
breast	-	503	B
cancer	-	510	I
,	-	516	O
colorectal	-	518	B
cancer	-	529	I
,	-	535	O
ovarian	-	537	B
cancer	-	545	I
,	-	551	O
endometrial	-	553	B
cancer	-	565	I
,	-	571	O
gallbladder	-	573	B
disease	-	585	I
,	-	592	O
cognitive	-	594	O
function	-	604	O
,	-	612	O
dementia	-	614	B
,	-	622	O
fractures	-	624	B
and	-	634	O
quality	-	638	O
of	-	646	O
life	-	649	O
.	-	653	O

SEARCH	16034922	655	O
STRATEGY	-	662	O
:	-	670	O

We	16034922	672	O
searched	-	675	O
the	-	684	O
following	-	688	O
databases	-	698	O
up	-	708	O
to	-	711	O
November	-	714	O
2004	-	723	O
:	-	727	O
the	-	729	O
Cochrane	-	733	O
Menstrual	-	742	O
Disorders	-	752	O
and	-	762	O
Subfertility	-	766	O
Group	-	779	O
Trials	-	785	O
Register	-	792	O
,	-	800	O
Cochrane	-	802	O
Central	-	811	O
Register	-	819	O
of	-	828	O
Controlled	-	831	O
Trials	-	842	O
(	-	849	O
CENTRAL	-	850	O
)	-	857	O
,	-	858	O
MEDLINE	-	860	O
,	-	867	O
EMBASE	-	869	O
,	-	875	O
Biological	-	877	O
Abstracts	-	888	O
.	-	897	O

Relevant	16034922	899	O
non	-	908	O
-	-	911	O
indexed	-	912	O
journals	-	920	O
and	-	929	O
conference	-	933	O
abstracts	-	944	O
were	-	954	O
also	-	959	O
searched	-	964	O
.	-	972	O

SELECTION	16034922	974	O
CRITERIA	-	984	O
:	-	992	O

Randomised	16034922	994	O
double	-	1005	O
-	-	1011	O
blind	-	1012	O
trials	-	1018	O
of	-	1025	O
HT	-	1028	O
(	-	1031	O
oestrogens	-	1032	O
with	-	1043	O
or	-	1048	O
without	-	1051	O
progestogens	-	1059	O
)	-	1071	O
versus	-	1073	O
placebo	-	1080	O
,	-	1087	O
taken	-	1089	O
for	-	1095	O
at	-	1099	O
least	-	1102	O
one	-	1108	O
year	-	1112	O
by	-	1117	O
perimenopausal	-	1120	O
or	-	1135	O
postmenopausal	-	1138	O
women	-	1153	O
.	-	1158	O

DATA	16034922	1160	O
COLLECTION	-	1165	O
AND	-	1176	O
ANALYSIS	-	1180	O
:	-	1188	O

Fifteen	16034922	1190	O
RCTs	-	1198	O
were	-	1203	O
included	-	1208	O
.	-	1216	O

Trials	16034922	1218	O
were	-	1225	O
assessed	-	1230	O
for	-	1239	O
quality	-	1243	O
and	-	1251	O
two	-	1255	O
review	-	1259	O
authors	-	1266	O
extracted	-	1274	O
data	-	1284	O
independently	-	1289	O
.	-	1302	O

They	16034922	1304	O
calculated	-	1309	O
risk	-	1320	O
ratios	-	1325	O
for	-	1332	O
dichotomous	-	1336	O
outcomes	-	1348	O
and	-	1357	O
weighted	-	1361	O
mean	-	1370	O
differences	-	1375	O
for	-	1387	O
continuous	-	1391	O
outcomes	-	1402	O
.	-	1410	O

Clinical	16034922	1412	O
heterogeneity	-	1421	O
precluded	-	1435	O
meta	-	1445	O
-	-	1449	O
analysis	-	1450	O
for	-	1459	O
most	-	1463	O
outcomes	-	1468	O
.	-	1476	O

MAIN	16034922	1478	O
RESULTS	-	1483	O
:	-	1490	O

All	16034922	1492	O
the	-	1496	O
statistically	-	1500	O
significant	-	1514	O
results	-	1526	O
were	-	1534	O
derived	-	1539	O
from	-	1547	O
the	-	1552	O
two	-	1556	O
biggest	-	1560	O
trials	-	1568	O
.	-	1574	O

In	16034922	1576	O
relatively	-	1579	O
healthy	-	1590	O
women	-	1598	O
,	-	1603	O
combined	-	1605	O
continuous	-	1614	O
HT	-	1625	O
significantly	-	1628	O
increased	-	1642	O
the	-	1652	O
risk	-	1656	O
of	-	1661	O
venous	-	1664	B
thromboembolism	-	1671	I
or	-	1687	O
coronary	-	1690	O
event	-	1699	O
(	-	1705	O
after	-	1706	O
one	-	1712	O
year	-	1716	O
's	-	1720	O
use	-	1723	O
)	-	1726	O
,	-	1727	O
stroke	-	1729	B
(	-	1736	O
after	-	1737	O
3	-	1743	O
years	-	1745	O
)	-	1750	O
,	-	1751	O
breast	-	1753	B
cancer	-	1760	I
(	-	1767	O
after	-	1768	O
5	-	1774	O
years	-	1776	O
)	-	1781	O
and	-	1783	O
gallbladder	-	1787	B
disease	-	1799	I
.	-	1806	O

Long	16034922	1808	O
-	-	1812	O
term	-	1813	O
oestrogen	-	1818	O
-	-	1827	O
only	-	1828	O
HT	-	1833	O
also	-	1836	O
significantly	-	1841	O
increased	-	1855	O
the	-	1865	O
risk	-	1869	O
of	-	1874	O
stroke	-	1877	B
and	-	1884	O
gallbladder	-	1888	B
disease	-	1900	I
.	-	1907	O

Overall	16034922	1909	O
,	-	1916	O
the	-	1918	O
only	-	1922	O
statistically	-	1927	O
significant	-	1941	O
benefits	-	1953	O
of	-	1962	O
HT	-	1965	O
were	-	1968	O
a	-	1973	O
decreased	-	1975	O
incidence	-	1985	O
of	-	1995	O
fractures	-	1998	B
and	-	2008	O
colon	-	2012	B
cancer	-	2018	I
with	-	2025	O
long	-	2030	O
-	-	2034	O
term	-	2035	O
use	-	2040	O
.	-	2043	O

Among	16034922	2045	O
relatively	-	2051	O
healthy	-	2062	O
women	-	2070	O
over	-	2076	O
65	-	2081	O
years	-	2084	O
taking	-	2090	O
continuous	-	2097	O
combined	-	2108	O
HT	-	2117	O
,	-	2119	O
there	-	2121	O
was	-	2127	O
a	-	2131	O
statistically	-	2133	O
significant	-	2147	O
increase	-	2159	O
in	-	2168	O
the	-	2171	O
incidence	-	2175	O
of	-	2185	O
dementia	-	2188	B
.	-	2196	O

Among	16034922	2198	O
women	-	2204	O
with	-	2210	O
cardiovascular	-	2215	B
disease	-	2230	I
,	-	2237	O
long	-	2239	O
-	-	2243	O
term	-	2244	O
use	-	2249	O
of	-	2253	O
combined	-	2256	O
continuous	-	2265	O
HT	-	2276	O
significantly	-	2279	O
increased	-	2293	O
the	-	2303	O
risk	-	2307	O
of	-	2312	O
venous	-	2315	B
thromboembolism	-	2322	I
.	-	2337	O

No	16034922	2339	O
trials	-	2342	O
focussed	-	2349	O
specifically	-	2358	O
on	-	2371	O
younger	-	2374	O
women	-	2382	O
.	-	2387	O

However	16034922	2389	O
,	-	2396	O
one	-	2398	O
trial	-	2402	O
analysed	-	2408	O
subgroups	-	2417	O
of	-	2427	O
2839	-	2430	O
relatively	-	2435	O
healthy	-	2446	O
50	-	2454	O
to	-	2457	O
59	-	2460	O
year	-	2463	O
-	-	2467	O
old	-	2468	O
women	-	2472	O
taking	-	2478	O
combined	-	2485	O
continuous	-	2494	O
HT	-	2505	O
and	-	2508	O
1637	-	2512	O
taking	-	2517	O
oestrogen	-	2524	O
-	-	2533	O
only	-	2534	O
HT	-	2539	O
,	-	2541	O
versus	-	2543	O
similar	-	2550	O
-	-	2557	O
sized	-	2558	O
placebo	-	2564	O
groups	-	2572	O
.	-	2578	O

The	16034922	2580	O
only	-	2584	O
significantly	-	2589	O
increased	-	2603	O
risk	-	2613	O
reported	-	2618	O
was	-	2627	O
for	-	2631	O
venous	-	2635	B
thromboembolism	-	2642	I
in	-	2658	O
women	-	2661	O
taking	-	2667	O
combined	-	2674	O
continuous	-	2683	O
HT	-	2694	O
;	-	2696	O
their	-	2698	O
absolute	-	2704	O
risk	-	2713	O
remained	-	2718	O
very	-	2727	O
low	-	2732	O
.	-	2735	O

AUTHORS	16034922	2737	O
'	-	2744	O
CONCLUSIONS	-	2746	O
:	-	2757	O

HT	16034922	2759	O
is	-	2762	O
not	-	2765	O
indicated	-	2769	O
for	-	2779	O
the	-	2783	O
routine	-	2787	O
management	-	2795	O
of	-	2806	O
chronic	-	2809	B
disease	-	2817	I
.	-	2824	O

We	16034922	2826	O
need	-	2829	O
more	-	2834	O
evidence	-	2839	O
on	-	2848	O
the	-	2851	O
safety	-	2855	O
of	-	2862	O
HT	-	2865	O
for	-	2868	O
menopausal	-	2872	O
symptom	-	2883	O
control	-	2891	O
,	-	2898	O
though	-	2900	O
short	-	2907	O
-	-	2912	O
term	-	2913	O
use	-	2918	O
appears	-	2922	O
to	-	2930	O
be	-	2933	O
relatively	-	2936	O
safe	-	2947	O
for	-	2952	O
healthy	-	2956	O
younger	-	2964	O
women	-	2972	O
.	-	2977	O

Drug	16083708	0	B
-	-	4	I
induced	-	5	I
liver	-	13	I
injury	-	19	I
:	-	25	O
an	-	27	O
analysis	-	30	O
of	-	39	O
461	-	42	O
incidences	-	46	O
submitted	-	57	O
to	-	67	O
the	-	70	O
Spanish	-	74	O
registry	-	82	O
over	-	91	O
a	-	96	O
10	-	98	O
-	-	100	O
year	-	101	O
period	-	106	O
.	-	112	O

BACKGROUND	16083708	114	O
&	-	125	O
AIMS	-	127	O
:	-	131	O

Progress	16083708	133	O
in	-	142	O
the	-	145	O
understanding	-	149	O
of	-	163	O
susceptibility	-	166	O
factors	-	181	O
to	-	189	O
drug	-	192	B
-	-	196	I
induced	-	197	I
liver	-	205	I
injury	-	211	I
(	-	218	O
DILI	-	219	B
)	-	223	O
and	-	225	O
outcome	-	229	O
predictability	-	237	O
are	-	252	O
hampered	-	256	O
by	-	265	O
the	-	268	O
lack	-	272	O
of	-	277	O
systematic	-	280	O
programs	-	291	O
to	-	300	O
detect	-	303	O
bona	-	310	O
fide	-	315	O
cases	-	320	O
.	-	325	O

METHODS	16083708	327	O
:	-	334	O

A	16083708	336	O
cooperative	-	338	O
network	-	350	O
was	-	358	O
created	-	362	O
in	-	370	O
1994	-	373	O
in	-	378	O
Spain	-	381	O
to	-	387	O
identify	-	390	O
all	-	399	O
suspicions	-	403	O
of	-	414	O
DILI	-	417	B
following	-	422	O
a	-	432	O
prospective	-	434	O
structured	-	446	O
report	-	457	O
form	-	464	O
.	-	468	O

The	16083708	470	O
liver	-	474	B
damage	-	480	I
was	-	487	O
characterized	-	491	O
according	-	505	O
to	-	515	O
hepatocellular	-	518	O
,	-	532	O
cholestatic	-	534	B
,	-	545	O
and	-	547	O
mixed	-	551	O
laboratory	-	557	O
criteria	-	568	O
and	-	577	O
to	-	581	O
histologic	-	584	O
criteria	-	595	O
when	-	604	O
available	-	609	O
.	-	618	O

Further	16083708	620	O
evaluation	-	628	O
of	-	639	O
causality	-	642	O
assessment	-	652	O
was	-	663	O
centrally	-	667	O
performed	-	677	O
.	-	686	O

RESULTS	16083708	688	O
:	-	695	O

Since	16083708	697	O
April	-	703	O
1994	-	709	O
to	-	714	O
August	-	717	O
2004	-	724	O
,	-	728	O
461	-	730	O
out	-	734	O
of	-	738	O
570	-	741	O
submitted	-	745	O
cases	-	755	O
,	-	760	O
involving	-	762	O
505	-	772	O
drugs	-	776	O
,	-	781	O
were	-	783	O
deemed	-	788	O
to	-	795	O
be	-	798	O
related	-	801	O
to	-	809	O
DILI	-	812	B
.	-	816	O

The	16083708	818	O
antiinfective	-	822	O
group	-	836	O
of	-	842	O
drugs	-	845	O
was	-	851	O
the	-	855	O
more	-	859	O
frequently	-	864	O
incriminated	-	875	O
,	-	887	O
amoxicillin	-	889	O
-	-	900	O
clavulanate	-	901	O
accounting	-	913	O
for	-	924	O
the	-	928	O
12	-	932	O
.	-	934	O
8	-	935	O
%	-	936	O
of	-	938	O
the	-	941	O
whole	-	945	O
series	-	951	O
.	-	957	O

The	16083708	959	O
hepatocellular	-	963	O
pattern	-	978	O
of	-	986	O
damage	-	989	O
was	-	996	O
the	-	1000	O
most	-	1004	O
common	-	1009	O
(	-	1016	O
58	-	1017	O
%	-	1019	O
)	-	1020	O
,	-	1021	O
was	-	1023	O
inversely	-	1027	O
correlated	-	1037	O
with	-	1048	O
age	-	1053	O
(	-	1057	O
P	-	1058	O
<	-	1060	O
.	-	1062	O
0001	-	1063	O
)	-	1067	O
,	-	1068	O
and	-	1070	O
had	-	1074	O
the	-	1078	O
worst	-	1082	O
outcome	-	1088	O
(	-	1096	O
Cox	-	1097	O
regression	-	1101	O
,	-	1111	O
P	-	1113	O
<	-	1115	O
.	-	1117	O
034	-	1118	O
)	-	1121	O
.	-	1122	O

Indeed	16083708	1124	O
,	-	1130	O
the	-	1132	O
incidence	-	1136	O
of	-	1146	O
liver	-	1149	O
transplantation	-	1155	O
and	-	1171	O
death	-	1175	O
in	-	1181	O
this	-	1184	O
group	-	1189	O
was	-	1195	O
11	-	1199	O
.	-	1201	O
7	-	1202	O
%	-	1203	O
if	-	1205	O
patients	-	1208	O
had	-	1217	O
jaundice	-	1221	B
at	-	1230	O
presentation	-	1233	O
,	-	1245	O
whereas	-	1247	O
the	-	1255	O
corresponding	-	1259	O
figure	-	1273	O
was	-	1280	O
3	-	1284	O
.	-	1285	O
8	-	1286	O
%	-	1287	O
in	-	1289	O
nonjaundiced	-	1292	O
patients	-	1305	O
(	-	1314	O
P	-	1315	O
<	-	1317	O
.	-	1319	O
04	-	1320	O
)	-	1322	O
.	-	1323	O

Factors	16083708	1325	O
associated	-	1333	O
with	-	1344	O
the	-	1349	O
development	-	1353	O
of	-	1365	O
fulminant	-	1368	B
hepatic	-	1378	I
failure	-	1386	I
were	-	1394	O
female	-	1399	O
sex	-	1406	O
(	-	1410	O
OR	-	1411	O
=	-	1414	O
25	-	1416	O
;	-	1418	O
95	-	1420	O
%	-	1422	O
CI	-	1424	O
:	-	1426	O
4	-	1428	O
.	-	1429	O
1	-	1430	O
-	-	1431	O
151	-	1432	O
;	-	1435	O
P	-	1437	O
<	-	1439	O
.	-	1441	O
0001	-	1442	O
)	-	1446	O
,	-	1447	O
hepatocellular	-	1449	O
damage	-	1464	O
(	-	1471	O
OR	-	1472	O
=	-	1475	O
7	-	1477	O
.	-	1478	O
9	-	1479	O
;	-	1480	O
95	-	1482	O
%	-	1484	O
CI	-	1486	O
:	-	1488	O
1	-	1490	O
.	-	1491	O
6	-	1492	O
-	-	1493	O
37	-	1494	O
;	-	1496	O
P	-	1498	O
<	-	1500	O
.	-	1502	O
009	-	1503	O
)	-	1506	O
,	-	1507	O
and	-	1509	O
higher	-	1513	O
baseline	-	1520	O
plasma	-	1529	O
bilirubin	-	1536	O
value	-	1546	O
(	-	1552	O
OR	-	1553	O
=	-	1556	O
1	-	1558	O
.	-	1559	O
15	-	1560	O
;	-	1562	O
95	-	1564	O
%	-	1566	O
CI	-	1568	O
:	-	1570	O
1	-	1572	O
.	-	1573	O
09	-	1574	O
-	-	1576	O
1	-	1577	O
.	-	1578	O
22	-	1579	O
;	-	1581	O
P	-	1583	O
<	-	1585	O
.	-	1587	O
0001	-	1588	O
)	-	1592	O
.	-	1593	O

CONCLUSIONS	16083708	1595	O
:	-	1606	O

Patients	16083708	1608	O
with	-	1617	O
drug	-	1622	O
-	-	1626	O
induced	-	1627	O
hepatocellular	-	1635	O
jaundice	-	1650	B
have	-	1659	O
11	-	1664	O
.	-	1666	O
7	-	1667	O
%	-	1668	O
chance	-	1670	O
of	-	1677	O
progressing	-	1680	O
to	-	1692	O
death	-	1695	O
or	-	1701	O
transplantation	-	1704	O
.	-	1719	O

Amoxicillin	16083708	1721	O
-	-	1732	O
clavulanate	-	1733	O
stands	-	1745	O
out	-	1752	O
as	-	1756	O
the	-	1759	O
most	-	1763	O
common	-	1768	O
drug	-	1775	O
related	-	1780	O
to	-	1788	O
DILI	-	1791	B
.	-	1795	O

Morphological	16092435	0	O
evaluation	-	14	O
of	-	25	O
the	-	28	O
effect	-	32	O
of	-	39	O
d	-	42	O
-	-	43	O
ribose	-	44	O
on	-	51	O
adriamycin	-	54	O
-	-	64	O
evoked	-	65	O
cardiotoxicity	-	72	B
in	-	87	O
rats	-	90	O
.	-	94	O

The	16092435	96	O
influence	-	100	O
of	-	110	O
d	-	113	O
-	-	114	O
ribose	-	115	O
on	-	122	O
adriamycin	-	125	O
-	-	135	O
induced	-	136	O
myocardiopathy	-	144	B
in	-	159	O
rats	-	162	O
was	-	167	O
studied	-	171	O
.	-	178	O

Adriamycin	16092435	180	O
in	-	191	O
the	-	194	O
cumulative	-	198	O
dose	-	209	O
of	-	214	O
25	-	217	O
mg	-	220	O
/	-	222	O
kg	-	223	O
evoked	-	226	O
fully	-	233	O
developed	-	239	O
cardiac	-	249	B
toxicity	-	257	I
.	-	265	O

D	16092435	267	O
-	-	268	O
ribose	-	269	O
in	-	276	O
the	-	279	O
multiple	-	283	O
doses	-	292	O
of	-	298	O
200	-	301	O
mg	-	305	O
/	-	307	O
kg	-	308	O
did	-	311	O
not	-	315	O
influence	-	319	O
ADR	-	329	O
cardiotoxicity	-	333	B
.	-	347	O

In	16112787	0	O
vivo	-	3	O
evidences	-	8	O
suggesting	-	18	O
the	-	29	O
role	-	33	O
of	-	38	O
oxidative	-	41	O
stress	-	51	O
in	-	58	O
pathogenesis	-	61	O
of	-	74	O
vancomycin	-	77	O
-	-	87	O
induced	-	88	O
nephrotoxicity	-	96	B
:	-	110	O
protection	-	112	O
by	-	123	O
erdosteine	-	126	O
.	-	136	O

The	16112787	138	O
aims	-	142	O
of	-	147	O
this	-	150	O
study	-	155	O
were	-	161	O
to	-	166	O
examine	-	169	O
vancomycin	-	177	O
(	-	188	O
VCM	-	189	O
)	-	192	O
-	-	193	O
induced	-	194	O
oxidative	-	202	O
stress	-	212	O
that	-	219	O
promotes	-	224	O
production	-	233	O
of	-	244	O
reactive	-	247	O
oxygen	-	256	O
species	-	263	O
(	-	271	O
ROS	-	272	O
)	-	275	O
and	-	277	O
to	-	281	O
investigate	-	284	O
the	-	296	O
role	-	300	O
of	-	305	O
erdosteine	-	308	O
,	-	318	O
an	-	320	O
expectorant	-	323	O
agent	-	335	O
,	-	340	O
which	-	342	O
has	-	348	O
also	-	352	O
antioxidant	-	357	O
properties	-	369	O
,	-	379	O
on	-	381	O
kidney	-	384	O
tissue	-	391	O
against	-	398	O
the	-	406	O
possible	-	410	O
VCM	-	419	O
-	-	422	O
induced	-	423	O
renal	-	431	B
impairment	-	437	I
in	-	448	O
rats	-	451	O
.	-	455	O

Rats	16112787	457	O
were	-	462	O
divided	-	467	O
into	-	475	O
three	-	480	O
groups	-	486	O
:	-	492	O
sham	-	494	O
,	-	498	O
VCM	-	500	O
and	-	504	O
VCM	-	508	O
plus	-	512	O
erdosteine	-	517	O
.	-	527	O

VCM	16112787	529	O
was	-	533	O
administrated	-	537	O
intraperitoneally	-	551	O
(	-	569	O
i	-	570	O
.	-	571	O
p	-	572	O
.	-	573	O
)	-	574	O
with	-	576	O
200mgkg	-	581	O
(	-	588	O
-	-	589	O
1	-	590	O
)	-	591	O
twice	-	593	O
daily	-	599	O
for	-	605	O
7	-	609	O
days	-	611	O
.	-	615	O

Erdosteine	16112787	617	O
was	-	628	O
administered	-	632	O
orally	-	645	O
.	-	651	O

VCM	16112787	653	O
administration	-	657	O
to	-	672	O
control	-	675	O
rats	-	683	O
significantly	-	688	O
increased	-	702	O
renal	-	712	O
malondialdehyde	-	718	O
(	-	734	O
MDA	-	735	O
)	-	738	O
and	-	740	O
urinary	-	744	O
N	-	752	O
-	-	753	O
acetyl	-	754	O
-	-	760	O
beta	-	761	O
-	-	765	O
d	-	766	O
-	-	767	O
glucosaminidase	-	768	O
(	-	784	O
NAG	-	785	O
,	-	788	O
a	-	790	O
marker	-	792	O
of	-	799	O
renal	-	802	B
tubular	-	808	I
injury	-	816	I
)	-	822	O
excretion	-	824	O
but	-	834	O
decreased	-	838	O
superoxide	-	848	O
dismutase	-	859	O
(	-	869	O
SOD	-	870	O
)	-	873	O
and	-	875	O
catalase	-	879	O
(	-	888	O
CAT	-	889	O
)	-	892	O
activities	-	894	O
.	-	904	O

Erdosteine	16112787	906	O
administration	-	917	O
with	-	932	O
VCM	-	937	O
injections	-	941	O
caused	-	952	O
significantly	-	959	O
decreased	-	973	O
renal	-	983	O
MDA	-	989	O
and	-	993	O
urinary	-	997	O
NAG	-	1005	O
excretion	-	1009	O
,	-	1018	O
and	-	1020	O
increased	-	1024	O
SOD	-	1034	O
activity	-	1038	O
,	-	1046	O
but	-	1048	O
not	-	1052	O
CAT	-	1056	O
activity	-	1060	O
in	-	1069	O
renal	-	1072	O
tissue	-	1078	O
when	-	1085	O
compared	-	1090	O
with	-	1099	O
VCM	-	1104	O
alone	-	1108	O
.	-	1113	O

Erdosteine	16112787	1115	O
showed	-	1126	O
histopathological	-	1133	O
protection	-	1151	O
against	-	1162	O
VCM	-	1170	O
-	-	1173	O
induced	-	1174	O
nephrotoxicity	-	1182	B
.	-	1196	O

There	16112787	1198	O
were	-	1204	O
a	-	1209	O
significant	-	1211	O
dilatation	-	1223	O
of	-	1234	O
tubular	-	1237	O
lumens	-	1245	O
,	-	1251	O
extensive	-	1253	O
epithelial	-	1263	O
cell	-	1274	O
vacuolization	-	1279	O
,	-	1292	O
atrophy	-	1294	B
,	-	1301	O
desquamation	-	1303	B
,	-	1315	O
and	-	1317	O
necrosis	-	1321	B
in	-	1330	O
VCM	-	1333	O
-	-	1336	O
treated	-	1337	O
rats	-	1345	O
more	-	1350	O
than	-	1355	O
those	-	1360	O
of	-	1366	O
the	-	1369	O
control	-	1373	O
and	-	1381	O
the	-	1385	O
erdosteine	-	1389	O
groups	-	1400	O
.	-	1406	O

Erdosteine	16112787	1408	O
caused	-	1419	O
a	-	1426	O
marked	-	1428	O
reduction	-	1435	O
in	-	1445	O
the	-	1448	O
extent	-	1452	O
of	-	1459	O
tubular	-	1462	O
damage	-	1470	O
.	-	1476	O

It	16112787	1478	O
is	-	1481	O
concluded	-	1484	O
that	-	1494	O
oxidative	-	1499	O
tubular	-	1509	O
damage	-	1517	O
plays	-	1524	O
an	-	1530	O
important	-	1533	O
role	-	1543	O
in	-	1548	O
the	-	1551	O
VCM	-	1555	O
-	-	1558	O
induced	-	1559	O
nephrotoxicity	-	1567	B
and	-	1582	O
the	-	1586	O
modulation	-	1590	O
of	-	1601	O
oxidative	-	1604	O
stress	-	1614	O
with	-	1621	O
erdosteine	-	1626	O
reduces	-	1637	O
the	-	1645	O
VCM	-	1649	O
-	-	1652	O
induced	-	1653	O
kidney	-	1661	B
damage	-	1668	I
both	-	1675	O
at	-	1680	O
the	-	1683	O
biochemical	-	1687	O
and	-	1699	O
histological	-	1703	O
levels	-	1716	O
.	-	1722	O

Does	16309808	0	O
domperidone	-	5	O
potentiate	-	17	O
mirtazapine	-	28	O
-	-	39	O
associated	-	40	O
restless	-	51	B
legs	-	60	I
syndrome	-	65	I
?	-	73	O

There	16309808	75	O
is	-	81	O
now	-	84	O
evidence	-	88	O
to	-	97	O
suggest	-	100	O
a	-	108	O
central	-	110	O
role	-	118	O
for	-	123	O
the	-	127	O
dopaminergic	-	131	O
system	-	144	O
in	-	151	O
restless	-	154	B
legs	-	163	I
syndrome	-	168	I
(	-	177	O
RLS	-	178	B
)	-	181	O
.	-	182	O

For	16309808	184	O
example	-	188	O
,	-	195	O
the	-	197	O
symptoms	-	201	O
of	-	210	O
RLS	-	213	B
can	-	217	O
be	-	221	O
dramatically	-	224	O
improved	-	237	O
by	-	246	O
levodopa	-	249	O
and	-	258	O
dopamine	-	262	O
agonists	-	271	O
,	-	279	O
whereas	-	281	O
central	-	289	O
dopamine	-	297	O
D2	-	306	O
receptor	-	309	O
antagonists	-	318	O
can	-	330	O
induce	-	334	O
or	-	341	O
aggravate	-	344	O
RLS	-	354	B
symptoms	-	358	O
.	-	366	O

To	16309808	368	O
our	-	371	O
knowledge	-	375	O
,	-	384	O
there	-	386	O
is	-	392	O
no	-	395	O
previous	-	398	O
report	-	407	O
regarding	-	414	O
whether	-	424	O
domperidone	-	432	O
,	-	443	O
a	-	445	O
peripheral	-	447	O
dopamine	-	458	O
D2	-	467	O
receptor	-	470	O
antagonist	-	479	O
,	-	489	O
can	-	491	O
also	-	495	O
induce	-	500	O
or	-	507	O
aggravate	-	510	O
symptoms	-	520	O
of	-	529	O
RLS	-	532	B
.	-	535	O

Mirtazapine	16309808	537	O
,	-	548	O
the	-	550	O
first	-	554	O
noradrenergic	-	560	O
and	-	574	O
specific	-	578	O
serotonergic	-	587	O
antidepressant	-	600	O
(	-	615	O
NaSSA	-	616	O
)	-	621	O
,	-	622	O
has	-	624	O
been	-	628	O
associated	-	633	O
with	-	644	O
RLS	-	649	B
in	-	653	O
several	-	656	O
recent	-	664	O
publications	-	671	O
.	-	683	O

The	16309808	685	O
authors	-	689	O
report	-	697	O
here	-	704	O
a	-	709	O
depressed	-	711	O
patient	-	721	O
comorbid	-	729	O
with	-	738	O
postprandial	-	743	B
dyspepsia	-	756	I
who	-	766	O
developed	-	770	O
RLS	-	780	B
after	-	784	O
mirtazapine	-	790	O
had	-	802	O
been	-	806	O
added	-	811	O
to	-	817	O
his	-	820	O
domperidone	-	824	O
therapy	-	836	O
.	-	843	O

Our	16309808	845	O
patient	-	849	O
started	-	857	O
to	-	865	O
have	-	868	O
symptoms	-	873	O
of	-	882	O
RLS	-	885	B
only	-	889	O
after	-	894	O
he	-	900	O
had	-	903	O
been	-	907	O
treated	-	912	O
with	-	920	O
mirtazapine	-	925	O
,	-	936	O
and	-	938	O
his	-	942	O
RLS	-	946	B
symptoms	-	950	O
resolved	-	959	O
completely	-	968	O
upon	-	979	O
discontinuation	-	984	O
of	-	1000	O
his	-	1003	O
mirtazapine	-	1007	O
.	-	1018	O

Such	16309808	1020	O
a	-	1025	O
temporal	-	1027	O
relationship	-	1036	O
between	-	1049	O
the	-	1057	O
use	-	1061	O
of	-	1065	O
mirtazapine	-	1068	O
and	-	1080	O
the	-	1084	O
symptoms	-	1088	O
of	-	1097	O
RLS	-	1100	B
in	-	1104	O
our	-	1107	O
patient	-	1111	O
did	-	1119	O
not	-	1123	O
support	-	1127	O
a	-	1135	O
potentiating	-	1137	O
effect	-	1150	O
of	-	1157	O
domperione	-	1160	O
on	-	1171	O
mirtazapine	-	1174	O
-	-	1185	O
associated	-	1186	O
RLS	-	1197	B
.	-	1200	O

However	16309808	1202	O
,	-	1209	O
physicians	-	1211	O
should	-	1222	O
be	-	1229	O
aware	-	1232	O
of	-	1238	O
the	-	1241	O
possibility	-	1245	O
that	-	1257	O
mirtazapine	-	1262	O
can	-	1274	O
be	-	1278	O
associated	-	1281	O
with	-	1292	O
RLS	-	1297	B
in	-	1301	O
some	-	1304	O
individuals	-	1309	O
,	-	1320	O
especially	-	1322	O
those	-	1333	O
receiving	-	1339	O
concomitant	-	1349	O
dopamine	-	1361	O
D2	-	1370	O
receptor	-	1373	O
antagonists	-	1382	O
.	-	1393	O

Antiandrogenic	16323982	0	O
therapy	-	15	O
can	-	23	O
cause	-	27	O
coronary	-	33	B
arterial	-	42	I
disease	-	51	I
.	-	58	O

AIM	16323982	60	O
:	-	63	O

To	16323982	65	O
study	-	68	O
the	-	74	O
change	-	78	O
of	-	85	O
lipid	-	88	O
metabolism	-	94	O
by	-	105	O
antiandrogen	-	108	O
therapy	-	121	O
in	-	129	O
patients	-	132	O
with	-	141	O
prostate	-	146	B
cancer	-	155	I
.	-	161	O

MATERIALS	16323982	163	O
AND	-	173	O
METHODS	-	177	O
:	-	184	O

We	16323982	186	O
studied	-	189	O
with	-	197	O
a	-	202	O
2	-	204	O
.	-	205	O
5	-	206	O
years	-	208	O
follow	-	214	O
-	-	220	O
up	-	221	O
the	-	224	O
changes	-	228	O
in	-	236	O
plasma	-	239	O
cholesterols	-	246	O
(	-	259	O
C	-	260	O
)	-	261	O
,	-	262	O
triglycerides	-	264	O
(	-	278	O
TG	-	279	O
)	-	281	O
,	-	282	O
lipoproteins	-	284	O
(	-	297	O
LP	-	298	O
)	-	300	O
,	-	301	O
and	-	303	O
apolipoproteins	-	307	O
(	-	323	O
Apo	-	324	O
)	-	327	O

B	16323982	329	O
-	-	330	O
100	-	331	O
,	-	334	O
A	-	336	O
-	-	337	O
I	-	338	O
,	-	339	O
and	-	341	O
A	-	345	O
-	-	346	O
II	-	347	O
pro	-	350	O
fi	-	354	O
les	-	357	O
in	-	361	O
24	-	364	O
patients	-	367	O
of	-	376	O
mean	-	379	O
age	-	384	O

60	16323982	388	O
years	-	391	O
with	-	397	O
low	-	402	O
risk	-	406	O
prostate	-	411	B
cancer	-	420	I
(	-	427	O
stage	-	428	O
:	-	433	O
T1cN0M0	-	435	O
,	-	442	O
Gleason	-	444	O

score	16323982	452	O
:	-	457	O
2	-	459	O
-	-	460	O
5	-	461	O
)	-	462	O
during	-	464	O
treatment	-	471	O
with	-	481	O
cyproterone	-	486	O
acetate	-	498	O
(	-	506	O
CPA	-	507	O
)	-	510	O
without	-	512	O
surgical	-	520	O
management	-	529	O
or	-	540	O
radiation	-	543	O
therapy	-	553	O
.	-	560	O

RESULTS	16323982	562	O
:	-	569	O

Significant	16323982	571	O
decreases	-	583	O
of	-	593	O
HDL	-	596	O
-	-	599	O
C	-	600	O
,	-	601	O
Apo	-	603	O
A	-	607	O

-	16323982	608	O
I	-	609	O
and	-	611	O
Apo	-	615	O
A	-	619	O
-	-	620	O
II	-	621	O
and	-	624	O
an	-	628	O
increase	-	631	O
of	-	640	O
triglyceride	-	643	O
levels	-	656	O
in	-	663	O
VLDL	-	666	O
were	-	671	O
induced	-	676	O
by	-	684	O
CPA	-	687	O
.	-	690	O

After	16323982	692	O
a	-	698	O
period	-	700	O
of	-	707	O
2	-	710	O
.	-	711	O
5	-	712	O
years	-	714	O
on	-	720	O
CPA	-	723	O
treatment	-	727	O
,	-	736	O
four	-	738	O
patients	-	743	O
out	-	752	O
of	-	756	O
twenty	-	759	O
-	-	765	O
four	-	766	O
were	-	771	O
found	-	776	O
to	-	782	O
be	-	785	O
affected	-	788	O
by	-	797	O
coronary	-	800	B
heart	-	809	I
disease	-	815	I
.	-	822	O

CONCLUSIONS	16323982	824	O
:	-	835	O

Ischaemic	16323982	837	O
coronary	-	847	B
arteriosclerosis	-	856	I
with	-	873	O
an	-	878	O
incidence	-	881	O
rate	-	891	O
of	-	896	O
16	-	899	O
.	-	901	O
6	-	902	O
%	-	903	O
as	-	905	O
caused	-	908	O
by	-	915	O
prolonged	-	918	O
CPA	-	928	O
therapy	-	932	O
is	-	940	O
mediated	-	943	O
through	-	952	O
changes	-	960	O
in	-	968	O
HDL	-	971	O
cholesterol	-	975	O
,	-	986	O
Apo	-	988	O
A	-	992	O
-	-	993	O
I	-	994	O
and	-	996	O
Apo	-	1000	O
A	-	1004	O
-	-	1005	O
II	-	1006	O
pro	-	1009	O
fi	-	1013	O
les	-	1016	O
,	-	1019	O
other	-	1021	O
than	-	1027	O
the	-	1032	O
well	-	1036	O
-	-	1040	O
known	-	1041	O
hyperglyceridemic	-	1047	B
effect	-	1065	I
caused	-	1072	O
by	-	1079	O
estrogen	-	1082	O
.	-	1090	O

5	16369751	0	O
-	-	1	O
Fluorouracil	-	2	O
cardiotoxicity	-	15	B
induced	-	30	O
by	-	38	O
alpha	-	41	O
-	-	46	O
fluoro	-	47	O
-	-	53	O
beta	-	54	O
-	-	58	O
alanine	-	59	O
.	-	66	O

Cardiotoxicity	16369751	68	B
is	-	83	O
a	-	86	O
rare	-	88	O
complication	-	93	O
occurring	-	106	O
during	-	116	O
5	-	123	O
-	-	124	O
fluorouracil	-	125	O
(	-	138	O
5	-	139	O
-	-	140	O
FU	-	141	O
)	-	143	O
treatment	-	145	O
for	-	155	O
malignancies	-	159	B
.	-	171	O

We	16369751	173	O
herein	-	176	O
report	-	183	O
the	-	190	O
case	-	194	O
of	-	199	O
a	-	202	O
70	-	204	O
-	-	206	O
year	-	207	O
-	-	211	O
old	-	212	O
man	-	216	O
with	-	220	O
5	-	225	O
-	-	226	O
FU	-	227	O
-	-	229	O
induced	-	230	O
cardiotoxicity	-	238	B
,	-	252	O
in	-	254	O
whom	-	257	O
a	-	262	O
high	-	264	O
serum	-	269	O
level	-	275	O
of	-	281	O
alpha	-	284	O
-	-	289	O
fluoro	-	290	O
-	-	296	O
beta	-	297	O
-	-	301	O
alanine	-	302	O
(	-	310	O
FBAL	-	311	O
)	-	315	O
was	-	317	O
observed	-	321	O
.	-	329	O

The	16369751	331	O
patient	-	335	O
,	-	342	O
who	-	344	O
had	-	348	O
unresectable	-	352	O
colon	-	365	B
cancer	-	371	I
metastases	-	378	O
to	-	389	O
the	-	392	O
liver	-	396	O
and	-	402	O
lung	-	406	O
,	-	410	O
was	-	412	O
referred	-	416	O
to	-	425	O
us	-	428	O
for	-	431	O
chemotherapy	-	435	O
from	-	448	O
an	-	453	O
affiliated	-	456	O
hospital	-	467	O
;	-	475	O
he	-	477	O
had	-	480	O
no	-	484	O
cardiac	-	487	O
history	-	495	O
.	-	502	O

After	16369751	504	O
admission	-	510	O
,	-	519	O
the	-	521	O
patient	-	525	O
received	-	533	O
a	-	542	O
continuous	-	544	O
intravenous	-	555	O
infusion	-	567	O
of	-	576	O
5	-	579	O
-	-	580	O
FU	-	581	O
(	-	584	O
1000	-	585	O
mg	-	590	O
/	-	592	O
day	-	593	O
)	-	596	O
,	-	597	O
during	-	599	O
which	-	606	O
precordial	-	612	B
pain	-	623	I
with	-	628	O
right	-	633	B
bundle	-	639	I
branch	-	646	I
block	-	653	I
occurred	-	659	O
concomitantly	-	668	O
with	-	682	O
a	-	687	O
high	-	689	O
serum	-	694	O
FBAL	-	700	O
concentration	-	705	O
of	-	719	O
1955	-	722	O
ng	-	727	O
/	-	729	O
ml	-	730	O
.	-	732	O

Both	16369751	734	O
the	-	739	O
precordial	-	743	B
pain	-	754	I
and	-	759	O
the	-	763	O
electrocardiographic	-	767	O
changes	-	788	O
disappeared	-	796	O
spontaneously	-	808	O
after	-	822	O
the	-	828	O
discontinuation	-	832	O
of	-	848	O
5	-	851	O
-	-	852	O
FU	-	853	O
.	-	855	O

As	16369751	857	O
the	-	860	O
precordial	-	864	B
pain	-	875	I
in	-	880	O
this	-	883	O
patient	-	888	O
was	-	896	O
considered	-	900	O
to	-	911	O
have	-	914	O
been	-	919	O
due	-	924	O
to	-	928	O
5	-	931	O
-	-	932	O
FU	-	933	O
-	-	935	O
induced	-	936	O
cardiotoxicity	-	944	B
,	-	958	O
the	-	960	O
administration	-	964	O
of	-	979	O
5	-	982	O
-	-	983	O
FU	-	984	O
was	-	987	O
abandoned	-	991	O
.	-	1000	O

Instead	16369751	1002	O
,	-	1009	O
oral	-	1011	O
administration	-	1016	O
of	-	1031	O
S	-	1034	O
-	-	1035	O
1	-	1036	O
(	-	1038	O
a	-	1039	O
derivative	-	1041	O
of	-	1052	O
5	-	1055	O
-	-	1056	O
FU	-	1057	O
)	-	1059	O
,	-	1060	O
at	-	1062	O
200	-	1065	O
mg	-	1069	O
/	-	1071	O
day	-	1072	O
twice	-	1076	O
a	-	1082	O
week	-	1084	O
,	-	1088	O
was	-	1090	O
instituted	-	1094	O
,	-	1104	O
because	-	1106	O
S	-	1114	O
-	-	1115	O
1	-	1116	O
has	-	1118	O
a	-	1122	O
strong	-	1124	O
inhibitory	-	1131	O
effect	-	1142	O
on	-	1149	O
dihydropyrimidine	-	1152	O
dehydrogenase	-	1170	O
,	-	1183	O
which	-	1185	O
catalyzes	-	1191	O
the	-	1201	O
degradative	-	1205	O
of	-	1217	O
5	-	1220	O
-	-	1221	O
FU	-	1222	O
into	-	1225	O
FBAL	-	1230	O
.	-	1234	O

The	16369751	1236	O
serum	-	1240	O
FBAL	-	1246	O
concentration	-	1251	O
subsequently	-	1265	O
decreased	-	1278	O
to	-	1288	O
352	-	1291	O
ng	-	1295	O
/	-	1297	O
ml	-	1298	O
,	-	1300	O
the	-	1302	O
same	-	1306	O
as	-	1311	O
the	-	1314	O
value	-	1318	O
measured	-	1324	O
on	-	1333	O
the	-	1336	O
first	-	1340	O
day	-	1346	O
of	-	1350	O
S	-	1353	O
-	-	1354	O
1	-	1355	O
administration	-	1357	O
.	-	1371	O

Thereafter	16369751	1373	O
,	-	1383	O
no	-	1385	O
cardiac	-	1388	B
symptoms	-	1396	I
were	-	1405	O
observed	-	1410	O
.	-	1418	O

The	16369751	1420	O
patient	-	1424	O
achieved	-	1432	O
a	-	1441	O
partial	-	1443	O
response	-	1451	O
6	-	1460	O
months	-	1462	O
after	-	1469	O
the	-	1475	O
initiation	-	1479	O
of	-	1490	O
the	-	1493	O
S	-	1497	O
-	-	1498	O
1	-	1499	O
treatment	-	1501	O
.	-	1510	O

The	16369751	1512	O
experience	-	1516	O
of	-	1527	O
this	-	1530	O
case	-	1535	O
,	-	1539	O
together	-	1541	O
with	-	1550	O
a	-	1555	O
review	-	1557	O
of	-	1564	O
the	-	1567	O
literature	-	1571	O
,	-	1581	O
suggests	-	1583	O
that	-	1592	O
FBAL	-	1597	O
is	-	1602	O
related	-	1605	O
to	-	1613	O
5	-	1616	O
-	-	1617	O
FU	-	1618	O
-	-	1620	O
induced	-	1621	O
cardiotoxicity	-	1629	B
.	-	1643	O

S	16369751	1645	O
-	-	1646	O
1	-	1647	O
may	-	1649	O
be	-	1653	O
administered	-	1656	O
safely	-	1669	O
to	-	1676	O
patients	-	1679	O
with	-	1688	O
5	-	1693	O
-	-	1694	O
FU	-	1695	O
-	-	1697	O
induced	-	1698	O
cardiotoxicity	-	1706	B
.	-	1720	O

The	16565833	0	O
influence	-	4	O
of	-	14	O
the	-	17	O
time	-	21	O
interval	-	26	O
between	-	35	O
monoHER	-	43	O
and	-	51	O
doxorubicin	-	55	O
administration	-	67	O
on	-	82	O
the	-	85	O
protection	-	89	O
against	-	100	O
doxorubicin	-	108	O
-	-	119	O
induced	-	120	O
cardiotoxicity	-	128	B
in	-	143	O
mice	-	146	O
.	-	150	O

PURPOSE	16565833	152	O
:	-	159	O

Despite	16565833	161	O
its	-	169	O
well	-	173	O
-	-	177	O
known	-	178	O
cardiotoxicity	-	184	B
,	-	198	O
the	-	200	O
anthracyclin	-	204	O
doxorubicin	-	217	O
(	-	229	O
DOX	-	230	O
)	-	233	O
continues	-	235	O
to	-	245	O
be	-	248	O
an	-	251	O
effective	-	254	O
and	-	264	O
widely	-	268	O
used	-	275	O
chemotherapeutic	-	280	O
agent	-	297	O
.	-	302	O

DOX	16565833	304	O
-	-	307	O
induced	-	308	O
cardiac	-	316	B
damage	-	324	I
presumably	-	331	O
results	-	342	O
from	-	350	O
the	-	355	O
formation	-	359	O
of	-	369	O
free	-	372	O
radicals	-	377	O
by	-	386	O
DOX	-	389	O
.	-	392	O

Reactive	16565833	394	O
oxygen	-	403	O
species	-	410	O
particularly	-	418	O
affect	-	431	O
the	-	438	O
cardiac	-	442	O
myocytes	-	450	O
because	-	459	O
these	-	467	O
cells	-	473	O
seem	-	479	O
to	-	484	O
have	-	487	O
a	-	492	O
relatively	-	494	O
poor	-	505	O
antioxidant	-	510	O
defense	-	522	O
system	-	530	O
.	-	536	O

The	16565833	538	O
semisynthetic	-	542	O
flavonoid	-	556	O
monohydroxyethylrutoside	-	566	O
(	-	591	O
monoHER	-	592	O
)	-	599	O
showed	-	601	O
cardioprotection	-	608	O
against	-	625	O
DOX	-	633	O
-	-	636	O
induced	-	637	O
cardiotoxicity	-	645	B
through	-	660	O
its	-	668	O
radical	-	672	O
scavenging	-	680	O
and	-	691	O
iron	-	695	O
chelating	-	700	O
properties	-	710	O
.	-	720	O

Because	16565833	722	O
of	-	730	O
the	-	733	O
relatively	-	737	O
short	-	748	O
final	-	754	O
half	-	760	O
-	-	764	O
life	-	765	O
of	-	770	O
monoHER	-	773	O
(	-	781	O
about	-	782	O
30	-	788	O
min	-	791	O
)	-	794	O
,	-	795	O
it	-	797	O
is	-	800	O
expected	-	803	O
that	-	812	O
the	-	817	O
time	-	821	O
interval	-	826	O
between	-	835	O
monoHER	-	843	O
and	-	851	O
DOX	-	855	O
might	-	859	O
be	-	865	O
of	-	868	O
influence	-	871	O
on	-	881	O
the	-	884	O
cardioprotective	-	888	O
effect	-	905	O
of	-	912	O
monoHER	-	915	O
.	-	922	O

Therefore	16565833	924	O
,	-	933	O
the	-	935	O
aim	-	939	O
of	-	943	O
the	-	946	O
present	-	950	O
study	-	958	O
was	-	964	O
to	-	968	O
investigate	-	971	O
this	-	983	O
possible	-	988	O
effect	-	997	O
.	-	1003	O

METHODS	16565833	1005	O
:	-	1012	O

Six	16565833	1014	O
groups	-	1018	O
of	-	1025	O
6	-	1028	O
BALB	-	1030	O
/	-	1034	O
c	-	1035	O
mice	-	1037	O
were	-	1042	O
treated	-	1047	O
with	-	1055	O
saline	-	1060	O
,	-	1066	O
DOX	-	1068	O
alone	-	1072	O
or	-	1078	O
DOX	-	1081	O
(	-	1085	O
4	-	1086	O
mg	-	1088	O
/	-	1090	O
kg	-	1091	O
i	-	1094	O
.	-	1095	O
v	-	1096	O
.	-	1097	O
)	-	1098	O
preceded	-	1100	O
by	-	1109	O
monoHER	-	1112	O
(	-	1120	O
500	-	1121	O
mg	-	1125	O
/	-	1127	O
kg	-	1128	O
i	-	1131	O
.	-	1132	O
p	-	1133	O
.	-	1134	O
)	-	1135	O
with	-	1137	O
an	-	1142	O
interval	-	1145	O
of	-	1154	O
10	-	1157	O
,	-	1159	O
30	-	1161	O
,	-	1163	O
60	-	1165	O
or	-	1168	O
120	-	1171	O
min	-	1175	O
.	-	1178	O

After	16565833	1180	O
a	-	1186	O
6	-	1188	O
-	-	1189	O
week	-	1190	O
treatment	-	1195	O
period	-	1205	O
and	-	1212	O
additional	-	1216	O
observation	-	1227	O
for	-	1239	O
2	-	1243	O
weeks	-	1245	O
,	-	1250	O
the	-	1252	O
mice	-	1256	O
were	-	1261	O
sacrificed	-	1266	O
.	-	1276	O

Their	16565833	1278	O
cardiac	-	1284	O
tissues	-	1292	O
were	-	1300	O
processed	-	1305	O
for	-	1315	O
light	-	1319	O
microscopy	-	1325	O
,	-	1335	O
after	-	1337	O
which	-	1343	O
cardiomyocyte	-	1349	B
damage	-	1363	I
was	-	1370	O
evaluated	-	1374	O
according	-	1384	O
to	-	1394	O
Billingham	-	1397	O
(	-	1408	O
in	-	1409	O
Cancer	-	1412	B
Treat	-	1419	O
Rep	-	1425	O

62	16565833	1429	O
(	-	1431	O
6	-	1432	O
)	-	1433	O
:	-	1434	O
865	-	1435	O
-	-	1438	O
872	-	1439	O
,	-	1442	O
1978	-	1444	O
)	-	1448	O
.	-	1449	O

Microscopic	16565833	1451	O
evaluation	-	1463	O
revealed	-	1474	O
that	-	1483	O
treatment	-	1488	O
with	-	1498	O
DOX	-	1503	O
alone	-	1507	O
induced	-	1513	O
significant	-	1521	O
cardiac	-	1533	B
damage	-	1541	I
in	-	1548	O
comparison	-	1551	O
to	-	1562	O
the	-	1565	O
saline	-	1569	O
control	-	1576	O
group	-	1584	O
(	-	1590	O
P	-	1591	O
<	-	1592	O
0	-	1593	O
.	-	1594	O
001	-	1595	O
)	-	1598	O
.	-	1599	O

RESULTS	16565833	1601	O
:	-	1608	O

The	16565833	1610	O
number	-	1614	O
of	-	1621	O
damaged	-	1624	O
cardiomyocytes	-	1632	O
was	-	1647	O
9	-	1651	O
.	-	1652	O
6	-	1653	O
-	-	1654	O
fold	-	1655	O
(	-	1660	O
95	-	1661	O
%	-	1663	O
CI	-	1665	O
4	-	1668	O
.	-	1669	O
4	-	1670	O
-	-	1671	O
21	-	1672	O
.	-	1674	O
0	-	1675	O
)	-	1676	O
higher	-	1678	O
in	-	1685	O
mice	-	1688	O
treated	-	1693	O
with	-	1701	O
DOX	-	1706	O
alone	-	1710	O
than	-	1716	O
that	-	1721	O
in	-	1726	O
animals	-	1729	O
of	-	1737	O
the	-	1740	O
control	-	1744	O
group	-	1752	O
.	-	1757	O

The	16565833	1759	O
ratio	-	1763	O
of	-	1769	O
aberrant	-	1772	O
cardiomyocytes	-	1781	O
in	-	1796	O
mice	-	1799	O
treated	-	1804	O
with	-	1812	O
DOX	-	1817	O
preceded	-	1821	O
by	-	1830	O
monoHER	-	1833	O
and	-	1841	O
those	-	1845	O
in	-	1851	O
mice	-	1854	O
treated	-	1859	O
with	-	1867	O
saline	-	1872	O
ranged	-	1879	O
from	-	1886	O
1	-	1891	O
.	-	1892	O
6	-	1893	O
to	-	1895	O
2	-	1898	O
.	-	1899	O
8	-	1900	O
(	-	1902	O
mean	-	1903	O
2	-	1908	O
.	-	1909	O
2	-	1910	O
,	-	1911	O
95	-	1913	O
%	-	1915	O
CI	-	1917	O
1	-	1920	O
.	-	1921	O
2	-	1922	O
-	-	1923	O
4	-	1924	O
.	-	1925	O
1	-	1926	O
,	-	1927	O
P	-	1929	O
=	-	1930	O
0	-	1931	O
.	-	1932	O
019	-	1933	O
)	-	1936	O
.	-	1937	O

The	16565833	1939	O
mean	-	1943	O
protective	-	1948	O
effect	-	1959	O
by	-	1966	O
adding	-	1969	O
monoHER	-	1976	O
before	-	1984	O
DOX	-	1991	O
led	-	1995	O
to	-	1999	O
a	-	2002	O
significant	-	2004	O
4	-	2016	O
.	-	2017	O
4	-	2018	O
-	-	2019	O
fold	-	2020	O
reduction	-	2025	O
(	-	2035	O
P	-	2036	O
<	-	2037	O
0	-	2038	O
.	-	2039	O
001	-	2040	O
,	-	2043	O
95	-	2045	O
%	-	2047	O
CI	-	2049	O
2	-	2052	O
.	-	2053	O
3	-	2054	O
-	-	2055	O
8	-	2056	O
.	-	2057	O
2	-	2058	O
)	-	2059	O
of	-	2061	O
abnormal	-	2064	O
cardiomyocytes	-	2073	O
.	-	2087	O

This	16565833	2089	O
protective	-	2094	O
effect	-	2105	O
did	-	2112	O
not	-	2116	O
depend	-	2120	O
on	-	2127	O
the	-	2130	O
time	-	2134	O
interval	-	2139	O
between	-	2148	O
monoHER	-	2156	O
and	-	2164	O
DOX	-	2168	O
administration	-	2172	O
(	-	2187	O
P	-	2188	O
=	-	2189	O
0	-	2190	O
.	-	2191	O
345	-	2192	O
)	-	2195	O
.	-	2196	O

CONCLUSION	16565833	2198	O
:	-	2208	O

The	16565833	2210	O
results	-	2214	O
indicate	-	2222	O
that	-	2231	O
in	-	2236	O
an	-	2239	O
outpatient	-	2242	O
clinical	-	2253	O
setting	-	2262	O
monoHER	-	2270	O
may	-	2278	O
be	-	2282	O
administered	-	2285	O
shortly	-	2298	O
before	-	2306	O
DOX	-	2313	O
.	-	2316	O

Clinical	16723784	0	O
evaluation	-	9	O
of	-	20	O
adverse	-	23	O
effects	-	31	O
during	-	39	O
bepridil	-	46	O
administration	-	55	O
for	-	70	O
atrial	-	74	B
fibrillation	-	81	I
and	-	94	I
flutter	-	98	I
.	-	105	O

BACKGROUND	16723784	107	O
:	-	117	O

Bepridil	16723784	119	O
hydrochloride	-	128	O
(	-	142	O
Bpd	-	143	O
)	-	146	O
has	-	148	O
attracted	-	152	O
attention	-	162	O
as	-	172	O
an	-	175	O
effective	-	178	O
drug	-	188	O
for	-	193	O
atrial	-	197	B
fibrillation	-	204	I
(	-	217	O
AF	-	218	B
)	-	220	O
and	-	222	O
atrial	-	226	B
flutter	-	233	I
(	-	241	O
AFL	-	242	B
)	-	245	O
.	-	246	O

However	16723784	248	O
,	-	255	O
serious	-	257	O
adverse	-	265	O
effects	-	273	O
,	-	280	O
including	-	282	O
torsade	-	292	B
de	-	300	I
pointes	-	303	I
(	-	311	O
Tdp	-	312	B
)	-	315	O
,	-	316	O
have	-	318	O
been	-	323	O
reported	-	328	O
.	-	336	O

METHODS	16723784	338	O
AND	-	346	O
RESULTS	-	350	O
:	-	357	O

Adverse	16723784	359	O
effects	-	367	O
of	-	375	O
Bpd	-	378	O
requiring	-	382	O
discontinuation	-	392	O
of	-	408	O
treatment	-	411	O
were	-	421	O
evaluated	-	426	O
.	-	435	O

Bpd	16723784	437	O
was	-	441	O
administered	-	445	O
to	-	458	O
459	-	461	O
patients	-	465	O
(	-	474	O
361	-	475	O
males	-	479	O
,	-	484	O
63	-	486	O
+	-	488	O
/	-	489	O
-	-	490	O
12	-	491	O
years	-	494	O
old	-	500	O
)	-	503	O
comprising	-	505	O
378	-	516	O
AF	-	520	B
and	-	523	O
81	-	527	O
AFL	-	530	B
cases	-	534	O
.	-	539	O

Mean	16723784	541	O
left	-	546	O
ventricular	-	551	O
ejection	-	563	O
fraction	-	572	O
and	-	581	O
atrial	-	585	O
dimension	-	592	O
(	-	602	O
LAD	-	603	O
)	-	606	O
were	-	608	O
66	-	613	O
+	-	615	O
/	-	616	O
-	-	617	O
11	-	618	O
%	-	620	O
and	-	622	O
40	-	626	O
+	-	628	O
/	-	629	O
-	-	630	O
6	-	631	O
mm	-	633	O
,	-	635	O
respectively	-	637	O
.	-	649	O

Adverse	16723784	651	O
effects	-	659	O
were	-	667	O
observed	-	672	O
in	-	681	O
19	-	684	O
patients	-	687	O
(	-	696	O
4	-	697	O
%	-	698	O
)	-	699	O
during	-	701	O
an	-	708	O
average	-	711	O
follow	-	719	O
-	-	725	O
up	-	726	O
of	-	729	O
20	-	732	O
months	-	735	O
.	-	741	O

There	16723784	743	O
was	-	749	O
marked	-	753	O
QT	-	760	B
prolongation	-	763	I
greater	-	776	O
than	-	784	O
0	-	789	O
.	-	790	O
55	-	791	O
s	-	794	O
in	-	796	O
13	-	799	O
patients	-	802	O
,	-	810	O
bradycardia	-	812	B
less	-	824	O
than	-	829	O
40	-	834	O
beats	-	837	O
/	-	842	O
min	-	843	O
in	-	847	O
6	-	850	O
patients	-	852	O
,	-	860	O
dizziness	-	862	B
and	-	872	O
general	-	876	O
fatigue	-	884	B
in	-	892	O
1	-	895	O
patient	-	897	O
each	-	905	O
.	-	909	O

In	16723784	911	O
4	-	914	O
of	-	916	O
13	-	919	O
patients	-	922	O
with	-	931	O
QT	-	936	B
prolongation	-	939	I
,	-	951	O
Tdp	-	953	B
occurred	-	957	O
.	-	965	O

The	16723784	967	O
major	-	971	O
triggering	-	977	O
factors	-	988	O
of	-	996	O
Tdp	-	999	B
were	-	1003	O
hypokalemia	-	1008	B
and	-	1020	O
sudden	-	1024	O
decrease	-	1031	O
in	-	1040	O
heart	-	1043	O
rate	-	1049	O
.	-	1053	O

There	16723784	1055	O
were	-	1061	O
no	-	1066	O
differences	-	1069	O
in	-	1081	O
the	-	1084	O
clinical	-	1088	O
backgrounds	-	1097	O
of	-	1109	O
the	-	1112	O
patients	-	1116	O
with	-	1125	O
and	-	1130	O
without	-	1134	O
Tdp	-	1142	B
other	-	1146	O
than	-	1152	O
LAD	-	1157	O
and	-	1161	O
age	-	1165	O
,	-	1168	O
which	-	1170	O
were	-	1176	O
larger	-	1181	O
and	-	1188	O
older	-	1192	O
in	-	1198	O
the	-	1201	O
patients	-	1205	O
with	-	1214	O
Tdp	-	1219	B
.	-	1222	O

CONCLUSION	16723784	1224	O
:	-	1234	O

Careful	16723784	1236	O
observation	-	1244	O
of	-	1256	O
serum	-	1259	O
potassium	-	1265	O
concentration	-	1275	O
and	-	1289	O
the	-	1293	O
ECG	-	1297	O
should	-	1301	O
always	-	1308	O
be	-	1315	O
done	-	1318	O
during	-	1323	O
Bpd	-	1330	O
administration	-	1334	O
,	-	1348	O
particularly	-	1350	O
in	-	1363	O
elderly	-	1366	O
patients	-	1374	O
.	-	1382	O

Enhanced	16731636	0	O
isoproterenol	-	9	O
-	-	22	O
induced	-	23	O
cardiac	-	31	B
hypertrophy	-	39	I
in	-	51	O
transgenic	-	54	O
rats	-	65	O
with	-	70	O
low	-	75	O
brain	-	79	O
angiotensinogen	-	85	O
.	-	100	O

We	16731636	102	O
have	-	105	O
previously	-	110	O
shown	-	121	O
that	-	127	O
a	-	132	O
permanent	-	134	O
deficiency	-	144	O
in	-	155	O
the	-	158	O
brain	-	162	O
renin	-	168	O
-	-	173	O
angiotensin	-	174	O
system	-	186	O
(	-	193	O
RAS	-	194	O
)	-	197	O
may	-	199	O
increase	-	203	O
the	-	212	O
sensitivity	-	216	O
of	-	228	O
the	-	231	O
baroreflex	-	235	O
control	-	246	O
of	-	254	O
heart	-	257	O
rate	-	263	O
.	-	267	O

In	16731636	269	O
this	-	272	O
study	-	277	O
we	-	283	O
aimed	-	286	O
at	-	292	O
studying	-	295	O
the	-	304	O
involvement	-	308	O
of	-	320	O
the	-	323	O
brain	-	327	O
RAS	-	333	O
in	-	337	O
the	-	340	O
cardiac	-	344	O
reactivity	-	352	O
to	-	363	O
the	-	366	O
beta	-	370	O
-	-	374	O
adrenoceptor	-	375	O
(	-	388	O
beta	-	389	O
-	-	393	O
AR	-	394	O
)	-	396	O
agonist	-	398	O
isoproterenol	-	406	O
(	-	420	O
Iso	-	421	O
)	-	424	O
.	-	425	O

Transgenic	16731636	427	O
rats	-	438	O
with	-	443	O
low	-	448	O
brain	-	452	O
angiotensinogen	-	458	O
(	-	474	O
TGR	-	475	O
)	-	478	O
were	-	480	O
used	-	485	O
.	-	489	O

In	16731636	491	O
isolated	-	494	O
hearts	-	503	O
,	-	509	O
Iso	-	511	O
induced	-	515	O
a	-	523	O
significantly	-	525	O
greater	-	539	O
increase	-	547	O
in	-	556	O
left	-	559	O
ventricular	-	564	O
(	-	576	O
LV	-	577	O
)	-	579	O
pressure	-	581	O
and	-	590	O
maximal	-	594	O
contraction	-	602	O
(	-	614	O
+	-	615	O
dP	-	616	O
/	-	618	O
dt	-	619	O
(	-	621	O
max	-	622	O
)	-	625	O
)	-	626	O
in	-	628	O
the	-	631	O
TGR	-	635	O
than	-	639	O
in	-	644	O
the	-	647	O
Sprague	-	651	O
-	-	658	O
Dawley	-	659	O
(	-	666	O
SD	-	667	O
)	-	669	O
rats	-	671	O
.	-	675	O

LV	16731636	677	B
hypertrophy	-	680	I
induced	-	692	O
by	-	700	O
Iso	-	703	O
treatment	-	707	O
was	-	717	O
significantly	-	721	O
higher	-	735	O
in	-	742	O
TGR	-	745	O
than	-	749	O
in	-	754	O
SD	-	757	O
rats	-	760	O
(	-	765	O
in	-	766	O
g	-	769	O
LV	-	771	O
wt	-	774	O
/	-	776	O
100	-	777	O
g	-	781	O
body	-	783	O
wt	-	788	O
,	-	790	O
0	-	792	O
.	-	793	O
28	-	794	O
+	-	797	O
/	-	798	O
-	-	799	O

0	16731636	801	O
.	-	802	O
004	-	803	O
vs	-	807	O
.	-	809	O
0	-	811	O
.	-	812	O
24	-	813	O
+	-	816	O
/	-	817	O
-	-	818	O

0	16731636	820	O
.	-	821	O
004	-	822	O
,	-	825	O
respectively	-	827	O
)	-	839	O
.	-	840	O

The	16731636	842	O
greater	-	846	O
LV	-	854	B
hypertrophy	-	857	I
in	-	869	O
TGR	-	872	O
rats	-	876	O
was	-	881	O
associated	-	885	O
with	-	896	O
more	-	901	O
pronounced	-	906	O
downregulation	-	917	O
of	-	932	O
beta	-	935	O
-	-	939	O
AR	-	940	O
and	-	943	O
upregulation	-	947	O
of	-	960	O
LV	-	963	O
beta	-	966	O
-	-	970	O
AR	-	971	O
kinase	-	974	O
-	-	980	O
1	-	981	O
mRNA	-	983	O
levels	-	988	O
compared	-	995	O
with	-	1004	O
those	-	1009	O
in	-	1015	O
SD	-	1018	O
rats	-	1021	O
.	-	1025	O

The	16731636	1027	O
decrease	-	1031	O
in	-	1040	O
the	-	1043	O
heart	-	1047	O
rate	-	1053	O
(	-	1058	O
HR	-	1059	O
)	-	1061	O
induced	-	1063	O
by	-	1071	O
the	-	1074	O
beta	-	1078	O
-	-	1082	O
AR	-	1083	O
antagonist	-	1086	O
metoprolol	-	1097	O
in	-	1108	O
conscious	-	1111	O
rats	-	1121	O
was	-	1126	O
significantly	-	1130	O
attenuated	-	1144	O
in	-	1155	O
TGR	-	1158	O
compared	-	1162	O
with	-	1171	O
SD	-	1176	O
rats	-	1179	O
(	-	1184	O
-	-	1185	O
9	-	1186	O
.	-	1187	O
9	-	1188	O
+	-	1190	O
/	-	1191	O
-	-	1192	O

1	16731636	1194	O
.	-	1195	O
7	-	1196	O
%	-	1197	O
vs	-	1199	O
.	-	1201	O
-	-	1203	O
18	-	1204	O
.	-	1206	O
1	-	1207	O
+	-	1209	O
/	-	1210	O
-	-	1211	O

1	16731636	1213	O
.	-	1214	O
5	-	1215	O
%	-	1216	O
)	-	1217	O
,	-	1218	O
whereas	-	1220	O
the	-	1228	O
effect	-	1232	O
of	-	1239	O
parasympathetic	-	1242	O
blockade	-	1258	O
by	-	1267	O
atropine	-	1270	O
on	-	1279	O
HR	-	1282	O
was	-	1285	O
similar	-	1289	O
in	-	1297	O
both	-	1300	O
strains	-	1305	O
.	-	1312	O

These	16731636	1314	O
results	-	1320	O
indicate	-	1328	O
that	-	1337	O
TGR	-	1342	O
are	-	1346	O
more	-	1350	O
sensitive	-	1355	O
to	-	1365	O
beta	-	1368	O
-	-	1372	O
AR	-	1373	O
agonist	-	1376	O
-	-	1383	O
induced	-	1384	O
cardiac	-	1392	B
inotropic	-	1400	I
response	-	1410	O
and	-	1419	O
hypertrophy	-	1423	B
,	-	1434	O
possibly	-	1436	O
due	-	1445	O
to	-	1449	O
chronically	-	1452	O
low	-	1464	O
sympathetic	-	1468	O
outflow	-	1480	O
directed	-	1488	O
to	-	1497	O
the	-	1500	O
heart	-	1504	O
.	-	1509	O

Drug	16801510	0	O
-	-	4	O
induced	-	5	O
long	-	13	B
QT	-	18	I
syndrome	-	21	I
in	-	30	O
injection	-	33	O
drug	-	43	O
users	-	48	O
receiving	-	54	O
methadone	-	64	O
:	-	73	O
high	-	75	O
frequency	-	80	O
in	-	90	O
hospitalized	-	93	O
patients	-	106	O
and	-	115	O
risk	-	119	O
factors	-	124	O
.	-	131	O

BACKGROUND	16801510	133	O
:	-	143	O

Drug	16801510	145	O
-	-	149	O
induced	-	150	O
long	-	158	B
QT	-	163	I
syndrome	-	166	I
is	-	175	O
a	-	178	O
serious	-	180	O
adverse	-	188	O
drug	-	196	O
reaction	-	201	O
.	-	209	O

Methadone	16801510	211	O
prolongs	-	221	O
the	-	230	O
QT	-	234	O
interval	-	237	O
in	-	246	O
vitro	-	249	O
in	-	255	O
a	-	258	O
dose	-	260	O
-	-	264	O
dependent	-	265	O
manner	-	275	O
.	-	281	O

In	16801510	283	O
the	-	286	O
inpatient	-	290	O
setting	-	300	O
,	-	307	O
the	-	309	O
frequency	-	313	O
of	-	323	O
QT	-	326	B
interval	-	329	I
prolongation	-	338	I
with	-	351	O
methadone	-	356	O
treatment	-	366	O
,	-	375	O
its	-	377	O
dose	-	381	O
dependence	-	386	O
,	-	396	O
and	-	398	O
the	-	402	O
importance	-	406	O
of	-	417	O
cofactors	-	420	O
such	-	430	O
as	-	435	O
drug	-	438	O
-	-	442	O
drug	-	443	O
interactions	-	448	O
remain	-	461	O
unknown	-	468	O
.	-	475	O

METHODS	16801510	477	O
:	-	484	O

We	16801510	486	O
performed	-	489	O
a	-	499	O
systematic	-	501	O
,	-	511	O
retrospective	-	513	O
study	-	527	O
comparing	-	533	O
active	-	543	O
or	-	550	O
former	-	553	O
intravenous	-	560	O
drug	-	572	O
users	-	577	O
receiving	-	583	O
methadone	-	593	O
and	-	603	O
those	-	607	O
not	-	613	O
receiving	-	617	O
methadone	-	627	O
among	-	637	O
all	-	643	O
patients	-	647	O
hospitalized	-	656	O
over	-	669	O
a	-	674	O
5	-	676	O
-	-	677	O
year	-	678	O
period	-	683	O
in	-	690	O
a	-	693	O
tertiary	-	695	O
care	-	704	O
hospital	-	709	O
.	-	717	O

A	16801510	719	O
total	-	721	O
of	-	727	O
167	-	730	O
patients	-	734	O
receiving	-	743	O
methadone	-	753	O
fulfilled	-	763	O
the	-	773	O
inclusion	-	777	O
criteria	-	787	O
and	-	796	O
were	-	800	O
compared	-	805	O
with	-	814	O
a	-	819	O
control	-	821	O
group	-	829	O
of	-	835	O
80	-	838	O
injection	-	841	O
drug	-	851	O
users	-	856	O
not	-	862	O
receiving	-	866	O
methadone	-	876	O
.	-	885	O

In	16801510	887	O
addition	-	890	O
to	-	899	O
methadone	-	902	O
dose	-	912	O
,	-	916	O
15	-	918	O
demographic	-	921	O
,	-	932	O
biological	-	934	O
,	-	944	O
and	-	946	O
pharmacological	-	950	O
variables	-	966	O
were	-	976	O
considered	-	981	O
as	-	992	O
potential	-	995	O
risk	-	1005	O
factors	-	1010	O
for	-	1018	O
QT	-	1022	B
prolongation	-	1025	I
.	-	1037	O

RESULTS	16801510	1039	O
:	-	1046	O

Among	16801510	1048	O
167	-	1054	O
methadone	-	1058	O
maintenance	-	1068	O
patients	-	1080	O
,	-	1088	O
the	-	1090	O
prevalence	-	1094	O
of	-	1105	O
QTc	-	1108	O
prolongation	-	1112	O
to	-	1125	O
0	-	1128	O
.	-	1129	O
50	-	1130	O
second	-	1133	O
(	-	1139	O
(	-	1140	O
1	-	1141	O
/	-	1142	O
2	-	1143	O
)	-	1144	O
)	-	1145	O
or	-	1147	O
longer	-	1150	O
was	-	1157	O
16	-	1161	O
.	-	1163	O
2	-	1164	O
%	-	1165	O
compared	-	1167	O
with	-	1176	O
0	-	1181	O
%	-	1182	O
in	-	1184	O
80	-	1187	O
control	-	1190	O
subjects	-	1198	O
.	-	1206	O

Six	16801510	1208	O
patients	-	1212	O
(	-	1221	O
3	-	1222	O
.	-	1223	O
6	-	1224	O
%	-	1225	O
)	-	1226	O
in	-	1228	O
the	-	1231	O
methadone	-	1235	O
group	-	1245	O
presented	-	1251	O
torsades	-	1261	B
de	-	1270	I
pointes	-	1273	I
.	-	1280	O

QTc	16801510	1282	O
length	-	1286	O
was	-	1293	O
weakly	-	1297	O
but	-	1304	O
significantly	-	1308	O
associated	-	1322	O
with	-	1333	O
methadone	-	1338	O
daily	-	1348	O
dose	-	1354	O
(	-	1359	O
Spearman	-	1360	O
rank	-	1369	O
correlation	-	1374	O
coefficient	-	1386	O
,	-	1397	O
0	-	1399	O
.	-	1400	O
20	-	1401	O
;	-	1403	O
P	-	1405	O
<	-	1406	O
.	-	1407	O
01	-	1408	O
)	-	1410	O
.	-	1411	O

Multivariate	16801510	1413	O
regression	-	1426	O
analysis	-	1437	O
allowed	-	1446	O
attribution	-	1454	O
of	-	1466	O
31	-	1469	O
.	-	1471	O
8	-	1472	O
%	-	1473	O
of	-	1475	O
QTc	-	1478	O
variability	-	1482	O
to	-	1494	O
methadone	-	1497	O
dose	-	1507	O
,	-	1511	O
cytochrome	-	1513	O
P	-	1524	O
-	-	1525	O
450	-	1526	O
3A4	-	1530	O
drug	-	1534	O
-	-	1538	O
drug	-	1539	O
interactions	-	1544	O
,	-	1556	O
hypokalemia	-	1558	B
,	-	1569	O
and	-	1571	O
altered	-	1575	O
liver	-	1583	O
function	-	1589	O
.	-	1597	O

CONCLUSIONS	16801510	1599	O
:	-	1610	O

QT	16801510	1612	B
interval	-	1615	I
prolongation	-	1624	I
in	-	1637	O
methadone	-	1640	O
maintenance	-	1650	O
patients	-	1662	O
hospitalized	-	1671	O
in	-	1684	O
a	-	1687	O
tertiary	-	1689	O
care	-	1698	O
center	-	1703	O
is	-	1710	O
a	-	1713	O
frequent	-	1715	O
finding	-	1724	O
.	-	1731	O

Methadone	16801510	1733	O
dose	-	1743	O
,	-	1747	O
presence	-	1749	O
of	-	1758	O
cytochrome	-	1761	O
P	-	1772	O
-	-	1773	O
450	-	1774	O
3A4	-	1778	O
inhibitors	-	1782	O
,	-	1792	O
potassium	-	1794	O
level	-	1804	O
,	-	1809	O
and	-	1811	O
liver	-	1815	O
function	-	1821	O
contribute	-	1830	O
to	-	1841	O
QT	-	1844	B
prolongation	-	1847	I
.	-	1859	O

Long	16801510	1861	B
QT	-	1866	I
syndrome	-	1869	I
can	-	1878	O
occur	-	1882	O
with	-	1888	O
low	-	1893	O
doses	-	1897	O
of	-	1903	O
methadone	-	1906	O
.	-	1915	O

Mechanisms	16810074	0	O
of	-	11	O
hypertension	-	14	B
induced	-	27	O
by	-	35	O
nitric	-	38	O
oxide	-	45	O
(	-	51	O
NO	-	52	O
)	-	54	O
deficiency	-	56	O
:	-	66	O
focus	-	68	O
on	-	74	O
venous	-	77	O
function	-	84	O
.	-	92	O

Loss	16810074	94	O
of	-	99	O
endothelial	-	102	O
cell	-	114	O
-	-	118	O
derived	-	119	O
nitric	-	127	O
oxide	-	134	O
(	-	140	O
NO	-	141	O
)	-	143	O
in	-	145	O
hypertension	-	148	B
is	-	161	O
a	-	164	O
hallmark	-	166	O
of	-	175	O
arterial	-	178	B
dysfunction	-	187	I
.	-	198	O

Experimental	16810074	200	O
hypertension	-	213	B
created	-	226	O
by	-	234	O
the	-	237	O
removal	-	241	O
of	-	249	O
NO	-	252	O
,	-	254	O
however	-	256	O
,	-	263	O
involves	-	265	O
mechanisms	-	274	O
in	-	285	O
addition	-	288	O
to	-	297	O
decreased	-	300	O
arterial	-	310	O
vasodilator	-	319	O
activity	-	331	O
.	-	339	O

These	16810074	341	O
include	-	347	O
augmented	-	355	O
endothelin	-	365	O
-	-	375	O
1	-	376	O
(	-	378	O
ET	-	379	O
-	-	381	O
1	-	382	O
)	-	383	O
release	-	385	O
,	-	392	O
increased	-	394	O
sympathetic	-	404	O
nervous	-	416	O
system	-	424	O
activity	-	431	O
,	-	439	O
and	-	441	O
elevated	-	445	O
tissue	-	454	O
oxidative	-	461	O
stress	-	471	O
.	-	477	O

We	16810074	479	O
hypothesized	-	482	O
that	-	495	O
increased	-	500	O
venous	-	510	O
smooth	-	517	O
muscle	-	524	O
(	-	531	O
venomotor	-	532	O
)	-	541	O
tone	-	543	O
plays	-	548	O
a	-	554	O
role	-	556	O
in	-	561	O
Nomega	-	564	O
-	-	570	O
nitro	-	571	O
-	-	576	O
L	-	577	O
-	-	578	O
arginine	-	579	O
(	-	588	O
LNNA	-	589	O
)	-	593	O
hypertension	-	595	B
through	-	608	O
these	-	616	O
mechanisms	-	622	O
.	-	632	O

Rats	16810074	634	O
were	-	639	O
treated	-	644	O
with	-	652	O
the	-	657	O
NO	-	661	O
synthase	-	664	O
inhibitor	-	673	O
LNNA	-	683	O
(	-	688	O
0	-	689	O
.	-	690	O
5	-	691	O
g	-	693	O
/	-	694	O
L	-	695	O
in	-	697	O
drinking	-	700	O
water	-	709	O
)	-	714	O
for	-	716	O
2	-	720	O
weeks	-	722	O
.	-	727	O

Mean	16810074	729	O
arterial	-	734	O
pressure	-	743	O
of	-	752	O
conscious	-	755	O
rats	-	765	O
was	-	770	O
119	-	774	O
+	-	778	O
/	-	779	O
-	-	780	O

2	16810074	782	O
mm	-	784	O
Hg	-	787	O
in	-	790	O
control	-	793	O
and	-	801	O
194	-	805	O
+	-	809	O

/	16810074	810	O
-	-	811	O
5	-	813	O
mm	-	815	O
Hg	-	818	O
in	-	821	O
LNNA	-	824	O
rats	-	829	O
(	-	834	O
P	-	835	O
<	-	836	O
0	-	837	O
.	-	838	O
05	-	839	O
)	-	841	O
.	-	842	O

Carotid	16810074	844	O
arteries	-	852	O
and	-	861	O
vena	-	865	O
cava	-	870	O
were	-	875	O
removed	-	880	O
for	-	888	O
measurement	-	892	O
of	-	904	O
isometric	-	907	O
contraction	-	917	O
.	-	928	O

Maximal	16810074	930	O
contraction	-	938	O
to	-	950	O
norepinephrine	-	953	O
was	-	968	O
modestly	-	972	O
reduced	-	981	O
in	-	989	O
arteries	-	992	O
from	-	1001	O
LNNA	-	1006	O
compared	-	1011	O
with	-	1020	O
control	-	1025	O
rats	-	1033	O
whereas	-	1038	O
the	-	1046	O
maximum	-	1050	O
contraction	-	1058	O
to	-	1070	O
ET	-	1073	O
-	-	1075	O
1	-	1076	O
was	-	1078	O
significantly	-	1082	O
reduced	-	1096	O
(	-	1104	O
54	-	1105	O
%	-	1107	O
control	-	1109	O
)	-	1116	O
.	-	1117	O

Maximum	16810074	1119	O
contraction	-	1127	O
of	-	1139	O
vena	-	1142	O
cava	-	1147	O
to	-	1152	O
norepinephrine	-	1155	O
(	-	1170	O
37	-	1171	O
%	-	1173	O
control	-	1175	O
)	-	1182	O
also	-	1184	O
was	-	1189	O
reduced	-	1193	O
but	-	1201	O
no	-	1205	O
change	-	1208	O
in	-	1215	O
response	-	1218	O
to	-	1227	O
ET	-	1230	O
-	-	1232	O
1	-	1233	O
was	-	1235	O
observed	-	1239	O
.	-	1247	O

Mean	16810074	1249	O
circulatory	-	1254	O
filling	-	1266	O
pressure	-	1274	O
,	-	1282	O
an	-	1284	O
in	-	1287	O
vivo	-	1290	O
measure	-	1295	O
of	-	1303	O
venomotor	-	1306	O
tone	-	1316	O
,	-	1320	O
was	-	1322	O
not	-	1326	O
elevated	-	1330	O
in	-	1339	O
LNNA	-	1342	O
hypertension	-	1347	B
at	-	1360	O
1	-	1363	O
or	-	1365	O
2	-	1368	O
weeks	-	1370	O
after	-	1376	O
LNNA	-	1382	O
.	-	1386	O

The	16810074	1388	O
superoxide	-	1392	O
scavenger	-	1403	O
tempol	-	1413	O
(	-	1420	O
30	-	1421	O
,	-	1423	O
100	-	1425	O
,	-	1428	O
and	-	1430	O
300	-	1434	O
micromol	-	1438	O
kg	-	1447	O
(	-	1449	O
-	-	1450	O
1	-	1451	O
)	-	1452	O
,	-	1453	O
IV	-	1455	O
)	-	1457	O
did	-	1459	O
not	-	1463	O
change	-	1467	O
arterial	-	1474	O
pressure	-	1483	O
in	-	1492	O
control	-	1495	O
rats	-	1503	O
but	-	1508	O
caused	-	1512	O
a	-	1519	O
dose	-	1521	O
-	-	1525	O
dependent	-	1526	O
decrease	-	1536	O
in	-	1545	O
LNNA	-	1548	O
rats	-	1553	O
(	-	1558	O
-	-	1559	O
18	-	1560	O
+	-	1563	O
/	-	1564	O
-	-	1565	O

8	16810074	1567	O
,	-	1568	O
-	-	1570	O
26	-	1571	O

+	16810074	1574	O
/	-	1575	O
-	-	1576	O

15	16810074	1578	O
,	-	1580	O
and	-	1582	O
-	-	1586	O
54	-	1587	O
+	-	1590	O
/	-	1591	O
-	-	1592	O

11	16810074	1594	O
mm	-	1597	O
Hg	-	1600	O
)	-	1602	O
.	-	1603	O

Similarly	16810074	1605	O
,	-	1614	O
ganglionic	-	1616	O
blockade	-	1627	O
with	-	1636	O
hexamethonium	-	1641	O
caused	-	1655	O
a	-	1662	O
significantly	-	1664	O
greater	-	1678	O
fall	-	1686	O
in	-	1691	O
LNNA	-	1694	O
hypertensive	-	1699	B
rats	-	1712	O
(	-	1717	O
76	-	1718	O
+	-	1721	O
/	-	1722	O
-	-	1723	O

9	16810074	1725	O
mm	-	1727	O
Hg	-	1730	O
)	-	1732	O
compared	-	1734	O
with	-	1743	O
control	-	1748	O
rats	-	1756	O
(	-	1761	O
35	-	1762	O
+	-	1765	O
/	-	1766	O
-	-	1767	O

10	16810074	1769	O
mm	-	1772	O
Hg	-	1775	O
)	-	1777	O
.	-	1778	O

Carotid	16810074	1780	O
arteries	-	1788	O
,	-	1796	O
vena	-	1798	O
cava	-	1803	O
,	-	1807	O
and	-	1809	O
sympathetic	-	1813	O
ganglia	-	1825	O
from	-	1833	O
LNNA	-	1838	O
rats	-	1843	O
had	-	1848	O
higher	-	1852	O
basal	-	1859	O
levels	-	1865	O
of	-	1872	O
superoxide	-	1875	O
compared	-	1886	O
with	-	1895	O
those	-	1900	O
from	-	1906	O
control	-	1911	O
rats	-	1919	O
.	-	1923	O

These	16810074	1925	O
data	-	1931	O
suggest	-	1936	O
that	-	1944	O
while	-	1949	O
NO	-	1955	O
deficiency	-	1958	O
increases	-	1969	O
oxidative	-	1979	O
stress	-	1989	O
and	-	1996	O
sympathetic	-	2000	O
activity	-	2012	O
in	-	2021	O
both	-	2024	O
arterial	-	2029	O
and	-	2038	O
venous	-	2042	O
vessels	-	2049	O
,	-	2056	O
the	-	2058	O
impact	-	2062	O
on	-	2069	O
veins	-	2072	O
does	-	2078	O
not	-	2083	O
make	-	2087	O
a	-	2092	O
major	-	2094	O
contribution	-	2100	O
to	-	2113	O
this	-	2116	O
form	-	2121	O
of	-	2126	O
hypertension	-	2129	B
.	-	2141	O

Association	16867246	0	O
of	-	12	O
DRD2	-	15	O
polymorphisms	-	20	O
and	-	34	O
chlorpromazine	-	38	O
-	-	52	O
induced	-	53	O
extrapyramidal	-	61	B
syndrome	-	76	I
in	-	85	O
Chinese	-	88	O
schizophrenic	-	96	B
patients	-	110	O
.	-	118	O

AIM	16867246	120	O
:	-	123	O

Extrapyramidal	16867246	125	B
syndrome	-	140	I
(	-	149	O
EPS	-	150	B
)	-	153	O
is	-	155	O
most	-	158	O
commonly	-	163	O
affected	-	172	O
by	-	181	O
typical	-	184	O
antipsychotic	-	192	O
drugs	-	206	O
that	-	212	O
have	-	217	O
a	-	222	O
high	-	224	O
affinity	-	229	O
with	-	238	O
the	-	243	O
D2	-	247	O
receptor	-	250	O
.	-	258	O

Recently	16867246	260	O
,	-	268	O
many	-	270	O
research	-	275	O
groups	-	284	O
have	-	291	O
reported	-	296	O
on	-	305	O
the	-	308	O
positive	-	312	O
relationship	-	321	O
between	-	334	O
the	-	342	O
genetic	-	346	O
variations	-	354	O
in	-	365	O
the	-	368	O
DRD2	-	372	O
gene	-	377	O
and	-	382	O
the	-	386	O
therapeutic	-	390	O
response	-	402	O
in	-	411	O
schizophrenia	-	414	B
patients	-	428	O
as	-	437	O
a	-	440	O
result	-	442	O
of	-	449	O
the	-	452	O
role	-	456	O
of	-	461	O
variations	-	464	O
in	-	475	O
the	-	478	O
receptor	-	482	O
in	-	491	O
modulating	-	494	O
receptor	-	505	O
expression	-	514	O
.	-	524	O

In	16867246	526	O
this	-	529	O
study	-	534	O
,	-	539	O
we	-	541	O
evaluate	-	544	O
the	-	553	O
role	-	557	O
DRD2	-	562	O
plays	-	567	O
in	-	573	O
chlorpromazine	-	576	O
-	-	590	O
induced	-	591	O
EPS	-	599	B
in	-	603	O
schizophrenic	-	606	B
patients	-	620	O
.	-	628	O

METHODS	16867246	630	O
:	-	637	O

We	16867246	639	O
identified	-	642	O
seven	-	653	O
SNP	-	659	O
(	-	662	O
single	-	663	O
nucleotide	-	670	O
polymorphism	-	681	O
)	-	693	O

(	16867246	695	O
-	-	696	O
141Cins	-	697	O
>	-	704	O

del	16867246	705	O
,	-	708	O
TaqIB	-	710	O
,	-	715	O
TaqID	-	717	O
,	-	722	O
Ser311Cys	-	724	O
,	-	733	O
rs6275	-	735	O
,	-	741	O
rs6277	-	743	O
and	-	750	O
TaqIA	-	754	O
)	-	759	O
in	-	761	O
the	-	764	O
DRD2	-	768	O
gene	-	773	O
in	-	778	O
146	-	781	O
schizophrenic	-	785	B
inpatients	-	799	O
(	-	810	O
59	-	811	O
with	-	814	O
EPS	-	819	B
and	-	823	O
87	-	827	O
without	-	830	O
EPS	-	838	B
according	-	842	O
to	-	852	O
the	-	855	O
Simpson	-	859	O
-	-	866	O
Angus	-	867	O
Scale	-	873	O
)	-	878	O
treated	-	880	O
with	-	888	O
chlorpromazine	-	893	O
after	-	908	O
8	-	914	O
weeks	-	916	O
.	-	921	O

The	16867246	923	O
alleles	-	927	O
of	-	935	O
all	-	938	O
loci	-	942	O
were	-	947	O
determined	-	952	O
by	-	963	O
PCR	-	966	O
(	-	970	O
polymerase	-	971	O
chain	-	982	O
reaction	-	988	O
)	-	996	O
.	-	997	O

RESULTS	16867246	999	O
:	-	1006	O

Polymorphisms	16867246	1008	O
TaqID	-	1022	O
,	-	1027	O
Ser311Cys	-	1029	O
and	-	1039	O
rs6277	-	1043	O
were	-	1050	O
not	-	1055	O
polymorphic	-	1059	O
in	-	1071	O
the	-	1074	O
population	-	1078	O
recruited	-	1089	O
in	-	1099	O
the	-	1102	O
present	-	1106	O
study	-	1114	O
.	-	1119	O

No	16867246	1121	O
statistical	-	1124	O
significance	-	1136	O
was	-	1149	O
found	-	1153	O
in	-	1159	O
the	-	1162	O
allele	-	1166	O
distribution	-	1173	O
of	-	1186	O
-	-	1189	O
141Cins	-	1190	O
>	-	1197	O
del	-	1198	O
,	-	1201	O
TaqIB	-	1203	O
,	-	1208	O
rs6275	-	1210	O
and	-	1217	O
TaqIA	-	1221	O
or	-	1227	O
in	-	1230	O
the	-	1233	O
estimated	-	1237	O
haplotypes	-	1247	O
(	-	1258	O
constituted	-	1259	O
by	-	1271	O
TaqIB	-	1274	O
,	-	1279	O
rs6275	-	1281	O
and	-	1288	O
TaqIA	-	1292	O
)	-	1297	O
in	-	1299	O
linkage	-	1302	O
disequilibrium	-	1310	O
between	-	1325	O
the	-	1333	O
two	-	1337	O
groups	-	1341	O
.	-	1347	O

CONCLUSION	16867246	1349	O
:	-	1359	O

Our	16867246	1361	O
results	-	1365	O
did	-	1373	O
not	-	1377	O
lend	-	1381	O
strong	-	1386	O
support	-	1393	O
to	-	1401	O
the	-	1404	O
view	-	1408	O
that	-	1413	O
the	-	1418	O
genetic	-	1422	O
variation	-	1430	O
of	-	1440	O
the	-	1443	O
DRD2	-	1447	O
gene	-	1452	O
plays	-	1457	O
a	-	1463	O
major	-	1465	O
role	-	1471	O
in	-	1476	O
the	-	1479	O
individually	-	1483	O
variable	-	1496	O
adverse	-	1505	O
effect	-	1513	O
induced	-	1520	O
by	-	1528	O
chlorpromazine	-	1531	O
,	-	1545	O
at	-	1547	O
least	-	1550	O
in	-	1556	O
Chinese	-	1559	O
patients	-	1567	O
with	-	1576	O
schizophrenia	-	1581	B
.	-	1594	O

Our	16867246	1596	O
results	-	1600	O
confirmed	-	1608	O
a	-	1618	O
previous	-	1620	O
study	-	1629	O
on	-	1635	O
the	-	1638	O
relationship	-	1642	O
between	-	1655	O
DRD2	-	1663	O
and	-	1668	O
EPS	-	1672	B
in	-	1676	O
Caucasians	-	1679	O
.	-	1689	O

Physical	16876986	0	O
training	-	9	O
decreases	-	18	O
susceptibility	-	28	O
to	-	43	O
subsequent	-	46	O
pilocarpine	-	57	O
-	-	68	O
induced	-	69	O
seizures	-	77	B
in	-	86	O
the	-	89	O
rat	-	93	O
.	-	96	O

Regular	16876986	98	O
motor	-	106	O
activity	-	112	O
has	-	121	O
many	-	125	O
benefits	-	130	O
for	-	139	O
mental	-	143	O
and	-	150	O
physical	-	154	O
condition	-	163	O
but	-	173	O
its	-	177	O
implications	-	181	O
for	-	194	O
epilepsy	-	198	B
are	-	207	O
still	-	211	O
controversial	-	217	O
.	-	230	O

In	16876986	232	O
order	-	235	O
to	-	241	O
elucidate	-	244	O
this	-	254	O
problem	-	259	O
,	-	266	O
we	-	268	O
have	-	271	O
studied	-	276	O
the	-	284	O
effect	-	288	O
of	-	295	O
long	-	298	O
-	-	302	O
term	-	303	O
physical	-	308	O
activity	-	317	O
on	-	326	O
susceptibility	-	329	O
to	-	344	O
subsequent	-	347	O
seizures	-	358	B
.	-	366	O

Male	16876986	368	O
Wistar	-	373	O
rats	-	380	O
were	-	385	O
subjected	-	390	O
to	-	400	O
repeated	-	403	O
training	-	412	O
sessions	-	421	O
in	-	430	O
a	-	433	O
treadmill	-	435	O
and	-	445	O
swimming	-	449	O
pool	-	458	O
.	-	462	O

Thereafter	16876986	464	O
,	-	474	O
seizures	-	476	B
were	-	485	O
induced	-	490	O
by	-	498	O
pilocarpine	-	501	O
injections	-	513	O
in	-	524	O
trained	-	527	O
and	-	535	O
non	-	539	O
-	-	542	O
trained	-	543	O
control	-	551	O
groups	-	559	O
.	-	565	O

During	16876986	567	O
the	-	574	O
acute	-	578	O
period	-	584	O
of	-	591	O
status	-	594	B
epilepticus	-	601	I
,	-	612	O
we	-	614	O
measured	-	617	O
:	-	625	O
(	-	627	O
1	-	628	O
)	-	629	O
the	-	631	O
latency	-	635	O
of	-	643	O
the	-	646	O
first	-	650	O
motor	-	656	O
sign	-	662	O
,	-	666	O
(	-	668	O
2	-	669	O
)	-	670	O
the	-	672	O
intensity	-	676	O
of	-	686	O
seizures	-	689	B
,	-	697	O
(	-	699	O
3	-	700	O
)	-	701	O
the	-	703	O
time	-	707	O
when	-	712	O
it	-	717	O
occurred	-	720	O
within	-	729	O
the	-	736	O
6	-	740	O
-	-	741	O
h	-	742	O
observation	-	744	O
period	-	756	O
,	-	762	O
and	-	764	O
(	-	768	O
4	-	769	O
)	-	770	O
the	-	772	O
time	-	776	O
when	-	781	O
the	-	786	O
acute	-	790	O
period	-	796	O
ended	-	803	O
.	-	808	O

All	16876986	810	O
these	-	814	O
behavioral	-	820	O
parameters	-	831	O
showed	-	842	O
statistically	-	849	O
significant	-	863	O
changes	-	875	O
suggesting	-	883	O
that	-	894	O
regular	-	899	O
physical	-	907	O
exercises	-	916	O
decrease	-	926	O
susceptibility	-	935	O
to	-	950	O
subsequently	-	953	O
induced	-	966	O
seizures	-	974	B
and	-	983	O
ameliorate	-	987	O
the	-	998	O
course	-	1002	O
of	-	1009	O
experimentally	-	1012	O
induced	-	1027	O
status	-	1035	B
epilepticus	-	1042	I
.	-	1053	O

Tonic	16880771	0	O
dopaminergic	-	6	O
stimulation	-	19	O
impairs	-	31	B
associative	-	39	I
learning	-	51	I
in	-	60	O
healthy	-	63	O
subjects	-	71	O
.	-	79	O

Endogenous	16880771	81	O
dopamine	-	92	O
plays	-	101	O
a	-	107	O
central	-	109	O
role	-	117	O
in	-	122	O
salience	-	125	O
coding	-	134	O
during	-	141	O
associative	-	148	O
learning	-	160	O
.	-	168	O

Administration	16880771	170	O
of	-	185	O
the	-	188	O
dopamine	-	192	O
precursor	-	201	O
levodopa	-	211	O
enhances	-	220	O
learning	-	229	O
in	-	238	O
healthy	-	241	O
subjects	-	249	O
and	-	258	O
stroke	-	262	B
patients	-	269	O
.	-	277	O

Because	16880771	279	O
levodopa	-	287	O
increases	-	296	O
both	-	306	O
phasic	-	311	O
and	-	318	O
tonic	-	322	O
dopaminergic	-	328	O
neurotransmission	-	341	O
,	-	358	O
the	-	360	O
critical	-	364	O
mechanism	-	373	O
mediating	-	383	O
the	-	393	O
enhancement	-	397	O
of	-	409	O
learning	-	412	O
is	-	421	O
unresolved	-	424	O
.	-	434	O

We	16880771	436	O
here	-	439	O
probed	-	444	O
how	-	451	O
selective	-	455	O
tonic	-	465	O
dopaminergic	-	471	O
stimulation	-	484	O
affects	-	496	O
associative	-	504	O
learning	-	516	O
.	-	524	O

Forty	16880771	526	O
healthy	-	532	O
subjects	-	540	O
were	-	549	O
trained	-	554	O
in	-	562	O
a	-	565	O
novel	-	567	O
vocabulary	-	573	O
of	-	584	O
45	-	587	O
concrete	-	590	O
nouns	-	599	O
over	-	605	O
the	-	610	O
course	-	614	O
of	-	621	O
5	-	624	O
consecutive	-	626	O
training	-	638	O
days	-	647	O
in	-	652	O
a	-	655	O
prospective	-	657	O
,	-	668	O
randomized	-	670	O
,	-	680	O
double	-	682	O
-	-	688	O
blind	-	689	O
,	-	694	O
placebo	-	696	O
-	-	703	O
controlled	-	704	O
design	-	715	O
.	-	721	O

Subjects	16880771	723	O
received	-	732	O
the	-	741	O
tonically	-	745	O
stimulating	-	755	O
dopamine	-	767	O
-	-	775	O
receptor	-	776	O
agonist	-	785	O
pergolide	-	793	O
(	-	803	O
0	-	804	O
.	-	805	O
1	-	806	O
mg	-	808	O
)	-	810	O
vs	-	812	O
placebo	-	815	O
120	-	823	O
min	-	827	O
before	-	831	O
training	-	838	O
on	-	847	O
each	-	850	O
training	-	855	O
day	-	864	O
.	-	867	O

The	16880771	869	O
dopamine	-	873	O
agonist	-	882	O
significantly	-	890	O
impaired	-	904	B
novel	-	913	I
word	-	919	I
learning	-	924	I
compared	-	933	O
to	-	942	O
placebo	-	945	O
.	-	952	O

This	16880771	954	O
learning	-	959	O
decrement	-	968	O
persisted	-	978	O
up	-	988	O
to	-	991	O
the	-	994	O
last	-	998	O
follow	-	1003	O
-	-	1009	O
up	-	1010	O
4	-	1013	O
weeks	-	1015	O
post	-	1021	O
-	-	1025	O
training	-	1026	O
.	-	1034	O

Subjects	16880771	1036	O
treated	-	1045	O
with	-	1053	O
pergolide	-	1058	O
also	-	1068	O
showed	-	1073	O
restricted	-	1080	O
emotional	-	1091	O
responses	-	1101	O
compared	-	1111	O
to	-	1120	O
the	-	1123	O
PLACEBO	-	1127	O
group	-	1135	O
.	-	1140	O

The	16880771	1142	O
extent	-	1146	O
of	-	1153	O
'	-	1156	O
flattened	-	1157	O
'	-	1166	O
affect	-	1168	O
with	-	1175	O
pergolide	-	1180	O
was	-	1190	O
related	-	1194	O
to	-	1202	O
the	-	1205	O
degree	-	1209	O
of	-	1216	O
learning	-	1219	O
inhibition	-	1228	O
.	-	1238	O

These	16880771	1240	O
findings	-	1246	O
suggest	-	1255	O
that	-	1263	O
tonic	-	1268	O
occupation	-	1274	O
of	-	1285	O
dopamine	-	1288	O
receptors	-	1297	O
impairs	-	1307	O
learning	-	1315	O
by	-	1324	O
competition	-	1327	O
with	-	1339	O
phasic	-	1344	O
dopamine	-	1351	O
signals	-	1360	O
.	-	1367	O

Thus	16880771	1369	O
,	-	1373	O
phasic	-	1375	O
signaling	-	1382	O
seems	-	1392	O
to	-	1398	O
be	-	1401	O
the	-	1404	O
critical	-	1408	O
mechanism	-	1417	O
by	-	1427	O
which	-	1430	O
dopamine	-	1436	O
enhances	-	1445	O
associative	-	1454	O
learning	-	1466	O
in	-	1475	O
healthy	-	1478	O
subjects	-	1486	O
and	-	1495	O
stroke	-	1499	B
patients	-	1506	O
.	-	1514	O

Minocycline	16906379	0	O
-	-	11	O
induced	-	12	O
vasculitis	-	20	B
fulfilling	-	31	O
the	-	42	O
criteria	-	46	O
of	-	55	O
polyarteritis	-	58	B
nodosa	-	72	I
.	-	78	O

A	16906379	80	O
47	-	82	O
-	-	84	O
year	-	85	O
-	-	89	O
old	-	90	O
man	-	94	O
who	-	98	O
had	-	102	O
been	-	106	O
taking	-	111	O
minocycline	-	118	O
for	-	130	O
palmoplantar	-	134	B
pustulosis	-	147	I
developed	-	158	O
fever	-	168	B
,	-	173	O
myalgias	-	175	B
,	-	183	O
polyneuropathy	-	185	B
,	-	199	O
and	-	201	O
testicular	-	205	B
pain	-	216	I
,	-	220	O
with	-	222	O
elevated	-	227	O
C	-	236	O
-	-	237	O
reactive	-	238	O
protein	-	247	O
(	-	255	O
CRP	-	256	O
)	-	259	O
.	-	260	O

Neither	16906379	262	O
myeloperoxidase	-	270	O
-	-	285	O
nor	-	287	O
proteinase	-	291	O
-	-	301	O
3	-	302	O
-	-	303	O
antineutrophil	-	304	O
cytoplasmic	-	319	O
antibody	-	331	O
was	-	340	O
positive	-	344	O
.	-	352	O

These	16906379	354	O
manifestations	-	360	O
met	-	375	O
the	-	379	O
American	-	383	O
College	-	392	O
of	-	400	O
Rheumatology	-	403	O
1990	-	416	O
criteria	-	421	O
for	-	430	O
the	-	434	O
classification	-	438	O
of	-	453	O
polyarteritis	-	456	B
nodosa	-	470	I
.	-	476	O

Stopping	16906379	478	O
minocycline	-	487	O
led	-	499	O
to	-	503	O
amelioration	-	506	O
of	-	519	O
symptoms	-	522	O
and	-	531	O
normalization	-	535	O
of	-	549	O
CRP	-	552	O
level	-	556	O
.	-	561	O

To	16906379	563	O
our	-	566	O
knowledge	-	570	O
,	-	579	O
this	-	581	O
is	-	586	O
the	-	589	O
second	-	593	O
case	-	600	O
of	-	605	O
minocycline	-	608	O
-	-	619	O
induced	-	620	O
vasculitis	-	628	B
satisfying	-	639	O
the	-	650	O
criteria	-	654	O
.	-	662	O

Differential	16906379	664	O
diagnosis	-	677	O
for	-	687	O
drug	-	691	O
-	-	695	O
induced	-	696	O
disease	-	704	O
is	-	712	O
invaluable	-	715	O
even	-	726	O
for	-	731	O
patients	-	735	O
with	-	744	O
classical	-	749	O
polyarteritis	-	759	B
nodosa	-	773	I
.	-	779	O

Intramuscular	16911931	0	O
hepatitis	-	14	B
B	-	24	I
immune	-	26	O
globulin	-	33	O
combined	-	42	O
with	-	51	O
lamivudine	-	56	O
in	-	67	O
prevention	-	70	O
of	-	81	O
hepatitis	-	84	B
B	-	94	I
recurrence	-	96	O
after	-	107	O
liver	-	113	O
transplantation	-	119	O
.	-	134	O

BACKGROUND	16911931	136	O
:	-	146	O
Combined	-	148	O
hepatitis	-	157	B
B	-	167	I
immune	-	169	O
globulin	-	176	O
(	-	185	O
HBIg	-	186	O
)	-	190	O
and	-	192	O
lamivudine	-	196	O
in	-	207	O
prophylaxis	-	210	O
of	-	222	O
the	-	225	O
recurrence	-	229	O
of	-	240	O
hepatitis	-	243	B
B	-	253	I
after	-	255	O
liver	-	261	O
transplantation	-	267	O
has	-	283	O
significantly	-	287	O
improved	-	301	O
the	-	310	O
survival	-	314	O
of	-	323	O
HBsAg	-	326	O
positive	-	332	O
patients	-	341	O
.	-	349	O

This	16911931	351	O
study	-	356	O
was	-	362	O
undertaken	-	366	O
to	-	377	O
evaluate	-	380	O
the	-	389	O
outcomes	-	393	O
of	-	402	O
liver	-	405	O
transplantation	-	411	O
for	-	427	O
patients	-	431	O
with	-	440	O
hepatitis	-	445	B
B	-	455	I
virus	-	457	O
(	-	463	O
HBV	-	464	O
)	-	467	O
.	-	468	O

METHODS	16911931	470	O
:	-	477	O

A	16911931	479	O
retrospective	-	481	O
chart	-	495	O
analysis	-	501	O
and	-	510	O
a	-	514	O
review	-	516	O
of	-	523	O
the	-	526	O
organ	-	530	O
transplant	-	536	O
database	-	547	O
identified	-	556	O
51	-	567	O
patients	-	570	O
(	-	579	O
43	-	580	O
men	-	583	O
and	-	587	O
8	-	591	O
women	-	593	O
)	-	598	O
transplanted	-	600	O
for	-	613	O
benign	-	617	O
HBV	-	624	O
-	-	627	O
related	-	628	O
cirrhotic	-	636	B
diseases	-	646	I
between	-	655	O
June	-	663	O
2002	-	668	O
and	-	673	O
December	-	677	O
2004	-	686	O
who	-	691	O
had	-	695	O
survived	-	699	O
more	-	708	O
than	-	713	O
3	-	718	O
months	-	720	O
.	-	726	O

HBIg	16911931	728	O
was	-	733	O
administered	-	737	O
intravenously	-	750	O
during	-	764	O
the	-	771	O
first	-	775	O
week	-	781	O
and	-	786	O
intramuscularly	-	790	O
thereafter	-	806	O
.	-	816	O

RESULTS	16911931	818	O
:	-	825	O

At	16911931	827	O
a	-	830	O
median	-	832	O
follow	-	839	O
-	-	845	O
up	-	846	O
of	-	849	O
14	-	852	O
.	-	854	O
1	-	855	O
months	-	857	O
,	-	863	O
the	-	865	O
overall	-	869	O
recurrence	-	877	O
rate	-	888	O
in	-	893	O
the	-	896	O
51	-	900	O
patients	-	903	O
was	-	912	O
3	-	916	O
.	-	917	O
9	-	918	O
%	-	919	O
(	-	921	O
2	-	922	O
/	-	923	O
51	-	924	O
)	-	926	O
.	-	927	O

The	16911931	929	O
overall	-	933	O
patient	-	941	O
survival	-	949	O
was	-	958	O
88	-	962	O
.	-	964	O
3	-	965	O
%	-	966	O
,	-	967	O
and	-	969	O
82	-	973	O
.	-	975	O
4	-	976	O
%	-	977	O
after	-	979	O
1	-	985	O
and	-	987	O
2	-	991	O
years	-	993	O
,	-	998	O
respectively	-	1000	O
.	-	1012	O

A	16911931	1014	O
daily	-	1016	O
oral	-	1022	O
dose	-	1027	O
of	-	1032	O
100	-	1035	O
mg	-	1039	O
lamivudine	-	1042	O
for	-	1053	O
2	-	1057	O
weeks	-	1059	O
before	-	1065	O
transplantation	-	1072	O
for	-	1088	O
10	-	1092	O
patients	-	1095	O
enabled	-	1104	O
57	-	1112	O
.	-	1114	O
1	-	1115	O
%	-	1116	O
(	-	1118	O
4	-	1119	O
/	-	1120	O
7	-	1121	O
)	-	1122	O
and	-	1124	O
62	-	1128	O
.	-	1130	O
5	-	1131	O
%	-	1132	O
(	-	1134	O
5	-	1135	O
/	-	1136	O
8	-	1137	O
)	-	1138	O
of	-	1140	O
HBV	-	1143	O
-	-	1146	O
DNA	-	1147	O
and	-	1151	O
HBeAg	-	1155	O
positive	-	1161	O
patients	-	1170	O
respectively	-	1179	O
to	-	1192	O
convert	-	1195	O
to	-	1203	O
be	-	1206	O
negative	-	1209	O
.	-	1217	O

Intramuscular	16911931	1219	O
HBIg	-	1233	O
was	-	1238	O
well	-	1242	O
tolerated	-	1247	O
in	-	1257	O
all	-	1260	O
patients	-	1264	O
.	-	1272	O

CONCLUSION	16911931	1274	O
:	-	1284	O

Lamivudine	16911931	1286	O
combined	-	1297	O
with	-	1306	O
intramuscular	-	1311	O
HBIg	-	1325	O
can	-	1330	O
effectively	-	1334	O
prevent	-	1346	O
allograft	-	1354	O
from	-	1364	O
the	-	1369	O
recurrence	-	1373	O
of	-	1384	O
HBV	-	1387	O
after	-	1391	O
liver	-	1397	O
transplantation	-	1403	O
.	-	1418	O

Anticonvulsant	16920333	0	O
effect	-	15	O
of	-	22	O
eslicarbazepine	-	25	O
acetate	-	41	O
(	-	49	O
BIA	-	50	O
2	-	54	O
-	-	55	O
093	-	56	O
)	-	59	O
on	-	61	O
seizures	-	64	B
induced	-	73	O
by	-	81	O
microperfusion	-	84	O
of	-	99	O
picrotoxin	-	102	O
in	-	113	O
the	-	116	O
hippocampus	-	120	O
of	-	132	O
freely	-	135	O
moving	-	142	O
rats	-	149	O
.	-	153	O

Eslicarbazepine	16920333	155	O
acetate	-	171	O
(	-	179	O
BIA	-	180	O
2	-	184	O
-	-	185	O
093	-	186	O
,	-	189	O
S	-	191	O
-	-	192	O
(	-	193	O
-	-	194	O
)	-	195	O
-	-	196	O
10	-	197	O
-	-	199	O
acetoxy	-	200	O
-	-	207	O
10	-	208	O
,	-	210	O
11	-	211	O
-	-	213	O
dihydro	-	214	O
-	-	221	O
5H	-	222	O
-	-	224	O
dibenzo	-	225	O
/	-	232	O
b	-	233	O
,	-	234	O
f	-	235	O
/	-	236	O
azepine	-	237	O
-	-	244	O
5	-	245	O
-	-	246	O
carboxamide	-	247	O
)	-	258	O
is	-	260	O
a	-	263	O
novel	-	265	O
antiepileptic	-	271	O
drug	-	285	O
,	-	289	O
now	-	291	O
in	-	295	O
Phase	-	298	O
III	-	304	O
clinical	-	308	O
trials	-	317	O
,	-	323	O
designed	-	325	O
with	-	334	O
the	-	339	O
aim	-	343	O
of	-	347	O
improving	-	350	O
efficacy	-	360	O
and	-	369	O
safety	-	373	O
in	-	380	O
comparison	-	383	O
with	-	394	O
the	-	399	O
structurally	-	403	O
related	-	416	O
drugs	-	424	O
carbamazepine	-	430	O
(	-	444	O
CBZ	-	445	O
)	-	448	O
and	-	450	O
oxcarbazepine	-	454	O
(	-	468	O
OXC	-	469	O
)	-	472	O
.	-	473	O

We	16920333	475	O
have	-	478	O
studied	-	483	O
the	-	491	O
effects	-	495	O
of	-	503	O
oral	-	506	O
treatment	-	511	O
with	-	521	O
eslicarbazepine	-	526	O
acetate	-	542	O
on	-	550	O
a	-	553	O
whole	-	555	O
-	-	560	O
animal	-	561	O
model	-	568	O
in	-	574	O
which	-	577	O
partial	-	583	O
seizures	-	591	B
can	-	600	O
be	-	604	O
elicited	-	607	O
repeatedly	-	616	O
on	-	627	O
different	-	630	O
days	-	640	O
without	-	645	O
changes	-	653	O
in	-	661	O
threshold	-	664	O
or	-	674	O
seizure	-	677	B
patterns	-	685	O
.	-	693	O

In	16920333	695	O
the	-	698	O
animals	-	702	O
treated	-	710	O
with	-	718	O
threshold	-	723	O
doses	-	733	O
of	-	739	O
picrotoxin	-	742	O
,	-	752	O
the	-	754	O
average	-	758	O
number	-	766	O
of	-	773	O
seizures	-	776	B
was	-	785	O
2	-	789	O
.	-	790	O
3	-	791	O
+	-	792	O
/	-	793	O
-	-	794	O
1	-	795	O
.	-	796	O
2	-	797	O
,	-	798	O
and	-	800	O
average	-	804	O
seizure	-	812	B
duration	-	820	O
was	-	829	O
39	-	833	O
.	-	835	O
5	-	836	O
+	-	837	O
/	-	838	O
-	-	839	O
8	-	840	O
.	-	841	O
4s	-	842	O
.	-	844	O
Pre	-	846	O
-	-	849	O
treatment	-	850	O
with	-	860	O
a	-	865	O
dose	-	867	O
of	-	872	O
30	-	875	O
mg	-	878	O
/	-	880	O
kg	-	881	O
2h	-	884	O
before	-	887	O
picrotoxin	-	894	O
microperfusion	-	905	O
prevented	-	920	O
seizures	-	930	B
in	-	939	O
the	-	942	O
75	-	946	O
%	-	948	O
of	-	950	O
the	-	953	O
rats	-	957	O
.	-	961	O

Lower	16920333	963	O
doses	-	969	O
(	-	975	O
3	-	976	O
and	-	978	O
10mg	-	982	O
/	-	986	O
kg	-	987	O
)	-	989	O
did	-	991	O
not	-	995	O
suppress	-	999	O
seizures	-	1008	B
,	-	1016	O
however	-	1018	O
,	-	1025	O
after	-	1027	O
administration	-	1033	O
of	-	1048	O
10mg	-	1051	O
/	-	1055	O
kg	-	1056	O
,	-	1058	O
significant	-	1060	O
reductions	-	1072	O
in	-	1083	O
seizures	-	1086	B
duration	-	1095	O
(	-	1104	O
24	-	1105	O
.	-	1107	O
3	-	1108	O
+	-	1109	O
/	-	1110	O
-	-	1111	O
6	-	1112	O
.	-	1113	O
8s	-	1114	O
)	-	1116	O
and	-	1118	O
seizure	-	1122	B
number	-	1130	O
(	-	1137	O
1	-	1138	O
.	-	1139	O
6	-	1140	O
+	-	1141	O
/	-	1142	O
-	-	1143	O
0	-	1144	O
.	-	1145	O
34	-	1146	O
)	-	1148	O
were	-	1150	O
found	-	1155	O
.	-	1160	O

No	16920333	1162	O
adverse	-	1165	O
effects	-	1173	O
of	-	1181	O
eslicarbazepine	-	1184	O
acetate	-	1200	O
were	-	1208	O
observed	-	1213	O
in	-	1222	O
the	-	1225	O
behavioral	-	1229	O
/	-	1239	O
EEG	-	1240	O
patterns	-	1244	O
studied	-	1253	O
,	-	1260	O
including	-	1262	O
sleep	-	1272	O
/	-	1277	O
wakefulness	-	1278	O
cycle	-	1290	O
,	-	1295	O
at	-	1297	O
the	-	1300	O
doses	-	1304	O
studied	-	1310	O
.	-	1317	O

Acute	17028363	0	B
renal	-	6	I
failure	-	12	I
associated	-	20	O
with	-	31	O
prolonged	-	36	O
intake	-	46	O
of	-	53	O
slimming	-	56	O
pills	-	65	O
containing	-	71	O
anthraquinones	-	82	O
.	-	96	O

Chinese	17028363	98	O
herbal	-	106	O
medicine	-	113	O
preparations	-	122	O
are	-	135	O
widely	-	139	O
available	-	146	O
and	-	156	O
often	-	160	O
regarded	-	166	O
by	-	175	O
the	-	178	O
public	-	182	O
as	-	189	O
natural	-	192	O
and	-	200	O
safe	-	204	O
remedies	-	209	O
for	-	218	O
a	-	222	O
variety	-	224	O
of	-	232	O
medical	-	235	O
conditions	-	243	O
.	-	253	O

Nephropathy	17028363	255	B
caused	-	267	O
by	-	274	O
Chinese	-	277	O
herbs	-	285	O
has	-	291	O
previously	-	295	O
been	-	306	O
reported	-	311	O
,	-	319	O
usually	-	321	O
involving	-	329	O
the	-	339	O
use	-	343	O
of	-	347	O
aristolochic	-	350	O
acids	-	363	O
.	-	368	O

We	17028363	370	O
report	-	373	O
a	-	380	O
23	-	382	O
-	-	384	O
year	-	385	O
-	-	389	O
old	-	390	O
woman	-	394	O
who	-	400	O
developed	-	404	O
acute	-	414	B
renal	-	420	I
failure	-	426	I
following	-	434	O
prolonged	-	444	O
use	-	454	O
of	-	458	O
a	-	461	O
proprietary	-	463	O
Chinese	-	475	O
herbal	-	483	O
slimming	-	490	O
pill	-	499	O
that	-	504	O
contained	-	509	O
anthraquinone	-	519	O
derivatives	-	533	O
,	-	544	O
extracted	-	546	O
from	-	556	O
Rhizoma	-	561	O
Rhei	-	569	O
(	-	574	O
rhubarb	-	575	O
)	-	582	O
.	-	583	O

The	17028363	585	O
renal	-	589	B
injury	-	595	I
was	-	602	O
probably	-	606	O
aggravated	-	615	O
by	-	626	O
the	-	629	O
concomitant	-	633	O
intake	-	645	O
of	-	652	O
a	-	655	O
non	-	657	O
-	-	660	O
steroidal	-	661	O
anti	-	671	O
-	-	675	O
inflammatory	-	676	O
drug	-	689	O
,	-	693	O
diclofenac	-	695	O
.	-	705	O

Renal	17028363	707	O
pathology	-	713	O
was	-	723	O
that	-	727	O
of	-	732	O
hypocellular	-	735	O
interstitial	-	748	O
fibrosis	-	761	B
.	-	769	O

Spontaneous	17028363	771	O
renal	-	783	O
recovery	-	789	O
occurred	-	798	O
upon	-	807	O
cessation	-	812	O
of	-	822	O
the	-	825	O
slimming	-	829	O
pills	-	838	O
,	-	843	O
but	-	845	O
mild	-	849	O
interstitial	-	854	O
fibrosis	-	867	B
and	-	876	O
tubular	-	880	O
atrophy	-	888	B
was	-	896	O
still	-	900	O
evident	-	906	O
histologically	-	914	O
4	-	929	O
months	-	931	O
later	-	938	O
.	-	943	O

Although	17028363	945	O
a	-	954	O
causal	-	956	O
relationship	-	963	O
between	-	976	O
the	-	984	O
use	-	988	O
of	-	992	O
an	-	995	O
anthraquinone	-	998	O
-	-	1011	O
containing	-	1012	O
herbal	-	1023	O
agent	-	1030	O
and	-	1036	O
renal	-	1040	B
injury	-	1046	I
remains	-	1053	O
to	-	1061	O
be	-	1064	O
proven	-	1067	O
,	-	1073	O
phytotherapy	-	1075	O
-	-	1087	O
associated	-	1088	O
interstitial	-	1099	O
nephropathy	-	1112	B
should	-	1124	O
be	-	1131	O
considered	-	1134	O
in	-	1145	O
patients	-	1148	O
who	-	1157	O
present	-	1161	O
with	-	1169	O
unexplained	-	1174	O
renal	-	1186	B
failure	-	1192	I
.	-	1199	O

Chloroacetaldehyde	17035713	0	O
as	-	19	O
a	-	22	O
sulfhydryl	-	24	O
reagent	-	35	O
:	-	42	O
the	-	44	O
role	-	48	O
of	-	53	O
critical	-	56	O
thiol	-	65	O
groups	-	71	O
in	-	78	O
ifosfamide	-	81	O
nephropathy	-	92	B
.	-	103	O

Chloroacetaldehyde	17035713	105	O
(	-	124	O
CAA	-	125	O
)	-	128	O
is	-	130	O
a	-	133	O
metabolite	-	135	O
of	-	146	O
the	-	149	O
alkylating	-	153	O
agent	-	164	O
ifosfamide	-	170	O
(	-	181	O
IFO	-	182	O
)	-	185	O
and	-	187	O
putatively	-	191	O
responsible	-	202	O
for	-	214	O
renal	-	218	B
damage	-	224	I
following	-	231	O
anti	-	241	O
-	-	245	O
tumor	-	246	B
therapy	-	252	O
with	-	260	O
IFO	-	265	O
.	-	268	O

Depletion	17035713	270	O
of	-	280	O
sulfhydryl	-	283	O
(	-	294	O
SH	-	295	O
)	-	297	O
groups	-	299	O
has	-	306	O
been	-	310	O
reported	-	315	O
from	-	324	O
cell	-	329	O
culture	-	334	O
,	-	341	O
animal	-	343	O
and	-	350	O
clinical	-	354	O
studies	-	363	O
.	-	370	O

In	17035713	372	O
this	-	375	O
work	-	380	O
the	-	385	O
effect	-	389	O
of	-	396	O
CAA	-	399	O
on	-	403	O
human	-	406	O
proximal	-	412	O
tubule	-	421	O
cells	-	428	O
in	-	434	O
primary	-	437	O
culture	-	445	O
(	-	453	O
hRPTEC	-	454	O
)	-	460	O
was	-	462	O
investigated	-	466	O
.	-	478	O

Toxicity	17035713	480	B
of	-	489	O
CAA	-	492	O
was	-	496	O
determined	-	500	O
by	-	511	O
protein	-	514	O
content	-	522	O
,	-	529	O
cell	-	531	O
number	-	536	O
,	-	542	O
LDH	-	544	O
release	-	548	O
,	-	555	O
trypan	-	557	O
blue	-	564	O
exclusion	-	569	O
assay	-	579	O
and	-	585	O
caspase	-	589	O
-	-	596	O
3	-	597	O
activity	-	599	O
.	-	607	O

Free	17035713	609	O
thiols	-	614	O
were	-	621	O
measured	-	626	O
by	-	635	O
the	-	638	O
method	-	642	O
of	-	649	O
Ellman	-	652	O
.	-	658	O

CAA	17035713	660	O
reduced	-	664	O
hRPTEC	-	672	O
cell	-	679	O
number	-	684	O
and	-	691	O
protein	-	695	O
,	-	702	O
induced	-	704	O
a	-	712	O
loss	-	714	O
in	-	719	O
free	-	722	O
intracellular	-	727	O
thiols	-	741	O
and	-	748	O
an	-	752	O
increase	-	755	O
in	-	764	O
necrosis	-	767	B
markers	-	776	O
.	-	783	O

CAA	17035713	785	O
but	-	789	O
not	-	793	O
acrolein	-	797	O
inhibited	-	806	O
the	-	816	O
cysteine	-	820	O
proteases	-	829	O
caspase	-	839	O
-	-	846	O
3	-	847	O
,	-	848	O
caspase	-	850	O
-	-	857	O
8	-	858	O
and	-	860	O
cathepsin	-	864	O
B	-	874	O
.	-	875	O
Caspase	-	877	O
activation	-	885	O
by	-	896	O
cisplatin	-	899	O
was	-	909	O
inhibited	-	913	O
by	-	923	O
CAA	-	926	O
.	-	929	O

In	17035713	931	O
cells	-	934	O
stained	-	940	O
with	-	948	O
fluorescent	-	953	O
dyes	-	965	O
targeting	-	970	O
lysosomes	-	980	O
,	-	989	O
CAA	-	991	O
induced	-	995	O
an	-	1003	O
increase	-	1006	O
in	-	1015	O
lysosomal	-	1018	O
size	-	1028	O
and	-	1033	O
lysosomal	-	1037	O
leakage	-	1047	O
.	-	1054	O

The	17035713	1056	O
effects	-	1060	O
of	-	1068	O
CAA	-	1071	O
on	-	1075	O
cysteine	-	1078	O
protease	-	1087	O
activities	-	1096	O
and	-	1107	O
thiols	-	1111	O
could	-	1118	O
be	-	1124	O
reproduced	-	1127	O
in	-	1138	O
cell	-	1141	O
lysate	-	1146	O
.	-	1152	O

Acidification	17035713	1154	O
,	-	1167	O
which	-	1169	O
slowed	-	1175	O
the	-	1182	O
reaction	-	1186	O
of	-	1195	O
CAA	-	1198	O
with	-	1202	O
thiol	-	1207	O
donors	-	1213	O
,	-	1219	O
could	-	1221	O
also	-	1227	O
attenuate	-	1232	O
effects	-	1242	O
of	-	1250	O
CAA	-	1253	O
on	-	1257	O
necrosis	-	1260	B
markers	-	1269	O
,	-	1276	O
thiol	-	1278	O
depletion	-	1284	O
and	-	1294	O
cysteine	-	1298	O
protease	-	1307	O
inhibition	-	1316	O
in	-	1327	O
living	-	1330	O
cells	-	1337	O
.	-	1342	O

Thus	17035713	1344	O
,	-	1348	O
CAA	-	1350	O
directly	-	1354	O
reacts	-	1363	O
with	-	1370	O
cellular	-	1375	O
protein	-	1384	O
and	-	1392	O
non	-	1396	O
-	-	1399	O
protein	-	1400	O
thiols	-	1408	O
,	-	1414	O
mediating	-	1416	O
its	-	1426	O
toxicity	-	1430	B
on	-	1439	O
hRPTEC	-	1442	O
.	-	1448	O

This	17035713	1450	O
effect	-	1455	O
can	-	1462	O
be	-	1466	O
reduced	-	1469	O
by	-	1477	O
acidification	-	1480	O
.	-	1493	O

Therefore	17035713	1495	O
,	-	1504	O
urinary	-	1506	O
acidification	-	1514	O
could	-	1528	O
be	-	1534	O
an	-	1537	O
option	-	1540	O
to	-	1547	O
prevent	-	1550	O
IFO	-	1558	O
nephropathy	-	1562	B
in	-	1574	O
patients	-	1577	O
.	-	1585	O

Stereological	17042797	0	O
methods	-	14	O
reveal	-	22	O
the	-	29	O
robust	-	33	O
size	-	40	O
and	-	45	O
stability	-	49	O
of	-	59	O
ectopic	-	62	O
hilar	-	70	O
granule	-	76	O
cells	-	84	O
after	-	90	O
pilocarpine	-	96	O
-	-	107	O
induced	-	108	O
status	-	116	B
epilepticus	-	123	I
in	-	135	O
the	-	138	O
adult	-	142	O
rat	-	148	O
.	-	151	O

Following	17042797	153	O
status	-	163	B
epilepticus	-	170	I
in	-	182	O
the	-	185	O
rat	-	189	O
,	-	192	O
dentate	-	194	O
granule	-	202	O
cell	-	210	O
neurogenesis	-	215	O
increases	-	228	O
greatly	-	238	O
,	-	245	O
and	-	247	O
many	-	251	O
of	-	256	O
the	-	259	O
new	-	263	O
neurons	-	267	O
appear	-	275	O
to	-	282	O
develop	-	285	O
ectopically	-	293	O
,	-	304	O
in	-	306	O
the	-	309	O
hilar	-	313	O
region	-	319	O
of	-	326	O
the	-	329	O
hippocampal	-	333	O
formation	-	345	O
.	-	354	O

It	17042797	356	O
has	-	359	O
been	-	363	O
suggested	-	368	O
that	-	378	O
the	-	383	O
ectopic	-	387	O
hilar	-	395	O
granule	-	401	O
cells	-	409	O
could	-	415	O
contribute	-	421	O
to	-	432	O
the	-	435	O
spontaneous	-	439	O
seizures	-	451	B
that	-	460	O
ultimately	-	465	O
develop	-	476	O
after	-	484	O
status	-	490	B
epilepticus	-	497	I
.	-	508	O

However	17042797	510	O
,	-	517	O
the	-	519	O
population	-	523	O
has	-	534	O
never	-	538	O
been	-	544	O
quantified	-	549	O
,	-	559	O
so	-	561	O
it	-	564	O
is	-	567	O
unclear	-	570	O
whether	-	578	O
it	-	586	O
is	-	589	O
substantial	-	592	O
enough	-	604	O
to	-	611	O
have	-	614	O
a	-	619	O
strong	-	621	O
influence	-	628	O
on	-	638	O
epileptogenesis	-	641	O
.	-	656	O

To	17042797	658	O
quantify	-	661	O
this	-	670	O
population	-	675	O
,	-	685	O
the	-	687	O
total	-	691	O
number	-	697	O
of	-	704	O
ectopic	-	707	O
hilar	-	715	O
granule	-	721	O
cells	-	729	O
was	-	735	O
estimated	-	739	O
using	-	749	O
unbiased	-	755	O
stereology	-	764	O
at	-	775	O
different	-	778	O
times	-	788	O
after	-	794	O
pilocarpine	-	800	O
-	-	811	O
induced	-	812	O
status	-	820	B
epilepticus	-	827	I
.	-	838	O

The	17042797	840	O
number	-	844	O
of	-	851	O
hilar	-	854	O
neurons	-	860	O
immunoreactive	-	868	O
for	-	883	O
Prox	-	887	O
-	-	891	O
1	-	892	O
,	-	893	O
a	-	895	O
granule	-	897	O
-	-	904	O
cell	-	905	O
-	-	909	O
specific	-	910	O
marker	-	919	O
,	-	925	O
was	-	927	O
estimated	-	931	O
using	-	941	O
the	-	947	O
optical	-	951	O
fractionator	-	959	O
method	-	972	O
.	-	978	O

The	17042797	980	O
results	-	984	O
indicate	-	992	O
that	-	1001	O
the	-	1006	O
size	-	1010	O
of	-	1015	O
the	-	1018	O
hilar	-	1022	O
ectopic	-	1028	O
granule	-	1036	O
cell	-	1044	O
population	-	1049	O
after	-	1060	O
status	-	1066	B
epilepticus	-	1073	I
is	-	1085	O
substantial	-	1088	O
,	-	1099	O
and	-	1101	O
stable	-	1105	O
over	-	1112	O
time	-	1117	O
.	-	1121	O

Interestingly	17042797	1123	O
,	-	1136	O
the	-	1138	O
size	-	1142	O
of	-	1147	O
the	-	1150	O
population	-	1154	O
appears	-	1165	O
to	-	1173	O
be	-	1176	O
correlated	-	1179	O
with	-	1190	O
the	-	1195	O
frequency	-	1199	O
of	-	1209	O
behavioral	-	1212	O
seizures	-	1223	B
,	-	1231	O
because	-	1233	O
animals	-	1241	O
with	-	1249	O
more	-	1254	O
ectopic	-	1259	O
granule	-	1267	O
cells	-	1275	O
in	-	1281	O
the	-	1284	O
hilus	-	1288	O
have	-	1294	O
more	-	1299	O
frequent	-	1304	O
behavioral	-	1313	O
seizures	-	1324	B
.	-	1332	O

The	17042797	1334	O
hilar	-	1338	O
ectopic	-	1344	O
granule	-	1352	O
cell	-	1360	O
population	-	1365	O
does	-	1376	O
not	-	1381	O
appear	-	1385	O
to	-	1392	O
vary	-	1395	O
systematically	-	1400	O
across	-	1415	O
the	-	1422	O
septotemporal	-	1426	O
axis	-	1440	O
,	-	1444	O
although	-	1446	O
it	-	1455	O
is	-	1458	O
associated	-	1461	O
with	-	1472	O
an	-	1477	O
increase	-	1480	O
in	-	1489	O
volume	-	1492	O
of	-	1499	O
the	-	1502	O
hilus	-	1506	O
.	-	1511	O

The	17042797	1513	O
results	-	1517	O
provide	-	1525	O
new	-	1533	O
insight	-	1537	O
into	-	1545	O
the	-	1550	O
potential	-	1554	O
role	-	1564	O
of	-	1569	O
ectopic	-	1572	O
hilar	-	1580	O
granule	-	1586	O
cells	-	1594	O
in	-	1600	O
the	-	1603	O
pilocarpine	-	1607	O
model	-	1619	O
of	-	1625	O
temporal	-	1628	B
lobe	-	1637	I
epilepsy	-	1642	I
.	-	1650	O

A	17069550	0	O
prospective	-	2	O
,	-	13	O
open	-	15	O
-	-	19	O
label	-	20	O
trial	-	26	O
of	-	32	O
galantamine	-	35	O
in	-	47	O
autistic	-	50	B
disorder	-	59	I
.	-	67	O

OBJECTIVE	17069550	69	O
:	-	78	O
Post	-	80	O
-	-	84	O
mortem	-	85	O
studies	-	92	O
have	-	100	O
reported	-	105	O
abnormalities	-	114	O
of	-	128	O
the	-	131	O
cholinergic	-	135	O
system	-	147	O
in	-	154	O
autism	-	157	B
.	-	163	O

The	17069550	165	O
purpose	-	169	O
of	-	177	O
this	-	180	O
study	-	185	O
was	-	191	O
to	-	195	O
assess	-	198	O
the	-	205	O
use	-	209	O
of	-	213	O
galantamine	-	216	O
,	-	227	O
an	-	229	O
acetylcholinesterase	-	232	O
inhibitor	-	253	O
and	-	263	O
nicotinic	-	267	O
receptor	-	277	O
modulator	-	286	O
,	-	295	O
in	-	297	O
the	-	300	O
treatment	-	304	O
of	-	314	O
interfering	-	317	O
behaviors	-	329	O
in	-	339	O
children	-	342	O
with	-	351	O
autism	-	356	B
.	-	362	O

METHODS	17069550	364	O
:	-	371	O

Thirteen	17069550	373	O
medication	-	382	O
-	-	392	O
free	-	393	O
children	-	398	O
with	-	407	O
autism	-	412	B
(	-	419	O
mean	-	420	O
age	-	425	O
,	-	428	O
8	-	430	O
.	-	431	O
8	-	432	O
+	-	434	O
/	-	435	O
-	-	436	O

3	17069550	438	O
.	-	439	O
5	-	440	O
years	-	442	O
)	-	447	O
participated	-	449	O
in	-	462	O
a	-	465	O
12	-	467	O
-	-	469	O
week	-	470	O
,	-	474	O
open	-	476	O
-	-	480	O
label	-	481	O
trial	-	487	O
of	-	493	O
galantamine	-	496	O
.	-	507	O

Patients	17069550	509	O
were	-	518	O
rated	-	523	O
monthly	-	529	O
by	-	537	O
parents	-	540	O
on	-	548	O
the	-	551	O
Aberrant	-	555	O
Behavior	-	564	O
Checklist	-	573	O
(	-	583	O
ABC	-	584	O
)	-	587	O
and	-	589	O
the	-	593	O
Conners	-	597	O
'	-	604	O
Parent	-	606	O
Rating	-	613	O
Scale	-	620	O
-	-	625	O
Revised	-	626	O
,	-	633	O
and	-	635	O
by	-	639	O
a	-	642	O
physician	-	644	O
using	-	654	O
the	-	660	O
Children	-	664	O
's	-	672	O
Psychiatric	-	675	O
Rating	-	687	O
Scale	-	694	O
and	-	700	O
the	-	704	O
Clinical	-	708	O
Global	-	717	O
Impressions	-	724	O
scale	-	736	O
.	-	741	O

RESULTS	17069550	743	O
:	-	750	O

Patients	17069550	752	O
showed	-	761	O
a	-	768	O
significant	-	770	O
reduction	-	782	O
in	-	792	O
parent	-	795	O
-	-	801	O
rated	-	802	O
irritability	-	808	B
and	-	821	O
social	-	825	O
withdrawal	-	832	O
on	-	843	O
the	-	846	O
ABC	-	850	O
as	-	854	O
well	-	857	O
as	-	862	O
significant	-	865	O
improvements	-	877	O
in	-	890	O
emotional	-	893	O
lability	-	903	O
and	-	912	O
inattention	-	916	O
on	-	928	O
the	-	931	O
Conners	-	935	O
'	-	942	O
Parent	-	944	O
Rating	-	951	O
Scale	-	958	O
-	-	963	O
-	-	964	O
Revised	-	965	O
.	-	972	O

Similarly	17069550	974	O
,	-	983	O
clinician	-	985	O
ratings	-	995	O
showed	-	1003	O
reductions	-	1010	O
in	-	1021	O
the	-	1024	O
anger	-	1028	O
subscale	-	1034	O
of	-	1043	O
the	-	1046	O
Children	-	1050	O
's	-	1058	O
Psychiatric	-	1061	O
Rating	-	1073	O
Scale	-	1080	O
.	-	1085	O

Eight	17069550	1087	O
of	-	1093	O
13	-	1096	O
participants	-	1099	O
were	-	1112	O
rated	-	1117	O
as	-	1123	O
responders	-	1126	O
on	-	1137	O
the	-	1140	O
basis	-	1144	O
of	-	1150	O
their	-	1153	O
improvement	-	1159	O
scores	-	1171	O
on	-	1178	O
the	-	1181	O
Clinical	-	1185	O
Global	-	1194	O
Impressions	-	1201	O
scale	-	1213	O
.	-	1218	O

Overall	17069550	1220	O
,	-	1227	O
galantamine	-	1229	O
was	-	1241	O
well	-	1245	O
-	-	1249	O
tolerated	-	1250	O
,	-	1259	O
with	-	1261	O
no	-	1266	O
significant	-	1269	O
adverse	-	1281	O
effects	-	1289	O
apart	-	1297	O
from	-	1303	O
headaches	-	1308	B
in	-	1318	O
one	-	1321	O
patient	-	1325	O
.	-	1332	O

CONCLUSION	17069550	1334	O
:	-	1344	O

In	17069550	1346	O
this	-	1349	O
open	-	1354	O
trial	-	1359	O
,	-	1364	O
galantamine	-	1366	O
was	-	1378	O
well	-	1382	O
-	-	1386	O
tolerated	-	1387	O
and	-	1397	O
appeared	-	1401	O
to	-	1410	O
be	-	1413	O
beneficial	-	1416	O
for	-	1427	O
the	-	1431	O
treatment	-	1435	O
of	-	1445	O
interfering	-	1448	O
behaviors	-	1460	O
in	-	1470	O
children	-	1473	O
with	-	1482	O
autism	-	1487	B
,	-	1493	O
particularly	-	1495	O
aggression	-	1508	B
,	-	1518	O
behavioral	-	1520	B
dyscontrol	-	1531	I
,	-	1541	O
and	-	1543	O
inattention	-	1547	B
.	-	1558	O

Further	17069550	1560	O
controlled	-	1568	O
trials	-	1579	O
are	-	1586	O
warranted	-	1590	O
.	-	1599	O

Randomized	17151160	0	O
comparison	-	11	O
of	-	22	O
olanzapine	-	25	O
versus	-	36	O
risperidone	-	43	O
for	-	55	O
the	-	59	O
treatment	-	63	O
of	-	73	O
first	-	76	O
-	-	81	O
episode	-	82	O
schizophrenia	-	90	B
:	-	103	O
4	-	105	O
-	-	106	O
month	-	107	O
outcomes	-	113	O
.	-	121	O

OBJECTIVE	17151160	123	O
:	-	132	O

The	17151160	134	O
authors	-	138	O
compared	-	146	O
4	-	155	O
-	-	156	O
month	-	157	O
treatment	-	163	O
outcomes	-	173	O
for	-	182	O
olanzapine	-	186	O
versus	-	197	O
risperidone	-	204	O
in	-	216	O
patients	-	219	O
with	-	228	O
first	-	233	O
-	-	238	O
episode	-	239	O
schizophrenia	-	247	B
spectrum	-	261	O
disorders	-	270	O
.	-	279	O

METHOD	17151160	281	O
:	-	287	O

One	17151160	289	O
hundred	-	293	O
twelve	-	301	O
subjects	-	308	O
(	-	317	O
70	-	318	O
%	-	320	O
male	-	322	O
;	-	326	O
mean	-	328	O
age	-	333	O
=	-	336	O
23	-	337	O
.	-	339	O
3	-	340	O
years	-	342	O
[	-	348	O
SD	-	349	O
=	-	352	O
5	-	354	O
.	-	355	O
1	-	356	O
]	-	357	O
)	-	358	O
with	-	360	O
first	-	365	O
-	-	370	O
episode	-	371	O
schizophrenia	-	379	B
(	-	393	O
75	-	394	O
%	-	396	O
)	-	397	O
,	-	398	O
schizophreniform	-	400	B
disorder	-	417	I
(	-	426	O
17	-	427	O
%	-	429	O
)	-	430	O
,	-	431	O
or	-	433	O
schizoaffective	-	436	B
disorder	-	452	I
(	-	461	O
8	-	462	O
%	-	463	O
)	-	464	O
were	-	466	O
randomly	-	471	O
assigned	-	480	O
to	-	489	O
treatment	-	492	O
with	-	502	O
olanzapine	-	507	O
(	-	518	O
2	-	519	O
.	-	520	O
5	-	521	O
-	-	522	O
20	-	523	O
mg	-	526	O
/	-	528	O
day	-	529	O
)	-	532	O
or	-	534	O
risperidone	-	537	O
(	-	549	O
1	-	550	O
-	-	551	O
6	-	552	O
mg	-	554	O
/	-	556	O
day	-	557	O
)	-	560	O
.	-	561	O

RESULTS	17151160	563	O
:	-	570	O

Response	17151160	572	O
rates	-	581	O
did	-	587	O
not	-	591	O
significantly	-	595	O
differ	-	609	O
between	-	616	O
olanzapine	-	624	O
(	-	635	O
43	-	636	O
.	-	638	O
7	-	639	O
%	-	640	O
,	-	641	O
95	-	643	O
%	-	645	O
CI	-	647	O
=	-	649	O
28	-	650	O
.	-	652	O
8	-	653	O
%	-	654	O
-	-	655	O
58	-	656	O
.	-	658	O
6	-	659	O
%	-	660	O
)	-	661	O
and	-	663	O
risperidone	-	667	O
(	-	679	O
54	-	680	O
.	-	682	O
3	-	683	O
%	-	684	O
,	-	685	O
95	-	687	O
%	-	689	O
CI	-	691	O
=	-	693	O
39	-	694	O
.	-	696	O
9	-	697	O
%	-	698	O
-	-	699	O
68	-	700	O
.	-	702	O
7	-	703	O
%	-	704	O
)	-	705	O
.	-	706	O

Among	17151160	708	O
those	-	714	O
responding	-	720	O
to	-	731	O
treatment	-	734	O
,	-	743	O
more	-	745	O
subjects	-	750	O
in	-	759	O
the	-	762	O
olanzapine	-	766	O
group	-	777	O
(	-	783	O
40	-	784	O
.	-	786	O
9	-	787	O
%	-	788	O
,	-	789	O
95	-	791	O
%	-	793	O
CI	-	795	O
=	-	797	O
16	-	798	O
.	-	800	O
8	-	801	O
%	-	802	O
-	-	803	O
65	-	804	O
.	-	806	O
0	-	807	O
%	-	808	O
)	-	809	O
than	-	811	O
in	-	816	O
the	-	819	O
risperidone	-	823	O
group	-	835	O
(	-	841	O
18	-	842	O
.	-	844	O
9	-	845	O
%	-	846	O
,	-	847	O
95	-	849	O
%	-	851	O
CI	-	853	O
=	-	855	O
0	-	856	O
%	-	857	O
-	-	858	O
39	-	859	O
.	-	861	O
2	-	862	O
%	-	863	O
)	-	864	O
had	-	866	O
subsequent	-	870	O
ratings	-	881	O
not	-	889	O
meeting	-	893	O
response	-	901	O
criteria	-	910	O
.	-	918	O

Negative	17151160	920	O
symptom	-	929	O
outcomes	-	937	O
and	-	946	O
measures	-	950	O
of	-	959	O
parkinsonism	-	962	B
and	-	975	O
akathisia	-	979	B
did	-	989	O
not	-	993	O
differ	-	997	O
between	-	1004	O
medications	-	1012	O
.	-	1023	O

Extrapyramidal	17151160	1025	B
symptom	-	1040	I
severity	-	1048	O
scores	-	1057	O
were	-	1064	O
1	-	1069	O
.	-	1070	O
4	-	1071	O
(	-	1073	O
95	-	1074	O
%	-	1076	O
CI	-	1078	O
=	-	1080	O
1	-	1081	O
.	-	1082	O
2	-	1083	O
-	-	1084	O
1	-	1085	O
.	-	1086	O
6	-	1087	O
)	-	1088	O
with	-	1090	O
risperidone	-	1095	O
and	-	1107	O
1	-	1111	O
.	-	1112	O
2	-	1113	O
(	-	1115	O
95	-	1116	O
%	-	1118	O
CI	-	1120	O
=	-	1122	O
1	-	1123	O
.	-	1124	O
0	-	1125	O
-	-	1126	O
1	-	1127	O
.	-	1128	O
4	-	1129	O
)	-	1130	O
with	-	1132	O
olanzapine	-	1137	O
.	-	1147	O

Significantly	17151160	1149	O
more	-	1163	O
weight	-	1168	B
gain	-	1175	I
occurred	-	1180	O
with	-	1189	O
olanzapine	-	1194	O
than	-	1205	O
with	-	1210	O
risperidone	-	1215	O
:	-	1226	O
the	-	1228	O
increase	-	1232	O
in	-	1241	O
weight	-	1244	O
at	-	1251	O
4	-	1254	O
months	-	1256	O
relative	-	1263	O
to	-	1272	O
baseline	-	1275	O
weight	-	1284	O
was	-	1291	O
17	-	1295	O
.	-	1297	O
3	-	1298	O
%	-	1299	O
(	-	1301	O
95	-	1302	O
%	-	1304	O
CI	-	1306	O
=	-	1308	O
14	-	1309	O
.	-	1311	O
2	-	1312	O
%	-	1313	O
-	-	1314	O
20	-	1315	O
.	-	1317	O
5	-	1318	O
%	-	1319	O
)	-	1320	O
with	-	1322	O
olanzapine	-	1327	O
and	-	1338	O
11	-	1342	O
.	-	1344	O
3	-	1345	O
%	-	1346	O
(	-	1348	O
95	-	1349	O
%	-	1351	O
CI	-	1353	O
=	-	1355	O
8	-	1356	O
.	-	1357	O
4	-	1358	O
%	-	1359	O
-	-	1360	O
14	-	1361	O
.	-	1363	O
3	-	1364	O
%	-	1365	O
)	-	1366	O
with	-	1368	O
risperidone	-	1373	O
.	-	1384	O

Body	17151160	1386	O
mass	-	1391	O
index	-	1396	O
at	-	1402	O
baseline	-	1405	O
and	-	1414	O
at	-	1418	O
4	-	1421	O
months	-	1423	O
was	-	1430	O
24	-	1434	O
.	-	1436	O
3	-	1437	O
(	-	1439	O
95	-	1440	O
%	-	1442	O
CI	-	1444	O
=	-	1446	O
22	-	1447	O
.	-	1449	O
8	-	1450	O
-	-	1451	O
25	-	1452	O
.	-	1454	O
7	-	1455	O
)	-	1456	O
versus	-	1458	O
28	-	1465	O
.	-	1467	O
2	-	1468	O
(	-	1470	O
95	-	1471	O
%	-	1473	O
CI	-	1475	O
=	-	1477	O
26	-	1478	O
.	-	1480	O
7	-	1481	O
-	-	1482	O
29	-	1483	O
.	-	1485	O
7	-	1486	O
)	-	1487	O
with	-	1489	O
olanzapine	-	1494	O
and	-	1505	O
23	-	1509	O
.	-	1511	O
9	-	1512	O
(	-	1514	O
95	-	1515	O
%	-	1517	O
CI	-	1519	O
=	-	1521	O
22	-	1522	O
.	-	1524	O
5	-	1525	O
-	-	1526	O
25	-	1527	O
.	-	1529	O
3	-	1530	O
)	-	1531	O
versus	-	1533	O
26	-	1540	O
.	-	1542	O
7	-	1543	O
(	-	1545	O
95	-	1546	O
%	-	1548	O
CI	-	1550	O
=	-	1552	O
25	-	1553	O
.	-	1555	O
2	-	1556	O
-	-	1557	O
28	-	1558	O
.	-	1560	O
2	-	1561	O
)	-	1562	O
with	-	1564	O
risperidone	-	1569	O
.	-	1580	O

CONCLUSIONS	17151160	1582	O
:	-	1593	O

Clinical	17151160	1595	O
outcomes	-	1604	O
with	-	1613	O
risperidone	-	1618	O
were	-	1630	O
equal	-	1635	O
to	-	1641	O
those	-	1644	O
with	-	1650	O
olanzapine	-	1655	O
,	-	1665	O
and	-	1667	O
response	-	1671	O
may	-	1680	O
be	-	1684	O
more	-	1687	O
stable	-	1692	O
.	-	1698	O

Olanzapine	17151160	1700	O
may	-	1711	O
have	-	1715	O
an	-	1720	O
advantage	-	1723	O
for	-	1733	O
motor	-	1737	O
side	-	1743	O
effects	-	1748	O
.	-	1755	O

Both	17151160	1757	O
medications	-	1762	O
caused	-	1774	O
substantial	-	1781	O
rapid	-	1793	O
weight	-	1799	B
gain	-	1806	I
,	-	1810	O
but	-	1812	O
weight	-	1816	B
gain	-	1823	I
was	-	1828	O
greater	-	1832	O
with	-	1840	O
olanzapine	-	1845	O
.	-	1855	O

Early	17159032	0	O
paracentral	-	6	O
visual	-	18	B
field	-	25	I
loss	-	31	I
in	-	36	O
patients	-	39	O
taking	-	48	O
hydroxychloroquine	-	55	O
.	-	73	O

OBJECTIVE	17159032	75	O
:	-	84	O

To	17159032	86	O
review	-	89	O
the	-	96	O
natural	-	100	O
history	-	108	O
and	-	116	O
ocular	-	120	O
and	-	127	O
systemic	-	131	O
adverse	-	140	O
effects	-	148	O
of	-	156	O
patients	-	159	O
taking	-	168	O
hydroxychloroquine	-	175	O
sulfate	-	194	O
who	-	202	O
attended	-	206	O
an	-	215	O
ophthalmic	-	218	O
screening	-	229	O
program	-	239	O
.	-	246	O

DESIGN	17159032	248	O
:	-	254	O

Retrospective	17159032	256	O
study	-	270	O
.	-	275	O

RESULTS	17159032	277	O
:	-	284	O

Records	17159032	286	O
of	-	294	O
262	-	297	O
patients	-	301	O
who	-	310	O
were	-	314	O
taking	-	319	O
hydroxychloroquine	-	326	O
and	-	345	O
screened	-	349	O
in	-	358	O
the	-	361	O
Department	-	365	O
of	-	376	O
Ophthalmology	-	379	O
were	-	393	O
reviewed	-	398	O
.	-	406	O

Of	17159032	408	O
the	-	411	O
262	-	415	O
patients	-	419	O
,	-	427	O
14	-	429	O
(	-	432	O
18	-	433	O
%	-	435	O
)	-	436	O
of	-	438	O
76	-	441	O
who	-	444	O
had	-	448	O
stopped	-	452	O
treatment	-	460	O
at	-	470	O
the	-	473	O
time	-	477	O
of	-	482	O
the	-	485	O
study	-	489	O
experienced	-	495	O
documented	-	507	O
adverse	-	518	O
effects	-	526	O
.	-	533	O

Systemic	17159032	535	O
adverse	-	544	O
effects	-	552	O
occurred	-	560	O
in	-	569	O
8	-	572	O
patients	-	574	O
(	-	583	O
10	-	584	O
.	-	586	O
5	-	587	O
%	-	588	O
)	-	589	O
and	-	591	O
ocular	-	595	O
adverse	-	602	O
effects	-	610	O
,	-	617	O
in	-	619	O
5	-	622	O
(	-	624	O
6	-	625	O
.	-	626	O
5	-	627	O
%	-	628	O
)	-	629	O
.	-	630	O

Thirty	17159032	632	O
-	-	638	O
five	-	639	O
patients	-	644	O
(	-	653	O
13	-	654	O
.	-	656	O
4	-	657	O
%	-	658	O
)	-	659	O
had	-	661	O
visual	-	665	B
field	-	672	I
abnormalities	-	678	I
,	-	691	O
which	-	693	O
were	-	699	O
attributed	-	704	O
to	-	715	O
hydroxychloroquine	-	718	O
treatment	-	737	O
in	-	747	O
4	-	750	O
patients	-	752	O
(	-	761	O
1	-	762	O
.	-	763	O
5	-	764	O
%	-	765	O
)	-	766	O
.	-	767	O

Three	17159032	769	O
of	-	775	O
the	-	778	O
4	-	782	O
patients	-	784	O
were	-	793	O
taking	-	798	O
less	-	805	O
than	-	810	O
6	-	815	O
.	-	816	O
5	-	817	O
mg	-	819	O
/	-	821	O
kg	-	822	O
per	-	825	O
day	-	829	O
and	-	833	O
all	-	837	O
patients	-	841	O
had	-	850	O
normal	-	854	O
renal	-	861	O
and	-	867	O
liver	-	871	O
function	-	877	O
test	-	886	O
results	-	891	O
.	-	898	O

CONCLUSIONS	17159032	900	O
:	-	911	O

The	17159032	913	O
current	-	917	O
study	-	925	O
used	-	931	O
a	-	936	O
protocol	-	938	O
of	-	947	O
visual	-	950	O
acuity	-	957	O
and	-	964	O
color	-	968	O
vision	-	974	O
assessment	-	981	O
,	-	991	O
funduscopy	-	993	O
,	-	1003	O
and	-	1005	O
Humphrey	-	1009	O
10	-	1018	O
-	-	1020	O
2	-	1021	O
visual	-	1023	O
field	-	1030	O
testing	-	1036	O
and	-	1044	O
shows	-	1048	O
that	-	1054	O
visual	-	1059	B
field	-	1066	I
defects	-	1072	I
appeared	-	1080	O
before	-	1089	O
any	-	1096	O
corresponding	-	1100	O
changes	-	1114	O
in	-	1122	O
any	-	1125	O
other	-	1129	O
tested	-	1135	O
clinical	-	1142	O
parameters	-	1151	O
;	-	1161	O
the	-	1163	O
defects	-	1167	O
were	-	1175	O
reproducible	-	1180	O
and	-	1193	O
the	-	1197	O
test	-	1201	O
parameters	-	1206	O
were	-	1217	O
reliable	-	1222	O
.	-	1230	O

Patients	17159032	1232	O
taking	-	1241	O
hydroxychloroquine	-	1248	O
can	-	1267	O
demonstrate	-	1271	O
a	-	1283	O
toxic	-	1285	O
reaction	-	1291	O
in	-	1300	O
the	-	1303	O
retina	-	1307	O
despite	-	1314	O
the	-	1322	O
absence	-	1326	O
of	-	1334	O
known	-	1337	O
risk	-	1343	O
factors	-	1348	O
.	-	1355	O

Screening	17159032	1357	O
,	-	1366	O
including	-	1368	O
Humphrey	-	1378	O
10	-	1387	O
-	-	1389	O
2	-	1390	O
visual	-	1392	O
field	-	1399	O
assessment	-	1405	O
,	-	1415	O
is	-	1417	O
recommended	-	1420	O
2	-	1432	O
years	-	1434	O
after	-	1440	O
the	-	1446	O
initial	-	1450	O
baseline	-	1458	O
and	-	1467	O
yearly	-	1471	O
thereafter	-	1478	O
.	-	1488	O

Peri	17223814	0	O
-	-	4	O
operative	-	5	O
atrioventricular	-	15	B
block	-	32	I
as	-	38	O
a	-	41	O
result	-	43	O
of	-	50	O
chemotherapy	-	53	O
with	-	66	O
epirubicin	-	71	O
and	-	82	O
paclitaxel	-	86	O
.	-	96	O

A	17223814	98	O
47	-	100	O
-	-	102	O
year	-	103	O
-	-	107	O
old	-	108	O
woman	-	112	O
presented	-	118	O
for	-	128	O
mastectomy	-	132	O
and	-	143	O
immediate	-	147	O
latissimus	-	157	O
dorsi	-	168	O
flap	-	174	O
reconstruction	-	179	O
having	-	194	O
been	-	201	O
diagnosed	-	206	O
with	-	216	O
carcinoma	-	221	B
of	-	231	I
the	-	234	I
breast	-	238	I
6	-	245	O
months	-	247	O
previously	-	254	O
.	-	264	O

In	17223814	266	O
the	-	269	O
preceding	-	273	O
months	-	283	O
she	-	290	O
had	-	294	O
received	-	298	O
neo	-	307	O
-	-	310	O
adjuvant	-	311	O
chemotherapy	-	320	O
with	-	333	O
epirubicin	-	338	O
,	-	348	O
paclitaxel	-	350	O
(	-	361	O
Taxol	-	362	O
)	-	367	O
and	-	369	O
cyclophosphamide	-	373	O
.	-	389	O

This	17223814	391	O
had	-	396	O
been	-	400	O
apparently	-	405	O
uncomplicated	-	416	O
and	-	430	O
she	-	434	O
had	-	438	O
maintained	-	442	O
a	-	453	O
remarkably	-	455	O
high	-	466	O
level	-	471	O
of	-	477	O
physical	-	480	O
activity	-	489	O
.	-	497	O

She	17223814	499	O
was	-	503	O
found	-	507	O
to	-	513	O
be	-	516	O
bradycardic	-	519	B
at	-	531	O
pre	-	534	O
-	-	537	O
operative	-	538	O
assessment	-	548	O
but	-	559	O
had	-	563	O
no	-	567	O
cardiac	-	570	O
symptoms	-	578	O
.	-	586	O

Second	17223814	588	O
degree	-	595	O
Mobitz	-	602	O
type	-	609	O
II	-	614	O
atrioventricular	-	617	B
block	-	634	I
was	-	640	O
diagnosed	-	644	O
on	-	654	O
electrocardiogram	-	657	O
,	-	674	O
and	-	676	O
temporary	-	680	O
transvenous	-	690	O
ventricular	-	702	O
pacing	-	714	O
instituted	-	721	O
in	-	732	O
the	-	735	O
peri	-	739	O
-	-	743	O
operative	-	744	O
period	-	754	O
.	-	760	O

We	17223814	762	O
discuss	-	765	O
how	-	773	O
evidence	-	777	O
-	-	785	O
based	-	786	O
guidelines	-	792	O
would	-	803	O
not	-	809	O
have	-	813	O
been	-	818	O
helpful	-	823	O
in	-	831	O
this	-	834	O
case	-	839	O
,	-	843	O
and	-	845	O
how	-	849	O
chemotherapy	-	853	O
can	-	866	O
exhibit	-	870	O
substantial	-	878	O
cardiotoxicity	-	890	B
that	-	905	O
may	-	910	O
develop	-	914	O
over	-	922	O
many	-	927	O
years	-	932	O
.	-	937	O

We	17223814	939	O
suggest	-	942	O
that	-	950	O
patients	-	955	O
who	-	964	O
have	-	968	O
received	-	973	O
chemotherapy	-	982	O
at	-	995	O
any	-	998	O
time	-	1002	O
should	-	1007	O
have	-	1014	O
a	-	1019	O
pre	-	1021	O
-	-	1024	O
operative	-	1025	O
electrocardiogram	-	1035	O
even	-	1053	O
if	-	1058	O
they	-	1061	O
are	-	1066	O
asymptomatic	-	1070	O
.	-	1082	O

Risks	17255138	0	O
and	-	6	O
benefits	-	10	O
of	-	19	O
COX	-	22	O
-	-	25	O
2	-	26	O
inhibitors	-	28	O
vs	-	39	O
non	-	42	O
-	-	45	O
selective	-	46	O
NSAIDs	-	56	O
:	-	62	O

does	17255138	64	O
their	-	69	O
cardiovascular	-	75	O
risk	-	90	O
exceed	-	95	O
their	-	102	O
gastrointestinal	-	108	O
benefit	-	125	O
?	-	132	O

A	17255138	134	O
retrospective	-	136	O
cohort	-	150	O
study	-	157	O
.	-	162	O

OBJECTIVES	17255138	164	O
:	-	174	O

The	17255138	176	O
risk	-	180	O
of	-	185	O
acute	-	188	B
myocardial	-	194	I
infarction	-	205	I
(	-	216	O
AMI	-	217	B
)	-	220	O
with	-	222	O
COX	-	227	O
-	-	230	O
2	-	231	O
inhibitors	-	233	O
may	-	244	O
offset	-	248	O
their	-	255	O
gastrointestinal	-	261	O
(	-	278	O
GI	-	279	O
)	-	281	O
benefit	-	283	O
compared	-	291	O
with	-	300	O
non	-	305	O
-	-	308	O
selective	-	309	O
(	-	319	O
NS	-	320	O
)	-	322	O
non	-	324	O
-	-	327	O
steroidal	-	328	O
anti	-	338	O
-	-	342	O
inflammatory	-	343	O
drugs	-	356	O
(	-	362	O
NSAIDs	-	363	O
)	-	369	O
.	-	370	O

We	17255138	372	O
aimed	-	375	O
to	-	381	O
compare	-	384	O
the	-	392	O
risks	-	396	O
of	-	402	O
hospitalization	-	405	O
for	-	421	O
AMI	-	425	B
and	-	429	O
GI	-	433	B
bleeding	-	436	I
among	-	445	O
elderly	-	451	O
patients	-	459	O
using	-	468	O
COX	-	474	O
-	-	477	O
2	-	478	O
inhibitors	-	480	O
,	-	490	O
NS	-	492	O
-	-	494	O
NSAIDs	-	495	O
and	-	502	O
acetaminophen	-	506	O
.	-	519	O

METHODS	17255138	521	O
:	-	528	O

We	17255138	530	O
conducted	-	533	O
a	-	543	O
retrospective	-	545	O
cohort	-	559	O
study	-	566	O
using	-	572	O
administrative	-	578	O
data	-	593	O
of	-	598	O
patients	-	601	O
>	-	610	O
or	-	612	O
=	-	615	O
65	-	616	O
years	-	619	O
of	-	625	O
age	-	628	O
who	-	632	O
filled	-	636	O
a	-	643	O
prescription	-	645	O
for	-	658	O
NSAID	-	662	O
or	-	668	O
acetaminophen	-	671	O
during	-	685	O
1999	-	692	O
-	-	696	O
2002	-	697	O
.	-	701	O

Outcomes	17255138	703	O
were	-	712	O
compared	-	717	O
using	-	726	O
Cox	-	732	O
regression	-	736	O
models	-	747	O
with	-	754	O
time	-	759	O
-	-	763	O
dependent	-	764	O
exposures	-	774	O
.	-	783	O

RESULTS	17255138	785	O
:	-	792	O

Person	17255138	794	O
-	-	800	O
years	-	801	O
of	-	807	O
exposure	-	810	O
among	-	819	O

non	17255138	825	O
-	-	828	O
users	-	829	O
of	-	835	O
aspirin	-	838	O
were	-	846	O
:	-	850	O
75	-	852	O
,	-	854	O
761	-	855	O
to	-	859	O
acetaminophen	-	862	O
,	-	875	O
42	-	877	O
,	-	879	O
671	-	880	O
to	-	884	O
rofecoxib	-	887	O
65	-	897	O
,	-	899	O
860	-	900	O
to	-	904	O
celecoxib	-	907	O
,	-	916	O
and	-	918	O
37	-	922	O
,	-	924	O
495	-	925	O
to	-	929	O
NS	-	932	O
-	-	934	O
NSAIDs	-	935	O
.	-	941	O

Among	17255138	943	O
users	-	949	O
of	-	955	O
aspirin	-	958	O
,	-	965	O
they	-	967	O
were	-	972	O
:	-	976	O
14	-	978	O
,	-	980	O
671	-	981	O
to	-	985	O
rofecoxib	-	988	O
,	-	997	O
22	-	999	O
,	-	1001	O
875	-	1002	O
to	-	1006	O
celecoxib	-	1009	O
,	-	1018	O
9	-	1020	O
,	-	1021	O
832	-	1022	O
to	-	1026	O
NS	-	1029	O
-	-	1031	O
NSAIDs	-	1032	O
and	-	1039	O
38	-	1043	O
,	-	1045	O
048	-	1046	O
to	-	1050	O
acetaminophen	-	1053	O
.	-	1066	O

Among	17255138	1068	O
non	-	1074	O
-	-	1077	O
users	-	1078	O
of	-	1084	O
aspirin	-	1087	O
,	-	1094	O
the	-	1096	O
adjusted	-	1100	O
hazard	-	1109	O
ratios	-	1116	O
(	-	1123	O
95	-	1124	O
%	-	1126	O
confidence	-	1128	O
interval	-	1139	O
)	-	1147	O
of	-	1149	O
hospitalization	-	1152	O
for	-	1168	O
AMI	-	1172	B
/	-	1175	O
GI	-	1176	O
vs	-	1179	O
the	-	1182	O
acetaminophen	-	1186	O
(	-	1200	O
with	-	1201	O
no	-	1206	O
aspirin	-	1209	O
)	-	1216	O
group	-	1218	O
were	-	1224	O
:	-	1228	O
rofecoxib	-	1230	O
1	-	1240	O
.	-	1241	O
27	-	1242	O
(	-	1245	O
1	-	1246	O
.	-	1247	O
13	-	1248	O
,	-	1250	O
1	-	1252	O
.	-	1253	O
42	-	1254	O
)	-	1256	O
,	-	1257	O
celecoxib	-	1259	O
0	-	1269	O
.	-	1270	O
93	-	1271	O
(	-	1274	O
0	-	1275	O
.	-	1276	O
83	-	1277	O
,	-	1279	O
1	-	1281	O
.	-	1282	O
03	-	1283	O
)	-	1285	O
,	-	1286	O
naproxen	-	1288	O
1	-	1297	O
.	-	1298	O
59	-	1299	O
(	-	1302	O
1	-	1303	O
.	-	1304	O
31	-	1305	O
,	-	1307	O
1	-	1309	O
.	-	1310	O
93	-	1311	O
)	-	1313	O
,	-	1314	O
diclofenac	-	1316	O
1	-	1327	O
.	-	1328	O
17	-	1329	O
(	-	1332	O
0	-	1333	O
.	-	1334	O
99	-	1335	O
,	-	1337	O
1	-	1339	O
.	-	1340	O
38	-	1341	O
)	-	1343	O
and	-	1345	O
ibuprofen	-	1349	O
1	-	1359	O
.	-	1360	O
05	-	1361	O
(	-	1364	O
0	-	1365	O
.	-	1366	O
74	-	1367	O
,	-	1369	O
1	-	1371	O
.	-	1372	O
51	-	1373	O
)	-	1375	O
.	-	1376	O

Among	17255138	1378	O
users	-	1384	O
of	-	1390	O
aspirin	-	1393	O
,	-	1400	O
they	-	1402	O
were	-	1407	O
:	-	1411	O
rofecoxib	-	1413	O
1	-	1423	O
.	-	1424	O
73	-	1425	O
(	-	1428	O
1	-	1429	O
.	-	1430	O
52	-	1431	O
,	-	1433	O
1	-	1435	O
.	-	1436	O
98	-	1437	O
)	-	1439	O
,	-	1440	O
celecoxib	-	1442	O
1	-	1452	O
.	-	1453	O
34	-	1454	O
(	-	1457	O
1	-	1458	O
.	-	1459	O
19	-	1460	O
,	-	1462	O
1	-	1464	O
.	-	1465	O
52	-	1466	O
)	-	1468	O
,	-	1469	O
ibuprofen	-	1471	O
1	-	1481	O
.	-	1482	O
51	-	1483	O
(	-	1486	O
0	-	1487	O
.	-	1488	O
95	-	1489	O
,	-	1491	O
2	-	1493	O
.	-	1494	O
41	-	1495	O
)	-	1497	O
,	-	1498	O
diclofenac	-	1500	O
1	-	1511	O
.	-	1512	O
69	-	1513	O
(	-	1516	O
1	-	1517	O
.	-	1518	O
35	-	1519	O
,	-	1521	O
2	-	1523	O
.	-	1524	O
10	-	1525	O
)	-	1527	O
,	-	1528	O
naproxen	-	1530	O
1	-	1539	O
.	-	1540	O
35	-	1541	O
(	-	1544	O
0	-	1545	O
.	-	1546	O
97	-	1547	O
,	-	1549	O
1	-	1551	O
.	-	1552	O
88	-	1553	O
)	-	1555	O
and	-	1557	O
acetaminophen	-	1561	O
1	-	1575	O
.	-	1576	O
29	-	1577	O
(	-	1580	O
1	-	1581	O
.	-	1582	O
17	-	1583	O
,	-	1585	O
1	-	1587	O
.	-	1588	O
42	-	1589	O
)	-	1591	O
.	-	1592	O

CONCLUSION	17255138	1594	O
:	-	1604	O

Among	17255138	1606	O
non	-	1612	O
-	-	1615	O
users	-	1616	O
of	-	1622	O
aspirin	-	1625	O
,	-	1632	O
naproxen	-	1634	O
seemed	-	1643	O
to	-	1650	O
carry	-	1653	O
the	-	1659	O
highest	-	1663	O
risk	-	1671	O
for	-	1676	O
AMI	-	1680	B
/	-	1683	O
GI	-	1684	B
bleeding	-	1687	I
.	-	1695	O

The	17255138	1697	O
AMI	-	1701	B
/	-	1704	O
GI	-	1705	O
toxicity	-	1708	B
of	-	1717	O
celecoxib	-	1720	O
was	-	1730	O
similar	-	1734	O
to	-	1742	O
that	-	1745	O
of	-	1750	O
acetaminophen	-	1753	O
and	-	1767	O
seemed	-	1771	O
to	-	1778	O
be	-	1781	O
better	-	1784	O
than	-	1791	O
those	-	1796	O
of	-	1802	O
rofecoxib	-	1805	O
and	-	1815	O
NS	-	1819	O
-	-	1821	O
NSAIDs	-	1822	O
.	-	1828	O

Among	17255138	1830	O
users	-	1836	O
of	-	1842	O
aspirin	-	1845	O
,	-	1852	O
both	-	1854	O
celecoxib	-	1859	O
and	-	1869	O
naproxen	-	1873	O
seemed	-	1882	O
to	-	1889	O
be	-	1892	O
the	-	1895	O
least	-	1899	O
toxic	-	1905	O
.	-	1910	O

Quinine	17297207	0	O
-	-	7	O
induced	-	8	O
arrhythmia	-	16	B
in	-	27	O
a	-	30	O
patient	-	32	O
with	-	40	O
severe	-	45	B
malaria	-	52	I
.	-	59	O

It	17297207	61	O
was	-	64	O
reported	-	68	O
that	-	77	O
there	-	82	O
was	-	88	O
a	-	92	O
case	-	94	O
of	-	99	O
severe	-	102	B
malaria	-	109	I
patient	-	117	O
with	-	125	O
jaundice	-	130	B
who	-	139	O
presented	-	143	O
with	-	153	O
arrhythmia	-	158	B
(	-	169	O
premature	-	170	B
ventricular	-	180	I
contraction	-	192	I
)	-	203	O
while	-	205	O
getting	-	211	O
quinine	-	219	O
infusion	-	227	O
was	-	236	O
reported	-	240	O
.	-	248	O

A	17297207	250	O
man	-	252	O
,	-	255	O
25	-	257	O
years	-	260	O
old	-	266	O
,	-	269	O
was	-	271	O
admitted	-	275	O
to	-	284	O
hospital	-	287	O
with	-	296	O
high	-	301	O
fever	-	306	B
,	-	311	O
chill	-	313	B
,	-	318	O
vomiting	-	320	B
,	-	328	O
jaundice	-	330	B
.	-	338	O

The	17297207	340	O
patient	-	344	O
was	-	352	O
fully	-	356	O
conscious	-	362	O
,	-	371	O
blood	-	373	O
pressure	-	379	O

120	17297207	388	O
/	-	391	O
80	-	392	O
mmHg	-	395	O
,	-	399	O
pulse	-	401	O
rate	-	407	O
100	-	412	O
x	-	416	O
/	-	417	O
minute	-	418	O
,	-	424	O
regular	-	426	O
.	-	433	O

On	17297207	435	O
admission	-	438	O
,	-	447	O
laboratory	-	449	O
examination	-	460	O
showed	-	472	O
Plasmodium	-	479	O
falciparum	-	490	O
(	-	501	O
+	-	502	O
+	-	503	O
+	-	504	O
+	-	505	O
)	-	506	O
,	-	507	O
total	-	509	O
bilirubin	-	515	O
8	-	525	O
.	-	526	O
25	-	527	O
mg	-	530	O
/	-	532	O
dL	-	533	O
,	-	535	O
conjugated	-	537	O
bilirubin	-	548	O
4	-	558	O
.	-	559	O
36	-	560	O
mg	-	563	O
/	-	565	O
dL	-	566	O
,	-	568	O
unconjugated	-	570	O
bilirubin	-	583	O
3	-	593	O
.	-	594	O
89	-	595	O
mg	-	598	O
/	-	600	O
dL	-	601	O
,	-	603	O
potassium	-	605	O
3	-	615	O
.	-	616	O
52	-	617	O
meq	-	620	O
/	-	623	O
L	-	624	O
Patient	-	626	O
was	-	634	O
diagnosed	-	638	O
as	-	648	O
severe	-	651	B
malaria	-	658	I
with	-	666	O
jaundice	-	671	B
and	-	680	O
got	-	684	O
quinine	-	688	O
infusion	-	696	O
in	-	705	O
dextrose	-	708	O
5	-	717	O
%	-	718	O
500	-	720	O
mg	-	724	O
/	-	726	O
8	-	727	O
hour	-	729	O
.	-	733	O

On	17297207	735	O
the	-	738	O
second	-	742	O
day	-	749	O
the	-	753	O
patient	-	757	O
had	-	765	O
vomitus	-	769	B
,	-	776	O
diarrhea	-	778	B
,	-	786	O
tinnitus	-	788	B
,	-	796	O
loss	-	798	B
of	-	803	I
hearing	-	806	I
.	-	813	O

After	17297207	815	O
30	-	821	O
hours	-	824	O
of	-	830	O
quinine	-	833	O
infusion	-	841	O
the	-	850	O
patient	-	854	O
felt	-	862	O
palpitation	-	867	B
and	-	879	O
electrocardiography	-	883	O
(	-	903	O
ECG	-	904	O
)	-	907	O
recording	-	909	O
showed	-	919	O
premature	-	926	B
ventricular	-	936	I
contraction	-	948	I
(	-	960	O
PVC	-	961	B
)	-	964	O
>	-	966	O
5	-	968	O
x	-	970	O
/	-	971	O
minute	-	972	O
,	-	978	O
trigemini	-	980	O
,	-	989	O
constant	-	991	O
type	-	1000	O
-	-	1004	O
-	-	1005	O
sinoatrial	-	1006	B
block	-	1017	I
,	-	1022	O
positive	-	1024	O
U	-	1033	O
wave	-	1035	O
.	-	1039	O

He	17297207	1041	O
was	-	1044	O
treated	-	1048	O
with	-	1056	O
lidocaine	-	1061	O
50	-	1071	O
mg	-	1074	O
intravenously	-	1077	O
followed	-	1091	O
by	-	1100	O
infusion	-	1103	O
1500	-	1112	O
mg	-	1117	O
in	-	1120	O
dextrose	-	1123	O
5	-	1132	O
%	-	1133	O
/	-	1134	O
24	-	1135	O
hour	-	1138	O
and	-	1143	O
potassium	-	1147	O
aspartate	-	1157	O
tablet	-	1167	O
.	-	1173	O

Quinine	17297207	1175	O
infusion	-	1183	O
was	-	1192	O
discontinued	-	1196	O
and	-	1209	O
changed	-	1213	O
with	-	1221	O
sulfate	-	1226	O
quinine	-	1234	O
tablets	-	1242	O
.	-	1249	O

Three	17297207	1251	O
hours	-	1257	O
later	-	1263	O
the	-	1269	O
patient	-	1273	O
felt	-	1281	O
better	-	1286	O
,	-	1292	O
the	-	1294	O
frequency	-	1298	O
of	-	1308	O
PVC	-	1311	B
reduced	-	1315	O
to	-	1323	O
4	-	1326	O
-	-	1328	O
5	-	1330	O
x	-	1332	O
/	-	1333	O
minute	-	1334	O
and	-	1341	O
on	-	1345	O
the	-	1348	O
third	-	1352	O
day	-	1358	O
ECG	-	1362	O
was	-	1366	O
normal	-	1370	O
,	-	1376	O
potassium	-	1378	O
level	-	1388	O
was	-	1394	O
3	-	1398	O
.	-	1399	O
34	-	1400	O
meq	-	1403	O
/	-	1406	O
L	-	1407	O
.	-	1408	O

He	17297207	1410	O
was	-	1413	O
discharged	-	1417	O
on	-	1428	O
7th	-	1431	O
day	-	1435	O
in	-	1439	O
good	-	1442	O
condition	-	1447	O
.	-	1456	O

Quinine	17297207	1458	O
,	-	1465	O
like	-	1467	O
quinidine	-	1472	O
,	-	1481	O
is	-	1483	O
a	-	1486	O
chincona	-	1488	O
alkaloid	-	1497	O
that	-	1506	O
has	-	1511	O
anti	-	1515	O
-	-	1519	O
arrhythmic	-	1520	B
property	-	1531	O
,	-	1539	O
although	-	1541	O
it	-	1550	O
also	-	1553	O
pro	-	1558	O
-	-	1561	O
arrhythmic	-	1562	B
that	-	1573	O
can	-	1578	O
cause	-	1582	O
various	-	1588	O
arrhythmias	-	1596	B
,	-	1607	O
including	-	1609	O
severe	-	1619	O
arrhythmia	-	1626	B
such	-	1637	O
as	-	1642	O
multiple	-	1645	O
PVC	-	1654	B
.	-	1657	O

Administration	17297207	1659	O
of	-	1674	O
parenteral	-	1677	O
quinine	-	1688	O
must	-	1696	O
be	-	1701	O
done	-	1704	O
carefully	-	1709	O
and	-	1719	O
with	-	1723	O
good	-	1728	O
observation	-	1733	O
because	-	1745	O
of	-	1753	O
its	-	1756	O
pro	-	1760	O
-	-	1763	O
arrhythmic	-	1764	B
effect	-	1775	O
,	-	1781	O
especially	-	1783	O
in	-	1794	O
older	-	1797	O
patients	-	1803	O
who	-	1812	O
have	-	1816	O
heart	-	1821	B
diseases	-	1827	I
or	-	1836	O
patients	-	1839	O
with	-	1848	O
electrolyte	-	1853	B
disorder	-	1865	I
(	-	1874	O
hypokalemia	-	1875	B
)	-	1886	O
which	-	1888	O
frequently	-	1894	O
occurs	-	1905	O
due	-	1912	O
to	-	1916	O
vomiting	-	1919	B
and	-	1928	O
or	-	1932	O
diarrhea	-	1935	B
in	-	1944	O
malaria	-	1947	B
cases	-	1955	O
.	-	1960	O

Penicillamine	17346443	0	O
-	-	13	O
related	-	14	O
lichenoid	-	22	B
dermatitis	-	32	I
and	-	43	O
utility	-	47	O
of	-	55	O
zinc	-	58	O
acetate	-	63	O
in	-	71	O
a	-	74	O
Wilson	-	76	B
disease	-	83	I
patient	-	91	O
with	-	99	O
hepatic	-	104	O
presentation	-	112	O
,	-	124	O
anxiety	-	126	B
and	-	134	O
SPECT	-	138	O
abnormalities	-	144	O
.	-	157	O

Wilson	17346443	159	B
's	-	165	I
disease	-	168	I
is	-	176	O
an	-	179	O
autosomal	-	182	O
recessive	-	192	O
disorder	-	202	O
of	-	211	O
hepatic	-	214	O
copper	-	222	O
metabolism	-	229	O
with	-	240	O
consequent	-	245	O
copper	-	256	O
accumulation	-	263	O
and	-	276	O
toxicity	-	280	B
in	-	289	O
many	-	292	O
tissues	-	297	O
and	-	305	O
consequent	-	309	O
hepatic	-	320	B
,	-	327	I
neurologic	-	329	I
and	-	340	I
psychiatric	-	344	I
disorders	-	356	I
.	-	365	O

We	17346443	367	O
report	-	370	O
a	-	377	O
case	-	379	O
of	-	384	O
Wilson	-	387	B
's	-	393	I
disease	-	396	I
with	-	404	O
chronic	-	409	B
liver	-	417	I
disease	-	423	I
;	-	430	O
moreover	-	432	O
,	-	440	O
in	-	442	O
our	-	445	O
patient	-	449	O
,	-	456	O
presenting	-	458	O
also	-	469	O
with	-	474	O
high	-	479	O
levels	-	484	O
of	-	491	O
state	-	494	O
anxiety	-	500	B
without	-	508	O
depression	-	516	B
,	-	526	O
99mTc	-	528	O
-	-	533	O
ECD	-	534	O
-	-	537	O
SPECT	-	538	O
showed	-	544	O
cortical	-	551	O
hypoperfusion	-	560	O
in	-	574	O
frontal	-	577	O
lobes	-	585	O
,	-	590	O
more	-	592	O
marked	-	597	O
on	-	604	O
the	-	607	O
left	-	611	O
frontal	-	616	O
lobe	-	624	O
.	-	628	O

During	17346443	630	O
the	-	637	O
follow	-	641	O
-	-	647	O
up	-	648	O
of	-	651	O
our	-	654	O
patient	-	658	O
,	-	665	O
penicillamine	-	667	O
was	-	681	O
interrupted	-	685	O
after	-	697	O
the	-	703	O
appearance	-	707	O
of	-	718	O
a	-	721	O
lichenoid	-	723	B
dermatitis	-	733	I
,	-	743	O
and	-	745	O
zinc	-	749	O
acetate	-	754	O
permitted	-	762	O
to	-	772	O
continue	-	775	O
the	-	784	O
successful	-	788	O
treatment	-	799	O
of	-	809	O
the	-	812	O
patient	-	816	O
without	-	824	O
side	-	832	O
-	-	836	O
effects	-	837	O
.	-	844	O

In	17346443	846	O
our	-	849	O
case	-	853	O
the	-	858	O
therapy	-	862	O
with	-	870	O
zinc	-	875	O
acetate	-	880	O
represented	-	888	O
an	-	900	O
effective	-	903	O
treatment	-	913	O
for	-	923	O
a	-	927	O
Wilson	-	929	B
's	-	935	I
disease	-	938	I
patient	-	946	O
in	-	954	O
which	-	957	O
penicillamine	-	963	O
-	-	976	O
related	-	977	O
side	-	985	O
effects	-	990	O
appeared	-	998	O
.	-	1006	O

The	17346443	1008	O
safety	-	1012	O
of	-	1019	O
the	-	1022	O
zinc	-	1026	O
acetate	-	1031	O
allowed	-	1039	O
us	-	1047	O
to	-	1050	O
avoid	-	1053	O
other	-	1059	O
potentially	-	1065	O
toxic	-	1077	O
chelating	-	1083	O
drugs	-	1093	O
;	-	1098	O
this	-	1100	O
observation	-	1105	O
is	-	1117	O
in	-	1120	O
line	-	1123	O
with	-	1128	O
the	-	1133	O
growing	-	1137	O
evidence	-	1145	O
on	-	1154	O
the	-	1157	O
efficacy	-	1161	O
of	-	1170	O
the	-	1173	O
drug	-	1177	O
in	-	1182	O
the	-	1185	O
treatment	-	1189	O
of	-	1199	O
Wilson	-	1202	B
's	-	1208	I
disease	-	1211	I
.	-	1218	O

Since	17346443	1220	O
most	-	1226	O
of	-	1231	O
Wilson	-	1234	B
's	-	1240	I
disease	-	1243	I
penicillamine	-	1251	O
-	-	1264	O
treated	-	1265	O
patients	-	1273	O
do	-	1282	O
not	-	1285	O
seem	-	1289	O
to	-	1294	O
develop	-	1297	O
this	-	1305	O
skin	-	1310	B
lesion	-	1315	I
,	-	1321	O
it	-	1323	O
could	-	1326	O
be	-	1332	O
conceivable	-	1335	O
that	-	1347	O
a	-	1352	O
specific	-	1354	O
genetic	-	1363	O
factor	-	1371	O
is	-	1378	O
involved	-	1381	O
in	-	1390	O
drug	-	1393	O
response	-	1398	O
.	-	1406	O

Further	17346443	1408	O
studies	-	1416	O
are	-	1424	O
needed	-	1428	O
for	-	1435	O
a	-	1439	O
better	-	1441	O
clarification	-	1448	O
of	-	1462	O
Wilson	-	1465	B
's	-	1471	I
disease	-	1474	I
therapy	-	1482	O
,	-	1489	O
and	-	1491	O
in	-	1495	O
particular	-	1498	O
to	-	1509	O
differentiate	-	1512	O
specific	-	1526	O
therapies	-	1535	O
for	-	1545	O
different	-	1549	O
Wilson	-	1559	B
's	-	1565	I
disease	-	1568	I
phenotypes	-	1576	O
.	-	1586	O

A	17351238	0	O
dramatic	-	2	O
drop	-	11	B
in	-	16	I
blood	-	19	I
pressure	-	25	I
following	-	34	O
prehospital	-	44	O
GTN	-	56	O
administration	-	60	O
.	-	74	O

A	17351238	76	O
male	-	78	O
in	-	83	O
his	-	86	O
sixties	-	90	O
with	-	98	O
no	-	103	O
history	-	106	O
of	-	114	O
cardiac	-	117	O
chest	-	125	B
pain	-	131	I
awoke	-	136	O
with	-	142	O
chest	-	147	B
pain	-	153	I
following	-	158	O
an	-	168	O
afternoon	-	171	O
sleep	-	181	O
.	-	186	O

The	17351238	188	O
patient	-	192	O
did	-	200	O
not	-	204	O
self	-	208	O
medicate	-	213	O
.	-	221	O

The	17351238	223	O
patient	-	227	O
's	-	234	O
observations	-	237	O
were	-	250	O
within	-	255	O
normal	-	262	O
limits	-	269	O
,	-	275	O
he	-	277	O
was	-	280	O
administered	-	284	O
oxygen	-	297	O
via	-	304	O
a	-	308	O
face	-	310	O
mask	-	315	O
and	-	320	O
glyceryl	-	324	O
trinitrate	-	333	O
(	-	344	O
GTN	-	345	O
)	-	348	O
.	-	349	O

Several	17351238	351	O
minutes	-	359	O
after	-	367	O
the	-	373	O
GTN	-	377	O
the	-	381	O
patient	-	385	O
experienced	-	393	O
a	-	405	O
sudden	-	407	O
drop	-	414	B
in	-	419	I
blood	-	422	I
pressure	-	428	I
and	-	437	O
heart	-	441	O
rate	-	447	O
,	-	451	O
this	-	453	O
was	-	458	O
rectified	-	462	O
by	-	472	O
atropine	-	475	O
sulphate	-	484	O
and	-	493	O
a	-	497	O
fluid	-	499	O
challenge	-	505	O
.	-	514	O

There	17351238	516	O
was	-	522	O
no	-	526	O
further	-	529	O
deterioration	-	537	O
in	-	551	O
the	-	554	O
patient	-	558	O
's	-	565	O
condition	-	568	O
during	-	578	O
transport	-	585	O
to	-	595	O
hospital	-	598	O
.	-	606	O

There	17351238	608	O
are	-	614	O
very	-	618	O
few	-	623	O
documented	-	627	O
case	-	638	O
like	-	643	O
this	-	648	O
in	-	653	O
the	-	656	O
prehospital	-	660	O
scientific	-	672	O
literature	-	683	O
.	-	693	O

The	17351238	695	O
cause	-	699	O
appears	-	705	O
to	-	713	O
be	-	716	O
the	-	719	O
Bezold	-	723	O
-	-	729	O
Jarish	-	730	O
reflex	-	737	O
,	-	743	O
stimulation	-	745	O
of	-	757	O
the	-	760	O
ventricular	-	764	O
walls	-	776	O
which	-	782	O
in	-	788	O
turn	-	791	O
decreases	-	796	O
sympathetic	-	806	O
outflow	-	818	O
from	-	826	O
the	-	831	O
vasomotor	-	835	O
centre	-	845	O
.	-	851	O

Prehospital	17351238	853	O
care	-	865	O
providers	-	870	O
who	-	880	O
are	-	884	O
managing	-	888	O
any	-	897	O
patient	-	901	O
with	-	909	O
a	-	914	O
syncopal	-	916	B
episode	-	925	I
that	-	933	O
fails	-	938	O
to	-	944	O
recover	-	947	O
within	-	955	O
a	-	962	O
reasonable	-	964	O
time	-	975	O
frame	-	980	O
should	-	986	O
consider	-	993	O
the	-	1002	O
Bezold	-	1006	O
-	-	1012	O
Jarisch	-	1013	O
reflex	-	1021	O
as	-	1028	O
the	-	1031	O
cause	-	1035	O
and	-	1041	O
manage	-	1045	O
the	-	1052	O
patient	-	1056	O
accordingly	-	1064	O
.	-	1075	O

Acute	17356399	0	B
encephalopathy	-	6	I
and	-	21	O
cerebral	-	25	B
vasospasm	-	34	I
after	-	44	O
multiagent	-	50	O
chemotherapy	-	61	O
including	-	74	O
PEG	-	84	O
-	-	87	O
asparaginase	-	88	O
and	-	101	O
intrathecal	-	105	O
cytarabine	-	117	O
for	-	128	O
the	-	132	O
treatment	-	136	O
of	-	146	O
acute	-	149	B
lymphoblastic	-	155	I
leukemia	-	169	I
.	-	177	O

A	17356399	179	O
7	-	181	O
-	-	182	O
year	-	183	O
-	-	187	O
old	-	188	O
girl	-	192	O
with	-	197	O
an	-	202	O
unusual	-	205	O
reaction	-	213	O
to	-	222	O
induction	-	225	O
chemotherapy	-	235	O
for	-	248	O
precursor	-	252	O
B	-	262	O
-	-	263	O
cell	-	264	O
acute	-	269	B
lymphoblastic	-	275	I
leukemia	-	289	I
(	-	298	O
ALL	-	299	B
)	-	302	O
is	-	304	O
described	-	307	O
.	-	316	O

The	17356399	318	O
patient	-	322	O
developed	-	330	O
acute	-	340	B
encephalopathy	-	346	I
evidenced	-	361	O
by	-	371	O
behavioral	-	374	O
changes	-	385	O
,	-	392	O
aphasia	-	394	B
,	-	401	O
incontinence	-	403	B
,	-	415	O
visual	-	417	B
hallucinations	-	424	I
,	-	438	O
and	-	440	O
right	-	444	O
-	-	449	O
sided	-	450	O
weakness	-	456	B
with	-	465	O
diffuse	-	470	O
cerebral	-	478	B
vasospasm	-	487	I
on	-	497	O
magnetic	-	500	O
resonance	-	509	O
angiography	-	519	O
after	-	531	O
the	-	537	O
administration	-	541	O
of	-	556	O
intrathecal	-	559	O
cytarabine	-	571	O
.	-	581	O

Vincristine	17356399	583	O
,	-	594	O
dexamethasone	-	596	O
,	-	609	O
and	-	611	O
polyethylene	-	615	O
glycol	-	628	O
-	-	634	O
asparaginase	-	635	O
were	-	648	O
also	-	653	O
administered	-	658	O
before	-	671	O
the	-	678	O
episode	-	682	O
as	-	690	O
part	-	693	O
of	-	698	O
induction	-	701	O
therapy	-	711	O
.	-	718	O

Neurologic	17356399	720	O
status	-	731	O
returned	-	738	O
to	-	747	O
baseline	-	750	O
within	-	759	O
10	-	766	O
days	-	769	O
of	-	774	O
the	-	777	O
acute	-	781	O
event	-	787	O
,	-	792	O
and	-	794	O
magnetic	-	798	O
resonance	-	807	O
angiography	-	817	O
findings	-	829	O
returned	-	838	O
to	-	847	O
normal	-	850	O
4	-	857	O
months	-	859	O
later	-	866	O
.	-	871	O

Comparison	17379047	0	O
of	-	11	O
valsartan	-	14	O
/	-	23	O
hydrochlorothiazide	-	24	O
combination	-	44	O
therapy	-	56	O
at	-	64	O
doses	-	67	O
up	-	73	O
to	-	76	O
320	-	79	O
/	-	82	O
25	-	83	O
mg	-	86	O
versus	-	89	O
monotherapy	-	96	O
:	-	107	O
a	-	109	O
double	-	111	O
-	-	117	O
blind	-	118	O
,	-	123	O
placebo	-	125	O
-	-	132	O
controlled	-	133	O
study	-	144	O
followed	-	150	O
by	-	159	O
long	-	162	O
-	-	166	O
term	-	167	O
combination	-	172	O
therapy	-	184	O
in	-	192	O
hypertensive	-	195	B
adults	-	208	O
.	-	214	O

BACKGROUND	17379047	216	O
:	-	226	O

One	17379047	228	O
third	-	232	O
of	-	238	O
patients	-	241	O
treated	-	250	O
for	-	258	O
hypertension	-	262	B
attain	-	275	O
adequate	-	282	O
blood	-	291	O
pressure	-	297	O
(	-	306	O
BP	-	307	O
)	-	309	O
control	-	311	O
,	-	318	O
and	-	320	O
multidrug	-	324	O
regimens	-	334	O
are	-	343	O
often	-	347	O
required	-	353	O
.	-	361	O

Given	17379047	363	O
the	-	369	O
lifelong	-	373	O
nature	-	382	O
of	-	389	O
hypertension	-	392	B
,	-	404	O
there	-	406	O
is	-	412	O
a	-	415	O
need	-	417	O
to	-	422	O
evaluate	-	425	O
the	-	434	O
long	-	438	O
-	-	442	O
term	-	443	O
efficacy	-	448	O
and	-	457	O
tolerability	-	461	O
of	-	474	O
higher	-	477	O
doses	-	484	O
of	-	490	O
combination	-	493	O
anti	-	505	O
-	-	509	O
hypertensive	-	510	B
therapies	-	523	O
.	-	532	O

OBJECTIVE	17379047	534	O
:	-	543	O

This	17379047	545	O
study	-	550	O
investigated	-	556	O
the	-	569	O
efficacy	-	573	O
and	-	582	O
tolerability	-	586	O
of	-	599	O
valsartan	-	602	O
(	-	612	O
VAL	-	613	O
)	-	616	O
or	-	618	O
hydrochlorothiazide	-	621	O
(	-	641	O
HCTZ	-	642	O
)	-	646	O
-	-	647	O
monotherapy	-	648	O
and	-	660	O
higher	-	664	O
-	-	670	O
dose	-	671	O
combinations	-	676	O
in	-	689	O
patients	-	692	O
with	-	701	O
essential	-	706	B
hypertension	-	716	I
.	-	728	O

METHODS	17379047	730	O
:	-	737	O

The	17379047	739	O
first	-	743	O
part	-	749	O
of	-	754	O
this	-	757	O
study	-	762	O
was	-	768	O
an	-	772	O
8	-	775	O
-	-	776	O
week	-	777	O
,	-	781	O
multicenter	-	783	O
,	-	794	O
randomized	-	796	O
,	-	806	O
double	-	808	O
-	-	814	O
blind	-	815	O
,	-	820	O
placebo	-	822	O
controlled	-	830	O
,	-	840	O
parallel	-	842	O
-	-	850	O
group	-	851	O
trial	-	857	O
.	-	862	O

Patients	17379047	864	O
with	-	873	O
essential	-	878	B
hypertension	-	888	I
(	-	901	O
mean	-	902	O
sitting	-	907	O
diastolic	-	915	O
BP	-	925	O
[	-	928	O
MSDBP	-	929	O
]	-	934	O
,	-	935	O
>	-	937	O
or	-	939	O
=	-	942	O
95	-	943	O
mm	-	946	O
Hg	-	949	O
and	-	952	O
<	-	956	O
110	-	957	O
mm	-	961	O
Hg	-	964	O
)	-	966	O
were	-	968	O
randomized	-	973	O
to	-	984	O
1	-	987	O
of	-	989	O
8	-	992	O
treatment	-	994	O
groups	-	1004	O
:	-	1010	O
VAL	-	1012	O
160	-	1016	O
or	-	1020	O
320	-	1023	O
mg	-	1027	O
;	-	1029	O
HCTZ	-	1031	O
12	-	1036	O
.	-	1038	O
5	-	1039	O
or	-	1041	O
25	-	1044	O
mg	-	1047	O
;	-	1049	O
VAL	-	1051	O
/	-	1054	O
HCTZ	-	1055	O
160	-	1060	O
/	-	1063	O
12	-	1064	O
.	-	1066	O
5	-	1067	O
,	-	1068	O
320	-	1070	O
/	-	1073	O
12	-	1074	O
.	-	1076	O
5	-	1077	O
,	-	1078	O
or	-	1080	O
320	-	1083	O
/	-	1086	O
25	-	1087	O
mg	-	1090	O
;	-	1092	O
or	-	1094	O
placebo	-	1097	O
.	-	1104	O

Mean	17379047	1106	O
changes	-	1111	O
in	-	1119	O
MSDBP	-	1122	O
and	-	1128	O
mean	-	1132	O
sitting	-	1137	O
systolic	-	1145	O
BP	-	1154	O
(	-	1157	O
MSSBP	-	1158	O
)	-	1163	O
were	-	1165	O
analyzed	-	1170	O
at	-	1179	O
the	-	1182	O
8	-	1186	O
-	-	1187	O
week	-	1188	O
core	-	1193	O
study	-	1198	O
end	-	1204	O
point	-	1208	O
.	-	1213	O

VAL	17379047	1215	O
/	-	1218	O
HCTZ	-	1219	O
320	-	1224	O
/	-	1227	O
12	-	1228	O
.	-	1230	O
5	-	1231	O
and	-	1233	O
320	-	1237	O
/	-	1240	O
25	-	1241	O
mg	-	1244	O
were	-	1247	O
further	-	1252	O
investigated	-	1260	O
in	-	1273	O
a	-	1276	O
54	-	1278	O
-	-	1280	O
week	-	1281	O
,	-	1285	O
open	-	1287	O
-	-	1291	O
label	-	1292	O
extension	-	1298	O
.	-	1307	O

Response	17379047	1309	O
was	-	1318	O
defined	-	1322	O
as	-	1330	O
MSDBP	-	1333	O
<	-	1339	O
90	-	1340	O
mm	-	1343	O
Hg	-	1346	O
or	-	1349	O
a	-	1352	O
>	-	1354	O
or	-	1356	O
=	-	1359	O
10	-	1360	O
mm	-	1363	O
Hg	-	1366	O
decrease	-	1369	O
compared	-	1378	O
to	-	1387	O
baseline	-	1390	O
.	-	1398	O

Control	17379047	1400	O
was	-	1408	O
defined	-	1412	O
as	-	1420	O
MSDBP	-	1423	O
<	-	1429	O
90	-	1430	O
mm	-	1433	O
Hg	-	1436	O
compared	-	1439	O
with	-	1448	O
baseline	-	1453	O
.	-	1461	O

Tolerability	17379047	1463	O
was	-	1476	O
assessed	-	1480	O
by	-	1489	O
monitoring	-	1492	O
adverse	-	1503	O
events	-	1511	O
at	-	1518	O
randomization	-	1521	O
and	-	1535	O
all	-	1539	O
subsequent	-	1543	O
study	-	1554	O
visits	-	1560	O
and	-	1567	O
regular	-	1571	O
evaluation	-	1579	O
of	-	1590	O
hematology	-	1593	O
and	-	1604	O
blood	-	1608	O
chemistry	-	1614	O
.	-	1623	O

RESULTS	17379047	1625	O
:	-	1632	O

A	17379047	1634	O
total	-	1636	O
of	-	1642	O
1346	-	1645	O
patients	-	1650	O
were	-	1659	O
randomized	-	1664	O
into	-	1675	O
the	-	1680	O
8	-	1684	O
-	-	1685	O
week	-	1686	O
core	-	1691	O
study	-	1696	O
(	-	1702	O
734	-	1703	O
men	-	1707	O
,	-	1710	O
612	-	1712	O
women	-	1716	O
;	-	1721	O
924	-	1723	O
white	-	1727	O
,	-	1732	O
291	-	1734	O
black	-	1738	O
,	-	1743	O
23	-	1745	O
Asian	-	1748	O
,	-	1753	O
108	-	1755	O
other	-	1759	O
;	-	1764	O
mean	-	1766	O
age	-	1771	O
,	-	1774	O
52	-	1776	O
.	-	1778	O
7	-	1779	O
years	-	1781	O
;	-	1786	O
mean	-	1788	O
weight	-	1793	O
,	-	1799	O
92	-	1801	O
.	-	1803	O
6	-	1804	O
kg	-	1806	O
)	-	1808	O
.	-	1809	O

All	17379047	1811	O
active	-	1815	O
treatments	-	1822	O
were	-	1833	O
associated	-	1838	O
with	-	1849	O
significantly	-	1854	O
reduced	-	1868	O
MSSBP	-	1876	O
and	-	1882	O
MSDBP	-	1886	O
during	-	1892	O
the	-	1899	O
core	-	1903	O
8	-	1908	O
-	-	1909	O
week	-	1910	O
study	-	1915	O
,	-	1920	O
with	-	1922	O
each	-	1927	O
monotherapy	-	1932	O
significantly	-	1944	O
contributing	-	1958	O
to	-	1971	O
the	-	1974	O
overall	-	1978	O
effect	-	1986	O
of	-	1993	O
combination	-	1996	O
therapy	-	2008	O
(	-	2016	O
VAL	-	2017	O
and	-	2021	O
HCTZ	-	2025	O
,	-	2029	O
P	-	2031	O
<	-	2033	O
0	-	2035	O
.	-	2036	O
001	-	2037	O
)	-	2040	O
.	-	2041	O

Each	17379047	2043	O
combination	-	2048	O
was	-	2060	O
associated	-	2064	O
with	-	2075	O
significantly	-	2080	O
greater	-	2094	O
reductions	-	2102	O
in	-	2113	O
MSSBP	-	2116	O
and	-	2122	O
MSDBP	-	2126	O
compared	-	2132	O
with	-	2141	O
the	-	2146	O
monotherapies	-	2150	O
and	-	2164	O
placebo	-	2168	O
(	-	2176	O
all	-	2177	O
,	-	2180	O
P	-	2182	O
<	-	2184	O
0	-	2186	O
.	-	2187	O
001	-	2188	O
)	-	2191	O
.	-	2192	O

The	17379047	2194	O
mean	-	2198	O
reduction	-	2203	O
in	-	2213	O
MSSBP	-	2216	O
/	-	2221	O
MSDBP	-	2222	O
with	-	2228	O
VAL	-	2233	O
/	-	2236	O
HCTZ	-	2237	O
320	-	2242	O
/	-	2245	O
25	-	2246	O
mg	-	2249	O
was	-	2252	O
24	-	2256	O
.	-	2258	O
7	-	2259	O
/	-	2260	O
16	-	2261	O
.	-	2263	O
6	-	2264	O
mm	-	2266	O
Hg	-	2269	O
,	-	2271	O
compared	-	2273	O
with	-	2282	O
5	-	2287	O
.	-	2288	O
9	-	2289	O
/	-	2290	O
7	-	2291	O
.	-	2292	O
0	-	2293	O
mm	-	2295	O
Hg	-	2298	O
with	-	2301	O
placebo	-	2306	O
.	-	2313	O

The	17379047	2315	O
reduction	-	2319	O
in	-	2329	O
MSSBP	-	2332	O
was	-	2338	O
significantly	-	2342	O
greater	-	2356	O
with	-	2364	O
VAL	-	2369	O
/	-	2372	O
HCTZ	-	2373	O
320	-	2378	O
/	-	2381	O
25	-	2382	O
mg	-	2385	O
compared	-	2388	O
with	-	2397	O
VAL	-	2402	O
/	-	2405	O
HCTZ	-	2406	O
160	-	2411	O
/	-	2414	O
12	-	2415	O
.	-	2417	O
5	-	2418	O
mg	-	2420	O
(	-	2423	O
P	-	2424	O
<	-	2426	O
0	-	2428	O
.	-	2429	O
002	-	2430	O
)	-	2433	O
.	-	2434	O

Rates	17379047	2436	O
of	-	2442	O
response	-	2445	O
and	-	2454	O
BP	-	2458	O
control	-	2461	O
were	-	2469	O
significantly	-	2474	O
higher	-	2488	O
in	-	2495	O
the	-	2498	O
groups	-	2502	O
that	-	2509	O
received	-	2514	O
combination	-	2523	O
treatment	-	2535	O
compared	-	2545	O
with	-	2554	O
those	-	2559	O
that	-	2565	O
received	-	2570	O
monotherapy	-	2579	O
.	-	2590	O

The	17379047	2592	O
incidence	-	2596	O
of	-	2606	O
hypokalemia	-	2609	B
was	-	2621	O
lower	-	2625	O
with	-	2631	O
VAL	-	2636	O
/	-	2639	O
HCTZ	-	2640	O
combinations	-	2645	O
(	-	2658	O
1	-	2659	O
.	-	2660	O
8	-	2661	O
%	-	2662	O
-	-	2663	O
6	-	2664	O
.	-	2665	O
1	-	2666	O
%	-	2667	O
)	-	2668	O
than	-	2670	O
with	-	2675	O
HCTZ	-	2680	O
monotherapies	-	2685	O
(	-	2699	O
7	-	2700	O
.	-	2701	O
1	-	2702	O
%	-	2703	O
-	-	2704	O
13	-	2705	O
.	-	2707	O
3	-	2708	O
%	-	2709	O
)	-	2710	O
.	-	2711	O

The	17379047	2713	O
majority	-	2717	O
of	-	2726	O
adverse	-	2729	O
events	-	2737	O
in	-	2744	O
the	-	2747	O
core	-	2751	O
study	-	2756	O
were	-	2762	O
of	-	2767	O
mild	-	2770	O
to	-	2775	O
moderate	-	2778	O
severity	-	2787	O
.	-	2795	O

The	17379047	2797	O
efficacy	-	2801	O
and	-	2810	O
tolerability	-	2814	O
of	-	2827	O
VAL	-	2830	O
/	-	2833	O
HCTZ	-	2834	O
combinations	-	2839	O
were	-	2852	O
maintained	-	2857	O
during	-	2868	O
the	-	2875	O
extension	-	2879	O
(	-	2889	O
797	-	2890	O
patients	-	2894	O
)	-	2902	O
.	-	2903	O

CONCLUSIONS	17379047	2905	O
:	-	2916	O

In	17379047	2918	O
this	-	2921	O
study	-	2926	O
population	-	2932	O
,	-	2942	O
combination	-	2944	O
therapies	-	2956	O
with	-	2966	O
VAL	-	2971	O
/	-	2974	O
HCTZ	-	2975	O
were	-	2980	O
associated	-	2985	O
with	-	2996	O
significantly	-	3001	O
greater	-	3015	O
BP	-	3023	O
reductions	-	3026	O
compared	-	3037	O
with	-	3046	O
either	-	3051	O
monotherapy	-	3058	O
,	-	3069	O
were	-	3071	O
well	-	3076	O
tolerated	-	3081	O
,	-	3090	O
and	-	3092	O
were	-	3096	O
associated	-	3101	O
with	-	3112	O
less	-	3117	O
hypokalemia	-	3122	B
than	-	3134	O
HCTZ	-	3139	O
alone	-	3144	O
.	-	3149	O

Succimer	17384765	0	O
chelation	-	9	O
improves	-	19	O
learning	-	28	O
,	-	36	O
attention	-	38	O
,	-	47	O
and	-	49	O
arousal	-	53	O
regulation	-	61	O
in	-	72	O
lead	-	75	O
-	-	79	O
exposed	-	80	O
rats	-	88	O
but	-	93	O
produces	-	97	O
lasting	-	106	O
cognitive	-	114	B
impairment	-	124	I
in	-	135	O
the	-	138	O
absence	-	142	O
of	-	150	O
lead	-	153	O
exposure	-	158	O
.	-	166	O

BACKGROUND	17384765	168	O
:	-	178	O
There	-	180	O
is	-	186	O
growing	-	189	O
pressure	-	197	O
for	-	206	O
clinicians	-	210	O
to	-	221	O
prescribe	-	224	O
chelation	-	234	O
therapy	-	244	O
at	-	252	O
only	-	255	O
slightly	-	260	O
elevated	-	269	O
blood	-	278	O
lead	-	284	O
levels	-	289	O
.	-	295	O

However	17384765	297	O
,	-	304	O
very	-	306	O
few	-	311	O
studies	-	315	O
have	-	323	O
evaluated	-	328	O
whether	-	338	O
chelation	-	346	O
improves	-	356	O
cognitive	-	365	O
outcomes	-	375	O
in	-	384	O
Pb	-	387	O
-	-	389	O
exposed	-	390	O
children	-	398	O
,	-	406	O
or	-	408	O
whether	-	411	O
these	-	419	O
agents	-	425	O
have	-	432	O
adverse	-	437	O
effects	-	445	O
that	-	453	O
may	-	458	O
affect	-	462	O
brain	-	469	O
development	-	475	O
in	-	487	O
the	-	490	O
absence	-	494	O
of	-	502	O
Pb	-	505	O
exposure	-	508	O
.	-	516	O

OBJECTIVES	17384765	518	O
:	-	528	O

The	17384765	530	O
present	-	534	O
study	-	542	O
was	-	548	O
designed	-	552	O
to	-	561	O
answer	-	564	O
these	-	571	O
questions	-	577	O
,	-	586	O
using	-	588	O
a	-	594	O
rodent	-	596	O
model	-	603	O
of	-	609	O
early	-	612	O
childhood	-	618	O
Pb	-	628	O
exposure	-	631	O
and	-	640	O
treatment	-	644	O
with	-	654	O
succimer	-	659	O
,	-	667	O
a	-	669	O
widely	-	671	O
used	-	678	O
chelating	-	683	O
agent	-	693	O
for	-	699	O
the	-	703	O
treatment	-	707	O
of	-	717	O
Pb	-	720	B
poisoning	-	723	I
.	-	732	O

RESULTS	17384765	734	O
:	-	741	O

Pb	17384765	743	O
exposure	-	746	O
produced	-	755	O
lasting	-	764	O
impairments	-	772	B
in	-	784	I
learning	-	787	I
,	-	795	I
attention	-	797	I
,	-	806	I
inhibitory	-	808	I
control	-	819	I
,	-	826	I
and	-	828	I
arousal	-	832	I
regulation	-	840	I
,	-	850	O
paralleling	-	852	O
the	-	864	O
areas	-	868	O
of	-	874	O
dysfunction	-	877	O
seen	-	889	O
in	-	894	O
Pb	-	897	O
-	-	899	O
exposed	-	900	O
children	-	908	O
.	-	916	O

Succimer	17384765	918	O
treatment	-	927	O
of	-	937	O
the	-	940	O
Pb	-	944	O
-	-	946	O
exposed	-	947	O
rats	-	955	O
significantly	-	960	O
improved	-	974	O
learning	-	983	O
,	-	991	O
attention	-	993	O
,	-	1002	O
and	-	1004	O
arousal	-	1008	O
regulation	-	1016	O
,	-	1026	O
although	-	1028	O
the	-	1037	O
efficacy	-	1041	O
of	-	1050	O
the	-	1053	O
treatment	-	1057	O
varied	-	1067	O
as	-	1074	O
a	-	1077	O
function	-	1079	O
of	-	1088	O
the	-	1091	O
Pb	-	1095	O
exposure	-	1098	O
level	-	1107	O
and	-	1113	O
the	-	1117	O
specific	-	1121	O
functional	-	1130	O
deficit	-	1141	O
.	-	1148	O

In	17384765	1150	O
contrast	-	1153	O
,	-	1161	O
succimer	-	1163	O
treatment	-	1172	O
of	-	1182	O
rats	-	1185	O
not	-	1190	O
previously	-	1194	O
exposed	-	1205	O
to	-	1213	O
Pb	-	1216	O
produced	-	1219	O
lasting	-	1228	O
and	-	1236	O
pervasive	-	1240	O
cognitive	-	1250	B
and	-	1260	I
affective	-	1264	I
dysfunction	-	1274	I
comparable	-	1286	O
in	-	1297	O
magnitude	-	1300	O
to	-	1310	O
that	-	1313	O
produced	-	1318	O
by	-	1327	O
the	-	1330	O
higher	-	1334	O
Pb	-	1341	O
exposure	-	1344	O
regimen	-	1353	O
.	-	1360	O

CONCLUSIONS	17384765	1362	O
:	-	1373	O

These	17384765	1375	O
are	-	1381	O
the	-	1385	O
first	-	1389	O
data	-	1395	O
,	-	1399	O
to	-	1401	O
our	-	1404	O
knowledge	-	1408	O
,	-	1417	O
to	-	1419	O
show	-	1422	O
that	-	1427	O
treatment	-	1432	O
with	-	1442	O
any	-	1447	O
chelating	-	1451	O
agent	-	1461	O
can	-	1467	O
alleviate	-	1471	O
cognitive	-	1481	B
deficits	-	1491	I
due	-	1500	O
to	-	1504	O
Pb	-	1507	O
exposure	-	1510	O
.	-	1518	O

These	17384765	1520	O
findings	-	1526	O
suggest	-	1535	O
that	-	1543	O
it	-	1548	O
may	-	1551	O
be	-	1555	O
possible	-	1558	O
to	-	1567	O
identify	-	1570	O
a	-	1579	O
succimer	-	1581	O
treatment	-	1590	O
protocol	-	1600	O
that	-	1609	O
improves	-	1614	O
cognitive	-	1623	O
outcomes	-	1633	O
in	-	1642	O
Pb	-	1645	O
-	-	1647	O
exposed	-	1648	O
children	-	1656	O
.	-	1664	O

However	17384765	1666	O
,	-	1673	O
they	-	1675	O
also	-	1680	O
suggest	-	1685	O
that	-	1693	O
succimer	-	1698	O
treatment	-	1707	O
should	-	1717	O
be	-	1724	O
strongly	-	1727	O
discouraged	-	1736	O
for	-	1748	O
children	-	1752	O
who	-	1761	O
do	-	1765	O
not	-	1768	O
have	-	1772	O
elevated	-	1777	O
tissue	-	1786	O
levels	-	1793	O
of	-	1800	O
Pb	-	1803	O
or	-	1806	O
other	-	1809	O
heavy	-	1815	O
metals	-	1821	O
.	-	1827	O

Caffeine	17445520	0	O
challenge	-	9	O
test	-	19	O
in	-	24	O
panic	-	27	B
disorder	-	33	I
and	-	42	O
depression	-	46	B
with	-	57	O
panic	-	62	B
attacks	-	68	I
.	-	75	O

Our	17445520	77	O
aim	-	81	O
was	-	85	O
to	-	89	O
observe	-	92	O
if	-	100	O
patients	-	103	O
with	-	112	O
panic	-	117	B
disorder	-	123	I
(	-	132	O
PD	-	133	B
)	-	135	O
and	-	137	O
patients	-	141	O
with	-	150	O
major	-	155	B
depression	-	161	I
with	-	172	O
panic	-	177	B
attacks	-	183	I
(	-	191	O
MDP	-	192	B
)	-	195	O
(	-	197	O
Diagnostic	-	198	O
and	-	209	O
Statistical	-	213	O
Manual	-	225	O
of	-	232	O
Mental	-	235	B
Disorders	-	242	I
,	-	251	O
Fourth	-	253	O
Edition	-	260	O
criteria	-	268	O
)	-	276	O
respond	-	278	O
in	-	286	O
a	-	289	O
similar	-	291	O
way	-	299	O
to	-	303	O
the	-	306	O
induction	-	310	O
of	-	320	O
panic	-	323	B
attacks	-	329	I
by	-	337	O
an	-	340	O
oral	-	343	O
caffeine	-	348	O
challenge	-	357	O
test	-	367	O
.	-	371	O

We	17445520	373	O
randomly	-	376	O
selected	-	385	O
29	-	394	O
patients	-	397	O
with	-	406	O
PD	-	411	B
,	-	413	O
27	-	415	O
with	-	418	O
MDP	-	423	B
,	-	426	O
25	-	428	O
with	-	431	O
major	-	436	B
depression	-	442	I
without	-	453	O
panic	-	461	B
attacks	-	467	I
(	-	475	O
MD	-	476	B
)	-	478	O
,	-	479	O
and	-	481	O
28	-	485	O
healthy	-	488	O
volunteers	-	496	O
.	-	506	O

The	17445520	508	O
patients	-	512	O
had	-	521	O
no	-	525	O
psychotropic	-	528	O
drug	-	541	O
for	-	546	O
at	-	550	O
least	-	553	O
a	-	559	O
4	-	561	O
-	-	562	O
week	-	563	O
period	-	568	O
.	-	574	O

In	17445520	576	O
a	-	579	O
randomized	-	581	O
double	-	592	O
-	-	598	O
blind	-	599	O
experiment	-	605	O
performed	-	616	O
in	-	626	O
2	-	629	O
occasions	-	631	O
7	-	641	O
days	-	643	O
apart	-	648	O
,	-	653	O
480	-	655	O
mg	-	659	O
caffeine	-	662	O
and	-	671	O
a	-	675	O
caffeine	-	677	O
-	-	685	O
free	-	686	O
(	-	691	O
placebo	-	692	O
)	-	699	O
solution	-	701	O
were	-	710	O
administered	-	715	O
in	-	728	O
a	-	731	O
coffee	-	733	O
form	-	740	O
and	-	745	O
anxiety	-	749	B
scales	-	757	O
were	-	764	O
applied	-	769	O
before	-	777	O
and	-	784	O
after	-	788	O
each	-	794	O
test	-	799	O
.	-	803	O

A	17445520	805	O
total	-	807	O
of	-	813	O
58	-	816	O
.	-	818	O
6	-	819	O
%	-	820	O
(	-	822	O
n	-	823	O
=	-	825	O
17	-	827	O
)	-	829	O
of	-	831	O
patients	-	834	O
with	-	843	O
PD	-	848	B
,	-	850	O
44	-	852	O
.	-	854	O
4	-	855	O
%	-	856	O
(	-	858	O
n	-	859	O
=	-	861	O
12	-	863	O
)	-	865	O
of	-	867	O
patients	-	870	O
with	-	879	O
MDP	-	884	B
,	-	887	O
12	-	889	O
.	-	891	O
0	-	892	O
%	-	893	O
(	-	895	O
n	-	896	O
=	-	898	O
3	-	900	O
)	-	901	O
of	-	903	O
patients	-	906	O
with	-	915	O
MD	-	920	B
,	-	922	O
and	-	924	O
7	-	928	O
.	-	929	O
1	-	930	O
%	-	931	O
(	-	933	O
n	-	934	O
=	-	935	O
2	-	937	O
)	-	938	O
of	-	940	O
control	-	943	O
subjects	-	951	O
had	-	960	O
a	-	964	O
panic	-	966	B
attack	-	972	I
after	-	979	O
the	-	985	O
480	-	989	O
-	-	992	O
mg	-	993	O
caffeine	-	996	O
challenge	-	1005	O
test	-	1015	O
(	-	1020	O
chi	-	1021	O
(	-	1024	O
2	-	1025	O
)	-	1026	O
(	-	1027	O
3	-	1028	O
)	-	1029	O
=	-	1031	O

16	17445520	1033	O
.	-	1035	O
22	-	1036	O
,	-	1038	O
P	-	1040	O
=	-	1042	O
.	-	1044	O
001	-	1045	O
)	-	1048	O
.	-	1049	O

The	17445520	1051	O
patients	-	1055	O
with	-	1064	O
PD	-	1069	B
and	-	1072	O
MDP	-	1076	B
were	-	1080	O
more	-	1085	O
sensitive	-	1090	O
to	-	1100	O
caffeine	-	1103	O
than	-	1112	O
were	-	1117	O
patients	-	1122	O
with	-	1131	O
MD	-	1136	B
and	-	1139	O
healthy	-	1143	O
volunteers	-	1151	O
.	-	1161	O

No	17445520	1163	O
panic	-	1166	B
attack	-	1172	I
was	-	1179	O
observed	-	1183	O
after	-	1192	O
the	-	1198	O
caffeine	-	1202	O
-	-	1210	O
free	-	1211	O
solution	-	1216	O
intake	-	1225	O
.	-	1231	O

The	17445520	1233	O
patients	-	1237	O
with	-	1246	O
MD	-	1251	B
had	-	1254	O
a	-	1258	O
lower	-	1260	O
heart	-	1266	O
rate	-	1272	O
response	-	1277	O
to	-	1286	O
the	-	1289	O
test	-	1293	O
than	-	1298	O
all	-	1303	O
the	-	1307	O
other	-	1311	O
groups	-	1317	O
(	-	1324	O
2	-	1325	O
-	-	1326	O
way	-	1327	O
analysis	-	1331	O
of	-	1340	O
variance	-	1343	O
,	-	1351	O
group	-	1353	O
by	-	1359	O
time	-	1362	O
interaction	-	1367	O
with	-	1379	O
Greenhouse	-	1384	O
-	-	1394	O
Geisser	-	1395	O
correction	-	1403	O
:	-	1413	O
F	-	1415	O
(	-	1416	O
3	-	1417	O
,	-	1418	O
762	-	1419	O
)	-	1422	O
=	-	1424	O
2	-	1426	O
.	-	1427	O
85	-	1428	O
,	-	1430	O
P	-	1432	O
=	-	1434	O
.	-	1436	O
026	-	1437	O
)	-	1440	O
.	-	1441	O

Our	17445520	1443	O
data	-	1447	O
suggest	-	1452	O
that	-	1460	O
there	-	1465	O
is	-	1471	O
an	-	1474	O
association	-	1477	O
between	-	1489	O
panic	-	1497	B
attacks	-	1503	I
,	-	1510	O
no	-	1512	O
matter	-	1515	O
if	-	1522	O
associated	-	1525	O
with	-	1536	O
PD	-	1541	B
or	-	1544	O
MDP	-	1547	B
,	-	1550	O
and	-	1552	O
hyperreactivity	-	1556	O
to	-	1572	O
an	-	1575	O
oral	-	1578	O
caffeine	-	1583	O
challenge	-	1592	O
test	-	1602	O
.	-	1606	O

Mitral	17484470	0	O
annuloplasty	-	7	O
as	-	20	O
a	-	23	O
ventricular	-	25	O
restoration	-	37	O
method	-	49	O
for	-	56	O
the	-	60	O
failing	-	64	B
left	-	72	I
ventricle	-	77	I
:	-	86	O
a	-	88	O
pilot	-	90	O
study	-	96	O
.	-	101	O

BACKGROUND	17484470	103	O
AND	-	114	O
AIM	-	118	O
OF	-	122	O
THE	-	125	O
STUDY	-	129	O
:	-	134	O

Undersized	17484470	136	O
mitral	-	147	O
annuloplasty	-	154	O
(	-	167	O
MAP	-	168	O
)	-	171	O
is	-	173	O
effective	-	176	O
in	-	186	O
patients	-	189	O
with	-	198	O
dilated	-	203	B
cardiomyopathy	-	211	I
and	-	226	O
functional	-	230	O
mitral	-	241	B
regurgitation	-	248	I
(	-	262	O
MR	-	263	B
)	-	265	O
since	-	267	O
,	-	272	O
as	-	274	O
well	-	277	O
as	-	282	O
addressing	-	285	O
the	-	296	O
MR	-	300	B
,	-	302	O
the	-	304	O
MAP	-	308	O
may	-	312	O
also	-	316	O
reshape	-	321	O
the	-	329	O
dilated	-	333	O
left	-	341	O
ventricular	-	346	O
(	-	358	O
LV	-	359	O
)	-	361	O
base	-	363	O
.	-	367	O

However	17484470	369	O
,	-	376	O
the	-	378	O
direct	-	382	O
benefits	-	389	O
of	-	398	O
this	-	401	O
possible	-	406	O
reshaping	-	415	O
on	-	425	O
LV	-	428	O
function	-	431	O
in	-	440	O
the	-	443	O
absence	-	447	O
of	-	455	O
underlying	-	458	O
MR	-	469	B
remain	-	472	O
incompletely	-	479	O
understood	-	492	O
.	-	502	O

The	17484470	504	O
study	-	508	O
aim	-	514	O
was	-	518	O
to	-	522	O
identify	-	525	O
these	-	534	O
benefits	-	540	O
in	-	549	O
a	-	552	O
canine	-	554	O
model	-	561	O
of	-	567	O
acute	-	570	O
heart	-	576	B
failure	-	582	I
.	-	589	O

METHODS	17484470	591	O
:	-	598	O

Six	17484470	600	O
dogs	-	604	O
underwent	-	609	O
MAP	-	619	O
with	-	623	O
a	-	628	O
prosthetic	-	630	O
band	-	641	O
on	-	646	O
the	-	649	O
posterior	-	653	O
mitral	-	663	O
annulus	-	670	O
,	-	677	O
using	-	679	O
four	-	685	O
mattress	-	690	O
sutures	-	699	O
.	-	706	O

The	17484470	708	O
sutures	-	712	O
were	-	720	O
passed	-	725	O
individually	-	732	O
through	-	745	O
four	-	753	O
tourniquets	-	758	O
and	-	770	O
exteriorized	-	774	O
untied	-	787	O
via	-	794	O
the	-	798	O
left	-	802	O
atriotomy	-	807	O
.	-	816	O

Sonomicrometry	17484470	818	O
crystals	-	833	O
were	-	842	O
implanted	-	847	O
around	-	857	O
the	-	864	O
mitral	-	868	O
annulus	-	875	O
and	-	883	O
left	-	887	O
ventricle	-	892	O
to	-	902	O
measure	-	905	O
geometry	-	913	O
and	-	922	O
regional	-	926	O
function	-	935	O
.	-	943	O

Acute	17484470	945	O
heart	-	951	B
failure	-	957	I
was	-	965	O
induced	-	969	O
by	-	977	O
propranolol	-	980	O
and	-	992	O
volume	-	996	O
loading	-	1003	O
after	-	1011	O
weaning	-	1017	O
from	-	1025	O
cardiopulmonary	-	1030	O
bypass	-	1046	O
;	-	1052	O
an	-	1054	O
absence	-	1057	O
of	-	1065	O
MR	-	1068	B
was	-	1071	O
confirmed	-	1075	O
by	-	1085	O
echocardiography	-	1088	O
.	-	1104	O

MAP	17484470	1106	O
was	-	1110	O
accomplished	-	1114	O
by	-	1127	O
cinching	-	1130	O
the	-	1139	O
tourniquets	-	1143	O
.	-	1154	O

Data	17484470	1156	O
were	-	1161	O
acquired	-	1166	O
at	-	1175	O
baseline	-	1178	O
,	-	1186	O
after	-	1188	O
induction	-	1194	O
of	-	1204	O
acute	-	1207	O
heart	-	1213	B
failure	-	1219	I
,	-	1226	O
and	-	1228	O
after	-	1232	O
MAP	-	1238	O
.	-	1241	O

RESULTS	17484470	1243	O
:	-	1250	O

MAP	17484470	1252	O
decreased	-	1256	O
mitral	-	1266	O
annular	-	1273	O
dimensions	-	1281	O
in	-	1292	O
both	-	1295	O
commissure	-	1300	O
-	-	1310	O
commissure	-	1311	O
and	-	1322	O
septal	-	1326	O
-	-	1332	O
lateral	-	1333	O
directions	-	1341	O
.	-	1351	O

Concomitantly	17484470	1353	O
,	-	1366	O
the	-	1368	O
diastolic	-	1372	O
diameter	-	1382	O
of	-	1391	O
the	-	1394	O
LV	-	1398	O
base	-	1401	O
and	-	1406	O
LV	-	1410	O
sphericity	-	1413	O
decreased	-	1424	O
(	-	1434	O
i	-	1435	O
.	-	1436	O
e	-	1437	O
.	-	1438	O
,	-	1439	O
improved	-	1441	O
)	-	1449	O
from	-	1451	O
37	-	1456	O
.	-	1458	O
4	-	1459	O
+	-	1461	O
/	-	1462	O
-	-	1463	O

9	17484470	1465	O
.	-	1466	O
3	-	1467	O
to	-	1469	O
35	-	1472	O
.	-	1474	O
9	-	1475	O
+	-	1477	O
/	-	1478	O
-	-	1479	O

10	17484470	1481	O
mm	-	1484	O
(	-	1487	O
p	-	1488	O
=	-	1490	O
0	-	1492	O
.	-	1493	O
063	-	1494	O
)	-	1497	O
,	-	1498	O
and	-	1500	O
from	-	1504	O
67	-	1509	O
.	-	1511	O
9	-	1512	O
+	-	1514	O
/	-	1515	O
-	-	1516	O

18	17484470	1518	O
.	-	1520	O
6	-	1521	O
%	-	1522	O
to	-	1524	O
65	-	1527	O
.	-	1529	O
3	-	1530	O
+	-	1532	O
/	-	1533	O
-	-	1534	O

18	17484470	1536	O
.	-	1538	O
9	-	1539	O
%	-	1540	O
(	-	1542	O
p	-	1543	O
=	-	1545	O
0	-	1547	O
.	-	1548	O
016	-	1549	O
)	-	1552	O
,	-	1553	O
respectively	-	1555	O
.	-	1567	O

Decreases	17484470	1569	O
were	-	1579	O
evident	-	1584	O
in	-	1592	O
both	-	1595	O
LV	-	1600	O
end	-	1603	O
-	-	1606	O
diastolic	-	1607	O
pressure	-	1617	O
(	-	1626	O
from	-	1627	O
17	-	1632	O
+	-	1635	O
/	-	1636	O
-	-	1637	O

7	17484470	1639	O
to	-	1641	O
15	-	1644	O
+	-	1647	O
/	-	1648	O
-	-	1649	O

6	17484470	1651	O
mmHg	-	1653	O
,	-	1657	O
p	-	1659	O
=	-	1661	O
0	-	1663	O
.	-	1664	O
0480	-	1665	O
and	-	1670	O
Tau	-	1674	O
(	-	1678	O
from	-	1679	O
48	-	1684	O
+	-	1687	O
/	-	1688	O
-	-	1689	O

8	17484470	1691	O
to	-	1693	O
45	-	1696	O
+	-	1699	O
/	-	1700	O
-	-	1701	O

8	17484470	1703	O
ms	-	1705	O
,	-	1707	O
p	-	1709	O
<	-	1711	O
0	-	1712	O
.	-	1713	O
01	-	1714	O
)	-	1716	O
,	-	1717	O
while	-	1719	O
fractional	-	1725	O
shortening	-	1736	O
at	-	1747	O
the	-	1750	O
LV	-	1754	O
base	-	1757	O
increased	-	1762	O
from	-	1772	O
7	-	1777	O
.	-	1778	O
7	-	1779	O
+	-	1781	O
/	-	1782	O
-	-	1783	O

4	17484470	1785	O
.	-	1786	O
5	-	1787	O
%	-	1788	O
to	-	1790	O
9	-	1793	O
.	-	1794	O
4	-	1795	O
+	-	1797	O
/	-	1798	O
-	-	1799	O

4	17484470	1801	O
.	-	1802	O
5	-	1803	O
%	-	1804	O
(	-	1806	O
p	-	1807	O
=	-	1809	O
0	-	1811	O
.	-	1812	O
045	-	1813	O
)	-	1816	O
.	-	1817	O

After	17484470	1819	O
MAP	-	1825	O
,	-	1828	O
increases	-	1830	O
were	-	1840	O
identified	-	1845	O
in	-	1856	O
both	-	1859	O
cardiac	-	1864	O
output	-	1872	O
(	-	1879	O
from	-	1880	O
1	-	1885	O
.	-	1886	O
54	-	1887	O
+	-	1890	O
/	-	1891	O
-	-	1892	O

0	17484470	1894	O
.	-	1895	O
57	-	1896	O
to	-	1899	O
1	-	1902	O
.	-	1903	O
65	-	1904	O
+	-	1907	O
/	-	1908	O
-	-	1909	O

0	17484470	1911	O
.	-	1912	O
57	-	1913	O
1	-	1916	O
/	-	1917	O
min	-	1918	O
)	-	1921	O
and	-	1923	O
Emax	-	1927	O
(	-	1932	O
from	-	1933	O
1	-	1938	O
.	-	1939	O
86	-	1940	O
+	-	1943	O
/	-	1944	O
-	-	1945	O

0	17484470	1947	O
.	-	1948	O
9	-	1949	O
to	-	1951	O
2	-	1954	O
.	-	1955	O
41	-	1956	O
+	-	1959	O
/	-	1960	O
-	-	1961	O

1	17484470	1963	O
.	-	1964	O
31	-	1965	O
mmHg	-	1968	O
/	-	1972	O
ml	-	1973	O
)	-	1975	O
.	-	1976	O

CONCLUSION	17484470	1978	O
:	-	1988	O

The	17484470	1990	O
data	-	1994	O
acquired	-	1999	O
suggest	-	2008	O
that	-	2016	O
isolated	-	2021	O
MAP	-	2030	O
may	-	2034	O
have	-	2038	O
certain	-	2043	O
benefits	-	2051	O
on	-	2060	O
LV	-	2063	O
dimension	-	2066	O
/	-	2075	O
function	-	2076	O
in	-	2085	O
acute	-	2088	O
heart	-	2094	B
failure	-	2100	I
,	-	2107	O
even	-	2109	O
in	-	2114	O
the	-	2117	O
absence	-	2121	O
of	-	2129	O
MR	-	2132	B
.	-	2134	O

However	17484470	2136	O
,	-	2143	O
further	-	2145	O
investigations	-	2153	O
are	-	2168	O
warranted	-	2172	O
in	-	2182	O
a	-	2185	O
model	-	2187	O
of	-	2193	O
chronic	-	2196	O
heart	-	2204	B
failure	-	2210	I
.	-	2217	O

Piperacillin	17496739	0	O
/	-	12	O
tazobactam	-	13	O
-	-	23	O
induced	-	24	O
seizure	-	32	B
rapidly	-	40	O
reversed	-	48	O
by	-	57	O
high	-	60	O
flux	-	65	O
hemodialysis	-	70	O
in	-	83	O
a	-	86	O
patient	-	88	O
on	-	96	O
peritoneal	-	99	O
dialysis	-	110	O
.	-	118	O

Despite	17496739	120	O
popular	-	128	O
use	-	136	O
of	-	140	O
piperacillin	-	143	O
,	-	155	O
the	-	157	O
dire	-	161	O
neurotoxicity	-	166	B
associated	-	180	O
with	-	191	O
piperacillin	-	196	O
still	-	209	O
goes	-	215	O
unrecognized	-	220	O
,	-	232	O
leading	-	234	O
to	-	242	O
a	-	245	O
delay	-	247	O
in	-	253	O
appropriate	-	256	O
management	-	268	O
.	-	278	O

We	17496739	280	O
report	-	283	O
a	-	290	O
57	-	292	O
-	-	294	O
year	-	295	O
-	-	299	O
old	-	300	O
woman	-	304	O
with	-	310	O
end	-	315	B
-	-	318	I
stage	-	319	I
renal	-	325	I
disease	-	331	I
receiving	-	339	O
continuous	-	349	O
ambulatory	-	360	O
peritoneal	-	371	O
dialysis	-	382	O
(	-	391	O
CAPD	-	392	O
)	-	396	O
,	-	397	O
who	-	399	O
developed	-	403	O
slurred	-	413	O
speech	-	421	O
,	-	427	O
tremor	-	429	B
,	-	435	O
bizarre	-	437	O
behavior	-	445	O
,	-	453	O
progressive	-	455	O
mental	-	467	O
confusion	-	474	B
,	-	483	O
and	-	485	O
2	-	489	O
episodes	-	491	O
of	-	500	O
generalized	-	503	O
tonic	-	515	B
-	-	520	I
clonic	-	521	I
seizure	-	528	I
(	-	536	O
GTCS	-	537	B
)	-	541	O
after	-	543	O
5	-	549	O
doses	-	551	O
of	-	557	O
piperacillin	-	560	O
/	-	572	O
tazobactam	-	573	O
(	-	584	O
2	-	585	O
g	-	587	O
/	-	588	O
250	-	589	O
mg	-	593	O
)	-	595	O
were	-	597	O
given	-	602	O
for	-	608	O
bronchiectasis	-	612	B
with	-	627	O
secondary	-	632	B
infection	-	642	I
.	-	651	O

The	17496739	653	O
laboratory	-	657	O
data	-	668	O
revealed	-	673	O
normal	-	682	O
plasma	-	689	O
electrolyte	-	696	O
and	-	708	O
ammonia	-	712	O
levels	-	720	O
but	-	727	O
leukocytosis	-	731	B
.	-	743	O

Neurologic	17496739	745	O
examinations	-	756	O
showed	-	769	O
dysarthria	-	776	B
and	-	787	O
bilateral	-	791	O
Babinski	-	801	O
sign	-	810	O
.	-	814	O

Computed	17496739	816	O
tomography	-	825	O
of	-	836	O
brain	-	839	O
and	-	845	O
electroencephalogram	-	849	O
were	-	870	O
unremarkable	-	875	O
.	-	887	O

Despite	17496739	889	O
the	-	897	O
use	-	901	O
of	-	905	O
antiepileptic	-	908	O
agents	-	922	O
,	-	928	O
another	-	930	O
GTCS	-	938	B
episode	-	943	O
recurred	-	951	O
after	-	960	O
the	-	966	O
sixth	-	970	O
dose	-	976	O
of	-	981	O
piperacillin	-	984	O
/	-	996	O
tazobactam	-	997	O
.	-	1007	O

Brain	17496739	1009	O
magnetic	-	1015	O
resonance	-	1024	O
imaging	-	1034	O
did	-	1042	O
not	-	1046	O
demonstrate	-	1050	O
acute	-	1062	O
infarction	-	1068	B
and	-	1079	O
organic	-	1083	B
brain	-	1091	I
lesions	-	1097	I
.	-	1104	O

Initiation	17496739	1106	O
of	-	1117	O
high	-	1120	O
-	-	1124	O
flux	-	1125	O
hemodialysis	-	1130	O
rapidly	-	1143	O
reversed	-	1151	O
the	-	1160	O
neurologic	-	1164	O
symptoms	-	1175	O
within	-	1184	O
4	-	1191	O
hours	-	1193	O
.	-	1198	O

Piperacillin	17496739	1200	O
-	-	1212	O
induced	-	1213	O
encephalopathy	-	1221	B
should	-	1236	O
be	-	1243	O
considered	-	1246	O
in	-	1257	O
any	-	1260	O
uremic	-	1264	B
patients	-	1271	O
with	-	1280	O
unexplained	-	1285	O
neurological	-	1297	O
manifestations	-	1310	O
.	-	1324	O

CAPD	17496739	1326	O
is	-	1331	O
inefficient	-	1334	O
in	-	1346	O
removing	-	1349	O
piperacillin	-	1358	O
,	-	1370	O
whereas	-	1372	O
hemodialysis	-	1380	O
can	-	1393	O
rapidly	-	1397	O
terminate	-	1405	O
the	-	1415	O
piperacillin	-	1419	O
-	-	1431	O
induced	-	1432	O
encephalopathy	-	1440	B
.	-	1454	O

Frequency	17543491	0	O
of	-	10	O
transient	-	13	O
ipsilateral	-	23	O
vocal	-	35	B
cord	-	41	I
paralysis	-	46	I
in	-	56	O
patients	-	59	O
undergoing	-	68	O
carotid	-	79	O
endarterectomy	-	87	O
under	-	102	O
local	-	108	O
anesthesia	-	114	O
.	-	124	O

BACKGROUND	17543491	126	O
:	-	136	O
Especially	-	138	O
because	-	149	O
of	-	157	O
improvements	-	160	O
in	-	173	O
clinical	-	176	O
neurologic	-	185	O
monitoring	-	196	O

,	17543491	206	O
carotid	-	208	O
endarterectomy	-	216	O
done	-	231	O
under	-	236	O
local	-	242	O
anesthesia	-	248	O
has	-	259	O
become	-	263	O
the	-	270	O
technique	-	274	O
of	-	284	O
choice	-	287	O
in	-	294	O
several	-	297	O
centers	-	305	O
.	-	312	O

Temporary	17543491	314	O
ipsilateral	-	324	O
vocal	-	336	B
nerve	-	342	I
palsies	-	348	I
due	-	356	O
to	-	360	O
local	-	363	O
anesthetics	-	369	O
have	-	381	O
been	-	386	O
described	-	391	O
,	-	400	O
however	-	402	O
.	-	409	O

Such	17543491	411	O
complications	-	416	O
are	-	430	O
most	-	434	O
important	-	439	O
in	-	449	O
situations	-	452	O
where	-	463	O
there	-	469	O
is	-	475	O
a	-	478	O
pre	-	480	O
-	-	483	O
existing	-	484	O
contralateral	-	493	O
paralysis	-	507	B
.	-	516	O

We	17543491	518	O
therefore	-	521	O
examined	-	531	O
the	-	540	O
effect	-	544	O
of	-	551	O
local	-	554	O
anesthesia	-	560	O
on	-	571	O
vocal	-	574	O
cord	-	580	O
function	-	585	O
to	-	594	O
better	-	597	O
understand	-	604	O
its	-	615	O
possible	-	619	O
consequences	-	628	O
.	-	640	O

METHODS	17543491	642	O
:	-	649	O

This	17543491	651	O
prospective	-	656	O
study	-	668	O
included	-	674	O
28	-	683	O
patients	-	686	O
undergoing	-	695	O
carotid	-	706	O
endarterectomy	-	714	O
under	-	729	O
local	-	735	O
anesthesia	-	741	O
.	-	751	O

Vocal	17543491	753	O
cord	-	759	O
function	-	764	O
was	-	773	O
evaluated	-	777	O
before	-	787	O
,	-	793	O
during	-	795	O
,	-	801	O
and	-	803	O
after	-	807	O
surgery	-	813	O
(	-	821	O
postoperative	-	822	O
day	-	836	O
1	-	840	O
)	-	841	O
using	-	843	O
flexible	-	849	O
laryngoscopy	-	858	O
.	-	870	O

Anesthesia	17543491	872	O
was	-	883	O
performed	-	887	O
by	-	897	O
injecting	-	900	O
20	-	910	O
to	-	913	O
40	-	916	O
mL	-	919	O
of	-	922	O
a	-	925	O
mixture	-	927	O
of	-	935	O
long	-	938	O
-	-	942	O
acting	-	943	O
(	-	950	O
ropivacaine	-	951	O
)	-	962	O
and	-	964	O
short	-	968	O
-	-	973	O
acting	-	974	O
(	-	981	O
prilocaine	-	982	O
)	-	992	O
anesthetic	-	994	O
.	-	1004	O

RESULTS	17543491	1006	O
:	-	1013	O

All	17543491	1015	O
patients	-	1019	O
had	-	1028	O
normal	-	1032	O
vocal	-	1039	O
cord	-	1045	O
function	-	1050	O
preoperatively	-	1059	O
.	-	1073	O

Twelve	17543491	1075	O
patients	-	1082	O
(	-	1091	O
43	-	1092	O
%	-	1094	O
)	-	1095	O
were	-	1097	O
found	-	1102	O
to	-	1108	O
have	-	1111	O
intraoperative	-	1116	O
ipsilateral	-	1131	O
vocal	-	1143	B
cord	-	1149	I
paralysis	-	1154	I
.	-	1163	O

It	17543491	1165	O
resolved	-	1168	O
in	-	1177	O
all	-	1180	O
cases	-	1184	O
<	-	1190	O
or	-	1192	O
=	-	1195	O
24	-	1196	O
hours	-	1199	O
.	-	1204	O

There	17543491	1206	O
were	-	1212	O
no	-	1217	O
significant	-	1220	O
differences	-	1232	O
in	-	1244	O
operating	-	1247	O
time	-	1257	O
or	-	1262	O
volume	-	1265	O
or	-	1272	O
frequency	-	1275	O
of	-	1285	O
anesthetic	-	1288	O
administration	-	1299	O
in	-	1314	O
patients	-	1317	O
with	-	1326	O
temporary	-	1331	O
vocal	-	1341	B
cord	-	1347	I
paralysis	-	1352	I
compared	-	1362	O
with	-	1371	O
those	-	1376	O
without	-	1382	O
.	-	1389	O

CONCLUSION	17543491	1391	O
:	-	1401	O

Local	17543491	1403	O
anesthesia	-	1409	O
led	-	1420	O
to	-	1424	O
temporary	-	1427	O
ipsilateral	-	1437	O
vocal	-	1449	B
cord	-	1455	I
paralysis	-	1460	I
in	-	1470	O
almost	-	1473	O
half	-	1480	O
of	-	1485	O
these	-	1488	O
patients	-	1494	O
.	-	1502	O

Because	17543491	1504	O
pre	-	1512	O
-	-	1515	O
existing	-	1516	O
paralysis	-	1525	B
is	-	1535	O
of	-	1538	O
a	-	1541	O
relevant	-	1543	O
frequency	-	1552	O
(	-	1562	O
up	-	1563	O
to	-	1566	O
3	-	1569	O
%	-	1570	O
)	-	1571	O
,	-	1572	O
a	-	1574	O
preoperative	-	1576	O
evaluation	-	1589	O
of	-	1600	O
vocal	-	1603	O
cord	-	1609	O
function	-	1614	O
before	-	1623	O
carotid	-	1630	O
endarterectomy	-	1638	O
under	-	1653	O
local	-	1659	O
anesthesia	-	1665	O
is	-	1676	O
recommended	-	1679	O
to	-	1691	O
avoid	-	1694	O
intraoperative	-	1700	O
bilateral	-	1715	O
paralysis	-	1725	B
.	-	1734	O

In	17543491	1736	O
patients	-	1739	O
with	-	1748	O
preoperative	-	1753	O
contralateral	-	1766	O
vocal	-	1780	B
cord	-	1786	I
paralysis	-	1791	I
,	-	1800	O
surgery	-	1802	O
under	-	1810	O
general	-	1816	O
anesthesia	-	1824	O
should	-	1835	O
be	-	1842	O
considered	-	1845	O
.	-	1855	O

Neuroprotective	17572393	0	O
effects	-	16	O
of	-	24	O
melatonin	-	27	O
upon	-	37	O
the	-	42	O
offspring	-	46	O
cerebellar	-	56	O
cortex	-	67	O
in	-	74	O
the	-	77	O
rat	-	81	O
model	-	85	O
of	-	91	O
BCNU	-	94	O
-	-	98	O
induced	-	99	O
cortical	-	107	B
dysplasia	-	116	I
.	-	125	O

Cortical	17572393	127	B
dysplasia	-	136	I
is	-	146	O
a	-	149	O
malformation	-	151	O
characterized	-	164	O
by	-	178	O
defects	-	181	O
in	-	189	O
proliferation	-	192	O
,	-	205	O
migration	-	207	O
and	-	217	O
maturation	-	221	O
.	-	231	O

This	17572393	233	O
study	-	238	O
was	-	244	O
designed	-	248	O
to	-	257	O
evaluate	-	260	O
the	-	269	O
alterations	-	273	O
in	-	285	O
offspring	-	288	O
rat	-	298	O
cerebellum	-	302	O
induced	-	313	O
by	-	321	O
maternal	-	324	O
exposure	-	333	O
to	-	342	O
carmustine	-	345	O
-	-	355	O
[	-	356	O
1	-	357	O
,	-	358	O
3	-	359	O
-	-	360	O
bis	-	361	O
(	-	365	O
2	-	366	O
-	-	367	O
chloroethyl	-	368	O
)	-	379	O
-	-	380	O
1	-	381	O
-	-	382	O
nitrosoure	-	383	O
]	-	393	O
(	-	395	O
BCNU	-	396	O
)	-	400	O
and	-	402	O
to	-	406	O
investigate	-	409	O
the	-	421	O
effects	-	425	O
of	-	433	O
exogenous	-	436	O
melatonin	-	446	O
upon	-	456	O
cerebellar	-	461	O
BCNU	-	472	O
-	-	476	O
induced	-	477	O
cortical	-	485	B
dysplasia	-	494	I
,	-	503	O
using	-	505	O
histological	-	511	O
and	-	524	O
biochemical	-	528	O
analyses	-	540	O
.	-	548	O

Pregnant	17572393	550	O
Wistar	-	559	O
rats	-	566	O
were	-	571	O
assigned	-	576	O
to	-	585	O
five	-	588	O
groups	-	593	O
:	-	599	O
intact	-	601	O
-	-	607	O
control	-	608	O
,	-	615	O
saline	-	617	O
-	-	623	O
control	-	624	O
,	-	631	O
melatonin	-	633	O
-	-	642	O
treated	-	643	O
,	-	650	O
BCNU	-	652	O
-	-	656	O
exposed	-	657	O
and	-	665	O
BCNU	-	669	O
-	-	673	O
exposed	-	674	O
plus	-	682	O
melatonin	-	687	O
.	-	696	O

Rats	17572393	698	O
were	-	703	O
exposed	-	708	O
to	-	716	O
BCNU	-	719	O
on	-	724	O
embryonic	-	727	O
day	-	737	O
15	-	741	O
and	-	744	O
melatonin	-	748	O
was	-	758	O
given	-	762	O
until	-	768	O
delivery	-	774	O
.	-	782	O

Immuno	17572393	784	O
/	-	790	O
histochemistry	-	791	O
and	-	806	O
electron	-	810	O
microscopy	-	819	O
were	-	830	O
carried	-	835	O
out	-	843	O
on	-	847	O
the	-	850	O
offspring	-	854	O
cerebellum	-	864	O
,	-	874	O
and	-	876	O
levels	-	880	O
of	-	887	O
malondialdehyde	-	890	O
and	-	906	O
superoxide	-	910	O
dismutase	-	921	O
were	-	931	O
determined	-	936	O
.	-	946	O

Histopathologically	17572393	948	O
,	-	967	O
typical	-	969	O
findings	-	977	O
were	-	986	O
observed	-	991	O
in	-	1000	O
the	-	1003	O
cerebella	-	1007	O
from	-	1017	O
the	-	1022	O
control	-	1026	O
groups	-	1034	O
,	-	1040	O
but	-	1042	O
the	-	1046	O
findings	-	1050	O
consistent	-	1059	O
with	-	1070	O
early	-	1075	O
embryonic	-	1081	O
development	-	1091	O
were	-	1103	O
noted	-	1108	O
in	-	1114	O
BCNU	-	1117	O
-	-	1121	O
exposed	-	1122	O
cortical	-	1130	B
dysplasia	-	1139	I
group	-	1149	O
.	-	1154	O

There	17572393	1156	O
was	-	1162	O
a	-	1166	O
marked	-	1168	O
increase	-	1175	O
in	-	1184	O
the	-	1187	O
number	-	1191	O
of	-	1198	O
TUNEL	-	1201	O
positive	-	1207	O
cells	-	1216	O
and	-	1222	O
nestin	-	1226	O
positive	-	1233	O
cells	-	1242	O
in	-	1248	O
BCNU	-	1251	O
-	-	1255	O
exposed	-	1256	O
group	-	1264	O
,	-	1269	O
but	-	1271	O
a	-	1275	O
decreased	-	1277	O
immunoreactivity	-	1287	O
to	-	1304	O
glial	-	1307	O
fibrillary	-	1313	O
acidic	-	1324	O
protein	-	1331	O
,	-	1338	O
synaptophysin	-	1340	O
and	-	1354	O
transforming	-	1358	O
growth	-	1371	O
factor	-	1378	O
beta1	-	1385	O
was	-	1391	O
observed	-	1395	O
,	-	1403	O
indicating	-	1405	O
a	-	1416	O
delayed	-	1418	O
maturation	-	1426	O
,	-	1436	O
and	-	1438	O
melatonin	-	1442	O
significantly	-	1452	O
reversed	-	1466	O
these	-	1475	O
changes	-	1481	O
.	-	1488	O

Malondialdehyde	17572393	1490	O
level	-	1506	O
in	-	1512	O
BCNU	-	1515	O
-	-	1519	O
exposed	-	1520	O
group	-	1528	O
was	-	1534	O
higher	-	1538	O
than	-	1545	O
those	-	1550	O
in	-	1556	O
control	-	1559	O
groups	-	1567	O
and	-	1574	O
melatonin	-	1578	O
decreased	-	1588	O
malondialdehyde	-	1598	O
levels	-	1614	O
in	-	1621	O
BCNU	-	1624	O
group	-	1629	O
(	-	1635	O
P	-	1636	O
<	-	1637	O
0	-	1638	O
.	-	1639	O
01	-	1640	O
)	-	1642	O
,	-	1643	O
while	-	1645	O
there	-	1651	O
were	-	1657	O
no	-	1662	O
significant	-	1665	O
differences	-	1677	O
in	-	1689	O
the	-	1692	O
superoxide	-	1696	O
dismutase	-	1707	O
levels	-	1717	O
between	-	1724	O
these	-	1732	O
groups	-	1738	O
.	-	1744	O

These	17572393	1746	O
data	-	1752	O
suggest	-	1757	O
that	-	1765	O
exposure	-	1770	O
of	-	1779	O
animals	-	1782	O
to	-	1790	O
BCNU	-	1793	O
during	-	1798	O
pregnancy	-	1805	O
leads	-	1815	O
to	-	1821	O
delayed	-	1824	O
maturation	-	1832	O
of	-	1843	O
offspring	-	1846	O
cerebellum	-	1856	O
and	-	1867	O
melatonin	-	1871	O
protects	-	1881	O
the	-	1890	O
cerebellum	-	1894	O
against	-	1905	O
the	-	1913	O
effects	-	1917	O
of	-	1925	O
BCNU	-	1928	O
.	-	1932	O

Myo	17828434	0	O
-	-	3	O
inositol	-	4	O
-	-	12	O
1	-	13	O
-	-	14	O
phosphate	-	15	O

(	17828434	25	O
MIP	-	26	O
)	-	29	O
synthase	-	31	O
inhibition	-	40	O
:	-	50	O
in	-	52	O
-	-	54	O
vivo	-	55	O
study	-	60	O
in	-	66	O
rats	-	69	O
.	-	73	O

Lithium	17828434	75	O
and	-	83	O
valproate	-	87	O
are	-	97	O
the	-	101	O
prototypic	-	105	O
mood	-	116	O
stabilizers	-	121	O
and	-	133	O
have	-	137	O
diverse	-	142	O
structures	-	150	O
and	-	161	O
targets	-	165	O
.	-	172	O

Both	17828434	174	O
drugs	-	179	O
influence	-	185	O
inositol	-	195	O
metabolism	-	204	O
.	-	214	O

Lithium	17828434	216	O
inhibits	-	224	O
IMPase	-	233	O
and	-	240	O
valproate	-	244	O
inhibits	-	254	O

MIP	17828434	263	O
synthase	-	267	O
.	-	275	O

This	17828434	277	O
study	-	282	O
shows	-	288	O
that	-	294	O
MIP	-	299	O
synthase	-	303	O
inhibition	-	312	O
does	-	323	O
not	-	328	O
replicate	-	332	O
or	-	342	O
augment	-	345	O
the	-	353	O
effects	-	357	O
of	-	365	O
lithium	-	368	O
in	-	376	O
the	-	379	O
inositol	-	383	O
sensitive	-	392	O
pilocarpine	-	402	O
-	-	413	O
induced	-	414	O
seizures	-	422	B
model	-	431	O
.	-	436	O

This	17828434	438	O
lack	-	443	O
of	-	448	O
effects	-	451	O
may	-	459	O
stem	-	463	O
from	-	468	O
the	-	473	O
low	-	477	O
contribution	-	481	O
of	-	494	O
de	-	497	O
-	-	499	O
novo	-	500	O
synthesis	-	505	O
to	-	515	O
cellular	-	518	O
inositol	-	527	O
supply	-	536	O
or	-	543	O
to	-	546	O
the	-	549	O
inhibition	-	553	O
of	-	564	O
the	-	567	O
de	-	571	O
-	-	573	O
novo	-	574	O
synthesis	-	579	O
by	-	589	O
lithium	-	592	O
itself	-	600	O
.	-	606	O

Non	17879100	0	O
-	-	3	O
steroidal	-	4	O
anti	-	14	O
-	-	18	O
inflammatory	-	19	O
drugs	-	32	O
-	-	37	O
associated	-	38	O
acute	-	49	O
interstitial	-	55	B
nephritis	-	68	I
with	-	78	O
granular	-	83	O
tubular	-	92	O
basement	-	100	O
membrane	-	109	O
deposits	-	118	O
.	-	126	O

Acute	17879100	128	B
tubulo	-	134	I
-	-	140	I
interstitial	-	141	I
nephritis	-	154	I
(	-	164	O
ATIN	-	165	B
)	-	169	O
is	-	171	O
an	-	174	O
important	-	177	O
cause	-	187	O
of	-	193	O
acute	-	196	B
renal	-	202	I
failure	-	208	I
resulting	-	216	O
from	-	226	O
a	-	231	O
variety	-	233	O
of	-	241	O
insults	-	244	O
,	-	251	O
including	-	253	O
immune	-	263	O
complex	-	270	O
-	-	277	O
mediated	-	278	O
tubulo	-	287	B
-	-	293	I
interstitial	-	294	I
injury	-	307	I
,	-	313	O
but	-	315	O
drugs	-	319	O
such	-	325	O
as	-	330	O
non	-	333	O
-	-	336	O
steroidal	-	337	O
anti	-	347	O
-	-	351	O
inflammatory	-	352	O
drugs	-	365	O
(	-	371	O
NSAIDs	-	372	O
)	-	378	O
are	-	380	O
a	-	384	O
far	-	386	O
more	-	390	O
frequent	-	395	O
cause	-	404	O
.	-	409	O

Overall	17879100	411	O
,	-	418	O
as	-	420	O
an	-	423	O
entity	-	426	O
,	-	432	O
ATIN	-	434	B
remains	-	439	O
under	-	447	O
-	-	452	O
diagnosed	-	453	O
,	-	462	O
as	-	464	O
symptoms	-	467	O
resolve	-	476	O
spontaneously	-	484	O
if	-	498	O
the	-	501	O
medication	-	505	O
is	-	516	O
stopped	-	519	O
.	-	526	O

We	17879100	528	O
report	-	531	O
on	-	538	O
a	-	541	O
14	-	543	O
-	-	545	O
year	-	546	O
-	-	550	O
old	-	551	O
boy	-	555	O
who	-	559	O
developed	-	563	O
acute	-	573	B
renal	-	579	I
failure	-	585	I
2	-	593	O
weeks	-	595	O
after	-	601	O
aortic	-	607	O
valve	-	614	O
surgery	-	620	O
.	-	627	O

He	17879100	629	O
was	-	632	O
put	-	636	O
on	-	640	O
aspirin	-	643	O
following	-	651	O
surgery	-	661	O
and	-	669	O
took	-	673	O
ibuprofen	-	678	O
for	-	688	O
fever	-	692	B
for	-	698	O
nearly	-	702	O
a	-	709	O
week	-	711	O
prior	-	716	O
to	-	722	O
presentation	-	725	O
.	-	737	O

He	17879100	739	O
then	-	742	O
presented	-	747	O
to	-	757	O
the	-	760	O
emergency	-	764	O
department	-	774	O
feeling	-	785	O
quite	-	793	O
ill	-	799	O
and	-	803	O
was	-	807	O
found	-	811	O
to	-	817	O
have	-	820	O
a	-	825	O
blood	-	827	O
urea	-	833	O
nitrogen	-	838	O
(	-	847	O
BUN	-	848	O
)	-	851	O
concentration	-	853	O
of	-	867	O
of	-	870	O
147	-	873	O
mg	-	877	O
/	-	879	O
dl	-	880	O
,	-	882	O
creatinine	-	884	O
of	-	895	O
15	-	898	O
.	-	900	O
3	-	901	O
mg	-	903	O
/	-	905	O
dl	-	906	O
and	-	909	O
serum	-	913	O
potassium	-	919	O
of	-	929	O
8	-	932	O
.	-	933	O
7	-	934	O
mEq	-	936	O
/	-	939	O
l	-	940	O
.	-	941	O

Dialysis	17879100	943	O
was	-	952	O
immediately	-	956	O
initiated	-	968	O
.	-	977	O

A	17879100	979	O
kidney	-	981	O
biopsy	-	988	O
showed	-	995	O
inflammatory	-	1002	O
infiltrate	-	1015	O
consistent	-	1026	O
with	-	1037	O
ATIN	-	1042	B
.	-	1046	O

However	17879100	1048	O
,	-	1055	O
in	-	1057	O
the	-	1060	O
tubular	-	1064	O
basement	-	1072	O
membrane	-	1081	O
(	-	1090	O
TBM	-	1091	O
)	-	1094	O
,	-	1095	O
very	-	1097	O
intense	-	1102	O
granular	-	1110	O
deposits	-	1119	O
of	-	1128	O
polyclonal	-	1131	O
IgG	-	1142	O
and	-	1146	O
C3	-	1150	O
were	-	1153	O
noted	-	1158	O
.	-	1163	O

He	17879100	1165	O
needed	-	1168	O
dialysis	-	1175	O
for	-	1184	O
2	-	1188	O
weeks	-	1190	O
and	-	1196	O
was	-	1200	O
treated	-	1204	O
successfully	-	1212	O
with	-	1225	O
steroids	-	1230	O
for	-	1239	O
6	-	1243	O
months	-	1245	O
.	-	1251	O

His	17879100	1253	O
renal	-	1257	O
recovery	-	1263	O
and	-	1272	O
disappearance	-	1276	O
of	-	1290	O
proteinuria	-	1293	B
took	-	1305	O
a	-	1310	O
year	-	1312	O
.	-	1316	O

In	17879100	1318	O
conclusion	-	1321	O
,	-	1331	O
this	-	1333	O
is	-	1338	O
a	-	1341	O
first	-	1343	O
report	-	1349	O
of	-	1356	O
NSAIDs	-	1359	O
-	-	1365	O
associated	-	1366	O
ATIN	-	1377	B
,	-	1381	O
showing	-	1383	O
deposits	-	1391	O
of	-	1400	O
granular	-	1403	O
immune	-	1412	O
complex	-	1419	O
present	-	1427	O
only	-	1435	O
in	-	1440	O
the	-	1443	O
TBM	-	1447	O
and	-	1451	O
not	-	1455	O
in	-	1459	O
the	-	1462	O
glomeruli	-	1466	O
.	-	1475	O

Rifampicin	17879217	0	O
-	-	10	O
associated	-	11	O
segmental	-	22	O
necrotizing	-	32	O
glomerulonephritis	-	44	B
in	-	63	O
staphylococcal	-	66	B
endocarditis	-	81	I
.	-	93	O

Segmental	17879217	95	O
necrotising	-	105	O
glomerulonephritis	-	117	B
has	-	136	O
been	-	140	O
reported	-	145	O
as	-	154	O
complication	-	157	O
of	-	170	O
rifampicin	-	173	O
therapy	-	184	O
in	-	192	O
patients	-	195	O
receiving	-	204	O
treatment	-	214	O
for	-	224	O
tuberculosis	-	228	B
.	-	240	O

Changing	17879217	242	O
epidemiology	-	251	O
of	-	264	O
infections	-	267	B
such	-	278	O
as	-	283	O
infective	-	286	B
endocarditis	-	296	I
(	-	309	O
IE	-	310	B
)	-	312	O
has	-	314	O
led	-	318	O
to	-	322	O
an	-	325	O
increase	-	328	O
in	-	337	O
the	-	340	O
use	-	344	O
of	-	348	O
rifampicin	-	351	O
for	-	362	O
Staphylococcal	-	366	B
infections	-	381	I
.	-	391	O

We	17879217	393	O
describe	-	396	O
a	-	405	O
case	-	407	O
of	-	412	O
a	-	415	O
patient	-	417	O
with	-	425	O
Staphylococcal	-	430	B
IE	-	445	I
who	-	448	O
developed	-	452	O
acute	-	462	B
renal	-	468	I
failure	-	474	I
secondary	-	482	O
to	-	492	O
a	-	495	O
segmental	-	497	O
necrotising	-	507	O
glomerulonephritis	-	519	B
while	-	538	O
being	-	544	O
treated	-	550	O
with	-	558	O
rifampicin	-	563	O
,	-	573	O
and	-	575	O
review	-	579	O
the	-	586	O
literature	-	590	O
regarding	-	601	O
this	-	611	O
complication	-	616	O
of	-	629	O
rifampicin	-	632	O
therapy	-	643	O
.	-	650	O

Rate	17954033	0	O
of	-	5	O
YMDD	-	8	O
motif	-	13	O
mutants	-	19	O
in	-	27	O
lamivudine	-	30	O
-	-	40	O
untreated	-	41	O
Iranian	-	51	O
patients	-	59	O
with	-	68	O
chronic	-	73	B
hepatitis	-	81	I
B	-	91	I
virus	-	93	I
infection	-	99	I
.	-	108	O

BACKGROUND	17954033	110	O
:	-	120	O
Lamivudine	-	122	O
is	-	133	O
used	-	136	O
for	-	141	O
the	-	145	O
treatment	-	149	O
of	-	159	O
chronic	-	162	B
hepatitis	-	170	I
B	-	180	I
patients	-	182	O
.	-	190	O

Recent	17954033	192	O
studies	-	199	O
show	-	207	O
that	-	212	O
the	-	217	O
YMDD	-	221	O
motif	-	226	O
mutants	-	232	O
(	-	240	O
resistant	-	241	O
hepatitis	-	251	B
B	-	261	I
virus	-	263	O
)	-	268	O
occur	-	270	O
as	-	276	O
natural	-	279	O
genome	-	287	O
variability	-	294	O
in	-	306	O
lamivudine	-	309	O
-	-	319	O
untreated	-	320	O
chronic	-	330	B
hepatitis	-	338	I
B	-	348	I
patients	-	350	O
.	-	358	O

In	17954033	360	O
this	-	363	O
study	-	368	O
we	-	374	O
aimed	-	377	O
to	-	383	O
determine	-	386	O
the	-	396	O
rate	-	400	O
of	-	405	O
YMDD	-	408	O
motif	-	413	O
mutants	-	419	O
in	-	427	O
lamivudine	-	430	O
-	-	440	O
untreated	-	441	O
chronic	-	451	B
hepatitis	-	459	I
B	-	469	I
patients	-	471	O
in	-	480	O
Iran	-	483	O
.	-	487	O

PATIENTS	17954033	489	O
AND	-	498	O
METHODS	-	502	O
:	-	509	O

A	17954033	511	O
total	-	513	O
of	-	519	O
77	-	522	O
chronic	-	525	B
hepatitis	-	533	I
B	-	543	I
patients	-	545	O
who	-	554	O
had	-	558	O
not	-	562	O
been	-	566	O
treated	-	571	O
with	-	579	O
lamivudine	-	584	O
were	-	595	O
included	-	600	O
in	-	609	O
the	-	612	O
study	-	616	O
.	-	621	O

Serum	17954033	623	O
samples	-	629	O
from	-	637	O
patients	-	642	O
were	-	651	O
tested	-	656	O
by	-	663	O
polymerase	-	666	O
chain	-	677	O
reaction	-	683	O
-	-	691	O
restriction	-	692	O
fragment	-	704	O
length	-	713	O
polymorphism	-	720	O
(	-	733	O
PCR	-	734	O
-	-	737	O
RFLP	-	738	O
)	-	742	O
for	-	744	O
detection	-	748	O
of	-	758	O
YMDD	-	761	O
motif	-	766	O
mutants	-	772	O
.	-	779	O

All	17954033	781	O
patients	-	785	O
were	-	794	O
also	-	799	O
tested	-	804	O
for	-	811	O
liver	-	815	O
enzymes	-	821	O
,	-	828	O
anti	-	830	O
-	-	834	O
HCV	-	835	O
,	-	838	O
HBeAg	-	840	O
,	-	845	O
and	-	847	O
anti	-	851	O
-	-	855	O
HBe	-	856	O
.	-	859	O

RESULTS	17954033	861	O
:	-	868	O

Of	17954033	870	O
the	-	873	O
77	-	877	O
patients	-	880	O
enrolled	-	889	O
in	-	898	O
the	-	901	O
study	-	905	O
,	-	910	O
73	-	912	O
%	-	914	O
were	-	916	O
male	-	921	O
and	-	926	O
27	-	930	O
%	-	932	O
were	-	934	O
female	-	939	O
.	-	945	O

Mean	17954033	947	O
ALT	-	952	O
and	-	956	O
AST	-	960	O
levels	-	964	O
were	-	971	O
124	-	976	O
.	-	979	O
4	-	980	O
+	-	981	O
/	-	982	O
-	-	983	O
73	-	984	O
.	-	986	O
4	-	987	O
and	-	989	O
103	-	993	O
.	-	996	O
1	-	997	O
+	-	998	O
/	-	999	O
-	-	1000	O
81	-	1001	O
IU	-	1004	O
/	-	1006	O
l	-	1007	O
,	-	1008	O
respectively	-	1010	O
.	-	1022	O

HBeAg	17954033	1024	O
was	-	1030	O
positive	-	1034	O
in	-	1043	O
40	-	1046	O
%	-	1048	O
and	-	1050	O
anti	-	1054	O
-	-	1058	O
HBe	-	1059	O
in	-	1063	O
60	-	1066	O
%	-	1068	O
of	-	1070	O
the	-	1073	O
patients	-	1077	O
.	-	1085	O

Anti	17954033	1087	O
-	-	1091	O
HCV	-	1092	O
was	-	1096	O
negative	-	1100	O
in	-	1109	O
all	-	1112	O
of	-	1116	O
them	-	1119	O
.	-	1123	O

YMDD	17954033	1125	O
motif	-	1130	O
mutants	-	1136	O
were	-	1144	O
not	-	1149	O
detected	-	1153	O
in	-	1162	O
any	-	1165	O
of	-	1169	O
the	-	1172	O
patients	-	1176	O
despite	-	1185	O
the	-	1193	O
liver	-	1197	O
enzyme	-	1203	O
levels	-	1210	O
and	-	1217	O
the	-	1221	O
presence	-	1225	O
of	-	1234	O
HBeAg	-	1237	O
or	-	1243	O
anti	-	1246	O
-	-	1250	O
HBe	-	1251	O
.	-	1254	O
CONCLUSION	-	1256	O
:	-	1266	O

Although	17954033	1268	O
the	-	1277	O
natural	-	1281	O
occurrence	-	1289	O
of	-	1300	O
YMDD	-	1303	O
motif	-	1308	O
mutants	-	1314	O
in	-	1322	O
lamivudine	-	1325	O
-	-	1335	O
untreated	-	1336	O
patients	-	1346	O
with	-	1355	O
chronic	-	1360	B
hepatitis	-	1368	I
B	-	1378	I
has	-	1380	O
been	-	1384	O
reported	-	1389	O
,	-	1397	O
these	-	1399	O
mutants	-	1405	O
were	-	1413	O
not	-	1418	O
detected	-	1422	O
in	-	1431	O
Iranian	-	1434	O
lamivudine	-	1442	O
-	-	1452	O
untreated	-	1453	O
chronic	-	1463	B
hepatitis	-	1471	I
B	-	1481	I
patients	-	1483	O
.	-	1491	O

Branch	18025637	0	O
retinal	-	7	B
vein	-	15	I
occlusion	-	20	I
and	-	30	O
fluoxetine	-	34	O
.	-	44	O

A	18025637	46	O
case	-	48	O
of	-	53	O
branch	-	56	O
retinal	-	63	B
vein	-	71	I
occlusion	-	76	I
associated	-	86	O
with	-	97	O
fluoxetine	-	102	O
-	-	112	O
induced	-	113	O
secondary	-	121	O
hypertension	-	131	B
is	-	144	O
described	-	147	O
.	-	156	O

Although	18025637	158	O
an	-	167	O
infrequent	-	170	O
complication	-	181	O
of	-	194	O
selective	-	197	O
serotonin	-	207	O
reuptake	-	217	O
inhibitor	-	226	O
therapy	-	236	O
,	-	243	O
it	-	245	O
is	-	248	O
important	-	251	O
that	-	261	O
ophthalmologists	-	266	O
are	-	283	O
aware	-	287	O
that	-	293	O
these	-	298	O
agents	-	304	O
can	-	311	O
cause	-	315	O
hypertension	-	321	B
because	-	334	O
this	-	342	O
class	-	347	O
of	-	353	O
drugs	-	356	O
is	-	362	O
widely	-	365	O
prescribed	-	372	O
.	-	382	O

The	18165598	0	O
differential	-	4	O
effects	-	17	O
of	-	25	O
bupivacaine	-	28	O
and	-	40	O
lidocaine	-	44	O
on	-	54	O
prostaglandin	-	57	O
E2	-	71	O
release	-	74	O
,	-	81	O
cyclooxygenase	-	83	O
gene	-	98	O
expression	-	103	O
and	-	114	O
pain	-	118	B
in	-	123	O
a	-	126	O
clinical	-	128	O
pain	-	137	B
model	-	142	O
.	-	147	O

BACKGROUND	18165598	149	O
:	-	159	O

In	18165598	161	O
addition	-	164	O
to	-	173	O
blocking	-	176	O
nociceptive	-	185	O
input	-	197	O
from	-	203	O
surgical	-	208	O
sites	-	217	O
,	-	222	O
long	-	224	O
-	-	228	O
acting	-	229	O
local	-	236	O
anesthetics	-	242	O
might	-	254	O
directly	-	260	O
modulate	-	269	O
inflammation	-	278	B
.	-	290	O

In	18165598	292	O
the	-	295	O
present	-	299	O
study	-	307	O
,	-	312	O
we	-	314	O
describe	-	317	O
the	-	326	O
proinflammatory	-	330	O
effects	-	346	O
of	-	354	O
bupivacaine	-	357	O
on	-	369	O
local	-	372	O
prostaglandin	-	378	O
E2	-	392	O
(	-	395	O
PGE2	-	396	O
)	-	400	O
production	-	402	O
and	-	413	O
cyclooxygenase	-	417	O
(	-	432	O
COX	-	433	O
)	-	436	O
gene	-	438	O
expression	-	443	O
that	-	454	O
increases	-	459	O
postoperative	-	469	B
pain	-	483	I
in	-	488	O
human	-	491	O
subjects	-	497	O
.	-	505	O

METHODS	18165598	507	O
:	-	514	O
Subjects	-	516	O
(	-	525	O
n	-	526	O
=	-	528	O
114	-	530	O
)	-	533	O
undergoing	-	535	O
extraction	-	546	O
of	-	557	O
impacted	-	560	O
third	-	569	O
molars	-	575	O
received	-	582	O
either	-	591	O
2	-	598	O
%	-	599	O
lidocaine	-	601	O
or	-	611	O
0	-	614	O
.	-	615	O
5	-	616	O
%	-	617	O
bupivacaine	-	619	O
before	-	631	O
surgery	-	638	O
and	-	646	O
either	-	650	O
rofecoxib	-	657	O
50	-	667	O
mg	-	670	O
or	-	673	O
placebo	-	676	O
orally	-	684	O
90	-	691	O
min	-	694	O
before	-	698	O
surgery	-	705	O
and	-	713	O
for	-	717	O
the	-	721	O
following	-	725	O
48	-	735	O
h	-	738	O
.	-	739	O
Oral	-	741	O
mucosal	-	746	O
biopsies	-	754	O
were	-	763	O
taken	-	768	O
before	-	774	O
surgery	-	781	O
and	-	789	O
48	-	793	O
h	-	796	O
after	-	798	O
surgery	-	804	O
.	-	811	O

After	18165598	813	O
extraction	-	819	O
,	-	829	O
a	-	831	O
microdialysis	-	833	O
probe	-	847	O
was	-	853	O
placed	-	857	O
at	-	864	O
the	-	867	O
surgical	-	871	O
site	-	880	O
for	-	885	O
PGE2	-	889	O
and	-	894	O
thromboxane	-	898	O
B2	-	910	O
(	-	913	O
TXB2	-	914	O
)	-	918	O
measurements	-	920	O
.	-	932	O

RESULTS	18165598	934	O
:	-	941	O

The	18165598	943	O
bupivacaine	-	947	O
/	-	958	O
rofecoxib	-	959	O
group	-	969	O
reported	-	975	O
significantly	-	984	O
less	-	998	O
pain	-	1003	B
,	-	1007	O
as	-	1009	O
assessed	-	1012	O
by	-	1021	O
a	-	1024	O
visual	-	1026	O
analog	-	1033	O
scale	-	1040	O
,	-	1045	O
compared	-	1047	O
with	-	1056	O
the	-	1061	O
other	-	1065	O
three	-	1071	O
treatment	-	1077	O
groups	-	1087	O
over	-	1094	O
the	-	1099	O
first	-	1103	O
4	-	1109	O
h	-	1111	O
.	-	1112	O

However	18165598	1114	O
,	-	1121	O
the	-	1123	O
bupivacaine	-	1127	O
/	-	1138	O
placebo	-	1139	O
group	-	1147	O
reported	-	1153	O
significantly	-	1162	O
more	-	1176	O
pain	-	1181	B
at	-	1186	O
24	-	1189	O
h	-	1192	O
and	-	1194	O
PGE2	-	1198	O
levels	-	1203	O
during	-	1210	O
the	-	1217	O
first	-	1221	O
4	-	1227	O
h	-	1229	O
were	-	1231	O
significantly	-	1236	O
higher	-	1250	O
than	-	1257	O
the	-	1262	O
other	-	1266	O
three	-	1272	O
treatment	-	1278	O
groups	-	1288	O
.	-	1294	O

Moreover	18165598	1296	O
,	-	1304	O
bupivacaine	-	1306	O
significantly	-	1318	O
increased	-	1332	O
COX	-	1342	O
-	-	1345	O
2	-	1346	O
gene	-	1348	O
expression	-	1353	O
at	-	1364	O
48	-	1367	O
h	-	1370	O
as	-	1372	O
compared	-	1375	O
with	-	1384	O
the	-	1389	O
lidocaine	-	1393	O
/	-	1402	O
placebo	-	1403	O
group	-	1411	O
.	-	1416	O

Thromboxane	18165598	1418	O
levels	-	1430	O
were	-	1437	O
not	-	1442	O
significantly	-	1446	O
affected	-	1460	O
by	-	1469	O
any	-	1472	O
of	-	1476	O
the	-	1479	O
treatments	-	1483	O
,	-	1493	O
indicating	-	1495	O
that	-	1506	O
the	-	1511	O
effects	-	1515	O
seen	-	1523	O
were	-	1528	O
attributable	-	1533	O
to	-	1546	O
inhibition	-	1549	O
of	-	1560	O
COX	-	1563	O
-	-	1566	O
2	-	1567	O
,	-	1568	O
but	-	1570	O
not	-	1574	O
COX	-	1578	O
-	-	1581	O
1	-	1582	O
.	-	1583	O

CONCLUSIONS	18165598	1585	O
:	-	1596	O

These	18165598	1598	O
results	-	1604	O
suggest	-	1612	O
that	-	1620	O
bupivacaine	-	1625	O
stimulates	-	1637	O
COX	-	1648	O
-	-	1651	O
2	-	1652	O
gene	-	1654	O
expression	-	1659	O
after	-	1670	O
tissue	-	1676	B
injury	-	1683	I
,	-	1689	O
which	-	1691	O
is	-	1697	O
associated	-	1700	O
with	-	1711	O
higher	-	1716	O
PGE2	-	1723	O
production	-	1728	O
and	-	1739	O
pain	-	1743	B
after	-	1748	O
the	-	1754	O
local	-	1758	O
anesthetic	-	1764	O
effect	-	1775	O
dissipates	-	1782	O
.	-	1792	O

p75NTR	18189308	0	O
expression	-	7	O
in	-	18	O
rat	-	21	O
urinary	-	25	O
bladder	-	33	O
sensory	-	41	O
neurons	-	49	O
and	-	57	O
spinal	-	61	O
cord	-	68	O
with	-	73	O
cyclophosphamide	-	78	O
-	-	94	O
induced	-	95	O
cystitis	-	103	B
.	-	111	O

A	18189308	113	O
role	-	115	O
for	-	120	O
nerve	-	124	O
growth	-	130	O
factor	-	137	O
(	-	144	O
NGF	-	145	O
)	-	148	O
in	-	150	O
contributing	-	153	O
to	-	166	O
increased	-	169	O
voiding	-	179	O
frequency	-	187	O
and	-	197	O
altered	-	201	O
sensation	-	209	O
from	-	219	O
the	-	224	O
urinary	-	228	O
bladder	-	236	O
has	-	244	O
been	-	248	O
suggested	-	253	O
.	-	262	O

Previous	18189308	264	O
studies	-	273	O
have	-	281	O
examined	-	286	O
the	-	295	O
expression	-	299	O
and	-	310	O
regulation	-	314	O
of	-	325	O
tyrosine	-	328	O
kinase	-	337	O
receptors	-	344	O
(	-	354	O
Trks	-	355	O
)	-	359	O
in	-	361	O
micturition	-	364	O
reflexes	-	376	O
with	-	385	O
urinary	-	390	B
bladder	-	398	I
inflammation	-	406	I
.	-	418	O

The	18189308	420	O
present	-	424	O
studies	-	432	O
examine	-	440	O
the	-	448	O
expression	-	452	O
and	-	463	O
regulation	-	467	O
of	-	478	O
another	-	481	O
receptor	-	489	O
known	-	498	O
to	-	504	O
bind	-	507	O
NGF	-	512	O
,	-	515	O
p75	-	517	O
(	-	520	O
NTR	-	521	O
)	-	524	O
,	-	525	O
after	-	527	O
various	-	533	O
durations	-	541	O
of	-	551	O
bladder	-	554	B
inflammation	-	562	I
induced	-	575	O
by	-	583	O
cyclophosphamide	-	586	O
(	-	603	O
CYP	-	604	O
)	-	607	O
.	-	608	O

CYP	18189308	610	O
-	-	613	O
induced	-	614	O
cystitis	-	622	B
increased	-	631	O
(	-	641	O
P	-	642	O
<	-	644	O
or	-	646	O
=	-	649	O
0	-	651	O
.	-	652	O
001	-	653	O

)	18189308	656	O
p75	-	658	O
(	-	661	O
NTR	-	662	O
)	-	665	O
expression	-	667	O
in	-	678	O
the	-	681	O
superficial	-	685	O
lateral	-	697	O
and	-	705	O
medial	-	709	O
dorsal	-	716	O
horn	-	723	O
in	-	728	O
L1	-	731	O
-	-	733	O
L2	-	734	O
and	-	737	O
L6	-	741	O
-	-	743	O
S1	-	744	O
spinal	-	747	O
segments	-	754	O
.	-	762	O

The	18189308	764	O
number	-	768	O
of	-	775	O
p75	-	778	O
(	-	781	O
NTR	-	782	O
)	-	785	O
-	-	786	O
immunoreactive	-	787	O
(	-	802	O
-	-	803	O
IR	-	804	O
)	-	806	O
cells	-	808	O
in	-	814	O
the	-	817	O
lumbosacral	-	821	O
dorsal	-	833	O
root	-	840	O
ganglia	-	845	O
(	-	853	O
DRG	-	854	O
)	-	857	O
also	-	859	O
increased	-	864	O
(	-	874	O
P	-	875	O
<	-	877	O
or	-	879	O
=	-	882	O
0	-	884	O
.	-	885	O
05	-	886	O
)	-	888	O
with	-	890	O
CYP	-	895	O
-	-	898	O
induced	-	899	O
cystitis	-	907	B
(	-	916	O
acute	-	917	O
,	-	922	O
intermediate	-	924	O
,	-	936	O
and	-	938	O
chronic	-	942	O
)	-	949	O
.	-	950	O

Quantitative	18189308	952	O
,	-	964	O
real	-	966	O
-	-	970	O
time	-	971	O
polymerase	-	976	O
chain	-	987	O
reaction	-	993	O
also	-	1002	O
demonstrated	-	1007	O
significant	-	1020	O
increases	-	1032	O
(	-	1042	O
P	-	1043	O
<	-	1045	O
or	-	1047	O
=	-	1050	O
0	-	1052	O
.	-	1053	O
01	-	1054	O
)	-	1056	O
in	-	1058	O
p75	-	1061	O
(	-	1064	O
NTR	-	1065	O
)	-	1068	O
mRNA	-	1070	O
in	-	1075	O
DRG	-	1078	O
with	-	1082	O
intermediate	-	1087	O
and	-	1100	O
chronic	-	1104	O
CYP	-	1112	O
-	-	1115	O
induced	-	1116	O
cystitis	-	1124	B
.	-	1132	O

Retrograde	18189308	1134	O
dye	-	1145	O
-	-	1148	O
tracing	-	1149	O
techniques	-	1157	O
with	-	1168	O
Fastblue	-	1173	O
were	-	1182	O
used	-	1187	O
to	-	1192	O
identify	-	1195	O
presumptive	-	1204	O
bladder	-	1216	O
afferent	-	1224	O
cells	-	1233	O
in	-	1239	O
the	-	1242	O
lumbosacral	-	1246	O
DRG	-	1258	O
.	-	1261	O

In	18189308	1263	O
bladder	-	1266	O
afferent	-	1274	O
cells	-	1283	O
in	-	1289	O
DRG	-	1292	O
,	-	1295	O
p75	-	1297	O
(	-	1300	O
NTR	-	1301	O
)	-	1304	O
-	-	1305	O
IR	-	1306	O
was	-	1309	O
also	-	1313	O
increased	-	1318	O
(	-	1328	O
P	-	1329	O
<	-	1331	O
or	-	1333	O
=	-	1336	O
0	-	1338	O
.	-	1339	O
01	-	1340	O
)	-	1342	O
with	-	1344	O
cystitis	-	1349	B
.	-	1357	O

In	18189308	1359	O
addition	-	1362	O
to	-	1371	O
increases	-	1374	O
in	-	1384	O
p75	-	1387	O
(	-	1390	O
NTR	-	1391	O
)	-	1394	O
-	-	1395	O
IR	-	1396	O
in	-	1399	O
DRG	-	1402	O
cell	-	1406	O
bodies	-	1411	O
,	-	1417	O
increases	-	1419	O
(	-	1429	O
P	-	1430	O
<	-	1432	O
or	-	1434	O
=	-	1437	O
0	-	1439	O
.	-	1440	O
001	-	1441	O
)	-	1444	O
in	-	1446	O
pericellular	-	1449	O
(	-	1462	O
encircling	-	1463	O
DRG	-	1474	O
cells	-	1478	O
)	-	1483	O
p75	-	1485	O
(	-	1488	O
NTR	-	1489	O
)	-	1492	O
-	-	1493	O
IR	-	1494	O
in	-	1497	O
DRG	-	1500	O
also	-	1504	O
increased	-	1509	O
.	-	1518	O

Confocal	18189308	1520	O
analyses	-	1529	O
demonstrated	-	1538	O
that	-	1551	O
pericellular	-	1556	O
p75	-	1569	O
(	-	1572	O
NTR	-	1573	O
)	-	1576	O
-	-	1577	O
IR	-	1578	O
was	-	1581	O
not	-	1585	O
colocalized	-	1589	O
with	-	1601	O
the	-	1606	O
glial	-	1610	O
marker	-	1616	O
,	-	1622	O
glial	-	1624	O
fibrillary	-	1630	O
acidic	-	1641	O
protein	-	1648	O
(	-	1656	O
GFAP	-	1657	O
)	-	1661	O
.	-	1662	O

These	18189308	1664	O
studies	-	1670	O
demonstrate	-	1678	O
that	-	1690	O
p75	-	1695	O
(	-	1698	O
NTR	-	1699	O
)	-	1702	O
expression	-	1704	O
in	-	1715	O
micturition	-	1718	O
reflexes	-	1730	O
is	-	1739	O
present	-	1742	O
constitutively	-	1750	O
and	-	1765	O
modified	-	1769	O
by	-	1778	O
bladder	-	1781	B
inflammation	-	1789	I
.	-	1801	O

The	18189308	1803	O
functional	-	1807	O
significance	-	1818	O
of	-	1831	O
p75	-	1834	O
(	-	1837	O
NTR	-	1838	O
)	-	1841	O
expression	-	1843	O
in	-	1854	O
micturition	-	1857	O
reflexes	-	1869	O
remains	-	1878	O
to	-	1886	O
be	-	1889	O
determined	-	1892	O
.	-	1902	O

Azathioprine	18340638	0	O
-	-	12	O
induced	-	13	O
suicidal	-	21	O
erythrocyte	-	30	O
death	-	42	O
.	-	47	O

BACKGROUND	18340638	49	O
:	-	59	O

Azathioprine	18340638	61	O
is	-	74	O
widely	-	77	O
used	-	84	O
as	-	89	O
an	-	92	O
immunosuppressive	-	95	O
drug	-	113	O
.	-	117	O

The	18340638	119	O
side	-	123	O
effects	-	128	O
of	-	136	O
azathioprine	-	139	O
include	-	152	O
anemia	-	160	B
,	-	166	O
which	-	168	O
has	-	174	O
been	-	178	O
attributed	-	183	O
to	-	194	O
bone	-	197	O
marrow	-	202	O
suppression	-	209	O
.	-	220	O

Alternatively	18340638	222	O
,	-	235	O
anemia	-	237	B
could	-	244	O
result	-	250	O
from	-	257	O
accelerated	-	262	O
suicidal	-	274	O
erythrocyte	-	283	O
death	-	295	O
or	-	301	O
eryptosis	-	304	O
,	-	313	O
which	-	315	O
is	-	321	O
characterized	-	324	O
by	-	338	O
exposure	-	341	O
of	-	350	O
phosphatidylserine	-	353	O
(	-	372	O
PS	-	373	O
)	-	375	O
at	-	377	O
the	-	380	O
erythrocyte	-	384	O
surface	-	396	O
and	-	404	O
by	-	408	O
cell	-	411	O
shrinkage	-	416	O
.	-	425	O

METHODS	18340638	427	O
:	-	434	O

The	18340638	436	O
present	-	440	O
experiments	-	448	O
explored	-	460	O
whether	-	469	O
azathioprine	-	477	O
influences	-	490	O
eryptosis	-	501	O
.	-	510	O

According	18340638	512	O
to	-	522	O
annexin	-	525	O
V	-	533	O
binding	-	535	O
,	-	542	O
erythrocytes	-	544	O
from	-	557	O
patients	-	562	O
indeed	-	571	O
showed	-	578	O
a	-	585	O
significant	-	587	O
increase	-	599	O
of	-	608	O
PS	-	611	O
exposure	-	614	O
within	-	623	O
1	-	630	O
week	-	632	O
of	-	637	O
treatment	-	640	O
with	-	650	O
azathioprine	-	655	O
.	-	667	O

In	18340638	669	O
a	-	672	O
second	-	674	O
series	-	681	O
,	-	687	O
cytosolic	-	689	O
Ca2	-	699	O
+	-	702	O
activity	-	704	O
(	-	713	O
Fluo3	-	714	O
fluorescence	-	720	O
)	-	732	O
,	-	733	O
cell	-	735	O
volume	-	740	O
(	-	747	O
forward	-	748	O
scatter	-	756	O
)	-	763	O
,	-	764	O
and	-	766	O
PS	-	770	O
-	-	772	O
exposure	-	773	O
(	-	782	O
annexin	-	783	O
V	-	791	O
binding	-	793	O
)	-	800	O
were	-	802	O
determined	-	807	O
by	-	818	O
FACS	-	821	O
analysis	-	826	O
in	-	835	O
erythrocytes	-	838	O
from	-	851	O
healthy	-	856	O
volunteers	-	864	O
.	-	874	O

RESULTS	18340638	876	O
:	-	883	O

Exposure	18340638	885	O
to	-	894	O
azathioprine	-	897	O
(	-	910	O
>	-	911	O
or	-	913	O
=	-	916	O
2	-	917	O
microg	-	919	O
/	-	925	O
mL	-	926	O
)	-	928	O
for	-	930	O
48	-	934	O
hours	-	937	O
increased	-	943	O
cytosolic	-	953	O
Ca2	-	963	O
+	-	966	O
activity	-	968	O
and	-	977	O
annexin	-	981	O
V	-	989	O
binding	-	991	O
and	-	999	O
decreased	-	1003	O
forward	-	1013	O
scatter	-	1021	O
.	-	1028	O

The	18340638	1030	O
effect	-	1034	O
of	-	1041	O
azathioprine	-	1044	O
on	-	1057	O
both	-	1060	O
annexin	-	1065	O
V	-	1073	O
binding	-	1075	O
and	-	1083	O
forward	-	1087	O
scatter	-	1095	O
was	-	1103	O
significantly	-	1107	O
blunted	-	1121	O
in	-	1129	O
the	-	1132	O
nominal	-	1136	O
absence	-	1144	O
of	-	1152	O
extracellular	-	1155	O
Ca2	-	1169	O
+	-	1172	O
.	-	1173	O

CONCLUSIONS	18340638	1175	O
:	-	1186	O

Azathioprine	18340638	1188	O
triggers	-	1201	O
suicidal	-	1210	O
erythrocyte	-	1219	O
death	-	1231	O
,	-	1236	O
an	-	1238	O
effect	-	1241	O
presumably	-	1248	O
contributing	-	1259	O
to	-	1272	O
azathioprine	-	1275	O
-	-	1287	O
induced	-	1288	O
anemia	-	1296	B
.	-	1302	O

Clinical	18399341	0	O
comparison	-	9	O
of	-	20	O
cardiorespiratory	-	23	O
effects	-	41	O
during	-	49	O
unilateral	-	56	O
and	-	67	O
conventional	-	71	O
spinal	-	84	O
anaesthesia	-	91	O
.	-	102	O

BACKGROUND	18399341	104	O
:	-	114	O
Spinal	-	116	O
anaesthesia	-	123	O
is	-	135	O
widely	-	138	O
employed	-	145	O
in	-	154	O
clinical	-	157	O
practice	-	166	O
but	-	175	O
has	-	179	O
the	-	183	O
main	-	187	O
drawback	-	192	O
of	-	201	O
post	-	204	O
-	-	208	O
spinal	-	209	O
block	-	216	O
hypotension	-	222	B
.	-	233	O

Efforts	18399341	235	O
must	-	243	O
therefore	-	248	O
continue	-	258	O
to	-	267	O
be	-	270	O
made	-	273	O
to	-	278	O
obviate	-	281	O
this	-	289	O
setback	-	294	O
OBJECTIVE	-	302	O
:	-	311	O
To	-	313	O
evaluate	-	316	O
the	-	325	O
cardiovascular	-	329	O
and	-	344	O
respiratory	-	348	O
changes	-	360	O
during	-	368	O
unilateral	-	375	O
and	-	386	O
conventional	-	390	O
spinal	-	403	O
anaesthesia	-	410	O
.	-	421	O

METHODS	18399341	423	O
:	-	430	O

With	18399341	432	O
ethical	-	437	O
approval	-	445	O
,	-	453	O
we	-	455	O
studied	-	458	O
74	-	466	O
American	-	469	O
Society	-	478	O
of	-	486	O
Anesthesiologists	-	489	O
(	-	507	O
ASA	-	508	O
)	-	511	O
,	-	512	O
physical	-	514	O
status	-	523	O
class	-	530	O
1	-	536	O
and	-	538	O
2	-	542	O
patients	-	544	O
scheduled	-	553	O
for	-	563	O
elective	-	567	O
unilateral	-	576	O
lower	-	587	O
limb	-	593	O
surgery	-	598	O
.	-	605	O

Patients	18399341	607	O
were	-	616	O
randomly	-	621	O
allocated	-	630	O
into	-	640	O
one	-	645	O
of	-	649	O
two	-	652	O
groups	-	656	O
:	-	662	O
lateral	-	664	O
and	-	672	O
conventional	-	676	O
spinal	-	689	O
anaesthesia	-	696	O
groups	-	708	O
.	-	714	O

In	18399341	716	O
the	-	719	O
lateral	-	723	O
position	-	731	O
with	-	740	O
operative	-	745	O
side	-	755	O
down	-	760	O
,	-	764	O
patients	-	766	O
recived	-	775	O
10	-	783	O
mg	-	786	O
(	-	789	O
2mls	-	790	O
)	-	794	O
of	-	796	O
0	-	799	O
.	-	800	O
5	-	801	O
%	-	802	O
hyperbaric	-	804	O
bupivacaine	-	815	O
through	-	827	O
a	-	835	O
25	-	837	O
-	-	839	O
gauge	-	840	O
spinal	-	846	O
needle	-	853	O
.	-	859	O

Patients	18399341	861	O
in	-	870	O
the	-	873	O
unilateral	-	877	O
group	-	888	O
were	-	894	O
maintained	-	899	O
in	-	910	O
the	-	913	O
lateral	-	917	O
position	-	925	O
for	-	934	O
15	-	938	O
minutes	-	941	O
following	-	949	O
spinal	-	959	O
injection	-	966	O
while	-	976	O
those	-	982	O
in	-	988	O
the	-	991	O
conventional	-	995	O
group	-	1008	O
were	-	1014	O
turned	-	1019	O
supine	-	1026	O
immediately	-	1033	O
after	-	1045	O
injection	-	1051	O
.	-	1060	O

Blood	18399341	1062	O
pressure	-	1068	O
,	-	1076	O
heart	-	1078	O
rate	-	1084	O
,	-	1088	O
respiratory	-	1090	O
rate	-	1102	O
and	-	1107	O
oxygen	-	1111	O
saturation	-	1118	O
were	-	1129	O
monitored	-	1134	O
over	-	1144	O
1	-	1149	O
hour	-	1151	O
.	-	1155	O

RESULTS	18399341	1157	O
:	-	1164	O

Three	18399341	1166	O
patients	-	1172	O
(	-	1181	O
8	-	1182	O
.	-	1183	O
1	-	1184	O
%	-	1185	O
)	-	1186	O
in	-	1188	O
the	-	1191	O
unilateral	-	1195	O
group	-	1206	O
and	-	1212	O
5	-	1216	O
(	-	1218	O
13	-	1219	O
.	-	1221	O
5	-	1222	O
%	-	1223	O
)	-	1224	O
in	-	1226	O
the	-	1229	O
conventional	-	1233	O
group	-	1246	O
developed	-	1252	O
hypotension	-	1262	B
,	-	1273	O
P	-	1275	O
=	-	1276	O
0	-	1278	O
.	-	1279	O
71	-	1280	O
.	-	1282	O

Four	18399341	1284	O
(	-	1289	O
10	-	1290	O
.	-	1292	O
8	-	1293	O
%	-	1294	O
)	-	1295	O
patients	-	1297	O
in	-	1306	O
the	-	1309	O
conventional	-	1313	O
group	-	1326	O
and	-	1332	O
1	-	1336	O
(	-	1338	O
2	-	1339	O
.	-	1340	O
7	-	1341	O
%	-	1342	O
)	-	1343	O
in	-	1345	O
the	-	1348	O
unilateral	-	1352	O
group	-	1363	O
,	-	1368	O
P	-	1370	O
=	-	1371	O
0	-	1373	O
.	-	1374	O
17	-	1375	O
required	-	1378	O
epinephrine	-	1387	O
infusion	-	1399	O
to	-	1408	O
treat	-	1411	O
hypotension	-	1417	B
.	-	1428	O

Patients	18399341	1430	O
in	-	1439	O
the	-	1442	O
conventional	-	1446	O
group	-	1459	O
had	-	1465	O
statistically	-	1469	O
significant	-	1483	O
greater	-	1495	O
fall	-	1503	O
in	-	1508	O
the	-	1511	O
systolic	-	1515	O
blood	-	1524	O
pressures	-	1530	O
at	-	1540	O
15	-	1543	O
,	-	1545	O
30	-	1547	O
and	-	1550	O
45	-	1554	O
minutes	-	1557	O
when	-	1565	O
compared	-	1570	O
to	-	1579	O
the	-	1582	O
baseline	-	1586	O
(	-	1595	O
P	-	1596	O
=	-	1597	O
0	-	1599	O
.	-	1600	O
003	-	1601	O
,	-	1604	O
0	-	1606	O
.	-	1607	O
001	-	1608	O
and	-	1612	O
0	-	1616	O
.	-	1617	O
004	-	1618	O
)	-	1621	O
.	-	1622	O

The	18399341	1624	O
mean	-	1628	O
respiratory	-	1633	O
rate	-	1645	O
and	-	1650	O
oxygen	-	1654	O
saturations	-	1661	O
in	-	1673	O
the	-	1676	O
two	-	1680	O
groups	-	1684	O
were	-	1691	O
similar	-	1696	O
.	-	1703	O

CONCLUSION	18399341	1705	O
:	-	1715	O

Compared	18399341	1717	O
to	-	1726	O
conventional	-	1729	O
spinal	-	1742	O
anaesthesia	-	1749	O
,	-	1760	O
unilateral	-	1762	O
spinal	-	1773	O
anaesthesia	-	1780	O
was	-	1792	O
associated	-	1796	O
with	-	1807	O
fewer	-	1812	O
cardiovascular	-	1818	O
perturbations	-	1833	O
.	-	1846	O

Also	18399341	1848	O
,	-	1852	O
the	-	1854	O
type	-	1858	O
of	-	1863	O
spinal	-	1866	O
block	-	1873	O
instituted	-	1879	O
affected	-	1890	O
neither	-	1899	O
the	-	1907	O
respiratory	-	1911	O
rate	-	1923	O
nor	-	1928	O
the	-	1932	O
arterial	-	1936	O
oxygen	-	1945	O
saturation	-	1952	O
.	-	1962	O

Spectrum	18422462	0	O
of	-	9	O
adverse	-	12	O
events	-	20	O
after	-	27	O
generic	-	33	O
HAART	-	41	O
in	-	47	O
southern	-	50	O
Indian	-	59	O
HIV	-	66	B
-	-	69	I
infected	-	70	I
patients	-	79	O
.	-	87	O

To	18422462	89	O
determine	-	92	O
the	-	102	O
incidence	-	106	O
of	-	116	O
clinically	-	119	O
significant	-	130	O
adverse	-	142	O
events	-	150	O
after	-	157	O
long	-	163	O
-	-	167	O
term	-	168	O
,	-	172	O
fixed	-	174	O
-	-	179	O
dose	-	180	O
,	-	184	O
generic	-	186	O
highly	-	194	O
active	-	201	O
antiretroviral	-	208	O
therapy	-	223	O
(	-	231	O
HAART	-	232	O
)	-	237	O
use	-	239	O
among	-	243	O
HIV	-	249	B
-	-	252	I
infected	-	253	I
individuals	-	262	O
in	-	274	O
South	-	277	O
India	-	283	O
,	-	288	O
we	-	290	O
examined	-	293	O
the	-	302	O
experiences	-	306	O
of	-	318	O
3154	-	321	O
HIV	-	326	B
-	-	329	I
infected	-	330	I
individuals	-	339	O
who	-	351	O
received	-	355	O
a	-	364	O
minimum	-	366	O
of	-	374	O
3	-	377	O
months	-	379	O
of	-	386	O
generic	-	389	O
HAART	-	397	O
between	-	403	O
February	-	411	O
1996	-	420	O
and	-	425	O
December	-	429	O
2006	-	438	O
at	-	443	O
a	-	446	O
tertiary	-	448	O
HIV	-	457	O
care	-	461	O
referral	-	466	O
center	-	475	O
in	-	482	O
South	-	485	O
India	-	491	O
.	-	496	O

The	18422462	498	O
most	-	502	O
common	-	507	O
regimens	-	514	O
were	-	523	O
3TC	-	528	O
+	-	532	O
d4	-	534	O
T	-	536	O
+	-	538	O
nevirapine	-	540	O
(	-	551	O
NVP	-	552	O
)	-	555	O
(	-	557	O
54	-	558	O
.	-	560	O
8	-	561	O
%	-	562	O
)	-	563	O
,	-	564	O
zidovudine	-	566	O
(	-	577	O
AZT	-	578	O
)	-	581	O
+	-	583	O
3TC	-	585	O
+	-	589	O
NVP	-	591	O
(	-	595	O
14	-	596	O
.	-	598	O
5	-	599	O
%	-	600	O
)	-	601	O
,	-	602	O
3TC	-	604	O
+	-	608	O
d4	-	610	O
T	-	612	O
+	-	614	O
efavirenz	-	616	O
(	-	626	O
EFV	-	627	O
)	-	630	O
(	-	632	O
20	-	633	O
.	-	635	O
1	-	636	O
%	-	637	O
)	-	638	O
,	-	639	O
and	-	641	O
AZT	-	645	O
+	-	649	O
3TC	-	651	O
+	-	655	O
EFV	-	657	O
(	-	661	O
5	-	662	O
.	-	663	O
4	-	664	O
%	-	665	O
)	-	666	O
.	-	667	O

The	18422462	669	O
most	-	673	O
common	-	678	O
adverse	-	685	O
events	-	693	O
and	-	700	O
median	-	704	O
CD4	-	711	O
at	-	715	O
time	-	718	O
of	-	723	O
event	-	726	O
were	-	732	O
rash	-	737	B
(	-	742	O
15	-	743	O
.	-	745	O
2	-	746	O
%	-	747	O
;	-	748	O
CD4	-	750	O
,	-	753	O
285	-	755	O
cells	-	759	O
/	-	764	O
microL	-	765	O
)	-	771	O
and	-	773	O
peripheral	-	777	B
neuropathy	-	788	I
(	-	799	O
9	-	800	O
.	-	801	O
0	-	802	O
%	-	803	O
and	-	805	O
348	-	809	O
cells	-	813	O
/	-	818	O
microL	-	819	O
)	-	825	O
.	-	826	O

Clinically	18422462	828	O
significant	-	839	O
anemia	-	851	B
(	-	858	O
hemoglobin	-	859	O
<	-	870	O
7	-	871	O
g	-	873	O
/	-	874	O
dL	-	875	O
)	-	877	O
was	-	879	O
observed	-	883	O
in	-	892	O
5	-	895	O
.	-	896	O
4	-	897	O
%	-	898	O
of	-	900	O
patients	-	903	O
(	-	912	O
CD4	-	913	O
,	-	916	O
165	-	918	O
cells	-	922	O
/	-	927	O
microL	-	928	O
)	-	934	O
and	-	936	O
hepatitis	-	940	B
(	-	950	O
clinical	-	951	O
jaundice	-	960	B
with	-	969	O
alanine	-	974	O
aminotransferase	-	982	O
>	-	999	O
5	-	1001	O
times	-	1003	O
upper	-	1009	O
limits	-	1015	O
of	-	1022	O
normal	-	1025	O
)	-	1031	O
in	-	1033	O
3	-	1036	O
.	-	1037	O
5	-	1038	O
%	-	1039	O
of	-	1041	O
patients	-	1044	O
(	-	1053	O
CD4	-	1054	O
,	-	1057	O
260	-	1059	O
cells	-	1063	O
/	-	1068	O
microL	-	1069	O
)	-	1075	O
.	-	1076	O

Women	18422462	1078	O
were	-	1084	O
significantly	-	1089	O
more	-	1103	O
likely	-	1108	O
to	-	1115	O
experience	-	1118	O
lactic	-	1129	B
acidosis	-	1136	I
,	-	1144	O
while	-	1146	O
men	-	1152	O
were	-	1156	O
significantly	-	1161	O
more	-	1175	O
likely	-	1180	O
to	-	1187	O
experience	-	1190	O
immune	-	1201	B
reconstitution	-	1208	I
syndrome	-	1223	I
(	-	1232	O
p	-	1233	O
<	-	1235	O
0	-	1237	O
.	-	1238	O
05	-	1239	O
)	-	1241	O
.	-	1242	O

Among	18422462	1244	O
the	-	1250	O
patients	-	1254	O
with	-	1263	O
1	-	1268	O
year	-	1270	O
of	-	1275	O
follow	-	1278	O
-	-	1284	O
up	-	1285	O
,	-	1287	O
NVP	-	1289	O
therapy	-	1293	O
was	-	1301	O
significantly	-	1305	O
associated	-	1319	O
with	-	1330	O
developing	-	1335	O
rash	-	1346	B
and	-	1351	O
d4	-	1355	O
T	-	1357	O
therapy	-	1359	O
with	-	1367	O
developing	-	1372	O
peripheral	-	1383	B
neuropathy	-	1394	I
(	-	1405	O
p	-	1406	O
<	-	1408	O
0	-	1410	O
.	-	1411	O
05	-	1412	O
)	-	1414	O
.	-	1415	O

Anemia	18422462	1417	B
and	-	1424	O
hepatitis	-	1428	B
often	-	1438	O
occur	-	1444	O
within	-	1450	O
12	-	1457	O
weeks	-	1460	O
of	-	1466	O
initiating	-	1469	O
generic	-	1480	O
HAART	-	1488	O
.	-	1493	O

Frequent	18422462	1495	O
and	-	1504	O
early	-	1508	O
monitoring	-	1514	O
for	-	1525	O
these	-	1529	O
toxicities	-	1535	B
is	-	1546	O
warranted	-	1549	O
in	-	1559	O
developing	-	1562	O
countries	-	1573	O
where	-	1583	O
generic	-	1589	O
HAART	-	1597	O
is	-	1603	O
increasingly	-	1606	O
available	-	1619	O
.	-	1628	O

Thalidomide	18450790	0	O
and	-	12	O
sensory	-	16	B
neurotoxicity	-	24	I
:	-	37	O
a	-	39	O
neurophysiological	-	41	O
study	-	60	O
.	-	65	O

BACKGROUND	18450790	67	O
:	-	77	O

Recent	18450790	79	O
studies	-	86	O
confirmed	-	94	O
a	-	104	O
high	-	106	O
incidence	-	111	O
of	-	121	O
sensory	-	124	B
axonal	-	132	I
neuropathy	-	139	I
in	-	150	O
patients	-	153	O
treated	-	162	O
with	-	170	O
different	-	175	O
doses	-	185	O
of	-	191	O
thalidomide	-	194	O
.	-	205	O

The	18450790	207	O
study	-	211	O
's	-	216	O
aims	-	219	O
were	-	224	O
to	-	229	O
measure	-	232	O
variations	-	240	O
in	-	251	O
sural	-	254	O
nerve	-	260	O
sensory	-	266	O
action	-	274	O
potential	-	281	O
(	-	291	O
SAP	-	292	O
)	-	295	O
amplitude	-	297	O
in	-	307	O
patients	-	310	O
with	-	319	O
refractory	-	324	O
cutaneous	-	335	B
lupus	-	345	I
erythematosus	-	351	I
(	-	365	O
CLE	-	366	B
)	-	369	O
treated	-	371	O
with	-	379	O
thalidomide	-	384	O
and	-	396	O
use	-	400	O
these	-	404	O
findings	-	410	O
to	-	419	O
identify	-	422	O
the	-	431	O
neurotoxic	-	435	B
potential	-	446	O
of	-	456	O
thalidomide	-	459	O
and	-	471	O
the	-	475	O
recovery	-	479	O
capacity	-	488	O
of	-	497	O
sensory	-	500	O
fibres	-	508	O
after	-	515	O
discontinuation	-	521	O
of	-	537	O
treatment	-	540	O
.	-	549	O

PATIENTS	18450790	551	O
AND	-	560	O
METHODS	-	564	O
:	-	571	O

Clinical	18450790	573	O
and	-	582	O
electrophysiological	-	586	O
data	-	607	O
in	-	612	O
12	-	615	O
female	-	618	O
patients	-	625	O
with	-	634	O
CLE	-	639	B
during	-	643	O
treatment	-	650	O
with	-	660	O
thalidomide	-	665	O
and	-	677	O
up	-	681	O
to	-	684	O
47	-	687	O
months	-	690	O
after	-	697	O
discontinuation	-	703	O
of	-	719	O
treatment	-	722	O
were	-	732	O
analysed	-	737	O
.	-	745	O

Sural	18450790	747	O
nerve	-	753	O
SAP	-	759	O
amplitude	-	763	O
reduction	-	773	O
>	-	783	O
or	-	785	O
=	-	788	O
40	-	789	O
%	-	791	O
was	-	793	O
the	-	797	O
criteria	-	801	O
for	-	810	O
discontinuing	-	814	O
therapy	-	828	O
.	-	835	O

RESULTS	18450790	837	O
:	-	844	O

During	18450790	846	O
treatment	-	853	O
,	-	862	O
11	-	864	O
patients	-	867	O
showed	-	876	O
a	-	883	O
reduction	-	885	O
in	-	895	O
sural	-	898	O
nerve	-	904	O
SAP	-	910	O
amplitude	-	914	O
compared	-	924	O
to	-	933	O
baseline	-	936	O
values	-	945	O
(	-	952	O
9	-	953	O
with	-	955	O
a	-	960	O
reduction	-	962	O
>	-	972	O
or	-	974	O
=	-	977	O
50	-	978	O
%	-	980	O
and	-	982	O
2	-	986	O
<	-	988	O
50	-	989	O
%	-	991	O
)	-	992	O
.	-	993	O

One	18450790	995	O
patient	-	999	O
showed	-	1007	O
no	-	1014	O
changes	-	1017	O
in	-	1025	O
SAP	-	1028	O
amplitude	-	1032	O
.	-	1041	O

Five	18450790	1043	O
patients	-	1048	O
complained	-	1057	O
of	-	1068	O
paresthesias	-	1071	B
and	-	1084	O
leg	-	1088	O
cramps	-	1092	B
.	-	1098	O

After	18450790	1100	O
thalidomide	-	1106	O
treatment	-	1118	O
,	-	1127	O
sural	-	1129	O
SAP	-	1135	O
amplitude	-	1139	O
recovered	-	1149	O
in	-	1159	O
3	-	1162	O
patients	-	1164	O
.	-	1172	O

At	18450790	1174	O
detection	-	1177	O
of	-	1187	O
reduction	-	1190	O
in	-	1200	O
sural	-	1203	O
nerve	-	1209	O
SAP	-	1215	O
amplitude	-	1219	O
,	-	1228	O
the	-	1230	O
median	-	1234	O
thalidomide	-	1241	O
cumulative	-	1253	O
dose	-	1264	O
was	-	1269	O
21	-	1273	O
.	-	1275	O
4	-	1276	O
g	-	1278	O
.	-	1279	O

The	18450790	1281	O
threshold	-	1285	O
neurotoxic	-	1295	B
dosage	-	1306	O
is	-	1313	O
lower	-	1316	O
than	-	1322	O
previously	-	1327	O
reported	-	1338	O
.	-	1346	O

CONCLUSIONS	18450790	1348	O
:	-	1359	O

Sural	18450790	1361	O
nerve	-	1367	O
SAP	-	1373	O
amplitude	-	1377	O
reduction	-	1387	O
is	-	1397	O
a	-	1400	O
reliable	-	1402	O
and	-	1411	O
sensitive	-	1415	O
marker	-	1425	O
of	-	1432	O
degeneration	-	1435	O
and	-	1448	O
recovery	-	1452	O
of	-	1461	O
sensory	-	1464	O
fibres	-	1472	O
.	-	1478	O

This	18450790	1480	O
electrophysiological	-	1485	O
parameter	-	1506	O
provides	-	1516	O
information	-	1525	O
about	-	1537	O
subclinical	-	1543	O
neurotoxic	-	1555	B
potential	-	1566	O
of	-	1576	O
thalidomide	-	1579	O
but	-	1591	O
is	-	1595	O
not	-	1598	O
helpful	-	1602	O
in	-	1610	O
predicting	-	1613	O
the	-	1624	O
appearance	-	1628	O
of	-	1639	O
sensory	-	1642	O
symptoms	-	1650	O
.	-	1658	O

Amiodarone	18801087	0	O
-	-	10	O
related	-	11	O
pulmonary	-	19	B
mass	-	29	I
and	-	34	O
unique	-	38	O
membranous	-	45	B
glomerulonephritis	-	56	I
in	-	75	O
a	-	78	O
patient	-	80	O
with	-	88	O
valvular	-	93	B
heart	-	102	I
disease	-	108	I
:	-	115	O

Diagnostic	18801087	117	O
pitfall	-	128	O
and	-	136	O
new	-	140	O
findings	-	144	O
.	-	152	O

Amiodarone	18801087	154	O
is	-	165	O
an	-	168	O
anti	-	171	O
-	-	175	O
arrhythmic	-	176	B
drug	-	187	O
for	-	192	O
life	-	196	O
-	-	200	O
threatening	-	201	O
tachycardia	-	213	B
,	-	224	O
but	-	226	O
various	-	230	O
adverse	-	238	O
effects	-	246	O
have	-	254	O
been	-	259	O
reported	-	264	O
.	-	272	O

Reported	18801087	274	O
herein	-	283	O
is	-	290	O
an	-	293	O
autopsy	-	296	O
case	-	304	O
of	-	309	O
valvular	-	312	B
heart	-	321	I
disease	-	327	I
,	-	334	O
in	-	336	O
a	-	339	O
patient	-	341	O
who	-	349	O
developed	-	353	O
a	-	363	O
lung	-	365	B
mass	-	370	I
(	-	375	O
1	-	376	O
.	-	377	O
5	-	378	O
cm	-	380	O
in	-	383	O
diameter	-	386	O
)	-	394	O
and	-	396	O
proteinuria	-	400	B
(	-	412	O
2	-	413	O
.	-	414	O
76	-	415	O
g	-	418	O
/	-	419	O
day	-	420	O
)	-	423	O
after	-	425	O
treatment	-	431	O
with	-	441	O
amiodarone	-	446	O
for	-	457	O
a	-	461	O
long	-	463	O
time	-	468	O
.	-	472	O

The	18801087	474	O
lung	-	478	B
mass	-	483	I
was	-	488	O
highly	-	492	O
suspected	-	499	O
to	-	509	O
be	-	512	O
lung	-	515	B
cancer	-	520	I
on	-	527	O
CT	-	530	O
and	-	533	O
positron	-	537	O
emission	-	546	O
tomography	-	555	O
,	-	565	O
but	-	567	O
histologically	-	571	O
the	-	586	O
lesion	-	590	O
was	-	597	O
composed	-	601	O
of	-	610	O
lymphoplasmacytic	-	613	O
infiltrates	-	631	O
in	-	643	O
alveolar	-	646	O
walls	-	655	O
and	-	661	O
intra	-	665	O
-	-	670	O
alveolar	-	671	O
accumulation	-	680	O
of	-	693	O
foamy	-	696	O
macrophages	-	702	O
containing	-	714	O
characteristic	-	725	O
myelinoid	-	740	O
bodies	-	750	O
,	-	756	O
indicating	-	758	O
that	-	769	O
it	-	774	O
was	-	777	O
an	-	781	O
amiodarone	-	784	O
-	-	794	O
related	-	795	O
lesion	-	803	O
.	-	809	O

In	18801087	811	O
addition	-	814	O
,	-	822	O
the	-	824	O
lung	-	828	O
tissue	-	833	O
had	-	840	O
unevenly	-	844	O
distributed	-	853	O
hemosiderin	-	865	B
deposition	-	877	O
,	-	887	O
and	-	889	O
abnormally	-	893	O
tortuous	-	904	O
capillaries	-	913	O
were	-	925	O
seen	-	930	O
in	-	935	O
the	-	938	O
mass	-	942	O
and	-	947	O
in	-	951	O
heavily	-	954	O
hemosiderotic	-	962	B
lung	-	976	O
portions	-	981	O
outside	-	990	O
the	-	998	O
mass	-	1002	O
.	-	1006	O

In	18801087	1008	O
the	-	1011	O
kidneys	-	1015	O
,	-	1022	O
glomeruli	-	1024	O
had	-	1034	O
membrane	-	1038	O
spikes	-	1047	O
,	-	1053	O
prominent	-	1055	O
swelling	-	1065	O
of	-	1074	O
podocytes	-	1077	O
and	-	1087	O
subepithelial	-	1091	O
deposits	-	1105	O
,	-	1113	O
which	-	1115	O
were	-	1121	O
sometimes	-	1126	O
large	-	1136	O
and	-	1142	O
hump	-	1146	O
-	-	1150	O
like	-	1151	O
.	-	1155	O

Autoimmune	18801087	1157	B
diseases	-	1168	I
,	-	1176	O
viral	-	1178	B
hepatitis	-	1184	I
,	-	1193	O
malignant	-	1195	O
neoplasms	-	1205	B
or	-	1215	O
other	-	1218	O
diseases	-	1224	O
with	-	1233	O
a	-	1238	O
known	-	1240	O
relationship	-	1246	O
to	-	1259	O
membranous	-	1262	B
glomerulonephritis	-	1273	I
were	-	1292	O
not	-	1297	O
found	-	1301	O
.	-	1306	O

The	18801087	1308	O
present	-	1312	O
case	-	1320	O
highlights	-	1325	O
the	-	1336	O
possibility	-	1340	O
that	-	1352	O
differential	-	1357	O
diagnosis	-	1370	O
between	-	1380	O
an	-	1388	O
amiodarone	-	1391	O
-	-	1401	O
related	-	1402	O
pulmonary	-	1410	B
lesion	-	1420	I
and	-	1427	O
a	-	1431	O
neoplasm	-	1433	B
can	-	1442	O
be	-	1446	O
very	-	1449	O
difficult	-	1454	O
radiologically	-	1464	O
,	-	1478	O
and	-	1480	O
suggests	-	1484	O
that	-	1493	O
membranous	-	1498	B
glomerulonephritis	-	1509	I
might	-	1528	O
be	-	1534	O
another	-	1537	O
possible	-	1545	O
complication	-	1554	O
of	-	1567	O
amiodarone	-	1570	O
treatment	-	1581	O
.	-	1590	O

Risk	18945509	0	O
of	-	5	O
coronary	-	8	B
artery	-	17	I
disease	-	24	I
associated	-	32	O
with	-	43	O
initial	-	48	O
sulphonylurea	-	56	O
treatment	-	70	O
of	-	80	O
patients	-	83	O
with	-	92	O
type	-	97	B
2	-	102	I
diabetes	-	104	I
:	-	112	O
a	-	114	O
matched	-	116	O
case	-	124	O
-	-	128	O
control	-	129	O
study	-	137	O
.	-	142	O

AIMS	18945509	144	O
:	-	148	O

This	18945509	150	O
study	-	155	O
sought	-	161	O
to	-	168	O
assess	-	171	O
the	-	178	O
risk	-	182	O
of	-	187	O
developing	-	190	O
coronary	-	201	B
artery	-	210	I
disease	-	217	I
(	-	225	O
CAD	-	226	B
)	-	229	O
associated	-	231	O
with	-	242	O
initial	-	247	O
treatment	-	255	O
of	-	265	O
type	-	268	B
2	-	273	I
diabetes	-	275	I
with	-	284	O
different	-	289	O
sulphonylureas	-	299	O
.	-	313	O

METHODS	18945509	315	O
:	-	322	O

In	18945509	324	O
type	-	327	B
2	-	332	I
diabetic	-	334	I
patients	-	343	O
,	-	351	O
cases	-	353	O
who	-	359	O
developed	-	363	O
CAD	-	373	B
were	-	377	O
compared	-	382	O
retrospectively	-	391	O
with	-	407	O
controls	-	412	O
that	-	421	O
did	-	426	O
not	-	430	O
.	-	433	O

The	18945509	435	O
20	-	439	O
-	-	441	O
year	-	442	O
risk	-	447	O
of	-	452	O
CAD	-	455	B
at	-	459	O
diagnosis	-	462	O
of	-	472	O
diabetes	-	475	B
,	-	483	O
using	-	485	O
the	-	491	O
UKPDS	-	495	O
risk	-	501	O
engine	-	506	O
,	-	512	O
was	-	514	O
used	-	518	O
to	-	523	O
match	-	526	O
cases	-	532	O
with	-	538	O
controls	-	543	O
.	-	551	O

RESULTS	18945509	553	O
:	-	560	O

The	18945509	562	O
76	-	566	O
cases	-	569	O
of	-	575	O
CAD	-	578	B
were	-	582	O
compared	-	587	O
with	-	596	O
152	-	601	O
controls	-	605	O
.	-	613	O

The	18945509	615	O
hazard	-	619	O
of	-	626	O
developing	-	629	O
CAD	-	640	B
(	-	644	O
95	-	645	O
%	-	647	O
CI	-	649	O
)	-	651	O
associated	-	653	O
with	-	664	O
initial	-	669	O
treatment	-	677	O
increased	-	687	O
by	-	697	O
2	-	700	O
.	-	701	O
4	-	702	O
-	-	703	O
fold	-	704	O
(	-	709	O
1	-	710	O
.	-	711	O
3	-	712	O
-	-	713	O
4	-	714	O
.	-	715	O
3	-	716	O
,	-	717	O
P	-	719	O
=	-	720	O
0	-	721	O
.	-	722	O
004	-	723	O
)	-	726	O
with	-	728	O
glibenclamide	-	733	O
;	-	746	O
2	-	748	O
-	-	749	O
fold	-	750	O
(	-	755	O
0	-	756	O
.	-	757	O
9	-	758	O
-	-	759	O
4	-	760	O
.	-	761	O
6	-	762	O
,	-	763	O
P	-	765	O
=	-	766	O
0	-	767	O
.	-	768	O
099	-	769	O
)	-	772	O
with	-	774	O
glipizide	-	779	O
;	-	788	O
2	-	790	O
.	-	791	O
9	-	792	O
-	-	793	O
fold	-	794	O
(	-	799	O
1	-	800	O
.	-	801	O
6	-	802	O
-	-	803	O
5	-	804	O
.	-	805	O
1	-	806	O
,	-	807	O
P	-	809	O
=	-	810	O
0	-	811	O
.	-	812	O
000	-	813	O
)	-	816	O
with	-	818	O
either	-	823	O
,	-	829	O
and	-	831	O
was	-	835	O
unchanged	-	839	O
with	-	849	O
metformin	-	854	O
.	-	863	O

The	18945509	865	O
hazard	-	869	O
decreased	-	876	O
0	-	886	O
.	-	887	O
3	-	888	O
-	-	889	O
fold	-	890	O
(	-	895	O
0	-	896	O
.	-	897	O
7	-	898	O
-	-	899	O
1	-	900	O
.	-	901	O
7	-	902	O
,	-	903	O
P	-	905	O
=	-	906	O
0	-	907	O
.	-	908	O
385	-	909	O
)	-	912	O
with	-	914	O
glimepiride	-	919	O
,	-	930	O
0	-	932	O
.	-	933	O
4	-	934	O
-	-	935	O
fold	-	936	O
(	-	941	O
0	-	942	O
.	-	943	O
7	-	944	O
-	-	945	O
1	-	946	O
.	-	947	O
3	-	948	O
,	-	949	O
P	-	951	O
=	-	952	O
0	-	953	O
.	-	954	O
192	-	955	O
)	-	958	O
with	-	960	O
gliclazide	-	965	O
,	-	975	O
and	-	977	O
0	-	981	O
.	-	982	O
4	-	983	O
-	-	984	O
fold	-	985	O
(	-	990	O
0	-	991	O
.	-	992	O
7	-	993	O
-	-	994	O
1	-	995	O
.	-	996	O
1	-	997	O
,	-	998	O
P	-	1000	O
=	-	1001	O
0	-	1002	O
.	-	1003	O
09	-	1004	O
)	-	1006	O
with	-	1008	O
either	-	1013	O
.	-	1019	O

CONCLUSIONS	18945509	1021	O
:	-	1032	O

Initiating	18945509	1034	O
treatment	-	1045	O
of	-	1055	O
type	-	1058	B
2	-	1063	I
diabetes	-	1065	I
with	-	1074	O
glibenclamide	-	1079	O
or	-	1093	O
glipizide	-	1096	O
is	-	1106	O
associated	-	1109	O
with	-	1120	O
increased	-	1125	O
risk	-	1135	O
of	-	1140	O
CAD	-	1143	B
in	-	1147	O
comparison	-	1150	O
to	-	1161	O
gliclazide	-	1164	O
or	-	1175	O
glimepiride	-	1178	O
.	-	1189	O

If	18945509	1191	O
confirmed	-	1194	O
,	-	1203	O
this	-	1205	O
may	-	1210	O
be	-	1214	O
important	-	1217	O
because	-	1227	O
most	-	1235	O
Indian	-	1240	O
patients	-	1247	O
receive	-	1256	O
the	-	1264	O
cheaper	-	1268	O
older	-	1276	O
sulphonylureas	-	1282	O
,	-	1296	O
and	-	1298	O
present	-	1302	O
guidelines	-	1310	O
do	-	1321	O
not	-	1324	O
distinguish	-	1328	O
between	-	1340	O
individual	-	1348	O
agents	-	1359	O
.	-	1365	O

Reduced	18987260	0	O
progression	-	8	O
of	-	20	O
adriamycin	-	23	O
nephropathy	-	34	B
in	-	46	O
spontaneously	-	49	O
hypertensive	-	63	B
rats	-	76	O
treated	-	81	O
by	-	89	O
losartan	-	92	O
.	-	100	O

BACKGROUND	18987260	102	O
:	-	112	O

The	18987260	114	O
aim	-	118	O
of	-	122	O
the	-	125	O
study	-	129	O
was	-	135	O
to	-	139	O
investigate	-	142	O
the	-	154	O
antihypertensive	-	158	O
effects	-	175	O
of	-	183	O
angiotensin	-	186	O
II	-	198	O
type	-	201	O
-	-	205	O
1	-	206	O
receptor	-	208	O
blocker	-	217	O
,	-	224	O
losartan	-	226	O
,	-	234	O
and	-	236	O
its	-	240	O
potential	-	244	O
in	-	254	O
slowing	-	257	O
down	-	265	O
renal	-	270	B
disease	-	276	I
progression	-	284	O
in	-	296	O
spontaneously	-	299	O
hypertensive	-	313	B
rats	-	326	O
(	-	331	O
SHR	-	332	O
)	-	335	O
with	-	337	O
adriamycin	-	342	O
(	-	353	O
ADR	-	354	O
)	-	357	O
nephropathy	-	359	B
.	-	370	O

METHODS	18987260	372	O
:	-	379	O

Six	18987260	381	O
-	-	384	O
month	-	385	O
-	-	390	O
old	-	391	O
female	-	395	O
SHR	-	402	O
were	-	406	O
randomly	-	411	O
selected	-	420	O
in	-	429	O
six	-	432	O
groups	-	436	O
.	-	442	O

Two	18987260	444	O
control	-	448	O
groups	-	456	O
(	-	463	O
SH	-	464	O
(	-	466	O
6	-	467	O
)	-	468	O
,	-	469	O
SH	-	471	O
(	-	473	O
12	-	474	O
)	-	476	O
)	-	477	O
received	-	479	O
vehicle	-	488	O
.	-	495	O

Groups	18987260	497	O
ADR	-	504	O
(	-	507	O
6	-	508	O
)	-	509	O
,	-	510	O
ADR	-	512	O
+	-	515	O
LOS	-	516	O
(	-	519	O
6	-	520	O
)	-	521	O
and	-	523	O
ADR	-	527	O
(	-	530	O
12	-	531	O
)	-	533	O
,	-	534	O
and	-	536	O
ADR	-	540	O
+	-	543	O
LOS	-	544	O
(	-	547	O
12	-	548	O
)	-	550	O
received	-	552	O
ADR	-	561	O
(	-	565	O
2	-	566	O
mg	-	568	O
/	-	570	O
kg	-	571	O
/	-	573	O
b	-	574	O
.	-	575	O
w	-	576	O
.	-	577	O
i	-	579	O
.	-	580	O
v	-	581	O
.	-	582	O
)	-	583	O
twice	-	585	O
in	-	591	O
a	-	594	O
3	-	596	O
-	-	597	O
week	-	598	O
interval	-	603	O
.	-	611	O

Group	18987260	613	O
ADR	-	619	O
+	-	622	O
LOS	-	623	O
(	-	626	O
6	-	627	O
)	-	628	O
received	-	630	O
losartan	-	639	O
(	-	648	O
10	-	649	O
mg	-	652	O
/	-	654	O
kg	-	655	O
/	-	657	O
b	-	658	O
.	-	659	O
w	-	660	O
.	-	661	O
/	-	662	O
day	-	663	O
by	-	667	O
gavages	-	670	O
)	-	677	O
for	-	679	O
6	-	683	O
weeks	-	685	O
and	-	691	O
group	-	695	O
ADR	-	701	O
+	-	704	O
LOS	-	705	O
(	-	708	O
12	-	709	O
)	-	711	O
for	-	713	O
12	-	717	O
weeks	-	720	O
after	-	726	O
second	-	732	O
injection	-	739	O
of	-	749	O
ADR	-	752	O
.	-	755	O

Animals	18987260	757	O
were	-	765	O
killed	-	770	O
after	-	777	O
6	-	783	O
or	-	785	O
12	-	788	O
weeks	-	791	O
,	-	796	O
respectively	-	798	O
.	-	810	O

Haemodynamic	18987260	812	O
measurements	-	825	O
were	-	838	O
performed	-	843	O
on	-	853	O
anaesthetized	-	856	O
animals	-	870	O
,	-	877	O
blood	-	879	O
and	-	885	O
urine	-	889	O
samples	-	895	O
were	-	903	O
taken	-	908	O
for	-	914	O
biochemical	-	918	O
analysis	-	930	O
and	-	939	O
the	-	943	O
left	-	947	O
kidney	-	952	O
was	-	959	O
processed	-	963	O
for	-	973	O
morphological	-	977	O
studies	-	991	O
.	-	998	O

RESULTS	18987260	1000	O
:	-	1007	O

Short	18987260	1009	O
-	-	1014	O
term	-	1015	O
losartan	-	1020	O
treatment	-	1029	O
,	-	1038	O
besides	-	1040	O
antihypertensive	-	1048	O
effect	-	1065	O
,	-	1071	O
improved	-	1073	O
glomerular	-	1082	O
filtration	-	1093	O
rate	-	1104	O
and	-	1109	O
ameliorated	-	1113	O
glomerulosclerosis	-	1125	B
resulting	-	1144	O
in	-	1154	O
decreased	-	1157	O
proteinuria	-	1167	B
.	-	1178	O

Prolonged	18987260	1180	O
treatment	-	1190	O
with	-	1200	O
losartan	-	1205	O
showed	-	1214	O
further	-	1221	O
reduction	-	1229	O
of	-	1239	O
glomerulosclerosis	-	1242	B
associated	-	1261	O
with	-	1272	O
reduced	-	1277	O
progression	-	1285	O
of	-	1297	O
tubular	-	1300	O
atrophy	-	1308	B
and	-	1316	O
interstitial	-	1320	B
fibrosis	-	1333	I
,	-	1341	O
thus	-	1343	O
preventing	-	1348	O
heavy	-	1359	O
proteinuria	-	1365	B
and	-	1377	O
chronic	-	1381	B
renal	-	1389	I
failure	-	1395	I
.	-	1402	O

Losartan	18987260	1404	O
reduced	-	1413	O
uraemia	-	1421	B
and	-	1429	O
increased	-	1433	O
urea	-	1443	O
clearance	-	1448	O
in	-	1458	O
advanced	-	1461	O
ADR	-	1470	O
nephropathy	-	1474	B
in	-	1486	O
SHR	-	1489	O
.	-	1492	O

Histological	18987260	1494	O
examination	-	1507	O
showed	-	1519	O
that	-	1526	O
losartan	-	1531	O
could	-	1540	O
prevent	-	1546	O
tubular	-	1554	O
atrophy	-	1562	B
,	-	1569	O
interstitial	-	1571	O
infiltration	-	1584	O
and	-	1597	O
fibrosis	-	1601	B
in	-	1610	O
ADR	-	1613	O
nephropathy	-	1617	B
.	-	1628	O

CONCLUSION	18987260	1630	O
:	-	1640	O

Losartan	18987260	1642	O
reduces	-	1651	O
the	-	1659	O
rate	-	1663	O
of	-	1668	O
progression	-	1671	O
of	-	1683	O
ADR	-	1686	O
-	-	1689	O
induced	-	1690	O
focal	-	1698	B
segmental	-	1704	I
glomerulosclerosis	-	1714	I
to	-	1733	O
end	-	1736	B
-	-	1739	I
stage	-	1740	I
renal	-	1746	I
disease	-	1752	I
in	-	1760	O
SHR	-	1763	O
.	-	1766	O

The	19020118	0	O
risks	-	4	O
of	-	10	O
aprotinin	-	13	O
and	-	23	O
tranexamic	-	27	O
acid	-	38	O
in	-	43	O
cardiac	-	46	O
surgery	-	54	O
:	-	61	O
a	-	63	O
one	-	65	O
-	-	68	O
year	-	69	O
follow	-	74	O
-	-	80	O
up	-	81	O
of	-	84	O
1188	-	87	O
consecutive	-	92	O
patients	-	104	O
.	-	112	O

BACKGROUND	19020118	114	O
:	-	124	O

Our	19020118	126	O
aim	-	130	O
was	-	134	O
to	-	138	O
investigate	-	141	O
postoperative	-	153	O
complications	-	167	O
and	-	181	O
mortality	-	185	O
after	-	195	O
administration	-	201	O
of	-	216	O
aprotinin	-	219	O
compared	-	229	O
to	-	238	O
tranexamic	-	241	O
acid	-	252	O
in	-	257	O
an	-	260	O
unselected	-	263	O
,	-	273	O
consecutive	-	275	O
cohort	-	287	O
.	-	293	O

METHODS	19020118	295	O
:	-	302	O

Perioperative	19020118	304	O
data	-	318	O
from	-	323	O
consecutive	-	328	O
cardiac	-	340	O
surgery	-	348	O
patients	-	356	O
were	-	365	O
prospectively	-	370	O
collected	-	384	O
between	-	394	O
September	-	402	O
2005	-	412	O
and	-	417	O
June	-	421	O
2006	-	426	O
in	-	431	O
a	-	434	O
university	-	436	O
-	-	446	O
affiliated	-	447	O
clinic	-	458	O
(	-	465	O
n	-	466	O
=	-	468	O
1188	-	470	O
)	-	474	O
.	-	475	O

During	19020118	477	O
the	-	484	O
first	-	488	O
5	-	494	O
mo	-	496	O
,	-	498	O
596	-	500	O
patients	-	504	O
received	-	513	O
aprotinin	-	522	O
(	-	532	O
Group	-	533	O
A	-	539	O
)	-	540	O
;	-	541	O
in	-	543	O
the	-	546	O
next	-	550	O
5	-	555	O
mo	-	557	O
,	-	559	O
592	-	561	O
patients	-	565	O
were	-	574	O
treated	-	579	O
with	-	587	O
tranexamic	-	592	O
acid	-	603	O
(	-	608	O
Group	-	609	O
T	-	615	O
)	-	616	O
.	-	617	O

Except	19020118	619	O
for	-	626	O
antifibrinolytic	-	630	O
therapy	-	647	O
,	-	654	O
the	-	656	O
anesthetic	-	660	O
and	-	671	O
surgical	-	675	O
protocols	-	684	O
remained	-	694	O
unchanged	-	703	O
.	-	712	O

RESULTS	19020118	714	O
:	-	721	O

The	19020118	723	O
pre	-	727	O
-	-	730	O
and	-	732	O
intraoperative	-	736	O
variables	-	751	O
were	-	761	O
comparable	-	766	O
between	-	777	O
the	-	785	O
treatment	-	789	O
groups	-	799	O
.	-	805	O

Postoperatively	19020118	807	O
,	-	822	O
a	-	824	O
significantly	-	826	O
higher	-	840	O
incidence	-	847	O
of	-	857	O
seizures	-	860	B
was	-	869	O
found	-	873	O
in	-	879	O
Group	-	882	O
T	-	888	O
(	-	890	O
4	-	891	O
.	-	892	O
6	-	893	O
%	-	894	O
vs	-	896	O
1	-	899	O
.	-	900	O
2	-	901	O
%	-	902	O
,	-	903	O
P	-	905	O
<	-	907	O
0	-	909	O
.	-	910	O
001	-	911	O
)	-	914	O
.	-	915	O

This	19020118	917	O
difference	-	922	O
was	-	933	O
also	-	937	O
significant	-	942	O
in	-	954	O
the	-	957	O
primary	-	961	O
valve	-	969	O
surgery	-	975	O
and	-	983	O
the	-	987	O
high	-	991	O
risk	-	996	O
surgery	-	1001	O
subgroups	-	1009	O
(	-	1019	O
7	-	1020	O
.	-	1021	O
9	-	1022	O
%	-	1023	O
vs	-	1025	O
1	-	1028	O
.	-	1029	O
2	-	1030	O
%	-	1031	O
,	-	1032	O
P	-	1034	O
=	-	1036	O
0	-	1038	O
.	-	1039	O
003	-	1040	O
;	-	1043	O
7	-	1045	O
.	-	1046	O
3	-	1047	O
%	-	1048	O
vs	-	1050	O
2	-	1053	O
.	-	1054	O
4	-	1055	O
%	-	1056	O
,	-	1057	O
P	-	1059	O
=	-	1061	O
0	-	1063	O
.	-	1064	O
035	-	1065	O
,	-	1068	O
respectively	-	1070	O
)	-	1082	O
.	-	1083	O

Persistent	19020118	1085	O
atrial	-	1096	O
fibrillation	-	1103	O
(	-	1116	O
7	-	1117	O
.	-	1118	O
9	-	1119	O
%	-	1120	O
vs	-	1122	O
2	-	1125	O
.	-	1126	O
3	-	1127	O
%	-	1128	O
,	-	1129	O
P	-	1131	O
=	-	1133	O
0	-	1135	O
.	-	1136	O
020	-	1137	O
)	-	1140	O
and	-	1142	O
renal	-	1146	B
failure	-	1152	I
(	-	1160	O
9	-	1161	O
.	-	1162	O
7	-	1163	O
%	-	1164	O
vs	-	1166	O
1	-	1169	O
.	-	1170	O
7	-	1171	O
%	-	1172	O
,	-	1173	O
P	-	1175	O
=	-	1177	O
0	-	1179	O
.	-	1180	O
002	-	1181	O
)	-	1184	O
were	-	1186	O
also	-	1191	O
more	-	1196	O
common	-	1201	O
in	-	1208	O
Group	-	1211	O
T	-	1217	O
,	-	1218	O
in	-	1220	O
the	-	1223	O
primary	-	1227	O
valve	-	1235	O
surgery	-	1241	O
subgroup	-	1249	O
.	-	1257	O

On	19020118	1259	O
the	-	1262	O
contrary	-	1266	O
,	-	1274	O
among	-	1276	O
primary	-	1282	O
coronary	-	1290	O
artery	-	1299	O
bypass	-	1306	O
surgery	-	1313	O
patients	-	1321	O
,	-	1329	O
there	-	1331	O
were	-	1337	O
more	-	1342	O
acute	-	1347	O
myocardial	-	1353	B
infarctions	-	1364	I
and	-	1376	O
renal	-	1380	B
dysfunction	-	1386	I
in	-	1398	O
Group	-	1401	O
A	-	1407	O
(	-	1409	O
5	-	1410	O
.	-	1411	O
8	-	1412	O
%	-	1413	O
vs	-	1415	O
2	-	1418	O
.	-	1419	O
0	-	1420	O
%	-	1421	O
,	-	1422	O
P	-	1424	O
=	-	1426	O
0	-	1428	O
.	-	1429	O
027	-	1430	O
;	-	1433	O
22	-	1435	O
.	-	1437	O
5	-	1438	O
%	-	1439	O
vs	-	1441	O
15	-	1444	O
.	-	1446	O
2	-	1447	O
%	-	1448	O
,	-	1449	O
P	-	1451	O
=	-	1453	O
0	-	1455	O
.	-	1456	O
036	-	1457	O
,	-	1460	O
respectively	-	1462	O
)	-	1474	O
.	-	1475	O

The	19020118	1477	O
1	-	1481	O
-	-	1482	O
yr	-	1483	O
mortality	-	1486	O
was	-	1496	O
significantly	-	1500	O
higher	-	1514	O
after	-	1521	O
aprotinin	-	1527	O
treatment	-	1537	O
in	-	1547	O
the	-	1550	O
high	-	1554	O
risk	-	1559	O
surgery	-	1564	O
group	-	1572	O
(	-	1578	O
17	-	1579	O
.	-	1581	O
7	-	1582	O
%	-	1583	O
vs	-	1585	O
9	-	1588	O
.	-	1589	O
8	-	1590	O
%	-	1591	O
,	-	1592	O
P	-	1594	O
=	-	1596	O
0	-	1598	O
.	-	1599	O
034	-	1600	O
)	-	1603	O
.	-	1604	O

CONCLUSION	19020118	1606	O
:	-	1616	O

Both	19020118	1618	O
antifibrinolytic	-	1623	O
drugs	-	1640	O
bear	-	1646	O
the	-	1651	O
risk	-	1655	O
of	-	1660	O
adverse	-	1663	O
outcome	-	1671	O
depending	-	1679	O
on	-	1689	O
the	-	1692	O
type	-	1696	O
of	-	1701	O
cardiac	-	1704	O
surgery	-	1712	O
.	-	1719	O

Administration	19020118	1721	O
of	-	1736	O
aprotinin	-	1739	O
should	-	1749	O
be	-	1756	O
avoided	-	1759	O
in	-	1767	O
coronary	-	1770	O
artery	-	1779	O
bypass	-	1786	O
graft	-	1793	O
and	-	1799	O
high	-	1803	O
risk	-	1808	O
patients	-	1813	O
,	-	1821	O
whereas	-	1823	O
administration	-	1831	O
of	-	1846	O
tranexamic	-	1849	O
acid	-	1860	O
is	-	1865	O
not	-	1868	O
recommended	-	1872	O
in	-	1884	O
valve	-	1887	O
surgery	-	1893	O
.	-	1900	O

The	19108278	0	O
biological	-	4	O
properties	-	15	O
of	-	26	O
the	-	29	O
optical	-	33	O
isomers	-	41	O
of	-	49	O
propranolol	-	52	O
and	-	64	O
their	-	68	O
effects	-	74	O
on	-	82	O
cardiac	-	85	B
arrhythmias	-	93	I
.	-	104	O

1	19108278	106	O
.	-	107	O

The	19108278	109	O
optical	-	113	O
isomers	-	121	O
of	-	129	O
propranolol	-	132	O
have	-	144	O
been	-	149	O
compared	-	154	O
for	-	163	O
their	-	167	O
beta	-	173	O
-	-	177	O
blocking	-	178	O
and	-	187	O
antiarrhythmic	-	191	O
activities	-	206	O
.	-	216	O
2	-	217	O
.	-	218	O

In	19108278	220	O
blocking	-	223	O
the	-	232	O
positive	-	236	O
inotropic	-	245	O
and	-	255	O
chronotropic	-	259	O
responses	-	272	O
to	-	282	O
isoprenaline	-	285	O
,	-	297	O
(	-	299	O
+	-	300	O
)	-	301	O
-	-	302	O
propranolol	-	303	O
had	-	315	O
less	-	319	O
than	-	324	O
one	-	329	O
hundredth	-	333	O
the	-	343	O
potency	-	347	O
of	-	355	O
(	-	358	O
-	-	359	O
)	-	360	O
-	-	361	O
propranolol	-	362	O
.	-	373	O

At	19108278	375	O
dose	-	378	O
levels	-	383	O
of	-	390	O
(	-	393	O
+	-	394	O
)	-	395	O
-	-	396	O
propranolol	-	397	O
which	-	409	O
attenuated	-	415	O
the	-	426	O
responses	-	430	O
to	-	440	O
isoprenaline	-	443	O
,	-	455	O
there	-	457	O
was	-	463	O
a	-	467	O
significant	-	469	O
prolongation	-	481	O
of	-	494	O
the	-	497	O
PR	-	501	O
interval	-	504	O
of	-	513	O
the	-	516	O
electrocardiogram	-	520	O
.	-	537	O
3	-	538	O
.	-	539	O

The	19108278	541	O
metabolic	-	545	O
responses	-	555	O
to	-	565	O
isoprenaline	-	568	O
in	-	581	O
dogs	-	584	O
(	-	589	O
an	-	590	O
increase	-	593	O
in	-	602	O
circulating	-	605	O
glucose	-	617	O
,	-	624	O
lactate	-	626	O
and	-	634	O
free	-	638	O
fatty	-	643	O
acids	-	649	O
)	-	654	O
were	-	656	O
all	-	661	O
blocked	-	665	O
by	-	673	O
(	-	676	O
-	-	677	O
)	-	678	O
-	-	679	O
propranolol	-	680	O
.	-	691	O

(	19108278	693	O
+	-	694	O
)	-	695	O
-	-	696	O
Propranolol	-	697	O
had	-	709	O
no	-	713	O
effect	-	716	O
on	-	723	O
fatty	-	726	O
acid	-	732	O
mobilization	-	737	O
but	-	750	O
significantly	-	754	O
reduced	-	768	O
the	-	776	O
increments	-	780	O
in	-	791	O
both	-	794	O
lactate	-	799	O
and	-	807	O
glucose	-	811	O
.	-	818	O
4	-	819	O
.	-	820	O

Both	19108278	822	O
isomers	-	827	O
of	-	835	O
propranolol	-	838	O
possessed	-	850	O
similar	-	860	O
depressant	-	868	O
potency	-	879	O
on	-	887	O
isolated	-	890	O
atrial	-	899	O
muscle	-	906	O
taken	-	913	O
from	-	919	O
guinea	-	924	O
-	-	930	O
pigs	-	931	O
.	-	935	O
5	-	936	O
.	-	937	O

The	19108278	939	O
isomers	-	943	O
of	-	951	O
propranolol	-	954	O
exhibited	-	966	O
similar	-	976	O
local	-	984	O
anaesthetic	-	990	O
potencies	-	1002	O
on	-	1012	O
an	-	1015	O
isolated	-	1018	O
frog	-	1027	O
nerve	-	1032	O
preparation	-	1038	O
at	-	1050	O
a	-	1053	O
level	-	1055	O
approximately	-	1061	O
three	-	1075	O
times	-	1081	O
that	-	1087	O
of	-	1092	O
procaine	-	1095	O
.	-	1103	O

The	19108278	1105	O
racemic	-	1109	O
compound	-	1117	O
was	-	1126	O
significantly	-	1130	O
less	-	1144	O
potent	-	1149	O
than	-	1156	O
either	-	1161	O
isomer	-	1168	O
.	-	1174	O
6	-	1175	O
.	-	1176	O

Both	19108278	1178	O
isomers	-	1183	O
of	-	1191	O
propranolol	-	1194	O
were	-	1206	O
capable	-	1211	O
of	-	1219	O
preventing	-	1222	O
adrenaline	-	1233	O
-	-	1243	O
induced	-	1244	O
cardiac	-	1252	B
arrhythmias	-	1260	I
in	-	1272	O
cats	-	1275	O
anaesthetized	-	1280	O
with	-	1294	O
halothane	-	1299	O
,	-	1308	O
but	-	1310	O
the	-	1314	O
mean	-	1318	O
dose	-	1323	O
of	-	1328	O
(	-	1331	O
-	-	1332	O
)	-	1333	O
-	-	1334	O
propranolol	-	1335	O
was	-	1347	O
0	-	1351	O
.	-	1352	O
09	-	1353	O
+	-	1355	O
/	-	1356	O
-	-	1357	O
0	-	1358	O
.	-	1359	O
02	-	1360	O
mg	-	1363	O
/	-	1365	O
kg	-	1366	O
whereas	-	1369	O
that	-	1377	O
of	-	1382	O
(	-	1385	O
+	-	1386	O
)	-	1387	O
-	-	1388	O
propranolol	-	1389	O
was	-	1401	O
4	-	1405	O
.	-	1406	O
2	-	1407	O
+	-	1408	O
/	-	1409	O
-	-	1410	O
1	-	1411	O
.	-	1412	O
2	-	1413	O
mg	-	1415	O
/	-	1417	O
kg	-	1418	O
.	-	1420	O

At	19108278	1422	O
the	-	1425	O
effective	-	1429	O
dose	-	1439	O
level	-	1444	O
of	-	1450	O
(	-	1453	O
+	-	1454	O
)	-	1455	O
-	-	1456	O
propranolol	-	1457	O
there	-	1469	O
was	-	1475	O
a	-	1479	O
significant	-	1481	O
prolongation	-	1493	O
of	-	1506	O
the	-	1509	O
PR	-	1513	O
interval	-	1516	O
of	-	1525	O
the	-	1528	O
electrocardiogram	-	1532	O
.	-	1549	O

Blockade	19108278	1551	O
of	-	1560	O
arrhythmias	-	1563	B
with	-	1575	O
both	-	1580	O
isomers	-	1585	O
was	-	1593	O
surmountable	-	1597	O
by	-	1610	O
increasing	-	1613	O
the	-	1624	O
dose	-	1628	O
of	-	1633	O
adrenaline	-	1636	O
.	-	1646	O
7	-	1647	O
.	-	1648	O

Both	19108278	1650	O
isomers	-	1655	O
of	-	1663	O
propranolol	-	1666	O
were	-	1678	O
also	-	1683	O
capable	-	1688	O
of	-	1696	O
reversing	-	1699	O
ventricular	-	1709	B
tachycardia	-	1721	I
caused	-	1733	O
by	-	1740	O
ouabain	-	1743	O
in	-	1751	O
anaesthetized	-	1754	O
cats	-	1768	O
and	-	1773	O
dogs	-	1777	O
.	-	1781	O

The	19108278	1783	O
dose	-	1787	O
of	-	1792	O
(	-	1795	O
-	-	1796	O
)	-	1797	O
-	-	1798	O
propranolol	-	1799	O
was	-	1811	O
significantly	-	1815	O
smaller	-	1829	O
than	-	1837	O
that	-	1842	O
of	-	1847	O
(	-	1850	O
+	-	1851	O
)	-	1852	O
-	-	1853	O
propranolol	-	1854	O
in	-	1866	O
both	-	1869	O
species	-	1874	O
but	-	1882	O
much	-	1886	O
higher	-	1891	O
than	-	1898	O
that	-	1903	O
required	-	1908	O
to	-	1917	O
produce	-	1920	O
evidence	-	1928	O
of	-	1937	O
beta	-	1940	O
-	-	1944	O
blockade	-	1945	O
.	-	1953	O
8	-	1954	O
.	-	1955	O

The	19108278	1957	O
implications	-	1961	O
of	-	1974	O
these	-	1977	O
results	-	1983	O
are	-	1991	O
discussed	-	1995	O
.	-	2004	O

Topotecan	19139825	0	O
in	-	10	O
combination	-	13	O
with	-	25	O
radiotherapy	-	30	O
in	-	43	O
unresectable	-	46	O
glioblastoma	-	59	B
:	-	71	O
a	-	73	O
phase	-	75	O
2	-	81	O
study	-	83	O
.	-	88	O

Improving	19139825	90	O
glioblastoma	-	100	B
multiforme	-	113	I
(	-	124	O
GBM	-	125	B
)	-	128	O
treatment	-	130	O
with	-	140	O
radio	-	145	O
-	-	150	O
chemotherapy	-	151	O
remains	-	164	O
a	-	172	O
challenge	-	174	O
.	-	183	O

Topotecan	19139825	185	O
is	-	195	O
an	-	198	O
attractive	-	201	O
option	-	212	O
as	-	219	O
it	-	222	O
exhibits	-	225	O
growth	-	234	O
inhibition	-	241	O
of	-	252	O
human	-	255	O
glioma	-	261	B
as	-	268	O
well	-	271	O
as	-	276	O
brain	-	279	O
penetration	-	285	O
.	-	296	O

The	19139825	298	O
present	-	302	O
study	-	310	O
assessed	-	316	O
the	-	325	O
combination	-	329	O
of	-	341	O
radiotherapy	-	344	O
(	-	357	O
60	-	358	O
Gy	-	361	O
/	-	363	O
30	-	364	O
fractions	-	367	O
/	-	376	O
40	-	377	O
days	-	380	O
)	-	384	O
and	-	386	O
topotecan	-	390	O
(	-	400	O
0	-	401	O
.	-	402	O
9	-	403	O
mg	-	405	O
/	-	407	O
m	-	408	O
(	-	409	O
2	-	410	O
)	-	411	O
/	-	412	O
day	-	413	O
on	-	417	O
days	-	420	O
1	-	425	O
-	-	426	O
5	-	427	O
on	-	429	O
weeks	-	432	O
1	-	438	O
,	-	439	O
3	-	441	O
and	-	443	O
5	-	447	O
)	-	448	O
in	-	450	O
50	-	453	O
adults	-	456	O
with	-	463	O
histologically	-	468	O
proven	-	483	O
and	-	490	O
untreated	-	494	O
GBM	-	504	B
.	-	507	O

The	19139825	509	O
incidence	-	513	O
of	-	523	O
non	-	526	O
-	-	529	O
hematological	-	530	O
toxicities	-	544	B
was	-	555	O
low	-	559	O
and	-	563	O
grade	-	567	O
3	-	573	O
-	-	574	O
4	-	575	O
hematological	-	577	O
toxicities	-	591	B
were	-	602	O
reported	-	607	O
in	-	616	O
20	-	619	O
patients	-	622	O
(	-	631	O
mainly	-	632	O
lymphopenia	-	639	B
and	-	651	O
neutropenia	-	655	B
)	-	666	O
.	-	667	O

Partial	19139825	669	O
response	-	677	O
and	-	686	O
stabilization	-	690	O
rates	-	704	O
were	-	710	O
2	-	715	O
%	-	716	O
and	-	718	O
32	-	722	O
%	-	724	O
,	-	725	O
respectively	-	727	O
,	-	739	O
with	-	741	O
an	-	746	O
overall	-	749	O
time	-	757	O
to	-	762	O
progression	-	765	O
of	-	777	O
12	-	780	O
weeks	-	783	O
.	-	788	O

One	19139825	790	O
-	-	793	O
year	-	794	O
overall	-	799	O
survival	-	807	O
(	-	816	O
OS	-	817	O
)	-	819	O
rate	-	821	O
was	-	826	O
42	-	830	O
%	-	832	O
,	-	833	O
with	-	835	O
a	-	840	O
median	-	842	O
OS	-	849	O
of	-	852	O
40	-	855	O
weeks	-	858	O
.	-	863	O

Topotecan	19139825	865	O
in	-	875	O
combination	-	878	O
with	-	890	O
radiotherapy	-	895	O
was	-	908	O
well	-	912	O
tolerated	-	917	O
.	-	926	O

However	19139825	928	O
,	-	935	O
while	-	937	O
response	-	943	O
and	-	952	O
stabilization	-	956	O
concerned	-	970	O
one	-	980	O
-	-	983	O
third	-	984	O
of	-	990	O
the	-	993	O
patients	-	997	O
,	-	1005	O
the	-	1007	O
study	-	1011	O
did	-	1017	O
not	-	1021	O
show	-	1025	O
increased	-	1030	O
benefits	-	1040	O
in	-	1049	O
terms	-	1052	O
of	-	1058	O
survival	-	1061	O
in	-	1070	O
patients	-	1073	O
with	-	1082	O
unresectable	-	1087	O
GBM	-	1100	B
.	-	1103	O

Long	19154241	0	O
-	-	4	O
term	-	5	O
lithium	-	10	O
therapy	-	18	O
leading	-	26	O
to	-	34	O
hyperparathyroidism	-	37	B
:	-	56	O
a	-	58	O
case	-	60	O
report	-	65	O
.	-	71	O

PURPOSE	19154241	73	O
:	-	80	O

This	19154241	82	O
paper	-	87	O
reviews	-	93	O
the	-	101	O
effect	-	105	O
of	-	112	O
chronic	-	115	O
lithium	-	123	O
therapy	-	131	O
on	-	139	O
serum	-	142	O
calcium	-	148	O
level	-	156	O
and	-	162	O
parathyroid	-	166	O
glands	-	178	O
,	-	184	O
its	-	186	O
pathogenesis	-	190	O
,	-	202	O
and	-	204	O
treatment	-	208	O
options	-	218	O
.	-	225	O

We	19154241	227	O
examined	-	230	O
the	-	239	O
case	-	243	O
of	-	248	O
a	-	251	O
lithium	-	253	O
-	-	260	O
treated	-	261	O
patient	-	269	O
who	-	277	O
had	-	281	O
recurrent	-	285	O
hypercalcemia	-	295	B
to	-	309	O
better	-	312	O
understand	-	319	O
the	-	330	O
disease	-	334	O
process	-	342	O
.	-	349	O

CONCLUSION	19154241	351	O
:	-	361	O

Primary	19154241	363	B
hyperparathyroidism	-	371	I
is	-	391	O
a	-	394	O
rare	-	396	O
but	-	401	O
potentially	-	405	O
life	-	417	O
-	-	421	O
threatening	-	422	O
side	-	434	O
effect	-	439	O
of	-	446	O
long	-	449	O
-	-	453	O
term	-	454	O
lithium	-	459	O
therapy	-	467	O
.	-	474	O

Careful	19154241	476	O
patient	-	484	O
selection	-	492	O
and	-	502	O
long	-	506	O
-	-	510	O
term	-	511	O
follow	-	516	O
-	-	522	O
up	-	523	O
can	-	526	O
reduce	-	530	O
morbidity	-	537	O
.	-	546	O

PRACTICAL	19154241	548	O
IMPLICATIONS	-	558	O
:	-	570	O

As	19154241	572	O
much	-	575	O
as	-	580	O
15	-	583	O
%	-	585	O
of	-	587	O
lithium	-	590	O
-	-	597	O
treated	-	598	O
patients	-	606	O
become	-	615	O
hypercalcemic	-	622	B
.	-	635	O

By	19154241	637	O
routinely	-	640	O
monitoring	-	650	O
serum	-	661	O
calcium	-	667	O
levels	-	675	O
,	-	681	O
healthcare	-	683	O
providers	-	694	O
can	-	704	O
improve	-	708	O
the	-	716	O
quality	-	720	O
of	-	728	O
life	-	731	O
of	-	736	O
this	-	739	O
patient	-	744	O
group	-	752	O
.	-	757	O

Comparison	19178808	0	O
of	-	11	O
laryngeal	-	14	O
mask	-	24	O
with	-	29	O
endotracheal	-	34	O
tube	-	47	O
for	-	52	O
anesthesia	-	56	O
in	-	67	O
endoscopic	-	70	O
sinus	-	81	O
surgery	-	87	O
.	-	94	O

BACKGROUND	19178808	96	O
:	-	106	O

The	19178808	108	O
purpose	-	112	O
of	-	120	O
this	-	123	O
study	-	128	O
was	-	134	O
to	-	138	O
compare	-	141	O
surgical	-	149	O
conditions	-	158	O
,	-	168	O
including	-	170	O
the	-	180	O
amount	-	184	O
of	-	191	O
intraoperative	-	194	O
bleeding	-	209	B
as	-	218	O
well	-	221	O
as	-	226	O
intraoperative	-	229	O
blood	-	244	O
pressure	-	250	O
,	-	258	O
during	-	260	O
functional	-	267	O
endoscopic	-	278	O
sinus	-	289	O
surgery	-	295	O
(	-	303	O
FESS	-	304	O
)	-	308	O
using	-	310	O
flexible	-	316	O
reinforced	-	325	O
laryngeal	-	336	O
mask	-	346	O
airway	-	351	O
(	-	358	O
FRLMA	-	359	O
)	-	364	O
versus	-	366	O
endotracheal	-	373	O
tube	-	386	O
(	-	391	O
ETT	-	392	O
)	-	395	O
in	-	397	O
maintaining	-	400	O
controlled	-	412	O
hypotension	-	423	B
anesthesia	-	435	O
induced	-	446	O
by	-	454	O
propofol	-	457	O
-	-	465	O
remifentanil	-	466	O
total	-	479	O
i	-	485	O
.	-	486	O
v	-	487	O
.	-	488	O

anesthesia	19178808	490	O
(	-	501	O
TIVA	-	502	O
)	-	506	O
.	-	507	O

METHODS	19178808	509	O
:	-	516	O

Sixty	19178808	518	O
normotensive	-	524	O
American	-	537	O
Society	-	546	O
of	-	554	O
Anesthesiologists	-	557	O
I	-	575	O
-	-	576	O
II	-	577	O
adult	-	580	O
patients	-	586	O
undergoing	-	595	O
FESS	-	606	O
under	-	611	O
controlled	-	617	O
hypotension	-	628	B
anesthesia	-	640	O
caused	-	651	O
by	-	658	O
propofol	-	661	O
-	-	669	O
remifentanil	-	670	O
-	-	682	O
TIVA	-	683	O
were	-	688	O
randomly	-	693	O
assigned	-	702	O
into	-	711	O
two	-	716	O
groups	-	720	O
:	-	726	O
group	-	728	O
I	-	734	O
,	-	735	O
FRLMA	-	737	O
;	-	742	O
group	-	744	O
II	-	750	O
,	-	752	O
ETT	-	754	O
.	-	757	O

Hemorrhage	19178808	759	B
was	-	770	O
measured	-	774	O
and	-	783	O
the	-	787	O
visibility	-	791	O
of	-	802	O
the	-	805	O
operative	-	809	O
field	-	819	O
was	-	825	O
evaluated	-	829	O
according	-	839	O
to	-	849	O
a	-	852	O
six	-	854	O
-	-	857	O
point	-	858	O
scale	-	864	O
.	-	869	O

RESULTS	19178808	871	O
:	-	878	O

Controlled	19178808	880	O
hypotension	-	891	B
was	-	903	O
achieved	-	907	O
within	-	916	O
a	-	923	O
shorter	-	925	O
period	-	933	O
using	-	940	O
laryngeal	-	946	O
mask	-	956	O
using	-	961	O
lower	-	967	O
rates	-	973	O
of	-	979	O
remifentanil	-	982	O
infusion	-	995	O
and	-	1004	O
lower	-	1008	O
total	-	1014	O
dose	-	1020	O
of	-	1025	O
remifentanil	-	1028	O
.	-	1040	O

CONCLUSION	19178808	1042	O
:	-	1052	O

In	19178808	1054	O
summary	-	1057	O
,	-	1064	O
our	-	1066	O
results	-	1070	O
indicate	-	1078	O
that	-	1087	O
airway	-	1092	O
management	-	1099	O
using	-	1110	O
FRLMA	-	1116	O
during	-	1122	O
controlled	-	1129	O
hypotension	-	1140	B
anesthesia	-	1152	O
provided	-	1163	O
better	-	1172	O
surgical	-	1179	O
conditions	-	1188	O
in	-	1199	O
terms	-	1202	O
of	-	1208	O
quality	-	1211	O
of	-	1219	O
operative	-	1222	O
field	-	1232	O
and	-	1238	O
blood	-	1242	O
loss	-	1248	O
and	-	1253	O
allowed	-	1257	O
for	-	1265	O
convenient	-	1269	O
induced	-	1280	O
hypotension	-	1288	B
with	-	1300	O
low	-	1305	O
doses	-	1309	O
of	-	1315	O
remifentanil	-	1318	O
during	-	1331	O
TIVA	-	1338	O
in	-	1343	O
patients	-	1346	O
undergoing	-	1355	O
FESS	-	1366	O
.	-	1370	O

Nonalcoholic	19184102	0	B
fatty	-	13	I
liver	-	19	I
disease	-	25	I
during	-	33	O
valproate	-	40	O
therapy	-	50	O
.	-	57	O

Valproic	19184102	59	O
acid	-	68	O
(	-	73	O
VPA	-	74	O
)	-	77	O
is	-	79	O
effective	-	82	O
for	-	92	O
the	-	96	O
treatment	-	100	O
of	-	110	O
many	-	113	O
types	-	118	O
of	-	124	O
epilepsy	-	127	B
,	-	135	O
but	-	137	O
its	-	141	O
use	-	145	O
can	-	149	O
be	-	153	O
associated	-	156	O
with	-	167	O
an	-	172	O
increase	-	175	O
in	-	184	O
body	-	187	O
weight	-	192	O
.	-	198	O

We	19184102	200	O
report	-	203	O
a	-	210	O
case	-	212	O
of	-	217	O
nonalcoholic	-	220	B
fatty	-	233	I
liver	-	239	I
disease	-	245	I
(	-	253	O
NAFLD	-	254	B
)	-	259	O
arising	-	261	O
in	-	269	O
a	-	272	O
child	-	274	O
who	-	280	O
developed	-	284	O
obesity	-	294	B
during	-	302	O
VPA	-	309	O
treatment	-	313	O
.	-	322	O

Laboratory	19184102	324	O
data	-	335	O
revealed	-	340	O
hyperinsulinemia	-	349	B
with	-	366	O
insulin	-	371	B
resistance	-	379	I
.	-	389	O

After	19184102	391	O
the	-	397	O
withdrawal	-	401	O
of	-	412	O
VPA	-	415	O
therapy	-	419	O
,	-	426	O
our	-	428	O
patient	-	432	O
showed	-	440	O
a	-	447	O
significant	-	449	O
weight	-	461	B
loss	-	468	I
,	-	472	O
a	-	474	O
decrease	-	476	O
of	-	485	O
body	-	488	O
mass	-	493	O
index	-	498	O
,	-	503	O
and	-	505	O
normalization	-	509	O
of	-	523	O
metabolic	-	526	O
and	-	536	O
endocrine	-	540	O
parameters	-	550	O
;	-	560	O
moreover	-	562	O
,	-	570	O
ultrasound	-	572	O
measurements	-	583	O
showed	-	596	O
a	-	603	O
complete	-	605	O
normalization	-	614	O
.	-	627	O

The	19184102	629	O
present	-	633	O
case	-	641	O
suggests	-	646	O
that	-	655	O
obesity	-	660	B
,	-	667	O
hyperinsulinemia	-	669	B
,	-	685	O
insulin	-	687	B
resistance	-	695	I
,	-	705	O
and	-	707	O
long	-	711	O
-	-	715	O
term	-	716	O
treatment	-	721	O
with	-	731	O
VPA	-	736	O
may	-	740	O
be	-	744	O
all	-	747	O
associated	-	751	O
with	-	762	O
the	-	767	O
development	-	771	O
of	-	783	O
NAFLD	-	786	B
;	-	791	O
this	-	793	O
side	-	798	O
effect	-	803	O
is	-	810	O
reversible	-	813	O
after	-	824	O
VPA	-	830	O
withdrawal	-	834	O
.	-	844	O

Carbimazole	19263707	0	O
induced	-	12	O
ANCA	-	20	B
positive	-	25	I
vasculitis	-	34	I
.	-	44	O

Anti	19263707	46	O
-	-	50	O
thyroid	-	51	O
drugs	-	59	O
,	-	64	O
like	-	66	O
carbimazole	-	71	O
and	-	83	O
propylthiouracil	-	87	O
(	-	104	O
PTU	-	105	O
)	-	108	O
are	-	110	O
commonly	-	114	O
prescribed	-	123	O
for	-	134	O
the	-	138	O
treatment	-	142	O
of	-	152	O
hyperthyroidism	-	155	B
.	-	170	O

One	19263707	172	O
should	-	176	O
be	-	183	O
aware	-	186	O
of	-	192	O
the	-	195	O
side	-	199	O
effects	-	204	O
of	-	212	O
antithyroid	-	215	O
medications	-	227	O
.	-	238	O

Antineutrophil	19263707	240	B
cytoplasmic	-	255	I
antibody	-	267	I
(	-	276	I
ANCA	-	277	I
)	-	281	I
-	-	282	I
-	-	283	I
associated	-	284	I
vasculitis	-	295	I
is	-	306	O
a	-	309	O
potentially	-	311	O
life	-	323	O
-	-	327	O
threatening	-	328	O
adverse	-	340	O
effect	-	348	O
of	-	355	O
antithyroidmedications	-	358	O
.	-	380	O

We	19263707	382	O
report	-	385	O
a	-	392	O
patient	-	394	O
with	-	402	O
Graves	-	407	B
'	-	413	I
disease	-	415	I
who	-	423	O
developed	-	427	O
ANCA	-	437	O
positive	-	442	O
carbimazole	-	451	O
induced	-	463	O
vasculitis	-	471	B
.	-	481	O

The	19263707	483	O
episode	-	487	O
was	-	495	O
characterized	-	499	O
by	-	513	O
a	-	516	O
vasculitic	-	518	B
skin	-	529	B
rash	-	534	I
associated	-	539	O
with	-	550	O
large	-	555	O
joint	-	561	O
arthritis	-	567	B
,	-	576	O
pyrexia	-	578	B
and	-	586	O
parotiditis	-	590	B
but	-	602	O
no	-	606	O
renal	-	609	O
or	-	615	O
pulmonary	-	618	O
involvement	-	628	O
.	-	639	O

He	19263707	641	O
was	-	644	O
referred	-	648	O
to	-	657	O
us	-	660	O
for	-	663	O
neurological	-	667	O
evaluation	-	680	O
because	-	691	O
he	-	699	O
had	-	702	O
difficulty	-	706	O
in	-	717	O
getting	-	720	O
up	-	728	O
from	-	731	O
squatting	-	736	O
position	-	746	O
and	-	755	O
was	-	759	O
suspected	-	763	O
to	-	773	O
have	-	776	O
myositis	-	781	B
.	-	789	O

Carbimazole	19263707	791	O
and	-	803	O
methimazole	-	807	O
have	-	819	O
a	-	824	O
lower	-	826	O
incidence	-	832	O
of	-	842	O
reported	-	845	O
ANCA	-	854	O
positive	-	859	O
side	-	868	O
effects	-	873	O
than	-	881	O
PUT	-	886	O
.	-	889	O

To	19263707	891	O
the	-	894	O
best	-	898	O
of	-	903	O
our	-	906	O
knowledge	-	910	O
this	-	920	O
is	-	925	O
the	-	928	O
first	-	932	O
ANCA	-	938	O
positive	-	943	O
carbimazole	-	952	O
induced	-	964	O
vasculitis	-	972	B
case	-	983	O
reported	-	988	O
from	-	997	O
India	-	1002	O
.	-	1007	O

Aspirin	19293073	0	O
for	-	8	O
the	-	12	O
primary	-	16	O
prevention	-	24	O
of	-	35	O
cardiovascular	-	38	O
events	-	53	O
:	-	59	O
an	-	61	O
update	-	64	O
of	-	71	O
the	-	74	O
evidence	-	78	O
for	-	87	O
the	-	91	O
U	-	95	O
.	-	96	O
S	-	97	O
.	-	98	O
Preventive	-	100	O
Services	-	111	O
Task	-	120	O
Force	-	125	O
.	-	130	O

BACKGROUND	19293073	132	O
:	-	142	O

Coronary	19293073	144	B
heart	-	153	I
disease	-	159	I
and	-	167	O
cerebrovascular	-	171	B
disease	-	187	I
are	-	195	O
leading	-	199	O
causes	-	207	O
of	-	214	O
death	-	217	O
in	-	223	O
the	-	226	O
United	-	230	O
States	-	237	O
.	-	243	O

In	19293073	245	O
2002	-	248	O
,	-	252	O
the	-	254	O
U	-	258	O
.	-	259	O
S	-	260	O
.	-	261	O
Preventive	-	263	O
Services	-	274	O
Task	-	283	O
Force	-	288	O
(	-	294	O
USPSTF	-	295	O
)	-	301	O
strongly	-	303	O
recommended	-	312	O
that	-	324	O
clinicians	-	329	O
discuss	-	340	O
aspirin	-	348	O
with	-	356	O
adults	-	361	O
who	-	368	O
are	-	372	O
at	-	376	O
increased	-	379	O
risk	-	389	O
for	-	394	O
coronary	-	398	B
heart	-	407	I
disease	-	413	I
.	-	420	O

PURPOSE	19293073	422	O
:	-	429	O

To	19293073	431	O
determine	-	434	O
the	-	444	O
benefits	-	448	O
and	-	457	O
harms	-	461	O
of	-	467	O
taking	-	470	O
aspirin	-	477	O
for	-	485	O
the	-	489	O
primary	-	493	O
prevention	-	501	O
of	-	512	O
myocardial	-	515	B
infarctions	-	526	I
,	-	537	O
strokes	-	539	B
,	-	546	O
and	-	548	O
death	-	552	O
.	-	557	O

DATA	19293073	559	O
SOURCES	-	564	O
:	-	571	O
MEDLINE	-	573	O
and	-	581	O
Cochrane	-	585	O
Library	-	594	O
(	-	602	O
search	-	603	O
dates	-	610	O
,	-	615	O
1	-	617	O
January	-	619	O
2001	-	627	O
to	-	632	O
28	-	635	O
August	-	638	O
2008	-	645	O
)	-	649	O
,	-	650	O
recent	-	652	O
systematic	-	659	O
reviews	-	670	O
,	-	677	O
reference	-	679	O
lists	-	689	O
of	-	695	O
retrieved	-	698	O
articles	-	708	O
,	-	716	O
and	-	718	O
suggestions	-	722	O
from	-	734	O
experts	-	739	O
.	-	746	O

STUDY	19293073	748	O
SELECTION	-	754	O
:	-	763	O
English	-	765	O
-	-	772	O
language	-	773	O
randomized	-	782	O
,	-	792	O
controlled	-	794	O
trials	-	805	O
(	-	812	O
RCTs	-	813	O
)	-	817	O
;	-	818	O
case	-	820	O
-	-	824	O
control	-	825	O
studies	-	833	O
;	-	840	O
meta	-	842	O
-	-	846	O
analyses	-	847	O
;	-	855	O
and	-	857	O
systematic	-	861	O
reviews	-	872	O
of	-	880	O
aspirin	-	883	O
versus	-	891	O
control	-	898	O
for	-	906	O
the	-	910	O
primary	-	914	O
prevention	-	922	O
of	-	933	O
cardiovascular	-	936	B
disease	-	951	I
(	-	959	O
CVD	-	960	B
)	-	963	O
were	-	965	O
selected	-	970	O
to	-	979	O
answer	-	982	O
the	-	989	O
following	-	993	O
questions	-	1003	O
:	-	1012	O

Does	19293073	1014	O
aspirin	-	1019	O
decrease	-	1027	O
coronary	-	1036	O
heart	-	1045	O
events	-	1051	O
,	-	1057	O
strokes	-	1059	B
,	-	1066	O
death	-	1068	O
from	-	1074	O
coronary	-	1079	O
heart	-	1088	O
events	-	1094	O
or	-	1101	O
stroke	-	1104	B
,	-	1110	O
or	-	1112	O
all	-	1115	O
-	-	1118	O
cause	-	1119	O
mortality	-	1125	O
in	-	1135	O
adults	-	1138	O
without	-	1145	O
known	-	1153	O
CVD	-	1159	B
?	-	1162	O

Does	19293073	1164	O
aspirin	-	1169	O
increase	-	1177	O
gastrointestinal	-	1186	B
bleeding	-	1203	I
or	-	1212	O
hemorrhagic	-	1215	B
strokes	-	1227	I
?	-	1234	O

DATA	19293073	1236	O
EXTRACTION	-	1241	O
:	-	1251	O

All	19293073	1253	O
studies	-	1257	O
were	-	1265	O
reviewed	-	1270	O
,	-	1278	O
abstracted	-	1280	O
,	-	1290	O
and	-	1292	O
rated	-	1296	O
for	-	1302	O
quality	-	1306	O
by	-	1314	O
using	-	1317	O
predefined	-	1323	O
USPSTF	-	1334	O
criteria	-	1341	O
.	-	1349	O

DATA	19293073	1351	O
SYNTHESIS	-	1356	O
:	-	1365	O

New	19293073	1367	O
evidence	-	1371	O
from	-	1380	O
1	-	1385	O
good	-	1387	O
-	-	1391	O
quality	-	1392	O
RCT	-	1400	O
,	-	1403	O
1	-	1405	O
good	-	1407	O
-	-	1411	O
quality	-	1412	O
meta	-	1420	O
-	-	1424	O
analysis	-	1425	O
,	-	1433	O
and	-	1435	O
2	-	1439	O
fair	-	1441	O
-	-	1445	O
quality	-	1446	O
subanalyses	-	1454	O
of	-	1466	O
RCTs	-	1469	O
demonstrates	-	1474	O
that	-	1487	O
aspirin	-	1492	O
use	-	1500	O
reduces	-	1504	O
the	-	1512	O
number	-	1516	O
of	-	1523	O
CVD	-	1526	B
events	-	1530	O
in	-	1537	O
patients	-	1540	O
without	-	1549	O
known	-	1557	O
CVD	-	1563	B
.	-	1566	O

Men	19293073	1568	O
in	-	1572	O
these	-	1575	O
studies	-	1581	O
experienced	-	1589	O
fewer	-	1601	O
myocardial	-	1607	B
infarctions	-	1618	I
and	-	1630	O
women	-	1634	O
experienced	-	1640	O
fewer	-	1652	O
ischemic	-	1658	O
strokes	-	1667	B
.	-	1674	O

Aspirin	19293073	1676	O
does	-	1684	O
not	-	1689	O
seem	-	1693	O
to	-	1698	O
affect	-	1701	O
CVD	-	1708	B
mortality	-	1712	O
or	-	1722	O
all	-	1725	O
-	-	1728	O
cause	-	1729	O
mortality	-	1735	O
in	-	1745	O
either	-	1748	O
men	-	1755	O
or	-	1759	O
women	-	1762	O
.	-	1767	O

The	19293073	1769	O
use	-	1773	O
of	-	1777	O
aspirin	-	1780	O
for	-	1788	O
primary	-	1792	O
prevention	-	1800	O
increases	-	1811	O
the	-	1821	O
risk	-	1825	O
for	-	1830	O
major	-	1834	O
bleeding	-	1840	B
events	-	1849	O
,	-	1855	O
primarily	-	1857	O
gastrointestinal	-	1867	B
bleeding	-	1884	I
events	-	1893	O
,	-	1899	O
in	-	1901	O
both	-	1904	O
men	-	1909	O
and	-	1913	O
women	-	1917	O
.	-	1922	O

Men	19293073	1924	O
have	-	1928	O
an	-	1933	O
increased	-	1936	O
risk	-	1946	O
for	-	1951	O
hemorrhagic	-	1955	B
strokes	-	1967	I
with	-	1975	O
aspirin	-	1980	O
use	-	1988	O
.	-	1991	O

A	19293073	1993	O
new	-	1995	O
RCT	-	1999	O
and	-	2003	O
meta	-	2007	O
-	-	2011	O
analysis	-	2012	O
suggest	-	2021	O
that	-	2029	O
the	-	2034	O
risk	-	2038	O
for	-	2043	O
hemorrhagic	-	2047	B
strokes	-	2059	I
in	-	2067	O
women	-	2070	O
is	-	2076	O
not	-	2079	O
statistically	-	2083	O
significantly	-	2097	O
increased	-	2111	O
.	-	2120	O

LIMITATIONS	19293073	2122	O
:	-	2133	O

New	19293073	2135	O
evidence	-	2139	O
on	-	2148	O
aspirin	-	2151	O
for	-	2159	O
the	-	2163	O
primary	-	2167	O
prevention	-	2175	O
of	-	2186	O
CVD	-	2189	B
is	-	2193	O
limited	-	2196	O
.	-	2203	O

The	19293073	2205	O
dose	-	2209	O
of	-	2214	O
aspirin	-	2217	O
used	-	2225	O
in	-	2230	O
the	-	2233	O
RCTs	-	2237	O
varied	-	2242	O
,	-	2248	O
which	-	2250	O
prevented	-	2256	O
the	-	2266	O
estimation	-	2270	O
of	-	2281	O
the	-	2284	O
most	-	2288	O
appropriate	-	2293	O
dose	-	2305	O
for	-	2310	O
primary	-	2314	O
prevention	-	2322	O
.	-	2332	O

Several	19293073	2334	O
of	-	2342	O
the	-	2345	O
RCTs	-	2349	O
were	-	2354	O
conducted	-	2359	O
within	-	2369	O
populations	-	2376	O
of	-	2388	O
health	-	2391	O
professionals	-	2398	O
,	-	2411	O
which	-	2413	O
potentially	-	2419	O
limits	-	2431	O
generalizability	-	2438	O
.	-	2454	O

CONCLUSION	19293073	2456	O
:	-	2466	O

Aspirin	19293073	2468	O
reduces	-	2476	O
the	-	2484	O
risk	-	2488	O
for	-	2493	O
myocardial	-	2497	B
infarction	-	2508	I
in	-	2519	O
men	-	2522	O
and	-	2526	O
strokes	-	2530	B
in	-	2538	O
women	-	2541	O
.	-	2546	O

Aspirin	19293073	2548	O
use	-	2556	O
increases	-	2560	O
the	-	2570	O
risk	-	2574	O
for	-	2579	O
serious	-	2583	O
bleeding	-	2591	B
events	-	2600	O
.	-	2606	O

Reducing	19338378	0	O
harm	-	9	O
associated	-	14	O
with	-	25	O
anticoagulation	-	30	O
:	-	45	O
practical	-	47	O
considerations	-	57	O
of	-	72	O
argatroban	-	75	O
therapy	-	86	O
in	-	94	O
heparin	-	97	O
-	-	104	O
induced	-	105	O
thrombocytopenia	-	113	B
.	-	129	O

Argatroban	19338378	131	O
is	-	142	O
a	-	145	O
hepatically	-	147	O
metabolized	-	159	O
,	-	170	O
direct	-	172	O
thrombin	-	179	O
inhibitor	-	188	O
used	-	198	O
for	-	203	O
prophylaxis	-	207	O
or	-	219	O
treatment	-	222	O
of	-	232	O
thrombosis	-	235	B
in	-	246	O
heparin	-	249	O
-	-	256	O
induced	-	257	O
thrombocytopenia	-	265	B
(	-	282	O
HIT	-	283	B
)	-	286	O
and	-	288	O
for	-	292	O
patients	-	296	O
with	-	305	O
or	-	310	O
at	-	313	O
risk	-	316	O
of	-	321	O
HIT	-	324	B
undergoing	-	328	O
percutaneous	-	339	O
coronary	-	352	O
intervention	-	361	O
(	-	374	O
PCI	-	375	O
)	-	378	O
.	-	379	O

The	19338378	381	O
objective	-	385	O
of	-	395	O
this	-	398	O
review	-	403	O
is	-	410	O
to	-	413	O
summarize	-	416	O
practical	-	426	O
considerations	-	436	O
of	-	451	O
argatroban	-	454	O
therapy	-	465	O
in	-	473	O
HIT	-	476	B
.	-	479	O

The	19338378	481	O
US	-	485	O
FDA	-	488	O
-	-	491	O
recommended	-	492	O
argatroban	-	504	O
dose	-	515	O
in	-	520	O
HIT	-	523	B
is	-	527	O
2	-	530	O
microg	-	532	O
/	-	538	O
kg	-	539	O
/	-	541	O
min	-	542	O
(	-	546	O
reduced	-	547	O
in	-	555	O
patients	-	558	O
with	-	567	O
hepatic	-	572	B
impairment	-	580	I
and	-	591	O
in	-	595	O
paediatric	-	598	O
patients	-	609	O
)	-	617	O
,	-	618	O
adjusted	-	620	O
to	-	629	O
achieve	-	632	O
activated	-	640	O
partial	-	650	O
thromboplastin	-	658	O
times	-	673	O
(	-	679	O
aPTTs	-	680	O
)	-	685	O
1	-	687	O
.	-	688	O
5	-	689	O
-	-	690	O
3	-	691	O
times	-	693	O
baseline	-	699	O
(	-	708	O
not	-	709	O
>	-	713	O
100	-	714	O
seconds	-	718	O
)	-	725	O
.	-	726	O

Contemporary	19338378	728	O
experiences	-	741	O
indicate	-	753	O
that	-	762	O
reduced	-	767	O
doses	-	775	O
are	-	781	O
also	-	785	O
needed	-	790	O
in	-	797	O
patients	-	800	O
with	-	809	O
conditions	-	814	O
associated	-	825	O
with	-	836	O
hepatic	-	841	O
hypoperfusion	-	849	O
,	-	862	O
e	-	864	O
.	-	865	O
g	-	866	O
.	-	867	O
heart	-	869	B
failure	-	875	I
,	-	882	O
yet	-	884	O
are	-	888	O
unnecessary	-	892	O
for	-	904	O
renal	-	908	B
dysfunction	-	914	I
,	-	925	O
adult	-	927	O
age	-	933	O
,	-	936	O
sex	-	938	O
,	-	941	O
race	-	943	O
/	-	947	O
ethnicity	-	948	O
or	-	958	O
obesity	-	961	B
.	-	968	O

Argatroban	19338378	970	O
0	-	981	O
.	-	982	O
5	-	983	O
-	-	984	O
1	-	985	O
.	-	986	O
2	-	987	O
microg	-	989	O
/	-	995	O
kg	-	996	O
/	-	998	O
min	-	999	O
typically	-	1003	O
supports	-	1013	O
therapeutic	-	1022	O
aPTTs	-	1034	O
.	-	1039	O

The	19338378	1041	O
FDA	-	1045	O
-	-	1048	O
recommended	-	1049	O
dose	-	1061	O
during	-	1066	O
PCI	-	1073	O
is	-	1077	O
25	-	1080	O
microg	-	1083	O
/	-	1089	O
kg	-	1090	O
/	-	1092	O
min	-	1093	O
(	-	1097	O
350	-	1098	O
microg	-	1102	O
/	-	1108	O
kg	-	1109	O
initial	-	1112	O
bolus	-	1120	O
)	-	1125	O
,	-	1126	O
adjusted	-	1128	O
to	-	1137	O
achieve	-	1140	O
activated	-	1148	O
clotting	-	1158	O
times	-	1167	O
(	-	1173	O
ACTs	-	1174	O
)	-	1178	O
of	-	1180	O
300	-	1183	O
-	-	1186	O
450	-	1187	O
sec	-	1191	O
.	-	1194	O

For	19338378	1196	O
PCI	-	1200	O
,	-	1203	O
argatroban	-	1205	O
has	-	1216	O
not	-	1220	O
been	-	1224	O
investigated	-	1229	O
in	-	1242	O
hepatically	-	1245	O
impaired	-	1257	O
patients	-	1266	O
;	-	1274	O
dose	-	1276	O
adjustment	-	1281	O
is	-	1292	O
unnecessary	-	1295	O
for	-	1307	O
adult	-	1311	O
age	-	1317	O
,	-	1320	O
sex	-	1322	O
,	-	1325	O
race	-	1327	O
/	-	1331	O
ethnicity	-	1332	O
or	-	1342	O
obesity	-	1345	B
,	-	1352	O
and	-	1354	O
lesser	-	1358	O
doses	-	1365	O
may	-	1371	O
be	-	1375	O
adequate	-	1378	O
with	-	1387	O
concurrent	-	1392	O
glycoprotein	-	1403	O
IIb	-	1416	O
/	-	1419	O
IIIa	-	1420	O
inhibition	-	1425	O
.	-	1435	O

Argatroban	19338378	1437	O
prolongs	-	1448	O
the	-	1457	O
International	-	1461	O
Normalized	-	1475	O
Ratio	-	1486	O
,	-	1491	O
and	-	1493	O
published	-	1497	O
approaches	-	1507	O
for	-	1518	O
monitoring	-	1522	O
the	-	1533	O
argatroban	-	1537	O
-	-	1547	O
to	-	1548	O
-	-	1550	O
warfarin	-	1551	O
transition	-	1560	O
should	-	1571	O
be	-	1578	O
followed	-	1581	O
.	-	1589	O

Major	19338378	1591	O
bleeding	-	1597	B
with	-	1606	O
argatroban	-	1611	O
is	-	1622	O
0	-	1625	O
-	-	1626	O
10	-	1627	O
%	-	1629	O
in	-	1631	O
the	-	1634	O
non	-	1638	O
-	-	1641	O
interventional	-	1642	O
setting	-	1657	O
and	-	1665	O
0	-	1669	O
-	-	1670	O
5	-	1671	O
.	-	1672	O
8	-	1673	O
%	-	1674	O
periprocedurally	-	1676	O
.	-	1692	O

Argatroban	19338378	1694	O
has	-	1705	O
no	-	1709	O
specific	-	1712	O
antidote	-	1721	O
,	-	1729	O
and	-	1731	O
if	-	1735	O
excessive	-	1738	O
anticoagulation	-	1748	O
occurs	-	1764	O
,	-	1770	O
argatroban	-	1772	O
infusion	-	1783	O
should	-	1792	O
be	-	1799	O
stopped	-	1802	O
or	-	1810	O
reduced	-	1813	O
.	-	1820	O

Improved	19338378	1822	O
familiarity	-	1831	O
of	-	1843	O
healthcare	-	1846	O
professionals	-	1857	O
with	-	1871	O
argatroban	-	1876	O
therapy	-	1887	O
in	-	1895	O
HIT	-	1898	B
,	-	1901	O
including	-	1903	O
in	-	1913	O
special	-	1916	O
populations	-	1924	O
and	-	1936	O
during	-	1940	O
PCI	-	1947	O
,	-	1950	O
may	-	1952	O
facilitate	-	1956	O
reduction	-	1967	O
of	-	1977	O
harm	-	1980	O
associated	-	1985	O
with	-	1996	O
HIT	-	2001	B
(	-	2005	O
e	-	2006	O
.	-	2007	O
g	-	2008	O
.	-	2009	O
fewer	-	2011	O
thromboses	-	2017	O
)	-	2027	O
or	-	2029	O
its	-	2032	O
treatment	-	2036	O
(	-	2046	O
e	-	2047	O
.	-	2048	O
g	-	2049	O
.	-	2050	O
fewer	-	2052	O
argatroban	-	2058	O
medication	-	2069	O
errors	-	2080	O
)	-	2086	O
.	-	2087	O

Rhabdomyolysis	19392810	0	B
and	-	15	O
brain	-	19	O
ischemic	-	25	B
stroke	-	34	I
in	-	41	O
a	-	44	O
heroin	-	46	O
-	-	52	O
dependent	-	53	O
male	-	63	O
under	-	68	O
methadone	-	74	O
maintenance	-	84	O
therapy	-	96	O
.	-	103	O

OBJECTIVE	19392810	105	O
:	-	114	O

There	19392810	116	O
are	-	122	O
several	-	126	O
complications	-	134	O
associated	-	148	O
with	-	159	O
heroin	-	164	B
abuse	-	171	I
,	-	176	O
some	-	178	O
of	-	183	O
which	-	186	O
are	-	192	O
life	-	196	O
-	-	200	O
threatening	-	201	O
.	-	212	O

Methadone	19392810	214	O
may	-	224	O
aggravate	-	228	O
this	-	238	O
problem	-	243	O
.	-	250	O

METHOD	19392810	252	O
:	-	258	O

A	19392810	260	O
clinical	-	262	O
case	-	271	O
description	-	276	O
.	-	287	O

RESULTS	19392810	289	O
:	-	296	O

A	19392810	298	O
33	-	300	O
-	-	302	O
year	-	303	O
-	-	307	O
old	-	308	O
man	-	312	O
presented	-	316	O
with	-	326	O
rhabdomyolysis	-	331	B
and	-	346	O
cerebral	-	350	O
ischemic	-	359	B
stroke	-	368	I
after	-	375	O
intravenous	-	381	O
heroin	-	393	O
.	-	399	O

He	19392810	401	O
had	-	404	O
used	-	408	O
heroin	-	413	O
since	-	420	O
age	-	426	O
20	-	430	O
,	-	432	O
and	-	434	O
had	-	438	O
used	-	442	O
150	-	447	O
mg	-	451	O
methadone	-	454	O
daily	-	464	O
for	-	470	O
6	-	474	O
months	-	476	O
.	-	482	O

He	19392810	484	O
was	-	487	O
found	-	491	O
unconsciousness	-	497	B
at	-	513	O
home	-	516	O
and	-	521	O
was	-	525	O
sent	-	529	O
to	-	534	O
our	-	537	O
hospital	-	541	O
.	-	549	O

In	19392810	551	O
the	-	554	O
ER	-	558	O
,	-	560	O
his	-	562	O
opiate	-	566	O
level	-	573	O
was	-	579	O
4497	-	583	O
ng	-	588	O
/	-	590	O
ml	-	591	O
.	-	593	O

In	19392810	595	O
the	-	598	O
ICU	-	602	O
,	-	605	O
we	-	607	O
found	-	610	O
rhabdomyolysis	-	616	B
,	-	630	O
acute	-	632	B
renal	-	638	I
failure	-	644	I
and	-	652	O
acute	-	656	O
respiratory	-	662	B
failure	-	674	I
.	-	681	O

After	19392810	683	O
transfer	-	689	O
to	-	698	O
an	-	701	O
internal	-	704	O
ward	-	713	O
,	-	717	O
we	-	719	O
noted	-	722	O
aphasia	-	728	B
and	-	736	O
weakness	-	740	B
of	-	749	O
his	-	752	O
left	-	756	O
limbs	-	761	O
.	-	766	O

After	19392810	768	O
MRI	-	774	O
,	-	777	O
we	-	779	O
found	-	782	O
cerebral	-	788	B
ischemic	-	797	I
infarction	-	806	I
.	-	816	O

CONCLUSION	19392810	818	O
:	-	828	O

Those	19392810	830	O
using	-	836	O
methadone	-	842	O
and	-	852	O
heroin	-	856	O
simultaneously	-	863	O
may	-	878	O
increase	-	882	O
risk	-	891	O
of	-	896	O
rhabdomyolysis	-	899	B
and	-	914	O
ischemic	-	918	B
stroke	-	927	I
.	-	933	O

Patients	19392810	935	O
under	-	944	O
methadone	-	950	O
maintenance	-	960	O
therapy	-	972	O
should	-	980	O
be	-	987	O
warned	-	990	O
regarding	-	997	O
these	-	1007	O
serious	-	1013	O
adverse	-	1021	O
events	-	1029	O
.	-	1035	O

Hypotheses	19392810	1037	O
of	-	1048	O
heroin	-	1051	O
-	-	1057	O
related	-	1058	O
rhabdomyolysis	-	1066	B
and	-	1081	O
stroke	-	1085	B
in	-	1092	O
heroin	-	1095	O
abusers	-	1102	O
are	-	1110	O
discussed	-	1114	O
.	-	1123	O

Increased	19419794	0	O
vulnerability	-	10	O
to	-	24	O
6	-	27	O
-	-	28	O
hydroxydopamine	-	29	O
lesion	-	45	O
and	-	52	O
reduced	-	56	O
development	-	64	O
of	-	76	O
dyskinesias	-	79	B
in	-	91	O
mice	-	94	O
lacking	-	99	O
CB1	-	107	O
cannabinoid	-	111	O
receptors	-	123	O
.	-	132	O

Motor	19419794	134	O
impairment	-	140	O
,	-	150	O
dopamine	-	152	O
(	-	161	O
DA	-	162	O
)	-	164	O
neuronal	-	166	O
activity	-	175	O
and	-	184	O
proenkephalin	-	188	O
(	-	202	O
PENK	-	203	O
)	-	207	O
gene	-	209	O
expression	-	214	O
in	-	225	O
the	-	228	O
caudate	-	232	O
-	-	239	O
putamen	-	240	O
(	-	248	O
CPu	-	249	O
)	-	252	O
were	-	254	O
measured	-	259	O
in	-	268	O
6	-	271	O
-	-	272	O
OHDA	-	273	O
-	-	277	O
lesioned	-	278	O
and	-	287	O
treated	-	291	O
(	-	299	O
L	-	300	O
-	-	301	O
DOPA	-	302	O
+	-	306	O
benserazide	-	307	O
)	-	318	O
CB1	-	320	O
KO	-	324	O
and	-	327	O
WT	-	331	O
mice	-	334	O
.	-	338	O

A	19419794	340	O
lesion	-	342	O
induced	-	349	O
by	-	357	O
6	-	360	O
-	-	361	O
OHDA	-	362	O
produced	-	367	O
more	-	376	O
severe	-	381	O
motor	-	388	O
deterioration	-	394	O
in	-	408	O
CB1	-	411	O
KO	-	415	O
mice	-	418	O
accompanied	-	423	O
by	-	435	O
more	-	438	O
loss	-	443	O
of	-	448	O
DA	-	451	O
neurons	-	454	O
and	-	462	O
increased	-	466	O
PENK	-	476	O
gene	-	481	O
expression	-	486	O
in	-	497	O
the	-	500	O
CPu	-	504	O
.	-	507	O

Oxidative	19419794	509	O
/	-	518	O
nitrosative	-	519	O
and	-	531	O
neuroinflammatory	-	535	O
parameters	-	553	O
were	-	564	O
estimated	-	569	O
in	-	579	O
the	-	582	O
CPu	-	586	O
and	-	590	O
cingulate	-	594	O
cortex	-	604	O
(	-	611	O
Cg	-	612	O
)	-	614	O
.	-	615	O

CB1	19419794	617	O
KO	-	621	O
mice	-	624	O
exhibited	-	629	O
higher	-	639	O
MDA	-	646	O
levels	-	650	O
and	-	657	O
iNOS	-	661	O
protein	-	666	O
expression	-	674	O
in	-	685	O
the	-	688	O
CPu	-	692	O
and	-	696	O
Cg	-	700	O
compared	-	703	O
to	-	712	O
WT	-	715	O
mice	-	718	O
.	-	722	O

Treatment	19419794	724	O
with	-	734	O
L	-	739	O
-	-	740	O
DOPA	-	741	O
+	-	745	O
benserazide	-	746	O
(	-	758	O
12	-	759	O
weeks	-	762	O
)	-	767	O
resulted	-	769	O
in	-	778	O
less	-	781	O
severe	-	786	O
dyskinesias	-	793	B
in	-	805	O
CB1	-	808	O
KO	-	812	O
than	-	815	O
in	-	820	O
WT	-	823	O
mice	-	826	O
.	-	830	O

The	19419794	832	O
results	-	836	O
revealed	-	844	O
that	-	853	O
the	-	858	O
lack	-	862	O
of	-	867	O
cannabinoid	-	870	O
CB1	-	882	O
receptors	-	886	O
increased	-	896	O
the	-	906	O
severity	-	910	O
of	-	919	O
motor	-	922	O
impairment	-	928	O
and	-	939	O
DA	-	943	O
lesion	-	946	O
,	-	952	O
and	-	954	O
reduced	-	958	O
L	-	966	O
-	-	967	O
DOPA	-	968	O
-	-	972	O
induced	-	973	O
dyskinesias	-	981	B
.	-	992	O

These	19419794	994	O
results	-	1000	O
suggest	-	1008	O
that	-	1016	O
activation	-	1021	O
of	-	1032	O
CB1	-	1035	O
receptors	-	1039	O
offers	-	1049	O
neuroprotection	-	1056	O
against	-	1072	O
dopaminergic	-	1080	O
lesion	-	1093	O
and	-	1100	O
the	-	1104	O
development	-	1108	O
of	-	1120	O
L	-	1123	O
-	-	1124	O
DOPA	-	1125	O
-	-	1129	O
induced	-	1130	O
dyskinesias	-	1138	B
.	-	1149	O

Animal	19447152	0	O
model	-	7	O
of	-	13	O
mania	-	16	B
induced	-	22	O
by	-	30	O
ouabain	-	33	O
:	-	40	O
Evidence	-	42	O
of	-	51	O
oxidative	-	54	O
stress	-	64	O
in	-	71	O
submitochondrial	-	74	O
particles	-	91	O
of	-	101	O
the	-	104	O
rat	-	108	O
brain	-	112	O
.	-	117	O

The	19447152	119	O
intracerebroventricular	-	123	O
(	-	147	O
ICV	-	148	O
)	-	151	O
administration	-	153	O
of	-	168	O
ouabain	-	171	O
(	-	179	O
a	-	180	O
Na	-	182	O
(	-	184	O
+	-	185	O
)	-	186	O
/	-	187	O
K	-	188	O
(	-	189	O
+	-	190	O
)	-	191	O
-	-	192	O
ATPase	-	193	O
inhibitor	-	200	O
)	-	209	O
in	-	211	O
rats	-	214	O
has	-	219	O
been	-	223	O
suggested	-	228	O
to	-	238	O
mimic	-	241	O
some	-	247	O
symptoms	-	252	O
of	-	261	O
human	-	264	O
bipolar	-	270	B
mania	-	278	I
.	-	283	O

Clinical	19447152	285	O
studies	-	294	O
have	-	302	O
shown	-	307	O
that	-	313	O
bipolar	-	318	B
disorder	-	326	I
may	-	335	O
be	-	339	O
related	-	342	O
to	-	350	O
mitochondrial	-	353	B
dysfunction	-	367	I
.	-	378	O

Herein	19447152	380	O
,	-	386	O
we	-	388	O
investigated	-	391	O
the	-	404	O
behavioral	-	408	O
and	-	419	O
biochemical	-	423	O
effects	-	435	O
induced	-	443	O
by	-	451	O
the	-	454	O
ICV	-	458	O
administration	-	462	O
of	-	477	O
ouabain	-	480	O
in	-	488	O
rats	-	491	O
.	-	495	O

To	19447152	497	O
achieve	-	500	O
this	-	508	O
aim	-	513	O
,	-	516	O
the	-	518	O
effects	-	522	O
of	-	530	O
ouabain	-	533	O
injection	-	541	O
immediately	-	551	O
after	-	563	O
and	-	569	O
7	-	573	O
days	-	575	O
following	-	580	O
a	-	590	O
single	-	592	O
ICV	-	599	O
administration	-	603	O
(	-	618	O
at	-	619	O
concentrations	-	622	O
of	-	637	O
10	-	640	O
(	-	642	O
-	-	643	O
2	-	644	O
)	-	645	O
and	-	647	O
10	-	651	O
(	-	653	O
-	-	654	O
3	-	655	O
)	-	656	O
M	-	657	O
)	-	658	O
on	-	660	O
locomotion	-	663	O
was	-	674	O
measured	-	678	O
using	-	687	O
the	-	693	O
open	-	697	O
-	-	701	O
field	-	702	O
test	-	708	O
.	-	712	O

Additionally	19447152	714	O
,	-	726	O
thiobarbituric	-	728	O
acid	-	743	O
reactive	-	748	O
substances	-	757	O
(	-	768	O
TBARSs	-	769	O
)	-	775	O
and	-	777	O
superoxide	-	781	O
production	-	792	O
were	-	803	O
measured	-	808	O
in	-	817	O
submitochondrial	-	820	O
particles	-	837	O
of	-	847	O
the	-	850	O
prefrontal	-	854	O
cortex	-	865	O
,	-	871	O
hippocampus	-	873	O
,	-	884	O
striatum	-	886	O
and	-	895	O
amygdala	-	899	O
.	-	907	O

Our	19447152	909	O
findings	-	913	O
demonstrated	-	922	O
that	-	935	O
ouabain	-	940	O
at	-	948	O
10	-	951	O
(	-	953	O
-	-	954	O
2	-	955	O
)	-	956	O
and	-	958	O
10	-	962	O
(	-	964	O
-	-	965	O
3	-	966	O
)	-	967	O
M	-	968	O
induced	-	970	O
hyperlocomotion	-	978	B
in	-	994	O
rats	-	997	O
,	-	1001	O
and	-	1003	O
this	-	1007	O
response	-	1012	O
remained	-	1021	O
up	-	1030	O
to	-	1033	O
7	-	1036	O
days	-	1038	O
following	-	1043	O
a	-	1053	O
single	-	1055	O
ICV	-	1062	O
injection	-	1066	O
.	-	1075	O

In	19447152	1077	O
addition	-	1080	O
,	-	1088	O
we	-	1090	O
observed	-	1093	O
that	-	1102	O
the	-	1107	O
persistent	-	1111	O
increase	-	1122	O
in	-	1131	O
the	-	1134	O
rat	-	1138	O
spontaneous	-	1142	O
locomotion	-	1154	O
is	-	1165	O
associated	-	1168	O
with	-	1179	O
increased	-	1184	O
TBARS	-	1194	O
levels	-	1200	O
and	-	1207	O
superoxide	-	1211	O
generation	-	1222	O
in	-	1233	O
submitochondrial	-	1236	O
particles	-	1253	O
in	-	1263	O
the	-	1266	O
prefrontal	-	1270	O
cortex	-	1281	O
,	-	1287	O
striatum	-	1289	O
and	-	1298	O
amygdala	-	1302	O
.	-	1310	O

In	19447152	1312	O
conclusion	-	1315	O
,	-	1325	O
ouabain	-	1327	O
-	-	1334	O
induced	-	1335	O
mania	-	1343	B
-	-	1348	O
like	-	1349	O
behavior	-	1354	O
may	-	1363	O
provide	-	1367	O
a	-	1375	O
useful	-	1377	O
animal	-	1384	O
model	-	1391	O
to	-	1397	O
test	-	1400	O
the	-	1405	O
hypothesis	-	1409	O
of	-	1420	O
the	-	1423	O
involvement	-	1427	O
of	-	1439	O
oxidative	-	1442	O
stress	-	1452	O
in	-	1459	O
bipolar	-	1462	B
disorder	-	1470	I
.	-	1478	O

Intraoperative	19515070	0	O
dialysis	-	15	O
during	-	24	O
liver	-	31	O
transplantation	-	37	O
with	-	53	O
citrate	-	58	O
dialysate	-	66	O
.	-	75	O

Liver	19515070	77	O
transplantation	-	83	O
for	-	99	O
acutely	-	103	O
ill	-	111	O
patients	-	115	O
with	-	124	O
fulminant	-	129	B
liver	-	139	I
failure	-	145	I
carries	-	153	O
high	-	161	O
intraoperative	-	166	O
and	-	181	O
immediate	-	185	O
postoperative	-	195	O
risks	-	209	O
.	-	214	O

These	19515070	216	O
are	-	222	O
increased	-	226	O
with	-	236	O
the	-	241	O
presence	-	245	O
of	-	254	O
concomitant	-	257	O
acute	-	269	B
kidney	-	275	I
injury	-	282	I
(	-	289	O
AKI	-	290	B
)	-	293	O
and	-	295	O
intraoperative	-	299	O
dialysis	-	314	O
is	-	323	O
sometimes	-	326	O
required	-	336	O
to	-	345	O
allow	-	348	O
the	-	354	O
transplant	-	358	O
to	-	369	O
proceed	-	372	O
.	-	379	O

The	19515070	381	O
derangements	-	385	O
in	-	398	O
the	-	401	O
procoagulant	-	405	O
and	-	418	O
anticoagulant	-	422	O
pathways	-	436	O
during	-	445	O
fulminant	-	452	B
liver	-	462	I
failure	-	468	I
can	-	476	O
lead	-	480	O
to	-	485	O
difficulties	-	488	O
with	-	501	O
anticoagulation	-	506	O
during	-	522	O
dialysis	-	529	O
,	-	537	O
especially	-	539	O
when	-	550	O
continued	-	555	O
in	-	565	O
the	-	568	O
operating	-	572	O
room	-	582	O
.	-	586	O

Systemic	19515070	588	O
anticoagulation	-	597	O
is	-	613	O
unsafe	-	616	O
and	-	623	O
regional	-	627	O
citrate	-	636	O
anticoagulation	-	644	O
in	-	660	O
the	-	663	O
absence	-	667	O
of	-	675	O
a	-	678	O
functional	-	680	O
liver	-	691	O
carries	-	697	O
the	-	705	O
risk	-	709	O
of	-	714	O
citrate	-	717	O
toxicity	-	725	B
.	-	733	O

Citrate	19515070	735	O
dialysate	-	743	O
,	-	752	O
a	-	754	O
new	-	756	O
dialysate	-	760	O
with	-	770	O
citric	-	775	O
acid	-	782	O
can	-	787	O
be	-	791	O
used	-	794	O
for	-	799	O
anticoagulation	-	803	O
in	-	819	O
patients	-	822	O
who	-	831	O
can	-	835	O
not	-	838	O
tolerate	-	842	O
heparin	-	851	O
or	-	859	O
regional	-	862	O
citrate	-	871	O
.	-	878	O

We	19515070	880	O
report	-	883	O
a	-	890	O
case	-	892	O
of	-	897	O
a	-	900	O
40	-	902	O
-	-	904	O
year	-	905	O
-	-	909	O
old	-	910	O
female	-	914	O
with	-	921	O
acetaminophen	-	926	O
-	-	939	O
induced	-	940	O
fulminant	-	948	B
liver	-	958	I
failure	-	964	I
with	-	972	O
associated	-	977	O
AKI	-	988	B
who	-	992	O
underwent	-	996	O
intraoperative	-	1006	O
dialytic	-	1021	O
support	-	1030	O
during	-	1038	O
liver	-	1045	O
transplantation	-	1051	O
anticoagulated	-	1067	O
with	-	1082	O
citrate	-	1087	O
dialysate	-	1095	O
during	-	1105	O
the	-	1112	O
entire	-	1116	O
procedure	-	1123	O
.	-	1132	O

The	19515070	1134	O
patient	-	1138	O
tolerated	-	1146	O
the	-	1156	O
procedure	-	1160	O
well	-	1170	O
without	-	1175	O
any	-	1183	O
signs	-	1187	O
of	-	1193	O
citrate	-	1196	O
toxicity	-	1204	B
and	-	1213	O
maintained	-	1217	O
adequate	-	1228	O
anticoagulation	-	1237	O
for	-	1253	O
patency	-	1257	O
of	-	1265	O
the	-	1268	O
dialysis	-	1272	O
circuit	-	1281	O
.	-	1288	O

Citrate	19515070	1290	O
dialysate	-	1298	O
is	-	1308	O
a	-	1311	O
safe	-	1313	O
alternative	-	1318	O
for	-	1330	O
intradialytic	-	1334	O
support	-	1348	O
of	-	1356	O
liver	-	1359	O
transplantation	-	1365	O
in	-	1381	O
fulminant	-	1384	B
liver	-	1394	I
failure	-	1400	I
.	-	1407	O

Delirium	19531695	0	B
in	-	9	O
a	-	12	O
patient	-	14	O
with	-	22	O
toxic	-	27	O
flecainide	-	33	O
plasma	-	44	O
concentrations	-	51	O
:	-	65	O
the	-	67	O
role	-	71	O
of	-	76	O
a	-	79	O
pharmacokinetic	-	81	O
drug	-	97	O
interaction	-	102	O
with	-	114	O
paroxetine	-	119	O
.	-	129	O

OBJECTIVE	19531695	131	O
:	-	140	O

To	19531695	142	O
describe	-	145	O
a	-	154	O
case	-	156	O
of	-	161	O
flecainide	-	164	O
-	-	174	O
induced	-	175	O
delirium	-	183	B
associated	-	192	O
with	-	203	O
a	-	208	O
pharmacokinetic	-	210	O
drug	-	226	O
interaction	-	231	O
with	-	243	O
paroxetine	-	248	O
.	-	258	O

CASE	19531695	260	O
SUMMARY	-	265	O
:	-	272	O

A	19531695	274	O
69	-	276	O
-	-	278	O
year	-	279	O
-	-	283	O
old	-	284	O
white	-	288	O
female	-	294	O
presented	-	301	O
to	-	311	O
the	-	314	O
emergency	-	318	O
department	-	328	O
with	-	339	O
a	-	344	O
history	-	346	O
of	-	354	O
confusion	-	357	B
and	-	367	O
paranoia	-	371	B
over	-	380	O
the	-	385	O
past	-	389	O
several	-	394	O
days	-	402	O
.	-	406	O

On	19531695	408	O
admission	-	411	O
the	-	421	O
patient	-	425	O
was	-	433	O
taking	-	437	O
carvedilol	-	444	O
12	-	455	O
mg	-	458	O
twice	-	461	O
daily	-	467	O
,	-	472	O
warfarin	-	474	O
2	-	483	O
mg	-	485	O
/	-	487	O
day	-	488	O
,	-	491	O
folic	-	493	O
acid	-	499	O
1	-	504	O
mg	-	506	O
/	-	508	O
day	-	509	O
,	-	512	O
levothyroxine	-	514	O
100	-	528	O
microg	-	532	O
/	-	538	O
day	-	539	O
,	-	542	O
pantoprazole	-	544	O
40	-	557	O
mg	-	560	O
/	-	562	O
day	-	563	O
,	-	566	O
paroxetine	-	568	O
40	-	579	O
mg	-	582	O
/	-	584	O
day	-	585	O
,	-	588	O
and	-	590	O
flecainide	-	594	O
100	-	605	O
mg	-	609	O
twice	-	612	O
daily	-	618	O
.	-	623	O

Flecainide	19531695	625	O
had	-	636	O
been	-	640	O
started	-	645	O
2	-	653	O
weeks	-	655	O
prior	-	661	O
for	-	667	O
atrial	-	671	B
fibrillation	-	678	I
.	-	690	O

Laboratory	19531695	692	O
test	-	703	O
findings	-	708	O
on	-	717	O
admission	-	720	O
were	-	730	O
notable	-	735	O
only	-	743	O
for	-	748	O
a	-	752	O
flecainide	-	754	O
plasma	-	765	O
concentration	-	772	O
of	-	786	O
1360	-	789	O
microg	-	794	O
/	-	800	O
L	-	801	O
(	-	803	O
reference	-	804	O
range	-	814	O
200	-	820	O
-	-	823	O
1000	-	824	O
)	-	828	O
.	-	829	O

A	19531695	831	O
metabolic	-	833	O
drug	-	843	O
interaction	-	848	O
between	-	860	O
flecainide	-	868	O
and	-	879	O
paroxetine	-	883	O
,	-	893	O
which	-	895	O
the	-	901	O
patient	-	905	O
had	-	913	O
been	-	917	O
taking	-	922	O
for	-	929	O
more	-	933	O
than	-	938	O
5	-	943	O
years	-	945	O
,	-	950	O
was	-	952	O
considered	-	956	O
.	-	966	O

Paroxetine	19531695	968	O
was	-	979	O
discontinued	-	983	O
and	-	996	O
the	-	1000	O
dose	-	1004	O
of	-	1009	O
flecainide	-	1012	O
was	-	1023	O
reduced	-	1027	O
to	-	1035	O
50	-	1038	O
mg	-	1041	O
twice	-	1044	O
daily	-	1050	O
.	-	1055	O

Her	19531695	1057	O
delirium	-	1061	B
resolved	-	1070	O
3	-	1079	O
days	-	1081	O
later	-	1086	O
.	-	1091	O

DISCUSSION	19531695	1093	O
:	-	1103	O

Flecainide	19531695	1105	O
and	-	1116	O
pharmacologically	-	1120	O
similar	-	1138	O
agents	-	1146	O
that	-	1153	O
interact	-	1158	O
with	-	1167	O
sodium	-	1172	O
channels	-	1179	O
may	-	1188	O
cause	-	1192	O
delirium	-	1198	B
in	-	1207	O
susceptible	-	1210	O
patients	-	1222	O
.	-	1230	O

A	19531695	1232	O
MEDLINE	-	1234	O
search	-	1242	O
(	-	1249	O
1966	-	1250	O
-	-	1254	O
January	-	1255	O
2009	-	1263	O
)	-	1267	O
revealed	-	1269	O
one	-	1278	O
in	-	1282	O
vivo	-	1285	O
pharmacokinetic	-	1290	O
study	-	1306	O
on	-	1312	O
the	-	1315	O
interaction	-	1319	O
between	-	1331	O
flecainide	-	1339	O
,	-	1349	O
a	-	1351	O
CYP2D6	-	1353	O
substrate	-	1360	O
,	-	1369	O
and	-	1371	O
paroxetine	-	1375	O
,	-	1385	O
a	-	1387	O
CYP2D6	-	1389	O
inhibitor	-	1396	O
,	-	1405	O
as	-	1407	O
well	-	1410	O
as	-	1415	O
3	-	1418	O
case	-	1420	O
reports	-	1425	O
of	-	1433	O
flecainide	-	1436	O
-	-	1446	O
induced	-	1447	O
delirium	-	1455	B
.	-	1463	O

According	19531695	1465	O
to	-	1475	O
the	-	1478	O
Naranjo	-	1482	O
probability	-	1490	O
scale	-	1502	O
,	-	1507	O
flecainide	-	1509	O
was	-	1520	O
the	-	1524	O
probable	-	1528	O
cause	-	1537	O
of	-	1543	O
the	-	1546	O
patient	-	1550	O
's	-	1557	O
delirium	-	1560	B
;	-	1568	O
the	-	1570	O
Horn	-	1574	O
Drug	-	1579	O
Interaction	-	1584	O
Probability	-	1596	O
Scale	-	1608	O
indicates	-	1614	O
a	-	1624	O
possible	-	1626	O
pharmacokinetic	-	1635	O
drug	-	1651	O
interaction	-	1656	O
between	-	1668	O
flecainide	-	1676	O
and	-	1687	O
paroxetine	-	1691	O
.	-	1701	O

CONCLUSIONS	19531695	1703	O
:	-	1714	O

Supratherapeutic	19531695	1716	O
flecainide	-	1733	O
plasma	-	1744	O
concentrations	-	1751	O
may	-	1766	O
cause	-	1770	O
delirium	-	1776	B
.	-	1784	O

Because	19531695	1786	O
toxicity	-	1794	B
may	-	1803	O
occur	-	1807	O
when	-	1813	O
flecainide	-	1818	O
is	-	1829	O
prescribed	-	1832	O
with	-	1843	O
paroxetine	-	1848	O
and	-	1859	O
other	-	1863	O
potent	-	1869	O
CYP2D6	-	1876	O
inhibitors	-	1883	O
,	-	1893	O
flecainide	-	1895	O
plasma	-	1906	O
concentrations	-	1913	O
should	-	1928	O
be	-	1935	O
monitored	-	1938	O
closely	-	1948	O
with	-	1956	O
commencement	-	1961	O
of	-	1974	O
CYP2D6	-	1977	O
inhibitors	-	1984	O
.	-	1994	O

Efficacy	19549709	0	O
of	-	9	O
everolimus	-	12	O
(	-	23	O
RAD001	-	24	O
)	-	30	O
in	-	32	O
patients	-	35	O
with	-	44	O
advanced	-	49	O
NSCLC	-	58	B
previously	-	64	O
treated	-	75	O
with	-	83	O
chemotherapy	-	88	O
alone	-	101	O
or	-	107	O
with	-	110	O
chemotherapy	-	115	O
and	-	128	O
EGFR	-	132	O
inhibitors	-	137	O
.	-	147	O

BACKGROUND	19549709	149	O
:	-	159	O

Treatment	19549709	161	O
options	-	171	O
are	-	179	O
scarce	-	183	O
in	-	190	O
pretreated	-	193	O
advanced	-	204	O
non	-	213	B
-	-	216	I
small	-	217	I
-	-	222	I
cell	-	223	I
lung	-	228	I
cancer	-	233	I
(	-	240	O
NSCLC	-	241	B
)	-	246	O
patients	-	248	O
.	-	256	O

RAD001	19549709	258	O
,	-	264	O
an	-	266	O
oral	-	269	O
inhibitor	-	274	O
of	-	284	O
the	-	287	O
mammalian	-	291	O
target	-	301	O
of	-	308	O
rapamycin	-	311	O
(	-	321	O
mTOR	-	322	O
)	-	326	O
,	-	327	O
has	-	329	O
shown	-	333	O
phase	-	339	O
I	-	345	O
efficacy	-	347	O
in	-	356	O
NSCLC	-	359	B
.	-	364	O

METHODS	19549709	366	O
:	-	373	O

Stage	19549709	375	O
IIIb	-	381	O
or	-	386	O
IV	-	389	O
NSCLC	-	392	B
patients	-	398	O
,	-	406	O
with	-	408	O
two	-	413	O
or	-	417	O
fewer	-	420	O
prior	-	426	O
chemotherapy	-	432	O
regimens	-	445	O
,	-	453	O
one	-	455	O
platinum	-	459	O
based	-	468	O
(	-	474	O
stratum	-	475	O
1	-	483	O
)	-	484	O
or	-	486	O
both	-	489	O
chemotherapy	-	494	O
and	-	507	O
epidermal	-	511	O
growth	-	521	O
factor	-	528	O
receptor	-	535	O
tyrosine	-	544	O
kinase	-	553	O
inhibitors	-	560	O
(	-	571	O
stratum	-	572	O
2	-	580	O
)	-	581	O
,	-	582	O
received	-	584	O
RAD001	-	593	O
10	-	600	O
mg	-	603	O
/	-	605	O
day	-	606	O
until	-	610	O
progression	-	616	O
or	-	628	O
unacceptable	-	631	O
toxicity	-	644	B
.	-	652	O

Primary	19549709	654	O
objective	-	662	O
was	-	672	O
overall	-	676	O
response	-	684	O
rate	-	693	O
(	-	698	O
ORR	-	699	O
)	-	702	O
.	-	703	O

Analyses	19549709	705	O
of	-	714	O
markers	-	717	O
associated	-	725	O
with	-	736	O
the	-	741	O
mTOR	-	745	O
pathway	-	750	O
were	-	758	O
carried	-	763	O
out	-	771	O
on	-	775	O
archival	-	778	O
tumor	-	787	B
from	-	793	O
a	-	798	O
subgroup	-	800	O
using	-	809	O
immunohistochemistry	-	815	O
(	-	836	O
IHC	-	837	O
)	-	840	O
and	-	842	O
direct	-	846	O
mutation	-	853	O
sequencing	-	862	O
.	-	872	O

RESULTS	19549709	874	O
:	-	881	O

Eighty	19549709	883	O
-	-	889	O
five	-	890	O
patients	-	895	O
were	-	904	O
enrolled	-	909	O
,	-	917	O
42	-	919	O
in	-	922	O
stratum	-	925	O
1	-	933	O
and	-	935	O
43	-	939	O
in	-	942	O
stratum	-	945	O
.	-	952	O

ORR	19549709	954	O
was	-	958	O
4	-	962	O
.	-	963	O
7	-	964	O
%	-	965	O
(	-	967	O
7	-	968	O
.	-	969	O
1	-	970	O
%	-	971	O
stratum	-	973	O
1	-	981	O
;	-	982	O
2	-	984	O
.	-	985	O
3	-	986	O
%	-	987	O
stratum	-	989	O
2	-	997	O
)	-	998	O
.	-	999	O

Overall	19549709	1001	O
disease	-	1009	O
control	-	1017	O
rate	-	1025	O
was	-	1030	O
47	-	1034	O
.	-	1036	O
1	-	1037	O
%	-	1038	O
.	-	1039	O

Median	19549709	1041	O
progression	-	1048	O
-	-	1059	O
free	-	1060	O
survivals	-	1065	O
(	-	1075	O
PFSs	-	1076	O
)	-	1080	O
were	-	1082	O
2	-	1087	O
.	-	1088	O
6	-	1089	O
(	-	1091	O
stratum	-	1092	O
1	-	1100	O
)	-	1101	O
and	-	1103	O
2	-	1107	O
.	-	1108	O
7	-	1109	O
months	-	1111	O
(	-	1118	O
stratum	-	1119	O
2	-	1127	O
)	-	1128	O
.	-	1129	O

Common	19549709	1131	O
>	-	1138	O
or	-	1140	O
=	-	1143	O
grade	-	1144	O
3	-	1150	O
events	-	1152	O
were	-	1159	O
fatigue	-	1164	B
,	-	1171	O
dyspnea	-	1173	B
,	-	1180	O
stomatitis	-	1182	B
,	-	1192	O
anemia	-	1194	B
,	-	1200	O
and	-	1202	O
thrombocytopenia	-	1206	B
.	-	1222	O

Pneumonitis	19549709	1224	B
,	-	1235	O
probably	-	1237	O
or	-	1246	O
possibly	-	1249	O
related	-	1258	O
,	-	1265	O
mainly	-	1267	O
grade	-	1274	O
1	-	1280	O
/	-	1281	O
2	-	1282	O
,	-	1283	O
occurred	-	1285	O
in	-	1294	O
25	-	1297	O
%	-	1299	O
.	-	1300	O

Cox	19549709	1302	O
regression	-	1306	O
analysis	-	1317	O
of	-	1326	O
IHC	-	1329	O
scores	-	1333	O
found	-	1340	O
that	-	1346	O
only	-	1351	O
phospho	-	1356	O
AKT	-	1364	O
(	-	1368	O
pAKT	-	1369	O
)	-	1373	O
was	-	1375	O
a	-	1379	O
significant	-	1381	O
independent	-	1393	O
predictor	-	1405	O
of	-	1415	O
worse	-	1418	O
PFS	-	1424	O
.	-	1427	O

CONCLUSIONS	19549709	1429	O
:	-	1440	O

RAD001	19549709	1442	O
10	-	1449	O
mg	-	1452	O
/	-	1454	O
day	-	1455	O
was	-	1459	O
well	-	1463	O
tolerated	-	1468	O
,	-	1477	O
showing	-	1479	O
modest	-	1487	O
clinical	-	1494	O
activity	-	1503	O
in	-	1512	O
pretreated	-	1515	O
NSCLC	-	1526	B
.	-	1531	O

Evaluation	19549709	1533	O
of	-	1544	O
RAD001	-	1547	O
plus	-	1554	O
standard	-	1559	O
therapy	-	1568	O
for	-	1576	O
metastatic	-	1580	O
NSCLC	-	1591	B
continues	-	1597	O
.	-	1606	O

Posttransplant	19553912	0	O
anemia	-	15	B
:	-	21	O
the	-	23	O
role	-	27	O
of	-	32	O
sirolimus	-	35	O
.	-	44	O

Posttransplant	19553912	46	O
anemia	-	61	B
is	-	68	O
a	-	71	O
common	-	73	O
problem	-	80	O
that	-	88	O
may	-	93	O
hinder	-	97	O
patients	-	104	O
'	-	112	O
quality	-	114	O
of	-	122	O
life	-	125	O
.	-	129	O

It	19553912	131	O
occurs	-	134	O
in	-	141	O
12	-	144	O
to	-	147	O
76	-	150	O
%	-	152	O
of	-	154	O
patients	-	157	O
,	-	165	O
and	-	167	O
is	-	171	O
most	-	174	O
common	-	179	O
in	-	186	O
the	-	189	O
immediate	-	193	O
posttransplant	-	203	O
period	-	218	O
.	-	224	O

A	19553912	226	O
variety	-	228	O
of	-	236	O
factors	-	239	O
have	-	247	O
been	-	252	O
identified	-	257	O
that	-	268	O
increase	-	273	O
the	-	282	O
risk	-	286	O
of	-	291	O
posttransplant	-	294	O
anemia	-	309	B
,	-	315	O
of	-	317	O
which	-	320	O
the	-	326	O
level	-	330	O
of	-	336	O
renal	-	339	O
function	-	345	O
is	-	354	O
most	-	357	O
important	-	362	O
.	-	371	O

Sirolimus	19553912	373	O
,	-	382	O
a	-	384	O
mammalian	-	386	O
target	-	396	O
of	-	403	O
rapamycin	-	406	O
inhibitor	-	416	O
,	-	425	O
has	-	427	O
been	-	431	O
implicated	-	436	O
as	-	447	O
playing	-	450	O
a	-	458	O
special	-	460	O
role	-	468	O
in	-	473	O
posttransplant	-	476	O
anemia	-	491	B
.	-	497	O

This	19553912	499	O
review	-	504	O
considers	-	511	O
anemia	-	521	B
associated	-	528	O
with	-	539	O
sirolimus	-	544	O
,	-	553	O
including	-	555	O
its	-	565	O
presentation	-	569	O
,	-	581	O
mechanisms	-	583	O
,	-	593	O
and	-	595	O
management	-	599	O
.	-	609	O

Coronary	19655282	0	O
computerized	-	9	O
tomography	-	22	O
angiography	-	33	O
for	-	45	O
rapid	-	49	O
discharge	-	55	O
of	-	65	O
low	-	68	O
-	-	71	O
risk	-	72	O
patients	-	77	O
with	-	86	O
cocaine	-	91	O
-	-	98	O
associated	-	99	O
chest	-	110	B
pain	-	116	I
.	-	120	O

BACKGROUND	19655282	122	O
:	-	132	O

Most	19655282	134	O
patients	-	139	O
presenting	-	148	O
to	-	159	O
emergency	-	162	O
departments	-	172	O
(	-	184	O
EDs	-	185	O
)	-	188	O
with	-	190	O
cocaine	-	195	O
-	-	202	O
associated	-	203	O
chest	-	214	B
pain	-	220	I
are	-	225	O
admitted	-	229	O
for	-	238	O
at	-	242	O
least	-	245	O
12	-	251	O
hours	-	254	O
and	-	260	O
receive	-	264	O
a	-	272	O
""""	-	274	O
rule	-	275	O
out	-	280	O
acute	-	284	B
coronary	-	290	I
syndrome	-	299	I
""""	-	307	O
protocol	-	309	O
,	-	317	O
often	-	319	O
with	-	325	O
noninvasive	-	330	O
testing	-	342	O
prior	-	350	O
to	-	356	O
discharge	-	359	O
.	-	368	O

In	19655282	370	O
patients	-	373	O
without	-	382	O
cocaine	-	390	O
use	-	398	O
,	-	401	O
coronary	-	403	O
computerized	-	412	O
tomography	-	425	O
angiography	-	436	O
(	-	448	O
CTA	-	449	O
)	-	452	O
has	-	454	O
been	-	458	O
shown	-	463	O
to	-	469	O
be	-	472	O
useful	-	475	O
for	-	482	O
identifying	-	486	O
a	-	498	O
group	-	500	O
of	-	506	O
patients	-	509	O
at	-	518	O
low	-	521	O
risk	-	525	O
for	-	530	O
cardiac	-	534	O
events	-	542	O
who	-	549	O
can	-	553	O
be	-	557	O
safely	-	560	O
discharged	-	567	O
.	-	577	O

It	19655282	579	O
is	-	582	O
unclear	-	585	O
whether	-	593	O
a	-	601	O
coronary	-	603	O
CTA	-	612	O
strategy	-	616	O
would	-	625	O
be	-	631	O
efficacious	-	634	O
in	-	646	O
cocaine	-	649	O
-	-	656	O
associated	-	657	O
chest	-	668	B
pain	-	674	I
,	-	678	O
as	-	680	O
coronary	-	683	B
vasospasm	-	692	I
may	-	702	O
account	-	706	O
for	-	714	O
some	-	718	O
of	-	723	O
the	-	726	O
ischemia	-	730	B
.	-	738	O

We	19655282	740	O
studied	-	743	O
whether	-	751	O
a	-	759	O
negative	-	761	O
coronary	-	770	O
CTA	-	779	O
in	-	783	O
patients	-	786	O
with	-	795	O
cocaine	-	800	O
-	-	807	O
associated	-	808	O
chest	-	819	B
pain	-	825	I
could	-	830	O
identify	-	836	O
a	-	845	O
subset	-	847	O
safe	-	854	O
for	-	859	O
discharge	-	863	O
.	-	872	O

METHODS	19655282	874	O
:	-	881	O

We	19655282	883	O
prospectively	-	886	O
evaluated	-	900	O
the	-	910	O
safety	-	914	O
of	-	921	O
coronary	-	924	O
CTA	-	933	O
for	-	937	O
low	-	941	O
-	-	944	O
risk	-	945	O
patients	-	950	O
who	-	959	O
presented	-	963	O
to	-	973	O
the	-	976	O
ED	-	980	O
with	-	983	O
cocaineassociated	-	988	O
chest	-	1006	B
pain	-	1012	I
(	-	1017	O
self	-	1018	O
-	-	1022	O
reported	-	1023	O
or	-	1032	O
positive	-	1035	O
urine	-	1044	O
test	-	1050	O
)	-	1054	O
.	-	1055	O

Consecutive	19655282	1057	O
patients	-	1069	O
received	-	1078	O
either	-	1087	O
immediate	-	1094	O
coronary	-	1104	O
CTA	-	1113	O
in	-	1117	O
the	-	1120	O
ED	-	1124	O
(	-	1127	O
without	-	1128	O
serial	-	1136	O
markers	-	1143	O
)	-	1150	O
or	-	1152	O
underwent	-	1155	O
coronary	-	1165	O
CTA	-	1174	O
after	-	1178	O
a	-	1184	O
brief	-	1186	O
observation	-	1192	O
period	-	1204	O
with	-	1211	O
serial	-	1216	O
cardiac	-	1223	O
marker	-	1231	O
measurements	-	1238	O
.	-	1250	O

Patients	19655282	1252	O
with	-	1261	O
negative	-	1266	O
coronary	-	1275	O
CTA	-	1284	O
(	-	1288	O
maximal	-	1289	O
stenosis	-	1297	B
less	-	1306	O
than	-	1311	O
50	-	1316	O
%	-	1318	O
)	-	1319	O
were	-	1321	O
discharged	-	1326	O
.	-	1336	O

The	19655282	1338	O
main	-	1342	O
outcome	-	1347	O
was	-	1355	O
30	-	1359	O
-	-	1361	O
day	-	1362	O
cardiovascular	-	1366	O
death	-	1381	O
or	-	1387	O
myocardial	-	1390	B
infarction	-	1401	I
.	-	1411	O

RESULTS	19655282	1413	O
:	-	1420	O

A	19655282	1422	O
total	-	1424	O
of	-	1430	O
59	-	1433	O
patients	-	1436	O
with	-	1445	O
cocaine	-	1450	O
-	-	1457	O
associated	-	1458	O
chest	-	1469	B
pain	-	1475	I
were	-	1480	O
evaluated	-	1485	O
.	-	1494	O

Patients	19655282	1496	O
had	-	1505	O
a	-	1509	O
mean	-	1511	O
age	-	1516	O
of	-	1520	O
45	-	1523	O
.	-	1525	O
6	-	1526	O
+	-	1528	O
/	-	1529	O
-	-	1530	O

6	19655282	1532	O
.	-	1533	O
6	-	1534	O
yrs	-	1536	O
and	-	1540	O
were	-	1544	O
86	-	1549	O
%	-	1551	O
black	-	1553	O
,	-	1558	O
66	-	1560	O
%	-	1562	O
male	-	1564	O
.	-	1568	O

Seventy	19655282	1570	O
-	-	1577	O
nine	-	1578	O
percent	-	1583	O
had	-	1591	O
a	-	1595	O
normal	-	1597	O
or	-	1604	O
nonspecific	-	1607	O
ECG	-	1619	O
and	-	1623	O
85	-	1627	O
%	-	1629	O
had	-	1631	O
a	-	1635	O
TIMI	-	1637	O
score	-	1642	O
<	-	1648	O
2	-	1649	O
.	-	1650	O

Twenty	19655282	1652	O
patients	-	1659	O
received	-	1668	O
coronary	-	1677	O
CTA	-	1686	O
immediately	-	1690	O
in	-	1702	O
the	-	1705	O
ED	-	1709	O
,	-	1711	O
18	-	1713	O
of	-	1716	O
whom	-	1719	O
were	-	1724	O
discharged	-	1729	O
following	-	1740	O
CTA	-	1750	O
(	-	1754	O
90	-	1755	O
%	-	1757	O
)	-	1758	O
.	-	1759	O

Thirty	19655282	1761	O
-	-	1767	O
nine	-	1768	O
received	-	1773	O
coronary	-	1782	O
CTA	-	1791	O
after	-	1795	O
a	-	1801	O
brief	-	1803	O
observation	-	1809	O
period	-	1821	O
,	-	1827	O
with	-	1829	O
37	-	1834	O
discharged	-	1837	O
home	-	1848	O
following	-	1853	O
CTA	-	1863	O
(	-	1867	O
95	-	1868	O
%	-	1870	O
)	-	1871	O
.	-	1872	O

Six	19655282	1874	O
patients	-	1878	O
had	-	1887	O
coronary	-	1891	B
stenosis	-	1900	I
>	-	1909	O

or	19655282	1910	O
=	-	1912	O
50	-	1913	O
%	-	1915	O
.	-	1916	O

During	19655282	1918	O
the	-	1925	O
30	-	1929	O
-	-	1931	O
day	-	1932	O
follow	-	1936	O
-	-	1942	O
up	-	1943	O
period	-	1946	O
,	-	1952	O
no	-	1954	O
patients	-	1957	O
died	-	1966	O
of	-	1971	O
a	-	1974	O
cardiovascular	-	1976	O
event	-	1991	O
(	-	1997	O
0	-	1998	O
%	-	1999	O
;	-	2000	O
95	-	2002	O
%	-	2004	O
CI	-	2006	O
,	-	2008	O
0	-	2010	O
-	-	2011	O
6	-	2012	O
.	-	2013	O
1	-	2014	O
%	-	2015	O
)	-	2016	O
and	-	2018	O
no	-	2022	O
patient	-	2025	O
sustained	-	2033	O
a	-	2043	O
nonfatal	-	2045	O
myocardial	-	2054	B
infarction	-	2065	I
(	-	2076	O
0	-	2077	O
%	-	2078	O
;	-	2079	O
95	-	2081	O
%	-	2083	O
CI	-	2085	O
,	-	2087	O
0	-	2089	O
-	-	2090	O
6	-	2091	O
.	-	2092	O
1	-	2093	O
%	-	2094	O
)	-	2095	O
.	-	2096	O

CONCLUSIONS	19655282	2098	O
:	-	2109	O

Although	19655282	2111	O
cocaine	-	2120	O
-	-	2127	O
associated	-	2128	O
myocardial	-	2139	B
ischemia	-	2150	I
can	-	2159	O
result	-	2163	O
from	-	2170	O
coronary	-	2175	O
vasoconstriction	-	2184	O
,	-	2200	O
patients	-	2202	O
with	-	2211	O
cocaine	-	2216	O
associated	-	2224	O
chest	-	2235	B
pain	-	2241	I
,	-	2245	O
a	-	2247	O
non	-	2249	O
-	-	2252	O
ischemic	-	2253	B
ECG	-	2262	O
,	-	2265	O
and	-	2267	O
a	-	2271	O
TIMI	-	2273	O
risk	-	2278	O
score	-	2283	O
<	-	2289	O
2	-	2290	O
may	-	2292	O
be	-	2296	O
safely	-	2299	O
discharged	-	2306	O
from	-	2317	O
the	-	2322	O
ED	-	2326	O
after	-	2329	O
a	-	2335	O
negative	-	2337	O
coronary	-	2346	O
CTA	-	2355	O
with	-	2359	O
a	-	2364	O
low	-	2366	O
risk	-	2370	O
of	-	2375	O
30	-	2378	O
-	-	2380	O
day	-	2381	O
adverse	-	2385	O
events	-	2393	O
.	-	2399	O

Late	19715529	0	O
fulminant	-	5	O
posterior	-	15	B
reversible	-	25	I
encephalopathy	-	36	I
syndrome	-	51	I
after	-	60	O
liver	-	66	O
transplant	-	72	O
.	-	82	O

OBJECTIVES	19715529	84	O
:	-	94	O

Posterior	19715529	96	B
leukoencephalopathy	-	106	I
due	-	126	O
to	-	130	O
calcineurin	-	133	O
-	-	144	O
inhibitor	-	145	O
-	-	154	O
related	-	155	O
neurotoxicity	-	163	B
is	-	177	O
a	-	180	O
rare	-	182	O
but	-	187	O
severe	-	191	O
complication	-	198	O
that	-	211	O
results	-	216	O
from	-	224	O
treatment	-	229	O
with	-	239	O
immunosuppressive	-	244	O
agents	-	262	O
(	-	269	O
primarily	-	270	O
those	-	280	O
administered	-	286	O
after	-	299	O
a	-	305	O
liver	-	307	O
or	-	313	O
kidney	-	316	O
transplant	-	323	O
)	-	333	O
.	-	334	O

The	19715529	336	O
pathophysiologic	-	340	O
mechanisms	-	357	O
of	-	368	O
that	-	371	O
disorder	-	376	O
remain	-	385	O
unknown	-	392	O
.	-	399	O

CASE	19715529	401	O
:	-	405	O

We	19715529	407	O
report	-	410	O
the	-	417	O
case	-	421	O
of	-	426	O
a	-	429	O
46	-	431	O
-	-	433	O
year	-	434	O
-	-	438	O
old	-	439	O
woman	-	443	O
who	-	449	O
received	-	453	O
a	-	462	O
liver	-	464	O
transplant	-	470	O
in	-	481	O
our	-	484	O
center	-	488	O
as	-	495	O
treatment	-	498	O
for	-	508	O
alcoholic	-	512	B
cirrhosis	-	522	I
and	-	532	O
in	-	536	O
whom	-	539	O
either	-	544	O
a	-	551	O
fulminant	-	553	O
course	-	563	O
of	-	570	O
posterior	-	573	B
leukoencephalopathy	-	583	I
or	-	603	O
posterior	-	606	B
reversible	-	616	I
encephalopathy	-	627	I
syndrome	-	642	I
developed	-	651	O
110	-	661	O
days	-	665	O
after	-	670	O
transplant	-	676	O
.	-	686	O

After	19715529	688	O
an	-	694	O
initially	-	697	O
uneventful	-	707	O
course	-	718	O
after	-	725	O
the	-	731	O
transplant	-	735	O
,	-	745	O
the	-	747	O
patient	-	751	O
rapidly	-	759	O
fell	-	767	O
into	-	772	O
deep	-	777	O
coma	-	782	O
.	-	786	O

RESULTS	19715529	788	O
:	-	795	O

Cerebral	19715529	797	O
MRI	-	806	O
scan	-	810	O
showed	-	815	O
typical	-	822	O
signs	-	830	O
of	-	836	O
enhancement	-	839	O
in	-	851	O
the	-	854	O
pontine	-	858	O
and	-	866	O
posterior	-	870	O
regions	-	880	O
.	-	887	O

Switching	19715529	889	O
the	-	899	O
immunosuppressive	-	903	O
regimen	-	921	O
from	-	929	O
tacrolimus	-	934	O
to	-	945	O
cyclosporine	-	948	O
did	-	961	O
not	-	965	O
improve	-	969	O
the	-	977	O
clinical	-	981	O
situation	-	990	O
.	-	999	O

The	19715529	1001	O
termination	-	1005	O
of	-	1017	O
treatment	-	1020	O
with	-	1030	O
any	-	1035	O
calcineurin	-	1039	O
inhibitor	-	1051	O
resulted	-	1061	O
in	-	1070	O
a	-	1073	O
complete	-	1075	O
resolution	-	1084	O
of	-	1095	O
that	-	1098	O
complication	-	1103	O
.	-	1115	O

CONCLUSIONS	19715529	1117	O
:	-	1128	O

Posterior	19715529	1130	B
reversible	-	1140	I
encephalopathy	-	1151	I
syndrome	-	1166	I
after	-	1175	O
liver	-	1181	O
transplant	-	1187	O
is	-	1198	O
rare	-	1201	O
.	-	1205	O

We	19715529	1207	O
recommend	-	1210	O
a	-	1220	O
complete	-	1222	O
cessation	-	1231	O
of	-	1241	O
any	-	1244	O
calcineurin	-	1248	O
inhibitor	-	1260	O
rather	-	1270	O
than	-	1277	O
a	-	1282	O
dose	-	1284	O
reduction	-	1289	O
.	-	1298	O

Prolonged	19728177	0	O
hypothermia	-	10	B
as	-	22	O
a	-	25	O
bridge	-	27	O
to	-	34	O
recovery	-	37	O
for	-	46	O
cerebral	-	50	B
edema	-	59	I
and	-	65	O
intracranial	-	69	B
hypertension	-	82	I
associated	-	95	O
with	-	106	O
fulminant	-	111	B
hepatic	-	121	I
failure	-	129	I
.	-	136	O

BACKGROUND	19728177	138	O
:	-	148	O

To	19728177	150	O
review	-	153	O
evidence	-	160	O
-	-	168	O
based	-	169	O
treatment	-	175	O
options	-	185	O
in	-	193	O
patients	-	196	O
with	-	205	O
cerebral	-	210	B
edema	-	219	I
complicating	-	225	O
fulminant	-	238	B
hepatic	-	248	I
failure	-	256	I
(	-	264	O
FHF	-	265	B
)	-	268	O
and	-	270	O
discuss	-	274	O
the	-	282	O
potential	-	286	O
applications	-	296	O
of	-	309	O
hypothermia	-	312	B
.	-	323	O

METHOD	19728177	325	O
:	-	331	O

Case	19728177	333	O
-	-	337	O
based	-	338	O
observations	-	344	O
from	-	357	O
a	-	362	O
medical	-	364	O
intensive	-	372	O
care	-	382	O
unit	-	387	O
(	-	392	O
MICU	-	393	O
)	-	397	O
in	-	399	O
a	-	402	O
tertiary	-	404	O
care	-	413	O
facility	-	418	O
in	-	427	O
a	-	430	O
27	-	432	O
-	-	434	O
year	-	435	O
-	-	439	O
old	-	440	O
female	-	444	O
with	-	451	O
FHF	-	456	B
from	-	460	O
acetaminophen	-	465	O
and	-	479	O
resultant	-	483	O
cerebral	-	493	B
edema	-	502	I
.	-	507	O

RESULTS	19728177	509	O
:	-	516	O

Our	19728177	518	O
patient	-	522	O
was	-	530	O
admitted	-	534	O
to	-	543	O
the	-	546	O
MICU	-	550	O
after	-	555	O
being	-	561	O
found	-	567	O
unresponsive	-	573	O
with	-	586	O
presumed	-	591	O
toxicity	-	600	B
from	-	609	O
acetaminophen	-	614	O
which	-	628	O
was	-	634	O
ingested	-	638	O
over	-	647	O
a	-	652	O
2	-	654	O
-	-	655	O
day	-	656	O
period	-	660	O
.	-	666	O

The	19728177	668	O
patient	-	672	O
had	-	680	O
depressed	-	684	O
of	-	694	O
mental	-	697	O
status	-	704	O
lasting	-	711	O
at	-	719	O
least	-	722	O
24	-	728	O
h	-	731	O
prior	-	733	O
to	-	739	O
admission	-	742	O
.	-	751	O

Initial	19728177	753	O
evaluation	-	761	O
confirmed	-	772	O
FHF	-	782	B
from	-	786	O
acetaminophen	-	791	O
and	-	805	O
cerebral	-	809	B
edema	-	818	I
.	-	823	O

The	19728177	825	O
patient	-	829	O
was	-	837	O
treated	-	841	O
with	-	849	O
hyperosmolar	-	854	O
therapy	-	867	O
,	-	874	O
hyperventilation	-	876	B
,	-	892	O
sedation	-	894	O
,	-	902	O
and	-	904	O
chemical	-	908	O
paralysis	-	917	B
.	-	926	O

Her	19728177	928	O
intracranial	-	932	O
pressure	-	945	O
remained	-	954	O
elevated	-	963	O
despite	-	972	O
maximal	-	980	O
medical	-	988	O
therapy	-	996	O
.	-	1003	O

We	19728177	1005	O
then	-	1008	O
initiated	-	1013	O
therapeutic	-	1023	O
hypothermia	-	1035	B
which	-	1047	O
was	-	1053	O
continued	-	1057	O
for	-	1067	O
5	-	1071	O
days	-	1073	O
.	-	1077	O

At	19728177	1079	O
re	-	1082	O
-	-	1084	O
warming	-	1085	O
,	-	1092	O
patient	-	1094	O
had	-	1102	O
resolution	-	1106	O
of	-	1117	O
her	-	1120	O
cerebral	-	1124	B
edema	-	1133	I
and	-	1139	O
intracranial	-	1143	B
hypertension	-	1156	I
.	-	1168	O

At	19728177	1170	O
discharge	-	1173	O
,	-	1182	O
she	-	1184	O
had	-	1188	O
complete	-	1192	O
recovery	-	1201	O
of	-	1210	O
neurological	-	1213	O
and	-	1226	O
hepatic	-	1230	O
functions	-	1238	O
.	-	1247	O

CONCLUSION	19728177	1249	O
:	-	1259	O

In	19728177	1261	O
patients	-	1264	O
with	-	1273	O
FHF	-	1278	B
and	-	1282	O
cerebral	-	1286	B
edema	-	1295	I
from	-	1301	O
acetaminophen	-	1306	O
overdose	-	1320	B
,	-	1328	O
prolonged	-	1330	O
therapeutic	-	1340	O
hypothermia	-	1352	B
could	-	1364	O
potentially	-	1370	O
be	-	1382	O
used	-	1385	O
as	-	1390	O
a	-	1393	O
life	-	1395	O
saving	-	1400	O
therapy	-	1407	O
and	-	1415	O
a	-	1419	O
bridge	-	1421	O
to	-	1428	O
hepatic	-	1431	O
and	-	1439	O
neurological	-	1443	O
recovery	-	1456	O
.	-	1464	O

A	19728177	1466	O
clinical	-	1468	O
trial	-	1477	O
of	-	1483	O
hypothermia	-	1486	B
in	-	1498	O
patients	-	1501	O
with	-	1510	O
this	-	1515	O
condition	-	1520	O
is	-	1530	O
warranted	-	1533	O
.	-	1542	O

Binasal	19815465	0	B
visual	-	8	I
field	-	15	I
defects	-	21	I
are	-	29	O
not	-	33	O
specific	-	37	O
to	-	46	O
vigabatrin	-	49	O
.	-	59	O

This	19815465	61	O
study	-	66	O
investigated	-	72	O
the	-	85	O
visual	-	89	B
defects	-	96	I
associated	-	104	O
with	-	115	O
the	-	120	O
antiepileptic	-	124	O
drug	-	138	O
vigabatrin	-	143	O
(	-	154	O
VGB	-	155	O
)	-	158	O
.	-	159	O

Two	19815465	161	O
hundred	-	165	O
four	-	173	O
people	-	178	O
with	-	185	O
epilepsy	-	190	B
were	-	199	O
grouped	-	204	O
on	-	212	O
the	-	215	O
basis	-	219	O
of	-	225	O
antiepileptic	-	228	O
drug	-	242	O
therapy	-	247	O
(	-	255	O
current	-	256	O
,	-	263	O
previous	-	265	O
,	-	273	O
or	-	275	O
no	-	278	O
exposure	-	281	O
to	-	290	O
VGB	-	293	O
)	-	296	O
.	-	297	O

Groups	19815465	299	O
were	-	306	O
matched	-	311	O
with	-	319	O
respect	-	324	O
to	-	332	O
age	-	335	O
,	-	338	O
gender	-	340	O
,	-	346	O
and	-	348	O
seizure	-	352	B
frequency	-	360	O
.	-	369	O

All	19815465	371	O
patients	-	375	O
underwent	-	384	O
objective	-	394	O
assessment	-	404	O
of	-	415	O
electrophysiological	-	418	O
function	-	439	O
(	-	448	O
wide	-	449	O
-	-	453	O
field	-	454	O
multifocal	-	460	O
electroretinography	-	471	O
)	-	490	O
and	-	492	O
conventional	-	496	O
visual	-	509	O
field	-	516	O
testing	-	522	O
(	-	530	O
static	-	531	O
perimetry	-	538	O
)	-	547	O
.	-	548	O

Bilateral	19815465	550	O
visual	-	560	O
field	-	567	O
constriction	-	573	O
was	-	586	O
observed	-	590	O
in	-	599	O
59	-	602	O
%	-	604	O
of	-	606	O
patients	-	609	O
currently	-	618	O
taking	-	628	O
VGB	-	635	O
,	-	638	O
43	-	640	O
%	-	642	O
of	-	644	O
patients	-	647	O
who	-	656	O
previously	-	660	O
took	-	671	O
VGB	-	676	O
,	-	679	O
and	-	681	O
24	-	685	O
%	-	687	O
of	-	689	O
patients	-	692	O
with	-	701	O
no	-	706	O
exposure	-	709	O
to	-	718	O
VGB	-	721	O
.	-	724	O

Assessment	19815465	726	O
of	-	737	O
retinal	-	740	O
function	-	748	O
revealed	-	757	O
abnormal	-	766	O
responses	-	775	O
in	-	785	O
48	-	788	O
%	-	790	O
of	-	792	O
current	-	795	O
VGB	-	803	O
users	-	807	O
and	-	813	O
22	-	817	O
%	-	819	O
of	-	821	O
prior	-	824	O
VGB	-	830	O
users	-	834	O
,	-	839	O
but	-	841	O
in	-	845	O
none	-	848	O
of	-	853	O
the	-	856	O
patients	-	860	O
without	-	869	O
previous	-	877	O
exposure	-	886	O
to	-	895	O
VGB	-	898	O
.	-	901	O

Bilateral	19815465	903	B
visual	-	913	I
field	-	920	I
abnormalities	-	926	I
are	-	940	O
common	-	944	O
in	-	951	O
the	-	954	O
treated	-	958	O
epilepsy	-	966	B
population	-	975	O
,	-	985	O
irrespective	-	987	O
of	-	1000	O
drug	-	1003	O
history	-	1008	O
.	-	1015	O

Assessment	19815465	1017	O
by	-	1028	O
conventional	-	1031	O
static	-	1044	O
perimetry	-	1051	O
may	-	1061	O
neither	-	1065	O
be	-	1073	O
sufficiently	-	1076	O
sensitive	-	1089	O
nor	-	1099	O
specific	-	1103	O
to	-	1112	O
reliably	-	1115	O
identify	-	1124	O
retinal	-	1133	B
toxicity	-	1141	I
associated	-	1150	O
with	-	1161	O
VGB	-	1166	O
.	-	1169	O

Smoking	19841052	0	O
of	-	8	O
crack	-	11	O
cocaine	-	17	O
as	-	25	O
a	-	28	O
risk	-	30	O
factor	-	35	O
for	-	42	O
HIV	-	46	B
infection	-	50	I
among	-	60	O
people	-	66	O
who	-	73	O
use	-	77	O
injection	-	81	O
drugs	-	91	O
.	-	96	O

BACKGROUND	19841052	98	O
:	-	108	O

Little	19841052	110	O
is	-	117	O
known	-	120	O
about	-	126	O
the	-	132	O
possible	-	136	O
role	-	145	O
that	-	150	O
smoking	-	155	O
crack	-	163	O
cocaine	-	169	O
has	-	177	O
on	-	181	O
the	-	184	O
incidence	-	188	O
of	-	198	O
HIV	-	201	B
infection	-	205	I
.	-	214	O

Given	19841052	216	O
the	-	222	O
increasing	-	226	O
use	-	237	O
of	-	241	O
crack	-	244	O
cocaine	-	250	O
,	-	257	O
we	-	259	O
sought	-	262	O
to	-	269	O
examine	-	272	O
whether	-	280	O
use	-	288	O
of	-	292	O
this	-	295	O
illicit	-	300	O
drug	-	308	O
has	-	313	O
become	-	317	O
a	-	324	O
risk	-	326	O
factor	-	331	O
for	-	338	O
HIV	-	342	B
infection	-	346	I
.	-	355	O

METHODS	19841052	357	O
:	-	364	O

We	19841052	366	O
included	-	369	O
data	-	378	O
from	-	383	O
people	-	388	O
participating	-	395	O
in	-	409	O
the	-	412	O
Vancouver	-	416	O
Injection	-	426	O
Drug	-	436	O
Users	-	441	O
Study	-	447	O
who	-	453	O
reported	-	457	O
injecting	-	466	O
illicit	-	476	O
drugs	-	484	O
at	-	490	O
least	-	493	O
once	-	499	O
in	-	504	O
the	-	507	O
month	-	511	O
before	-	517	O
enrolment	-	524	O
,	-	533	O
lived	-	535	O
in	-	541	O
the	-	544	O
greater	-	548	O
Vancouver	-	556	O
area	-	566	O
,	-	570	O
were	-	572	O
HIV	-	577	O
-	-	580	O
negative	-	581	O
at	-	590	O
enrolment	-	593	O
and	-	603	O
completed	-	607	O
at	-	617	O
least	-	620	O
1	-	626	O
follow	-	628	O
-	-	634	O
up	-	635	O
study	-	638	O
visit	-	644	O
.	-	649	O

To	19841052	651	O
determine	-	654	O
whether	-	664	O
the	-	672	O
risk	-	676	O
of	-	681	O
HIV	-	684	B
seroconversion	-	688	I
among	-	703	O
daily	-	709	O
smokers	-	715	O
of	-	723	O
crack	-	726	O
cocaine	-	732	O
changed	-	740	O
over	-	748	O
time	-	753	O
,	-	757	O
we	-	759	O
used	-	762	O
Cox	-	767	O
proportional	-	771	O
hazards	-	784	O
regression	-	792	O
and	-	803	O
divided	-	807	O
the	-	815	O
study	-	819	O
into	-	825	O
3	-	830	O
periods	-	832	O
:	-	839	O
May	-	841	O
1	-	845	O
,	-	846	O
1996	-	848	O
-	-	852	O
Nov	-	853	O
.	-	856	O

30	19841052	858	O
,	-	860	O
1999	-	862	O

(	19841052	867	O
period	-	868	O
1	-	875	O
)	-	876	O
,	-	877	O
Dec	-	879	O
.	-	882	O
1	-	884	O
,	-	885	O
1999	-	887	O
-	-	891	O
Nov	-	892	O
.	-	895	O

30	19841052	897	O
,	-	899	O
2002	-	901	O

(	19841052	906	O
period	-	907	O
2	-	914	O
)	-	915	O
,	-	916	O
and	-	918	O
Dec	-	922	O
.	-	925	O
1	-	927	O
,	-	928	O
2002	-	930	O
-	-	934	O
Dec	-	935	O
.	-	938	O

30	19841052	940	O
,	-	942	O
2005	-	944	O

(	19841052	949	O
period	-	950	O
3	-	957	O
)	-	958	O
.	-	959	O

RESULTS	19841052	961	O
:	-	968	O

Overall	19841052	970	O
,	-	977	O
1048	-	979	O
eligible	-	984	O
injection	-	993	O
drug	-	1003	O
users	-	1008	O
were	-	1014	O
included	-	1019	O
in	-	1028	O
our	-	1031	O
study	-	1035	O
.	-	1040	O

Of	19841052	1042	O
these	-	1045	O
,	-	1050	O
137	-	1052	O
acquired	-	1056	O
HIV	-	1065	B
infection	-	1069	I
during	-	1079	O
follow	-	1086	O
-	-	1092	O
up	-	1093	O
.	-	1095	O

The	19841052	1097	O
mean	-	1101	O
proportion	-	1106	O
of	-	1117	O
participants	-	1120	O
who	-	1133	O
reported	-	1137	O
daily	-	1146	O
smoking	-	1152	O
of	-	1160	O
crack	-	1163	O
cocaine	-	1169	O
increased	-	1177	O
from	-	1187	O
11	-	1192	O
.	-	1194	O
6	-	1195	O
%	-	1196	O
in	-	1198	O
period	-	1201	O
1	-	1208	O
to	-	1210	O
39	-	1213	O
.	-	1215	O
7	-	1216	O
%	-	1217	O
in	-	1219	O
period	-	1222	O
3	-	1229	O
.	-	1230	O

After	19841052	1232	O
adjusting	-	1238	O
for	-	1248	O
potential	-	1252	O
confounders	-	1262	O
,	-	1273	O
we	-	1275	O
found	-	1278	O
that	-	1284	O
the	-	1289	O
risk	-	1293	O
of	-	1298	O
HIV	-	1301	B
seroconversion	-	1305	I
among	-	1320	O
participants	-	1326	O
who	-	1339	O
were	-	1343	O
daily	-	1348	O
smokers	-	1354	O
of	-	1362	O
crack	-	1365	O
cocaine	-	1371	O
increased	-	1379	O
over	-	1389	O
time	-	1394	O
(	-	1399	O
period	-	1400	O
1	-	1407	O
:	-	1408	O
hazard	-	1410	O
ratio	-	1417	O
[	-	1423	O
HR	-	1424	O
]	-	1426	O
1	-	1428	O
.	-	1429	O
03	-	1430	O
,	-	1432	O
95	-	1434	O
%	-	1436	O
confidence	-	1438	O
interval	-	1449	O
[	-	1458	O
CI	-	1459	O
]	-	1461	O
0	-	1463	O
.	-	1464	O
57	-	1465	O
-	-	1467	O
1	-	1468	O
.	-	1469	O
85	-	1470	O
;	-	1472	O
period	-	1474	O
2	-	1481	O
:	-	1482	O
HR	-	1484	O
1	-	1487	O
.	-	1488	O
68	-	1489	O
,	-	1491	O
95	-	1493	O
%	-	1495	O
CI	-	1497	O
1	-	1500	O
.	-	1501	O
01	-	1502	O
-	-	1504	O
2	-	1505	O
.	-	1506	O
80	-	1507	O
;	-	1509	O
and	-	1511	O
period	-	1515	O
3	-	1522	O
:	-	1523	O
HR	-	1525	O
2	-	1528	O
.	-	1529	O
74	-	1530	O
,	-	1532	O
95	-	1534	O
%	-	1536	O
CI	-	1538	O
1	-	1541	O
.	-	1542	O
06	-	1543	O
-	-	1545	O
7	-	1546	O
.	-	1547	O
11	-	1548	O
)	-	1550	O
.	-	1551	O

INTERPRETATION	19841052	1553	O
:	-	1567	O

Smoking	19841052	1569	O
of	-	1577	O
crack	-	1580	O
cocaine	-	1586	O
was	-	1594	O
found	-	1598	O
to	-	1604	O
be	-	1607	O
an	-	1610	O
independent	-	1613	O
risk	-	1625	O
factor	-	1630	O
for	-	1637	O
HIV	-	1641	B
seroconversion	-	1645	I
among	-	1660	O
people	-	1666	O
who	-	1673	O
were	-	1677	O
injection	-	1682	O
drug	-	1692	O
users	-	1697	O
.	-	1702	O

This	19841052	1704	O
finding	-	1709	O
points	-	1717	O
to	-	1724	O
the	-	1727	O
urgent	-	1731	O
need	-	1738	O
for	-	1743	O
evidence	-	1747	O
-	-	1755	O
based	-	1756	O
public	-	1762	O
health	-	1769	O
initiatives	-	1776	O
targeted	-	1788	O
at	-	1797	O
people	-	1800	O
who	-	1807	O
smoke	-	1811	O
crack	-	1817	O
cocaine	-	1823	O
.	-	1830	O

Fluoxetine	19914299	0	O
improves	-	11	O
the	-	20	O
memory	-	24	B
deficits	-	31	I
caused	-	40	O
by	-	47	O
the	-	50	O
chemotherapy	-	54	O
agent	-	67	O
5	-	73	O
-	-	74	O
fluorouracil	-	75	O
.	-	87	O

Cancer	19914299	89	B
patients	-	96	O
who	-	105	O
have	-	109	O
been	-	114	O
treated	-	119	O
with	-	127	O
systemic	-	132	O
adjuvant	-	141	O
chemotherapy	-	150	O
have	-	163	O
described	-	168	O
experiencing	-	178	O
deteriorations	-	191	O
in	-	206	O
cognition	-	209	O
.	-	218	O

A	19914299	220	O
widely	-	222	O
used	-	229	O
chemotherapeutic	-	234	O
agent	-	251	O
,	-	256	O
5	-	258	O
-	-	259	O
fluorouracil	-	260	O
(	-	273	O
5	-	274	O
-	-	275	O
FU	-	276	O
)	-	278	O
,	-	279	O
readily	-	281	O
crosses	-	289	O
the	-	297	O
blood	-	301	O
-	-	306	O
brain	-	307	O
barrier	-	313	O
and	-	321	O
so	-	325	O
could	-	328	O
have	-	334	O
a	-	339	O
direct	-	341	O
effect	-	348	O
on	-	355	O
brain	-	358	O
function	-	364	O
.	-	372	O

In	19914299	374	O
particular	-	377	O
this	-	388	O
anti	-	393	O
mitotic	-	398	O
drug	-	406	O
could	-	411	O
reduce	-	417	O
cell	-	424	O
proliferation	-	429	O
in	-	443	O
the	-	446	O
neurogenic	-	450	O
regions	-	461	O
of	-	469	O
the	-	472	O
adult	-	476	O
brain	-	482	O
.	-	487	O

In	19914299	489	O
contrast	-	492	O
reports	-	501	O
indicate	-	509	O
that	-	518	O
hippocampal	-	523	O
dependent	-	535	O
neurogenesis	-	545	O
and	-	558	O
cognition	-	562	O
are	-	572	O
enhanced	-	576	O
by	-	585	O
the	-	588	O
SSRI	-	592	O
antidepressant	-	597	O
Fluoxetine	-	612	O
.	-	622	O

In	19914299	624	O
this	-	627	O
investigation	-	632	O
the	-	646	O
behavioural	-	650	O
effects	-	662	O
of	-	670	O
chronic	-	673	O
(	-	681	O
two	-	682	O
week	-	686	O
)	-	690	O
treatment	-	692	O
with	-	702	O
5	-	707	O
-	-	708	O
FU	-	709	O
and	-	712	O
(	-	716	O
three	-	717	O
weeks	-	723	O
)	-	728	O
with	-	730	O
Fluoxetine	-	735	O
either	-	746	O
separately	-	753	O
or	-	764	O
in	-	767	O
combination	-	770	O
with	-	782	O
5	-	787	O
-	-	788	O
FU	-	789	O
were	-	792	O
tested	-	797	O
on	-	804	O
adult	-	807	O
Lister	-	813	O
hooded	-	820	O
rats	-	827	O
.	-	831	O

Behavioural	19914299	833	O
effects	-	845	O
were	-	853	O
tested	-	858	O
using	-	865	O
a	-	871	O
context	-	873	O
dependent	-	881	O
conditioned	-	891	O
emotional	-	903	O
response	-	913	O
test	-	922	O
(	-	927	O
CER	-	928	O
)	-	931	O
which	-	933	O
showed	-	939	O
that	-	946	O
animals	-	951	O
treated	-	959	O
with	-	967	O
5	-	972	O
-	-	973	O
FU	-	974	O
had	-	977	O
a	-	981	O
significant	-	983	O
reduction	-	995	O
in	-	1005	O
freezing	-	1008	O
time	-	1017	O
compared	-	1022	O
to	-	1031	O
controls	-	1034	O
.	-	1042	O

A	19914299	1044	O
separate	-	1046	O
group	-	1055	O
of	-	1061	O
animals	-	1064	O
was	-	1072	O
tested	-	1076	O
using	-	1083	O
a	-	1089	O
hippocampal	-	1091	O
dependent	-	1103	O
spatial	-	1113	O
working	-	1121	O
memory	-	1129	O
test	-	1136	O
,	-	1140	O
the	-	1142	O
object	-	1146	O
location	-	1153	O
recognition	-	1162	O
test	-	1174	O
(	-	1179	O
OLR	-	1180	O
)	-	1183	O
.	-	1184	O

Animals	19914299	1186	O
treated	-	1194	O
only	-	1202	O
with	-	1207	O
5	-	1212	O
-	-	1213	O
FU	-	1214	O
showed	-	1217	O
significant	-	1224	O
deficits	-	1236	O
in	-	1245	O
their	-	1248	O
ability	-	1254	O
to	-	1262	O
carry	-	1265	O
out	-	1271	O
the	-	1275	O
OLR	-	1279	O
task	-	1283	O
but	-	1288	O
co	-	1292	O
administration	-	1295	O
of	-	1310	O
Fluoxetine	-	1313	O
improved	-	1324	O
their	-	1333	O
performance	-	1339	O
.	-	1350	O

5	19914299	1352	O
-	-	1353	O
FU	-	1354	O
chemotherapy	-	1357	O
caused	-	1370	O
a	-	1377	O
significant	-	1379	O
reduction	-	1391	O
in	-	1401	O
the	-	1404	O
number	-	1408	O
of	-	1415	O
proliferating	-	1418	O
cells	-	1432	O
in	-	1438	O
the	-	1441	O
sub	-	1445	O
granular	-	1449	O
zone	-	1458	O
of	-	1463	O
the	-	1466	O
dentate	-	1470	O
gyrus	-	1478	O
compared	-	1484	O
to	-	1493	O
controls	-	1496	O
.	-	1504	O

This	19914299	1506	O
reduction	-	1511	O
was	-	1521	O
eliminated	-	1525	O
when	-	1536	O
Fluoxetine	-	1541	O
was	-	1552	O
co	-	1556	O
administered	-	1559	O
with	-	1572	O
5	-	1577	O
-	-	1578	O
FU	-	1579	O
.	-	1581	O

Fluoxetine	19914299	1583	O
on	-	1594	O
its	-	1597	O
own	-	1601	O
had	-	1605	O
no	-	1609	O
effect	-	1612	O
on	-	1619	O
proliferating	-	1622	O
cell	-	1636	O
number	-	1641	O
or	-	1648	O
behaviour	-	1651	O
.	-	1660	O

These	19914299	1662	O
findings	-	1668	O
suggest	-	1677	O
that	-	1685	O
5	-	1690	O
-	-	1691	O
FU	-	1692	O
can	-	1695	O
negatively	-	1699	O
affect	-	1710	O
both	-	1717	O
cell	-	1722	O
proliferation	-	1727	O
and	-	1741	O
hippocampal	-	1745	O
dependent	-	1757	O
working	-	1767	O
memory	-	1775	O
and	-	1782	O
that	-	1786	O
these	-	1791	O
deficits	-	1797	O
can	-	1806	O
be	-	1810	O
reversed	-	1813	O
by	-	1822	O
the	-	1825	O
simultaneous	-	1829	O
administration	-	1842	O
of	-	1857	O
the	-	1860	O
antidepressant	-	1864	O
Fluoxetine	-	1879	O
.	-	1889	O

Liver	19920070	0	O
-	-	5	O
specific	-	6	O
ablation	-	15	O
of	-	24	O
integrin	-	27	O
-	-	35	O
linked	-	36	O
kinase	-	43	O
in	-	50	O
mice	-	53	O
results	-	58	O
in	-	66	O
enhanced	-	69	O
and	-	78	O
prolonged	-	82	O
cell	-	92	O
proliferation	-	97	O
and	-	111	O
hepatomegaly	-	115	B
after	-	128	O
phenobarbital	-	134	O
administration	-	148	O
.	-	162	O

We	19920070	164	O
have	-	167	O
recently	-	172	O
demonstrated	-	181	O
that	-	194	O
disruption	-	199	O
of	-	210	O
extracellular	-	213	O
matrix	-	227	O
(	-	234	O
ECM	-	235	O
)	-	238	O
/	-	239	O
integrin	-	240	O
signaling	-	249	O
via	-	259	O
elimination	-	263	O
of	-	275	O
integrin	-	278	O
-	-	286	O
linked	-	287	O
kinase	-	294	O
(	-	301	O
ILK	-	302	O
)	-	305	O
in	-	307	O
hepatocytes	-	310	O
interferes	-	322	O
with	-	333	O
signals	-	338	O
leading	-	346	O
to	-	354	O
termination	-	357	O
of	-	369	O
liver	-	372	O
regeneration	-	378	O
.	-	390	O

This	19920070	392	O
study	-	397	O
investigates	-	403	O
the	-	416	O
role	-	420	O
of	-	425	O
ILK	-	428	O
in	-	432	O
liver	-	435	O
enlargement	-	441	O
induced	-	453	O
by	-	461	O
phenobarbital	-	464	O
(	-	478	O
PB	-	479	O
)	-	481	O
.	-	482	O

Wild	19920070	484	O
-	-	488	O
type	-	489	O
(	-	494	O
WT	-	495	O
)	-	497	O
and	-	499	O
ILK	-	503	O
:	-	506	O

liver	19920070	507	O
-	-	512	O
/	-	513	O
-	-	514	O
mice	-	516	O
were	-	521	O
given	-	526	O
PB	-	532	O
(	-	535	O
0	-	536	O
.	-	537	O
1	-	538	O
%	-	539	O
in	-	541	O
drinking	-	544	O
water	-	553	O
)	-	558	O
for	-	560	O
10	-	564	O
days	-	567	O
.	-	571	O

Livers	19920070	573	O
were	-	580	O
harvested	-	585	O
on	-	595	O
2	-	598	O
,	-	599	O
5	-	601	O
,	-	602	O
and	-	604	O
10	-	608	O
days	-	611	O
during	-	616	O
PB	-	623	O
administration	-	626	O
.	-	640	O

In	19920070	642	O
the	-	645	O
hepatocyte	-	649	O
-	-	659	O
specific	-	660	O
ILK	-	669	O
/	-	672	O
liver	-	673	O
-	-	678	O
/	-	679	O
-	-	680	O
mice	-	682	O
,	-	686	O
the	-	688	O
liver	-	692	O
:	-	697	O
body	-	698	O
weight	-	703	O
ratio	-	710	O
was	-	716	O
more	-	720	O
than	-	725	O
double	-	730	O
as	-	737	O
compared	-	740	O
to	-	749	O
0	-	752	O
h	-	754	O
at	-	756	O
day	-	759	O
2	-	763	O
(	-	765	O
2	-	766	O
.	-	767	O
5	-	768	O
times	-	770	O
)	-	775	O
,	-	776	O
while	-	778	O
at	-	784	O
days	-	787	O
5	-	792	O
and	-	794	O
10	-	798	O
,	-	800	O
it	-	802	O
was	-	805	O
enlarged	-	809	O
three	-	818	O
times	-	824	O
.	-	829	O

In	19920070	831	O
the	-	834	O
WT	-	838	O
mice	-	841	O
,	-	845	O
the	-	847	O
increase	-	851	O
was	-	860	O
as	-	864	O
expected	-	867	O
from	-	876	O
previous	-	881	O
literature	-	890	O
(	-	901	O
1	-	902	O
.	-	903	O
8	-	904	O
times	-	906	O
)	-	911	O
and	-	913	O
seems	-	917	O
to	-	923	O
have	-	926	O
leveled	-	931	O
off	-	939	O
after	-	943	O
day	-	949	O
2	-	953	O
.	-	954	O

There	19920070	956	O
were	-	962	O
slightly	-	967	O
increased	-	976	O
proliferating	-	986	O
cell	-	1000	O
nuclear	-	1005	O
antigen	-	1013	O
-	-	1020	O
positive	-	1021	O
cells	-	1030	O
in	-	1036	O
the	-	1039	O
ILK	-	1043	O
/	-	1046	O
liver	-	1047	O
-	-	1052	O
/	-	1053	O
-	-	1054	O
animals	-	1056	O
at	-	1064	O
day	-	1067	O
2	-	1071	O
as	-	1073	O
compared	-	1076	O
to	-	1085	O
WT	-	1088	O
after	-	1091	O
PB	-	1097	O
administration	-	1100	O
.	-	1114	O

In	19920070	1116	O
the	-	1119	O
WT	-	1123	O
animals	-	1126	O
,	-	1133	O
the	-	1135	O
proliferative	-	1139	O
response	-	1153	O
had	-	1162	O
come	-	1166	O
back	-	1171	O
to	-	1176	O
normal	-	1179	O
by	-	1186	O
days	-	1189	O
5	-	1194	O
and	-	1196	O
10	-	1200	O
.	-	1202	O

Hepatocytes	19920070	1204	O
of	-	1216	O
the	-	1219	O
ILK	-	1223	O
/	-	1226	O
liver	-	1227	O
-	-	1232	O
/	-	1233	O
-	-	1234	O
mice	-	1236	O
continued	-	1241	O
to	-	1251	O
proliferate	-	1254	O
up	-	1266	O
until	-	1269	O
day	-	1275	O
10	-	1279	O
.	-	1281	O

ILK	19920070	1283	O
/	-	1286	O

liver	19920070	1287	O
-	-	1292	O
/	-	1293	O
-	-	1294	O
mice	-	1296	O
also	-	1301	O
showed	-	1306	O
increased	-	1313	O
expression	-	1323	O
of	-	1334	O
key	-	1337	O
genes	-	1341	O
involved	-	1347	O
in	-	1356	O
hepatocyte	-	1359	O
proliferation	-	1370	O
at	-	1384	O
different	-	1387	O
time	-	1397	O
points	-	1402	O
during	-	1409	O
PB	-	1416	O
administration	-	1419	O
.	-	1433	O

In	19920070	1435	O
summary	-	1438	O
,	-	1445	O
ECM	-	1447	O
proteins	-	1451	O
communicate	-	1460	O
with	-	1472	O
the	-	1477	O
signaling	-	1481	O
machinery	-	1491	O
of	-	1501	O
dividing	-	1504	O
cells	-	1513	O
via	-	1519	O
ILK	-	1523	O
to	-	1527	O
regulate	-	1530	O
hepatocyte	-	1539	O
proliferation	-	1550	O
and	-	1564	O
termination	-	1568	O
of	-	1580	O
the	-	1583	O
proliferative	-	1587	O
response	-	1601	O
.	-	1609	O

Lack	19920070	1611	O
of	-	1616	O
ILK	-	1619	O
in	-	1623	O
the	-	1626	O
hepatocytes	-	1630	O
imparts	-	1642	O
prolonged	-	1650	O
proliferative	-	1660	O
response	-	1674	O
not	-	1683	O
only	-	1687	O
to	-	1692	O
stimuli	-	1695	O
related	-	1703	O
to	-	1711	O
liver	-	1714	O
regeneration	-	1720	O
but	-	1733	O
also	-	1737	O
to	-	1742	O
xenobiotic	-	1745	O
chemical	-	1756	O
mitogens	-	1765	O
,	-	1773	O
such	-	1775	O
as	-	1780	O
PB	-	1783	O
.	-	1785	O

Decreased	19967075	0	O
Expression	-	10	O
of	-	21	O
Na	-	24	O
/	-	26	O
K	-	27	O
-	-	28	O
ATPase	-	29	O
,	-	35	O
NHE3	-	37	O
,	-	41	O
NBC1	-	43	O
,	-	47	O
AQP1	-	49	O
and	-	54	O
OAT	-	58	O
in	-	62	O
Gentamicin	-	65	O
-	-	75	O
induced	-	76	O
Nephropathy	-	84	B
.	-	95	O

The	19967075	97	O
present	-	101	O
study	-	109	O
was	-	115	O
aimed	-	119	O
to	-	125	O
determine	-	128	O
whether	-	138	O
there	-	146	O
is	-	152	O
an	-	155	O
altered	-	158	O
regulation	-	166	O
of	-	177	O
tubular	-	180	O
transporters	-	188	O
in	-	201	O
gentamicin	-	204	O
-	-	214	O
induced	-	215	O
nephropathy	-	223	B
.	-	234	O

Sprague	19967075	236	O
-	-	243	O
Dawley	-	244	O
male	-	251	O
rats	-	256	O
(	-	261	O
200	-	262	O
~	-	265	O
250	-	266	O
g	-	270	O
)	-	271	O
were	-	273	O
subcutaneously	-	278	O
injected	-	293	O
with	-	302	O
gentamicin	-	307	O
(	-	318	O
100	-	319	O
mg	-	323	O
/	-	325	O
kg	-	326	O
per	-	329	O
day	-	333	O
)	-	336	O
for	-	338	O
7	-	342	O
days	-	344	O
,	-	348	O
and	-	350	O
the	-	354	O
expression	-	358	O
of	-	369	O
tubular	-	372	O
transporters	-	380	O
was	-	393	O
determined	-	397	O
by	-	408	O
immunoblotting	-	411	O
and	-	426	O
immunohistochemistry	-	430	O
.	-	450	O

The	19967075	452	O
mRNA	-	456	O
and	-	461	O
protein	-	465	O
expression	-	473	O
of	-	484	O
OAT	-	487	O
was	-	491	O
also	-	495	O
determined	-	500	O
.	-	510	O

Gentamicin	19967075	512	O
-	-	522	O
treated	-	523	O
rats	-	531	O
exhibited	-	536	O
significantly	-	546	O
decreased	-	560	O
creatinine	-	570	O
clearance	-	581	O
along	-	591	O
with	-	597	O
increased	-	602	O
plasma	-	612	O
creatinine	-	619	O
levels	-	630	O
.	-	636	O

Accordingly	19967075	638	O
,	-	649	O
the	-	651	O
fractional	-	655	O
excretion	-	666	O
of	-	676	O
sodium	-	679	O
increased	-	686	O
.	-	695	O

Urine	19967075	697	O
volume	-	703	O
was	-	710	O
increased	-	714	O
,	-	723	O
while	-	725	O
urine	-	731	O
osmolality	-	737	O
and	-	748	O
free	-	752	O
water	-	757	O
reabsorption	-	763	O
were	-	776	O
decreased	-	781	O
.	-	790	O

Immunoblotting	19967075	792	O
and	-	807	O
immunohistochemistry	-	811	O
revealed	-	832	O
decreased	-	841	O
expression	-	851	O
of	-	862	O
Na	-	865	O
(	-	867	O
+	-	868	O
)	-	869	O
/	-	870	O
K	-	871	O
(	-	872	O
+	-	873	O
)	-	874	O
-	-	875	O
ATPase	-	876	O
,	-	882	O
NHE3	-	884	O
,	-	888	O
NBC1	-	890	O
,	-	894	O
and	-	896	O
AQP1	-	900	O
in	-	905	O
the	-	908	O
kidney	-	912	O
of	-	919	O
gentamicin	-	922	O
-	-	932	O
treated	-	933	O
rats	-	941	O
.	-	945	O

The	19967075	947	O
expression	-	951	O
of	-	962	O
OAT1	-	965	O
and	-	970	O
OAT3	-	974	O
was	-	979	O
also	-	983	O
decreased	-	988	O
.	-	997	O

Gentamicin	19967075	999	O
-	-	1009	O
induced	-	1010	O
nephropathy	-	1018	B
may	-	1030	O
at	-	1034	O
least	-	1037	O
in	-	1043	O
part	-	1046	O
be	-	1051	O
causally	-	1054	O
related	-	1063	O
with	-	1071	O
a	-	1076	O
decreased	-	1078	O
expression	-	1088	O
of	-	1099	O
Na	-	1102	O
(	-	1104	O
+	-	1105	O
)	-	1106	O
/	-	1107	O
K	-	1108	O
(	-	1109	O
+	-	1110	O
)	-	1111	O
-	-	1112	O
ATPase	-	1113	O
,	-	1119	O
NHE3	-	1121	O
,	-	1125	O
NBC1	-	1127	O
,	-	1131	O
AQP1	-	1133	O
and	-	1138	O
OAT	-	1142	O
.	-	1145	O

Longitudinal	20024739	0	O
association	-	13	O
of	-	25	O
alcohol	-	28	O
use	-	36	O
with	-	40	O
HIV	-	45	B
disease	-	49	I
progression	-	57	O
and	-	69	O
psychological	-	73	O
health	-	87	O
of	-	94	O
women	-	97	O
with	-	103	O
HIV	-	108	O
.	-	111	O

We	20024739	113	O
evaluated	-	116	O
the	-	126	O
association	-	130	O
of	-	142	O
alcohol	-	145	O
consumption	-	153	O
and	-	165	O
depression	-	169	B
,	-	179	O
and	-	181	O
their	-	185	O
effects	-	191	O
on	-	199	O
HIV	-	202	B
disease	-	206	I
progression	-	214	O
among	-	226	O
women	-	232	O
with	-	238	O
HIV	-	243	O
.	-	246	O

The	20024739	248	O
study	-	252	O
included	-	258	O
871	-	267	O
women	-	271	O
with	-	277	O
HIV	-	282	O
who	-	286	O
were	-	290	O
recruited	-	295	O
from	-	305	O
1993	-	310	O
-	-	314	O
1995	-	315	O
in	-	320	O
four	-	323	O
US	-	328	O
cities	-	331	O
.	-	337	O

The	20024739	339	O
participants	-	343	O
had	-	356	O
physical	-	360	O
examination	-	369	O
,	-	380	O
medical	-	382	O
record	-	390	O
extraction	-	397	O
,	-	407	O
and	-	409	O
venipuncture	-	413	O
,	-	425	O
CD4	-	427	O
+	-	430	O
T	-	431	O
-	-	432	O
cell	-	433	O
counts	-	438	O
determination	-	445	O
,	-	458	O
measurement	-	460	O
of	-	472	O
depression	-	475	B
symptoms	-	486	O
(	-	495	O
using	-	496	O
the	-	502	O
self	-	506	O
-	-	510	O
report	-	511	O
Center	-	518	O
for	-	525	O
Epidemiological	-	529	O
Studies	-	545	O
-	-	552	O
Depression	-	553	B
Scale	-	564	O
)	-	569	O
,	-	570	O
and	-	572	O
alcohol	-	576	O
use	-	584	O
assessment	-	588	O
at	-	599	O
enrollment	-	602	O
,	-	612	O
and	-	614	O
semiannually	-	618	O
until	-	631	O
March	-	637	O
2000	-	643	O
.	-	647	O

Multilevel	20024739	649	O
random	-	660	O
coefficient	-	667	O
ordinal	-	679	O
models	-	687	O
as	-	694	O
well	-	697	O
as	-	702	O
multilevel	-	705	O
models	-	716	O
with	-	723	O
joint	-	728	O
responses	-	734	O
were	-	744	O
used	-	749	O
in	-	754	O
the	-	757	O
analysis	-	761	O
.	-	769	O

There	20024739	771	O
was	-	777	O
no	-	781	O
significant	-	784	O
association	-	796	O
between	-	808	O
level	-	816	O
of	-	822	O
alcohol	-	825	O
use	-	833	O
and	-	837	O
CD4	-	841	O
+	-	844	O
T	-	846	O
-	-	847	O
cell	-	848	O
counts	-	853	O
.	-	859	O

When	20024739	861	O
participants	-	866	O
were	-	879	O
stratified	-	884	O
by	-	895	O
antiretroviral	-	898	O
therapy	-	913	O
(	-	921	O
ART	-	922	O
)	-	925	O
use	-	927	O
,	-	930	O
the	-	932	O
association	-	936	O
between	-	948	O
alcohol	-	956	O
and	-	964	O
CD4	-	968	O
+	-	971	O
T	-	973	O
-	-	974	O
cell	-	975	O
did	-	980	O
not	-	984	O
reach	-	988	O
statistical	-	994	O
significance	-	1006	O
.	-	1018	O

The	20024739	1020	O
association	-	1024	O
between	-	1036	O
alcohol	-	1044	O
consumption	-	1052	O
and	-	1064	O
depression	-	1068	B
was	-	1079	O
significant	-	1083	O
(	-	1095	O
p	-	1096	O
<	-	1097	O
0	-	1098	O
.	-	1099	O
001	-	1100	O
)	-	1103	O
.	-	1104	O

Depression	20024739	1106	B
had	-	1117	O
a	-	1121	O
significant	-	1123	O
negative	-	1135	O
effect	-	1144	O
on	-	1151	O
CD4	-	1154	O
+	-	1157	O
T	-	1159	O
-	-	1160	O
cell	-	1161	O
counts	-	1166	O
over	-	1173	O
time	-	1178	O
regardless	-	1183	O
of	-	1194	O
ART	-	1197	O
use	-	1201	O
.	-	1204	O

Our	20024739	1206	O
findings	-	1210	O
suggest	-	1219	O
that	-	1227	O
alcohol	-	1232	O
consumption	-	1240	O
has	-	1252	O
a	-	1256	O
direct	-	1258	O
association	-	1265	O
with	-	1277	O
depression	-	1282	B
.	-	1292	O

Moreover	20024739	1294	O
,	-	1302	O
depression	-	1304	B
is	-	1315	O
associated	-	1318	O
with	-	1329	O
HIV	-	1334	B
disease	-	1338	I
progression	-	1346	O
.	-	1357	O

Our	20024739	1359	O
findings	-	1363	O
have	-	1372	O
implications	-	1377	O
for	-	1390	O
the	-	1394	O
provision	-	1398	O
of	-	1408	O
alcohol	-	1411	O
use	-	1419	O
interventions	-	1423	O
and	-	1437	O
psychological	-	1441	O
resources	-	1455	O
to	-	1465	O
improve	-	1468	O
the	-	1476	O
health	-	1480	O
of	-	1487	O
women	-	1490	O
with	-	1496	O
HIV	-	1501	O
.	-	1504	O

Chemokine	20034406	0	O
CCL2	-	10	O
and	-	15	O
its	-	19	O
receptor	-	23	O
CCR2	-	32	O
are	-	37	O
increased	-	41	O
in	-	51	O
the	-	54	O
hippocampus	-	58	O
following	-	70	O
pilocarpine	-	80	O
-	-	91	O
induced	-	92	O
status	-	100	B
epilepticus	-	107	I
.	-	118	O

BACKGROUND	20034406	120	O
:	-	130	O
Neuroinflammation	-	132	B
occurs	-	150	O
after	-	157	O
seizures	-	163	B
and	-	172	O
is	-	176	O
implicated	-	179	O
in	-	190	O
epileptogenesis	-	193	O
.	-	208	O

CCR2	20034406	210	O
is	-	215	O
a	-	218	O
chemokine	-	220	O
receptor	-	230	O
for	-	239	O
CCL2	-	243	O
and	-	248	O
their	-	252	O
interaction	-	258	O
mediates	-	270	O
monocyte	-	279	O
infiltration	-	288	O
in	-	301	O
the	-	304	O
neuroinflammatory	-	308	B
cascade	-	326	O
triggered	-	334	O
in	-	344	O
different	-	347	O
brain	-	357	O
pathologies	-	363	O
.	-	374	O

In	20034406	376	O
this	-	379	O
work	-	384	O
CCR2	-	389	O
and	-	394	O
CCL2	-	398	O
expression	-	403	O
were	-	414	O
examined	-	419	O
following	-	428	O
status	-	438	B
epilepticus	-	445	I
(	-	457	O
SE	-	458	B
)	-	460	O
induced	-	462	O
by	-	470	O
pilocarpine	-	473	O
injection	-	485	O
.	-	494	O

METHODS	20034406	496	O
:	-	503	O

SE	20034406	505	B
was	-	508	O
induced	-	512	O
by	-	520	O
pilocarpine	-	523	O
injection	-	535	O
.	-	544	O

Control	20034406	546	O
rats	-	554	O
were	-	559	O
injected	-	564	O
with	-	573	O
saline	-	578	O
instead	-	585	O
of	-	593	O
pilocarpine	-	596	O
.	-	607	O

Five	20034406	609	O
days	-	614	O
after	-	619	O
SE	-	625	B
,	-	627	O
CCR2	-	629	O
staining	-	634	O
in	-	643	O
neurons	-	646	O
and	-	654	O
glial	-	658	O
cells	-	664	O
was	-	670	O
examined	-	674	O
using	-	683	O
imunohistochemical	-	689	O
analyses	-	708	O
.	-	716	O

The	20034406	718	O
number	-	722	O
of	-	729	O
CCR2	-	732	O
positive	-	737	O
cells	-	746	O
was	-	752	O
determined	-	756	O
using	-	767	O
stereology	-	773	O
probes	-	784	O
in	-	791	O
the	-	794	O
hippocampus	-	798	O
.	-	809	O

CCL2	20034406	811	O
expression	-	816	O
in	-	827	O
the	-	830	O
hippocampus	-	834	O
was	-	846	O
examined	-	850	O
by	-	859	O
molecular	-	862	O
assay	-	872	O
.	-	877	O

RESULTS	20034406	879	O
:	-	886	O

Increased	20034406	888	O
CCR2	-	898	O
was	-	903	O
observed	-	907	O
in	-	916	O
the	-	919	O
hippocampus	-	923	O
after	-	935	O
SE	-	941	B
.	-	943	O

Seizures	20034406	945	B
also	-	954	O
resulted	-	959	O
in	-	968	O
alterations	-	971	O
to	-	983	O
the	-	986	O
cell	-	990	O
types	-	995	O
expressing	-	1001	O
CCR2	-	1012	O
.	-	1016	O

Increased	20034406	1018	O
numbers	-	1028	O
of	-	1036	O
neurons	-	1039	O
that	-	1047	O
expressed	-	1052	O
CCR2	-	1062	O
was	-	1067	O
observed	-	1071	O
following	-	1080	O
SE	-	1090	B
.	-	1092	O

Microglial	20034406	1094	O
cells	-	1105	O
were	-	1111	O
more	-	1116	O
closely	-	1121	O
apposed	-	1129	O
to	-	1137	O
the	-	1140	O
CCR2	-	1144	O
-	-	1148	O
labeled	-	1149	O
cells	-	1157	O
in	-	1163	O
SE	-	1166	B
rats	-	1169	O
.	-	1173	O

In	20034406	1175	O
addition	-	1178	O
,	-	1186	O
rats	-	1188	O
that	-	1193	O
experienced	-	1198	O
SE	-	1210	B
exhibited	-	1213	O
CCR2	-	1223	O
-	-	1227	O
labeling	-	1228	O
in	-	1237	O
populations	-	1240	O
of	-	1252	O
hypertrophied	-	1255	B
astrocytes	-	1269	O
,	-	1279	O
especially	-	1281	O
in	-	1292	O
CA1	-	1295	O
and	-	1299	O
dentate	-	1303	O
gyrus	-	1311	O
.	-	1316	O

These	20034406	1318	O
CCR2	-	1324	O
+	-	1328	O
astroctytes	-	1330	O
were	-	1342	O
not	-	1347	O
observed	-	1351	O
in	-	1360	O
control	-	1363	O
rats	-	1371	O
.	-	1375	O

Examination	20034406	1377	O
of	-	1389	O
CCL2	-	1392	O
expression	-	1397	O
showed	-	1408	O
that	-	1415	O
it	-	1420	O
was	-	1423	O
elevated	-	1427	O
in	-	1436	O
the	-	1439	O
hippocampus	-	1443	O
following	-	1455	O
SE	-	1465	B
.	-	1467	O

CONCLUSION	20034406	1469	O
:	-	1479	O

The	20034406	1481	O
data	-	1485	O
show	-	1490	O
that	-	1495	O
CCR2	-	1500	O
and	-	1505	O
CCL2	-	1509	O
are	-	1514	O
up	-	1518	O
-	-	1520	O
regulated	-	1521	O
in	-	1531	O
the	-	1534	O
hippocampus	-	1538	O
after	-	1550	O
pilocarpine	-	1556	O
-	-	1567	O
induced	-	1568	O
SE	-	1576	B
.	-	1578	O

Seizures	20034406	1580	B
also	-	1589	O
result	-	1594	O
in	-	1601	O
changes	-	1604	O
to	-	1612	O
CCR2	-	1615	O
receptor	-	1620	O
expression	-	1629	O
in	-	1640	O
neurons	-	1643	O
and	-	1651	O
astrocytes	-	1655	O
.	-	1665	O

These	20034406	1667	O
changes	-	1673	O
might	-	1681	O
be	-	1687	O
involved	-	1690	O
in	-	1699	O
detrimental	-	1702	O
neuroplasticity	-	1714	O
and	-	1730	O
neuroinflammatory	-	1734	B
changes	-	1752	O
that	-	1760	O
occur	-	1765	O
following	-	1771	O
seizures	-	1781	B
.	-	1789	O

Metallothionein	20046642	0	O
induction	-	16	O
reduces	-	26	O
caspase	-	34	O
-	-	41	O
3	-	42	O
activity	-	44	O
and	-	53	O
TNFalpha	-	57	O
levels	-	66	O
with	-	73	O
preservation	-	78	O
of	-	91	O
cognitive	-	94	O
function	-	104	O
and	-	113	O
intact	-	117	O
hippocampal	-	124	O
neurons	-	136	O
in	-	144	O
carmustine	-	147	O
-	-	157	O
treated	-	158	O
rats	-	166	O
.	-	170	O

Hippocampal	20046642	172	O
integrity	-	184	O
is	-	194	O
essential	-	197	O
for	-	207	O
cognitive	-	211	O
functions	-	221	O
.	-	230	O

On	20046642	232	O
the	-	235	O
other	-	239	O
hand	-	245	O
,	-	249	O
induction	-	251	O
of	-	261	O
metallothionein	-	264	O
(	-	280	O
MT	-	281	O
)	-	283	O
by	-	285	O
ZnSO	-	288	O
(	-	292	O
4	-	293	O
)	-	294	O
and	-	296	O
its	-	300	O
role	-	304	O
in	-	309	O
neuroprotection	-	312	O
has	-	328	O
been	-	332	O
documented	-	337	O
.	-	347	O

The	20046642	349	O
present	-	353	O
study	-	361	O
aimed	-	367	O
to	-	373	O
explore	-	376	O
the	-	384	O
effect	-	388	O
of	-	395	O
MT	-	398	O
induction	-	401	O
on	-	411	O
carmustine	-	414	O
(	-	425	O
BCNU	-	426	O
)	-	430	O
-	-	431	O
induced	-	432	O
hippocampal	-	440	O
cognitive	-	452	B
dysfunction	-	462	I
in	-	474	O
rats	-	477	O
.	-	481	O

A	20046642	483	O
total	-	485	O
of	-	491	O
60	-	494	O
male	-	497	O
Wistar	-	502	O
albino	-	509	O
rats	-	516	O
were	-	521	O
randomly	-	526	O
divided	-	535	O
into	-	543	O
four	-	548	O
groups	-	553	O
(	-	560	O
15	-	561	O
/	-	563	O
group	-	564	O
)	-	569	O
:	-	570	O
The	-	572	O
control	-	576	O
group	-	584	O
injected	-	590	O
with	-	599	O
single	-	604	O
doses	-	611	O
of	-	617	O
normal	-	620	O
saline	-	627	O
(	-	634	O
i	-	635	O
.	-	636	O
c	-	637	O
.	-	638	O
v	-	639	O
)	-	640	O
followed	-	642	O
24	-	651	O
h	-	654	O
later	-	656	O
by	-	662	O
BCNU	-	665	O
solvent	-	670	O
(	-	678	O
i	-	679	O
.	-	680	O
v	-	681	O
)	-	682	O
.	-	683	O

The	20046642	685	O
second	-	689	O
group	-	696	O
administered	-	702	O
ZnSO	-	715	O
(	-	719	O
4	-	720	O
)	-	721	O
(	-	723	O
0	-	724	O
.	-	725	O
1	-	726	O
micromol	-	728	O
/	-	736	O
10	-	737	O
microl	-	740	O
normal	-	747	O
saline	-	754	O
,	-	760	O
i	-	762	O
.	-	763	O
c	-	764	O
.	-	765	O
v	-	766	O
,	-	767	O
once	-	769	O
)	-	773	O
then	-	775	O
BCNU	-	780	O
solvent	-	785	O
(	-	793	O
i	-	794	O
.	-	795	O
v	-	796	O
)	-	797	O
after	-	799	O
24	-	805	O
h	-	808	O
.	-	809	O
Third	-	811	O
group	-	817	O
received	-	823	O
BCNU	-	832	O
(	-	837	O
20	-	838	O
mg	-	841	O
/	-	843	O
kg	-	844	O
,	-	846	O
i	-	848	O
.	-	849	O
v	-	850	O
,	-	851	O
once	-	853	O
)	-	857	O
24	-	859	O
h	-	862	O
after	-	864	O
injection	-	870	O
with	-	880	O
normal	-	885	O
saline	-	892	O
(	-	899	O
i	-	900	O
.	-	901	O
c	-	902	O
.	-	903	O
v	-	904	O
)	-	905	O
.	-	906	O

Fourth	20046642	908	O
group	-	915	O
received	-	921	O
a	-	930	O
single	-	932	O
dose	-	939	O
of	-	944	O
ZnSO	-	947	O
(	-	951	O
4	-	952	O
)	-	953	O
(	-	955	O
0	-	956	O
.	-	957	O
1	-	958	O
micromol	-	960	O
/	-	968	O
10	-	969	O
microl	-	972	O
normal	-	979	O
saline	-	986	O
,	-	992	O
i	-	994	O
.	-	995	O
c	-	996	O
.	-	997	O
v	-	998	O
)	-	999	O
then	-	1001	O
BCNU	-	1006	O
(	-	1011	O
20	-	1012	O
mg	-	1015	O
/	-	1017	O
kg	-	1018	O
,	-	1020	O
i	-	1022	O
.	-	1023	O
v	-	1024	O
,	-	1025	O
once	-	1027	O
)	-	1031	O
after	-	1033	O
24	-	1039	O
h	-	1042	O
.	-	1043	O

The	20046642	1045	O
obtained	-	1049	O
data	-	1058	O
revealed	-	1063	O
that	-	1072	O
BCNU	-	1077	O
administration	-	1082	O
resulted	-	1097	O
in	-	1106	O
deterioration	-	1109	B
of	-	1123	I
learning	-	1126	I
and	-	1135	I
short	-	1139	I
-	-	1144	I
term	-	1145	I
memory	-	1150	I
(	-	1157	O
STM	-	1158	O
)	-	1161	O
,	-	1162	O
as	-	1164	O
measured	-	1167	O
by	-	1176	O
using	-	1179	O
radial	-	1185	O
arm	-	1192	O
water	-	1196	O
maze	-	1202	O
,	-	1206	O
accompanied	-	1208	O
with	-	1220	O
decreased	-	1225	O
hippocampal	-	1235	O
glutathione	-	1247	O
reductase	-	1259	O
(	-	1269	O
GR	-	1270	O
)	-	1272	O
activity	-	1274	O
and	-	1283	O
reduced	-	1287	O
glutathione	-	1295	O
(	-	1307	O
GSH	-	1308	O
)	-	1311	O
content	-	1313	O
.	-	1320	O

Also	20046642	1322	O
,	-	1326	O
BCNU	-	1328	O
administration	-	1333	O
increased	-	1348	O
serum	-	1358	O
tumor	-	1364	B
necrosis	-	1370	B
factor	-	1379	O
-	-	1385	O
alpha	-	1386	O
(	-	1392	O
TNFalpha	-	1393	O
)	-	1401	O
,	-	1402	O
hippocampal	-	1404	O
MT	-	1416	O
and	-	1419	O
malondialdehyde	-	1423	O
(	-	1439	O
MDA	-	1440	O
)	-	1443	O
contents	-	1445	O
as	-	1454	O
well	-	1457	O
as	-	1462	O
caspase	-	1465	O
-	-	1472	O
3	-	1473	O
activity	-	1475	O
in	-	1484	O
addition	-	1487	O
to	-	1496	O
histological	-	1499	O
alterations	-	1512	O
.	-	1523	O

ZnSO	20046642	1525	O
(	-	1529	O
4	-	1530	O
)	-	1531	O
pretreatment	-	1533	O
counteracted	-	1546	O
BCNU	-	1559	O
-	-	1563	O
induced	-	1564	O
inhibition	-	1572	O
of	-	1583	O
GR	-	1586	O
and	-	1589	O
depletion	-	1593	O
of	-	1603	O
GSH	-	1606	O
and	-	1610	O
resulted	-	1614	O
in	-	1623	O
significant	-	1626	O
reduction	-	1638	O
in	-	1648	O
the	-	1651	O
levels	-	1655	O
of	-	1662	O
MDA	-	1665	O
and	-	1669	O
TNFalpha	-	1673	O
as	-	1682	O
well	-	1685	O
as	-	1690	O
the	-	1693	O
activity	-	1697	O
of	-	1706	O
caspase	-	1709	O
-	-	1716	O
3	-	1717	O
.	-	1718	O

The	20046642	1720	O
histological	-	1724	O
features	-	1737	O
were	-	1746	O
improved	-	1751	O
in	-	1760	O
hippocampus	-	1763	O
of	-	1775	O
rats	-	1778	O
treated	-	1783	O
with	-	1791	O
ZnSO	-	1796	O
(	-	1800	O
4	-	1801	O
)	-	1802	O
+	-	1804	O
BCNU	-	1806	O
compared	-	1811	O
to	-	1820	O
only	-	1823	O
BCNU	-	1828	O
-	-	1832	O
treated	-	1833	O
animals	-	1841	O
.	-	1848	O

In	20046642	1850	O
conclusion	-	1853	O
,	-	1863	O
MT	-	1865	O
induction	-	1868	O
halts	-	1878	O
BCNU	-	1884	O
-	-	1888	O
induced	-	1889	O
hippocampal	-	1897	O
toxicity	-	1909	B
as	-	1918	O
it	-	1921	O
prevented	-	1924	O
GR	-	1934	O
inhibition	-	1937	O
and	-	1948	O
GSH	-	1952	O
depletion	-	1956	O
and	-	1966	O
counteracted	-	1970	O
the	-	1983	O
increased	-	1987	O
levels	-	1997	O
of	-	2004	O
TNFalpha	-	2007	O
,	-	2015	O
MDA	-	2017	O
and	-	2021	O
caspase	-	2025	O
-	-	2032	O
3	-	2033	O
activity	-	2035	O
with	-	2044	O
subsequent	-	2049	O
preservation	-	2060	O
of	-	2073	O
cognition	-	2076	O
.	-	2085	O

Fatal	20129423	0	O
carbamazepine	-	6	O
induced	-	20	O
fulminant	-	28	B
eosinophilic	-	38	I
(	-	51	O
hypersensitivity	-	52	B
)	-	68	O
myocarditis	-	70	B
:	-	81	O
emphasis	-	83	O
on	-	92	O
anatomical	-	95	O
and	-	106	O
histological	-	110	O
characteristics	-	123	O
,	-	138	O
mechanisms	-	140	O
and	-	151	O
genetics	-	155	O
of	-	164	O
drug	-	167	B
hypersensitivity	-	172	I
and	-	189	O
differential	-	193	O
diagnosis	-	206	O
.	-	215	O

The	20129423	217	O
most	-	221	O
severe	-	226	O
adverse	-	233	O
reactions	-	241	O
to	-	251	O
carbamazepine	-	254	O
have	-	268	O
been	-	273	O
observed	-	278	O
in	-	287	O
the	-	290	O
haemopoietic	-	294	O
system	-	307	O
,	-	313	O
the	-	315	O
liver	-	319	O
and	-	325	O
the	-	329	O
cardiovascular	-	333	O
system	-	348	O
.	-	354	O

A	20129423	356	O
frequently	-	358	O
fatal	-	369	O
,	-	374	O
although	-	376	O
exceptionally	-	385	O
rare	-	399	O
side	-	404	O
effect	-	409	O
of	-	416	O
carbamazepine	-	419	O
is	-	433	O
necrotizing	-	436	O
eosinophilic	-	448	O
(	-	461	O
hypersensitivity	-	462	B
)	-	478	O
myocarditis	-	480	B
.	-	491	O

We	20129423	493	O
report	-	496	O
a	-	503	O
case	-	505	O
of	-	510	O
hypersensitivity	-	513	B
myocarditis	-	530	B
secondary	-	542	O
to	-	552	O
administration	-	555	O
of	-	570	O
carbamazepine	-	573	O
.	-	586	O

Acute	20129423	588	O
hypersensitivity	-	594	B
myocarditis	-	611	B
was	-	623	O
not	-	627	O
suspected	-	631	O
clinically	-	641	O
,	-	651	O
and	-	653	O
the	-	657	O
diagnosis	-	661	O
was	-	671	O
made	-	675	O
post	-	680	O
-	-	684	O
mortem	-	685	O
.	-	691	O

Histology	20129423	693	O
revealed	-	703	O
diffuse	-	712	O
infiltration	-	720	O
of	-	733	O
the	-	736	O
myocardium	-	740	O
by	-	751	O
eosinophils	-	754	O
and	-	766	O
lymphocytes	-	770	O
with	-	782	O
myocyte	-	787	O
damage	-	795	O
.	-	801	O

Clinically	20129423	803	O
,	-	813	O
death	-	815	O
was	-	821	O
due	-	825	O
to	-	829	O
cardiogenic	-	832	B
shock	-	844	I
.	-	849	O

To	20129423	851	O
best	-	854	O
of	-	859	O
our	-	862	O
knowledge	-	866	O
this	-	876	O
is	-	881	O
the	-	884	O
second	-	888	O
case	-	895	O
of	-	900	O
fatal	-	903	O
carbamazepine	-	909	O
induced	-	923	O
myocarditis	-	931	B
reported	-	943	O
in	-	952	O
English	-	955	O
literature	-	963	O
.	-	973	O

Neuropsychiatric	20169779	0	O
behaviors	-	17	O
in	-	27	O
the	-	30	O
MPTP	-	34	O
marmoset	-	39	O
model	-	48	O
of	-	54	O
Parkinson	-	57	B
's	-	66	I
disease	-	69	I
.	-	76	O

OBJECTIVES	20169779	78	O
:	-	88	O

Neuropsychiatric	20169779	90	O
symptoms	-	107	O
are	-	116	O
increasingly	-	120	O
recognised	-	133	O
as	-	144	O
a	-	147	O
significant	-	149	O
problem	-	161	O
in	-	169	O
patients	-	172	O
with	-	181	O
Parkinson	-	186	B
's	-	195	I
disease	-	198	I
(	-	206	O
PD	-	207	B
)	-	209	O
.	-	210	O

These	20169779	212	O
symptoms	-	218	O
may	-	227	O
be	-	231	O
due	-	234	O
to	-	238	O
'	-	241	O
sensitisation	-	242	O
'	-	255	O
following	-	257	O
repeated	-	267	O
levodopa	-	276	O
treatment	-	285	O
or	-	295	O
a	-	298	O
direct	-	300	O
effect	-	307	O
of	-	314	O
dopamine	-	317	O
on	-	326	O
the	-	329	O
disease	-	333	O
state	-	341	O
.	-	346	O

The	20169779	348	O
levodopa	-	352	O
-	-	360	O
treated	-	361	O
MPTP	-	369	O
-	-	373	O
lesioned	-	374	O
marmoset	-	383	O
was	-	392	O
used	-	396	O
as	-	401	O
a	-	404	O
model	-	406	O
of	-	412	O
neuropsychiatric	-	415	B
symptoms	-	432	I
in	-	441	O
PD	-	444	B
patients	-	447	O
.	-	455	O

Here	20169779	457	O
we	-	462	O
compare	-	465	O
the	-	473	O
time	-	477	O
course	-	482	O
of	-	489	O
levodopa	-	492	O
-	-	500	O
induced	-	501	O
motor	-	509	O
fluctuations	-	515	O
and	-	528	O
neuropsychiatric	-	532	B
-	-	548	I
like	-	549	I
behaviors	-	554	I
to	-	564	O
determine	-	567	O
the	-	577	O
relationship	-	581	O
between	-	594	O
duration	-	602	O
of	-	611	O
treatment	-	614	O
and	-	624	O
onset	-	628	O
of	-	634	O
symptoms	-	637	O
.	-	645	O

METHODS	20169779	647	O
:	-	654	O

Marmosets	20169779	656	O
were	-	666	O
administered	-	671	O
1	-	684	O
-	-	685	O
methyl	-	686	O
-	-	692	O
4	-	693	O
-	-	694	O
phenyl	-	695	O
-	-	701	O
1	-	702	O
,	-	703	O
2	-	704	O
,	-	705	O
3	-	706	O
,	-	707	O
6	-	708	O
-	-	709	O
tetrahydropyridine	-	710	O
(	-	729	O
2	-	730	O
.	-	731	O
0	-	732	O
mg	-	734	O
/	-	736	O
kg	-	737	O
s	-	740	O
.	-	741	O
c	-	742	O
.	-	743	O
)	-	744	O
for	-	746	O
five	-	750	O
days	-	755	O
,	-	759	O
resulting	-	761	O
in	-	771	O
stable	-	774	O
parkinsonism	-	781	B
.	-	793	O

Levodopa	20169779	795	O
(	-	804	O
15	-	805	O
mg	-	808	O
/	-	810	O
kg	-	811	O
and	-	814	O
benserazide	-	818	O
,	-	829	O
3	-	831	O
.	-	832	O
75	-	833	O
mg	-	836	O
/	-	838	O
kg	-	839	O
)	-	841	O

p	20169779	843	O
.	-	844	O
o	-	845	O
.	-	846	O

b	20169779	848	O
.	-	849	O
i	-	850	O
.	-	851	O
d	-	852	O
,	-	853	O
was	-	855	O
administered	-	859	O
for	-	872	O
30	-	876	O
days	-	879	O
.	-	883	O

Animals	20169779	885	O
were	-	893	O
evaluated	-	898	O
for	-	908	O
parkinsonian	-	912	B
disability	-	925	I
,	-	935	O
dyskinesia	-	937	B
and	-	948	O
on	-	952	O
-	-	954	O
time	-	955	O
(	-	960	O
motor	-	961	O
fluctuations	-	967	O
)	-	979	O
and	-	981	O
neuropsychiatric	-	985	B
-	-	1001	I
like	-	1002	I
behaviors	-	1007	I
on	-	1017	O
Day	-	1020	O
0	-	1024	O
(	-	1026	O
prior	-	1027	O
to	-	1033	O
levodopa	-	1036	O
)	-	1044	O
and	-	1046	O
on	-	1050	O
Days	-	1053	O
1	-	1058	O
,	-	1059	O
7	-	1061	O
,	-	1062	O
13	-	1064	O
,	-	1066	O
27	-	1068	O
and	-	1071	O
30	-	1075	O
of	-	1078	O
treatment	-	1081	O
using	-	1091	O
post	-	1097	O
hoc	-	1102	O
DVD	-	1106	O
analysis	-	1110	O
by	-	1119	O
a	-	1122	O
trained	-	1124	O
rater	-	1132	O
,	-	1137	O
blind	-	1139	O
to	-	1145	O
the	-	1148	O
treatment	-	1152	O
day	-	1162	O
.	-	1165	O

RESULTS	20169779	1167	O
:	-	1174	O

The	20169779	1176	O
neuropsychiatric	-	1180	B
-	-	1196	I
like	-	1197	I
behavior	-	1202	I
rating	-	1211	O
scale	-	1218	O
demonstrated	-	1224	O
high	-	1237	O
interrater	-	1242	O
reliability	-	1253	O
between	-	1265	O
three	-	1273	O
trained	-	1279	O
raters	-	1287	O
of	-	1294	O
differing	-	1297	O
professional	-	1307	O
backgrounds	-	1320	O
.	-	1331	O

As	20169779	1333	O
anticipated	-	1336	O
,	-	1347	O
animals	-	1349	O
exhibited	-	1357	O
a	-	1367	O
progressive	-	1369	O
increase	-	1381	O
in	-	1390	O
levodopa	-	1393	O
-	-	1401	O
induced	-	1402	O
motor	-	1410	O
fluctuations	-	1416	O
,	-	1428	O
dyskinesia	-	1430	B
and	-	1441	O
wearing	-	1445	O
-	-	1452	O
off	-	1453	O
,	-	1456	O
that	-	1458	O
correlated	-	1463	O
with	-	1474	O
the	-	1479	O
duration	-	1483	O
of	-	1492	O
levodopa	-	1495	O
therapy	-	1504	O
.	-	1511	O

In	20169779	1513	O
contrast	-	1516	O
,	-	1524	O
levodopa	-	1526	O
-	-	1534	O
induced	-	1535	O
neuropsychiatric	-	1543	B
-	-	1559	I
like	-	1560	I
behaviors	-	1565	I
were	-	1575	O
present	-	1580	O
on	-	1588	O
Day	-	1591	O
1	-	1595	O
of	-	1597	O
levodopa	-	1600	O
treatment	-	1609	O
and	-	1619	O
their	-	1623	O
severity	-	1629	O
did	-	1638	O
not	-	1642	O
correlate	-	1646	O
with	-	1656	O
duration	-	1661	O
of	-	1670	O
treatment	-	1673	O
.	-	1682	O

CONCLUSIONS	20169779	1684	O
:	-	1695	O

The	20169779	1697	O
data	-	1701	O
suggest	-	1706	O
that	-	1714	O
neuropsychiatric	-	1719	B
disorders	-	1736	I
in	-	1746	O
PD	-	1749	B
are	-	1752	O
more	-	1756	O
likely	-	1761	O
an	-	1768	O
interaction	-	1771	O
between	-	1783	O
levodopa	-	1791	O
and	-	1800	O
the	-	1804	O
disease	-	1808	O
state	-	1816	O
than	-	1822	O
a	-	1827	O
consequence	-	1829	O
of	-	1841	O
sensitisation	-	1844	O
to	-	1858	O
repeated	-	1861	O
dopaminergic	-	1870	O
therapy	-	1883	O
.	-	1890	O

Contrast	20192893	0	O
medium	-	9	O
nephrotoxicity	-	16	B
after	-	31	O
renal	-	37	O
artery	-	43	O
and	-	50	O
coronary	-	54	O
angioplasty	-	63	O
.	-	74	O

BACKGROUND	20192893	76	O
:	-	86	O

Renal	20192893	88	B
dysfunction	-	94	I
induced	-	106	O
by	-	114	O
iodinated	-	117	O
contrast	-	127	O
medium	-	136	O
(	-	143	O
CM	-	144	O
)	-	146	O
administration	-	148	O
can	-	163	O
minimize	-	167	O
the	-	176	O
benefit	-	180	O
of	-	188	O
the	-	191	O
interventional	-	195	O
procedure	-	210	O
in	-	220	O
patients	-	223	O
undergoing	-	232	O
renal	-	243	O
angioplasty	-	249	O
(	-	261	O
PTRA	-	262	O
)	-	266	O
.	-	267	O

PURPOSE	20192893	269	O
:	-	276	O

To	20192893	278	O
compare	-	281	O
the	-	289	O
susceptibility	-	293	O
to	-	308	O
nephrotoxic	-	311	B
effect	-	323	O
of	-	330	O
CM	-	333	O
in	-	336	O
patients	-	339	O
undergoing	-	348	O
PTRA	-	359	O
with	-	364	O
that	-	369	O
of	-	374	O
patients	-	377	O
submitted	-	386	O
to	-	396	O
percutaneous	-	399	O
coronary	-	412	O
intervention	-	421	O
(	-	434	O
PCI	-	435	O
)	-	438	O
.	-	439	O

MATERIAL	20192893	441	O
AND	-	450	O
METHODS	-	454	O
:	-	461	O

A	20192893	463	O
total	-	465	O
of	-	471	O
33	-	474	O
patients	-	477	O
successfully	-	486	O
treated	-	499	O
with	-	507	O
PTRA	-	512	O
(	-	517	O
PTRA	-	518	O
group	-	523	O
,	-	528	O
mean	-	530	O
age	-	535	O
70	-	539	O
+	-	541	O
/	-	542	O
-	-	543	O
12	-	544	O
years	-	547	O
,	-	552	O
23	-	554	O
female	-	557	O
,	-	563	O
basal	-	565	O
creatinine	-	571	O
1	-	582	O
.	-	583	O
46	-	584	O
+	-	586	O
/	-	587	O
-	-	588	O
0	-	589	O
.	-	590	O
79	-	591	O
,	-	593	O
range	-	595	O
0	-	601	O
.	-	602	O
7	-	603	O
-	-	604	O
4	-	605	O
.	-	606	O
9	-	607	O
mg	-	609	O
/	-	611	O
dl	-	612	O
)	-	614	O
were	-	616	O
compared	-	621	O
with	-	630	O
33	-	635	O
patients	-	638	O
undergoing	-	647	O
successful	-	658	O
PCI	-	669	O
(	-	673	O
PCI	-	674	O
group	-	678	O
)	-	683	O
,	-	684	O
matched	-	686	O
for	-	694	O
basal	-	698	O
creatinine	-	704	O
(	-	715	O
1	-	716	O
.	-	717	O
44	-	718	O
+	-	720	O
/	-	721	O
-	-	722	O
0	-	723	O
.	-	724	O
6	-	725	O
,	-	726	O
range	-	728	O
0	-	734	O
.	-	735	O
7	-	736	O
-	-	737	O
3	-	738	O
.	-	739	O
4	-	740	O
mg	-	742	O
/	-	744	O
dl	-	745	O
)	-	747	O
,	-	748	O
gender	-	750	O
,	-	756	O
and	-	758	O
age	-	762	O
.	-	765	O

In	20192893	767	O
both	-	770	O
groups	-	775	O
postprocedural	-	782	O
(	-	797	O
48	-	798	O
h	-	801	O
)	-	802	O
serum	-	804	O
creatinine	-	810	O
was	-	821	O
measured	-	825	O
.	-	833	O

RESULTS	20192893	835	O
:	-	842	O

Postprocedural	20192893	844	O
creatinine	-	859	O
level	-	870	O
decreased	-	876	O
nonsignificantly	-	886	O
in	-	903	O
the	-	906	O
PTRA	-	910	O
group	-	915	O
(	-	921	O
1	-	922	O
.	-	923	O
46	-	924	O
+	-	926	O
/	-	927	O
-	-	928	O
0	-	929	O
.	-	930	O
8	-	931	O
vs	-	933	O
.	-	935	O
1	-	937	O
.	-	938	O
34	-	939	O
+	-	941	O
/	-	942	O
-	-	943	O
0	-	944	O
.	-	945	O
5	-	946	O
mg	-	948	O
/	-	950	O
dl	-	951	O
,	-	953	O
P	-	955	O
=	-	956	O
NS	-	957	O
)	-	959	O
and	-	961	O
increased	-	965	O
significantly	-	975	O
in	-	989	O
the	-	992	O
PCI	-	996	O
group	-	1000	O
(	-	1006	O
1	-	1007	O
.	-	1008	O
44	-	1009	O
+	-	1011	O
/	-	1012	O
-	-	1013	O
0	-	1014	O
.	-	1015	O
6	-	1016	O
vs	-	1018	O
.	-	1020	O
1	-	1022	O
.	-	1023	O
57	-	1024	O
+	-	1026	O
/	-	1027	O
-	-	1028	O
0	-	1029	O
.	-	1030	O
7	-	1031	O
mg	-	1033	O
/	-	1035	O
dl	-	1036	O
,	-	1038	O
P	-	1040	O
<	-	1041	O
0	-	1042	O
.	-	1043	O
02	-	1044	O
)	-	1046	O
.	-	1047	O

Changes	20192893	1049	O
in	-	1057	O
serum	-	1060	O
creatinine	-	1066	O
after	-	1077	O
intervention	-	1083	O
(	-	1096	O
after	-	1097	O
-	-	1102	O
before	-	1103	O
)	-	1109	O
were	-	1111	O
significantly	-	1116	O
different	-	1130	O
between	-	1140	O
the	-	1148	O
PTRA	-	1152	O
and	-	1157	O
PCI	-	1161	O
groups	-	1165	O
(	-	1172	O
-	-	1173	O
0	-	1174	O
.	-	1175	O
12	-	1176	O
+	-	1178	O
/	-	1179	O
-	-	1180	O
0	-	1181	O
.	-	1182	O
5	-	1183	O
vs	-	1185	O
.	-	1187	O
0	-	1189	O
.	-	1190	O
13	-	1191	O
+	-	1193	O
/	-	1194	O
-	-	1195	O
0	-	1196	O
.	-	1197	O
3	-	1198	O
,	-	1199	O
P	-	1201	O
=	-	1202	O
0	-	1203	O
.	-	1204	O
014	-	1205	O
)	-	1208	O
.	-	1209	O

This	20192893	1211	O
difference	-	1216	O
was	-	1227	O
not	-	1231	O
related	-	1235	O
to	-	1243	O
either	-	1246	O
a	-	1253	O
different	-	1255	O
clinical	-	1265	O
risk	-	1274	O
profile	-	1279	O
or	-	1287	O
to	-	1290	O
the	-	1293	O
volume	-	1297	O
of	-	1304	O
CM	-	1307	O
administered	-	1310	O
.	-	1322	O

CONCLUSION	20192893	1324	O
:	-	1334	O

In	20192893	1336	O
this	-	1339	O
preliminary	-	1344	O
study	-	1356	O
patients	-	1362	O
submitted	-	1371	O
to	-	1381	O
PTRA	-	1384	O
showed	-	1389	O
a	-	1396	O
lower	-	1398	O
susceptibility	-	1404	O
to	-	1419	O
renal	-	1422	B
damage	-	1428	I
induced	-	1435	O
by	-	1443	O
CM	-	1446	O
administration	-	1449	O
than	-	1464	O
PCI	-	1469	O
patients	-	1473	O
.	-	1481	O

The	20192893	1483	O
effectiveness	-	1487	O
of	-	1501	O
PTRA	-	1504	O
on	-	1509	O
renal	-	1512	O
function	-	1518	O
seems	-	1527	O
to	-	1533	O
be	-	1536	O
barely	-	1539	O
influenced	-	1546	O
by	-	1557	O
CM	-	1560	O
toxicity	-	1563	B
.	-	1571	O

Medical	20408947	0	O
and	-	8	O
psychiatric	-	12	O
outcomes	-	24	O
for	-	33	O
patients	-	37	O
transplanted	-	46	O
for	-	59	O
acetaminophen	-	63	O
-	-	76	O
induced	-	77	O
acute	-	85	B
liver	-	91	I
failure	-	97	I
:	-	104	O
a	-	106	O
case	-	108	O
-	-	112	O
control	-	113	O
study	-	121	O
.	-	126	O

BACKGROUND	20408947	128	O
:	-	138	O
Acetaminophen	-	140	O
-	-	153	O
induced	-	154	O
hepatotoxicity	-	162	B
is	-	177	O
the	-	180	O
most	-	184	O
common	-	189	O
cause	-	196	O
of	-	202	O
acute	-	205	B
liver	-	211	I
failure	-	217	I
(	-	225	O
ALF	-	226	B
)	-	229	O
in	-	231	O
the	-	234	O
UK	-	238	O
.	-	240	O

Patients	20408947	242	O
often	-	251	O
consume	-	257	O
the	-	265	O
drug	-	269	O
with	-	274	O
suicidal	-	279	O
intent	-	288	O
or	-	295	O
with	-	298	O
a	-	303	O
background	-	305	O
of	-	316	O
substance	-	319	O
dependence	-	329	O
.	-	339	O

AIMS	20408947	341	O
AND	-	346	O
METHODS	-	350	O
:	-	357	O

We	20408947	359	O
compared	-	362	O
the	-	371	O
severity	-	375	O
of	-	384	O
pretransplant	-	387	O
illness	-	401	O
,	-	408	O
psychiatric	-	410	O
co	-	422	O
-	-	424	O
morbidity	-	425	O
,	-	434	O
medical	-	436	O
and	-	444	O
psychosocial	-	448	O
outcomes	-	461	O
of	-	470	O
all	-	473	O
patients	-	477	O
who	-	486	O
had	-	490	O
undergone	-	494	O
liver	-	504	O
transplantation	-	510	O
(	-	526	O
LT	-	527	O
)	-	529	O
emergently	-	531	O
between	-	542	O
1999	-	550	O
-	-	554	O
2004	-	555	O
for	-	560	O
acetaminophen	-	564	O
-	-	577	O
induced	-	578	O
ALF	-	586	B
(	-	590	O
n	-	591	O
=	-	592	O
36	-	593	O
)	-	595	O
with	-	597	O
age	-	602	O
-	-	605	O
and	-	607	O
sex	-	611	O
-	-	614	O
matched	-	615	O
patients	-	623	O
undergoing	-	632	O
emergent	-	643	O
LT	-	652	O
for	-	655	O
non	-	659	O
-	-	662	O
acetaminophen	-	663	O
-	-	676	O
induced	-	677	O
ALF	-	685	B
(	-	689	O
n	-	690	O
=	-	691	O
35	-	692	O
)	-	694	O
and	-	696	O
elective	-	700	O
LT	-	709	O
for	-	712	O
chronic	-	716	B
liver	-	724	I
disease	-	730	I
(	-	738	O
CLD	-	739	B
,	-	742	O
n	-	744	O
=	-	745	O
34	-	746	O
)	-	748	O
.	-	749	O

RESULTS	20408947	751	O
:	-	758	O

Acetaminophen	20408947	760	O
-	-	773	O
induced	-	774	O
ALF	-	782	B
patients	-	786	O
undergoing	-	795	O
LT	-	806	O
had	-	809	O
a	-	813	O
greater	-	815	O
severity	-	823	O
of	-	832	O
pre	-	835	O
-	-	838	O
LT	-	839	O
illness	-	842	O
reflected	-	850	O
by	-	860	O
higher	-	863	O
Acute	-	870	O
Physiology	-	876	O
and	-	887	O
Chronic	-	891	O
Health	-	899	O
Evaluation	-	906	O
II	-	917	O
scores	-	920	O
and	-	927	O
requirement	-	931	O
for	-	943	O
organ	-	947	O
support	-	953	O
compared	-	961	O
with	-	970	O
the	-	975	O
other	-	979	O
two	-	985	O
groups	-	989	O
.	-	995	O

Twenty	20408947	997	O
(	-	1004	O
56	-	1005	O
%	-	1007	O
)	-	1008	O
acetaminophen	-	1010	O
-	-	1023	O
induced	-	1024	O
ALF	-	1032	B
patients	-	1036	O
had	-	1045	O
a	-	1049	O
formal	-	1051	O
psychiatric	-	1058	O
diagnosis	-	1070	O
before	-	1080	O
LT	-	1087	O
(	-	1090	O
non	-	1091	O
-	-	1094	O
acetaminophen	-	1095	O
-	-	1108	O
induced	-	1109	O
ALF	-	1117	B
=	-	1120	O
0	-	1121	O
/	-	1122	O
35	-	1123	O
,	-	1125	O
CLD	-	1127	B
=	-	1130	O
2	-	1131	O
/	-	1132	O
34	-	1133	O
;	-	1135	O
P	-	1137	O
<	-	1138	O
0	-	1139	O
.	-	1140	O
01	-	1141	O
for	-	1144	O
all	-	1148	O
)	-	1151	O
and	-	1153	O
nine	-	1157	O
(	-	1162	O
25	-	1163	O
%	-	1165	O
)	-	1166	O
had	-	1168	O
a	-	1172	O
previous	-	1174	O
suicide	-	1183	O
attempt	-	1191	O
.	-	1198	O

During	20408947	1200	O
follow	-	1207	O
-	-	1213	O
up	-	1214	O
(	-	1217	O
median	-	1218	O
5	-	1225	O
years	-	1227	O
)	-	1232	O
,	-	1233	O
there	-	1235	O
were	-	1241	O
no	-	1246	O
significant	-	1249	O
differences	-	1261	O
in	-	1273	O
rejection	-	1276	O
(	-	1286	O
acute	-	1287	O
and	-	1293	O
chronic	-	1297	O
)	-	1304	O
,	-	1305	O
graft	-	1307	O
failure	-	1313	O
or	-	1321	O
survival	-	1324	O
between	-	1333	O
the	-	1341	O
groups	-	1345	O
(	-	1352	O
acetaminophen	-	1353	O
-	-	1366	O
induced	-	1367	O
ALF	-	1375	B
1	-	1379	O
year	-	1381	O
87	-	1386	O
%	-	1388	O
,	-	1389	O
5	-	1391	O
years	-	1393	O
75	-	1399	O
%	-	1401	O
;	-	1402	O
non	-	1404	O
-	-	1407	O
acetaminophen	-	1408	O
-	-	1421	O
induced	-	1422	O
ALF	-	1430	B
88	-	1434	O
%	-	1436	O
,	-	1437	O
78	-	1439	O
%	-	1441	O
;	-	1442	O
CLD	-	1444	B
93	-	1448	O
%	-	1450	O
,	-	1451	O
82	-	1453	O
%	-	1455	O
:	-	1456	O
P	-	1458	O
>	-	1459	O
0	-	1460	O
.	-	1461	O
6	-	1462	O
log	-	1464	O
rank	-	1468	O
)	-	1472	O
.	-	1473	O

Two	20408947	1475	O
acetaminophen	-	1479	O
-	-	1492	O
induced	-	1493	O
ALF	-	1501	B
patients	-	1505	O
reattempted	-	1514	O
suicide	-	1526	O
post	-	1534	O
-	-	1538	O
LT	-	1539	O
(	-	1542	O
one	-	1543	O
died	-	1547	O
8	-	1552	O
years	-	1554	O
post	-	1560	O
-	-	1564	O
LT	-	1565	O
)	-	1567	O
.	-	1568	O

CONCLUSIONS	20408947	1570	O
:	-	1581	O

Despite	20408947	1583	O
a	-	1591	O
high	-	1593	O
prevalence	-	1598	O
of	-	1609	O
psychiatric	-	1612	O
disturbance	-	1624	O
,	-	1635	O
outcomes	-	1637	O
for	-	1646	O
patients	-	1650	O
transplanted	-	1659	O
emergently	-	1672	O
for	-	1683	O
acetaminophen	-	1687	O
-	-	1700	O
induced	-	1701	O
ALF	-	1709	B
were	-	1713	O
comparable	-	1718	O
to	-	1729	O
those	-	1732	O
transplanted	-	1738	O
for	-	1751	O
non	-	1755	O
-	-	1758	O
acetaminophen	-	1759	O
-	-	1772	O
induced	-	1773	O
ALF	-	1781	B
and	-	1785	O
electively	-	1789	O
for	-	1800	O
CLD	-	1804	B
.	-	1807	O

Multidisciplinary	20408947	1809	O
approaches	-	1827	O
with	-	1838	O
long	-	1843	O
-	-	1847	O
term	-	1848	O
psychiatric	-	1853	O
follow	-	1865	O
-	-	1871	O
up	-	1872	O
may	-	1875	O
contribute	-	1879	O
to	-	1890	O
low	-	1893	O
post	-	1897	O
-	-	1901	O
transplant	-	1902	O
suicide	-	1913	O
rates	-	1921	O
seen	-	1927	O
and	-	1932	O
low	-	1936	O
rates	-	1940	O
of	-	1946	O
graft	-	1949	O
loss	-	1955	O
because	-	1960	O
of	-	1968	O
non	-	1971	O
-	-	1974	O
compliance	-	1975	O
.	-	1985	O

Studies	20447294	0	O
of	-	8	O
synergy	-	11	O
between	-	19	O
morphine	-	27	O
and	-	36	O
a	-	40	O
novel	-	42	O
sodium	-	48	O
channel	-	55	O
blocker	-	63	O
,	-	70	O
CNSB002	-	72	O
,	-	79	O
in	-	81	O
rat	-	84	O
models	-	88	O
of	-	95	O
inflammatory	-	98	O
and	-	111	O
neuropathic	-	115	B
pain	-	127	I
.	-	131	O

OBJECTIVE	20447294	133	O
:	-	142	O

This	20447294	144	O
study	-	149	O
determined	-	155	O
the	-	166	O
antihyperalgesic	-	170	O
effect	-	187	O
of	-	194	O
CNSB002	-	197	O
,	-	204	O
a	-	206	O
sodium	-	208	O
channel	-	215	O
blocker	-	223	O
with	-	231	O
antioxidant	-	236	O
properties	-	248	O
given	-	259	O
alone	-	265	O
and	-	271	O
in	-	275	O
combinations	-	278	O
with	-	291	O
morphine	-	296	O
in	-	305	O
rat	-	308	O
models	-	312	O
of	-	319	O
inflammatory	-	322	O
and	-	335	O
neuropathic	-	339	B
pain	-	351	I
.	-	355	O

DESIGN	20447294	357	O
:	-	363	O

Dose	20447294	365	O
response	-	370	O
curves	-	379	O
for	-	386	O
nonsedating	-	390	O
doses	-	402	O
of	-	408	O
morphine	-	411	O
and	-	420	O
CNSB002	-	424	O
given	-	432	O
intraperitoneally	-	438	O
alone	-	456	O
and	-	462	O
together	-	466	O
in	-	475	O
combinations	-	478	O
were	-	491	O
constructed	-	496	O
for	-	508	O
antihyperalgesic	-	512	O
effect	-	529	O
using	-	536	O
paw	-	542	O
withdrawal	-	546	O
from	-	557	O
noxious	-	562	O
heat	-	570	O
in	-	575	O
two	-	578	O
rat	-	582	O
pain	-	586	B
models	-	591	O
:	-	597	O
carrageenan	-	599	O
-	-	610	O
induced	-	611	O
paw	-	619	O
inflammation	-	623	B
and	-	636	O
streptozotocin	-	640	O
(	-	655	O
STZ	-	656	O
)	-	659	O
-	-	660	O
induced	-	661	O
diabetic	-	669	B
neuropathy	-	678	I
.	-	688	O

RESULTS	20447294	690	O
:	-	697	O

The	20447294	699	O
maximum	-	703	O
nonsedating	-	711	O
doses	-	723	O
were	-	729	O
:	-	733	O
morphine	-	735	O
,	-	743	O
3	-	745	O
.	-	746	O
2	-	747	O
mg	-	749	O
/	-	751	O
kg	-	752	O
;	-	754	O
CNSB002	-	756	O
10	-	764	O
.	-	766	O
0	-	767	O
mg	-	769	O
/	-	771	O
kg	-	772	O
;	-	774	O
5	-	776	O
.	-	777	O
0	-	778	O
mg	-	780	O
/	-	782	O
kg	-	783	O
CNSB002	-	786	O
with	-	794	O
morphine	-	799	O
3	-	808	O
.	-	809	O
2	-	810	O
mg	-	812	O
/	-	814	O
kg	-	815	O
in	-	818	O
combination	-	821	O
.	-	832	O

The	20447294	834	O
doses	-	838	O
calculated	-	844	O
to	-	855	O
cause	-	858	O
50	-	864	O
%	-	866	O
reversal	-	868	O
of	-	877	O
hyperalgesia	-	880	B
(	-	893	O
ED50	-	894	O
)	-	898	O
were	-	900	O
7	-	905	O
.	-	906	O
54	-	907	O
(	-	910	O
1	-	911	O
.	-	912	O
81	-	913	O
)	-	915	O
and	-	917	O
4	-	921	O
.	-	922	O
83	-	923	O
(	-	926	O
1	-	927	O
.	-	928	O
54	-	929	O
)	-	931	O
in	-	933	O
the	-	936	O
carrageenan	-	940	O
model	-	952	O
and	-	958	O
44	-	962	O
.	-	964	O
18	-	965	O
(	-	968	O
1	-	969	O
.	-	970	O
37	-	971	O
)	-	973	O
and	-	975	O
9	-	979	O
.	-	980	O
14	-	981	O
(	-	984	O
1	-	985	O
.	-	986	O
24	-	987	O
)	-	989	O
in	-	991	O
the	-	994	O
STZ	-	998	O
-	-	1001	O
induced	-	1002	O
neuropathy	-	1010	B
model	-	1021	O
for	-	1027	O
CNSB002	-	1031	O
and	-	1039	O
morphine	-	1043	O
,	-	1051	O
respectively	-	1053	O
(	-	1066	O
mg	-	1067	O
/	-	1069	O
kg	-	1070	O
;	-	1072	O
mean	-	1074	O
,	-	1078	O
SEM	-	1080	O
)	-	1083	O
.	-	1084	O

These	20447294	1086	O
values	-	1092	O
were	-	1099	O
greater	-	1104	O
than	-	1112	O
the	-	1117	O
maximum	-	1121	O
nonsedating	-	1129	O
doses	-	1141	O
.	-	1146	O

The	20447294	1148	O
ED50	-	1152	O
values	-	1157	O
for	-	1164	O
morphine	-	1168	O
when	-	1177	O
given	-	1182	O
in	-	1188	O
combination	-	1191	O
with	-	1203	O
CNSB002	-	1208	O
(	-	1216	O
5	-	1217	O
mg	-	1219	O
/	-	1221	O
kg	-	1222	O
)	-	1224	O
were	-	1226	O
less	-	1231	O
than	-	1236	O
the	-	1241	O
maximum	-	1245	O
nonsedating	-	1253	O
dose	-	1265	O
:	-	1269	O
0	-	1271	O
.	-	1272	O
56	-	1273	O
(	-	1276	O
1	-	1277	O
.	-	1278	O
55	-	1279	O
)	-	1281	O
in	-	1283	O
the	-	1286	O
carrageenan	-	1290	O
model	-	1302	O
and	-	1308	O
1	-	1312	O
.	-	1313	O
37	-	1314	O
(	-	1317	O
1	-	1318	O
.	-	1319	O
23	-	1320	O
)	-	1322	O
in	-	1324	O
the	-	1327	O
neuropathy	-	1331	B
model	-	1342	O
(	-	1348	O
mg	-	1349	O
/	-	1351	O
kg	-	1352	O
;	-	1354	O
mean	-	1356	O
,	-	1360	O
SEM	-	1362	O
)	-	1365	O
.	-	1366	O

The	20447294	1368	O
antinociception	-	1372	O
after	-	1388	O
morphine	-	1394	O
(	-	1403	O
3	-	1404	O
.	-	1405	O
2	-	1406	O
mg	-	1408	O
/	-	1410	O
kg	-	1411	O
)	-	1413	O
was	-	1415	O
increased	-	1419	O
by	-	1429	O
co	-	1432	O
-	-	1434	O
administration	-	1435	O
with	-	1450	O
CNSB002	-	1455	O
from	-	1463	O
28	-	1468	O
.	-	1470	O
0	-	1471	O
and	-	1473	O
31	-	1477	O
.	-	1479	O
7	-	1480	O
%	-	1481	O
to	-	1483	O
114	-	1486	O
.	-	1489	O
6	-	1490	O
and	-	1492	O
56	-	1496	O
.	-	1498	O
9	-	1499	O
%	-	1500	O
reversal	-	1502	O
of	-	1511	O
hyperalgesia	-	1514	B
in	-	1527	O
the	-	1530	O
inflammatory	-	1534	O
and	-	1547	O
neuropathic	-	1551	B
models	-	1563	O
,	-	1569	O
respectively	-	1571	O
(	-	1584	O
P	-	1585	O
<	-	1587	O
0	-	1589	O
.	-	1590	O
01	-	1591	O
;	-	1593	O
one	-	1595	O
-	-	1598	O
way	-	1599	O
analysis	-	1603	O
of	-	1612	O
variance	-	1615	O
-	-	1623	O
significantly	-	1624	O
greater	-	1638	O
than	-	1646	O
either	-	1651	O
drug	-	1658	O
given	-	1663	O
alone	-	1669	O
)	-	1674	O
.	-	1675	O

CONCLUSIONS	20447294	1677	O
:	-	1688	O

The	20447294	1690	O
maximum	-	1694	O
antihyperalgesic	-	1702	O
effect	-	1719	O
achievable	-	1726	O
with	-	1737	O
nonsedating	-	1742	O
doses	-	1754	O
of	-	1760	O
morphine	-	1763	O
may	-	1772	O
be	-	1776	O
increased	-	1779	O
significantly	-	1789	O
when	-	1803	O
the	-	1808	O
drug	-	1812	O
is	-	1817	O
used	-	1820	O
in	-	1825	O
combination	-	1828	O
with	-	1840	O
CNSB002	-	1845	O
.	-	1852	O

Heparin	20495512	0	O
-	-	7	O
induced	-	8	O
thrombocytopenia	-	16	B
:	-	32	O
a	-	34	O
practical	-	36	O
review	-	46	O
.	-	52	O

Heparin	20495512	54	O
-	-	61	O
induced	-	62	O
thrombocytopenia	-	70	B
(	-	87	O
HIT	-	88	B
)	-	91	O
remains	-	93	O
under	-	101	O
-	-	106	O
recognized	-	107	O
despite	-	118	O
its	-	126	O
potentially	-	130	O
devastating	-	142	O
outcomes	-	154	O
.	-	162	O

It	20495512	164	O
begins	-	167	O
when	-	174	O
heparin	-	179	O
exposure	-	187	O
stimulates	-	196	O
the	-	207	O
formation	-	211	O
of	-	221	O
heparin	-	224	O
-	-	231	O
platelet	-	232	O
factor	-	241	O
4	-	248	O
antibodies	-	250	O
,	-	260	O
which	-	262	O
in	-	268	O
turn	-	271	O
triggers	-	276	O
the	-	285	O
release	-	289	O
of	-	297	O
procoagulant	-	300	O
platelet	-	313	O
particles	-	322	O
.	-	331	O

Thrombosis	20495512	333	B
and	-	344	O
thrombocytopenia	-	348	B
that	-	365	O
follow	-	370	O
comprise	-	377	O
the	-	386	O
2	-	390	O
hallmark	-	392	O
traits	-	401	O
of	-	408	O
HIT	-	411	B
,	-	414	O
with	-	416	O
the	-	421	O
former	-	425	O
largely	-	432	O
responsible	-	440	O
for	-	452	O
significant	-	456	O
vascular	-	468	O
complications	-	477	O
.	-	490	O

The	20495512	492	O
prevalence	-	496	O
of	-	507	O
HIT	-	510	B
varies	-	514	O
among	-	521	O
several	-	527	O
subgroups	-	535	O
,	-	544	O
with	-	546	O
greater	-	551	O
incidence	-	559	O
in	-	569	O
surgical	-	572	O
as	-	581	O
compared	-	584	O
with	-	593	O
medical	-	598	O
populations	-	606	O
.	-	617	O

HIT	20495512	619	B
must	-	623	O
be	-	628	O
acknowledged	-	631	O
for	-	644	O
its	-	648	O
intense	-	652	O
predilection	-	660	O
for	-	673	O
thrombosis	-	677	B
and	-	688	O
suspected	-	692	O
whenever	-	702	O
thrombosis	-	711	B
occurs	-	722	O
after	-	729	O
heparin	-	735	O
exposure	-	743	O
.	-	751	O

Early	20495512	753	O
recognition	-	759	O
that	-	771	O
incorporates	-	776	O
the	-	789	O
clinical	-	793	O
and	-	802	O
serologic	-	806	O
clues	-	816	O
is	-	822	O
paramount	-	825	O
to	-	835	O
timely	-	838	O
institution	-	845	O
of	-	857	O
treatment	-	860	O
,	-	869	O
as	-	871	O
its	-	874	O
delay	-	878	O
may	-	884	O
result	-	888	O
in	-	895	O
catastrophic	-	898	O
outcomes	-	911	O
.	-	919	O

The	20495512	921	O
treatment	-	925	O
of	-	935	O
HIT	-	938	B
mandates	-	942	O
an	-	951	O
immediate	-	954	O
cessation	-	964	O
of	-	974	O
all	-	977	O
heparin	-	981	O
exposure	-	989	O
and	-	998	O
the	-	1002	O
institution	-	1006	O
of	-	1018	O
an	-	1021	O
antithrombotic	-	1024	O
therapy	-	1039	O
,	-	1046	O
most	-	1048	O
commonly	-	1053	O
using	-	1062	O
a	-	1068	O
direct	-	1070	O
thrombin	-	1077	O
inhibitor	-	1086	O
.	-	1095	O

Current	20495512	1097	O
""""	-	1105	O
diagnostic	-	1106	O
""""	-	1116	O
tests	-	1118	O
,	-	1123	O
which	-	1125	O
primarily	-	1131	O
include	-	1141	O
functional	-	1149	O
and	-	1160	O
antigenic	-	1164	O
assays	-	1174	O
,	-	1180	O
have	-	1182	O
more	-	1187	O
of	-	1192	O
a	-	1195	O
confirmatory	-	1197	O
than	-	1210	O
diagnostic	-	1215	O
role	-	1226	O
in	-	1231	O
the	-	1234	O
management	-	1238	O
of	-	1249	O
HIT	-	1252	B
.	-	1255	O

Special	20495512	1257	O
attention	-	1265	O
must	-	1275	O
be	-	1280	O
paid	-	1283	O
to	-	1288	O
cardiac	-	1291	O
patients	-	1299	O
who	-	1308	O
are	-	1312	O
often	-	1316	O
exposed	-	1322	O
to	-	1330	O
heparin	-	1333	O
multiple	-	1341	O
times	-	1350	O
during	-	1356	O
their	-	1363	O
course	-	1369	O
of	-	1376	O
treatment	-	1379	O
.	-	1388	O

Direct	20495512	1390	O
thrombin	-	1397	O
inhibitors	-	1406	O
are	-	1417	O
appropriate	-	1421	O
,	-	1432	O
evidence	-	1434	O
-	-	1442	O
based	-	1443	O
alternatives	-	1449	O
to	-	1462	O
heparin	-	1465	O
in	-	1473	O
patients	-	1476	O
with	-	1485	O
a	-	1490	O
history	-	1492	O
of	-	1500	O
HIT	-	1503	B
,	-	1506	O
who	-	1508	O
need	-	1512	O
to	-	1517	O
undergo	-	1520	O
percutaneous	-	1528	O
coronary	-	1541	O
intervention	-	1550	O
.	-	1562	O

As	20495512	1564	O
heparin	-	1567	O
remains	-	1575	O
one	-	1583	O
of	-	1587	O
the	-	1590	O
most	-	1594	O
frequently	-	1599	O
used	-	1610	O
medications	-	1615	O
today	-	1627	O
with	-	1633	O
potential	-	1638	O
for	-	1648	O
HIT	-	1652	B
with	-	1656	O
every	-	1661	O
heparin	-	1667	O
exposure	-	1675	O
,	-	1683	O
a	-	1685	O
close	-	1687	O
vigilance	-	1693	O
of	-	1703	O
platelet	-	1706	O
counts	-	1715	O
must	-	1722	O
be	-	1727	O
practiced	-	1730	O
whenever	-	1740	O
heparin	-	1749	O
is	-	1757	O
initiated	-	1760	O
.	-	1769	O

Abductor	20513036	0	O
paralysis	-	9	B
after	-	19	O
botox	-	25	O
injection	-	31	O
for	-	41	O
adductor	-	45	B
spasmodic	-	54	I
dysphonia	-	64	I
.	-	73	O

OBJECTIVES	20513036	75	O
/	-	85	O
HYPOTHESIS	-	86	O

:	20513036	96	O
Botulinum	-	98	O
toxin	-	108	O
(	-	114	O
Botox	-	115	O
)	-	120	O
injections	-	122	O
into	-	133	O
the	-	138	O
thyroarytenoid	-	142	O
muscles	-	157	O
are	-	165	O
the	-	169	O
current	-	173	O
standard	-	181	O
of	-	190	O
care	-	193	O
for	-	198	O
adductor	-	202	B
spasmodic	-	211	I
dysphonia	-	221	I
(	-	231	O
ADSD	-	232	B
)	-	236	O
.	-	237	O

Reported	20513036	239	O
adverse	-	248	O
effects	-	256	O
include	-	264	O
a	-	272	O
period	-	274	O
of	-	281	O
breathiness	-	284	O
,	-	295	O
throat	-	297	B
pain	-	304	I
,	-	308	O
and	-	310	O
difficulty	-	314	O
with	-	325	O
swallowing	-	330	O
liquids	-	341	O
.	-	348	O

Here	20513036	350	O
we	-	355	O
report	-	358	O
multiple	-	365	O
cases	-	374	O
of	-	380	O
bilateral	-	383	O
abductor	-	393	O
paralysis	-	402	B
following	-	412	O
Botox	-	422	O
injections	-	428	O
for	-	439	O
ADSD	-	443	B
,	-	447	O
a	-	449	O
complication	-	451	O
previously	-	464	O
unreported	-	475	O
.	-	485	O

STUDY	20513036	487	O
DESIGN	-	493	O
:	-	499	O

Retrospective	20513036	501	O
case	-	515	O
series	-	520	O
.	-	526	O

METHODS	20513036	528	O
:	-	535	O

Patients	20513036	537	O
that	-	546	O
received	-	551	O
Botox	-	560	O
injections	-	566	O
for	-	577	O
spasmodic	-	581	B
dysphonia	-	591	I
between	-	601	O
January	-	609	O
2000	-	617	O
and	-	622	O
October	-	626	O
2009	-	634	O
were	-	639	O
evaluated	-	644	O
.	-	653	O

Patients	20513036	655	O
with	-	664	O
ADSD	-	669	B
were	-	674	O
identified	-	679	O
.	-	689	O

The	20513036	691	O
number	-	695	O
of	-	702	O
treatments	-	705	O
received	-	716	O
and	-	725	O
adverse	-	729	O
effects	-	737	O
were	-	745	O
noted	-	750	O
.	-	755	O

For	20513036	757	O
patients	-	761	O
with	-	770	O
bilateral	-	775	O
abductor	-	785	O
paralysis	-	794	B
,	-	803	O
age	-	805	O
,	-	808	O
sex	-	810	O
,	-	813	O
paralytic	-	815	O
Botox	-	825	O
dose	-	831	O
,	-	835	O
prior	-	837	O
Botox	-	843	O
dose	-	849	O
,	-	853	O
and	-	855	O
course	-	859	O
following	-	866	O
paralysis	-	876	B
were	-	886	O
noted	-	891	O
.	-	896	O

RESULTS	20513036	898	O
:	-	905	O

From	20513036	907	O
a	-	912	O
database	-	914	O
of	-	923	O
452	-	926	O
patients	-	930	O
receiving	-	939	O
Botox	-	949	O
,	-	954	O
352	-	956	O
patients	-	960	O
had	-	969	O
been	-	973	O
diagnosed	-	978	O
with	-	988	O
ADSD	-	993	B
.	-	997	O

Of	20513036	999	O
these	-	1002	O
352	-	1008	O
patients	-	1012	O
,	-	1020	O
eight	-	1022	O
patients	-	1028	O
suffered	-	1037	O
bilateral	-	1046	O
abductor	-	1056	O
paralysis	-	1065	B
,	-	1074	O
and	-	1076	O
two	-	1080	O
suffered	-	1084	O
this	-	1093	O
complication	-	1098	O
twice	-	1111	O
.	-	1116	O

All	20513036	1118	O
affected	-	1122	O
patients	-	1131	O
were	-	1140	O
females	-	1145	O
over	-	1153	O
the	-	1158	O
age	-	1162	O
of	-	1166	O
50	-	1169	O
years	-	1172	O
.	-	1177	O

Most	20513036	1179	O
patients	-	1184	O
had	-	1193	O
received	-	1197	O
treatments	-	1206	O
prior	-	1217	O
to	-	1223	O
abductor	-	1226	O
paralysis	-	1235	B
and	-	1245	O
continued	-	1249	O
receiving	-	1259	O
after	-	1269	O
paralysis	-	1275	B
.	-	1284	O

Seven	20513036	1286	O
patients	-	1292	O
recovered	-	1301	O
after	-	1311	O
a	-	1317	O
brief	-	1319	O
period	-	1325	O
of	-	1332	O
activity	-	1335	O
restrictions	-	1344	O
,	-	1356	O
and	-	1358	O
one	-	1362	O
underwent	-	1366	O
a	-	1376	O
tracheotomy	-	1378	O
.	-	1389	O

The	20513036	1391	O
incidence	-	1395	O
of	-	1405	O
abductor	-	1408	O
paralysis	-	1417	B
after	-	1427	O
Botox	-	1433	O
injection	-	1439	O
for	-	1449	O
ADSD	-	1453	B
was	-	1458	O
0	-	1462	O
.	-	1463	O
34	-	1464	O
%	-	1466	O
.	-	1467	O

CONCLUSIONS	20513036	1469	O
:	-	1480	O

Bilateral	20513036	1482	O
abductor	-	1492	O
paralysis	-	1501	B
is	-	1511	O
a	-	1514	O
rare	-	1516	O
complication	-	1521	O
of	-	1534	O
Botox	-	1537	O
injections	-	1543	O
for	-	1554	O
ADSD	-	1558	B
,	-	1562	O
causing	-	1564	O
difficulty	-	1572	O
with	-	1583	O
breathing	-	1588	O
upon	-	1598	O
exertion	-	1603	O
.	-	1611	O

The	20513036	1613	O
likely	-	1617	O
mechanism	-	1624	O
of	-	1634	O
paralysis	-	1637	B
is	-	1647	O
diffusion	-	1650	O
of	-	1660	O
Botox	-	1663	O
around	-	1669	O
the	-	1676	O
muscular	-	1680	O
process	-	1689	O
of	-	1697	O
the	-	1700	O
arytenoid	-	1704	O
to	-	1714	O
the	-	1717	O
posterior	-	1721	O
cricoarytenoid	-	1731	O
muscles	-	1746	O
.	-	1753	O

The	20513036	1755	O
paralysis	-	1759	B
is	-	1769	O
temporary	-	1772	O
,	-	1781	O
and	-	1783	O
watchful	-	1787	O
waiting	-	1796	O
with	-	1804	O
restriction	-	1809	O
of	-	1821	O
activity	-	1824	O
is	-	1833	O
the	-	1836	O
recommended	-	1840	O
management	-	1852	O
.	-	1862	O

Mitochondrial	20566328	0	B
impairment	-	14	I
contributes	-	25	O
to	-	37	O
cocaine	-	40	O
-	-	47	O
induced	-	48	O
cardiac	-	56	B
dysfunction	-	64	I
:	-	75	O
Prevention	-	77	O
by	-	88	O
the	-	91	O
targeted	-	95	O
antioxidant	-	104	O
MitoQ	-	116	O
.	-	121	O

The	20566328	123	O
goal	-	127	O
of	-	132	O
this	-	135	O
study	-	140	O
was	-	146	O
to	-	150	O
assess	-	153	O
mitochondrial	-	160	O
function	-	174	O
and	-	183	O
ROS	-	187	O
production	-	191	O
in	-	202	O
an	-	205	O
experimental	-	208	O
model	-	221	O
of	-	227	O
cocaine	-	230	O
-	-	237	O
induced	-	238	O
cardiac	-	246	B
dysfunction	-	254	I
.	-	265	O

We	20566328	267	O
hypothesized	-	270	O
that	-	283	O
cocaine	-	288	B
abuse	-	296	I
may	-	302	O
lead	-	306	O
to	-	311	O
altered	-	314	O
mitochondrial	-	322	O
function	-	336	O
that	-	345	O
in	-	350	O
turn	-	353	O
may	-	358	O
cause	-	362	O
left	-	368	B
ventricular	-	373	I
dysfunction	-	385	I
.	-	396	O

Seven	20566328	398	O
days	-	404	O
of	-	409	O
cocaine	-	412	O
administration	-	420	O
to	-	435	O
rats	-	438	O
led	-	443	O
to	-	447	O
an	-	450	O
increased	-	453	O
oxygen	-	463	O
consumption	-	470	O
detected	-	482	O
in	-	491	O
cardiac	-	494	O
fibers	-	502	O
,	-	508	O
specifically	-	510	O
through	-	523	O
complex	-	531	O
I	-	539	O
and	-	541	O
complex	-	545	O
III	-	553	O
.	-	556	O

ROS	20566328	558	O
levels	-	562	O
were	-	569	O
increased	-	574	O
,	-	583	O
specifically	-	585	O
in	-	598	O
interfibrillar	-	601	O
mitochondria	-	616	O
.	-	628	O

In	20566328	630	O
parallel	-	633	O
there	-	642	O
was	-	648	O
a	-	652	O
decrease	-	654	O
in	-	663	O
ATP	-	666	O
synthesis	-	670	O
,	-	679	O
whereas	-	681	O
no	-	689	O
difference	-	692	O
was	-	703	O
observed	-	707	O
in	-	716	O
subsarcolemmal	-	719	O
mitochondria	-	734	O
.	-	746	O

This	20566328	748	O
uncoupling	-	753	O
effect	-	764	O
on	-	771	O
oxidative	-	774	O
phosphorylation	-	784	O
was	-	800	O
not	-	804	O
detectable	-	808	O
after	-	819	O
short	-	825	O
-	-	830	O
term	-	831	O
exposure	-	836	O
to	-	845	O
cocaine	-	848	O
,	-	855	O
suggesting	-	857	O
that	-	868	O
these	-	873	O
mitochondrial	-	879	B
abnormalities	-	893	I
were	-	907	O
a	-	912	O
late	-	914	O
rather	-	919	O
than	-	926	O
a	-	931	O
primary	-	933	O
event	-	941	O
in	-	947	O
the	-	950	O
pathological	-	954	O
response	-	967	O
to	-	976	O
cocaine	-	979	O
.	-	986	O

MitoQ	20566328	988	O
,	-	993	O
a	-	995	O
mitochondrial	-	997	O
-	-	1010	O
targeted	-	1011	O
antioxidant	-	1020	O
,	-	1031	O
was	-	1033	O
shown	-	1037	O
to	-	1043	O
completely	-	1046	O
prevent	-	1057	O
these	-	1065	O
mitochondrial	-	1071	B
abnormalities	-	1085	I
as	-	1099	O
well	-	1102	O
as	-	1107	O
cardiac	-	1110	B
dysfunction	-	1118	I
characterized	-	1130	O
here	-	1144	O
by	-	1149	O
a	-	1152	O
diastolic	-	1154	B
dysfunction	-	1164	I
studied	-	1176	O
with	-	1184	O
a	-	1189	O
conductance	-	1191	O
catheter	-	1203	O
to	-	1212	O
obtain	-	1215	O
pressure	-	1222	O
-	-	1230	O
volume	-	1231	O
data	-	1238	O
.	-	1242	O

Taken	20566328	1244	O
together	-	1250	O
,	-	1258	O
these	-	1260	O
results	-	1266	O
extend	-	1274	O
previous	-	1281	O
studies	-	1290	O
and	-	1298	O
demonstrate	-	1302	O
that	-	1314	O
cocaine	-	1319	O
-	-	1326	O
induced	-	1327	O
cardiac	-	1335	B
dysfunction	-	1343	I
may	-	1355	O
be	-	1359	O
due	-	1362	O
to	-	1366	O
a	-	1369	O
mitochondrial	-	1371	B
defect	-	1385	I
.	-	1391	O

Trimethoprim	20589632	0	O
-	-	12	O
induced	-	13	O
immune	-	21	O
hemolytic	-	28	B
anemia	-	38	I
in	-	45	O
a	-	48	O
pediatric	-	50	O
oncology	-	60	O
patient	-	69	O
presenting	-	77	O
as	-	88	O
an	-	91	O
acute	-	94	O
hemolytic	-	100	O
transfusion	-	110	O
reaction	-	122	O
.	-	130	O

A	20589632	132	O
10	-	134	O
-	-	136	O
year	-	137	O
-	-	141	O
old	-	142	O
male	-	146	O
with	-	151	O
acute	-	156	B
leukemia	-	162	I
presented	-	171	O
with	-	181	O
post	-	186	O
-	-	190	O
chemotherapy	-	191	O
anemia	-	204	B
.	-	210	O

During	20589632	212	O
red	-	219	O
cell	-	223	O
transfusion	-	228	O
,	-	239	O
he	-	241	O
developed	-	244	O
hemoglobinuria	-	254	B
.	-	268	O

Transfusion	20589632	270	O
reaction	-	282	O
workup	-	291	O
was	-	298	O
negative	-	302	O
.	-	310	O

Drug	20589632	312	O
-	-	316	O
induced	-	317	O
immune	-	325	O
hemolytic	-	332	B
anemia	-	342	I
was	-	349	O
suspected	-	353	O
because	-	363	O
of	-	371	O
positive	-	374	O
direct	-	383	O
antiglobulin	-	390	O
test	-	403	O
,	-	407	O
negative	-	409	O
eluate	-	418	O
,	-	424	O
and	-	426	O
microspherocytes	-	430	O
on	-	447	O
smear	-	450	O
pre	-	456	O
-	-	459	O
and	-	461	O
post	-	465	O
-	-	469	O
transfusion	-	470	O
.	-	481	O

Drug	20589632	483	O
studies	-	488	O
using	-	496	O
the	-	502	O
indirect	-	506	O
antiglobulin	-	515	O
test	-	528	O
were	-	533	O
strongly	-	538	O
positive	-	547	O
with	-	556	O
trimethoprim	-	561	O
and	-	574	O
trimethoprim	-	578	O
-	-	590	O
sulfamethoxazole	-	591	O
but	-	608	O
negative	-	612	O
with	-	621	O
sulfamethoxazole	-	626	O
.	-	642	O

The	20589632	644	O
patient	-	648	O
recovered	-	656	O
after	-	666	O
discontinuing	-	672	O
the	-	686	O
drug	-	690	O
,	-	694	O
with	-	696	O
no	-	701	O
recurrence	-	704	O
in	-	715	O
2	-	718	O
years	-	720	O
.	-	725	O

Other	20589632	727	O
causes	-	733	O
of	-	740	O
anemia	-	743	B
should	-	750	O
be	-	757	O
considered	-	760	O
in	-	771	O
patients	-	774	O
with	-	783	O
worse	-	788	O
-	-	793	O
than	-	794	O
-	-	798	O
expected	-	799	O
anemia	-	808	B
after	-	815	O
chemotherapy	-	821	O
.	-	833	O

Furthermore	20589632	835	O
,	-	846	O
hemolysis	-	848	B
during	-	858	O
transfusion	-	865	O
is	-	877	O
not	-	880	O
always	-	884	O
a	-	891	O
transfusion	-	893	O
reaction	-	905	O
.	-	913	O

Blockade	20682692	0	O
of	-	9	O
endothelial	-	12	O
-	-	23	O
mesenchymal	-	24	O
transition	-	36	O
by	-	47	O
a	-	50	O
Smad3	-	52	O
inhibitor	-	58	O
delays	-	68	O
the	-	75	O
early	-	79	O
development	-	85	O
of	-	97	O
streptozotocin	-	100	O
-	-	114	O
induced	-	115	O
diabetic	-	123	B
nephropathy	-	132	I
.	-	143	O

OBJECTIVE	20682692	145	O
:	-	154	O

A	20682692	156	O
multicenter	-	158	O
,	-	169	O
controlled	-	171	O
trial	-	182	O
showed	-	188	O
that	-	195	O
early	-	200	O
blockade	-	206	O
of	-	215	O
the	-	218	O
renin	-	222	O
-	-	227	O
angiotensin	-	228	O
system	-	240	O
in	-	247	O
patients	-	250	O
with	-	259	O
type	-	264	B
1	-	269	I
diabetes	-	271	I
and	-	280	O
normoalbuminuria	-	284	O
did	-	301	O
not	-	305	O
retard	-	309	O
the	-	316	O
progression	-	320	O
of	-	332	O
nephropathy	-	335	B
,	-	346	O
suggesting	-	348	O
that	-	359	O
other	-	364	O
mechanism	-	370	O
(	-	379	O
s	-	380	O
)	-	381	O
are	-	383	O
involved	-	387	O
in	-	396	O
the	-	399	O
pathogenesis	-	403	O
of	-	416	O
early	-	419	O
diabetic	-	425	B
nephropathy	-	434	I
(	-	446	O
diabetic	-	447	B
nephropathy	-	456	I
)	-	467	O
.	-	468	O

We	20682692	470	O
have	-	473	O
previously	-	478	O
demonstrated	-	489	O
that	-	502	O
endothelial	-	507	O
-	-	518	O
mesenchymal	-	519	O
-	-	530	O
transition	-	531	O
(	-	542	O
EndoMT	-	543	O
)	-	549	O
contributes	-	551	O
to	-	563	O
the	-	566	O
early	-	570	O
development	-	576	O
of	-	588	O
renal	-	591	O
interstitial	-	597	O
fibrosis	-	610	B
independently	-	619	O
of	-	633	O
microalbuminuria	-	636	O
in	-	653	O
mice	-	656	O
with	-	661	O
streptozotocin	-	666	O
(	-	681	O
STZ	-	682	O
)	-	685	O
-	-	686	O
induced	-	687	O
diabetes	-	695	B
.	-	703	O

In	20682692	705	O
the	-	708	O
present	-	712	O
study	-	720	O
,	-	725	O
we	-	727	O
hypothesized	-	730	O
that	-	743	O
blocking	-	748	O
EndoMT	-	757	O
reduces	-	764	O
the	-	772	O
early	-	776	O
development	-	782	O
of	-	794	O
diabetic	-	797	B
nephropathy	-	806	I
.	-	817	O

RESEARCH	20682692	819	O
DESIGN	-	828	O
AND	-	835	O
METHODS	-	839	O
:	-	846	O

EndoMT	20682692	848	O
was	-	855	O
induced	-	859	O
in	-	867	O
a	-	870	O
mouse	-	872	O
pancreatic	-	878	O
microvascular	-	889	O
endothelial	-	903	O
cell	-	915	O
line	-	920	O
(	-	925	O
MMEC	-	926	O
)	-	930	O
in	-	932	O
the	-	935	O
presence	-	939	O
of	-	948	O
advanced	-	951	O
glycation	-	960	O
end	-	970	O
products	-	974	O
(	-	983	O
AGEs	-	984	O
)	-	988	O
and	-	990	O
in	-	994	O
the	-	997	O
endothelial	-	1001	O
lineage	-	1013	O
-	-	1020	O
traceble	-	1021	O
mouse	-	1030	O
line	-	1036	O
Tie2	-	1041	O
-	-	1045	O
Cre	-	1046	O
;	-	1049	O
Loxp	-	1050	O
-	-	1054	O
EGFP	-	1055	O
by	-	1060	O
administration	-	1063	O
of	-	1078	O
AGEs	-	1081	O
,	-	1085	O
with	-	1087	O
nonglycated	-	1092	O
mouse	-	1104	O
albumin	-	1110	O
serving	-	1118	O
as	-	1126	O
a	-	1129	O
control	-	1131	O
.	-	1138	O

Phosphorylated	20682692	1140	O
Smad3	-	1155	O
was	-	1161	O
detected	-	1165	O
by	-	1174	O
immunoprecipitation	-	1177	O
/	-	1196	O
Western	-	1197	O
blotting	-	1205	O
and	-	1214	O
confocal	-	1218	O
microscopy	-	1227	O
.	-	1237	O

Blocking	20682692	1239	O
studies	-	1248	O
using	-	1256	O
receptor	-	1262	O
for	-	1271	O
AGE	-	1275	O
siRNA	-	1279	O
and	-	1285	O
a	-	1289	O
specific	-	1291	O
inhibitor	-	1300	O
of	-	1310	O
Smad3	-	1313	O
(	-	1319	O
SIS3	-	1320	O
)	-	1324	O
were	-	1326	O
performed	-	1331	O
in	-	1341	O
MMECs	-	1344	O
and	-	1350	O
in	-	1354	O
STZ	-	1357	O
-	-	1360	O
induced	-	1361	O
diabetic	-	1369	B
nephropathy	-	1378	I
in	-	1390	O
Tie2	-	1393	O
-	-	1397	O
Cre	-	1398	O
;	-	1401	O
Loxp	-	1402	O
-	-	1406	O
EGFP	-	1407	O
mice	-	1412	O
.	-	1416	O

RESULTS	20682692	1418	O
:	-	1425	O

Confocal	20682692	1427	O
microscopy	-	1436	O
and	-	1447	O
real	-	1451	O
-	-	1455	O
time	-	1456	O
PCR	-	1461	O
demonstrated	-	1465	O
that	-	1478	O
AGEs	-	1483	O
induced	-	1488	O
EndoMT	-	1496	O
in	-	1503	O
MMECs	-	1506	O
and	-	1512	O
in	-	1516	O
Tie2	-	1519	O
-	-	1523	O
Cre	-	1524	O
;	-	1527	O
Loxp	-	1528	O
-	-	1532	O
EGFP	-	1533	O
mice	-	1538	O
.	-	1542	O

Immunoprecipitation	20682692	1544	O
/	-	1563	O
Western	-	1564	O
blotting	-	1572	O
showed	-	1581	O
that	-	1588	O
Smad3	-	1593	O
was	-	1599	O
activated	-	1603	O
by	-	1613	O
AGEs	-	1616	O
but	-	1621	O
was	-	1625	O
inhibited	-	1629	O
by	-	1639	O
SIS3	-	1642	O
in	-	1647	O
MMECs	-	1650	O
and	-	1656	O
in	-	1660	O
STZ	-	1663	O
-	-	1666	O
induced	-	1667	O
diabetic	-	1675	B
nephropathy	-	1684	I
.	-	1695	O

Confocal	20682692	1697	O
microscopy	-	1706	O
and	-	1717	O
real	-	1721	O
-	-	1725	O
time	-	1726	O
PCR	-	1731	O
further	-	1735	O
demonstrated	-	1743	O
that	-	1756	O
SIS3	-	1761	O
abrogated	-	1766	O
EndoMT	-	1776	O
,	-	1782	O
reduced	-	1784	O
renal	-	1792	O
fibrosis	-	1798	B
,	-	1806	O
and	-	1808	O
retarded	-	1812	O
progression	-	1821	O
of	-	1833	O
nephropathy	-	1836	B
.	-	1847	O

CONCLUSIONS	20682692	1849	O
:	-	1860	O

EndoMT	20682692	1862	O
is	-	1869	O
a	-	1872	O
novel	-	1874	O
pathway	-	1880	O
leading	-	1888	O
to	-	1896	O
early	-	1899	O
development	-	1905	O
of	-	1917	O
diabetic	-	1920	B
nephropathy	-	1929	I
.	-	1940	O

Blockade	20682692	1942	O
of	-	1951	O
EndoMT	-	1954	O
by	-	1961	O
SIS3	-	1964	O
may	-	1969	O
provide	-	1973	O
a	-	1981	O
new	-	1983	O
strategy	-	1987	O
to	-	1996	O
retard	-	1999	O
the	-	2006	O
progression	-	2010	O
of	-	2022	O
diabetic	-	2025	B
nephropathy	-	2034	I
and	-	2046	O
other	-	2050	O
diabetes	-	2056	B
complications	-	2065	I
.	-	2078	O

Cytostatic	20828385	0	O
and	-	11	O
anti	-	15	O
-	-	19	O
angiogenic	-	20	O
effects	-	31	O
of	-	39	O
temsirolimus	-	42	O
in	-	55	O
refractory	-	58	O
mantle	-	69	B
cell	-	76	I
lymphoma	-	81	I
.	-	89	O

Mantle	20828385	91	B
cell	-	98	I
lymphoma	-	103	I
(	-	112	O
MCL	-	113	B
)	-	116	O
is	-	118	O
a	-	121	O
rare	-	123	O
and	-	128	O
aggressive	-	132	O
type	-	143	O
of	-	148	O
B	-	151	B
-	-	152	I
cell	-	153	I
non	-	158	I
-	-	161	I
Hodgkin	-	162	I
's	-	169	I
lymphoma	-	172	I
.	-	180	O

Patients	20828385	182	O
become	-	191	O
progressively	-	198	O
refractory	-	212	O
to	-	223	O
conventional	-	226	O
chemotherapy	-	239	O
,	-	251	O
and	-	253	O
their	-	257	O
prognosis	-	263	O
is	-	273	O
poor	-	276	O
.	-	280	O

However	20828385	282	O
,	-	289	O
a	-	291	O
38	-	293	O
%	-	295	O
remission	-	297	O
rate	-	307	O
has	-	312	O
been	-	316	O
recently	-	321	O
reported	-	330	O
in	-	339	O
refractory	-	342	O
MCL	-	353	B
treated	-	357	O
with	-	365	O
temsirolimus	-	370	O
,	-	382	O
a	-	384	O
mTOR	-	386	O
inhibitor	-	391	O
.	-	400	O

Here	20828385	401	O
we	-	406	O
had	-	409	O
the	-	413	O
opportunity	-	417	O
to	-	429	O
study	-	432	O
a	-	438	O
case	-	440	O
of	-	445	O
refractory	-	448	O
MCL	-	459	B
who	-	463	O
had	-	467	O
tumor	-	471	B
regression	-	477	O
two	-	488	O
months	-	492	O
after	-	499	O
temsirolimus	-	505	O
treatment	-	518	O
,	-	527	O
and	-	529	O
a	-	533	O
progression	-	535	O
-	-	546	O
free	-	547	O
survival	-	552	O
of	-	561	O
10	-	564	O
months	-	567	O
.	-	573	O

In	20828385	575	O
this	-	578	O
case	-	583	O
,	-	587	O
lymph	-	589	O
node	-	595	O
biopsies	-	600	O
were	-	609	O
performed	-	614	O
before	-	624	O
and	-	631	O
six	-	635	O
months	-	639	O
after	-	646	O
temsirolimus	-	652	O
therapy	-	665	O
.	-	672	O

Comparison	20828385	674	O
of	-	685	O
the	-	688	O
two	-	692	O
biopsies	-	696	O
showed	-	705	O
that	-	712	O
temsirolimus	-	717	O
inhibited	-	730	O
tumor	-	740	B
cell	-	746	O
proliferation	-	751	O
through	-	765	O
cell	-	773	O
cycle	-	778	O
arrest	-	784	O
,	-	790	O
but	-	792	O
did	-	796	O
not	-	800	O
induce	-	804	O
any	-	811	O
change	-	815	O
in	-	822	O
the	-	825	O
number	-	829	O
of	-	836	O
apoptotic	-	839	O
tumor	-	849	B
cells	-	855	O
.	-	860	O

Apart	20828385	862	O
from	-	868	O
this	-	873	O
cytostatic	-	878	O
effect	-	889	O
,	-	895	O
temsirolimus	-	897	O
had	-	910	O
an	-	914	O
antiangiogenic	-	917	O
effect	-	932	O
with	-	939	O
decrease	-	944	O
of	-	953	O
tumor	-	956	B
microvessel	-	962	O
density	-	974	O
and	-	982	O
of	-	986	O
VEGF	-	989	O
expression	-	994	O
.	-	1004	O

Moreover	20828385	1006	O
,	-	1014	O
numerous	-	1016	O
patchy	-	1025	O
,	-	1031	O
well	-	1033	O
-	-	1037	O
limited	-	1038	O
fibrotic	-	1046	O
areas	-	1055	O
,	-	1060	O
compatible	-	1062	O
with	-	1073	O
post	-	1078	O
-	-	1082	O
necrotic	-	1083	B
tissue	-	1092	O
repair	-	1099	O
,	-	1105	O
were	-	1107	O
found	-	1112	O
after	-	1118	O
6	-	1124	O
-	-	1125	O
month	-	1126	O
temsirolimus	-	1132	O
therapy	-	1145	O
.	-	1152	O

Thus	20828385	1154	O
,	-	1158	O
temsirolimus	-	1160	O
reduced	-	1173	O
tumor	-	1181	B
burden	-	1187	O
through	-	1194	O
associated	-	1202	O
cytostatic	-	1213	O
and	-	1224	O
anti	-	1228	O
-	-	1232	O
angiogenic	-	1233	O
effects	-	1244	O
.	-	1251	O

This	20828385	1252	O
dual	-	1257	O
effect	-	1262	O
of	-	1269	O
temsirolimus	-	1272	O
on	-	1285	O
tumor	-	1288	B
tissue	-	1294	O
could	-	1301	O
contribute	-	1307	O
to	-	1318	O
its	-	1321	O
recently	-	1325	O
reported	-	1334	O
efficiency	-	1343	O
in	-	1354	O
refractory	-	1357	O
MCL	-	1368	B
resistant	-	1372	O
to	-	1382	O
conventional	-	1385	O
chemotherapy	-	1398	O
.	-	1410	O

Syncope	20859899	0	B
caused	-	8	O
by	-	15	O
hyperkalemia	-	18	B
during	-	31	O
use	-	38	O
of	-	42	O
a	-	45	O
combined	-	47	O
therapy	-	56	O
with	-	64	O
the	-	69	O
angiotensin	-	73	O
-	-	84	O
converting	-	85	O
enzyme	-	96	O
inhibitor	-	103	O
and	-	113	O
spironolactone	-	117	O
.	-	131	O

A	20859899	133	O
76	-	135	O
year	-	138	O
-	-	142	O
old	-	143	O
woman	-	147	O
with	-	153	O
a	-	158	O
history	-	160	O
of	-	168	O
coronary	-	171	O
artery	-	180	O
bypass	-	187	O
grafting	-	194	O
and	-	203	O
prior	-	207	O
myocardial	-	213	B
infarction	-	224	I
was	-	235	O
transferred	-	239	O
to	-	251	O
the	-	254	O
emergency	-	258	O
room	-	268	O
with	-	273	O
loss	-	278	B
of	-	283	I
consciousness	-	286	I
due	-	300	O
to	-	304	O
marked	-	307	O
bradycardia	-	314	B
caused	-	326	O
by	-	333	O
hyperkalemia	-	336	B
.	-	348	O

The	20859899	350	O
concentration	-	354	O
of	-	368	O
serum	-	371	O
potassium	-	377	O
was	-	387	O
high	-	391	O
,	-	395	O
and	-	397	O
normal	-	401	O
sinus	-	408	O
rhythm	-	414	O
was	-	421	O
restored	-	425	O
after	-	434	O
correction	-	440	O
of	-	451	O
the	-	454	O
serum	-	458	O
potassium	-	464	O
level	-	474	O
.	-	479	O

The	20859899	481	O
cause	-	485	O
of	-	491	O
hyperkalemia	-	494	B
was	-	507	O
considered	-	511	O
to	-	522	O
be	-	525	O
several	-	528	O
doses	-	536	O
of	-	542	O
spiranolactone	-	545	O
,	-	559	O
an	-	561	O
aldosterone	-	564	O
antagonist	-	576	O
,	-	586	O
in	-	588	O
addition	-	591	O
to	-	600	O
the	-	603	O
long	-	607	O
-	-	611	O
term	-	612	O
intake	-	617	O
of	-	624	O
ramipril	-	627	O
,	-	635	O
an	-	637	O
ACE	-	640	O
inhibitor	-	644	O
.	-	653	O

This	20859899	655	O
case	-	660	O
is	-	665	O
a	-	668	O
good	-	670	O
example	-	675	O
of	-	683	O
electrolyte	-	686	O
imbalance	-	698	O
causing	-	708	O
acute	-	716	O
life	-	722	O
-	-	726	O
threatening	-	727	O
cardiac	-	739	O
events	-	747	O
.	-	753	O

Clinicians	20859899	755	O
should	-	766	O
be	-	773	O
alert	-	776	O
to	-	782	O
the	-	785	O
possibility	-	789	O
of	-	801	O
hyperkalemia	-	804	B
,	-	816	O
especially	-	818	O
in	-	829	O
elderly	-	832	O
patients	-	840	O
using	-	849	O
ACE	-	855	O
/	-	858	O
ARB	-	859	O
in	-	863	O
combination	-	866	O
with	-	878	O
potassium	-	883	O
sparing	-	893	O
agents	-	901	O
and	-	908	O
who	-	912	O
have	-	916	O
mild	-	921	O
renal	-	926	B
disturbance	-	932	I
.	-	943	O

Diffuse	20927253	0	O
skeletal	-	8	O
pain	-	17	B
after	-	22	O
administration	-	28	O
of	-	43	O
alendronate	-	46	O
.	-	57	O

BACKGROUND	20927253	59	O
:	-	69	O
Osteoporosis	-	71	B
is	-	84	O
caused	-	87	O
by	-	94	O
bone	-	97	O
resorption	-	102	O
in	-	113	O
excess	-	116	O
of	-	123	O
bone	-	126	O
formation	-	131	O
,	-	140	O
and	-	142	O
bisphosphonates	-	146	O
,	-	161	O
are	-	163	O
used	-	167	O
to	-	172	O
inhibit	-	175	O
bone	-	183	O
resorption	-	188	O
.	-	198	O

Alendronate	20927253	200	O
,	-	211	O
a	-	213	O
biphosphonate	-	215	O
,	-	228	O
is	-	230	O
effective	-	233	O
for	-	243	O
both	-	247	O
the	-	252	O
treatment	-	256	O
and	-	266	O
prevention	-	270	O
of	-	281	O
osteoporosis	-	284	B
in	-	297	O
postmenopausal	-	300	O
women	-	315	O
.	-	320	O

Side	20927253	322	O
effects	-	327	O
are	-	335	O
relatively	-	339	O
few	-	350	O
and	-	354	O
prominently	-	358	O
gastrointestinal	-	370	O
.	-	386	O

Musculoskeletal	20927253	388	B
pain	-	404	I
may	-	409	O
be	-	413	O
an	-	416	O
important	-	419	O
side	-	429	O
effect	-	434	O
in	-	441	O
these	-	444	O
patients	-	450	O
.	-	458	O

We	20927253	460	O
presented	-	463	O
a	-	473	O
patient	-	475	O
admitted	-	483	O
to	-	492	O
our	-	495	O
out	-	499	O
-	-	502	O
patient	-	503	O
clinic	-	511	O
with	-	518	O
diffuse	-	523	O
skeletal	-	531	O
pain	-	540	B
after	-	545	O
three	-	551	O
consecutive	-	557	O
administration	-	569	O
of	-	584	O
alendronate	-	587	O
.	-	598	O

CONCLUSION	20927253	600	O
:	-	610	O

We	20927253	612	O
conclude	-	615	O
that	-	624	O
patients	-	629	O
with	-	638	O
osteoporosis	-	643	B
can	-	656	O
report	-	660	O
pain	-	667	B
,	-	671	O
and	-	673	O
bisphosphonate	-	677	O
-	-	691	O
related	-	692	O
pain	-	700	B
should	-	705	O
also	-	712	O
be	-	717	O
considered	-	720	O
before	-	731	O
ascribing	-	738	O
this	-	748	O
complaint	-	753	O
to	-	763	O
osteoporosis	-	766	B
.	-	778	O

Cerebrospinal	20959502	0	O
fluid	-	14	O
penetration	-	20	O
of	-	32	O
high	-	35	O
-	-	39	O
dose	-	40	O
daptomycin	-	45	O
in	-	56	O
suspected	-	59	O
Staphylococcus	-	69	O
aureus	-	84	O
meningitis	-	91	B
.	-	101	O

OBJECTIVE	20959502	103	O
:	-	112	O

To	20959502	114	O
report	-	117	O
a	-	124	O
case	-	126	O
of	-	131	O
methicillin	-	134	O
-	-	145	O
sensitive	-	146	O
Staphylococcus	-	156	O
aureus	-	171	O
(	-	178	O
MSSA	-	179	O
)	-	183	O
bacteremia	-	185	B
with	-	196	O
suspected	-	201	O
MSSA	-	211	O
meningitis	-	216	B
treated	-	227	O
with	-	235	O
high	-	240	O
-	-	244	O
dose	-	245	O
daptomycin	-	250	O
assessed	-	261	O
with	-	270	O
concurrent	-	275	O
serum	-	286	O
and	-	292	O
cerebrospinal	-	296	O
fluid	-	310	O
(	-	316	O
CSF	-	317	O
)	-	320	O
concentrations	-	322	O
.	-	336	O

CASE	20959502	338	O
SUMMARY	-	343	O
:	-	350	O

A	20959502	352	O
54	-	354	O
-	-	356	O
year	-	357	O
-	-	361	O
old	-	362	O
male	-	366	O
presented	-	371	O
to	-	381	O
the	-	384	O
emergency	-	388	O
department	-	398	O
with	-	409	O
generalized	-	414	O
weakness	-	426	B
and	-	435	O
presumed	-	439	O
health	-	448	O
-	-	454	O
care	-	455	O
-	-	459	O
associated	-	460	O
pneumonia	-	471	B
shown	-	481	O
on	-	487	O
chest	-	490	O
radiograph	-	496	O
.	-	506	O

Treatment	20959502	508	O
was	-	518	O
empirically	-	522	O
initiated	-	534	O
with	-	544	O
vancomycin	-	549	O
,	-	559	O
levofloxacin	-	561	O
,	-	573	O
and	-	575	O
piperacillin	-	579	O
/	-	591	O
tazobactam	-	592	O
.	-	602	O

Blood	20959502	604	O
cultures	-	610	O
revealed	-	619	O
S	-	628	O
.	-	629	O
aureus	-	631	O
susceptible	-	638	O
to	-	650	O
oxacillin	-	653	O
.	-	662	O

Empiric	20959502	664	O
antibiotic	-	672	O
treatment	-	683	O
was	-	693	O
narrowed	-	697	O
to	-	706	O
nafcillin	-	709	O
on	-	719	O
day	-	722	O
4	-	726	O
.	-	727	O

On	20959502	729	O
day	-	732	O
8	-	736	O
,	-	737	O
the	-	739	O
patient	-	743	O
developed	-	751	O
acute	-	761	B
renal	-	767	I
failure	-	773	I
(	-	781	O
serum	-	782	O
creatinine	-	788	O
1	-	799	O
.	-	800	O
9	-	801	O
mg	-	803	O
/	-	805	O
dL	-	806	O
,	-	808	O
increased	-	810	O
from	-	820	O
1	-	825	O
.	-	826	O
2	-	827	O
mg	-	829	O
/	-	831	O
dL	-	832	O
the	-	835	O
previous	-	839	O
day	-	848	O
and	-	852	O
0	-	856	O
.	-	857	O
8	-	858	O
mg	-	860	O
/	-	862	O
dL	-	863	O
on	-	866	O
admission	-	869	O
)	-	878	O
.	-	879	O

The	20959502	881	O
patient	-	885	O
's	-	892	O
Glasgow	-	895	O
Coma	-	903	O
Score	-	908	O
was	-	914	O
3	-	918	O
,	-	919	O
with	-	921	O
normal	-	926	O
findings	-	933	O
shown	-	942	O
on	-	948	O
computed	-	951	O
tomography	-	960	O
scan	-	971	O
of	-	976	O
the	-	979	O
head	-	983	O
72	-	988	O
hours	-	991	O
following	-	997	O
an	-	1007	O
episode	-	1010	O
of	-	1018	O
cardiac	-	1021	B
arrest	-	1029	I
on	-	1036	O
day	-	1039	O
10	-	1043	O
.	-	1045	O

The	20959502	1047	O
patient	-	1051	O
experienced	-	1059	O
relapsing	-	1071	O
MSSA	-	1081	O
bacteremia	-	1086	B
on	-	1097	O
day	-	1100	O
9	-	1104	O
,	-	1105	O
increasing	-	1107	O
the	-	1118	O
suspicion	-	1122	O
for	-	1132	O
a	-	1136	O
central	-	1138	O
nervous	-	1146	O
system	-	1154	O
(	-	1161	O
CNS	-	1162	O
)	-	1165	O
infection	-	1167	B
.	-	1176	O

Nafcillin	20959502	1178	O
was	-	1188	O
discontinued	-	1192	O
and	-	1205	O
daptomycin	-	1209	O
9	-	1220	O
mg	-	1222	O
/	-	1224	O
kg	-	1225	O
daily	-	1228	O
was	-	1234	O
initiated	-	1238	O
for	-	1248	O
suspected	-	1252	O
meningitis	-	1262	B
and	-	1273	O
was	-	1277	O
continued	-	1281	O
until	-	1291	O
the	-	1297	O
patient	-	1301	O
's	-	1308	O
death	-	1311	O
on	-	1317	O
day	-	1320	O
16	-	1324	O
.	-	1326	O

Daptomycin	20959502	1328	O
serum	-	1339	O
and	-	1345	O
CSF	-	1349	O
trough	-	1353	O
concentrations	-	1360	O
were	-	1375	O
11	-	1380	O
.	-	1382	O
21	-	1383	O
ug	-	1386	O
/	-	1388	O
mL	-	1389	O
and	-	1392	O
0	-	1396	O
.	-	1397	O
52	-	1398	O
ug	-	1401	O
/	-	1403	O
mL	-	1404	O
,	-	1406	O
respectively	-	1408	O
,	-	1420	O
prior	-	1422	O
to	-	1428	O
the	-	1431	O
third	-	1435	O
dose	-	1441	O
.	-	1445	O

Lumbar	20959502	1447	O
puncture	-	1454	O
results	-	1463	O
were	-	1471	O
inconclusive	-	1476	O
and	-	1489	O
no	-	1493	O
further	-	1496	O
blood	-	1504	O
cultures	-	1510	O
were	-	1519	O
positive	-	1524	O
for	-	1533	O
MSSA	-	1537	O
.	-	1541	O

Creatine	20959502	1543	O
kinase	-	1552	O
levels	-	1559	O
were	-	1566	O
normal	-	1571	O
prior	-	1578	O
to	-	1584	O
daptomycin	-	1587	O
therapy	-	1598	O
and	-	1606	O
were	-	1610	O
not	-	1615	O
reassessed	-	1619	O
.	-	1629	O

DISCUSSION	20959502	1631	O
:	-	1641	O

Daptomycin	20959502	1643	O
was	-	1654	O
initiated	-	1658	O
in	-	1668	O
our	-	1671	O
patient	-	1675	O
secondary	-	1683	O
to	-	1693	O
possible	-	1696	O
nafcillin	-	1705	O
-	-	1714	O
induced	-	1715	O
acute	-	1723	O
interstitial	-	1729	B
nephritis	-	1742	I
and	-	1752	O
relapsing	-	1756	O
bacteremia	-	1766	B
.	-	1776	O

At	20959502	1778	O
a	-	1781	O
dose	-	1783	O
of	-	1788	O
9	-	1791	O
mg	-	1793	O
/	-	1795	O
kg	-	1796	O
,	-	1798	O
resultant	-	1800	O
penetration	-	1810	O
of	-	1822	O
5	-	1825	O
%	-	1826	O
was	-	1828	O
higher	-	1832	O
than	-	1839	O
in	-	1844	O
previous	-	1847	O
reports	-	1856	O
,	-	1863	O
more	-	1865	O
consistent	-	1870	O
with	-	1881	O
inflamed	-	1886	O
meninges	-	1895	O
.	-	1903	O

CONCLUSIONS	20959502	1905	O
:	-	1916	O

High	20959502	1918	O
-	-	1922	O
dose	-	1923	O
daptomycin	-	1928	O
may	-	1939	O
be	-	1943	O
an	-	1946	O
alternative	-	1949	O
option	-	1961	O
for	-	1968	O
MSSA	-	1972	O
bacteremia	-	1977	B
with	-	1988	O
or	-	1993	O
without	-	1996	O
a	-	2004	O
CNS	-	2006	O
source	-	2010	O
in	-	2017	O
patients	-	2020	O
who	-	2029	O
have	-	2033	O
failed	-	2038	O
or	-	2045	O
can	-	2048	O
not	-	2051	O
tolerate	-	2055	O
standard	-	2064	O
therapy	-	2073	O
.	-	2080	O

Further	20959502	2082	O
clinical	-	2090	O
evaluation	-	2099	O
in	-	2110	O
patients	-	2113	O
with	-	2122	O
confirmed	-	2127	O
meningitis	-	2137	B
is	-	2148	O
warranted	-	2151	O
.	-	2160	O

The	21195121	0	O
role	-	4	O
of	-	9	O
nitric	-	12	O
oxide	-	19	O
in	-	25	O
convulsions	-	28	B
induced	-	40	O
by	-	48	O
lindane	-	51	O
in	-	59	O
rats	-	62	O
.	-	66	O

Lindane	21195121	68	O
is	-	76	O
an	-	79	O
organochloride	-	82	O
pesticide	-	97	O
and	-	107	O
scabicide	-	111	O
.	-	120	O

It	21195121	122	O
evokes	-	125	O
convulsions	-	132	B
mainly	-	144	O
trough	-	151	O
the	-	158	O
blockage	-	162	O
of	-	171	O
GABA	-	174	O
(	-	178	O
A	-	179	O
)	-	180	O
receptors	-	182	O
.	-	191	O

Nitric	21195121	193	O
oxide	-	200	O
(	-	206	O
NO	-	207	O
)	-	209	O
,	-	210	O
gaseous	-	212	O
neurotransmitter	-	220	O
,	-	236	O
has	-	238	O
contradictor	-	242	O
role	-	255	O
in	-	260	O
epileptogenesis	-	263	O
due	-	279	O
to	-	283	O
opposite	-	286	O
effects	-	295	O
of	-	303	O
L	-	306	O
-	-	307	O
arginine	-	308	O
,	-	316	O
precursor	-	318	O
of	-	328	O
NO	-	331	O
syntheses	-	334	O
(	-	344	O
NOS	-	345	O
)	-	348	O
,	-	349	O
and	-	351	O
L	-	355	O
-	-	356	O
NAME	-	357	O
(	-	362	O
NOS	-	363	O
inhibitor	-	367	O
)	-	376	O
observed	-	378	O
in	-	387	O
different	-	390	O
epilepsy	-	400	B
models	-	409	O
.	-	415	O

The	21195121	417	O
aim	-	421	O
of	-	425	O
the	-	428	O
current	-	432	O
study	-	440	O
was	-	446	O
to	-	450	O
determine	-	453	O
the	-	463	O
effects	-	467	O
of	-	475	O
NO	-	478	O
on	-	481	O
the	-	484	O
behavioral	-	488	O
and	-	499	O
EEG	-	503	O
characteristics	-	507	O
of	-	523	O
lindane	-	526	O
-	-	533	O
induced	-	534	O
epilepsy	-	542	B
in	-	551	O
male	-	554	O
Wistar	-	559	O
albino	-	566	O
rats	-	573	O
.	-	577	O

The	21195121	579	O
administration	-	583	O
of	-	598	O
L	-	601	O
-	-	602	O
arginine	-	603	O
(	-	612	O
600	-	613	O
,	-	616	O
800	-	618	O
and	-	622	O
1000	-	626	O
mg	-	631	O
/	-	633	O
kg	-	634	O
,	-	636	O
i	-	638	O
.	-	639	O
p	-	640	O
.	-	641	O
)	-	642	O

in	21195121	644	O
dose	-	647	O
-	-	651	O
dependent	-	652	O
manner	-	662	O
significantly	-	669	O
increased	-	683	O
convulsion	-	693	B
incidence	-	704	O
and	-	714	O
severity	-	718	O
and	-	727	O
shortened	-	731	O
latency	-	741	O
time	-	749	O
to	-	754	O
first	-	757	O
convulsion	-	763	B
elicited	-	774	O
by	-	783	O
lower	-	786	O
lindane	-	792	O
dose	-	800	O
(	-	805	O
4	-	806	O
mg	-	808	O
/	-	810	O
kg	-	811	O
,	-	813	O
i	-	815	O
.	-	816	O
p	-	817	O
.	-	818	O
)	-	819	O

.	21195121	820	O

On	21195121	822	O
the	-	825	O
contrary	-	829	O
,	-	837	O
pretreatment	-	839	O
with	-	852	O
L	-	857	O
-	-	858	O
NAME	-	859	O
(	-	864	O
500	-	865	O
,	-	868	O
700	-	870	O
and	-	874	O
900	-	878	O
mg	-	882	O
/	-	884	O
kg	-	885	O
,	-	887	O
i	-	889	O
.	-	890	O
p	-	891	O
.	-	892	O
)	-	893	O
decreased	-	895	O
convulsion	-	905	B
incidence	-	916	O
and	-	926	O
severity	-	930	O
and	-	939	O
prolonged	-	943	O
latency	-	953	O
time	-	961	O
to	-	966	O
convulsion	-	969	B
following	-	980	O
injection	-	990	O
with	-	1000	O
a	-	1005	O
convulsive	-	1007	B
dose	-	1018	O
of	-	1023	O
lindane	-	1026	O
(	-	1034	O
8	-	1035	O
mg	-	1037	O
/	-	1039	O
kg	-	1040	O
,	-	1042	O
i	-	1044	O
.	-	1045	O
p	-	1046	O
.	-	1047	O
)	-	1048	O
.	-	1049	O

EEG	21195121	1051	O
analyses	-	1055	O
showed	-	1064	O
increase	-	1071	O
of	-	1080	O
number	-	1083	O
and	-	1090	O
duration	-	1094	O
of	-	1103	O
ictal	-	1106	O
periods	-	1112	O
in	-	1120	O
EEG	-	1123	O
of	-	1127	O
rats	-	1130	O
receiving	-	1135	O
l	-	1145	O
-	-	1146	O
arginine	-	1147	O
prior	-	1156	O
to	-	1162	O
lindane	-	1165	O
and	-	1173	O
decrease	-	1177	O
of	-	1186	O
this	-	1189	O
number	-	1194	O
in	-	1201	O
rats	-	1204	O
pretreated	-	1209	O
with	-	1220	O
L	-	1225	O
-	-	1226	O
NAME	-	1227	O
.	-	1231	O

These	21195121	1233	O
results	-	1239	O
support	-	1247	O
the	-	1255	O
conclusion	-	1259	O
that	-	1270	O
NO	-	1275	O
plays	-	1278	O
a	-	1284	O
role	-	1286	O
of	-	1291	O
endogenous	-	1294	O
convulsant	-	1305	O
in	-	1316	O
rat	-	1319	O
model	-	1323	O
of	-	1329	O
lindane	-	1332	O
seizures	-	1340	B
.	-	1348	O

Long	24055495	0	O
-	-	4	O
term	-	5	O
oral	-	10	O
galactose	-	15	O
treatment	-	25	O
prevents	-	35	O
cognitive	-	44	B
deficits	-	54	I
in	-	63	O
male	-	66	O
Wistar	-	71	O
rats	-	78	O
treated	-	83	O
intracerebroventricularly	-	91	O
with	-	117	O
streptozotocin	-	122	O
.	-	136	O

Basic	24055495	138	O
and	-	144	O
clinical	-	148	O
research	-	157	O
has	-	166	O
demonstrated	-	170	O
that	-	183	O
dementia	-	188	B
of	-	197	O
sporadic	-	200	O
Alzheimer	-	209	B
's	-	218	I
disease	-	221	I
(	-	229	O
sAD	-	230	O
)	-	233	O
type	-	235	O
is	-	240	O
associated	-	243	O
with	-	254	O
dysfunction	-	259	O
of	-	271	O
the	-	274	O
insulin	-	278	O
-	-	285	O
receptor	-	286	O
(	-	295	O
IR	-	296	O
)	-	298	O
system	-	300	O
followed	-	307	O
by	-	316	O
decreased	-	319	O
glucose	-	329	O
transport	-	337	O
via	-	347	O
glucose	-	351	O
transporter	-	359	O
GLUT4	-	371	O
and	-	377	O
decreased	-	381	O
glucose	-	391	O
metabolism	-	399	O
in	-	410	O
brain	-	413	O
cells	-	419	O
.	-	424	O

An	24055495	426	O
alternative	-	429	O
source	-	441	O
of	-	448	O
energy	-	451	O
is	-	458	O
d	-	461	O
-	-	462	O
galactose	-	463	O
(	-	473	O
the	-	474	O
C	-	478	O
-	-	479	O
4	-	480	O
-	-	481	O
epimer	-	482	O
of	-	489	O
d	-	492	O
-	-	493	O
glucose	-	494	O
)	-	501	O
which	-	503	O
is	-	509	O
transported	-	512	O
into	-	524	O
the	-	529	O
brain	-	533	O
by	-	539	O
insulin	-	542	O
-	-	549	O
independent	-	550	O
GLUT3	-	562	O
transporter	-	568	O
where	-	580	O
it	-	586	O
might	-	589	O
be	-	595	O
metabolized	-	598	O
to	-	610	O
glucose	-	613	O
via	-	621	O
the	-	625	O
Leloir	-	629	O
pathway	-	636	O
.	-	643	O

Exclusively	24055495	645	O
parenteral	-	657	O
daily	-	668	O
injections	-	674	O
of	-	685	O
galactose	-	688	O
induce	-	698	O
memory	-	705	B
deterioration	-	712	I
in	-	726	O
rodents	-	729	O
and	-	737	O
are	-	741	O
used	-	745	O
to	-	750	O
generate	-	753	O
animal	-	762	O
aging	-	769	O
model	-	775	O
,	-	780	O
but	-	782	O
the	-	786	O
effects	-	790	O
of	-	798	O
oral	-	801	O
galactose	-	806	O
treatment	-	816	O
on	-	826	O
cognitive	-	829	O
functions	-	839	O
have	-	849	O
never	-	854	O
been	-	860	O
tested	-	865	O
.	-	871	O

We	24055495	873	O
have	-	876	O
investigated	-	881	O
the	-	894	O
effects	-	898	O
of	-	906	O
continuous	-	909	O
daily	-	920	O
oral	-	926	O
galactose	-	931	O
(	-	941	O
200	-	942	O
mg	-	946	O
/	-	948	O
kg	-	949	O
/	-	951	O
day	-	952	O
)	-	955	O
treatment	-	957	O
on	-	967	O
cognitive	-	970	B
deficits	-	980	I
in	-	989	O
streptozotocin	-	992	O
-	-	1006	O
induced	-	1007	O
(	-	1015	O
STZ	-	1016	O
-	-	1019	O
icv	-	1020	O
)	-	1023	O
rat	-	1025	O
model	-	1029	O
of	-	1035	O
sAD	-	1038	O
,	-	1041	O
tested	-	1043	O
by	-	1050	O
Morris	-	1053	O
Water	-	1060	O
Maze	-	1066	O
and	-	1071	O
Passive	-	1075	O
Avoidance	-	1083	O
test	-	1093	O
,	-	1097	O
respectively	-	1099	O
.	-	1111	O

One	24055495	1113	O
month	-	1117	O
of	-	1123	O
oral	-	1126	O
galactose	-	1131	O
treatment	-	1141	O
initiated	-	1151	O
immediately	-	1161	O
after	-	1173	O
the	-	1179	O
STZ	-	1183	O
-	-	1186	O
icv	-	1187	O
administration	-	1191	O
,	-	1205	O
successfully	-	1207	O
prevented	-	1220	O
development	-	1230	O
of	-	1242	O
the	-	1245	O
STZ	-	1249	O
-	-	1252	O
icv	-	1253	O
-	-	1256	O
induced	-	1257	O
cognitive	-	1265	B
deficits	-	1275	I
.	-	1283	O

Beneficial	24055495	1285	O
effect	-	1296	O
of	-	1303	O
oral	-	1306	O
galactose	-	1311	O
was	-	1321	O
independent	-	1325	O
of	-	1337	O
the	-	1340	O
rat	-	1344	O
age	-	1348	O
and	-	1352	O
of	-	1356	O
the	-	1359	O
galactose	-	1363	O
dose	-	1373	O
ranging	-	1378	O
from	-	1386	O
100	-	1391	O
to	-	1395	O
300	-	1398	O
mg	-	1402	O
/	-	1404	O
kg	-	1405	O
/	-	1407	O
day	-	1408	O
.	-	1411	O

Additionally	24055495	1413	O
,	-	1425	O
oral	-	1427	O
galactose	-	1432	O
administration	-	1442	O
led	-	1457	O
to	-	1461	O
the	-	1464	O
appearance	-	1468	O
of	-	1479	O
galactose	-	1482	O
in	-	1492	O
the	-	1495	O
blood	-	1499	O
.	-	1504	O

The	24055495	1506	O
increase	-	1510	O
of	-	1519	O
galactose	-	1522	O
concentration	-	1532	O
in	-	1546	O
the	-	1549	O
cerebrospinal	-	1553	O
fluid	-	1567	O
was	-	1573	O
several	-	1577	O
times	-	1585	O
lower	-	1591	O
after	-	1597	O
oral	-	1603	O
than	-	1608	O
after	-	1613	O
parenteral	-	1619	O
administration	-	1630	O
of	-	1645	O
the	-	1648	O
same	-	1652	O
galactose	-	1657	O
dose	-	1667	O
.	-	1671	O

Oral	24055495	1673	O
galactose	-	1678	O
exposure	-	1688	O
might	-	1697	O
have	-	1703	O
beneficial	-	1708	O
effects	-	1719	O
on	-	1727	O
learning	-	1730	O
and	-	1739	O
memory	-	1743	O
ability	-	1750	O
and	-	1758	O
could	-	1762	O
be	-	1768	O
worth	-	1771	O
investigating	-	1777	O
for	-	1791	O
improvement	-	1795	O
of	-	1807	O
cognitive	-	1810	B
deficits	-	1820	I
associated	-	1829	O
with	-	1840	O
glucose	-	1845	B
hypometabolism	-	1853	I
in	-	1868	O
AD	-	1871	B
.	-	1873	O

